Penetration	Mental
and	Mental
accumulation	Mental
of	O
moxifloxacin	O
in	O
uterine	O
tissue	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
moxifloxacin	O
penetrates	O
the	O
uterine	O
tissue	O
and	O
accumulates	O
at	O
levels	O
sufficient	O
to	O
eradicate	Physical
the	Physical
major	Physical
pathogens	Physical
causing	O
pelvic	O
inflammatory	O
disease	O
(	O
PID	O
)	O
.	O

METHOD	O
In	O
a	O
prospective	O
,	O
multicenter	O
,	O
open-label	O
,	O
parallel-group	O
study	O
we	O
determined	O
the	O
concentration	O
of	O
moxifloxacin	O
in	O
plasma	O
and	O
uterine	O
tissue	O
after	O
a	O
single	O
,	O
400-mg	O
intravenous	O
dose	O
of	O
moxifloxacin	O
.	O

Study	O
participants	O
were	O
randomized	O
for	O
time	O
of	O
tissue	O
sampling	O
,	O
which	O
was	O
performed	O
1	O
,	O
2	O
,	O
4	O
,	O
7	O
,	O
or	O
24	O
hours	O
following	O
the	O
moxifloxacin	O
infusion	O
.	O

RESULTS	O
Of	O
43	O
participants	O
,	O
40	O
were	O
randomized	O
to	O
tissue	O
sampling	O
.	O

Moxifloxacin	Physical
accumulated	Physical
in	Physical
uterine	Physical
tissue	Physical
and	Physical
concentrations	Physical
were	O
highest	O
1	O
hour	O
after	O
infusion	O
in	O
both	O
plasma	O
and	O
tissue	O
.	O

Tissue	Physical
to	Physical
plasma	Physical
ratios	Physical
remained	O
between	O
1.7	O
and	O
2.1	O
for	O
24	O
hours	O
.	O

Moxifloxacin	O
was	O
found	O
to	O
be	O
safe	Others
and	Others
well	Others
tolerated	Others
.	O

CONCLUSION	O
Based	O
on	O
known	O
minimum	O
inhibitory	O
concentration	O
data	O
,	O
the	O
uterine	Physical
tissue	Physical
concentrations	Physical
of	O
moxifloxacin	O
achieved	O
over	O
24	O
hours	O
would	O
be	O
sufficient	O
to	O
eradicate	O
the	O
range	O
of	O
bacterial	O
pathogens	O
responsible	O
for	O
PID	O
.	O

Comparison	O
of	O
yoga	O
versus	O
stretching	O
for	O
chronic	Pain
low	Pain
back	Pain
pain	Pain
:	O
protocol	O
for	O
the	O
Yoga	O
Exercise	O
Self-care	O
(	O
YES	O
)	O
trial	O
.	O

BACKGROUND	O
Back	Pain
pain	Pain
,	O
one	O
of	O
the	O
most	O
prevalent	O
conditions	O
afflicting	O
American	O
adults	O
,	O
is	O
the	O
leading	O
reason	O
for	O
using	O
complementary	O
and	O
alternative	O
medicine	O
(	O
CAM	O
)	O
therapies	O
.	O

Yoga	O
is	O
an	O
increasingly	O
popular	O
mind-body	O
CAM	O
therapy	O
often	O
used	O
for	O
relieving	Pain
back	Pain
pain	Pain
and	O
several	O
small	O
studies	O
have	O
found	O
yoga	O
effective	O
for	O
this	O
condition	O
.	O

This	O
study	O
will	O
assess	O
whether	O
yoga	O
is	O
effective	O
for	O
treating	O
chronic	Pain
low	Pain
back	Pain
pain	Pain
compared	O
with	O
self	O
care	O
and	O
exercise	O
and	O
will	O
explore	O
the	O
mechanisms	O
responsible	O
for	O
any	O
observed	O
benefits	O
.	O

METHODS/DESIGN	O
A	O
total	O
of	O
210	O
participants	O
with	O
low	O
back	O
pain	O
lasting	O
at	O
least	O
3	O
months	O
will	O
be	O
recruited	O
from	O
primary	O
care	O
clinics	O
of	O
a	O
large	O
healthcare	O
system	O
based	O
in	O
Seattle	O
.	O

They	O
will	O
be	O
randomized	O
in	O
a	O
2:2:1	O
ratio	O
to	O
receive	O
12	O
weekly	O
yoga	O
classes	O
,	O
12	O
weekly	O
conventional	O
therapeutic	O
exercise	O
classes	O
of	O
comparable	O
physical	O
exertion	O
,	O
or	O
a	O
self-care	O
book	O
.	O

Interviewers	O
masked	O
to	O
participants	O
'	O
treatment	O
group	O
will	O
assess	O
outcomes	O
at	O
baseline	O
and	O
6	O
,	O
12	O
and	O
26	O
weeks	O
after	O
randomization	O
.	O

Primary	O
outcomes	O
will	O
be	O
back-related	Physical
dysfunction	Physical
and	Physical
symptom	Physical
bothersomeness	Physical
.	Physical

In	O
addition	O
,	O
data	O
will	O
be	O
collected	O
on	O
physical	Physical
measurements	Physical
(	O
e.g.	O
,	O
flexion	Physical
)	O
at	O
baseline	O
and	O
12	O
weeks	O
and	O
saliva	O
samples	O
will	O
be	O
obtained	O
at	O
baseline	O
,	O
6	O
and	O
12	O
weeks	O
.	O

Information	O
will	O
be	O
collected	O
on	O
specific	O
physical	O
,	O
psychological	O
,	O
and	O
physiological	O
factors	O
to	O
allow	O
exploration	O
of	O
possible	O
mechanisms	O
of	O
action	O
through	O
which	O
yoga	O
could	O
relieve	Pain
back	Pain
pain	Pain
and	Pain
dysfunction	Pain
.	Pain

The	O
effectiveness	O
of	O
yoga	O
will	O
be	O
assessed	O
using	O
analysis	O
of	O
covariance	O
(	O
using	O
general	O
estimating	O
equations	O
-	O
GEE	O
)	O
within	O
an	O
intention-to-treat	O
context	O
.	O

If	O
yoga	O
is	O
found	O
effective	O
,	O
further	O
analyses	O
will	O
explore	O
whether	O
yoga	O
's	O
benefits	O
are	O
attributable	O
to	O
physical	O
,	O
psychological	O
and/or	O
physiological	O
factors	O
.	O

CONCLUSIONS	O
This	O
study	O
will	O
provide	O
the	O
clearest	O
evidence	O
to	O
date	O
about	O
the	O
value	O
of	O
yoga	O
as	O
a	O
therapeutic	O
option	O
for	O
treating	O
chronic	Pain
back	Pain
pain	Pain
,	O
and	O
if	O
the	O
results	O
are	O
positive	O
,	O
will	O
help	O
focus	O
future	O
,	O
more	O
in-depth	O
,	O
research	O
on	O
the	O
most	O
promising	O
potential	O
mechanisms	O
of	O
action	O
identified	O
by	O
this	O
study	O
.	O

Early	O
withdrawal	O
of	O
calcineurin	O
inhibitors	O
and	O
everolimus	O
monotherapy	O
in	O
de	O
novo	O
liver	O
transplant	O
recipients	O
preserves	O
renal	O
function	O
.	O

We	O
designed	O
a	O
randomized	O
trial	O
to	O
assess	O
whether	O
the	O
early	O
withdrawal	O
of	O
cyclosporine	O
(	O
CsA	O
)	O
followed	O
by	O
the	O
initiation	O
of	O
everolimus	O
(	O
Evr	O
)	O
monotherapy	O
in	O
de	O
novo	O
liver	O
transplantation	O
(	O
LT	O
)	O
patients	O
would	O
result	O
in	O
superior	O
renal	O
function	O
compared	O
to	O
a	O
CsA-based	O
immunosuppression	O
protocol	O
.	O

All	O
patients	O
were	O
treated	O
with	O
CsA	O
for	O
the	O
first	O
10	O
days	O
and	O
then	O
randomized	O
to	O
receive	O
Evr	O
in	O
combination	O
with	O
CsA	O
up	O
to	O
day	O
30	O
,	O
then	O
either	O
continued	O
on	O
Evr	O
monotherapy	O
(	O
Evr	O
group	O
)	O
or	O
maintained	O
on	O
CsA	O
with/without	O
mycophenolate	O
mofetil	O
(	O
CsA	O
group	O
)	O
in	O
case	O
of	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O

Seventy-eight	O
patients	O
were	O
randomized	O
(	O
Evr	O
n	O
=	O
52	O
;	O
CsA	O
n	O
=	O
26	O
)	O
.	O

The	O
1-year	Others
freedom	Others
from	Others
efficacy	Others
failure	Others
in	O
Evr	O
group	O
was	O
75	O
%	O
versus	O
69.2	O
%	O
in	O
CsA	O
group	O
,	O
p	O
=	O
0.36	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
patient	Mortality
survival	Mortality
between	O
the	O
two	O
groups	O
.	O

Mean	Physical
modification	Physical
of	Physical
diet	Physical
in	Physical
renal	Physical
disease	Physical
(	Physical
MDRD	Physical
)	Physical
was	O
significantly	O
better	O
in	O
the	O
Evr	O
group	O
at	O
12	O
months	O
(	O
87.7	O
?	O
26.1	O
vs.	O
59.9	O
?	O
12.6	O
mL/min	O
;	O
p	O
<	O
0.001	O
)	O
.	O

The	O
incidence	O
of	O
CKD	O
stage	O
?	O
3	O
(	O
estimated	O
glomerular	O
filtration	O
rate	O
<	O
60	O
mL/min	O
)	O
was	O
higher	O
in	O
the	O
CsA	O
group	O
at	O
1	O
year	O
(	O
52.2	O
%	O
vs.	O
15.4	O
%	O
,	O
p	O
=	O
0.005	O
)	O
.	O

The	O
results	O
indicate	O
that	O
early	O
withdrawal	O
of	O
CsA	O
followed	O
by	O
Evr	O
monotherapy	O
in	O
de	O
novo	O
LT	O
patients	O
is	O
associated	O
with	O
an	O
improvement	O
in	O
renal	O
function	O
,	O
with	O
a	O
similar	O
incidence	O
of	O
rejection	O
and	O
major	O
complications	O
.	O

[	O
Comparison	O
between	O
anterior	O
rhinomanometry	O
and	O
impulse-oscillometric	O
rhinometry	O
found	O
within	O
nasal	Physical
allergen	Physical
provocation	Physical
]	O
.	O

UNLABELLED	O
Besides	O
the	O
standard	O
method	O
of	O
anterior	O
rhinomanometry	O
(	O
aR	O
)	O
,	O
the	O
impulse-oscillometric	O
rhinometry	O
(	O
IOS	O
)	O
is	O
available	O
for	O
measurements	O
of	O
the	O
nasal	Physical
resistance	Physical
.	O

The	O
aR	O
is	O
a	O
procedure	O
dependent	O
on	O
the	O
cooperation	O
of	O
the	O
patient	O
,	O
whereas	O
IOS	O
is	O
measured	O
regardless	O
from	O
the	O
breathing	O
activities	O
of	O
the	O
patient	O
.	O

We	O
examined	O
weather	O
the	O
resistance-measurement	O
by	O
means	O
of	O
IOS	O
in	O
comparison	O
to	O
the	O
aR	O
is	O
a	O
more	O
suitable	O
method	O
for	O
nasal	Physical
allergic	Physical
provocation	Physical
.	O

METHOD	O
17	O
patients	O
with	O
anamnestic	O
known	O
rhinokonjunktivitis	O
(	O
6	O
f	O
,	O
11	O
m	O
)	O
had	O
a	O
pricktest	O
and	O
then	O
a	O
nasal	O
provocation	O
testing	O
with	O
an	O
allergen	O
which	O
provoked	O
a	O
reaction	O
on	O
the	O
skin	O
.	O

The	O
complete	O
resistance	Physical
of	O
the	O
nose	O
was	O
measured	O
in	O
a	O
randomized	O
order	O
by	O
means	O
of	O
aR	O
and	O
IOS	O
.	O

RESULTS	O
The	O
complete	Physical
resistance	Physical
showed	O
neither	O
in	O
the	O
basic	O
measurement	O
(	O
aR	O
0,38	O
+/-	O
0,14	O
kPa/l/s	O
;	O
IOS	O
0,38	O
+/-	O
0,11	O
kPa/l/s	O
)	O
nor	O
in	O
the	O
control	O
solution	O
(	O
aR	O
0,38	O
+/-	O
0,14	O
;	O
IOS	O
0,39	O
+/-	O
0,14	O
)	O
nor	O
after	O
application	O
of	O
the	O
allergenic	O
solution	O
(	O
15	O
min	O
:	O
aR	O
0,69	O
+/-	O
0,27	O
;	O
IOS	O
0,77	O
+/-	O
0,42	O
;	O
30	O
min	O
:	O
aR	O
0,65	O
+/-	O
0,29	O
;	O
IOS	O
0,6	O
+/-	O
0,38	O
)	O
a	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
.	O

The	O
results	O
of	O
the	O
measurement	Physical
of	Physical
aR	Physical
and	Physical
IOS	Physical
after	O
the	O
allergenic	O
solution	O
showed	O
a	O
positive	O
correlation	Physical
(	O
15	O
min	O
:	O
r	O
=	O
0,63	O
,	O
p	O
<	O
0,01	O
;	O
30	O
min	O
:	O
r	O
=	O
0,67	O
,	O
p	O
<	O
0,01	O
)	O
.	O

We	O
found	O
by	O
means	O
of	O
clinic	O
and	O
measurement	O
methods	O
in	O
the	O
aR	O
of	O
7	O
patients	O
a	O
positive	O
reaction	O
,	O
within	O
7	O
patient	O
a	O
negative	O
reaction	O
,	O
3	O
patients	O
had	O
a	O
unspecific	Physical
nasal	Physical
hyperreactivity	Physical
.	O

There	O
was	O
a	O
correspondence	O
in	O
6	O
of	O
the	O
7	O
patients	O
with	O
positive	O
reaction	O
in	O
aR	O
between	O
both	O
methods	O
.	O

4	O
of	O
the	O
7	O
results	O
with	O
negative	O
reaction	O
in	O
the	O
aR	O
would	O
have	O
been	O
positive	O
then	O
underlying	O
the	O
same	O
criteria	O
in	O
the	O
IOS	O
without	O
announcing	O
the	O
symptomscore	Physical
a	O
relevant	O
clinical	O
symptomatic	O
while	O
testing	O
.	O

CONCLUSION	O
IOS	O
is	O
a	O
suitable	O
procedure	O
for	O
nasal	O
provocation	O
testing	O
and	O
provides	O
results	O
similar	O
to	O
the	O
aR	O
.	O

In	O
comparison	O
to	O
aR	O
IOS	O
is	O
not	O
dependent	O
on	O
the	O
patients	O
cooperation	O
.	O

Due	O
to	O
its	O
higher	O
sensitivity	O
the	O
valid	O
limits	O
of	O
the	O
aR	O
at	O
provocation	O
testings	O
can	O
not	O
be	O
transferred	O
to	O
IOS	O
to	O
avoid	O
a	O
false	Physical
positive	Physical
reaction	Physical
.	O

Weight	O
and	O
lean	O
body	O
mass	O
change	O
with	O
antiretroviral	O
initiation	O
and	O
impact	O
on	O
bone	O
mineral	O
density	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effect	O
that	O
initiating	O
different	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
regimens	O
has	O
on	O
weight	O
,	O
BMI	O
,	O
and	O
lean	O
body	O
mass	O
(	O
LBM	O
)	O
and	O
explore	O
how	O
changes	O
in	O
body	O
composition	O
are	O
associated	O
with	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
.	O

METHODS	O
A5224s	O
was	O
a	O
sub-study	O
of	O
A5202	O
,	O
a	O
prospective	O
trial	O
of	O
1857	O
ART-naive	O
participants	O
randomized	O
to	O
blinded	O
abacavir-lamivudine	O
(	O
ABC/3TC	O
)	O
or	O
tenofovir	O
DF-emtricitabine	O
(	O
TDF/FTC	O
)	O
with	O
open-label	O
efavirenz	O
(	O
EFV	O
)	O
or	O
atazanavir-ritonavir	O
(	O
ATV/r	O
)	O
.	O

All	O
participants	O
underwent	O
dual-energy	O
absorptiometry	O
(	O
DXA	O
)	O
and	O
abdominal	O
computed	O
tomography	O
for	O
body	O
composition	O
.	O

Analyses	O
used	O
two-sample	O
t-tests	O
and	O
linear	O
regression	O
.	O

RESULTS	O
A5224s	O
included	O
269	O
participants	O
:	O
85	O
%	O
men	O
,	O
47	O
%	O
white	O
non-Hispanic	O
,	O
median	O
age	O
38	O
years	O
,	O
HIV-1	O
RNA	O
4.6	O
log10	O
copies/ml	O
,	O
and	O
CD4	O
cell	O
count	O
233	O
cells/?l	O
.	O

Overall	O
,	O
significant	O
gains	O
occurred	O
in	O
weight	O
,	O
BMI	O
,	O
and	O
LBM	O
at	O
96	O
weeks	O
post-randomization	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O

Assignment	O
to	O
ATV/r	O
(	O
vs.	O
EFV	O
)	O
resulted	O
in	O
significantly	O
greater	O
weight	O
(	O
mean	O
difference	O
3.35	O
kg	O
)	O
and	O
BMI	O
gain	O
(	O
0.88	O
kg/m	O
;	O
both	O
P=0.02	O
)	O
,	O
but	O
not	O
LBM	O
(	O
0.67	O
kg	O
;	O
P=0.15	O
)	O
,	O
whereas	O
ABC/3TC	O
and	O
TDF/FTC	O
were	O
not	O
significantly	O
different	O
(	O
P?0.10	O
)	O
.	O

In	O
multivariable	O
analysis	O
,	O
only	O
lower	O
baseline	O
CD4	O
cell	O
count	O
and	O
higher	O
HIV-1	O
RNA	O
were	O
associated	O
with	O
greater	O
increase	O
in	O
weight	O
,	O
BMI	O
,	O
or	O
LBM	O
.	O

In	O
multivariable	O
analyses	O
,	O
increased	O
LBM	O
was	O
associated	O
with	O
an	O
increased	O
hip	O
BMD	O
.	O

CONCLUSION	O
ABC/3TC	O
vs.	O
TDF/FTC	O
did	O
not	O
differ	O
in	O
change	O
in	O
weight	O
,	O
BMI	O
,	O
or	O
LBM	O
;	O
ATV/r	O
vs.	O
EFV	O
resulted	O
in	O
greater	O
weight	O
and	O
BMI	O
gain	O
but	O
not	O
LBM	O
.	O

A	O
positive	O
association	O
between	O
increased	O
LBM	O
and	O
increased	O
hip	O
BMD	O
should	O
be	O
further	O
investigated	O
through	O
prospective	O
interventional	O
studies	O
to	O
verify	O
the	O
impact	O
of	O
increased	O
LBM	O
on	O
hip	O
BMD	O
.	O

Effect	O
of	O
macronutrient	O
composition	O
of	O
the	O
diet	O
on	O
the	O
regulation	Physical
of	Physical
lipolysis	Physical
in	Physical
adipose	Physical
tissue	Physical
at	O
rest	O
and	O
during	O
exercise	O
:	O
microdialysis	O
study	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
elucidate	O
,	O
using	O
a	O
microdialysis	O
technique	O
,	O
whether	O
modifications	O
in	O
the	O
proportion	O
of	O
fat	O
in	O
the	O
diet	O
influence	O
lipid	Mental
mobilization	Mental
from	O
adipose	O
tissue	O
in	O
situ	O
.	O

Nine	O
healthy	O
volunteers	O
(	O
age	O
,	O
23.4	O
+/-	O
0.2	O
years	O
;	O
body	O
mas	O
index	O
[	O
BMI	O
]	O
,	O
23.5	O
+/-	O
1.6	O
kg/m	O
(	O
2	O
)	O
)	O
were	O
fed	O
,	O
in	O
random	O
order	O
,	O
with	O
a	O
high-fat	O
diet	O
(	O
HFD	O
)	O
(	O
65	O
%	O
of	O
energy	O
content	O
fat	O
,	O
15	O
%	O
protein	O
,	O
20	O
%	O
carbohydrate	O
)	O
or	O
a	O
high-carbohydrate	O
diet	O
(	O
HCD	O
)	O
(	O
70	O
%	O
carbohydrate	O
,	O
15	O
%	O
protein	O
,	O
15	O
%	O
fat	O
)	O
for	O
5	O
days	O
,	O
with	O
a	O
washout	O
period	O
of	O
10	O
days	O
between	O
the	O
diets	O
.	O

Subjects	O
were	O
studied	O
in	O
the	O
fasting	O
state	O
on	O
the	O
morning	O
following	O
days	O
4	O
and	O
5	O
of	O
each	O
diet	O
.	O

We	O
measured	O
the	O
concentration	Physical
of	Physical
extracellular	Physical
glycerol	Physical
(	Physical
EGC	Physical
)	Physical
in	Physical
adipose	Physical
tissue	Physical
in	O
response	O
to	O
(	O
1	O
)	O
pharmacologic	O
stimulation	O
with	O
isoprenaline	O
(	O
1	O
and	O
10	O
micromol/L	O
)	O
in	O
situ	O
,	O
(	O
2	O
)	O
stimulation	O
with	O
intravenous	O
infusion	O
of	O
epinephrine	O
(	O
0.0375	O
microg/min/kg	O
body	O
weight	O
)	O
,	O
and	O
(	O
3	O
)	O
submaximal	O
aerobic	O
exercise	O
(	O
50	O
%	O
V*O2max	O
,	O
60-minute	O
duration	O
)	O
.	O

No	O
effect	O
of	O
the	O
diet	Physical
composition	Physical
was	O
found	O
in	O
the	O
increases	Physical
of	Physical
EGC	Physical
in	O
response	O
to	O
isoprenaline	O
(	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
:	O
HFD	O
,	O
1,534	O
+/-	O
370	O
micromol/90	O
min	O
;	O
HCD	O
,	O
1,108	O
+/-	O
465	O
micromol/90	O
min	O
;	O
not	O
significant	O
[	O
NS	O
]	O
)	O
or	O
epinephrine	Physical
stimulations	Physical
(	O
AUC	O
:	O
HFD	O
,	O
190	O
+/-	O
92	O
micromol/30	O
min	O
;	O
HCD	O
,	O
251	O
+/-	O
298	O
micromol/30	O
min	O
;	O
NS	O
)	O
.	O

The	O
exercise-induced	Physical
increase	Physical
in	Physical
EGC	Physical
was	Physical
higher	Physical
during	O
the	O
HFD	O
(	O
AUC	O
:	O
HFD	O
,	O
1,641	O
+/-	O
181	O
micromol/60	O
min	O
;	O
HCD	O
,	O
963	O
+/-	O
156	O
micromol/60	O
min	O
;	O
P	O
<	O
.05	O
)	O
and	O
was	O
associated	O
with	O
a	O
higher	Physical
exercise-induced	Physical
response	Physical
of	O
norepinephrine	O
(	O
P	O
<	O
.05	O
)	O
and	O
epinephrine	O
(	O
P	O
=.056	O
)	O
and	O
lower	O
insulinemia	Physical
during	O
exercise	O
.	O

The	O
results	O
suggest	O
that	O
macronutrient	O
composition	O
of	O
diet	O
does	O
not	O
affect	O
the	O
beta-adrenergic	Others
responsiveness	Others
of	Others
adipose	Others
tissue	Others
to	O
catecholamine	O
action	O
at	O
rest	O
.	O

During	O
exercise	O
,	O
the	O
HFD	O
promotes	O
higher	O
lipolysis	O
in	O
adipose	O
tissue	O
and	O
this	O
is	O
associated	O
with	O
a	O
higher	O
catecholamine	O
response	O
and	O
lower	O
insulinemia	O
.	O

The	O
antiemetic	Others
efficacy	Others
of	O
prophylactic	O
granisetron	O
in	O
gynecologic	O
surgery	O
.	O

Postoperative	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
are	O
common	O
after	O
recovery	O
from	O
anesthesia	O
.	O

We	O
examined	O
the	O
prophylactic	O
effect	O
of	O
granisetron	O
on	O
postoperative	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
in	O
120	O
female	O
patients	O
(	O
ASA	O
physical	O
status	O
I	O
)	O
undergoing	O
gynecologic	O
surgery	O
.	O

They	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
(	O
n	O
=	O
40	O
for	O
each	O
)	O
:	O
saline	O
(	O
as	O
a	O
control	O
)	O
,	O
granisetron	O
20	O
micrograms/kg	O
,	O
and	O
granisetron	O
40	O
micrograms/kg	O
.	O

Saline	O
or	O
granisetron	O
was	O
given	O
intravenously	O
(	O
IV	O
)	O
over	O
5	O
min	O
approximately	O
30	O
min	O
before	O
the	O
end	O
of	O
anesthesia	O
.	O

Nausea	Adverseeffect
,	Adverseeffect
vomiting	Adverseeffect
,	Physical
and	Physical
safety	Others
assessments	Others
were	O
performed	O
during	O
the	O
24-h	O
recovery	O
period	O
.	O

For	O
the	O
24-h	O
period	O
after	O
surgery	O
,	O
the	O
number	Others
of	Others
emesis-free	Others
patients	Others
was	O
significantly	O
larger	O
in	O
the	O
granisetron	O
groups	O
than	O
in	O
the	O
control	O
group	O
(	O
83	O
%	O
,	O
78	O
%	O
,	O
and	O
20	O
%	O
of	O
patients	O
receiving	O
granisetron	O
20	O
micrograms/kg	O
and	O
40	O
micrograms/kg	O
,	O
and	O
saline	O
,	O
respectively	O
)	O
.	O

Granisetron	O
at	O
both	O
doses	O
also	O
was	O
superior	O
to	O
the	O
control	O
for	O
the	O
prevention	O
of	O
nausea	Adverseeffect
over	O
the	O
24-h	O
study	O
period	O
(	Others
nausea	Adverseeffect
visual	Adverseeffect
analog	Adverseeffect
scales	Adverseeffect
at	O
24-h	O
postsurgery	O
:	O
49	O
mm	O
,	O
17	O
mm	O
,	O
and	O
18	O
mm	O
in	O
the	O
control	O
,	O
granisetron	O
20	O
micrograms/kg	O
,	O
and	O
granisetron	O
40	O
micrograms/kg	O
groups	O
,	O
respectively	O
)	O
.	O

Fewer	O
patients	O
received	O
rescue	Physical
antiemetics	Physical
in	O
the	O
granisetron	O
groups	O
than	O
in	O
the	O
control	O
group	O
(	O
10	O
%	O
,	O
10	O
%	O
,	O
and	O
43	O
%	O
of	O
patients	O
in	O
granisetron	O
20	O
micrograms/kg	O
and	O
40	O
micrograms/kg	O
,	O
and	O
the	O
control	O
groups	O
,	O
respectively	O
)	O
.	O

The	O
adverse	Adverseeffect
events	Adverseeffect
in	O
the	O
granisetron	O
groups	O
were	O
similar	O
to	O
those	O
in	O
the	O
control	O
group	O
.	O

The	O
administration	O
of	O
granisetron	O
had	O
no	O
significant	O
effect	O
on	O
vital	Physical
signs	Physical
or	Others
clinical	Physical
laboratory	Physical
test	Physical
profiles	Physical
.	O

Granisetron	O
given	O
at	O
20	O
or	O
40	O
micrograms/kg	O
i.v	O
.	O

during	O
anesthesia	O
appears	O
to	O
be	O
a	O
simple	Others
,	Others
effective	Others
,	Others
and	Others
safe	Others
method	Others
for	O
preventing	O
postoperative	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
.	O

Nasal	O
versus	O
oronasal	O
continuous	O
positive	O
airway	O
pressure	O
masks	O
for	O
obstructive	O
sleep	O
apnea	O
:	O
a	O
pilot	O
investigation	O
of	O
pressure	O
requirement	O
,	O
residual	O
disease	O
,	O
and	O
leak	O
.	O

PURPOSE	O
This	O
single-blinded	O
,	O
randomized	O
,	O
controlled	O
pilot	O
study	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
a	O
difference	O
between	O
nasal	O
and	O
oronasal	O
masks	O
in	O
therapeutic	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
requirement	O
,	O
residual	O
disease	O
,	O
or	O
leak	O
when	O
treating	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
and	O
if	O
differences	O
were	O
related	O
to	O
measures	O
of	O
upper	O
airway	O
size	O
.	O

METHODS	O
Patients	O
with	O
severe	O
OSA	O
currently	O
using	O
CPAP	O
at	O
?4	O
h/night	O
with	O
a	O
nasal	O
mask	O
were	O
examined	O
(	O
including	O
Mallampati	O
scale	O
,	O
incisal	O
relationship	O
,	O
and	O
mandibular	O
protrusion	O
)	O
and	O
then	O
randomized	O
to	O
receive	O
auto-positive	O
airway	O
pressure	O
(	O
PAP	O
)	O
or	O
fixed	O
CPAP	O
at	O
a	O
manually	O
titrated	O
pressure	O
for	O
1	O
week	O
each	O
at	O
home	O
,	O
with	O
immediate	O
crossover	O
.	O

Within	O
each	O
week	O
,	O
a	O
nasal	O
mask	O
and	O
two	O
oronasal	O
masks	O
were	O
to	O
be	O
used	O
for	O
two	O
or	O
three	O
nights	O
each	O
in	O
random	O
order	O
.	O

Data	O
were	O
downloaded	O
from	O
the	O
device	O
.	O

RESULTS	O
Twelve	O
patients	O
completed	O
the	O
trial	O
(	O
mean	O
?	O
SD	O
AHI	O
59.8	O
?	O
28.6	O
events/h	O
;	O
CPAP	O
11.1	O
?	O
3.2	O
cmH	O
(	O
2	O
)	O
O	O
;	O
BMI	O
37.7	O
?	O
5.0	O
kg/m	O
(	O
2	O
)	O
)	O
.	O

During	O
auto-PAP	O
,	O
the	O
median	O
95th	O
percentile	O
pressure	O
delivered	O
with	O
all	O
masks	O
was	O
within	O
0.5	O
cmH	O
(	O
2	O
)	O
O	O
(	O
p	O
>	O
0.05	O
)	O
.	O

During	O
CPAP	O
,	O
median	O
residual	O
AHI	O
was	O
0.61	O
(	O
IQR	O
=	O
1.18	O
)	O
for	O
the	O
nasal	O
mask	O
,	O
1.70	O
(	O
IQR	O
=	O
4.04	O
)	O
for	O
oronasal	O
mask	O
1	O
,	O
and	O
2.48	O
(	O
IQR	O
=	O
3.74	O
)	O
for	O
oronasal	O
mask	O
2	O
(	O
p	O
=	O
0.03	O
)	O
.	O

The	O
95th	O
percentile	O
leak	O
was	O
lowest	O
with	O
the	O
nasal	O
mask	O
during	O
both	O
CPAP	O
and	O
auto-PAP	O
(	O
both	O
p	O
<	O
0.01	O
)	O
.	O

Differences	O
in	O
pressure	O
or	O
residual	O
disease	O
were	O
not	O
related	O
to	O
measures	O
of	O
upper	O
airway	O
shape	O
or	O
body	O
habitus	O
.	O

CONCLUSIONS	O
In	O
obese	O
OSA	O
patients	O
changing	O
from	O
a	O
nasal	O
to	O
oronasal	O
mask	O
increased	O
leak	O
and	O
residual	O
AHI	O
but	O
did	O
not	O
affect	O
the	O
therapeutic	O
pressure	O
requirement	O
.	O

The	O
findings	O
of	O
the	O
current	O
study	O
highlight	O
mask	O
leak	O
as	O
the	O
major	O
difficulty	O
in	O
the	O
use	O
of	O
oronasal	O
masks	O
.	O

Secondary	O
prevention	O
of	O
macrovascular	Physical
events	Physical
in	O
patients	O
with	O
type	O
2	O
diabetes	O
in	O
the	O
PROactive	O
Study	O
(	O
PROspective	O
pioglitAzone	O
Clinical	O
Trial	O
In	O
macroVascular	O
Events	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Patients	O
with	O
type	O
2	O
diabetes	O
are	O
at	O
high	O
risk	O
of	O
fatal	O
and	O
non-fatal	O
myocardial	Physical
infarction	Physical
and	O
stroke	Physical
.	O

There	O
is	O
indirect	O
evidence	O
that	O
agonists	O
of	O
peroxisome	O
proliferator-activated	O
receptor	O
gamma	O
(	O
PPAR	O
gamma	O
)	O
could	O
reduce	O
macrovascular	Physical
complications	Physical
.	O

Our	O
aim	O
,	O
therefore	O
,	O
was	O
to	O
ascertain	O
whether	O
pioglitazone	O
reduces	O
macrovascular	Physical
morbidity	Physical
and	O
mortality	Mortality
in	O
high-risk	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

METHODS	O
We	O
did	O
a	O
prospective	O
,	O
randomised	O
controlled	O
trial	O
in	O
5238	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
had	O
evidence	O
of	O
macrovascular	Physical
disease	Physical
.	O

We	O
recruited	O
patients	O
from	O
primary-care	O
practices	O
and	O
hospitals	O
.	O

We	O
assigned	O
patients	O
to	O
oral	O
pioglitazone	O
titrated	O
from	O
15	O
mg	O
to	O
45	O
mg	O
(	O
n=2605	O
)	O
or	O
matching	O
placebo	O
(	O
n=2633	O
)	O
,	O
to	O
be	O
taken	O
in	O
addition	O
to	O
their	O
glucose-lowering	O
drugs	O
and	O
other	O
medications	O
.	O

Our	O
primary	O
endpoint	O
was	O
the	O
composite	Mortality
of	Mortality
all-cause	Mortality
mortality	Mortality
,	O
non	Physical
fatal	Physical
myocardial	Physical
infarction	Physical
(	O
including	O
silent	Physical
myocardial	Physical
infarction	Physical
)	O
,	O
stroke	Physical
,	O
acute	Physical
coronary	Physical
syndrome	Physical
,	O
endovascular	Physical
or	Physical
surgical	Physical
intervention	Physical
in	Physical
the	Physical
coronary	Physical
or	Physical
leg	Physical
arteries	Physical
,	O
and	O
amputation	Physical
above	Physical
the	Physical
ankle	Physical
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
as	O
an	O
International	O
Standard	O
Randomised	O
Controlled	O
Trial	O
,	O
number	O
ISRCTN	O
NCT00174993	O
.	O

FINDINGS	O
Two	O
patients	O
were	O
lost	O
to	O
follow-up	O
,	O
but	O
were	O
included	O
in	O
analyses	O
.	O

The	O
average	O
time	O
of	O
observation	O
was	O
34.5	O
months	O
.	O

514	O
of	O
2605	O
patients	O
in	O
the	O
pioglitazone	O
group	O
and	O
572	O
of	O
2633	O
patients	O
in	O
the	O
placebo	O
group	O
had	O
at	O
least	O
one	O
event	O
in	O
the	O
primary	Physical
composite	Physical
endpoint	Physical
(	O
HR	O
0.90	O
,	O
95	O
%	O
CI	O
0.80-1.02	O
,	O
p=0.095	O
)	O
.	O

The	O
main	O
secondary	O
endpoint	O
was	O
the	O
composite	Mortality
of	Mortality
all-cause	Mortality
mortality	Mortality
,	Physical
non-fatal	Physical
myocardial	Physical
infarction	Physical
,	Physical
and	Physical
stroke	Physical
.	O

301	O
patients	O
in	O
the	O
pioglitazone	O
group	O
and	O
358	O
in	O
the	O
placebo	O
group	O
reached	O
this	O
endpoint	Physical
(	O
0.84	O
,	O
0.72-0.98	O
,	O
p=0.027	O
)	O
.	O

Overall	Others
safety	Others
and	O
tolerability	Others
was	O
good	O
with	O
no	O
change	O
in	O
the	O
safety	Others
profile	Others
of	O
pioglitazone	O
identified	O
.	O

6	O
%	O
(	O
149	O
of	O
2065	O
)	O
and	O
4	O
%	O
(	O
108	O
of	O
2633	O
)	O
of	O
those	O
in	O
the	O
pioglitazone	O
and	O
placebo	O
groups	O
,	O
respectively	O
,	O
were	O
admitted	O
to	O
hospital	O
with	O
heart	Physical
failure	Physical
;	O
mortality	Mortality
rates	Mortality
from	Mortality
heart	Mortality
failure	Mortality
did	O
not	O
differ	O
between	O
groups	O
.	O

INTERPRETATION	O
Pioglitazone	O
reduces	O
the	O
composite	O
of	O
all-cause	O
mortality	Mortality
,	O
non-fatal	Physical
myocardial	Physical
infarction	Physical
,	O
and	O
stroke	Physical
in	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
have	O
a	O
high	O
risk	O
of	O
macrovascular	O
events	O
.	O

Comparison	O
of	O
menopausal	O
symptoms	O
during	O
the	O
first	O
year	O
of	O
adjuvant	O
therapy	O
with	O
either	O
exemestane	O
or	O
tamoxifen	O
in	O
early	O
breast	O
cancer	O
:	O
report	O
of	O
a	O
Tamoxifen	O
Exemestane	O
Adjuvant	O
Multicenter	O
trial	O
substudy	O
.	O

PURPOSE	O
Hormonal	O
breast	O
cancer	O
treatment	O
increases	O
menopausal	Physical
symptoms	Physical
in	O
women	O
.	O

This	O
study	O
investigated	O
differences	O
between	O
the	O
symptoms	O
associated	O
with	O
either	O
adjuvant	O
tamoxifen	O
or	O
exemestane	O
.	O

PATIENTS	O
AND	O
METHODS	O
Ten	O
common	O
symptoms	O
were	O
assessed	O
by	O
self-report	O
questionnaire	O
administered	O
to	O
1,614	O
consecutive	O
patients	O
at	O
baseline	O
and	O
every	O
3	O
months	O
during	O
the	O
first	O
year	O
of	O
a	O
double-blind	O
,	O
randomized	O
trial	O
of	O
postmenopausal	O
women	O
with	O
early	O
hormone	O
receptor-positive	O
breast	O
cancer	O
.	O

Symptoms	O
were	O
categorized	O
as	O
none	O
,	O
mild	O
,	O
moderate	O
,	O
or	O
severe	O
.	O

A	O
hot	Physical
flash	Physical
score	Physical
was	O
calculated	O
at	O
each	O
time	O
point	O
.	O

Symptoms	O
were	O
analyzed	O
by	O
repeated-measures	O
analysis	O
of	O
variance	O
.	O

Each	O
time	O
period	O
was	O
tested	O
repeatedly	O
against	O
the	O
baseline	O
;	O
an	O
overall	O
P	O
value	O
was	O
assigned	O
for	O
each	O
reported	O
symptom	O
.	O

RESULTS	O
Compliance	O
was	O
excellent	O
,	O
with	O
7,286	O
questionnaires	O
analyzed	O
.	O

Baseline	O
symptom	Physical
prevalence	O
ranged	O
from	O
2	O
%	O
(	O
vaginal	O
bleeding	O
)	O
to	O
60	O
%	O
to	O
70	O
%	O
(	O
bone/muscle	Physical
aches	Physical
and	O
low	Physical
energy	Physical
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
vaginal	Physical
bleeding	Physical
,	Physical
mood	Mental
alteration	Mental
,	Physical
or	Physical
low	Physical
energy	Physical
.	O

Patients	O
receiving	O
tamoxifen	O
had	O
significantly	O
more	O
vaginal	Physical
discharge	Physical
(	O
P	O
<	O
.0001	O
)	O
.	O

Exemestane	O
patients	O
reported	O
more	O
bone/muscle	Physical
aches	Physical
(	O
P	O
<	O
.0001	O
)	O
,	O
vaginal	Physical
dryness	Physical
(	O
P	O
=	O
.0004	O
)	O
,	O
and	O
difficulty	Physical
sleeping	Physical
(	O
P	O
=	O
.03	O
)	O
.	O

In	O
both	O
groups	O
,	O
the	O
hot	Physical
flash	Physical
score	Physical
peaked	O
at	O
3	O
months	O
and	O
decreased	O
thereafter	O
.	O

At	O
12	O
months	O
,	O
patients	O
receiving	O
tamoxifen	O
had	O
a	O
significantly	O
higher	O
mean	O
hot	Physical
flash	Physical
score	Physical
(	O
P	O
=	O
.03	O
)	O
,	O
with	O
daily	O
hot	Physical
flashes	Physical
increasing	O
from	O
baseline	O
by	O
33	O
%	O
compared	O
with	O
a	O
7	O
%	O
increase	O
from	O
baseline	O
with	O
exemestane	O
.	O

CONCLUSION	O
At	O
12	O
months	O
,	O
exemestane	O
was	O
associated	O
with	O
fewer	O
hot	Physical
flashes	Physical
and	O
less	O
vaginal	Physical
discharge	Physical
than	O
tamoxifen	O
,	O
but	O
with	O
more	O
vaginal	Physical
dryness	Physical
,	O
bone/muscle	Physical
aches	Physical
,	O
and	O
difficulty	Mental
sleeping	Mental
.	O

Symptoms	O
were	O
common	O
in	O
both	O
groups	O
.	O

Comparison	O
of	O
regimens	O
of	O
amphotericin	O
B	O
deoxycholate	O
in	O
kala-azar	O
.	O

A	O
total	O
of	O
288	O
parasitologically	O
proved	O
patients	O
of	O
kala-azar	O
were	O
randomly	O
allocated	O
to	O
three	O
treatment	O
groups	O
.	O

Patients	O
in	O
groups	O
A	O
,	O
B	O
and	O
C	O
received	O
amphotericin	O
B	O
(	O
AMB	O
)	O
in	O
a	O
dose	O
of	O
1	O
mg/kg	O
body	O
weight	O
(	O
bw	O
)	O
/day	O
,	O
0.75	O
mg/kg	O
bw/day	O
and	O
0.5	O
mg/kg	O
bw/day	O
for	O
20	O
days	O
respectively	O
.	O

Apparent	Physical
cure	Physical
(	O
afebrile	O
at	O
the	O
end	O
of	O
therapy	O
)	O
occurred	O
in	O
all	O
patients	O
and	O
parasitological	Physical
cure	Physical
in	O
96	O
(	O
100	O
%	O
)	O
,	O
92	O
(	O
96	O
%	O
)	O
and	O
84	O
(	O
88	O
%	O
)	O
patients	O
respectively	O
in	O
groups	O
A	O
,	O
B	O
and	O
C.	O
Ultimate	Physical
cure	Physical
(	O
no	O
relapse	O
in	O
six	O
months	O
of	O
follow	O
up	O
)	O
occurred	O
in	O
95	O
(	O
99	O
%	O
)	O
,	O
87	O
(	O
91	O
%	O
)	O
and	O
79	O
(	O
82	O
%	O
)	O
patients	O
in	O
groups	O
A	O
,	O
B	O
and	O
C	O
respectively	O
.	O

The	O
difference	O
between	O
the	O
ultimate	Others
cure	Others
in	O
the	O
three	O
groups	O
was	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
incidence	O
of	O
adverse	Adverseeffect
events	Adverseeffect
(	Adverseeffect
rise	Adverseeffect
in	Adverseeffect
serum	Adverseeffect
creatinine	Adverseeffect
and	Adverseeffect
fall	Adverseeffect
in	Adverseeffect
serum	Adverseeffect
potassium	Adverseeffect
,	Adverseeffect
loss	Adverseeffect
of	Adverseeffect
appetite	Adverseeffect
and	Adverseeffect
shivering	Adverseeffect
,	O
rigor	O
and	O
fever	O
during	O
infusion	O
indicative	O
of	O
renal	O
,	O
GIT	O
and	O
infusion	O
related	O
toxicities	O
respectively	O
)	O
was	O
similar	O
in	O
the	O
three	O
groups	O
.	O

This	O
study	O
showed	O
that	O
amphotericin	O
B	O
should	O
be	O
given	O
at	O
a	O
dosage	O
of	O
1	O
mg/kg	O
bw/day	O
for	O
20	O
days	O
for	O
Indian	O
kala-azar	O
patients	O
to	O
minimise	O
relapses	Physical
and	O
prevent	O
development	Physical
of	O
drug	Others
unresponsiveness	Others
.	Physical

Effects	O
of	O
glucose-insulin-potassium	O
infusion	O
on	O
ST-elevation	Physical
myocardial	Physical
infarction	Physical
in	O
patients	O
treated	O
with	O
thrombolytic	O
therapy	O
.	O

The	O
role	O
of	O
glucose-insulin-potassium	O
(	O
GIK	O
)	O
infusion	O
in	O
the	O
management	O
of	O
acute	Physical
myocardial	Physical
infarction	Physical
is	O
not	O
well	O
established	O
.	O

This	O
prospective	O
,	O
randomized	O
study	O
comprised	O
120	O
patients	O
who	O
had	O
ST-elevation	O
myocardial	O
infarction	O
that	O
was	O
treated	O
within	O
12	O
hours	O
from	O
symptom	O
onset	O
with	O
a	O
high	O
dose	O
of	O
GIK	O
(	O
25	O
%	O
glucose	O
,	O
50	O
IU	O
of	O
soluble	O
insulin	O
per	O
liter	O
,	O
and	O
80	O
mmol	O
of	O
potassium	O
chloride	O
per	O
liter	O
at	O
1	O
ml/kg/hour	O
over	O
24	O
hours	O
)	O
as	O
adjunct	O
to	O
thrombolytic	O
therapy	O
(	O
1.5	O
MU	O
of	O
streptokinase/30	O
to	O
60	O
minutes	O
;	O
GIK	O
group	O
)	O
or	O
thrombolytic	O
therapy	O
alone	O
(	O
control	O
group	O
)	O
.	O

The	O
primary	O
end	O
point	O
of	O
the	O
study	O
was	O
the	O
rate	Physical
of	Physical
major	Physical
adverse	Physical
cardiac	Physical
events	Physical
(	Physical
MACEs	Physical
)	Physical
at	Physical
1	Physical
month	Physical
,	O
defined	O
as	O
a	Physical
composite	Physical
of	Physical
cardiac	Physical
death	Physical
,	Physical
reinfarction	Physical
,	Physical
serious	Physical
arrhythmias	Physical
(	Physical
ventricular	Physical
fibrillation	Physical
and/or	Physical
tachycardia	Physical
)	Physical
,	Physical
and	Physical
severe	Physical
heart	Physical
failure	Physical
.	O

The	O
secondary	O
end	O
points	O
were	O
the	O
rate	Physical
of	Physical
MACEs	Physical
at	Physical
1	Physical
year	Physical
and	O
improvement	O
in	O
left	Physical
ventricular	Physical
systolic	Physical
function	Physical
.	O

The	O
incidence	Physical
of	Physical
MACEs	Physical
at	Physical
1	Physical
month	Physical
was	O
significantly	O
lower	O
in	O
the	O
GIK	O
group	O
(	O
10	O
%	O
vs	O
32.5	O
%	O
,	O
relative	O
risk	O
0.24	O
,	O
95	O
%	O
confidence	O
interval	O
0.09	O
to	O
0.63	O
,	O
p	O
=	O
0.0043	O
)	O
.	O

Patients	O
in	O
the	O
GIK	O
group	O
had	O
significant	O
decreases	O
in	O
ventricular	Physical
tachycardia	Physical
and/or	Physical
fibrillation	Physical
(	O
1.3	O
%	O
vs	O
15.0	O
%	O
,	O
p	O
=	O
0.003	O
)	O
and	O
severe	O
heart	Physical
failure	Physical
(	O
3	O
%	O
vs	O
12.5	O
%	O
,	O
p	O
=	O
0.031	O
)	O
.	O

The	O
rate	Physical
of	Physical
MACEs	Physical
at	Physical
1	Physical
year	Physical
was	O
also	O
significantly	O
lower	O
in	O
the	O
GIK	O
group	O
(	O
13	O
%	O
vs	O
40.0	O
%	O
,	O
relative	O
risk	O
0.22	O
,	O
95	O
%	O
confidence	O
interval	O
0.09	O
to	O
0.55	O
,	O
p	O
=	O
0.0012	O
)	O
.	O

After	O
1	O
year	O
,	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
left	Physical
ventricular	Physical
ejection	Physical
fraction	Physical
in	O
the	O
GIK	O
group	O
(	O
from	O
48	O
+/-	O
8	O
%	O
to	O
51	O
+/-	O
10	O
%	O
,	O
p	O
<	O
0.01	O
)	O
,	O
which	O
was	O
not	O
observed	O
in	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
high-dose	O
GIK	O
,	O
used	O
as	O
an	O
adjunct	O
to	O
thrombolytic	O
therapy	O
,	O
was	O
safe	Others
and	O
improved	O
clinical	Physical
outcome	Physical
at	O
1	O
month	O
.	O

The	O
beneficial	O
effect	O
of	O
GIK	O
infusion	O
was	O
maintained	O
up	O
to	O
1	O
year	O
.	O

A	O
prospective	O
,	O
randomized	O
trial	O
of	O
clear	O
liquids	O
versus	O
low-fat	O
solid	O
diet	O
as	O
the	O
initial	O
meal	O
in	O
mild	O
acute	O
pancreatitis	O
.	O

BACKGROUND	O
&	O
AIMS	O
Patients	O
recovering	O
from	O
mild	O
acute	O
pancreatitis	O
typically	O
receive	O
a	O
clear	O
liquid	O
diet	O
(	O
CLD	O
)	O
when	O
ready	O
to	O
initiate	O
oral	O
nutrition	O
.	O

Patient	O
discharge	O
then	O
depends	O
on	O
their	O
successful	O
advancement	O
to	O
solid	O
food	O
.	O

We	O
hypothesized	O
that	O
initiating	O
oral	O
nutrition	O
with	O
a	O
low-fat	O
solid	O
diet	O
(	O
LFSD	O
)	O
after	O
mild	O
pancreatitis	O
would	O
be	O
well	O
tolerated	O
and	O
would	O
result	O
in	O
a	O
shorter	O
length	Others
of	Others
hospitalization	Others
(	O
LOH	O
)	O
.	O

METHODS	O
Patients	O
with	O
mild	O
pancreatitis	O
were	O
randomized	O
to	O
a	O
CLD	O
or	O
LFSD	O
when	O
they	O
were	O
ready	O
to	O
resume	O
oral	O
nutrition	O
.	O

Decisions	O
about	O
diet	O
advancement	O
and	O
hospital	O
discharge	O
were	O
at	O
the	O
discretion	O
of	O
the	O
medical	O
team	O
,	O
without	O
input	O
from	O
study	O
team	O
members	O
.	O

Patients	O
were	O
monitored	O
daily	O
for	O
recurrence	O
of	O
pain	Pain
,	O
need	Physical
to	Physical
stop	Physical
feeding	Physical
,	Pain
post-refeeding	Physical
LOH	Physical
(	O
primary	O
end	O
point	O
)	O
,	O
and	O
for	O
28	O
days	O
post-refeeding	O
to	O
capture	O
re-admission	Others
rates	Others
.	O

RESULTS	O
We	O
randomized	O
121	O
patients	O
:	O
66	O
to	O
CLD	O
and	O
55	O
to	O
LFSD	O
.	O

The	O
number	Physical
of	Physical
patients	Physical
requiring	Physical
cessation	Physical
of	Physical
feeding	Physical
because	Pain
of	Pain
pain	Pain
or	Pain
nausea	Physical
was	O
similar	O
in	O
both	O
groups	O
(	O
6	O
%	O
for	O
CLD	O
,	O
11	O
%	O
for	O
LFSD	O
;	O
P	O
=	O
.51	O
)	O
.	O

The	O
median	Physical
LOH	Physical
after	Physical
refeeding	Physical
was	O
identical	O
in	O
both	O
groups	O
(	O
1-day	O
interquartile	O
range	O
,	O
1-2	O
;	O
P	O
=	O
.77	O
)	O
.	O

Patients	O
in	O
the	O
LFSD	O
arm	O
consumed	O
significantly	O
more	O
calories	Physical
and	Physical
grams	Physical
of	Physical
fat	Physical
than	O
those	O
in	O
the	O
CLD	O
arm	O
during	O
their	O
first	O
meal	O
and	O
on	O
study	O
day	O
1	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
28-day	Others
re-admission	Others
rates	Others
between	O
the	O
2	O
arms	O
.	O

CONCLUSIONS	O
Initiating	O
oral	O
nutrition	O
after	O
mild	Physical
acute	Physical
pancreatitis	Physical
with	O
an	O
LFSD	Physical
appeared	O
safe	O
and	O
provided	O
more	O
calories	O
than	O
a	O
CLD	O
,	O
but	O
did	O
not	O
result	O
in	O
a	O
shorter	O
LOH	Others
.	O

[	O
Prevention	O
of	O
thromboembolism	Physical
in	O
patients	O
operated	O
on	O
for	O
hip	O
prosthesis	O
]	O
.	O

The	O
latest	O
research	O
into	O
the	O
prevention	O
of	O
peri-	Physical
and	Physical
postoperative	Physical
thromboembolic	Physical
disease	Physical
has	O
found	O
orthopaedic	O
surgery	O
patients	O
to	O
be	O
most	O
at	O
risk	O
.	O

As	O
the	O
genesis	O
of	O
deep	O
venous	O
thrombosis	O
(	O
DVT	O
)	O
is	O
due	O
to	O
haemodynamic	O
,	O
hemorheologic	O
and	O
parietal	O
factors	O
,	O
various	O
prophylactic	O
measures	O
have	O
been	O
considered	O
in	O
the	O
past	O
,	O
measures	O
which	O
have	O
not	O
proved	O
able	O
to	O
provide	O
satisfactory	O
protection	O
in	O
orthopaedics	O
.	O

The	O
results	O
obtained	O
with	O
Defibrotide	O
in	O
a	O
random	O
and	O
controlled	O
clinical	O
study	O
versus	O
calcium	O
heparin	O
involving	O
211	O
patients	O
of	O
both	O
sexes	O
candidates	O
to	O
receive	O
total	O
hip	O
arthroplasty	O
and	O
presenting	O
at	O
least	O
one	O
major	O
thromboembolic	O
risk	O
factor	O
are	O
reported	O
.	O

The	O
patients	O
were	O
assigned	O
at	O
random	O
to	O
one	O
of	O
the	O
following	O
treatments	O
:	O
1	O
)	O
Defibrotide	O
at	O
a	O
dose	O
of	O
400	O
mg	O
b.i.d	O
.	O

i.v	O
.	O

in	O
50	O
ml	O
phleboclysis	O
in	O
5	O
minutes	O
(	O
n	O
=	O
108	O
)	O
;	O
2	O
)	O
calcium	O
heparin	O
at	O
a	O
dose	O
of	O
5000	O
IU	O
t.i.d	O
.	O

subcutaneously	O
(	O
n	O
=	O
103	O
)	O
.	O

The	O
treatment	O
began	O
the	O
day	O
before	O
operation	O
and	O
continued	O
on	O
average	O
up	O
to	O
the	O
eighth	O
day	O
for	O
the	O
Defibrotide	O
group	O
.	O

With	O
the	O
control	O
group	O
it	O
continued	O
until	O
discharge	O
(	O
usually	O
on	O
the	O
15th	O
day	O
)	O
and	O
at	O
home	O
for	O
about	O
three	O
weeks	O
until	O
the	O
completion	O
of	O
the	O
physiotherapy	O
cycle	O
.	O

In	O
the	O
108	O
patients	O
treated	O
with	O
Defibrotide	O
only	O
one	O
case	O
of	O
DVT	Physical
was	O
reported	O
and	O
in	O
none	O
of	O
these	O
patients	O
were	O
symptoms	Physical
or	Physical
signs	Physical
of	Physical
pulmonary	Physical
embolism	Physical
encountered	O
.	O

In	O
the	O
group	O
treated	O
with	O
calcium	O
heparin	O
2	O
cases	O
of	O
clinically	O
and	O
radiologically	Physical
diagnosed	Physical
pulmonary	Physical
embolism	Physical
and	O
4	O
cases	Physical
of	Physical
DVT	Physical
were	O
observed	O
.	O

Although	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
,	O
the	O
tendency	O
favours	O
Defibrotide	O
.	O

Statistically	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
was	O
the	O
difference	O
in	O
postoperative	Physical
bleeding	Physical
evaluated	Physical
with	O
particular	O
attention	O
in	O
patients	O
of	O
advanced	O
age	O
.	O

Further	O
,	O
in	O
the	O
Defibrotide	O
group	O
,	O
scarring	Physical
was	O
considered	O
excellent	O
in	O
96	O
%	O
of	O
cases	O
while	O
in	O
the	O
heparin	O
group	O
scarring	Physical
was	O
excellent	O
in	O
85	O
%	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

To	O
conclude	O
,	O
the	O
sure	O
clinical	Others
effectiveness	Others
,	Others
tolerance	Others
,	Others
handiness	Others
and	Others
lack	Others
of	Others
interference	Others
with	Others
clotting	Others
functions	Others
make	O
Defibrotide	O
a	O
really	O
useful	O
drug	O
for	O
the	O
prevention	O
of	O
thromboembolic	Physical
episodes	O
in	O
patients	O
undergoing	O
major	O
orthopaedic	O
surgery	O
.	O

Tumor	Physical
budding	Physical
is	O
an	O
independent	O
predictor	O
of	O
outcome	O
in	O
AJCC/UICC	O
stage	O
II	O
colorectal	O
cancer	O
.	O

BACKGROUND	O
In	O
colorectal	O
cancer	O
,	O
the	O
morphology	O
of	O
the	O
invasive	O
tumor	O
margin	O
may	O
reflect	O
aggressiveness	O
of	O
tumor	O
growth	O
,	O
thus	O
providing	O
important	O
prognostic	O
information	O
.	O

The	O
tumor	O
growth	O
pattern	O
according	O
to	O
Jass	O
and	O
the	O
extent	O
of	O
tumor	O
budding	O
were	O
analyzed	O
in	O
patients	O
with	O
American	O
Joint	O
Committee	O
on	O
Cancer/Union	O
for	O
International	O
Cancer	O
Control	O
(	O
AJCC/UICC	O
)	O
stage	O
II	O
disease	O
.	O

METHODS	O
Tumors	O
of	O
120	O
randomly	O
selected	O
patients	O
with	O
AJCC/UICC	O
stage	O
II	O
disease	O
were	O
retrospectively	O
reviewed	O
for	O
tumor	O
growth	O
pattern	O
(	O
expanding	O
vs.	O
infiltrating	O
)	O
and	O
the	O
extent	O
of	O
tumor	O
budding	O
,	O
with	O
high-grade	O
budding	O
reflecting	O
presence	O
of	O
10	O
or	O
more	O
budding	O
foci	O
scattered	O
at	O
the	O
invasive	O
tumor	O
margin	O
.	O

Progression-free	Mortality
and	Others
cancer-specific	Mortality
survivals	Mortality
were	O
determined	O
by	O
the	O
Kaplan-Meier	O
method	O
.	O

For	O
multivariable	O
analysis	O
,	O
Cox	O
's	O
proportional	O
hazards	O
regression	O
models	O
were	O
performed	O
.	O

RESULTS	O
The	O
infiltrating	O
growth	O
pattern	O
was	O
significantly	O
associated	O
with	O
histological	O
subtype	O
and	O
lymphovascular	O
invasion	O
,	O
while	O
high-grade	O
budding	O
was	O
significantly	O
associated	O
with	O
tumor	Physical
grade	Physical
and	O
lymphovascular	Physical
invasion	Physical
.	O

High-grade	O
budding	O
,	O
but	O
not	O
the	O
infiltrating	O
growth	O
pattern	O
,	O
was	O
significantly	O
associated	O
with	O
outcome	O
in	O
univariable	O
analysis	O
.	O

Cox	O
's	O
proportional	O
hazards	O
regression	O
models	O
proved	O
tumor	O
budding	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
disease	Physical
progression	Physical
(	O
hazard	O
ratio	O
3.91	O
,	O
95	O
%	O
confidence	O
interval	O
1.3-11.77	O
;	O
P	O
=	O
0.02	O
)	O
and	O
cancer-related	O
death	O
(	O
hazard	O
ratio	O
5.90	O
,	O
95	O
%	O
confidence	O
interval	O
1.62-21.51	O
;	O
P	O
=	O
0.007	O
)	O
.	O

The	O
combination	O
of	O
infiltrating	O
growth	O
pattern	O
and	O
high-grade	O
budding	O
did	O
not	O
have	O
a	O
stronger	O
prognostic	O
significance	O
than	O
tumor	O
budding	O
alone	O
.	O

CONCLUSIONS	O
Tumor	O
budding	O
independently	O
predicted	O
patient	O
outcome	O
in	O
patients	O
with	O
AJCC/UICC	O
stage	O
II	O
colorectal	O
cancer	O
and	O
may	O
therefore	O
be	O
used	O
for	O
accurate	O
prognostication	O
,	O
patient	O
counseling	O
,	O
and	O
design	O
of	O
clinical	O
trials	O
by	O
using	O
integrated	O
multimodal	O
therapy	O
.	O

2-Chloroprocaine	O
antagonism	O
of	O
epidural	O
morphine	O
analgesia	O
.	O

BACKGROUND	O
2-Chloroprocaine	O
(	O
2-CP	O
)	O
used	O
for	O
lumbar	O
epidural	O
anesthesia	O
(	O
LEA	O
)	O
reportedly	O
decreases	O
the	O
efficacy	O
of	O
epidural	O
morphine	O
(	O
EM	O
)	O
administered	O
for	O
post-cesarean	O
section	O
(	O
CS	O
)	O
analgesia	O
.	O

The	O
amount	O
of	O
supplemental	O
i.v	O
.	O

morphine	O
self-administered	O
by	O
the	O
patient	O
via	O
the	O
patient-controlled	O
analgesia	O
device	O
(	O
PCA	O
)	O
is	O
used	O
to	O
study	O
the	O
interaction	O
between	O
EM	O
and	O
2-CP	O
.	O

METHODS	O
Forty-two	O
patients	O
scheduled	O
for	O
elective	O
CS	O
were	O
randomly	O
divided	O
into	O
3	O
equal	O
groups	O
,	O
and	O
received	O
2-CP	O
,	O
2-CP	O
+	O
epinephrine	O
(	O
Epi	O
,	O
5	O
micrograms.ml-1	O
)	O
or	O
2	O
%	O
lidocaine	O
(	O
Lido	O
)	O
with	O
Epi	O
for	O
LEA	O
.	O

All	O
patients	O
received	O
5	O
mg	O
EM	O
and	O
i.v	O
.	O

PCA	O
morphine	O
for	O
postoperative	O
pain	O
.	O

Cumulative	Others
amount	Others
of	Others
i.v	Others
.	Others

morphine	Others
used	Others
in	Others
the	Others
first	Others
24	Others
hours	Others
as	O
well	O
as	O
the	O
amount	Others
of	Others
the	Others
drug	Others
used	Others
during	Others
each	Others
2-h	Others
period	Others
were	O
noted	O
.	O

Nonparametric	O
analysis	O
of	O
variance	O
and	O
Chi-squared	O
analysis	O
were	O
used	O
for	O
statistical	O
comparisons	O
.	O

RESULTS	O
The	O
mean	Others
cumulative	Others
24-h	Others
i.v	Others
.	Others

PCA	Others
morphine	Others
requirement	Others
in	O
the	O
2-CP	O
,	O
2-CP+Epi	O
and	O
Lido+Epi	O
groups	O
respectively	O
was	O
20.5	O
+/-	O
24	O
,	O
33.1.5	O
+/-	O
27	O
and	O
4.07	O
+/-	O
(	O
mean	O
+/-	O
SD	O
)	O
.	O

The	O
Lido	O
+	O
Epi	O
group	O
used	O
significantly	O
less	Others
morphine	Others
(	O
P	O
=	O
0.01	O
)	O
compared	O
to	O
either	O
of	O
the	O
2-CP	O
groups	O
with	O
no	O
significant	O
difference	O
between	O
the	O
2-CP	O
groups	O
.	O

The	O
maximum	Others
i.v	Others
.	Others

PCA	Others
morphine	Others
use	Others
occurred	O
in	O
the	O
first	O
4	O
hours	O
following	O
surgery	O
in	O
all	O
three	O
groups	O
.	O

CONCLUSION	O
Analgesic	Others
efficacy	Others
of	O
EM	O
is	O
decreased	O
when	O
2-CP	O
is	O
used	O
for	O
LEA	O
compared	O
to	O
when	O
Lido	O
+	O
Epi	O
is	O
used	O
.	O

Impact	O
of	O
a	O
leptin	O
single	O
nucleotide	O
polymorphism	O
and	O
zilpaterol	O
hydrochloride	O
on	O
growth	O
and	O
carcass	O
characteristics	O
in	O
finishing	O
steers	O
.	O

A	O
total	O
of	O
4,178	O
steers	O
(	O
mean	O
initial	O
BW	O
=	O
403.9	O
?	O
16.04	O
kg	O
)	O
were	O
used	O
to	O
test	O
the	O
interactive	O
effects	O
,	O
if	O
any	O
,	O
of	O
leptin	O
R25C	O
genotypes	O
(	O
CC	O
,	O
CT	O
,	O
or	O
TT	O
)	O
and	O
zilpaterol	O
hydrochloride	O
(	O
ZH	O
)	O
feeding	O
duration	O
on	O
growth	O
performance	O
and	O
carcass	O
traits	O
.	O

Steers	O
were	O
blocked	O
by	O
arrival	O
at	O
the	O
feed	O
yard	O
,	O
genotyped	O
for	O
the	O
leptin	O
SNP	O
,	O
allotted	O
to	O
genotype-specific	O
pens	O
(	O
90	O
steers/pen	O
)	O
,	O
and	O
assigned	O
randomly	O
within	O
genotype	O
and	O
block	O
to	O
0	O
or	O
21	O
d	O
of	O
dietary	O
ZH	O
.	O

All	O
pens	O
within	O
a	O
block	O
were	O
slaughtered	O
on	O
the	O
same	O
day	O
(	O
132.1	O
?	O
10.9	O
d	O
on	O
feed	O
)	O
.	O

Final	O
BW	O
of	O
steers	O
fed	O
ZH	O
was	O
6.0	O
kg	O
heavier	O
(	O
P	O
=	O
0.008	O
)	O
,	O
and	O
ZH-fed	O
steers	O
had	O
greater	O
(	O
P	O
=	O
0.003	O
)	O
ADG	O
than	O
steers	O
not	O
fed	O
ZH	O
.	O

Feeding	O
ZH	O
decreased	O
DMI	O
in	O
steers	O
with	O
increased	O
frequency	O
of	O
the	O
T	O
allele	O
(	O
9.67	O
,	O
9.53	O
,	O
and	O
9.28	O
kg/d	O
for	O
CC	O
,	O
CT	O
,	O
and	O
TT	O
,	O
respectively	O
)	O
,	O
but	O
DMI	O
increased	O
with	O
the	O
frequency	O
of	O
the	O
T	O
allele	O
(	O
9.68	O
,	O
9.90	O
,	O
and	O
10.1	O
kg	O
for	O
CC	O
,	O
CT	O
,	O
and	O
TT	O
,	O
respectively	O
)	O
when	O
ZH	O
was	O
not	O
fed	O
(	O
leptin	O
genotype	O
?	O
ZH	O
,	O
P	O
=	O
0.011	O
)	O
.	O

At	O
the	O
conclusion	O
of	O
the	O
study	O
,	O
ultrasonic	Physical
fat	Physical
was	O
greatest	O
for	O
TT	O
steers	O
(	O
11.4	O
?	O
0.28	O
mm	O
)	O
and	O
least	O
(	O
P	O
=	O
0.003	O
)	O
for	O
CC	O
steers	O
(	O
11.0	O
?	O
0.25	O
mm	O
)	O
.	O

Regardless	O
of	O
ZH-feeding	O
duration	O
,	O
TT	O
steers	O
produced	O
a	O
greater	O
(	O
P	O
=	O
0.006	O
)	O
percentage	O
of	O
USDA	O
yield	O
grade	O
(	O
YG	O
)	O
4	O
or	O
higher	O
carcasses	O
(	O
5.4	O
vs.	O
2.7	O
%	O
)	O
and	O
a	O
lesser	O
(	O
P	O
=	O
0.006	O
)	O
percentage	O
of	O
YG	O
1	O
carcasses	O
(	O
17.7	O
vs.	O
26.8	O
%	O
)	O
than	O
CC	O
steers	O
.	O

In	O
addition	O
,	O
ZH-fed	O
steers	O
produced	O
a	O
greater	O
(	O
P	O
<	O
0.001	O
)	O
percentage	O
of	O
USDA	O
YG	O
1	O
carcasses	O
(	O
25.9	O
vs.	O
16.2	O
%	O
)	O
and	O
a	O
lesser	O
(	O
P	O
<	O
0.001	O
)	O
percentage	O
of	O
YG	O
4	O
or	O
higher	O
carcasses	O
(	O
1.6	O
vs.	O
6.0	O
%	O
)	O
than	O
steers	O
fed	O
the	O
control	O
diet	O
.	O

Marbling	O
scores	O
and	O
the	O
percentage	O
of	O
carcasses	O
grading	O
USDA	O
Choice	O
and	O
Prime	O
were	O
greater	O
in	O
TT	O
than	O
CC	O
steers	O
when	O
fed	O
diets	O
devoid	O
of	O
ZH	O
,	O
but	O
both	O
marbling	O
and	O
quality	O
grades	O
did	O
not	O
differ	O
among	O
leptin	O
genotypes	O
when	O
fed	O
ZH	O
for	O
21	O
d	O
(	O
leptin	O
genotype	O
?	O
ZH	O
,	O
P	O
?	O
0.03	O
)	O
.	O

The	O
amount	O
of	O
HCW	O
gain	O
tended	O
to	O
be	O
less	O
(	O
P	O
=	O
0.095	O
)	O
for	O
steers	O
of	O
the	O
TT	O
genotype	O
(	O
12.7	O
kg	O
)	O
than	O
either	O
CC	O
(	O
16.3	O
kg	O
)	O
or	O
CT	O
(	O
17.0	O
kg	O
)	O
genotypes	O
.	O

Results	O
indicated	O
that	O
leptin	O
R25C	O
genotype	O
impacted	O
most	O
traits	O
associated	O
with	O
fatness	O
whereas	O
feeding	O
ZH	O
for	O
21	O
d	O
affected	O
HCW	O
and	O
ADG	O
positively	O
but	O
impacted	O
feed	O
intake	O
,	O
marbling	O
,	O
and	O
USDA	O
quality	O
grades	O
negatively	O
.	O

Bacterial	O
ribosomal	O
immunostimulants	O
prime	O
alveolar	O
macrophages	O
in	O
vivo	O
to	O
produce	O
interleukin	O
1	O
in	O
vitro	O
.	O

Alveolar	O
macrophages	O
(	O
AMs	O
)	O
may	O
play	O
a	O
key	O
role	O
in	O
human	O
respiratory	O
immune	O
defenses	O
,	O
partially	O
by	O
synthesizing	O
and	O
releasing	O
interleukin	O
1	O
(	O
IL	O
=	O
1	O
)	O
.	O

D53	O
(	O
Ribomunyl	O
)	O
,	O
a	O
composite	O
bacterial	O
ribosomal	O
immunostimulant	O
,	O
has	O
been	O
recognized	O
as	O
an	O
efficient	O
prevention	O
of	O
respiratory	Physical
tract	Physical
infections	Physical
.	O

In	O
vitro	O
,	O
D53	O
enhances	O
the	O
IL-1	Physical
production	Physical
by	O
mouse	O
spleen	O
adherent	O
cells	O
.	O

A	O
thymocyte	O
proliferative	O
response	O
assay	O
was	O
used	O
to	O
evaluate	O
the	O
in	Physical
vitro	Physical
IL-1	Physical
production	Physical
by	O
AMs	O
in	O
healthy	O
subjects	O
who	O
received	O
D53	O
immunostimulant	O
.	O

Twelve	O
nonsmoking	O
healthy	O
subjects	O
took	O
part	O
in	O
a	O
prospective	O
double-blind	O
placebo	O
control	O
study	O
.	O

On	O
day	O
1	O
,	O
a	O
first	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
was	O
performed	O
to	O
assess	O
IL-1	Physical
production	Physical
by	O
unstimulated	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulated	O
AM	O
.	O

Then	O
,	O
subjects	O
were	O
randomized	O
to	O
receive	O
D53	O
(	O
n	O
=	O
6	O
)	O
or	O
its	O
placebo	O
(	O
n	O
=	O
6	O
)	O
by	O
both	O
oral	O
and	O
subcutaneous	O
injection	O
routes	O
from	O
day	O
1	O
to	O
day	O
15	O
.	O

On	O
day	O
15	O
,	O
a	O
second	O
BAL	O
was	O
done	O
and	O
AM	Physical
IL-1	Physical
production	Physical
was	O
again	O
tested	O
.	O

IL-1	Physical
production	Physical
on	O
day	O
15	O
did	O
not	O
significantly	O
differ	O
from	O
day	O
1	O
in	O
both	O
D53-treated	O
and	O
placebo	O
groups	O
either	O
when	O
AMs	O
were	O
unstimulated	O
or	O
were	O
stimulated	O
with	O
concentrations	O
of	O
LPS	O
resulting	O
in	O
maximal	O
IL-1	Physical
production	Physical
.	O

However	O
,	O
in	O
the	O
D53-treated	O
group	O
,	O
but	O
not	O
in	O
the	O
placebo	O
group	O
,	O
IL-1	Physical
production	Physical
induced	O
by	O
low	O
LPS	Physical
concentration	Physical
(	O
5	O
mg/L	O
)	O
was	O
significantly	O
higher	O
(	O
mean	O
+/-	O
SEM	O
:	O
1,238	O
+/-	O
287	O
U/10	O
(	O
6	O
)	O
AM	O
)	O
on	O
day	O
15	O
in	O
comparison	O
with	O
day	O
1	O
(	O
577	O
+/-	O
113	O
U/10	O
(	O
6	O
)	O
AM	O
;	O
p	O
less	O
than	O
0.05	O
,	O
Wilcoxon	O
W	O
test	O
)	O
and	O
in	O
comparison	O
with	O
the	O
control	O
group	O
(	O
day	O
15	O
IL-1	Physical
production	O
induced	O
by	O
5	O
mg/L	O
LPS	O
,	O
758	O
+/-	O
175	O
U/10	O
(	O
6	O
)	O
AM	O
;	O
p	O
less	O
than	O
0.05	O
,	O
Mann-Whitney	O
U	O
test	O
)	O
.	O

Moreover	O
,	O
in	O
the	O
D53-treated	O
group	O
,	O
the	O
optimal	Physical
LPS	Physical
concentration	Physical
(	O
ie	O
,	O
LPS	O
concentration	O
that	O
induced	O
maximal	O
IL-1	O
production	O
)	O
was	O
significantly	O
lower	O
on	O
day	O
15	O
(	O
mean	O
+/-	O
SD	O
:	O
11	O
+/-	O
7	O
mg/L	O
)	O
than	O
on	O
day	O
1	O
(	O
16	O
+/-	O
7	O
mg/L	O
;	O
p	O
less	O
than	O
0.05	O
Wilcoxon	O
W	O
test	O
)	O
.	O

We	O
conclude	O
that	O
D53	O
immunostimulant	O
in	O
vivo	O
primes	O
AM	O
to	O
produce	O
IL-1	Physical
following	O
low	Physical
LPS	Physical
concentration	Physical
stimulation	O
.	O

This	O
may	O
partially	O
explain	O
the	O
protective	O
effect	O
of	O
D53	O
immunostimulant	O
against	O
respiratory	Physical
tract	Physical
infection	Physical
.	O

[	O
Intravenous	O
treatment	O
of	O
postpartum	O
anemia	O
with	O
trivalent	O
ferrum	O
preparation	O
]	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
To	O
assess	O
the	O
effectivity	Others
and	O
safeness	Others
of	O
intravenous	O
treatment	O
of	O
pospartal	O
anemia	O
with	O
trivalent	O
ferrum	O
preparation	O
.	O

TYPE	O
OF	O
THE	O
STUDY	O
Prospective	O
randomized	O
study	O
.	O

SETTING	O
Department	O
of	O
Obstetric	O
and	O
Gynecology	O
2nd	O
Medical	O
Faculty	O
Charles	O
University	O
and	O
Teaching	O
Hospital	O
Motol	O
,	O
Prague	O
,	O
and	O
Department	O
of	O
Obstetric	O
and	O
Gynecology	O
1st	O
Medical	O
Faculty	O
and	O
Teaching	O
Hospital	O
Bulovka	O
,	O
Prague	O
.	O

METHODS	O
500	O
mg	O
of	O
sacharose	O
ferric	O
oxide	O
(	O
Venofer	O
)	O
was	O
intravenously	O
administered	O
in	O
two	O
days	O
regimen	O
to	O
50	O
women	O
with	O
clinical	O
and	O
lab	O
signs	O
of	O
postpartal	O
anemia	O
.	O

The	O
effect	O
of	O
administered	O
drug	O
was	O
determined	O
by	O
comparsion	Physical
of	Physical
values	Physical
of	Physical
red	Physical
blood	Physical
count	Physical
recovered	O
before	O
the	O
treatment	O
,	O
2nd	O
or	O
3rd	O
day	O
post	O
administration	O
and	O
two	O
weeks	O
later	O
.	O

The	O
serum	Physical
values	Physical
of	Physical
soluble	Physical
transferrin	Physical
receptors	Physical
and	Physical
ferritin	Physical
were	O
observed	O
as	O
markers	Physical
of	Physical
iron	Physical
cell	Physical
saturation	Physical
and	O
body	Physical
iron	Physical
reserves	Physical
,	O
too	O
.	O

Integral	O
part	O
of	O
the	O
study	O
was	O
the	O
monitoring	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
during	O
the	O
treatment	O
.	O

RESULTS	O
Venofer	O
came	O
in	O
sight	O
as	O
effective	Others
drug	O
in	O
the	O
treatment	O
of	O
pospartal	Physical
anemia	Physical
and	O
could	O
become	O
as	O
the	O
alternative	O
to	O
blood	O
transfusion	O
in	O
mid-severe	O
cases	O
.	O

It	O
should	O
be	O
emphasized	O
that	O
we	O
have	O
not	O
encountered	O
any	O
serious	Adverseeffect
adverse	Adverseeffect
event	Adverseeffect
with	O
intravenous	O
trivalent	O
saccharose	O
ferric	O
oxide	O
treatment	O
.	O

Pilot	O
study	O
of	O
imiquimod	O
5	O
%	O
cream	O
as	O
adjunctive	O
therapy	O
to	O
curettage	O
and	O
electrodesiccation	O
for	O
nodular	O
basal	O
cell	O
carcinoma	O
.	O

BACKGROUND	O
Curettage	O
and	O
electrodesiccation	O
(	O
C	O
&	O
D	O
)	O
is	O
a	O
widely	O
used	O
method	O
to	O
treat	O
nodular	O
basal	O
cell	O
carcinoma	O
(	O
BCC	O
)	O
.	O

However	O
,	O
residual	O
tumor	O
is	O
present	O
immediately	O
after	O
the	O
procedure	O
in	O
approximately	O
20	O
to	O
40	O
%	O
of	O
cases	O
.	O

Imiquimod	O
,	O
a	O
topical	O
immune	O
response	O
modifier	O
that	O
targets	O
Toll-like	O
receptor	O
7	O
,	O
is	O
currently	O
approved	O
for	O
superficial	O
BCC	O
.	O

OBJECTIVE	O
In	O
a	O
double-blind	O
,	O
vehicle-controlled	O
study	O
,	O
the	O
administration	O
of	O
imiquimod	O
after	O
C	O
&	O
D	O
was	O
investigated	O
to	O
determine	O
if	O
the	O
combination	O
regimen	O
would	O
reduce	O
the	O
frequency	O
of	O
residual	O
tumor	O
compared	O
with	O
C	O
&	O
D	O
alone	O
in	O
patients	O
with	O
nodular	O
BCC	O
.	O

METHODS	O
Twenty	O
patients	O
received	O
three	O
cycles	O
of	O
C	O
&	O
D	O
followed	O
by	O
imiquimod	O
5	O
%	O
or	O
vehicle	O
cream	O
once	O
daily	O
for	O
1	O
month	O
as	O
adjunctive	O
therapy	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
frequency	O
of	O
residual	O
tumor	O
.	O

The	O
secondary	O
end	O
points	O
included	O
the	O
time	O
to	O
heal	O
and	O
cosmetic	O
appearance	O
.	O

RESULTS	O
Twenty	O
patients	O
were	O
randomized	O
to	O
the	O
imiquimod	O
(	O
n	O
=	O
10	O
)	O
or	O
vehicle	O
(	O
n	O
=	O
10	O
)	O
treatment	O
group	O
.	O

At	O
8	O
weeks	O
,	O
the	O
proportion	Physical
of	Physical
patients	Physical
with	Physical
residual	Physical
tumor	Physical
was	O
substantially	O
decreased	O
with	O
imiquimod	O
therapy	O
(	O
10	O
%	O
)	O
compared	O
with	O
vehicle	O
(	O
40	O
%	O
)	O
.	O

Wounds	O
in	O
the	O
vehicle	O
group	O
healed	O
more	O
quickly	O
than	O
those	O
in	O
the	O
imiquimod	O
group	O
,	O
although	O
by	O
8	O
weeks	O
,	O
all	O
excision	O
sites	O
were	O
healed	O
.	O

The	O
majority	O
of	O
scars	O
in	O
the	O
control	O
group	O
were	O
atrophic	O
and	O
hypopigmented	O
,	O
whereas	O
most	O
scars	O
in	O
the	O
imiquimod	O
group	O
were	O
flat	O
and	O
slightly	O
pink	O
.	O

CONCLUSION	O
Imiquimod	O
5	O
%	O
cream	O
once	O
daily	O
for	O
1	O
month	O
as	O
adjunctive	O
therapy	O
after	O
C	O
&	O
D	O
substantially	O
reduced	O
the	O
frequency	O
of	O
residual	O
tumor	O
and	O
improved	O
the	O
cosmetic	O
appearance	O
compared	O
with	O
C	O
&	O
D	O
alone	O
.	O

These	O
preliminary	O
results	O
suggest	O
that	O
further	O
studies	O
to	O
investigate	O
imiquimod	O
adjunctive	O
therapy	O
are	O
warranted	O
.	O

Spotty	O
calcification	O
as	O
a	O
marker	O
of	O
accelerated	O
progression	Physical
of	Physical
coronary	Physical
atherosclerosis	Physical
:	O
insights	O
from	O
serial	O
intravascular	O
ultrasound	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
atheroma	Physical
progression	Physical
in	O
patients	O
with	O
spotty	O
calcification	O
.	O

BACKGROUND	O
Although	O
extensively	O
calcified	O
atherosclerotic	O
lesions	O
have	O
been	O
proposed	O
to	O
be	O
clinically	O
quiescent	O
,	O
the	O
presence	O
of	O
spotty	O
calcification	O
within	O
plaque	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
ischemic	O
cardiovascular	O
events	O
.	O

The	O
relationship	O
between	O
spotty	O
calcification	O
and	O
disease	Physical
progression	Physical
has	O
not	O
been	O
investigated	O
.	O

METHODS	O
A	O
total	O
of	O
1,347	O
stable	O
patients	O
with	O
angiographic	O
coronary	O
artery	O
disease	O
underwent	O
serial	O
evaluation	O
of	O
atheroma	Physical
burden	Physical
with	O
intravascular	O
ultrasound	O
imaging	O
.	O

Patients	O
with	O
spotty	O
calcification	O
were	O
identified	O
based	O
on	O
the	O
presence	O
of	O
lesions	O
(	O
1	O
to	O
4	O
mm	O
in	O
length	O
)	O
containing	O
an	O
arc	O
of	O
calcification	O
of	O
<	O
90?	O
.	O

Clinical	O
characteristics	O
and	O
disease	O
progression	O
were	O
compared	O
between	O
patients	O
with	O
spotty	O
calcification	O
(	O
n	O
=	O
922	O
)	O
and	O
those	O
with	O
no	O
calcification	O
(	O
n	O
=	O
425	O
)	O
.	O

RESULTS	O
Patients	O
with	O
spotty	O
calcification	O
were	O
older	O
(	O
age	O
56	O
years	O
vs.	O
54	O
years	O
;	O
p	O
=	O
0.001	O
)	O
,	O
more	O
likely	O
to	O
be	O
male	O
(	O
68	O
%	O
vs.	O
54	O
%	O
;	O
p	O
=	O
0.01	O
)	O
,	O
and	O
have	O
a	O
history	O
of	O
diabetes	O
mellitus	O
(	O
30	O
%	O
vs.	O
24	O
%	O
;	O
p	O
=	O
0.01	O
)	O
and	O
myocardial	O
infarction	O
(	O
28	O
%	O
vs.	O
20	O
%	O
;	O
p	O
=	O
0.004	O
)	O
,	O
and	O
have	O
lower	O
on-treatment	O
high-density	O
lipoprotein	O
cholesterol	O
levels	O
(	O
48	O
?	O
16	O
mg/dl	O
vs.	O
51	O
?	O
17	O
mg/dl	O
;	O
p	O
=	O
0.001	O
)	O
.	O

Patients	O
with	O
spotty	O
calcification	O
demonstrated	O
a	O
greater	O
percent	O
atheroma	O
volume	O
(	O
PAV	O
)	O
(	O
36.0	O
?	O
7.6	O
%	O
vs.	O
29.0	O
?	O
8.5	O
%	O
;	O
p	O
<	O
0.001	O
)	O
and	O
total	O
atheroma	O
volume	O
(	O
174.6	O
?	O
71.9	O
mm	O
(	O
3	O
)	O
vs.	O
133.9	O
?	O
64.9	O
mm	O
(	O
3	O
)	O
;	O
p	O
<	O
0.001	O
)	O
.	O

On	O
serial	O
evaluation	O
,	O
spotty	O
calcification	O
was	O
associated	O
with	O
greater	O
progression	O
of	O
PAV	O
(	O
+0.43	O
?	O
0.07	O
%	O
vs.	O
+0.02	O
?	O
0.11	O
%	O
;	O
p	O
=	O
0.002	O
)	O
.	O

Although	O
intensive	O
low-density	O
lipoprotein	O
cholesterol	O
and	O
blood	O
pressure	O
lowering	O
therapy	O
slowed	O
disease	O
progression	O
,	O
these	O
efficacies	O
were	O
attenuated	O
in	O
patients	O
with	O
spotty	O
calcification	O
.	O

CONCLUSIONS	O
The	O
presence	O
of	O
spotty	O
calcification	O
is	O
associated	O
with	O
more	O
extensive	O
and	O
diffuse	O
coronary	O
atherosclerosis	O
and	O
accelerated	O
disease	O
progression	O
despite	O
use	O
of	O
medical	O
therapies	O
.	O

Metabolic	O
responses	O
to	O
oral	O
surgery	O
under	O
local	O
anesthesia	O
and	O
sedation	O
with	O
intravenous	O
midazolam	O
:	O
the	O
effects	O
of	O
two	O
different	O
local	O
anesthetics	O
.	O

The	O
effects	O
of	O
epinephrine-free	O
and	O
epinephrine-containing	O
local	O
anesthetic	O
solutions	O
on	O
plasma	Physical
potassium	Physical
and	Physical
blood	Physical
glucose	Physical
concentrations	Physical
were	O
investigated	O
in	O
20	O
patients	O
undergoing	O
oral	O
surgery	O
with	O
intravenous	O
midazolam	O
sedation	O
.	O

Ten	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
4.4	O
mL	O
of	O
2	O
%	O
lidocaine	O
with	O
1:80,000	O
epinephrine	O
as	O
a	O
local	O
anesthetic	O
and	O
10	O
were	O
given	O
4.4	O
mL	O
of	O
3	O
%	O
prilocaine	O
with	O
0.03	O
IU/mL	O
felypressin	O
.	O

There	O
were	O
significant	O
changes	O
from	O
baseline	O
potassium	Physical
and	Physical
glucose	Physical
concentrations	Physical
both	O
within	O
and	O
between	O
treatments	O
in	O
the	O
early	O
postinjection	O
period	O
.	O

The	O
epinephrine-containing	O
local	O
anesthetic	O
significantly	O
reduced	O
the	O
plasma	Physical
potassium	Physical
concentration	Physical
10	Physical
min	Physical
after	Physical
injection	Physical
,	O
by	O
0.16	O
+/-	O
0.20	O
mmol/L	O
(	O
mean	O
+/-	O
SD	O
)	O
,	O
and	O
increased	O
the	O
blood	Physical
glucose	Physical
concentration	Physical
at	O
10	O
,	O
20	O
,	O
and	O
30	O
min	O
(	O
by	O
0.46	O
+/-	O
0.37	O
,	O
0.63	O
+/-	O
0.45	O
,	O
and	O
0.56	O
+/-	O
0.28	O
mmol/L	O
,	O
respectively	O
)	O
.	O

Conversely	O
,	O
plasma	Physical
potassium	Physical
increased	O
and	O
blood	Physical
glucose	Physical
decreased	O
10	O
,	O
20	O
,	O
and	O
30	O
min	O
following	O
the	O
administration	O
of	O
the	O
epinephrine-free	O
solution	O
.	O

At	O
30	Physical
min	Physical
potassium	Physical
was	O
increased	O
by	O
0.24	O
+/-	O
0.16	O
mmol/L	O
,	O
and	O
glucose	Physical
was	O
decreased	O
by	O
0.23	O
+/-	O
0.16	O
mmol/L	O
.	O

It	O
is	O
concluded	O
that	O
epinephrine-free	O
and	O
epinephrine-containing	O
local	O
anesthetics	O
differ	O
in	O
their	O
metabolic	O
effects	O
during	O
oral	O
surgery	O
with	O
midazolam	O
sedation	O
.	O

Comparison	O
of	O
different	O
long-term	O
asthma	O
treatments	O
in	O
subjects	O
with	O
mild-to-moderate	O
asthma	O
.	O

In	O
order	O
to	O
compare	O
the	O
efficacy	O
of	O
different	O
asthma	O
treatment	O
in	O
subjects	O
with	O
mild-to-moderate	O
asthma	O
,	O
three	O
groups	O
of	O
11	O
patients	O
were	O
treated	O
with	O
nedocromil	O
sodium	O
(	O
NS	O
)	O
,	O
beclomethasone	O
dipropionate	O
(	O
BDP	O
)	O
and	O
beclomethasone	O
dipropionate	O
plus	O
salmeterol	O
(	O
BDP	O
+	O
S	O
)	O
in	O
an	O
open	O
,	O
randomized	O
study	O
.	O

Symptom	O
score	O
,	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
maximal	O
amplitude	O
,	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
,	O
and	O
methacholine	O
reactivity	O
were	O
measured	O
at	O
the	O
baseline	O
and	O
at	O
intervals	O
of	O
3	O
months	O
up	O
to	O
12	O
months	O
.	O

After	O
3	O
months	O
,	O
symptoms	O
reduced	O
significantly	O
in	O
all	O
treatment	O
groups	O
,	O
while	O
PEF	O
variability	O
improved	O
in	O
BDP	O
and	O
BDP	O
+	O
S	O
groups	O
;	O
FEV1	O
and	O
bronchial	O
responsiveness	O
to	O
methacholine	O
were	O
significantly	O
improved	O
in	O
comparison	O
with	O
baseline	O
value	O
in	O
the	O
BDP	O
+	O
S	O
group	O
only	O
.	O

No	Others
significant	Others
difference	Others
was	O
observed	O
after	O
6	O
and	O
12	O
months	O
of	O
treatment	O
in	O
PEF	Physical
variability	Physical
,	O
FEV1	Physical
or	O
bronchial	Physical
hyperreactivity	Physical
in	O
the	O
NS	O
group	O
compared	O
with	O
baseline	O
values	O
,	O
while	O
a	O
significant	O
difference	O
was	O
observed	O
in	O
symptom	O
score	O
.	O

BDP	O
group	O
showed	O
a	O
significant	O
improvement	O
in	O
FEV1	Physical
and	Physical
bronchial	Physical
reactivity	Physical
to	O
methacholine	O
after	O
6	O
and	O
12	O
months	O
of	O
treatment	O
.	O

In	O
the	O
BDP	O
+	O
S	O
group	O
,	O
the	O
improvement	O
in	O
symptoms	Physical
and	Physical
pulmonary	Physical
function	Physical
persisted	O
until	O
the	O
end	O
of	O
the	O
study	O
.	O

In	O
conclusion	O
,	O
the	O
combination	O
of	O
beclomethasone	O
dipropionate	O
and	O
salmeterol	O
improved	O
pulmonary	Physical
function	Physical
and	O
bronchial	Physical
reactivity	Physical
earlier	O
than	O
beclomethasone	O
dipropionate	O
alone	O
,	O
while	O
nedocromil	O
sodium	O
improved	O
symptoms	O
but	O
not	O
pulmonary	O
function	O
.	O

Assuming	O
that	O
bronchial	Physical
reactivity	Physical
could	O
be	O
an	O
indirect	O
measurement	O
of	O
airway	O
inflammation	O
,	O
overtreatment	O
of	O
asthma	O
in	O
relationship	O
with	O
the	O
classification	O
of	O
asthma	O
severity	O
of	O
the	O
International	O
Guidelines	O
could	O
improve	O
both	O
airway	O
inflammation	O
and	O
the	O
prognosis	O
of	O
airway	O
obstruction	O
.	O

Effect	O
of	O
surgical	O
technique	O
in	O
subtotal	O
and	O
bilateral	O
thyroidectomy	O
on	O
risk	O
of	O
postoperative	O
parathyroid	O
insufficiency	O
development	O
--	O
our	O
experience	O
.	O

One	O
of	O
the	O
postoperative	O
complications	O
after	O
strumectomy	O
is	O
hypoparathyroidism	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
surgical	O
technique	O
on	O
the	O
development	Physical
of	Physical
parathyroid	Physical
gland	Physical
insufficiency	Physical
in	O
our	O
group	O
of	O
patients	O
.	O

Subtotal	O
,	O
bilateral	O
strumectomies	O
were	O
performed	O
according	O
to	O
Rothmund	O
's	O
suggestions	O
.	O

Randomized	O
controlled	O
trial	O
was	O
performed	O
in	O
two	O
groups	O
.	O

In	O
the	O
first	O
group	O
of	O
19	O
patients	O
,	O
main	O
trunk	O
of	O
the	O
inferior	O
thyroid	O
artery	O
was	O
ligated	O
and	O
in	O
the	O
second	O
one	O
consisting	O
of	O
18	O
patients	O
,	O
only	O
the	O
branches	O
of	O
this	O
artery	O
were	O
ligated	O
.	O

Total	Physical
calcium	Physical
and	Physical
PTH	Physical
levels	Physical
were	O
evaluated	O
pre-	O
and	O
postoperatively	O
.	O

Based	O
on	O
the	O
biochemical	O
and	O
clinical	O
data	O
,	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
development	Physical
of	Physical
postoperative	Physical
hypoparathyroidism	Physical
in	O
relation	O
to	O
performed	O
surgical	O
techniques	O
were	O
observed	O
.	O

Ipratropium	O
bromide	O
nasal	O
spray	O
for	O
treatment	O
of	O
rhinorrhea	O
in	O
the	O
laryngectomized	O
patient	O
:	O
a	O
pilot	O
study	O
.	O

Many	O
who	O
have	O
had	O
a	O
total	O
laryngectomy	O
complain	O
of	O
unrelenting	O
rhinorrhea	O
that	O
is	O
often	O
very	O
difficult	O
to	O
control	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
effect	O
of	O
ipratropium	O
bromide	O
(	O
IB	O
)	O
,	O
an	O
anticholinergic	O
nasal	O
spray	O
,	O
on	O
rhinorrhea	O
in	O
these	O
patients	O
.	O

This	O
was	O
designed	O
as	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
pilot	O
study	O
.	O

Participants	O
were	O
selected	O
if	O
they	O
had	O
a	O
total	O
laryngectomy	O
and	O
complained	O
of	O
rhinorrhea	O
.	O

They	O
were	O
asked	O
to	O
rate	O
the	O
severity	Physical
and	O
duration	Physical
of	Physical
their	Physical
rhinorrhea	Physical
each	O
day	O
throughout	O
the	O
study	O
on	O
a	O
scale	O
from	O
zero	O
to	O
six	O
.	O

Each	O
participant	O
was	O
initially	O
given	O
a	O
saline	O
nasal	O
spray	O
for	O
one	O
week	O
.	O

They	O
were	O
then	O
randomized	O
to	O
use	O
either	O
IB	O
or	O
saline	O
for	O
the	O
double-blinded	O
portion	O
of	O
the	O
study	O
.	O

Two	O
sprays	O
of	O
IB	O
at	O
a	O
dose	O
of	O
42	O
micrograms/spray	O
(	O
0.06	O
%	O
)	O
,	O
or	O
saline	O
,	O
were	O
administered	O
intranasally	O
twice	O
daily	O
for	O
two	O
weeks	O
,	O
after	O
which	O
time	O
the	O
participants	O
were	O
given	O
another	O
nasal	O
spray	O
(	O
either	O
IB	O
or	O
saline	O
)	O
for	O
the	O
crossover	O
portion	O
of	O
the	O
study	O
.	O

Six	O
patients	O
entered	O
and	O
completed	O
the	O
study	O
.	O

Those	O
patients	O
using	O
the	O
IB	O
recorded	O
a	O
mean	O
55	O
%	O
decline	Others
in	Others
severity	Others
and	O
a	O
mean	O
51	O
%	O
decline	Physical
in	Physical
duration	Physical
of	Physical
the	Physical
rhinorrhea	Physical
as	O
compared	O
to	O
placebo	O
.	O

The	O
relief	O
in	O
both	O
severity	Physical
and	Physical
duration	Physical
of	Physical
rhinorrhea	Physical
obtained	O
by	O
patients	O
was	O
analyzed	O
using	O
the	O
Wilcoxon	Others
signed-rank	Others
test	Others
and	O
found	O
to	O
be	O
highly	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Despite	O
the	O
limitations	O
of	O
a	O
small	O
sample	O
size	O
in	O
this	O
study	O
,	O
ipratropium	O
bromide	O
nasal	O
spray	O
significantly	O
reduced	O
both	O
the	O
severity	Physical
and	Physical
duration	Physical
of	Physical
rhinorrhea	Physical
in	O
laryngectomized	O
patients	O
.	O

We	O
suggest	O
ipratropium	O
nasal	O
spray	O
as	O
a	O
safe	O
,	O
effective	O
way	O
to	O
treat	O
chronic	O
rhinorrhea	O
in	O
laryngectomized	O
patients	O
,	O
improving	O
their	O
quality	Others
of	Others
life	Others
.	O

[	O
Cannulation	O
of	O
the	O
internal	O
jugular	O
vein	O
using	O
2	O
ultrasonic	O
technics	O
.	O

A	O
comparative	O
controlled	O
study	O
]	O
.	O

The	O
internal	O
jugular	O
vein	O
(	O
IJV	O
)	O
is	O
a	O
common	O
access	O
route	O
to	O
the	O
central	O
venous	O
system	O
.	O

Anatomical	O
landmarks	O
(	O
group	O
I	O
)	O
are	O
normally	O
used	O
for	O
localization	O
of	O
the	O
IJV	O
.	O

We	O
have	O
compared	O
this	O
method	O
with	O
two	O
other	O
methods	O
based	O
on	O
ultrasonic	O
waves	O
to	O
identify	O
the	O
IJV	O
and	O
the	O
carotid	O
artery	O
(	O
CA	O
)	O
(	O
even	O
in	O
atypical	O
positions	O
)	O
.	O

We	O
employed	O
an	O
ultrasound	O
Doppler	O
device	O
in	O
group	O
II	O
and	O
a	O
real-time	O
ultrasonograph	O
in	O
group	O
III	O
.	O

Central	O
venous	O
catheters	O
were	O
placed	O
into	O
the	O
right	O
IJV	O
by	O
the	O
Seldinger	O
technique	O
.	O

The	O
IJV	Physical
could	O
be	O
located	O
in	O
all	O
patients	O
with	O
both	O
ultrasound	O
methods	O
,	O
but	O
the	O
course	O
of	O
the	O
IJV	Physical
could	O
only	O
be	O
identified	O
by	O
ultrasonography	O
.	O

For	O
this	O
reason	O
,	O
the	O
direction	O
of	O
the	O
IJV	O
was	O
classified	O
as	O
typical	O
in	O
80	O
%	O
of	O
group	O
I	O
,	O
in	O
85	O
%	O
of	O
group	O
II	O
,	O
but	O
in	O
only	O
45	O
%	O
of	O
group	O
III	O
.	O

No	O
intergroup	O
differences	O
were	O
found	O
with	O
respect	O
to	O
the	O
number	Others
of	Others
punctures	Others
(	O
mean	O
value	O
1.6	O
+/-	O
0.83	O
)	O
and	O
the	O
incidence	Adverseeffect
of	Adverseeffect
complications	Adverseeffect
.	O

The	O
time	Others
required	Others
to	Others
locate	Others
the	Others
site	Others
and	O
direction	Others
of	Others
puncture	Others
increased	O
with	O
technical	O
sophistication	O
.	O

There	O
was	O
,	O
however	O
,	O
no	O
difference	O
in	O
the	O
total	Others
time	Others
for	Others
catheter	Others
placement	Others
,	O
because	O
puncture	O
was	O
performed	O
faster	O
when	O
aided	O
by	O
sonography	O
.	O

In	O
four	O
patients	O
in	O
groups	O
I	O
and	O
II	O
,	O
in	O
whom	O
attempts	O
to	O
puncture	O
the	O
IJV	O
had	O
not	O
been	O
successful	O
,	O
this	O
could	O
subsequently	O
be	O
achieved	O
with	O
ultrasonographic	O
aid	O
.	O

One	O
patient	O
(	O
group	O
I	O
)	O
displayed	O
a	O
hematoma	Adverseeffect
following	O
inadvertent	O
puncture	O
of	O
the	O
CA	O
.	O

In	O
one	O
patient	O
in	O
group	O
II	O
the	O
IJV	O
and	O
CA	O
could	O
not	O
be	O
distinguished	O
as	O
one	O
was	O
overlying	O
the	O
other	O
.	O

The	O
echocamera	O
provided	O
improved	O
localization	O
of	O
the	O
IJV	O
and	O
the	O
CA	O
in	O
comparison	O
with	O
the	O
Doppler	O
ultrasound	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Effect	O
of	O
laquinimod	O
on	O
MRI-monitored	Physical
disease	Physical
activity	Physical
in	O
patients	O
with	O
relapsing-remitting	O
multiple	O
sclerosis	O
:	O
a	O
multicentre	O
,	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
phase	O
IIb	O
study	O
.	O

BACKGROUND	O
A	O
24-week	O
phase	O
II	O
trial	O
has	O
shown	O
that	O
0.3	O
mg	O
of	O
laquinimod	O
given	O
daily	O
to	O
patients	O
with	O
relapsing-remitting	O
multiple	O
sclerosis	O
was	O
well	O
tolerated	O
and	O
reduced	O
the	O
formation	O
of	O
active	Physical
lesions	Physical
.	O

We	O
assessed	O
the	O
effect	O
of	O
oral	O
daily	O
0.3	O
and	O
0.6	O
mg	O
laquinimod	O
on	O
MRI-monitored	Physical
disease	Physical
activity	O
in	O
a	O
36-week	O
double-blind	O
,	O
placebo-controlled	O
phase	O
IIb	O
study	O
.	O

METHODS	O
The	O
study	O
was	O
done	O
in	O
51	O
centres	O
in	O
nine	O
countries	O
.	O

Inclusion	O
criteria	O
were	O
one	O
or	O
more	O
relapses	O
in	O
the	O
year	O
before	O
entry	O
and	O
at	O
least	O
one	O
gadolinium	Physical
enhancing	Physical
(	Physical
GdE	Physical
)	Physical
lesion	Physical
on	O
screening	O
MRI	O
.	O

Of	O
720	O
patients	O
screened	O
,	O
306	O
eligible	O
patients	O
were	O
enrolled	O
.	O

Patients	O
,	O
aged	O
18-50	O
years	O
,	O
were	O
randomly	O
assigned	O
to	O
placebo	O
(	O
n=102	O
)	O
,	O
laquinimod	O
0.3	O
mg	O
a	O
day	O
(	O
n=98	O
)	O
,	O
or	O
0.6	O
mg	O
a	O
day	O
(	O
n=106	O
)	O
.	O

Brain	Physical
MRI	Physical
scans	Physical
and	Physical
clinical	Physical
assessments	Physical
were	O
done	O
at	O
week	O
-4	O
,	O
baseline	O
,	O
and	O
monthly	O
from	O
week	O
12	O
to	O
week	O
36	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
cumulative	Physical
number	Physical
of	Physical
GdE	Physical
lesions	Physical
at	O
weeks	O
24	O
,	O
28	O
,	O
32	O
,	O
and	O
36	O
.	O

The	O
principal	O
analysis	O
of	O
the	O
primary	O
endpoint	O
was	O
done	O
on	O
the	O
intention-to-treat	O
cohort	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials.gov	O
,	O
number	O
NCT00349193	O
.	O

FINDINGS	O
Compared	O
with	O
placebo	O
,	O
treatment	O
with	O
laquinimod	O
0.6	O
mg	O
per	O
day	O
showed	O
a	O
40.4	O
%	O
reduction	O
of	O
the	O
baseline	O
adjusted	O
mean	O
cumulative	Physical
number	Physical
of	Physical
GdE	Physical
lesions	Physical
per	Physical
scan	Physical
on	O
the	O
last	O
four	O
scans	O
(	O
simple	O
means	O
4.2	O
[	O
SD	O
9.2	O
]	O
vs	O
2.6	O
[	O
5.3	O
]	O
,	O
p=0.0048	O
)	O
;	O
treatment	O
with	O
0.3	O
mg	O
per	O
day	O
showed	O
no	O
significant	O
effects	O
(	O
3.9	O
[	O
5.5	O
]	O
vs	O
placebo	O
,	O
p=0.6740	O
)	O
.	O

Both	O
doses	O
of	O
laquinimod	O
were	O
well	O
tolerated	O
,	O
with	O
some	O
transient	O
and	O
dose-dependent	O
increases	O
in	O
liver	Physical
enzymes	Physical
.	O

A	O
case	O
of	O
Budd-Chiari	Adverseeffect
syndrome-ie	Adverseeffect
,	O
a	O
thrombotic	Physical
venous	Physical
outflow	Physical
obstruction	Adverseeffect
of	Adverseeffect
the	Adverseeffect
liver-occurred	Adverseeffect
after	O
1	O
month	O
of	O
exposure	O
in	O
a	O
patient	O
with	O
underlying	O
hypercoagulability	O
who	O
received	O
0.6	O
mg	O
laquinimod	O
.	O

Anticoagulant	O
treatment	O
resulted	O
in	O
a	O
decline	O
of	O
liver	Physical
enzymes	Physical
to	O
normal	O
without	O
any	O
clinical	O
signs	O
of	O
hepatic	Physical
decompensation	Physical
.	O

INTERPRETATION	O
In	O
patients	O
with	O
relapsing-remitting	O
multiple	O
sclerosis	O
,	O
0.6	O
mg	O
per	O
day	O
laquinimod	O
significantly	O
reduced	O
MRI-measured	Physical
disease	Physical
activity	Physical
and	O
was	O
well	O
tolerated	O
.	O

Pharmacokinetic	O
properties	O
of	O
YM17E	O
,	O
an	O
inhibitor	O
of	O
acyl	O
coenzyme	O
A	O
:	O
cholesterol	O
acyl	O
transferase	O
,	O
and	O
serum	Physical
cholesterol	Physical
levels	Physical
in	O
healthy	O
volunteers	O
.	O

We	O
conducted	O
a	O
single	O
and	O
repeat	O
oral	O
dose	O
study	O
of	O
YM17E	O
,	O
a	O
novel	O
inhibitor	O
of	O
acyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
:	O
cholesterol	O
acyltransferase	O
,	O
in	O
healthy	O
male	O
volunteers	O
to	O
evaluate	O
the	O
pharmacokinetic	Others
profile	Others
,	Others
tolerability	Others
and	Others
effect	Others
of	Others
the	Others
drug	Others
on	Others
serum	Others
cholesterol	Others
.	Others

In	O
the	O
single	O
administration	O
study	O
,	O
YM17E	O
was	O
administered	O
after	O
a	O
meal	O
to	O
two	O
groups	O
of	O
subjects	O
(	O
each	O
containing	O
six	O
subjects	O
taking	O
the	O
drug	O
and	O
three	O
taking	O
placebo	O
)	O
receiving	O
3	O
,	O
60	O
and	O
300	O
mg	O
or	O
15	O
,	O
60	O
and	O
450	O
mg	O
YM17E	O
,	O
respectively	O
.	O

Plasma	Physical
concentrations	Physical
of	O
unchanged	O
drug	O
following	O
single	O
oral	O
administration	O
at	O
3-300	O
mg	O
after	O
a	O
meal	O
increased	O
with	O
increasing	O
dose	O
.	O

In	O
contrast	O
,	O
plasma	Physical
concentrations	Physical
after	O
administration	O
of	O
450	O
mg	O
were	O
almost	O
the	O
same	O
as	O
after	O
300	O
mg	O
.	O

Unchanged	O
YM17E	O
was	O
not	O
detected	O
in	O
urine	O
after	O
single	O
administration	O
,	O
suggesting	O
that	O
it	O
was	O
excreted	O
via	O
the	O
bile	O
or	O
urine	O
after	O
metabolism	O
.	O

Five	O
active	O
metabolites	O
(	O
M1	O
,	O
M2-a	O
,	O
M2-b	O
,	O
M3	O
and	O
M4	O
)	O
were	O
observed	O
in	O
plasma	O
at	O
concentrations	O
comparable	O
to	O
those	O
of	O
unchanged	O
YM17E	O
.	O

Their	O
plasma	Physical
concentrations	Physical
increased	O
in	O
a	O
slightly	O
greater	O
than	O
dose-dependent	O
manner	O
from	O
3	O
to	O
300	O
mg	O
.	O

The	O
effect	O
of	O
food	O
was	O
studied	O
in	O
an	O
open	O
crossover	O
design	O
with	O
a	O
1-week	O
washout	O
period	O
.	O

Twelve	O
subjects	O
received	O
150	O
mg	O
YM17E	O
in	O
both	O
the	O
fasted	O
and	O
post-prandial	O
states	O
.	O

The	O
AUC	Others
and	Others
Cmax	Others
after	O
fasting	O
were	O
closely	O
similar	O
to	O
those	O
after	O
a	O
meal	O
,	O
showing	O
that	O
bioavailability	O
was	O
not	O
affected	O
by	O
food	O
intake	O
.	O

In	O
the	O
repeated	O
oral	O
dose	O
study	O
,	O
the	O
subjects	O
received	O
test	O
drug	O
at	O
150	O
mg	O
or	O
300	O
mg	O
(	O
n	O
=	O
6	O
each	O
)	O
or	O
placebo	O
(	O
n	O
=	O
3	O
)	O
twice	O
a	O
day	O
(	O
after	O
breakfast	O
and	O
after	O
dinner	O
)	O
for	O
7	O
days	O
.	O

On	O
days	O
1	O
and	O
7	O
,	O
the	O
subjects	O
received	O
YM17E	O
once	O
a	O
day	O
(	O
after	O
breakfast	O
)	O
for	O
evaluation	O
of	O
pharmacokinetic	O
properties	O
.	O

After	O
repeated	O
oral	O
administration	O
of	O
150	O
mg	O
b.d.	O
,	O
plasma	Physical
concentrations	Physical
reached	O
steady	O
state	O
by	O
day	O
5	O
(	O
mean	O
Cmin	O
48.6	O
ng.ml-1	O
)	O
.	O

After	O
repeated	O
administration	O
of	O
300	O
mg	O
b.d.	O
,	O
plasma	Physical
concentrations	Physical
prior	O
to	O
each	O
daily	O
morning	O
dose	O
increased	O
up	O
to	O
the	O
5th	O
day	O
(	O
mean	O
Cmin	O
166.6	O
ng.ml-1	O
)	O
and	O
then	O
tended	O
to	O
decrease	O
until	O
the	O
7th	O
day	O
.	O

No	O
significant	Physical
signs	Physical
,	Physical
symptoms	Physical
or	Physical
changes	Physical
in	Physical
serum	Physical
cholesterol	Physical
levels	Physical
were	O
observed	O
during	O
the	O
single	O
and	O
repeated	O
oral	O
dose	O
studies	O
at	O
150	O
mg	O
b.d	O
.	O

Although	O
statistical	O
analysis	O
was	O
not	O
conducted	O
because	O
of	O
the	O
small	O
number	O
of	O
subjects	O
,	O
all	O
subjects	O
receiving	O
repeated	O
oral	O
administration	O
of	O
300	O
mg	O
twice	O
daily	O
showed	O
a	O
25	O
%	O
decrease	O
in	O
serum	Physical
cholesterol	Physical
level	O
on	O
day	O
7	O
,	O
but	O
also	O
the	O
simultaneous	O
occurrence	O
of	O
diarrhoea	Adverseeffect
.	O

Use	O
of	O
Interceed	O
(	O
TC7	O
)	O
absorbable	O
adhesion	O
barrier	O
to	O
reduce	O
postoperative	Physical
adhesion	Physical
reformation	Physical
in	O
infertility	O
and	O
endometriosis	O
surgery	O
.	O

The	O
Obstetrics	O
and	O
Gynecology	O
Adhesion	O
Prevention	O
Committee	O
.	O

Interceed	O
(	O
TC7	O
)	O
is	O
a	O
fabric	O
composed	O
of	O
oxidized	O
,	O
regenerated	O
cellulose	O
that	O
was	O
designed	O
to	O
reduce	O
the	O
formation	O
of	O
postsurgical	O
adhesions	O
.	O

We	O
evaluated	O
Interceed	O
(	O
TC7	O
)	O
in	O
a	O
randomized	O
,	O
multicenter	O
clinical	O
study	O
.	O

Sixty-three	O
infertility	O
patients	O
had	O
bilateral	O
pelvic	O
sidewall	O
adhesions	O
removed	O
at	O
laparotomy	O
.	O

One	O
pelvic	O
sidewall	O
was	O
covered	O
by	O
Interceed	O
(	O
TC7	O
)	O
and	O
the	O
other	O
was	O
left	O
uncovered	O
.	O

The	O
deperitonealized	O
areas	O
(	O
N	O
=	O
205	O
)	O
of	O
all	O
sidewalls	O
were	O
divided	O
into	O
three	O
groups	O
:	O
less	O
than	O
100	O
mm2	O
,	O
N	O
=	O
72	O
;	O
100-1000	O
mm2	O
,	O
N	O
=	O
95	O
;	O
and	O
more	O
than	O
1000	O
mm2	O
,	O
N	O
=	O
38	O
.	O

The	O
effectiveness	Physical
of	Physical
Interceed	Physical
(	Physical
TC7	Physical
)	Physical
was	O
evaluated	O
at	O
laparoscopy	O
10-98	O
days	O
after	O
laparotomy	O
.	O

Significantly	O
more	O
adhesions	Physical
were	O
observed	O
at	O
laparoscopy	O
on	O
the	O
control	O
pelvic	O
sidewalls	O
(	O
48	O
of	O
63	O
,	O
76	O
%	O
)	O
than	O
on	O
the	O
treated	O
sides	O
(	O
26	O
of	O
63	O
,	O
41	O
%	O
)	O
(	O
P	O
less	O
than	O
.0001	O
)	O
.	O

The	O
Interceed	Others
(	Others
TC7	Others
)	Others
-treated	Others
sidewalls	O
also	O
had	O
significantly	O
less	O
area	Physical
involved	Physical
with	Physical
adhesions	Physical
at	O
laparoscopy	O
(	O
P	O
less	O
than	O
.05	O
,	O
P	O
less	O
than	O
.001	O
,	O
and	O
P	O
less	O
than	O
.001	O
in	O
the	O
three	O
groups	O
,	O
respectively	O
)	O
.	O

Twenty-eight	O
women	O
with	O
severe	O
endometriosis	O
also	O
had	O
significantly	O
more	O
adhesions	Physical
on	O
the	O
control	O
side	O
(	O
23	O
of	O
28	O
,	O
82	O
%	O
)	O
than	O
on	O
the	O
treated	O
side	O
(	O
14	O
of	O
28	O
,	O
50	O
%	O
)	O
(	O
P	O
less	O
than	O
.05	O
)	O
.	O

We	O
conclude	O
that	O
Interceed	O
(	O
TC7	O
)	O
effectively	O
reduced	O
the	O
incidence	O
and	O
extent	O
of	O
postoperative	Physical
adhesions	Physical
,	O
even	O
in	O
patients	O
with	O
severe	O
endometriosis	O
.	O

Improved	O
frontoparietal	Physical
white	Physical
matter	Physical
integrity	Physical
in	O
overweight	O
children	O
is	O
associated	O
with	O
attendance	O
at	O
an	O
after-school	O
exercise	O
program	O
.	O

Aerobic	O
fitness	O
is	O
associated	O
with	O
white	Physical
matter	Physical
integrity	Physical
(	Physical
WMI	Physical
)	Physical
in	O
adults	O
as	O
measured	O
by	O
diffusion	Physical
tensor	Physical
imaging	Physical
(	Physical
DTI	Physical
)	Physical
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
an	O
8-month	O
exercise	O
intervention	O
on	O
WMI	Physical
in	O
children	O
.	O

Participants	O
were	O
18	O
sedentary	O
,	O
overweight	O
(	O
BMI?85th	O
percentile	O
)	O
8-	O
to	O
11-year-old	O
children	O
(	O
94	O
%	O
Black	O
)	O
,	O
randomly	O
assigned	O
to	O
either	O
an	O
aerobic	O
exercise	O
(	O
n=10	O
)	O
or	O
sedentary	O
attention	O
control	O
group	O
(	O
n=8	O
)	O
.	O

Each	O
group	O
was	O
offered	O
an	O
instructor-led	O
after-school	O
program	O
every	O
school	O
day	O
for	O
approximately	O
8	O
months	O
.	O

Before	O
and	O
after	O
the	O
program	O
,	O
all	O
subjects	O
participated	O
in	O
DTI	O
scans	O
.	O

Tractography	O
was	O
conducted	O
to	O
isolate	O
the	O
superior	O
longitudinal	O
fasciculus	O
and	O
investigate	O
whether	O
the	O
exercise	O
intervention	O
affected	O
WMI	O
in	O
this	O
region	O
.	O

There	O
was	O
no	O
group	O
by	O
time	O
interaction	O
for	O
WMI	O
in	O
the	O
superior	O
longitudinal	O
fasciculus	O
.	O

There	O
was	O
a	O
group	O
by	O
time	O
by	O
attendance	O
interaction	O
,	O
however	O
,	O
such	O
that	O
higher	O
attendance	O
at	O
the	O
exercise	O
intervention	O
,	O
but	O
not	O
the	O
control	O
intervention	O
,	O
was	O
associated	O
with	O
increased	O
WMI	O
.	O

Heart	O
rate	O
and	O
the	O
total	O
dose	O
of	O
exercise	O
correlated	O
with	O
WMI	O
changes	O
in	O
the	O
exercise	O
group	O
.	O

In	O
the	O
overall	O
sample	O
,	O
increased	O
WMI	O
was	O
associated	O
with	O
improved	O
scores	O
on	O
a	O
measure	O
of	O
attention	O
and	O
improved	O
teacher	O
ratings	O
of	O
executive	O
function	O
.	O

This	O
study	O
indicates	O
that	O
participating	O
in	O
an	O
exercise	O
intervention	O
improves	O
WMI	O
in	O
children	O
as	O
compared	O
to	O
a	O
sedentary	O
after-school	O
program	O
.	O

[	O
Effect	O
of	O
acupuncture	O
on	O
rehabilitation	O
training	O
of	O
child	O
's	O
autism	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
effect	O
of	O
acupuncture	O
on	O
rehabilitation	O
training	O
for	O
children	O
's	O
autism	O
.	O

METHODS	O
Forty	O
autistic	O
children	O
receiving	O
rehabilitation	O
training	O
were	O
divided	O
into	O
a	O
control	O
group	O
and	O
a	O
treatment	O
group	O
,	O
20	O
cases	O
in	O
each	O
group	O
.	O

The	O
control	O
group	O
received	O
rehabilitation	O
training	O
including	O
ABA	O
training	O
,	O
the	O
Conductive	O
Education	O
Approach	O
and	O
the	O
training	O
of	O
sensory	O
integration	O
,	O
about	O
90	O
sessions	O
for	O
each	O
training	O
;	O
the	O
treatment	O
group	O
received	O
acupuncture	O
treatment	O
for	O
60-90	O
sessions	O
after	O
the	O
rehabilitation	O
training	O
.	O

Their	O
results	O
were	O
detected	O
by	O
the	O
revised	Mental
Chinese	Mental
version	Mental
of	Mental
Psycho-Educational	Mental
Profile	Mental
for	Mental
autistic	Mental
and	Mental
developmentally	Mental
disabled	Mental
children	Mental
(	Mental
C-PEP	Mental
)	Mental
.	O

RESULTS	O
The	O
markedly	O
effective	Others
rate	Others
was	O
55.0	O
%	O
in	O
the	O
treatment	O
group	O
and	O
15.0	O
%	O
in	O
the	O
control	O
group	O
with	O
a	O
very	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
;	O
the	O
differences	O
before	O
and	O
after	O
training	O
in	O
some	O
projects	O
such	O
as	O
the	O
total	Mental
score	Mental
of	Mental
development	Mental
,	Mental
imitation	Mental
,	Mental
oral	Mental
cognition	Mental
in	O
the	O
treatment	O
group	O
were	O
very	O
significantly	O
different	O
from	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
Acupuncture	O
combined	O
with	O
scientific	O
and	O
effective	O
rehabilitation	O
training	O
has	O
a	O
better	O
therapeutic	Physical
effect	Physical
than	O
that	O
of	O
the	O
simple	O
rehabilitation	O
training	O
for	O
child	O
's	O
autism	O
.	O

Impact	O
of	O
disease	O
severity	O
on	O
outcome	O
of	O
antiviral	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
:	O
Lessons	O
from	O
the	O
HALT-C	O
trial	O
.	O

In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
advanced	O
fibrosis	O
and	O
cirrhosis	O
are	O
associated	O
with	O
lower	O
rates	O
of	O
sustained	Physical
virologic	Physical
response	Physical
(	Physical
SVR	Physical
)	Physical
to	O
interferon	O
(	O
IFN	O
)	O
-based	O
therapy	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
virologic	Physical
response	Physical
to	O
retreatment	O
with	O
peginterferon	O
alfa-2a	O
and	O
ribavirin	O
(	O
RBV	O
)	O
,	O
as	O
a	O
function	O
of	O
the	O
baseline	O
fibrosis	O
score	O
(	O
Ishak	O
staging	O
)	O
and	O
platelet	O
count	O
,	O
in	O
1,046	O
patients	O
enrolled	O
in	O
the	O
Hepatitis	O
C	O
Antiviral	O
Long-term	O
Treatment	O
against	O
Cirrhosis	O
(	O
HALT-C	O
)	O
Trial	O
.	O

All	O
patients	O
had	O
failed	O
prior	O
treatment	O
with	O
IFN	O
or	O
peginterferon	O
+/-	O
RBV	O
and	O
had	O
Ishak	O
fibrosis	O
scores	O
>	O
or	O
=	O
3	O
.	O

Four	O
groups	O
of	O
patients	O
with	O
increasingly	O
severe	O
liver	O
disease	O
were	O
compared	O
:	O
(	O
A	O
)	O
bridging	O
fibrosis	O
(	O
Ishak	O
3	O
and	O
4	O
)	O
with	O
platelet	O
counts	O
>	O
125,000/mm3	O
(	O
n	O
=	O
559	O
)	O
;	O
(	O
B	O
)	O
bridging	O
fibrosis	O
with	O
platelet	O
counts	O
<	O
or	O
=125,000/mm3	O
(	O
n	O
=	O
96	O
)	O
;	O
(	O
C	O
)	O
cirrhosis	O
(	O
Ishak	O
5	O
and	O
6	O
)	O
with	O
platelet	O
counts	O
>	O
125,000/mm3	O
(	O
n	O
=	O
198	O
)	O
;	O
and	O
(	O
D	O
)	O
cirrhosis	O
with	O
platelet	O
counts	O
<	O
or	O
=125,000/mm3	O
(	O
n	O
=	O
193	O
)	O
.	O

SVR	Physical
rates	Physical
were	O
23	O
%	O
,	O
17	O
%	O
,	O
10	O
%	O
,	O
and	O
9	O
%	O
in	O
groups	O
A	O
,	O
B	O
,	O
C	O
,	O
and	O
D	O
,	O
respectively	O
(	O
P	O
<	O
.0001	O
for	O
trend	O
)	O
.	O

Reduction	Physical
in	Physical
SVR	Physical
as	O
a	O
function	O
of	O
increasingly	O
severe	O
disease	O
was	O
independent	O
of	O
age	O
,	O
percent	O
African	O
American	O
,	O
HCV	O
genotype	O
,	O
HCV	O
level	O
,	O
and	O
type	O
of	O
prior	O
therapy	O
.	O

Dose	O
reduction	O
lowered	O
SVR	Physical
frequencies	Physical
,	O
but	O
to	O
a	O
lesser	O
extent	O
than	O
disease	O
severity	O
.	O

By	O
logistic	O
regression	O
,	O
cirrhosis	Physical
(	O
P	O
<	O
.0001	O
)	O
was	O
the	O
major	O
determinant	O
that	O
impaired	O
virologic	Physical
response	Physical
,	O
independent	O
of	O
dose	O
reduction	O
or	O
platelet	O
count	O
.	O

In	O
conclusion	O
,	O
disease	O
severity	O
is	O
a	O
major	O
independent	O
determinant	O
of	O
rate	Physical
of	Physical
SVR	Physical
in	O
patients	O
with	O
advanced	O
chronic	O
hepatitis	O
C.	O
New	O
strategies	O
are	O
needed	O
to	O
optimize	O
antiviral	O
therapy	O
in	O
these	O
difficult-to-cure	O
patients	O
.	O

[	O
Effectiveness	O
of	O
adjuvant	O
hormone	O
therapy	O
in	O
breast	O
cancer	O
]	O
.	O

A	O
third	O
series	O
of	O
randomized	O
tests	O
was	O
undertaken	O
to	O
evaluate	Others
the	O
efficacy	Physical
of	O
postoperative	O
adjuvant	O
hormone	O
therapy	O
(	O
tamoxifen	O
,	O
diethylstilbestrol	O
,	O
orimethen	O
amino	O
glutethymide	O
)	O
in	O
breast	O
cancer	O
patients	O
.	O

Tamoxifen	O
was	O
studied	O
in	O
176	O
patients	O
with	O
T1-2N0M0	O
tumors	O
.	O

Five-year	Mortality
recurrence-free	Mortality
survival	Mortality
was	O
registered	O
in	O
85.2	O
%	O
of	O
menopausal	O
patients	O
treated	O
with	O
tamoxifen	O
versus	O
71.1	O
%	O
in	O
control	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Five-year	Mortality
recurrence-free	Mortality
survival	Mortality
in	O
menopausal	O
females	O
with	O
breast	O
tumors	O
,	O
stage	O
IIb	O
,	O
was	O
71.1	O
%	O
among	O
those	O
treated	O
with	O
diethylstilbestrol	O
and	O
as	O
low	O
as	O
57.4	O
%	O
in	O
the	O
tamoxifen	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Untoward	Adverseeffect
side-effect	Adverseeffect
incidence	Adverseeffect
was	O
much	Physical
higher	Physical
in	O
the	O
diethylstilbestrol	O
group	O
(	O
30.4	O
%	O
)	O
as	O
compared	O
with	O
tamoxifen	O
(	O
3.5	O
%	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
for	O
the	O
relationship	O
between	O
orimethen	O
and	O
tamoxifen	O
treatment	O
with	O
respect	O
to	O
5-year	Mortality
survival	Mortality
and	Mortality
recurrence-free	Mortality
survival	Mortality
.	Mortality

Efficacy	Others
,	Others
safety	Others
,	Others
and	Others
steady-state	Others
pharmacokinetics	Others
of	O
once-a-day	O
controlled-release	O
morphine	O
(	O
MS	O
Contin	O
XL	O
)	O
in	O
cancer	O
pain	O
.	O

The	O
efficacy	Others
,	Others
safety	Others
,	Others
and	Others
pharmacokinetics	Others
of	O
a	O
novel	O
once-daily	O
morphine	O
formulation	O
(	O
OAD	O
morphine	O
)	O
and	O
a	O
12-hourly	O
formulation	O
(	O
twice-daily	O
CR	O
morphine	O
)	O
were	O
compared	O
in	O
a	O
double-blind	O
,	O
multi-centered	O
crossover	O
study	O
.	O

Chronic	O
cancer	O
pain	O
patients	O
(	O
n=25	O
)	O
were	O
randomized	O
to	O
OAD	O
morphine	O
(	O
mean	O
238	O
+/-	O
319	O
mg	O
q24h	O
)	O
or	O
twice-daily	O
CR	O
morphine	O
(	O
mean	O
119	O
+/-	O
159	O
mg	O
q12h	O
)	O
for	O
one	O
week	O
.	O

They	O
then	O
crossed	O
over	O
to	O
the	O
alternate	O
drug	O
,	O
which	O
also	O
was	O
taken	O
for	O
one	O
week	O
.	O

There	O
was	O
no	O
difference	O
between	O
treatments	O
for	O
evaluations	O
of	O
overall	Pain
pain	Pain
intensity	Pain
,	O
analgesic	Others
efficacy	Others
,	O
or	O
adverse	Adverseeffect
events	Adverseeffect
.	O

However	O
,	O
whereas	O
pain	Pain
scores	Pain
increased	O
during	O
the	O
day	O
on	O
twice-daily	O
CR	O
morphine	O
(	O
P=0.0108	O
)	O
,	O
they	O
remained	O
stable	O
on	O
OAD	O
morphine	O
.	O

Most	O
patients	O
(	O
68	O
%	O
)	O
chose	O
once-daily	O
dosing	O
for	O
continuing	O
pain	Pain
management	Pain
(	O
P=0.015	O
)	O
.	O

The	O
AUC	Others
ratio	Others
was	O
100.3	O
%	O
,	O
indicating	O
equivalent	O
absorption	O
.	O

Fluctuation	Others
indices	Others
were	O
93.5	O
+/-	O
28.8	O
%	O
and	O
179.3	O
+/-	O
41.3	O
%	O
(	O
P=0.0001	O
)	O
for	O
OAD	O
morphine	O
and	O
twice-daily	O
CR	O
morphine	O
,	O
respectively	O
.	O

OAD	O
morphine	O
provides	O
analgesia	O
similar	O
to	O
twice-daily	O
CR	O
morphine	O
with	O
reduced	O
fluctuation	Physical
in	Physical
plasma	Physical
morphine	Physical
concentration	Physical
and	O
more	O
stable	O
pain	Pain
control	Pain
.	O

[	O
Treatment	O
of	O
autism	O
children	O
:	O
observation	O
on	O
efficacy	O
of	O
behavior	O
training	O
with	O
retention	O
of	O
needles	O
on	O
head	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
effect	O
difference	O
of	O
behavior	O
training	O
with	O
head	O
needling	O
retention	O
and	O
behavior	O
training	O
after	O
acupuncture	O
for	O
autism	O
children	O
.	O

METHODS	O
Sixty	O
qualified	O
autism	O
children	O
were	O
divided	O
randomly	O
into	O
simultaneous	O
head	O
needling	O
retention	O
and	O
behavior	O
training	O
group	O
(	O
trial	O
group	O
)	O
and	O
behavior	O
training	O
after	O
acupuncture	O
treatment	O
group	O
(	O
control	O
group	O
)	O
with	O
30	O
case	O
in	O
each	O
group	O
.	O

Retention	O
needles	O
on	O
the	O
head	O
with	O
simultaneous	O
behavior	O
training	O
was	O
applied	O
for	O
the	O
trial	O
group	O
.	O

The	O
main	O
acupoints	O
included	O
Sishen	O
Xue	O
,	O
Dingshen	O
Sanxue	O
(	O
3	O
points	O
for	O
mental	O
tranquilization	O
)	O
,	O
Nao	O
Sanxue	O
(	O
3	O
points	O
for	O
the	O
function	O
of	O
brain	O
)	O
,	O
Shou	O
Zhisanxue	O
(	O
3	O
points	O
for	O
mental	O
activities	O
on	O
hand	O
)	O
and	O
Zozhi	O
Sonxue	O
(	O
3	O
points	O
for	O
mental	O
activities	O
on	O
foot	O
)	O
.	O

Other	O
points	O
were	O
combined	O
according	O
to	O
conditions	O
of	O
patients	O
.	O

Needles	O
on	O
the	O
4	O
extremities	O
were	O
withdrawn	O
first	O
after	O
30	O
minutes	O
,	O
needles	O
on	O
head	O
were	O
remained	O
during	O
behavior	O
training	O
.	O

While	O
behavior	O
training	O
was	O
applied	O
to	O
the	O
control	O
group	O
when	O
acupuncture	O
treatment	O
was	O
completely	O
accomplished	O
.	O

Treatments	O
were	O
applied	O
once	O
a	O
day	O
to	O
both	O
groups	O
.	O

And	O
3	O
months	O
was	O
taken	O
as	O
one	O
observation	O
cycle	O
.	O

Estimation	O
was	O
made	O
on	O
therapeutic	Mental
effect	Mental
and	O
developing	Mental
level	Mental
of	Mental
autism	Mental
children	Mental
with	Mental
CARS	Mental
and	Mental
PEP	Mental
.	O

RESULTS	O
The	O
total	Others
effective	Others
rate	Others
of	O
the	O
trial	O
group	O
was	O
83.3	O
%	O
(	O
25/30	O
)	O
,	O
better	O
than	O
66.7	O
%	O
(	O
20/30	O
)	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
CARS	Mental
scores	Mental
of	O
both	O
groups	O
declined	O
after	O
the	O
treatment	O
.	O

And	O
the	O
score	O
of	O
trail	O
group	O
was	O
lower	O
than	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

While	O
the	O
PEP	Mental
scores	Mental
of	O
both	O
groups	O
increased	O
,	O
and	O
the	O
score	O
of	O
trail	O
group	O
was	O
higher	O
than	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

The	O
increasing	O
level	O
of	O
scores	Mental
of	Mental
cognitive	Mental
understanding	Mental
and	Mental
cognitive	Mental
expression	Mental
were	O
all	O
better	O
than	O
the	O
control	O
group	O
(	O
all	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
The	O
effect	O
of	O
behavior	O
training	O
with	O
head	O
needle	O
retention	O
on	O
autism	O
children	O
is	O
better	O
than	O
behavior	O
training	O
after	O
acupuncture	O
treatment	O
,	O
especially	O
in	O
enhancing	Mental
cognition	Mental
understanding	Mental
and	Mental
cognition	Mental
expression	Mental
.	Mental

Injury	Others
and	Others
illness	Others
costs	Others
in	O
the	O
Certified	O
Safe	O
Farm	O
study	O
.	O

CONTEXT	O
The	O
Certified	O
Safe	O
Farm	O
(	O
CSF	O
)	O
intervention	O
program	O
aims	O
to	O
reduce	O
occupational	O
injuries	O
and	O
illnesses	O
,	O
and	O
promote	O
wellness	O
to	O
reduce	O
health	O
care	O
and	O
related	O
costs	O
to	O
farmers	O
,	O
insurers	O
,	O
and	O
other	O
stakeholders	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
cost	Others
effectiveness	Others
of	Others
CSF	Others
.	O

METHODS	O
Farms	O
(	O
316	O
)	O
located	O
in	O
a	O
9-county	O
area	O
of	O
northwestern	O
Iowa	O
were	O
recruited	O
and	O
randomized	O
into	O
intervention	O
and	O
control	O
cohorts	O
.	O

Intervention	O
farms	O
received	O
occupational	O
health	O
screenings	O
,	O
health	O
and	O
wellness	O
screening	O
,	O
education	O
,	O
on-farm	O
safety	O
reviews	O
,	O
and	O
performance	O
incentives	O
.	O

For	O
both	O
cohorts	O
,	O
quarterly	O
calls	O
over	O
3	O
years	O
were	O
used	O
to	O
collect	O
self-reported	O
occupational	O
injury	O
and	O
illness	O
information	O
,	O
including	O
costs	O
to	O
the	O
farmers	O
and	O
their	O
insurers	O
.	O

FINDINGS	O
Annual	Others
occupational	Others
injury	Others
and	Others
illness	Others
costs	Others
per	O
farmer	O
paid	O
by	O
insurers	O
were	O
45	O
%	O
lower	O
in	O
the	O
intervention	O
cohort	O
(	O
$	O
183	O
)	O
than	O
in	O
the	O
control	O
cohort	O
(	O
$	O
332	O
)	O
.	O

Although	O
out-of-pocket	Others
expenses	Others
were	O
similar	O
for	O
both	O
cohorts	O
,	O
combined	Others
costs	Others
of	Others
insurance	Others
and	Others
out-of-pocket	Others
expenses	Others
were	O
27	O
%	O
lower	O
in	O
the	O
intervention	O
cohort	O
(	O
$	O
374/year	O
per	O
farmer	O
)	O
compared	O
to	O
the	O
control	O
cohort	O
(	O
$	O
512/year	O
per	O
farmer	O
)	O
.	O

Within	O
the	O
cohort	O
of	O
intervention	O
farmers	O
,	O
annual	Others
occupational	Others
injury	Others
and	Others
illness	Others
cost	Others
savings	Others
were	O
directly	O
associated	O
with	O
on-farm	O
safety	O
review	O
scores	O
.	O

Reported	O
health	Others
care	Others
costs	Others
were	O
$	O
237	O
per	O
farmer	O
in	O
the	O
safest	O
farms	O
(	O
those	O
farms	O
scoring	O
in	O
the	O
highest	O
tertile	O
)	O
versus	O
$	O
485	O
per	O
farmer	O
in	O
the	O
least	O
safe	O
farms	O
(	O
lowest	O
tertile	O
)	O
.	O

CONCLUSIONS	O
Results	O
suggest	O
that	O
farmers	O
receiving	O
the	O
intervention	O
had	O
lower	O
health	Others
care	Others
costs	Others
for	O
occupational	O
injuries	O
and	O
illnesses	O
than	O
control	O
farmers	O
.	O

These	O
cost	Others
savings	Others
more	O
than	O
cover	O
the	O
cost	O
of	O
providing	O
CSF	O
services	O
(	O
about	O
$	O
100	O
per	O
farm	O
per	O
year	O
)	O
.	O

Effect	O
of	O
fats	O
high	O
in	O
individual	O
saturated	O
fatty	O
acids	O
on	O
plasma	Physical
lipoprotein	Physical
[	Physical
a	Physical
]	Physical
levels	Physical
in	O
young	O
healthy	O
men	O
.	O

Plasma	Physical
lipoprotein	Physical
[	Physical
a	Physical
]	Physical
(	Physical
Lp	Physical
[	Physical
a	Physical
]	Physical
)	Physical
is	O
associated	O
with	O
atherogenesis	O
and	O
thrombogenesis	O
.	O

We	O
examined	O
how	O
plasma	O
Lp	O
[	O
a	O
]	O
in	O
healthy	O
young	O
men	O
was	O
affected	O
by	O
fats	O
high	O
in	O
stearic	O
(	O
C18	O
)	O
,	O
palmitic	O
(	O
C16	O
)	O
,	O
and	O
lauric+myristic	O
(	O
C12+	O
C14	O
)	O
acid	O
(	O
experiment	O
I	O
,	O
15	O
subjects	O
)	O
,	O
and	O
by	O
fats	O
high	O
in	O
myristic	O
(	O
C14	O
)	O
and	O
palmitic	O
(	O
C16	O
)	O
acid	O
(	O
experiment	O
II	O
,	O
12	O
subjects	O
)	O
.	O

Strictly	O
controlled	O
isocaloric	O
diets	O
with	O
36	O
%	O
of	O
energy	O
from	O
test	O
fats	O
were	O
served	O
in	O
random	O
order	O
for	O
3	O
weeks	O
separated	O
by	O
wash-out	O
period	O
(	O
s	O
)	O
.	O

Diets	O
high	O
in	O
C18	O
gave	O
significantly	O
higher	O
levels	Physical
of	Physical
Lp	Physical
[	Physical
a	Physical
]	Physical
(	O
51	O
(	O
12-560	O
)	O
mg/L	O
)	O
than	O
diets	O
high	O
in	O
C16	O
(	O
38	O
(	O
12-533	O
mg/L	O
)	O
(	O
P	O
=	O
0.020	O
)	O
and	O
C12	O
+	O
C14	O
(	O
34	O
(	O
12-534	O
)	O
mg/L	O
)	O
(	O
P	O
=	O
0.002	O
)	O
.	O

These	O
differences	Physical
were	O
observed	O
in	O
several	O
of	O
the	O
subjects	O
in	O
experiment	O
I	O
.	O

In	O
experiment	O
II	O
we	O
saw	O
no	O
difference	O
in	O
plasma	Physical
Lp	Physical
[	Physical
a	Physical
]	Physical
after	O
diets	O
high	O
in	O
C16	O
and	O
C14	O
.	O

Our	O
observations	O
suggest	O
that	O
a	O
fat	O
high	O
in	O
stearic	O
acid	O
might	O
affect	O
Lp	Physical
[	Physical
a	Physical
]	Physical
in	O
a	O
different	O
way	O
than	O
fats	O
high	O
in	O
palmitic	O
and	O
myristic+lauric	O
acid	O
.	O

Lp	Physical
[	Physical
a	Physical
]	Physical
concentrations	Physical
were	O
not	O
associate	O
with	O
changes	O
in	O
tissue-plasminogen	Physical
activator	Physical
(	Physical
t-PA	Physical
)	Physical
activity	Physical
,	O
factor	Physical
VII	Physical
coagualant	Physical
activity	Physical
,	O
or	O
plasma	Physical
LDL	Physical
cholesterol	Physical
.	O

A	O
prospective	O
multicenter	O
randomized	O
comparative	O
study	O
between	O
the	O
U-	O
and	O
H-type	O
methods	O
of	O
the	O
TVT	O
SECUR	O
procedure	O
for	O
the	O
treatment	O
of	O
female	O
stress	O
urinary	O
incontinence	O
:	O
1-year	O
follow-up	O
.	O

BACKGROUND	O
No	O
studies	O
have	O
been	O
published	O
comparing	O
the	O
U-	O
and	O
H-type	O
methods	O
of	O
the	O
TVT	O
SECUR	O
(	O
TVT-S	O
)	O
procedure	O
.	O

OBJECTIVE	O
Our	O
aim	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
the	O
two	O
types	O
of	O
TVT-S	O
for	O
female	O
stress	O
urinary	O
incontinence	O
(	O
SUI	O
)	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
Women	O
with	O
urodynamic	O
SUI	O
were	O
enrolled	O
in	O
this	O
12-mo	O
multicenter	O
randomized	O
study	O
.	O

INTERVENTION	O
Subjects	O
were	O
randomly	O
allocated	O
to	O
either	O
the	O
U-	O
or	O
H-type	O
method	O
of	O
TVT-S.	O
MEASUREMENTS	O
Pre-	O
and	O
postoperative	O
evaluations	O
included	O
a	O
standing	Others
stress	Others
test	Others
,	O
the	O
Sandvik	Others
questionnaire	Others
,	O
the	O
Incontinence	Others
Quality	Others
of	Others
Life	Others
(	Others
I-QOL	Others
)	Others
questionnaire	Others
,	O
and	O
the	O
International	Others
Consultation	Others
on	Others
Incontinence	Others
Questionnaire-Female	Others
Lower	Others
Urinary	Others
Tract	Others
Symptoms	Others
(	Others
ICIQ-FLUTS	Others
)	Others
.	O

Patients	O
'	O
satisfaction	Others
and	O
complications	Adverseeffect
were	O
evaluated	O
.	O

Objective	O
and	O
subjective	O
cures	O
were	O
defined	O
as	O
no	O
leakage	O
on	O
the	O
stress	Others
test	Others
and	O
responses	O
on	O
the	O
Sandvik	Others
questionnaire	Others
,	O
respectively	O
.	O

We	O
compared	O
the	O
surgical	O
outcomes	O
between	O
the	O
two	O
methods	O
.	O

RESULTS	O
AND	O
LIMITATIONS	O
Of	O
285	O
women	O
,	O
144	O
had	O
the	O
U-type	O
method	O
and	O
141	O
had	O
the	O
H-type	O
method	O
.	O

Objective	Others
cure	Others
rates	Others
were	O
87.5	O
%	O
for	O
the	O
U-type	O
method	O
and	O
80.1	O
%	O
for	O
the	O
H-type	O
method	O
(	O
p=0.091	O
)	O
.	O

Subjective	Others
cure	Others
rates	Others
were	O
77.1	O
%	O
for	O
the	O
U-type	O
method	O
and	O
75.7	O
%	O
for	O
the	O
H-type	O
method	O
(	O
p=0.786	O
)	O
.	O

Improvement	O
in	O
I-QOL	Others
and	Others
domain	Others
scores	Others
of	Others
the	Others
ICIQ-FLUTS	Others
(	Others
filling	Others
and	Others
incontinence	Others
sum	Others
,	Others
QOL	Others
score	Others
)	Others
,	O
and	O
patients	Mental
'	Mental
satisfaction	Mental
favored	O
the	O
U-type	O
method	O
.	O

There	O
were	O
three	O
cases	O
of	O
intraoperative	Physical
vaginal	Physical
wall	Physical
perforation	Physical
,	O
one	O
case	O
of	O
increased	Adverseeffect
bleeding	Adverseeffect
,	O
and	O
three	O
cases	O
of	O
temporary	Physical
postoperative	Physical
retention	Physical
.	O

A	O
power	O
calculation	O
was	O
not	O
performed	O
,	O
and	O
some	O
baseline	O
characteristics	O
were	O
not	O
balanced	O
between	O
the	O
two	O
methods	O
.	O

CONCLUSIONS	O
Both	O
methods	O
of	O
TVT-S	O
provided	O
comparable	O
cure	Others
rates	Others
for	O
female	O
SUI	O
.	O

However	O
,	O
QOL	Others
and	O
treatment	Others
satisfaction	Others
favored	O
the	O
U-type	O
method	O
.	O

TRIAL	O
REGISTRATION	O
The	O
protocol	O
of	O
this	O
study	O
was	O
not	O
registered	O
.	O

Activator	O
protein-1	O
(	O
AP-1	O
)	O
signalling	O
in	O
human	O
atherosclerosis	O
:	O
results	O
of	O
a	O
systematic	O
evaluation	O
and	O
intervention	O
study	O
.	O

Animal	O
studies	O
implicate	O
the	O
AP-1	O
(	O
activator	O
protein-1	O
)	O
pro-inflammatory	O
pathway	O
as	O
a	O
promising	O
target	O
in	O
the	O
treatment	O
of	O
atherosclerotic	O
disease	O
.	O

It	O
is	O
,	O
however	O
,	O
unclear	O
whether	O
these	O
observations	O
apply	O
to	O
human	O
atherosclerosis	O
.	O

Therefore	O
we	O
evaluated	O
the	O
profile	O
of	O
AP-1	O
activation	O
through	O
histological	O
analysis	O
and	O
tested	O
the	O
potential	O
benefit	O
of	O
AP-1	O
inhibition	O
in	O
a	O
clinical	O
trial	O
.	O

AP-1	O
activation	O
was	O
quantified	O
by	O
phospho-c-Jun	O
nuclear	O
translocation	O
(	O
immunohistochemistry	O
)	O
on	O
a	O
biobank	O
of	O
aortic	O
wall	O
samples	O
from	O
organ	O
donors	O
.	O

The	O
effect	O
of	O
AP-1	Physical
inhibition	Physical
on	O
vascular	O
parameters	O
was	O
tested	O
through	O
a	O
double	O
blind	O
placebo-controlled	O
cross-over	O
study	O
of	O
28	O
days	O
doxycycline	O
or	O
placebo	O
in	O
patients	O
with	O
symptomatic	O
peripheral	O
artery	O
disease	O
.	O

Vascular	O
function	O
was	O
assessed	O
by	O
brachial	O
dilation	O
as	O
well	O
as	O
by	O
plasma	O
samples	O
analysed	O
for	O
hs-CRP	O
(	O
high-sensitivity	O
C-reactive	O
protein	O
)	O
,	O
IL-6	O
(	O
interleukin-6	O
)	O
,	O
IL-8	O
,	O
ICAM-1	O
(	O
intercellular	O
adhesion	O
molecule-1	O
)	O
,	O
vWF	O
(	O
von	O
Willebrand	O
factor	O
)	O
,	O
MCP-1	O
(	O
monocyte	O
chemoattractant	O
protein-1	O
)	O
,	O
PAI-1	O
(	O
plasminogen	O
activator	O
inhibitor-1	O
)	O
and	O
fibrinogen	O
.	O

Histological	O
evaluation	O
of	O
human	O
atherosclerosis	O
showed	O
minimal	O
AP-1	O
activation	O
in	O
non-diseased	O
arterial	O
wall	O
(	O
i.e	O
.	O

vessel	O
wall	O
without	O
any	O
signs	O
of	O
atherosclerotic	O
disease	O
)	O
.	O

A	O
gradual	O
increase	O
of	O
AP-1	O
activation	O
was	O
found	O
in	O
non-progressive	O
and	O
progressive	O
phases	O
of	O
atherosclerosis	O
respectively	O
(	O
P	O
<	O
0.044	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
progressive	O
and	O
vulnerable	O
lesions	O
.	O

The	O
expression	O
of	O
phospho-c-Jun	O
diminished	O
as	O
the	O
lesion	O
stabilized	O
(	O
P	O
<	O
0.016	O
)	O
and	O
does	O
not	O
significantly	O
differ	O
from	O
the	O
normal	O
aortic	O
wall	O
(	O
P	O
<	O
0.33	O
)	O
.	O

Evaluation	O
of	O
the	O
doxycycline	O
intervention	O
only	O
revealed	O
a	O
borderline-significant	O
reduction	O
of	O
circulating	O
hs-CRP	O
levels	O
(	O
-0.51	O
?g/ml	O
,	O
P=0.05	O
)	O
and	O
did	O
not	O
affect	O
any	O
of	O
the	O
other	O
markers	O
of	O
systemic	O
inflammation	O
and	O
vascular	O
function	O
.	O

Our	O
studies	O
do	O
not	O
characterize	O
AP-1	O
as	O
a	O
therapeutic	O
target	O
for	O
progressive	O
human	O
atherosclerotic	O
disease	O
.	O

Midazolam	O
vs	O
ondansetron	O
for	O
preventing	O
postoperative	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

We	O
compared	O
the	O
prophylactic	O
anti-emetic	O
efficacy	O
of	O
midazolam	O
and	O
ondansetron	O
in	O
90	O
patients	O
scheduled	O
for	O
minor	O
gynaecological	O
(	O
hysteroscopy	O
)	O
or	O
urological	O
(	O
ureteroscopy	O
)	O
procedures	O
planned	O
to	O
last	O
1-2	O
h	O
under	O
sevoflurane	O
anaesthesia	O
with	O
spontaneous	O
ventilation	O
of	O
the	O
lungs	O
via	O
a	O
laryngeal	O
mask	O
airway	O
.	O

Midazolam	O
2	O
mg	O
or	O
ondansetron	O
4	O
mg	O
were	O
administered	O
intravenously	O
30	O
min	O
before	O
the	O
end	O
of	O
surgery	O
.	O

The	O
proportions	O
of	O
patients	O
who	O
experienced	O
postoperative	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
in	O
the	O
first	O
24	O
h	O
(	O
30	O
%	O
and	O
27	O
%	O
for	O
the	O
midazolam	O
and	O
ondansetron	O
groups	O
,	O
respectively	O
)	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

The	O
incidence	O
of	O
postoperative	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
was	O
significantly	O
smaller	O
in	O
both	O
groups	O
than	O
predicted	O
according	O
to	O
the	O
patients	O
'	O
underlying	O
risks	O
(	O
midazolam	O
group	O
:	O
p	O
=	O
0.018	O
;	O
ondansetron	O
group	O
:	O
p	O
=	O
0.017	O
)	O
.	O

There	O
were	O
no	Others
significant	Others
differences	Others
in	O
average	Physical
sedation	Physical
scores	Physical
or	O
pain	Physical
scores	Physical
.	O

Treatment	O
using	O
ondansetron	O
for	O
anti-emetic	O
prophylaxis	O
did	O
not	O
provide	O
a	O
superior	O
benefit	O
compared	O
to	O
midazolam	O
in	O
the	O
present	O
study	O
.	O

Effect	O
of	O
simultaneous	O
didanosine	O
administration	O
on	O
itraconazole	Others
absorption	Others
in	O
healthy	O
volunteers	O
.	O

STUDY	O
OBJECTIVE	O
To	O
investigate	O
the	O
effect	O
of	O
simultaneously	O
administered	O
didanosine	O
(	O
ddI	O
)	O
on	O
the	O
absorption	O
of	O
a	O
single	O
dose	O
of	O
itraconazole	O
.	O

DESIGN	O
Randomized	O
,	O
crossover	O
,	O
unblinded	O
single-dose	O
pharmacokinetic	O
study	O
in	O
healthy	O
volunteers	O
.	O

Comparisons	O
of	O
itraconazole	O
alone	O
and	O
itraconazole	O
with	O
simultaneous	O
ddI	O
were	O
performed	O
on	O
days	O
1	O
and	O
15	O
.	O

SETTING	O
A	O
university	O
medical	O
center	O
.	O

PATIENTS	O
Seven	O
healthy	O
men	O
and	O
women	O
.	O

Six	O
subjects	O
(	O
86	O
%	O
)	O
completed	O
the	O
study	O
;	O
one	O
was	O
removed	O
due	O
to	O
the	O
development	O
of	O
a	O
rash	O
.	O

INTERVENTIONS	O
Volunteers	O
received	O
a	O
single	O
200-mg	O
oral	O
dose	O
of	O
itraconazole	O
or	O
itraconazole	O
with	O
concomitant	O
oral	O
ddI	O
300	O
mg	O
(	O
two	O
150-mg	O
tablets	O
)	O
dispersed	O
in	O
240	O
ml	O
water	O
.	O

Each	O
regimen	O
was	O
separated	O
by	O
a	O
2-week	O
washout	O
period	O
.	O

Serum	O
samples	O
were	O
obtained	O
frequently	O
for	O
12	O
hours	O
after	O
the	O
dose	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Concentrations	O
of	O
itraconazole	O
were	O
determined	O
using	O
a	O
microbiologic	O
assay	O
.	O

Individual	O
concentrations	O
in	O
serum	Physical
versus	Physical
time	Physical
data	Physical
were	O
evaluated	O
by	O
linear	O
regression	O
analysis	O
.	O

Peak	Others
serum	Others
concentration	Others
and	O
time	Others
to	Others
peak	Others
were	O
determined	O
by	O
visual	O
inspection	O
of	O
each	O
individual	O
's	O
serum	O
concentration-time	O
curve	O
.	O

A	O
mean	Others
+/-	Others
SD	Others
peak	Others
serum	Others
itraconazole	Others
concentration	Others
of	O
0.90	O
+/-	O
0.30	O
micrograms/ml	O
was	O
observed	O
at	O
3.0	O
+/-	O
0.7	O
hours	O
when	O
itraconazole	O
was	O
administered	O
alone	O
,	O
compared	O
with	O
undetectable	O
levels	O
in	O
all	O
patients	O
during	O
therapy	O
with	O
ddI	O
.	O

CONCLUSIONS	O
Simultaneous	O
oral	O
administration	O
of	O
ddI	O
significantly	O
decreases	O
absorption	Others
of	Others
itraconazole	Others
.	O

These	O
drugs	O
should	O
not	O
be	O
administered	O
concurrently	O
.	O

Short-term	O
effects	O
of	O
prednisolone	O
and	O
dexamethasone	O
on	O
circulating	Physical
concentrations	Physical
of	Physical
leptin	Physical
and	Physical
sex	Physical
hormone-binding	Physical
globulin	Physical
in	O
children	O
being	O
treated	O
for	O
acute	O
lymphoblastic	O
leukaemia	O
.	O

OBJECTIVE	O
Disturbances	O
in	O
body	O
weight	O
regulation	O
are	O
often	O
encountered	O
during	O
glucocorticoid	O
treatment	O
and	O
are	O
associated	O
with	O
increased	O
insulin	O
resistance	O
and	O
truncal	O
fat	O
accumulation	O
.	O

Children	O
were	O
investigated	O
who	O
were	O
receiving	O
glucocorticoid	O
treatment	O
for	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
ALL	O
)	O
.	O

They	O
were	O
randomized	O
to	O
receive	O
either	O
prednisolone	O
or	O
dexamethasone	O
as	O
part	O
of	O
induction	O
of	O
remission	O
.	O

This	O
randomization	O
process	O
provided	O
a	O
suitable	O
opportunity	O
to	O
compare	O
the	O
effects	O
of	O
these	O
two	O
administered	O
steroid	O
on	O
surrogate	O
markers	O
of	O
adipocyte	O
activity	O
(	O
leptin	O
)	O
and	O
hyperinsulinaemia/insulin	O
resistance	O
(	O
SHBG	O
)	O
.	O

DESIGN	O
AND	O
PATIENTS	O
Prospective	O
study	O
over	O
16	O
weeks	O
of	O
children	O
randomized	O
to	O
receive	O
prednisolone	O
(	O
40	O
mg/m2	O
)	O
or	O
dexamethasone	O
(	O
6.5	O
mg/m2	O
)	O
as	O
part	O
of	O
the	O
MRC-ALL97/99	O
induction	O
chemotherapy	O
for	O
ALL	O
.	O

Nineteen	O
children	O
(	O
8	O
male	O
,	O
11	O
female	O
)	O
with	O
a	O
median	O
age	O
5.9	O
years	O
(	O
range	O
2.6-13	O
years	O
)	O
were	O
recruited	O
into	O
the	O
study	O
.	O

Main	O
outcome	O
measures	O
were	O
body	Physical
mass	Physical
index	Physical
(	Physical
BMI	Physical
)	Physical
,	O
serum	Physical
leptin	Physical
and	Physical
sex	Physical
hormone	Physical
binding	Physical
globulin	Physical
(	Physical
SHBG	Physical
)	Physical
.	O

RESULTS	O
Glucocorticoid	O
administration	O
for	O
5	O
weeks	O
resulted	O
in	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
increases	O
in	O
BMI	Physical
,	O
leptin	Physical
(	Physical
corrected	Physical
for	Physical
BMI	Physical
)	Physical
and	Physical
the	Physical
leptin	Physical
:	Physical
SHBG	Physical
ratio	Physical
and	Physical
lowering	Physical
of	Physical
SHBG	Physical
.	O

Dose	O
for	O
dose	O
,	O
dexamethasone	O
was	O
significantly	O
more	O
potent	O
than	O
prednisolone	O
in	O
altering	O
these	O
parameters	O
.	O

CONCLUSIONS	O
Short-term	O
glucocorticoid	O
treatment	O
has	O
significant	O
effects	O
on	O
BMI	O
,	O
leptin	O
and	O
SHBG	O
.	O

The	O
leptin	O
:	O
SHBG	O
ratio	O
increase	O
indicates	O
that	O
this	O
may	O
be	O
a	O
novel	O
and	O
sensitive	O
biochemical	O
marker	O
of	O
metabolic	O
change	O
.	O

Our	O
results	O
suggest	O
that	O
glucocorticoid	O
treatment	O
regimens	O
should	O
be	O
kept	O
as	O
short	O
as	O
possible	O
to	O
avoid	O
possible	O
detrimental	O
effects	O
associated	O
with	O
increased	O
adiposity	O
and	O
insulin	O
resistance	O
.	O

Marginal	O
zone	O
B	O
cell	O
lymphoma	O
of	O
the	O
parotid	O
glands	O
:	O
results	O
of	O
a	O
randomised	O
trial	O
comparing	O
radiotherapy	O
to	O
combined	O
therapy	O
.	O

39	O
patients	O
with	O
marginal	O
zone	O
B	O
cell	O
lymphoma	O
(	O
MZBCL	O
)	O
of	O
the	O
parotid	O
glands	O
(	O
stages	O
I	O
or	O
II	O
)	O
were	O
studied	O
.	O

They	O
were	O
randomized	O
to	O
be	O
treated	O
with	O
either	O
radiotherapy	O
alone	O
(	O
extended	O
fields	O
,	O
4500	O
cGy	O
)	O
or	O
radiotherapy	O
(	O
the	O
same	O
schedule	O
)	O
plus	O
adjuvant	O
chemotherapy	O
(	O
cyclophosphamide	O
,	O
vincristine	O
and	O
prednisone	O
)	O
.	O

The	O
end	Physical
points	Physical
were	O
survival	Mortality
and	Mortality
time	Mortality
to	Mortality
treatment	Mortality
failure	Mortality
(	Mortality
TTF	Mortality
)	Mortality
.	Mortality

Patients	O
who	O
received	O
radiotherapy	O
alone	O
had	O
a	O
complete	Physical
remission	Physical
rate	Physical
of	O
100	O
%	O
,	O
the	O
TTF	Others
was	O
90	O
%	O
at	O
5	O
years	O
and	O
overall	Mortality
survival	Mortality
at	O
5	O
years	O
was	O
90	O
%	O
with	O
no	O
statistical	O
difference	O
when	O
compared	O
with	O
patients	O
who	O
received	O
combined	O
therapy	O
[	O
100	O
,	O
80	O
and	O
95	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.5	O
)	O
]	O
.	O

Although	O
adjuvant	O
chemotherapy	O
was	O
well	O
tolerated	Others
,	O
the	O
use	O
of	O
this	O
therapeutic	O
approach	O
in	O
patients	O
with	O
early	O
stage	O
MZBCL	O
did	O
not	O
offer	O
any	O
advantage	O
over	O
radiotherapy	O
alone	O
as	O
the	O
initial	O
treatment	O
.	O

Until	O
now	O
,	O
radiotherapy	O
was	O
considered	O
the	O
treatment	O
of	O
choice	O
in	O
this	O
clinical	O
setting	O
of	O
patients	O
.	O

Effects	O
of	O
two-month	O
vocal	O
exercising	O
with	O
and	O
without	O
spectral	O
biofeedback	O
on	O
student	O
actors	O
'	O
speaking	O
voice	O
.	O

Twelve	O
student	O
actors	O
(	O
6	O
males	O
,	O
6	O
females	O
)	O
were	O
given	O
voice	O
training	O
for	O
two	O
months	O
.	O

Randomly	O
selected	O
,	O
half	O
of	O
the	O
students	O
(	O
3	O
males	O
,	O
3	O
females	O
)	O
was	O
trained	O
in	O
the	O
traditional	O
way	O
,	O
while	O
the	O
other	O
half	O
was	O
given	O
biofeedback	O
with	O
real-time	O
spectrum	O
analysis	O
.	O

The	O
aim	O
was	O
a	O
ringing	Others
voice	Others
quality	Others
with	Others
strong	Others
overtones	Others
at	Others
3-5	Others
kHz	Others
.	O

Text	O
samples	O
read	O
at	O
different	O
loudness	O
levels	O
were	O
recorded	O
before	O
and	O
after	O
training	O
.	O

Fundamental	Others
frequency	Others
(	Others
F0	Others
)	Others
,	Others
sound	Others
pressure	Others
level	Others
(	Others
SPL	Others
)	Others
and	O
long-term-average	Others
spectrum	Others
(	Others
LTAS	Others
)	Others
analyses	Others
were	O
made	O
.	O

Voice	Others
quality	Others
was	O
evaluated	O
by	O
two	O
voice	O
trainers	O
.	O

Sound	Others
energy	Others
at	Others
3-5	Others
kHz	Others
increased	O
by	O
3-4	O
dB	O
(	O
1.5-14.5	O
dB	O
)	O
across	O
groups	O
after	O
training	O
.	O

This	O
change	O
,	O
which	O
was	O
slightly	O
larger	O
for	O
the	O
biofeedback	O
(	O
BF	O
)	O
group	O
,	O
did	O
not	O
correlate	O
with	O
SPL	Others
.	O

F0	Others
increased	O
slightly	O
in	O
the	O
BF	O
group	O
and	O
decreased	O
in	O
the	O
control	O
group	O
.	O

The	O
relative	Others
dB	Others
level	Others
of	Others
fundamental	Others
decreased	O
significantly	O
more	O
in	O
the	O
BF	O
group	O
probably	O
suggesting	O
a	O
tighter	O
adduction	O
.	O

Voice	Others
quality	Others
improved	O
in	O
both	O
groups	O
.	O

Visual	O
feedback	O
seems	O
to	O
add	O
some	O
efficacy	Others
in	O
voice	O
training	O
.	O

However	O
,	O
there	O
is	O
a	O
danger	O
of	O
hyperfunctional	O
voice	O
production	O
if	O
other	O
sensory	O
feedback	O
is	O
neglected	O
.	O

Intravenous	O
magnesium	O
sulfate	O
in	O
acute	Physical
severe	Physical
asthma	Physical
not	O
responding	O
to	O
conventional	O
therapy	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
early	O
administration	O
of	O
intravenous	O
Magnesium	O
sulfate	O
(	O
i.v	O
.	O

MgSO4	O
)	O
in	O
children	O
with	O
acute	O
severe	O
asthma	O
not	O
responding	O
to	O
conventional	O
therapy	O
.	O

DESIGN	O
Randomized	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

SETTING	O
Pediatric	O
emergency	O
service	O
of	O
a	O
large	O
teaching	O
hospital	O
.	O

SUBJECTS	O
47	O
children	O
aged	O
between	O
1-12	O
years	O
with	O
acute	O
severe	O
asthma	O
showing	O
inadequate	Others
or	Others
poor	Others
response	Others
to	O
3	O
doses	O
of	O
nebulized	O
salbutamol	O
given	O
at	O
an	O
interval	O
of	O
20	O
min	O
each	O
.	O

INTERVENTION	O
The	O
MgSO4	O
group	O
received	O
0.2	O
ml/kg	O
of	O
50	O
%	O
MgSO4	O
as	O
intravenous	O
(	O
i.v	O
.	O

)	O
infusion	O
over	O
35	O
minutes	O
and	O
the	O
placebo	O
group	O
received	O
normal	O
saline	O
infusion	O
in	O
the	O
same	O
dose	O
and	O
at	O
the	O
same	O
rate	O
.	O

MgSO4	O
solution	O
and	O
normal	O
saline	O
were	O
coded	O
and	O
dispensed	O
in	O
identical	O
containers	O
.	O

Decoding	O
was	O
done	O
at	O
the	O
completion	O
of	O
the	O
study	O
.	O

All	O
the	O
patients	O
received	O
oxygen	O
,	O
nebulized	O
salbutamol	O
,	O
i.v	O
.	O

aminophylline	O
and	O
corticosteroids	O
.	O

RESULTS	O
MgSO4	O
group	O
showed	O
early	Others
and	Others
significant	Others
improvement	Others
as	O
compared	O
to	O
placebo	O
group	O
in	O
PEFR	Physical
and	O
SaO2	Physical
at	O
30	O
min	O
and	O
1	O
,	O
2	O
,	O
3	O
and	O
7	O
hours	O
after	O
stopping	O
the	O
infusion	O
(	O
p	O
ranging	O
from	O
<	O
0.05	O
to	O
<	O
0.01	O
)	O
.	O

The	O
clinical	Physical
asthma	Physical
score	Physical
also	O
showed	O
significant	O
improvement	O
in	O
the	O
MgSO4	O
group	O
1	O
,	O
2	O
,	O
3	O
and	O
11	O
hours	O
after	O
stopping	O
the	O
infusion	O
(	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
Addition	O
of	O
MgSO4	O
to	O
conventional	O
therapy	O
helps	O
in	O
achieving	O
earlier	O
improvement	Physical
in	Physical
clinical	Physical
signs	Physical
and	O
symptoms	Physical
of	Physical
asthma	Physical
and	O
PEFR	Physical
in	O
patients	O
not	O
responding	O
to	O
conventional	O
therapy	O
alone	O
.	O

Multicenter	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
to	O
assess	O
the	O
acute	Physical
prokinetic	Physical
efficacy	Physical
of	O
nizatidine-controlled	O
release	O
(	O
150	O
and	O
300	O
mg	O
)	O
in	O
patients	O
with	O
gastroesophageal	O
reflux	O
disease	O
.	O

INTRODUCTION	O
The	O
aim	O
of	O
the	O
study	O
is	O
to	O
test	O
whether	O
nizatidine	O
delivered	O
via	O
a	O
unique	O
bimodal	O
pulsatile-controlled	O
release	O
system	O
,	O
nizatidine	O
controlled	O
release	O
(	O
CR	O
)	O
,	O
accelerates	O
gastric	Physical
emptying	Physical
in	O
patients	O
with	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
.	O

METHODS	O
Combined	O
data	O
were	O
analyzed	O
on	O
39	O
patients	O
with	O
delayed	Physical
gastric	Physical
emptying	Physical
(	O
DGE	O
)	O
from	O
2	O
studies	O
(	O
n	O
=	O
84	O
)	O
assessing	O
the	O
prokinetic	O
effect	O
of	O
nizatidine	O
CR	O
.	O

A	O
single-blind	O
placebo	O
baseline	O
was	O
followed	O
by	O
double-blind	O
nizatidine	O
CR	O
(	O
150	O
and	O
300	O
mg	O
)	O
in	O
randomized	O
sequence	O
,	O
2	O
to	O
5	O
days	O
apart	O
.	O

Each	O
dose	O
was	O
followed	O
1	O
hour	O
later	O
by	O
an	O
egg-beater	O
meal	O
,	O
labeled	O
with	O
Tc99m	O
.	O

Gamma	Physical
camera	Physical
images	Physical
were	O
obtained	O
at	O
meal	O
completion	O
,	O
1-	O
,	O
2-	O
,	O
3-	O
and	O
4-hour	O
postmeal	O
.	O

All	O
the	O
84	O
patients	O
were	O
classified	O
at	O
baseline	O
with	O
DGE	Physical
(	O
gastric	O
retention	O
>	O
6.3	O
%	O
at	O
4	O
hours	O
)	O
or	O
normal	Physical
gastric	Physical
emptying	Physical
.	O

RESULTS	O
In	O
the	O
39	O
patients	O
identified	O
with	O
DGE	O
,	O
change	O
from	O
placebo	O
baseline	O
(	O
CFB	Physical
)	O
for	O
percent	Physical
gastric	Physical
retention	Physical
at	O
4-hour	O
postmeal	O
with	O
nizatidine	O
CR	O
(	O
150	O
and	O
300	O
mg	O
)	O
was	O
each	O
improved	O
and	O
statistically	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
a	O
subgroup	O
of	O
diabetic	O
patients	O
with	O
DGE	O
(	O
n	O
=	O
10	O
)	O
,	O
the	O
CFB	O
with	O
nizatidine	O
CR	O
(	O
300	O
mg	O
)	O
was	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
at	O
3-	O
and	O
4-hour	O
postmeal	O
.	O

CONCLUSIONS	O
Nizatidine	O
CR	O
(	O
150	O
and	O
300	O
mg	O
)	O
significantly	O
enhanced	O
gastric	Physical
emptying	Physical
of	O
a	O
standard	O
meal	O
in	O
patients	O
with	O
GERD	O
with	O
DGE	O
.	O

Recovery	Physical
after	O
prolonged	O
anaesthesia	O
for	O
acoustic	O
neuroma	O
surgery	O
:	O
desflurane	O
versus	O
isoflurane	O
.	O

In	O
this	O
study	O
,	O
33	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
desflurane	O
(	O
D	O
)	O
or	O
isoflurane	O
(	O
I	O
)	O
for	O
acoustic	O
neuroma	O
surgery	O
.	O

The	O
time	O
from	O
end	O
of	O
the	O
procedure	O
to	O
spontaneous	O
breathing	O
,	O
extubation	O
,	O
eye-opening	O
,	O
hand-squeezing	O
to	O
command	O
,	O
and	O
ability	O
to	O
state	O
name	O
,	O
birthdate	O
and	O
phone	O
number	O
were	O
recorded	O
.	O

The	O
Steward	O
recovery	O
score	O
was	O
also	O
recorded	O
every	O
five	O
minutes	O
during	O
the	O
first	O
20	O
minutes	O
postoperatively	O
and	O
then	O
every	O
10	O
to	O
15	O
minutes	O
.	O

Groups	O
were	O
similar	O
regarding	O
patient	O
characteristics	O
,	O
depth	O
of	O
anaesthesia	O
,	O
sufentanil	O
total	O
dose	O
,	O
anaesthesia	O
duration	O
(	O
D	O
:	O
349.1	O
+/-	O
19.1	O
min	O
;	O
I	O
:	O
349.2	O
+/-	O
22.9	O
min	O
)	O
,	O
haemodynamic/respiratory	O
parameters	O
,	O
and	O
surgical	O
conditions	O
(	O
assessed	O
by	O
a	O
bleeding	O
score	O
)	O
.	O

The	O
emergence	Physical
time	Physical
in	O
the	O
D	O
group	O
was	O
significantly	O
faster	O
than	O
the	O
I	O
group	O
(	O
D	O
:	O
14.9	O
+/-	O
2.4	O
min	O
vs	O
I	O
:	O
29.2	O
+/-	O
2.4	O
min	O
for	O
eye-opening	O
)	O
.	O

Full	Physical
recovery	Physical
also	O
occurred	O
earlier	O
in	O
the	O
D	O
group	O
(	O
D	O
:	O
22.1	O
+/-	O
3.1	O
min	O
vs	O
I	O
:	O
37.6	O
+/-	O
4.0	O
min	O
,	O
P	O
<	O
0.005	O
for	O
stating	O
name	O
)	O
.	O

Steward	Physical
recovery	Physical
scores	Physical
were	O
also	O
better	O
during	O
the	O
first	O
postoperative	O
hour	O
in	O
the	O
D	O
group	O
(	O
D	O
:	O
40	O
min	O
vs	O
I	O
:	O
90	O
min	O
,	O
P	O
<	O
0.005	O
for	O
100	O
%	O
of	O
patients	O
with	O
Steward	O
score	O
of	O
6	O
)	O
.	O

The	O
results	O
indicate	O
that	O
desflurane	O
is	O
associated	O
with	O
similar	O
operating	O
conditions	O
and	O
faster	O
postoperative	Physical
recovery	Physical
following	O
acoustic	O
neuroma	O
surgery	O
.	O

The	O
faster	O
recovery	Physical
following	O
desflurane	O
may	O
be	O
desirable	O
after	O
long	O
surgical	O
procedures	O
,	O
enabling	O
the	O
patient	O
's	O
full	O
cooperation	O
and	O
facilitating	O
early	O
diagnosis	O
of	O
any	O
potential	O
neurological	O
deficit	O
.	O

Augmented	O
soft	O
tissue	O
mobilization	O
vs	O
natural	O
history	O
in	O
the	O
treatment	O
of	O
lateral	O
epicondylitis	O
:	O
a	O
pilot	O
study	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
augmented	O
soft	O
tissue	O
mobilization	O
(	O
ASTM	O
)	O
on	O
the	O
treatment	O
of	O
lateral	O
epicondylitis	O
.	O

METHODS	O
This	O
randomized	O
clinical	O
study	O
assessed	O
27	O
subjects	O
(	O
12	O
men	O
and	O
15	O
women	O
)	O
with	O
lateral	O
epicondylitis	O
and	O
were	O
divided	O
randomly	O
into	O
2	O
groups	O
.	O

The	O
experimental	O
group	O
(	O
n	O
=	O
15	O
)	O
received	O
ASTM	O
twice	O
a	O
week	O
for	O
5	O
weeks	O
.	O

The	O
subjects	O
of	O
the	O
control	O
group	O
(	O
n	O
=	O
12	O
)	O
received	O
advice	O
on	O
the	O
natural	O
evolution	O
of	O
lateral	O
epicondylitis	O
,	O
computer	O
ergonomics	O
,	O
and	O
stretching	O
exercises	O
.	O

Patient-rated	O
outcome	O
was	O
assessed	O
at	O
baseline	O
and	O
after	O
6	O
weeks	O
and	O
3	O
months	O
using	O
a	O
visual	O
analog	O
scale	O
and	O
the	O
Patient-Rated	O
Tennis	O
Elbow	O
Evaluation	O
.	O

The	O
function	O
was	O
assessed	O
using	O
the	O
pain-free	Pain
grip	Pain
strength	Pain
at	O
baseline	O
and	O
after	O
6	O
weeks	O
.	O

RESULTS	O
Both	O
groups	O
showed	O
improvements	Pain
in	Pain
pain-free	Pain
grip	Pain
strength	Pain
,	O
visual	Physical
analog	Physical
scale	Physical
,	O
and	O
Patient-Rated	Physical
Tennis	Physical
Elbow	Physical
Evaluation	Physical
.	O

Sample	O
size	O
for	O
larger	O
future	O
randomized	O
clinical	O
trial	O
was	O
116	O
participants	O
.	O

CONCLUSION	O
A	O
larger	O
study	O
investigating	O
the	O
same	O
hypothesis	O
is	O
warranted	O
to	O
detect	O
difference	O
in	O
the	O
effects	O
of	O
these	O
treatments	O
strategies	O
.	O

The	O
study	O
design	O
is	O
feasible	O
,	O
and	O
minor	O
improvements	O
will	O
help	O
to	O
minimize	O
the	O
potential	O
bias	O
.	O

Clinical	O
benefit	O
with	O
docetaxel	O
plus	O
fluorouracil	O
and	O
cisplatin	O
compared	O
with	O
cisplatin	O
and	O
fluorouracil	O
in	O
a	O
phase	O
III	O
trial	O
of	O
advanced	O
gastric	O
or	O
gastroesophageal	O
cancer	O
adenocarcinoma	O
:	O
the	O
V-325	O
Study	O
Group	O
.	O

PURPOSE	O
For	O
patients	O
with	O
advanced	O
gastric	O
or	O
gastroesophageal	O
cancer	O
(	O
AGGEC	O
)	O
providing	O
clinical	O
benefit	O
with	O
improved	O
palliation	O
is	O
highly	O
desirable	O
.	O

However	O
,	O
a	O
prospective	O
evaluation	O
of	O
clinical	O
benefit	O
in	O
AGGEC	O
patients	O
has	O
never	O
before	O
been	O
reported	O
in	O
a	O
phase	O
III	O
setting	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
a	O
multinational	O
trial	O
(	O
V325	O
)	O
,	O
445	O
patients	O
were	O
randomly	O
assigned	O
and	O
treated	O
with	O
either	O
docetaxel	O
plus	O
cisplatin	O
and	O
fluorouracil	O
(	O
DCF	O
)	O
or	O
cisplatin	O
and	O
fluorouracil	O
(	O
CF	O
)	O
.	O

Clinical	O
benefit	O
was	O
prospectively	O
evaluated	O
in	O
this	O
trial	O
as	O
a	O
secondary	O
end	O
point	O
.	O

The	O
primary	O
measure	O
for	O
clinical	O
benefit	O
analysis	O
was	O
time	Physical
to	Physical
definitive	Physical
worsening	Physical
by	O
one	O
or	O
more	O
categories	O
of	O
Karnofsky	Physical
performance	Physical
status	Physical
(	O
KPS	O
)	O
.	O

Secondary	O
clinical	O
benefit	O
end	O
points	O
included	O
time	Physical
to	Physical
5	Physical
%	Physical
definitive	Physical
weight	Physical
loss	Physical
,	Physical
time	Physical
to	Physical
definitive	Physical
worsening	Physical
of	Physical
appetite	Physical
by	Physical
one	Physical
grade	Physical
,	Physical
pain-free	Mortality
survival	Mortality
(	Physical
defined	Physical
as	Physical
time	Pain
to	Pain
first	Pain
appearance	Pain
of	Pain
pain	Pain
)	Physical
,	Physical
and	Physical
time	Physical
to	Physical
first	Physical
cancer	Physical
pain-related	Physical
opioid	Physical
intake	Physical
.	Physical

Clinical	O
benefit	O
assessments	O
were	O
recorded	O
at	O
each	O
clinic	O
visit	O
.	O

RESULTS	O
Clinical	O
benefit	O
assessments	O
were	O
performed	O
in	O
more	O
than	O
75	O
%	O
of	O
patients	O
throughout	O
V325	O
.	O

DCF	O
significantly	O
prolonged	O
time	Physical
to	Physical
definitive	Physical
worsening	Physical
of	Physical
KPS	Physical
compared	O
with	O
CF	O
(	O
median	O
,	O
6.1	O
v	O
4.8	O
months	O
;	O
hazard	O
ratio	O
,	O
1.38	O
;	O
95	O
%	O
CI	O
,	O
1.08	O
to	O
1.76	O
;	O
log-rank	O
P	O
=	O
.009	O
)	O
.	O

Although	O
time	Physical
to	Physical
definitive	Physical
weight	Physical
loss	Physical
and	Physical
time	Physical
to	Physical
definitive	Physical
worsening	Physical
of	Physical
appetite	Physical
favored	O
DCF	O
,	O
the	O
results	O
were	O
not	O
statistically	O
significant	O
.	O

Pain-free	Pain
survival	Pain
and	Pain
time	Pain
to	Pain
first	Pain
cancer	Pain
pain-related	Pain
opioid	Pain
intake	Pain
were	O
comparable	O
.	O

CONCLUSION	O
To	O
our	O
knowledge	O
,	O
V325	O
is	O
the	O
first	O
phase	O
III	O
trial	O
to	O
report	O
clinical	O
benefit	O
in	O
AGGEC	O
patients	O
.	O

Clinical	O
benefit	O
was	O
assessed	O
beyond	O
protocol-specific	O
chemotherapy	O
.	O

The	O
addition	O
of	O
D	O
to	O
CF	O
not	O
only	O
significantly	O
improved	O
clinical	O
benefit	O
but	O
also	O
improved	O
quality	Others
of	Others
life	Others
,	Physical
time	Physical
to	Physical
progression	Physical
,	Physical
and	Physical
overall	Mortality
survival	Mortality
compared	O
with	O
CF	O
.	O

Effects	O
of	O
short-	O
and	O
long-term	O
risperidone	O
treatment	O
on	O
prolactin	Physical
levels	Physical
in	O
children	O
with	O
autism	O
.	O

BACKGROUND	O
The	O
effects	O
of	O
short-	O
and	O
long-term	O
risperidone	O
treatment	O
on	O
serum	O
prolactin	O
were	O
assessed	O
in	O
children	O
and	O
adolescents	O
with	O
autism	O
.	O

METHODS	O
Patients	O
with	O
autism	O
(	O
N	O
=	O
101	O
,	O
5-17	O
years	O
of	O
age	O
)	O
were	O
randomized	O
to	O
an	O
8-week	O
trial	O
of	O
risperidone	O
or	O
placebo	O
and	O
63	O
then	O
took	O
part	O
in	O
a	O
4-month	O
open-label	O
follow-up	O
phase	O
.	O

Serum	O
samples	O
were	O
obtained	O
at	O
Baseline	O
and	O
Week-8	O
(	O
N	O
=	O
78	O
)	O
,	O
and	O
at	O
6-month	O
(	O
N	O
=	O
43	O
)	O
and	O
22-month	O
(	O
N	O
=	O
30	O
)	O
follow-up	O
.	O

Serum	O
prolactin	O
was	O
determined	O
by	O
immunoradiometric	O
assay	O
;	O
dopamine	Others
type-2	Others
receptor	Others
(	Others
DRD2	Others
)	Others
polymorphisms	Others
were	Others
genotyped	Others
.	Others

RESULTS	O
Baseline	Physical
prolactin	Physical
levels	Physical
were	O
similar	O
in	O
the	O
risperidone	O
(	O
N	O
=	O
42	O
)	O
and	O
placebo	O
(	O
N	O
=	O
36	O
)	O
groups	O
(	O
9.3	O
+/-	O
7.5	O
and	O
9.3	O
+/-	O
7.6	O
ng/ml	O
,	O
respectively	O
)	O
.	O

After	O
8	O
weeks	O
of	O
risperidone	O
,	O
prolactin	Physical
increased	O
to	O
39.0	O
+/-	O
19.2	O
ng/ml	O
,	O
compared	O
with	O
10.1	O
+/-	O
8.8	O
ng/ml	O
for	O
placebo	O
(	O
p	O
<	O
.0001	O
)	O
.	O

Prolactin	Physical
levels	Physical
were	O
also	O
significantly	O
increased	O
at	O
6	O
months	O
(	O
32.4	O
+/-	O
17.8	O
ng/ml	O
;	O
N	O
=	O
43	O
,	O
p	O
<	O
.0001	O
)	O
and	O
at	O
22	O
months	O
(	O
N	O
=	O
30	O
,	O
25.3	O
+/-	O
15.6	O
ng/ml	O
,	O
p	O
<	O
.0001	O
)	O
.	O

Prolactin	Physical
levels	Physical
were	O
not	O
associated	O
with	O
adverse	O
effects	O
and	O
DRD2	O
alleles	O
(	O
Taq1A	O
,	O
-141C	O
Ins/Del	O
,	O
C957T	O
)	O
did	O
not	O
significantly	O
influence	O
baseline	O
levels	O
or	O
risperidone-induced	O
increases	O
in	O
prolactin	O
.	O

CONCLUSIONS	O
Risperidone	O
treatment	O
was	O
associated	O
with	O
two-	O
to	O
four-fold	O
mean	O
increases	O
in	O
serum	O
prolactin	O
in	O
children	O
with	O
autism	O
.	O

Although	O
risperidone-induced	O
increases	O
tended	O
to	O
diminish	O
with	O
time	O
,	O
further	O
research	O
on	O
the	O
consequences	O
of	O
long-term	O
prolactin	O
elevations	O
in	O
children	O
and	O
adolescents	O
is	O
needed	O
.	O

Evaluating	O
the	O
impact	O
of	O
peer	O
,	O
nurse	O
case-managed	O
,	O
and	O
standard	O
HIV	O
risk-reduction	O
programs	O
on	O
psychosocial	Mental
and	Mental
health-promoting	Mental
behavioral	Mental
outcomes	Mental
among	O
homeless	O
women	O
.	O

Investigators	O
examined	O
the	O
6-month	O
impact	O
of	O
three	O
cognitive-behavioral	O
HIV	O
risk-reduction	O
programs	O
on	O
behavioral	Mental
factors	Mental
(	O
substance	O
use	O
and	O
sexual	O
risk	O
behaviors	O
)	O
and	O
cognitive	Others
and	Others
psychological	Others
resources	Others
of	O
325	O
women	O
who	O
resided	O
in	O
emergency	O
or	O
sober-living	O
shelters	O
and	O
their	O
308	O
intimate	O
sexual	O
partners	O
.	O

Participants	O
were	O
randomized	O
by	O
shelter	O
to	O
a	O
peer-mentored	Others
,	Others
a	Others
nurse	Others
case-managed	Others
,	Others
or	Others
a	Others
standard	Others
care	Others
HIV	Others
risk-reduction	Others
program	O
.	O

Significant	O
improvements	O
were	O
observed	O
in	O
all	O
groups	O
in	O
all	O
behavioral	Mental
factors	Mental
and	Mental
cognitive	Mental
and	Mental
psychological	Mental
resources	Mental
except	O
for	O
self-esteem	Mental
.	Mental

Participants	O
in	O
the	O
peer-mentored	O
and	O
nurse	O
case-managed	O
groups	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
standard	O
group	O
in	O
self-esteem	Mental
,	Mental
life	Mental
satisfaction	Mental
,	Mental
psychological	Mental
well-being	Mental
,	Mental
use	Mental
of	Mental
noninjection	Mental
drugs	Mental
,	Mental
sex	Mental
with	Mental
multiple	Mental
partners	Mental
,	Mental
and	Mental
unprotected	Mental
sex	Mental
at	O
6	O
months	O
(	O
n	O
=	O
633	O
)	O
.	O

It	O
was	O
concluded	O
that	O
a	O
standard	O
approach	O
by	O
health	O
care	O
professionals	O
appears	O
to	O
effectively	O
modify	Mental
HIV	Mental
risk	Mental
behaviors	Mental
for	O
a	O
majority	O
of	O
homeless	O
participants	O
and	O
may	O
have	O
important	O
economic	O
and	O
policy	O
implications	O
.	O

Further	O
,	O
the	O
impact	O
of	O
short-term	O
programs	O
that	O
address	O
psychological	O
vulnerabilities	O
of	O
impoverished	O
populations	O
needs	O
to	O
be	O
studied	O
further	O
.	O

Temporal	O
discounting	O
:	O
the	O
differential	O
effect	O
of	O
proximal	O
and	O
distal	O
consequences	O
on	O
confession	O
decisions	O
.	O

Drawing	O
on	O
the	O
psychological	O
principle	O
that	O
proximal	O
consequences	O
influence	O
behavior	O
more	O
strongly	O
than	O
distal	O
consequences	O
,	O
the	O
authors	O
tested	O
the	O
hypothesis	O
that	O
criminal	O
suspects	O
exhibit	O
a	O
short-sightedness	O
during	O
police	O
interrogation	O
that	O
increases	O
their	O
risk	Mental
for	Mental
confession	Mental
.	Mental

Consistent	O
with	O
this	O
hypothesis	O
,	O
Experiment	O
1	O
showed	O
that	O
participants	O
(	O
N	O
=	O
81	O
)	O
altered	O
how	O
frequently	O
they	O
admitted	Mental
to	Mental
criminal	Mental
and	Mental
unethical	Mental
behaviors	Mental
during	O
an	O
interview	O
to	O
avoid	O
a	O
proximal	O
consequence	O
even	O
though	O
doing	O
so	O
increased	O
their	O
risk	O
of	O
incurring	O
a	O
distal	Mental
consequence	Mental
.	Mental

Experiment	O
2	O
(	O
N	O
=	O
143	O
)	O
yielded	O
the	O
same	O
pattern	O
,	O
but	O
with	O
a	O
procedure	O
that	O
reversed	O
the	O
order	O
of	O
the	O
proximal	Mental
and	Mental
distal	Mental
consequences	Mental
,	O
thereby	O
ruling	O
out	O
the	O
possibility	O
that	O
it	O
was	O
the	O
unique	O
characteristics	O
of	O
the	O
consequences	O
rather	O
than	O
their	O
proximity	O
that	O
influenced	O
the	O
admission	Physical
rate	Physical
.	O

The	O
authors	O
discuss	O
the	O
supported	O
psychological	O
process	O
as	O
a	O
potential	O
explanation	O
for	O
several	O
well-established	O
findings	O
reported	O
in	O
the	O
literature	O
on	O
confessions	O
.	O

Thrombin-activatable	O
fibrinolysis	O
inhibitor	O
in	O
hypothyroidism	O
and	O
hyperthyroxinaemia	O
.	O

Endocrine	O
disorders	O
affect	O
both	O
the	O
coagulation	O
and	O
fibrinolytic	O
systems	O
,	O
and	O
have	O
been	O
associated	O
with	O
the	O
development	O
of	O
cardiovascular	O
diseases	O
.	O

Thrombin-activatable	O
fibrinolysis	O
inhibitor	O
(	O
TAFI	O
)	O
is	O
a	O
link	O
between	O
coagulation	O
and	O
the	O
fibrinolytic	O
system	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
thyroid	O
hormone	O
excess	O
and	O
deficiency	O
on	O
TAFI	O
levels	O
and	O
function	O
.	O

The	O
effect	O
of	O
hyperthyroxinemia	O
on	O
TAFI	O
was	O
studied	O
in	O
healthy	O
volunteers	O
who	O
were	O
randomised	O
to	O
receive	O
levothyroxine	O
or	O
no	O
medication	O
for	O
14	O
days	O
in	O
a	O
crossover	O
design	O
.	O

The	O
effect	O
of	O
hypothyroidism	O
on	O
TAFI	O
was	O
studied	O
in	O
a	O
multicentre	O
observational	O
cohort	O
study	O
.	O

Blood	O
was	O
drawn	O
before	O
treatment	O
of	O
patients	O
with	O
newly	O
diagnosed	O
hypothyroidism	O
and	O
when	O
euthyroidism	O
was	O
achieved	O
.	O

Plasma	Physical
clot-lysis	Physical
times	Physical
,	O
activated	Physical
TAFI	Physical
(	Physical
TAFIa	Physical
)	Physical
-dependent	Physical
prolongation	Physical
of	Physical
clot-lysis	Physical
and	O
TAFI	Physical
levels	Physical
were	O
measured	O
.	O

Thyroid	Physical
hormone	Physical
excess	Physical
resulted	O
in	O
a	O
hypofibrinolytic	Physical
condition	Physical
and	O
in	O
an	O
enhanced	O
TAFIa-dependent	Physical
prolongation	Physical
of	Physical
clot	Physical
lysis	Physical
.	O

A	O
trend	O
towards	O
decreased	Physical
plasma	Physical
TAFI	Physical
levels	Physical
was	O
observed	O
in	O
healthy	O
volunteers	O
who	O
used	O
levothyroxine	O
.	O

Hypothyroidism	O
resulted	O
in	O
hyperfibrinolysis	Physical
and	O
a	O
reduced	Physical
TAFIa-dependent	Physical
prolongation	Physical
of	Physical
clot	Physical
lysis	Physical
.	O

In	O
conclusion	O
,	O
alterations	O
of	O
TAFIa-dependent	Physical
prolongation	Physical
of	Physical
clot	Physical
lysis	Physical
in	O
patients	O
with	O
thyroid	O
disorders	O
may	O
cause	O
an	O
impaired	O
haemostatic	Physical
balance	Physical
.	O

The	O
disturbed	Physical
haemostatic	Physical
balance	Physical
in	O
patients	O
with	O
hyperthyroidism	O
might	O
make	O
them	O
prone	O
to	O
thrombosis	O
,	O
while	O
the	O
risk	O
for	O
bleeding	Physical
may	O
increase	O
in	O
patients	O
with	O
hypothyroidism	O
.	O

Impacts	O
of	O
a	O
disease	O
management	O
program	O
for	O
dually	O
eligible	O
beneficiaries	O
.	O

The	O
LifeMasters	O
Supported	O
SelfCare	O
demonstration	O
program	O
provides	O
disease	O
management	O
(	O
DM	O
)	O
services	O
to	O
Florida	O
Medicare	O
beneficiaries	O
who	O
are	O
also	O
enrolled	O
in	O
Medicaid	O
and	O
have	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
,	O
diabetes	O
,	O
or	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

The	O
population-based	O
program	O
provides	O
primarily	O
telephonic	O
patient	O
education	O
and	O
monitoring	O
services	O
.	O

Findings	O
from	O
the	O
randomized	O
,	O
intent-to-treat	O
design	O
over	O
the	O
first	O
18	O
months	O
of	O
operations	O
show	O
virtually	O
no	O
overall	O
impacts	Others
on	Others
hospital	Others
or	Others
emergency	Others
room	Others
(	Others
ER	Others
)	Others
use	Others
,	O
Medicare	Others
expenditures	Others
,	O
quality	Others
of	Others
care	Others
,	O
or	O
prescription	Others
drug	Others
use	Others
for	O
the	O
33,000	O
enrollees	O
.	O

However	O
,	O
for	O
beneficiaries	O
with	O
CHF	O
who	O
resided	O
in	O
high-cost	O
South	O
Florida	O
counties	O
,	O
the	O
program	O
reduced	O
Medicare	Others
expenditures	Others
by	O
9.6	O
percent	O
.	O

Effect	O
of	O
supplementary	O
antioxidant	O
vitamin	O
intake	O
on	O
carotid	Physical
arterial	Physical
wall	Physical
intima-media	Physical
thickness	Physical
in	O
a	O
controlled	O
clinical	O
trial	O
of	O
cholesterol	O
lowering	O
.	O

BACKGROUND	O
There	O
is	O
accumulating	O
experimental	O
,	O
epidemiological	O
,	O
and	O
clinical	O
evidence	O
of	O
an	O
association	O
between	O
anti-oxidant	O
vitamin	O
intake	O
and	O
reduced	O
risk	O
of	O
coronary	O
heart	O
disease	O
.	O

Using	O
data	O
from	O
the	O
Cholesterol	O
Lowering	O
Atherosclerosis	O
Study	O
(	O
CLAS	O
)	O
,	O
we	O
explored	O
the	O
association	O
of	O
self-selected	O
supplementary	O
antioxidant	O
vitamin	O
intake	O
on	O
the	O
rate	O
of	O
progression	O
of	O
early	O
preintrusive	O
atherosclerosis	O
.	O

METHODS	O
AND	O
RESULTS	O
CLAS	O
was	O
an	O
arterial	O
imaging	O
trial	O
in	O
which	O
nonsmoking	O
40-	O
to	O
59-year-old	O
men	O
with	O
previous	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
were	O
randomized	O
to	O
colestipol/niacin	O
plus	O
diet	O
or	O
placebo	O
plus	O
diet	O
.	O

The	O
rate	O
of	O
progression	O
of	O
early	O
preintrusive	O
atherosclerosis	Physical
was	O
determined	O
in	O
146	O
subjects	O
using	O
high-resolution	O
B-mode	O
ultrasound	O
quantification	O
of	O
the	O
distal	O
common	O
carotid	O
artery	O
far	O
wall	O
intima-media	O
thickness	O
(	O
IMT	O
)	O
.	O

From	O
the	O
nutritional	O
supplement	O
database	O
,	O
22	O
subjects	O
had	O
an	O
on-trial	O
average	O
supplementary	O
vitamin	O
E	O
intake	O
of	O
>	O
or	O
=	O
100	O
IU	O
per	O
day	O
(	O
high	O
users	O
)	O
and	O
29	O
subjects	O
had	O
an	O
average	O
on-trial	O
supplementary	O
vitamin	O
C	O
intake	O
of	O
>	O
or	O
=	O
250	O
mg	O
per	O
day	O
(	O
high	O
users	O
)	O
.	O

Within	O
the	O
placebo	O
group	O
,	O
less	Physical
carotid	Physical
IMT	Physical
progression	Physical
was	O
found	O
for	O
high	O
supplementary	O
vitamin	O
E	O
users	O
when	O
compared	O
with	O
low	O
vitamin	O
E	O
users	O
(	O
0.008	O
versus	O
0.023	O
mm/y	O
,	O
P	O
=	O
.03	O
)	O
.	O

No	O
effect	O
of	O
vitamin	Physical
E	O
within	O
the	O
drug	O
group	O
was	O
found	O
.	O

No	O
effect	O
of	O
vitamin	O
C	O
within	O
the	O
drug	O
or	O
placebo	O
group	O
was	O
found	O
.	O

CONCLUSIONS	O
Supplementary	O
vitamin	O
E	O
intake	O
appears	O
to	O
be	O
effective	O
in	O
reducing	O
the	O
progression	Physical
of	Physical
atherosclerosis	Physical
in	O
subjects	O
not	O
treated	O
with	O
lipid-lowering	O
drugs	O
while	O
the	O
process	O
is	O
still	O
confined	O
to	O
the	O
arterial	O
wall	O
(	O
early	O
preintrusive	O
atherosclerosis	O
)	O
.	O

Local	O
warming	O
and	O
insertion	O
of	O
peripheral	O
venous	O
cannulas	O
:	O
single	O
blinded	O
prospective	O
randomised	O
controlled	O
trial	O
and	O
single	O
blinded	O
randomised	O
crossover	O
trial	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
local	O
warming	O
of	O
the	O
lower	O
arm	O
and	O
hand	O
facilitates	O
peripheral	Physical
venous	Physical
cannulation	Physical
.	Others

DESIGN	O
Single	O
blinded	O
prospective	O
randomised	O
controlled	O
trial	O
and	O
single	O
blinded	O
randomised	O
crossover	O
trial	O
.	O

SETTING	O
Neurosurgical	O
unit	O
and	O
haematology	O
ward	O
of	O
university	O
hospital	O
.	O

PARTICIPANTS	O
100	O
neurosurgical	O
patients	O
and	O
40	O
patients	O
with	O
leukaemia	O
who	O
required	O
chemotherapy	O
.	O

INTERVENTIONS	O
Neurosurgical	O
patients	O
'	O
hands	O
and	O
forearms	O
were	O
covered	O
for	O
15	O
minutes	O
with	O
a	O
carbon	O
fibre	O
heating	O
mitt	O
.	O

Patients	O
were	O
assigned	O
randomly	O
to	O
active	O
warming	O
at	O
52	O
degrees	O
C	O
or	O
passive	O
insulation	O
(	O
heater	O
not	O
activated	O
)	O
.	O

The	O
same	O
warming	O
system	O
was	O
used	O
for	O
10	O
minutes	O
in	O
patients	O
with	O
leukaemia	O
.	O

They	O
were	O
assigned	O
randomly	O
to	O
active	O
warming	O
or	O
passive	O
insulation	O
on	O
day	O
1	O
and	O
given	O
alternative	O
treatment	O
during	O
the	O
subsequent	O
visit	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
PRIMARY	O
:	O
success	Others
rate	Others
for	Others
insertion	Others
of	Others
18	Others
gauge	Others
cannula	Others
into	Others
vein	Others
on	Others
back	Others
of	Others
hand	Others
.	Others

SECONDARY	O
:	O
time	Others
required	Others
for	Others
successful	Others
cannulation	Others
.	Others

RESULTS	O
In	O
neurosurgical	O
patients	O
,	O
it	O
took	O
36	O
seconds	O
(	O
95	O
%	O
confidence	O
interval	O
31	O
to	O
40	O
seconds	O
)	O
to	O
insert	Others
a	Others
cannula	Others
in	O
the	O
active	O
warming	O
group	O
and	O
62	O
(	O
50	O
to	O
74	O
)	O
seconds	O
in	O
the	O
passive	O
insulation	O
group	O
(	O
P=0.002	O
)	O
.	O

Three	O
(	O
6	O
%	O
)	O
first	O
attempts	O
failed	Others
in	O
the	O
active	O
warming	O
group	O
compared	O
with	O
14	O
(	O
28	O
%	O
)	O
in	O
the	O
passive	O
insulation	O
group	O
(	O
P=0.008	O
)	O
.	O

The	O
crossover	O
study	O
in	O
patients	O
with	O
leukaemia	O
showed	O
that	O
insertion	Others
time	Others
was	O
reduced	O
by	O
20	O
seconds	O
(	O
8	O
to	O
32	O
,	O
P=0.013	O
)	O
with	O
active	O
warming	O
and	O
that	O
failure	Others
rates	Others
at	Others
first	Others
attempt	Others
were	O
6	O
%	O
with	O
warming	O
and	O
30	O
%	O
with	O
passive	O
insulation	O
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
Local	O
warming	O
facilitates	O
the	O
insertion	Others
of	Others
peripheral	Others
venous	Others
cannulas	Others
,	O
reducing	O
both	O
time	Others
and	Others
number	Others
of	Others
attempts	Others
required	Others
.	Others

This	O
may	O
decrease	O
the	O
time	Others
staff	O
spend	O
inserting	Others
cannulas	Others
,	O
reduce	O
supply	Others
costs	Others
,	O
and	O
improve	O
patient	O
satisfaction	O
.	O

Effect	O
of	O
different	O
rates	O
of	O
infusion	O
of	O
propofol	O
for	O
induction	Physical
of	Physical
anaesthesia	Physical
in	O
elderly	O
patients	O
.	O

The	O
effect	O
of	O
changing	O
the	O
rate	O
of	O
infusion	O
of	O
propofol	O
for	O
induction	Physical
of	Physical
anaesthesia	Physical
was	O
studied	O
in	O
60	O
elderly	O
patients	O
.	O

Propofol	O
was	O
administered	O
at	O
300	O
,	O
600	O
or	O
1200	O
ml	O
h-1	O
until	O
loss	Physical
of	Physical
consciousness	Physical
(	O
as	O
judged	O
by	O
loss	Physical
of	Physical
verbal	Physical
contact	Physical
with	Physical
the	Physical
patient	Physical
)	O
had	O
been	O
achieved	O
.	O

The	O
duration	Others
of	Others
induction	Others
was	O
significantly	O
longer	O
(	O
P	O
less	O
than	O
0.001	O
)	O
with	O
the	O
slower	O
infusion	O
rates	O
(	O
104	O
,	O
68	O
and	O
51	O
s	O
)	O
,	O
but	O
the	O
total	Others
dose	Others
used	Others
was	O
significantly	O
less	O
(	O
P	O
less	O
than	O
0.001	O
)	O
in	O
these	O
patients	O
(	O
1.2	O
,	O
1.6	O
and	O
2.5	O
mg	O
kg-1	O
,	O
respectively	O
)	O
.	O

The	O
decrease	O
in	O
systolic	Physical
and	Physical
diastolic	Physical
arterial	Physical
pressure	Physical
was	O
significantly	O
less	O
in	O
the	O
300-ml	O
h-1	O
group	O
at	O
the	O
end	O
of	O
induction	O
and	O
immediately	O
after	O
induction	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
incidence	Physical
of	Physical
apnoea	Physical
was	O
also	O
significantly	O
less	O
in	O
the	O
slower	O
infusion	O
group	O
.	O

Duration	Others
of	Others
chemotherapy	Others
in	O
small	O
cell	O
lung	O
cancer	O
:	O
a	O
Cancer	O
Research	O
Campaign	O
trial	O
.	O

A	O
total	O
of	O
610	O
patients	O
with	O
small	O
cell	O
lung	O
cancer	O
were	O
entered	O
into	O
a	O
randomised	O
trial	O
designed	O
to	O
assess	O
the	O
effect	O
of	O
duration	O
of	O
initial	O
chemotherapy	O
on	O
survival	O
.	O

Patients	O
were	O
randomised	O
to	O
receive	O
either	O
four	O
or	O
eight	O
courses	O
of	O
cytotoxic	O
chemotherapy	O
with	O
cyclophosphamide	O
,	O
vincristine	O
and	O
etoposide	O
and	O
also	O
randomised	O
to	O
receive	O
,	O
on	O
disease	O
progression	O
,	O
either	O
second	O
line	O
chemotherapy	O
(	O
methotrexate	O
and	O
doxorubicin	O
)	O
or	O
symptomatic	O
treatment	O
only	O
.	O

In	O
the	O
whole	O
study	O
196	O
(	O
32.1	O
%	O
)	O
had	O
limited	O
disease	O
and	O
414	O
(	O
67.9	O
%	O
)	O
extensive	O
disease	O
.	O

During	O
initial	O
chemotherapy	O
the	O
response	Others
rate	Others
(	Others
complete	Others
and	Others
partial	Others
responses	Others
)	Others
after	O
four	O
courses	O
of	O
treatment	O
was	O
61	O
%	O
with	O
no	O
significant	O
increase	O
in	O
patients	O
receiving	O
eight	O
courses	O
(	O
63	O
%	O
)	O
.	O

In	O
those	O
randomised	O
to	O
receive	O
relapse	O
chemotherapy	O
the	O
response	Others
rate	Others
was	O
improved	O
slightly	O
for	O
those	O
who	O
had	O
originally	O
received	O
four	O
courses	O
of	O
chemotherapy	O
(	O
25.6	O
%	O
)	O
over	O
those	O
receiving	O
eight	O
(	O
18.7	O
%	O
)	O
.	O

The	O
overall	O
results	O
show	O
that	O
of	O
the	O
four	O
possible	O
treatment	O
randomizations	O
,	O
four	O
courses	O
of	O
chemotherapy	O
alone	O
is	O
inferior	O
in	O
terms	O
of	O
overall	O
survival	O
(	O
30	O
weeks	O
median	O
survival	O
)	O
to	O
the	O
other	O
three	O
treatment	O
options	O
(	O
39	O
weeks	O
median	O
survival	O
,	O
P	O
less	O
than	O
0.01	O
)	O
.	O

In	O
patients	O
responding	O
to	O
initial	O
chemotherapy	O
the	O
disadvantage	O
of	O
four	O
courses	O
of	O
chemotherapy	O
alone	O
was	O
apparent	O
(	O
median	O
survival	O
of	O
40	O
weeks	O
versus	O
49	O
weeks	O
,	O
P	O
=	O
0.003	O
)	O
but	O
not	O
if	O
drug	O
treatment	O
was	O
given	O
on	O
relapse	O
.	O

The	O
study	O
shows	O
that	O
limiting	O
treatment	O
to	O
four	O
courses	O
of	O
chemotherapy	O
alone	O
is	O
associated	O
with	O
inferior	O
survival	O
,	O
but	O
this	O
is	O
not	O
the	O
case	O
if	O
chemotherapy	O
is	O
given	O
at	O
relapse	O
.	O

[	O
The	O
anti-ischemic	Physical
effect	Physical
of	O
phosphodiesterase	O
III	O
inhibitors	O
]	O
.	O

When	O
enoximone	O
is	O
acutely	O
administered	O
to	O
patients	O
with	O
stable	O
angina	O
and	O
angiographically	O
proven	O
relevant	O
coronary	O
stenosis	O
i.v	O
.	O

application	O
of	O
0.75	O
mg/kg	O
exhibits	O
pronounced	O
antiischemic	Physical
effects	Physical
.	O

This	O
could	O
be	O
observed	O
in	O
patients	O
during	O
exercise	O
and	O
in	O
those	O
in	O
whom	O
the	O
ischemia	Physical
was	O
provoked	O
by	O
rapid	O
cardiac	O
stimulation	O
.	O

The	O
antiischemic	Physical
effects	Physical
were	O
documented	O
by	O
relief	Others
of	Others
symptoms	Others
,	O
reduction	O
of	O
ST-depression	Physical
,	O
improvement	O
of	O
impaired	O
myocardial	Physical
wall	Physical
motion	Physical
,	O
decrease	O
to	O
normalization	O
of	O
pathologically	Physical
elevated	Physical
filling	Physical
pressure	Physical
,	O
amelioration	Physical
of	Physical
coronary	Physical
blood	Physical
flow	Physical
as	O
evidenced	O
by	O
myocard	O
scintigraphy	O
and	O
washout	O
time	O
of	O
an	O
intracoronarily	O
injected	O
echo-contrast	O
medium	O
.	O

There	O
was	O
also	O
a	O
definite	O
improvement	O
of	O
ischemia-caused	Physical
mitral	Physical
regurgitation	Physical
.	O

Similar	O
observations	O
were	O
found	O
when	O
the	O
drug	O
was	O
injected	O
in	O
the	O
diseased	O
coronary	O
arteries	O
in	O
a	O
small	O
dose	O
(	O
0.075	O
mg/kg	O
)	O
so	O
that	O
peripheral	Physical
effects	Physical
were	O
not	O
present	O
.	O

In	O
comparison	O
to	O
the	O
Ca	O
(	O
++	O
)	O
-blocker	O
Gallopamil	O
the	O
antiischemic	Physical
effects	Physical
of	O
Enoximone	O
were	O
more	O
pronounced	O
,	O
a	O
synergistic	Physical
action	Physical
was	O
,	O
however	O
,	O
observed	O
.	O

Negative	Physical
dromotropic	Physical
effects	Physical
of	O
Gallopamil	O
could	O
be	O
abolished	O
by	O
Enoximone	O
.	O

With	O
oral	O
administration	O
of	O
the	O
drug	O
over	O
a	O
period	O
of	O
one	O
week	O
antiischemic	Physical
effects	Physical
could	O
also	O
be	O
documented	O
with	O
Holter	Others
monitoring	Others
as	O
well	O
as	O
during	O
exercise	O
.	O

There	O
was	O
a	O
reduction	O
of	O
ST-depression	Physical
both	O
at	O
spontaneously	O
occurring	O
ischemic	O
episodes	O
and	O
during	O
exercise	O
,	O
in	O
the	O
number	Physical
and	Physical
duration	Physical
of	Physical
episodes	Physical
of	Physical
silent	Physical
ischemia	Physical
,	O
particularly	O
,	O
however	O
,	O
a	O
decrease	O
in	O
symptomatic	Physical
episodes	Physical
.	O

In	O
none	O
of	O
the	O
patients	O
under	O
study	O
proarrhythmic	Physical
effects	Physical
were	O
observed	O
.	O

Extra	O
virgin	O
olive	O
oil	O
(	O
EVOO	O
)	O
consumption	O
and	O
antioxidant	Physical
status	Physical
in	O
healthy	O
institutionalized	O
elderly	O
humans	O
.	O

Recent	O
studies	O
show	O
that	O
the	O
elderly	O
have	O
increased	O
oxidative	O
stress	O
and	O
impaired	O
antioxidant	O
defense	O
systems	O
.	O

Our	O
study	O
aims	O
to	O
evaluate	O
the	O
effects	O
of	O
daily	O
consumption	O
of	O
EVOO	O
in	O
the	O
healthy	O
institutionalized	O
elderly	O
.	O

We	O
studied	O
anthropometric	Physical
,	Physical
biochemical	Physical
and	Physical
antioxidant	Physical
parameters	Physical
in	O
62	O
subjects	O
aged	O
65-96	O
years	O
after	O
a	O
6-week	O
daily	O
intake	O
of	O
polyphenol-rich	O
EVOO	O
with	O
high	O
oleuropein	O
derivative	O
contents	O
.	O

Subjects	O
were	O
divided	O
into	O
a	O
control	O
group	O
(	O
CG	O
)	O
who	O
maintained	O
their	O
dietary	O
habits	O
(	O
n=39	O
)	O
and	O
an	O
olive	O
group	O
(	O
OG	O
)	O
who	O
consumed	O
EVOO	O
as	O
the	O
only	O
added	O
fat	O
,	O
plus	O
a	O
daily	O
dose	O
of	O
50ml	O
(	O
n=23	O
)	O
.	O

We	O
found	O
a	O
significant	O
reduction	O
of	O
total	Physical
cholesterol	Physical
(	Physical
TC	Physical
)	Physical
,	Physical
HDL	Physical
,	Physical
LDL	Physical
and	Physical
TGs	Physical
in	O
OG	O
subjects	O
and	O
a	O
significant	O
increase	O
of	O
HDL	O
levels	O
.	O

There	O
was	O
no	O
significant	O
variation	O
in	O
the	O
CG	O
parameters	O
.	O

In	O
OG	O
the	O
total	Physical
antioxidant	Physical
capacity	Physical
(	Physical
TAC	Physical
)	Physical
in	Physical
plasma	Physical
increased	O
with	O
significant	O
differences	O
over	O
CG	O
.	O

Plasma	Physical
hydroxytyrosol	Physical
(	Physical
OH-Tyr	Physical
)	Physical
concentration	Physical
showed	O
a	O
significant	O
increase	O
after	O
EVOO	O
intervention	O
.	O

Daily	O
consumption	O
of	O
EVOO	O
was	O
found	O
to	O
have	O
positive	O
effects	O
on	O
lipid	Physical
profiles	Physical
,	O
OH-Tyr	Physical
levels	Physical
and	O
TAC	Physical
.	O

The	O
results	O
also	O
show	O
a	O
significant	O
increase	O
of	O
catalase	Physical
(	Physical
CAT	Physical
)	Physical
in	O
erythrocytes	O
and	O
a	O
decrease	O
(	O
p	O
<	O
0.05	O
)	O
in	O
superoxide	Physical
dismutase	Physical
(	Physical
SOD	Physical
)	Physical
and	Physical
glutathione	Physical
peroxidase	Physical
(	Physical
GH-PX	Physical
)	Physical
activity	Physical
after	O
EVOO	O
intake	O
.	O

To	O
our	O
knowledge	O
,	O
no	O
other	O
study	O
has	O
examined	O
the	O
effects	O
of	O
EVOO	O
consumption	O
on	O
biochemical	Others
parameters	Others
,	O
antioxidant	Others
capacity	Others
and	O
antioxidant	Physical
enzyme	Physical
activity	Physical
in	O
healthy	O
elderly	O
subjects	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
nutritional	O
intervention	O
with	O
EVOO	O
improves	O
antioxidant	O
status	O
in	O
healthy	O
elderly	O
people	O
.	O

Comparative	O
clinical	O
and	O
microbiological	O
effects	O
of	O
subgingival	O
metronidazole	O
application	O
in	O
adult	O
periodontitis	O
;	O
12-months	O
results	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
clinical	O
and	O
microbiological	O
effects	O
of	O
subgingival	O
application	O
of	O
25	O
%	O
metronidazole	O
dental	O
gel	O
as	O
an	O
adjunct	O
to	O
scaling	O
and	O
root	O
planing	O
(	O
SRP	O
)	O
in	O
the	O
treatment	O
of	O
adult	O
periodontitis	O
.	O

Eighty	O
teeth	O
in	O
18	O
patients	O
were	O
evaluated	O
using	O
a	O
split	O
mouth	O
design	O
.	O

The	O
test	O
teeth	O
received	O
SRP	O
and	O
a	O
25	O
%	O
metronidazole	O
gel	O
applied	O
subgingivally	O
on	O
days	O
0	O
and	O
7	O
.	O

The	O
control	O
teeth	O
received	O
SRP	O
only	O
.	O

Clinical	O
and	O
microbiological	O
examinations	O
were	O
carried	O
out	O
before	O
treatment	O
and	O
on	O
weeks	O
1	O
,	O
3	O
,	O
7	O
,	O
13	O
,	O
26	O
,	O
38	O
and	O
52	O
of	O
the	O
experimental	O
period	O
.	O

Colony	O
forming	O
units	O
of	O
Porphyromonas	O
gingivalis	O
and	O
Prevotella	O
intermedia	O
/	O
Prevotella	O
nigrescens	O
were	O
determined	O
.	O

Both	O
treatments	O
provided	O
significant	O
improvements	O
in	O
all	O
the	O
clinical	Physical
and	Physical
microbiological	Physical
parameters	Physical
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
none	O
of	O
the	O
differences	O
between	O
the	O
study	O
groups	O
were	O
statistically	O
significant	O
(	O
P	O
>	O
0.05	O
)	O
.	O

As	O
a	O
conclusion	O
,	O
the	O
present	O
study	O
does	O
not	O
provide	O
evidence	Others
in	Others
favour	Others
of	Others
the	Others
routine	Others
use	Others
of	Others
adjunctive	Others
metronidazole	Others
dental	Others
gel	Others
in	O
the	O
treatment	O
of	O
adult	Physical
periodontitis	Physical
.	O

Bupropion	O
SR	O
and	O
counseling	O
for	O
smoking	O
cessation	O
in	O
actual	O
practice	O
:	O
predictors	O
of	O
outcome	O
.	O

To	O
date	O
,	O
only	O
one	O
study	O
has	O
been	O
published	O
on	O
individual	O
characteristics	O
associated	O
with	O
outcome	O
following	O
standard	O
treatment	O
with	O
bupropion	O
SR	O
for	O
smoking	O
cessation	O
.	O

To	O
investigate	O
treatment	O
outcome	O
beyond	O
the	O
6-week	O
end-of-treatment	O
point	O
,	O
the	O
present	O
study	O
examined	O
characteristics	O
associated	O
with	O
more	O
clinically	O
relevant	O
smoking	O
endpoints	O
following	O
treatment	O
with	O
bupropion	O
SR	O
in	O
a	O
large	O
health	O
care	O
system	O
.	O

A	O
total	O
of	O
1,524	O
smokers	O
(	O
649	O
men	O
and	O
875	O
women	O
)	O
of	O
average	O
age	O
45.1	O
years	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
combinations	O
of	O
bupropion	O
SR	O
(	O
150	O
or	O
300	O
mg	O
)	O
and	O
behavioral	O
counseling	O
(	O
tailored	O
mailings	O
or	O
proactive	O
telephone	O
counseling	O
)	O
and	O
assessed	O
for	O
point-prevalent	O
smoking	O
status	O
at	O
3	O
and	O
12	O
months	O
.	O

Multiple	O
logistic	O
regression	O
analyses	O
of	O
potential	O
risk	O
factors	O
for	O
12-month	O
point-prevalent	O
smoking	O
and	O
for	O
persistent	O
smoking	O
(	O
point-prevalent	O
smoking	O
at	O
both	O
follow-ups	O
)	O
following	O
treatment	O
were	O
conducted	O
for	O
men	O
and	O
women	O
combined	O
and	O
separately	O
.	O

Risk	O
factors	O
for	O
smoking	O
at	O
both	O
endpoints	O
in	O
the	O
combined	O
sample	O
included	O
treatment	O
with	O
tailored	O
mailings	O
,	O
female	O
gender	O
,	O
younger	O
age	O
,	O
higher	O
levels	O
of	O
tobacco	O
dependence	O
,	O
shorter	O
previous	O
quit	O
attempts	O
,	O
previous	O
use	O
of	O
nicotine	O
replacement	O
therapy	O
,	O
and	O
report	O
of	O
current	O
depressive	O
symptoms	O
or	O
lifetime	O
depression	O
.	O

Risk	O
factors	O
for	O
smoking	O
following	O
treatment	O
identified	O
in	O
women	O
only	O
included	O
treatment	O
with	O
the	O
lower	O
dose	O
of	O
bupropion	O
SR	O
,	O
younger	O
age	O
,	O
and	O
higher	O
perceived	O
stress	O
,	O
whereas	O
those	O
that	O
were	O
unique	O
to	O
men	O
included	O
the	O
presence	O
of	O
lifetime	O
depression	O
.	O

The	O
results	O
are	O
discussed	O
in	O
terms	O
of	O
their	O
implications	O
for	O
the	O
need	Others
for	Others
more	Others
effective	Others
treatments	Others
in	O
general	O
,	O
and	O
the	O
role	O
of	O
individual	O
differences	O
in	O
the	O
likelihood	O
of	O
returning	Mental
to	Mental
smoking	Mental
following	Mental
treatment	Mental
for	O
quitting	O
.	O

Effect	O
of	O
marine	O
oils	O
supplementation	O
on	O
coagulation	O
and	O
cellular	O
activation	O
in	O
whole	O
blood	O
.	O

A	O
study	O
was	O
performed	O
to	O
explore	O
the	O
effects	O
of	O
supplemental	O
intake	O
of	O
various	O
marine	O
oils	O
known	O
to	O
be	O
part	O
of	O
the	O
Eskimo	O
diet	O
.	O

Healthy	O
men	O
and	O
women	O
(	O
134	O
)	O
were	O
randomly	O
selected	O
to	O
consume	O
15	O
mL/d	O
of	O
oil	O
from	O
blubber	O
of	O
seal	O
,	O
cod	O
liver	O
,	O
seal/cod	O
liver	O
,	O
blubber	O
of	O
Minke	O
whale	O
,	O
or	O
no	O
oil	O
for	O
ten	O
weeks	O
.	O

Total	Physical
cholesterol	Physical
was	O
unchanged	O
in	O
the	O
oil	O
groups	O
,	O
whereas	O
high	Physical
density	Physical
lipoprotein	Physical
cholesterol	Physical
increased	O
7	O
%	O
in	O
the	O
seal/cod	O
liver	O
oil	O
(	O
CLO	O
)	O
group	O
(	O
P	O
<	O
0.05	O
)	O
and	O
11	O
%	O
in	O
the	O
whale	O
oil	O
group	O
(	O
P	O
<	O
0.005	O
)	O
.	O

Triacylglycerol	Physical
was	O
significantly	O
reduced	O
in	O
the	O
CLO	O
group	O
only	O
.	O

The	O
concentration	Physical
of	Physical
prothrombin	Physical
fragment	Physical
1	Physical
+	Physical
2	Physical
was	O
reduced	O
25	O
%	O
(	O
P	O
<	O
0.05	O
)	O
after	O
whale	O
oil	O
supplementation	O
.	O

No	O
change	O
in	O
fibrinogen	Physical
or	Physical
factor	Physical
VIIc	Physical
was	O
detected	O
.	O

Tumor	Physical
necrosis	Physical
factor	Physical
generation	Physical
in	Physical
lipopolysaccharide	Physical
(	Physical
LPS	Physical
)	Physical
-stimulated	Physical
blood	Physical
was	O
30	O
%	O
reduced	O
after	O
whale	O
oil	O
(	O
P	O
<	O
0.05	O
)	O
,	O
but	O
was	O
unaffected	O
by	O
intake	O
of	O
seal	O
or	O
CLO	O
.	O

The	O
LPS-induced	Physical
tissue	Physical
factor	Physical
activity	Physical
in	Physical
monocytes	Physical
was	O
reduced	O
to	O
a	O
significant	O
degree	O
only	O
in	O
the	O
seal/CLO	O
group	O
(	O
34	O
%	O
)	O
and	O
whale	O
oil	O
group	O
(	O
35	O
%	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
most	O
dramatic	O
change	O
in	O
thromboxane	Physical
B2	Physical
in	O
LPS-stimulated	O
blood	O
was	O
seen	O
after	O
whale	O
oil	O
intake	O
with	O
44	O
%	O
reduction	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Supplementation	O
of	O
a	O
regular	O
diet	O
with	O
a	O
combination	O
of	O
seal	O
oil	O
and	O
CLO	O
and	O
especially	O
with	O
whale	O
oil	O
seems	O
to	O
have	O
beneficial	O
effects	O
on	O
several	O
products	O
thought	O
to	O
be	O
associated	O
with	O
cardiovascular	O
and	O
thrombotic	O
diseases	O
.	O

Neurophysiological	Mental
responses	Mental
to	Mental
faces	Mental
and	Mental
gaze	Mental
direction	Mental
differentiate	O
children	O
with	O
ASD	O
,	O
ADHD	O
and	O
ASD+ADHD	O
.	O

Children	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
demonstrate	O
face	Mental
processing	Mental
abnormalities	Mental
that	O
may	O
underlie	O
social	O
impairment	O
.	O

Despite	O
substantial	O
overlap	O
between	O
ASD	O
and	O
ADHD	O
,	O
ERP	Mental
markers	Mental
of	Mental
face	Mental
and	Mental
gaze	Mental
processing	Mental
have	O
not	O
been	O
directly	O
compared	O
across	O
pure	O
and	O
comorbid	O
cases	O
.	O

Children	O
with	O
ASD	O
(	O
n=19	O
)	O
,	O
ADHD	O
(	O
n=18	O
)	O
,	O
comorbid	O
ASD+ADHD	O
(	O
n=29	O
)	O
and	O
typically	O
developing	O
(	O
TD	O
)	O
controls	O
(	O
n=26	O
)	O
were	O
presented	O
with	O
upright/inverted	O
faces	O
with	O
direct/averted	O
gaze	O
,	O
with	O
concurrent	O
recording	O
of	O
the	O
P1	O
and	O
N170	O
components	O
.	O

While	O
the	O
N170	O
was	O
predominant	O
in	O
the	O
right	O
hemisphere	O
in	O
TD	O
and	O
ADHD	O
,	O
children	O
with	O
ASD	O
(	O
ASD/ASD+ADHD	O
)	O
showed	O
a	O
bilateral	O
distribution	O
.	O

In	O
addition	O
,	O
children	O
with	O
ASD	O
demonstrated	O
altered	O
response	Mental
to	Mental
gaze	Mental
direction	Mental
on	O
P1	O
latency	O
and	O
no	O
sensitivity	Mental
to	Mental
gaze	Mental
direction	Mental
on	O
midline-N170	O
amplitude	O
compared	O
to	O
TD	O
and	O
ADHD	O
.	O

In	O
contrast	O
,	O
children	O
with	O
ADHD	O
(	O
ADHD/ASD+ADHD	O
)	O
exhibited	O
a	O
reduced	O
face	Mental
inversion	Mental
effect	Mental
on	O
P1	O
latency	O
compared	O
to	O
TD	O
and	O
ASD	O
.	O

These	O
findings	O
suggest	O
children	O
with	O
ASD	O
have	O
specific	O
abnormalities	Mental
in	Mental
gaze	Mental
processing	Mental
and	Mental
altered	Mental
neural	Mental
specialisation	Mental
,	O
whereas	O
children	O
with	O
ADHD	O
show	O
abnormalities	Mental
at	O
early	O
visual	O
attention	O
stages	O
.	O

Children	O
with	O
ASD+ADHD	O
are	O
an	O
additive	O
co-occurrence	O
with	O
deficits	O
of	O
both	O
disorders	O
.	O

Elucidating	O
the	O
neural	O
basis	O
of	O
the	O
overlap	O
between	O
ASD	O
and	O
ADHD	O
is	O
likely	O
to	O
inform	O
aetiological	O
investigation	O
and	O
clinical	O
assessment	O
.	O

Improving	O
maternal	Mental
mental	Mental
health	Mental
after	O
a	O
child	O
's	O
diagnosis	O
of	O
autism	O
spectrum	O
disorder	O
:	O
results	O
from	O
a	O
randomized	O
clinical	O
trial	O
.	O

IMPORTANCE	O
The	O
prevalence	O
of	O
psychological	O
distress	O
among	O
mothers	O
of	O
children	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
suggests	O
a	O
need	O
for	O
interventions	O
that	O
address	O
parental	Mental
mental	Mental
health	Mental
during	O
the	O
critical	O
period	O
after	O
the	O
child	O
's	O
autism	O
diagnosis	O
when	O
parents	O
are	O
learning	O
to	O
navigate	O
the	O
complex	O
system	O
of	O
autism	O
services	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
a	O
brief	O
cognitive	O
behavioral	O
intervention	O
,	O
problem-solving	O
education	O
(	O
PSE	O
)	O
,	O
decreases	O
parenting	Physical
stress	Physical
and	O
maternal	Physical
depressive	Physical
symptoms	Physical
during	O
the	O
period	O
immediately	O
following	O
a	O
child	O
's	O
diagnosis	O
of	O
ASD	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
A	O
randomized	O
clinical	O
trial	O
compared	O
6	O
sessions	O
of	O
PSE	O
with	O
usual	O
care	O
.	O

Settings	O
included	O
an	O
autism	O
clinic	O
and	O
6	O
community-based	O
early	O
intervention	O
programs	O
that	O
primarily	O
serve	O
low-income	O
families	O
.	O

Participants	O
were	O
mothers	O
of	O
122	O
young	O
children	O
(	O
mean	O
age	O
,	O
34	O
months	O
)	O
who	O
recently	O
received	O
a	O
diagnosis	O
of	O
ASD	O
.	O

Among	O
mothers	O
assessed	O
for	O
eligibility	O
,	O
17.0	O
%	O
declined	O
participation	O
.	O

We	O
report	O
outcomes	O
after	O
3	O
months	O
of	O
follow-up	O
(	O
immediate	O
postdiagnosis	O
period	O
)	O
.	O

INTERVENTIONS	O
Problem-solving	O
education	O
is	O
a	O
brief	O
,	O
cognitive	O
intervention	O
delivered	O
in	O
six	O
30-minute	O
individualized	O
sessions	O
by	O
existing	O
staff	O
(	O
early	O
intervention	O
programs	O
)	O
or	O
research	O
staff	O
without	O
formal	O
mental	O
health	O
training	O
(	O
autism	O
clinic	O
)	O
.	O

MAIN	O
OUTCOMES	O
AND	O
MEASURES	O
Primary	O
outcomes	O
were	O
parental	Mental
stress	Mental
and	O
maternal	Mental
depressive	Mental
symptoms	Mental
.	O

RESULTS	O
Fifty-nine	O
mothers	O
were	O
randomized	O
to	O
receive	O
PSE	O
and	O
63	O
to	O
receive	O
usual	O
care	O
.	O

The	O
follow-up	O
rate	O
was	O
91.0	O
%	O
.	O

Most	O
intervention	O
mothers	O
(	O
78.0	O
%	O
)	O
received	O
the	O
full	O
PSE	O
course	O
.	O

At	O
the	O
3-month	O
follow-up	O
assessment	O
,	O
PSE	O
mothers	O
were	O
significantly	O
less	O
likely	O
than	O
those	O
serving	O
as	O
controls	O
to	O
have	O
clinically	O
significant	O
parental	Mental
stress	Mental
(	O
3.8	O
%	O
vs	O
29.3	O
%	O
;	O
adjusted	O
relative	O
risk	O
[	O
aRR	O
]	O
,	O
0.17	O
;	O
95	O
%	O
CI	O
,	O
0.04	O
to	O
0.65	O
)	O
.	O

For	O
depressive	Mental
symptoms	Mental
,	O
the	O
risk	O
reduction	O
in	O
clinically	O
significant	O
symptoms	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
5.7	O
%	O
vs	O
22.4	O
%	O
;	O
aRR	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
,	O
0.10	O
to	O
1.08	O
)	O
;	O
however	O
,	O
the	O
reduction	O
in	O
mean	O
depressive	Mental
symptoms	Mental
was	O
statistically	O
significant	O
(	O
Quick	O
Inventory	O
of	O
Depressive	O
Symptomatology	O
score	O
,	O
4.6	O
with	O
PSE	O
vs	O
6.9	O
with	O
usual	O
care	O
;	O
adjusted	O
mean	O
difference	O
,	O
-1.67	O
;	O
95	O
%	O
CI	O
,	O
-3.17	O
to	O
-0.18	O
)	O
.	O

CONCLUSIONS	O
AND	O
RELEVANCE	O
The	O
positive	O
effects	O
of	O
PSE	O
in	O
reducing	O
parenting	Mental
stress	Mental
and	O
depressive	Mental
symptoms	Mental
during	O
the	O
critical	O
postdiagnosis	O
period	O
,	O
when	O
parents	O
are	O
asked	O
to	O
navigate	O
a	O
complex	O
service	O
delivery	O
system	O
,	O
suggest	O
that	O
it	O
may	O
have	O
a	O
place	O
in	O
clinical	O
practice	O
.	O

Further	O
work	O
will	O
monitor	O
these	O
families	O
for	O
a	O
total	O
of	O
9	O
months	O
to	O
determine	O
the	O
trajectory	O
of	O
outcomes	O
.	O

TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT01021384	O
.	O

Getting	O
a	O
high	O
response	O
rate	O
of	O
sexual	O
behavior	O
survey	O
among	O
the	O
general	O
population	O
in	O
Japan	O
:	O
three	O
different	O
methods	O
of	O
survey	O
on	O
sexual	O
behavior	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
specify	O
the	O
most	O
accurate	O
,	O
reliable	O
and	O
valid	O
technique	O
for	O
a	O
general	O
sexual	O
behavioral	O
survey	O
in	O
Japan	O
.	O

This	O
pilot	O
study	O
was	O
conducted	O
to	O
assure	O
a	O
high	O
response	O
rate	O
and	O
to	O
keep	O
respondents	O
'	O
privacy	O
confidential	O
by	O
using	O
an	O
anonymous	O
questionnaire	O
survey	O
technique	O
.	O

The	O
sample	O
(	O
360	O
potential	O
respondents	O
)	O
was	O
selected	O
randomly	O
from	O
basic	O
resident	O
registers	O
in	O
two	O
geographically	O
different	O
areas	O
.	O

From	O
the	O
registries	O
,	O
90	O
residents	O
,	O
aged	O
20	O
to	O
49	O
years	O
old	O
,	O
were	O
randomly	O
selected	O
to	O
represent	O
each	O
sex	O
from	O
each	O
area	O
.	O

The	O
subjects	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
each	O
having	O
a	O
different	O
procedure	O
of	O
requesting	O
the	O
completion	O
of	O
the	O
survey	O
and	O
providing	O
the	O
questionnaires	O
:	O
(	O
1	O
)	O
Postal	O
Group	O
,	O
(	O
2	O
)	O
Telephone	O
Group	O
,	O
and	O
(	O
3	O
)	O
Face-to-face	O
Group	O
.	O

The	O
survey	O
was	O
carried	O
out	O
from	O
October	O
1995	O
to	O
February	O
1996	O
.	O

Effective	Others
response	Others
rates	Others
for	O
the	O
above	O
mentioned	O
three	O
groups	O
were	O
69.2	O
%	O
,	O
69.2	O
%	O
and	O
55.8	O
%	O
,	O
respectively	O
.	O

It	O
is	O
difficult	O
to	O
determine	O
the	O
best	O
method	O
when	O
only	O
considering	O
the	O
effective	Others
response	Others
rates	Others
.	Physical

However	O
,	O
judging	O
from	O
our	O
effort	O
and	O
expense	O
,	O
the	O
mail	O
survey	O
is	O
the	O
best	O
possible	O
procedure	O
and	O
would	O
be	O
a	O
reasonable	O
method	O
for	O
a	O
national	O
sexual	O
behavior	O
survey	O
.	O

Secondary	O
caries	O
formation	O
in	O
vitro	O
around	O
glass	O
ionomer-lined	O
amalgam	O
and	O
composite	O
restorations	O
.	O

The	O
aim	O
of	O
this	O
in	O
vitro	O
secondary	O
caries	O
study	O
was	O
to	O
examine	O
the	O
glass-ionomer	O
liner	O
's	O
effect	O
on	O
wall-lesion	O
inhibition	O
when	O
a	O
conventional	O
and	O
a	O
light-cured	O
glass	O
ionomer	O
liner	O
was	O
placed	O
under	O
amalgam	O
and	O
composite	O
resin	O
restorations	O
.	O

Class	O
V	O
preparations	O
in	O
extracted	O
upper	O
premolars	O
were	O
used	O
and	O
ten	O
restorations	O
were	O
used	O
for	O
each	O
of	O
the	O
following	O
groups	O
:	O
(	O
i	O
)	O
two	O
layers	O
of	O
copal	O
varnish	O
and	O
amalgam	O
;	O
(	O
ii	O
)	O
conventional	O
glass-ionomer	O
and	O
amalgam	O
;	O
(	O
iii	O
)	O
light-cured	O
glass-ionomer	O
and	O
amalgam	O
;	O
(	O
iv	O
)	O
bonding	O
agent	O
and	O
light-cured	O
composite	O
resin	O
;	O
(	O
v	O
)	O
conventional	O
glass-ionomer	O
,	O
bonding	O
agent	O
and	O
light-cured	O
composite	O
resin	O
;	O
(	O
vi	O
)	O
light-cured	O
glass-ionomer	O
,	O
extended	O
0.3	O
mm	O
short	O
of	O
the	O
enamel	O
margin	O
bonding	O
agent	O
and	O
light-cured	O
composite	O
resin	O
;	O
and	O
(	O
vii	O
)	O
light-cured	O
glass-ionomer	O
,	O
extended	O
1	O
mm	O
short	O
of	O
the	O
enamel	O
margin	O
,	O
bonding	O
agent	O
and	O
light-cured	O
composite	O
resin	O
.	O

The	O
teeth	O
were	O
thermocycled	O
and	O
artificial	O
caries	O
were	O
created	O
using	O
an	O
acid-gel	O
.	O

The	O
results	O
of	O
this	O
study	O
showed	O
that	O
artificial	Physical
recurrent	Physical
caries	Physical
can	O
be	O
reduced	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
with	O
a	O
glass-ionomer	O
liner	O
under	O
amalgam	O
restorations	O
.	O

The	O
results	O
also	O
showed	O
that	O
when	O
the	O
light-cured	O
glass-ionomer	O
liner	O
was	O
placed	O
0.3	O
mm	O
from	O
the	O
cavosurface	O
margin	O
under	O
composite	O
resin	O
restoration	O
,	O
the	O
artificial	Physical
recurrent	Physical
caries	Physical
reduced	Physical
significantly	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Treatment	O
of	O
familial	O
hypercholesterolemia	O
with	O
a	O
combination	O
of	O
bezafibrate	O
and	O
guar	O
.	O

The	O
effect	Physical
of	O
guar	O
(	O
15.6	O
g/day	O
)	O
,	O
a	O
dietary	O
fibre	O
,	O
and	O
simultaneous	O
administration	O
of	O
bezafibrate	O
(	O
600	O
mg/day	O
)	O
during	O
dietetic	O
treatment	O
on	O
the	O
plasma	O
lipoproteins	O
and	O
apolipoproteins	O
was	O
investigated	O
in	O
12	O
patients	O
with	O
familial	O
hypercholesterolemia	O
(	O
corresponding	O
to	O
the	O
HLP	O
type	O
IIa	O
pattern	O
)	O
.	O

Either	O
bezafibrate	O
alone	O
or	O
bezafibrate	O
in	O
combination	O
with	O
guar	O
was	O
administered	O
in	O
a	O
cross-over	O
study	O
for	O
3	O
months	O
.	O

Guar	O
led	O
to	O
an	O
additional	O
lowering	O
of	O
the	O
total	Physical
cholesterol	Physical
in	O
the	O
plasma	O
by	O
7	O
%	O
(	O
P	O
less	O
than	O
or	O
equal	O
to	O
0.05	O
)	O
associated	O
with	O
a	O
fall	O
of	O
the	O
low	Physical
density	Physical
lipoprotein	Physical
cholesterol	Physical
(	Physical
LDL-cholesterol	Physical
(	O
LDL-cholesterol	O
)	O
by	O
13	O
%	O
(	O
P	O
less	O
than	O
or	O
equal	O
to	O
0.01	O
)	O
without	O
any	O
changes	O
in	O
the	O
very	O
low	O
density	O
lipoprotein	O
(	O
VLDL	O
)	O
and	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterols	O
.	O

In	O
parallel	O
with	O
the	O
decrease	O
in	O
LDL-cholesterol	Physical
,	O
the	O
apoprotein	Physical
B	Physical
also	O
was	O
diminished	O
by	O
20	O
%	O
(	O
P	O
less	O
than	O
or	O
equal	O
to	O
0.05	O
)	O
.	O

The	O
plasma	Physical
triglyceride	Physical
level	Physical
and	Physical
the	Physical
triglyceride	Physical
distribution	Physical
within	O
the	O
individual	O
lipoprotein	O
fractions	O
were	O
not	O
altered	O
in	O
any	O
consistent	O
manner	O
by	O
the	O
addition	O
of	O
guar	O
.	O

Neither	O
the	O
fasting	Physical
plasma	Physical
glucose	Physical
level	Physical
nor	Physical
the	Physical
body	Physical
weight	Physical
were	O
affected	O
.	O

The	O
side-effects	O
due	O
to	O
guar	O
treatment	O
consisted	O
of	O
slight	Adverseeffect
nausea	Adverseeffect
,	Adverseeffect
meteorism	Adverseeffect
and	Adverseeffect
constipation	Adverseeffect
,	O
but	O
this	O
did	O
not	O
in	O
any	O
of	O
the	O
cases	O
lead	O
to	O
early	O
termination	O
of	O
the	O
study	O
.	O

These	O
results	O
demonstrate	O
that	O
guar	O
exerts	O
its	O
cholesterol-lowering	O
effect	O
in	O
addition	O
to	O
that	O
of	O
bezafibrate	O
.	O

Onset/offset	Physical
characteristics	Physical
and	Physical
intubating	Physical
conditions	Physical
of	O
rapacuronium	O
:	O
a	O
comparison	O
with	O
rocuronium	O
.	O

We	O
compared	O
onset	Physical
and	Physical
offset	Physical
of	Physical
action	Physical
and	Physical
tracheal	Physical
intubating	Physical
conditions	Physical
after	O
rapacuronium	O
and	O
rocuronium	O
in	O
60	O
patients	O
in	O
a	O
randomized	O
,	O
assessor-blinded	O
study	O
.	O

Following	O
induction	O
of	O
anaesthesia	O
with	O
propofol	O
2.5	O
mg	O
kg-1	O
,	O
either	O
rapacuronium	O
1.5	O
mg	O
kg-1	O
(	O
n	O
=	O
30	O
)	O
or	O
rocuronium	O
0.6	O
mg	O
kg-1	O
(	O
n	O
=	O
30	O
)	O
was	O
administered	O
to	O
facilitate	O
tracheal	O
intubation	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
either	O
a	O
propofol	O
infusion	O
(	O
100	O
micrograms	O
kg-1	O
min-1	O
)	O
or	O
sevoflurane	O
(	O
1	O
%	O
end-tidal	O
)	O
with	O
66	O
%	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
,	O
n	O
=	O
15	O
in	O
each	O
subgroup	O
.	O

Neuromuscular	Others
monitoring	Others
was	O
performed	O
using	O
an	O
electromyographic	O
(	O
EMG	O
)	O
device	O
(	O
Datex	O
Relaxograph	O
)	O
.	O

The	O
lag	Others
times	Others
(	O
mean	O
42	O
(	O
SD	O
11	O
)	O
s	O
and	O
44	O
(	O
16	O
)	O
s	O
)	O
,	O
maximum	Others
block	Others
(	O
99	O
(	O
2	O
)	O
%	O
and	O
98	O
(	O
3	O
)	O
%	O
)	O
and	O
intubating	Physical
conditions	Physical
at	Physical
60	Physical
s	Physical
(	O
good-to-excellent	O
in	O
86	O
%	O
and	O
84	O
%	O
of	O
patients	O
)	O
were	O
similar	O
for	O
rapacuronium	O
and	O
rocuronium	O
,	O
respectively	O
.	O

The	O
onset	Others
time	Others
of	O
rapacuronium	O
was	O
shorter	O
than	O
rocuronium	O
(	O
87	O
(	O
20	O
)	O
vs	O
141	O
(	O
65	O
)	O
s	O
,	O
P	O
<	O
0.001	O
)	O
,	O
and	O
the	O
degree	Physical
of	Physical
block	Physical
at	Physical
60	Physical
s	Physical
was	O
greater	O
(	O
69	O
(	O
26	O
)	O
vs	O
50	O
(	O
27	O
)	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Twenty-five	O
per	O
cent	O
recovery	Physical
was	O
shorter	O
with	O
rapacuronium	O
than	O
rocuronium	O
during	O
propofol	O
(	O
15.0	O
(	O
3.2	O
)	O
vs	O
39.1	O
(	O
14.2	O
)	O
min	O
,	O
P	O
<	O
0.001	O
)	O
and	O
sevoflurane	O
(	O
15.1	O
(	O
4.2	O
)	O
vs	O
47.8	O
(	O
19.0	O
)	O
min	O
,	O
P	O
<	O
0.001	O
)	O
anaesthesia	O
.	O

We	O
conclude	O
that	O
rapacuronium	O
1.5	O
mg	O
kg-1	O
had	O
a	O
more	O
rapid	O
onset	O
,	O
similar	O
intubating	Physical
conditions	Physical
,	O
and	O
shorter	O
recovery	O
times	O
than	O
rocuronium	O
0.6	O
mg	O
kg-1	O
.	O

Postoperative	O
analgesia	O
with	O
preoperative	O
oral	O
ibuprofen	O
or	O
acetaminophen	O
in	O
children	O
undergoing	O
myringotomy	O
.	O

Previous	O
studies	O
have	O
shown	O
over	O
70	O
%	O
of	O
children	O
require	O
analgesics	O
following	O
bilateral	O
myringotomy	O
and	O
tube	O
placement	O
(	O
BM	O
&	O
T	O
)	O
.	O

This	O
double-blind	O
,	O
placebo-controlled	O
study	O
compared	O
the	O
postoperative	O
analgesic	O
effects	O
of	O
preoperatively	O
administered	O
oral	O
acetaminophen	O
or	O
ibuprofen	O
.	O

Forty	O
three	O
ASA	O
I	O
or	O
II	O
children	O
age	O
six	O
months	O
or	O
older	O
scheduled	O
for	O
elective	O
BM	O
&	O
T	O
were	O
randomized	O
to	O
receive	O
acetaminophen	O
(	O
paracetamol	O
)	O
15	O
mg.kg-1	O
,	O
ibuprofen	O
10	O
mg.kg-1	O
,	O
or	O
placebo	O
.	O

Postoperative	O
pain	O
was	O
assessed	O
using	O
the	O
Children	Others
's	Others
Hospital	Others
of	Others
Eastern	Others
Ontario	Others
Pain	Others
Scale	Others
(	Others
CHEOPS	Others
)	Others
upon	O
arrival	O
to	O
the	O
PACU	O
and	O
at	O
5	O
,	O
10	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
and	O
60	O
min	O
.	O

CHEOP	O
scores	O
did	O
not	O
differ	O
between	O
the	O
groups	O
at	O
any	O
time	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
number	O
of	O
children	O
receiving	O
rescue	Others
analgesia	Others
.	O

This	O
study	O
showed	O
no	O
benefit	O
of	O
preoperatively	O
administered	O
oral	O
ibuprofen	O
10	O
mg.kg-1	O
or	O
acetaminophen	O
15	O
mg.kg-1	O
over	O
placebo	O
for	O
the	O
relief	O
of	O
postoperative	O
pain	O
in	O
children	O
undergoing	O
BM	O
&	O
T	O
.	O

Repeatability	O
and	O
protocol	O
comparability	O
of	O
presyncopal	O
symptom	O
limited	O
lower	O
body	O
negative	O
pressure	O
exposures	O
.	O

Data	O
on	O
repeatability	O
and	O
comparability	O
of	O
different	O
presyncopal	O
symptom-limited	O
lower	O
body	O
negative	O
pressure	O
(	O
PSL-LBNP	O
)	O
exposure	O
protocols	O
,	O
while	O
scarce	O
,	O
are	O
critical	O
to	O
the	O
interpretation	O
of	O
studies	O
using	O
PSL-LBNP	O
methods	O
.	O

To	O
investigate	O
if	O
PSL-LBNP	O
tolerance	O
,	O
heart	O
rate	O
,	O
and	O
blood	O
pressure	O
were	O
repeatable	O
,	O
11	O
subjects	O
were	O
exposed	O
to	O
4	O
PSL-LBNP	O
tests	O
;	O
each	O
test	O
occurring	O
at	O
the	O
same	O
time	O
of	O
day	O
,	O
separated	O
by	O
at	O
least	O
72	O
h	O
,	O
and	O
using	O
the	O
same	O
protocol	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
either	O
the	O
heart	Physical
rate	Physical
or	Physical
blood	Physical
pressure	Physical
responses	Physical
to	O
the	O
PSL-LBNP	O
or	O
the	O
tolerance	Others
indices	Others
(	O
cumulative	O
stress	O
index	O
;	O
maximum	O
negative	O
pressure	O
tolerated	O
;	O
and	O
duration	O
of	O
negative	O
pressure	O
exposure	O
)	O
.	O

To	O
study	O
the	O
comparability	O
of	O
different	O
PSL-LBNP	O
protocols	O
,	O
nine	O
subjects	O
were	O
exposed	O
randomly	O
to	O
five	O
PSL-LBNP	O
tests	O
using	O
protocols	O
that	O
varied	O
in	O
stage	O
duration	O
but	O
not	O
pressure	O
profile	O
.	O

The	O
protocols	O
had	O
1-	O
,	O
3-	O
,	O
5-	O
,	O
7-	O
,	O
or	O
9-min	O
stage	O
durations	O
.	O

These	O
PSL-LBNP	O
exposures	O
were	O
conducted	O
at	O
the	O
same	O
time	O
of	O
day	O
and	O
separated	O
by	O
at	O
least	O
72	O
h.	O
While	O
no	O
differences	O
were	O
noted	O
in	O
either	O
the	O
response	O
pattern	O
or	O
magnitude	O
of	O
heart	Physical
rate	Physical
or	Physical
blood	Physical
pressure	Physical
to	O
the	O
differing	O
protocols	O
,	O
the	O
cumulative	Others
stress	Others
index	Others
and	Physical
the	Physical
duration	Physical
of	Physical
negative	Physical
pressure	Physical
exposure	Physical
varied	O
proportionally	O
with	O
the	O
length	O
of	O
the	O
stage	O
durations	O
.	O

With	O
the	O
exception	O
of	O
the	O
1-min	O
protocol	O
,	O
the	O
maximum	O
negative	O
pressure	O
tolerated	O
did	O
not	O
vary	O
regardless	O
of	O
the	O
protocol	O
used	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Timing	Mortality
of	Mortality
death	Mortality
and	O
myocardial	Physical
infarction	Physical
in	O
patients	O
with	O
non-ST	O
elevation	O
acute	O
coronary	O
syndromes	O
:	O
insights	O
from	O
randomized	O
clinical	O
trials	O
.	O

BACKGROUND	O
Adverse	O
events	O
occur	O
following	O
non-ST	O
elevation	O
acute	O
coronary	O
syndromes	O
(	O
NSTE	O
ACS	O
)	O
.	O

However	O
,	O
the	O
timing	O
of	O
these	O
events	O
in	O
relation	O
to	O
index	O
event	O
is	O
less	O
clear	O
.	O

METHODS	O
Accordingly	O
,	O
we	O
evaluated	O
26,466	O
NSTE	O
ACS	O
patients	O
from	O
the	O
Global	O
Use	O
of	O
Strategies	O
to	O
Open	O
Occluded	O
Arteries	O
in	O
Acute	O
Coronary	O
Syndromes	O
(	O
GUSTO-IIb	O
)	O
,	O
Platelet	O
Glycoprotein	O
IIb/IIIa	O
in	O
Unstable	O
Angina	O
:	O
Receptor	O
Suppression	O
Using	O
Integrilin	O
Therapy	O
(	O
PURSUIT	O
)	O
,	O
and	O
Platelet	O
IIb/IIIa	O
Antagonism	O
for	O
the	O
Reduction	O
of	O
Acute	O
Coronary	O
Syndrome	O
Events	O
in	O
a	O
Global	O
Organization	O
Network	O
(	O
PARAGON	O
)	O
A	O
and	O
B	O
trials	O
to	O
ascertain	O
the	O
timing	O
of	O
adverse	O
events	O
.	O

Outcomes	O
of	O
interest	O
were	O
death	Mortality
,	O
myocardial	Physical
infarction	Physical
(	Physical
MI	Physical
)	Physical
,	O
and	O
death	Mortality
or	O
MI	Physical
at	Physical
180	Physical
days	Physical
.	O

Logistic	O
regression	O
modeling	O
for	O
death	O
was	O
used	O
to	O
categorize	O
patients	O
into	O
low-	O
,	O
medium-	O
,	O
and	O
high-risk	O
groups	O
.	O

RESULTS	O
At	O
6	O
months	O
,	O
6.2	O
%	O
of	O
patients	O
died	Mortality
,	O
12.1	O
%	O
had	O
MI	Physical
,	O
and	O
15.7	O
%	O
suffered	O
death	Mortality
or	O
MI	Physical
.	O

From	O
15	O
%	O
to	O
40	O
%	O
of	O
these	O
events	O
occurred	O
beyond	O
30	O
days	O
.	O

At	O
6	O
months	O
,	O
3	O
%	O
,	O
4	O
%	O
,	O
and	O
13	O
%	O
of	O
patients	O
died	O
in	O
low-	O
,	O
medium-	O
,	O
and	O
high-risk	O
groups	O
,	O
respectively	O
.	O

However	O
,	O
the	O
proportion	Mortality
of	Mortality
patients	Mortality
dying	Mortality
beyond	O
30	O
days	O
was	O
similar	O
in	O
the	O
three	O
groups	O
(	O
44	O
%	O
,	O
43	O
%	O
,	O
and	O
41	O
%	O
of	O
death	O
,	O
respectively	O
)	O
.	O

Similarly	O
,	O
whereas	O
death	Mortality
or	O
MI	Mortality
increased	O
with	O
higher	O
risk	O
(	O
11	O
%	O
,	O
14	O
%	O
,	O
and	O
23	O
%	O
,	O
respectively	O
)	O
,	O
the	O
proportion	Physical
of	Physical
patients	Physical
with	O
this	O
event	O
beyond	O
30	O
days	O
did	O
not	O
differ	O
in	O
the	O
three	O
strata	O
(	O
22	O
%	O
,	O
20	O
%	O
,	O
and	O
25	O
%	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
Our	O
study	O
provides	O
important	O
insights	O
into	O
the	O
timing	O
of	O
adverse	O
events	O
and	O
suggests	O
that	O
the	O
substantial	O
proportion	O
of	O
patients	O
suffer	O
subsequent	O
adverse	O
events	O
after	O
their	O
index	O
NSTE	O
ACS	O
.	O

Thus	O
,	O
these	O
data	O
call	O
for	O
continuous	O
surveillance	O
for	O
these	O
events	O
and	O
efforts	O
beyond	O
the	O
acute	O
phase	O
at	O
increasing	O
adherence	O
to	O
evidence-based	O
therapies	O
to	O
improve	O
the	O
outcomes	O
of	O
these	O
patients	O
.	O

Parenteral	O
troxerutin	O
and	O
carbazochrome	O
combination	O
in	O
the	O
treatment	O
of	O
post-hemorrhoidectomy	O
status	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
phase	O
IV	O
study	O
.	O

Flavonoids	O
,	O
such	O
as	O
troxerutin	O
,	O
have	O
been	O
shown	O
to	O
be	O
safe	O
and	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
chronic	O
venous	O
insufficiency	O
.	O

The	O
fixed	O
combination	O
between	O
troxerutin	O
150	O
mg	O
and	O
carbazochrome	O
1.5	O
mg	O
(	O
Fleboside	O
ampoules	O
)	O
was	O
previously	O
shown	O
to	O
have	O
a	O
good	O
efficacy	O
and	O
safety	O
profile	O
in	O
non-surgical	O
patients	O
with	O
acute	O
uncomplicated	O
hemorrhoids	O
.	O

The	O
purpose	O
of	O
this	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
the	O
active	O
combination	O
in	O
the	O
treatment	O
of	O
post-hemorrhoidectomy	O
patients	O
.	O

30	O
patients	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
two	O
treatments	O
:	O
troxerutin	O
150	O
mg	O
and	O
carbazochrome	O
1.5	O
mg	O
,	O
or	O
placebo	O
,	O
i.m	O
.	O

3	O
ml	O
ampoules	O
twice	O
a	O
day	O
for	O
five	O
consecutive	O
days	O
after	O
the	O
surgical	O
procedure	O
,	O
starting	O
from	O
the	O
day	O
of	O
surgery	O
.	O

Efficacy	Others
parameters	O
were	O
assessed	O
as	O
follows	O
:	O
at	O
baseline	O
(	O
T1	O
)	O
,	O
after	O
the	O
first	O
administration	O
(	O
T2	O
;	O
day	O
of	O
surgery	O
)	O
,	O
the	O
second	O
day	O
after	O
the	O
surgical	O
procedure	O
(	O
T3	O
)	O
,	O
and	O
the	O
fifth	O
day	O
after	O
the	O
surgical	O
procedure	O
(	O
T4	O
)	O
;	O
hemorrhoidal	Physical
symptoms	Physical
based	Physical
on	Physical
a	Physical
visual	Physical
analogue	Physical
scale	Physical
(	Physical
VAS	Physical
)	Physical
:	O
pain	Pain
,	O
discharge	Physical
,	Physical
bleeding	Physical
,	Physical
inflammation	Physical
,	Physical
and	Physical
pruritus	Physical
;	O
analgesic	Others
intake	Others
,	Others
if	Others
any	Others
;	Others
time	Others
to	Others
restore	Others
a	Others
physiological	Others
defecation	Others
;	O
edema	O
evaluation	O
(	O
based	O
on	O
a	O
four-point	O
scale	O
:	O
0	O
=	O
absent	O
;	O
1	O
=	O
mild	O
;	O
2	O
=	O
moderate	O
;	O
3	O
=	O
severe	O
)	O
;	O
camera	Physical
pictures	Physical
taken	Physical
at	Physical
T1	Physical
and	Physical
T4	Physical
(	O
in	O
selected	O
patients	O
)	O
;	O
and	O
blood	Physical
coagulation	Physical
tests	Physical
.	Physical

Analysis	O
between	O
treatment	O
groups	O
revealed	O
a	O
highly	O
significant	Physical
difference	Physical
at	O
T3	O
and	O
T4	O
for	O
the	O
total	Others
VAS	Others
score	Others
(	O
p	O
=	O
0.007	O
and	O
p	O
=	O
0.001	O
,	O
respectively	O
)	O
in	O
favor	O
of	O
the	O
active	O
combination	O
treatment	O
.	O

A	O
statistically	O
significant	O
difference	O
was	O
also	O
observed	O
for	O
bleeding	Physical
and	O
pruritus	Physical
at	O
T3	O
and	O
for	O
these	O
two	O
parameters	O
and	O
both	O
inflammation	Physical
and	O
edema	Physical
at	O
T4	O
(	O
p	O
<	O
0.001	O
)	O
in	O
favor	O
of	O
the	O
active	O
combination	O
group	O
.	O

No	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
were	O
reported	O
.	O

Neither	O
the	O
active	O
combination	O
nor	O
placebo	O
affected	O
blood	Physical
coagulation	Physical
tests	O
.	O

We	O
conclude	O
that	O
intramuscular	O
administration	O
of	O
the	O
fixed	O
combination	O
of	O
troxerutin	O
150	O
mg	O
and	O
carbazochrome	O
1.5	O
mg	O
is	O
effective	O
,	O
well	O
tolerated	O
and	O
superior	O
to	O
placebo	O
in	O
improving	O
hemorrhoidal	O
and	O
post-surgical	O
symptoms	O
during	O
the	O
five	O
days	O
following	O
surgery	O
.	O

[	O
Validity	O
of	O
cardiotocography	O
in	O
the	O
detection	O
of	O
umbilical	Physical
cord	Physical
complications	Physical
]	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
validity	O
of	O
cardiotocography	O
for	O
the	O
detection	O
of	O
cord	Physical
complications	Physical
.	Physical

MATERIAL	O
AND	O
METHODS	O
A	O
low-risk	O
population	O
of	O
4196	O
cases	O
was	O
selected	O
in	O
which	O
cord	O
complications	O
have	O
been	O
recognized	O
in	O
34.3	O
%	O
.	O

Cases	O
with	O
cord	O
complications	O
and	O
controls	O
were	O
paired	O
by	O
parity	O
,	O
gestational	O
age	O
,	O
maternal	O
age	O
and	O
mode	O
of	O
delivery	O
.	O

25	O
pairs	O
were	O
randomly	O
selected	O
.	O

50	O
tracings	O
were	O
presented	O
twice	O
to	O
4	O
obstetricians	O
in	O
a	O
double-blind	O
manner	O
.	O

As	O
parameters	O
for	O
the	O
determination	O
of	O
the	O
validity	O
of	O
fetal	O
monitoring	O
the	O
reliability	O
,	O
positive	O
(	O
ppv	O
)	O
and	O
negative	O
predictive	O
value	O
(	O
npv	O
)	O
,	O
sensitivity	O
and	O
specificity	O
were	O
used	O
.	O

Inter-	O
and	O
intra-observer	O
variability	O
were	O
also	O
examined	O
.	O

RESULTS	O
Reliability	Others
52	O
%	O
,	O
ppv	Physical
52	O
%	O
,	O
npv	Physical
52	O
%	O
,	O
sensitivity	Others
46	O
%	O
,	O
specificity	Others
58	O
%	O
.	O

Interobserver	O
variability	O
:	O
All	O
4	O
obstetricians	O
agreed	O
in	O
47	O
of	O
100	O
evaluations	O
.	O

The	O
level	Others
of	Others
agreement	Others
was	O
higher	O
in	O
the	O
controls	O
(	O
63	O
%	O
)	O
than	O
in	O
the	O
cord	O
complication	O
group	O
(	O
56	O
%	O
)	O
.	O

The	O
intraobserver	Others
variability	Others
was	O
25	O
%	O
.	O

CONCLUSIONS	O
Cardiotocography	O
is	O
not	O
useful	O
for	O
the	O
detection	Physical
of	Physical
cord	Physical
complications	Physical
.	Physical

The	O
range	O
of	O
possibilities	O
has	O
not	O
been	O
exploited	O
yet	O
,	O
even	O
for	O
the	O
evaluation	O
of	O
the	O
fetal	O
state	O
.	O

Language	Mental
outcome	Mental
in	O
autism	O
:	O
randomized	O
comparison	O
of	O
joint	O
attention	O
and	O
play	O
interventions	O
.	O

This	O
study	O
reports	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
aimed	O
at	O
joint	O
attention	O
(	O
JA	O
)	O
and	O
symbolic	O
play	O
(	O
SP	O
)	O
in	O
preschool	O
children	O
with	O
autism	O
,	O
with	O
prediction	O
to	O
language	Mental
outcome	Mental
12	O
months	O
later	O
.	O

Participants	O
were	O
58	O
children	O
(	O
46	O
boys	O
)	O
with	O
autism	O
between	O
3	O
and	O
4	O
years	O
of	O
age	O
.	O

Children	O
were	O
randomized	O
to	O
a	O
JA	O
intervention	O
,	O
an	O
SP	O
intervention	O
,	O
or	O
control	O
group	O
.	O

Interventions	O
were	O
conducted	O
30	O
min	O
daily	O
for	O
5-6	O
weeks	O
.	O

Assessments	O
of	O
JA	Mental
skills	Mental
,	O
SP	Mental
skills	Mental
,	O
mother-child	Mental
interactions	Mental
,	O
and	O
language	Mental
development	Mental
were	O
collected	O
at	O
4	O
time	O
points	O
:	O
pre-	O
and	O
postintervention	O
and	O
6	O
and	O
12	O
months	O
postintervention	O
by	O
independent	O
testers	O
.	O

Results	O
indicate	O
that	O
expressive	Mental
language	Mental
gains	Mental
were	O
greater	O
for	O
both	O
treatment	O
groups	O
compared	O
with	O
the	O
control	O
group	O
,	O
and	O
results	O
could	O
not	O
be	O
explained	O
by	O
differences	O
in	O
other	O
interventions	O
in	O
which	O
children	O
participated	O
.	O

For	O
children	O
beginning	O
treatment	O
with	O
the	O
lowest	O
language	O
levels	O
,	O
the	O
JA	O
intervention	O
improved	Mental
language	Mental
outcome	Mental
significantly	O
more	O
than	O
did	O
the	O
SP	O
or	O
control	O
interventions	O
.	O

These	O
findings	O
suggest	O
clinically	O
significant	O
benefits	O
of	O
actively	O
treating	O
JA	O
and	O
SP	O
skills	O
in	O
young	O
children	O
with	O
autism	O
.	O

Intravenous	O
flecainide	O
versus	O
verapamil	O
for	O
acute	O
conversion	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
or	O
flutter	O
to	O
sinus	O
rhythm	O
.	O

In	O
a	O
single-blind	O
randomized	O
study	O
,	O
the	O
efficacy	Others
of	O
intravenous	O
flecainide	O
(	O
2	O
mg/kg/10	O
minutes	O
)	O
versus	O
verapamil	O
(	O
10	O
mg/1	O
minute	O
)	O
was	O
assessed	O
in	O
40	O
patients	O
with	O
paroxysmal	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
or	O
atrial	O
flutter	O
(	O
AFI	O
)	O
.	O

The	O
treatment	O
was	O
considered	O
successful	O
if	O
sinus	Physical
rhythm	Physical
occurred	O
within	O
1	O
hour	O
.	O

Of	O
20	O
patients	O
receiving	O
flecainide	O
,	O
14	O
of	O
17	O
(	O
82	O
%	O
)	O
with	O
AF	O
converted	O
to	O
sinus	O
rhythm	O
,	O
but	O
in	O
3	O
patients	O
with	O
AFI	O
flecainide	O
failed	O
.	O

All	O
patients	O
treated	O
with	O
verapamil	O
(	O
17	O
AF	O
,	O
3	O
AFI	O
)	O
showed	O
lower	Physical
ventricular	Physical
rates	Physical
after	O
1	O
hour	O
;	O
however	O
,	O
only	O
1	O
(	O
6	O
%	O
)	O
with	O
AF	O
converted	O
to	O
sinus	O
rhythm	O
and	O
1	O
(	O
6	O
%	O
)	O
converted	O
to	O
AFI	O
.	O

Patients	O
who	O
did	O
not	O
convert	O
to	O
sinus	O
rhythm	O
after	O
treatment	O
with	O
verapamil	O
were	O
treated	O
with	O
flecainide	O
and	O
observed	O
for	O
another	O
hour	O
.	O

After	O
the	O
change	O
to	O
flecainide	O
,	O
9	O
of	O
15	O
patients	O
(	O
60	O
%	O
)	O
with	O
AF	O
still	O
converted	Physical
.	Physical

Thus	O
,	O
23	O
of	O
32	O
patients	O
(	O
72	O
%	O
)	O
with	O
AF	O
and	O
none	O
of	O
7	O
with	O
AFI	O
converted	O
to	O
sinus	Physical
rhythm	Physical
after	O
treatment	O
with	O
flecainide	O
.	O

Conversion	Physical
to	Physical
sinus	Physical
rhythm	Physical
was	O
achieved	O
in	O
19	O
of	O
22	O
patients	O
(	O
86	O
%	O
)	O
when	O
AF	O
lasted	O
less	O
than	O
24	O
hours	O
and	O
in	O
4	O
of	O
10	O
(	O
40	O
%	O
)	O
when	O
the	O
arrhythmia	O
lasted	O
greater	O
than	O
24	O
hours	O
.	O

Transient	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
were	O
noted	O
in	O
10	O
patients	O
(	O
26	O
%	O
)	O
after	O
flecainide	O
.	O

In	O
summary	O
,	O
flecainide	O
is	O
an	O
effective	Others
and	Others
safe	Others
drug	Others
for	O
conversion	O
of	O
paroxysmal	O
AF	O
to	O
sinus	O
rhythm	O
,	O
but	O
ineffective	O
for	O
AFI	Physical
.	Physical

Verapamil	O
appears	O
to	O
be	O
of	O
no	O
use	O
for	O
conversion	Physical
of	Physical
AF	Physical
or	Physical
AFI	Physical
to	O
sinus	O
rhythm	O
.	O

Thromboprophylaxis	O
by	O
low-molecular-weight	O
heparin	O
in	O
elective	O
hip	O
surgery	O
.	O

A	O
placebo	O
controlled	O
study	O
.	O

In	O
a	O
double-blind	O
,	O
randomised	O
study	O
of	O
thromboprophylaxis	O
in	O
patients	O
undergoing	O
total	O
hip	O
replacement	O
,	O
we	O
compared	O
a	O
low-molecular-weight	O
heparin	O
with	O
a	O
placebo	O
.	O

Of	O
the	O
120	O
patients	O
enrolled	O
,	O
112	O
completed	O
the	O
trial	O
;	O
58	O
in	O
the	O
treatment	O
group	O
and	O
54	O
in	O
the	O
placebo	O
group	O
.	O

Nine	O
(	O
16	O
%	O
)	O
patients	O
in	O
the	O
treatment	O
group	O
and	O
19	O
(	O
35	O
%	O
)	O
in	O
the	O
placebo	O
group	O
developed	O
deep	Physical
venous	Physical
thrombosis	Physical
,	O
diagnosed	O
by	O
the	O
125I-fibrinogen	O
uptake	O
test	O
(	O
p	O
<	O
0.02	O
)	O
.	O

Verification	O
was	O
obtained	O
by	O
phlebography	O
in	O
86	O
%	O
of	O
the	O
patients	O
.	O

Prolonged	O
surgery	O
increased	O
the	O
risk	Physical
of	Physical
thrombosis	Physical
in	O
the	O
placebo	O
group	O
but	O
not	O
in	O
the	O
treatment	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

There	O
were	O
significantly	O
more	O
cases	Physical
of	Physical
deep	Physical
venous	Physical
thrombosis	Physical
in	O
the	O
placebo	O
group	O
during	O
the	O
first	O
four	O
postoperative	O
days	O
(	O
p	O
<	O
0.02	O
)	O
.	O

The	O
groups	O
did	O
not	O
differ	O
with	O
respect	O
to	O
peroperative	Physical
and	Physical
postoperative	Physical
bleeding	Physical
.	O

Low-molecular-weight	O
heparin	O
offers	O
safe	O
and	O
easily	O
administered	O
thromboprophylaxis	O
in	O
total	O
hip	O
replacement	O
.	O

Somatostatin	O
and	O
ranitidine	O
in	O
the	O
treatment	O
of	O
non-variceal	O
upper	O
gastrointestinal	O
bleeding	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
study	O
.	O

BACKGROUND/AIMS	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	Others
of	O
somatostatin	O
vs.	O
ranitidine	O
in	O
controlling	O
acute	Physical
non-variceal	Physical
gastrointestinal	Physical
bleeding	Physical
.	O

METHODOLOGY	O
A	O
total	O
of	O
48	O
patients	O
with	O
acute	O
upper	O
gastrointestinal	O
bleeding	O
due	O
to	O
duodenal	O
or	O
gastric	O
ulcer	O
were	O
divided	O
into	O
2	O
groups	O
.	O

Group	O
I	O
consisted	O
of	O
15	O
patients	O
with	O
Forrest	O
IB	O
and	O
Group	O
II	O
consisted	O
of	O
30	O
patients	O
with	O
Forrest	O
II	O
.	O

Two	O
regimens	O
were	O
randomly	O
allocated	O
to	O
all	O
patients	O
within	O
half	O
an	O
hour	O
after	O
the	O
endoscopic	O
procedure	O
:	O
1	O
)	O
somatostatin-UCB	O
250	O
mcg	O
i.v	O
.	O

bolus	O
followed	O
by	O
continuous	O
i.v	O
.	O

infusion	O
at	O
a	O
rate	O
of	O
6	O
mg/d	O
for	O
72	O
h	O
,	O
or	O
2	O
)	O
ranitidine	O
300	O
mg/d	O
by	O
continuous	O
i.v	O
.	O

infusion	O
for	O
72	O
h.	O
RESULTS	O
In	O
Group	O
I	O
,	O
although	O
mean	Physical
blood	Physical
transfusion	Physical
requirements	Physical
(	O
no	O
.	O

of	O
units	O
)	O
were	O
lower	O
in	O
patients	O
treated	O
with	O
somatostatin	O
than	O
in	O
those	O
treated	O
with	O
ranitidine	O
,	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
mean	O
+/-	O
SD	O
:	O
2.56	O
+/-	O
3.05	O
vs.	O
5.17	O
+/-	O
4.96	O
,	O
respectively	O
;	O
P	O
>	O
0.05	O
)	O
;	O
the	O
time	Physical
of	Physical
bleeding	Physical
stop	Physical
was	O
shorter	O
in	O
the	O
somatostatin	O
group	O
than	O
in	O
the	O
ranitidine	O
group	O
(	O
mean	O
+/-	O
SD	O
:	O
3.24	O
+/-	O
2.45	O
vs.	O
11.25	O
+/-	O
11.63	O
,	O
respectively	O
;	O
P	O
=	O
0.0383	O
)	O
.	O

The	O
rebleeding	Physical
and	O
the	O
mortality	Mortality
rates	Mortality
did	O
not	O
differ	O
between	O
the	O
treatment	O
groups	O
in	O
both	O
Group	O
I	O
and	O
Group	O
II	O
.	O

CONCLUSIONS	O
Somatostatin	O
is	O
more	O
effective	Others
than	O
ranitidine	O
in	O
controlling	O
acute	Physical
non-variceal	Physical
gastrointestinal	Physical
bleeding	Physical
in	O
patients	O
with	O
Forrest	O
IB	O
bleeding	O
activity	O
.	O

Somatostatin	O
has	O
no	O
additional	Others
benefit	Others
in	O
those	O
with	O
Forrest	O
II	O
bleeding	O
activity	O
.	O

Pre-transplant	O
pharmacokinetic	O
profiling	O
and	O
tacrolimus	Physical
requirements	Physical
post-transplant	Physical
.	O

AIM	O
To	O
determine	O
the	O
proportion	O
of	O
patients	O
achieving	O
tacrolimus	Physical
whole-blood	Physical
concentrations	Physical
of	O
?10	O
ng/mL	O
within	O
3	O
days	O
of	O
kidney	O
transplantation	O
,	O
after	O
randomization	O
either	O
to	O
standard	O
dosing	O
(	O
control	O
group	O
)	O
or	O
post-transplantation	O
dosing	O
guided	O
by	O
a	O
2-hour	O
(	O
C	O
(	O
2	O
)	O
)	O
level	O
following	O
a	O
preoperative	O
tacrolimus	O
dose	O
(	O
T2	O
group	O
)	O
.	O

METHODS	O
The	O
first	O
postoperative	O
tacrolimus	O
dose	O
was	O
given	O
either	O
according	O
to	O
standard	O
care	O
(	O
control	O
group	O
)	O
or	O
0.15	O
mg/kg	O
b.d	O
.	O

if	O
the	O
pre-transplant	O
C	O
(	O
2	O
)	O
level	O
was	O
?20	O
ng/mL	O
,	O
0.1	O
mg/kg	O
b.d	O
.	O

if	O
the	O
C	O
(	O
2	O
)	O
level	O
was	O
21-59	O
ng/mL	O
or	O
0.05	O
mg/kg	O
b.d	O
.	O

if	O
the	O
C	O
(	O
2	O
)	O
level	O
was	O
?60	O
ng/mL	O
(	O
T2	O
group	O
)	O
.	O

Subsequent	O
dosing	O
in	O
both	O
groups	O
was	O
based	O
upon	O
tacrolimus	O
trough	O
level	O
monitoring	O
.	O

Participants	O
received	O
concomitant	O
mycophenolate	O
mofetil	O
and	O
steroids	O
.	O

RESULTS	O
Ninety	O
patients	O
were	O
recruited	O
,	O
of	O
which	O
84	O
were	O
included	O
in	O
the	O
analysis	O
(	O
control	O
group	O
n=43	O
;	O
T2	O
group	O
n=41	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
proportion	O
of	O
subjects	O
achieving	O
tacrolimus	O
trough	O
levels	O
?10	O
ng/mL	O
(	O
82.9	O
%	O
Control	O
vs	O
93.0	O
%	O
T2	O
;	O
P=0.19	O
)	O
or	O
between	O
10	O
and	O
15	O
ng/mL	O
(	O
41.5	O
%	O
Control	O
vs	O
41.9	O
%	O
T2	O
;	O
P=0.97	O
)	O
at	O
day	O
3	O
post	O
transplant	O
.	O

The	O
T2	O
group	O
achieved	O
tacrolimus	O
trough	O
levels	O
of	O
?10	O
ng/mL	O
significantly	O
faster	O
than	O
the	O
control	O
group	O
(	O
100	O
%	O
achievement	O
in	O
14	O
days	O
(	O
Control	O
)	O
versus	O
4	O
days	O
(	O
T2	O
)	O
;	O
P=0.01	O
)	O
.	O

CONCLUSION	O
Performing	O
a	O
pre-transplant	O
tacrolimus	O
C	O
(	O
2	O
)	O
does	O
not	O
significantly	O
increase	O
the	O
high	O
proportion	O
of	O
subjects	O
achieving	O
10	O
ng/mL	O
tacrolimus	O
concentrations	O
by	O
day	O
3	O
using	O
routine	O
protocols	O
.	O

However	O
,	O
compared	O
with	O
standard	O
care	O
,	O
performing	O
a	O
pre-transplant	O
tacrolimus	O
C	O
(	O
2	O
)	O
does	O
lead	O
to	O
patients	O
achieving	O
a	O
whole-blood	O
concentration	O
of	O
?10	O
ng/mL	O
sooner	O
.	O

Serum	Physical
C-peptide	Physical
after	O
6	O
months	O
on	O
glibenclamide	O
remains	O
higher	O
than	O
during	O
insulin	O
treatment	O
.	O

Serum	Physical
C-peptide	Physical
was	O
measured	O
fasting	O
and	O
6	O
minutes	O
after	O
glucagon	O
(	O
1	O
mg	O
given	O
intravenously	O
)	O
in	O
49	O
patients	O
with	O
non-insulin-dependent	O
diabetes	O
mellitus	O
,	O
after	O
4	O
and	O
6	O
months	O
of	O
successive	O
periods	O
of	O
treatment	O
with	O
insulin	O
and	O
oral	O
hypoglycaemics	O
(	O
glibenclamide	O
and	O
metformin	O
)	O
,	O
given	O
in	O
random	O
order	O
.	O

Glycaemic	Physical
control	Physical
was	O
not	O
significantly	O
different	O
on	O
the	O
two	O
treatments	O
,	O
but	O
C-peptide	Physical
was	O
much	O
higher	O
while	O
the	O
patients	O
were	O
on	O
glibenclamide	O
.	O

We	O
conclude	O
that	O
glibenclamide	O
stimulates	O
pancreatic	O
insulin	O
production	O
even	O
after	O
6	O
months	O
treatment	O
.	O

The	O
effect	Adverseeffect
of	O
oral	O
sodium	O
acetate	O
administration	O
on	O
plasma	Physical
acetate	Physical
concentration	Physical
and	O
acid-base	Physical
state	Physical
in	O
horses	O
.	O

AIM	O
Sodium	O
acetate	O
(	O
NaAcetate	O
)	O
has	O
received	O
some	O
attention	O
as	O
an	O
alkalinizing	O
agent	O
and	O
possible	O
alternative	O
energy	O
source	O
for	O
the	O
horse	O
,	O
however	O
the	O
effects	O
of	O
oral	O
administration	O
remain	O
largely	O
unknown	O
.	O

The	O
present	O
study	O
used	O
the	O
physicochemical	O
approach	O
to	O
characterize	O
the	O
changes	O
in	O
acid-base	Physical
status	Physical
occurring	O
after	O
oral	O
NaAcetate/acetic	O
acid	O
(	O
NAA	O
)	O
administration	O
in	O
horses	O
.	O

METHODS	O
Jugular	Physical
venous	Physical
blood	Physical
was	O
sampled	O
from	O
9	O
exercise-conditioned	O
horses	O
on	O
2	O
separate	O
occasions	O
,	O
at	O
rest	O
and	O
for	O
24	O
h	O
following	O
a	O
competition	O
exercise	O
test	O
(	O
CET	O
)	O
designed	O
to	O
simulate	O
the	O
speed	O
and	O
endurance	O
test	O
of	O
3-day	O
event	O
.	O

Immediately	O
after	O
the	O
CETs	O
horses	O
were	O
allowed	O
water	O
ad	O
libitum	O
and	O
either	O
:	O
1	O
)	O
8	O
L	O
of	O
a	O
hypertonic	O
NaAcetate/acetic	O
acid	O
solution	O
via	O
nasogastric	O
tube	O
followed	O
by	O
a	O
typical	O
hay/grain	O
meal	O
(	O
NAA	O
trial	O
)	O
;	O
or	O
2	O
)	O
a	O
hay/grain	O
meal	O
alone	O
(	O
Control	O
trial	O
)	O
.	O

RESULTS	O
Oral	O
NAA	O
resulted	O
in	O
a	O
profound	Physical
plasma	Physical
alkalosis	Physical
marked	O
by	O
decreased	O
plasma	Physical
[	Physical
H+	Physical
]	Physical
and	O
increased	O
plasma	Physical
[	Physical
TCO2	Physical
]	Physical
and	Physical
[	Physical
HCO3-	Physical
]	Physical
compared	O
to	O
Control	O
.	O

The	O
primary	O
contributor	O
to	O
the	O
plasma	Physical
alkalosis	Physical
was	O
an	O
increased	O
[	O
SID	Physical
]	O
,	O
as	O
a	O
result	O
of	O
increased	O
plasma	O
[	O
Na+	O
]	O
and	O
decreased	O
plasma	O
[	O
Cl-	O
]	O
.	O

An	O
increased	O
[	Physical
Atot	Physical
]	Physical
,	O
due	O
to	O
increased	O
[	Physical
PP	Physical
]	Physical
and	O
a	O
sustained	O
increase	O
in	O
plasma	Physical
[	Physical
acetate	Physical
]	Physical
,	O
contributed	O
a	O
minor	O
acidifying	Adverseeffect
effect	Adverseeffect
.	O

CONCLUSION	O
It	O
is	O
concluded	O
that	O
oral	O
NaAcetate	O
could	O
be	O
used	O
as	O
both	O
an	O
alkalinizing	O
agent	O
and	O
an	O
alternative	O
energy	O
source	O
in	O
the	O
horse	O
.	O

Alinidine	O
in	O
chronic	O
stable	O
angina	O
:	O
the	O
effect	O
on	O
diastolic	Physical
perfusion	Physical
time	Physical
.	Physical

The	O
present	O
study	O
has	O
been	O
performed	O
to	O
assess	O
the	O
effects	O
of	O
alinidine	O
on	O
diastolic	O
duration	O
during	O
exercise	O
in	O
chronic	O
coronary	O
artery	O
disease	O
.	O

Twelve	O
male	O
patients	O
with	O
stable	O
effort	O
angina	O
and	O
without	O
previous	O
myocardial	O
infarction	O
were	O
studied	O
.	O

They	O
received	O
alinidine	O
or	O
placebo	O
in	O
a	O
double-blind	O
randomized	O
crossover	O
trial	O
for	O
3	O
days	O
after	O
a	O
wash-out	O
period	O
of	O
4	O
days	O
.	O

Alinidine	O
was	O
administered	O
at	O
a	O
dosage	O
of	O
30	O
mg	O
3	O
times	O
a	O
day	O
.	O

At	O
the	O
end	O
of	O
each	O
treatment	O
the	O
patients	O
underwent	O
upright	O
bicycle	O
exercise	O
.	O

Left	O
ventricular	Physical
time	O
intervals	O
were	O
obtained	Physical
by	O
means	O
of	O
carotid	O
thermistor	O
plethysmography	O
.	O

Diastolic	Physical
duration	Physical
was	O
calculated	Others
by	Others
subtracting	Others
the	Others
electromechanical	Others
systole	Others
from	Others
the	Others
R-R	Others
interval	Others
and	Others
expressed	Others
as	Others
a	Others
percentage	Others
of	Others
the	Others
cardiac	Others
cycle	Others
(	Others
%	Others
D	Others
)	Others
.	Others

Alinidine	O
increased	O
both	O
total	O
exercise	O
duration	O
from	O
246.7	O
+/-	O
120.7	O
to	O
346.6	O
+/-	O
114.1	O
s	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
time	O
to	O
0.1-mV	O
ST	O
segment	O
depression	O
from	O
98.3	O
+/-	O
53	O
to	O
187.2	O
+/-	O
105	O
s	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Similarly	O
the	O
drug	O
induced	Physical
a	Physical
reduction	Physical
of	Physical
the	Physical
rate-pressure	Physical
product	Physical
and	O
of	O
the	O
extent	O
of	O
ischemic	O
ST	O
segment	O
depression	O
during	O
exercise	O
.	O

%	O
D	O
was	O
increased	O
by	O
alinidine	O
both	O
at	O
rest	O
and	O
during	O
exercise	O
.	O

A	O
direct	O
linear	Physical
regression	Physical
between	O
R-R	O
and	O
%	O
D	O
was	O
found	O
after	O
both	O
alinidine	O
and	O
placebo	O
treatments	O
either	O
at	O
rest	O
or	O
during	O
exercise	O
.	O

Nevertheless	O
,	O
no	O
difference	O
was	O
observed	O
between	O
both	O
slopes	O
and	O
intercepts	O
.	O

Therefore	O
,	O
since	O
the	O
relationship	O
between	O
R-R	O
interval	O
and	O
%	O
D	O
was	O
unaffected	O
by	O
alinidine	O
,	O
it	O
was	O
possible	O
to	O
hypothesize	O
that	O
the	O
changes	O
in	O
diastolic	Others
duration	Others
were	O
due	O
only	O
to	O
the	O
bradycardic	O
action	O
of	O
the	O
drug	O
.	O

Immunogenicity	Physical
and	O
reactogenicity	Physical
of	O
a	O
group	O
C	O
meningococcal	O
conjugate	O
vaccine	O
compared	O
with	O
a	O
group	O
A+C	O
meningococcal	O
polysaccharide	O
vaccine	O
in	O
adolescents	O
in	O
a	O
randomised	O
observer-blind	O
controlled	O
trial	O
.	O

This	O
study	O
evaluated	O
the	O
immunogenicity	Physical
and	O
reactogenicity	Physical
of	O
a	O
group	O
C	O
meningococcal	O
conjugate	O
vaccine	O
(	O
MenC	O
)	O
compared	O
with	O
a	O
group	O
A+C	O
meningococcal	O
polysaccharide	O
vaccine	O
(	O
MenPS	O
)	O
in	O
healthy	O
adolescents	O
.	O

Subjects	O
were	O
randomised	O
to	O
receive	O
one	O
dose	O
of	O
either	O
MenC	O
(	O
n=92	O
)	O
or	O
MenPS	O
(	O
n=90	O
)	O
.	O

Group	O
C	O
meningococcal	Physical
IgG	Physical
antibody	Physical
concentrations	Physical
and	Physical
bactericidal	Physical
titres	Physical
were	O
higher	O
in	O
the	O
MenC	O
group	O
than	O
the	O
MenPS	O
group	O
at	O
1	O
month	O
(	O
22.8	O
U/ml	O
vs	O
4.0	O
U/ml	O
,	O
p	O
<	O
0.001	O
,	O
and	O
87	O
vs	O
20	O
,	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
and	O
12	O
months	O
(	O
6.1	O
U/ml	O
vs	O
3.0	O
U/ml	O
,	O
p	O
<	O
0.001	O
,	O
and	O
81.3	O
vs	O
20.2	O
,	O
p	O
<	O
0.001	O
,	O
respectively	O
)	O
.	O

No	O
differences	O
in	O
post	Physical
immunisation	Physical
reaction	Physical
rates	Physical
were	O
noted	O
between	O
the	O
two	O
vaccinated	O
groups	O
.	O

This	O
study	O
demonstrated	O
the	O
safety	O
and	O
enhanced	O
immunogenicity	Physical
of	O
the	O
candidate	O
meningococcal	O
conjugate	O
vaccine	O
as	O
compared	O
with	O
the	O
licensed	O
polysaccharide	O
vaccine	O
in	O
adolescents	O
.	O

Comparative	O
evaluation	O
of	O
cefotaxime	O
and	O
cephamandole	O
in	O
the	O
prevention	O
of	O
post-operative	Adverseeffect
infective	Adverseeffect
complications	Adverseeffect
following	O
emergency	O
abdominal	O
surgery	O
.	O

In	O
previous	O
published	O
work	O
we	O
described	O
57	O
patients	O
undergoing	O
emergency	O
abdominal	O
surgery	O
,	O
prospectively	O
randomised	O
to	O
receive	O
either	O
cefotaxime	O
or	O
cephamandole	O
as	O
a	O
single-antibiotic	O
,	O
three-dose	O
,	O
peri-operative	O
prophylaxis	O
against	O
post-operative	O
infective	O
complications	O
.	O

This	O
earlier	O
work	O
suggested	O
that	O
cefotaxime	O
might	O
be	O
more	O
effective	O
than	O
cephamandole	O
in	O
preventing	O
wound	O
sepsis	O
in	O
emergency	O
abdominal	O
surgery	O
.	O

We	O
describe	O
here	O
our	O
findings	O
in	O
a	O
further	O
63	O
patients	O
undergoing	O
emergency	O
abdominal	O
surgery	O
who	O
were	O
similarly	O
allocated	O
into	O
either	O
a	O
cefotaxime	O
or	O
cephamandole	O
antibiotic	O
group	O
.	O

Infective	Adverseeffect
complications	Adverseeffect
occurred	O
in	O
12/32	O
(	O
37	O
per	O
cent	O
)	O
of	O
the	O
cefotaxime	O
group	O
and	O
15/31	O
(	O
48	O
per	O
cent	O
)	O
of	O
the	O
cephamandole	O
group	O
.	O

Wound	Adverseeffect
infections	Adverseeffect
occurred	O
in	O
5/32	O
(	O
16	O
per	O
cent	O
)	O
of	O
the	O
cefotaxime	O
group	O
and	O
9/31	O
(	O
29	O
per	O
cent	O
)	O
of	O
the	O
cephamandole	O
group	O
.	O

The	O
organisms	O
cultured	O
and	O
their	O
sensitivities	O
are	O
discussed	O
in	O
detail	O
.	O

The	O
total	O
of	O
120	O
patients	O
studied	O
in	O
the	O
two	O
series	O
showed	O
wound	Adverseeffect
infection	Adverseeffect
to	O
occur	O
in	O
13	O
per	O
cent	O
of	O
the	O
62	O
patients	O
receiving	O
cefotaxime	O
and	O
30	O
per	O
cent	O
of	O
the	O
58	O
patients	O
receiving	O
cephamandole	O
.	O

This	O
difference	O
reaches	O
statistical	O
significance	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Possible	O
mechanisms	O
to	O
explain	O
this	O
finding	O
are	O
discussed	O
.	O

Again	O
we	O
found	O
the	O
regime	O
of	O
4	O
g	O
of	O
cefotaxime	O
given	O
peri-operatively	O
to	O
be	O
a	O
simple	Others
,	Others
safe	Others
and	Others
effective	Others
single	Others
agent	Others
as	Others
prophylaxis	Others
for	Others
emergency	Others
abdominal	Others
surgery	Others
.	O

Effect	O
of	O
inhaled	O
heparin	O
on	O
adenosine-induced	O
bronchial	O
hyperreactivity	O
.	O

Glycosaminoglycan	O
heparin	O
possesses	O
multiple	O
noncoagulant	O
properties	O
including	O
antiinflammatory	O
actions	O
.	O

We	O
have	O
previously	O
shown	O
that	O
heparin	O
attenuates	O
the	O
methacholine-induced	O
bronchoconstriction	O
in	O
humans	O
.	O

In	O
contrast	O
to	O
methacholine	O
,	O
a	O
stimulus	O
that	O
induces	O
airway	O
constriction	O
mainly	O
by	O
direct	O
stimulation	O
of	O
airway	O
smooth	O
muscle	O
cells	O
,	O
adenosine	O
airway	O
responsiveness	O
reflects	O
indirectly	O
induced	O
airway	O
narrowing	O
via	O
inflammatory	O
mediators	O
or	O
neural	O
reflex	O
mechanisms	O
.	O

Whether	O
heparin	O
modulates	O
bronchial	O
hyperreactivity	O
induced	O
by	O
adenosine	O
,	O
is	O
not	O
well	O
known	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
inhaled	O
heparin	O
on	O
adenosine-induced	O
bronchoconstriction	O
and	O
compared	O
the	O
inhibitory	O
role	O
of	O
heparin	O
on	O
the	O
adenosine	O
challenge	O
test	O
with	O
that	O
on	O
the	O
methacholine	O
challenge	O
test	O
.	O

Fifteen	O
subjects	O
(	O
7	O
males	O
,	O
8	O
females	O
)	O
with	O
mild	O
asthma	O
were	O
included	O
in	O
the	O
study	O
.	O

Bronchial	O
provocation	O
tests	O
were	O
performed	O
in	O
a	O
single-blind	O
,	O
crossover	O
,	O
randomized	O
order	O
,	O
and	O
repeated	O
45	O
minutes	O
after	O
placebo	O
or	O
aerosolized	O
heparin	O
inhalation	O
(	O
1,000	O
U/kg	O
)	O
.	O

The	O
heparin	O
increased	O
the	O
geometric	Others
mean	Others
log	Others
methacholine	Others
PD20	Others
value	Others
from	O
0.47	O
+/-	O
0.16	O
(	O
2.95	O
mg/ml	O
)	O
to	O
0.96	O
+/-	O
0.10	O
(	O
8.91	O
mg/ml	O
)	O
,	O
(	O
P	O
<	O
0.0009	O
)	O
in	O
15	O
patients	O
and	O
the	O
geometric	Others
mean	Others
log	Others
adenosine	Others
PD20	Others
values	Others
from	O
1.59	O
+/-	O
0.23	O
(	O
38.9	O
mg/ml	O
)	O
to	O
1.98	O
+/-	O
0.14	O
(	O
97.7	O
mg/ml	O
)	O
(	O
NS	O
)	O
in	O
7	O
patients	O
whose	O
baseline	O
adenosine	O
PD20	O
levels	O
were	O
less	O
than	O
200	O
mg/ml	O
.	O

The	O
degree	Others
of	Others
protection	Others
by	O
heparin	O
against	O
adenosine-induced	O
bronchoconstriction	O
was	O
not	O
correlated	O
with	O
that	O
against	O
methacholine-induced	O
bronchoconstriction	O
(	O
r	O
=	O
0.60	O
,	O
NS	O
)	O
.	O

The	O
data	O
suggest	O
that	O
inhaled	O
heparin	O
may	O
have	O
an	O
inhibitory	O
effect	O
on	O
the	O
methacholine	O
bronchial	O
challenge	O
,	O
and	O
thus	O
,	O
most	O
likely	O
directs	O
its	O
effect	O
against	O
smooth	O
muscle	O
.	O

Heparin	O
caused	O
less	O
attenuation	O
of	O
a	O
challenge	O
with	O
adenosine	O
and	O
probably	O
does	O
not	O
affect	O
mast	O
cell	O
degranulation	O
.	O

[	O
Opiate	O
hypothesis	O
in	O
infantile	O
autism	O
?	O
Therapeutic	O
trials	O
with	O
naltrexone	O
]	O
.	O

The	O
opioid	O
hypothesis	O
suggests	O
that	O
childhood	O
autism	O
may	O
result	O
from	O
excessive	O
brain	O
opioid	O
activity	O
during	O
neonatal	O
period	O
which	O
may	O
constitutionally	O
inhibit	O
social	O
motivation	O
,	O
yielding	O
autistic	O
isolation	O
and	O
aloofness	O
(	O
Panksepp	O
,	O
1979	O
)	O
.	O

This	O
hypothesis	O
has	O
now	O
received	O
strong	O
support	O
and	O
is	O
currently	O
based	O
on	O
three	O
types	O
of	O
arguments	O
:	O
(	O
1	O
)	O
similarity	O
between	O
autistic	O
symptomatology	O
and	O
abnormal	O
behaviors	O
induced	O
in	O
young	O
animals	O
by	O
injections	O
of	O
exogenous	O
opioids	O
,	O
such	O
as	O
increasing	O
social	O
aloofness	O
and	O
decreasing	O
social	O
vocalization	O
;	O
(	O
2	O
)	O
direct	O
biochemical	O
evidence	O
of	O
abnormalities	O
of	O
peripheral	O
endogenous	O
opioids	O
being	O
reported	O
in	O
autism	O
and	O
(	O
3	O
)	O
therapeutic	O
effects	O
of	O
the	O
long	O
lasting	O
opioid	O
receptor	O
blocking	O
agent	O
naltrexone	O
in	O
autism	O
.	O

In	O
this	O
article	O
,	O
we	O
give	O
description	O
of	O
open	O
and	O
double-blind	O
studies	O
of	O
naltrexone	O
in	O
autism	O
.	O

Naltrexone	O
has	O
been	O
tested	O
in	O
several	O
open	O
studies	O
.	O

We	O
performed	O
an	O
open	O
trial	O
with	O
naltrexone	O
in	O
2	O
autistic	O
girls	O
,	O
displaying	O
serious	O
self-injurious	O
behavior	O
,	O
reduced	O
crying	O
and	O
a	O
marked	O
preference	O
for	O
salty	O
and	O
spicy	O
foods	O
,	O
symptoms	O
that	O
could	O
be	O
related	O
to	O
a	O
dysfunction	O
of	O
the	O
opioid	O
system	O
.	O

With	O
dosages	O
of	O
1	O
mg/kg/day	O
,	O
we	O
observed	O
an	O
immediate	O
reduction	Mental
of	Mental
hyperactivity	Mental
,	Mental
self-injurious	Mental
behavior	Mental
and	Mental
aggressiveness	Mental
,	Mental
while	Mental
attention	Mental
improved	Mental
.	O

In	O
addition	O
,	O
social	Mental
behaviors	Mental
,	Mental
smiling	Mental
,	Mental
social	Mental
seeking	Mental
behaviors	Mental
and	Mental
play	Mental
interactions	Mental
increased	O
(	O
Leboyer	O
,	O
Bouvard	O
et	O
Dugas	O
,	O
1988	O
)	O
.	O

Campbell	O
et	O
al	O
.	O

(	O
1988	O
)	O
has	O
also	O
reported	O
a	O
tranquilizing	Mental
and	Mental
a	Mental
stimulating	Mental
effect	Mental
in	O
6	O
out	O
of	O
8	O
children	O
with	O
autism	O
.	O

We	O
did	O
confirm	O
these	O
preliminary	O
results	O
in	O
a	O
double-blind	O
study	O
performed	O
on	O
4	O
children	O
with	O
autism	O
.	O

In	O
a	O
cross-over	O
double-blind	O
study	O
,	O
three	O
dosages	O
of	O
naltrexone	O
(	O
0.5	O
,	O
1	O
and	O
2	O
mg/kg/day	O
)	O
and	O
placebo	O
were	O
compared	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
comparison	O
of	O
the	O
efficacy	O
of	O
heparinized	O
and	O
nonheparinized	O
solutions	O
for	O
maintenance	Physical
of	Physical
perioperative	Physical
radial	Physical
arterial	Physical
catheter	Physical
patency	Physical
and	O
subsequent	Physical
occlusion	Physical
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
study	O
,	O
we	O
compared	O
heparinized	O
and	O
nonheparinized	O
infusions	O
for	O
the	O
maintenance	Physical
of	Physical
perioperative	Physical
arterial	Physical
catheter	Physical
patency	Physical
and	O
the	O
incidence	Physical
of	Physical
subsequent	Physical
radial	Physical
arterial	Physical
occlusion	Physical
.	O

Two-hundred	O
patients	O
were	O
randomized	O
into	O
2	O
groups	O
to	O
receive	O
heparinized	O
(	O
group	O
H	O
,	O
n	O
=	O
100	O
)	O
or	O
nonheparinized	O
(	O
group	O
S	O
,	O
n	O
=	O
100	O
)	O
flush	O
solutions	O
.	O

Radial	Physical
and	Physical
ulnar	Physical
blood	Physical
flows	Physical
were	O
assessed	O
using	O
Doppler	Others
probe	Others
and	Others
pulse	Others
oximetry	Others
before	O
,	O
just	O
after	O
,	O
and	O
24	O
h	O
after	O
decannulation	Others
by	O
the	O
same	O
investigator	O
.	O

The	O
cannulation	O
site	O
was	O
examined	O
for	O
complications	Adverseeffect
such	Adverseeffect
as	Adverseeffect
hematoma	Adverseeffect
,	Adverseeffect
nerve	Adverseeffect
injury	Adverseeffect
,	Adverseeffect
and	Adverseeffect
infection	Adverseeffect
.	O

The	O
mean	O
duration	O
of	O
cannulations	Others
was	O
378	O
+/-	O
159.0	O
min	O
in	O
group	O
H	O
and	O
332	O
+/-	O
154.6	O
min	O
in	O
group	O
S.	O
The	O
mean	O
number	O
of	O
corrective	O
interventions	O
caused	O
by	O
dampening	O
of	O
the	O
pressure	O
wave	O
(	O
mean	O
number	O
of	O
positional	O
changes	O
[	O
group	O
S	O
,	O
1.5	O
+/-	O
2.0	O
;	O
group	O
H	O
,	O
1.4	O
+/-	O
3.8	O
]	O
and	O
mean	O
number	O
of	O
manual	O
flushes	O
[	O
group	O
S	O
,	O
1.3	O
+/-	O
1.7	O
;	O
group	O
H	O
,	O
1.2	O
+/-	O
1.2	O
]	O
)	O
was	O
not	O
significantly	O
different	O
in	O
both	O
groups	O
.	O

After	O
decannulation	O
,	O
partial	Physical
or	Physical
total	Physical
occlusion	Physical
developed	O
in	O
20	O
group	O
H	O
patients	O
and	O
16	O
group	O
S	O
patients	O
(	O
not	O
significant	O
)	O
.	O

The	O
incidence	O
of	O
occlusion	Physical
was	O
correlated	O
to	O
the	O
presence	O
of	O
hematoma	Physical
at	O
the	O
puncture	O
site	O
after	O
decannulation	O
(	O
P	O
=	O
0.013	O
)	O
,	O
long	Others
duration	Others
of	Others
cannulation	Others
(	O
P	O
=	O
0.04	O
)	O
,	O
and	O
age	O
<	O
65	O
yr	O
(	O
P	O
=	O
0.009	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
significant	O
difference	O
between	O
heparinized	O
and	O
nonheparinized	O
flush	O
solutions	O
for	O
the	O
maintenance	Others
of	Others
perioperative	Others
radial	Others
artery	Others
catheter	Others
patency	Others
.	O

Syncope	O
Evaluation	O
in	O
the	O
Emergency	O
Department	O
Study	O
(	O
SEEDS	O
)	O
:	O
a	O
multidisciplinary	O
approach	O
to	O
syncope	O
management	O
.	O

BACKGROUND	O
The	O
primary	O
aim	O
and	O
central	O
hypothesis	O
of	O
the	O
study	O
are	O
that	O
a	O
designated	O
syncope	O
unit	O
in	O
the	O
emergency	O
department	O
improves	O
diagnostic	O
yield	O
and	O
reduces	O
hospital	O
admission	O
for	O
patients	O
with	O
syncope	O
who	O
are	O
at	O
intermediate	O
risk	O
for	O
an	O
adverse	O
cardiovascular	O
outcome	O
.	O

METHODS	O
AND	O
RESULTS	O
In	O
this	O
prospective	O
,	O
randomized	O
,	O
single-center	O
study	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
2	O
treatment	O
arms	O
:	O
syncope	O
unit	O
evaluation	O
and	O
standard	O
care	O
.	O

The	O
2	O
groups	O
were	O
compared	O
with	O
chi2	O
test	O
for	O
independence	O
of	O
categorical	O
variables	O
.	O

Wilcoxon	O
rank	O
sum	O
test	O
was	O
used	O
for	O
continuous	O
variables	O
.	O

Survival	Mortality
was	O
estimated	O
with	O
the	O
Kaplan-Meier	O
method	O
.	O

One	O
hundred	O
three	O
consecutive	O
patients	O
(	O
53	O
women	O
;	O
mean	O
age	O
64+/-17	O
years	O
)	O
entered	O
the	O
study	O
.	O

Fifty-one	O
patients	O
were	O
randomized	O
to	O
the	O
syncope	O
unit	O
.	O

For	O
the	O
syncope	O
unit	O
and	O
standard	O
care	O
patients	O
,	O
the	O
presumptive	Others
diagnosis	Others
was	O
established	O
in	O
34	O
(	O
67	O
%	O
)	O
and	O
5	O
(	O
10	O
%	O
)	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
hospital	Others
admission	Others
was	O
required	O
for	O
22	O
(	O
43	O
%	O
)	O
and	O
51	O
(	O
98	O
%	O
)	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
total	Others
patient-hospital	Others
days	Others
were	O
reduced	O
from	O
140	O
to	O
64	O
.	O

Actuarial	Mortality
survival	Mortality
was	O
97	O
%	O
and	O
90	O
%	O
(	O
P=0.30	O
)	O
,	O
and	O
survival	Mortality
free	Mortality
from	Mortality
recurrent	Mortality
syncope	Mortality
was	O
88	O
%	O
and	O
89	O
%	O
(	O
P=0.72	O
)	O
at	O
2	O
years	O
for	O
the	O
syncope	O
unit	O
and	O
standard	O
care	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
The	O
novel	O
syncope	O
unit	O
designed	O
for	O
this	O
study	O
significantly	O
improved	O
diagnostic	Others
yield	Others
in	O
the	O
emergency	O
department	O
and	O
reduced	O
hospital	Others
admission	Others
and	O
total	Others
length	Others
of	Others
hospital	Others
stay	Others
without	O
affecting	O
recurrent	O
syncope	O
and	O
all-cause	O
mortality	Mortality
among	O
intermediate-risk	O
patients	O
.	O

Observations	O
from	O
the	O
present	O
study	O
provide	O
benchmark	O
data	O
for	O
improving	O
patient	O
care	O
and	O
effectively	O
utilizing	O
healthcare	O
resources	O
.	O

The	O
individual	O
responsiveness	O
to	O
growth	O
hormone	O
(	O
GH	O
)	O
treatment	O
in	O
GH-deficient	O
adults	O
is	O
dependent	O
on	O
the	O
level	O
of	O
GH-binding	O
protein	O
,	O
body	Physical
mass	Physical
index	Physical
,	O
age	O
,	O
and	O
gender	O
.	O

The	O
aim	O
of	O
the	O
present	O
trial	O
was	O
to	O
study	O
the	O
individual	O
responsiveness	O
to	O
GH	O
treatment	O
in	O
terms	O
of	O
body	O
composition	O
and	O
to	O
search	O
for	O
possible	O
predictors	O
of	O
the	O
response	O
in	O
GH-deficient	O
adults	O
.	O

Sixty-eight	O
patients	O
(	O
44	O
men	O
and	O
24	O
women	O
)	O
with	O
a	O
mean	O
age	O
of	O
44.3	O
(	O
1.2	O
)	O
yr	O
and	O
verified	O
GH	O
deficiency	O
participated	O
in	O
a	O
2-phase	O
treatment	O
trial	O
with	O
an	O
initial	O
randomized	O
,	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
6-month	O
period	O
,	O
followed	O
by	O
an	O
open	O
treatment	O
period	O
,	O
thereby	O
ensuring	O
all	O
patients	O
12	O
months	O
of	O
GH	O
treatment	O
.	O

Recombinant	O
human	O
GH	O
was	O
administered	O
sc	O
daily	O
at	O
bedtime	O
,	O
with	O
a	O
target	O
dose	O
of	O
12	O
micrograms/kg	O
x	O
day	O
.	O

GHBP	O
was	O
measured	O
by	O
ligand-mediated	O
immunofunctional	O
assay	O
,	O
and	O
serum	O
insulin-like	O
growth	O
factor	O
I	O
(	O
IGF-I	O
)	O
was	O
determined	O
by	O
RIA	O
after	O
acid-ethanol	O
extraction	O
,	O
using	O
a	O
truncated	O
IGF-I	O
analog	O
as	O
the	O
radioligand	O
.	O

Lean	Physical
body	Physical
mass	Physical
(	Physical
LBM	Physical
)	Physical
and	O
body	Physical
fat	Physical
(	Physical
BF	Physical
)	Physical
were	O
determined	O
by	O
dual	O
energy	O
x-ray	O
absorptiometry	O
,	O
and	O
total	O
body	O
water	O
(	O
TBW	O
)	O
was	O
determined	O
by	O
bioelectrical	O
impedance	O
.	O

During	O
the	O
placebo	O
control	O
period	O
,	O
serum	Physical
IGF-I	Physical
,	O
LBM	Physical
,	O
and	O
TBW	Physical
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
whereas	O
BF	Physical
decreased	O
(	O
P	O
<	O
0.001	O
)	O
and	O
serum	Physical
GHBP	Physical
was	O
unchanged	O
in	O
the	O
group	O
treated	O
with	O
GH	O
compared	O
with	O
the	O
patients	O
treated	O
with	O
placebo	O
.	O

After	O
12	O
months	O
of	O
GH	O
treatment	O
,	O
the	O
individual	O
changes	O
in	O
BF	Physical
ranged	O
from	O
-12.5	O
to	O
4.3	O
kg	O
and	O
from	O
-4.5	O
to	O
10.1	O
kg	O
in	O
LBM	O
.	O

Age	O
(	O
P	O
<	O
0.05	O
)	O
and	O
baseline	Physical
GHBP	Physical
level	Physical
(	O
P	O
<	O
0.01	O
)	O
were	O
inversely	O
correlated	O
with	O
the	O
increase	O
in	O
LBM	O
.	O

The	O
GH-induced	Physical
increment	Physical
in	Physical
IGF-I	Physical
and	Physical
TBW	Physical
was	O
greater	O
in	O
men	O
than	O
in	O
women	O
(	O
P	O
<	O
0.01	O
)	O
,	O
whereas	O
the	O
decreases	O
in	O
BF	Physical
were	O
similar	O
in	O
men	O
and	O
women	O
.	O

This	O
trial	O
demonstrates	O
the	O
variability	O
in	O
responsiveness	O
to	O
GH	O
administration	O
in	O
GH-deficient	O
adults	O
.	O

The	O
best	O
response	O
to	O
GH	O
was	O
obtained	O
in	O
younger	O
patients	O
with	O
low	O
GHBP	O
levels	O
.	O

Furthermore	O
,	O
men	O
responded	O
better	O
than	O
women	O
.	O

[	O
EMLA	O
cream	O
(	O
lidocaine/prilocaine	O
)	O
versus	O
infiltration	O
analgesia	O
with	O
carbocaine	O
(	O
mepivacaine	O
)	O
in	O
vasectomy	O
]	O
.	O

The	O
analgesic	Pain
efficacy	Pain
of	O
EMLA	O
cream	O
was	O
compared	O
with	O
infiltration	O
with	O
1	O
%	O
carbocaine	O
in	O
13	O
bilateral	O
vasectomies	O
.	O

Twelve	O
patients	O
preferred	O
infiltration	O
analgesia	O
.	O

EMLA	O
analgesia	O
was	O
only	Others
effective	Others
in	Others
the	Others
skin	Others
,	O
and	O
had	Others
to	Others
be	Others
supplemented	Others
as	O
the	O
incision	O
reached	O
subcutaneous	O
tissue	O
.	O

7-hexanoyltaxol-eluting	O
stent	O
for	O
prevention	O
of	O
neointimal	O
growth	O
:	O
an	O
intravascular	O
ultrasound	O
analysis	O
from	O
the	O
Study	O
to	O
COmpare	O
REstenosis	O
rate	O
between	O
QueST	O
and	O
QuaDS-QP2	O
(	O
SCORE	O
)	O
.	O

BACKGROUND	O
Inhibition	O
of	O
neointimal	O
tissue	O
growth	O
has	O
been	O
demonstrated	O
in	O
preliminary	O
human	O
feasibility	O
studies	O
with	O
a	O
stent-based	O
polymer	O
sleeve	O
delivering	O
7-hexanoyltaxol	O
.	O

The	O
Study	O
to	O
COmpare	O
REstenosis	O
rate	O
between	O
QueST	O
and	O
QuaDS-QP2	O
(	O
SCORE	O
)	O
trial	O
is	O
a	O
human	O
,	O
randomized	O
,	O
multicenter	O
trial	O
comparing	O
7-hexanoyltaxol	O
(	O
QP2	O
)	O
-eluting	O
stents	O
(	O
qDES	O
)	O
with	O
bare	O
metal	O
stents	O
(	O
BMS	O
)	O
in	O
the	O
treatment	O
of	O
de	O
novo	O
coronary	O
lesions	O
.	O

The	O
purpose	O
of	O
this	O
substudy	O
was	O
to	O
evaluate	O
the	O
acute	Physical
expansion	Physical
property	Physical
and	O
long-term	Physical
neointimal	Physical
responses	Physical
of	O
qDES	O
compared	O
with	O
BMS	O
as	O
assessed	O
by	O
intravascular	O
ultrasound	O
(	O
IVUS	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
A	O
total	O
of	O
122	O
(	O
qDES	O
66	O
,	O
BMS	O
56	O
)	O
patients	O
were	O
enrolled	O
into	O
the	O
IVUS	O
substudy	O
.	O

All	O
IVUS	O
images	O
(	O
immediately	O
after	O
the	O
procedure	O
and	O
at	O
6-month	O
follow-up	O
)	O
were	O
analyzed	O
at	O
an	O
independent	O
core	O
laboratory	O
in	O
a	O
blind	O
manner	O
.	O

At	O
baseline	O
,	O
qDES	O
achieved	O
stent	Physical
expansion	Physical
similar	O
to	O
BMS	O
.	O

At	O
follow-up	O
,	O
qDES	O
showed	O
reduced	O
neointimal	Physical
growth	Physical
by	O
70	O
%	O
at	O
the	O
tightest	O
cross	O
section	O
and	O
by	O
68	O
%	O
over	O
the	O
stented	O
segment	O
(	O
P	O
<	O
0.0001	O
for	O
both	O
)	O
,	O
resulting	O
in	O
a	O
significantly	O
larger	O
lumen	O
in	O
qDES	O
than	O
in	O
BMS	O
.	O

Unlike	O
intracoronary	O
brachytherapy	O
,	O
there	O
was	O
no	O
evidence	O
of	O
negative	Adverseeffect
edge	Adverseeffect
effects	Adverseeffect
,	Adverseeffect
unhealed	Adverseeffect
dissections	Adverseeffect
,	Adverseeffect
or	Adverseeffect
late	Adverseeffect
stent-vessel	Adverseeffect
wall	Adverseeffect
malapposition	Adverseeffect
over	O
the	O
stented	O
and	O
adjacent	O
references	O
segments	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
Detailed	O
IVUS	O
analysis	O
revealed	O
that	O
qDES	O
had	O
comparable	O
acute	O
mechanical	O
and	O
superior	O
long-term	O
biological	O
effects	O
to	O
BMS	O
.	O

Although	O
the	O
long-term	O
benefits	O
and	O
limitations	O
of	O
this	O
technology	O
require	O
further	O
investigation	O
,	O
the	O
reduction	O
in	O
neointimal	O
thickenings	O
demonstrated	O
that	O
local	O
delivery	O
of	O
7-hexanoyltaxol	O
through	O
polymer	O
sleeves	O
augments	O
conventional	O
mechanical	O
treatment	O
of	O
atherosclerotic	O
disease	O
.	O

Carbenicillin-trimethoprim/sulfamethoxazole	O
versus	O
carbenicillin-gentamicin	O
as	O
empiric	O
therapy	O
of	O
infection	O
in	O
granulocytopenic	O
patients	O
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

The	O
results	O
of	O
therapy	O
with	O
carbenicillin	O
plus	O
trimethoprim-sulfamethoxazole	O
(	O
C-T/S	O
)	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
carbenicillin	O
plus	O
gentamicin	O
(	O
C-G	O
)	O
in	O
a	O
prospective	O
double-blind	O
study	O
of	O
empiric	O
antibiotic	O
therapy	O
in	O
granulocytopenic	O
patients	O
.	O

Patients	O
were	O
stratified	O
into	O
two	O
groups	O
:	O
favorable-prognosis	O
,	O
group	O
1	O
(	O
carcinoma	O
,	O
lymphoma	O
,	O
multiple	O
myeloma	O
)	O
,	O
or	O
unfavorable-prognosis	O
,	O
group	O
2	O
(	O
acute	O
leukemia	O
,	O
bone	O
marrow	O
transplantation	O
)	O
,	O
based	O
on	O
anticipated	O
duration	O
of	O
granulocytopenia	O
.	O

Over-all	O
,	O
empiric	O
antibiotic	O
trials	O
were	O
more	O
often	O
successful	Others
(	O
P	O
=	O
0.004	O
)	O
in	O
group	O
1	O
(	O
55	O
of	O
62	O
patients	O
or	O
89	O
per	O
cent	O
)	O
than	O
in	O
group	O
2	O
(	O
42	O
of	O
64	O
patients	O
,	O
66	O
per	O
cent	O
)	O
mwithin	O
group	O
1	O
,	O
there	O
was	O
a	O
favorable	Others
outcome	Others
in	O
30	O
of	O
32	O
(	O
94	O
per	O
cent	O
)	O
C-T/S	O
trials	O
and	O
in	O
25	O
of	O
30	O
(	O
83	O
per	O
cent	O
)	O
C-G	O
trials	O
(	O
P	O
=	O
0.25	O
)	O
;	O
within	O
group	O
2	O
,	O
there	O
was	O
a	O
favorable	O
outcome	O
in	O
23	O
of	O
30	O
(	O
77	O
per	O
cent	O
)	O
C-T/S	O
trials	O
and	O
in	O
19	O
of	O
34	O
(	O
56	O
per	O
cent	O
)	O
C-G	O
trials	O
(	O
P	O
=	O
0.14	O
)	O
,	O
Combined	O
results	O
in	O
both	O
groups	O
indicated	O
a	O
higher	O
proportion	O
of	O
favorable	Others
outcome	Others
in	O
C-T/S	O
trials	O
(	O
53	O
of	O
62	O
,	O
85	O
per	O
cent	O
)	O
than	O
in	O
C-G	O
trials	O
(	O
44	O
of	O
64	O
,	O
69	O
per	O
cent	O
)	O
.	O

Further	O
analysis	Physical
(	Physical
Manetl-Naenszel	Physical
test	Physical
)	O
showed	O
the	O
over-all	O
difference	O
in	O
outcome	O
to	O
be	O
significant	O
(	O
P	O
=	O
0.049	O
)	O
,	O
but	O
the	O
general	O
applicability	O
of	O
this	O
result	O
may	O
be	O
limited	O
by	O
the	O
rather	O
low	O
incidence	O
of	O
gram-negative	O
bacterial	O
infections	O
in	O
this	O
study	O
.	O

There	O
was	O
no	Others
difference	Others
between	O
the	O
treatment	O
regimens	O
in	O
antibiotic	Physical
toxicity	Physical
,	O
and	O
serious	Physical
superinfection	Physical
occurred	O
only	O
in	O
group	O
2	O
patients	O
(	O
21	O
per	O
cent	O
of	O
trials	O
)	O
,	O
equally	O
divided	O
between	O
treatment	O
arms	O
.	O

Initial	O
protocol	O
dosing	O
achieved	O
target	O
plasma	O
levels	O
of	O
trimethoprim	O
(	O
3	O
to	O
8	O
micrograms/ml	O
)	O
or	O
gentamicin	O
(	O
4	O
to	O
10	O
micrograms/ml	O
)	O
in	O
57	O
of	O
68	O
(	O
84	O
per	O
cent	O
)	O
C-T/S	O
trials	O
compared	O
to	O
21	O
of	O
60	O
(	O
35	O
per	O
cent	O
)	O
C-G	O
trials	O
.	O

Addictive	Mental
internet	Mental
use	Mental
among	O
Korean	O
adolescents	O
:	O
a	O
national	O
survey	O
.	O

BACKGROUND	O
A	O
psychological	O
disorder	O
called	O
'Internet	O
addiction	O
'	O
has	O
newly	O
emerged	O
along	O
with	O
a	O
dramatic	O
increase	O
of	O
worldwide	O
Internet	O
use	O
.	O

However	O
,	O
few	O
studies	O
have	O
used	O
population-level	O
samples	O
nor	O
taken	O
into	O
account	O
contextual	O
factors	O
on	O
Internet	O
addiction	O
.	O

METHODS	O
AND	O
FINDINGS	O
We	O
identified	O
57,857	O
middle	O
and	O
high	O
school	O
students	O
(	O
13-18	O
year	O
olds	O
)	O
from	O
a	O
Korean	O
nationally	O
representative	O
survey	O
,	O
which	O
was	O
surveyed	O
in	O
2009	O
.	O

To	O
identify	O
associated	O
factors	O
with	O
addictive	Mental
Internet	Mental
use	Mental
,	O
two-level	O
multilevel	O
regression	O
models	O
were	O
fitted	O
with	O
individual-level	O
responses	O
(	O
1st	O
level	O
)	O
nested	O
within	O
schools	O
(	O
2nd	O
level	O
)	O
to	O
estimate	O
associations	O
of	O
individual	O
and	O
school	O
characteristics	O
simultaneously	O
.	O

Gender	O
differences	O
of	O
addictive	Mental
Internet	Mental
use	O
were	O
estimated	O
with	O
the	O
regression	O
model	O
stratified	O
by	O
gender	O
.	O

Significant	O
associations	O
were	O
found	O
between	O
addictive	O
Internet	Mental
use	Mental
and	O
school	O
grade	O
,	O
parental	O
education	O
,	O
alcohol	O
use	O
,	O
tobacco	O
use	O
,	O
and	O
substance	O
use	O
.	O

Female	O
students	O
in	O
girls	O
'	O
schools	O
were	O
more	O
likely	O
to	O
use	Mental
Internet	Mental
addictively	Mental
than	O
those	O
in	O
coeducational	O
schools	O
.	O

Our	O
results	O
also	O
revealed	O
significant	O
gender	O
differences	O
of	O
addictive	Mental
Internet	Mental
use	O
in	O
its	O
associated	O
individual-	O
and	O
school-level	O
factors	O
.	O

CONCLUSIONS	O
Our	O
results	O
suggest	O
that	O
multilevel	O
risk	O
factors	O
along	O
with	O
gender	O
differences	O
should	O
be	O
considered	O
to	O
protect	O
adolescents	O
from	O
addictive	Mental
Internet	Mental
use	Mental
.	O

Concomitant	O
radiochemotherapy	O
vs	O
radiotherapy	O
alone	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
:	O
a	O
Hellenic	O
Cooperative	O
Oncology	O
Group	O
Phase	O
III	O
Study	O
.	O

The	O
primary	O
objective	O
of	O
the	O
present	O
randomized	O
phase	O
III	O
trial	O
was	O
to	O
compare	O
the	O
3-yr	Mortality
survival	Mortality
rate	Mortality
of	O
patients	O
treated	O
with	O
standard	O
fractionated	O
radiotherapy	O
(	O
RT	O
)	O
alone	O
or	O
with	O
the	O
same	O
RT	O
concomitantly	O
with	O
cisplatin	O
(	O
DDP	O
)	O
or	O
carboplatin	O
(	O
Cb	O
)	O
.	O

From	O
January	O
1995	O
until	O
July	O
1999	O
,	O
124	O
patients	O
with	O
histologically	O
proven	O
locally	O
advanced	O
non-nasopharyngeal	O
head	O
and	O
neck	O
cancer	O
(	O
HNC	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
RT	O
monotherapy	O
(	O
70	O
Gy	O
,	O
Group	O
A	O
)	O
or	O
the	O
same	O
RT	O
concomitantly	O
with	O
DDP	O
(	O
100	O
mg/m2	O
on	O
d	O
2	O
,	O
22	O
,	O
42	O
,	O
Group	O
B	O
)	O
or	O
Cb	O
(	O
7	O
AUC	O
on	O
d	O
2	O
,	O
22	O
,	O
42	O
,	O
Group	O
C	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
complete	Others
response	Others
rates	Others
between	O
patients	O
treated	O
with	O
RT	O
alone	O
or	O
combined	O
chemoradiotherapy	O
.	O

However	O
,	O
median	Physical
time	Physical
to	Physical
progression	Physical
(	Physical
TTP	Physical
)	Physical
and	O
overall	Mortality
survival	Mortality
(	Mortality
OS	Mortality
)	Mortality
were	O
significantly	O
longer	O
in	O
patients	O
treated	O
with	O
concomitant	O
chemoradiotherapy	O
.	O

Thus	O
,	O
median	Physical
TTP	Physical
was	O
6.3	O
,	O
45.2	O
,	O
and	O
17.7	O
mo	O
in	O
groups	O
A	O
,	O
B	O
,	O
and	O
C	O
respectively	O
(	O
p	O
=	O
0.0002	O
)	O
.	O

Similarly	O
,	O
median	Mortality
OS	Mortality
was	O
12.2	O
,	O
48.6	O
,	O
and	O
24.5	O
mo	O
,	O
respectively	O
(	O
p	O
=	O
0.0003	O
)	O
.	O

At	O
3	O
yr	O
follow-up	O
,	O
17.5	O
%	O
of	O
patients	O
in	O
group	O
A	O
were	O
alive	Mortality
compared	O
to	O
52	O
%	O
in	O
group	O
B	O
and	O
42	O
%	O
in	O
group	O
C	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Patients	O
treated	O
with	O
concomitant	O
chemoradiotherapy	O
experienced	O
more	O
frequently	O
severe	Physical
hematological	Physical
toxicity	Physical
.	O

Also	O
,	O
severe	Adverseeffect
nausea/vomiting	Adverseeffect
was	O
more	O
pronounced	O
in	O
group	O
B	O
,	O
as	O
expected	O
.	O

The	O
present	O
study	O
clearly	O
demonstrated	O
that	O
concomitant	O
chemoradiotherapy	O
with	O
platinum	O
analogs	O
significantly	O
prolongs	O
3-yr	Mortality
survival	Mortality
and	Mortality
median	Mortality
OS	Mortality
in	O
patients	O
with	O
locally	O
advanced	O
HNC	O
compared	O
to	O
conventional	O
RT	O
alone	O
.	O

Predictors	O
of	O
stable	O
return-to-work	O
in	O
non-acute	O
,	O
non-specific	O
spinal	O
pain	O
:	O
low	O
total	O
prior	O
sick-listing	O
,	O
high	O
self	O
prediction	O
and	O
young	O
age	O
.	O

A	O
two-year	O
prospective	O
cohort	O
study	O
.	O

BACKGROUND	O
Non-specific	O
spinal	O
pain	O
(	O
NSP	O
)	O
,	O
comprising	O
back	O
and/or	O
neck	O
pain	O
,	O
is	O
one	O
of	O
the	O
leading	O
disorders	O
in	O
long-term	O
sick-listing	O
.	O

During	O
2000-2004	O
,	O
125	O
Swedish	O
primary-care	O
patients	O
with	O
non-acute	O
NSP	O
,	O
full-time	O
sick-listed	O
6	O
weeks-2	O
years	O
,	O
were	O
included	O
in	O
a	O
randomized	O
controlled	O
trial	O
to	O
compare	O
a	O
cognitive-behavioural	O
programme	O
with	O
traditional	O
primary	O
care	O
.	O

This	O
prospective	O
cohort	O
study	O
is	O
a	O
re-assessment	O
of	O
the	O
data	O
from	O
the	O
randomized	O
trial	O
with	O
the	O
2	O
treatment	O
groups	O
considered	O
as	O
a	O
single	O
cohort	O
.	O

The	O
aim	O
was	O
to	O
investigate	O
which	O
baseline	O
variables	O
predict	O
a	O
stable	O
return-to-work	O
during	O
a	O
2-year	O
period	O
after	O
baseline	O
:	O
objective	O
variables	O
from	O
function	O
tests	O
,	O
socioeconomic	O
,	O
subjective	O
and/or	O
treatment	O
variables	O
.	O

Stable	O
return-to-work	O
was	O
a	O
return-to-work	O
lasting	O
for	O
at	O
least	O
1	O
month	O
from	O
the	O
start	O
of	O
follow-up	O
.	O

METHODS	O
Stable	O
return-to-work	O
was	O
the	O
outcome	O
variable	O
,	O
the	O
above-mentioned	O
factors	O
were	O
the	O
predictive	O
variables	O
in	O
multiple-logistic	O
regression	O
models	O
,	O
one	O
per	O
follow-up	O
at	O
6	O
,	O
12	O
,	O
18	O
and	O
24	O
months	O
after	O
baseline	O
.	O

The	O
factors	O
from	O
univariate	O
analyzes	O
with	O
a	O
p-value	O
of	O
at	O
most	O
.10	O
were	O
included	O
.	O

The	O
non-significant	O
variables	O
were	O
excluded	O
stepwise	O
to	O
yield	O
models	O
comprising	O
only	O
significant	O
factors	O
(	O
p	O
<	O
.05	O
)	O
.	O

As	O
the	O
comparatively	O
few	O
cases	O
made	O
it	O
risky	O
to	O
associate	O
certain	O
predictors	O
with	O
certain	O
time-points	O
,	O
we	O
finally	O
considered	O
the	O
predictors	O
which	O
were	O
represented	O
in	O
at	O
least	O
3	O
follow-ups	O
.	O

They	O
are	O
presented	O
with	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
.	O

RESULTS	O
Three	O
variables	O
qualified	O
,	O
all	O
of	O
them	O
represented	O
in	O
3	O
follow-ups	O
:	O
Low	Others
total	Others
prior	Others
sick-listing	Others
(	Others
including	Others
all	Others
diagnoses	Others
)	Others
was	O
the	O
strongest	Others
predictor	Others
in	O
2	O
follow-ups	O
,	O
18	O
and	O
24	O
months	O
,	O
OR	O
4.8	O
[	O
1.9-12.3	O
]	O
and	O
3.8	O
[	O
1.6-8.7	O
]	O
respectively	O
,	O
High	Others
self	Others
prediction	Others
(	O
the	O
patients	O
'	O
own	O
belief	O
in	O
return-to-work	O
)	O
was	O
the	O
strongest	O
at	O
12	O
months	O
,	O
OR	O
5.2	O
[	O
1.5-17.5	O
]	O
and	O
Young	Physical
age	Physical
(	O
max	O
44	O
years	O
)	O
the	O
second	O
strongest	O
at	O
18	O
months	O
,	O
OR	O
3.5	O
[	O
1.3-9.1	O
]	O
.	O

CONCLUSIONS	O
In	O
primary-care	O
patients	O
with	O
non-acute	O
NSP	O
,	O
the	O
strong	O
predictors	O
of	O
stable	O
return-to-work	O
were	O
2	O
socioeconomic	O
variables	O
,	O
Low	O
total	O
prior	O
sick-listing	O
and	O
Young	O
age	O
,	O
and	O
1	O
subjective	O
variable	O
,	O
High	O
self-prediction	O
.	O

Objective	O
variables	O
from	O
function	O
tests	O
and	O
treatment	O
variables	O
were	O
non-predictors	O
.	O

Except	O
for	O
Young	O
age	O
,	O
the	O
predictors	O
have	O
previously	O
been	O
insufficiently	O
studied	O
,	O
and	O
so	O
our	O
study	O
should	O
widen	O
knowledge	O
within	O
clinical	O
practice	O
.	O

[	O
Clinical	O
study	O
on	O
treatment	O
of	O
endometriosis-related	O
infertility	O
patients	O
by	O
laparoscopic	O
surgery	O
in	O
combination	O
of	O
quyu	O
jiedu	O
recipe	O
]	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
clinical	Others
efficacy	Others
of	O
the	O
laparoscopic	O
surgery	O
in	O
combination	O
of	O
Quyu	O
Jiedu	O
Recipe	O
(	O
QYJDR	O
)	O
on	O
endometriosis	O
(	O
EMs	O
)	O
-related	O
infertility	O
patients	O
.	O

METHODS	O
130	O
EMs-related	O
infertility	O
patients	O
of	O
blood	O
stasis	O
and	O
toxin	O
accumulation	O
syndrome	O
diagnosed	O
and	O
treated	O
by	O
laparoscopic	O
surgery	O
were	O
randomly	O
assigned	O
to	O
two	O
groups	O
,	O
i.e.	O
,	O
the	O
test	O
group	O
(	O
75	O
cases	O
)	O
and	O
the	O
control	O
group	O
(	O
55	O
cases	O
)	O
.	O

All	O
patients	O
received	O
routine	O
progesterone	O
treatment	O
after	O
laparoscopic	O
surgery	O
.	O

QYJDR	O
was	O
given	O
to	O
patients	O
in	O
the	O
test	O
group	O
after	O
laparoscopic	O
surgery	O
,	O
lasting	O
for	O
twelve	O
months	O
.	O

The	O
pregnancy	Physical
rate	Physical
within	O
one	O
year	O
after	O
laparoscopic	O
surgery	O
were	O
compared	O
between	O
the	O
two	O
groups	O
.	O

The	O
Chinese	Physical
medicine	Physical
syndrome	Physical
integrals	Physical
,	Physical
serum	Physical
endometrium	Physical
antibody	Physical
(	Physical
EMAb	Physical
)	Physical
and	Physical
cancer	Physical
antigen	Physical
125	Physical
(	Physical
CA125	Physical
)	Physical
levels	Physical
were	O
compared	O
between	O
before	O
drug	O
therapy	O
and	O
three	O
months	O
after	O
drug	O
therapy	O
.	O

RESULTS	O
The	O
pregnancy	Physical
rate	Physical
within	O
one	O
year	O
after	O
laparoscopic	O
surgery	O
was	O
higher	O
in	O
the	O
test	O
group	O
than	O
in	O
the	O
control	O
group	O
[	O
61.33	O
%	O
(	O
46/75	O
)	O
vs	O
45.45	O
%	O
(	O
25/55	O
)	O
]	O
,	O
showing	O
significant	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
Chinese	Physical
medicine	Physical
syndrome	Physical
integral	Physical
was	O
(	O
16.07	O
+/-	O
6.77	O
)	O
score	O
and	O
(	O
7.25	O
+/-	O
3.27	O
)	O
score	O
before	O
and	O
3	O
months	O
after	O
drug	O
therapy	O
in	O
the	O
test	O
group	O
,	O
while	O
it	O
was	O
(	O
15.92	O
+/-	O
7.51	O
)	O
score	O
and	O
(	O
12.73	O
+/-	O
6.12	O
)	O
score	O
in	O
the	O
control	O
group	O
.	O

The	O
Chinese	Physical
medicine	Physical
syndrome	Physical
integral	Physical
after	O
drug	O
therapy	O
was	O
lower	O
than	O
that	O
before	O
drug	O
therapy	O
in	O
the	O
same	O
group	O
.	O

Besides	O
,	O
the	O
integral	O
difference	O
between	O
before	O
and	O
after	O
drug	O
therapy	O
was	O
higher	O
in	O
the	O
test	O
group	O
than	O
in	O
the	O
control	O
group	O
[	O
(	O
9.12	O
+/-	O
6.16	O
)	O
score	O
vs	O
(	O
3.48	O
+/-	O
2.06	O
)	O
score	O
)	O
]	O
,	O
showing	O
statistical	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
.	O

After	O
three-month	O
drug	O
therapy	O
,	O
the	O
serum	Physical
EMAb	Physical
negative	Physical
conversion	Physical
rate	Physical
was	O
obviously	O
higher	O
in	O
the	O
test	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
44.44	O
%	O
vs	O
15.62	O
%	O
)	O
,	O
showing	O
statistical	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
serum	Physical
CA125	Physical
level	Physical
was	O
(	O
31.88	O
+/-	O
15.78	O
)	O
U/mL	O
before	O
drug	O
therapy	O
and	O
(	O
18.82	O
+/-	O
10.08	O
)	O
U/mL	O
three	O
months	O
after	O
drug	O
therapy	O
in	O
the	O
test	O
group	O
,	O
while	O
it	O
was	O
(	O
30.63	O
+/-	O
19.28	O
)	O
U/mL	O
and	O
(	O
18.05	O
+/-	O
11.20	O
)	O
U/mL	O
respectively	O
in	O
the	O
control	O
group	O
.	O

It	O
was	O
lowered	O
after	O
drug	O
therapy	O
in	O
the	O
two	O
groups	O
with	O
statistical	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
was	O
no	O
statistical	O
difference	O
between	O
the	O
two	O
groups	O
after	O
drug	O
therapy	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSIONS	O
The	O
laparoscopic	O
surgery	O
in	O
combination	O
of	O
QYJDR	O
could	O
effectively	O
improve	O
clinical	O
symptoms	O
of	O
EMs	O
patients	O
of	O
blood	Physical
stasis	Physical
and	O
toxin	Physical
accumulation	Physical
syndrome	Physical
,	O
promote	O
negative	Physical
conversion	Physical
of	Physical
EMAb	Physical
,	O
lower	O
serum	Physical
CA125	Physical
levels	Physical
,	O
and	O
elevate	O
the	O
clinical	Physical
pregnancy	Physical
rate	Physical
.	O

QYJDR	O
is	O
an	O
effective	O
formula	O
in	O
treatment	O
of	O
EMs-related	Physical
infertility	Physical
.	O

Training	O
referential	O
communicative	O
skills	O
to	O
individuals	O
with	O
autism	O
spectrum	O
disorder	O
:	O
a	O
pilot	O
study	O
.	O

The	O
present	O
study	O
reports	O
the	O
effects	O
of	O
referential	O
communication	O
training	O
in	O
individuals	O
formally	O
diagnosed	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

Participants	O
were	O
20	O
children	O
with	O
ASD	O
(	O
M	O
age	O
=	O
14.3	O
yr.	O
,	O
SD	O
=	O
4.2	O
;	O
6	O
girls	O
,	O
14	O
boys	O
)	O
in	O
the	O
role	O
of	O
speakers	O
and	O
20	O
control	O
children	O
,	O
who	O
acted	O
as	O
listeners	O
.	O

They	O
were	O
all	O
enrolled	O
in	O
mainstream	O
compulsory	O
education	O
.	O

Inclusion/exclusion	O
criteria	O
were	O
defined	O
according	O
to	O
the	O
clinical	O
diagnosis	O
of	O
ASD	O
,	O
the	O
presence	O
or	O
absence	O
of	O
additional	O
or	O
associated	O
disability	O
,	O
previous	O
training	O
in	O
referential	O
communication	O
,	O
and	O
any	O
drug	O
treatment	O
.	O

Speakers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
groups	O
(	O
trained	O
vs	O
untrained	O
)	O
.	O

Linguistic	Physical
age	Physical
,	Mental
cognitive	Physical
level	Physical
and	Physical
autistic	Physical
symptoms	Physical
were	O
analyzed	O
,	O
respectively	O
,	O
with	O
the	O
Peabody	Mental
Picture	Mental
Vocabulary	Mental
Test	Mental
(	Mental
PPVT	Mental
)	Mental
,	Mental
the	Mental
Wechsler	Mental
Intelligence	Mental
Scale	Mental
(	Mental
WISC-R	Mental
or	Mental
WAIS-III	Mental
)	Mental
,	Mental
and	Mental
the	Mental
Autistic	Mental
Behavior	Mental
Checklist	Mental
(	Mental
ABC	Mental
)	Mental
.	Mental

Communicative	Mental
abilities	Mental
were	O
analyzed	O
through	O
two	O
indexes	O
related	O
to	O
message	O
complexity	O
and	O
self-regulation	O
.	O

The	O
trained	O
group	O
was	O
trained	O
in	O
referential	O
communication	O
tasks	O
(	O
task	O
analysis	O
,	O
role	O
taking	O
,	O
and	O
task	O
evaluation	O
)	O
,	O
while	O
the	O
untrained	O
group	O
took	O
part	O
in	O
a	O
communicative	O
game	O
but	O
without	O
any	O
specific	O
communicative	O
training	O
.	O

The	O
results	O
showed	O
that	O
the	O
complexity	Physical
of	Physical
emitted	Physical
messages	Physical
had	O
improved	O
statistically	O
significantly	O
in	O
the	O
trained	O
group	O
as	O
an	O
effect	O
of	O
training	O
.	O

Ecological	O
referential	O
communication	O
is	O
shown	O
to	O
be	O
an	O
appropriate	O
paradigm	O
for	O
studying	O
the	O
communicative	O
process	O
and	O
its	O
products	O
and	O
could	O
be	O
used	O
to	O
develop	O
and	O
implement	O
a	O
training	O
program	O
focused	O
on	O
those	O
skills	O
in	O
which	O
individuals	O
with	O
ASD	O
are	O
most	O
deficient	O
.	O

Effect	Others
of	O
reduced	O
alcohol	O
consumption	O
on	O
blood	Physical
pressure	Physical
in	O
untreated	O
hypertensive	O
men	O
.	O

Fifty-four	O
untreated	O
,	O
mildly	O
hypertensive	O
men	O
whose	O
daily	O
alcohol	O
consumption	O
was	O
>	O
or	O
=	O
28	O
ml	O
ethanol	O
and	O
who	O
drank	O
at	O
least	O
4	O
times	O
per	O
week	O
took	O
part	O
in	O
a	O
randomized	O
,	O
controlled	O
crossover	O
trial	O
.	O

The	O
purpose	O
of	O
the	O
trial	O
was	O
to	O
test	O
the	O
effects	Others
of	O
alcohol	O
reduction	O
on	O
blood	Physical
pressure	Physical
.	Physical

After	O
a	O
2-week	O
familiarization	O
period	O
,	O
the	O
participants	O
were	O
assigned	O
to	O
either	O
a	O
reduced	O
alcohol	O
drinking	O
group	O
or	O
a	O
usual	O
drinking	O
group	O
for	O
3	O
weeks	O
(	O
experimental	O
period	O
1	O
)	O
.	O

The	O
situation	O
was	O
then	O
reversed	O
for	O
the	O
next	O
3	O
weeks	O
(	O
experimental	O
period	O
2	O
)	O
.	O

The	O
participants	O
were	O
requested	O
to	O
limit	O
their	O
daily	O
alcohol	O
consumption	O
to	O
zero	O
or	O
reduce	O
it	O
as	O
much	O
as	O
possible	O
for	O
the	O
reduced	O
alcohol	O
consumption	O
period	O
.	O

The	O
self-reported	Physical
alcohol	Physical
consumption	Physical
was	O
56.1	O
+/-	O
3.6	O
(	O
SEM	O
)	O
ml/day	O
during	O
the	O
usual	O
alcohol	O
drinking	O
period	O
and	O
26.1	O
+/-	O
3.0	O
ml/day	O
during	O
the	O
period	O
of	O
reduced	O
alcohol	O
consumption	O
.	O

Systolic	Physical
and	Physical
diastolic	Physical
blood	Physical
pressures	Physical
in	O
the	O
intervention	O
group	O
were	O
found	O
by	O
analysis	O
of	O
variance	O
to	O
be	O
significantly	O
lower	O
(	O
2.6-4.8	O
and	O
2.2-3.0	O
mm	O
Hg	O
,	O
respectively	O
)	O
than	O
those	O
in	O
the	O
control	O
group	O
during	O
experimental	O
period	O
2	O
for	O
systolic	Physical
blood	Physical
pressure	Physical
and	O
experimental	O
period	O
1	O
for	O
diastolic	Physical
blood	Physical
pressure	Physical
.	Physical

Significant	O
(	O
3.6	O
mm	O
Hg	O
)	O
and	O
nonsignificant	O
(	O
1.9	O
mm	O
Hg	O
)	O
decreases	O
in	O
systolic	Physical
and	Physical
diastolic	Physical
blood	Physical
pressure	Physical
,	O
respectively	O
,	O
were	O
observed	O
.	O

The	O
method	O
of	O
Hills	O
and	O
Armitage	O
was	O
used	O
,	O
reducing	O
ethanol	O
in	O
daily	O
alcohol	O
consumption	O
by	O
28	O
ml	O
.	O

The	O
lowering	O
effect	O
of	O
reduced	O
alcohol	O
consumption	O
on	O
blood	O
pressure	O
was	O
independent	O
of	O
changes	O
in	O
salt	O
consumption	O
,	O
which	O
were	O
estimated	O
by	O
24-hour	O
urine	O
collection	O
and	O
body	O
weight	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Association	O
of	O
chronic	O
kidney	O
disease	O
with	O
outcomes	O
in	O
chronic	Physical
heart	Physical
failure	Physical
:	O
a	O
propensity-matched	O
study	O
.	O

BACKGROUND	O
Chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
is	O
associated	O
with	O
increased	O
mortality	Mortality
in	O
patients	O
with	O
heart	O
failure	O
(	O
HF	O
)	O
.	O

However	O
,	O
its	O
association	O
with	O
hospitalization	O
in	O
HF	O
patients	O
has	O
not	O
been	O
well	O
studied	O
.	O

METHODS	O
Of	O
7788	O
patients	O
in	O
the	O
Digitalis	O
Investigation	O
Group	O
trial	O
,	O
3527	O
had	O
CKD	O
,	O
defined	O
by	O
an	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
<	O
60	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
body	O
surface	O
area	O
(	O
BSA	O
)	O
.	O

Propensity	O
scores	O
for	O
CKD	O
were	O
calculated	O
using	O
a	O
multivariable	O
logistic	O
regression	O
model	O
and	O
used	O
to	O
match	O
2399	O
pairs	O
of	O
patients	O
with	O
and	O
without	O
CKD	O
.	O

Matched	O
Cox	O
regression	O
analyses	O
were	O
used	O
to	O
estimate	O
association	O
of	O
CKD	O
with	O
outcomes	O
.	O

RESULTS	O
All-cause	Others
hospitalization	Others
occurred	O
in	O
1636	O
(	O
rate	O
,	O
4233/10,000	O
person-years	O
)	O
and	O
1587	O
(	O
rate	O
,	O
3733/10,000	O
person-years	O
)	O
patients	O
respectively	O
,	O
with	O
and	O
without	O
CKD	O
(	O
matched	O
hazard	O
ratio	O
[	O
HR	O
]	O
for	O
CKD	O
,	O
1.18	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.08-1.29	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Matched	Physical
HR	Physical
for	Physical
cardiovascular	Physical
and	Physical
HF	Physical
hospitalization	Physical
were	O
respectively	O
1.17	O
(	O
95	O
%	O
CI	O
,	O
1.06-1.28	O
,	O
P	O
=	O
0.002	O
)	O
and	O
1.28	O
(	O
95	O
%	O
CI	O
,	O
1.13-1.45	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Compared	O
to	O
GFR	O
>	O
or=60	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
BSA	O
,	O
HR	Physical
for	Physical
all-cause	Physical
hospitalization	Physical
for	Physical
GFR	Physical
45-59	O
and	O
<	O
45	O
ml/min/1.73	O
m	O
(	O
2	O
)	O
BSA	O
were	O
respectively	O
1.04	O
(	O
95	O
%	O
CI	O
,	O
0.94-1.16	O
;	O
P	O
=	O
0.422	O
)	O
and	O
1.58	O
(	O
95	O
%	O
CI	O
,	O
1.34-1.87	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Similarly	O
,	O
HR	Mortality
for	Mortality
all-cause	Mortality
death	Mortality
for	Mortality
GFR	Mortality
45-59	Mortality
and	Mortality
<	Mortality
45	Mortality
ml/min/1.73	Mortality
m	Mortality
(	Mortality
2	Mortality
)	Mortality
BSA	Mortality
were	O
respectively	O
1.03	O
(	O
95	O
%	O
CI	O
,	O
0.90-1.18	O
;	O
P	O
=	O
0.651	O
)	O
and	O
1.70	O
(	O
95	O
%	O
CI	O
,	O
1.40-2.07	O
;	O
P	O
<	O
0.0001	O
)	O
.	O

Matched	Mortality
HR	Mortality
for	Mortality
death	Mortality
due	Mortality
to	Mortality
cardiovascular	Mortality
causes	Mortality
and	Mortality
progressive	Mortality
HF	Mortality
were	O
respectively	O
1.24	O
(	O
95	O
%	O
CI	O
,	O
1.09-1.40	O
;	O
P	O
=	O
0.001	O
)	O
and	O
1.42	O
(	O
95	O
%	O
CI	O
,	O
1.16-1.72	O
;	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSION	O
CKD	O
was	O
associated	O
with	O
increased	O
mortality	Mortality
and	O
hospitalization	Others
in	O
ambulatory	O
patients	O
with	O
chronic	O
HF	O
,	O
which	O
increased	O
progressively	O
with	O
worsening	O
kidney	Physical
function	Physical
.	Physical

Increased	Physical
growth	Physical
hormone	Physical
response	O
to	O
sumatriptan	O
challenge	O
in	O
adult	O
autistic	O
disorders	O
.	O

Serotonergic	O
(	O
5-HT	O
)	O
abnormalities	O
have	O
been	O
documented	O
in	O
autism	O
.	O

To	O
assess	O
sensitivity	O
of	O
the	O
5-HT1d	O
receptor	O
,	O
growth	Physical
hormone	Physical
response	Physical
to	O
the	O
5-HT1d	O
receptor	O
agonist	O
sumatriptan	O
was	O
studied	O
in	O
adult	O
autistic	O
patients	O
and	O
matched	O
normal	O
controls	O
.	O

In	O
this	O
study	O
,	O
11	O
adult	O
patients	O
with	O
autism	O
or	O
Asperger	O
's	O
disorder	O
were	O
compared	O
with	O
nine	O
matched	O
controls	O
.	O

All	O
subjects	O
were	O
randomized	O
to	O
single	O
dose	O
sumatriptan	O
(	O
6	O
mg	O
SQ	O
)	O
and	O
placebo	O
challenges	O
,	O
separated	O
by	O
a	O
1-week	O
interval	O
,	O
and	O
growth	Physical
hormone	Physical
was	O
measured	O
before	O
and	O
during	O
the	O
challenges	O
.	O

The	O
results	O
showed	O
a	O
highly	O
significant	O
diagnosisxdrugxtime	Physical
interaction	Physical
on	O
repeated	O
measure	O
analysis	O
covaried	O
for	O
baseline	O
.	O

This	O
suggests	O
that	O
autistic	O
patients	O
had	O
significantly	O
greater	O
growth	Physical
hormone	Physical
response	Physical
to	O
sumatriptan	O
than	O
normal	O
controls	O
,	O
independent	O
of	O
placebo	O
effects	O
.	O

Therefore	O
,	O
abnormalities	O
in	O
5-HT	O
regulation	O
in	O
autism	O
may	O
be	O
related	O
to	O
increased	O
sensitivity	O
of	O
the	O
5-HT1d	O
inhibitory	O
receptor	O
in	O
autism	O
.	O

Physical	O
activity	O
in	O
first-degree	O
relatives	O
of	O
breast	O
cancer	O
patients	O
.	O

This	O
study	O
sought	O
to	O
evaluate	O
physical	O
activity	O
in	O
women	O
at	O
moderate	O
risk	O
for	O
breast	O
cancer	O
,	O
the	O
correlates	O
of	O
engaging	O
in	O
regular	O
physical	O
activity	O
,	O
and	O
whether	O
physical	O
activity	O
relates	O
to	O
psychological	Mental
well-being	Mental
.	Physical

The	O
results	O
revealed	O
that	O
55	O
%	O
of	O
women	O
were	O
regularly	O
active	O
.	O

Logistic	O
regression	O
models	O
indicated	O
that	O
positive	O
affect	O
was	O
associated	O
with	O
increased	O
and	O
negative	O
affect	O
was	O
associated	O
with	O
decreased	O
overall	O
and	O
leisure	Mental
activity	Mental
.	Others

Older	O
,	O
married	O
,	O
and	O
employed	O
women	O
were	O
more	O
likely	O
to	O
engage	O
in	O
household/occupational	Mental
activity	Mental
,	O
whereas	O
women	O
who	O
perceived	O
their	O
risk	O
for	O
breast	O
cancer	O
as	O
high	O
were	O
less	O
likely	O
.	O

More	O
educated	O
women	O
and	O
those	O
with	O
higher	O
perceived	O
risk	O
were	O
more	O
likely	O
to	O
engage	O
in	O
leisure	Mental
activity	Mental
,	O
and	O
married	O
women	O
were	O
less	O
likely	O
.	O

These	O
results	O
suggest	O
a	O
need	O
to	O
increase	O
activity	O
levels	O
in	O
women	O
at	O
moderate	O
risk	O
for	O
breast	O
cancer	O
,	O
provide	O
variables	O
upon	O
which	O
interventions	O
can	O
be	O
tailored	O
to	O
promote	O
activity	O
,	O
and	O
point	O
to	O
psychological	O
benefits	O
of	O
activity	O
in	O
this	O
population	O
.	O

Dose-response	O
relationship	O
of	O
complementary	O
radiotherapy	O
following	O
four	O
cycles	O
of	O
combination	O
chemotherapy	O
in	O
intermediate-stage	O
Hodgkin	O
's	O
disease	O
.	O

PURPOSE	O
To	O
determine	O
the	O
appropriate	O
irradiation	O
dose	O
after	O
four	O
cycles	O
of	O
modern	O
combination	O
chemotherapy	O
in	O
nonbulky	O
involved	O
field	O
(	O
IF/BF	O
)	O
and	O
noninvolved	O
extended-field	O
(	O
EF/IF	O
)	O
sites	O
in	O
patients	O
with	O
intermediate-stage	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
HD	O
patients	O
in	O
stage	O
I	O
to	O
IIIA	O
with	O
a	O
large	O
mediastinal	O
mass	O
,	O
E	O
stage	O
,	O
or	O
massive	O
spleen	O
involvement	O
were	O
treated	O
with	O
two	O
double	O
cycles	O
of	O
alternating	O
cyclophosphamide	O
,	O
vincristine	O
,	O
procarbazine	O
,	O
and	O
prednisone	O
(	O
COPP	O
)	O
plus	O
doxorubicin	O
,	O
bleomycin	O
,	O
vinblastine	O
,	O
and	O
dacarbazine	O
(	O
ABVD	O
)	O
followed	O
by	O
EF	O
irradiation	O
in	O
two	O
successive	O
trials	O
(	O
HD1	O
and	O
HD5	O
)	O
.	O

In	O
the	O
HD1	O
trial	O
(	O
1983	O
to	O
1988	O
)	O
,	O
146	O
patients	O
who	O
responded	O
to	O
chemotherapy	O
were	O
randomized	O
to	O
receive	O
20	O
Gy	O
(	O
70	O
patients	O
)	O
or	O
40	O
Gy	O
(	O
76	O
patients	O
)	O
of	O
EF	O
irradiation	O
in	O
all	O
fields	O
outside	O
bulky	O
disease	O
sites	O
.	O

A	O
cohort	O
of	O
111	O
patients	O
who	O
fulfilled	O
the	O
same	O
inclusion	O
criteria	O
in	O
the	O
subsequent	O
trial	O
HD5	O
(	O
1988	O
to	O
1993	O
)	O
were	O
treated	O
with	O
30	O
Gy	O
.	O

Bulky	O
disease	O
always	O
received	O
40	O
Gy	O
.	O

RESULTS	O
Freedom-from-treatment-failure	Physical
(	Physical
FFTF	Physical
)	Physical
and	O
survival	Mortality
(	Mortality
SV	Mortality
)	Mortality
curves	Mortality
showed	O
no	O
differences	O
between	O
the	O
20-	O
,	O
30-	O
,	O
and	O
40-Gy	O
groups	O
.	O

However	O
,	O
acute	Physical
toxicities	Physical
were	O
more	O
frequent	O
in	O
the	O
40-Gy	O
arm	O
.	O

Analysis	Physical
of	Physical
relapse	Physical
patterns	Physical
showed	O
that	O
18	O
of	O
26	O
relapsing	O
patients	O
either	O
failed	O
to	O
respond	O
in	O
initial	O
bulky	O
sites	O
(	O
n	O
=	O
5	O
)	O
or	O
had	O
an	O
extranodal	O
relapse	O
(	O
n	O
=	O
9	O
)	O
or	O
both	O
(	O
n	O
=	O
4	O
)	O
.	O

After	O
5	O
years	O
,	O
the	O
cumulative	O
risk	Physical
for	Physical
relapse	Physical
in	O
bulky	O
sites	O
is	O
10	O
%	O
,	O
despite	O
40	O
Gy	O
of	O
radiation	O
.	O

CONCLUSION	O
Our	O
results	O
strongly	O
suggest	O
that	O
there	O
is	O
no	O
relevant	O
radiotherapy	Physical
dose	Physical
effect	Physical
in	O
the	O
range	O
between	O
20	O
Gy	O
and	O
40	O
Gy	O
in	O
IF/BF	O
and	O
EF/IF	O
after	O
4	O
months	O
of	O
modern	O
polychemotherapy	O
in	O
patients	O
with	O
intermediate-stage	O
HD	O
.	O

Relapse	O
patterns	O
indicate	O
that	O
patients	O
destined	O
to	O
relapse	O
need	O
more	O
systemic	O
,	O
rather	O
than	O
local	O
,	O
treatment	O
.	O

Based	O
on	O
our	O
data	O
,	O
we	O
conclude	O
that	O
20	O
Gy	O
is	O
sufficient	O
in	O
EF/IF	O
of	O
intermediate-stage	O
HD	O
following	O
four	O
cycles	O
of	O
modern	O
polychemotherapy	O
.	O

Circadian	O
changes	O
in	O
the	O
pharmacokinetics	Physical
of	O
oral	O
ketoprofen	O
.	O

Several	O
investigations	O
which	O
have	O
taken	O
treatment	O
time	O
into	O
account	O
have	O
shown	O
that	O
the	O
pharmacokinetic	O
parameters	O
,	O
the	O
therapeutic	Others
efficacy	Others
and	O
even	O
the	O
toxicity	Physical
of	O
a	O
large	O
number	O
of	O
products	O
may	O
vary	O
according	O
to	O
the	O
administration	O
schedule	O
.	O

The	O
present	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
evaluate	O
any	O
circadian	O
changes	O
in	O
pharmacokinetic	O
parameters	O
of	O
ketoprofen	O
,	O
a	O
new	O
non-steroidal	O
anti-inflammatory	O
drug	O
(	O
NSAID	O
)	O
.	O

This	O
randomised	O
crossover	O
study	O
consisted	O
of	O
a	O
single	O
oral	O
dose	O
of	O
ketoprofen	O
100mg	O
administered	O
to	O
8	O
healthy	O
male	O
volunteers	O
,	O
mean	O
age	O
27.2	O
years	O
,	O
at	O
07.00	O
hours	O
,	O
13.00	O
hours	O
,	O
19.00	O
hours	O
or	O
01.00	O
hours	O
in	O
4	O
study	O
periods	O
during	O
the	O
first	O
3	O
months	O
of	O
the	O
year	O
.	O

The	O
order	O
of	O
administration	O
was	O
randomised	O
,	O
with	O
each	O
subject	O
acting	O
as	O
his	O
own	O
control	O
.	O

A	O
total	O
of	O
14	O
blood	O
and	O
4	O
urine	O
samples	O
were	O
taken	O
over	O
a	O
12-hour	O
period	O
.	O

The	O
peak	Physical
plasma	Physical
concentration	Physical
was	O
twice	O
as	O
high	O
after	O
drug	O
administration	O
at	O
07.00	O
hours	O
(	O
13.4	O
+/-	O
1	O
mg/L	O
)	O
than	O
after	O
other	O
administration	O
times	O
(	O
13.00	O
hours	O
:	O
6.9	O
+/-	O
1	O
;	O
19.00	O
hours	O
:	O
7.2	O
+/-	O
0.7	O
;	O
01.00	O
hours	O
:	O
6.3	O
+/-	O
0.5	O
mg/L	O
)	O
[	O
p	O
less	O
than	O
0.001	O
]	O
.	O

The	O
time	Physical
to	Physical
reach	Physical
peak	Physical
concentration	Physical
was	O
much	O
longer	O
after	O
drug	O
administration	O
at	O
01.00	O
hours	O
(	O
135	O
+/-	O
16.7	O
min	O
)	O
than	O
at	O
07.00	O
(	O
73.1	O
+/-	O
14.1	O
min	O
)	O
,	O
13.00	O
(	O
75	O
+/-	O
16.5	O
min	O
)	O
or	O
19.00	O
hours	O
(	O
82.5	O
+/-	O
12.7	O
min	O
)	O
[	O
p	O
less	O
than	O
0.05	O
]	O
.	O

The	O
lag	Others
time	Others
was	O
significantly	O
longer	O
at	O
01.00	O
hours	O
than	O
at	O
13.00	O
hours	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

The	O
absorption	Physical
rate	Physical
constant	O
after	O
treatment	O
at	O
01.00	O
hours	O
was	O
less	O
than	O
at	O
the	O
other	O
times	O
of	O
administration	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
bodyweight-corrected	Physical
area	Physical
under	Physical
the	Physical
curve	Physical
(	Physical
AUC0-12	Physical
)	Physical
was	O
greater	O
after	O
07.00	O
hours	O
than	O
after	O
13.00	O
(	O
p	O
less	O
than	O
0.01	O
)	O
or	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
greater	O
after	O
01.00	O
hours	O
than	O
after	O
13.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
elimination	Physical
half-life	Physical
was	O
significantly	O
longer	O
after	O
administration	O
at	O
01.00	O
hours	O
than	O
after	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
while	O
the	O
total	Others
clearance	Others
was	O
lowest	O
at	O
07.00	O
hours	O
.	O

Cosinor	O
analysis	O
demonstrated	O
statistically	O
significant	O
circadian	Physical
rhythms	Physical
for	O
all	O
pharmacokinetic	O
parameters	O
described	O
above	O
.	O

The	O
amount	O
of	O
ketoprofen	O
eliminated	O
in	O
the	O
urine	O
was	O
delayed	O
,	O
and	O
was	O
significantly	O
greater	O
after	O
the	O
administration	O
at	O
01.00	O
hours	O
than	O
07.00	O
hours	O
or	O
19.00	O
hours	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

The	O
relationship	O
between	O
absorption	O
,	O
diffusion	O
and/or	O
elimination	O
mechanisms	O
of	O
the	O
drug	O
are	O
discussed	O
.	O

Pre-bent	O
instruments	O
used	O
in	O
single-port	O
laparoscopic	O
surgery	O
versus	O
conventional	O
laparoscopic	O
surgery	O
:	O
comparative	O
study	O
of	O
performance	O
in	O
a	O
dry	O
lab	O
.	O

BACKGROUND	O
Different	O
types	O
of	O
single-incision	O
laparoscopic	O
surgery	O
(	O
SILS	O
)	O
have	O
become	O
increasingly	O
popular	O
.	O

Although	O
SILS	O
is	O
technically	O
even	O
more	O
challenging	O
than	O
conventional	O
laparoscopy	O
,	O
published	O
data	O
of	O
first	O
clinical	O
series	O
seem	O
to	O
demonstrate	O
the	O
feasibility	O
of	O
these	O
approaches	O
.	O

Various	O
attempts	O
have	O
been	O
made	O
to	O
overcome	O
restrictions	O
due	O
to	O
loss	O
of	O
triangulation	O
in	O
SILS	O
by	O
specially	O
designed	O
SILS-specific	O
instruments	O
.	O

This	O
study	O
involving	O
novices	O
in	O
a	O
dry	O
lab	O
compared	O
task	Mental
performances	Mental
between	O
conventional	O
laparoscopic	O
surgery	O
(	O
CLS	O
)	O
and	O
single-port	O
laparoscopic	O
surgery	O
(	O
SPLS	O
)	O
using	O
newly	O
designed	O
pre-bent	O
instruments	O
.	O

METHODS	O
In	O
this	O
study	O
,	O
90	O
medical	O
students	O
without	O
previous	O
experience	O
in	O
laparoscopic	O
techniques	O
were	O
randomly	O
assigned	O
to	O
undergo	O
one	O
of	O
three	O
procedures	O
:	O
CLS	O
,	O
SPLS	O
using	O
two	O
pre-bent	O
instruments	O
(	O
SPLS-pp	O
)	O
,	O
or	O
SPLS	O
using	O
one	O
pre-bent	O
and	O
one	O
straight	O
laparoscopic	O
instrument	O
(	O
SPLS-ps	O
)	O
.	O

In	O
the	O
dry	O
lab	O
,	O
the	O
participants	O
performed	O
four	O
typical	O
laparoscopic	O
tasks	O
of	O
increasing	O
difficulty	O
.	O

Evaluation	O
included	O
performance	Mental
times	Mental
or	O
number	Mental
of	Mental
completed	Mental
tasks	Mental
within	Mental
a	Mental
given	Mental
time	Mental
frame	Mental
.	O

All	O
performances	Mental
were	O
videotaped	O
and	O
evaluated	O
for	O
unsuccessful	Mental
attempts	Mental
and	Mental
unwanted	Mental
interactions	Mental
of	Mental
instruments	Mental
.	O

Using	O
subjective	Others
questionnaires	Others
,	O
the	O
participants	O
rated	Mental
difficulties	Mental
with	Mental
two-dimensional	Mental
vision	Mental
and	Mental
coordination	Mental
of	Mental
instruments	Mental
.	O

RESULTS	O
Task	Mental
performances	Mental
were	O
significantly	O
better	O
in	O
the	O
CLS	O
group	O
than	O
in	O
either	O
SPLS	O
group	O
.	O

The	O
SPLS-ps	O
group	O
showed	O
a	O
tendency	O
toward	O
better	O
performances	Others
than	O
the	O
SPLS-pp	O
group	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
.	O

Video	O
sequences	O
and	O
participants`	O
questionnaires	O
showed	O
instrument	Mental
interaction	Mental
as	O
the	O
major	Adverseeffect
problem	Adverseeffect
in	O
the	O
single-incision	O
surgery	O
groups	O
.	O

CONCLUSIONS	O
Although	O
SILS	O
is	O
feasible	O
,	O
as	O
shown	O
in	O
clinical	O
series	O
published	O
by	O
laparoscopically	O
experienced	O
experts	O
,	O
SILS	O
techniques	O
are	O
demanding	O
due	O
to	O
restrictions	O
that	O
come	O
with	O
the	O
loss	O
of	O
triangulation	O
.	O

These	O
can	O
be	O
compensated	O
only	O
partially	O
by	O
currently	O
available	O
SILS-designed	O
instruments	O
.	O

The	O
future	O
of	O
SILS	O
depends	O
on	O
further	O
improvements	O
in	O
the	O
available	O
equipment	O
or	O
the	O
development	O
of	O
new	O
approaches	O
such	O
as	O
needlescopically	O
assisted	O
or	O
robotically	O
assisted	O
procedures	O
.	O

Efficacy	Others
of	O
dose-intensified	O
MEC	O
(	O
methotrexate	O
,	O
epirubicin	O
and	O
cisplatin	O
)	O
chemotherapy	O
for	O
advanced	O
urothelial	O
carcinoma	O
:	O
a	O
prospective	O
randomized	O
trial	O
comparing	O
MEC	O
and	O
M-VAC	O
(	O
methotrexate	O
,	O
vinblastine	O
,	O
doxorubicin	O
and	O
cisplatin	O
)	O
.	O

Japanese	O
Urothelial	O
Cancer	O
Research	O
Group	O
.	O

BACKGROUND	O
To	O
evaluate	O
the	O
antitumor	Others
activity	Others
in	O
patients	O
with	O
T3b	O
,	O
T4	O
or	O
metastatic	O
urothelial	O
carcinoma	O
treated	O
with	O
MEC	O
or	O
M-VAC	O
chemotherapy	O
,	O
by	O
performing	O
a	O
multi-center	O
randomized	O
prospective	O
study	O
.	O

METHODS	O
From	O
1991	O
to	O
1995	O
,	O
89	O
patients	O
with	O
T3b	O
,	O
T4	O
or	O
metastatic	O
urothelial	O
carcinoma	O
were	O
randomly	O
allocated	O
to	O
a	O
methotrexate	O
,	O
epirubicin	O
and	O
cisplatin	O
chemotherapy	O
group	O
(	O
arm	O
1	O
:	O
S-MEC	O
therapy	O
;	O
n	O
=	O
29	O
)	O
,	O
a	O
dose-intensified	O
MEC	O
therapy	O
combined	O
with	O
G-CSF	O
group	O
(	O
arm	O
2	O
:	O
I-MEC	O
therapy	O
;	O
n	O
=	O
30	O
)	O
or	O
a	O
methotrexate	O
,	O
vinblastine	O
,	O
doxorubicin	O
and	O
cisplatin	O
chemotherapy	O
(	O
arm	O
3	O
:	O
M-VAC	O
therapy	O
;	O
n	O
=	O
30	O
)	O
.	O

At	O
the	O
registration	O
center	O
,	O
the	O
patients	O
were	O
stratified	O
into	O
previously	O
untreated	O
patients	O
and	O
patients	O
with	O
recurrence	O
after	O
radical	O
operation	O
and	O
then	O
randomly	O
allocated	O
to	O
the	O
treatment	O
groups	O
.	O

In	O
each	O
arm	O
,	O
two	O
or	O
more	O
courses	O
of	O
chemotherapy	O
(	O
4-week	O
cycles	O
)	O
were	O
performed	O
.	O

RESULTS	O
Of	O
the	O
88	O
eligible	O
patients	O
,	O
four	O
treated	O
with	O
S-MEC	O
therapy	O
and	O
two	O
treated	O
with	O
I-MEC	O
therapy	O
showed	O
CR	O
.	O

The	O
response	Others
rates	Others
(	O
CR	O
+	O
PR	O
)	O
were	O
52	O
%	O
(	O
15/29	O
)	O
with	O
S-MEC	O
therapy	O
,	O
76	O
%	O
(	O
22/29	O
)	O
with	O
I-MEC	O
therapy	O
and	O
47	O
%	O
(	O
14/30	O
)	O
with	O
M-VAC	O
therapy	O
.	O

The	O
response	Others
rate	Others
with	Others
I-MEC	Others
therapy	Others
was	O
significantly	O
higher	O
than	O
that	O
with	O
M-VAC	O
therapy	O
(	O
P	O
=	O
0.02	O
)	O
.	O

Although	O
the	O
incidence	O
of	O
leukopenia	O
was	O
low	O
with	O
I-MEC	Others
therapy	Others
,	O
the	O
incidence	O
of	O
thrombocytopenia	Physical
was	O
high	O
with	O
this	O
therapy	O
.	O

CONCLUSION	O
MEC	O
therapy	O
used	O
in	O
this	O
study	O
is	O
promising	O
in	O
terms	O
of	O
the	O
antitumor	Others
effects	Others
.	Others

A	O
double-blind	O
comparative	O
study	O
of	O
ofloxacin	O
otic	O
drops	O
versus	O
neomycin-polymyxin	O
B-hydrocortisone	O
otic	O
drops	O
in	O
the	O
medical	O
treatment	O
of	O
chronic	O
suppurative	O
otitis	O
media	O
.	O

Active	O
chronic	O
suppurative	O
otitis	O
media	O
poses	O
a	O
management	O
problem	O
when	O
patients	O
are	O
being	O
considered	O
for	O
surgical	O
treatment	O
.	O

Topical	O
antibiotics	O
have	O
demonstrated	O
varying	O
degrees	O
of	O
success	O
in	O
the	O
management	O
of	O
discharging	O
ears	O
.	O

The	O
introduction	O
of	O
quinolones	O
has	O
revived	O
interest	O
in	O
these	O
topical	O
agents	O
.	O

This	O
double-blind	O
study	O
compares	O
two	O
antibiotics	O
,	O
namely	O
ofloxacin	O
and	O
neomycin-polymyxin	O
B	O
,	O
with	O
similar	O
in	O
vitro	O
sensitivities	O
to	O
Gram	O
positive	O
and	O
Gram	O
negative	O
organisms	O
.	O

Fifty-two	O
patients	O
were	O
selected	O
randomly	O
and	O
the	O
results	O
show	O
that	O
ofloxacin	O
eardrops	O
have	O
marginal	O
benefits	O
in	O
symptomatic	Physical
improvement	Physical
(	O
89	O
per	O
cent	O
versus	O
79	O
per	O
cent	O
,	O
p	O
=	O
0.27	O
)	O
and	O
bacterial	Physical
eradication	Physical
(	O
81	O
per	O
cent	O
versus	O
75	O
per	O
cent	O
,	O
p	O
=	O
0.81	O
)	O
in	O
active	Physical
chronic	Physical
suppurative	Physical
otitis	Physical
media	Physical
.	O

Significantly	O
fewer	O
patients	O
(	O
seven	O
per	O
cent	O
versus	O
29	O
per	O
cent	O
,	O
p	O
=	O
0.04	O
)	O
in	O
the	O
ofloxacin	O
group	O
had	O
active	O
disease	Physical
at	O
the	O
end	O
of	O
the	O
two-week	O
treatment	O
.	O

We	O
recommend	O
the	O
use	O
of	O
ofloxacin	O
eardrops	O
in	O
managing	O
active	O
chronic	O
suppurative	O
otitis	O
media	O
since	O
it	O
has	O
high	O
clinical	Others
efficacy	Others
,	O
contains	O
no	O
steroid	O
component	O
and	O
has	O
no	O
demonstrated	O
risk	Adverseeffect
of	Adverseeffect
ototoxicity	Adverseeffect
.	O

Promoting	O
physical	O
activity	O
in	O
patients	O
with	O
colon	O
adenomas	O
:	O
a	O
randomized	O
pilot	O
intervention	O
trial	O
.	O

BACKGROUND	O
Physical	O
activity	O
decreases	O
risk	O
of	O
colon	O
polyps	O
and	O
colon	O
cancer	O
and	O
might	O
reduce	O
risk	O
of	O
colon	O
cancer	O
recurrence	O
.	O

Focusing	O
on	O
recent	O
calls	O
for	O
translation	O
of	O
epidemiologic	O
evidence	O
into	O
clinical	O
care	O
,	O
our	O
pilot	O
study	O
delivered	O
an	O
evidence-based	O
physical	O
activity	O
intervention	O
in	O
adults	O
with	O
polyps	O
,	O
who	O
are	O
thus	O
at	O
elevated	O
risk	O
of	O
developing	O
colon	O
cancer	O
.	O

The	O
objective	O
was	O
to	O
evaluate	O
change	O
in	O
physical	O
activity	O
,	O
measured	O
by	O
steps	O
per	O
day	O
and	O
minutes	O
of	O
moderate/vigorous	Mental
physical	O
activity	O
.	O

METHODS	O
Sixteen	O
adults	O
with	O
adenomas	O
detected	O
and	O
removed	O
at	O
screening	O
colonoscopy	O
were	O
recruited	O
to	O
a	O
12-week	O
physical	O
activity	O
intervention	O
.	O

Participants	O
were	O
randomized	O
to	O
receive	O
a	O
standard	O
(	O
30	O
minutes/day	O
)	O
or	O
high	O
(	O
60	O
minutes/day	O
)	O
walking	O
program	O
.	O

Physical	O
activity	O
was	O
measured	O
via	O
blinded	O
pedometer	O
and	O
accelerometer	O
at	O
baseline	O
and	O
follow-up	O
.	O

Intervention	O
messages	O
focused	O
on	O
self-monitoring	O
using	O
pedometers	O
and	O
overcoming	O
barriers	O
to	O
engaging	O
in	O
physical	O
activity	O
.	O

RESULTS	O
Participants	O
in	O
both	O
arms	O
significantly	O
increased	O
objectively	O
measured	Mental
minutes	Mental
of	Mental
moderate/vigorous	Mental
physical	Mental
activity	Mental
over	O
the	O
course	O
of	O
the	O
intervention	O
.	O

Both	O
arms	O
exceeded	O
the	O
intervention	O
goal	O
,	O
but	O
there	O
was	O
not	O
a	O
significant	O
difference	O
between	O
arms	O
at	O
follow-up	O
.	O

Results	O
were	O
similar	O
for	O
pedometer	Others
measured	Others
physical	Others
activity	Others
,	O
with	O
a	O
significant	O
overall	O
increase	Mental
in	Mental
steps/day	Mental
from	O
baseline	O
to	O
follow-up	O
,	O
but	O
no	O
between	O
arm	O
difference	O
in	O
change	O
.	O

CONCLUSION	O
Simple	O
interventions	O
of	O
minimal	O
contact	O
time	O
focusing	O
on	O
walking	O
can	O
significantly	O
increase	O
physical	O
activity	O
in	O
individuals	O
at	O
increased	O
risk	O
of	O
developing	O
colon	O
cancer	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
NCT01476631	O
.	O

Effect	O
of	O
duloxetine	O
on	O
pain	Pain
,	O
function	Physical
,	O
and	O
quality	Others
of	Others
life	Others
among	O
patients	O
with	O
chemotherapy-induced	O
painful	O
peripheral	O
neuropathy	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

IMPORTANCE	O
There	O
are	O
no	O
known	O
effective	O
treatments	O
for	O
painful	O
chemotherapy-induced	O
peripheral	O
neuropathy	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
duloxetine	O
,	O
60	O
mg	O
daily	O
,	O
on	O
average	Pain
pain	Pain
severity	Pain
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
trial	O
at	O
8	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
-funded	O
cooperative	O
research	O
networks	O
that	O
enrolled	O
231	O
patients	O
who	O
were	O
25	O
years	O
or	O
older	O
being	O
treated	O
at	O
community	O
and	O
academic	O
settings	O
between	O
April	O
2008	O
and	O
March	O
2011	O
.	O

Study	O
follow-up	O
was	O
completed	O
July	O
2012	O
.	O

Stratified	O
by	O
chemotherapeutic	O
drug	O
and	O
comorbid	O
pain	O
risk	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
duloxetine	O
followed	O
by	O
placebo	O
or	O
placebo	O
followed	O
by	O
duloxetine	O
.	O

Eligibility	O
required	O
that	O
patients	O
have	O
grade	O
1	O
or	O
higher	O
sensory	O
neuropathy	O
according	O
to	O
the	O
NCI	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
and	O
at	O
least	O
4	O
on	O
a	O
scale	O
of	O
0	O
to	O
10	O
,	O
representing	O
average	O
chemotherapy-induced	O
pain	O
,	O
after	O
paclitaxel	O
,	O
other	O
taxane	O
,	O
or	O
oxaliplatin	O
treatment	O
.	O

INTERVENTIONS	O
The	O
initial	O
treatment	O
consisted	O
of	O
taking	O
1	O
capsule	O
daily	O
of	O
either	O
30	O
mg	O
of	O
duloxetine	O
or	O
placebo	O
for	O
the	O
first	O
week	O
and	O
2	O
capsules	O
of	O
either	O
30	O
mg	O
of	O
duloxetine	O
or	O
placebo	O
daily	O
for	O
4	O
additional	O
weeks	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
hypothesis	O
was	O
that	O
duloxetine	O
would	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
decreasing	O
chemotherapy-induced	Pain
peripheral	Pain
neuropathic	Pain
pain	Pain
.	O

Pain	Pain
severity	Pain
was	O
assessed	O
using	O
the	O
Brief	Pain
Pain	Pain
Inventory-Short	Pain
Form	Pain
average	Pain
pain	Pain
item	Pain
with	O
0	O
representing	O
no	O
pain	Pain
and	O
10	O
representing	O
as	O
bad	O
as	O
can	O
be	O
imagined	O
.	O

RESULTS	O
Individuals	O
receiving	O
duloxetine	O
as	O
their	O
initial	O
5-week	O
treatment	O
reported	O
a	O
mean	O
decrease	O
in	O
average	O
pain	O
of	O
1.06	O
(	O
95	O
%	O
CI	O
,	O
0.72-1.40	O
)	O
vs	O
0.34	O
(	O
95	O
%	O
CI	O
,	O
0.01-0.66	O
)	O
among	O
those	O
who	O
received	O
placebo	O
(	O
P	O
=	O
.003	O
;	O
effect	O
size	O
,	O
0.513	O
)	O
.	O

The	O
observed	O
mean	O
difference	O
in	O
the	O
average	Pain
pain	Pain
score	Pain
between	O
duloxetine	O
and	O
placebo	O
was	O
0.73	O
(	O
95	O
%	O
CI	O
,	O
0.26-1.20	O
)	O
.	O

Fifty-nine	O
percent	O
of	O
those	O
initially	O
receiving	O
duloxetine	O
vs	O
38	O
%	O
of	O
those	O
initially	O
receiving	O
placebo	O
reported	O
decreased	O
pain	Pain
of	O
any	O
amount	O
.	O

CONCLUSION	O
AND	O
RELEVANCE	O
Among	O
patients	O
with	O
painful	O
chemotherapy-induced	O
peripheral	O
neuropathy	O
,	O
the	O
use	O
of	O
duloxetine	O
compared	O
with	O
placebo	O
for	O
5	O
weeks	O
resulted	O
in	O
a	O
greater	O
reduction	O
in	O
pain	Pain
.	O

TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00489411	O
.	O

[	O
Observation	O
on	O
therapeutic	O
effect	O
of	O
picking	O
therapy	O
on	O
Graves	O
'	O
disease	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
therapeutic	O
effect	O
of	O
picking	O
therapy	O
on	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
and	O
its	O
effects	O
on	O
thyroid	O
function	O
.	O

METHODS	O
Sixty	O
cases	O
of	O
GD	O
were	O
randomly	O
divided	O
into	O
a	O
treatment	O
group	O
(	O
pricking	O
therapy	O
group	O
)	O
and	O
a	O
control	O
group	O
(	O
medication	O
group	O
)	O
.	O

They	O
were	O
treated	O
respectively	O
with	O
pricking	O
thyroid	O
gland	O
high	O
point	O
or	O
oral	O
administration	O
of	O
tapazole	O
.	O

And	O
changes	O
of	O
total	Physical
triiodothyronine	Physical
(	Physical
TT3	Physical
)	Physical
,	Physical
total	Physical
thyroxine	Physical
(	Physical
TT4	Physical
)	Physical
,	Physical
free	Physical
T3	Physical
(	Physical
FT3	Physical
)	Physical
,	Physical
free	Physical
T4	Physical
(	Physical
FT4	Physical
)	Physical
,	Physical
thyroxine	Physical
receptor	Physical
antibody	Physical
(	Physical
TRAb	Physical
)	Physical
,	Physical
supersensitive	Physical
thyrotropin	Physical
(	Physical
S-TSH	Physical
)	Physical
after	O
treatment	O
were	O
investigated	O
.	O

RESULTS	O
The	O
total	O
effective	O
rate	O
was	O
93.33	O
%	O
in	O
the	O
treatment	O
group	O
and	O
76.67	O
%	O
in	O
the	O
control	O
group	O
with	O
a	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

After	O
treatment	O
,	O
serum	Physical
TT3	Physical
,	Physical
TT4	Physical
,	Physical
FT3	Physical
,	Physical
FT4	Physical
and	Physical
S-TSH	Physical
contents	Physical
had	O
very	O
significant	O
change	O
in	O
the	O
two	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
,	O
TRAb	O
had	O
very	O
significant	O
change	O
in	O
the	O
treatment	O
group	O
(	O
P	O
<	O
0.01	O
)	O
and	O
no	O
significant	O
change	O
in	O
the	O
control	O
group	O
(	O
P	O
>	O
0.05	O
)	O
there	O
were	O
significant	O
differences	O
in	O
decrease	O
of	O
TT3	Physical
,	Physical
FT3	Physical
,	Physical
TRAb	Physical
(	O
P	O
<	O
0.05	O
)	O
and	O
no	O
significant	O
difference	O
in	O
decrease	O
of	O
TT4	Physical
,	Physical
FT4	Physical
and	Physical
increase	Physical
of	Physical
S-TSH	Physical
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
Pricking	O
therapy	O
has	O
a	O
definite	O
therapeutic	O
effect	O
on	O
Graves	O
'	O
disease	O
,	O
which	O
is	O
carried	O
out	O
through	O
regulating	O
thyroid	O
function	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
MRI	O
study	O
of	O
anti-herpes	O
virus	O
therapy	O
in	O
MS	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
treatment	O
with	O
the	O
antiherpes	O
drug	O
valacyclovir	O
on	O
MRI-evident	Physical
lesions	Physical
in	O
patients	O
with	O
relapsing-remitting	O
MS	O
in	O
a	O
phase	O
2	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

BACKGROUND	O
It	O
has	O
been	O
postulated	O
from	O
virologic	O
studies	O
that	O
herpesvirus	O
infection	O
could	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
MS.	O
METHODS	O
Patients	O
were	O
eligible	O
for	O
the	O
study	O
if	O
they	O
had	O
had	O
two	O
or	O
more	O
MS	O
relapses	O
in	O
the	O
2-year	O
period	O
before	O
enrollment	O
.	O

Seventy	O
patients	O
with	O
Expanded	O
Disability	O
Status	O
Scale	O
scores	O
of	O
0	O
to	O
5.5	O
were	O
randomly	O
assigned	O
to	O
receive	O
1	O
gram	O
of	O
valacyclovir	O
(	O
n	O
=	O
36	O
)	O
or	O
placebo	O
(	O
n	O
=	O
34	O
)	O
three	O
times	O
daily	O
for	O
24	O
weeks	O
.	O

Patients	O
underwent	O
MRI	O
every	O
fourth	O
week	O
for	O
32	O
weeks	O
:	O
twice	O
during	O
pretreatment	O
,	O
six	O
times	O
during	O
treatment	O
,	O
and	O
once	O
after	O
treatment	O
.	O

Scoring	Physical
of	Physical
neurologic	Physical
disability	Physical
was	O
performed	O
at	O
the	O
start	O
and	O
end	O
of	O
the	O
treatment	O
period	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
number	Physical
of	Physical
new	Physical
active	Physical
MRI-evident	Physical
lesions	Physical
over	O
24	O
weeks	O
of	O
treatment	O
.	O

Secondary	O
endpoints	O
included	O
other	Physical
MRI	Physical
measures	Physical
and	O
clinical	Physical
endpoints	Physical
.	O

RESULTS	O
The	O
mean	O
number	O
of	O
new	Physical
active	Physical
lesions	Physical
+/-	O
SD	O
per	O
patient	O
during	O
24	O
weeks	O
of	O
treatment	O
with	O
valacyclovir	O
was	O
11.9	O
+/-	O
17.6	O
and	O
that	O
during	O
placebo	O
treatment	O
was	O
14.5	O
+/-	O
21.4	O
.	O

A	O
protocol-planned	O
exploratory	O
analysis	O
stratified	O
patients	O
according	O
to	O
baseline	O
activity	O
;	O
this	O
analysis	O
showed	O
that	O
patients	O
with	O
high	O
levels	O
of	O
disease	O
activity	O
in	O
the	O
valacyclovir	O
treatment	O
group	O
(	O
n	O
=	O
17	O
)	O
developed	O
fewer	O
new	Physical
active	Physical
lesions	Physical
per	O
scan	O
than	O
did	O
those	O
in	O
the	O
placebo	O
treatment	O
group	O
(	O
n	O
=	O
11	O
)	O
.	O

The	O
median	O
number	O
(	O
Q	O
(	O
1	O
)	O
,	O
Q	O
(	O
3	O
)	O
range	O
)	O
of	O
active	Physical
lesions	Physical
was	O
2.0	O
(	O
1.38	O
,	O
3.96	O
)	O
in	O
the	O
valacyclovir	O
treatment	O
group	O
and	O
6.5	O
(	O
2.63	O
,	O
9.0	O
)	O
in	O
the	O
placebo	O
treatment	O
group	O
.	O

CONCLUSIONS	O
Valacyclovir	O
treatment	O
did	O
not	O
reduce	O
the	O
formation	O
of	O
active	Physical
lesions	Physical
in	O
patients	O
with	O
relapsing-remitting	O
MS	O
who	O
had	O
two	O
or	O
more	O
relapses	O
during	O
the	O
previous	O
2-year	O
period	O
.	O

In	O
a	O
subgroup	O
of	O
patients	O
with	O
high	O
levels	O
of	O
disease	O
activity	O
who	O
had	O
more	O
than	O
one	O
active	O
MRI-evident	O
lesion	O
during	O
4	O
weeks	O
,	O
valacyclovir	O
treatment	O
was	O
associated	O
with	O
a	O
reduced	O
number	O
of	O
new	Physical
active	Physical
MRI-evident	Physical
lesions	Physical
and	O
with	O
an	O
increase	O
in	O
the	O
number	O
of	O
scans	O
free	O
of	O
new	Physical
active	Physical
lesions	Physical
.	O

The	O
results	O
of	O
the	O
exploratory	O
subgroup	O
analysis	O
provide	O
support	O
for	O
further	O
studies	O
of	O
antiherpes	O
therapy	O
for	O
patients	O
with	O
MS	O
and	O
high	O
levels	O
of	O
MRI-evident	O
disease	O
activity	O
.	O

Functional	O
outcome	O
following	O
intramedullary	O
nailing	O
of	O
the	O
femur	O
:	O
a	O
prospective	O
randomized	O
comparison	O
of	O
piriformis	O
fossa	O
and	O
greater	O
trochanteric	O
entry	O
portals	O
.	O

BACKGROUND	O
The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
prospectively	O
compare	O
the	O
functional	O
outcome	O
of	O
intramedullary	O
nailing	O
of	O
the	O
femur	O
performed	O
with	O
use	O
of	O
a	O
trochanteric	O
and	O
a	O
piriformis	O
fossa	O
entry	O
portal	O
.	O

METHODS	O
One	O
hundred	O
and	O
ten	O
patients	O
with	O
a	O
femoral	O
shaft	O
fracture	O
were	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
study	O
.	O

Fifty-four	O
patients	O
were	O
randomized	O
to	O
Group	O
A	O
(	O
piriformis	O
fossa	O
portal	O
)	O
and	O
fifty-six	O
to	O
Group	O
B	O
(	O
trochanteric	O
portal	O
)	O
.	O

Outcome	O
measures	O
included	O
the	O
Western	O
Ontario	O
and	O
McMaster	O
Universities	O
(	O
WOMAC	O
)	O
Osteoarthritis	O
Index	O
hip	O
function	O
score	O
,	O
pain	O
,	O
and	O
blinded	O
functional	O
evaluation	O
by	O
a	O
physical	O
therapist	O
.	O

RESULTS	O
Most	O
measures	O
of	O
hip	O
function	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
.	O

The	O
WOMAC	Physical
score	Physical
at	O
three	O
,	O
six	O
,	O
and	O
twelve	O
months	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
piriformis	O
fossa	O
and	O
trochanteric	O
nailing	O
groups	O
.	O

Functional	O
tests	O
included	O
the	O
chair	O
stand	O
test	O
and	O
the	O
timed	O
up	O
and	O
go	O
test	O
.	O

Patients	O
in	O
Group	O
B	O
had	O
significantly	O
better	O
scores	O
on	O
the	O
chair	Others
stand	Others
test	Others
(	O
13.3	O
compared	O
with	O
11.1	O
in	O
Group	O
A	O
,	O
p	O
=	O
0.04	O
)	O
at	O
six	O
months	O
postoperatively	O
,	O
but	O
there	O
was	O
no	O
difference	O
at	O
twelve	O
months	O
(	O
14.0	O
compared	O
with	O
13.6	O
)	O
.	O

The	O
two	O
groups	O
did	O
not	O
differ	O
significantly	O
on	O
the	O
timed	O
up	O
and	O
go	O
test	O
at	O
either	O
six	O
or	O
twelve	O
months	O
.	O

The	O
two	O
groups	O
also	O
did	O
not	O
differ	O
on	O
the	O
muscle	Physical
strength	Physical
testing	Physical
.	O

Intraoperative	O
parameters	O
differed	O
significantly	O
between	O
the	O
groups	O
with	O
respect	Others
to	Others
operative	Others
time	Others
,	O
fluoroscopy	Others
time	Others
,	O
and	O
incision	Others
length	Others
,	O
with	O
the	O
difference	O
favoring	O
Group	O
B	O
for	O
each	O
parameter	O
.	O

Analog	O
pain	O
scale	O
values	O
were	O
similar	O
in	O
Group	O
A	O
(	O
2.49	O
)	O
and	O
Group	O
B	O
(	O
2.15	O
)	O
at	O
twelve	O
months	O
postoperatively	O
.	O

CONCLUSIONS	O
Patients	O
in	O
our	O
prospective	O
randomized	O
study	O
who	O
were	O
treated	O
with	O
trochanteric	O
nailing	O
did	O
not	O
differ	O
in	O
hip	Physical
function	Physical
at	O
one	O
year	O
postoperatively	O
compared	O
with	O
patients	O
treated	O
with	O
intramedullary	O
nailing	O
through	O
the	O
piriformis	O
fossa	O
.	O

The	O
values	O
of	O
several	O
intraoperative	O
parameters	O
were	O
significantly	O
better	O
in	O
the	O
trochanteric	O
nailing	O
group	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
functional	O
hip	O
outcome	O
of	O
femoral	O
intramedullary	O
nailing	O
performed	O
through	O
the	O
greater	O
trochanter	O
is	O
equal	O
to	O
that	O
of	O
intramedullary	O
nailing	O
performed	O
through	O
the	O
piriformis	O
fossa	O
.	O

Chlorhexidine	O
swabbing	O
applications	O
under	O
various	O
conditions	O
of	O
use	O
in	O
preventive	O
oral	O
care	O
for	O
persons	O
with	O
disabilities	O
.	O

A	O
sample	O
of	O
44	O
adults	O
with	O
severe	O
disabilities	O
completed	O
a	O
randomized	O
single-blind	O
cross-over	O
study	O
testing	O
chlorhexidine	O
swabbing	O
under	O
various	O
conditions	O
:	O
with/without	O
prior	O
dental	O
prophylaxis	O
,	O
reduced	O
frequency	O
of	O
application	O
(	O
2	O
vs.	O
5	O
times	O
per	O
week	O
)	O
,	O
and	O
prolonged	O
use	O
(	O
42	O
weeks	O
)	O
.	O

All	O
subjects	O
received	O
therapeutic	O
doses	O
of	O
10	O
mL	O
0.12	O
%	O
chlorhexidine	O
gluconate	O
(	O
Peridex	O
,	O
Procter	O
&	O
Gamble	O
)	O
and	O
10	O
mL	O
0.05	O
%	O
NaF	O
applied	O
with	O
a	O
Toothette	O
(	O
Sage	O
Products	O
)	O
.	O

Clinical	Others
effectiveness	Others
of	O
chlorhexidine	O
swabbing	O
compared	O
with	O
placebo	O
was	O
previously	O
reported	O
.	O

In	O
the	O
present	O
study	O
,	O
while	O
initial	O
benefits	O
were	O
observed	O
to	O
be	O
independent	O
of	O
dental	O
prophylaxis	O
,	O
significant	O
reductions	O
in	O
periodontal	Physical
scores	Physical
were	O
sustained	O
by	O
a	O
combination	O
of	O
dental	O
prophylaxis	O
and	O
swabbing	O
protocol	O
,	O
at	O
reduced	O
frequency	O
of	O
application	O
and	O
over	O
prolonged	O
time	O
.	O

High	O
levels	O
of	O
acceptance	Others
and	Others
compliance	Others
by	O
subjects/caregivers	O
were	O
maintained	O
.	O

Subjects/caregivers	O
reported	O
improvements	Physical
in	Physical
dental	Physical
health	Physical
as	Physical
well	Physical
as	Physical
in	Physical
attitude	Physical
,	Physical
quality	Others
of	Others
life	Others
,	Others
and	Others
smile	Others
.	Physical

Chlorhexidine	O
swabbing	O
at	O
maintenance	O
frequency	O
,	O
combined	O
with	O
periodic	O
dental	O
prophylaxis	O
,	O
may	O
offer	O
an	O
effective	O
and	O
pragmatic	O
long-term	O
preventive	O
regimen	O
for	O
persons	O
with	O
disabilities	O
.	O

Improving	O
emotion	Mental
regulation	Mental
with	O
CBT	O
in	O
young	O
children	O
with	O
high	O
functioning	O
autism	O
spectrum	O
disorders	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
AND	O
AIMS	O
This	O
pilot	O
study	O
tested	O
the	O
efficacy	O
of	O
a	O
developmentally	O
modified	O
CBT	O
for	O
young	O
children	O
with	O
Autism	O
Spectrum	O
Disorders	O
(	O
ASD	O
)	O
to	O
teach	O
emotion	Mental
regulation	Mental
strategies	O
for	O
reducing	O
anger	Mental
and	O
anxiety	Mental
,	O
commonly	O
noted	O
problems	O
in	O
this	O
population	O
.	O

METHOD	O
Eleven	O
5-7	O
year-old	O
children	O
participated	O
in	O
a	O
CBT-group	O
while	O
parents	O
participated	O
in	O
psychoeducation	O
.	O

Children	O
were	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
delayed-treatment	O
control	O
group	O
.	O

RESULTS	O
From	O
pre-	O
to	O
post-treatment	O
,	O
all	O
children	O
had	O
less	O
parent	O
reported	O
negativity/lability	Mental
,	O
better	O
parent	O
reported	O
emotion	Mental
regulation	Mental
,	O
and	O
shorter	Mental
outbursts	Mental
,	O
and	O
also	O
generated	Mental
more	Mental
coping	Mental
strategies	Mental
in	O
response	O
to	O
vignettes	O
.	O

Parents	O
also	O
reported	O
increases	O
in	O
their	O
own	O
confidence	Mental
and	O
their	O
child	O
's	O
ability	Mental
to	Mental
deal	Mental
with	Mental
anger	Mental
and	Mental
anxiety	Mental
.	O

CONCLUSIONS	O
This	O
study	O
suggests	O
that	O
young	O
children	O
with	O
high	O
functioning	O
ASD	O
may	O
benefit	O
from	O
CBT	O
to	O
improve	O
regulation	Mental
of	Mental
anger	Mental
and	Mental
anxiety	Mental
,	O
and	O
parent	O
training	O
may	O
improve	O
parental	Mental
self-efficacy	Mental
.	O

Future	O
studies	O
are	O
needed	O
to	O
make	O
conclusions	O
about	O
its	O
efficacy	O
.	O

Stage	O
II	O
carcinoma	O
of	O
the	O
ovary	O
:	O
an	O
analysis	O
of	O
survival	Mortality
after	O
comprehensive	O
surgical	O
staging	O
and	O
adjuvant	O
therapy	O
.	O

Ninety-three	O
women	O
with	O
FIGO	O
stage	O
II	O
epithelial	O
ovarian	O
carcinoma	O
underwent	O
comprehensive	O
surgical	O
staging	O
and	O
were	O
randomized	O
prospectively	O
to	O
therapy	O
consisting	O
of	O
either	O
intraperitoneal	O
radioactive	O
phosphorus	O
or	O
oral	O
melphalan	O
.	O

No	O
patient	O
had	O
gross	O
residual	O
disease	O
at	O
the	O
time	O
of	O
randomization	O
.	O

Ten	O
of	O
the	O
forty-five	O
women	O
treated	O
with	O
melphalan	O
experienced	O
severe	Physical
bone	Physical
marrow	Physical
depression	Physical
at	O
some	O
time	O
during	O
therapy	O
and	O
two	O
women	O
expired	Physical
from	Physical
leukemia	Physical
.	O

Four	O
of	O
the	O
forty-eight	O
women	O
treated	O
with	O
intraperitoneal	O
phosphorus	O
required	O
surgical	Physical
reexploration	Physical
for	Physical
intestinal	Physical
obstruction	Physical
or	Physical
bowel	Physical
injury	Physical
.	O

Twenty-one	O
women	O
died	Mortality
of	O
their	O
disease	O
.	O

Survival	Mortality
was	O
not	O
statistically	O
different	O
between	O
the	O
two	O
treatment	O
arms	O
.	O

The	O
5-year	Mortality
actuarial	Mortality
survival	Mortality
was	O
78	O
%	O
.	O

Analgesic	O
efficacy	O
of	O
low-dose	O
diclofenac	O
versus	O
paracetamol	O
and	O
placebo	O
in	O
postoperative	O
dental	O
pain	O
.	O

AIMS	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
diclofenac-K	O
(	O
12.5	O
mg	O
)	O
vs	O
paracetamol	O
(	O
500	O
mg	O
)	O
and	O
placebo	O
given	O
in	O
a	O
flexible	O
dosage	O
regimen	O
to	O
treat	O
pain	O
resulting	O
from	O
extraction	O
of	O
impacted	O
third	O
molar	O
teeth	O
.	O

METHODS	O
This	O
was	O
a	O
2-day	O
,	O
double-blind	O
,	O
double-dummy	O
,	O
randomized	O
,	O
parallel-group	O
,	O
placebo-controlled	O
study	O
of	O
diclofenac-K	O
(	O
12.5	O
mg	O
)	O
tablets	O
vs	O
paracetamol	O
(	O
500	O
mg	O
)	O
tablets	O
and	O
placebo	O
in	O
patients	O
with	O
moderate	O
or	O
severe	O
pain	O
within	O
8	O
hours	O
of	O
extraction	O
of	O
impacted	O
third	O
molars	O
.	O

RESULTS	O
After	O
the	O
first	O
2-tablet	O
dose	O
,	O
patients	O
took	O
on	O
average	O
2.5	O
additional	O
tablets	O
of	O
diclofenac-K	O
or	O
2.4	O
tablets	O
of	O
paracetamol	O
,	O
almost	O
all	O
as	O
1-tablet	O
doses	O
.	O

Most	O
placebo	O
patients	O
discontinued	O
by	O
taking	O
rescue	Physical
medication	Physical
(	O
ibuprofen	O
200	O
mg	O
)	O
on	O
the	O
first	O
day	O
.	O

Pain	Pain
relief	Pain
after	O
the	O
initial	O
dose	O
of	O
diclofenac-K	O
(	O
2	O
x	O
12.5	O
mg	O
)	O
was	O
superior	O
to	O
placebo	O
(	O
P	O
<	O
.01	O
for	O
all	O
efficacy	O
outcomes	O
)	O
and	O
comparable	O
to	O
paracetamol	O
(	O
2	O
x	O
500	O
mg	O
)	O
.	O

About	O
30	O
%	O
of	O
patients	O
in	O
each	O
active	O
treatment	O
group	O
took	O
rescue	Physical
medication	Physical
during	O
the	O
study	O
,	O
compared	O
to	O
78	O
%	O
on	O
placebo	O
.	O

About	O
70	O
%	O
in	O
each	O
active	O
treatment	O
group	O
considered	O
the	O
overall	Pain
pain	Pain
relief	Pain
to	O
be	O
some	O
,	O
a	O
lot	O
,	O
or	O
complete	O
compared	O
to	O
only	O
15	O
%	O
on	O
placebo	O
.	O

The	O
incidence	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
in	O
each	O
active	O
treatment	O
group	O
was	O
low	O
and	O
comparable	O
between	O
the	O
treatments	O
.	O

CONCLUSION	O
An	O
initial	O
double-dose	O
of	O
diclofenac-K	O
(	O
2	O
x	O
12.5	O
mg	O
)	O
or	O
paracetamol	O
(	O
2	O
x	O
500	O
mg	O
)	O
adequately	O
relieved	O
the	O
most	O
intense	O
postoperative	Pain
pain	Pain
,	O
and	O
the	O
flexible	O
multiple	O
dose	O
regimen	O
(	O
1	O
or	O
2	O
tablets	O
)	O
maintained	O
adequate	O
pain	Pain
relief	Pain
thereafter	O
.	O

Most	O
patients	O
needed	O
only	O
1-tablet	O
doses	O
following	O
the	O
initial	O
2-tablet	O
dose	O
.	O

Evaluation	O
of	O
the	O
effect	O
of	O
low	O
level	O
laser	O
on	O
prevention	Physical
of	Physical
chemotherapy-induced	Physical
mucositis	Physical
.	O

Radiotherapy	O
in	O
the	O
head	O
and	O
neck	O
region	O
and	O
chemotherapy	O
might	O
give	O
rise	O
to	O
oral	O
mucositis	O
which	O
is	O
a	O
severe	O
and	O
painful	O
inflammation	O
.	O

There	O
is	O
no	O
known	O
definite	O
cure	O
for	O
mucositis	O
.	O

A	O
number	O
of	O
studies	O
have	O
attempted	O
to	O
evaluate	O
the	O
effect	O
of	O
low-power	O
laser	O
on	O
radiotherapy-	Others
and	O
chemotherapy-induced	Physical
mucositis	Physical
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
effect	O
of	O
low-power	O
laser	O
on	O
the	O
prevention	Physical
of	Physical
mucositis	Physical
,	Physical
xerostomia	Physical
and	Physical
pain	Physical
as	Physical
a	Physical
result	Physical
of	Physical
chemotherapy	Physical
.	O

The	O
subjects	O
in	O
this	O
double-blind	O
randomized	O
controlled	O
study	O
were	O
24	O
adult	O
patients	O
who	O
underwent	O
chemotherapy	O
during	O
2009-2010	O
.	O

The	O
results	O
showed	O
that	O
low-power	O
laser	O
was	O
able	O
to	O
decrease	O
the	O
effect	Physical
of	Physical
chemotherapy	Physical
on	Physical
oral	Physical
mucositis	Physical
,	Physical
xerostomia	Physical
and	Physical
pain	Physical
in	Physical
a	Physical
variety	Physical
of	Physical
malignancies	Physical
(	O
P	O
&	O
lt	O
;	O
0.05	O
)	O
.	O

It	O
can	O
be	O
concluded	O
that	O
low-power	O
laser	O
might	O
decrease	O
the	O
intensity	Physical
of	Physical
mucositis	Physical
.	O

Oxaprozin	O
versus	O
diclofenac	O
in	O
NSAID-refractory	O
periarthritis	O
pain	O
of	O
the	O
shoulder	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
oxaprozin	O
in	O
comparison	O
with	O
diclofenac	O
in	O
patients	O
with	O
periarthritis	O
pain	O
of	O
the	O
shoulder	O
previously	O
unsuccessfully	O
treated	O
with	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
other	O
than	O
diclofenac	O
and	O
oxaprozin	O
.	O

METHODS	O
In	O
this	O
open	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
study	O
,	O
eligible	O
patients	O
with	O
periarthritis	O
of	O
the	O
shoulder	O
were	O
randomised	O
to	O
receive	O
either	O
oxaprozin	O
1200	O
mg	O
once	O
daily	O
(	O
n	O
=	O
49	O
)	O
or	O
diclofenac	O
50	O
mg	O
three	O
times	O
daily	O
(	O
n	O
=	O
47	O
)	O
.	O

The	O
treatment	O
period	O
was	O
15	O
+/-	O
1	O
days	O
.	O

The	O
study	O
was	O
planned	O
on	O
a	O
hypothesis	O
of	O
equivalence	O
between	O
the	O
two	O
study	O
drugs	O
.	O

The	O
primary	O
study	O
endpoint	O
was	O
the	O
change	Pain
from	Pain
baseline	Pain
at	Pain
day	Pain
15	Pain
in	Pain
the	Pain
patient-assessed	Pain
shoulder	Pain
pain	Pain
score	Pain
.	O

Secondary	O
efficacy	O
variables	O
included	O
investigator-assessed	Physical
shoulder	Physical
function	Physical
,	O
patient-assessed	O
quality	O
of	O
life	O
on	O
the	O
Short-Form-36	O
(	O
SF-36	O
)	O
Acute	O
Health	O
Survey	O
and	O
both	O
patients	O
'	O
and	O
investigators	O
'	O
overall	O
assessment	O
of	O
efficacy	Others
.	O

RESULTS	O
At	O
day	O
15	O
,	O
the	O
mean	O
changes	O
in	O
shoulder	Pain
pain	Pain
score	Pain
from	O
baseline	O
in	O
the	O
oxaprozin	O
and	O
diclofenac	O
groups	O
were	O
-5.85	O
+/-	O
SD	O
4.62	O
and	O
-5.54	O
+/-	O
SD	O
4.41	O
,	O
respectively	O
.	O

The	O
difference	Others
between	O
the	O
two	O
groups	O
was	O
not	O
statistically	O
significant	O
,	O
confirming	O
the	O
hypothesis	O
of	O
the	O
study	O
that	O
oxaprozin	O
is	O
as	O
effective	O
as	O
diclofenac	O
.	O

Investigator-assessed	Physical
shoulder	Physical
function	Physical
improved	O
in	O
both	O
groups	O
but	O
more	O
so	O
in	O
the	O
oxaprozin	O
group	O
(	O
p	O
=	O
0.028	O
at	O
day	O
15	O
)	O
.	O

Quality	Physical
of	Physical
life	Physical
as	Physical
measured	Physical
by	Physical
SF-36	Physical
total	Physical
score	Physical
was	O
also	O
improved	O
in	O
both	O
treatment	O
groups	O
,	O
with	O
a	O
trend	O
toward	O
greater	O
improvement	O
in	O
the	O
oxaprozin	O
group	O
.	O

Furthermore	O
,	O
a	O
significantly	O
more	O
favourable	O
effect	Others
on	O
the	O
SF-36	Physical
'mental	Physical
health	Physical
'	Physical
item	Physical
was	O
observed	O
in	O
oxaprozin	O
compared	O
with	O
diclofenac-treated	O
patients	O
at	O
day	O
15	O
(	O
p	O
=	O
0.0202	O
)	O
.	O

As	O
assessed	O
by	O
investigators	O
,	O
the	O
overall	O
efficacy	O
of	O
oxaprozin	O
was	O
superior	O
to	O
that	O
for	O
diclofenac	O
at	O
visit	O
3	O
(	O
8	O
+/-	O
1	O
days	O
)	O
(	O
p	O
=	O
0.0067	O
)	O
.	O

Patients	O
also	O
assessed	O
the	O
overall	O
efficacy	Others
of	O
oxaprozin	O
as	O
superior	O
to	O
that	O
of	O
diclofenac	O
at	O
visits	O
3	O
(	O
8	O
+/-	O
1	O
days	O
)	O
(	O
p	O
=	O
0.0235	O
)	O
and	O
4	O
(	O
15	O
+/-	O
1	O
days	O
)	O
(	O
p	O
=	O
0.0272	O
)	O
.	O

Only	O
six	O
adverse	Adverseeffect
events	Adverseeffect
,	O
all	O
of	O
which	O
were	O
mild	O
or	O
moderate	O
in	O
intensity	O
and	O
occurred	O
in	O
four	O
diclofenac	O
recipients	O
,	O
were	O
observed	O
in	O
the	O
study	O
.	O

CONCLUSIONS	O
As	O
expected	O
,	O
once-daily	O
oxaprozin	O
proved	O
to	O
be	O
as	O
effective	O
as	O
diclofenac	O
three	O
times	O
daily	O
in	O
reducing	O
the	O
primary	O
efficacy	O
variable	O
of	O
patient-assessed	Pain
shoulder	Pain
pain	Pain
score	Pain
in	O
patients	O
with	O
periarthritis	O
of	O
the	O
shoulder	O
refractory	O
to	O
previous	O
treatments	O
with	O
other	O
NSAIDs	O
.	O

Oxaprozin	O
was	O
shown	O
to	O
be	O
superior	O
to	O
diclofenac	O
in	O
improving	O
shoulder	Physical
function	Physical
and	O
was	O
considered	O
by	O
investigators	O
and	O
patients	O
to	O
have	O
greater	O
overall	O
efficacy	O
than	O
diclofenac	O
.	O

In	O
addition	O
,	O
oxaprozin	O
showed	O
a	O
trend	O
toward	O
superior	O
results	O
in	O
improving	O
patients	O
'	O
quality	Physical
of	Physical
life	Physical
compared	O
with	O
diclofenac	O
.	O

A	O
trend	O
towards	O
better	O
tolerability	Others
results	Others
for	O
oxaprozin	O
compared	O
with	O
diclofenac	O
was	O
also	O
noted	O
.	O

Acute	O
prolactin	O
and	O
oxytocin	O
responses	O
and	O
milk	Physical
yield	Physical
to	O
infant	O
suckling	O
and	O
artificial	Others
methods	Others
of	Others
expression	Others
in	O
lactating	O
women	O
.	O

Breast-feeding	O
is	O
today	O
the	O
major	O
form	O
of	O
infant	O
nutrition	O
in	O
the	O
immediate	O
postpartum	O
period	O
.	O

Despite	O
this	O
,	O
recent	O
trends	O
in	O
modern	O
life-styles	O
have	O
raised	O
obstacles	O
to	O
successful	O
lactation	O
.	O

These	O
include	O
infant	O
illness	O
and	O
maternal	O
responsibilities	O
outside	O
the	O
home	O
,	O
both	O
requiring	O
separation	O
from	O
the	O
mother	O
.	O

While	O
the	O
hormonal	O
dynamics	O
of	O
infant	O
suckling	O
are	O
understood	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
artificial	O
methods	O
of	O
milk	Others
expression	Others
.	O

A	O
variety	O
of	O
breast	O
pumps	O
exist	O
in	O
the	O
current	O
US	O
market	O
which	O
vary	O
considerably	O
in	O
price	O
and	O
effectiveness	O
.	O

To	O
understand	O
better	O
the	O
ability	O
of	O
these	O
pumps	O
to	O
assist	O
women	O
in	O
the	O
maintenance	O
of	O
lactation	O
,	O
the	O
current	O
study	O
was	O
undertaken	O
to	O
evaluate	O
their	O
effects	O
on	O
milk	Others
yield	Others
and	Others
prolactin	Others
and	Others
oxytocin	Others
release	Others
when	O
compared	O
to	O
natural	O
infant	O
suckling	O
.	O

Twenty-three	O
women	O
who	O
were	O
exclusively	O
breast-feeding	O
their	O
infants	O
were	O
randomly	O
assigned	O
to	O
serially	O
use	O
several	O
pumping	O
methods	O
,	O
as	O
well	O
as	O
infant	O
suckling	O
,	O
with	O
blood	O
being	O
taken	O
at	O
10-minute	O
intervals	O
to	O
determine	O
the	O
hormonal	O
responses	O
.	O

The	O
results	O
reveal	O
variability	O
in	O
the	O
prolactin	Others
responses	Others
to	O
the	O
artificial	O
pumping	O
methods	O
,	O
with	O
the	O
greatest	O
responses	O
found	O
with	O
an	O
electric	O
pulsatile	O
pump	O
;	O
these	O
responses	O
compare	O
favorably	O
with	O
those	O
of	O
natural	O
infant	O
suckling	O
.	O

Other	O
methods	O
were	O
less	O
successful	O
in	O
causing	O
prolactin	Others
elevations	Others
.	O

No	O
differences	O
were	O
seen	O
among	O
the	O
methods	O
in	O
the	O
oxytocin	Others
response	Others
.	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
striking	O
differences	O
in	O
the	O
ability	O
of	O
breast-pumping	O
methods	O
to	O
produce	O
an	O
acute	Others
and	Others
sustained	Others
prolactin	Others
rise	Others
in	O
breast-feeding	O
mothers	O
.	O

The	O
large	O
discrepancies	O
found	O
suggest	O
the	O
need	O
for	O
further	O
studies	O
in	O
to	O
enable	O
women	O
and	O
health	O
care	O
providers	O
to	O
choose	O
the	O
most	O
appropriate	O
method	O
for	O
milk	O
expression	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Effect	O
of	O
light-cured	O
filled	O
sealant	O
on	O
shear	O
bond	O
strength	O
of	O
metal	O
and	O
ceramic	O
brackets	O
bonded	O
with	O
a	O
resin-modified	O
glass	O
ionomer	O
cement	O
.	O

INTRODUCTION	O
Our	O
objective	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
highly	O
filled	O
light-cured	O
sealant	O
(	O
HFLCS	O
)	O
on	O
the	O
shear	O
bond	O
strength	O
and	O
bond	O
failure	O
site	O
of	O
metal	O
and	O
ceramic	O
brackets	O
bonded	O
with	O
resin-modified	O
glass	O
ionomer	O
cement	O
(	O
RMGIC	O
)	O
.	O

METHODS	O
Eighty	O
freshly	O
extracted	O
maxillary	O
premolars	O
were	O
randomly	O
divided	O
into	O
4	O
groups	O
(	O
20	O
in	O
each	O
group	O
)	O
.	O

In	O
all	O
groups	O
,	O
the	O
teeth	O
were	O
etched	O
with	O
37	O
%	O
phosphoric	O
acid	O
for	O
20	O
seconds	O
,	O
and	O
RMGIC	O
(	O
Fuji	O
Ortho	O
LC	O
,	O
GC	O
Europe	O
,	O
Leuven	O
,	O
Belgium	O
)	O
was	O
used	O
for	O
bracket	O
bonding	O
.	O

In	O
groups	O
1	O
and	O
3	O
,	O
the	O
brackets	O
were	O
bonded	O
directly	O
to	O
etched	O
enamel	O
surfaces	O
;	O
in	O
groups	O
2	O
and	O
4	O
,	O
the	O
etched	O
enamel	O
was	O
covered	O
with	O
HFLCS	O
(	O
Pro	O
Seal	O
,	O
Reliance	O
Orthodontic	O
Products	O
,	O
Itasca	O
,	O
Ill	O
)	O
.	O

Groups	O
1	O
and	O
2	O
received	O
metal	O
brackets	O
,	O
and	O
groups	O
3	O
and	O
4	O
had	O
ceramic	O
brackets	O
.	O

The	O
specimens	O
were	O
stored	O
in	O
distilled	O
water	O
at	O
room	O
temperature	O
for	O
24	O
hours	O
and	O
subsequently	O
tested	O
in	O
shear	O
mode	O
with	O
a	O
universal	O
testing	O
machine	O
.	O

After	O
debonding	O
,	O
the	O
teeth	O
and	O
the	O
brackets	O
were	O
examined	O
under	O
a	O
stereomicroscope	O
(	O
model	O
SMZ-1B	O
,	O
Nikon	O
,	O
Osaka	O
,	O
Japan	O
)	O
at	O
20-times	O
magnification	O
to	O
assess	O
the	O
residual	O
adhesive	O
on	O
the	O
tooth	O
surfaces	O
.	O

RESULTS	O
Interaction	O
between	O
HFLCS	O
and	O
bracket	O
type	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.15	O
)	O
.	O

Pretreatment	O
with	O
HFLCS	O
did	O
not	O
cause	O
a	O
statistically	O
significant	O
change	O
in	O
the	O
shear	Others
bond	Others
values	Others
of	Others
either	Others
metal	Others
or	Others
ceramic	Others
brackets	Others
(	O
P	O
=	O
0.38	O
)	O
.	O

Shear	Others
bond	Others
values	Others
of	Others
the	Others
ceramic	Others
brackets	Others
were	O
higher	O
than	O
those	O
of	O
the	O
metal	O
brackets	O
independent	O
of	O
HFLCS	O
application	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
bond	Others
failure	Others
modes	Others
in	O
the	O
4	O
groups	O
.	O

CONCLUSIONS	O
HFLCS	O
application	O
on	O
enamel	O
etched	O
with	O
37	O
%	O
phosphoric	O
acid	O
did	O
not	O
affect	O
the	O
bond	Others
strength	Others
values	Others
and	O
the	O
bond	Others
failure	Others
modes	Others
of	O
metal	O
and	O
ceramic	O
brackets	O
bonded	O
with	O
RMGIC	O
.	O

RESULTS	O
Interaction	O
between	O
HFLCS	O
and	O
bracket	O
type	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0.15	O
)	O
.	O

Pretreatment	O
with	O
HFLCS	O
did	O
not	O
cause	O
a	O
statistically	O
significant	O
change	O
in	O
the	O
shear	Others
bond	Others
values	Others
of	Others
either	Others
metal	Others
or	Others
ceramic	Others
brackets	Others
(	O
P	O
=	O
0.38	O
)	O
.	O

Shear	Others
bond	Others
values	Others
of	Others
the	Others
ceramic	Others
brackets	Others
were	O
higher	O
than	O
those	O
of	O
the	O
metal	O
brackets	O
independent	O
of	O
HFLCS	O
application	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
differences	O
were	O
found	O
in	O
bond	O
failure	O
modes	O
in	O
the	O
4	O
groups	O
.	O

CONCLUSIONS	O
HFLCS	O
application	O
on	O
enamel	O
etched	O
with	O
37	O
%	O
phosphoric	O
acid	O
did	O
not	O
affect	O
the	O
bond	O
strength	O
values	O
and	O
the	O
bond	O
failure	O
modes	O
of	O
metal	O
and	O
ceramic	O
brackets	O
bonded	O
with	O
RMGIC	O
.	O

Cognitive	O
effects	O
of	O
lithium	O
carbonate	O
and	O
haloperidol	O
in	O
treatment-resistant	O
aggressive	O
children	O
.	O

The	O
effects	O
of	O
lithium	O
carbonate	O
and	O
haloperidol	O
on	O
cognition	O
were	O
examined	O
in	O
a	O
placebo-controlled	O
,	O
double-blind	O
study	O
of	O
61	O
treatment-resistant	O
,	O
hospitalized	O
school-aged	O
children	O
.	O

They	O
all	O
had	O
a	O
DSM-III	O
diagnosis	O
of	O
conduct	O
disorder	O
--	O
undersocialized	O
,	O
aggressive	O
,	O
with	O
a	O
profile	O
of	O
highly	O
explosive	O
and	O
aggressive	O
behavior	O
.	O

Children	O
were	O
assessed	O
at	O
the	O
end	O
of	O
a	O
two-week	O
placebo-baseline	O
period	O
and	O
again	O
after	O
four	O
weeks	O
of	O
treatment	O
.	O

Drug	O
effects	O
on	O
cognition	O
were	O
mild	O
.	O

Haloperidol	O
(	O
mean	O
dose	O
,	O
2.95	O
mg/day	O
)	O
caused	O
significant	O
decreases	O
in	O
Porteus	Mental
Maze	Mental
test	Mental
quotient	Mental
scores	Mental
and	O
a	O
slowing	Mental
of	Mental
reaction	Mental
time	Mental
(	Mental
RT	Mental
)	Mental
on	O
a	O
simple	O
RT	O
task	O
.	O

Lithium	O
carbonate	O
(	O
mean	O
dose	O
,	O
1,166	O
mg/day	O
)	O
adversely	O
affected	O
qualitative	Mental
scores	Mental
on	Mental
the	Mental
Porteus	Mental
Maze	Mental
test	Mental
.	O

No	O
significant	O
treatment	O
effects	O
were	O
found	O
for	O
the	O
Matching	Mental
Familiar	Mental
Figures	Mental
Test	Mental
,	Mental
short-term	Mental
recognition	Mental
memory	Mental
and	Others
concept	Mental
attainment	Mental
tasks	Mental
,	Mental
or	Mental
the	Mental
Stroop	Mental
Test	Mental
.	O

Comparison	O
of	O
enflurane	O
and	O
halothane	O
in	O
hypotensive	O
eye	O
surgery	O
.	O

Thirty	O
patients	O
undergoing	O
elective	O
eye	O
surgery	O
had	O
anaesthesia	O
induced	O
with	O
sodium	O
thiopentone	O
,	O
suxamethonium	O
and	O
d-tubocurarine	O
chloride	O
.	O

Patients	O
were	O
ventilated	O
with	O
nitrous	O
oxide	O
,	O
oxygen	O
and	O
either	O
halothane	O
or	O
enflurane	O
.	O

The	O
volatile	O
agents	O
were	O
used	O
to	O
decrease	O
the	O
systolic	Physical
blood	Physical
pressure	Physical
to	O
80	O
mmHg	O
.	O

The	O
volatile	Physical
agent	Physical
concentration	Physical
in	Physical
the	Physical
blood	Physical
was	O
measured	O
at	O
30	O
min	O
intervals	O
.	O

Both	O
agents	O
were	O
effective	O
in	O
producing	O
hypotension	Physical
,	O
but	O
enflurane	O
was	O
the	O
more	O
potent	O
hypotensive	O
agent	O
in	O
terms	O
of	O
MAC	O
equivalents	O
.	O

There	O
was	O
no	O
significant	O
differences	O
between	O
the	O
agents	O
with	O
respect	O
to	O
speed	Mental
of	Mental
recovery	Mental
.	O

Brief	O
report	O
:	O
effects	O
of	O
cognitive	O
behavioral	O
therapy	O
on	O
parent-reported	Mental
autism	Mental
symptoms	Mental
in	O
school-age	O
children	O
with	O
high-functioning	O
autism	O
.	O

This	O
pilot	O
study	O
tested	O
the	O
effect	O
of	O
cognitive	O
behavioral	O
therapy	O
(	O
CBT	O
)	O
on	O
parent-reported	O
autism	O
symptoms	O
.	O

Nineteen	O
children	O
with	O
autism	O
spectrum	O
disorders	O
and	O
an	O
anxiety	O
disorder	O
(	O
7-11	O
years	O
old	O
)	O
were	O
randomly	O
assigned	O
to	O
16	O
sessions	O
of	O
CBT	O
or	O
a	O
waitlist	O
condition	O
.	O

The	O
CBT	O
program	O
emphasized	O
in	O
vivo	O
exposure	O
supported	O
by	O
parent	O
training	O
and	O
school	O
consultation	O
to	O
promote	O
social	O
communication	O
and	O
emotion	O
regulation	O
skills	O
.	O

Parents	O
completed	O
a	O
standardized	Others
autism	Others
symptom	Others
checklist	Others
at	O
baseline	O
and	O
posttreatment/postwaitlist	O
and	O
3-month	O
follow-up	O
assessments	O
.	O

CBT	O
outperformed	O
the	O
waitlist	O
condition	O
at	O
posttreatment/postwaitlist	O
on	O
total	Mental
parent-reported	Mental
autism	Mental
symptoms	Mental
(	O
Cohen	O
's	O
d	O
effect	O
size	O
=	O
.77	O
)	O
.	O

Treatment	O
gains	O
were	O
maintained	O
at	O
3-month	O
follow-up	O
.	O

Further	O
investigation	O
of	O
this	O
intervention	O
modality	O
with	O
larger	O
samples	O
and	O
broader	O
outcome	O
measures	O
appears	O
to	O
be	O
indicated	O
.	O

Double-blind	O
,	O
placebo-controlled	O
,	O
dose-ranging	O
study	O
of	O
new	O
recombinant	O
hypoallergenic	O
Bet	O
v	O
1	O
in	O
an	O
environmental	O
exposure	O
chamber	O
.	O

BACKGROUND	O
Recombinant	O
allergens	O
offer	O
a	O
tool	O
for	O
improving	O
specific	O
immunotherapy	O
(	O
SIT	O
)	O
.	O

OBJECTIVE	O
To	O
find	O
the	O
optimal	O
dose	O
of	O
a	O
new	O
hypoallergenic	O
folding	O
variant	O
of	O
recombinant	O
Bet	O
v	O
1	O
(	O
rBet	O
v	O
1-FV	O
)	O
as	O
SIT	O
for	O
patients	O
with	O
birch	O
pollen	O
allergy	O
.	O

METHODS	O
Before	O
SIT	O
,	O
thirty-seven	O
adult	O
patients	O
were	O
exposed	O
for	O
eight	O
hours	O
in	O
an	O
environmental	O
exposure	O
chamber	O
(	O
EEC	O
)	O
to	O
birch	O
pollen	O
at	O
an	O
average	O
concentration	O
of	O
3500	O
?	O
500	O
grains/m	O
(	O
3	O
)	O
,	O
then	O
randomized	O
to	O
four	O
maintenance	O
dose	O
groups	O
of	O
rBet	O
v	O
1-FV	O
and	O
one	O
placebo	O
group	O
:	O
20	O
?g	O
(	O
n	O
=	O
7	O
)	O
,	O
80	O
?g	O
(	O
n	O
=	O
8	O
)	O
,	O
160	O
?g	O
(	O
n	O
=	O
7	O
)	O
,	O
320	O
?g	O
(	O
n	O
=	O
8	O
)	O
,	O
and	O
placebo	O
(	O
n	O
=	O
7	O
)	O
.	O

Patients	O
were	O
treated	O
for	O
10	O
weeks	O
with	O
weekly	O
injections	O
and	O
then	O
re-exposed	O
in	O
the	O
EEC	O
.	O

The	O
optimal	O
dose	O
for	O
SIT	O
was	O
assessed	O
using	O
efficacy	O
results	O
from	O
the	O
EEC	O
,	O
IgG	O
responses	O
,	O
and	O
tolerability	O
.	O

RESULTS	O
Thirty-six	O
patients	O
were	O
evaluable	O
for	O
efficacy	O
assessment	O
.	O

The	O
total	O
symptom	O
score	O
significantly	O
decreased	O
in	O
all	O
active	O
groups	O
compared	O
with	O
placebo	O
(	O
-18.8	O
%	O
for	O
placebo	O
patients	O
;	O
-71.9	O
%	O
,	O
P	O
=	O
0.0022	O
for	O
20	O
?g	O
;	O
-75.6	O
%	O
,	O
P	O
=	O
0.0007	O
for	O
80	O
?g	O
;	O
-81.8	O
%	O
,	O
P	O
=	O
0.0009	O
for	O
160	O
?g	O
;	O
-78.3	O
%	O
,	O
P	O
=	O
0.0003	O
for	O
320	O
?g	O
)	O
.	O

IgG1	Physical
increased	O
significantly	O
in	O
all	O
active	O
groups	O
compared	O
to	O
placebo	O
.	O

All	O
four	O
active	O
doses	O
were	O
well	O
tolerated	O
,	O
no	O
serious	O
adverse	O
event	O
occurred	O
;	O
two	O
Grade	Adverseeffect
II	Adverseeffect
reactions	Adverseeffect
,	O
according	O
to	O
EAACI	O
classification	O
,	O
were	O
observed	O
,	O
one	O
in	O
each	O
of	O
the	O
160-	O
and	O
320-?g	O
groups	O
.	O

CONCLUSIONS	O
Considering	O
efficacy	O
,	O
immunological	O
response	O
,	O
and	O
tolerability	O
,	O
a	O
maintenance	O
dose	O
of	O
80	O
?g	O
of	O
rBet	O
v	O
1-FV	O
appears	O
to	O
be	O
the	O
ideal	O
dose	O
for	O
allergen	O
immunotherapy	O
in	O
birch	O
pollen	O
allergic	O
patients	O
.	O

Predicting	O
completion	O
of	O
treatment	O
among	O
foreign-born	O
adolescents	O
treated	O
for	O
latent	O
tuberculosis	O
infection	O
in	O
Los	O
Angeles	O
.	O

SETTING	O
Two	O
health	O
clinics	O
in	O
Los	O
Angeles	O
County	O
,	O
California	O
.	O

OBJECTIVE	O
To	O
identify	O
factors	O
associated	O
with	O
completion	O
of	O
care	O
among	O
foreign-born	O
adolescents	O
treated	O
for	O
latent	O
tuberculosis	O
infection	O
(	O
LTBI	O
)	O
.	O

DESIGN	O
A	O
total	O
of	O
766	O
low-income	O
adolescents	O
(	O
79	O
%	O
participation	O
rate	O
)	O
,	O
including	O
610	O
foreign-born	O
,	O
were	O
recruited	O
.	O

In	O
prospective	O
face-to-face	O
interviews	O
,	O
data	O
were	O
obtained	O
on	O
socio-demographic	O
and	O
lifestyle	O
characteristics	O
,	O
psychosocial	O
factors	O
and	O
clinic-related	O
variables	O
.	O

Medical	O
chart	O
data	O
were	O
abstracted	O
regarding	O
clinic	O
appointment	O
keeping	O
and	O
completion	O
of	O
treatment	O
.	O

Univariate	O
and	O
multivariate	O
logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
identify	O
factors	O
associated	O
with	O
completion	O
of	O
care	O
.	O

RESULTS	O
Foreign-born	O
adolescents	O
were	O
more	O
likely	O
to	O
complete	Physical
care	Physical
than	O
US-born	O
adolescents	O
,	O
with	O
82	O
%	O
completion	O
of	O
care	O
rate	O
.	O

In	O
logistic	O
regression	O
analyses	O
after	O
controlling	O
for	O
age	O
,	O
medication	Mental
taking	Mental
behavior	Mental
(	O
OR	O
1.26	O
,	O
95	O
%	O
CI	O
1.15-1.39	O
)	O
,	O
living	Mental
with	Mental
both	Mental
parents	Mental
(	O
OR	O
1.74	O
,	O
95	O
%	O
CI	O
1.02-2.97	O
)	O
,	O
sexual	Mental
intercourse	Mental
(	O
OR	O
0.66	O
,	O
95	O
%	O
CI	O
0.36-1.19	O
)	O
and	O
speaking	Mental
mostly	Mental
or	Mental
only	Mental
English	Mental
with	Mental
parents	Mental
(	O
OR	O
0.39	O
,	O
95	O
%	O
CI	O
0.15-1.03	O
)	O
were	O
independently	O
associated	O
with	O
completion	O
of	O
care	O
.	O

CONCLUSION	O
These	O
findings	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
factors	O
that	O
may	O
explain	O
why	O
some	O
adolescents	O
complete	O
care	O
whereas	O
others	O
do	O
not	O
.	O

They	O
provide	O
supportive	O
evidence	O
that	O
tailored	O
intervention	O
programs	O
should	O
be	O
developed	O
to	O
support	O
the	O
screening	O
and	O
completion	O
of	O
treatment	O
of	O
foreign-born	O
adolescents	O
.	O

The	O
preparation	O
of	O
patients	O
for	O
cardiac	O
surgery	O
.	O

This	O
study	O
examines	O
the	O
impact	O
of	O
a	O
preadmission	O
telephone	O
intervention	O
on	O
anxiety	Mental
,	O
knowledge	Mental
,	O
and	O
readiness	Mental
for	Mental
discharge	Mental
for	O
patients	O
attending	O
a	O
preadmission	O
teaching	O
program	O
prior	O
to	O
cardiac	O
surgery	O
.	O

The	O
primary	O
goal	O
of	O
the	O
telephone	O
intervention	O
was	O
to	O
provide	O
support	O
by	O
giving	O
additional	O
information	O
about	O
individual	O
concerns	O
.	O

The	O
telephone	O
intervention	O
did	O
not	O
have	O
an	O
effect	O
on	O
anxiety	Mental
and	O
knowledge	Mental
.	O

A	O
significantly	O
higher	O
level	Mental
of	Mental
anxiety	Mental
was	O
found	O
in	O
the	O
experimental	O
group	O
on	O
admission	O
,	O
but	O
this	O
difference	O
became	O
nonsignificant	O
when	O
baseline	O
level	O
and	O
length	O
of	O
waiting	O
time	O
were	O
entered	O
as	O
covariates	O
.	O

The	O
more	O
anxious	O
group	O
rated	O
their	O
perceived	Mental
knowledge	Mental
level	O
lower	O
,	O
despite	O
the	O
fact	O
that	O
both	O
groups	O
had	O
similar	O
scores	Mental
in	Mental
actual	Mental
knowledge	Mental
.	O

Given	O
the	O
potential	O
barrier	O
that	O
anxiety	O
can	O
pose	O
for	O
patient	O
learning	O
,	O
nurses	O
need	O
to	O
adapt	O
their	O
interventions	O
to	O
deal	O
with	O
the	O
patients	O
'	O
feelings	O
of	O
anxiety	Mental
that	O
accompany	O
cardiac	O
surgery	O
to	O
make	O
the	O
learning	O
process	O
effective	O
.	O

Group	O
cognitive	O
behavior	O
therapy	O
for	O
children	O
with	O
high-functioning	O
autism	O
spectrum	O
disorders	O
and	O
anxiety	O
:	O
a	O
randomized	O
trial	O
.	O

BACKGROUND	O
Children	O
with	O
high-functioning	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
are	O
at	O
high	O
risk	O
for	O
developing	O
significant	O
anxiety	Physical
.	O

Anxiety	O
can	O
adversely	O
impact	O
functioning	O
across	O
school	O
,	O
home	O
and	O
community	O
environments	O
.	O

Cognitive	O
behavioral	O
therapies	O
(	O
CBT	O
)	O
are	O
frequently	O
used	O
with	O
success	O
for	O
children	O
with	O
anxiety	Mental
symptoms	Mental
.	Mental

Modified	O
CBT	O
interventions	O
for	O
anxiety	O
in	O
children	O
with	O
ASD	O
have	O
also	O
yielded	O
promising	O
results	O
.	O

METHODS	O
Fifty	O
children	O
with	O
high-functioning	O
ASD	O
and	O
anxiety	O
were	O
randomizedto	O
group	O
CBT	O
or	O
treatment-as-usual	O
(	O
TAU	O
)	O
for	O
12	O
weeks	O
.	O

Independent	O
clinical	O
evaluators	O
,	O
blind	O
to	O
condition	O
,	O
completed	O
structured	O
interviews	O
(	O
Anxiety	O
Disorders	O
Interview	O
Schedule	O
?	O
Parent	O
Version	O
;	O
ADIS-P	O
)	O
pre-	O
and	O
post-intervention	O
condition	O
.	O

RESULTS	O
Forty-seven	O
children	O
completed	O
either	O
the	O
CBT	O
or	O
TAU	O
condition	O
.	O

Results	O
indicated	O
markedly	O
better	O
outcomes	O
for	O
the	O
CBT	O
group	O
.	O

Significant	O
differences	O
by	O
group	O
were	O
noted	O
in	O
Clinician	O
Severity	O
Ratings	O
,	O
diagnostic	Mental
status	Mental
,	O
and	O
clinician	O
ratings	O
of	O
global	O
improvement	O
.	O

In	O
the	O
intent-to-treat	O
sample	O
,	O
10	O
of	O
20	O
children	O
(	O
50	O
%	O
)	O
in	O
the	O
CBT	O
group	O
had	O
a	O
clinically	O
meaningful	O
positive	O
treatment	O
response	O
,	O
compared	O
to	O
2	O
of	O
23	O
children	O
(	O
8.7	O
%	O
)	O
in	O
the	O
TAU	O
group	O
.	O

CONCLUSIONS	O
Initial	O
results	O
from	O
this	O
randomized	O
,	O
designed	O
treatment	O
study	O
suggest	O
that	O
agroup	O
CBT	O
intervention	O
specifically	O
developed	O
for	O
children	O
with	O
ASD	O
may	O
be	O
effective	O
in	O
decreasing	O
anxiety	O
.	O

Limitations	O
of	O
this	O
study	O
include	O
small	O
sample	O
size	O
,	O
lack	O
of	O
an	O
attention	O
control	O
group	O
,	O
and	O
use	O
of	O
outcome	O
measures	O
normed	O
with	O
typically	O
developing	O
children	O
Recombinant	O
human	O
granulocyte	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
and	O
GM-CSF	O
)	O
administered	O
following	O
cytotoxic	O
chemotherapy	O
have	O
a	O
similar	O
ability	O
to	O
mobilize	O
peripheral	O
blood	O
stem	O
cells	O
.	O

The	O
availability	O
of	O
hematopoietic	O
growth	O
factors	O
has	O
greatly	O
facilitated	O
the	O
mobilization	Physical
and	Physical
collection	Physical
of	Physical
peripheral	Physical
blood	Physical
stem	Physical
cells	Physical
(	Physical
PBSC	Physical
)	Physical
.	O

It	O
was	O
the	O
aim	O
of	O
this	O
double-blind	O
study	O
to	O
compare	O
the	O
PBSC-mobilizing	O
efficacy	O
of	O
recombinant	O
human	O
G-CSF	O
and	O
GM-CSF	O
when	O
administered	O
post-chemotherapy	O
.	O

Twenty-six	O
patients	O
with	O
relapsed	O
Hodgkin	O
's	O
disease	O
were	O
included	O
in	O
the	O
study	O
.	O

Their	O
median	O
age	O
was	O
31	O
years	O
(	O
range	O
,	O
22-59	O
)	O
and	O
14	O
patients	O
were	O
males	O
and	O
12	O
were	O
females	O
.	O

Patients	O
were	O
pretreated	O
with	O
a	O
median	O
of	O
eight	O
cycles	O
of	O
cytotoxic	O
chemotherapy	O
,	O
while	O
18	O
patients	O
had	O
undergone	O
extended	O
field	O
irradiation	O
.	O

The	O
patients	O
received	O
dexamethasone	O
24	O
mg	O
days	O
1-7	O
,	O
melphalan	O
30	O
mg/m2	O
day	O
3	O
,	O
BCNU	O
60	O
mg/m2	O
day	O
3	O
,	O
etoposide	O
75	O
mg/m2	O
days	O
4-7	O
,	O
Ara-C	O
100	O
mg/m2	O
twice	O
daily	O
days	O
4-7	O
(	O
Dexa-BEAM	O
)	O
.	O

Twelve	O
patients	O
were	O
randomized	O
to	O
receive	O
5/microg/kg/day	O
G-CSF	O
and	O
14	O
patients	O
to	O
receive	O
5	O
microg/kg/day	O
GM-CSF	O
,	O
both	O
administered	O
subcutaneously	O
starting	O
on	O
day	O
1	O
after	O
the	O
end	O
of	O
Dexa-BEAM	O
.	O

Primary	O
endpoints	O
of	O
the	O
study	O
were	O
the	O
number	Others
of	Others
CD34+	Others
cells	Others
harvested	Others
per	Others
kg	Others
body	Others
weight	Others
on	Others
the	Others
occasion	Others
of	Others
six	Others
consecutive	Others
leukaphereses	Others
and	O
the	O
time	Others
needed	Others
for	Others
hematological	Others
reconstitution	Others
following	Others
autografting	Others
.	O

Twenty-one	O
patients	O
completed	O
PBSC	O
collection	O
,	O
and	O
six	O
patients	O
of	O
the	O
G-CSF	O
group	O
and	O
nine	O
of	O
the	O
GM-CSF	O
group	O
were	O
autografted	O
.	O

No	O
difference	O
was	O
observed	O
with	O
respect	O
to	O
the	O
median	Others
yield	Others
of	Others
CFU-GM	Others
and	Others
CD34+	Others
cells	Others
:	O
32.5	O
x	O
10	O
(	O
4	O
)	O
/kg	O
vs	O
31.3	O
x	O
10	O
(	O
4	O
)	O
/kg	O
CFU-GM	O
,	O
and	O
7.6	O
x	O
10	O
(	O
6	O
)	O
/kg	O
vs	O
5.6	O
x	O
10	O
(	O
6	O
)	O
/kg	O
CD34+	O
cells	O
,	O
for	O
G-CSF	Others
and	O
GM-CSF	Others
,	O
respectively	O
(	O
U	O
test	O
,	O
P=	O
0.837	O
and	O
0.696	O
)	O
.	O

High-dose	O
chemotherapy	O
consisted	O
of	O
cyclophosphamide	O
1.7	O
g/m2	O
days	O
1-4	O
,	O
BCNU	O
150	O
mg/m2	O
days	O
1-4	O
,	O
etoposide	O
400	O
mg/m2	O
days	O
1-4	O
.	O

All	O
patients	O
transplanted	O
with	O
more	O
than	O
5	O
x	O
10	O
(	O
6	O
)	O
CD34+	O
cells/kg	O
had	O
a	O
rapid	O
platelet	Physical
recovery	Physical
(	O
20	O
x	O
10	O
(	O
9	O
)	O
/l	O
)	O
between	O
6	O
and	O
11	O
days	O
and	O
neutrophil	Physical
recovery	Physical
(	O
0.5	O
x	O
10	O
(	O
9	O
)	O
/1	O
)	O
between	O
9	O
and	O
16	O
days	O
,	O
while	O
patients	O
transplanted	O
with	O
less	O
than	O
5	O
x	O
10	O
(	O
6	O
)	O
/kg	O
had	O
a	O
delayed	O
reconstitution	O
,	O
regardless	O
of	O
the	O
kind	O
of	O
growth	O
factor	O
used	O
for	O
PBSC	O
mobilization	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
in	O
patients	O
with	O
Hodgkin	O
's	O
disease	O
G-CSF	O
and	O
GM-CSF	O
given	O
after	O
salvage	O
chemotherapy	O
appear	O
to	O
be	O
not	O
different	O
in	O
their	O
ability	Others
to	Others
mobilize	Others
PBSC	Physical
resulting	O
in	O
a	O
similar	O
time	Others
needed	Others
for	Others
hematological	Others
reconstitution	Others
when	O
autografted	O
following	O
high-dose	O
therapy	O
.	O

Transesophageal	O
echocardiography	O
in	O
quantification	O
of	O
emboli	O
during	O
femoral	O
nailing	O
:	O
reamed	O
versus	O
unreamed	O
techniques	O
.	O

We	O
quantified	O
the	O
embolic	O
load	O
to	O
the	O
lungs	O
created	O
with	O
two	O
different	O
techniques	O
of	O
femoral	O
nailing	O
.	O

Eleven	O
patients	O
with	O
12	O
traumatic	O
femur	O
fractures	O
were	O
randomized	O
to	O
reamed	O
(	O
7	O
fractures	O
)	O
and	O
unreamed	O
(	O
5	O
fractures	O
)	O
groups	O
.	O

Intramedullary	O
nailing	O
was	O
with	O
the	O
AO/ASIF*	O
universal	O
reamed	O
or	O
unreamed	O
nail	O
.	O

Transesophageal	O
echocardiography	O
(	O
TEE	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
quantity	Physical
and	Physical
quality	Physical
of	Physical
emboli	Physical
generated	Physical
by	Physical
nailing	Physical
.	O

Data	O
were	O
analyzed	O
using	O
software	O
that	O
digitized	O
the	O
TEE	O
images	O
and	O
quantified	O
the	O
area	O
of	O
embolic	O
particles	O
in	O
each	O
frame	O
.	O

The	O
duration	O
of	O
each	O
level	O
of	O
embolic	O
phenomena	O
(	O
zero	O
,	O
moderate	O
,	O
severe	O
)	O
was	O
used	O
to	O
determine	O
total	O
embolic	O
load	O
with	O
various	O
steps	O
(	O
fracture	O
manipulation	O
,	O
proximal	O
portal	O
opening	O
,	O
reaming	O
,	O
and	O
nail	O
passage	O
)	O
.	O

Manual	O
grading	O
of	O
emboli	Physical
correlated	O
highly	O
with	O
software	O
quantification	O
.	O

Our	O
data	O
confirm	O
the	O
presence	O
and	O
similarity	O
of	O
emboli	Physical
generation	Physical
with	Physical
both	Physical
methods	Physical
of	Physical
intramedullary	Physical
nailing	Physical
.	O

Unreamed	Physical
nails	Physical
do	O
not	O
protect	O
the	O
patient	O
from	O
pulmonary	O
embolization	O
of	O
marrow	O
contents	O
.	O

Randomized	O
clinical	O
trial	O
comparing	O
systemic	O
interferon	O
with	O
diathermocoagulation	O
in	O
primary	O
multiple	O
and	O
widespread	O
anogenital	O
condyloma	O
.	O

Two	O
hundred	O
three	O
patients	O
(	O
median	O
age	O
26	O
years	O
;	O
range	O
18-45	O
)	O
with	O
untreated	O
multiple	O
and	O
widespread	O
anogenital	O
condyloma	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
study	O
arms	O
in	O
order	O
to	O
compare	O
the	O
efficacy	Others
,	O
toxicity	Physical
,	O
and	O
tolerability	Others
of	O
recombinant	O
interferon	O
alpha-2b	O
with	O
those	O
of	O
diathermocoagulation	O
.	O

Of	O
200	O
evaluable	O
patients	O
,	O
51	O
were	O
treated	O
intramuscularly	O
(	O
IM	O
)	O
with	O
3	O
x	O
10	O
(	O
6	O
)	O
U	O
(	O
3	O
MU	O
)	O
/m2	O
daily	O
for	O
3	O
weeks	O
(	O
total	O
dose	O
63	O
MU/m2	O
)	O
,	O
50	O
received	O
subcutaneous	O
thrice-weekly	O
injections	O
of	O
3	O
MU/m2	O
for	O
4	O
weeks	O
(	O
total	O
dose	O
36	O
MU/m2	O
)	O
,	O
51	O
underwent	O
diathermocoagulation	O
,	O
and	O
48	O
were	O
not	O
treated	O
and	O
were	O
used	O
as	O
a	O
control	O
group	O
.	O

Six	O
months	O
after	O
the	O
end	O
of	O
treatment	O
,	O
the	O
overall	Others
response	Others
rate	Others
(	Others
complete	Others
and	Others
partial	Others
responses	Others
)	Others
was	O
70	O
%	O
:	O
57	O
and	O
82	O
%	O
for	O
patients	O
receiving	O
interferon	O
alpha-2b	O
(	O
IM	O
and	O
subcutaneously	O
)	O
and	O
diathermocoagulation	O
,	O
respectively	O
,	O
and	O
8	O
%	O
for	O
the	O
control	O
group	O
.	O

After	O
6	O
months	O
from	O
therapy	O
,	O
no	O
significant	O
differences	O
in	O
complete	Others
response	Others
were	O
found	O
among	O
the	O
different	O
types	O
of	O
treatment	O
:	O
20	O
,	O
20	O
,	O
and	O
35	O
%	O
for	O
the	O
two	O
interferon	O
groups	O
and	O
the	O
diathermocoagulation	O
group	O
,	O
respectively	O
.	O

Fifteen	O
and	O
two	O
complete	O
responders	O
in	O
the	O
cauterization	O
and	O
interferon	O
groups	O
,	O
respectively	O
,	O
experienced	O
disease	Physical
recurrence	Physical
(	O
P	O
less	O
than	O
.01	O
)	O
.	O

All	O
patients	O
given	O
interferon	O
therapy	O
complained	O
of	O
flu-like	Adverseeffect
symptoms	Adverseeffect
,	O
which	O
declined	O
progressively	O
after	O
the	O
first	O
week	O
of	O
treatment	O
.	O

Fatigue	Adverseeffect
,	O
lasting	O
as	O
long	O
as	O
patients	O
received	O
interferon	O
,	O
was	O
the	O
most	O
prevalent	O
chronic	O
side	Adverseeffect
effect	Adverseeffect
.	O

We	O
conclude	O
that	O
systemic	O
recombinant	O
interferon	O
alpha-2b	O
is	O
active	O
in	O
treating	O
patients	O
with	O
primary	O
condyloma	O
lesions	O
and	O
does	O
so	O
as	O
well	O
as	O
cauterization	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Measurement	O
of	O
transfer	Physical
factor	Physical
during	O
constant	O
exhalation	O
.	O

BACKGROUND	O
Transfer	Physical
factor	Physical
of	Physical
the	Physical
lung	Physical
for	Physical
carbon	Physical
monoxide	Physical
(	Physical
TLCO	Physical
)	Physical
was	O
measured	O
by	O
a	O
new	O
method	O
based	O
on	O
analysis	O
of	O
the	O
ratio	O
of	O
the	O
concentrations	O
of	O
carbon	O
monoxide	O
to	O
an	O
inert	O
gas	O
(	O
methane	O
)	O
relative	O
to	O
lung	O
volume	O
during	O
a	O
constant	O
exhalation	O
.	O

Since	O
this	O
new	O
technique	O
is	O
based	O
solely	O
upon	O
exhalation	O
,	O
anomalies	O
associated	O
with	O
inspiration	O
and	O
breath	O
holding	O
do	O
not	O
affect	O
results	O
.	O

Additionally	O
,	O
because	O
prolonged	O
breath	O
holding	O
is	O
not	O
required	O
,	O
measurements	O
can	O
readily	O
be	O
made	O
in	O
dyspnoeic	O
patients	O
.	O

METHODS	O
Exhalation	Physical
TLCO	Physical
(	Physical
TLCO	Physical
,	Physical
ex	Physical
)	Physical
was	O
compared	O
with	O
the	O
standard	Physical
(	Physical
Jones	Physical
and	Physical
Meade	Physical
)	Physical
10	Physical
second	Physical
breath	Physical
holding	Physical
TLCO	Physical
(	Physical
TLCO	Physical
,	Physical
bh	Physical
)	Physical
in	O
100	O
consecutive	O
patients	O
.	O

Patients	O
did	O
not	O
practise	O
the	O
exhalation	O
manoeuvre	O
prior	O
to	O
testing	O
.	O

RESULTS	O
The	O
comparative	O
results	O
were	O
very	O
close	O
;	O
mean	O
difference	O
(	O
bias	O
)	O
+/-	O
standard	O
deviation	O
(	O
precision	O
)	O
was	O
0.05	O
(	O
0.84	O
)	O
mmol/min/kPa	O
.	O

The	O
relation	Physical
was	O
equally	O
strong	O
in	O
patients	O
with	O
severe	O
pulmonary	O
disease	O
;	O
for	O
patients	O
with	O
FEV1	O
<	O
1.51	O
the	O
mean	O
difference	O
was	O
0.21	O
(	O
0.80	O
)	O
mmol/min/kPa	O
.	O

CONCLUSIONS	O
Since	O
the	O
results	O
were	O
essentially	O
identical	O
between	O
the	O
techniques	O
,	O
it	O
seems	O
that	O
comparable	Physical
pathophysiological	Physical
factors	Physical
affect	O
TLCO	O
during	O
breath	O
holding	O
and	O
constant	O
exhalation	O
.	O

Constant	O
exhalation	O
may	O
therefore	O
be	O
a	O
useful	O
alternative	O
to	O
the	O
breath	O
holding	O
technique	O
for	O
clinical	O
measurement	O
of	O
TLCO	O
.	O

Which	O
socio-demographic	O
factors	O
are	O
associated	O
with	O
participation	O
in	O
oral	O
cancer	O
screening	O
in	O
the	O
developing	O
world	O
?	O
Results	O
from	O
a	O
population-based	O
screening	O
project	O
in	O
India	O
.	O

BACKGROUND	O
This	O
study	O
examines	O
socio-demographic	O
determinants	O
of	O
participation	O
in	O
a	O
population-based	O
randomized	O
controlled	O
trial	O
that	O
proved	O
that	O
oral	O
visual	O
inspection	O
was	O
effective	O
in	O
reducing	O
oral	Mortality
cancer	Mortality
mortality	Mortality
in	O
high-risk	O
individuals	O
in	O
India	O
.	O

METHODS	O
Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
establish	O
socio-demographic	O
characteristics	O
of	O
participants	O
versus	O
non-participants	O
in	O
the	O
intervention	O
arm	O
.	O

Compliance	Mental
with	Mental
referral	Mental
was	O
analysed	O
according	O
to	O
the	O
socio-demographic	O
characteristics	O
of	O
screen-positives	O
.	O

RESULTS	O
Of	O
96,517	O
eligible	O
subjects	O
,	O
87,655	O
were	O
screened	O
,	O
8688	O
individuals	O
never	O
received	O
the	O
invitation	O
and	O
174	O
refused	O
screening	O
.	O

Compared	O
to	O
the	O
non-screened	O
,	O
a	O
higher	O
proportion	O
of	O
screened	Others
individuals	O
were	O
women	O
(	O
OR=4.51	O
;	O
CI	O
:	O
4.28-4.75	O
)	O
,	O
lived	O
in	O
better	O
housing	O
(	O
OR=1.35	O
;	O
CI	O
:	O
1.25-1.41	O
)	O
,	O
had	O
television/radio	O
(	O
OR=1.50	O
;	O
CI	O
:	O
1.43-1.58	O
)	O
and	O
were	O
tobacco	O
and	O
alcohol	O
users	O
(	O
OR=2.75	O
;	O
CI	O
:	O
2.57-2.95	O
)	O
.	O

Being	O
65	O
and	O
older	O
decreased	O
the	O
chances	Others
of	Others
screening	Others
(	O
OR=0.39	O
;	O
CI	O
:	O
0.37-0.42	O
)	O
,	O
as	O
well	O
as	O
living	Others
in	Others
high-size	Others
households	Others
(	O
OR=0.73	O
;	O
CI	O
:	O
0.68-0.78	O
)	O
.	O

Sixty-three	O
percent	O
of	O
5143	O
screen-positives	O
complied	O
with	O
referral	Others
.	Others

Controlling	O
for	O
all	O
other	O
factors	O
,	O
individuals	O
older	O
than	O
44	O
,	O
and	O
those	O
with	O
more	O
advanced	O
lesions	O
were	O
more	O
likely	O
to	O
comply	O
with	O
referral	Others
(	O
p	O
<	O
0.001	O
)	O
.	O

Individuals	O
living	O
in	O
better	O
housing	O
were	O
less	O
likely	O
to	O
comply	Others
with	Others
referral	Others
(	O
OR=0.79	O
;	O
CI	O
:	O
0.65-0.95	O
)	O
.	O

CONCLUSIONS	O
In	O
summary	O
,	O
adequate	O
coverage	O
can	O
be	O
obtained	O
in	O
population-based	O
oral	O
screening	O
in	O
developing	O
countries	O
.	O

The	O
study	O
underscores	O
the	O
important	O
role	O
of	O
patient-provider	O
communication	O
in	O
assuring	O
high	O
compliance	O
with	O
referral	O
.	O

Primary	O
deep	O
sclerectomy	O
versus	O
primary	O
deep	O
sclerectomy	O
with	O
the	O
use	O
of	O
mitomycin	O
C	O
in	O
primary	O
open-angle	O
glaucoma	O
.	O

PURPOSE	O
To	O
prospectively	O
study	O
and	O
compare	O
the	O
effectiveness	Others
and	O
the	O
safety	Others
of	O
primary	O
deep	O
sclerectomy	O
with	O
and	O
without	O
the	O
use	O
of	O
mitomycin	O
C	O
in	O
eyes	O
with	O
open-angle	O
glaucoma	O
.	O

PATIENTS	O
AND	O
METHODS	O
A	O
total	O
of	O
90	O
eyes	O
of	O
90	O
patients	O
with	O
primary	O
open-angle	O
glaucoma	O
or	O
pseudoexfoliative	O
glaucoma	O
underwent	O
deep	O
sclerectomy	O
.	O

Patients	O
were	O
enrolled	O
consecutively	O
and	O
assigned	O
randomly	O
to	O
undergo	O
deep	O
sclerectomy	O
without	O
the	O
use	O
of	O
mitomycin	O
C	O
(	O
DS	O
group	O
)	O
and	O
deep	O
sclerectomy	O
with	O
the	O
application	O
of	O
mitomycin	O
C	O
(	O
DSMMC	O
group	O
)	O
in	O
a	O
concentration	O
of	O
0.2	O
mg/mL	O
for	O
2.5	O
minutes	O
,	O
before	O
the	O
superficial	O
scleral	O
flap	O
formation	O
.	O

RESULTS	O
The	O
intraocular	Physical
pressure	Physical
was	O
significantly	O
decreased	O
by	O
7.13	O
mm	O
Hg	O
or	O
27.59	O
%	O
in	O
the	O
DS	O
group	O
and	O
by	O
11.68	O
mm	O
Hg	O
or	O
42.25	O
%	O
in	O
the	O
DSMMC	O
group	O
at	O
the	O
end	O
of	O
the	O
follow-up	O
period	O
.	O

The	O
intraocular	Physical
pressure	Physical
reduction	Physical
in	O
the	O
DSMMC	O
group	O
was	O
statistically	O
significant	O
when	O
compared	O
with	O
that	O
in	O
the	O
DS	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
complete	O
(	O
IOP	O
<	O
22	O
mm	O
Hg	O
without	O
medication	O
)	O
and	O
qualified	O
(	O
IOP	O
<	O
22	O
mm	O
Hg	O
with	O
or	O
without	O
medication	O
)	O
success	Others
rates	Others
at	O
the	O
end	O
of	O
the	O
follow-up	O
period	O
were	O
42.5	O
%	O
and	O
72.5	O
%	O
in	O
the	O
DS	O
group	O
and	O
50	O
%	O
and	O
95	O
%	O
in	O
the	O
DSMMC	O
group	O
.	O

The	O
qualified	Others
success	Others
rate	Others
in	O
the	O
DSMMC	O
group	O
was	O
statistically	O
significant	O
when	O
compared	O
with	O
that	O
in	O
the	O
DS	O
group	O
.	O

Differences	O
in	O
complications	O
(	Adverseeffect
choroidal	Adverseeffect
detachment	Adverseeffect
,	Adverseeffect
hyphema	Adverseeffect
,	Adverseeffect
leakage	Adverseeffect
)	Adverseeffect
seen	O
between	O
the	O
two	O
groups	O
were	O
statistically	O
nonsignificant	O
.	O

A	O
hemorrhagic	Physical
detachment	Physical
of	Physical
the	Physical
Descemet	Physical
membrane	Physical
was	O
observed	O
in	O
one	O
eye	O
in	O
the	O
DSMMC	O
group	O
.	O

CONCLUSIONS	O
The	O
use	O
of	O
intraoperative	O
mitomycin	O
C	O
during	O
deep	O
sclerectomy	O
significantly	O
reduced	O
the	O
postoperative	O
IOP	O
and	O
increased	O
the	O
success	O
rate	O
of	O
the	O
procedure	O
.	O

Prehydration	O
alone	O
is	O
sufficient	O
to	O
prevent	O
contrast-induced	O
nephropathy	O
after	O
day-only	O
angiography	O
procedures	O
--	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Contrast	O
agents	O
used	O
in	O
angiography	O
procedures	O
for	O
patients	O
with	O
cardiovascular	O
disease	O
are	O
known	O
to	O
cause	O
contrast-induced	O
nephropathy	O
(	O
CIN	O
)	O
,	O
which	O
may	O
be	O
partially	O
due	O
to	O
the	O
production	O
of	O
nephrotoxic	O
oxygen-free	O
radicals	O
.	O

It	O
is	O
uncertain	O
whether	O
administration	O
of	O
intravenous	O
(	O
IV	O
)	O
anti-oxidant	O
,	O
N-acetylcysteine	O
(	O
NAC	O
)	O
,	O
can	O
prevent	O
reduction	O
in	O
renal	O
function	O
and	O
whether	O
this	O
is	O
a	O
cost-effective	O
approach	O
.	O

METHODS	O
Sixty-five	O
day-only	O
patients	O
with	O
renal	O
impairment	O
(	O
mean	O
serum	O
creatinine	O
concentration	O
0.16+/-0.03	O
mmol/l	O
)	O
due	O
to	O
undergo	O
coronary	O
or	O
peripheral	O
angiography	O
and/or	O
stenting	O
were	O
randomly	O
assigned	O
to	O
IV	O
NAC	O
300	O
or	O
600	O
mg	O
immediately	O
before	O
and	O
after	O
the	O
procedure	O
or	O
IV	O
fluid	O
alone	O
.	O

RESULTS	O
Of	O
the	O
60	O
patients	O
with	O
complete	O
data	O
,	O
none	O
had	O
acute	O
CIN	O
(	O
increase	O
in	O
serum	O
creatinine	O
concentration	O
>	O
or	O
=	O
0.044	O
mmol/l	O
,	O
48	O
h	O
after	O
administration	O
of	O
contrast	O
agent	O
)	O
.	O

Eight	O
patients	O
(	O
13	O
%	O
)	O
have	O
demonstrated	O
an	O
increase	O
in	O
their	O
serum	Physical
creatinine	Physical
concentration	Physical
>	O
or	O
=	O
0.044	O
mmol/l	O
30	O
days	O
after	O
administration	O
of	O
contrast	O
agent	O
:	O
2/19	O
(	O
11	O
%	O
)	O
in	O
the	O
control	O
group	O
,	O
2/21	O
(	O
10	O
%	O
)	O
in	O
the	O
600	O
mg	O
NAC	O
group	O
and	O
4/20	O
(	O
20	O
%	O
)	O
the	O
300	O
mg	O
NAC	O
group	O
(	O
p	O
=	O
0.66	O
)	O
.	O

The	O
mean	Others
volumes	Others
of	Others
contrast	Others
agent	Others
used	O
and	O
prehydration	O
given	O
for	O
each	O
of	O
the	O
three	O
groups	O
did	O
not	O
differ	O
significantly	O
(	O
p	O
>	O
0.83	O
)	O
.	O

There	O
was	O
significant	O
improvement	O
in	O
creatinine	Physical
clearance	Physical
within	O
each	O
group	O
from	O
baseline	O
to	O
30	O
days	O
(	O
p	O
<	O
or	O
=	O
0.03	O
)	O
,	O
but	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
at	O
48	O
h	O
and	O
30	O
days	O
(	O
p	O
>	O
or	O
=	O
0.43	O
)	O
.	O

Considering	O
the	O
cost	O
of	O
NAC	O
and	O
its	O
administration	O
,	O
we	O
estimate	O
that	O
this	O
would	O
translate	O
to	O
a	O
saving	Others
of	O
dollar	O
26,637	O
per	O
annum	O
.	O

CONCLUSION	O
For	O
day-stay	O
patients	O
with	O
mild-to-moderate	O
chronic	O
renal	O
impairment	O
undergoing	O
angiography	O
and/or	O
intervention	O
,	O
prehydration	O
alone	O
is	O
less	O
complicated	O
and	O
more	O
cost-effective	O
than	O
a	O
combination	O
of	O
IV	O
NAC	O
(	O
at	O
doses	O
used	O
)	O
and	O
hydration	O
.	O

A	O
randomized	O
trial	O
of	O
immunotherapy	O
for	O
persistent	O
genital	O
warts	O
.	O

AIM	O
To	O
determine	O
whether	O
immunotherapy	O
with	O
HPV6	O
L1	O
virus	O
like	O
particles	O
(	O
VLPs	O
)	O
without	O
adjuvant	O
(	O
VLP	O
immunotherapy	O
)	O
reduces	O
recurrence	O
of	O
genital	Physical
warts	Physical
following	O
destructive	O
therapy	O
.	O

TRIAL	O
DESIGN	O
A	O
randomized	O
placebo	O
controlled	O
blinded	O
study	O
of	O
treatment	O
of	O
recurrent	O
genital	O
warts	O
amenable	O
to	O
destructive	O
therapy	O
,	O
conducted	O
independently	O
in	O
Australia	O
and	O
China	O
.	O

METHODS	O
Patients	O
received	O
conventional	O
destructive	O
therapy	O
of	O
all	O
evident	O
warts	O
together	O
with	O
intramuscular	O
administration	O
of	O
1	O
?g	O
,	O
5	O
?g	O
or	O
25	O
?g	O
of	O
VLP	O
immunotherapy	O
,	O
or	O
of	O
placebo	O
immunotherapy	O
(	O
0.9	O
%	O
NaCl	O
)	O
,	O
as	O
immunotherapy	O
at	O
week	O
0	O
and	O
week	O
4	O
.	O

Primary	O
outcome	O
,	O
assessed	O
at	O
week	O
8	O
,	O
was	O
recurrence	O
of	O
visible	O
warts	O
.	O

RESULTS	O
Of	O
33	O
protocol	O
compliant	O
Brisbane	O
recipients	O
of	O
placebo	O
immunotherapy	O
,	O
11	O
were	O
disease	O
free	O
at	O
two	O
months	O
,	O
and	O
a	O
further	O
9	O
demonstrated	O
reduction	O
of	O
>	O
50	O
%	O
in	O
total	O
wart	O
area	O
.	O

Wart	O
area	O
reduction	O
following	O
destructive	O
treatment	O
correlated	O
with	O
prior	O
duration	O
of	O
disease	O
.	O

Among	O
102	O
protocol	O
compliant	O
Brisbane	O
recipients	O
of	O
VLP	O
immunotherapy	O
,	O
disease	O
reduction	O
was	O
significantly	O
greater	O
than	O
among	O
the	O
placebo	O
immunotherapy	O
(	O
50	O
%	O
?	O
s.e.m	O
.	O

7	O
%	O
)	O
recipients	O
for	O
subjects	O
receiving	O
5	O
?g	O
or	O
25	O
?g	O
of	O
VLP	O
immunotherapy/dose	O
(	O
71	O
%	O
?	O
s.e.m	O
.	O

7	O
%	O
)	O
but	O
not	O
for	O
those	O
receiving	O
1	O
?g	O
VLP	O
immunotherapy/dose	O
(	O
42	O
%	O
?	O
7	O
%	O
)	O
.	O

Of	O
52	O
protocol	O
compliant	O
placebo	O
immunotherapy	O
recipients	O
in	O
Wenzhou	O
,	O
37	O
were	O
disease	O
free	O
at	O
two	O
months	O
,	O
and	O
a	O
further	O
8	O
had	O
>	O
50	O
%	O
disease	O
reduction	O
.	O

Prior	O
disease	O
duration	O
was	O
much	O
shorter	O
in	O
Wenzhou	O
subject	O
(	O
8.1	O
?	O
1.1	O
mo	O
)	O
than	O
in	O
Brisbane	O
subjects	O
(	O
53.7	O
?	O
5.5	O
mo	O
)	O
.	O

No	O
significant	O
reduction	O
in	O
mean	O
wart	O
area	O
was	O
observed	O
for	O
the	O
168	O
Wenzhou	O
protocol	O
compliant	O
subjects	O
who	O
also	O
received	O
VLP	O
immunotherapy	O
.	O

CONCLUSIONS	O
This	O
study	O
confirms	O
the	O
findings	O
in	O
a	O
previous	O
open	O
label	O
trial	O
that	O
administration	O
of	O
VLP	O
immunotherapy	O
may	O
assist	O
in	O
clearance	O
of	O
recurrent	O
genital	O
warts	O
in	O
patients	O
for	O
whom	O
destructive	O
therapy	O
is	O
unsuccessful	O
and	O
that	O
unsuccessful	O
destructive	O
therapy	O
is	O
more	O
common	O
with	O
increasing	O
prior	O
disease	O
duration	O
.	O

Walking	O
trials	O
in	O
postmenopausal	O
women	O
:	O
effect	O
of	O
one	O
vs	O
two	O
daily	O
bouts	O
on	O
aerobic	Physical
fitness	Physical
.	Physical

We	O
compared	O
the	O
effects	O
of	O
one	O
vs	O
two	O
daily	O
bouts	O
of	O
walking	O
on	O
aerobic	Physical
fitness	Physical
and	O
body	Physical
composition	Physical
in	O
postmenopausal	O
women	O
.	O

One	O
hundred	O
and	O
thirty-four	O
subjects	O
were	O
randomized	O
into	O
exercise	O
groups	O
or	O
a	O
control	O
group	O
and	O
130	O
completed	O
the	O
study	O
.	O

The	O
subjects	O
walked	O
5	O
d/week	O
for	O
15	O
weeks	O
at	O
65	O
%	O
of	O
their	O
maximal	O
aerobic	O
power	O
expending	O
300	O
kcal	O
(	O
1255	O
kJ	O
)	O
in	O
exercise	O
in	O
one	O
(	O
Group	O
S1	O
)	O
or	O
two	O
daily	O
sessions	O
(	O
Group	O
S2	O
)	O
.	O

VO	Physical
(	Physical
2max	Physical
)	Physical
was	O
measured	O
in	O
a	O
direct	O
maximal	O
treadmill	O
test	O
.	O

Body	Physical
mass	Physical
index	Physical
(	Physical
BMI	Physical
)	Physical
was	O
calculated	O
and	O
the	O
percentage	O
of	O
body	O
fat	O
(	O
fat	O
%	O
)	O
estimated	O
using	O
skinfold	O
measurements	O
.	O

The	O
net	O
change	O
in	O
the	O
VO	Physical
(	Physical
2max	Physical
)	Physical
was	O
2.5	O
mL	O
min/kg	O
(	O
95	O
%	O
CI	O
1.5	O
,	O
3.5	O
)	O
(	O
8.7	O
%	O
)	O
in	O
Group	O
S1	O
and	O
2.5	O
mL	O
min/kg	O
(	O
95	O
%	O
CI	O
1.5	O
,	O
3.5	O
)	O
(	O
8.8	O
%	O
)	O
in	O
Group	O
S2	O
.	O

The	O
net	Physical
change	Physical
in	Physical
body	Physical
mass	Physical
was	O
-1.2	O
kg	O
(	O
95	O
%	O
CI-1.9	O
,	O
-0.5	O
)	O
in	O
Group	O
S1	O
and	O
-1.1	O
kg	O
(	O
95	O
%	O
CI	O
-1.8	O
,	O
-0.4	O
)	O
in	O
Group	O
S2	O
.	O

The	O
net	Physical
fat	Physical
%	Physical
change	Physical
was	O
-2.1	O
%	O
(	O
95	O
%	O
CI-2.7	O
,	O
-1.4	O
)	O
in	O
Group	O
S1	O
and	O
-1.7	O
%	O
(	O
95	O
%	O
CI-2.3	O
,	O
-1.0	O
)	O
in	O
Group	O
S2	O
.	O

Exercise	O
improved	O
the	O
maximal	O
aerobic	O
power	O
and	O
body	O
composition	O
equally	O
when	O
walking	O
was	O
performed	O
in	O
one	O
or	O
two	O
daily	O
bouts	O
.	O

Vitamin	O
C	O
and	O
acute	O
illness	O
in	O
Navajo	O
school	O
children	O
.	O

To	O
evaluate	O
earlier	O
observations	O
,	O
including	O
our	O
own	O
,	O
showing	O
usefulness	O
of	O
vitamin	O
C	O
for	O
managing	O
the	O
common	O
cold	O
,	O
we	O
performed	O
a	O
double-blind	O
trial	O
of	O
vitamin	O
C	O
versus	O
placebo	O
in	O
868	O
children	O
.	O

There	O
was	O
no	O
difference	O
in	O
number	Physical
becoming	Physical
ill	Physical
(	O
133	O
versus	O
129	O
)	O
,	O
number	Physical
of	Physical
episodes	Physical
(	O
166	O
versus	O
159	O
)	O
or	O
mean	Physical
illness	Physical
duration	Physical
(	O
5.5	O
versus	O
5.8	O
days	O
)	O
between	O
the	O
groups	O
.	O

Children	O
receiving	O
vitamin	O
C	O
had	O
fewer	O
throat	Physical
cultures	Physical
yielding	O
beta-hemolytic	Physical
streptococcus	Physical
(	O
six	O
versus	O
13	O
,	O
P	O
less	O
than	O
0.10	O
)	O
,	O
but	O
no	O
difference	O
in	O
overall	Physical
complicated	Physical
illness	Physical
rate	Physical
(	O
24	O
versus	O
25	O
)	O
.	O

Plasma	Physical
ascorbic	Physical
acid	Physical
levels	Physical
were	O
higher	O
in	O
the	O
vitamin	O
group	O
24	O
to	O
26	O
hours	O
after	O
supplementation	O
(	O
1.28	O
versus	O
1.04	O
mg	O
per	O
100	O
ml	O
,	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Children	O
with	O
high	O
plasma	O
ascorbic	O
acid	O
concentrations	O
had	O
longer	O
mean	Physical
illness	Physical
(	O
6.8	O
versus	O
4.0	O
days	O
,	O
P	O
less	O
than	O
0.05	O
)	O
than	O
those	O
with	O
low	O
levels	O
.	O

Vitamin	O
C	O
does	O
not	O
seem	O
to	O
be	O
an	O
effective	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
upper	O
respiratory	O
illness	O
.	O

Are	O
prenatal	O
ultrasound	O
scans	O
associated	O
with	O
the	O
autism	Physical
phenotype	Physical
?	O
Follow-up	O
of	O
a	O
randomised	O
controlled	O
trial	O
.	O

An	O
existing	O
randomised	O
controlled	O
trial	O
was	O
used	O
to	O
investigate	O
whether	O
multiple	O
ultrasound	O
scans	O
may	O
be	O
associated	O
with	O
the	O
autism	Mental
phenotype	Mental
.	Physical

From	O
2,834	O
single	O
pregnancies	O
,	O
1,415	O
were	O
selected	O
at	O
random	O
to	O
receive	O
ultrasound	O
imaging	O
and	O
continuous	O
wave	O
Doppler	O
flow	O
studies	O
at	O
five	O
points	O
throughout	O
pregnancy	O
(	O
Intensive	O
)	O
and	O
1,419	O
to	O
receive	O
a	O
single	O
imaging	O
scan	O
at	O
18	O
weeks	O
(	O
Regular	O
)	O
,	O
with	O
further	O
scans	O
only	O
as	O
indicated	O
on	O
clinical	O
grounds	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	Mental
of	Mental
Autism	Physical
Spectrum	Physical
Disorder	Physical
between	O
the	O
Regular	O
(	O
9/1,125	O
,	O
0.8	O
%	O
)	O
and	O
Intensive	O
(	O
7/1,167	O
,	O
0.6	O
%	O
)	O
groups	O
,	O
nor	O
a	O
difference	O
between	O
groups	O
in	O
the	O
level	Mental
of	Mental
autistic-like	Mental
traits	Mental
in	O
early	O
adulthood	O
.	O

There	O
is	O
no	O
clear	O
link	O
between	O
the	O
frequency	Physical
and	O
timing	Physical
of	O
prenatal	O
ultrasound	O
scans	O
and	O
the	O
autism	Mental
phenotype	Mental
.	O

Registration	O
accuracy	O
of	O
153Gd	O
transmission	O
images	O
of	O
the	O
brain	O
.	O

PURPOSE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
accuracy	O
of	O
non-rigid	O
nine-parameter	O
image	O
registrations	O
based	O
on	O
153Gd	O
transmission	O
computed	O
tomography	O
(	O
TCT	O
)	O
images	O
as	O
compared	O
with	O
those	O
based	O
on	O
99mTc-ethyl	O
cysteinate	O
dimer	O
(	O
ECD	O
)	O
images	O
and	O
to	O
assess	O
whether	O
normalised	O
mutual	O
information	O
(	O
NMI	O
)	O
or	O
count	O
difference	O
(	O
CD	O
)	O
should	O
be	O
used	O
.	O

METHODS	O
TCT	O
and	O
ECD	O
data	O
were	O
acquired	O
in	O
25	O
randomly	O
selected	O
patients	O
.	O

Emission	O
images	O
were	O
registered	O
to	O
an	O
ECD	O
template	O
with	O
a	O
CD	O
cost	O
function	O
.	O

The	O
same	O
registration	O
parameters	O
were	O
applied	O
to	O
the	O
transmission	O
images	O
to	O
create	O
a	O
TCT	O
template	O
.	O

All	O
TCT	O
images	O
were	O
registered	O
to	O
the	O
TCT	O
template	O
and	O
the	O
same	O
registration	O
parameters	O
were	O
applied	O
to	O
the	O
ECD	O
images	O
.	O

The	O
procedure	O
was	O
repeated	O
with	O
NMI	O
as	O
cost	O
function	O
.	O

Accuracy	O
of	O
both	O
ECD-based	O
and	O
TCT-based	O
registrations	O
was	O
assessed	O
by	O
comparing	O
the	O
normalisation	O
parameter	O
values	O
and	O
regional	O
activities	O
in	O
the	O
spatially	O
normalised	O
ECD	O
images	O
,	O
using	O
a	O
mixed-model	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

Scheffe	O
post	O
hoc	O
tests	O
were	O
performed	O
.	O

RESULTS	O
No	Others
significant	Others
differences	Others
were	O
found	O
between	O
ECD/CD	O
,	O
ECD/NMI	O
and	O
TCT/CD	O
,	O
suggesting	O
that	O
ECD	O
registration	O
can	O
be	O
done	O
with	O
either	O
CD	O
or	O
NMI	O
,	O
and	O
that	O
TCT	O
registration	O
using	O
CD	O
is	O
equally	O
as	O
accurate	O
as	O
ECD	O
registration	O
.	O

The	O
accuracy	Others
of	Others
TCT	Others
registration	Others
with	O
NMI	O
was	O
lower	Others
,	O
with	O
discrepancies	O
occurring	O
in	O
the	O
frontal	O
inferior	O
region	O
and	O
the	O
cerebellum	O
.	O

The	O
analysis	O
of	O
normalisation	O
parameters	O
indicated	O
that	O
z-scaling	O
is	O
underestimated	O
and	O
yz-rotation	O
overestimated	O
with	O
TCT/NMI	O
registration	O
.	O

CONCLUSION	O
We	O
conclude	O
that	O
ECD	O
registrations	O
with	O
CD	O
or	O
NMI	O
are	O
as	O
accurate	O
as	O
TCT	O
registrations	O
with	O
CD	O
and	O
that	O
TCT	O
registrations	O
with	O
NMI	O
should	O
be	O
avoided	O
.	O

Effect	O
of	O
increasing	O
doses	O
of	O
labetalol	O
on	O
blood	Physical
pressure	Physical
,	O
plasma	Physical
renin	Physical
activity	Physical
and	O
aldosterone	Physical
in	O
hypertensive	O
patients	O
.	O

1	O
.	O

Four	O
different	O
doses	O
of	O
labetalol	O
(	O
150	O
,	O
300	O
,	O
600	O
and	O
900	O
mg/day	O
)	O
were	O
given	O
for	O
1	O
week	O
to	O
each	O
of	O
four	O
groups	O
of	O
patients	O
with	O
essential	O
hypertension	O
(	O
six	O
patients	O
for	O
each	O
group	O
)	O
.	O

2	O
.	O

Labetalol	O
decreased	O
mean	O
blood	Physical
pressure	Physical
and	O
heart	Physical
rate	Physical
to	O
the	O
same	O
extent	O
on	O
the	O
first	O
and	O
the	O
seventh	O
days	O
of	O
treatment	O
.	O

Only	O
standing	O
blood	Physical
pressure	Physical
showed	O
a	O
dose-dependent	O
inhibition	O
both	O
in	O
the	O
supine	O
and	O
upright	O
position	O
.	O

3	O
.	O

Labetalol	O
exerted	O
a	O
net	O
inhibitory	O
effect	O
on	O
plasma	Physical
renin	Physical
activity	Physical
,	O
which	O
was	O
related	O
to	O
basal	O
renin	O
values	O
and	O
was	O
already	O
maximal	O
at	O
the	O
lowest	O
doses	O
.	O

This	O
effect	O
was	O
well	O
maintained	O
in	O
the	O
supine	O
position	O
.	O

This	O
effect	O
was	O
well	O
maintained	O
in	O
the	O
supine	O
position	O
,	O
although	O
during	O
standing	O
it	O
tended	O
to	O
be	O
less	O
evident	O
with	O
increasing	O
doses	O
.	O

4	O
.	O

Urinary	Physical
aldosterone	Physical
was	O
decreased	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
its	O
changes	O
were	O
largely	O
independent	O
fashion	O
and	O
its	O
changes	O
were	O
largely	O
independent	O
of	O
plasma	O
renin	O
activity	O
.	O

5	O
.	O

Neither	O
basal	Physical
values	Physical
nor	Physical
changes	Physical
of	Physical
renin	Physical
and	O
aldosterone	Physical
were	O
related	O
to	O
the	O
hypotensive	O
effect	O
of	O
labetalol	O
.	O

6	O
.	O

During	O
labetalol	O
treatment	O
urinary	Physical
sodium	Physical
excretion	Physical
fell	Physical
for	O
2-3	O
days	O
and	O
then	O
returned	O
to	O
basal	O
values	O
.	O

The	O
retentive	O
effect	O
of	O
labetalol	O
on	O
sodium	O
was	O
directly	O
related	O
to	O
the	O
decrease	O
of	O
blood	Physical
pressure	Physical
,	O
and	O
the	O
successive	Physical
sodium	Physical
escape	Physical
might	O
be	O
explained	O
either	O
by	O
the	O
observed	O
increase	O
of	O
plasma	O
volume	O
(	O
indirectly	O
measured	O
by	O
packed	O
cell	O
volume	O
)	O
or	O
by	O
aldosterone	O
inhibition	O
.	O

Adequacy	O
of	O
hot	O
biopsy	O
for	O
the	O
treatment	O
of	O
diminutive	O
polyps	O
:	O
a	O
prospective	O
randomized	O
trial	O
.	O

Patients	O
with	O
diminutive	O
polyps	O
in	O
the	O
rectum	O
or	O
sigmoid	O
colon	O
were	O
randomized	O
to	O
hot	O
biopsy	O
treatment	O
for	O
either	O
1	O
)	O
electrocautery	O
for	O
2	O
s	O
(	O
fixed	O
duration	O
cautery	O
)	O
or	O
2	O
)	O
cautery	O
until	O
visible	O
necrosis	O
of	O
the	O
polyp	O
base	O
was	O
evident	O
(	O
variable	O
duration	O
cautery	O
)	O
.	O

Sigmoidoscopy	O
was	O
performed	O
4	O
wk	O
after	O
treatment	O
to	O
determine	O
the	O
adequacy	O
of	O
polyp	O
eradication	O
.	O

In	O
the	O
fixed	O
duration	O
cautery	O
group	O
,	O
11	O
of	O
21	O
polyps	O
(	O
52	O
%	O
)	O
were	O
eradicated	Physical
,	O
compared	O
with	O
12	O
of	O
14	O
polyps	O
(	O
86	O
%	O
)	O
in	O
the	O
variable	O
duration	O
cautery	O
group	O
(	O
p	O
=	O
0.04	O
)	O
.	O

When	O
analyzed	O
according	O
to	O
whether	O
or	O
not	O
visible	Physical
necrosis	Physical
was	O
achieved	O
(	O
some	O
of	O
the	O
polyps	O
in	O
the	O
fixed	O
duration	O
cautery	O
group	O
showed	O
necrosis	O
with	O
2	O
s	O
cautery	O
)	O
,	O
19	O
of	O
23	O
polyps	O
(	O
83	O
%	O
)	O
were	O
eradicated	Physical
when	O
necrosis	O
was	O
evident	O
,	O
compared	O
to	O
5	O
of	O
12	O
(	O
42	O
%	O
)	O
without	O
necrosis	O
(	O
p	O
=	O
0.004	O
)	O
.	O

We	O
conclude	O
that	O
hot	O
biopsy	O
treatment	O
for	O
diminutive	O
polyps	O
is	O
significantly	O
more	O
effective	O
when	O
visible	O
necrosis	O
is	O
achieved	O
during	O
cautery	O
.	O

Furthermore	O
,	O
even	O
with	O
visible	O
necrosis	O
,	O
there	O
is	O
a	O
17	O
%	O
failure	O
rate	O
of	O
polyp	O
eradication	O
.	O

Phase	O
III	O
study	O
of	O
the	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
(	O
ECOG	O
2597	O
)	O
:	O
induction	O
chemotherapy	O
followed	O
by	O
either	O
standard	O
thoracic	O
radiotherapy	O
or	O
hyperfractionated	O
accelerated	O
radiotherapy	O
for	O
patients	O
with	O
unresectable	O
stage	O
IIIA	O
and	O
B	O
non-small-cell	O
lung	O
cancer	O
.	O

PURPOSE	O
To	O
compare	O
once-daily	O
radiation	O
therapy	O
(	O
qdRT	O
)	O
with	O
hyperfractionated	O
accelerated	O
radiation	O
therapy	O
(	O
HART	O
)	O
after	O
two	O
cycles	O
of	O
induction	O
chemotherapy	O
.	O

PATIENTS	O
AND	O
METHODS	O
Eligible	O
patients	O
were	O
treatment	O
naive	O
,	O
and	O
had	O
stage	O
IIIA	O
and	O
B	O
unresectable	O
non-small-cell	O
lung	O
cancer	O
,	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
performance	O
status	O
0/1	O
,	O
and	O
normal	O
organ	O
function	O
.	O

Induction	O
chemotherapy	O
consisted	O
of	O
two	O
cycles	O
of	O
carboplatin	O
area	O
under	O
time-concentration	O
curve	O
6	O
mg/mL	O
.	O

min	O
plus	O
paclitaxel	O
225	O
mg/m2	O
on	O
day	O
1	O
.	O

RT	O
consisted	O
of	O
arm	O
1	O
(	O
qdRT	O
)	O
,	O
64	O
Gy	O
(	O
2	O
Gy/d	O
)	O
,	O
versus	O
arm	O
2	O
(	O
HART	O
)	O
,	O
57.6	O
Gy	O
(	O
1.5	O
Gy	O
tid	O
for	O
2.5	O
weeks	O
)	O
.	O

A	O
total	O
of	O
388	O
patients	O
were	O
needed	O
to	O
detect	O
a	O
50	O
%	O
increase	O
in	O
median	O
survival	O
from	O
14	O
months	O
of	O
qdRT	O
to	O
21	O
months	O
of	O
HART	O
;	O
accrual	O
was	O
not	O
achieved	O
and	O
the	O
study	O
closed	O
prematurely	O
.	O

RESULTS	O
Of	O
141	O
patients	O
enrolled	O
,	O
83	O
%	O
were	O
randomly	O
assigned	O
after	O
chemotherapy	O
to	O
qdRT	O
(	O
n	O
=	O
59	O
)	O
or	O
HART	O
(	O
n	O
=	O
60	O
)	O
.	O

Median	Mortality
survival	Mortality
was	O
20.3	O
and	O
14.9	O
months	O
for	O
HART	O
and	O
qdRT	O
,	O
respectively	O
(	O
P	O
=	O
.28	O
)	O
.	O

Overall	Others
response	Others
was	O
25	O
%	O
and	O
22	O
%	O
for	O
HART	O
and	O
qdRT	O
,	O
respectively	O
(	O
P	O
=	O
.69	O
)	O
.	O

Two-	Mortality
and	Mortality
3-year	Mortality
survival	Mortality
was	O
44	O
%	O
and	O
34	O
%	O
for	O
HART	O
,	O
and	O
24	O
%	O
and	O
14	O
%	O
for	O
qdRT	O
,	O
respectively	O
.	O

Grade	Adverseeffect
>	Adverseeffect
or	Adverseeffect
=	Adverseeffect
3	Adverseeffect
toxicities	Adverseeffect
included	O
esophagitis	O
in	O
14	O
v	O
nine	O
patients	O
,	O
and	O
pneumonitis	O
in	O
0	O
v	O
6	O
patients	O
for	O
HART	O
and	O
qdRT	O
,	O
respectively	O
.	O

Any	O
subsequent	O
trials	O
of	O
the	O
HART	O
regimen	O
must	O
address	O
the	O
issues	O
that	O
led	O
to	O
early	O
closure	O
,	O
including	O
slow	Physical
accrual	Physical
,	Physical
logistics	Physical
of	Physical
HART	Physical
,	Physical
mucosal	Physical
toxicity	Physical
,	O
and	O
the	O
fact	O
that	O
concurrent	O
chemoradiotherapy	O
now	O
seems	O
more	O
effective	O
than	O
sequential	O
treatment	O
.	O

CONCLUSION	O
After	O
two	O
cycles	O
of	O
induction	O
chemotherapy	O
with	O
carboplatin-paclitaxel	O
,	O
HART	O
is	O
feasible	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
.	O

Although	O
statistical	O
significance	O
was	O
not	O
achieved	O
and	O
the	O
study	O
closed	O
early	O
,	O
there	O
was	O
a	O
positive	O
statistical	O
trend	O
suggesting	O
a	O
survival	O
advantage	O
with	O
the	O
HART	O
regimen	O
.	O

Double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
risperidone	O
plus	O
amantadine	O
in	O
children	O
with	O
autism	O
:	O
a	O
10-week	O
randomized	O
study	O
.	O

OBJECTIVE	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
adding	O
amantadine	O
to	O
risperidone	O
for	O
treatment	O
of	O
autism	O
.	O

METHODS	O
Forty	O
outpatients	O
aged	O
4	O
to12	O
years	O
,	O
who	O
were	O
diagnosed	O
with	O
autism	O
spectrum	O
disorders	O
based	O
on	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
,	O
Fourth	O
Edition	O
,	O
Text	O
Revision	O
criteria	O
,	O
were	O
assigned	O
to	O
this	O
double-blind	O
clinical	O
trial	O
.	O

The	O
subjects	O
were	O
divided	O
randomly	O
into	O
2	O
groups	O
.	O

One	O
group	O
received	O
risperidone	O
plus	O
amantadine	O
,	O
and	O
the	O
other	O
group	O
received	O
risperidone	O
plus	O
placebo	O
.	O

The	O
dose	O
of	O
risperidone	O
was	O
titrated	O
between	O
1	O
and	O
2.0	O
mg/d	O
,	O
and	O
the	O
dose	O
of	O
amantadine	O
was	O
100	O
or	O
150	O
mg/d	O
for	O
patients	O
less	O
than	O
30	O
kg	O
or	O
more	O
than	O
30	O
kg	O
,	O
respectively	O
.	O

The	O
patients	O
were	O
assessed	O
using	O
the	O
Aberrant	Mental
Behavioral	Mental
Checklist-Community	Mental
(	Mental
ABC-C	Mental
)	Mental
and	Mental
adverse	Adverseeffect
effects	Adverseeffect
checklist	Adverseeffect
as	O
well	O
as	O
clinical	Mental
global	Mental
impression-improvement	Mental
(	Mental
CGI-I	Mental
)	Mental
at2	O
checkpoints	O
of	O
5-week	O
intervals	O
after	O
the	O
baseline	O
.	O

Informed	O
consentwas	O
obtained	O
from	O
the	O
parents	O
of	O
each	O
participant	O
.	O

RESULTS	O
Among	O
ABC-C	Mental
subscales	Mental
,	Mental
Hyperactivity	Mental
and	Mental
Irritability	Mental
showed	O
significantly	O
greater	O
reduction	O
in	O
the	O
amantadine	O
group	O
than	O
the	O
placebo	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
adverse	Adverseeffect
effects	Adverseeffect
between	O
the	O
2	O
groups	O
.	O

The	O
CGI-I	Mental
scores	Mental
show	O
significant	O
improvement	O
in	O
the	O
amantadine	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
The	O
present	O
study	O
suggests	O
that	O
amantadine	O
may	O
be	O
a	O
potential	O
adjunctive	O
treatment	O
strategy	O
for	O
autism	O
and	O
it	O
was	O
generally	O
well	O
tolerated	O
.	O

Increase	O
in	O
2-long	O
terminal	O
repeat	O
circles	O
and	O
decrease	O
in	O
D-dimer	O
after	O
raltegravir	O
intensification	O
in	O
patients	O
with	O
treated	O
HIV	O
infection	O
:	O
a	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O

BACKGROUND	O
The	O
degree	O
to	O
which	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
continues	O
to	O
replicate	O
during	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
is	O
controversial	O
.	O

We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
to	O
assess	O
whether	O
raltegravir	O
intensification	O
reduces	O
low-level	Physical
viral	Physical
replication	Physical
,	O
as	O
defined	O
by	O
an	O
increase	O
in	O
the	O
level	O
of	O
2-long	Physical
terminal	Physical
repeat	Physical
(	O
2-LTR	O
)	O
circles	O
.	O

METHODS	O
Thirty-one	O
subjects	O
with	O
an	O
ART-suppressed	O
plasma	O
HIV	O
RNA	O
level	O
of	O
<	O
40	O
copies/mL	O
and	O
a	O
CD4	O
(	O
+	O
)	O
T-cell	O
count	O
of	O
?350	O
cells/mm	O
(	O
3	O
)	O
for	O
?1	O
year	O
were	O
randomly	O
assigned	O
to	O
receive	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
or	O
placebo	O
for	O
24	O
weeks	O
.	O

2-LTR	O
circles	O
were	O
analyzed	O
by	O
droplet	O
digital	O
polymerase	O
chain	O
reaction	O
at	O
weeks	O
0	O
,	O
1	O
,	O
2	O
,	O
and	O
8	O
.	O

RESULTS	O
The	O
median	Physical
duration	Physical
of	Physical
ART	Physical
suppression	Physical
was	O
3.8	O
years	O
.	O

The	O
raltegravir	O
group	O
had	O
a	O
significant	O
increase	O
in	O
the	O
level	Physical
of	Physical
2-LTR	Physical
circles	Physical
,	O
compared	O
to	O
the	O
placebo	O
group	O
.	O

The	O
week	O
1	O
to	O
0	O
ratio	O
was	O
8.8-fold	O
higher	O
(	O
P	O
=	O
.0025	O
)	O
and	O
the	O
week	O
2	O
to	O
0	O
ratio	O
was	O
5.7-fold	O
higher	O
(	O
P	O
=	O
.023	O
)	O
in	O
the	O
raltegravir	O
vs.	O
placebo	O
group	O
.	O

Intensification	O
also	O
led	O
to	O
a	O
statistically	O
significant	O
decrease	O
in	O
the	O
D-dimer	O
level	O
,	O
compared	O
to	O
placebo	O
(	O
P	O
=	O
.045	O
)	O
.	O

CONCLUSIONS	O
Raltegravir	O
intensification	O
resulted	O
in	O
a	O
rapid	O
increase	O
in	O
the	O
level	O
of	O
2-LTR	O
circles	O
in	O
a	O
proportion	O
of	O
subjects	O
,	O
indicating	O
that	O
low-level	O
viral	O
replication	O
persists	O
in	O
some	O
individuals	O
even	O
after	O
long-term	O
ART	O
.	O

Intensification	O
also	O
reduced	O
the	O
D-dimer	O
level	O
,	O
a	O
coagulation	O
biomarker	O
that	O
is	O
predictive	O
of	O
morbidity	O
and	O
mortality	O
among	O
patients	O
receiving	O
treatment	O
for	O
HIV	O
infection	O
.	O

Cardiac	O
and	O
haemodynamic	O
measurements	O
in	O
hypertensive	O
pregnancy	O
.	O

1	O
.	O

Haemodynamic	O
and	O
left	O
ventricular	O
variables	O
were	O
determined	O
by	O
M-mode	O
echocardiography	O
in	O
21	O
normotensive	O
and	O
36	O
hypertensive	O
patients	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
.	O

2	O
.	O

Blood	Physical
pressure	Physical
of	O
hypertensive	O
patients	O
was	O
lowered	O
by	O
bed	O
rest	O
only	O
,	O
or	O
by	O
oxprenolol	O
or	O
methyldopa	O
,	O
but	O
remained	O
elevated	O
.	O

3	O
.	O

Cardiac	Physical
output	Physical
was	O
raised	O
in	O
the	O
last	O
trimester	O
of	O
pregnancy	O
in	O
both	O
normotensive	O
and	O
hypertensive	O
patients	O
.	O

4	O
.	O

Left	Physical
ventricular	Physical
mass	Physical
was	O
increased	O
in	O
normal	O
pregnancy	O
,	O
but	O
displayed	O
an	O
exaggerated	O
increase	O
in	O
hypertensive	O
patients	O
.	O

5	O
.	O

Total	Physical
peripheral	Physical
resistance	Physical
was	O
inappropriately	O
elevated	O
in	O
hypertensive	O
pregnancy	O
,	O
except	O
in	O
the	O
oxprenolol-treated	O
group	O
.	O

6	O
.	O

There	O
ws	O
no	O
reduction	O
in	O
heart	Physical
rate	Physical
or	Others
cardiac	Physical
output	Physical
in	O
the	O
group	O
treated	O
with	O
beta-adrenoreceptor	O
blocking	O
agents	O
.	O

These	O
factors	O
,	O
in	O
combination	O
with	O
normal	O
peripheral	O
resistance	O
,	O
may	O
contribute	O
to	O
the	O
improvement	O
in	O
foetal	Physical
outcome	Physical
described	O
in	O
maternal	O
hypertension	O
of	O
pregnancy	O
treated	O
with	O
oxprenolol	O
.	O

Rye	O
bran	O
bread	O
intake	O
elevates	O
urinary	Physical
excretion	Physical
of	Physical
ferulic	Physical
acid	Physical
in	O
humans	O
,	O
but	O
does	O
not	O
affect	O
the	O
susceptibility	Physical
of	Physical
LDL	Physical
to	Physical
oxidation	Physical
ex	O
vivo	O
.	O

BACKGROUND	O
Rye	O
bread	O
contributes	O
an	O
important	O
part	O
of	O
the	O
whole	O
grain	O
intake	O
in	O
the	O
Scandinavian	O
diet	O
.	O

Ferulic	O
acid	O
is	O
the	O
major	O
phenolic	O
compound	O
in	O
rye	O
bran	O
and	O
is	O
an	O
antioxidant	O
in	O
vitro	O
and	O
may	O
,	O
therefore	O
,	O
contribute	O
to	O
cardioprotective	O
effects	O
of	O
whole	O
grain	O
consumption	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
Firstly	O
,	O
to	O
evaluate	O
the	O
bioavailability	Others
and	Adverseeffect
potential	Others
antioxidative	Others
effects	Others
in	O
humans	O
of	O
ferulic	O
acid	O
from	O
rye	O
.	O

Secondly	O
,	O
to	O
evaluate	O
urine	Physical
levels	Physical
of	Physical
ferulic	Physical
acid	Physical
as	O
a	O
possible	O
biomarker	O
of	O
the	O
ordinary	O
dietary	O
intake	O
of	O
ferulic	O
acid	O
.	O

METHODS	O
We	O
determined	O
the	O
urinary	Physical
excretion	Physical
of	Physical
ferulic	Physical
acid	Physical
in	O
18	O
postmenopausal	O
women	O
after	O
a	O
dietary	O
intake	O
of	O
rye	O
bran	O
or	O
an	O
inert	O
wheat	O
bran	O
(	O
control	O
)	O
in	O
a	O
crossover	O
study	O
(	O
2	O
x	O
6	O
weeks	O
with	O
4	O
weeks	O
washout	O
)	O
.	O

The	O
potential	O
antioxidative	O
effect	O
of	O
the	O
rye	O
bran	O
intervention	O
was	O
investigated	O
by	O
measuring	O
low-density	Physical
lipoprotein	Physical
(	Physical
LDL	Physical
)	Physical
susceptibility	Physical
to	Physical
copper	Physical
oxidation	Physical
ex	Physical
vivo	Physical
.	O

The	O
subjects	O
ingested	O
rye	O
bran	O
enriched	O
breads	O
equivalent	O
to	O
approximately	O
10.2	O
mg	O
ferulic	O
acid	O
per	O
day	O
.	O

RESULTS	O
The	O
urinary	Physical
excretion	Physical
of	Physical
ferulic	Physical
acid	Physical
averaged	O
approximately	O
4.8	O
mg	O
per	O
day	O
during	O
intervention	O
with	O
rye	O
bran	O
breads	O
and	O
approximately	O
1.9	O
mg	O
per	O
day	O
on	O
the	O
control	O
breads	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Rye	O
bran	O
intervention	O
had	O
no	O
influence	O
on	O
lag	Physical
time	Physical
or	Physical
propagation	Physical
rate	Physical
of	Physical
the	Physical
LDL	Physical
oxidation	Physical
ex	O
vivo	O
.	O

CONCLUSIONS	O
The	O
present	O
study	O
demonstrated	O
that	O
ferulic	O
acid	O
from	O
rye	O
bran	O
is	O
bioavailable	O
and	O
that	O
the	O
urinary	O
concentration	O
of	O
ferulic	O
acid	O
reflects	O
the	O
dietary	O
intake	O
of	O
this	O
hydroxycinnamic	O
acid	O
.	O

Within	O
the	O
period	O
of	O
intervention	O
,	O
the	O
elevated	O
ferulic	O
acid	O
did	O
not	O
produce	O
a	O
measurable	O
antioxidative	Physical
effect	Physical
on	O
the	O
subjects	O
'	O
LDL	O
.	O

It	O
is	O
suggested	O
that	O
the	O
determination	O
of	O
ferulic	O
acid	O
in	O
urine	O
is	O
a	O
useful	O
biomarker	O
to	O
assess	O
the	O
intake	Physical
of	Physical
ferulic	Physical
acid	Physical
from	O
a	O
regular	O
diet	O
.	O

Effects	O
of	O
omeprazole	O
and	O
amoxycillin	O
on	O
the	O
human	O
oral	O
and	O
gastrointestinal	O
microflora	O
in	O
patients	O
with	O
Helicobacter	O
pylori	O
infection	O
.	O

Fourteen	O
patients	O
with	O
Helicobacter	O
pylori	O
infection	O
were	O
treated	O
with	O
omeprazole	O
capsules	O
20	O
mg	O
and	O
amoxycillin	O
capsules	O
1000	O
mg	O
twice	O
daily	O
for	O
14	O
days	O
and	O
14	O
patients	O
with	O
omeprazole	O
capsules	O
20	O
mg	O
and	O
placebo	O
twice	O
daily	O
for	O
14	O
days	O
.	O

Samples	O
from	O
saliva	O
,	O
dental	O
plaque	O
and	O
faeces	O
and	O
biopsies	O
from	O
antrum	O
and	O
corpus	O
were	O
analysed	O
in	O
order	O
to	O
determine	O
the	O
ecological	O
changes	O
in	O
the	O
normal	O
microflora	O
.	O

Several	O
microorganisms	O
were	O
affected	O
by	O
both	O
treatment	O
regimens	O
.	O

Two	O
patients	O
were	O
colonised	O
with	O
enterobacteria	O
in	O
the	O
oral	O
cavity	O
and	O
stomach	O
during	O
the	O
omeprazole	O
plus	O
amoxycillin	O
treatment	O
.	O

A	O
general	Others
increase	Others
in	Others
the	Others
number	Others
of	Others
microorganisms	Others
from	Others
gastric	Others
mucosa	Others
was	O
observed	O
in	O
both	O
treatment	O
groups	O
.	O

A	O
selection	Others
of	Others
resistant	Others
enterobacteria	Others
and	O
an	O
increase	Others
in	Others
beta-lactamase	Others
production	Others
was	O
observed	O
in	O
the	O
faecal	O
samples	O
during	O
the	O
omeprazole	O
plus	O
amoxycillin	O
treatment	O
.	O

Eradication	Others
of	Others
H.	Others
pylori	Others
in	Others
the	Others
omeprazole-amoxycillin	Others
group	Others
was	O
50	O
%	O
and	O
in	O
the	O
omeprazole	O
placebo	O
group	O
0	O
%	O
four	O
weeks	O
after	O
treatment	O
.	O

No	Others
viable	Others
H.	Others
pylori	Others
were	O
cultivated	O
in	O
the	O
saliva	Physical
,	O
dental	Physical
plaque	Physical
or	O
faecal	Physical
samples	Physical
.	O

Treatment	O
with	O
omeprazole	O
20	O
mg	O
and	O
amoxycillin	O
1000	O
mg	O
twice	O
daily	O
for	O
14	O
days	O
altered	O
the	O
normal	O
microflora	O
in	O
the	O
oral	O
,	O
gastric	O
and	O
intestinal	O
tract	O
and	O
antibiotic	O
resistant	O
microorganisms	O
increased	O
in	O
numbers	O
in	O
the	O
intestinal	Physical
microflora	Physical
.	Physical

New	O
hope	O
for	O
children	O
with	O
Kawasaki	O
disease	O
.	O

Kawasaki	O
disease	O
is	O
now	O
the	O
most	O
common	O
cause	O
of	O
acquired	O
heart	O
disease	O
in	O
America	O
's	O
children	O
.	O

It	O
is	O
an	O
acute	O
febrile	O
illness	O
that	O
may	O
cause	O
coronary	O
artery	O
aneurysm	O
formation	O
in	O
infected	O
children	O
.	O

The	O
results	O
of	O
a	O
multicenter	O
,	O
randomized	O
trial	O
on	O
the	O
effect	O
of	O
intravenous	O
administration	O
of	O
gamma	O
globulin	O
(	O
IVGG	O
)	O
plus	O
aspirin	O
versus	O
aspirin	O
alone	O
upon	O
coronary	O
aneurysm	O
formation	O
show	O
a	O
decrease	O
in	O
coronary	Physical
aneurysm	Physical
formation	Physical
from	O
the	O
usual	O
20	O
%	O
-30	O
%	O
to	O
3	O
%	O
.	O

Administration	O
of	O
IVGG	O
presents	O
some	O
unique	O
challenges	O
for	O
nurses	O
.	O

Also	O
,	O
the	O
pediatric	O
nurse	O
must	O
educate	O
parents	O
and	O
children	O
about	O
this	O
disease	O
to	O
prepare	O
them	O
for	O
discharge	O
and	O
long-term	O
follow-up	O
care	O
.	O

Human	O
motor	O
responses	O
to	O
simultaneous	O
aversive	O
stimulation	O
and	O
failure	O
on	O
a	O
valued	O
task	O
.	O

The	O
effects	O
of	O
presentation	O
of	O
an	O
aversive	O
stimulus	O
and	O
simultaneous	O
failure	O
on	O
a	O
bogus	O
intelligence	O
test	O
upon	O
a	O
subject	O
's	O
aggressive	Mental
reactions	Mental
were	O
studied	O
.	O

The	O
subject	O
's	O
fist	Mental
clenching	Mental
was	O
used	O
as	O
an	O
indicator	Mental
of	Mental
aggression	Mental
.	O

Four	O
conditions	O
,	O
generated	O
by	O
the	O
combinations	O
of	O
two	O
kinds	O
of	O
stimulus	O
delivered	O
to	O
the	O
subjects	O
(	O
aversive	O
or	O
nonaversive	O
)	O
and	O
two	O
outcomes	O
of	O
the	O
task	O
(	O
failure	O
or	O
success	O
)	O
,	O
were	O
investigated	O
.	O

20	O
female	O
and	O
20	O
male	O
students	O
(	O
ages	O
:	O
17-34	O
years	O
)	O
were	O
instructed	O
,	O
upon	O
the	O
reception	O
of	O
an	O
aversive	O
or	O
nonaversive	O
acoustic	O
signal	O
,	O
to	O
press	O
with	O
the	O
right	O
hand	O
a	O
device	O
that	O
displayed	O
a	O
slide	O
.	O

Each	O
slide	O
presented	O
an	O
item	O
from	O
an	O
intelligence	O
test	O
,	O
to	O
which	O
the	O
subjects	O
were	O
either	O
allowed	O
to	O
answer	O
successfully	O
(	O
success	O
)	O
or	O
not	O
(	O
failure	O
)	O
.	O

Failure	O
increased	O
the	O
subject	O
's	O
autonomic	Mental
arousal	Mental
,	Mental
as	O
measured	O
by	O
photoplethysmographic	O
sensors	O
,	O
in	O
all	O
stimulation	O
conditions	O
,	O
but	O
only	O
the	O
condition	O
with	O
aversive	O
stimulation	O
increased	O
the	O
speed	Mental
of	Mental
clenching	Mental
.	O

This	O
was	O
interpreted	O
as	O
indicating	O
subject	O
's	O
tendencies	Mental
to	Mental
aggression	Mental
.	O

These	O
results	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
effects	O
of	O
frustration	O
.	O

Effect	O
of	O
antipsychotic	O
drugs	O
on	O
cortical	Physical
thickness	Physical
.	Physical

A	O
randomized	O
controlled	O
one-year	O
follow-up	O
study	O
of	O
haloperidol	O
,	O
risperidone	O
and	O
olanzapine	O
.	O

BACKGROUND	O
Imaging	O
evidence	O
indicates	O
that	O
brain	O
alterations	O
are	O
primary	O
to	O
the	O
full-blown	O
onset	O
of	O
schizophrenia	O
and	O
seem	O
to	O
progress	O
across	O
time	O
.	O

The	O
potential	O
effects	Others
of	Others
antipsychotic	Others
medication	Others
on	O
brain	O
structure	O
represent	O
a	O
key	O
factor	O
in	O
understanding	O
brain	O
changes	O
in	O
psychosis	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
low	O
doses	O
of	O
haloperidol	O
,	O
risperidone	O
and	O
olanzapine	O
on	O
cortical	Physical
thickness	Physical
.	O

METHOD	O
We	O
investigated	O
the	O
effects	O
of	O
risperidone	O
(	O
N=16	O
)	O
,	O
olanzapine	O
(	O
N=18	O
)	O
and	O
low	O
doses	O
of	O
haloperidol	O
(	O
N=18	O
)	O
in	O
cortical	O
thickness	O
changes	O
during	O
1-year	O
follow-up	O
period	O
in	O
a	O
large	O
and	O
heterogeneous	O
sample	O
of	O
schizophrenia	O
spectrum	O
patients	O
.	O

The	O
relationship	O
between	O
cortical	Physical
thickness	Physical
changes	Physical
and	O
clinical	Physical
and	O
cognitive	Mental
outcome	Mental
was	O
also	O
assessed	O
.	O

A	O
group	O
of	O
45	O
healthy	O
volunteers	O
was	O
also	O
longitudinally	O
evaluated	O
.	O

Magnetic	O
resonance	O
imaging	O
brain	O
scans	O
(	O
1.5T	O
)	O
were	O
obtained	O
and	O
images	O
were	O
analyzed	O
by	O
using	O
BRAINS2	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
effects	O
of	O
time	O
(	O
F	O
(	O
1,47	O
)	O
<	O
1.66	O
;	O
P	O
>	O
0.204	O
)	O
,	O
treatment	O
group	O
(	O
F	O
(	O
2,47	O
)	O
<	O
1.47	O
;	O
P	O
>	O
0.242	O
)	O
or	O
group-by-time	O
interaction	O
(	O
F	O
(	O
2,47	O
)	O
<	O
1.82	O
;	O
P	O
>	O
0.174	O
)	O
for	O
any	O
of	O
the	O
cortical	Physical
thickness	Physical
variables	Physical
.	Physical

When	O
the	O
group	O
of	O
healthy	O
controls	O
was	O
included	O
in	O
the	O
analyses	O
,	O
it	O
is	O
of	O
note	O
that	O
group-by-time	O
interaction	O
showed	O
a	O
significant	O
result	O
for	O
the	O
frontal	O
lobe	O
at	O
trend	O
level	O
(	O
F	O
(	O
3,81	O
)	O
=2.686	O
;	O
P=0.052	O
)	O
.	O

After	O
the	O
Bonferroni	O
adjustment	O
for	O
multiple	O
comparisons	O
,	O
there	O
were	O
no	O
significant	O
associations	O
between	O
changes	Physical
in	Physical
cortical	Physical
thickness	Physical
and	O
clinical	O
and	O
cognitive	O
outcome	O
.	O

CONCLUSIONS	O
Low	O
doses	O
of	O
haloperidol	O
,	O
risperidone	O
,	O
and	O
olanzapine	O
seem	O
to	O
equally	O
affect	O
gray	Physical
matter	Physical
cortical	Physical
thickness	Physical
,	Physical
overall	Physical
and	Physical
lobes	Physical
,	O
at	O
the	O
medium-term	O
(	O
1	O
year	O
)	O
.	O

The	O
clinical	O
effectiveness	O
of	O
treatments	O
was	O
not	O
significantly	O
related	O
to	O
changes	O
in	O
cortical	Physical
thickness	Physical
.	O

The	O
efficacy	O
of	O
audiotapes	O
in	O
promoting	Mental
psychological	Mental
well-being	Mental
in	O
cancer	O
patients	O
:	O
a	O
randomised	O
,	O
controlled	O
trial	O
.	O

Open	O
or	O
uncontrolled	O
studies	O
have	O
suggested	O
that	O
providing	O
cancer	O
patients	O
with	O
audiotapes	O
of	O
their	O
clinical	O
interviews	O
can	O
improve	O
information	Mental
recall	Mental
and	O
reduce	O
psychological	Mental
distress	Mental
.	O

We	O
tested	O
these	O
hypotheses	O
in	O
a	O
'clinician-blind	O
'	O
,	O
prospective	O
,	O
randomised	O
controlled	O
trial	O
.	O

A	O
total	O
of	O
117	O
patients	O
newly	O
referred	O
to	O
a	O
medical	O
oncology	O
clinic	O
who	O
were	O
to	O
be	O
given	O
'bad	O
news	O
'	O
had	O
their	O
consultations	O
audiotaped	O
.	O

Blind	O
to	O
the	O
clinician	O
,	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
a	O
copy	O
of	O
the	O
tape	O
to	O
play	O
at	O
home	O
or	O
not	O
(	O
control	O
group	O
)	O
.	O

At	O
6	O
months	O
follow-up	O
,	O
tape	O
group	O
patients	O
reported	O
positive	Mental
attitudes	Mental
to	O
the	O
audiotape	O
and	O
were	O
shown	O
to	O
recall	Mental
significantly	Mental
more	Mental
information	Mental
about	Mental
their	Mental
illness	Mental
than	O
did	O
controls	O
.	O

Overall	O
improvement	O
in	O
psychological	Mental
distress	Mental
at	O
1	O
and	O
6	O
months	O
follow-up	O
,	O
as	O
measured	O
with	O
the	O
30-item	Mental
General	Mental
Health	Mental
Questionnaire	Mental
and	Mental
the	Mental
Hospital	Mental
Anxiety	Mental
and	Mental
Depression	Mental
Scale	Mental
was	O
no	O
different	O
in	O
the	O
two	O
groups	O
.	O

However	O
,	O
a	O
second-order	O
interaction	O
suggested	O
that	O
poor-prognosis	O
patients	O
were	O
disadvantaged	O
specifically	O
by	O
access	O
to	O
the	O
audiotape	O
,	O
with	O
less	O
improvement	O
in	O
psychological	Mental
distress	Mental
at	O
6	O
months	O
follow-up	O
than	O
non-tape	O
controls	O
.	O

Patient	O
access	O
to	O
audiotapes	O
of	O
clinical	O
interviews	O
promotes	O
factual	Mental
retention	Mental
but	O
does	O
not	O
reliably	O
reduce	O
psychological	Mental
distress	Mental
and	O
may	O
be	O
actively	O
unhelpful	O
in	O
some	O
subgroups	O
of	O
patients	O
.	O

Investigation	O
of	O
erosion	Physical
and	O
abrasion	Physical
on	O
enamel	Physical
and	Physical
dentine	Physical
:	O
a	O
model	O
in	O
situ	O
using	O
toothpastes	O
of	O
different	O
abrasivity	O
.	O

BACKGROUND	O
Studies	O
in	O
vitro	O
suggest	O
that	O
abrasion	Physical
and	O
erosion	Physical
may	O
act	O
synergistically	O
to	O
produce	O
wear	Physical
of	Physical
enamel	Physical
and	Physical
dentine	Physical
.	O

Methods	O
in	O
situ	O
are	O
recently	O
available	O
to	O
study	O
separately	O
erosion	Physical
and	O
abrasion	Physical
of	O
dental	Physical
tissues	Physical
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
combine	O
two	O
in	O
situ	O
protocols	O
to	O
study	O
the	O
interplay	O
between	O
erosion	Physical
and	O
abrasion	Physical
of	O
enamel	Physical
and	O
dentine	Physical
.	O

METHOD	O
The	O
study	O
was	O
a	O
single-blind	O
,	O
randomised	O
,	O
five-treatment	O
cross-over	O
design	O
involving	O
15	O
healthy	O
volunteers	O
.	O

During	O
each	O
10-day	O
study	O
period	O
,	O
subjects	O
wore	O
from	O
0900	O
to	O
1700	O
h	O
an	O
upper	O
removable	O
acrylic	O
appliance	O
holding	O
one	O
polished	O
enamel	O
and	O
one	O
polished	O
dentine	O
specimen	O
.	O

The	O
specimen	O
treatment	O
regimens	O
were	O
:	O
1	O
.	O

Drinking	O
water	O
and	O
brushing	O
with	O
toothpaste	O
A	O
.	O

2	O
.	O

Drinking	O
water	O
and	O
brushing	O
with	O
toothpaste	O
B	O
.	O

3	O
.	O

Drinking	O
orange	O
juice	O
.	O

4	O
.	O

Drinking	O
orange	O
juice	O
and	O
brushing	O
with	O
toothpaste	O
A	O
.	O

5	O
.	O

Drinking	O
orange	O
juice	O
and	O
brushing	O
with	O
toothpaste	O
B	O
.	O

Drinking	O
and	O
brushing	O
times	O
were	O
around	O
0900	O
,	O
1100	O
,	O
1300	O
and	O
1500	O
h.	O
Drinks	O
were	O
consumed	O
as	O
250	O
ml	O
over	O
10	O
min	O
and	O
brushing	O
ex	O
vivo	O
for	O
1	O
min	O
to	O
each	O
specimen	O
.	O

Measurement	O
of	O
tissue	Physical
loss	Physical
was	O
made	O
on	O
days	O
5	O
and	O
10	O
of	O
each	O
period	O
using	O
a	O
profilometer	O
.	O

RESULTS	O
All	O
treatments	O
produced	O
increasing	O
tissue	Physical
loss	Physical
over	Physical
time	Physical
,	O
which	O
was	O
considerably	O
greater	O
for	O
dentine	O
than	O
enamel	O
.	O

For	O
enamel	O
,	O
the	O
data	O
at	O
days	O
5	O
and	O
10	O
showed	O
a	O
significant	O
effect	O
for	O
erosion	Physical
(	O
i.e	O
.	O

orange	O
juice	O
was	O
significantly	O
more	O
erosive	O
than	O
water	O
)	O
,	O
but	O
no	O
significant	O
effect	O
for	O
abrasion	Physical
(	O
i.e	O
.	O

no	O
significant	O
difference	O
between	O
the	O
two	O
toothpaste	O
treatments	O
)	O
.	O

The	O
combined	O
orange	O
juice	O
and	O
toothpaste	O
effects	O
were	O
directional	O
for	O
synergy	O
but	O
did	O
not	O
reach	O
significance	O
.	O

For	O
dentine	O
at	O
day	O
10	O
,	O
many	O
specimens	O
exceeded	O
the	O
50	O
microm	O
set	O
limit	O
of	O
the	O
profilometer	O
and	O
only	O
day	O
5	O
data	O
were	O
considered	O
.	O

There	O
were	O
significant	O
effects	O
for	O
erosion	Physical
(	O
orange	O
juice	O
produced	O
significantly	O
more	O
erosion	O
than	O
water	O
)	O
and	O
for	O
abrasion	Physical
(	O
paste	O
A	O
was	O
significantly	O
more	O
abrasive	O
to	O
dentine	O
than	O
paste	O
B	O
)	O
.	O

The	O
synergy	Physical
effect	Physical
could	O
not	O
be	O
examined	O
for	O
dentine	O
due	O
to	O
the	O
truncation	O
effect	O
as	O
the	O
set	O
limit	O
of	O
the	O
profilometer	O
was	O
exceeded	O
.	O

CONCLUSIONS	O
Erosion	O
increases	O
the	O
susceptibility	Physical
of	Physical
enamel	Physical
to	O
toothpaste	Physical
abrasion	Physical
.	O

Dentine	O
is	O
considerably	O
more	O
susceptible	O
than	O
enamel	O
to	O
erosion	Physical
and	O
abrasion	Physical
alone	O
or	O
combined	O
.	O

Dentine	Physical
loss	Physical
appears	O
to	O
correlate	O
with	O
toothpaste	O
abrasivity	O
(	O
RDA	O
value	O
)	O
.	O

Study	O
of	O
cytosine	O
arabinoside	O
(	O
NSC-63878	O
)	O
synchronization	O
plus	O
vincristine	O
(	O
NSC-67574	O
)	O
,	O
prednisone	O
(	O
NSC-10023	O
)	O
,	O
and	O
L-asparaginase	O
(	O
NSC-109229	O
)	O
for	O
remission	O
induction	O
in	O
advanced	O
acute	O
leukemia	O
in	O
children	O
.	O

Cytosine	O
arabinoside	O
(	O
CA	O
)	O
was	O
utilized	O
in	O
efforts	O
to	O
synchronize	O
leukemic	O
cells	O
in	O
DNA	O
synthesis	O
for	O
treatment	O
with	O
vincristine	O
,	O
prednisone	O
,	O
and	O
L-asparaginase	O
in	O
children	O
with	O
acute	O
leukemia	O
in	O
relapse	O
.	O

The	O
results	O
did	O
not	O
indicate	O
any	O
therapeutic	Physical
advantage	Physical
for	O
patients	O
treated	O
with	O
this	O
combination	O
compared	O
to	O
those	O
treated	O
without	O
any	O
attempt	O
at	O
CA	O
synchronization	O
.	O

Mass	O
inoculation	O
in	O
a	O
community	O
:	O
the	O
effect	O
of	O
primary	O
prevention	O
of	O
stress	Mental
reactions	Mental
.	O

This	O
study	O
assessed	O
the	O
effectiveness	O
of	O
a	O
brief	O
,	O
situation-specific	O
,	O
group-administered	O
preparatory	O
intervention	O
in	O
a	O
nonclient	O
school	O
population	O
undergoing	O
mass	O
inoculation	O
against	O
rubella	O
.	O

Fifty-one	O
girls	O
were	O
randomly	O
assigned	O
to	O
practice	O
,	O
no-practice	O
,	O
or	O
control	O
groups	O
.	O

Both	O
the	O
practice	O
and	O
the	O
no-practice	O
groups	O
received	O
information	O
that	O
described	O
the	O
inoculation	O
procedure	O
and	O
how	O
to	O
cope	O
with	O
it	O
by	O
using	O
cognitive-behavioral	O
coping	O
skills	O
.	O

The	O
practice	O
group	O
was	O
encouraged	O
to	O
perform	O
coping	O
techniques	O
of	O
this	O
type	O
,	O
whereas	O
the	O
no-practice	O
group	O
was	O
told	O
only	O
that	O
the	O
intervention	O
would	O
help	O
them	O
during	O
the	O
inoculation	O
.	O

Subjects	O
in	O
both	O
practice	O
and	O
no-practice	O
groups	O
reported	O
less	O
anxiety	Mental
and	O
exhibited	O
more	O
cooperative	Mental
behavior	Mental
during	O
inoculation	O
than	O
subjects	O
in	O
the	O
control	O
group	O
,	O
and	O
those	O
who	O
were	O
guided	O
and	O
prompted	O
to	O
actively	O
practice	O
derived	O
greater	O
benefit	O
.	O

Diet	O
and	O
tobacco	O
use	O
:	O
analysis	O
of	O
data	O
from	O
the	O
diabetic	O
control	O
and	O
complications	O
trial	O
,	O
a	O
randomized	O
study	O
.	O

CONTEXT	O
The	O
Diabetic	O
Control	O
and	O
Complications	O
Trial	O
(	O
DCCT	O
)	O
researchers	O
kept	O
careful	O
records	O
of	O
the	O
food	O
consumption	O
and	O
tobacco	O
using	O
habits	O
of	O
type	O
1	O
diabetic	O
subjects	O
.	O

However	O
,	O
they	O
did	O
not	O
report	O
the	O
relationship	O
of	O
tobacco	Mental
using	Mental
habits	Mental
with	O
dietary	Mental
intake	Mental
.	O

OBJECTIVE	O
Analyze	O
the	O
relationship	Physical
between	Physical
tobacco	Mental
smoking	Mental
and	Physical
intake	Mental
of	Mental
macro	Mental
and	Mental
micronutrients	Mental
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Referral	O
clinics	O
in	O
27	O
academic	O
centers	O
.	O

PATIENTS	O
Type	O
1	O
diabetics	O
.	O

INTERVENTION	O
Using	O
the	O
data	O
sets	O
of	O
the	O
DCCT	O
,	O
this	O
study	O
analyzed	O
the	O
strengths	O
of	O
the	O
associations	O
between	O
smoking	O
and	O
macronutrient	Physical
consumption	Physical
,	O
hemoglobin	Physical
A1c	Physical
(	Physical
HbA1c	Physical
)	Physical
,	O
body	Physical
mass	Physical
index	Physical
(	Physical
BMI	Physical
)	Physical
,	O
and	O
serum	Physical
lipid	Physical
levels	Physical
at	O
the	O
study	O
baseline	O
,	O
2	O
years	O
,	O
and	O
4	O
years	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Statistically	O
significant	O
correlations	O
between	O
smoking	O
and	O
nutrient	Others
intake	Others
,	O
HbA1c	Physical
,	O
and	O
serum	Physical
lipid	Physical
levels	Physical
.	O

RESULTS	O
Cigarette	Mental
,	Mental
cigar	Mental
,	Mental
or	Mental
pipe	Mental
use	Mental
at	O
each	O
time	O
interval	O
correlated	O
with	O
significantly	O
increased	O
caloric	Physical
intake	Physical
in	O
males	O
but	O
not	O
in	O
females	O
.	O

In	O
both	O
males	O
and	O
females	O
,	O
tobacco	Physical
users	Physical
consumed	Physical
more	Physical
fat	Mental
,	Mental
cholesterol	Mental
,	Mental
and	Mental
alcohol	Mental
.	O

Female	O
smokers	O
had	O
higher	O
serum	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
/high-density	O
lipoprotein	O
(	O
HDL	O
)	O
ratios	O
and	O
triglycerides	O
.	O

Serum	Physical
cholesterols	Physical
,	O
LDL/HDL	Physical
ratios	Physical
,	O
LDL	Physical
cholesterols	Physical
,	O
and	O
triglyceride	Physical
determinations	Physical
in	O
male	O
tobacco	O
users	O
significantly	O
exceeded	O
those	O
in	O
nonsmoking	O
males	O
.	O

HDL	Physical
cholesterols	Physical
were	O
lower	O
in	O
both	O
female	O
and	O
male	O
tobacco	O
users	O
.	O

Nutrient	Mental
intake	Mental
of	O
former	O
tobacco	O
users	O
resembled	O
that	O
of	O
nonusers	O
rather	O
than	O
current	O
users	O
.	O

CONCLUSIONS	O
A	O
significant	O
association	O
exists	O
between	O
smoking	O
and	O
a	O
diet	Physical
with	Physical
higher	Physical
risks	Physical
of	Physical
atherosclerosis	Physical
,	Physical
cancer	Physical
,	Physical
and	Physical
other	Physical
degenerative	Physical
diseases	Physical
.	O

The	O
strong	O
association	O
of	O
tobacco	O
with	O
heart	O
disease	O
,	O
stroke	O
,	O
vasculopathies	O
,	O
and	O
various	O
malignancies	O
may	O
be	O
in	O
part	O
due	O
to	O
its	O
association	O
with	O
a	O
higher	O
fat	O
diet	O
.	O

The	O
higher	O
fat	O
diet	O
of	O
tobacco	O
users	O
probably	O
accounts	O
in	O
part	O
for	O
their	O
higher	O
risk	O
of	O
developing	O
type	O
2	O
diabetes	O
and	O
hyperlipidemia	O
.	O

Tobacco	O
users	O
should	O
be	O
informed	O
about	O
the	O
diet	Mental
and	O
tobacco	Mental
use	Mental
association	O
.	O

Effect	O
of	O
indomethacin	O
phonophoresis	O
on	O
the	O
relief	O
of	O
temporomandibular	O
joint	O
pain	O
.	O

The	O
pain-relieving	Pain
effect	Pain
of	O
indomethacin	O
phonophoresis	O
on	O
temporomandibular	Pain
(	Pain
TMJ	Pain
)	Pain
joint	Pain
pain	Pain
was	O
evaluated	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

Twenty	O
subjects	O
,	O
who	O
have	O
TMJ	O
pain	O
,	O
were	O
included	O
for	O
this	O
study	O
and	O
randomly	O
assigned	O
to	O
either	O
the	O
experimental	O
group	O
(	O
n	O
=	O
10	O
)	O
or	O
the	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
.	O

Each	O
treatment	O
consisted	O
of	O
the	O
application	O
of	O
ultrasound	O
massage	O
(	O
1.0	O
MHz	O
,	O
0.8	O
to	O
1.5	O
W/cm2	O
continuous	O
output	O
)	O
for	O
15	O
minutes	O
to	O
the	O
painful	O
temporomandibular	O
joint	O
.	O

As	O
a	O
conducting	O
medium	O
,	O
1	O
%	O
indomethacin	O
cream	O
was	O
used	O
for	O
the	O
experimental	O
group	O
and	O
placebo	O
cream	O
for	O
the	O
control	O
group	O
respectively	O
.	O

Pre-	O
and	O
post-treatment	O
pain	Pain
levels	Pain
and	Pain
pain	Pain
sensitivity	Pain
were	O
assessed	O
with	O
visual	Physical
analogue	Physical
scales	Physical
(	Physical
VAS	Physical
)	Physical
and	O
pressure	Pain
pain	Pain
threshold	Pain
(	Pain
PPT	Pain
)	Pain
.	Pain

Mean	O
data	O
indicated	O
that	O
post-treatment	Physical
VAS	Physical
was	O
significantly	O
decreased	O
and	O
post-treatment	Pain
PPT	Pain
was	O
significantly	O
increased	O
in	O
the	O
experimental	O
group	O
,	O
not	O
in	O
the	O
control	O
group	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
indomethacin	O
phonophoresis	O
provides	O
significant	O
pain	Pain
relieving	O
effect	O
over	O
the	O
TMJ	O
pain	O
.	O

Aripiprazole	O
treatment	O
of	O
irritability	O
associated	O
with	O
autistic	O
disorder	O
and	O
the	O
relationship	O
between	O
prior	O
antipsychotic	O
exposure	O
,	O
adverse	O
events	O
,	O
and	O
weight	O
change	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
prior	O
antipsychotic	O
exposure	O
(	O
PAE	O
)	O
on	O
safety	Others
and	Others
tolerability	Others
outcomes	Others
in	O
pediatric	O
subjects	O
receiving	O
aripiprazole	O
treatment	O
.	O

METHODS	O
This	O
study	O
was	O
a	O
post-hoc	O
analysis	O
of	O
pooled	O
data	O
from	O
two	O
8-week	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
studies	O
evaluating	O
aripiprazole	O
for	O
the	O
treatment	O
of	O
irritability	O
in	O
pediatric	O
subjects	O
with	O
autistic	O
disorder	O
,	O
aged	O
6-17	O
years	O
.	O

Subjects	O
were	O
stratified	O
by	O
PAE	O
;	O
adverse	O
events	O
(	O
AEs	O
)	O
,	O
and	O
changes	O
in	O
weight	O
,	O
and	O
metabolic	O
measures	O
were	O
evaluated	O
.	O

For	O
subjects	O
receiving	O
aripiprazole	O
,	O
regardless	O
of	O
PAE	O
,	O
baseline	O
weight	O
,	O
age	O
,	O
gender	O
,	O
and	O
symptom	O
severity	O
were	O
evaluated	O
in	O
a	O
regression	O
model	O
predicting	O
body	O
weight	O
change	O
.	O

RESULTS	O
Of	O
316	O
randomized	O
subjects	O
,	O
259	O
(	O
82.0	O
%	O
)	O
were	O
antipsychotic	O
na?ve	O
(	O
AN	O
)	O
and	O
57	O
(	O
18.0	O
%	O
)	O
had	O
a	O
PAE	O
.	O

Aripiprazole-treated	O
AN	O
subjects	O
were	O
more	O
likely	O
than	O
PAE	O
subjects	O
to	O
report	O
somnolence	O
(	O
11.9	O
%	O
vs.	O
2.8	O
%	O
)	O
,	O
sedation	O
(	O
22.7	O
%	O
vs.	O
11.1	O
%	O
)	O
,	O
or	O
fatigue	O
(	O
17.0	O
%	O
vs.	O
13.9	O
%	O
)	O
.	O

Rates	O
of	O
extrapyramidal	O
disorder	O
and	O
drooling	O
,	O
but	O
not	O
akathisia	O
or	O
tremor	O
,	O
were	O
marginally	O
higher	O
in	O
AN	O
subjects	O
.	O

Overall	O
,	O
10.8	O
%	O
of	O
aripiprazole-treated	O
AN	O
subjects	O
had	O
at	O
least	O
one	O
AE	O
leading	O
to	O
discontinuation	O
compared	O
with	O
8.3	O
%	O
of	O
aripiprazole-treated	O
PAE	O
subjects	O
.	O

AN	O
subjects	O
receiving	O
aripiprazole	O
had	O
a	O
larger	O
change	O
in	O
weight	O
from	O
baseline	O
to	O
endpoint	O
compared	O
with	O
those	O
receiving	O
placebo	O
(	O
1.9	O
vs.	O
0.7	O
kg	O
;	O
treatment	O
difference	O
1.2	O
kg	O
,	O
95	O
%	O
CI	O
:	O
0.5	O
,	O
1.9	O
)	O
than	O
PAE	O
subjects	O
receiving	O
aripiprazole	O
compared	O
with	O
subjects	O
receiving	O
placebo	O
(	O
0.4	O
vs.	O
-0.4	O
kg	O
;	O
treatment	O
difference	O
0.9	O
kg	O
,	O
95	O
%	O
CI	O
:	O
-0.6	O
,	O
2.4	O
)	O
.	O

Regression	O
analysis	O
identified	O
that	O
younger	O
subjects	O
with	O
higher	O
baseline	O
weight	O
z-score	O
were	O
at	O
highest	O
risk	O
for	O
weight	O
gain	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
metabolic	O
measures	O
compared	O
with	O
placebo	O
in	O
either	O
group	O
.	O

CONCLUSIONS	O
Weight	O
gain	O
was	O
more	O
pronounced	O
in	O
AN	O
subjects	O
and	O
more	O
likely	O
to	O
occur	O
in	O
younger	O
subjects	O
with	O
a	O
higher	O
baseline	O
weight	O
z-score	O
.	O

AN	O
subjects	O
were	O
more	O
likely	O
to	O
experience	O
AEs	O
related	O
to	O
somnolence	O
.	O

However	O
,	O
based	O
on	O
discontinuations	O
rates	O
from	O
AEs	O
,	O
overall	O
tolerability	O
was	O
good	O
for	O
both	O
AN	O
and	O
PAE	O
groups	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
Study	O
of	O
aripiprazole	O
in	O
the	O
treatment	O
of	O
children	O
and	O
adolescents	O
with	O
autistic	O
disorder	O
.	O

Registry	O
:	O
www.clinicaltrials.gov	O
.	O

Identifiers	O
:	O
NCT00332241	O
and	O
NCT00337571	O
.	O

Why	O
the	O
prone	O
position	O
is	O
a	O
risk	O
factor	O
for	O
sudden	O
infant	O
death	O
syndrome	O
.	O

INTRODUCTION	O
The	O
laryngeal	O
chemoreflex	O
may	O
explain	O
why	O
prone	O
sleeping	O
increases	O
the	O
risk	O
of	O
sudden	O
infant	O
death	O
syndrome	O
(	O
SIDS	O
)	O
.	O

Swallowing	O
and	O
arousal	O
are	O
crucial	O
to	O
prevent	O
laryngeal	O
chemoreflex	O
stimulation	O
.	O

Our	O
aim	O
was	O
to	O
examine	O
these	O
reflexes	Physical
and	Physical
breathing	Physical
responses	Physical
in	O
healthy	O
neonates	O
after	O
pharyngeal	O
infusion	O
of	O
water	O
in	O
the	O
supine	O
versus	O
the	O
prone	O
position	O
,	O
controlling	O
for	O
sleep	O
state	O
.	O

METHODS	O
A	O
total	O
of	O
10	O
term	O
infants	O
were	O
recruited	O
after	O
parental	O
consent	O
and	O
ethics	O
approval	O
.	O

Polygraphic	O
recordings	O
included	O
sleep	Physical
state	Physical
(	Physical
active	Physical
and	Physical
quiet	Physical
sleep	Physical
by	Physical
electroencephalogram	Physical
,	Physical
eye	Physical
movements	Physical
,	Physical
breathing	Physical
,	Physical
and	Physical
behavior	Mental
)	Physical
,	Physical
cardiorespiratory	Physical
measurements	Physical
(	Physical
nasal	Physical
airflow	Physical
,	Physical
chest	Physical
wall	Physical
movements	Physical
,	Physical
heart	Physical
rate	Physical
,	Physical
and	Physical
oxygen	Physical
saturation	Physical
)	Physical
,	Physical
swallowing	Physical
,	Physical
and	Physical
esophageal	Physical
activity	Physical
(	Physical
solid	Physical
state	Physical
pressure	Physical
catheter	Physical
)	Physical
.	O

Initial	O
sleeping	O
position	O
was	O
assigned	O
randomly	O
.	O

Measurements	O
were	O
made	O
for	O
1	O
minute	O
before	O
and	O
after	O
0.4	O
mL	O
of	O
water	O
was	O
instilled	O
into	O
the	O
oropharynx	O
.	O

To	O
detect	O
a	O
30	O
%	O
decrease	O
in	O
swallowing	Physical
,	O
power	O
analysis	O
indicated	O
that	O
>	O
/=10	O
babies	O
were	O
required	O
.	O

Analysis	O
,	O
blinded	O
to	O
position	O
,	O
was	O
made	O
using	O
nonparametric	O
statistics	O
.	O

RESULTS	O
Of	O
the	O
164	O
infusions	O
,	O
the	O
most	O
commonly	O
evoked	O
airway	O
protective	O
responses	O
to	O
pharyngeal	O
infusion	O
were	O
swallowing	Physical
(	O
95	O
%	O
)	O
and	O
arousal	Physical
(	O
54	O
%	O
)	O
.	O

After	O
infusion	O
in	O
active	O
sleep	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
swallowing	Physical
and	Physical
breathing	Physical
when	O
the	O
prone	O
position	O
was	O
compared	O
with	O
the	O
supine	O
position	O
(	O
prone	O
:	O
21.3	O
[	O
1.0	O
]	O
swallows/min	Physical
and	O
-9.6	O
[	O
2.1	O
]	O
breaths/min	Physical
;	O
and	O
supine	O
:	O
32	O
(	O
2.2	O
)	O
and	O
-2	O
.	O

9	O
(	O
1.5	O
)	O
,	O
respectively	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
occurrence	O
of	O
arousal	Physical
after	O
water	O
infusion	O
.	O

CONCLUSION	O
These	O
data	O
suggest	O
that	O
airway	O
protection	O
is	O
compromised	O
in	O
the	O
prone	O
sleeping	O
position	O
during	O
active	O
sleep	O
,	O
even	O
in	O
healthy	O
infants	O
exposed	O
to	O
minute	O
pharyngeal	O
fluid	O
volumes	O
of	O
0.4	O
mL	O
.	O

This	O
is	O
because	O
swallowing	Physical
rate	Physical
is	O
reduced	O
significantly	O
,	O
and	O
there	O
is	O
no	O
compensatory	O
increase	O
in	O
arousal	Physical
.	O

The	O
reduction	O
in	O
airway	Physical
protective	Physical
reflexes	Physical
when	O
in	O
the	O
prone	O
position	O
and	O
in	O
active	O
sleep	O
may	O
be	O
the	O
mechanism	O
for	O
the	O
increased	O
risk	O
of	O
SIDS	O
in	O
the	O
prone	O
position	O
.	O

[	O
A	O
randomized	O
study	O
of	O
prophylactic	O
intravesical	O
instillation	O
of	O
pirarubicin	O
(	O
THP	O
)	O
prior	O
to	O
transurethral	O
resection	O
of	O
superficial	Physical
bladder	Physical
cancer	Physical
]	O
.	O

A	O
prospective	O
randomized	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
efficacy	O
of	O
prophylactic	O
intravesical	O
instillation	O
of	O
pirarubicin	O
(	O
THP	O
)	O
prior	O
to	O
transurethral	Physical
resection	Physical
(	Physical
TUR	Physical
)	Physical
of	Physical
superficial	Physical
bladder	Physical
cancer	Physical
.	Others

A	O
total	O
of	O
63	O
patients	O
were	O
randomized	O
into	O
two	O
groups	O
,	O
the	O
THP	O
group	O
and	O
the	O
control	O
group	O
.	O

In	O
the	O
THP	O
group	O
,	O
30	O
mg	O
of	O
THP	O
dissolved	O
in	O
50	O
ml	O
saline	O
was	O
administered	O
4	O
times	O
intravesically	O
for	O
4	O
consecutive	O
days	O
before	O
TUR	O
.	O

In	O
the	O
control	O
group	O
,	O
no	O
instillation	O
was	O
performed	O
before	O
TUR	O
.	O

The	O
patients	O
were	O
followed	O
by	O
cystoscopy	O
and	O
urinary	O
cytology	O
every	O
3	O
months	O
.	O

The	O
non-recurrence	Others
rates	Others
in	O
the	O
THP	O
group	O
and	O
control	O
group	O
were	O
54.1	O
%	O
versus	O
37.6	O
%	O
at	O
1	O
year	O
and	O
40.4	O
%	O
versus	O
26.8	O
%	O
at	O
2	O
years	O
,	O
respectively	O
(	O
P	O
=	O
0.086	O
)	O
.	O

Time	Physical
to	Physical
recurrence	Physical
for	Physical
tumors	Physical
larger	Physical
than	Physical
1	Physical
cm	Physical
was	O
significantly	O
longer	O
in	O
the	O
THP	O
group	O
(	O
P	O
=	O
0.0137	O
)	O
.	O

Time	Physical
to	Physical
recurrence	Physical
for	Physical
single	Physical
and	Physical
grade	Physical
1+2	Physical
tumors	Physical
tended	O
to	O
be	O
longer	O
in	O
the	O
THP	O
group	O
(	O
P	O
=	O
0.09	O
,	O
P	O
=	O
0.079	O
)	O
.	O

No	O
significant	O
adverse	Adverseeffect
effects	Adverseeffect
were	O
observed	O
in	O
any	O
patient	O
.	O

Our	O
findings	O
suggest	O
that	O
intravesical	O
THP	O
instillation	O
prior	O
to	O
TUR	O
would	O
be	O
effective	Others
for	O
patients	O
with	O
single	Physical
,	Physical
low	Physical
grade	Physical
lesions	Physical
larger	Physical
than	Physical
1	Physical
cm	Physical
of	O
superficial	Physical
bladder	Physical
cancer	Physical
.	O

The	O
additive	O
analgesic	O
efficacy	O
of	O
acetaminophen	O
,	O
1000	O
mg	O
,	O
and	O
codeine	O
,	O
60	O
mg	O
,	O
in	O
dental	O
pain	O
.	O

In	O
a	O
double-blind	O
,	O
randomized	O
,	O
single-dose	O
trial	O
the	O
analgesic	O
contribution	O
of	O
acetaminophen	O
,	O
1000	O
mg	O
,	O
and	O
codeine	O
,	O
60	O
mg	O
,	O
was	O
determined	O
.	O

The	O
study	O
was	O
a	O
2	O
X	O
2	O
factorial	O
experiment	O
in	O
which	O
120	O
patients	O
suffering	O
from	O
pain	O
as	O
a	O
result	O
of	O
oral	O
surgery	O
rated	O
their	O
pain	Pain
intensity	Pain
and	O
pain	Pain
relief	Pain
for	O
up	O
to	O
5	O
hours	O
after	O
a	O
single	O
dose	O
of	O
one	O
of	O
:	O
1000	O
mg	O
acetaminophen	O
,	O
60	O
mg	O
codeine	O
,	O
1000	O
mg	O
acetaminophen	O
plus	O
60	O
mg	O
codeine	O
,	O
or	O
placebo	O
.	O

The	O
factorial	O
analysis	O
showed	O
that	O
both	O
1000	O
mg	O
acetaminophen	O
and	O
60	O
mg	O
codeine	O
made	O
a	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0.05	O
)	O
contribution	O
to	O
the	O
analgesic	Others
effectiveness	Others
of	Pain
the	Pain
combination	Pain
on	Pain
all	Pain
measures	Pain
of	Pain
efficacy	Pain
(	O
sum	Pain
of	Pain
pain	Pain
intensity	Pain
differences	Pain
,	O
largest	Pain
pain	Pain
intensity	Pain
difference	Pain
,	O
total	Pain
pain	Pain
relief	Pain
,	O
largest	Pain
pain	Pain
relief	Pain
,	O
and	O
time	Pain
to	Pain
remedication	Pain
)	O
.	O

The	O
incidence	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
did	O
not	O
appear	O
to	O
differ	O
among	O
the	O
treatments	O
,	O
including	O
placebo	O
.	O

Optimum	O
frequency	O
of	O
exercise	O
for	O
bone	Physical
health	Physical
:	O
randomised	O
controlled	O
trial	O
of	O
a	O
high-impact	O
unilateral	O
intervention	O
.	O

INTRODUCTION	O
Exercise	O
can	O
increase	O
bone	Physical
strength	Physical
,	O
but	O
to	O
be	O
effective	O
in	O
reducing	O
fracture	Adverseeffect
risk	Adverseeffect
,	O
exercise	O
must	O
be	O
feasible	O
enough	O
to	O
be	O
adopted	O
into	O
daily	O
life	O
and	O
influence	O
potentially	O
vulnerable	O
skeletal	O
sites	O
such	O
as	O
the	O
superolateral	O
cortex	O
of	O
the	O
femoral	O
neck	O
,	O
where	O
thinning	O
is	O
associated	O
with	O
increased	O
fracture	Adverseeffect
risk	Adverseeffect
.	O

Brief	O
,	O
high-impact	O
exercise	O
increases	O
femoral	Physical
neck	Physical
bone	Physical
density	Physical
but	O
the	O
optimal	O
frequency	O
of	O
such	O
exercise	O
and	O
the	O
location	O
of	O
bone	O
accrual	O
is	O
unknown	O
.	O

This	O
study	O
thus	O
examined	O
(	O
1	O
)	O
the	O
effectiveness	O
of	O
different	O
weekly	O
frequencies	O
of	O
exercise	O
on	O
femoral	Physical
neck	Physical
BMD	Physical
and	O
(	O
2	O
)	O
whether	Physical
BMD	Physical
change	Physical
differed	Physical
between	Physical
hip	Physical
sites	Physical
using	O
a	O
high-impact	O
,	O
unilateral	O
intervention	O
.	O

METHODS	O
Healthy	O
premenopausal	O
women	O
were	O
randomly	O
assigned	O
to	O
exercise	O
0	O
,	O
2	O
,	O
4	O
,	O
or	O
7	O
days/week	O
for	O
6	O
months	O
.	O

The	O
exercise	O
intervention	O
incorporated	O
50	O
multidirectional	O
hops	O
on	O
one	O
randomly	O
selected	O
leg	O
.	O

BMD	Physical
was	O
measured	O
by	O
DXA	O
at	O
baseline	O
and	O
after	O
6	O
months	O
of	O
exercise	O
.	O

Changes	O
in	O
the	O
exercise	O
leg	O
were	O
compared	O
between	O
groups	O
using	O
ANCOVA	O
,	O
with	O
change	O
in	O
the	O
control	O
leg	O
and	O
baseline	O
BMD	O
as	O
covariates	O
.	O

RM-MANOVA	O
was	O
conducted	O
to	O
determine	O
whether	O
bone	Physical
changes	Physical
from	O
exercise	O
differed	O
between	O
hip	O
sites	O
.	O

RESULTS	O
61	O
women	O
(	O
age	O
33.6+/-11.1	O
years	O
)	O
completed	O
the	O
intervention	O
.	O

Compliance	O
amongst	O
exercisers	O
was	O
86.7+/-10.6	O
%	O
.	O

Peak	Physical
ground	Physical
reaction	Physical
forces	Physical
during	O
exercise	O
increased	O
from	O
2.5	O
to	O
2.8	O
times	O
body	O
weight	O
.	O

The	O
change	Physical
in	Physical
femoral	Physical
neck	Physical
BMD	Physical
in	O
the	O
exercise	O
limb	O
(	O
adjusted	O
for	O
change	O
in	O
the	O
control	O
limb	O
and	O
baseline	O
BMD	O
)	O
differed	O
between	O
groups	O
(	O
p=0.015	O
)	O
,	O
being	O
-0.3	O
%	O
(	O
-1.2	O
to	O
0.6	O
)	O
,	O
0.0	O
%	O
(	O
-1.0	O
to	O
1.0	O
)	O
,	O
0.9	O
%	O
(	O
-0.1	O
to	O
2.0	O
)	O
and	O
1.8	O
%	O
(	O
0.8	O
to	O
2.8	O
)	O
in	O
those	O
exercising	O
0	O
,	O
2	O
,	O
4	O
and	O
7	O
days	O
per	O
week	O
,	O
respectively	O
.	O

When	O
BMD	Physical
changes	Physical
at	Physical
upper	Physical
neck	Physical
,	Physical
lower	Physical
neck	Physical
and	Physical
trochanter	Physical
were	O
compared	O
using	O
RM-MANOVA	O
,	O
a	O
significant	O
exercise	O
effect	O
was	O
observed	O
(	O
p=0.048	O
)	O
,	O
but	O
this	O
did	O
not	O
differ	O
significantly	O
between	O
sites	O
(	O
p=0.439	O
)	O
despite	O
greatest	O
mean	O
increases	O
at	O
the	O
upper	O
femoral	O
neck	O
.	O

CONCLUSIONS	O
Brief	O
,	O
daily	O
hopping	O
exercises	O
increased	O
femoral	Physical
neck	Physical
BMD	Physical
in	O
premenopausal	O
women	O
but	O
less	O
frequent	O
exercise	O
was	O
not	O
effective	O
.	O

Brief	O
high-impact	O
exercise	O
may	O
have	O
a	O
role	O
in	O
reducing	O
hip	Physical
fragility	Physical
,	O
but	O
may	O
need	O
to	O
be	O
performed	O
frequently	O
for	O
optimal	O
response	O
.	O

[	O
Combined	O
preoperative	O
xeloda	O
and	O
radiotherapy	O
for	O
lower	O
rectal	O
cancer	O
]	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
combined	O
preoperative	O
xeloda	O
and	O
pelvic	O
radiotherapy	O
on	O
locally	O
advanced	O
lower	O
rectal	O
cancer	O
.	O

METHODS	O
Sixty	O
lower	O
rectal	O
cancer	O
patients	O
were	O
divided	O
randomly	O
into	O
two	O
groups	O
.	O

30	O
patients	O
(	O
Group	O
A	O
)	O
were	O
treated	O
with	O
operation	O
alone	O
and	O
30	O
patients	O
(	O
Group	O
B	O
)	O
were	O
treated	O
with	O
xeloda	O
and	O
radiotherapy	O
before	O
operation	O
.	O

RESULTS	O
The	O
operative	Others
resection	Others
,	Others
anal	Physical
preservation	Physical
and	Others
local	Others
recurrence	Others
rates	Others
were	O
86.66	O
%	O
,	O
33.33	O
%	O
,	O
15.38	O
%	O
in	O
group	O
A	O
and	O
100	O
%	O
,	O
83.33	O
%	O
,	O
0	O
%	O
in	O
group	O
B	O
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
Combined	O
preoperative	O
xeloda	O
and	O
radiotherapy	O
for	O
lower	O
rectal	O
cancer	O
is	O
able	O
to	O
significantly	O
improve	O
the	O
operative	O
resection	O
,	O
anal	O
preservation	O
and	O
decrease	O
the	O
local	O
recurrence	O
rates	O
.	O

Immunotherapy	O
using	O
BCG	O
during	O
remission	O
induction	O
and	O
as	O
the	O
sole	O
form	O
of	O
maintenance	O
in	O
acute	O
myeloid	O
leukaemia	O
.	O

Thirty-two	O
adults	O
with	O
acute	O
myeloid	O
leukaemia	O
(	O
AML	O
)	O
were	O
randomized	O
to	O
receive	O
,	O
from	O
the	O
time	O
of	O
diagnosis	O
,	O
either	O
chemotherapy	O
alone	O
(	O
C	O
group	O
)	O
or	O
chemotherapy	O
plus	O
Bacille	O
Calmette-Gu?rin	O
vaccine	O
(	O
BCG	O
)	O
(	O
C+I	O
group	O
)	O
.	O

After	O
remission	O
induction	O
and	O
consolidation	O
,	O
chemotherapy	O
was	O
stopped	O
in	O
both	O
groups	O
but	O
BCG	O
was	O
continued	O
in	O
the	O
C+I	O
group	O
.	O

The	O
overall	O
survival	O
of	O
the	O
C+I	O
group	O
was	O
significantly	O
increased	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
increase	O
in	O
the	O
duration	O
of	O
first	O
remission	O
in	O
the	O
C+I	O
group	O
(	O
0.05	O
less	O
than	O
P	O
less	O
than	O
0.1	O
)	O
nor	O
in	O
the	O
time	O
from	O
first	O
relapse	O
to	O
death	O
(	O
0.05	O
less	O
than	O
P	O
less	O
than	O
0.1	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
first	O
or	O
second	O
remissions	O
,	O
and	O
the	O
time	O
taken	O
to	O
enter	O
remission	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

Comparison	O
with	O
the	O
results	O
of	O
other	O
trials	O
suggests	O
that	O
the	O
use	O
of	O
maintenance	O
chemotherapy	O
in	O
addition	O
to	O
immunotherapy	O
produces	O
longer	O
remissions	O
.	O

Five	O
patients	O
in	O
the	O
C	O
group	O
developed	O
leukaemic	O
central-nervous-system	O
(	O
CSN	O
)	O
involvement	O
,	O
in	O
comparison	O
with	O
none	O
in	O
the	O
C+I	O
group	O
.	O

CNS	O
relapse	O
did	O
not	O
produce	O
a	O
significant	O
decrease	O
in	O
remission	O
length	O
(	O
P	O
greater	O
than	O
0.1	O
)	O
but	O
reduction	O
in	O
survival	O
after	O
CNS	O
relapse	O
was	O
highly	O
significant	O
(	O
P	O
=	O
0.001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
administration	O
of	O
BCG	O
from	O
an	O
early	O
stage	O
in	O
the	O
treatment	O
of	O
AML	O
may	O
protect	O
the	O
CNS	O
against	O
leukaemic	O
infiltration	O
and	O
therefore	O
serve	O
as	O
a	O
simple	O
,	O
innocuous	O
form	O
of	O
CNS	O
prophylaxis	O
.	O

Effect	Physical
of	O
motivational	O
music	O
on	O
lactate	Physical
levels	Physical
during	O
recovery	O
from	O
intense	O
exercise	O
.	O

The	O
effects	O
of	O
music	O
played	O
during	O
an	O
exercise	O
task	O
on	O
athletic	O
performance	O
have	O
been	O
previously	O
studied	O
.	O

Yet	O
,	O
these	O
results	O
are	O
not	O
applicable	O
for	O
competitive	O
athletes	O
,	O
who	O
can	O
use	O
music	O
only	O
during	O
warm-up	O
or	O
recovery	O
from	O
exercise	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
motivational	O
music	O
(	O
music	O
that	O
stimulates	O
or	O
inspires	O
physical	O
activity	O
)	O
during	O
recovery	Physical
from	Physical
intense	Physical
exercise	Physical
,	O
on	O
activity	Physical
pattern	Physical
,	Physical
rate	Physical
of	Physical
perceived	Physical
exertion	Physical
(	Physical
RPE	Physical
)	Physical
,	Physical
and	Physical
blood	Physical
lactate	Physical
concentration	Physical
.	Physical

Twenty	O
young	O
,	O
active	O
men	O
(	O
mean	O
age	O
26.2	O
?	O
2.1	O
years	O
)	O
performed	O
a	O
6-minute	O
run	O
at	O
peak	O
oxygen	O
consumption	O
speed	O
(	O
predetermined	O
from	O
the	O
VO	O
(	O
2	O
)	O
max	O
test	O
)	O
.	O

The	O
mean	O
heart	O
rate	O
(	O
HR	O
)	O
,	O
RPE	O
,	O
number	O
of	O
steps	O
(	O
determined	O
by	O
step	O
counter	O
)	O
,	O
and	O
blood	O
lactate	O
concentrations	O
were	O
determined	O
at	O
3	O
,	O
6	O
,	O
9	O
,	O
12	O
,	O
and	O
15	O
minutes	O
during	O
the	O
recovery	O
from	O
the	O
exercise	O
,	O
with	O
and	O
without	O
motivational	O
music	O
(	O
2	O
separate	O
sessions	O
,	O
at	O
random	O
order	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
mean	O
HR	O
during	O
the	O
recovery	O
with	O
and	O
without	O
music	O
.	O

Listening	O
to	O
motivational	O
music	O
during	O
the	O
recovery	O
was	O
associated	O
with	O
increased	O
voluntary	O
activity	O
of	O
the	O
participants	O
,	O
determined	O
by	O
increased	O
number	O
of	O
steps	O
(	O
499.4	O
?	O
220.1	O
vs.	O
413.2	O
?	O
150.6	O
steps	O
,	O
with	O
and	O
without	O
music	O
,	O
respectively	O
;	O
p	O
?	O
0.05	O
)	O
.	O

The	O
increased	O
number	O
of	O
steps	O
during	O
the	O
recovery	O
was	O
accompanied	O
by	O
a	O
significantly	O
greater	O
decrease	O
in	O
blood	O
lactate	O
concentration	O
percentage	O
(	O
28.1	O
?	O
12.2	O
vs.	O
22.8	O
?	O
10.9	O
%	O
,	O
with	O
and	O
without	O
music	O
,	O
respectively	O
,	O
p	O
?	O
0.05	O
)	O
.	O

This	O
was	O
associated	O
with	O
a	O
greater	O
decrease	O
in	O
RPE	O
(	O
77.7	O
?	O
14.4	O
vs.	O
73.1	O
?	O
14.7	O
%	O
with	O
and	O
without	O
music	O
,	O
respectively	O
;	O
p	O
?	O
0.05	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
listening	O
to	O
motivational	O
music	O
during	O
nonstructured	O
recovery	O
from	O
intense	O
exercise	O
leads	O
to	O
increased	O
activity	O
,	O
faster	O
lactate	O
clearance	O
,	O
and	O
reduced	O
RPE	O
and	O
therefore	O
may	O
be	O
used	O
by	O
athletes	O
in	O
their	O
effort	O
to	O
enhance	O
recovery	O
.	O

Relationship	O
between	O
baseline	O
blood	O
pressure	O
parameters	O
(	O
including	O
mean	O
pressure	O
,	O
pulse	O
pressure	O
,	O
and	O
variability	O
)	O
and	O
early	O
outcome	O
after	O
stroke	O
:	O
data	O
from	O
the	O
Tinzaparin	O
in	O
Acute	O
Ischaemic	O
Stroke	O
Trial	O
(	O
TAIST	O
)	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
High	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
acute	O
stroke	O
is	O
associated	O
independently	O
with	O
a	O
poor	O
outcome	O
.	O

Recent	O
evidence	O
suggests	O
that	O
other	O
hemodynamic	O
parameters	O
may	O
also	O
be	O
associated	O
with	O
outcomes	O
following	O
stroke	O
.	O

METHODS	O
The	O
relationship	O
between	O
baseline	O
BP	O
,	O
heart	O
rate	O
,	O
and	O
other	O
hemodynamic	O
parameters	O
,	O
and	O
early	O
outcomes	O
were	O
assessed	O
using	O
data	O
from	O
TAIST	O
trial	O
.	O

RESULTS	O
Death	Mortality
or	O
neurological	Physical
deterioration	Physical
at	Physical
day	Physical
10	Physical
was	O
associated	O
,	O
both	O
in	O
unadjusted	O
and	O
adjusted	O
analyses	O
,	O
with	O
systolic	Physical
BP	Physical
(	O
adjusted	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
mean	Physical
arterial	Physical
pressure	Physical
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.04	O
)	O
,	O
pulse	Physical
pressure	Physical
(	O
OR	O
,	O
1.02	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.03	O
)	O
,	O
and	O
BP	Physical
variability	Physical
(	O
OR	O
,	O
1.03	O
;	O
95	O
%	O
CI	O
,	O
1.01-1.05	O
)	O
.	O

Similar	O
relationships	O
were	O
noted	O
for	O
deterioration	Physical
alone	Physical
,	O
and	O
recurrent	Physical
stroke	Physical
.	O

CONCLUSIONS	O
Early	O
death	Mortality
or	O
neurologic	Physical
deterioration	Physical
,	O
deterioration	Physical
,	O
and	O
recurrent	Physical
stroke	Physical
are	O
associated	O
independently	O
with	O
high	Physical
systolic	Physical
BP	Physical
,	O
mean	Physical
arterial	Physical
pressure	Physical
,	O
pulse	Physical
pressure	Physical
,	O
and	O
BP	Physical
variability	Physical
.	O

These	O
measures	O
offer	O
potential	O
therapeutic	O
targets	O
for	O
improving	O
early	O
outcome	O
after	O
acute	O
ischemic	O
stroke	O
.	O

A	O
randomized	O
,	O
prospective	O
trial	O
of	O
adjuvant	O
chemotherapy	O
in	O
adults	O
with	O
soft	O
tissue	O
sarcomas	O
of	O
the	O
head	O
and	O
neck	O
,	O
breast	O
,	O
and	O
trunk	O
.	O

Since	O
1977	O
,	O
31	O
patients	O
were	O
entered	O
in	O
a	O
randomized	O
,	O
prospective	O
study	O
testing	O
the	O
efficacy	O
of	O
adjuvant	O
chemotherapy	O
after	O
aggressive	O
local	O
treatment	O
of	O
high-grade	O
sarcomas	O
of	O
the	O
head	O
,	O
neck	O
,	O
breast	O
,	O
and	O
trunk	O
(	O
excluding	O
retroperitoneal	O
sarcomas	O
)	O
.	O

All	O
patients	O
had	O
complete	O
resection	O
of	O
gross	O
tumor	O
and	O
underwent	O
postoperative	O
radiotherapy	O
(	O
6000-6300	O
rads	O
over	O
7-8	O
weeks	O
)	O
.	O

Seventeen	O
patients	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
doxorubicin	O
(	O
less	O
than	O
or	O
equal	O
to	O
550	O
mg/m2	O
)	O
,	O
cyclophosphamide	O
(	O
less	O
than	O
or	O
equal	O
to	O
5500	O
mg/m2	O
)	O
,	O
and	O
methotrexate	O
(	O
less	O
than	O
or	O
equal	O
to	O
1000	O
mg/kg	O
)	O
.	O

Three-year	O
actuarial	Mortality
disease-free	Mortality
survival	Mortality
in	O
the	O
chemotherapy	O
arm	O
was	O
77	O
%	O
,	O
compared	O
to	O
49	O
%	O
in	O
the	O
no-chemotherapy	O
arm	O
(	O
P	O
=	O
0.075	O
)	O
.	O

Three-year	O
overall	Mortality
actuarial	Mortality
survivals	Mortality
in	O
the	O
two	O
treatment	O
arms	O
,	O
however	O
,	O
were	O
68	O
%	O
and	O
58	O
%	O
,	O
respectively	O
(	O
P	O
=	O
0.38	O
)	O
.	O

Considering	O
only	O
patients	O
with	O
tumors	O
of	O
the	O
trunk	O
(	O
22	O
patients	O
)	O
,	O
3-year	O
actuarial	O
disease-free	O
survival	O
in	O
the	O
chemotherapy	O
arm	O
was	O
92	O
%	O
,	O
compared	O
to	O
47	O
%	O
in	O
the	O
no-chemotherapy	O
arm	O
(	O
P	O
=	O
0.006	O
)	O
.	O

Actuarial	O
3-year	O
overall	O
survival	O
in	O
the	O
chemotherapy	O
arm	O
was	O
82	O
%	O
,	O
compared	O
to	O
61	O
%	O
in	O
the	O
no-chemotherapy	O
arm	O
(	O
P	O
=	O
0.18	O
)	O
.	O

An	O
additional	O
26	O
patients	O
were	O
treated	O
in	O
an	O
identical	O
fashion	O
,	O
but	O
were	O
not	O
part	O
of	O
the	O
randomized	O
trial	O
because	O
of	O
contraindications	O
to	O
chemotherapy	O
,	O
refusal	O
to	O
enter	O
the	O
randomized	O
trial	O
,	O
or	O
because	O
they	O
were	O
treated	O
before	O
1977	O
in	O
a	O
trial	O
in	O
which	O
all	O
patients	O
received	O
chemotherapy	O
.	O

Considering	O
the	O
entire	O
group	O
of	O
57	O
patients	O
,	O
follow-up	O
ranged	O
from	O
10	O
to	O
86	O
months	O
(	O
median	O
,	O
35	O
months	O
)	O
.	O

Local	Others
control	Others
was	O
achieved	O
in	O
46	O
patients	O
(	O
81	O
%	O
)	O
;	O
3-year	O
actuarial	Mortality
disease-free	Mortality
and	Mortality
overall	Mortality
survivals	Mortality
were	O
67	O
%	O
and	O
77	O
%	O
,	O
respectively	O
.	O

A	O
tendency	O
toward	O
improved	O
disease-free	Mortality
survival	Mortality
was	O
apparent	O
among	O
patients	O
treated	O
with	O
chemotherapy	O
(	O
P	O
=	O
0.018	O
)	O
,	O
but	O
there	O
was	O
no	O
statistically	O
significant	O
improvement	O
in	O
overall	Mortality
actuarial	Mortality
survival	Mortality
(	O
P	O
=	O
0.46	O
)	O
.	O

The	O
subgroup	O
of	O
patients	O
with	O
sarcomas	O
of	O
the	O
trunk	O
(	O
39	O
patients	O
)	O
demonstrated	O
the	O
greatest	O
benefit	O
from	O
chemotherapy	O
,	O
with	O
regard	O
to	O
disease-free	Mortality
survival	Mortality
(	O
P	O
less	O
than	O
or	O
equal	O
to	O
0.001	O
)	O
.	O

The	O
most	O
significant	O
toxicity	Physical
associated	O
with	O
chemotherapy	O
was	O
doxorubicin-induced	Adverseeffect
cardiomyopathy	Adverseeffect
,	O
which	O
resulted	O
in	O
clinically	O
apparent	O
congestive	Physical
heart	Physical
failure	Physical
in	O
five	O
patients	O
.	O

Thus	O
,	O
the	O
use	O
of	O
chemotherapy	O
when	O
combined	O
with	O
aggressive	O
local	O
measures	O
appears	O
to	O
improve	O
disease-free	Mortality
survival	Mortality
,	O
but	O
additional	O
patients	O
and	O
longer	O
follow-up	O
are	O
necessary	O
to	O
determine	O
if	O
improved	O
overall	Mortality
survival	Mortality
will	O
result	O
.	O

Effects	O
of	O
a	O
caregiver	O
intervention	O
on	O
negative	O
caregiver	O
appraisals	O
of	O
behavior	O
problems	O
in	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
:	O
results	O
of	O
a	O
randomized	O
trial	O
.	O

Behavioral	O
problems	O
are	O
among	O
the	O
most	O
challenging	O
aspects	O
of	O
caring	O
for	O
a	O
person	O
with	O
Alzheimer	O
's	O
disease	O
.	O

A	O
sample	O
of	O
406	O
spouses-caregivers	O
of	O
patients	O
with	O
Alzheimer	O
's	O
disease	O
was	O
randomized	O
to	O
an	O
active	O
multicomponent	O
counseling	O
and	O
support	O
intervention	O
condition	O
or	O
to	O
a	O
usual	O
care	O
condition	O
.	O

Caregivers	O
reported	O
on	O
the	O
frequency	Mental
of	Mental
troublesome	Mental
patient	Mental
behaviors	Mental
and	Mental
their	Mental
reactions	Mental
to	Mental
them	Mental
at	O
baseline	O
and	O
at	O
regular	O
follow-up	O
interviews	O
.	O

Random-effects	O
regression	O
models	O
over	O
the	O
first	O
4	O
years	O
after	O
randomization	O
revealed	O
that	O
,	O
although	O
the	O
intervention	O
did	O
not	O
affect	O
the	O
frequency	O
of	O
patient	O
behavioral	O
problems	O
,	O
it	O
did	O
significantly	O
reduce	O
caregivers	Mental
'	Mental
reaction	Mental
ratings	Mental
.	Mental

Because	O
caregiver	O
appraisals	O
have	O
been	O
found	O
to	O
mediate	O
the	O
impact	O
of	O
caregiving	O
stress	O
on	O
depression	O
and	O
to	O
predict	O
nursing	O
home	O
placement	O
rates	O
,	O
they	O
deserve	O
greater	O
attention	O
as	O
an	O
important	O
target	O
of	O
intervention	O
services	O
.	O

Early	O
versus	O
late	O
replacement	O
of	O
autotransfused	O
blood	O
in	O
elective	O
spinal	O
surgery	O
.	O

A	O
prospective	O
randomized	O
study	O
.	O

The	O
use	O
of	O
autologous	O
blood	O
is	O
a	O
well	O
established	O
and	O
extremely	O
popular	O
technique	O
to	O
decrease	O
the	O
necessity	O
for	O
homologous	O
transfusions	O
and	O
the	O
attendant	O
risks	O
of	O
hepatitis	O
,	O
HIV	O
,	O
and	O
HTLV	O
--	O
I/II	O
infections	O
.	O

The	O
most	O
beneficial	O
timing	O
for	O
autologous	O
reinfusion	O
of	O
predonated	O
blood	O
remains	O
unknown	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
optimal	O
timing	O
of	O
autologous	O
blood	O
reinfusion	O
in	O
elective	O
spinal	O
surgery	O
.	O

Fifty-seven	O
patients	O
were	O
prospectively	O
individually	O
randomly	O
allocated	O
into	O
early	O
versus	O
delayed	O
reinfusion	O
groups	O
prior	O
to	O
undergoing	O
elective	O
spinal	O
surgery	O
by	O
a	O
single	O
surgeon	O
.	O

Three	O
surgical	O
subgroups	O
were	O
entered	O
into	O
the	O
study	O
:	O
anterior/posterior	O
(	O
A/P	O
)	O
spinal	O
fusion	O
patients	O
,	O
posterior	O
thoracolumbar	O
scoliosis	O
fusion	O
patients	O
(	O
PSF	O
)	O
,	O
and	O
degenerative	O
posterior	O
lumbar	O
fusion	O
patients	O
(	O
LF	O
)	O
.	O

Randomization	O
was	O
successful	O
in	O
that	O
three	O
was	O
no	O
significant	O
difference	O
in	O
male	O
to	O
female	O
ratio	O
,	O
age	O
,	O
preoperative	O
hemoglobin	O
,	O
or	O
number	O
of	O
units	O
predonated	O
between	O
the	O
early	O
and	O
delayed	O
reinfusion	O
groups	O
.	O

Likewise	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
details	O
of	O
the	O
operative	O
procedure	O
when	O
compared	O
as	O
a	O
group	O
for	O
the	O
early	O
versus	O
delayed	O
reinfusion	O
groups	O
.	O

A	O
significant	O
increase	O
in	O
the	O
postoperative	O
day	Physical
#	Physical
1	Physical
,	Physical
2	Physical
and	Physical
3	Physical
hemoglobin	Physical
was	O
seen	O
in	O
the	O
early	O
reinfusion	O
group	O
,	O
while	O
there	O
was	O
no	O
significant	O
difference	O
seen	O
in	O
the	O
postoperative	O
day	O
#	O
7	O
hemoglobin	O
between	O
the	O
early	O
versus	O
delayed	O
reinfusion	O
group	O
.	O

There	O
was	O
no	O
effect	O
of	O
surgical	O
grouping	O
on	O
these	O
significant	O
comparisons	O
.	O

Earlier	O
patient	Others
mobilization	Others
was	O
also	O
seen	O
in	O
the	O
early	O
reinfusion	O
groups	O
for	O
the	O
A/P	O
and	O
PSF	O
groups	O
.	O

There	O
was	O
no	O
difference	O
in	O
patients	O
'	O
subjective	O
evaluation	O
of	O
satisfaction	O
and	O
discomfort	O
between	O
the	O
early	O
or	O
delayed	O
reinfusion	O
groups	O
as	O
determined	O
by	O
blinded	O
interview	O
on	O
days	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
7	O
postoperatively	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Determinants	O
of	O
exclusive	O
breastfeeding	O
in	O
an	O
urban	O
population	O
of	O
primiparas	O
in	O
Lebanon	O
:	O
a	O
cross-sectional	O
study	O
.	O

BACKGROUND	O
The	O
proportion	O
of	O
mothers	O
who	O
exclusively	O
breastfeed	O
their	O
babies	O
up	O
to	O
6	O
months	O
remains	O
low	O
.	O

Determinants	O
of	O
breastfeeding	O
practices	O
have	O
been	O
largely	O
documented	O
in	O
high-income	O
countries	O
.	O

Little	O
evidence	O
exists	O
on	O
possible	O
predictors	O
of	O
breastfeeding	O
behaviors	O
in	O
the	O
Middle	O
East	O
.	O

Our	O
aim	O
was	O
to	O
assess	O
the	O
prevalence	O
of	O
breastfeeding	O
in	O
Beirut	O
and	O
determine	O
the	O
factors	O
that	O
impact	O
breastfeeding	O
behavior	O
in	O
this	O
population	O
.	O

METHODS	O
Data	O
for	O
this	O
longitudinal	O
study	O
is	O
nested	O
within	O
a	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
assessing	O
the	O
impact	O
of	O
a	O
24-hour	O
hotline	O
and	O
postpartum	O
support	O
film	O
on	O
postpartum	O
stress	O
.	O

Healthy	O
first-time	O
mothers	O
delivering	O
in	O
the	O
capital	O
Beirut	O
between	O
March	O
and	O
July	O
2009	O
,	O
were	O
interviewed	O
at	O
1-3	O
days	O
and	O
8-12	O
weeks	O
post	O
delivery	O
.	O

A	O
multiple	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
determine	O
the	O
factors	O
associated	O
with	O
exclusive	O
breastfeeding	O
at	O
8-12	O
weeks	O
postpartum	O
.	O

RESULTS	O
The	O
overall	Physical
breastfeeding	Physical
rate	Physical
at	O
8-12	O
weeks	O
postpartum	O
was	O
67	O
%	O
.	O

The	O
exclusive	Physical
breastfeeding	Physical
rate	Physical
was	O
27.4	O
%	O
.	O

Factors	O
associated	O
with	O
exclusive	O
breastfeeding	O
included	O
maternal	Others
work	Others
(	O
OR=3.92	O
;	O
p-value	O
<	O
0.001	O
)	O
,	O
planned	Others
pregnancy	Others
(	O
OR=2.42	O
,	O
p-value=0.010	O
)	O
,	O
intention	Others
to	Others
breastfeed	Others
(	O
OR=3.28	O
;	O
p-value=0.043	O
)	O
,	O
source	Others
of	Others
maternal	Others
emotional	Others
support	Others
(	O
OR=1.87	O
,	O
p-value=0.039	O
)	O
and	O
the	O
use	Others
the	Others
postpartum	Others
support	Others
video	Others
,	Others
the	Others
hotline	Others
service	Others
or	Others
both	Others
(	O
OR=2.55	O
,	O
p-value=0.044	O
;	O
OR=3.87	O
,	O
p-value=0.004	O
and	O
OR=4.13	O
,	O
p-value=0.003	O
)	O
.	O

CONCLUSIONS	O
The	O
proportion	O
of	O
healthy	O
first-time	O
mothers	O
who	O
exclusively	O
breastfeed	O
in	O
Beirut	O
is	O
extremely	O
low	O
.	O

Factors	O
associated	O
with	O
breastfeeding	O
behavior	O
are	O
diverse	O
.	O

Future	O
research	O
and	O
interventions	O
should	O
target	O
different	O
levels	O
of	O
the	O
maternal-child	O
pair	O
's	O
ecosystem	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
,	O
NCT00857051	O
.	O

Citalopram	O
for	O
post-stroke	O
pathological	O
crying	O
.	O

Post-stroke	O
pathological	O
crying	O
is	O
a	O
distressing	O
condition	O
in	O
which	O
episodes	O
occur	O
in	O
response	O
to	O
minor	O
stimuli	O
without	O
associated	O
mood	O
changes	O
.	O

There	O
is	O
preliminary	O
evidence	O
of	O
disturbed	O
serotoninergic	O
neurotransmission	O
in	O
such	O
cases	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
selective	Physical
serotonin	Physical
reuptake	Physical
inhibitor	Physical
citalopram	Physical
on	O
uncontrolled	Mental
crying	Mental
in	O
stroke	O
patients	O
in	O
a	O
double-blind	O
placebo-controlled	O
crossover	O
study	O
.	O

16	O
consecutive	O
patients	O
(	O
median	O
age	O
58.5	O
years	O
,	O
range	O
40-83	O
)	O
entered	O
the	O
9-week	O
study	O
a	O
median	O
of	O
168	O
days	O
(	O
range	O
6-913	O
)	O
post	O
stroke	O
and	O
were	O
treated	O
with	O
citalopram	O
10-20	O
mg	O
daily	O
for	O
3	O
weeks	O
.	O

Crying	Mental
history	Mental
was	O
determined	O
from	O
semistructured	O
interviews	O
and	O
from	O
diaries	O
kept	O
by	O
the	O
patients	O
.	O

Psychiatric	Mental
assessment	Mental
was	O
made	O
with	O
the	O
Hamilton	Mental
depression	Mental
scale	Mental
(	O
HDS	O
)	O
,	O
and	O
unwanted	Adverseeffect
effects	Adverseeffect
were	O
measured	O
with	O
the	O
UKU	Adverseeffect
side-effect	Adverseeffect
scale	Adverseeffect
.	O

In	O
13	O
patients	O
in	O
whom	O
frequency	Mental
of	Mental
crying	Mental
could	O
be	O
assessed	O
,	O
the	O
number	Mental
of	Mental
daily	Mental
crying	Mental
episodes	Mental
decreased	O
by	O
at	O
least	O
50	O
%	O
in	O
all	O
cases	O
during	O
citalopram	O
treatment	O
vs	O
2	O
patients	O
during	O
placebo	O
treatment	O
(	O
p	O
<	O
0.005	O
,	O
McNemar	O
's	O
test	O
)	O
,	O
the	O
effect	O
being	O
rapid	O
(	O
1-3	O
days	O
)	O
and	O
pronounced	O
in	O
11	O
(	O
73	O
%	O
)	O
.	O

There	O
was	O
a	O
concomitant	O
significant	O
decrease	Mental
in	Mental
depression	Mental
rating	Mental
from	O
HDS	O
8.9	O
to	O
5.3	O
(	O
p	O
<	O
0.005	O
,	O
Wilcoxon	O
's	O
test	O
)	O
.	O

Citalopram	O
was	O
well	O
tolerated	O
,	O
the	O
few	O
side-effects	O
being	O
mild	O
and	O
transient	O
.	O

We	O
conclude	O
that	O
serotoninergic	O
neurotransmission	O
plays	O
an	O
important	O
part	O
in	O
post-stroke	O
pathological	O
crying	O
and	O
that	O
citalopram	O
is	O
an	O
effective	O
and	O
well-tolerated	O
treatment	O
.	O

Effect	O
of	O
gemfibrozil	O
on	O
change	O
in	O
renal	O
function	O
in	O
men	O
with	O
moderate	O
chronic	O
renal	O
insufficiency	O
and	O
coronary	O
disease	O
.	O

BACKGROUND	O
Limited	O
data	O
suggest	O
that	O
low	O
levels	O
of	O
serum	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
)	O
and	O
high	O
levels	O
of	O
triglyceride-rich	O
lipoproteins	O
may	O
be	O
associated	O
with	O
more	O
rapid	O
rates	O
of	O
kidney	O
function	O
loss	O
in	O
individuals	O
with	O
chronic	O
renal	O
insufficiency	O
(	O
CRI	O
)	O
.	O

Although	O
fibric	O
acid	O
derivatives	O
increase	O
serum	O
HDL-C	O
levels	O
and	O
decrease	O
triglyceride	O
levels	O
,	O
their	O
effects	O
on	O
renal	O
function	O
are	O
largely	O
unknown	O
.	O

We	O
conducted	O
this	O
study	O
to	O
determine	O
whether	O
gemfibrozil	O
reduced	O
rates	O
of	O
renal	O
function	O
loss	O
in	O
people	O
with	O
moderate	O
CRI	O
.	O

METHODS	O
This	O
was	O
a	O
post	O
hoc	O
subgroup	O
analysis	O
in	O
the	O
Veterans	O
Affairs	O
High-Density	O
Lipoprotein	O
Intervention	O
Trial	O
,	O
a	O
randomized	O
double-blind	O
trial	O
of	O
gemfibrozil	O
versus	O
placebo	O
in	O
2,531	O
men	O
with	O
coronary	O
disease	O
,	O
HDL-C	O
levels	O
of	O
40	O
mg/dL	O
or	O
less	O
(	O
<	O
or	O
=1.0	O
mmol/L	O
)	O
,	O
low-density	O
lipoprotein	O
cholesterol	O
levels	O
of	O
140	O
mg/dL	O
or	O
less	O
(	O
<	O
or	O
=3.6	O
mmol/L	O
)	O
,	O
and	O
a	O
range	O
of	O
triglyceride	O
values	O
.	O

Moderate	O
CRI	O
is	O
defined	O
as	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
of	O
30	O
to	O
59.9	O
mL/min/1.73	O
m2	O
at	O
baseline	O
.	O

Multivariate	O
regression	O
was	O
used	O
to	O
calculate	O
rates	O
of	O
decline	O
in	O
estimated	O
GFR	O
for	O
individuals	O
administered	O
gemfibrozil	O
or	O
placebo	O
,	O
controlling	O
for	O
prospectively	O
determined	O
potential	O
confounders	O
.	O

RESULTS	O
Change	Physical
in	Physical
renal	Physical
function	Physical
could	O
be	O
calculated	O
in	O
1,981	O
individuals	O
,	O
of	O
whom	O
399	O
individuals	O
(	O
20.2	O
%	O
)	O
were	O
eligible	O
for	O
inclusion	O
.	O

Among	O
399	O
study	O
subjects	O
,	O
the	O
rate	Physical
of	Physical
change	Physical
in	Physical
renal	Physical
function	Physical
in	O
the	O
gemfibrozil	O
group	O
during	O
a	O
median	O
of	O
61	O
months	O
was	O
not	O
significantly	O
different	O
from	O
that	O
in	O
the	O
placebo	O
group	O
(	O
0.49	O
mL/min/1.73	O
m2/y	O
faster	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.09	O
slower	O
to	O
1.09	O
faster	O
;	O
P	O
=	O
0.10	O
)	O
.	O

No	O
clinically	O
relevant	O
effect	O
of	O
gemfibrozil	O
on	O
renal	Physical
function	Physical
was	O
observed	O
in	O
groups	O
defined	O
by	O
baseline	Physical
lipid	Physical
levels	Physical
,	O
kidney	Physical
function	Physical
,	O
diabetic	Physical
status	Physical
,	O
or	O
other	O
components	Physical
of	Physical
the	Physical
metabolic	Physical
syndrome	Physical
.	O

The	O
incidence	O
of	O
transient	O
(	O
10	O
%	O
versus	O
4	O
%	O
;	O
P	O
=	O
0.01	O
)	O
,	O
but	O
not	O
sustained	O
(	O
9	O
%	O
versus	O
4	O
%	O
;	O
P	O
=	O
0.07	O
)	O
,	O
increases	O
in	O
serum	Physical
creatinine	Physical
levels	Physical
of	O
0.5	O
mg/dL	O
or	O
greater	O
(	O
>	O
or	O
=44	O
micromol/L	O
)	O
was	O
significantly	O
greater	O
in	O
the	O
gemfibrozil	O
group	O
.	O

However	O
,	O
in	O
5	O
subjects	O
with	O
acute	O
increases	O
in	O
serum	Physical
creatinine	Physical
levels	Physical
,	O
serum	Physical
creatine	Physical
kinase	Physical
levels	Physical
were	O
significantly	O
elevated	O
as	O
well	O
,	O
suggesting	O
that	O
myocyte	O
toxicity	O
may	O
have	O
been	O
responsible	O
.	O

Even	O
when	O
these	O
individuals	O
were	O
excluded	O
,	O
no	O
clinically	O
significant	O
effect	O
of	O
gemfibrozil	O
on	O
kidney	Physical
function	Physical
was	O
observed	O
.	O

CONCLUSION	O
Gemfibrozil	O
does	O
not	O
appear	O
to	O
exert	O
a	O
clinically	O
relevant	O
effect	O
on	O
rates	O
of	O
kidney	Physical
function	Physical
loss	O
in	O
individuals	O
with	O
moderate	O
CRI	O
,	O
low	O
HDL-C	O
levels	O
,	O
and	O
concomitant	O
coronary	O
disease	O
.	O

A	O
randomized	O
trial	O
of	O
tailored	O
skin	O
cancer	O
prevention	O
messages	O
for	O
adults	O
:	O
Project	O
SCAPE	O
.	O

OBJECTIVES	O
We	O
evaluated	O
the	O
impact	O
of	O
a	O
mailed	O
,	O
tailored	O
intervention	O
on	O
skin	Physical
cancer	Physical
prevention	O
and	O
skin	Mental
self-examination	Mental
behaviors	Mental
of	O
adults	O
at	O
moderate	O
and	O
high	O
risk	O
for	O
skin	O
cancer	O
.	O

METHODS	O
Adults	O
at	O
moderate	O
and	O
high	O
risk	O
for	O
skin	O
cancer	O
were	O
recruited	O
in	O
primary	O
health	O
care	O
settings	O
in	O
Honolulu	O
,	O
HI	O
,	O
and	O
Long	O
Island	O
,	O
NY	O
.	O

After	O
completing	O
a	O
baseline	O
survey	O
,	O
participants	O
were	O
randomized	O
to	O
2	O
groups	O
.	O

The	O
treatment	O
group	O
received	O
tailored	O
materials	O
,	O
including	O
personalized	O
risk	O
feedback	O
,	O
and	O
the	O
control	O
group	O
received	O
general	O
educational	O
materials	O
.	O

Multivariate	O
analyses	O
compared	O
sun	Mental
protection	Mental
and	O
skin	Mental
self-examination	Mental
between	O
groups	O
,	O
controlling	O
for	O
location	O
,	O
risk	O
level	O
,	O
gender	O
,	O
and	O
age	O
.	O

RESULTS	O
A	O
total	O
of	O
596	O
adults	O
completed	O
the	O
trial	O
.	O

The	O
tailored	O
materials	O
had	O
a	O
significant	O
effect	O
on	O
overall	Mental
sun-protection	Mental
habits	Mental
,	Mental
the	Mental
use	Mental
of	Mental
hats	Mental
,	Mental
the	Mental
use	Mental
of	Mental
sunglasses	Mental
,	Mental
and	Mental
the	Mental
recency	Mental
of	Mental
skin	Mental
self-examination	Mental
.	O

Some	O
effects	O
were	O
moderated	O
by	O
location	O
and	O
risk	O
level	O
.	O

CONCLUSIONS	O
Tailored	O
communications	O
including	O
personalized	O
risk	O
feedback	O
can	O
improve	O
sun-protection	Mental
behaviors	Mental
and	O
skin	Mental
self-examination	Mental
among	O
adults	O
at	O
increased	O
risk	O
for	O
skin	O
cancer	O
.	O

These	O
convenient	O
,	O
low-cost	O
interventions	O
can	O
be	O
implemented	O
in	O
a	O
variety	O
of	O
settings	O
and	O
should	O
be	O
tested	O
further	O
to	O
assess	O
their	O
long-term	O
effectiveness	O
.	O

Comparison	O
of	O
the	O
evolutional	Others
process	Others
of	O
children	O
with	O
autism	O
spectrum	O
disorders	O
in	O
different	O
language	O
therapeutic	O
interventions	O
.	O

PURPOSE	O
To	O
analyze	O
and	O
compare	O
the	Mental
extension	Mental
and	Mental
the	Mental
speed	Mental
of	Mental
the	Mental
evolutional	Mental
process	Mental
of	O
children	O
with	O
Autism	O
Spectrum	O
Disorders	O
in	O
direct	O
and	O
indirect	O
interventions	O
as	O
opposed	O
to	O
only	O
indirect	O
intervention	O
.	O

METHODS	O
The	O
design	O
of	O
this	O
study	O
is	O
a	O
clinical	O
trial	O
.	O

The	O
sample	O
was	O
composed	O
of	O
11	O
children	O
diagnosed	O
with	O
Autism	O
(	O
n=6	O
)	O
and	O
Asperger	O
syndrome	O
(	O
n=5	O
)	O
by	O
a	O
multidisciplinary	O
team	O
,	O
that	O
attended	O
specialized	O
speech-language	O
pathology	O
therapy	O
at	O
the	O
institution	O
were	O
the	O
study	O
was	O
carried	O
out	O
.	O

These	O
children	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
Therapy	O
Group	O
(	O
TG	O
)	O
-	O
composed	O
by	O
six	O
subjects	O
receiving	O
both	O
direct	O
and	O
indirect	O
intervention	O
;	O
and	O
Orientation	O
Group	O
(	O
OG	O
)	O
-	O
constituted	O
by	O
five	O
subjects	O
receiving	O
exclusively	O
indirect	O
intervention	O
.	O

It	O
was	O
used	O
the	O
Autism	Mental
Behavior	Mental
Checklist	Mental
(	Mental
ABC	Mental
)	Mental
to	O
interview	O
the	O
mothers	O
,	O
and	O
the	O
Sample	Mental
of	Mental
Vocal	Mental
Behavior	Mental
(	Mental
SVB	Mental
)	Mental
,	O
in	O
three	O
occasions	O
:	O
at	O
the	O
beginning	O
of	O
the	O
intervention	O
process	O
(	O
time	O
0	O
)	O
,	O
six	O
months	O
later	O
(	O
time	O
1	O
)	O
and	O
12	O
months	O
later	O
(	O
time	O
2	O
)	O
.	O

RESULTS	O
It	O
was	O
observed	O
greater	O
speed	Others
and	Others
extension	Others
in	Others
the	Others
evolutional	Others
process	Others
of	O
the	O
TG	O
Group	O
,	O
both	O
in	O
the	O
analysis	O
of	O
the	O
Autism	Mental
Behavior	Mental
Checklist	Mental
(	Mental
total	Mental
and	Mental
partial	Mental
scores	Mental
)	Mental
and	O
the	O
Sample	O
of	O
Vocal	O
Behavior	O
,	O
especially	O
in	O
the	O
item	O
Full	O
Language	O
.	O

The	O
performance	O
of	O
children	O
with	O
Asperger	O
syndrome	O
was	O
considered	O
more	O
positive	O
when	O
compared	O
to	O
that	O
of	O
children	O
with	O
autism	O
.	O

There	O
was	O
greater	O
evolution	Others
in	O
younger	O
children	O
and	O
with	O
normal	O
,	O
mild	O
,	O
and	O
moderate	O
adaptive	Mental
functioning	Mental
.	O

CONCLUSION	O
The	O
tendency	O
towards	O
better	O
performance	Mental
of	O
the	O
children	O
attending	O
direct	O
and	O
indirect	O
intervention	O
showed	O
that	O
this	O
association	O
is	O
fundamental	O
in	O
the	O
therapeutic	O
process	O
of	O
children	O
with	O
Autism	O
Spectrum	O
Disorders	O
.	O

Psoriasis	O
of	O
the	O
scalp	O
treated	O
with	O
Grenz	O
rays	O
or	O
topical	O
corticosteroid	O
combined	O
with	O
Grenz	O
rays	O
.	O

A	O
comparative	O
randomized	O
trial	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
Grenz	O
ray	O
therapy	O
alone	O
compared	O
with	O
Grenz	O
rays	O
combined	O
with	O
a	O
topical	O
corticosteroid	O
(	O
betamethasone	O
dipropionate	O
)	O
in	O
psoriasis	O
of	O
the	O
scalp	O
,	O
40	O
patients	O
were	O
randomized	O
into	O
two	O
groups	O
.	O

One	O
group	O
received	O
4	O
Gy	O
of	O
Grenz	O
rays	O
administered	O
on	O
six	O
occasions	O
at	O
intervals	O
of	O
1	O
week	O
and	O
the	O
other	O
group	O
was	O
given	O
the	O
same	O
Grenz	O
ray	O
treatment	O
plus	O
topical	O
corticosteroid	O
.	O

The	O
patients	O
were	O
assessed	O
before	O
and	O
after	O
Grenz	O
ray	O
therapy	O
and	O
were	O
followed-up	O
for	O
6	O
months	O
.	O

Of	O
the	O
37	O
patients	O
who	O
completed	O
the	O
trial	O
16	O
out	O
of	O
19	O
(	O
84	O
%	O
)	O
of	O
the	O
patients	O
in	O
the	O
Grenz	O
ray	O
group	O
,	O
and	O
13	O
out	O
of	O
18	O
(	O
72	O
%	O
)	O
of	O
the	O
patients	O
in	O
the	O
combination	O
group	O
healed	Physical
.	O

The	O
remission	Physical
time	Physical
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

Of	O
the	O
patients	O
who	O
healed	Physical
,	O
5	O
of	O
16	O
patients	O
in	O
the	O
Grenz	O
ray	O
only	O
group	O
and	O
4	O
of	O
13	O
patients	O
in	O
the	O
combination	O
group	O
remained	Physical
healed	Physical
at	O
6	O
months	O
.	O

We	O
conclude	O
that	O
Grenz	O
ray	O
therapy	O
is	O
a	O
useful	O
treatment	Others
modality	O
for	O
scalp	Physical
psoriasis	Physical
,	O
but	O
that	O
the	O
addition	O
of	O
a	O
topical	O
corticosteroid	O
has	O
only	O
a	O
minor	Physical
effect	Physical
.	O

Removal	O
of	O
inflammatory	O
cytokines	O
and	O
endotoxin	O
by	O
veno-venous	O
continuous	O
renal	O
replacement	O
therapy	O
for	O
burned	O
patients	O
with	O
sepsis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
veno-venous	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
on	O
the	O
plasma	O
levels	O
of	O
endotoxin	O
and	O
cytokines	O
in	O
severely	O
burned	O
patients	O
with	O
sepsis	O
.	O

METHODS	O
Twenty	O
adult	O
severely	O
burned	O
patients	O
with	O
sepsis	O
were	O
studied	O
.	O

For	O
the	O
diagnosis	O
of	O
sepsis	O
,	O
patients	O
were	O
randomly	O
divided	O
into	O
CRRT	O
(	O
n=10	O
)	O
and	O
Control	O
(	O
n=10	O
)	O
.	O

Both	O
groups	O
received	O
conventional	O
therapy	O
after	O
admission	O
.	O

Veno-venous	O
CRRT	O
was	O
administered	O
to	O
10	O
patients	O
in	O
the	O
CRRT	O
group	O
whenever	O
patients	O
were	O
determined	O
to	O
be	O
septic	O
.	O

The	O
plasma	O
level	O
of	O
endotoxin	O
,	O
TNF-alpha	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
and	O
IL-8	O
were	O
measured	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
6	O
,	O
12	O
,	O
36	O
and	O
60	O
h	O
after	O
CRRT	O
initiation	O
,	O
and	O
at	O
0	O
,	O
12	O
,	O
36	O
and	O
60	O
h	O
after	O
the	O
patients	O
were	O
diagnosed	O
as	O
having	O
sepsis	O
in	O
the	O
Control	O
group	O
.	O

MAIN	O
RESULTS	O
Plasma	Physical
level	Physical
of	Physical
endotoxin	Physical
and	O
all	Physical
the	Physical
cytokines	Physical
after	Physical
CRRT	Physical
initiation	Physical
were	O
significantly	O
lower	O
than	O
those	O
before	O
the	O
treatment	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
serial	Physical
change	Physical
of	Physical
endotoxin	Physical
,	Physical
IL-1	Physical
beta	Physical
,	Physical
IL-6	Physical
and	Physical
IL-8	Physical
was	O
significantly	O
lower	O
at	O
12	O
,	O
36	O
and	O
60	O
h	O
after	O
treatment	O
compared	O
with	O
Control	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

A	O
significant	O
decrease	O
in	O
plasma	Physical
TNF-alpha	Physical
levels	Physical
was	O
seen	O
at	O
36	O
and	O
60	O
h	O
after	O
treatment	O
compared	O
with	O
Control	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
Plasma	O
endotoxin	O
and	O
cytokines	O
(	O
TNF-alpha	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
and	O
IL-8	O
)	O
can	O
be	O
removed	O
effectively	O
with	O
CRRT	O
in	O
severely	O
burned	O
patients	O
with	O
sepsis	O
.	O

A	O
single	O
infusion	O
of	O
intravenous	O
ketamine	O
improves	O
pain	O
relief	O
in	O
patients	O
with	O
critical	O
limb	O
ischaemia	O
:	O
results	O
of	O
a	O
double	O
blind	O
randomised	O
controlled	O
trial	O
.	O

We	O
report	O
the	O
first	O
double	O
blind	O
randomised	O
controlled	O
trial	O
of	O
regular	O
opioids	O
and	O
an	O
infusion	O
of	O
low	O
dose	O
(	O
0.6	O
mg/kg	O
)	O
intravenous	O
ketamine	O
compared	O
with	O
opioids	O
and	O
placebo	O
in	O
patients	O
with	O
allodynia	O
,	O
hyperalgesia	O
and	O
hyperpathia	O
secondary	O
to	O
critical	O
limb	O
ischaemia	O
.	O

Thirty-five	O
patients	O
completed	O
the	O
study	O
,	O
18	O
received	O
regular	O
opioids	O
plus	O
ketamine	O
,	O
while	O
17	O
received	O
regular	O
opioids	O
plus	O
placebo	O
.	O

Using	O
the	O
Brief	Pain
Pain	Pain
Inventory	Pain
,	Pain
the	Pain
%	Pain
pain	Pain
relief	Pain
that	O
the	O
patients	O
in	O
the	O
ketamine	O
group	O
attributed	O
to	O
their	O
medication	O
improved	O
significantly	O
from	O
50	O
%	O
immediately	O
pre-infusion	O
to	O
65	O
%	O
24	O
h	O
post-infusion	O
and	O
69	O
%	O
5	O
days	O
post	O
infusion	O
.	O

Over	O
the	O
same	O
period	O
,	O
the	O
pain	Pain
relief	Pain
achieved	Pain
by	O
the	O
placebo	O
group	O
rose	O
from	O
58	O
%	O
pre-infusion	O
to	O
56	O
%	O
24	O
h	O
post	O
infusion	O
and	O
then	O
50	O
%	O
relief	O
5	O
days	O
later	O
.	O

This	O
was	O
statistically	Others
significant	Others
(	O
P	O
<	O
0.05	O
)	O
using	O
both	O
the	O
t-test	Others
and	Others
the	Others
Wilcoxon	Others
Rank	Others
Sum	Others
test	Others
.	Others

The	O
ketamine	O
group	O
also	O
showed	O
a	O
statistically	O
significant	O
difference	O
24	O
h	O
post	O
infusion	O
of	O
the	O
effect	O
of	O
pain	Pain
on	O
their	O
general	O
activity	O
(	O
P=0.03	O
)	O
and	O
on	O
their	O
enjoyment	O
of	O
life	O
(	O
P=0.004	O
)	O
.	O

This	O
study	O
shows	O
that	O
combining	O
a	O
single	O
infusion	O
of	O
low	O
dose	O
ketamine	O
with	O
regular	O
opioid	O
analgesia	O
can	O
result	O
in	O
a	O
significant	O
improvement	O
in	O
pain	Physical
relief	Physical
for	O
this	O
patient	O
group	O
.	O

Randomized	O
placebo	O
controlled	O
human	O
volunteer	O
trial	O
of	O
a	O
live	O
oral	O
cholera	O
vaccine	O
VA1.3	O
for	O
safety	Others
and	O
immune	O
response	O
.	O

A	O
live	O
oral	O
cholera	O
vaccine	O
developed	O
from	O
a	O
non-toxigenic	O
Vibrio	O
cholerae	O
O1	O
El	O
Tor	O
strain	O
VA1.3	O
was	O
tested	O
in	O
a	O
double-blind	O
randomized	O
placebo	O
controlled	O
study	O
for	O
safety	O
and	O
immunogenicity	O
in	O
304	O
men	O
aged	O
between	O
16	O
and	O
50	O
years	O
from	O
Kolkata	O
,	O
India	O
.	O

A	O
dose	O
of	O
5	O
x	O
10	O
(	O
9	O
)	O
CFU	O
(	O
n=186	O
)	O
or	O
a	O
placebo	O
(	O
n=116	O
)	O
containing	O
the	O
diluent	O
buffer	O
was	O
administered	O
.	O

The	O
vaccine	O
did	O
not	O
elicit	O
adverse	Adverseeffect
events	Adverseeffect
except	O
in	O
two	O
vaccine	O
recipients	O
with	O
mild	Adverseeffect
diarrhoea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
.	O

None	O
excreted	O
the	O
vaccine	O
strain	O
.	O

Vibriocidal	Physical
antibody	Physical
response	Physical
developed	O
in	O
105/186	O
(	O
57	O
%	O
)	O
and	O
5/116	O
(	O
4	O
%	O
)	O
in	O
vaccine	O
and	O
placebo	O
recipients	O
,	O
respectively	O
.	O

In	O
a	O
subgroup	O
,	O
anti-CT	Physical
antibody	Physical
rose	Physical
(	O
>	O
or	O
=2-folds	O
)	O
in	O
23/30	O
(	O
77	O
%	O
)	O
and	O
6/19	O
(	O
32	O
%	O
)	O
in	O
vaccine	O
and	O
placebo	O
recipients	O
,	O
respectively	O
.	O

These	O
studies	O
demonstrate	O
that	O
VA1.3	O
at	O
a	O
dose	O
of	O
5	O
x	O
10	O
(	O
9	O
)	O
is	O
safe	Others
and	Others
immunogenic	Others
in	O
adults	O
from	O
a	O
cholera	O
endemic	O
region	O
.	O

An	O
exploratory	O
,	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
of	O
practice	O
nurse	O
training	O
in	O
the	O
use	O
of	O
asthma	O
action	O
plans	O
.	O

INTRODUCTION	O
To	O
investigate	O
the	O
feasibility	Others
of	O
improving	O
asthma	O
management	O
-	O
in	O
particular	O
,	O
the	O
implementation	O
of	O
individualised	O
asthma	O
action	O
plans	O
(	O
AAPs	O
)	O
for	O
poorly-controlled	O
adult	O
asthma	O
patients	O
-	O
by	O
providing	O
training	O
in	O
asthma-focused	O
clinical	O
and	O
communication	O
skills	O
for	O
practice	O
nurses	O
who	O
deliver	O
asthma	O
clinics	O
.	O

METHODS	O
A	O
pragmatic	O
,	O
cluster	O
randomised	O
trial	O
with	O
an	O
intervention	O
(	O
an	O
interactive	O
seminar	O
)	O
delivered	O
at	O
practice	O
level	O
(	O
n=13	O
practices	O
;	O
6=intervention	O
,	O
7=control	O
)	O
.	O

The	O
impact	O
of	O
the	O
intervention	O
was	O
assessed	O
against	O
patient	Physical
outcomes	Physical
:	Physical
routinely	Physical
available	Physical
asthma	Physical
outcome	Physical
measures	Physical
(	Physical
beta2-agonist	Others
prescription	Others
rate	Others
and	Physical
number	Others
of	Others
oral	Others
steroid	Others
courses	Others
)	Physical
for	O
asthma	O
patients	O
identified	O
as	O
being	O
poorly-controlled	O
from	O
practice	O
records	O
;	O
and	O
questionnaire	Others
data	Others
-	Physical
Mini	Physical
Asthma	Physical
Quality	Physical
of	Physical
Life	Physical
Questionnaire	Physical
(	Physical
AQLQ	Physical
)	Physical
and	Physical
the	Physical
Asthma	Physical
Control	Physical
Questionnaire	Physical
(	Physical
ACQ	Physical
)	Physical
-	O
from	O
a	O
subset	O
of	O
consenting	O
patients	O
.	O

Data	O
was	O
collected	O
at	O
baseline	O
and	O
at	O
6-month	O
follow-up	O
.	O

ANALYSISs	O
:	O
Routine	O
data	O
was	O
analysed	O
for	O
629	O
patients	O
.	O

236	O
(	O
37	O
%	O
)	O
of	O
these	O
patients	O
consented	O
to	O
provide	O
questionnaire	O
data	O
at	O
baseline	O
,	O
with	O
75	O
%	O
returning	O
questionnaires	O
at	O
follow-up	O
.	O

After	O
adjustment	O
for	O
baseline	O
and	O
practice	O
,	O
there	O
was	O
a	O
significant	O
difference	O
at	O
followup	O
between	O
intervention	O
and	O
control	O
practices	O
on	O
the	O
Mini	Physical
AQLQ	Physical
only	O
(	O
p=0.03	O
)	O
.	O

Estimates	O
for	O
subsequent	O
sample	O
sizes	O
to	O
inform	O
future	O
trials	O
of	O
asthma	O
training	O
were	O
identified	O
.	O

CONCLUSION	O
Training	O
designed	O
to	O
support	O
practice	O
nurses	O
in	O
implementing	O
individualised	O
AAPs	O
impacted	O
on	O
one	O
patient	O
outcome	O
only	O
.	O

This	O
disappointing	O
outcome	O
may	O
have	O
been	O
due	O
to	O
many	O
different	O
factors	O
such	O
as	O
outcome	O
measure	O
limitations	O
,	O
data	O
collection	O
problems	O
,	O
and	O
underestimating	O
the	O
complexity	O
of	O
supporting	O
practice	O
nurses	O
in	O
behaviour	O
change	O
.	O

Ascaris	O
and	O
growth	O
rates	O
:	O
a	O
randomized	O
trial	O
of	O
treatment	O
.	O

Three	O
hundred	O
forty-one	O
Tanzanian	O
preschool	O
children	O
were	O
randomly	O
assigned	O
to	O
levamisole	O
or	O
placebo	O
treatment	O
given	O
at	O
three-month	O
intervals	O
.	O

Weights	Physical
and	Physical
heights	Physical
were	O
measured	O
at	O
the	O
tri-monthly	O
treatment	O
visits	O
for	O
a	O
period	O
of	O
one	O
year	O
.	O

Among	O
the	O
273	O
children	O
who	O
were	O
seen	O
and	O
weighed	O
at	O
the	O
one-year	O
follow-up	O
visit	O
,	O
the	O
rate	Physical
of	Physical
weight	Physical
gain	Physical
was	O
8	O
per	O
cent	O
greater	O
for	O
those	O
receiving	O
levamisole	O
than	O
for	O
placebo-treated	O
controls	O
(	O
p	O
=	O
.06	O
)	O
.	O

In	O
78	O
children	O
known	O
to	O
be	O
infected	O
with	O
Ascaris	O
at	O
baseline	O
,	O
the	O
rate	Physical
of	Physical
weight	Physical
gain	Physical
was	O
21	O
per	O
cent	O
greater	O
in	O
children	O
treated	O
with	O
levamisole	O
than	O
in	O
those	O
receiving	O
placebo	O
(	O
p	O
=	O
.03	O
)	O
.	O

The	O
rate	Physical
of	Physical
height	Physical
gain	Physical
was	O
no	O
different	O
for	O
treatment	O
and	O
placebo	O
groups	O
.	O

Prospective	O
trial	O
of	O
intraoperative	O
mitomycin	O
C	O
in	O
the	O
treatment	O
of	O
primary	O
pterygium	O
.	O

AIMS	O
A	O
prospective	O
,	O
randomised	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
study	O
of	O
intraoperative	O
mitomycin	O
C	O
as	O
adjunctive	O
treatment	O
of	O
primary	O
pterygium	O
was	O
conducted	O
.	O

METHODS	O
A	O
total	O
of	O
66	O
eyes	O
of	O
54	O
patients	O
with	O
primary	O
pterygium	O
were	O
treated	O
with	O
excision	O
,	O
with	O
or	O
without	O
a	O
single	O
intraoperative	O
application	O
of	O
mitomycin	O
C	O
(	O
0.1	O
mg/ml	O
for	O
5	O
minutes	O
)	O
to	O
evaluate	O
the	O
efficacy	Others
and	Others
toxicity	Others
of	O
this	O
adjunctive	O
treatment	O
.	O

The	O
mean	O
follow	O
up	O
was	O
14.1	O
months	O
(	O
range	O
12-23	O
months	O
)	O
.	O

RESULTS	O
Of	O
the	O
36	O
eyes	O
that	O
underwent	O
simple	O
excision	O
,	O
14	O
(	O
38.8	O
%	O
)	O
exhibited	O
recurrences	Physical
whereas	O
only	O
one	O
of	O
30	O
eyes	O
(	O
3.33	O
%	O
)	O
treated	O
with	O
excision	O
and	O
intraoperative	O
application	O
of	O
mitomycin	O
C	O
had	O
recurrence	Physical
(	O
p	O
=	O
0.0006	O
)	O
.	O

Neither	O
serious	O
ocular	Adverseeffect
complications	Adverseeffect
nor	Adverseeffect
systemic	Adverseeffect
toxicity	Adverseeffect
were	O
noted	O
in	O
the	O
mitomycin	O
C	O
treated	O
group	O
.	O

CONCLUSION	O
Intraoperative	O
mitomycin	O
C	O
appears	O
to	O
be	O
an	O
effective	O
and	O
safe	O
adjunctive	O
treatment	O
of	O
primary	O
pterygium	O
.	O

[	O
Results	O
of	O
a	O
cooperative	O
prospective	O
study	O
of	O
treatment	O
of	O
primary	O
digestive	O
localizations	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
]	O
.	O

We	O
report	O
the	O
results	O
of	O
chemotherapy	O
treatment	O
in	O
82	O
patients	O
presenting	O
with	O
primary	O
digestive	O
lymphoma	O
and	O
included	O
in	O
a	O
study	O
conducted	O
between	O
October	O
1977	O
and	O
October	O
1985	O
.	O

There	O
were	O
31	O
gastric	O
lymphoma	O
,	O
18	O
small	O
intestinal	O
lymphomas	O
,	O
and	O
19	O
with	O
multiple	O
involvement	O
:	O
63	O
patients	O
had	O
had	O
a	O
surgical	O
staging	O
with	O
total	O
tumor	O
resection	O
in	O
15	O
cases	O
.	O

Nineteen	O
patients	O
with	O
limited	O
disease	O
(	O
ID	O
and	O
IID	O
)	O
were	O
randomly	O
assigned	O
to	O
either	O
a	O
3-week	O
chemotherapy	O
regimen	O
associated	O
with	O
whole	O
abdominal	O
radiotherapy	O
or	O
chemotherapy	O
for	O
3	O
years	O
.	O

Twenty-seven	O
stage	O
IIID	O
and	O
thirty-six	O
stage	O
IV	O
were	O
treated	O
with	O
chemotherapy	O
alone	O
for	O
3	O
years	O
.	O

Low	O
grade	O
lymphomas	O
(	O
16	O
patients	O
)	O
received	O
a	O
cyclophosphamide	O
,	O
vincristine	O
,	O
prednisone	O
association	O
.	O

Intermediate	O
(	O
56	O
patients	O
)	O
and	O
high	O
grade	O
(	O
10	O
patients	O
)	O
lymphomas	O
received	O
cyclophosphamide	O
,	O
vincristine	O
,	O
adriamycin	O
,	O
prednisone	O
.	O

The	O
overall	Physical
complete	Physical
remission	Physical
obtained	O
was	O
63	O
p.	O
100	O
(	O
51	O
patients	O
)	O
with	O
17	O
patients	O
in	O
relapse	Physical
within	O
6	O
to	O
40	O
months	O
.	O

Overall	Mortality
survival	Mortality
was	O
46	O
p.	O
100	O
at	O
5	O
years	O
.	O

Survival	Mortality
was	O
dependent	O
on	O
abdominal	Physical
extension	Physical
,	Physical
histologic	Physical
grade	Physical
according	Physical
to	Physical
the	Physical
new	Physical
working	Physical
formulation	Physical
used	Physical
for	Physical
lymph-node	Physical
lymphomas	Physical
,	Physical
initial	Physical
localization	Physical
(	O
gastric	O
lymphomas	O
have	O
the	O
best	O
survival	O
)	O
and	O
achievement	O
of	O
complete	Physical
remission	Physical
.	O

Chemotherapy	O
is	O
an	O
effective	O
treatment	Others
for	O
primary	O
digestive	O
lymphomas	O
.	O

The	O
role	O
of	O
surgery	O
in	O
the	O
management	O
of	O
lymphomas	O
has	O
to	O
be	O
defined	O
by	O
further	O
studies	O
.	O

Screening	O
,	O
brief	O
intervention	O
,	O
and	O
referral	O
to	O
treatment	O
(	O
SBIRT	O
)	O
in	O
a	O
Polish	O
emergency	O
department	O
:	O
three-month	O
outcomes	O
of	O
a	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

OBJECTIVE	O
A	O
randomized	O
,	O
controlled	O
trial	O
of	O
screening	O
,	O
brief	O
intervention	O
,	O
and	O
referral	O
to	O
treatment	O
(	O
SBIRT	O
)	O
for	O
drinking	O
and	O
related	O
problems	O
among	O
at-risk	O
and	O
dependent	O
drinkers	O
was	O
conducted	O
in	O
an	O
emergency	O
department	O
(	O
ED	O
)	O
in	O
Sosnowiec	O
,	O
Poland	O
,	O
among	O
patients	O
ages	O
18	O
years	O
and	O
older	O
.	O

METHOD	O
Data	O
were	O
collected	O
over	O
a	O
23-week	O
period	O
,	O
from	O
4:00	O
PM	O
to	O
midnight	O
,	O
and	O
resulted	O
in	O
446	O
patients	O
being	O
recruited	O
into	O
the	O
study	O
(	O
90	O
%	O
of	O
those	O
who	O
screened	O
positive	O
)	O
and	O
randomized	O
to	O
three	O
conditions	O
following	O
a	O
two-stage	O
process	O
:	O
screened	O
only	O
(	O
n	O
=	O
147	O
)	O
,	O
assessed	O
(	O
n	O
=	O
152	O
)	O
,	O
and	O
received	O
intervention	O
(	O
n	O
=	O
147	O
)	O
.	O

Patients	O
in	O
the	O
assessment	O
(	O
85	O
%	O
)	O
and	O
intervention	O
(	O
83	O
%	O
)	O
conditions	O
were	O
blindly	O
reassessed	O
at	O
3	O
months	O
via	O
a	O
telephone	O
interview	O
.	O

RESULTS	O
At	O
3-month	O
follow-up	O
,	O
both	O
groups	O
showed	O
significant	O
decreases	O
in	O
the	O
proportion	O
who	O
were	O
positive	O
for	O
at-risk	O
drinking	O
,	O
the	O
primary	O
outcome	O
variable	O
.	O

Both	O
groups	O
also	O
showed	O
significant	O
decreases	O
in	O
drinking	Mental
days	Mental
per	Mental
week	Mental
,	O
drinks	Mental
per	Mental
drinking	Mental
day	Mental
,	O
maximum	Mental
drinks	Mental
per	Mental
occasion	Mental
,	O
and	O
negative	Mental
consequences	Mental
of	Mental
drinking	Mental
.	O

Using	O
analysis	O
of	O
covariance	O
to	O
control	O
for	O
baseline	O
measures	O
and	O
demographic	O
characteristics	O
,	O
no	O
difference	O
in	O
outcome	O
measures	O
was	O
found	O
between	O
intervention	O
and	O
assessment	O
conditions	O
.	O

Subgroup	O
analysis	O
found	O
some	O
significant	O
interactions	O
between	O
intervention	O
and	O
secondary	O
outcomes	O
.	O

CONCLUSIONS	O
Although	O
the	O
main	O
findings	O
were	O
similar	O
to	O
those	O
from	O
other	O
brief-intervention	O
studies	O
in	O
Western	O
cultures	O
,	O
findings	O
here	O
also	O
suggest	O
that	O
intervention	O
may	O
have	O
differential	O
benefits	O
for	O
specific	O
subgroups	O
of	O
patients	O
in	O
the	O
ED	O
,	O
an	O
area	O
of	O
research	O
that	O
may	O
warrant	O
additional	O
study	O
of	O
brief	O
intervention	O
in	O
the	O
ED	O
setting	O
.	O

The	O
effect	O
of	O
calcium	O
supplementation	O
on	O
bone	O
density	O
in	O
premenarcheal	O
females	O
:	O
a	O
co-twin	O
approach	O
.	O

The	O
age	O
and	O
developmental	O
stage	O
at	O
which	O
calcium	O
supplementation	O
produces	O
the	O
greatest	O
bone	O
effects	O
remain	O
controversial	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
calcium	O
supplementation	O
may	O
improve	O
bone	Physical
accrual	Physical
in	O
premenarcheal	O
females	O
.	O

Fifty-one	O
pairs	O
of	O
premenarcheal	O
female	O
twins	O
(	O
27	O
monozygotic	O
and	O
24	O
dizygotic	O
;	O
mean	O
+/-	O
sd	O
age	O
,	O
10.3	O
+/-	O
1.5	O
yr	O
)	O
participated	O
in	O
a	O
randomized	O
,	O
single-blind	O
,	O
placebo-controlled	O
trial	O
with	O
one	O
twin	O
of	O
each	O
pair	O
receiving	O
a	O
1200-mg	O
calcium	O
carbonate	O
(	O
Caltrate	O
)	O
supplement	O
.	O

Areal	Physical
bone	Physical
mineral	Physical
density	Physical
(	Physical
aBMD	Physical
)	Physical
was	O
measured	O
at	O
baseline	O
and	O
6	O
,	O
12	O
,	O
18	O
and	O
24	O
months	O
.	O

There	O
were	O
no	O
within-pair	O
differences	O
in	O
height	O
,	O
weight	O
,	O
or	O
calcium	O
intake	O
at	O
baseline	O
.	O

Calcium	O
supplementation	O
was	O
associated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
increased	O
aBMD	Physical
compared	O
with	O
placebo	O
,	O
adjusted	O
for	O
age	O
,	O
height	O
,	O
and	O
weight	O
at	O
the	O
following	O
time	O
points	O
from	O
baseline	O
:	O
total	O
hip	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
,	O
12	O
months	O
(	O
1.6	O
%	O
)	O
,	O
and	O
18	O
months	O
(	O
2.4	O
%	O
)	O
;	O
lumbar	O
spine	O
,	O
12	O
months	O
(	O
1.0	O
%	O
)	O
;	O
femoral	O
neck	O
,	O
6	O
months	O
(	O
1.9	O
%	O
)	O
.	O

Adjusted	Physical
total	Physical
body	Physical
bone	Physical
mineral	Physical
content	Physical
was	O
higher	O
in	O
the	O
calcium	O
group	O
at	O
6	O
months	O
(	O
2.0	O
%	O
)	O
,	O
12	O
months	O
(	O
2.5	O
%	O
)	O
,	O
18	O
months	O
(	O
4.6	O
%	O
)	O
,	O
and	O
24	O
months	O
(	O
3.7	O
%	O
)	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.	O

Calcium	O
supplementation	O
was	O
effective	O
in	O
increasing	O
aBMD	Physical
at	O
regional	O
sites	O
over	O
the	O
first	O
12-18	O
months	O
,	O
but	O
these	O
gains	O
were	O
not	O
maintained	O
to	O
24	O
months	O
.	O

Randomized	O
clinical	O
trial	O
comparing	O
laparoscopic	O
and	O
open	O
surgery	O
in	O
patients	O
with	O
rectal	O
cancer	O
.	O

BACKGROUND	O
The	O
laparoscopic	O
treatment	O
of	O
rectal	O
cancer	O
is	O
controversial	O
.	O

This	O
study	O
compared	O
surgical	O
outcomes	O
after	O
laparoscopic	O
and	O
open	O
approaches	O
for	O
mid	O
and	O
low	O
rectal	O
cancers	O
.	O

METHODS	O
Some	O
204	O
patients	O
with	O
mid	O
and	O
low	O
rectal	O
adenocarcinomas	O
were	O
allocated	O
randomly	O
to	O
open	O
(	O
103	O
)	O
or	O
laparoscopic	O
(	O
101	O
)	O
surgery	O
.	O

The	O
surgical	O
team	O
was	O
the	O
same	O
for	O
both	O
procedures	O
.	O

Most	O
patients	O
had	O
stage	O
II	O
or	O
III	O
disease	O
,	O
and	O
received	O
neoadjuvant	O
therapy	O
with	O
oral	O
capecitabine	O
and	O
50-54	O
Gy	O
external	O
beam	O
radiotherapy	O
.	O

RESULTS	O
Sphincter-preserving	O
surgery	O
was	O
performed	O
in	O
78.6	O
and	O
76.2	O
per	O
cent	O
of	O
patients	O
in	O
the	O
open	O
and	O
laparoscopic	O
groups	O
respectively	O
.	O

Blood	Adverseeffect
loss	Adverseeffect
was	O
significantly	O
greater	O
for	O
open	O
surgery	O
(	O
P	O
<	O
0.001	O
)	O
and	O
operating	Others
time	Others
was	O
significantly	O
greater	O
for	O
laparoscopic	O
surgery	O
(	O
P	O
=	O
0.020	O
)	O
,	O
and	O
return	O
to	O
diet	O
and	O
hospital	Others
stay	Others
were	O
longer	O
for	O
open	O
surgery	O
.	O

Complication	Adverseeffect
rates	Adverseeffect
,	Adverseeffect
and	Adverseeffect
involvement	Adverseeffect
of	Adverseeffect
circumferential	Adverseeffect
and	Adverseeffect
radial	Adverseeffect
margins	Adverseeffect
were	O
similar	O
for	O
both	O
procedures	O
,	O
but	O
the	O
number	O
of	O
isolated	O
lymph	O
nodes	O
was	O
greater	O
in	O
the	O
laparoscopic	O
group	O
(	O
mean	O
13.63	O
versus	O
11.57	O
;	O
P	O
=	O
0.026	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
local	Mortality
recurrence	Mortality
,	Mortality
disease-free	Mortality
or	Mortality
overall	Mortality
survival	Mortality
.	Mortality

CONCLUSION	O
Laparoscopic	O
surgery	O
for	O
rectal	O
cancer	O
has	O
a	O
similar	O
complication	O
rate	O
to	O
open	O
surgery	O
,	O
with	O
less	O
blood	Adverseeffect
loss	Adverseeffect
,	O
rapid	O
intestinal	Adverseeffect
recovery	Adverseeffect
,	O
shorter	O
hospital	Others
stay	Others
,	O
and	O
no	O
compromise	O
of	O
oncological	Physical
outcomes	Physical
.	Physical

Randomized	O
study	O
of	O
six	O
umbilical	O
cord	O
care	O
regimens	O
.	O

Comparing	O
length	O
of	O
attachment	O
,	O
microbial	O
control	O
,	O
and	O
satisfaction	O
.	O

Two	O
hundred	O
and	O
seventy	O
one	O
infants	O
were	O
enrolled	O
in	O
a	O
study	O
to	O
compare	O
six	O
different	O
methods	O
of	O
treating	O
the	O
umbilical	O
cord	O
.	O

Antimicrobial	O
control	O
was	O
equal	O
for	O
all	O
methods	O
.	O

Repeated	O
triple	O
dye	O
application	O
was	O
considered	O
least	Physical
acceptable	Physical
by	O
staff	O
and	O
parents	O
and	O
had	O
the	O
longest	Physical
attachment	Physical
time	Physical
.	Physical

Povidone-iodine	O
was	O
associated	O
with	O
the	O
shortest	O
attachment	Mental
time	Mental
and	O
was	O
most	O
liked	O
.	O

If	O
there	O
is	O
no	O
special	O
need	O
to	O
treat	O
a	O
specific	Physical
nosocomial	Physical
outbreak	Physical
,	Physical
duration	Physical
of	Physical
cord	Physical
attachment	Physical
and	Physical
satisfaction	Physical
of	Physical
staff	Physical
and	Physical
parents	Physical
can	O
help	O
clinicians	O
decide	O
on	O
a	O
cord	O
care	O
regimen	O
.	O

Effects	O
of	O
an	O
antimicrobial	O
additive	O
to	O
toothbrushes	O
on	O
residual	Physical
periodontal	Physical
pathogens	Physical
.	Physical

OBJECTIVE	O
Previous	O
studies	O
have	O
reported	O
the	O
link	O
between	O
residual	O
microbial	O
contamination	O
of	O
toothbrushes	O
and	O
periodontal	O
diseases	O
.	O

The	O
goal	O
of	O
this	O
pilot	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
an	O
antimicrobial	O
additive	O
(	O
Microban	O
)	O
to	O
toothbrushes	O
on	O
residual	Others
retention	Others
of	Others
periodontal	Others
pathogens	Others
.	Others

METHODOLOGY	O
Twenty	O
patients	O
had	O
one	O
side	O
of	O
their	O
mouths	O
brushed	O
with	O
a	O
toothbrush	O
containing	O
the	O
antimicrobial	O
agent	O
(	O
experimental	O
side	O
)	O
,	O
and	O
the	O
other	O
side	O
with	O
a	O
toothbrush	O
containing	O
no	O
agent	O
(	O
control	O
)	O
.	O

Toothbrushes	O
were	O
air-dried	O
(	O
25	O
degrees	O
C	O
)	O
for	O
four	O
or	O
24	O
hours	O
.	O

Toothbrush	O
heads	O
were	O
vortexed	O
and	O
cultured	O
for	O
Prevotella	O
species	O
(	O
Ps	O
)	O
,	O
Porphyromonas	O
gingivalis	O
(	O
Pg	O
)	O
,	O
Actinobacillus	O
actinomycetemcomitans	O
(	O
Aa	O
)	O
,	O
and	O
non-specific	O
colony-forming	O
units	O
(	O
NS	O
)	O
.	O

The	O
plates	O
were	O
incubated	O
and	O
counted	O
.	O

Means	O
and	O
standard	O
deviations	O
were	O
calculated	O
,	O
and	O
data	O
were	O
analyzed	O
using	O
a	O
series	O
of	O
t-tests	O
(	O
paired	O
and	O
unpaired	O
)	O
and	O
Wilcoxon	O
matched-pairs	O
signed-rank	O
test	O
.	O

RESULTS	O
No	O
significant	O
inter-	O
or	O
intra-group	O
differences	O
in	O
mean	Others
counts	Others
were	O
found	O
;	O
however	O
,	O
when	O
four-hour	O
and	O
24-hour	O
data	O
for	O
Aa	Others
,	Others
Pg	Others
,	Others
or	Others
NS	Others
were	O
combined	O
,	O
experimental	Others
counts	Others
were	O
lower	O
than	O
controls	O
in	O
39/50	O
(	O
78	O
%	O
)	O
of	O
the	O
matched	O
pairs	O
(	O
Wilcoxon	O
signed-rank	O
test	O
p	O
=	O
0.01	O
)	O
.	O

CONCLUSION	O
Toothbrushes	O
containing	O
the	O
antimicrobial	O
additive	O
showed	O
lower	O
microbial	Others
counts	Others
than	O
those	O
without	O
,	O
but	O
between-group	O
means	O
were	O
not	O
statistically	O
significant	O
.	O

Long-term	O
results	O
regarding	O
the	O
use	O
of	O
recombinant	O
interferon	O
alpha-2b	O
in	O
the	O
treatment	O
of	O
II	O
type	O
mixed	O
essential	O
cryoglobulinemia	O
.	O

Thirty-three	O
patients	O
with	O
II	O
type	O
mixed	O
essential	O
cryoglobulinemia	O
(	O
MEC	O
)	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
one	O
to	O
receive	O
combined	O
therapy	O
including	O
prednisone	O
plus	O
interferon	O
,	O
the	O
other	O
to	O
receive	O
prednisone	O
therapy	O
.	O

Interferon	O
was	O
administered	O
as	O
induction	O
treatment	O
(	O
3	O
Mu/day	O
)	O
and	O
then	O
as	O
maintenance	O
therapy	O
(	O
3	O
Mu	O
three	O
times	O
a	O
week	O
)	O
.	O

83	O
%	O
of	O
the	O
combined	O
therapy	O
patients	O
responded	O
as	O
opposed	O
to	O
27	O
%	O
of	O
the	O
prednisone	O
treated	O
patients	O
.	O

Among	O
the	O
patients	O
that	O
responded	O
to	O
combined	O
therapy	O
,	O
nine	O
of	O
them	O
had	O
a	O
complete	O
response	O
,	O
four	O
a	O
partial	O
response	O
,	O
and	O
two	O
a	O
minor	O
response	O
.	O

None	O
of	O
the	O
patients	O
treated	O
with	O
prednisone	O
therapy	O
responded	O
completely	O
but	O
only	O
two	O
had	O
a	O
partial	O
and	O
two	O
a	O
minor	O
response	O
.	O

Four	O
patients	O
(	O
three	O
of	O
combined	O
therapy	O
and	O
one	O
of	O
prednisone	O
therapy	O
)	O
showed	O
proteinuria	Physical
before	O
the	O
treatment	O
which	O
improved	O
at	O
the	O
end	O
of	O
the	O
induction	O
therapy	O
.	O

Ten	O
patients	O
showed	O
anti-HCV	Physical
positivity	Physical
which	O
remained	O
unchanged	O
after	O
the	O
treatment	O
.	O

Three	O
patients	O
showed	O
liver	Physical
involvement	Physical
secondary	O
to	O
cryoglobulinemia	O
and	O
an	O
improvement	O
of	O
histological	Physical
pattern	Physical
after	O
the	O
induction	O
with	O
combined	O
therapy	O
.	O

One	O
patient	O
showed	O
an	O
improvement	O
of	O
peripheral	Physical
neuropathy	Physical
after	O
induction	O
with	O
the	O
combined	O
therapy	O
.	O

These	O
data	O
suggest	O
the	O
effectiveness	O
of	O
interferon	O
given	O
as	O
induction	O
and	O
as	O
maintenance	O
treatment	O
in	O
the	O
therapy	O
of	O
II	O
type	O
mixed	O
essential	O
cryoglobulinemia	O
.	O

Effect	O
of	O
micronutrient	O
supplement	O
on	O
health	Physical
and	Physical
nutritional	Physical
status	Physical
of	O
schoolchildren	O
:	O
study	O
design	O
.	O

OBJECTIVE	O
We	O
tested	O
the	O
hypothesis	O
that	O
supplementation	O
with	O
a	O
micronutrient-fortified	O
beverage	O
improves	O
micronutrient	O
status	O
and	O
physical	O
and	O
mental	O
development	O
in	O
apparently	O
healthy	O
schoolchildren	O
.	O

METHODS	O
The	O
study	O
was	O
carried	O
out	O
in	O
middle-income	O
students	O
in	O
two	O
residential	O
schools	O
that	O
catered	O
to	O
children	O
from	O
a	O
semi-urban	O
population	O
near	O
Hyderabad	O
,	O
India	O
.	O

Included	O
were	O
869	O
children	O
who	O
were	O
6	O
to	O
16	O
y	O
of	O
age	O
in	O
grades	O
1	O
to	O
10	O
.	O

Because	O
children	O
at	O
each	O
grade	O
were	O
distributed	O
across	O
two	O
classrooms	O
(	O
clusters	O
)	O
and	O
were	O
homogeneous	O
,	O
each	O
grade	O
was	O
considered	O
to	O
consist	O
of	O
a	O
matched	O
pair	O
.	O

There	O
were	O
thus	O
10	O
pairs	O
available	O
for	O
the	O
study	O
.	O

Classes	O
in	O
each	O
grade	O
were	O
randomized	O
to	O
receive	O
a	O
micronutrient-enriched	O
beverage	O
or	O
a	O
placebo	O
without	O
added	O
micronutrients	O
.	O

The	O
study	O
was	O
double	O
blinded	O
and	O
the	O
duration	O
was	O
14	O
mo	O
,	O
with	O
supervised	O
feeding	O
of	O
the	O
micronutrient-enriched	O
beverage	O
.	O

The	O
effect	O
of	O
the	O
micronutrients	O
on	O
the	O
outcome	Physical
variables	Physical
growth	Physical
,	Physical
biochemical	Physical
status	Physical
,	O
mental	Mental
function	Mental
,	O
and	O
bone	Physical
health	Physical
were	O
assessed	O
.	O

RESULTS	O
The	O
number	O
of	O
matched	O
pairs	O
varied	O
between	O
seven	O
and	O
eight	O
,	O
and	O
the	O
required	O
number	O
of	O
children	O
per	O
treatment	O
group	O
ranged	O
from	O
32	O
in	O
the	O
case	O
of	O
bone	O
heath	O
to	O
177	O
for	O
body	O
weight	O
.	O

The	O
power	O
of	O
the	O
outcome	O
variables	O
ranged	O
from	O
74	O
%	O
to	O
100	O
%	O
and	O
was	O
adequate	O
for	O
successful	O
pairing	O
.	O

The	O
effect	O
assessed	O
at	O
the	O
end	O
of	O
supplementation	O
showed	O
that	O
the	O
intervention	O
was	O
beneficial	Others
.	O

CONCLUSIONS	O
Designing	O
an	O
intervention	O
,	O
choosing	O
outcome	O
variables	O
,	O
and	O
implementing	O
the	O
protocol	O
in	O
a	O
typical	O
Indian	O
school	O
setting	O
were	O
achieved	O
.	O

Preliminary	O
evaluation	O
of	O
psychoeducational	O
support	O
interventions	O
on	O
quality	Others
of	Others
life	Others
in	O
rural	O
breast	O
cancer	O
survivors	O
after	O
primary	O
treatment	O
.	O

Although	O
most	O
cancer	O
survivors	O
are	O
at	O
risk	O
for	O
being	O
lost	O
in	O
the	O
transition	O
from	O
treatment	O
to	O
survivorship	O
,	O
rural	O
breast	O
cancer	O
survivors	O
face	O
special	O
challenges	O
that	O
might	O
place	O
them	O
at	O
particular	O
risk	O
.	O

This	O
small-scale	O
preliminary	O
study	O
had	O
2	O
specific	O
aims	O
:	O
(	O
aim	O
1	O
)	O
establish	O
the	O
feasibility	O
of	O
rural	O
breast	O
cancer	O
survivors	O
participation	O
in	O
a	O
longitudinal	O
quality	Others
of	Others
life	Others
(	Others
QOL	Others
)	Others
intervention	O
trial	O
and	O
(	O
aim	O
2	O
)	O
determine	O
the	O
effects	O
of	O
the	O
Breast	O
Cancer	O
Education	O
Intervention	O
(	O
BCEI	O
)	O
on	O
overall	Others
QOL	Others
.	Others

Fifty-three	O
rural	O
breast	O
cancer	O
survivors	O
were	O
randomized	O
to	O
either	O
an	O
experimental	O
(	O
n	O
=	O
27	O
)	O
or	O
a	O
wait-control	O
arm	O
(	O
n	O
=	O
26	O
)	O
.	O

Participants	O
in	O
the	O
experimental	O
arm	O
received	O
the	O
BCEI	O
consisting	O
of	O
3	O
face-to-face	O
education	O
and	O
support	O
sessions	O
and	O
2	O
face-to-face	O
and	O
3	O
telephone	O
follow-up	O
sessions	O
,	O
along	O
with	O
supplemental	O
written	O
and	O
audiotape	O
materials	O
over	O
a	O
6-month	O
period	O
.	O

Breast	O
Cancer	O
Education	O
Intervention	O
modules	O
and	O
interventions	O
are	O
organized	O
within	O
a	O
QOL	O
framework	O
.	O

To	O
address	O
the	O
possible	O
effects	O
of	O
attention	O
,	O
wait-control	O
participants	O
received	O
3	O
face-to-face	O
sessions	O
and	O
3	O
telephone	O
sessions	O
during	O
the	O
first	O
6	O
months	O
of	O
participation	O
in	O
the	O
study	O
,	O
but	O
not	O
the	O
BCEI	O
intervention	O
.	O

Research	O
questions	O
addressing	O
aim	O
1	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
can	O
rural	O
breast	O
cancer	O
survivors	O
be	O
recruited	O
into	O
a	O
longitudinal	O
intervention	O
trial	O
,	O
and	O
(	O
b	O
)	O
can	O
their	O
participation	O
be	O
retained	O
.	O

Research	O
questions	O
for	O
aim	O
2	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
do	O
participants	O
who	O
received	O
the	O
BCEI	O
show	O
improvement	O
in	O
overall	Physical
QOL	Physical
,	O
and	O
(	O
b	O
)	O
is	O
the	O
QOL	Physical
improvement	Physical
sustained	O
over	O
time	O
.	O

Data	O
were	O
analyzed	O
using	O
repeated-measures	O
general	O
linear	O
mixed	O
models	O
.	O

Results	O
demonstrated	O
the	O
ability	O
to	O
recruit	O
and	O
retain	O
53	O
rural	O
breast	O
cancer	O
survivors	O
,	O
that	O
the	O
experimental	O
arm	O
showed	O
improvement	O
in	O
overall	Physical
QOL	Physical
(	O
P	O
=	O
.013	O
)	O
,	O
and	O
that	O
there	O
were	O
significant	O
differences	O
in	O
overall	Physical
QOL	Physical
between	O
the	O
experimental	O
and	O
wait-control	O
groups	O
at	O
both	O
months	O
3	O
and	O
6	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
at	O
least	O
some	O
rural	O
breast	O
cancer	O
survivors	O
can	O
and	O
will	O
participate	O
in	O
a	O
larger	O
trial	O
and	O
will	O
maintain	O
their	O
participation	O
and	O
that	O
those	O
that	O
do	O
participate	O
experience	O
significant	O
QOL	Physical
benefit	O
.	O

Abrasive	Others
wear	Others
on	O
eroded	O
root	O
dentine	O
after	O
different	O
periods	O
of	O
exposure	O
to	O
saliva	O
in	O
situ	O
.	O

The	O
effect	O
of	O
salivary	O
exposure	O
time	O
on	O
the	O
abrasive	Others
wear	Others
of	O
acid-eroded	O
dentine	O
was	O
evaluated	O
in	O
situ	O
.	O

One-hundred	O
and	O
twenty	O
bovine	O
root	O
dentine	O
slabs	O
were	O
randomly	O
assigned	O
into	O
six	O
groups	O
(	O
A-F	O
)	O
and	O
placed	O
in	O
intraoral	O
palatal	O
devices	O
,	O
which	O
were	O
worn	O
by	O
10	O
volunteers	O
for	O
4	O
d.	O
On	O
the	O
first	O
day	O
,	O
no	O
erosive/abrasive	O
procedures	O
were	O
carried	O
out	O
.	O

On	O
the	O
following	O
3	O
d	O
,	O
erosive	O
challenges	O
were	O
performed	O
extraorally	O
,	O
two	O
times	O
per	O
day	O
,	O
by	O
immersing	O
the	O
device	O
for	O
90	O
s	O
in	O
a	O
soft	O
drink	O
.	O

Subsequently	O
,	O
the	O
group	O
A	O
specimens	O
were	O
immediately	O
brushed	O
(	O
40	O
strokes	O
)	O
,	O
and	O
the	O
others	O
were	O
brushed	O
after	O
the	O
following	O
times	O
:	O
B	O
,	O
20	O
min	O
;	O
C	O
,	O
40	O
min	O
;	O
and	O
D	O
,	O
60	O
min	O
.	O

Group	O
E	O
specimens	O
were	O
only	O
acid-eroded	O
and	O
those	O
of	O
group	O
F	O
were	O
only	O
brushed	O
.	O

Dentine	Others
wear	Others
was	O
measured	O
with	O
a	O
profilometer	O
.	O

anova	O
and	O
Dunnett	O
's	O
test	O
showed	O
that	O
groups	O
A-D	O
did	O
not	O
differ	O
statistically	O
from	O
the	O
control	O
group	O
E	O
but	O
differed	O
from	O
the	O
control	O
group	O
F.	O
The	O
lowest	O
mean	O
value	O
was	O
found	O
for	O
group	O
F.	O
Regression	O
analysis	O
was	O
unable	O
to	O
show	O
salivary	O
effect	O
on	O
dentine	Others
wear	Others
reduction	Others
.	O

The	O
data	O
suggest	O
that	O
the	O
exposure	O
time	O
of	O
saliva	O
of	O
up	O
to	O
60	O
min	O
has	O
no	O
effect	O
on	O
reducing	O
the	O
eroded	Others
dentine	Others
wear	Others
by	O
toothbrushing	O
.	O

Oral	O
amoxicillin	O
vs.	O
oral	O
erythromycin	O
in	O
the	O
treatment	Physical
of	Physical
pyoderma	Physical
in	O
Bamako	O
,	O
Mali	O
:	O
an	O
open	O
randomized	O
trial	O
.	O

BACKGROUND	O
Pyoderma	O
(	O
bacterial	O
superficial	O
skin	O
infection	O
)	O
is	O
an	O
extremely	O
common	O
disorder	O
in	O
tropical	O
developing	O
countries	O
.	O

In	O
these	O
settings	O
,	O
Streptococcus	O
pyogenes	O
is	O
considered	O
to	O
be	O
the	O
main	O
etiological	O
agent	O
.	O

Apart	O
from	O
epidemics	O
of	O
poststreptococcal	O
glomerulonephritis	O
where	O
mass	O
treatment	O
with	O
intramuscular	O
benzathine-penicillin	O
is	O
recommended	O
,	O
no	O
recommendation	O
exists	O
for	O
the	O
treatment	O
of	O
pyoderma	O
in	O
this	O
setting	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
oral	O
amoxicillin	O
in	O
the	O
treatment	O
of	O
pyoderma	O
in	O
Mali	O
,	O
by	O
comparison	O
with	O
oral	O
erythromycin	O
.	O

METHODS	O
In	O
Bamako	O
,	O
132	O
patients	O
with	O
pyoderma	O
,	O
diagnosed	O
and	O
graded	O
as	O
severe	O
on	O
clinical	O
grounds	O
,	O
were	O
randomly	O
assigned	O
to	O
an	O
oral	O
treatment	O
by	O
either	O
amoxicillin	O
(	O
50	O
mg/kg	O
per	O
day	O
)	O
or	O
erythromycin	O
;	O
infections	O
of	O
the	O
follicular	O
appendage	O
were	O
excluded	O
.	O

Both	O
drugs	O
were	O
associated	O
with	O
the	O
topical	O
application	O
of	O
povidone	O
iodine	O
.	O

The	O
patients	O
were	O
evaluated	O
openly	O
at	O
the	O
seventh	O
day	O
of	O
treatment	O
for	O
cure	O
or	O
marked	O
improvement	O
of	O
the	O
clinical	Others
features	Others
,	O
indicating	O
successful	Others
treatment	Others
.	O

RESULTS	O
Three	O
patients	O
were	O
lost	O
to	O
follow-up	O
.	O

Treatment	Others
was	Others
successful	Others
in	O
57	O
of	O
64	O
patients	O
treated	O
with	O
amoxicillin	O
vs.	O
58	O
of	O
65	O
patients	O
treated	O
with	O
erythromycin	O
(	O
P	O
=	O
0.00	O
)	O
.	O

CONCLUSIONS	O
Amoxicillin	Others
was	Others
as	Others
efficacious	Others
as	O
erythromycin	O
in	O
the	O
treatment	Physical
of	Physical
severe	Physical
pyoderma	Physical
in	O
Mali	O
.	O

Owing	O
to	O
its	O
efficacy	O
,	O
added	O
to	O
high	O
availability	O
and	O
low	O
cost	O
,	O
this	O
compound	O
should	O
be	O
considered	O
a	O
first-line	O
treatment	O
of	O
this	O
disorder	O
in	O
this	O
country	O
,	O
and	O
perhaps	O
in	O
other	O
countries	O
where	O
this	O
condition	O
presents	O
in	O
a	O
similar	O
way	O
.	O

Conservative	O
surgery	O
with	O
and	O
without	O
radiotherapy	O
in	O
elderly	O
patients	O
with	O
early-stage	O
breast	O
cancer	O
:	O
a	O
prospective	O
randomised	O
multicentre	O
trial	O
.	O

Breast	O
conserving	O
therapy	O
(	O
BCT	O
)	O
including	O
postoperative	O
irradiation	O
of	O
the	O
remaining	O
breast	O
tissue	O
is	O
generally	O
accepted	O
as	O
the	O
best	O
treatment	O
for	O
the	O
majority	O
of	O
patients	O
with	O
early-stage	O
breast	O
cancer	O
.	O

The	O
question	O
is	O
whether	O
there	O
is	O
a	O
necessity	O
for	O
irradiating	O
all	O
patients	O
.	O

Between	O
2001	O
and	O
2005	O
,	O
749	O
women	O
aged	O
55-75	O
years	O
with	O
infiltrating	O
breast	O
carcinoma	O
were	O
randomly	O
assigned	O
to	O
breast	O
conservative	O
surgery	O
,	O
with	O
or	O
without	O
radiotherapy	O
(	O
RT	O
)	O
,	O
to	O
evaluate	O
the	O
incidence	Physical
of	Physical
in-breast	Physical
recurrence	Physical
(	Physical
IBR	Physical
)	Physical
.	O

After	O
5	O
years	O
of	O
median	O
follow-up	O
,	O
the	O
cumulative	Physical
incidence	Physical
of	Physical
IBR	Physical
was	O
2.5	O
%	O
in	O
the	O
surgery-only	O
arm	O
and	O
0.7	O
%	O
in	O
the	O
surgery	O
plus	O
RT	O
arm	O
.	O

There	O
are	O
no	Others
differences	Others
in	O
terms	O
of	O
overall	Mortality
survival	Mortality
and	O
distant	Mortality
disease-free	Mortality
survival	Mortality
.	O

The	O
preliminary	O
evaluation	O
suggests	O
that	O
breast	O
irradiation	O
after	O
conservative	O
surgery	O
can	O
be	O
avoided	O
without	O
exposing	O
these	O
patients	O
to	O
an	O
increased	O
risk	Physical
of	Physical
distant-disease	Physical
recurrence	Physical
.	O

Prolonged	O
follow-up	O
will	O
further	O
clarify	O
the	O
possible	O
risks	O
and	O
late	O
sequelae	O
potentially	O
induced	O
by	O
breast	O
RT	O
.	O

Intraoperative	O
microscopy	O
of	O
bile	O
--	O
is	O
it	O
useful	O
?	O
Direct	O
microscopy	O
of	O
the	O
bile	O
was	O
performed	O
during	O
cholecystectomy	O
in	O
111	O
patients	O
in	O
an	O
attempt	O
to	O
identify	O
those	O
with	O
a	O
high	O
risk	O
of	O
wound	O
infection	O
.	O

Bacteria	O
were	O
identified	O
in	O
23	O
patients	O
,	O
11	O
of	O
83	O
undergoing	O
cholecystectomy	O
alone	O
and	O
12	O
of	O
28	O
undergoing	O
exploration	O
of	O
the	O
common	O
bile	O
duct	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

These	O
23	O
patients	O
were	O
randomly	O
allocated	O
to	O
an	O
antibiotic	O
group	O
or	O
a	O
control	O
group	O
;	O
there	O
was	O
one	O
wound	O
infection	O
in	O
the	O
antibiotic	O
group	O
and	O
two	O
in	O
the	O
control	O
group	O
.	O

A	O
total	O
of	O
14	O
patients	O
developed	O
wound	Physical
sepsis	Physical
.	Physical

Infection	Physical
was	O
more	O
likely	O
if	O
the	O
common	O
bile	O
duct	O
was	O
explored	O
(	O
6	O
of	O
28	O
)	O
rather	O
than	O
cholecystectomy	O
alone	O
(	O
8	O
of	O
83	O
)	O
.	O

There	O
was	O
a	O
poor	O
correlation	O
between	O
microscopy	O
and	O
culture	O
of	O
the	O
bile	O
for	O
bacteria	Adverseeffect
and	O
there	O
was	O
no	O
increase	O
in	O
sepsis	Physical
when	O
bacteria	O
were	O
observed	O
on	O
microscopy	O
.	O

We	O
were	O
not	O
able	O
to	O
identify	O
a	O
high	O
risk	O
group	O
of	O
patients	O
by	O
intraoperative	O
microscopy	O
of	O
bile	O
.	O

The	O
competition	O
between	O
enamel	O
and	O
dentin	O
adhesion	O
within	O
a	O
cavity	O
:	O
an	O
in	O
vitro	O
evaluation	O
of	O
class	O
V	O
restorations	O
.	O

To	O
gain	O
more	O
insight	O
into	O
the	O
consequences	O
of	O
curing	O
contraction	O
within	O
the	O
tooth	O
cavity	O
,	O
we	O
assessed	O
the	O
margin	O
behavior	O
of	O
12	O
contemporary	O
restorative	O
systems	O
in	O
class	O
V	O
restorations	O
with	O
margins	O
located	O
on	O
enamel	O
and	O
dentin	O
after	O
mechanical	O
loading	O
and	O
water	O
storage	O
.	O

Mixed	O
class	O
V	O
cavities	O
were	O
prepared	O
on	O
extracted	O
human	O
molars	O
and	O
restored	O
using	O
five	O
etch	O
and	O
rinse	O
and	O
seven	O
self-etch	O
adhesive	O
systems	O
with	O
their	O
corresponding	O
composites	O
.	O

Marginal	O
adaptation	O
was	O
evaluated	O
by	O
using	O
a	O
computer-assisted	O
quantitative	O
marginal	O
analysis	O
in	O
a	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
on	O
epoxy	O
replicas	O
before	O
,	O
after	O
thermal	O
and	O
mechanical	O
stressing	O
and	O
after	O
1	O
year	O
of	O
water	O
storage	O
.	O

The	O
interactions	O
of	O
testing	O
conditions	O
,	O
adhesive-composite	O
combination	O
and	O
tooth	O
substrate	O
with	O
marginal	O
adaptation	O
were	O
evaluated	O
by	O
two-way	O
ANOVA	O
.	O

Fatigue	Others
,	Others
stress	Others
and	Others
storage	Others
conditions	Others
had	O
significant	O
effects	O
on	O
the	O
marginal	Others
adaptation	Others
.	Others

Only	O
two	O
groups	O
(	O
Optibond	O
FL	O
and	O
G	O
Bond	O
)	O
presented	O
equal	O
percentages	O
of	O
marginal	Physical
adaptation	Physical
on	Physical
enamel	Physical
and	Others
dentin	Physical
;	Others
in	O
the	O
other	O
groups	O
,	O
the	O
rate	Physical
of	Physical
degradation	Physical
was	O
product	O
dependent	O
.	O

All	O
materials	O
tested	O
showed	O
a	O
distinct	O
behavior	O
on	O
enamel	Physical
and	O
dentin	Physical
.	O

In	O
addition	O
to	O
mechanical	O
resistance	O
and	O
long-term	O
stability	O
,	O
differences	O
within	O
materials	O
also	O
exist	O
in	O
their	O
ability	O
to	O
simultaneously	Others
bond	Others
to	Others
enamel	Others
and	Others
dentin	Others
.	Others

The	O
influence	O
of	O
serum	O
methotrexate	O
concentrations	O
and	O
drug	O
dosage	O
on	O
outcome	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukaemia	O
.	O

Sequential	O
methotrexate	O
(	O
Mtx	O
)	O
absorption	O
studies	O
were	O
undertaken	O
in	O
127	O
children	O
undergoing	O
treatment	O
for	O
childhood	O
non-T	O
acute	O
lymphoblastic	O
leukaemia	O
(	O
ALL	O
)	O
to	O
determine	O
whether	O
serum	O
drug	O
concentration	O
,	O
clearance	O
and	O
dosage	O
affect	O
event	Mental
free	Mental
survival	Mental
(	O
EFS	O
)	O
.	O

Higher	O
serum	O
concentration	O
and	O
area	O
under	O
the	O
plasma	O
concentration	O
curve	O
(	O
AUC	O
)	O
were	O
not	O
associated	O
with	O
an	O
improved	O
EFS	O
.	O

Methotrexate	Others
clearance	Others
was	O
not	O
found	O
to	O
be	O
of	O
prognostic	O
significance	O
.	O

Patients	O
who	O
tolerated	O
only	O
low	O
6-mercaptopurine	O
(	O
6-MP	O
)	O
doses	O
because	O
of	O
neutropaenia	O
and	O
those	O
who	O
randomly	O
were	O
prescribed	O
higher	O
doses	O
of	O
Mtx	O
had	O
a	O
lower	O
rate	Physical
of	Physical
leukaemia	Physical
relapse	Physical
after	O
the	O
completion	O
of	O
therapy	O
.	O

This	O
suggests	O
that	O
the	O
use	O
of	O
maintenance	O
therapy	O
in	O
maximally	O
tolerated	O
doses	O
may	O
be	O
associated	O
with	O
an	O
increased	O
survival	Mortality
in	O
childhood	O
ALL	O
.	O

Comparison	O
of	O
arch	O
dimension	O
changes	O
in	O
1-phase	O
vs	O
2-phase	O
treatment	O
of	O
Class	O
II	O
malocclusion	O
.	O

INTRODUCTION	O
We	O
compared	O
arch	O
dimension	O
changes	O
in	O
1-phase	O
and	O
2-phase	O
treatment	O
of	O
Class	O
II	O
malocclusion	O
.	O

This	O
was	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
conducted	O
in	O
the	O
Department	O
of	O
Orthodontics	O
at	O
the	O
University	O
of	O
Florida	O
between	O
1990	O
and	O
2003	O
.	O

METHODS	O
During	O
phase	O
1	O
treatment	O
,	O
86	O
subjects	O
were	O
treated	O
with	O
a	O
bionator	O
,	O
93	O
were	O
treated	O
with	O
headgear/biteplane	O
,	O
and	O
81	O
served	O
as	O
the	O
observation	O
group	O
.	O

For	O
phase	O
2	O
,	O
all	O
subjects	O
were	O
then	O
treated	O
with	O
full	O
orthodontic	O
appliances	O
.	O

Arch	O
dimensions	O
were	O
followed	O
;	O
maxillary	O
and	O
mandibular	O
alginate	O
impressions	O
were	O
taken	O
at	O
baseline	O
,	O
end	O
of	O
early	O
Class	O
II	O
treatment	O
or	O
observation	O
,	O
beginning	O
of	O
fixed	O
appliance	O
treatment	O
,	O
end	O
of	O
orthodontic	O
treatment	O
,	O
and	O
approximately	O
3	O
years	O
posttreatment	O
.	O

Alginate	O
impressions	O
were	O
taken	O
of	O
each	O
dental	O
arch	O
at	O
each	O
data	O
collection	O
point	O
.	O

These	O
were	O
poured	O
in	O
orthodontic	O
stone	O
,	O
trimmed	O
,	O
and	O
photocopied	O
from	O
the	O
occlusal	O
aspect	O
.	O

These	O
images	O
were	O
then	O
scanned	O
and	O
measured	O
.	O

RESULTS	O
Although	O
differences	O
between	O
the	O
treatment	O
groups	O
were	O
found	O
in	O
both	O
the	O
maxillary	O
and	O
mandibular	O
arches	O
after	O
phase	O
1	O
,	O
these	O
differences	O
were	O
no	O
longer	O
evident	O
by	O
the	O
end	O
of	O
full	O
orthodontic	O
treatment	O
or	O
after	O
posttreatment	O
retention	O
.	O

CONCLUSIONS	O
There	O
were	O
no	O
differences	O
in	O
arch	Others
dimensions	Others
after	O
1-phase	O
or	O
2-phase	O
treatment	O
of	O
Class	O
II	O
malocclusion	O
.	O

The	O
efficacy	O
of	O
early	O
continuous	O
positive	O
airway	O
pressure	O
therapy	O
in	O
patients	O
with	O
acute	O
cardiogenic	O
pulmonary	O
edema	O
.	O

Although	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
therapy	O
using	O
a	O
face	O
mask	O
is	O
known	O
to	O
improve	O
oxygenation	O
,	O
the	O
intrapulmonary	O
shunt	O
reduction	O
remains	O
unsettled	O
.	O

Our	O
study	O
was	O
designed	O
to	O
explore	O
this	O
issue	O
.	O

From	O
1985	O
to	O
1987	O
80	O
patients	O
with	O
acute	O
cardiogenic	O
pulmonary	O
edema	O
were	O
randomly	O
chosen	O
to	O
receive	O
either	O
serial	O
CPAP	O
therapy	O
or	O
high-flow	O
face	O
mask	O
oxygen	O
therapy	O
without	O
CPAP	O
(	O
control	O
)	O
for	O
the	O
purpose	O
of	O
evaluating	O
the	O
efficacy	O
of	O
CPAP	O
therapy	O
.	O

After	O
screening	O
for	O
exclusion	O
,	O
only	O
55	O
patients	O
were	O
included	O
in	O
the	O
first	O
3-hour	O
investigation	O
period	O
.	O

PaO2	Physical
in	O
the	O
CPAP	O
group	O
showed	O
a	O
significant	O
increase	O
by	O
the	O
end	O
of	O
the	O
initial	O
study	O
;	O
whereas	O
intrapulmonary	Physical
shunt	Physical
and	O
alveolar-arterial	Others
oxygen	Others
tension	Others
gradient	Others
AaDO2	Others
revealed	O
simultaneously	O
a	O
significant	O
reduction	O
.	O

Conversely	O
,	O
neither	O
PaO2	Others
nor	Others
intrapulmonary	Others
shunt	Others
(	Others
or	Others
AaDO2	Others
)	Others
in	O
the	O
control	O
group	O
demonstrated	O
any	O
significant	O
beneficial	O
changes	O
.	O

As	O
for	O
cardiovascular	O
function	O
,	O
only	O
the	O
CPAP	O
therapy	O
achieved	O
a	O
significant	O
reduction	O
in	O
rate	Physical
pressure	Physical
product	Physical
in	O
contrast	O
to	O
the	O
control	O
(	O
face	O
mask	O
)	O
therapy	O
alone	O
.	O

In	O
terms	O
of	O
therapeutic	Physical
failure	Physical
,	O
10	O
patients	O
in	O
the	O
control	O
group	O
failed	O
.	O

However	O
,	O
in	O
the	O
CPAP	O
group	O
only	O
5	O
patients	O
had	O
failed	O
at	O
the	O
end	O
of	O
the	O
first	O
3-hour	O
study	O
period	O
.	O

Overall	O
,	O
the	O
cumulative	Others
therapeutic	Others
failure	Others
rate	Others
was	O
28	O
%	O
in	O
the	O
CPAP	O
group	O
and	O
60	O
%	O
in	O
the	O
control	O
group	O
during	O
a	O
6-hour	O
observation	O
study	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
in	O
24-hour	O
hospital	O
mortality	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Multicenter	O
trial	O
of	O
cryotherapy	O
for	O
retinopathy	O
of	O
prematurity	O
:	O
preliminary	O
results	O
.	O

Cryotherapy	O
for	O
Retinopathy	O
of	O
Prematurity	O
Cooperative	O
Group	O
.	O

We	O
report	O
the	O
preliminary	O
3-month	O
outcome	O
of	O
a	O
multicenter	O
randomized	O
trial	O
of	O
cryotherapy	O
for	O
treatment	O
of	O
retinopathy	O
of	O
prematurity	O
(	O
ROP	O
)	O
.	O

Transscleral	O
cryotherapy	O
to	O
the	O
avascular	O
retina	O
was	O
applied	O
to	O
one	O
randomly	O
selected	O
eye	O
when	O
there	O
was	O
threshold	O
disease	O
(	O
defined	O
as	O
five	O
or	O
more	O
contiguous	O
or	O
eight	O
cumulative	O
30	O
degree	O
sectors	O
[	O
clock	O
hours	O
]	O
of	O
stage	O
3	O
ROP	O
in	O
zone	O
1	O
or	O
2	O
in	O
the	O
presence	O
of	O
plus	O
disease	O
)	O
.	O

An	O
unfavorable	O
outcome	O
was	O
defined	O
as	O
posterior	Physical
retinal	Physical
detachment	Physical
,	O
retinal	Physical
fold	Physical
involving	Physical
the	Physical
macula	Physical
,	O
or	O
retrolental	Physical
tissue	Physical
.	O

At	O
this	O
writing	O
,	O
172	O
infants	O
had	O
been	O
examined	O
3	O
months	O
after	O
randomization	O
.	O

An	O
unfavorable	O
outcome	O
was	O
significantly	O
less	O
frequent	O
in	O
the	O
eyes	O
undergoing	O
cryotherapy	O
(	O
21.8	O
%	O
)	O
compared	O
with	O
the	O
untreated	O
eyes	O
(	O
43	O
%	O
)	O
.	O

While	O
the	O
surgery	O
was	O
stressful	O
,	O
no	O
unexpected	Adverseeffect
complications	Adverseeffect
occurred	O
during	O
or	O
following	O
treatment	O
.	O

These	O
data	O
support	O
the	O
efficacy	Others
of	O
cryotherapy	O
in	O
reducing	O
by	O
approximately	O
one	O
half	O
the	O
risk	O
of	O
unfavorable	O
retinal	O
outcome	O
from	O
threshold	O
ROP	O
.	O

Randomized	O
comparison	O
of	O
two	O
communication	O
interventions	O
for	O
preschoolers	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
randomized	O
group	O
experiment	O
compared	O
the	O
efficacy	O
of	O
2	O
communication	O
interventions	O
(	O
Responsive	O
Education	O
and	O
Prelinguistic	O
Milieu	O
Teaching	O
[	O
RPMT	O
]	O
and	O
the	O
Picture	O
Exchange	O
Communication	O
System	O
[	O
PECS	O
]	O
)	O
in	O
36	O
preschoolers	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Each	O
treatment	O
was	O
delivered	O
3	O
times	O
per	O
week	O
,	O
in	O
20-min	O
sessions	O
,	O
for	O
6	O
months	O
.	O

The	O
results	O
revealed	O
that	O
the	O
RPMT	O
facilitated	O
the	O
frequency	Mental
of	Mental
generalized	Mental
turn	Mental
taking	Mental
and	O
generalized	Mental
initiating	Mental
joint	Mental
attention	Mental
more	O
than	O
did	O
the	O
PECS	O
.	O

The	O
latter	O
effect	O
occurred	O
only	O
for	O
children	O
who	O
began	O
treatment	O
with	O
at	O
least	O
some	O
initiating	Mental
joint	Mental
attention	Mental
.	O

In	O
contrast	O
,	O
the	O
PECS	O
facilitated	O
generalized	Mental
requests	Mental
more	O
than	O
the	O
RPMT	O
in	O
children	O
with	O
very	O
little	O
initiating	Mental
joint	Mental
attention	Mental
prior	O
to	O
treatment	O
.	O

These	O
effect	Others
sizes	Others
were	O
large	Others
.	O

Evaluation	O
of	O
postprocedure	O
cognitive	Mental
function	Mental
using	O
3	O
distinct	O
standard	O
sedation	O
regimens	O
for	O
endoscopic	O
procedures	O
.	O

The	O
primary	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
postprocedure	Mental
cognitive	Mental
function	Mental
associated	O
with	O
3	O
distinct	O
standard	O
sedation	O
regimens	O
used	O
for	O
endoscopic	O
procedures	O
.	O

A	O
secondary	O
aim	O
was	O
to	O
identify	O
complications	O
requiring	O
provider	O
interventions	O
.	O

Subjects	O
scheduled	O
for	O
colonoscopies	O
were	O
approached	O
for	O
enrollment	O
the	O
day	O
of	O
their	O
procedure	O
.	O

A	O
convenience	O
sample	O
of	O
96	O
subjects	O
was	O
randomly	O
assigned	O
.	O

Cognitive	O
function	O
was	O
recorded	O
on	O
the	O
day	O
of	O
surgery	O
using	O
the	O
Mini-Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
and	O
24	O
and	O
48	O
hours	O
postoperatively	O
using	O
the	O
Telephone	Mental
Interview	Mental
of	Mental
Cognitive	Mental
Status	Mental
(	Mental
TICS	Mental
)	Mental
.	O

The	O
propofol	O
plus	O
fentanyl	O
group	O
had	O
a	O
mean	Mental
TICS	Mental
score	Mental
of	O
34.53	O
at	O
24	O
hours	O
compared	O
with	O
34.96	O
at	O
48	O
hours	O
(	O
P	O
=	O
.017	O
)	O
.	O

The	O
midazolam	O
plus	O
fentanyl	O
group	O
had	O
a	O
mean	Mental
TICS	Mental
score	Mental
of	O
34.76	O
at	O
24	O
hours	O
compared	O
with	O
36.26	O
at	O
48	O
hours	O
(	O
P	O
=	O
.004	O
)	O
.	O

The	O
propofol-alone	O
group	O
had	O
a	O
mean	Mental
TICS	Mental
score	Mental
of	O
35.09	O
at	O
24	O
hours	O
compared	O
with	O
35.98	O
at	O
48	O
hours	O
(	O
P	O
=	O
.924	O
)	O
.	O

The	O
results	O
of	O
this	O
investigation	O
indicate	O
that	O
the	O
sedation	O
regimen	O
of	O
propofol	O
alone	O
has	O
the	O
least	O
impact	O
on	O
postprocedure	Mental
cognitive	Mental
function	Mental
.	O

Additionally	O
,	O
the	O
number	Others
of	Others
jaw	Others
lift	Others
interventions	Others
was	O
significantly	O
higher	O
in	O
both	O
groups	O
who	O
received	O
fentanyl	O
.	O

Weight-adjusted	O
dalteparin	O
for	O
prevention	O
of	O
vascular	Physical
thromboembolism	Physical
in	O
advanced	O
pancreatic	O
cancer	O
patients	O
decreases	O
serum	Physical
tissue	Physical
factor	Physical
and	Physical
serum-mediated	Physical
induction	Physical
of	Physical
cancer	Physical
cell	Physical
invasion	Physical
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
role	O
of	O
tissue	O
factor	O
and	O
serum-induced	O
cell	O
invasion	O
in	O
patients	O
with	O
advanced	Physical
pancreatic	Physical
cancer	Physical
(	O
APC	O
)	O
.	O

A	O
cohort	O
of	O
39	O
patients	O
with	O
APC	O
,	O
without	O
thrombosis	O
,	O
receiving	O
chemotherapy	O
,	O
were	O
entered	O
in	O
a	O
randomized	O
controlled	O
trial	O
(	O
ISRCTN	O
=	O
76464767	O
)	O
of	O
thromboprevention	O
with	O
weight-adjusted	O
dalteparin	O
(	O
WAD	O
)	O
.	O

A	O
total	O
of	O
19	O
patients	O
received	O
WAD	O
,	O
the	O
remaining	O
20	O
acting	O
as	O
a	O
control	O
group	O
.	O

Serum	O
from	O
baseline	O
and	O
week	O
8	O
was	O
analysed	O
for	O
circulating-tissue	O
factor	O
antigen	O
using	O
ELISA	O
.	O

Circulating-tissue	Physical
factor	Physical
antigen	Physical
rose	O
from	O
324	O
pg/ml	O
,	O
[	O
interquartile	O
range	O
(	O
IQR	O
)	O
282-347	O
pg/ml	O
]	O
to	O
356	O
pg/ml	O
,	O
(	O
IQR	O
319-431	O
pg/ml	O
)	O
in	O
controls	O
(	O
C	O
)	O
,	O
and	O
decreased	O
in	O
the	O
dalteparin-treated	O
group	O
(	O
D	O
)	O
from	O
336	O
pg/ml	O
(	O
IQR	O
281-346	O
pg/ml	O
)	O
to	O
303	O
pg/ml	O
(	O
IQR	O
274-339	O
pg/ml	O
)	O
.	O

The	O
difference	O
in	O
median	O
percentage	O
change	O
between	O
D	O
and	O
C	O
was	O
statistically	O
significant	O
[	O
-4.0	O
(	O
D	O
)	O
vs.	O
4.7	O
(	O
C	O
)	O
;	O
P	O
=	O
0.005	O
,	O
n	O
=	O
39	O
]	O
.	O

Serum-induced	Physical
cellular	Physical
invasion	Physical
of	Physical
MIA-Paca-2	Physical
cells	Physical
in	O
response	O
to	O
patient	O
serum	O
was	O
studied	O
using	O
a	O
Boyden	O
chamber	O
assay	O
in	O
30	O
patients	O
(	O
14	O
WAD	O
and	O
16	O
C	O
)	O
.	O

The	O
median	Others
percentage	Others
change	Others
between	O
C	O
and	O
D	O
was	O
significant	O
[	O
+54.9	O
(	O
C	O
)	O
vs.	O
-21.9	O
(	O
D	O
)	O
P	O
=	O
0.025	O
,	O
n	O
=	O
30	O
]	O
.	O

There	O
was	O
a	O
weak	O
correlation	O
between	O
BB-tissue	O
factor	O
reduction	O
and	O
cellular	O
invasion	O
reduction	O
(	O
Spearman	O
)	O
[	O
0.384	O
(	O
P	O
=	O
0.037	O
,	O
n	O
=	O
30	O
)	O
]	O
.	O

APC	O
patients	O
treated	O
with	O
WAD	O
have	O
lower	Physical
tissue	Physical
factor	Physical
antigen	Physical
levels	Physical
and	Physical
attenuated	Physical
induction	Physical
of	Physical
cellular	Physical
invasion	Physical
in	Physical
their	Physical
blood	Physical
.	O

These	O
assays	O
may	O
provide	O
useful	O
markers	O
to	O
guide	O
appropriate	O
dalteparin	O
(	O
and	O
other	O
low-molecular	O
weight	O
heparin	O
)	O
dosing	O
schedules	O
to	O
optimize	O
anticancer	Others
effects	Others
of	O
dalteparin	O
in	O
APC	O
.	O

Lack	O
of	O
efficacy	Others
of	O
citalopram	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
and	O
high	O
levels	O
of	O
repetitive	O
behavior	O
:	O
citalopram	O
ineffective	O
in	O
children	O
with	O
autism	O
.	O

CONTEXT	O
Selective	O
serotonin	O
reuptake	O
inhibitors	O
are	O
widely	O
prescribed	O
for	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
citalopram	O
hydrobromide	O
therapy	O
for	O
repetitive	O
behavior	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

DESIGN	O
National	O
Institutes	O
of	O
Health-sponsored	O
randomized	O
controlled	O
trial	O
.	O

SETTING	O
Six	O
academic	O
centers	O
,	O
including	O
Mount	O
Sinai	O
School	O
of	O
Medicine	O
,	O
North	O
Shore-Long	O
Island	O
Jewish	O
Health	O
System	O
,	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
,	O
University	O
of	O
California	O
at	O
Los	O
Angeles	O
,	O
Yale	O
University	O
,	O
and	O
Dartmouth	O
Medical	O
School	O
.	O

PARTICIPANTS	O
One	O
hundred	O
forty-nine	O
volunteers	O
5	O
to	O
17	O
years	O
old	O
(	O
mean	O
[	O
SD	O
]	O
age	O
,	O
9.4	O
[	O
3.1	O
]	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
citalopram	O
(	O
n	O
=	O
73	O
)	O
or	O
placebo	O
(	O
n	O
=	O
76	O
)	O
.	O

Participants	O
had	O
autistic	O
spectrum	O
disorders	O
,	O
Asperger	O
disorder	O
,	O
or	O
pervasive	O
developmental	O
disorder	O
,	O
not	O
otherwise	O
specified	O
;	O
had	O
illness	O
severity	O
ratings	O
of	O
at	O
least	O
moderate	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
,	O
Severity	O
of	O
Illness	O
Scale	O
;	O
and	O
scored	O
at	O
least	O
moderate	O
on	O
compulsive	O
behaviors	O
measured	O
with	O
the	O
Children	O
's	O
Yale-Brown	O
Obsessive	O
Compulsive	O
Scales	O
modified	O
for	O
pervasive	O
developmental	O
disorders	O
.	O

INTERVENTIONS	O
Twelve	O
weeks	O
of	O
citalopram	O
hydrobromide	O
(	O
10	O
mg/5	O
mL	O
)	O
or	O
placebo	O
.	O

The	O
mean	O
(	O
SD	O
)	O
maximum	O
dosage	O
of	O
citalopram	O
hydrobromide	O
was	O
16.5	O
(	O
6.5	O
)	O
mg/d	O
by	O
mouth	O
(	O
maximum	O
,	O
20	O
mg/d	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Positive	O
response	O
was	O
defined	O
by	O
a	O
score	O
of	O
much	O
improved	O
or	O
very	O
much	O
improved	O
on	O
the	O
Clinical	Mental
Global	Mental
Impressions	Mental
,	Mental
Improvement	Mental
subscale	Mental
.	Mental

An	O
important	O
secondary	O
outcome	O
was	O
the	O
score	O
on	O
the	O
Children	Mental
's	Mental
Yale-Brown	Mental
Obsessive	Mental
Compulsive	Mental
Scales	Mental
modified	Mental
for	Mental
pervasive	Mental
developmental	Mental
disorders	Mental
.	Mental

Adverse	Adverseeffect
events	Adverseeffect
were	O
systematically	O
elicited	O
using	O
the	O
Safety	O
Monitoring	O
Uniform	O
Report	O
Form	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	Mental
of	Mental
positive	Mental
response	Mental
on	O
the	O
Clinical	O
Global	O
Impressions	O
,	O
Improvement	O
subscale	O
between	O
the	O
citalopram-treated	O
group	O
(	O
32.9	O
%	O
)	O
and	O
the	O
placebo	O
group	O
(	O
34.2	O
%	O
)	O
(	O
relative	O
risk	O
,	O
0.96	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.61-1.51	O
;	O
P	O
>	O
.99	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
score	O
reduction	O
on	O
the	O
Children	O
's	O
Yale-Brown	O
Obsessive	O
Compulsive	O
Scales	O
modified	O
for	O
pervasive	O
developmental	O
disorders	O
from	O
baseline	O
(	O
mean	O
[	O
SD	O
]	O
,	O
-2.0	O
[	O
3.4	O
]	O
points	O
for	O
the	O
citalopram-treated	O
group	O
and	O
-1.9	O
[	O
2.5	O
]	O
points	O
for	O
the	O
placebo	O
group	O
;	O
P	O
=	O
.81	O
)	O
.	O

Citalopram	O
use	O
was	O
significantly	O
more	O
likely	O
to	O
be	O
associated	O
with	O
adverse	O
events	O
,	O
particularly	O
increased	O
energy	O
level	O
,	O
impulsiveness	O
,	O
decreased	O
concentration	Adverseeffect
,	Adverseeffect
hyperactivity	Adverseeffect
,	Adverseeffect
stereotypy	Adverseeffect
,	Adverseeffect
diarrhea	Adverseeffect
,	Adverseeffect
insomnia	Adverseeffect
,	Adverseeffect
and	Adverseeffect
dry	Adverseeffect
skin	Adverseeffect
or	Adverseeffect
pruritus	Adverseeffect
.	Adverseeffect

CONCLUSION	O
Results	O
of	O
this	O
trial	O
do	O
not	O
support	O
the	O
use	O
of	O
citalopram	O
for	O
the	O
treatment	O
of	O
repetitive	O
behavior	O
in	O
children	O
and	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Trial	O
Registration	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00086645	O
.	O

Magnetic	O
resonance	O
angiography	O
for	O
monitoring	O
prophylactic	O
endoscopic	O
treatment	O
of	O
high	O
risk	O
esophageal	O
varices	O
.	O

BACKGROUND	O
AND	O
STUDY	O
AIMS	O
Endoscopic	O
injection	O
sclerotherapy	O
(	O
EIS	O
)	O
and	O
endoscopic	O
variceal	O
ligation	O
(	O
EVL	O
)	O
are	O
used	O
worldwide	O
as	O
the	O
treatment	O
for	O
esophageal	O
varices	O
.	O

We	O
evaluated	O
portal	O
hemodynamics	O
using	O
magnetic	O
resonance	O
angiography	O
(	O
MRA	O
)	O
in	O
these	O
two	O
forms	O
of	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
The	O
study	O
was	O
carried	O
out	O
in	O
50	O
cirrhotic	O
patients	O
.	O

MRA	O
was	O
performed	O
to	O
identify	O
the	O
hepatofugal	O
supply	O
vein	O
selectively	O
for	O
esophageal	O
varices	O
.	O

Those	O
who	O
showed	O
a	O
positive	O
MR	O
angiogram	O
for	O
the	O
supply	O
vein	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
two	O
groups	O
,	O
using	O
the	O
sealed	O
envelope	O
method	O
,	O
and	O
underwent	O
either	O
EIS	O
or	O
EVL	O
.	O

On	O
the	O
other	O
hand	O
,	O
those	O
with	O
a	O
negative	O
angiogram	O
received	O
only	O
EVL	O
.	O

EIS	O
was	O
done	O
to	O
embolize	O
esophageal	O
varices	O
as	O
well	O
as	O
their	O
feeders	O
by	O
intravariceal	O
injection	O
of	O
sclerosant	O
under	O
fluoroscopic	O
guidance	O
.	O

RESULTS	O
A	O
positive	O
MR	O
angiogram	O
of	O
the	O
hepatofugal	O
left	O
gastric	O
vein	O
as	O
the	O
supply	O
vein	O
was	O
observed	O
in	O
41	O
patients	O
.	O

Nine	O
patients	O
showed	O
negative	O
MRA	O
results	O
.	O

Among	O
those	O
with	O
positive	O
angiograms	O
,	O
the	O
rate	Physical
of	Physical
eradication	Physical
of	Physical
the	Physical
left	Physical
gastric	Physical
vein	Physical
was	O
higher	O
in	O
the	O
EIS-treated	O
group	O
than	O
in	O
the	O
EVL	O
treated	O
group	O
(	O
50	O
%	O
vs.	O
8.6	O
%	O
)	O
.	O

After	O
either	O
treatment	O
,	O
the	O
recurrence-free	Physical
rate	Physical
for	Physical
high	Physical
risk	Physical
esophageal	Physical
varices	Physical
was	O
higher	O
in	O
patients	O
with	O
complete	O
eradication	O
of	O
the	O
left	O
gastric	O
vein	O
than	O
in	O
those	O
without	O
(	O
88	O
%	O
vs.	O
35	O
%	O
)	O
.	O

In	O
patients	O
with	O
negative	O
angiogram	O
results	O
,	O
who	O
only	O
underwent	O
EVL	O
,	O
high	O
risk	Physical
esophageal	Physical
varices	Physical
did	O
not	O
reappear	O
over	O
a	O
long	O
period	O
.	O

CONCLUSION	O
MRA	O
is	O
useful	O
for	O
evaluating	O
portal	O
hemodynamics	O
.	O

With	O
the	O
aim	O
of	O
avoiding	O
recurrence	O
of	O
esophageal	O
varices	O
,	O
EIS	O
was	O
suitable	O
for	O
patients	O
who	O
had	O
a	O
hepatofugal	O
supply	O
vein	O
for	O
the	O
varices	O
because	O
recurrence	O
could	O
be	O
prevented	O
by	O
embolization	O
of	O
the	O
supply	O
vein	O
.	O

EVL	O
may	O
be	O
expected	O
to	O
be	O
efficacious	O
in	O
patients	O
where	O
no	O
image	O
of	O
a	O
hepatofugal	O
supply	O
vein	O
is	O
found	O
on	O
MRA	O
.	O

Alternating	O
chemotherapy	O
in	O
small	O
cell	O
lung	O
cancer	O
.	O

Based	O
on	O
the	O
hypothesis	O
of	O
Goldie	O
and	O
Coldman	O
,	O
rapid	O
cyclic	O
alternating	O
chemotherapy	O
has	O
been	O
supposed	O
to	O
be	O
a	O
favorable	O
treatment	O
modality	O
in	O
small	O
cell	O
lung	O
cancer	O
.	O

This	O
approach	O
has	O
been	O
tested	O
in	O
a	O
large	O
series	O
of	O
trials	O
since	O
the	O
late	O
70	O
's	O
.	O

A	O
few	O
trials	O
performed	O
randomization	O
between	O
alternating	O
and	O
continuous	O
treatment	O
after	O
a	O
period	O
of	O
initial	O
common	O
continuous	O
therapy	O
.	O

The	O
results	O
of	O
these	O
studies	O
are	O
controversial	O
and	O
their	O
interpretation	O
is	O
complicated	O
by	O
the	O
effects	O
of	O
the	O
continuous	O
pretreatment	O
.	O

Recently	O
,	O
most	O
trials	O
were	O
designed	O
as	O
2-arm	O
approaches	O
with	O
a	O
comparison	O
of	O
continuous	O
standard	O
therapy	O
based	O
on	O
the	O
CAV-	O
or	O
CMC-protocol	O
with	O
an	O
alternating	O
schedule	O
often	O
consisting	O
of	O
the	O
CAV-	O
or	O
CMC-derived	O
combinations	O
and	O
a	O
second	O
regimen	O
including	O
cisplatinum	O
and/or	O
etoposide	O
.	O

In	O
these	O
trials	O
the	O
addition	O
of	O
the	O
second	O
regimen	O
in	O
the	O
alternating	O
treatment	O
arms	O
has	O
improved	O
the	O
treatment	O
results	O
.	O

However	O
,	O
these	O
trials	O
could	O
not	O
clarify	O
whether	O
this	O
advantage	O
was	O
due	O
to	O
the	O
concept	O
of	O
alternating	O
treatment	O
or	O
to	O
the	O
high	O
activity	O
of	O
new	O
drugs	O
given	O
early	O
in	O
the	O
course	O
of	O
therapy	O
in	O
the	O
alternating	O
treatment	O
arms	O
.	O

To	O
ameliorate	O
this	O
weakness	O
,	O
3	O
studies	O
were	O
designed	O
as	O
3-arms	O
approaches	O
using	O
both	O
alternating	O
protocols	O
as	O
continuous	O
control	O
arms	O
.	O

Whereas	O
one	O
investigation	O
noticed	O
an	O
advantage	O
of	O
the	O
alternating	O
schedule	O
,	O
the	O
two	O
others	O
observed	O
no	O
difference	O
.	O

These	O
studies	O
did	O
not	O
report	O
their	O
criteria	O
for	O
shifting	O
non-responding	O
patients	O
from	O
continuous	O
treatment	O
to	O
second	O
line	O
therapy	O
.	O

The	O
longer	O
these	O
patients	O
stayed	O
on	O
the	O
continuous	O
protocol	O
the	O
more	O
the	O
study	O
design	O
favoured	O
the	O
alternating	O
therapy	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
A	O
play	O
and	O
joint	O
attention	O
intervention	O
for	O
teachers	O
of	O
young	O
children	O
with	O
autism	O
:	O
a	O
randomized	O
controlled	O
pilot	O
study	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
pilot	O
test	O
a	O
classroom-based	O
intervention	O
focused	O
on	O
facilitating	O
play	O
and	O
joint	O
attention	O
for	O
young	O
children	O
with	O
autism	O
in	O
self-contained	O
special	O
education	O
classrooms	O
.	O

Thirty-three	O
children	O
with	O
autism	O
between	O
the	O
ages	O
of	O
3	O
and	O
6	O
years	O
participated	O
in	O
the	O
study	O
with	O
their	O
classroom	O
teachers	O
(	O
n	O
=	O
14	O
)	O
.	O

The	O
14	O
preschool	O
special	O
education	O
teachers	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
(	O
1	O
)	O
symbolic	O
play	O
then	O
joint	O
attention	O
intervention	O
,	O
(	O
2	O
)	O
joint	O
attention	O
then	O
symbolic	O
intervention	O
,	O
and	O
(	O
3	O
)	O
wait-list	O
control	O
period	O
then	O
further	O
randomized	O
to	O
either	O
group	O
1	O
or	O
group	O
2	O
.	O

In	O
the	O
intervention	O
,	O
teachers	O
participated	O
in	O
eight	O
weekly	O
individualized	O
1-h	O
sessions	O
with	O
a	O
researcher	O
that	O
emphasized	O
embedding	O
strategies	O
targeting	O
symbolic	O
play	O
and	O
joint	O
attention	O
into	O
their	O
everyday	O
classroom	O
routines	O
and	O
activities	O
.	O

The	O
main	O
child	O
outcome	O
variables	O
of	O
interest	O
were	O
collected	O
through	O
direct	O
classroom	O
observations	O
.	O

Findings	O
indicate	O
that	O
teachers	O
can	O
implement	O
an	O
intervention	Physical
to	Physical
significantly	Physical
improve	Physical
joint	Physical
engagement	Physical
of	O
young	O
children	O
with	O
autism	O
in	O
their	O
classrooms	O
.	O

Furthermore	O
,	O
multilevel	O
analyses	O
showed	O
significant	Physical
increases	Physical
in	Physical
joint	Physical
attention	Physical
and	Physical
symbolic	Physical
play	Physical
skills	Physical
.	Physical

Thus	O
,	O
these	O
pilot	O
data	O
emphasize	O
the	O
need	O
for	O
further	O
research	O
and	O
implementation	O
of	O
classroom-based	O
interventions	O
targeting	O
play	Physical
and	Physical
joint	Physical
attention	Physical
skills	Physical
for	O
young	O
children	O
with	O
autism	O
.	O

Intensive	O
behavioral	O
treatment	O
for	O
children	O
with	O
autism	Mental
:	O
four-year	O
outcome	O
and	O
predictors	O
.	O

Twenty-four	O
children	O
with	O
autism	O
were	O
randomly	O
assigned	O
to	O
a	O
clinic-directed	O
group	O
,	O
replicating	O
the	O
parameters	O
of	O
the	O
early	O
intensive	O
behavioral	O
treatment	O
developed	O
at	O
UCLA	O
,	O
or	O
to	O
a	O
parent-directed	O
group	O
that	O
received	O
intensive	O
hours	O
but	O
less	O
supervision	O
by	O
equally	O
well-trained	O
supervisors	O
.	O

Outcome	O
after	O
4	O
years	O
of	O
treatment	O
,	O
including	O
cognitive	Mental
,	Mental
language	Mental
,	Mental
adaptive	Mental
,	Mental
social	Mental
,	Mental
and	Mental
academic	Mental
measures	Mental
,	O
was	O
similar	O
for	O
both	O
groups	O
.	O

After	O
combining	O
groups	O
,	O
we	O
found	O
that	O
48	O
%	O
of	O
all	O
children	O
showed	O
rapid	Mental
learning	Mental
,	O
achieved	O
average	Mental
posttreatment	Mental
scores	Mental
,	O
and	O
at	O
age	O
7	O
,	O
were	O
succeeding	O
in	O
regular	O
education	O
classrooms	O
.	O

Treatment	O
outcome	O
was	O
best	O
predicted	O
by	O
pretreatment	Mental
imitation	Mental
,	Mental
language	Mental
,	Mental
and	Mental
social	Mental
responsiveness	Mental
.	O

These	O
results	O
are	O
consistent	O
with	O
those	O
reported	O
by	O
Lovaas	O
and	O
colleagues	O
(	O
Lovaas	O
,	O
1987	O
;	O
McEachin	O
,	O
Smith	O
,	O
&	O
Lovaas	O
,	O
1993	O
)	O
.	O

Effect	O
of	O
aliskiren	O
on	O
proteinuria	Physical
in	O
non-diabetic	O
chronic	O
kidney	O
disease	O
:	O
a	O
double-blind	O
,	O
crossover	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O

AIM	O
To	O
evaluate	O
the	O
proteinuria-lowering	Others
effect	Others
of	O
a	O
renin	O
inhibitor	O
(	O
aliskiren	O
)	O
,	O
compared	O
to	O
placebo	O
and	O
to	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
perindopril	O
)	O
,	O
in	O
patients	O
with	O
non-diabetic	O
chronic	O
kidney	O
disease	O
.	O

METHODS	O
A	O
randomised	O
,	O
double-blind	O
,	O
crossover	O
trial	O
was	O
performed	O
in	O
14	O
patients	O
with	O
nondiabetic	O
chronic	O
kidney	O
disease	O
with	O
24-h	O
mean	O
proteinuria	O
of	O
2.01	O
g	O
(	O
95	O
%	O
CI	O
,	O
1.36?2.66	O
)	O
and	O
estimated	O
creatinine	O
clearance	O
of	O
93?6.8	O
ml/min	O
.	O

The	O
study	O
consisted	O
of	O
five	O
treatment	O
periods	O
.	O

The	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
aliskiren	O
(	O
150	O
mg	O
)	O
,	O
aliskiren	O
(	O
300	O
mg	O
)	O
,	O
perindopril	O
(	O
5	O
mg	O
)	O
,	O
perindopril	O
(	O
10	O
mg	O
)	O
or	O
placebo	O
.	O

RESULTS	O
Aliskiren	O
and	O
perindopril	O
reduced	O
proteinuria	Physical
.	O

These	O
effects	O
were	O
dose-dependent	O
.	O

Furthermore	O
,	O
24-h	O
proteinuria	Physical
was	O
reduced	O
by	O
23	O
%	O
(	O
mean	O
95	O
%	O
CI	O
;	O
2?44	O
)	O
by	O
treatment	O
with	O
aliskiren	O
(	O
150	O
mg	O
)	O
,	O
by	O
36	O
%	O
(	O
95	O
%	O
CI	O
,	O
17?55	O
;	O
P	O
<	O
0.001	O
)	O
with	O
aliskiren	O
(	O
300	O
mg	O
)	O
,	O
by	O
7.1	O
%	O
(	O
95	O
%	O
CI	O
,	O
11?26	O
)	O
with	O
perindopril	O
(	O
5	O
mg	O
)	O
and	O
by	O
25	O
%	O
(	O
95	O
%	O
CI	O
,	O
11?39	O
;	O
P	O
<	O
0.05	O
)	O
with	O
perindopril	O
(	O
10	O
mg	O
)	O
,	O
compared	O
to	O
placebo	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
effects	O
of	O
aliskiren	O
and	O
perindopril	O
.	O

CONCLUSIONS	O
Aliskiren	O
significantly	O
reduced	O
proteinuria	Others
.	O

The	O
antiproteinuric	O
effect	O
is	O
probably	O
similar	O
to	O
that	O
of	O
perindopril	O
,	O
for	O
equivalent	O
hypotensive	O
dosages	O
.	O

The	O
renin	O
inhibitor	O
provides	O
a	O
promising	O
alternative	O
approach	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
chronic	O
proteinuric	O
non-diabetic	O
kidney	O
disease	O
.	O

A	O
randomized	O
placebo-controlled	O
trial	O
comparing	O
the	O
efficacy	O
of	O
etoricoxib	O
30	O
mg	O
and	O
ibuprofen	O
2400	O
mg	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
osteoarthritis	O
.	O

OBJECTIVE	O
We	O
compared	O
the	O
efficacy	O
of	O
etoricoxib	O
30	O
mg	O
to	O
placebo	O
and	O
ibuprofen	O
2400	O
mg	O
for	O
the	O
treatment	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
of	O
the	O
hip	O
and	O
knee	O
.	O

DESIGN	O
In	O
this	O
12-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-	O
and	O
active-comparator-controlled	O
trial	O
,	O
548	O
patients	O
(	O
median	O
age	O
63	O
years	O
)	O
with	O
OA	O
of	O
the	O
hip	O
or	O
knee	O
were	O
randomized	O
to	O
receive	O
placebo	O
,	O
etoricoxib	O
30	O
mg	O
q.d.	O
,	O
or	O
ibuprofen	O
800	O
mg	O
t.i.d	O
.	O

Demonstration	O
of	O
etoricoxib	O
's	O
efficacy	O
vs	O
placebo	O
and	O
comparison	O
of	O
its	O
efficacy	O
to	O
ibuprofen	O
were	O
assessed	O
using	O
three	O
co-primary	O
endpoints	O
:	O
Western	Pain
Ontario	Pain
and	Pain
McMaster	Pain
's	Pain
University	Pain
Osteoarthritis	Pain
Index	Pain
(	Pain
WOMAC	Pain
)	Pain
Pain	Pain
Subscale	Pain
(	Pain
WOMAC-PS	Pain
)	Pain
;	O
WOMAC	Physical
Physical	Physical
Function	Physical
Subscale	Physical
(	Physical
WOMAC-PFS	Physical
)	Physical
;	Others
and	O
Patient	Physical
Global	Physical
Assessment	Physical
of	Physical
Disease	Physical
Status	Physical
(	Physical
PGADS	Physical
)	Physical
.	O

Each	O
primary	O
endpoint	O
utilizes	O
a	O
0-100	O
mm	O
visual	O
analog	O
scale	O
.	O

To	O
demonstrate	O
comparable	O
efficacy	O
of	O
etoricoxib	O
vs	O
ibuprofen	O
,	O
the	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
for	O
the	O
difference	O
in	O
the	O
least	Physical
squares	Physical
(	Physical
LS	Physical
)	Physical
mean	Physical
change	Physical
over	O
12	O
weeks	O
for	O
all	O
three	O
co-primary	O
endpoints	O
had	O
to	O
fall	O
within	O
+/-10	O
mm	O
.	O

Safety	Physical
and	Physical
tolerability	Physical
data	Others
were	O
collected	O
throughout	O
the	O
study	O
.	O

RESULTS	O
Mean	Physical
baseline	Physical
values	Physical
for	O
the	O
three	O
co-primary	O
endpoints	O
ranged	O
from	O
62.52	O
to	O
70.14	O
mm	O
.	O

Both	O
etoricoxib	O
and	O
ibuprofen	O
demonstrated	O
superior	O
(	O
P	O
<	O
or	O
=0.002	O
)	O
efficacy	Others
for	O
all	O
primary	O
endpoints	O
.	O

The	O
LS	O
mean	O
(	O
mm	O
)	O
changes	O
(	O
95	O
%	O
CI	O
)	O
over	O
12	O
weeks	O
for	O
etoricoxib	O
and	O
ibuprofen	O
,	O
respectively	O
,	O
compared	O
to	O
placebo	O
were	O
given	O
as	O
follows	O
:	O
WOMAC-PS	Pain
:	O
-11.66	O
(	O
-16.31	O
,	O
-7.01	O
)	O
and	O
-7.62	O
(	O
-12.30	O
,	O
-2.94	O
)	O
;	O
WOMAC-PFS	Physical
:	O
-10.15	O
(	O
-14.74	O
,	O
-5.57	O
)	O
and	O
-7.23	O
(	O
-11.85	O
,	O
-2.61	O
)	O
;	O
PGADS	Physical
:	O
-11.65	O
(	O
-16.81	O
,	O
-6.50	O
)	O
and	O
-8.11	O
(	O
-13.30	O
,	O
-2.92	O
)	O
.	O

The	O
efficacy	Others
of	O
etoricoxib	O
30	O
mg	O
was	O
comparable	O
to	O
ibuprofen	O
2400	O
mg.	O
All	O
treatments	O
were	O
similarly	O
well	O
tolerated	Others
.	O

CONCLUSION	O
Treatment	O
with	O
etoricoxib	O
30	O
mg	O
q.d	O
.	O

provides	O
superior	O
efficacy	Others
vs	O
placebo	O
and	O
comparable	O
clinical	O
efficacy	O
vs	O
ibuprofen	O
2400	O
mg	O
(	O
800	O
mg	O
t.i.d	O
.	O

)	O
for	O
the	O
treatment	O
of	O
OA	O
of	O
the	O
hip	O
and	O
knee	O
.	O

Methylphenidate	O
and/or	O
a	O
nursing	O
telephone	O
intervention	O
for	O
fatigue	Physical
in	O
patients	O
with	O
advanced	O
cancer	O
:	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
phase	O
II	O
trial	O
.	O

PURPOSE	O
Cancer-related-fatigue	Physical
(	Physical
CRF	Physical
)	Physical
is	O
common	O
in	O
advanced	O
cancer	O
.	O

The	O
primary	O
objective	O
of	O
the	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
methylphenidate	O
(	O
MP	O
)	O
with	O
those	O
of	O
placebo	O
(	O
PL	O
)	O
on	O
CRF	O
as	O
measured	O
using	O
the	O
Functional	Physical
Assessment	Physical
of	Physical
Chronic	Physical
Illness	Physical
Therapy-Fatigue	Physical
(	Physical
FACIT-F	Physical
)	Physical
fatigue	O
subscale	O
.	O

The	O
effect	O
of	O
a	O
combined	O
intervention	O
including	O
MP	O
plus	O
a	O
nursing	O
telephone	O
intervention	O
(	O
NTI	O
)	O
was	O
also	O
assessed	O
.	O

PATIENTS	O
AND	O
METHODS	O
Patients	O
with	O
advanced	O
cancer	O
with	O
a	O
fatigue	O
score	O
of	O
?	O
4	O
out	O
of	O
10	O
on	O
the	O
Edmonton	O
Symptom	O
Assessment	O
Scale	O
(	O
ESAS	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
following	O
four	O
groups	O
:	O
MP+NTI	O
,	O
PL+NTI	O
,	O
MP	O
+	O
control	O
telephone	O
intervention	O
(	O
CTI	O
)	O
,	O
and	O
PL+CTI	O
.	O

Methylphenidate	O
dose	O
was	O
5	O
mg	O
every	O
2	O
hours	O
as	O
needed	O
up	O
to	O
20	O
mg	O
per	O
day	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
median	O
difference	O
in	O
FACIT-F	O
fatigue	O
at	O
day	O
15	O
.	O

Secondary	O
outcomes	O
included	O
anxiety	O
,	O
depression	O
,	O
and	O
sleep	O
.	O

RESULTS	O
One	O
hundred	O
forty-one	O
patients	O
were	O
evaluable	O
.	O

Median	O
FACIT-F	O
fatigue	O
scores	O
improved	O
from	O
baseline	O
to	O
day	O
15	O
in	O
all	O
groups	O
:	O
MP+NTI	O
(	O
median	O
score	O
,	O
4.5	O
;	O
P	O
=	O
.005	O
)	O
,	O
PL+NTI	O
(	O
median	O
score	O
,	O
8.0	O
;	O
P	O
<	O
.001	O
)	O
,	O
MP+CTI	O
(	O
median	O
score	O
,	O
7.0	O
;	O
P	O
=	O
.004	O
)	O
,	O
and	O
PL+CTI	O
(	O
median	O
score	O
,	O
5.0	O
;	O
P	O
=	O
.03	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
median	O
improvement	O
in	O
FACIT-F	O
fatigue	O
between	O
the	O
MP	O
and	O
PL	O
groups	O
(	O
5.5	O
v	O
6.0	O
,	O
respectively	O
;	O
P	O
=	O
.69	O
)	O
and	O
among	O
all	O
four	O
groups	O
(	O
P	O
=	O
.16	O
)	O
.	O

Fatigue	O
(	O
P	O
<	O
.001	O
)	O
,	O
nausea	O
(	O
P	O
=	O
.01	O
)	O
,	O
depression	O
(	O
P	O
=	O
.02	O
)	O
,	O
anxiety	O
(	O
P	O
=	O
.01	O
)	O
,	O
drowsiness	O
(	O
P	O
<	O
.001	O
)	O
,	O
appetite	O
(	O
P	O
=	O
.009	O
)	O
,	O
sleep	O
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
feeling	O
of	O
well-being	O
(	O
P	O
<	O
.001	O
)	O
,	O
as	O
measured	O
by	O
the	O
ESAS	O
,	O
significantly	O
improved	O
in	O
patients	O
who	O
received	O
NTI	O
.	O

Grade	O
?	O
3	O
adverse	O
events	O
did	O
not	O
differ	O
between	O
MP	O
and	O
PL	O
(	O
40	O
of	O
93	O
patients	O
v	O
29	O
of	O
97	O
patients	O
,	O
respectively	O
;	O
P	O
=	O
.06	O
)	O
.	O

CONCLUSION	O
MP	O
and	O
NTI	O
alone	O
or	O
combined	O
were	O
not	O
superior	O
to	O
placebo	O
in	O
improving	O
CRF	O
.	O

Effects	O
of	O
reducing	O
dietary	O
[	O
(	O
Na+	O
+	O
K+	O
)	O
-	O
(	O
Cl-	O
+	O
SO4=	O
)	O
]	O
on	O
the	O
rate	O
of	O
calcium	O
mobilisation	O
by	O
dairy	O
cows	O
at	O
parturition	O
.	O

The	O
effects	O
of	O
feeding	O
diets	O
with	O
different	O
milliequivalents	O
(	O
meq	O
)	O
of	O
dietary	O
[	O
(	O
Na+	O
+	O
K+	O
)	O
-	O
(	O
Cl-	O
+	O
SO4=	O
)	O
]	O
to	O
dairy	O
cows	O
during	O
the	O
last	O
seven	O
weeks	O
of	O
pregnancy	O
on	O
their	O
acid-base	O
status	O
and	O
calcium	O
mobilisation	O
rate	O
around	O
parturition	O
were	O
studied	O
.	O

Ten	O
monozygotic	O
twin	O
pairs	O
of	O
pregnant	O
cows	O
(	O
five	O
pairs	O
of	O
parity	O
1	O
or	O
2	O
,	O
and	O
five	O
pairs	O
of	O
parity	O
3	O
or	O
more	O
)	O
were	O
allocated	O
to	O
two	O
diets	O
which	O
were	O
formulated	O
to	O
provide	O
either	O
-4	O
meq	O
(	O
anion	O
diet	O
)	O
or	O
+572.5	O
meq	O
(	O
cation	O
diet	O
)	O
of	O
[	O
(	O
Na+	O
+	O
K+	O
)	O
-	O
(	O
Cl-	O
+	O
SO4=	O
)	O
]	O
kg-1	O
dietary	O
dry	O
matter	O
(	O
DM	O
)	O
.	O

The	O
daily	O
rations	O
consisted	O
of	O
4	O
kg	O
grass	O
hay	O
and	O
7	O
kg	O
concentrates	O
.	O

Changes	O
in	O
meq	O
of	O
dietary	Physical
[	Physical
(	Physical
Na+	Physical
+	Physical
K+	Physical
)	Physical
-	Physical
(	Physical
Cl-	Physical
+	Physical
SO4=	Physical
)	Physical
]	Physical
were	O
achieved	O
by	O
adding	O
KCl	O
,	O
K2SO4	O
and	O
(	O
NH4	O
)	O
2SO4	O
(	O
anion	O
diet	O
)	O
or	O
K2CO3	O
(	O
cation	O
diet	O
)	O
to	O
basal	O
concentrates	O
.	O

Plasma	Physical
calcium	Physical
concentration	Physical
and	O
blood	Physical
acid-base	Physical
parameters	Physical
were	O
not	O
affected	O
by	O
dietary	O
treatment	O
.	O

However	O
,	O
urinary	Physical
calcium	Physical
excretion	Physical
was	O
markedly	O
higher	O
and	O
urinary	Physical
pH	Physical
and	Physical
bicarbonate	Physical
excretion	Physical
significantly	O
lower	O
in	O
cows	O
fed	O
the	O
anion	O
diet	O
than	O
in	O
cows	O
fed	O
the	O
cation	O
diet	O
.	O

The	O
responses	O
to	O
hypocalcaemia	O
induced	O
by	O
an	O
intravenous	O
infusion	O
of	O
EDTA	O
solution	O
were	O
similar	O
in	O
the	O
cows	O
fed	O
either	O
diet	O
.	O

Human	O
papillomavirus	O
genotypes	O
in	O
cervical	O
intraepithelial	O
neoplasia	O
grade	O
3	O
.	O

BACKGROUND	O
There	O
are	O
few	O
large	O
case	O
series	O
describing	O
the	O
human	Physical
papillomavirus	Physical
(	Physical
HPV	Physical
)	Physical
genotypes	O
found	O
in	O
women	O
diagnosed	O
with	O
rigorously	O
reviewed	O
cervical	O
intraepithelial	O
neoplasia	O
grade	O
3	O
(	O
CIN3	O
)	O
,	O
cervical	O
precancer	O
.	O

METHODS	O
The	O
Atypical	O
Squamous	O
Cells	O
of	O
Undetermined	O
Significance	O
(	O
ASCUS	O
)	O
and	O
Low-Grade	O
Squamous	O
Intraepithelial	O
Lesion	O
(	O
LSIL	O
)	O
Triage	O
Study	O
(	O
ALTS	O
)	O
was	O
a	O
clinical	O
trial	O
to	O
evaluate	O
the	O
best	O
management	O
strategies	O
for	O
women	O
with	O
equivocal	O
(	O
ASCUS	O
)	O
or	O
mildly	O
abnormal	O
(	O
LSIL	O
)	O
Pap	O
tests	O
.	O

During	O
enrollment	O
and	O
the	O
2-year	O
follow-up	O
,	O
608	O
women	O
had	O
a	O
histopathologic	O
diagnosis	O
of	O
CIN3	O
and	O
PCR-based	O
HPV	O
genotyping	O
results	O
on	O
cervical	O
specimens	O
.	O

The	O
genotyping	O
results	O
were	O
ranked	O
hierarchically	O
according	O
to	O
cancer	O
risk	O
:	O
HPV16	O
>	O
other	O
carcinogenic	O
HPV	O
>	O
noncarcinogenic	O
HPV	O
>	O
PCR	O
negative	O
.	O

RESULTS	O
Among	O
the	O
608	O
women	O
diagnosed	O
with	O
CIN3	O
,	O
601	O
(	O
98.8	O
%	O
)	O
cases	O
were	O
positive	O
for	O
any	O
HPV	O
genotype	O
and	O
95.4	O
%	O
for	O
any	O
carcinogenic	Physical
HPV	Physical
.	Physical

HPV16	Physical
(	O
59.9	O
%	O
)	O
,	O
HPV31	Physical
(	O
18.1	O
%	O
)	O
,	O
HPV52	Physical
(	O
14.8	O
%	O
)	O
,	O
HPV51	Physical
(	O
14.0	O
%	O
)	O
,	O
and	O
HPV18	Physical
(	O
13.2	O
%	O
)	O
were	O
the	O
five	O
most	O
common	O
HPV	O
genotypes	O
detected	O
.	O

Younger	Physical
age	Physical
,	Physical
consensus	Physical
histologic	Physical
confirmation	Physical
,	O
smoking	Mental
,	Mental
and	Mental
multiparity	Mental
increased	O
the	O
likelihood	O
of	O
testing	Physical
HPV	Physical
16	Physical
positive	Physical
.	O

Specifically	O
,	O
HPV16-positive	Physical
CIN3	Physical
occurred	O
at	O
a	O
younger	O
age	O
than	O
CIN3	O
positive	O
for	O
other	O
carcinogenic	O
HPV	O
genotypes	O
(	O
median	O
of	O
23.5	O
years	O
versus	O
25	O
years	O
,	O
respectively	O
;	O
P	O
=	O
0.0003	O
,	O
Kruskal-Wallis	O
)	O
.	O

CONCLUSIONS	O
HPV16-positive	Physical
CIN3	Physical
was	O
more	O
commonly	O
diagnosed	O
in	O
younger	O
women	O
(	O
versus	O
older	O
women	O
)	O
,	O
with	O
consensus	O
diagnosis	O
(	O
versus	O
some	O
disagreement	O
between	O
reviewers	O
)	O
,	O
and	O
in	O
smokers	O
(	O
versus	O
nonsmokers	O
)	O
,	O
and	O
was	O
less	O
commonly	O
diagnosed	O
in	O
multiparous	O
women	O
compared	O
CIN3	Physical
positive	Physical
for	O
other	O
carcinogenic	Physical
HPV	Physical
genotypes	Physical
.	O

IMPACT	O
In	O
populations	O
vaccinated	O
against	O
HPV16	O
(	O
and	O
HPV18	O
)	O
,	O
the	O
median	O
age	O
of	O
CIN3	O
in	O
women	O
with	O
ASCUS	O
and	O
LSIL	O
cytology	O
should	O
shift	O
to	O
older	O
ages	O
,	O
possibly	O
permitting	O
later	O
age	O
at	O
first	O
screening	O
.	O

Erythropoiesis	O
after	O
therapy	O
with	O
recombinant	O
human	O
erythropoietin	O
:	O
a	O
dose-response	O
study	O
in	O
anemic	O
cancer	O
surgery	O
patients	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
Preoperative	O
treatment	O
with	O
600	O
U/kg	O
of	O
recombinant	O
human	O
erythropoietin	O
(	O
r-HuEPO	O
)	O
effectively	O
increases	O
erythropoiesis	Physical
in	O
cancer	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
erythropoietic	Physical
response	Physical
after	O
different	O
doses	O
of	O
r-HuEPO	O
in	O
order	O
to	O
find	O
the	O
minimum	O
effective	O
dose	O
.	O

MATERIALS	O
AND	O
METHODS	O
Twenty	O
anemic	O
sideropenic	O
patients	O
(	O
hemoglobin	O
<	O
/=110	O
g/l	O
;	O
serum	O
iron	O
<	O
600	O
microg/l	O
)	O
with	O
cancer	O
of	O
the	O
gastrointestinal	O
tract	O
were	O
randomly	O
allocated	O
to	O
two	O
groups	O
:	O
the	O
first	O
(	O
n	O
=	O
10	O
)	O
received	O
400	O
U/kg	O
of	O
r-Hu	O
EPO	O
divided	O
in	O
4	O
doses	O
(	O
100	O
U/kg	O
each	O
,	O
every	O
4	O
days	O
)	O
;	O
the	O
second	O
(	O
n	O
=	O
10	O
)	O
received	O
200	O
U/kg	O
of	O
r-HuEPO	O
(	O
50	O
U/kg	O
each	O
,	O
every	O
4	O
days	O
)	O
.	O

Both	O
groups	O
were	O
given	O
intravenous	O
iron	O
gluconate	O
(	O
125	O
mg	O
)	O
every	O
day	O
for	O
15	O
days	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
serum	Others
iron	Others
level	Others
significantly	Others
rose	Others
in	O
both	O
groups	O
.	O

The	O
production	O
of	O
new	Physical
red	Physical
blood	Physical
cells	Physical
was	O
176.3+/-90.8	O
ml	O
in	O
the	O
200	O
U/kg	O
group	O
and	O
268.4+/-79.4	O
ml	O
in	O
the	O
400	O
U/kg	O
group	O
(	O
p	O
=	O
0.036	O
)	O
.	O

The	O
increase	Physical
of	Physical
hemoglobin	Physical
was	O
significantly	O
higher	O
in	O
the	O
400	O
U/kg	O
group	O
(	O
22.3+/-2.0	O
g/l	O
)	O
than	O
in	O
the	O
200	O
U/kg	O
group	O
(	O
14.1+/-2.7	O
g/l	O
)	O
(	O
p	O
=	O
0.017	O
)	O
.	O

CONCLUSION	O
The	O
r-HuEPO	O
dose	O
of	O
400	O
U/kg	O
appears	O
significantly	O
more	O
effective	Others
than	O
the	O
200	O
U/kg	O
to	O
stimulate	O
erythropoiesis	O
in	O
anemic	O
sideropenic	O
cancer	O
patients	O
.	O

Relationships	O
between	O
age	O
at	O
diagnosis	O
,	O
clinical	O
features	O
,	O
and	O
outcome	O
of	O
therapy	O
in	O
children	O
treated	O
in	O
the	O
Medical	O
Research	O
Council	O
AML	O
10	O
and	O
12	O
trials	O
for	O
acute	O
myeloid	O
leukemia	O
.	O

Between	O
May	O
1988	O
and	O
June	O
2000	O
,	O
698	O
children	O
were	O
treated	O
in	O
the	O
Medical	O
Research	O
Council	O
acute	O
myeloid	O
leukemia	O
10	O
and	O
12	O
trials	O
.	O

The	O
presenting	O
features	O
and	O
outcomes	O
of	O
therapy	O
in	O
these	O
children	O
were	O
compared	O
by	O
age	O
.	O

Although	O
there	O
was	O
no	O
single	O
cutoff	O
in	O
age	O
,	O
younger	O
children	O
were	O
more	O
likely	O
to	O
have	O
intermediate	O
risk	O
and	O
less	O
likely	O
to	O
have	O
favorable	Physical
cytogenetics	Physical
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
they	O
had	O
a	O
higher	O
incidence	Physical
of	Physical
translocations	Physical
involving	Physical
chromosome	Physical
11q23	Physical
(	O
P	O
<	O
.001	O
)	O
.	O

The	O
distribution	O
of	O
French-American-British	O
(	O
FAB	O
)	O
types	O
also	O
varied	O
with	O
age	O
;	O
FAB	Physical
types	Physical
M5	Physical
(	O
P	O
<	O
.001	O
)	O
and	O
M7	Others
(	O
P	O
<	O
.001	O
)	O
were	O
more	O
common	O
in	O
early	O
childhood	O
,	O
whereas	O
older	O
children	O
were	O
more	O
likely	O
to	O
have	O
FAB	Others
types	Others
M0	Others
(	O
P	O
=.03	O
)	O
,	O
M1	O
(	O
P	O
=.04	O
)	O
,	O
M2	Others
(	O
P	O
=.005	O
)	O
,	O
and	O
M3	Others
(	O
P	O
<	O
.001	O
)	O
.	O

Involvement	O
of	O
the	O
central	O
nervous	O
system	O
at	O
diagnosis	O
was	O
also	O
more	O
common	O
in	O
the	O
youngest	O
children	O
(	O
P	O
=.01	O
)	O
.	O

Younger	O
children	O
had	O
more	O
severe	Physical
diarrhea	Physical
(	O
P	O
=.002	O
)	O
,	O
whereas	O
older	O
children	O
had	O
worse	O
nausea	Physical
and	Physical
vomiting	Physical
(	O
P	O
=.01	O
)	O
after	O
chemotherapy	O
.	O

When	O
adjusted	O
for	O
other	O
important	O
factors	O
,	O
complete	Physical
remission	Physical
rates	Physical
were	O
similar	O
(	O
P	O
=.5	O
)	O
and	O
although	O
there	O
was	O
less	O
resistant	O
disease	O
in	O
younger	O
children	O
(	O
P	O
=.003	O
)	O
,	O
this	O
was	O
partially	O
balanced	O
by	O
a	O
slight	O
increase	O
in	O
deaths	Mortality
during	O
induction	O
therapy	O
in	O
younger	O
patients	O
(	O
P	O
=.06	O
)	O
.	O

On	O
multivariate	O
analysis	O
overall	Mortality
survival	Mortality
(	O
P	O
=.02	O
)	O
,	O
event-free	Mortality
survival	Mortality
(	O
P	O
=.02	O
)	O
,	O
and	O
disease-free	Mortality
survival	Mortality
were	O
better	O
(	O
P	O
=.06	O
)	O
in	O
younger	O
children	O
due	O
to	O
a	O
lower	O
relapse	Physical
rate	Physical
(	O
P	O
=.02	O
)	O
especially	O
in	O
the	O
bone	O
marrow	O
(	O
P	O
=.02	O
)	O
.	O

Comparison	O
of	O
intermittent	O
or	O
continuous	O
methotrexate	O
plus	O
6-mercaptopurine	O
in	O
regimens	O
for	O
standard-risk	O
acute	O
lymphoblastic	O
leukemia	O
in	O
childhood	O
(	O
JCCLSG-S811	O
)	O
.	O

The	O
Japanese	O
Children	O
's	O
Cancer	O
and	O
Leukemia	O
Study	O
Group	O
.	O

From	O
1981	O
to	O
1983	O
,	O
131	O
previously	O
untreated	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
standard-risk	O
group	O
were	O
entered	O
to	O
the	O
protocol	O
JCCLSG-S811	O
.	O

Of	O
119	O
eligible	O
patients	O
,	O
115	O
(	O
96.6	O
%	O
)	O
attained	O
complete	O
remission	O
by	O
treatment	O
with	O
prednisone	O
(	O
PRD	O
)	O
plus	O
vincristine	O
(	O
VCR	O
)	O
or	O
vindesine	O
(	O
VDS	O
)	O
.	O

After	O
preventive	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
therapy	O
including	O
18	O
Gy	O
cranial	O
irradiation	O
and	O
three	O
doses	O
of	O
intrathecal	O
methotrexate	O
(	O
MTX	O
)	O
,	O
the	O
patients	O
were	O
assigned	O
randomly	O
to	O
the	O
two	O
maintenance	O
chemotherapies	O
,	O
Regimen	O
A	O
and	O
Regimen	O
B	O
.	O

Regimen	O
A	O
(	O
intermittent	O
regimen	O
)	O
consisted	O
of	O
PRD	O
(	O
120	O
mg/m2/day	O
by	O
mouth	O
for	O
5	O
days	O
)	O
plus	O
6-mercaptopurine	O
(	O
6MP	O
)	O
(	O
175	O
mg/m2/day	O
by	O
mouth	O
for	O
5	O
days	O
)	O
plus	O
VCR	O
(	O
2.0	O
mg/m2	O
intravenously	O
)	O
alternating	O
biweekly	O
with	O
MTX	O
(	O
225	O
mg/m2	O
intravenously	O
)	O
.	O

Regimen	O
B	O
(	O
continuous	O
regimen	O
)	O
consisted	O
of	O
6MP	O
(	O
50	O
mg/m2/day	O
by	O
mouth	O
)	O
plus	O
MTX	O
(	O
20	O
mg/m2/week	O
by	O
mouth	O
)	O
combined	O
with	O
pulses	Physical
of	Physical
PRD	Physical
and	Physical
VCR	Physical
(	O
the	O
same	O
dosages	O
as	O
Regimen	O
A	O
)	O
every	O
4	O
weeks	O
.	O

As	O
the	O
late	O
intensification	O
therapy	O
(	O
LIT	O
)	O
,	O
five	O
courses	O
of	O
high-dose	O
MTX	O
(	O
2000	O
mg/m2	O
per	O
dose	O
per	O
week	O
intravenously	O
for	O
three	O
doses	O
every	O
12	O
weeks	O
)	O
with	O
leucovorin	O
rescue	O
were	O
administered	O
to	O
all	O
patients	O
who	O
were	O
in	O
continuous	O
complete	O
remission	O
(	O
CCR	O
)	O
for	O
more	O
than	O
2	O
years	O
.	O

Sixty	O
and	O
55	O
patients	O
,	O
respectively	O
,	O
were	O
registered	O
in	O
Regimen	O
A	O
and	O
B	O
.	O

The	O
CCR	Physical
rates	Physical
in	O
Regimen	O
A	O
and	O
B	O
were	O
75.1	O
%	O
+/-	O
5.8	O
%	O
(	O
mean	O
+/-	O
1	O
SE	O
)	O
and	O
49.7	O
%	O
+/-	O
7.3	O
%	O
(	O
P	O
less	O
than	O
0.01	O
)	O
at	O
4	O
years	O
,	O
and	O
72.1	O
%	O
+/-	O
6.3	O
%	O
and	O
49.7	O
%	O
+/-	O
7.3	O
%	O
(	O
P	O
less	O
than	O
0.05	O
)	O
at	O
5	O
years	O
,	O
respectively	O
.	O

In	O
Regimen	O
B	O
,	O
CNS	Physical
and	Physical
testicular	Physical
relapses	Physical
increased	O
after	O
3	O
years	O
of	O
CCR	O
.	O

In	O
addition	O
,	O
the	O
patients	O
in	O
Regimen	O
B	O
had	O
a	O
much	O
higher	O
incidence	Physical
of	Physical
infections	Physical
than	O
Regimen	O
A	O
.	O

The	O
LIT	O
did	O
not	O
seem	O
to	O
have	O
important	O
effects	O
on	O
the	O
duration	Physical
of	Physical
CCR	Physical
.	O

From	O
these	O
data	O
we	O
conclude	O
that	O
the	O
intermittent	O
cyclic	O
regimen	O
of	O
6MP	O
and	O
MTX	O
may	O
be	O
more	O
effective	O
as	O
compared	O
to	O
the	O
continuous	O
administration	O
of	O
these	O
drugs	O
in	O
the	O
maintenance	O
chemotherapy	O
.	O

Alternative	O
voice	O
after	O
laryngectomy	O
using	O
a	O
sound-producing	O
voice	O
prosthesis	O
.	O

OBJECTIVE	O
To	O
improve	Physical
the	Physical
voice	Physical
quality	Physical
of	O
female	O
laryngectomees	O
and/or	O
laryngectomees	O
with	O
a	O
hypotonic	O
pharyngoesophageal	O
(	O
PE	O
)	O
segment	O
by	O
means	O
of	O
a	O
pneumatic	Physical
artificial	Physical
source	Physical
of	Physical
voice	Physical
incorporated	Physical
in	Physical
a	Physical
regular	Physical
tracheoesophageal	Physical
(	Physical
TE	Physical
)	Physical
shunt	Physical
valve	Physical
.	Physical

STUDY	O
DESIGN	O
Experimental	O
,	O
randomized	O
,	O
crossover	O
trial	O
.	O

METHODS	O
The	O
new	O
sound	O
source	O
consists	O
of	O
a	O
single	O
silicone	O
lip	O
,	O
which	O
performs	O
an	O
oscillatory	O
movement	O
driven	O
by	O
expired	O
pulmonary	O
air	O
flowing	O
along	O
the	O
outward-striking	O
lip	O
through	O
the	O
TE	O
shunt	O
valve	O
.	O

A	O
prototype	O
of	O
this	O
pneumatic	O
sound	O
source	O
is	O
evaluated	O
in	O
vitro	O
and	O
in	O
six	O
laryngectomees	O
.	O

In	O
vivo	O
evaluation	O
includes	O
speech	Physical
rate	Physical
,	Physical
maximal	Physical
phonation	Physical
time	Physical
,	Physical
perceptual	Physical
voice	Physical
evaluation	Physical
of	Physical
read-aloud	Physical
prose	Physical
by	Physical
an	Physical
expert	Physical
listener	Physical
,	Physical
speech	Physical
intelligibility	Physical
measurements	Physical
with	Physical
12	Physical
listeners	Physical
,	Physical
and	Physical
self-assessment	Physical
by	Physical
the	Physical
patients	Physical
.	Physical

Moreover	O
,	O
extensive	Others
acoustical	Others
and	Others
aerodynamic	Physical
in	Physical
vivo	Physical
registrations	Physical
are	O
performed	O
using	O
a	O
newly	Others
developed	Others
data	Others
acquisition	Others
system	Others
.	Others

RESULTS	O
The	O
current	O
prototype	O
seems	O
beneficial	O
in	O
female	O
laryngectomees	O
with	O
a	O
hypotonic	O
PE	O
segment	O
only	O
.	O

For	O
them	O
the	O
sound-producing	O
voice	O
prosthesis	O
improves	Physical
voice	Physical
quality	Physical
and	Physical
increases	Physical
the	Physical
average	Physical
pitch	Physical
of	Physical
voice	Physical
,	Physical
without	Physical
decreasing	Physical
intelligibility	Physical
or	Physical
necessitating	Physical
other	Physical
pressure	Physical
and	Physical
airflow	Physical
rates	Physical
than	Physical
regular	Physical
TE	Physical
shunt	Physical
speech	Physical
.	Physical

Pitch	Physical
regulation	Physical
of	O
this	O
prosthetic	O
voice	O
is	O
possible	O
,	O
yet	O
limited	O
.	O

CONCLUSIONS	O
The	O
mechanism	O
is	O
feasible	Others
and	O
does	O
not	O
result	O
in	O
unacceptable	O
airflow	O
resistance	O
.	O

For	O
this	O
new	O
mechanism	O
of	O
alaryngeal	O
voice	O
to	O
become	O
an	O
established	O
technique	O
for	O
postlaryngectomy	O
voice	O
restoration	O
,	O
a	O
voice	O
suitably	O
pitched	O
for	O
male	O
laryngectomees	O
has	O
to	O
be	O
generated	O
and	O
a	O
large	O
part	O
of	O
the	O
melodic	O
and	O
dynamic	O
range	O
of	O
the	O
sound	O
source	O
has	O
to	O
be	O
attainable	O
within	O
physiological	O
airflow	O
rates	O
.	O

Identifying	O
the	O
indications	O
for	O
laparoscopically	O
assisted	O
vaginal	O
hysterectomy	O
:	O
a	O
prospective	O
,	O
randomised	O
comparison	O
with	O
abdominal	O
hysterectomy	O
in	O
patients	O
with	O
symptomatic	O
uterine	O
fibroids	O
.	O

OBJECTIVE	O
To	O
compare	O
laparoscopically	O
assisted	O
vaginal	O
hysterectomy	O
(	O
LAVH	O
)	O
and	O
total	O
abdominal	O
hysterectomy	O
(	O
TAH	O
)	O
in	O
patients	O
with	O
uterine	O
fibroids	O
.	O

DESIGN	O
A	O
prospective	O
randomised	O
study	O
.	O

SETTING	O
The	O
San	O
Paolo	O
Hospital	O
,	O
Milan	O
.	O

POPULATION	O
Sixty-two	O
patients	O
,	O
who	O
were	O
not	O
suitable	O
for	O
a	O
vaginal	O
hysterectomy	O
,	O
requiring	O
treatment	O
for	O
uterine	O
fibroids	O
.	O

METHODS	O
Randomisation	O
between	O
LAVH	O
and	O
TAH	O
.	O

Comparison	O
of	O
outcomes	O
on	O
the	O
whole	O
series	O
,	O
patients	O
with	O
uteri	O
<	O
or	O
=	O
500	O
g	O
(	O
Group	O
1	O
)	O
and	O
patients	O
with	O
uteri	O
>	O
500	O
g	O
(	O
Group	O
2	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
To	O
establish	O
operating	Others
time	Others
,	O
blood	Physical
loss	Physical
,	O
complications	Adverseeffect
,	O
febrile	Mortality
morbidity	Mortality
,	O
analgesics	Others
administration	Others
and	O
hospital	Others
stay	Others
for	O
both	O
treatment	O
approaches	O
.	O

RESULTS	O
Median	Physical
uterine	Physical
weight	Physical
was	O
400	O
g	O
in	O
both	O
LAVH	O
and	O
TAH	O
group	O
.	O

Median	Others
operating	Others
time	Others
was	O
longer	O
for	O
LAVH	O
(	O
135	O
min	O
compared	O
with	O
120	O
min	O
for	O
TAH	O
;	O
P	O
=	O
0.001	O
)	O
,	O
but	O
patients	O
undergoing	O
LAVH	O
had	O
less	O
analgesics	Physical
administration	Physical
(	O
23	O
%	O
compared	O
with	O
77	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
a	O
shorter	O
median	Others
hospital	Others
stay	Others
(	O
3.8	O
compared	O
with	O
5.8	O
days	O
;	O
P	O
<	O
0.001	O
)	O
.	O

LAVH	O
,	O
when	O
compared	O
with	O
TAH	O
in	O
the	O
two	O
weight	O
subgroups	O
,	O
required	O
a	O
significantly	O
longer	O
operating	Others
time	Others
only	O
in	O
Group	O
2	O
,	O
significantly	O
reduced	O
analgesics	Physical
administration	Physical
only	O
in	O
Group	O
1	O
,	O
and	O
significantly	O
reduced	O
hospital	Others
stay	Others
in	O
both	O
groups	O
.	O

Conversions	O
of	O
LAVH	O
to	O
laparotomy	O
were	O
significantly	O
more	O
frequent	O
in	O
Group	O
2	O
(	O
3/11	O
)	O
than	O
in	O
Group	O
1	O
(	O
0/20	O
)	O
(	O
P	O
=	O
0.04	O
)	O
.	O

CONCLUSIONS	O
Compared	O
with	O
TAH	O
,	O
LAVH	O
has	O
advantages	Others
in	O
removing	O
uteri	O
weighing	O
<	O
or	O
=	O
500	O
g	O
,	O
with	O
comparable	O
operating	Others
time	Others
,	O
less	O
post-operative	Pain
pain	Pain
and	O
shorter	O
recovery	Physical
.	O

Among	O
uteri	O
weighing	O
>	O
500	O
g	O
LAVH	O
showed	O
a	O
shorter	O
recovery	O
,	O
but	O
longer	O
operating	O
time	O
than	O
TAH	O
and	O
a	O
27	O
%	O
rate	O
of	O
conversion	Physical
to	Physical
laparotomy	Physical
.	O

Sequential	O
therapy	O
versus	O
standard	O
triple-drug	O
therapy	O
for	O
Helicobacter	O
pylori	O
eradication	O
:	O
a	O
randomized	O
study	O
.	O

BACKGROUND	O
Antimicrobial	O
resistance	O
has	O
decreased	O
eradication	O
rates	O
for	O
Helicobacter	O
pylori	O
infection	O
worldwide	O
.	O

A	O
sequential	O
treatment	O
schedule	O
has	O
been	O
reported	O
to	O
be	O
effective	O
,	O
but	O
studies	O
published	O
to	O
date	O
were	O
performed	O
in	O
Italy	O
.	O

We	O
undertook	O
this	O
study	O
to	O
determine	O
whether	O
these	O
results	O
could	O
be	O
replicated	O
in	O
India	O
.	O

METHODS	O
A	O
randomized	O
,	O
open-labeled	O
,	O
prospective	O
controlled	O
trial	O
comparing	O
sequential	O
vs.	O
standard	O
triple-drug	O
therapy	O
was	O
carried	O
out	O
at	O
Lokmanya	O
Tilak	O
Municipal	O
General	O
Hospital	O
,	O
Mumbai	O
.	O

Two	O
hundred	O
and	O
thirty-one	O
patients	O
with	O
dyspepsia	O
were	O
randomized	O
to	O
a	O
10-day	O
sequential	O
regimen	O
(	O
40	O
mg	O
of	O
pantoprazole	O
,	O
1	O
g	O
of	O
amoxicillin	O
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
first	O
5	O
days	O
,	O
followed	O
by	O
40	O
mg	O
of	O
pantoprazole	O
,	O
500	O
mg	O
of	O
clarithromycin	O
,	O
and	O
500	O
mg	O
of	O
tinidazole	O
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
remaining	O
5	O
days	O
)	O
or	O
to	O
standard	O
14-day	O
therapy	O
(	O
40	O
mg	O
of	O
pantoprazole	O
,	O
500	O
mg	O
of	O
clarithromycin	O
,	O
and	O
1	O
g	O
of	O
amoxicillin	O
,	O
each	O
administered	O
twice	O
daily	O
)	O
.	O

RESULTS	O
The	O
eradication	Others
rate	Others
achieved	O
with	O
the	O
sequential	O
regimen	O
was	O
significantly	O
greater	O
than	O
that	O
obtained	O
with	O
the	O
triple	O
therapy	O
.	O

Per-protocol	Others
eradication	Others
rate	Others
of	O
sequential	O
therapy	O
was	O
92.4	O
%	O
(	O
95	O
%	O
CI	O
85.8-96.1	O
%	O
)	O
vs.	O
81.8	O
%	O
(	O
95	O
%	O
CI	O
73.9-87.8	O
%	O
)	O
(	O
p	O
=	O
0.027	O
)	O
for	O
standard	O
drug	O
therapy	O
.	O

Intention-to-treat	O
eradication	O
rates	O
were	O
88.2	O
%	O
(	O
95	O
%	O
CI	O
80.9-93.0	O
%	O
)	O
vs.	O
79.1	O
%	O
(	O
95	O
%	O
CI	O
71.1-85.4	O
%	O
)	O
,	O
p	O
=	O
0.029	O
,	O
respectively	O
.	O

The	O
incidence	O
of	O
major	O
and	O
minor	O
side	O
effects	O
between	O
therapy	O
groups	O
was	O
not	O
significantly	O
different	O
(	O
14.6	O
%	O
in	O
the	O
triple	O
therapy	O
group	O
vs.	O
23.5	O
%	O
in	O
sequential	O
group	O
,	O
p	O
=	O
0.12	O
)	O
.	O

Follow	O
up	O
was	O
incomplete	O
in	O
3.3	O
%	O
and	O
4.7	O
%	O
patients	O
in	O
standard	O
and	O
sequential	O
therapy	O
groups	O
,	O
respectively	O
.	O

Sequential	O
therapy	O
includes	O
one	O
additional	O
antibiotic	O
(	O
tinidazole	O
)	O
that	O
is	O
not	O
contained	O
in	O
standard	O
therapy	O
.	O

CONCLUSIONS	O
Sequential	O
therapy	O
was	O
significantly	O
better	O
than	O
standard	O
therapy	O
for	O
eradicating	O
H.	O
pylori	O
infection	O
.	O

Treating	O
the	O
substance-abusing	O
suicidal	O
patient	O
.	O

Studies	O
concerning	O
the	O
treatment	O
of	O
substance-abusing	O
suicidal	O
patients	O
are	O
scarce	O
despite	O
the	O
frequent	O
presence	O
of	O
suicidal	O
behavior	O
among	O
this	O
population	O
.	O

Indeed	O
,	O
suicidality	O
(	O
ideation	O
or	O
behavior	O
)	O
is	O
generally	O
an	O
exclusion	O
criterion	O
for	O
participation	O
in	O
treatment	O
studies	O
of	O
subjects	O
with	O
alcohol	O
or	O
drug	O
abuse	O
.	O

Consequently	O
,	O
to	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
optimal	O
treatment	O
of	O
this	O
population	O
.	O

The	O
first	O
study	O
involving	O
substance-abusing	O
suicidal	O
patients	O
was	O
an	O
open-label	O
trial	O
conducted	O
in	O
the	O
early	O
1990s	O
.	O

This	O
study	O
involved	O
12	O
patients	O
,	O
all	O
of	O
whom	O
demonstrated	O
recent	O
suicidal	Mortality
ideations	Mortality
and	O
had	O
made	O
a	O
lifetime	O
suicide	O
attempt	O
.	O

The	O
results	O
of	O
that	O
open-label	O
study	O
demonstrated	O
significant	O
within-group	O
improvement	O
in	O
both	O
depressive	Mortality
symptoms	Mortality
(	Mortality
including	Mortality
suicidal	Mortality
ideations	Mortality
)	Mortality
and	Mortality
level	Mortality
of	Mortality
drinking	Mortality
.	Mortality

However	O
,	O
substantial	O
residual	O
depressive	Mental
symptoms	Mental
and	Mental
drinking	Mental
persisted	O
at	O
the	O
end	O
of	O
the	O
trial	O
.	O

Also	O
,	O
because	O
no	O
placebo	O
control	O
group	O
was	O
utilized	O
,	O
the	O
authors	O
of	O
that	O
study	O
could	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
apparent	O
therapeutic	O
effect	O
from	O
fluoxetine	O
was	O
the	O
result	O
of	O
the	O
placebo	O
effect	O
.	O

To	O
date	O
,	O
only	O
one	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
subjects	O
with	O
alcohol	O
or	O
substance	O
abuse	O
has	O
included	O
substantial	O
numbers	O
of	O
suicidal	O
patients	O
.	O

The	O
study	O
involved	O
51	O
subjects	O
,	O
of	O
whom	O
20	O
(	O
39	O
%	O
)	O
had	O
made	O
a	O
suicide	O
attempt	O
in	O
the	O
current	O
depressive	O
episode	O
,	O
31	O
(	O
61	O
%	O
)	O
had	O
made	O
a	O
suicide	O
attempt	O
in	O
their	O
lifetime	O
,	O
and	O
46	O
(	O
90	O
%	O
)	O
had	O
reported	O
suicidal	O
ideations	O
in	O
the	O
week	O
before	O
hospitalization	O
.	O

The	O
results	O
of	O
that	O
double-blind	O
,	O
placebo-controlled	O
study	O
suggest	O
that	O
fluoxetine	O
was	O
effective	O
in	O
decreasing	O
but	O
not	O
eliminating	O
both	O
the	O
depressive	Mental
symptoms	Mental
(	Mental
including	Mental
suicidal	Mental
ideations	Mental
)	Mental
and	Mental
the	Mental
level	Mental
of	Mental
alcohol	Mental
consumption	Mental
among	O
a	O
study	O
group	O
of	O
subjects	O
with	O
comorbid	O
major	O
depressive	O
disorder	O
and	O
alcohol	O
dependence	O
,	O
many	O
of	O
whom	O
displayed	O
suicidal	O
ideations	O
.	O

A	O
secondary	O
data	O
analysis	O
from	O
that	O
study	O
suggested	O
that	O
cigarette	Mental
smoking	Mental
is	O
also	O
significantly	O
decreased	O
by	O
fluoxetine	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
decrease	O
is	O
limited	O
and	O
few	O
of	O
these	O
patients	O
totally	O
quit	O
smoking	O
with	O
fluoxetine	O
treatment	O
alone	O
.	O

Another	O
secondary	O
data	O
analysis	O
from	O
that	O
study	O
suggested	O
that	O
marijuana	Mental
smoking	Mental
was	O
also	O
significantly	O
decreased	O
in	O
a	O
subgroup	O
of	O
subjects	O
who	O
demonstrated	O
cannabis	O
abuse	O
and	O
that	O
the	O
magnitude	O
of	O
this	O
improvement	O
was	O
robust	O
.	O

A	O
third	O
secondary	O
data	O
analysis	O
from	O
that	O
study	O
suggested	O
that	O
cocaine	Mental
abuse	Mental
acts	O
as	O
a	O
predictor	O
of	O
poor	O
outcome	O
for	O
both	O
depressive	Mental
symptoms	Mental
(	Mental
including	Mental
suicidality	Mental
)	Mental
and	Mental
level	Mental
of	Mental
alcohol	Mental
use	Mental
in	O
this	O
population	O
.	O

The	O
results	O
of	O
a	O
1-year	O
naturalistic	O
follow-up	O
study	O
involving	O
the	O
patients	O
from	O
that	O
study	O
suggest	O
that	O
the	O
benefits	O
of	O
fluoxetine	O
in	O
decreasing	O
depressive	O
symptoms	O
and	O
level	O
of	O
drinking	O
persist	O
1	O
year	O
after	O
entering	O
the	O
treatment	O
program	O
.	O

To	O
date	O
,	O
no	O
other	O
double-blind	O
,	O
placebo-controlled	O
studies	O
involving	O
substantial	O
numbers	O
of	O
substance-abusing	O
suicidal	O
patients	O
have	O
been	O
reported	O
to	O
either	O
confirm	O
or	O
refute	O
these	O
findings	O
.	O

Further	O
studies	O
are	O
clearly	O
warranted	O
to	O
evaluate	O
the	O
efficacy	O
of	O
various	O
pharmacotherapeutic	O
agents	O
and	O
various	O
psychotherapies	O
in	O
the	O
treatment	O
of	O
substance-abusing	O
suicidal	O
patients	O
.	O

Fentanyl	O
supplementation	O
to	O
inhalation	O
anaesthesia	O
.	O

In	O
eight	O
out	O
of	O
15	O
healthy	O
patients	O
undergoing	O
body	O
surface	O
surgery	O
,	O
the	O
effect	O
of	O
a	O
fentanyl	O
infusion	O
on	O
a	O
conventional	O
thiopentone	O
,	O
nitrous	O
oxide	O
,	O
oxygen	O
and	O
halothane	O
anaesthetic	O
was	O
studied	O
.	O

The	O
fentanyl	O
infusion	O
(	O
2	O
micrograms/kg/hour	O
)	O
reduced	O
the	O
induction	Physical
dose	Physical
of	Physical
thiopentone	Physical
and	O
caused	O
marked	Physical
respiratory	Physical
depression	Physical
with	O
a	O
reduction	O
in	O
the	O
patients	O
'	O
response	O
to	O
surgery	O
.	O

The	O
mean	Physical
arterial	Physical
pressures	Physical
and	O
pulse	Physical
rates	Physical
were	O
not	O
significantly	O
different	O
in	O
each	O
group	O
throughout	O
the	O
course	O
of	O
the	O
operation	O
.	O

The	O
fentanyl	O
made	O
no	O
difference	O
to	O
the	O
patients	O
'	O
postoperative	O
analgesic	O
requirements	O
or	O
to	O
their	O
recovery	O
in	O
the	O
first	O
24	O
hours	O
.	O

Placebo-controlled	O
acute	O
dosage	O
naltrexone	O
study	O
in	O
young	O
autistic	O
children	O
.	O

In	O
a	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
trial	O
23	O
autistic	O
children	O
were	O
treated	O
with	O
a	O
single	O
40-mg	O
dose	O
of	O
the	O
opiate	O
antagonist	O
naltrexone	O
.	O

Drug	O
effects	Others
were	O
monitored	O
by	O
detailed	O
playroom	O
observations	O
,	O
actometers	O
,	O
and	O
parents	O
'	O
checklist	O
ratings	O
(	Mental
Aberrant	Mental
Behavior	Mental
Checklist	Mental
,	Mental
social	Mental
items	Mental
and	Mental
target	Mental
behaviors	Mental
)	Mental
.	Mental

Naltrexone	O
treatment	O
failed	O
to	O
produce	O
significant	Mental
changes	Mental
in	O
social	Mental
behavior	Mental
,	O
but	O
it	O
did	O
reduce	Mental
irritability	Mental
and	Mental
target	Mental
scores	Mental
on	Mental
behavior	Mental
checklists	Mental
.	Mental

The	O
playroom	O
data	O
indicated	O
that	O
naltrexone	O
significantly	O
affected	O
indices	O
of	O
activity	Mental
and	Mental
attention	Mental
.	O

Pre-operative	O
radiochemotherapy	O
for	O
rectal	O
cancer	O
.	O

A	O
prospective	O
randomized	O
trial	O
comparing	O
pre-operative	O
vs.	O
postoperative	O
radiochemotherapy	O
in	O
rectal	O
cancer	O
patients	O
.	O

PURPOSE	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
find	O
out	O
whether	O
pre-operative	O
radiochemotherapy	O
had	O
any	O
survival	Physical
advantage	Physical
over	O
postoperative	O
radiochemotherapy	O
for	O
rectal	O
carcinoma	O
patients	O
without	O
distant	O
metastasis	O
or	O
peritoneal	O
carcinomatosis	O
.	O

MATERIAL	O
AND	O
METHODS	O
Between	O
January	O
1998	O
and	O
December	O
2003	O
,	O
51	O
rectal	O
carcinoma	O
patients	O
without	O
distant	O
metastasis	O
or	O
peritoneal	O
carcinomatosis	O
were	O
randomly	O
divided	O
into	O
pre-operative	O
(	O
PRE	O
)	O
and	O
postoperative	O
(	O
POST	O
)	O
radiochemotherapy	O
groups	O
.	O

Twenty-six	O
were	O
assigned	O
to	O
the	O
PRE	O
group	O
and	O
were	O
operated	O
on	O
5	O
to	O
8	O
weeks	O
after	O
the	O
completion	O
of	O
radiotherapy	O
.	O

The	O
other	O
25	O
patients	O
were	O
operated	O
on	O
immediately	O
and	O
received	O
radiotherapy	O
postoperatively	O
2	O
to	O
4	O
weeks	O
after	O
surgery	O
.	O

The	O
patients	O
were	O
followed	O
up	O
for	O
between	O
4	O
to	O
51	O
months	O
.	O

RESULTS	O
In	O
the	O
PRE	O
group	O
the	O
rates	Physical
of	Physical
disease-free	Physical
survival	Physical
were	O
92	O
%	O
,	O
70	O
%	O
,	O
56	O
%	O
and	O
56	O
%	O
at	O
the	O
end	O
of	O
the	O
1st	O
,	O
2nd	O
,	O
3rd	O
and	O
4th	O
years	O
,	O
respectively	O
.	O

In	O
the	O
POST	O
group	O
those	O
percentages	O
were	O
83	O
%	O
,	O
68	O
%	O
,	O
51	O
%	O
and	O
51	O
%	O
at	O
the	O
1st	O
,	O
2nd	O
,	O
3rd	O
and	O
4th	O
years	O
,	O
respectively	O
(	O
p	O
=	O
0.707	O
)	O
.	O

One-year	Mortality
and	Mortality
4-year	Mortality
overall	Mortality
survival	Mortality
rates	Mortality
in	O
the	O
PRE	O
group	O
were	O
100	O
%	O
and	O
86	O
%	O
respectively	O
and	O
100	O
%	O
and	O
60	O
%	O
in	O
the	O
POST	O
group	O
(	O
p	O
=	O
0.520	O
)	O
.	O

CONCLUSION	O
No	O
statistical	O
difference	O
was	O
found	O
between	O
the	O
survival	Mortality
rates	Mortality
of	O
the	O
rectal	O
carcinoma	O
patients	O
receiving	O
radiotherapy	O
either	O
pre-operatively	O
or	O
postoperatively	O
.	O

However	O
,	O
the	O
disease-free	Mortality
survival	Mortality
rates	Mortality
of	O
the	O
PRE	O
group	O
were	O
higher	O
than	O
the	O
POST	O
group	O
's	O
during	O
each	O
year	O
and	O
overall	Mortality
survival	Mortality
rates	Mortality
were	O
higher	O
after	O
the	O
third	O
and	O
fourth	O
years	O
.	O

We	O
conclude	O
that	O
pre-operative	O
radiotherapy	O
is	O
at	Others
least	Others
as	Others
effective	Others
as	Others
postoperative	O
radiotherapy	O
.	O

Prospective	O
randomized	O
controlled	O
trial	O
comparing	O
plasmakinetic	O
vaporesection	O
and	O
conventional	O
transurethral	O
resection	O
of	O
the	O
prostate	O
.	O

OBJECTIVE	O
Plasmakinetic	O
vaporesection	O
of	O
the	O
prostate	O
(	O
PKVP	O
)	O
using	O
normal	O
saline	O
irrigation	O
has	O
the	O
theoretical	O
advantage	O
of	O
avoiding	O
transurethral	O
resection	O
syndrome	O
and	O
minimizing	O
blood	O
loss	O
.	O

It	O
may	O
also	O
shorten	O
the	O
operative	O
time	O
since	O
tissue	O
is	O
resected	O
instead	O
of	O
just	O
vaporized	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficiency	Others
,	O
safety	Others
and	O
advantages	Others
of	O
PKVP	O
compared	O
with	O
standard	O
transurethral	O
resection	O
of	O
the	O
prostate	O
(	O
TURP	O
)	O
at	O
a	O
regional	O
acute	O
hospital	O
.	O

METHODS	O
A	O
total	O
of	O
60	O
consecutive	O
men	O
admitted	O
from	O
a	O
waiting	O
list	O
for	O
surgery	O
for	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
were	O
prospectively	O
randomized	O
to	O
either	O
PKVP	O
or	O
TURP	O
.	O

Peri-	O
and	O
postoperative	O
outcome	O
data	O
at	O
3	O
months	O
were	O
obtained	O
.	O

RESULTS	O
The	O
PKVP	O
loop	O
achieved	O
a	O
fast	O
and	O
sharp	O
cutting	O
action	O
similar	O
to	O
that	O
with	O
the	O
traditional	O
TURP	O
loop	O
.	O

Data	O
analysis	O
was	O
based	O
on	O
51	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
methods	O
in	O
resection	Others
time	Others
,	O
postoperative	Others
catheterization	Others
time	Others
and	O
hospital	Others
stay	Others
.	O

The	O
mean	Physical
reductions	Physical
in	Physical
serum	Physical
sodium	Physical
2	O
hours	O
after	O
PKVP	O
and	O
on	O
postoperative	O
day	O
1	O
were	O
0.52	O
mmol/L	O
and	O
3.35	O
mmol/L	O
,	O
respectively	O
,	O
while	O
mean	O
reductions	O
in	O
haemoglobin	O
were	O
0.36	O
g/dL	O
and	O
0.24	O
g/dL	O
,	O
respectively	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
haemoglobin	Physical
reductions	Physical
between	O
PKVP	O
and	O
TURP	O
(	O
p	O
=	O
0.326	O
at	O
2	O
hours	O
;	O
p	O
=	O
0.192	O
on	O
day	O
1	O
)	O
and	O
serum	O
sodium	O
(	O
p	O
=	O
0.757	O
at	O
2	O
hours	O
;	O
p	O
=	O
0.888	O
on	O
day	O
1	O
)	O
.	O

Both	O
groups	O
achieved	O
comparable	O
improvement	O
in	O
International	Others
Prostate	Others
Symptom	Others
Score	Others
(	O
p	O
=	O
0.862	O
)	O
,	O
quality-of-life	O
score	O
(	O
p	O
=	O
0.169	O
)	O
and	O
peak	O
flow	O
rate	O
(	O
p	O
=	O
0.96	O
)	O
at	O
3-month	O
follow-up	O
.	O

CONCLUSION	O
PKVP	O
achieved	O
comparable	O
results	O
to	O
traditional	O
TURP	O
and	O
was	O
an	O
effective	Others
and	Others
safe	Others
procedure	O
.	O

However	O
,	O
it	O
did	O
not	O
demonstrate	O
obvious	O
advantages	O
over	O
TURP	O
in	O
this	O
acute	O
regional	O
hospital	O
regular	O
TURP	O
list	O
setting	O
.	O

A	O
clinical	O
trial	O
of	O
glutathione	O
supplementation	O
in	O
autism	O
spectrum	O
disorders	O
.	O

BACKGROUND	O
Recent	O
evidence	O
shows	O
that	O
subjects	O
diagnosed	O
with	O
an	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
have	O
significantly	O
lower	O
levels	O
of	O
glutathione	O
than	O
typically	O
developing	O
children	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
use	O
of	O
two	O
commonly	O
used	O
glutathione	O
supplements	O
in	O
subjects	O
diagnosed	O
with	O
an	O
ASD	O
to	O
determine	O
their	O
efficacy	O
in	O
increasing	O
blood	Physical
glutathione	Physical
levels	Physical
in	O
subjects	O
diagnosed	O
with	O
an	O
ASD	O
.	O

MATERIAL/METHODS	O
The	O
study	O
was	O
an	O
eight-week	O
,	O
open-label	O
trial	O
using	O
oral	O
lipoceutical	O
glutathione	O
(	O
n=13	O
)	O
or	O
transdermal	O
glutathione	O
(	O
n=13	O
)	O
in	O
children	O
,	O
3-13	O
years	O
of	O
age	O
,	O
with	O
a	O
diagnosis	O
of	O
an	O
ASD	O
.	O

Subjects	O
underwent	O
pre-	O
and	O
post-treatment	O
lab	O
testing	O
to	O
evaluate	O
plasma	Physical
reduced	Physical
glutathione	Physical
,	Physical
oxidized	Physical
glutathione	Physical
,	Physical
cysteine	Physical
,	Physical
taurine	Physical
,	Physical
free	Physical
and	Physical
total	Physical
sulfate	Physical
,	Physical
and	Physical
whole-blood	Physical
glutathione	Physical
levels	Physical
.	Physical

RESULTS	O
The	O
oral	O
treatment	O
group	O
showed	O
significant	O
increases	O
in	O
plasma	Physical
reduced	Physical
glutathione	Physical
,	O
but	O
not	O
whole-blood	Physical
glutathione	Physical
levels	O
following	O
supplementation	O
.	O

Both	O
the	O
oral	O
and	O
transdermal	O
treatment	O
groups	O
showed	O
significant	O
increases	O
in	O
plasma	Physical
sulfate	Physical
,	O
cysteine	Physical
,	O
and	O
taurine	Physical
following	O
supplementation	O
.	O

CONCLUSIONS	O
The	O
results	O
suggest	O
that	O
oral	O
and	O
transdermal	O
glutathione	O
supplementation	O
may	O
have	O
some	O
benefit	O
in	O
improving	O
some	O
of	O
the	O
transsulfuration	O
metabolites	O
.	O

Future	O
studies	O
among	O
subjects	O
diagnosed	O
with	O
an	O
ASD	O
should	O
further	O
explore	O
the	O
pharmacokinetics	O
of	O
glutathione	O
supplementation	O
and	O
evaluate	O
the	O
potential	O
effects	O
of	O
glutathione	O
supplementation	O
upon	O
clinical	O
symptoms	O
.	O

Suppression	O
of	O
immediate	O
and	O
late	O
anti-IgE-induced	Physical
skin	Physical
reactions	Physical
by	O
topically	O
applied	O
alcohol/onion	O
extract	O
.	O

In	O
a	O
double	O
blind	O
study	O
,	O
alcohol/onion	O
extract	O
(	O
5	O
%	O
ethanol	O
)	O
was	O
injected	O
simultaneously	O
with	O
20	O
IU	O
and	O
200	O
IU	O
rabbit	O
anti-human-IgE	O
intradermally	O
in	O
12	O
adult	O
volunteers	O
(	O
6	O
atopics	O
,	O
6	O
non-atopics	O
)	O
.	O

Diameters	O
of	O
wheals	O
and	O
flares	O
were	O
measured	O
10	O
min	O
after	O
and	O
compared	O
with	O
control	O
sites	O
challenged	O
with	O
20	O
IU	O
and	O
200	O
IU	O
anti-IgE	O
in	O
a	O
5	O
%	O
ethanol	O
solution	O
.	O

The	O
skin	O
sites	O
were	O
then	O
treated	O
epidermally	O
with	O
45	O
%	O
alcohol/onion	O
extract	O
and	O
45	O
%	O
ethanol	O
under	O
occlusion	O
.	O

Diameters	O
of	O
late	O
cutaneous	O
reactions	O
were	O
measured	O
hourly	O
.	O

Oedema	O
formation	O
was	O
clinically	O
estimated	O
according	O
to	O
an	O
arbitrary	O
scale	O
and	O
skin	O
thickness	O
measured	O
with	O
a	O
calliper	O
.	O

In	O
the	O
onion-treated	O
skin	O
sites	O
the	O
wheal	Physical
areas	Physical
were	O
significantly	O
reduced	O
(	O
20	O
IU	O
:	O
control	O
:	O
108	O
+/-	O
53	O
mm2	O
;	O
onion	O
69	O
+/-	O
42	O
mm2	O
,	O
P	O
less	O
than	O
0.05	O
;	O
200	O
IU	O
anti-IgE	O
:	O
control	O
:	O
152	O
+/-	O
25	O
mm2	O
,	O
onion	O
:	O
138	O
+/-	O
26	O
mm2	O
,	O
P	O
less	O
than	O
0.02	O
)	O
.	O

The	O
oedema	Physical
formation	Physical
during	O
the	O
late	O
phase	O
skin	O
reaction	O
was	O
markedly	O
depressed	O
(	O
P	O
less	O
than	O
0.005	O
at	O
2	O
h	O
,	O
P	O
less	O
than	O
0.01	O
at	O
4	O
and	O
6	O
h	O
,	O
P	O
less	O
than	O
0.02	O
at	O
8	O
h	O
)	O
.	O

The	O
extent	O
of	O
late	O
skin	Physical
reactions	Physical
was	O
slightly	O
,	O
but	O
not	O
significantly	O
reduced	O
.	O

Obviously	O
,	O
onions	O
contain	O
pharmacologically	O
active	O
substances	O
with	O
anti-inflammatory	O
and/or	O
allergic	O
properties	O
.	O

Approval	O
summary	O
:	O
imatinib	O
mesylate	Physical
in	O
the	O
treatment	O
of	O
metastatic	O
and/or	O
unresectable	O
malignant	O
gastrointestinal	Physical
stromal	Physical
tumors	Physical
.	O

The	O
purpose	O
of	O
the	O
present	O
application	O
was	O
to	O
fulfill	O
a	O
postmarketing	O
commitment	O
to	O
provide	O
long-term	O
efficacy	O
and	O
safety	O
data	O
on	O
treatment	O
with	O
imatinib	Physical
mesylate	Physical
(	O
Gleevec	O
;	O
Novartis	O
Pharmaceuticals	O
,	O
East	O
Hanover	O
,	O
NJ	O
)	O
in	O
patients	O
with	O
CD117	O
(	O
+	O
)	O
unresectable	O
and/or	O
metastatic	O
malignant	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
.	O

In	O
addition	O
,	O
this	O
application	O
also	O
provides	O
evidence	O
to	O
support	O
a	O
change	O
in	O
the	O
label	O
to	O
allow	O
for	O
an	O
escalation	O
of	O
imatinib	O
dosing	O
to	O
800	O
mg/day	O
for	O
patients	O
with	O
progressive	O
disease	O
on	O
a	O
lower	O
dose	O
.	O

Two	O
open-label	O
,	O
controlled	O
,	O
multicenter	O
,	O
intergroup	O
,	O
international	O
,	O
randomized	O
phase	O
III	O
studies	O
were	O
submitted	O
--	O
one	O
conducted	O
by	O
the	O
European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	Physical
(	O
n	O
=	O
946	O
)	O
and	O
the	O
other	O
by	O
the	O
Southwest	O
Oncology	Physical
Group	O
(	O
n	O
=	O
746	O
)	O
.	O

These	O
studies	O
compared	O
400	O
mg/day	O
of	O
imatinib	O
with	O
800	O
mg/day	O
of	O
imatinib	O
.	O

A	O
combined	O
analysis	O
of	O
the	O
two	O
studies	O
was	O
prospectively	O
defined	O
and	O
agreed	O
to	O
by	O
both	O
groups	O
.	O

Both	O
protocols	O
allowed	O
patients	O
randomized	O
to	O
the	O
400-mg/day	O
imatinib	O
arm	O
to	O
cross	O
over	O
to	O
800	O
mg/day	O
imatinib	Physical
at	O
progression	O
.	O

Objective	O
responses	O
were	O
achieved	O
in	O
>	O
50	O
%	O
of	O
patients	O
receiving	O
either	O
imatinib	O
dose	O
.	O

The	O
median	O
progression-free	Mortality
survival	Mortality
time	Mortality
was	O
approximately	O
20	O
months	O
and	O
the	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
time	O
was	O
approximately	O
49	O
months	O
.	O

In	O
the	O
combined	O
analysis	O
,	O
347	O
patients	O
crossed	O
over	O
to	O
800	O
mg/day	O
imatinib	O
at	O
the	O
time	O
of	O
progression	O
.	O

The	O
median	Physical
OS	Physical
time	O
after	O
crossover	O
was	O
14.3	O
months	O
.	O

The	O
most	O
common	O
adverse	Adverseeffect
events	Adverseeffect
(	Adverseeffect
AEs	Adverseeffect
)	Adverseeffect
were	O
fluid	O
retention	O
,	O
nausea	Physical
,	O
fatigue	Physical
,	Physical
skin	Physical
rash	Physical
,	Physical
gastrointestinal	Physical
complaints	Physical
,	O
and	O
myalgia	Physical
.	O

The	O
most	O
common	O
laboratory	O
abnormality	Physical
was	Physical
anemia	Physical
.	Adverseeffect

Most	O
often	O
the	O
AEs	Physical
were	O
of	O
mild-to-moderate	O
severity	O
.	O

Fluid	O
retention	O
events	O
and	O
skin	O
rash	O
were	O
numerically	O
reported	O
more	O
often	O
in	O
the	O
800-mg/day	O
treatment	O
cohort	O
of	O
patients	O
.	O

Safety	O
trial	O
of	O
the	O
vaginal	O
microbicide	O
cellulose	O
sulfate	O
gel	O
in	O
HIV-positive	O
men	O
.	O

OBJECTIVE	O
Cellulose	O
sulfate	O
(	O
CS	O
)	O
is	O
a	O
promising	O
vaginal	O
microbicide	O
.	O

Because	O
men	O
will	O
be	O
exposed	O
to	O
the	O
microbicide	O
when	O
engaging	O
in	O
vaginal	O
intercourse	O
,	O
safety	Others
and	Others
acceptability	Others
need	O
to	O
be	O
assessed	O
in	O
men	O
.	O

DESIGN	O
This	O
randomized	O
double-blind	O
phase	O
I	O
study	O
assessed	O
the	O
safety	Others
and	Others
acceptability	Others
of	O
seven	O
consecutive	O
daily	O
doses	O
of	O
CS	O
versus	O
KY	O
Jelly	O
in	O
36	O
HIV-positive	O
men	O
.	O

RESULTS	O
No	O
new	Physical
or	Physical
worsening	Physical
of	Physical
existing	Physical
genital	Physical
findings	Physical
were	O
observed	O
during	O
the	O
follow-up	O
examination	O
.	O

Mild	Physical
genital	Physical
symptoms	Physical
were	O
reported	O
in	O
42	O
%	O
of	O
CS	O
users	O
(	O
itching	Physical
,	O
burning	Physical
,	O
tingling	Physical
,	O
testicular	Physical
pain	Physical
,	O
dysuria	Physical
,	O
and	O
warm	Physical
or	Physical
cold	Physical
feeling	Physical
)	O
and	O
8	O
%	O
of	O
KY	O
Jelly	O
users	O
.	O

CONCLUSION	O
CS	O
gel	O
applied	O
to	O
the	O
penis	O
was	O
well	O
tolerated	Others
in	O
this	O
HIV-positive	O
male	O
population	O
.	O

The	O
itching	Physical
and	Physical
burning	Physical
symptoms	O
were	O
not	O
severe	O
and	O
can	O
be	O
explained	O
by	O
the	O
preservative	O
benzyl	O
alcohol	O
present	O
in	O
the	O
CS	O
gel	O
.	O

Is	O
anti-Pseudomonas	O
therapy	O
warranted	O
in	O
acute	O
respiratory	Physical
exacerbations	Physical
in	O
children	O
with	O
cystic	O
fibrosis	O
?	O
A	O
controlled	O
study	O
was	O
designed	O
to	O
clarify	O
the	O
indications	O
for	O
antibiotic	O
therapy	O
in	O
children	O
with	O
advanced	O
cystic	O
fibrosis	O
hospitalized	O
with	O
respiratory	O
exacerbations	O
.	O

Twenty-two	O
children	O
with	O
severe	O
CF	O
and	O
signs	O
of	O
acute	O
lower	O
respiratory	O
infection	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
cloxacillin	O
or	O
carbenicillin	O
plus	O
gentamicin	O
administered	O
intravenously	O
for	O
ten	O
days	O
.	O

Other	O
aspects	O
of	O
therapy	O
were	O
constant	O
.	O

The	O
groups	O
were	O
comparable	O
in	O
all	O
respects	O
and	O
Pseudomonas	O
aeruginosa	O
was	O
the	O
predominant	O
sputum	O
pathogen	O
in	O
most	O
patients	O
.	O

Clinical	Physical
improvement	Physical
,	Physical
chest	Physical
radiograph	Physical
changes	Physical
,	Physical
evidence	Physical
of	Physical
airway	Physical
obstruction	Physical
,	Physical
and	Physical
bacteriologic	Physical
flora	Physical
of	Physical
sputum	Physical
were	O
no	O
different	O
regardless	O
of	O
the	O
regimen	O
used	O
.	O

These	O
results	O
suggest	O
that	O
the	O
use	O
of	O
anti-Pseudomonas	O
medication	O
in	O
these	O
children	O
may	O
not	O
always	O
be	O
necessary	O
.	O

These	O
observations	O
need	O
to	O
be	O
confirmed	O
by	O
blind-controlled	O
studies	O
in	O
larger	O
numbers	O
of	O
patients	O
with	O
mild	O
as	O
well	O
as	O
severe	O
respiratory	O
involvement	O
.	O

Effect	O
of	O
L-carnitine	O
on	O
myocardial	O
metabolism	O
:	O
results	O
of	O
a	O
balanced	O
,	O
placebo-controlled	O
,	O
double-blind	O
study	O
in	O
patients	O
undergoing	O
open	O
heart	O
surgery	O
.	O

The	O
effects	O
of	O
L-carnitine	O
on	O
cardiac	O
performance	O
after	O
open	O
heart	O
surgery	O
were	O
evaluated	O
in	O
a	O
balanced	O
,	O
placebo-controlled	O
,	O
double-blind	O
study	O
in	O
38	O
patients	O
.	O

Preoperative	O
haemodynamic	O
status	O
was	O
good	O
in	O
all	O
of	O
them	O
.	O

Seventeen	O
subjects	O
underwent	O
mitral	O
valve	O
replacement	O
and	O
19	O
patients	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

Five	O
grams	O
L-carnitine	O
were	O
given	O
intravenously	O
over	O
2	O
h	O
,	O
twice	O
daily	O
for	O
5	O
consecutive	O
days	O
;	O
moreover	O
,	O
10	O
g	O
L-carnitine	O
in	O
1500	O
ml	O
cardioplegia	O
were	O
administered	O
through	O
the	O
aortic	O
root	O
after	O
aortic	O
cross-clamping	O
.	O

Surgery	O
was	O
always	O
planned	O
on	O
treatment	O
day	O
3	O
.	O

The	O
post-ischaemic	O
functional	O
recovery	O
of	O
the	O
heart	O
was	O
assessed	O
by	O
clinical	O
parameters	O
,	O
as	O
well	O
as	O
by	O
biochemical	O
and	O
ultrastructure	O
evaluations	O
on	O
biopsy	O
specimens	O
.	O

No	O
differences	O
were	O
found	O
between	O
the	O
control	O
and	O
the	O
treatment	O
group	O
with	O
respect	O
to	O
all	O
clinical	O
parameters	O
of	O
cardiac	O
performance	O
after	O
cardiopulmonary	O
bypass	O
.	O

At	O
anaesthesia	O
induction	O
,	O
serum	Physical
carnitine	Physical
was	O
significantly	O
increased	O
in	O
treated	O
patients	O
,	O
but	O
carnitine	Physical
concentrations	Physical
in	O
the	O
right	O
atrial	O
biopsy	O
obtained	O
just	O
before	O
aortic	O
declamping	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

In	O
patients	O
with	O
mitral	O
valve	O
replacement	O
,	O
L-carnitine	O
therapy	O
was	O
associated	O
with	O
significantly	O
higher	O
concentrations	O
of	O
pyruvate	Physical
,	O
ATP	Physical
and	O
creatine	Physical
phosphate	Physical
in	O
papillary	O
muscle	O
.	O

Glycogen	Physical
levels	Physical
were	O
also	O
higher	O
in	O
the	O
treated	O
group	O
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Myocardial	O
ultrastructure	O
on	O
septal	O
biopsies	O
,	O
obtained	O
within	O
5	O
min	O
from	O
weaning	O
from	O
extracorporeal	O
circulation	O
,	O
showed	O
better	O
preservation	O
scores	O
for	O
all	O
considered	O
parameters	O
(	O
nucleus	Physical
,	Physical
sarcoplasmic	Physical
reticulum	Physical
,	Physical
mitochondria	Physical
and	Physical
cellular	Physical
oedema	Physical
)	O
in	O
the	O
treated	O
subjects	O
,	O
although	O
the	O
difference	O
reached	O
statistical	O
significance	O
only	O
for	O
nuclei	O
.	O

When	O
biochemical	O
and	O
ultrastructural	O
data	O
are	O
considered	O
,	O
these	O
findings	O
suggest	O
that	O
L-carnitine	O
improves	O
myocardial	Physical
metabolism	Physical
.	O

However	O
,	O
it	O
can	O
not	O
be	O
concluded	O
that	O
L-carnitine	O
provides	O
an	O
advantageous	Others
support	Others
therapy	Others
for	O
well-compensated	O
patients	O
requiring	O
cardiac	O
surgery	O
.	O

In	O
contrast	O
,	O
the	O
positive	O
effects	O
of	O
L-carnitine	O
on	O
cardiac	Physical
recovery	Physical
after	O
bypass	O
might	O
become	O
clinically	O
relevant	O
in	O
the	O
surgical	O
setting	O
for	O
haemodynamically	O
compromised	O
patients	O
,	O
in	O
which	O
further	O
investigations	O
are	O
required	O
.	O

Phase-dependent	Physical
modulation	Physical
of	O
the	O
soleus	Physical
H-reflex	Physical
during	O
rhythmical	O
arm	O
swing	O
in	O
humans	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
investigate	O
modulation	Physical
of	Physical
the	Physical
soleus	Physical
H-reflex	Physical
during	O
rhythmic	O
arm	O
swing	O
in	O
humans	O
.	O

Significant	O
depression	O
of	O
the	O
soleus	O
H-reflex	Physical
was	O
observed	O
when	O
subjects	O
swung	O
their	O
ipsilateral	O
arms	O
or	O
both	O
arms	O
reciprocally	O
during	O
testing	O
.	O

The	O
degree	O
of	O
soleus	Physical
H-reflex	Physical
depression	Physical
appeared	O
directly	O
proportional	O
to	O
the	O
speed	O
of	O
the	O
arm	O
swing	O
.	O

This	O
depression	Physical
was	O
observed	O
in	O
the	O
conditioning-testing	O
intervals	O
of	O
400	O
,	O
500	O
,	O
and	O
600	O
msec	O
during	O
the	O
ipsilateral	O
backward	O
arm	O
swing	O
and	O
at	O
the	O
onset	O
of	O
the	O
ipsilateral	O
arm	O
forward	O
swing	O
.	O

This	O
phase	O
of	O
depression	Physical
partially	O
overlapped	O
the	O
phase	O
of	O
depression	O
of	O
the	O
soleus	O
H-reflex	O
during	O
walking	O
.	O

However	O
,	O
the	O
pattern	O
of	O
modulation	O
during	O
arm	O
swing	O
was	O
not	O
exactly	O
the	O
same	O
as	O
that	O
during	O
walking	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
the	O
ipsilateral	Physical
arm	Physical
swing	Physical
may	O
partially	O
affect	O
the	O
depression	Physical
of	Physical
the	Physical
soleus	Physical
H-reflex	Physical
during	O
the	O
arm	O
swing	O
phase	O
of	O
walking	O
but	O
is	O
not	O
responsible	O
for	O
depression	Physical
of	Physical
the	Physical
soleus	Physical
H-reflex	Physical
throughout	O
the	O
entire	O
walking	O
cycle	O
.	O

Safety	Others
,	O
tolerability	Others
,	O
and	O
changes	Physical
in	Physical
amyloid	Physical
beta	Physical
concentrations	Physical
after	O
administration	O
of	O
a	O
gamma-secretase	O
inhibitor	O
in	O
volunteers	O
.	O

Amyloid	O
beta	O
(	O
Abeta	O
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
disease	O
.	O

A	O
functional	O
gamma-secretase	O
inhibitor	O
,	O
LY450139	O
,	O
was	O
developed	O
that	O
inhibits	O
Abeta	O
formation	O
in	O
whole	O
cell	O
assays	O
,	O
transgenic	O
mice	O
,	O
and	O
beagle	O
dogs	O
.	O

The	O
authors	O
wished	O
to	O
determine	O
the	O
safety	O
and	O
tolerability	O
of	O
this	O
drug	O
,	O
and	O
the	O
reduction	O
of	O
Abeta	Physical
in	Physical
plasma	Physical
and	Physical
cerebrospinal	Physical
fluid	Physical
(	Physical
CSF	Physical
)	Physical
after	O
multiple	O
doses	O
.	O

Volunteer	O
subjects	O
(	O
N	O
=	O
37	O
)	O
were	O
studied	O
using	O
doses	O
from	O
5	O
to	O
50	O
mg/day	O
given	O
for	O
14	O
days	O
.	O

Plasma	Physical
and	Physical
CSF	Physical
concentrations	Physical
of	Physical
LY450139	Physical
,	Physical
Abeta	Physical
(	Physical
1-40	Physical
)	Physical
and	O
Abeta	Physical
(	Physical
1-X	Physical
)	Physical
(	Physical
Abeta	Physical
(	Physical
total	Physical
)	Physical
)	Physical
were	O
determined	O
,	O
and	O
safety	O
and	O
tolerability	O
were	O
assessed	O
.	O

The	O
plasma	O
half-life	O
of	O
LY450139	O
was	O
approximately	O
2.5	O
hours	O
.	O

Pharmacokinetic	O
analyses	O
showed	O
a	O
linear	O
relationship	O
between	O
dose	O
and	O
plasma	O
concentrations	O
,	O
with	O
a	O
Cmax	O
of	O
828	O
+/-	O
19.2	O
ng/mL	O
after	O
a	O
50-mg	O
dose	O
.	O

Plasma	Physical
Abeta	Physical
concentrations	Physical
decreased	O
in	O
a	O
dose-dependent	O
manner	O
over	O
a	O
6-hour	O
interval	O
following	O
drug	O
administration	O
,	O
with	O
a	O
maximum	O
decrease	O
of	O
approximately	O
40	O
%	O
relative	O
to	O
baseline	O
.	O

After	O
returning	O
to	O
baseline	O
,	O
Abeta	Physical
concentrations	Physical
were	O
transiently	O
increased	O
.	O

CSF	Physical
Abeta	Physical
concentrations	Physical
were	O
unchanged	O
.	O

Adverse	Adverseeffect
events	Adverseeffect
reported	O
by	O
subjects	O
taking	O
5-mg	O
,	O
20-mg	O
,	O
or	O
40-mg	O
doses	O
were	O
similar	O
to	O
those	O
reported	O
by	O
subjects	O
taking	O
placebo	O
.	O

Two	O
of	O
7	O
subjects	O
taking	O
50	O
mg/day	O
experienced	O
adverse	O
events	O
that	O
may	O
have	O
been	O
drug	O
related	O
.	O

In	O
this	O
phase	O
1	O
volunteer	O
study	O
,	O
reported	O
adverse	O
events	O
after	O
taking	O
LY450139	O
were	O
manageable	O
.	O

A	O
dose-dependent	O
reduction	O
in	O
plasma	Physical
Abeta	Physical
was	O
demonstrated	O
,	O
and	O
changes	O
in	O
plasma	Physical
Abeta	Physical
concentrations	O
were	O
temporally	O
related	O
to	O
the	O
pharmacokinetic	O
characteristics	O
of	O
LY450139	O
.	O

Analysis	Others
of	Others
treatment	Others
in	O
childhood	O
leukaemia	O
.	O

I.	O
Predisposition	O
to	O
methotrexate-induced	O
neutropenia	O
after	O
craniospinal	O
irradiation	O
.	O

Report	O
to	O
the	O
Medical	O
Research	O
Council	O
of	O
the	O
Working	O
Party	O
on	O
Leukaemia	O
in	O
Childhood	O
.	O

The	O
degree	O
of	O
drug-induced	O
neutropenia	Physical
resulting	O
from	O
a	O
controlled	O
trial	O
(	O
UKALL	O
I	O
)	O
of	O
treatment	O
in	O
acute	O
lymphoblastic	O
leukaemia	O
was	O
analysed	O
.	O

The	O
main	O
agent	O
associated	O
with	O
severe	O
neutropenia	O
was	O
methotrexate	O
,	O
and	O
methotrexate-induced	Physical
neutropenia	Physical
was	O
significantly	O
greater	O
in	O
patients	O
who	O
had	O
received	O
craniospinal	O
irradiation	O
.	O

The	O
synergistic	Adverseeffect
toxic	Adverseeffect
effect	Adverseeffect
of	O
irradiation	O
followed	O
by	O
methotrexate	O
treatment	O
seems	O
to	O
have	O
contributed	O
to	O
three	O
of	O
the	O
five	O
deaths	O
which	O
occurred	O
in	O
complete	O
remission	Physical
in	O
this	O
trial	O
;	O
all	O
deaths	O
in	O
remission	O
occurred	O
in	O
patients	O
who	O
had	O
received	O
central	O
nervous	O
system	O
prophylaxis	O
.	O

Analysis	O
of	O
patients	O
who	O
subsequently	O
relapsed	O
compared	O
with	O
those	O
still	O
in	O
remission	O
after	O
18	O
months	O
of	O
treatment	O
indicated	O
that	O
the	O
former	O
,	O
on	O
average	O
,	O
had	O
slightly	O
lower	O
neutrophil	Physical
counts	Physical
.	Physical

This	O
suggests	O
that	O
the	O
children	O
who	O
relapsed	O
did	O
not	O
receive	O
any	O
less	O
aggressive	O
treatment	O
than	O
those	O
who	O
remained	O
in	O
remission	O
.	O

Utilization	O
of	O
health	O
care	O
services	O
by	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

In	O
order	O
to	O
identify	O
healthcare	Others
resource	Others
use	Others
patterns	Others
associated	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
resource	O
utilization	O
(	O
RU	O
)	O
data	O
collection	O
was	O
integrated	O
into	O
a	O
randomized	O
,	O
double-blind	O
placebo-controlled	O
study	O
of	O
Viozan	O
(	O
sibenadet	O
HCl	O
)	O
.	O

This	O
study	O
enrolled	O
patients	O
with	O
symptomatic	O
,	O
smoking-related	O
COPD	O
,	O
randomized	O
to	O
receive	O
sibenadet	O
or	O
placebo	O
for	O
a	O
52-week	O
treatment	O
period	O
.	O

A	O
questionnaire	Physical
establishing	Physical
typical	Physical
pre-trial	Physical
,	Physical
COPD-related	Physical
RU	Physical
was	O
completed	O
by	O
each	O
patient	O
.	O

Subsequent	O
data	O
were	O
collected	O
by	O
means	O
of	O
an	O
Interactive	Others
Voice	Others
Response	Others
System	Others
(	Others
IVRS	Others
)	Others
at	O
30-day	O
intervals	O
(	O
14	O
time	O
points	O
)	O
during	O
the	O
study	O
and	O
in	O
the	O
follow-up	O
period	O
.	O

The	O
IVRS	O
system	O
facilitated	O
data	O
collection	O
and	O
minimized	O
inconvenience	O
to	O
the	O
patient	O
.	O

Compliance	O
with	O
the	O
requirement	O
to	O
record	O
details	O
of	O
the	O
healthcare	O
services	O
during	O
the	O
year-long	O
study	O
was	O
high	O
.	O

No	O
overall	O
trend	O
for	O
lower	O
RU	Physical
was	O
associated	O
with	O
sibenadet	O
therapy	O
,	O
which	O
correlates	O
with	O
the	O
lack	O
of	O
sustained	O
clinical	O
effect	O
seen	O
in	O
studies	O
conducted	O
concurrently	O
.	O

These	O
data	O
do	O
,	O
however	O
,	O
provide	O
valuable	O
information	O
on	O
RU	O
associated	O
with	O
COPD	O
and	O
insights	O
into	O
adjustments	O
associated	O
with	O
changes	O
in	O
disease	O
course	O
.	O

Physicians	O
were	O
seen	O
to	O
be	O
the	O
most	O
common	O
source	O
of	O
care	O
for	O
patients	O
with	O
COPD	O
and	O
more	O
of	O
the	O
patients	O
with	O
severe	O
COPD	O
(	O
stage	O
III	O
)	O
than	O
mild	O
(	O
stage	O
I	O
)	O
were	O
seen	O
to	O
utilize	O
the	O
most	O
expensive	O
resources	O
(	O
e.g	O
.	O

inpatient	Others
hospital	Others
care	Others
)	O
.	O

For	O
those	O
patients	O
who	O
experienced	O
an	O
exacerbation	O
during	O
the	O
trial	O
(	O
irrespective	O
of	O
treatment	O
group	O
)	O
,	O
resource	Others
use	Others
was	O
increased	O
during	O
the	O
periods	O
when	O
an	O
exacerbation	O
was	O
reported	O
when	O
compared	O
with	O
the	O
periods	O
before	O
or	O
after	O
an	O
exacerbation	O
.	O

The	O
proportion	Others
of	Others
cases	Others
attending	Others
the	Others
physician	Others
doubled	Others
and	Others
with	Others
a	Others
trip	Others
to	Others
the	Others
Emergency	Others
Room	Others
(	Others
ER	Others
)	Others
increased	O
approximately	O
ninefold	O
during	O
the	O
reporting	O
period	O
in	O
which	O
the	O
exacerbation	O
occurred	O
compared	O
with	O
the	O
previous	O
month	O
.	O

This	O
study	O
has	O
shown	O
that	O
use	O
of	O
an	O
IVRS	O
,	O
even	O
in	O
elderly	O
patients	O
,	O
is	O
an	O
effective	O
means	O
of	O
gathering	O
RU	O
data	O
over	O
long	O
periods	O
.	O

The	O
study	O
findings	O
suggest	O
that	O
the	O
advent	O
of	O
effective	O
therapeutic	O
interventions	O
,	O
particularly	O
any	O
with	O
the	O
ability	O
to	O
minimize	O
exacerbations	O
and	O
limit	O
disease	O
progression	O
,	O
could	O
impact	O
on	O
the	O
health	O
care	O
services	O
used	O
and	O
potentially	O
reduce	O
associated	O
costs	O
.	O

Double-blind	O
trial	O
comparing	O
the	O
effectiveness	O
of	O
the	O
homeopathic	O
preparation	O
Galphimia	O
potentiation	O
D6	O
,	O
Galphimia	O
dilution	O
10	O
(	O
-6	O
)	O
and	O
placebo	O
on	O
pollinosis	Physical
.	Physical

The	O
preparation	O
of	O
homeopathic	O
drugs	O
is	O
based	O
on	O
potentiation	O
.	O

In	O
this	O
potentiation	O
the	O
primary	O
substance	O
is	O
specially	O
mixed	O
with	O
a	O
carrier	O
(	O
typically	O
90	O
%	O
ethanol	O
)	O
in	O
the	O
ratio	O
1:10	O
.	O

Usually	O
this	O
potentiation	O
is	O
done	O
repeatedly	O
and	O
the	O
final	O
drug	O
is	O
labeled	O
,	O
e.g.	O
,	O
D6	O
which	O
means	O
a	O
6	O
times	O
decimal	O
potentiation	O
.	O

In	O
a	O
controlled	O
randomized	O
strictly	O
double-blind	O
trial	O
with	O
164	O
patients	O
the	O
effectiveness	O
of	O
homeopathically	O
prepared	O
Galphimia	O
D6	O
,	O
a	O
conventional	O
Galphimia	O
dilution	O
10	O
(	O
-6	O
)	O
and	O
a	O
placebo	O
was	O
investigated	O
for	O
the	O
therapy	O
of	O
pollinosis	O
.	O

The	O
average	Others
duration	Others
of	Others
treatment	Others
was	O
about	O
5	O
weeks	O
.	O

Although	O
no	O
statistical	O
significance	O
was	O
achieved	O
,	O
it	O
is	O
remarkable	O
that	O
there	O
was	O
a	O
clear	O
trend	O
for	O
the	O
superiority	Others
of	O
Galphimia	Physical
D6	Physical
while	O
the	O
Galphimia	O
dilution	O
10	O
(	O
-6	O
)	O
was	O
about	O
equally	O
effective	O
compared	O
with	O
placebo	O
.	O

The	O
study	O
itself	O
demonstrates	O
that	O
it	O
is	O
possible	O
to	O
do	O
strictly	O
controlled	O
trials	O
for	O
homeopathic	O
drugs	O
and	O
with	O
medical	O
practitioners	O
.	O

Bovine	O
pericardium	O
vs	O
dacron	O
for	O
patch	O
angioplasty	O
after	O
carotid	O
endarterectomy	O
:	O
a	O
prospective	O
randomized	O
study	O
.	O

HYPOTHESIS	O
Bovine	O
pericardium	O
(	O
BP	O
)	O
demonstrates	O
improved	O
intraoperative	O
hemostasis	O
and	O
equivalent	O
perioperative	O
morbidity	O
compared	O
with	O
Dacron	O
when	O
used	O
as	O
patch	O
material	O
for	O
angioplasty	O
following	O
carotid	O
endarterectomy	O
.	O

OBJECTIVE	O
To	O
prospectively	O
compare	O
BP	O
and	O
Dacron	O
patch	O
angioplasty	O
after	O
carotid	O
endarterectomy	O
in	O
a	O
randomized	O
fashion	O
.	O

METHODS	O
Ninety-five	O
consecutive	O
primary	O
carotid	O
endarterectomies	O
were	O
performed	O
in	O
a	O
prospective	O
randomized	O
fashion	O
in	O
92	O
patients	O
.	O

Fifty-one	O
procedures	O
were	O
performed	O
using	O
BP	O
and	O
44	O
using	O
Dacron	O
.	O

Intraoperative	O
suture	O
line	O
bleeding	O
was	O
subjectively	O
evaluated	O
by	O
observing	O
bleeding	O
at	O
3	O
and	O
4	O
minutes	O
following	O
carotid	O
cross-clamp	O
removal	O
and	O
then	O
objectively	O
weighing	O
the	O
sponge	O
used	O
to	O
tamponade	O
bleeding	O
during	O
these	O
time	O
intervals	O
.	O

Perioperative	Mortality
morbidity	Mortality
,	O
including	O
cervical	Physical
wound	Physical
hematoma	Physical
,	O
transient	Physical
ischemic	Physical
attack	Physical
,	O
and	O
stroke	Physical
,	O
and	O
perioperative	Mortality
mortality	Mortality
were	O
recorded	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
paired	O
t	O
tests	O
,	O
chi	O
(	O
2	O
)	O
analysis	O
,	O
Fisher	O
exact	O
test	O
,	O
or	O
multiple	O
linear	O
regression	O
as	O
appropriate	O
.	O

RESULTS	O
Suture	Physical
line	Physical
bleeding	Physical
at	Physical
3	Physical
minutes	Physical
was	O
present	O
in	O
7	O
(	O
14	O
%	O
)	O
of	O
51	O
patients	O
in	O
the	O
BP	O
group	O
and	O
24	O
(	O
55	O
%	O
)	O
of	O
44	O
patients	O
in	O
the	O
Dacron	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

Suture	Physical
line	Physical
bleeding	Physical
evaluated	Physical
at	Physical
4	Physical
minutes	Physical
was	O
present	O
in	O
2	O
(	O
4	O
%	O
)	O
of	O
51	O
patients	O
in	O
the	O
BP	O
group	O
and	O
13	O
(	O
30	O
%	O
)	O
of	O
44	O
patients	O
in	O
the	O
Dacron	O
group	O
(	O
P	O
=.001	O
)	O
.	O

Net	Physical
+/-	Physical
SEM	Physical
sponge	Physical
weight	Physical
(	Physical
total	Physical
intraoperative	Physical
suture	Physical
line	Physical
bleeding	Physical
)	Physical
was	O
6.25	O
+/-	O
0.55	O
g	O
in	O
the	O
BP	O
group	O
and	O
16.34	O
+/-	O
1.85	O
g	O
in	O
the	O
Dacron	O
group	O
(	O
P	O
<	O
.001	O
)	O
.	O

Total	Physical
suture	Physical
line	Physical
bleeding	Physical
was	O
significantly	O
affected	O
by	O
activated	O
clotting	O
time	O
;	O
however	O
,	O
multivariate	O
analysis	O
demonstrated	O
that	O
bleeding	Physical
was	O
significantly	O
less	O
with	O
BP	O
(	O
P	O
<	O
.001	O
)	O
even	O
after	O
adjusting	O
for	O
differences	O
in	O
activated	O
clotting	O
time	O
.	O

CONCLUSIONS	O
Bovine	O
pericardium	O
demonstrated	O
a	O
statistically	O
significant	O
decrease	O
in	O
intraoperative	O
suture	O
line	O
bleeding	O
compared	O
with	O
Dacron	O
.	O

Handling	O
characteristics	O
were	O
judged	O
by	O
the	O
surgeons	O
to	O
be	O
superior	O
for	O
BP	O
.	O

Therefore	O
,	O
we	O
believe	O
BP	O
may	O
be	O
an	O
alternative	O
to	O
Dacron	O
when	O
performing	O
patch	O
angioplasty	O
of	O
the	O
carotid	O
artery	O
after	O
endarterectomy	O
.	O

Object	Mental
interest	Mental
in	O
autism	O
spectrum	O
disorder	O
:	O
a	O
treatment	O
comparison	O
.	O

A	O
randomized	O
control	O
trial	O
comparing	O
two	O
social	O
communication	O
treatments	O
for	O
children	O
with	O
autism	O
spectrum	O
disorder	O
examined	O
the	O
effect	O
of	O
treatment	O
on	O
object	O
interest	O
.	O

Thirty-two	O
children	O
,	O
18-60	O
months	O
,	O
were	O
randomly	O
assigned	O
to	O
the	O
Picture	O
Exchange	O
Communication	O
System	O
(	O
PECS	O
)	O
or	O
Responsive	O
Education	O
and	O
Prelinguistic	O
Milieu	O
Teaching	O
(	O
RPMT	O
)	O
condition	O
.	O

Assessment	O
of	O
object	Mental
interest	Mental
was	O
conducted	O
in	O
an	O
unstructured	O
play	O
session	O
with	O
different	O
toys	O
,	O
activities	O
,	O
adult	O
,	O
and	O
location	O
than	O
experienced	O
in	O
treatment	O
.	O

Results	O
indicated	O
children	O
in	O
the	O
RPMT	O
condition	O
showed	O
greater	O
increases	O
in	O
object	Mental
interest	Mental
as	O
compared	O
to	O
children	O
in	O
the	O
PECS	O
condition	O
.	O

Because	O
child	O
characteristics	O
such	O
as	O
interest	O
in	O
objects	O
may	O
influence	O
response	O
to	O
interventions	O
using	O
object	O
play	O
as	O
contexts	O
for	O
treatment	O
,	O
it	O
is	O
important	O
to	O
improve	O
our	O
understanding	O
of	O
whether	O
intervention	O
can	O
affect	O
object	O
interest	O
.	O

Evaluation	O
of	O
hypertensive	O
patients	O
after	O
care	O
provided	O
by	O
community	O
pharmacists	O
in	O
a	O
rural	O
setting	O
.	O

We	O
evaluated	O
blood	Physical
pressure	Physical
control	Physical
,	O
quality	Others
of	Others
life	Others
,	O
quality	Others
of	Others
care	Others
,	O
and	O
satisfaction	Others
of	Others
patients	Others
who	O
were	O
monitored	O
by	O
specially	O
trained	O
community	O
pharmacists	O
in	O
a	O
group	O
medical	O
practice	O
.	O

After	O
participating	O
in	O
an	O
intensive	O
skill	O
development	O
program	O
,	O
pharmacists	O
performed	O
in	O
an	O
interdisciplinary	O
team	O
in	O
a	O
rural	O
clinic	O
.	O

The	O
primary	O
objective	O
was	O
assessed	O
by	O
evaluating	O
outcome	O
variables	O
at	O
6	O
months	O
compared	O
with	O
baseline	O
in	O
25	O
patients	O
randomly	O
assigned	O
to	O
a	O
study	O
group	O
.	O

A	O
control	O
group	O
of	O
26	O
patients	O
was	O
also	O
evaluated	O
to	O
determine	O
if	O
outcome	O
variables	O
remained	O
constant	O
from	O
baseline	O
to	O
6	O
months	O
.	O

Systolic	Physical
blood	Physical
pressure	Physical
was	O
reduced	O
in	O
the	O
study	O
group	O
(	O
151	O
mm	O
Hg	O
baseline	O
,	O
140	O
mm	O
Hg	O
at	O
6	O
mo	O
,	O
p	O
<	O
0.001	O
)	O
and	O
diastolic	Physical
blood	Physical
pressure	Physical
was	O
significantly	O
lower	O
at	O
2	O
,	O
4	O
,	O
and	O
5	O
months	O
compared	O
with	O
baseline	O
.	O

Ratings	O
from	O
a	O
blinded	O
peer	O
review	O
panel	O
indicated	O
significant	O
improvement	O
in	O
the	O
appropriateness	O
of	O
the	O
blood	O
pressure	O
regimen	O
,	O
going	O
from	O
8.7	O
+/-	O
4.7	O
to	O
10.9	O
+/-	O
4.5	O
in	O
the	O
study	O
group	O
(	O
p	O
<	O
0.01	O
)	O
,	O
but	O
they	O
did	O
not	O
change	O
in	O
the	O
control	O
group	O
.	O

Several	O
quality	Others
of	Others
life	Others
scores	Others
improved	O
significantly	O
in	O
the	O
study	O
group	O
after	O
6	O
months	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
included	O
physical	Physical
functioning	Physical
(	O
61.6	O
vs	O
70.7	O
)	O
,	O
physical	Physical
role	Physical
limitations	Physical
(	O
56.8	O
vs	O
72.8	O
)	O
,	O
and	O
bodily	Pain
pain	Pain
(	O
60.0	O
vs	O
71.7	O
)	O
at	O
baseline	O
and	O
6	O
months	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
control	O
group	O
.	O

Patient	Others
satisfaction	Others
scores	Others
were	O
consistently	O
higher	O
in	O
the	O
study	O
group	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Our	O
results	O
indicate	O
that	O
when	O
community	O
pharmacists	O
in	O
a	O
clinic	O
setting	O
are	O
trained	O
and	O
included	O
as	O
members	O
of	O
the	O
primary	O
care	O
team	O
,	O
significant	O
improvements	O
in	O
blood	Physical
pressure	Physical
control	Physical
,	O
quality	Others
of	Others
life	Others
,	O
and	O
patient	Mental
satisfaction	Mental
can	O
be	O
achieved	O
.	O

Recombinant	O
human	O
thrombopoietin	O
augments	O
mobilization	O
of	O
peripheral	Physical
blood	Physical
progenitor	Physical
cells	Physical
for	O
autologous	O
transplantation	O
.	O

This	O
study	O
assessed	O
the	O
ability	O
of	O
various	O
schedules	O
of	O
recombinant	O
human	O
thrombopoietin	O
(	O
rhTPO	O
)	O
to	O
enhance	O
mobilization	O
of	O
peripheral	O
blood	O
progenitor	O
cells	O
(	O
PBPCs	O
)	O
in	O
134	O
patients	O
with	O
cancer	O
undergoing	O
high-dose	O
chemotherapy	O
and	O
autologous	O
PBPC	O
transplantation	O
.	O

Patients	O
received	O
the	O
study	O
drug	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
before	O
initiation	O
of	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
10	O
microg/kg/day	O
on	O
day	O
5	O
and	O
pheresis	O
starting	O
on	O
day	O
9	O
.	O

Randomly	O
assigned	O
treatments	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
were	O
:	O
group	O
1	O
(	O
n=27	O
)	O
placebo	O
,	O
placebo	O
,	O
rhTPO	O
1.5	O
microg/kg	O
;	O
group	O
2	O
(	O
n=27	O
)	O
rhTPO	O
1.5	O
microg/kg	O
,	O
placebo	O
,	O
placebo	O
;	O
groups	O
3	O
(	O
n=28	O
)	O
and	O
4	O
(	O
n=22	O
)	O
rhTPO	O
0.5	O
microg/kg	O
on	O
all	O
3	O
treatment	O
days	O
;	O
and	O
group	O
5	O
(	O
n=30	O
)	O
placebo	O
on	O
all	O
3	O
treatment	O
days	O
.	O

After	O
high-dose	O
chemotherapy	O
and	O
PBPC	O
transplantation	O
,	O
groups	O
1	O
through	O
4	O
received	O
rhTPO	O
1.5	O
microg/kg	O
days	O
0	O
,	O
+2	O
,	O
+4	O
,	O
and	O
+6	O
with	O
either	O
G-CSF	O
5	O
microg/kg/day	O
(	O
groups	O
1-3	O
)	O
or	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
250	O
microg/m	O
(	O
2	O
)	O
/day	O
(	O
group	O
4	O
)	O
.	O

Group	O
5	O
received	O
placebo	O
plus	O
G-CSF	O
5	O
microg/kg/day	O
.	O

The	O
addition	O
of	O
rhTPO	O
to	O
G-CSF	O
increased	O
median	Physical
CD34+	Physical
cell	Physical
yield/pheresis	Physical
in	O
cohorts	O
in	O
which	O
rhTPO	O
was	O
started	O
before	O
day	O
5	O
,	O
with	O
higher	O
yields	O
in	O
groups	O
2	O
(	O
2.67	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
and	O
groups	O
3	O
and	O
4	O
(	O
3.10	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
than	O
in	O
group	O
1	O
(	O
1.86	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
or	O
group	O
5	O
(	O
1.65	O
x	O
10	O
(	O
6	O
)	O
/kg	O
)	O
(	O
P=.006	O
across	O
groups	O
)	O
.	O

Comparing	O
rhTPO	O
to	O
placebo	O
,	O
higher	O
percentages	O
of	O
patients	O
achieved	O
the	O
minimum	Physical
yield	Physical
of	Physical
CD34+	Physical
>	O
or	O
=2	O
x	O
10	O
(	O
6	O
)	O
/kg	O
(	O
92	O
%	O
v	O
75	O
%	O
;	O
P=.050	O
)	O
as	O
well	O
as	O
the	O
target	O
yield	O
of	O
CD34+	O
>	O
or	O
=5	O
x	O
10	O
(	O
6	O
)	O
/kg	O
(	O
73	O
%	O
v	O
46	O
%	O
;	O
P=	O
.041	O
)	O
.	O

rhTPO-treated	O
patients	O
required	O
fewer	O
phereses	O
to	O
achieve	O
minimum	O
(	O
P=	O
.011	O
)	O
and	O
target	O
(	O
P=	O
.015	O
)	O
CD34+	Physical
cell	Physical
values	Physical
.	O

rhTPO	O
given	O
after	O
transplantation	O
did	O
not	O
speed	O
platelet	Physical
recovery	Physical
.	O

No	O
neutralizing	O
antibodies	O
were	O
observed	O
.	O

We	O
conclude	O
that	O
rhTPO	O
can	O
safely	O
enhance	O
mobilization	O
of	O
PBPC	Physical
,	O
reduce	O
the	O
number	O
of	O
leukapheresis	Physical
,	O
and	O
allow	O
more	O
patients	O
to	O
meet	O
minimal	O
cell	O
yield	O
requirements	O
to	O
receive	O
high-dose	O
chemotherapy	O
with	O
PBPC	O
transplantation	O
.	O

A	O
randomised	O
comparison	O
of	O
three	O
drainage	O
systems	O
following	O
cholecystectomy	O
.	O

The	O
efficacy	Others
of	O
low	O
pressure	O
,	O
high	O
pressure	O
and	O
passive	O
drainage	O
systems	O
have	O
been	O
compared	O
after	O
cholecystectomy	O
.	O

Symptoms	Pain
of	Pain
pain	Pain
,	Physical
discomfort	Adverseeffect
and	Adverseeffect
nausea	Adverseeffect
were	O
compared	O
using	O
linear	O
analogue	O
scales	O
and	O
spirometry	O
was	O
used	O
to	O
examine	O
pre-operative	O
and	O
postoperative	O
respiratory	Physical
function	Physical
.	Physical

The	O
low	O
pressure	O
suction	O
drain	O
removed	O
an	O
intraperitoneal	Physical
marker	Physical
,	Physical
gentamicin	Physical
,	O
more	O
effectively	O
than	O
the	O
high	O
pressure	O
suction	O
drain	O
,	O
but	O
not	O
more	O
effectively	O
than	O
the	O
passive	O
drain	O
.	O

There	O
were	O
no	O
differences	O
in	O
postoperative	Physical
respiratory	Physical
function	Physical
nor	O
in	O
the	O
amount	Pain
of	Pain
pain	Pain
or	Pain
discomfort	Pain
between	O
the	O
groups	O
.	O

The	O
passive	O
drain	O
group	O
reported	O
less	O
nausea	Physical
than	O
the	O
suction	O
drain	O
groups	O
.	O

If	O
a	O
negative	O
pressure	O
drainage	O
system	O
is	O
to	O
be	O
used	O
,	O
a	O
low	O
pressure	O
suction	O
drain	O
should	O
be	O
used	O
in	O
preference	O
to	O
a	O
high	O
pressure	O
system	O
.	O

[	O
Clinical	O
observation	O
on	O
acupuncture	O
for	O
treatment	O
of	O
male	O
osteoporosis	O
]	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
therapeutic	O
effects	O
of	O
acupuncture	O
combined	O
with	O
drug	O
and	O
simple	O
drug	O
for	O
treatment	O
of	O
male	O
osteoporosis	O
.	O

METHODS	O
Fifty-five	O
cases	O
were	O
divided	O
into	O
an	O
observation	O
group	O
(	O
25	O
cases	O
)	O
and	O
a	O
control	O
group	O
(	O
30	O
cases	O
)	O
randomly	O
.	O

The	O
observation	O
group	O
was	O
treated	O
with	O
acupuncture	O
and	O
moxibustion	O
at	O
Pishu	O
(	O
BL	O
20	O
)	O
,	O
Shenshu	O
(	O
BL	O
23	O
)	O
,	O
Mingmen	O
(	O
GV	O
4	O
)	O
,	O
Shenque	O
(	O
CV	O
8	O
)	O
and	O
so	O
on	O
combined	O
with	O
taking	O
Alendronate	O
,	O
while	O
the	O
control	O
group	O
was	O
treated	O
with	O
taking	O
Alendronate	O
simply	O
.	O

The	O
improvement	O
of	O
both	O
Integral	Physical
of	Physical
Clinical	Physical
Symptoms	Physical
(	Physical
ICS	Physical
)	Physical
and	O
Bone	Physical
Mineral	Physical
Density	Physical
(	Physical
BMD	Physical
)	Physical
of	O
two	O
groups	O
was	O
observed	O
after	O
6	O
months	O
treatment	O
.	O

RESULTS	O
The	O
ICS	O
of	O
two	O
groups	O
after	O
treatment	O
both	O
decreased	O
significantly	O
(	O
both	O
P	O
<	O
0.001	O
)	O
,	O
and	O
the	O
decreasing	O
degree	O
in	O
observation	O
group	O
was	O
more	O
significant	O
than	O
that	O
in	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
BMD	Physical
of	Physical
lumbar	Physical
vertebrae	Physical
and	O
femur	O
in	O
observation	O
group	O
increased	O
obviously	O
than	O
that	O
before	O
treatment	O
(	O
P	O
<	O
0.01	O
,	O
P	O
<	O
0.05	O
)	O
.	O

The	O
increasing	O
degree	O
of	O
BMD	Physical
of	Physical
lumbar	Physical
vertebrae	Physical
in	O
observation	O
group	O
after	O
treatment	O
was	O
more	O
obvious	O
than	O
that	O
in	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
were	O
abdominal	Adverseeffect
pain	Adverseeffect
,	Adverseeffect
diarrhea	Adverseeffect
,	Adverseeffect
nausea	Adverseeffect
,	Adverseeffect
vomiting	Adverseeffect
,	Adverseeffect
dyspepsia	Adverseeffect
and	Adverseeffect
other	Adverseeffect
adverse	Adverseeffect
reaction	Adverseeffect
in	O
control	O
group	O
,	O
while	O
the	O
degree	O
and	O
occurrence	O
rate	O
of	O
those	O
in	O
observation	O
group	O
alleviated	O
and	O
decreased	O
obviously	O
.	O

CONCLUSION	O
The	O
effect	O
of	O
acupuncture	O
combined	O
with	O
drug	O
for	O
treatment	O
of	O
male	O
osteoporosis	O
is	O
good	O
with	O
little	O
adverse	O
reaction	O
.	O

This	O
method	O
is	O
better	O
than	O
taking	O
Alendronate	O
.	O

Pharmacist	O
directed	O
home	O
medication	O
reviews	O
in	O
patients	O
with	O
chronic	O
heart	O
failure	O
:	O
a	O
randomised	O
clinical	O
trial	O
.	O

BACKGROUND	O
Chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
accounts	O
for	O
significant	O
morbidity	O
,	O
mortality	O
and	O
health	O
expenditure	O
.	O

Furthermore	O
,	O
patients	O
with	O
CHF	O
are	O
often	O
on	O
numerous	O
pharmacological	O
agents	O
for	O
their	O
comorbidities	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
a	O
pharmacist	O
directed	O
home	O
medication	O
review	O
intervention	O
had	O
positive	O
effects	O
on	O
CHF	O
patient	O
outcomes	O
.	O

METHODS	O
A	O
total	O
of	O
120	O
patients	O
hospitalised	O
for	O
CHF	O
were	O
randomised	O
to	O
receive	O
a	O
pharmacist	O
directed	O
post-discharge	O
home	O
medication	O
review	O
(	O
n	O
=	O
64	O
,	O
53.3	O
%	O
)	O
or	O
standard	O
care	O
(	O
n	O
=	O
56	O
,	O
46.7	O
%	O
)	O
.	O

Participants	O
were	O
followed	O
for	O
6	O
months	O
.	O

Primary	O
outcomes	O
were	O
death	O
,	O
CHF	Physical
hospitalisation	Physical
and	O
length	O
of	O
hospital	O
stay	O
.	O

RESULTS	O
There	O
were	O
no	O
between	O
group	O
differences	O
in	O
mortality	Mortality
(	O
hazard	O
ratio	O
=	O
1.41	O
,	O
0.50	O
to	O
3.97	O
;	O
P	O
=	O
0.514	O
)	O
or	O
CHF	Physical
hospitalizations	Physical
(	O
incidence	O
rate	O
ratio	O
[	O
IRR	O
]	O
=	O
1.74	O
95	O
%	O
CI	O
:	O
0.85-3.60	O
P	O
=	O
0.131	O
)	O
over	O
the	O
6	O
month	O
follow-up	O
period	O
.	O

Days	Others
of	Others
hospital	Others
stay	Others
for	Others
CHF	Others
exacerbations	Others
in	O
the	O
6	O
month	O
follow-up	O
were	O
significantly	O
greater	O
in	O
the	O
intervention	O
group	O
(	O
IRR	O
=	O
2.34	O
95	O
%	O
CI	O
:	O
1.80-3.05	O
P	O
=	O
0.000	O
)	O
.	O

CONCLUSIONS	O
Post-discharge	O
pharmacy	O
directed	O
home	O
medication	O
review	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
mortality	O
and	O
health	O
care	O
utilisation	O
above	O
that	O
achieved	O
with	O
standard	O
care	O
.	O

The	O
post-acute	O
management	O
of	O
CHF	O
must	O
be	O
a	O
collaborative	O
multi-disciplinary	O
effort	O
by	O
the	O
health	O
care	O
team	O
as	O
it	O
is	O
the	O
additive	O
effect	O
of	O
interventions	O
that	O
are	O
most	O
effective	O
.	O

Isoniazid	O
prophylaxis	O
for	O
tuberculosis	O
in	O
HIV	O
infection	O
:	O
a	O
meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

OBJECTIVES	O
To	O
evaluate	O
the	O
efficacy	O
of	O
isoniazid	O
for	O
the	O
prevention	O
of	O
tuberculosis	O
in	O
tuberculin	O
skin	O
test-positive	O
and	O
negative	O
individuals	O
with	O
HIV	O
infection	O
.	O

DESIGN	O
Meta-analysis	O
of	O
randomized	O
controlled	O
trials	O
.	O

SETTING	O
Seven	O
trials	O
from	O
Mexico	O
,	O
Haiti	O
,	O
the	O
United	O
States	O
,	O
Zambia	O
,	O
Uganda	O
and	O
Kenya	O
.	O

PATIENTS	O
Individuals	O
free	O
from	O
tuberculosis	O
,	O
2367	O
persons	O
in	O
the	O
intervention	O
and	O
2162	O
in	O
the	O
control	O
groups	O
.	O

INTERVENTION	O
Comparison	Physical
of	Physical
isoniazid	Physical
with	Physical
placebo	Physical
or	Physical
no	Physical
prophylaxis	Physical
.	Physical

METHODS	O
A	O
systematic	O
search	O
of	O
the	O
literature	O
was	O
carried	O
out	O
from	O
1985	O
to	O
October	O
1997	O
for	O
randomized	O
controlled	O
trials	O
of	O
isoniazid	O
prophylaxis	O
in	O
HIV-infected	O
persons	O
.	O

Two	O
reviewers	O
evaluated	O
the	O
relevance	O
of	O
each	O
candidate	O
study	O
and	O
the	O
validity	O
of	O
eligible	O
trials	O
.	O

Studies	O
were	O
pooled	O
using	O
a	O
random	O
effect	O
model	O
,	O
conducting	O
secondary	O
analyses	O
for	O
tuberculin	O
skin	O
test-positive	O
and	O
negative	O
persons	O
.	O

RESULTS	O
Mean	O
follow-up	O
in	O
trials	O
varied	O
between	O
0.4	O
and	O
3.2	O
years	O
.	O

Pooling	O
all	O
seven	O
trials	O
,	O
a	O
risk	Others
ratio	Others
was	O
found	O
for	O
persons	O
treated	O
with	O
isoniazid	O
for	O
developing	O
tuberculosis	O
of	O
0.58	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
0.43-0.80	O
]	O
and	O
0.94	O
(	O
95	O
%	O
CI	O
,	O
0.83-1.07	O
)	O
for	O
death	Mortality
.	O

In	O
groups	O
of	O
tuberculin	O
skin	O
test-positive	O
and	O
negative	O
persons	O
,	O
the	O
risk	Others
ratio	Others
of	Others
tuberculosis	Others
was	O
0.40	O
(	O
95	O
%	O
CI	O
,	O
0.24-0.65	O
)	O
and	O
0.84	O
(	O
95	O
%	O
CI	O
,	O
0.54-1.30	O
)	O
,	O
respectively	O
,	O
and	O
the	O
difference	Others
in	Others
the	Others
effectiveness	Others
of	O
isoniazid	O
versus	O
placebo	O
between	O
these	O
groups	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
0.03	O
,	O
for	O
the	O
difference	O
of	O
summary	O
estimates	O
)	O
.	O

Consistency	O
of	O
results	O
was	O
found	O
across	O
trials	O
(	O
P	O
>	O
0.10	O
,	O
heterogeneity	O
value	O
)	O
for	O
all	O
comparisons	O
.	O

CONCLUSIONS	O
Prophylaxis	O
with	O
isoniazid	O
reduces	O
the	O
risk	O
of	O
tuberculosis	O
in	O
persons	O
with	O
HIV	O
infection	O
.	O

The	O
effect	O
is	O
restricted	O
to	O
tuberculin	O
skin	O
test-positive	O
persons	O
.	O

Effects	O
of	O
a	O
low-salt	O
diet	O
and	O
of	O
acute	O
salt	O
loading	O
on	O
blood	Physical
pressure	Physical
and	O
intralymphocytic	Physical
sodium	Physical
concentration	Physical
in	O
young	O
subjects	O
with	O
borderline	O
hypertension	O
.	O

1	O
.	O

Three	O
groups	O
of	O
young	O
patients	O
with	O
borderline	O
hypertension	O
were	O
studied	O
for	O
a	O
12	O
months	O
period	O
.	O

The	O
first	O
was	O
on	O
a	O
free	O
sodium	O
diet	O
while	O
the	O
second	O
was	O
on	O
a	O
low-salt	O
diet	O
.	O

The	O
third	O
group	O
of	O
patients	O
underwent	O
acute	O
salt	O
loading	O
.	O

2	O
.	O

After	O
12	O
months	O
the	O
group	O
on	O
free	O
diet	O
showed	O
a	O
significant	O
increase	O
of	O
intralymphocytic	Physical
sodium	Physical
but	O
no	O
change	O
in	O
blood	Physical
pressure	Physical
was	O
noted	O
.	O

Five	O
patients	O
who	O
were	O
re-checked	O
after	O
24	O
months	O
also	O
had	O
a	O
significant	O
increase	O
in	O
blood	Physical
pressure	Physical
.	O

3	O
.	O

Patients	O
treated	O
with	O
a	O
low-salt	O
diet	O
showed	O
a	O
significant	O
decrease	O
of	O
both	O
intralymphocytic	Physical
sodium	Physical
concentration	Physical
and	O
blood	Physical
pressure	Physical
.	O

4	O
.	O

After	O
acute	O
salt	O
loading	O
,	O
borderline	O
subjects	O
with	O
high	O
intralymphocytic	O
sodium	O
showed	O
a	O
significant	O
greater	O
natriuresis	Physical
whereas	O
intralymphocytic	Physical
sodium	Physical
increased	O
only	O
in	O
those	O
subjects	O
in	O
whom	O
it	O
was	O
initially	O
normal	O
.	O

Safety	Others
and	Physical
immunogenicity	Physical
of	O
a	O
cluster	O
specific	O
immunotherapy	O
in	O
children	O
with	O
bronchial	O
asthma	O
and	O
mite	O
allergy	O
.	O

BACKGROUND	O
Cluster	O
specific	O
immunotherapy	O
(	O
SIT	O
)	O
is	O
a	O
modern	O
form	O
of	O
allergen	O
immunotherapy	O
allowing	O
safe	O
administration	O
of	O
high	O
allergen	O
doses	O
in	O
a	O
short	O
time	O
interval	O
compared	O
to	O
classic	O
SIT	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
safety	Others
profile	Others
and	Others
immunological	Others
effect	Others
of	O
cluster	O
SIT	O
in	O
children	O
with	O
allergic	O
asthma	O
due	O
to	O
house	O
dust	O
mite	O
allergy	O
.	O

METHODS	O
A	O
total	O
of	O
34	O
children	O
(	O
6-18	O
years	O
)	O
with	O
allergic	O
asthma	O
were	O
assigned	O
to	O
cluster	O
(	O
n	O
=	O
22	O
)	O
or	O
classic	O
SIT	O
(	O
n	O
=	O
12	O
)	O
.	O

To	O
achieve	O
a	O
maintenance	O
dose	O
of	O
allergen	O
extract	O
,	O
cluster	O
patients	O
received	O
14	O
injections	O
of	O
house	O
dust	O
mite	O
allergen	O
within	O
6	O
weeks	O
,	O
whereas	O
the	O
classic	O
SIT	O
group	O
received	O
14	O
injections	O
within	O
14	O
weeks	O
.	O

Safety	Others
was	O
monitored	O
by	O
recording	O
adverse	O
events	O
.	O

Immunogenicity	Physical
was	O
measured	O
by	O
specific	O
IgG	O
(	O
Mite	O
)	O
and	O
IgG4	O
(	O
Mite	O
)	O
,	O
by	O
antibody-blocking	O
properties	O
on	O
basophil	O
activation	O
,	O
and	O
by	O
the	O
T	O
cell	O
subset	O
transcription	O
factors	O
Foxp3	O
,	O
T-bet	O
,	O
and	O
GATA-3	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
in	O
local	Adverseeffect
and	Adverseeffect
systemic	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
between	O
the	O
two	O
groups	O
.	O

In	O
the	O
cluster	O
group	O
,	O
serum	Physical
levels	Physical
of	Physical
specific	Physical
IgG	Physical
(	Physical
Mite	Physical
)	Physical
(	O
p	O
<	O
0.001	O
)	O
and	O
specific	Physical
IgG4	Physical
(	Physical
Mite	Physical
)	Physical
(	O
p	O
<	O
0.001	O
)	O
significantly	O
increased	O
after	O
8	O
weeks	O
,	O
while	O
it	O
took	O
12	O
weeks	O
in	O
the	O
classic	O
SIT	O
group	O
.	O

These	O
data	O
were	O
confirmed	O
by	O
blocking	O
CD63	Physical
expression	Physical
as	O
well	O
as	O
release	O
of	O
cysteinyl	O
leukotrienes	O
after	O
in	O
vitro	O
basophil	O
stimulation	O
.	O

No	O
differences	O
in	O
transcription	Physical
factor	Physical
expression	Physical
were	O
found	O
in	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
Cluster	O
SIT	O
is	O
safe	O
in	O
children	O
.	O

Additionally	O
,	O
our	O
data	O
demonstrated	O
an	O
even	O
more	O
rapid	O
induction	Physical
of	Physical
specific	Physical
immune	Physical
tolerance	Physical
.	O

Cluster	O
SIT	O
is	O
an	O
attractive	O
alternative	O
to	O
conventional	O
up-dosing	O
schedules	O
with	O
fewer	O
consultations	O
for	O
the	O
patients	O
.	O

Bronchoscopic	Physical
findings	O
in	O
patients	O
with	O
a	O
complete	O
radiographic	O
regression	O
of	O
small	Physical
cell	Physical
bronchogenic	Physical
carcinoma	Physical
.	Physical

Fibre-optic	O
bronchoscopy	O
was	O
performed	O
in	O
21	O
patients	O
with	O
small	Physical
cell	Physical
bronchogenic	Physical
carcinoma	Physical
who	O
demonstrated	O
a	O
complete	O
radiographic	O
regression	O
of	O
their	O
chest	O
lesions	O
after	O
3-4	O
months	O
of	O
combination	O
chemotherapy	O
.	O

Fifteen	O
patients	O
showed	O
abnormalities	Physical
at	O
the	O
site	Physical
of	O
the	O
original	O
tumour	Physical
consisting	O
of	O
nodular	Physical
elevations	Physical
,	Physical
narrowing	Physical
of	Physical
bronchi	Physical
and/or	Physical
fibrous	Physical
strands	Physical
or	Physical
membranes	Physical
.	Physical

Microscopic	O
evidence	O
of	O
residual	O
cancer	O
was	O
obtained	O
in	O
3	O
cases	O
.	O

In	O
3	O
out	O
of	O
8	O
patients	O
who	O
underwent	O
a	O
further	O
bronchoscopy	Physical
after	O
18	O
months	O
of	O
treatment	O
,	O
disappearance	O
of	O
nodules	Physical
was	O
noted	O
at	O
the	O
later	O
examination	O
.	O

Persistent	Physical
bronchial	Physical
narrowing	Physical
was	O
observed	O
in	O
patients	O
who	O
became	O
disease-free	O
2-yr	O
survivors	O
.	O

It	O
is	O
concluded	O
that	O
tumour	O
regression	O
may	O
be	O
accompanied	O
by	O
scar	Physical
formation	Physical
,	O
which	O
complicate	O
the	O
interpretation	O
of	O
post-treatment	Physical
abnormalities	Physical
,	O
and	O
that	O
further	O
regression	O
of	O
intrabronchial	O
lesions	O
may	O
occur	O
beyond	O
3-4	O
months	O
.	O

Clinical	Adverseeffect
effects	Adverseeffect
of	O
root	O
instrumentation	O
using	O
conventional	O
steel	O
or	O
non-tooth	O
substance	O
removing	O
plastic	O
curettes	O
during	O
supportive	O
periodontal	O
therapy	O
(	O
SPT	O
)	O
.	O

Although	O
root	O
instrumentation	O
has	O
been	O
accepted	O
as	O
the	O
most	O
important	O
cause-related	O
treatment	O
of	O
periodontal	O
diseases	O
,	O
repeated	O
scaling	O
and	O
root	O
planing	O
may	O
over	O
time	O
result	O
in	O
substantive	O
loss	O
of	O
tooth	O
substance	O
and	O
increased	O
sensitivity	O
of	O
the	O
teeth	O
.	O

In	O
an	O
effort	O
to	O
minimize	O
these	O
side	O
effects	O
of	O
therapy	O
,	O
non-root	O
substance	O
removing	O
curettes	O
have	O
been	O
developed	O
.	O

However	O
,	O
the	O
clinical	Physical
effects	Physical
of	O
such	O
plastic	O
curettes	O
with	O
regard	O
to	O
the	O
control	O
of	O
the	O
periodontal	O
infection	O
has	O
not	O
yet	O
been	O
established	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
,	O
therefore	O
,	O
to	O
compare	O
the	O
effects	O
of	O
root	O
instrumentation	O
using	O
plastic	O
curettes	O
(	O
Universal	O
Perio	O
Soft	O
Scaler	O
,	O
Hawe-Neos	O
Dental	O
,	O
Bioggio	O
,	O
TI	O
,	O
Switzerland	O
)	O
versus	O
conventional	O
steel	O
curettes	O
on	O
the	O
periodontal	O
conditions	O
during	O
supportive	O
periodontal	O
therapy	O
.	O

40	O
subjects	O
participated	O
in	O
this	O
parallel	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
prospective	O
longitudinal	O
clinical	O
study	O
following	O
active	O
peridontal	O
therapy	O
.	O

20	O
subjects	O
served	O
as	O
a	O
control	O
group	O
and	O
were	O
treated	O
with	O
conventional	O
steel	O
curettes	O
during	O
a	O
supportive	O
periodontal	O
care	O
visit	O
(	O
SPT	O
)	O
.	O

The	O
other	O
20	O
subjects	O
,	O
the	O
experimental	O
group	O
,	O
were	O
treated	O
using	O
plastic	O
curettes	O
during	O
a	O
similar	O
SPT	O
visit	O
.	O

Clinical	O
parameters	O
,	O
such	O
as	O
bleeding	Physical
on	Physical
probing	Physical
(	Physical
BOP	Physical
)	Physical
and	O
probing	Physical
pocket	Physical
depth	Physical
(	Physical
PPD	Physical
)	Physical
,	O
were	O
assessed	O
at	O
baseline	O
and	O
3-6	O
months	O
later	O
at	O
the	O
next	O
regular	O
SPT	O
visit	O
.	O

In	O
addition	O
,	O
the	O
BOP	Physical
percentage	Physical
was	O
determined	O
10	O
days	O
following	O
baseline	O
.	O

The	O
results	O
showed	O
that	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
2	O
treatment	O
modalities	O
regarding	O
BOP	Physical
and	O
PPD	Physical
at	O
any	O
observation	O
time	O
.	O

Both	O
treatments	O
were	O
effective	O
in	O
reducing	O
the	O
BOP	Physical
percentage	Physical
which	O
ranged	O
from	O
17-42	O
%	O
at	O
baseline	O
by	O
about	O
40	O
%	O
after	O
10	O
days	O
(	Physical
mean	Physical
BOP	Physical
baseline	O
:	O
26	O
%	O
,	O
mean	Physical
BOP	Physical
after	O
10	O
days	O
:	O
16	O
%	O
)	O
.	O

This	O
clinical	O
study	O
suggests	O
that	O
non-root	O
substance	O
removing	O
curettes	O
may	O
be	O
valuable	O
instruments	O
for	O
periodontally	O
treated	O
patients	O
during	O
maintenance	O
care	O
,	O
thus	O
minimizing	O
trauma	O
on	O
the	O
hard	O
structures	O
of	O
the	O
teeth	O
.	O

Synthesis	O
of	O
interleukin-1	O
beta	O
in	O
primary	O
biliary	O
cirrhosis	O
:	O
relationship	O
to	O
treatment	O
with	O
methotrexate	O
or	O
colchicine	O
and	O
disease	O
progression	O
.	O

Primary	O
biliary	O
cirrhosis	O
(	O
PBC	O
)	O
is	O
a	O
chronic	O
,	O
progressive	O
,	O
cholestatic	O
liver	O
disease	O
.	O

Interleukin-1	Physical
beta	Physical
(	Physical
IL-1	Physical
beta	Physical
)	Physical
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
PBC	O
by	O
contributing	O
to	O
altered	O
immune	O
function	O
and	O
fibrosis	O
.	O

Colchicine	O
or	O
methotrexate	O
has	O
some	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
PBC	O
,	O
and	O
also	O
affects	O
interleukin-1	Physical
(	Physical
IL-1	Physical
)	Physical
.	Physical

Therefore	O
,	O
we	O
prospectively	O
studied	O
the	O
synthesis	O
of	O
IL-1	Physical
beta	Physical
by	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
42	O
patients	O
with	O
PBC	O
entered	O
into	O
a	O
randomized	O
,	O
double-blind	O
,	O
double-dummy	O
controlled	O
trial	O
of	O
colchicine	O
and	O
methotrexate	O
.	O

PBMC	O
obtained	O
at	O
entry	O
,	O
6	O
,	O
12	O
,	O
18	O
,	O
and	O
24	O
months	O
were	O
stimulated	O
to	O
produce	O
IL-1	O
beta	O
with	O
phytohemagglutinin	O
(	O
PHA	O
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Staphylococcus	O
epidermidis	O
,	O
recombinant	O
IL-2	O
,	O
or	O
mitochondrial	O
antigen	O
.	O

Patients	O
in	O
the	O
two	O
treatment	O
groups	O
did	O
not	O
differ	O
at	O
entry	O
in	O
biochemical	Physical
measures	Physical
or	Physical
liver	Physical
histological	Physical
stage	Physical
.	Physical

Over	O
24	O
months	O
in	O
both	O
groups	O
,	O
serum	Physical
bilirubin	Physical
and	Physical
histologic	Physical
stage	Physical
remained	O
stable	O
and	O
alkaline	Physical
phosphatase	Physical
decreased	O
significantly	O
.	O

For	O
all	O
patients	O
,	O
synthesis	Physical
of	Physical
IL-1	Physical
beta	Physical
increased	O
constitutively	O
and	O
in	O
response	O
to	O
immune-mediated	O
stimulants	O
(	O
PHA	O
,	O
IL-2	O
,	O
and	O
mitochondrial	O
antigen	O
)	O
but	O
not	O
the	O
bacterial	O
stimulants	O
LPS	O
or	O
S	O
epidermidis	O
.	O

Compared	O
with	O
levels	O
of	O
IL-1	O
beta	O
at	O
entry	O
,	O
PHA	O
induced	O
increases	O
for	O
patients	O
treated	O
with	O
methotrexate	O
(	O
12	O
,	O
18	O
,	O
and	O
24	O
months	O
)	O
or	O
colchicine	O
(	O
18	O
and	O
24	O
months	O
)	O
.	O

At	O
24	O
months	O
,	O
IL-2-induced	Physical
IL-1	Physical
beta	Physical
synthesis	Physical
was	O
increased	O
in	O
patients	O
treated	O
with	O
methotrexate	O
,	O
whereas	O
S	Physical
epidermidis-induced	Physical
IL-1	Physical
beta	Physical
was	O
enhanced	O
in	O
colchicine-treated	O
patients	O
.	O

Before	O
treatment	O
,	O
IL-1	O
beta	O
production	O
did	O
not	O
relate	O
to	O
severity	O
of	O
disease	O
except	O
in	O
response	O
to	O
S	O
epidermidis	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Amonafide	O
:	O
An	O
active	O
agent	O
in	O
the	O
treatment	O
of	O
previously	O
untreated	O
advanced	O
breast	O
cancer	O
--	O
a	O
cancer	O
and	O
leukemia	O
group	O
B	O
study	O
(	O
CALGB	O
8642	O
)	O
.	O

Amonafide	O
is	O
a	O
new	O
imide	O
derivative	O
of	O
naphthalic	O
acid	O
.	O

The	O
drug	O
had	O
demonstrated	O
significant	O
activity	O
in	O
preclinical	O
studies	O
and	O
some	O
activity	O
in	O
Phase	O
I	O
trials	O
.	O

The	O
drug	O
is	O
extensively	O
metabolized	O
and	O
detected	O
in	O
plasma	O
and	O
urine	O
.	O

Its	O
toxicity	O
has	O
previously	O
been	O
correlated	O
to	O
the	O
formation	O
of	O
an	O
active	O
metabolite	O
,	O
N-acetyl-amonafide	O
.	O

Amonafide	O
was	O
chosen	O
for	O
inclusion	O
in	O
the	O
Cancer	O
and	O
Leukemia	O
Group	O
B	O
(	O
CALGB	O
)	O
master	O
metastatic	O
breast	O
cancer	O
protocol	O
.	O

CALGB	O
8642	O
randomizes	O
previously	O
untreated	O
metastatic	O
breast	O
cancer	O
patients	O
either	O
to	O
one	O
of	O
several	O
Phase	O
II	O
agents	O
given	O
for	O
up	O
to	O
four	O
cycles	O
and	O
then	O
followed	O
by	O
standard	O
cyclophosphamide-doxorubicin-5-fluorouracil	O
,	O
or	O
to	O
immediate	O
treatment	O
with	O
standard	O
cyclophosphamide-doxorubicin-5-fluorouracil	O
.	O

The	O
end	O
point	O
of	O
CALGB	O
8642	O
is	O
to	O
assess	O
the	O
difference	O
in	O
survival	Mortality
,	O
toxicity	Physical
,	O
and	O
overall	Physical
response	Physical
when	O
limited	O
exposure	O
to	O
Phase	O
II	O
agents	O
precedes	O
standard	O
chemotherapy	O
.	O

This	O
report	O
deals	O
only	O
with	O
amonafide	O
as	O
a	O
Phase	O
II	O
agent	O
.	O

Comparisons	O
with	O
the	O
cyclophosphamide-doxorubicin-5-fluorouracil	O
arm	O
will	O
not	O
be	O
addressed	O
.	O

Patients	O
had	O
to	O
have	O
histologically	O
documented	O
measurable	O
breast	O
cancer	O
and	O
a	O
performance	O
status	O
of	O
0-1	O
.	O

Patients	O
could	O
not	O
have	O
had	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
.	O

Prior	O
adjuvant	O
chemotherapy	O
was	O
permitted	O
.	O

Patients	O
could	O
not	O
have	O
visceral	O
crisis	O
.	O

Amonafide	O
was	O
given	O
at	O
300	O
mg/m2/day	O
i.v	O
.	O

for	O
5	O
days	O
,	O
and	O
repeated	O
at	O
21-day	O
intervals	O
for	O
a	O
maximum	O
of	O
four	O
cycles	O
.	O

Escalation	O
and	O
reduction	O
in	O
dose	O
was	O
mandated	O
dependent	O
on	O
hematotoxicity	Physical
or	O
lack	O
thereof	O
.	O

Toxicity	Physical
was	O
primarily	O
hematological	O
and	O
bimodal	O
:	O
32	O
%	O
had	O
grade	Physical
3	Physical
or	Physical
4	Physical
leukopenia	Physical
and	O
24	O
%	O
had	O
grade	Physical
3	Physical
or	Physical
4	Physical
thrombocytopenia	Physical
;	O
22	O
%	O
had	O
no	O
leukopenia	Physical
and	O
44	O
%	O
had	O
no	O
thrombocytopenia	Physical
.	O

The	O
response	Others
rate	Others
was	O
18	O
%	O
,	O
including	O
one	O
complete	O
response	O
.	O

When	O
response	O
was	O
analyzed	O
by	O
hematological	Physical
toxicity	Physical
,	O
there	O
was	O
a	O
35.7	O
%	O
response	O
if	O
patients	O
had	O
leukopenia	Physical
grade	O
3/4	O
(	O
versus	O
8.3	O
%	O
,	O
P	O
=	O
0.08	O
)	O
.	O

There	O
was	O
a	O
50	O
%	O
response	Others
if	O
patients	O
had	O
thrombocytopenia	Physical
grade	O
3/4	O
(	O
versus	O
7.1	O
%	O
,	O
P	O
=	O
<	O
0.01	O
)	O
.	O

We	O
conclude	O
that	O
amonafide	O
is	O
somewhat	O
active	O
in	O
previously	O
untreated	O
breast	O
cancer	O
patients	O
.	O

There	O
may	O
be	O
a	O
steep	Others
dose-response	Others
curve	Others
,	O
based	O
on	O
the	O
significant	O
correlation	O
between	O
myelosuppression	Physical
and	O
response	O
.	O

Rates	Others
of	Others
responses	Others
in	O
patients	O
adequately	O
dosed	O
(	O
i.e.	O
,	O
with	O
significant	O
hematotoxicity	O
)	O
with	O
amonafide	O
ranged	O
from	O
35	O
to	O
50	O
%	O
.	O

Further	O
studies	O
will	O
incorporate	O
individualized	O
dosing	O
based	O
on	O
pretreatment	O
acetylator	O
phenotyping	O
.	O

Oral	O
bioavailability	O
of	O
moxifloxacin	O
after	O
Roux-en-Y	O
gastric	O
bypass	O
surgery	O
.	O

OBJECTIVES	O
Roux-en-Y	O
gastric	O
bypass	O
surgery	O
is	O
the	O
most	O
commonly	O
performed	O
procedure	O
for	O
the	O
treatment	O
of	O
morbid	O
obesity	O
.	O

This	O
anatomical	O
alteration	O
may	O
affect	O
the	O
absorption	O
and	O
consequently	O
the	O
bioavailability	O
of	O
oral	O
drugs	O
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
oral	O
bioavailability	O
of	O
moxifloxacin	O
in	O
12	O
healthy	O
volunteers	O
who	O
underwent	O
gastric	O
bypass	O
surgery	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
randomized	O
crossover	O
study	O
,	O
each	O
subject	O
received	O
two	O
single	O
standard	O
doses	O
of	O
400	O
mg	O
of	O
moxifloxacin	O
orally	O
or	O
intravenously	O
administered	O
on	O
two	O
occasions	O
separated	O
by	O
a	O
washout	O
period	O
of	O
1	O
week	O
.	O

Serial	O
venous	O
blood	O
samples	O
were	O
drawn	O
up	O
to	O
72	O
h	O
after	O
dosing	O
and	O
moxifloxacin	Physical
plasma	Physical
levels	Physical
were	O
measured	O
by	O
a	O
validated	O
HPLC	O
method	O
with	O
fluorescence	O
detection	O
.	O

[	O
clinicaltrials.gov	O
database	O
(	O
identifier	O
:	O
NCT01130922	O
)	O
.	O

]	O
RESULTS	O
After	O
oral	O
dosing	O
,	O
moxifloxacin	Physical
plasma	Physical
concentrations	Physical
reached	O
a	O
maximum	O
(	O
C	O
(	O
max	O
)	O
)	O
of	O
3.38	O
?	O
1.41	O
mg/L	O
after	O
1.75	O
h	O
(	O
0.75-4.00	O
)	O
.	O

After	O
intravenous	O
dosing	O
,	O
C	O
(	O
max	O
)	O
and	O
T	O
(	O
max	O
)	O
were	O
4.53	O
?	O
1.43	O
mg/L	O
and	O
1.03	O
h	O
(	O
0.75-2.50	O
)	O
,	O
respectively	O
.	O

The	O
mean	Others
areas	Others
under	Others
the	Others
plasma	Others
concentration	Others
time	Others
curve	Others
extrapolated	O
to	O
infinity	O
(	O
AUC	O
(	O
?	O
)	O
)	O
were	O
46.2	O
?	O
1.4	O
mg	O
?	O
h/L	O
after	O
oral	O
dosing	O
and	O
52.3	O
?	O
1.3	O
mg	O
?	O
h/L	O
after	O
intravenous	O
dosing	O
,	O
resulting	O
in	O
a	O
mean	O
oral	O
bioavailability	O
of	O
88.32	O
%	O
[	O
90	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
85.64	O
%	O
-91.08	O
%	O
]	O
.	O

CONCLUSIONS	O
This	O
study	O
confirms	O
that	O
exposure	O
to	O
moxifloxacin	O
is	O
equivalent	O
for	O
oral	O
and	O
intravenous	O
administration	O
of	O
400	O
mg	O
dosages	O
in	O
healthy	O
volunteers	O
who	O
underwent	O
gastric	O
bypass	O
surgery	O
.	O

But	O
these	O
exposures	O
were	O
more	O
than	O
50	O
%	O
higher	O
than	O
those	O
described	O
for	O
subjects	O
without	O
gastric	O
bypass	O
.	O

This	O
may	O
suggest	O
a	O
higher	O
enterohepatic	O
recirculation	O
of	O
moxifloxacin	O
after	O
gastric	O
bypass	O
.	O

A	O
prospective	O
study	O
of	O
plasma	O
vitamin	O
D	O
metabolites	O
,	O
vitamin	O
D	O
receptor	O
polymorphisms	O
,	O
and	O
prostate	O
cancer	O
.	O

BACKGROUND	O
Vitamin	O
D	O
insufficiency	O
is	O
a	O
common	O
public	O
health	O
problem	O
nationwide	O
.	O

Circulating	O
25-hydroxyvitamin	O
D3	O
(	O
25	O
[	O
OH	O
]	O
D	O
)	O
,	O
the	O
most	O
commonly	O
used	O
index	O
of	O
vitamin	O
D	O
status	O
,	O
is	O
converted	O
to	O
the	O
active	O
hormone	O
1,25	O
dihydroxyvitamin	O
D3	O
(	O
1,25	O
[	O
OH	O
]	O
2D	O
)	O
,	O
which	O
,	O
operating	O
through	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
,	O
inhibits	O
in	O
vitro	O
cell	O
proliferation	O
,	O
induces	O
differentiation	O
and	O
apoptosis	O
,	O
and	O
may	O
protect	O
against	O
prostate	O
cancer	O
.	O

Despite	O
intriguing	O
results	O
from	O
laboratory	O
studies	O
,	O
previous	O
epidemiological	O
studies	O
showed	O
inconsistent	O
associations	O
of	O
circulating	O
levels	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
1,25	O
(	O
OH	O
)	O
2D	O
,	O
and	O
several	O
VDR	O
polymorphisms	O
with	O
prostate	O
cancer	O
risk	O
.	O

Few	O
studies	O
have	O
explored	O
the	O
joint	O
association	O
of	O
circulating	O
vitamin	O
D	O
levels	O
with	O
VDR	O
polymorphisms	O
.	O

METHODS	O
AND	O
FINDINGS	O
During	O
18	O
y	O
of	O
follow-up	O
of	O
14,916	O
men	O
initially	O
free	O
of	O
diagnosed	O
cancer	O
,	O
we	O
identified	O
1,066	O
men	O
with	O
incident	O
prostate	O
cancer	O
(	O
including	O
496	O
with	O
aggressive	O
disease	O
,	O
defined	O
as	O
stage	O
C	O
or	O
D	O
,	O
Gleason	O
7-10	O
,	O
metastatic	O
,	O
and	O
fatal	O
prostate	O
cancer	O
)	O
and	O
1,618	O
cancer-free	O
,	O
age-	O
and	O
smoking-matched	O
control	O
participants	O
in	O
the	O
Physicians	O
'	O
Health	O
Study	O
.	O

We	O
examined	O
the	O
associations	O
of	O
prediagnostic	O
plasma	O
levels	O
of	O
25	O
(	O
OH	O
)	O
D	O
and	O
1,25	O
(	O
OH	O
)	O
2D	O
,	O
individually	O
and	O
jointly	O
,	O
with	O
total	O
and	O
aggressive	O
disease	O
,	O
and	O
explored	O
whether	O
relations	O
between	O
vitamin	O
D	O
metabolites	O
and	O
prostate	O
cancer	O
were	O
modified	O
by	O
the	O
functional	O
VDR	O
FokI	O
polymorphism	O
,	O
using	O
conditional	O
logistic	O
regression	O
.	O

Among	O
these	O
US	O
physicians	O
,	O
the	O
median	Physical
plasma	Physical
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
levels	Physical
were	O
25	O
ng/ml	O
in	O
the	O
blood	O
samples	O
collected	O
during	O
the	O
winter	O
or	O
spring	O
and	O
32	O
ng/ml	O
in	O
samples	O
collected	O
during	O
the	O
summer	O
or	O
fall	O
.	O

Nearly	O
13	O
%	O
(	O
summer/fall	O
)	O
to	O
36	O
%	O
(	O
winter/spring	O
)	O
of	O
the	O
control	O
participants	O
were	O
deficient	O
in	O
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
(	O
<	O
20	O
ng/ml	O
)	O
and	O
51	O
%	O
(	O
summer/fall	O
)	O
and	O
77	O
%	O
(	O
winter/spring	O
)	O
had	O
insufficient	O
plasma	Physical
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
levels	Physical
(	O
<	O
32	O
ng/ml	O
)	O
.	O

Plasma	Physical
levels	Physical
of	Physical
1,25	Physical
(	Physical
OH	Physical
)	Physical
2D	Physical
did	Physical
not	O
vary	O
by	O
season	O
.	O

Men	O
whose	O
levels	O
for	O
both	O
25	O
(	O
OH	O
)	O
D	O
and	O
1,25	O
(	O
OH	O
)	O
2D	O
were	O
below	O
(	O
versus	O
above	O
)	O
the	O
median	O
had	O
a	O
significantly	O
increased	O
risk	Physical
of	Physical
aggressive	Physical
prostate	Physical
cancer	Physical
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.1	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1.2-3.4	O
)	O
,	O
although	O
the	O
interaction	O
between	O
the	O
two	O
vitamin	O
D	O
metabolites	O
was	O
not	O
statistically	O
significant	O
(	O
pinteraction	O
=	O
0.23	O
)	O
.	O

We	O
observed	O
a	O
significant	O
interaction	O
between	O
circulating	O
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
levels	Physical
and	O
the	Physical
VDR	Physical
FokI	Physical
genotype	Physical
(	O
pinteraction	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
those	O
with	O
plasma	Physical
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
levels	Physical
above	O
the	O
median	O
and	O
with	O
the	O
FokI	O
FF	O
or	O
Ff	O
genotype	O
,	O
men	O
who	O
had	O
low	O
25	O
(	O
OH	O
)	O
D	O
levels	O
and	O
the	O
less	O
functional	O
FokI	O
ff	O
genotype	O
had	O
increased	O
risks	Physical
of	Physical
total	Physical
(	O
OR	O
=	O
1.9	O
,	O
95	O
%	O
CI	O
1.1-3.3	O
)	O
and	O
aggressive	Physical
prostate	Physical
cancer	Physical
(	O
OR	O
=	O
2.5	O
,	O
95	O
%	O
CI	O
1.1-5.8	O
)	O
.	O

Among	O
men	O
with	O
plasma	Physical
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
levels	Physical
above	O
the	O
median	O
,	O
the	O
ff	O
genotype	O
was	O
no	O
longer	O
associated	O
with	O
risk	O
.	O

Conversely	O
,	O
among	O
men	O
with	O
the	O
ff	O
genotype	O
,	O
high	Physical
plasma	Physical
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
level	Physical
(	O
above	O
versus	O
below	O
the	O
median	O
)	O
was	O
related	O
to	O
significant	O
60	O
%	O
approximately	O
70	O
%	O
lower	O
risks	Physical
of	Physical
total	Physical
and	Physical
aggressive	Physical
prostate	Physical
cancer	Physical
.	O

CONCLUSIONS	O
Our	O
data	O
suggest	O
that	O
a	O
large	O
proportion	O
of	O
the	O
US	O
men	O
had	O
suboptimal	O
vitamin	O
D	O
status	O
(	O
especially	O
during	O
the	O
winter/spring	O
season	O
)	O
,	O
and	O
both	O
25	O
(	O
OH	O
)	O
D	O
and	O
1,25	O
(	O
OH	O
)	O
2D	O
may	O
play	O
an	O
important	O
role	O
in	O
preventing	O
prostate	O
cancer	O
progression	O
.	O

Moreover	O
,	O
vitamin	O
D	O
status	O
,	O
measured	O
by	O
25	Physical
(	Physical
OH	Physical
)	Physical
D	Physical
in	Physical
plasma	Physical
,	O
interacts	O
with	O
the	O
VDR	O
FokI	O
polymorphism	O
and	O
modifies	O
prostate	O
cancer	O
risk	O
.	O

Men	O
with	O
the	O
less	O
functional	O
FokI	O
ff	O
genotype	O
(	O
14	O
%	O
in	O
the	O
European-descent	O
population	O
of	O
this	O
cohort	O
)	O
are	O
more	O
susceptible	O
to	O
this	O
cancer	O
in	O
the	O
presence	O
of	O
low	O
25	O
(	O
OH	O
)	O
D	O
status	O
.	O

Hemostatic	Physical
function	Physical
of	O
aspirin-treated	O
platelets	O
vulnerable	O
to	O
cardiopulmonary	O
bypass	O
.	O

Altered	O
shear-induced	O
pathway	O
.	O

The	O
impaired	O
hemostasis	O
of	O
aspirin-treated	O
patients	O
is	O
an	O
annoying	O
problem	O
during	O
and	O
after	O
cardiopulmonary	O
bypass	O
.	O

The	O
hemostatic	Physical
function	Physical
of	O
platelets	O
comprises	O
two	O
mechanisms	O
:	O
the	O
shear-induced	O
and	O
the	O
cyclooxygenase	O
pathways	O
.	O

Because	O
the	O
latter	O
is	O
inhibited	O
in	O
aspirin-treated	O
patients	O
,	O
the	O
hemostatic	O
function	O
depends	O
mainly	O
on	O
the	O
former	O
pathway	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
cardiopulmonary	O
bypass	O
on	O
the	O
shear-induced	O
pathway	O
,	O
a	O
double-blind	O
study	O
of	O
preoperative	O
aspirin	O
treatment	O
(	O
325	O
mg	O
)	O
and	O
placebo	O
was	O
conducted	O
in	O
40	O
patients	O
undergoing	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

Postoperative	Physical
blood	Physical
loss	Physical
was	O
higher	O
in	O
the	O
aspirin-treated	O
patients	O
than	O
in	O
the	O
placebo-treated	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
shear-induced	Physical
hemostasis	Physical
was	O
monitored	O
by	O
the	O
in	O
vitro	O
bleeding	O
test	O
(	O
Thrombostat	O
)	O
,	O
which	O
mimics	O
bleeding	O
through	O
an	O
injured	O
arteriole	O
.	O

The	O
shear-induced	Physical
pathway	Physical
of	Physical
aspirin-treated	Physical
platelets	Physical
was	O
not	O
affected	O
before	O
cardiopulmonary	O
bypass	O
,	O
but	O
it	O
was	O
impaired	O
more	O
during	O
the	O
operation	O
(	O
p	O
<	O
0.01	O
)	O
and	O
remained	O
worse	O
afterward	O
(	O
p	O
<	O
0.05	O
)	O
,	O
compared	O
with	O
that	O
of	O
placebo-treated	O
platelets	O
.	O

The	O
inhibitory	O
effects	O
of	O
aspirin	O
on	O
thromboxane	Physical
production	Physical
and	Physical
on	Physical
collagen-induced	Physical
platelet	Physical
aggregation	Physical
remained	O
throughout	O
the	O
operation	O
.	O

In	O
aspirin-treated	O
platelets	O
,	O
the	O
aggregation	Physical
capacity	Physical
induced	O
by	O
adenosine	O
diphosphate	O
was	O
inhibited	O
before	O
the	O
operation	O
(	O
p	O
<	O
0.05	O
)	O
and	O
showed	O
substantial	O
recovery	O
during	O
the	O
operation	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
shear-induced	O
pathway	O
of	O
aspirin-treated	O
platelets	O
is	O
more	O
vulnerable	O
to	O
cardiopulmonary	O
bypass	O
than	O
the	O
pathway	O
in	O
normal	O
platelets	O
and	O
causes	O
severe	O
impairment	O
of	O
hemostasis	O
afterward	O
.	O

The	O
effect	O
of	O
a	O
parent-implemented	O
imitation	O
intervention	O
on	O
spontaneous	Mental
imitation	Mental
skills	Mental
in	O
young	O
children	O
with	O
autism	O
.	O

Children	O
with	O
autism	O
exhibit	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
spontaneously	Mental
imitate	Mental
the	O
play	Mental
actions	Mental
and	Mental
descriptive	Mental
gestures	Mental
of	O
others	O
.	O

Reciprocal	O
imitation	O
training	O
(	O
RIT	O
)	O
is	O
a	O
naturalistic	O
imitation	O
intervention	O
designed	O
to	O
teach	O
spontaneous	Mental
imitation	Mental
skills	Mental
during	O
play	O
.	O

This	O
study	O
assessed	O
the	O
effectiveness	Others
of	O
parent-implemented	O
RIT	O
using	O
a	O
multiple-baseline	O
design	O
across	O
three	O
young	O
children	O
with	O
autism	O
and	O
their	O
mothers	O
.	O

After	O
an	O
initial	O
baseline	O
,	O
mothers	O
were	O
taught	O
to	O
implement	O
RIT	O
techniques	O
with	O
their	O
child	O
twice	O
a	O
week	O
for	O
10	O
weeks	O
in	O
a	O
clinic	O
setting	O
.	O

Two	O
mothers	O
were	O
taught	O
to	O
use	O
RIT	O
to	O
teach	O
object	O
imitation	O
.	O

The	O
third	O
mother	O
was	O
taught	O
to	O
use	O
RIT	O
to	O
target	O
both	O
object	O
and	O
gesture	O
imitation	O
in	O
a	O
multiple-baseline	O
design	O
across	O
behaviors	O
.	O

Generalization	O
was	O
assessed	O
in	O
the	O
families	O
'	O
homes	O
at	O
the	O
end	O
of	O
treatment	O
and	O
a	O
1-month	O
follow-up	O
.	O

Parents	O
learned	Mental
to	O
use	O
the	O
intervention	O
strategies	O
and	O
their	O
children	O
exhibited	O
increases	O
in	O
spontaneous	Mental
imitation	Mental
.	O

These	O
findings	O
replicate	O
the	O
results	O
from	O
previous	O
studies	O
,	O
indicating	O
that	O
RIT	O
is	O
effective	O
for	O
teaching	O
imitation	Mental
skills	Mental
to	O
young	O
children	O
with	O
autism	O
in	O
a	O
naturalistic	O
setting	O
and	O
extend	O
the	O
findings	O
to	O
parents	O
.	O

Pimecrolimus	O
cream	O
1	O
%	O
vs.	O
betamethasone	O
17-valerate	O
0.1	O
%	O
cream	O
in	O
the	O
treatment	O
of	O
seborrhoeic	O
dermatitis	O
.	O

A	O
randomized	O
open-label	O
clinical	O
trial	O
.	O

BACKGROUND	O
Seborrhoeic	O
dermatitis	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
with	O
remissions	O
and	O
exacerbations	O
,	O
characterized	O
by	O
erythema	O
,	O
scaling	O
and	O
pruritus	O
primarily	O
on	O
the	O
face	O
,	O
scalp	O
and	O
chest	O
.	O

Corticosteroids	O
and	O
antifungals	O
are	O
the	O
mainstay	O
of	O
therapy	O
.	O

However	O
,	O
chronic	O
use	O
of	O
corticosteroids	O
is	O
associated	O
with	O
side-effects	O
such	O
as	O
skin	O
atrophy	O
and	O
telangiectasia	O
.	O

Pimecrolimus	O
,	O
an	O
inhibitor	O
of	O
calcineurin	O
,	O
has	O
been	O
used	O
successfully	O
in	O
one	O
patient	O
with	O
seborrhoeic	O
dermatitis	O
.	O

OBJECTIVES	O
The	O
objective	O
of	O
this	O
randomized	O
open-label	O
clinical	O
trial	O
was	O
to	O
compare	O
the	O
efficacy	Others
and	Others
tolerability	Others
of	O
pimecrolimus	O
in	O
comparison	O
with	O
a	O
potent	O
corticosteroid	O
(	O
betamethasone	O
17-valerate	O
)	O
in	O
the	O
treatment	O
of	O
seborrhoeic	O
dermatitis	O
.	O

METHODS	O
Twenty	O
patients	O
with	O
seborrhoeic	O
dermatitis	O
were	O
included	O
in	O
this	O
study	O
,	O
11	O
patients	O
in	O
the	O
pimecrolimus	O
1	O
%	O
cream	O
group	O
and	O
nine	O
patients	O
in	O
the	O
betamethasone	O
17-valerate	O
0.1	O
%	O
cream	O
group	O
.	O

Patients	O
were	O
instructed	O
to	O
use	O
a	O
thin	O
layer	O
of	O
the	O
study	O
products	O
twice	O
daily	O
at	O
the	O
lesional	O
area	O
and	O
to	O
discontinue	O
treatment	O
as	O
soon	O
as	O
symptoms	O
were	O
absent	O
.	O

Clinical	O
measures	O
assessed	O
were	O
erythema	Physical
,	Physical
scaling	Physical
and	Physical
pruritus	Physical
which	O
were	O
evaluated	O
using	O
a	O
four-point	O
scale	O
(	O
0-3	O
)	O
.	O

RESULTS	O
Both	O
pimecrolimus	O
and	O
betamethasone	O
were	O
highly	O
effective	Others
in	O
the	O
treatment	O
of	O
seborrhoeic	O
dermatitis	O
.	O

Betamethasone	O
reduced	O
all	O
three	O
parameters	O
,	O
erythema	Physical
,	O
scaling	Physical
and	O
pruritus	Physical
,	O
faster	O
than	O
pimecrolimus	O
,	O
but	O
the	O
differences	O
in	O
reduction	O
were	O
not	O
statistically	O
significant	O
.	O

Relapses	Physical
were	O
observed	O
more	O
frequently	O
and	O
were	O
more	O
severe	O
with	O
betamethasone	O
than	O
with	O
pimecrolimus	O
.	O

Moreover	O
,	O
pruritus	Physical
was	O
not	O
observed	O
after	O
discontinuation	O
of	O
treatment	O
from	O
day	O
15	O
and	O
beyond	O
in	O
the	O
pimecrolimus	O
group	O
,	O
whereas	O
it	O
was	O
reported	O
in	O
most	O
patients	O
of	O
the	O
betamethasone	O
group	O
.	O

This	O
difference	O
was	O
statistically	O
significant	O
.	O

CONCLUSIONS	O
It	O
appears	O
that	O
pimecrolimus	O
,	O
a	O
nonsteroidal	O
topical	O
treatment	O
,	O
may	O
be	O
an	O
excellent	O
alternative	O
therapeutic	O
modality	O
for	O
treating	O
seborrhoeic	O
dermatitis	O
.	O

Caudal	O
neostigmine	O
with	O
bupivacaine	O
produces	O
a	O
dose-independent	O
analgesic	O
effect	O
in	O
children	O
.	O

PURPOSE	O
To	O
evaluate	Others
the	O
analgesic	Others
efficacy	Others
and	Others
duration	Others
of	O
varying	O
doses	O
of	O
caudal	O
neostigmine	O
with	O
plain	O
bupivacaine	O
and	O
its	O
side	O
effects	O
in	O
children	O
undergoing	O
genito-urinary	O
surgery	O
.	O

METHODS	O
In	O
a	O
randomized	O
double-blind	O
prospective	O
study	O
80	O
boys	O
aged	O
two	O
to	O
eight	O
years	O
scheduled	O
for	O
surgical	O
repair	O
of	O
hypospadias	O
were	O
allocated	O
randomly	O
to	O
one	O
of	O
four	O
groups	O
(	O
n	O
=	O
20	O
each	O
)	O
and	O
received	O
either	O
only	O
caudal	O
0.25	O
%	O
plain	O
bupivacaine	O
0.5	O
mL.kg	O
(	O
-1	O
)	O
(	O
Group	O
I	O
)	O
or	O
0.25	O
%	O
plain	O
bupivacaine	O
0.5	O
mL.kg	O
(	O
-1	O
)	O
with	O
neostigmine	O
(	O
Groups	O
II-IV	O
)	O
in	O
doses	O
of	O
2	O
,	O
3	O
and	O
4	O
microg.kg	O
(	O
-1	O
)	O
respectively	O
.	O

Postoperative	Pain
pain	Pain
was	O
assessed	O
for	O
24	O
hr	O
using	O
an	O
objective	Pain
pain	Pain
score	Pain
.	Pain

Blood	Physical
pressure	Physical
,	Physical
heart	Physical
rate	Physical
,	Physical
oxygen	Physical
saturation	Physical
,	Physical
total	Physical
amount	Physical
of	Physical
analgesic	Physical
consumed	Physical
and	O
adverse	Adverseeffect
effects	Adverseeffect
were	O
also	O
recorded	O
.	O

RESULTS	O
The	O
duration	Pain
of	Pain
postoperative	Pain
analgesia	Pain
in	O
Group	O
I	O
(	O
5.1	O
+/-	O
2.3	O
hr	O
)	O
was	O
significantly	O
shorter	O
than	O
in	O
the	O
other	O
three	O
groups	O
(	O
II	O
-16.6	O
+/-	O
4.9	O
hr	O
;	O
III	O
-	O
17.2	O
+/-	O
5.5	O
hr	O
;	O
IV	O
-	O
17.0	O
+/-	O
5.8	O
hr	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Total	Physical
analgesic	Physical
(	Physical
paracetamol	Physical
)	Physical
consumption	Physical
was	O
significantly	O
more	O
in	O
Group	O
I	O
(	O
697.6	O
+/-	O
240.7	O
mg	O
)	O
than	O
in	O
the	O
groups	O
receiving	O
caudal	O
neostigmine	O
(	O
II	O
-	O
248.0	O
+/-	O
178.4	O
;	O
III	O
-	O
270.2	O
+/-	O
180.8	O
and	O
IV	O
-230.6	O
+/-	O
166.9	O
mg	O
;	O
P	O
<	O
0.05	O
)	O
.	O

Groups	O
II	O
,	O
III	O
and	O
IV	O
were	O
comparable	O
with	O
regards	O
to	O
duration	Pain
of	Pain
postoperative	Pain
analgesia	Pain
and	Pain
total	Pain
analgesic	Pain
consumption	Pain
(	O
P	O
>	O
0.05	O
)	O
.	O

Incidence	O
of	O
nausea	Adverseeffect
and	O
vomiting	Adverseeffect
were	O
comparable	O
in	O
all	O
four	O
groups	O
.	O

No	O
significant	O
alteration	O
in	O
vital	Adverseeffect
signs	Adverseeffect
or	O
any	O
other	O
adverse	O
effects	O
were	O
observed	O
.	O

CONCLUSIONS	O
Caudal	O
neostigmine	O
(	O
2	O
,	O
3	O
and	O
4	O
microg.kg	O
(	O
-1	O
)	O
)	O
with	O
bupivacaine	O
produces	O
a	O
dose-independent	O
analgesic	Physical
effect	Physical
(	O
approximately	O
16-17	O
hr	O
)	O
in	O
children	O
as	O
compared	O
to	O
those	O
receiving	O
caudal	O
bupivacaine	O
alone	O
(	O
approximately	O
five	O
hours	O
)	O
and	O
a	O
reduction	O
in	O
postoperative	Physical
rescue	Physical
analgesic	Physical
consumption	Physical
without	O
increasing	O
the	O
incidence	O
of	O
adverse	Adverseeffect
effects	Adverseeffect
.	O

Comparison	O
of	O
active-learning	O
strategies	O
for	O
motivational	Mental
interviewing	Mental
skills	Mental
,	Mental
knowledge	Mental
,	Mental
and	Mental
confidence	Mental
in	O
first-year	O
pharmacy	O
students	O
.	O

OBJECTIVE	O
To	O
compare	O
3	O
strategies	O
for	O
pharmacy	O
student	O
learning	O
of	O
motivational	O
interviewing	O
skills	Mental
,	Mental
knowledge	Mental
of	O
motivational	O
interviewing	O
principles	O
,	O
and	O
confidence	Mental
in	O
and	O
attitudes	Mental
toward	O
their	O
application	O
.	O

DESIGN	O
Following	O
a	O
motivational	O
interviewing	O
lecture	O
,	O
first-year	O
students	O
were	O
randomized	O
to	O
perform	O
practice	O
activities	O
(	O
written	O
dialogue	O
,	O
peer	O
role-play	O
,	O
or	O
mock-patient	O
counseling	O
activities	O
)	O
.	O

Motivational	Mental
interviewing	Mental
skills	Mental
,	Mental
knowledge	Others
,	Mental
confidence	Others
,	Mental
and	Mental
attitudes	Mental
were	O
measured	O
.	O

ASSESSMENT	O
All	O
students	O
demonstrated	O
improvement	O
in	O
skills	Mental
,	Mental
knowledge	Mental
,	Mental
and	Mental
confidence	Mental
.	Mental

Students	O
in	O
the	O
mock-patient	O
counseling	O
group	O
demonstrated	O
significantly	O
better	O
motivational	O
interviewing	O
skills	Mental
during	O
practice	O
and	O
trended	O
toward	O
higher	O
scores	O
on	O
the	O
summative	O
evaluation	O
.	O

They	O
also	O
demonstrated	O
a	O
significant	O
improvement	O
in	O
knowledge	Others
compared	O
with	O
that	O
of	O
the	O
written	O
dialogue	O
group	O
during	O
practice	O
.	O

Feedback	O
at	O
the	O
end	O
was	O
generally	O
positive	O
,	O
with	O
students	O
expressing	O
recognition	Mental
for	Mental
the	Mental
value	Mental
of	Mental
motivational	Mental
interviewing	Mental
.	Mental

CONCLUSIONS	O
Students	O
demonstrated	O
their	O
best	O
performance	O
of	O
motivational	Mental
interviewing	Mental
during	O
assessments	O
using	O
interactions	O
with	O
mock	O
or	O
standardized	O
patients	O
.	O

Impact	O
on	O
learning	Mental
of	O
an	O
e-learning	O
module	O
on	O
leukaemia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
e-learning	O
resources	O
may	O
be	O
beneficial	O
for	O
complex	O
or	O
conceptually	O
difficult	O
topics	O
.	O

Leukaemia	O
is	O
one	O
such	O
topic	O
,	O
yet	O
there	O
are	O
no	O
reports	O
on	O
the	O
efficacy	O
of	O
e-learning	O
for	O
leukaemia	O
.	O

This	O
study	O
compared	O
the	O
learning	O
impact	O
on	O
senior	O
medical	O
students	O
of	O
a	O
purpose-built	O
e-learning	O
module	O
on	O
leukaemia	O
,	O
compared	O
with	O
existing	O
online	O
resources	O
.	O

METHODS	O
A	O
randomised	O
controlled	O
trial	O
was	O
performed	O
utilising	O
volunteer	O
senior	O
medical	O
students	O
.	O

Participants	O
were	O
randomly	O
allocated	O
to	O
Study	O
and	O
Control	O
groups	O
.	O

Following	O
a	O
pre-test	O
on	O
leukaemia	O
administered	O
to	O
both	O
groups	O
,	O
the	O
Study	O
group	O
was	O
provided	O
with	O
access	O
to	O
the	O
new	O
e-learning	O
module	O
,	O
while	O
the	O
Control	O
group	O
was	O
directed	O
to	O
existing	O
online	O
resources	O
.	O

A	O
post-test	Others
and	Physical
an	Physical
evaluation	Others
questionnaire	Others
were	O
administered	O
to	O
both	O
groups	O
at	O
the	O
end	O
of	O
the	O
trial	O
period	O
.	O

RESULTS	O
Study	O
and	O
Control	O
groups	O
were	O
equivalent	O
in	O
gender	O
distribution	O
,	O
mean	O
academic	O
ability	O
,	O
pre-test	O
performance	O
and	O
time	O
studying	O
leukaemia	O
during	O
the	O
trial	O
.	O

The	O
Study	O
group	O
performed	O
significantly	O
better	O
than	O
the	O
Control	O
group	O
in	O
the	O
post-test	Others
,	O
in	O
which	O
the	O
group	O
to	O
which	O
the	O
students	O
had	O
been	O
allocated	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
performance	O
.	O

The	O
Study	O
group	O
's	O
evaluation	O
of	O
the	O
module	O
was	O
overwhelmingly	O
positive	O
.	O

CONCLUSIONS	O
A	O
targeted	O
e-learning	O
module	O
on	O
leukaemia	O
had	O
a	O
significant	O
effect	O
on	O
learning	Mental
in	O
this	O
cohort	O
,	O
compared	O
with	O
existing	O
online	O
resources	O
.	O

We	O
believe	O
that	O
the	O
interactivity	O
,	O
dialogic	O
feedback	O
and	O
integration	O
with	O
the	O
curriculum	O
offered	O
by	O
the	O
e-learning	O
module	O
contributed	O
to	O
its	O
impact	O
.	O

This	O
has	O
implications	O
for	O
e-learning	O
design	O
in	O
medicine	O
and	O
other	O
disciplines	O
.	O

Effect	O
of	O
aldose	O
reductase	O
inhibition	O
on	O
cardiovascular	Physical
reflex	Physical
tests	Physical
in	O
patients	O
with	O
definite	O
diabetic	O
autonomic	O
neuropathy	O
over	O
a	O
period	O
of	O
2	O
years	O
.	O

The	O
potential	O
of	O
the	O
aldose	O
reductase	O
inhibitor	O
tolrestat	O
to	O
ameliorate	O
definite	O
diabetic	O
autonomic	O
neuropathy	O
(	O
DAN	O
)	O
,	O
as	O
defined	O
by	O
standard	O
cardiovascular	O
autonomic	O
function	O
tests	O
,	O
was	O
evaluated	O
in	O
35	O
patients	O
over	O
a	O
period	O
of	O
2	O
years	O
,	O
with	O
repeated	O
measurements	O
at	O
3-month	O
intervals	O
.	O

The	O
effect	O
of	O
tolrestat	O
(	O
200	O
mg	O
a	O
day	O
)	O
was	O
compared	O
with	O
that	O
of	O
placebo	O
on	O
35	O
controls	O
with	O
diabetes	O
mellitus	O
,	O
of	O
similar	O
age	O
,	O
gender	O
,	O
and	O
glycemic	O
control	O
.	O

In	O
the	O
placebo	O
group	O
,	O
a	O
significant	O
deterioration	O
of	O
the	O
indices	O
,	O
with	O
the	O
exception	O
of	O
Valsalva	Physical
ratio	Physical
,	O
was	O
recorded	O
,	O
while	O
tolrestat	O
induced	O
a	O
significant	O
beneficial	O
change	O
in	O
the	O
values	Others
of	Others
most	Others
standard	Others
cardiovascular	Others
reflex	Others
tests	Others
,	O
in	O
comparison	O
to	O
baseline	O
and	O
placebo	O
.	O

The	O
deep	Physical
breathing	Physical
tests	Physical
(	O
expiration-inspiration	Physical
ratio	Physical
,	O
standard	Physical
deviation	Physical
,	O
and	O
mean	Physical
circular	Physical
resultant	Physical
of	Physical
R-R	Physical
intervals	Physical
)	O
,	O
postural	Physical
index	Physical
,	O
and	O
postural	Physical
hypotension	Physical
were	O
favorably	O
affected	O
.	O

Three	O
of	O
35	O
patients	O
on	O
tolrestat	O
(	O
8.6	O
%	O
)	O
developed	O
high	Physical
transaminases	Physical
levels	Physical
(	O
more	O
than	O
threefold	O
the	O
upper	O
normal	O
limit	O
)	O
and	O
were	O
withdrawn	O
from	O
the	O
study	O
.	O

In	O
conclusion	O
,	O
tolrestat	O
improved	O
autonomic	Physical
nervous	Physical
system	Physical
function	Physical
in	O
patients	O
with	O
definite	O
DAN	O
,	O
in	O
comparison	O
to	O
baseline	O
and	O
placebo	O
.	O

The	O
clinical	O
importance	O
of	O
this	O
finding	O
needs	O
further	O
investigation	O
.	O

A	O
randomised	O
prospective	O
study	O
comparing	O
the	O
new	O
vacuum	O
extractor	O
policy	O
with	O
forceps	O
delivery	O
.	O

OBJECTIVE	O
To	O
compare	O
assisted	O
vaginal	O
delivery	O
by	O
forceps	O
with	O
delivery	O
by	O
vacuum	O
extractor	O
,	O
where	O
a	O
new	O
vacuum	O
extractor	O
policy	O
was	O
employed	O
which	O
dictated	O
the	O
cup	O
to	O
be	O
used	O
in	O
specific	O
situations	O
.	O

DESIGN	O
Multicentre	O
randomised	O
controlled	O
trial	O
.	O

SETTING	O
Four	O
district	O
general	O
hospitals	O
in	O
the	O
West	O
Midlands	O
.	O

SUBJECTS	O
Six	O
hundred-seven	O
women	O
requiring	O
assisted	O
vaginal	O
delivery	O
,	O
of	O
whom	O
296	O
were	O
allocated	O
to	O
vacuum	O
extractor	O
delivery	O
and	O
311	O
to	O
forceps	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Delivery	Physical
success	Physical
rate	Physical
,	Physical
maternal	Physical
perineal	Physical
and	Physical
vaginal	Physical
injuries	Physical
,	Physical
maternal	Physical
anaesthetic	Physical
requirements	Physical
,	Physical
neonatal	Physical
scalp	Physical
and	Physical
facial	Physical
injuries	Physical
.	Physical

RESULTS	O
Of	O
the	O
vacuum	O
extractor	O
group	O
,	O
85	O
%	O
were	O
delivered	O
by	O
the	O
allocated	O
instrument	O
compared	O
to	O
90	O
%	O
in	O
the	O
forceps	O
group	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
0.64	O
;	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
0.4-1.04	O
)	O
.	O

However	O
,	O
more	O
women	O
in	O
the	O
vacuum	O
extractor	O
group	O
were	O
delivered	O
vaginally	O
(	O
98	O
%	O
)	O
than	O
in	O
the	O
forceps	O
group	O
(	O
96	O
%	O
)	O
.	O

There	O
were	O
significantly	O
fewer	O
women	O
with	O
anal	Physical
sphincter	Physical
damage	Physical
or	Physical
upper	Physical
vaginal	Physical
extensions	Physical
in	O
the	O
vacuum	O
extractor	O
group	O
(	O
11	O
%	O
vs	O
17	O
%	O
,	O
OR	O
0.6	O
;	O
95	O
%	O
CI	O
,	O
0.38-0.97	O
)	O
.	O

There	O
were	O
significantly	O
fewer	O
women	O
in	O
the	O
vacuum	O
extractor	O
group	O
requiring	O
epidural	Others
or	Others
spinal	Others
anaesthetics	Others
(	O
25.4	O
%	O
vs	O
32.7	O
%	O
,	O
OR	O
0.69	O
;	O
95	O
%	O
CI	O
0.49-0.99	O
)	O
or	O
general	Physical
anaesthetics	Physical
(	O
1	O
%	O
vs	O
4	O
%	O
,	O
OR	O
0.17	O
;	O
95	O
%	O
CI	O
0.04-0.76	O
)	O
.	O

Although	O
there	O
were	O
significantly	O
more	O
babies	O
in	O
the	O
vacuum	O
extractor	O
group	O
with	O
cephalhaematomata	Adverseeffect
(	O
9	O
%	O
vs	O
3	O
%	O
,	O
OR	O
3.3	O
;	O
95	O
%	O
CI	O
1.4-7.4	O
)	O
there	O
were	O
fewer	O
babies	O
in	O
the	O
vacuum	O
extractor	O
group	O
with	O
other	O
facial	Physical
injuries	Physical
.	O

There	O
were	O
three	O
babies	O
in	O
the	O
forceps	O
group	O
with	O
unexplained	Adverseeffect
neonatal	Adverseeffect
convulsions	Adverseeffect
.	Physical

CONCLUSIONS	O
Assisted	O
vaginal	O
delivery	O
using	O
the	O
new	O
vacuum	O
extractor	O
policy	O
is	O
associated	O
with	O
significantly	O
less	O
maternal	Physical
trauma	Physical
than	O
with	O
forceps	O
.	O

Further	O
studies	O
are	O
required	O
to	O
assess	O
neonatal	O
morbidity	O
adequately	O
.	O

Scintigraphic	O
evaluation	O
of	O
a	O
new	O
capsule-type	O
colon	O
specific	O
drug	O
delivery	O
system	O
in	O
healthy	O
volunteers	O
.	O

Colonic	O
drug	O
delivery	O
is	O
intended	O
for	O
local	O
or	O
systemic	O
therapies	O
.	O

The	O
lack	O
of	O
predictive	O
in	O
vitro	O
or	O
animal	O
model	O
leads	O
to	O
considerable	O
time	O
delays	O
in	O
colonic	O
product	O
development	O
.	O

The	O
objective	O
of	O
this	O
scintigraphic	O
study	O
was	O
to	O
provide	O
proof	O
of	O
concept	O
for	O
a	O
novel	O
capsule-type	O
colonic	O
delivery	O
system	O
(	O
Colon-Targeted	O
Delivery	O
Capsule	O
)	O
in	O
healthy	O
volunteers	O
.	O

The	O
human	O
data	O
validates	O
the	O
design	O
concept	O
behind	O
the	O
release	O
mechanism	O
,	O
in	O
that	O
capsule	O
disintegration	O
,	O
and	O
hence	O
drug	O
release	O
,	O
did	O
not	O
start	O
until	O
5	O
h	O
after	O
gastric	O
emptying	O
,	O
irrespective	O
of	O
whether	O
the	O
product	O
was	O
administered	O
to	O
fasted	O
or	O
fed	O
subjects	O
.	O

However	O
,	O
the	O
potential	O
for	O
prolonged	O
gastric	O
residence	O
for	O
large	O
enteric	O
coated	O
products	O
intended	O
for	O
intestinal	O
targeting	O
was	O
also	O
observed	O
;	O
overall	O
,	O
the	O
study	O
provides	O
a	O
focus	O
for	O
subsequent	O
product	O
development	O
and	O
highlights	O
the	O
role	O
of	O
scintigraphy	O
in	O
dynamically	O
visualizing	O
the	O
drug	O
delivery	O
process	O
.	O

[	O
Triple	O
therapy	O
regimens	O
involving	O
H2	O
blockaders	O
for	O
therapy	O
of	O
Helicobacter	Physical
pylori	Physical
infections	Physical
]	Physical
.	O

Comparison	Others
of	O
ranitidine	O
and	O
lansoprazole	O
in	O
short-term	O
low-dose	O
triple	O
therapy	O
for	O
Helicobacter	O
pylori	O
infection	O
.	O

To	O
evaluate	O
the	O
efficacy	Others
and	Others
safety	Others
of	O
two	O
1-week	O
low-dose	O
triple-therapy	O
drug	O
regimens	O
involving	O
antisecretory	O
drugs	O
for	O
Helicobacter	O
pylori	O
infection	O
,	O
99	O
patients	O
with	O
H.	O
pylori	O
infection	O
were	O
treated	O
with	O
either	O
lansoprazole	O
(	O
LPZ	O
)	O
or	O
ranitidine	O
(	O
RNT	O
)	O
used	O
together	O
with	O
clarithromycin	O
(	O
CAM	O
)	O
and	O
metrinidazole	O
(	O
MTZ	O
)	O
.	O

The	O
drug	O
combination	O
and	O
administration	O
periods	O
in	O
the	O
PPI	O
group	O
were	O
LPZ	O
30	O
mg	O
,	O
CAM	O
400	O
mg	O
,	O
MTZ	O
500	O
mg	O
(	O
LCM	O
group	O
)	O
.	O

The	O
ranitidine	O
group	O
received	O
RNT	O
300	O
mg	O
,	O
CAM	O
400	O
mg	O
,	O
MTZ	O
500	O
mg	O
(	O
RCM	O
group	O
)	O
.	O

The	O
cure	Others
rate	Others
of	Others
H.	Others
pylori	Physical
infection	Physical
was	O
88	O
%	O
in	O
the	O
LCM	O
group	O
;	O
95	O
%	O
CI	O
79-97	O
and	O
92	O
%	O
in	O
the	O
RCM	O
group	O
;	O
95	O
%	O
CI	O
84-99	O
.	O

Randomized	O
trial	O
of	O
a	O
stage-of-change	O
oriented	O
smoking	O
cessation	O
intervention	O
in	O
infertile	O
and	O
pregnant	O
women	O
.	O

OBJECTIVE	O
To	O
assess	O
a	O
stage-of-change	O
oriented	O
smoking	O
cessation	O
intervention	O
for	O
infertile	O
and	O
pregnant	O
women	O
,	O
compared	O
with	O
standard	O
of	O
care	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Three	O
university	O
teaching	O
hospitals	O
in	O
Hamilton	O
,	O
Ontario	O
,	O
Canada	O
.	O

PATIENT	O
(	O
S	O
)	O
Infertile	O
women	O
at	O
their	O
first	O
visit	O
to	O
a	O
tertiary	O
referral	O
infertility	O
clinic	O
(	O
n	O
=	O
94	O
)	O
and	O
new	O
patients	O
seeking	O
pre-natal	O
care	O
(	O
n	O
=	O
110	O
)	O
who	O
had	O
smoked	O
>	O
/=	O
3	O
cigarettes	O
in	O
the	O
past	O
six	O
months	O
.	O

INTERVENTION	O
(	O
S	O
)	O
A	O
three	O
to	O
five	O
minute	O
scripted	O
intervention	O
and	O
booklet	O
specific	O
to	O
the	O
woman	O
's	O
stage-of-change	O
in	O
the	O
smoking	O
continuum	O
,	O
versus	O
standard	O
of	O
care	O
.	O

Exhaled	O
carbon-monoxide	O
(	O
CO	O
)	O
monitoring	O
was	O
used	O
to	O
validate	O
exposure	O
in	O
both	O
groups	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
(	O
S	O
)	O
Delta	Mental
stage-of-change	Mental
and	Mental
rate	Mental
of	Mental
maintained	Mental
cessation	Mental
at	O
12	O
months	O
post	O
follow-up	O
.	O

RESULT	O
(	O
S	O
)	O
Intervention	O
and	O
control	O
were	O
similarly	O
effective	O
for	O
infertile	O
women	O
:	O
the	O
rate	Mental
of	Mental
maintained	Mental
cessation	Mental
rose	O
significantly	O
from	O
4	O
%	O
to	O
24	O
%	O
over	O
twelve	O
months	O
,	O
with	O
a	O
mean	Physical
delta	Physical
stage-of-change	Physical
0.28	O
.	O

In	O
prenatal	O
women	O
,	O
neither	O
approach	O
was	O
effective	O
.	O

Maintained	Others
cessation	Others
did	O
not	O
significantly	O
change	O
from	O
0	O
to	O
12	O
months	O
(	O
19	O
%	O
to	O
18	O
%	O
)	O
.	O

Mean	Others
delta	Others
stage-of-change	Others
declined	O
by	O
-0.62	O
.	O

CONCLUSION	O
(	O
S	O
)	O
For	O
infertile	O
women	O
,	O
basic	O
information	O
describing	O
the	O
impact	O
of	O
smoking	O
on	O
fertility	O
,	O
along	O
with	O
exhaled	O
CO	O
monitoring	O
and	O
a	O
more	O
intensive	O
intervention	O
were	O
both	O
highly	O
effective	O
.	O

In	O
pregnant	O
women	O
neither	O
approach	O
was	O
beneficial	O
,	O
with	O
some	O
evidence	O
of	O
post-partum	O
relapse	O
.	O

General	O
anaesthesia	O
for	O
caesarean	O
section	O
in	O
severe	O
pre-eclampsia	O
.	O

Comparison	O
of	O
the	O
renal	O
and	O
hepatic	O
effects	O
of	O
enflurane	O
and	O
halothane	O
.	O

In	O
a	O
randomized	O
study	O
of	O
patients	O
undergoing	O
Caesarean	O
section	O
,	O
either	O
enflurane	O
(	O
mean	O
0.24	O
MAC-h	O
)	O
or	O
halothane	O
(	O
mean	O
0.23	O
MAC-h	O
)	O
and	O
50	O
%	O
nitrous	O
oxide	O
in	O
oxygen	O
were	O
administered	O
to	O
women	O
(	O
n	O
=	O
12	O
)	O
with	O
severe	O
pre-eclampsia-eclampsia	O
and	O
to	O
16	O
healthy	O
pregnant	O
patients	O
with	O
normal	O
renal	O
and	O
hepatic	O
function	O
.	O

No	O
evidence	O
of	O
nephrotoxicity	Adverseeffect
was	O
found	O
in	O
any	O
pre-eclamptic	O
or	O
normal	O
patient	O
.	O

Metabolism	O
of	O
enflurane	O
resulted	O
in	O
plasma	Physical
inorganic	Physical
fluoride	Physical
concentrations	Physical
(	O
max	O
15	O
mumol	O
litre	O
-1	O
)	O
which	O
were	O
well	O
below	O
the	O
toxic	O
value	O
.	O

Postoperative	O
liver	Physical
function	Physical
tests	O
showed	O
no	O
important	O
changes	O
from	O
preoperative	O
values	O
,	O
although	O
reductive	O
metabolites	O
of	O
halothane	O
were	O
not	O
measured	O
.	O

In	O
patients	O
with	O
severe	O
pre-eclampsia	O
there	O
appears	O
no	O
contraindication	Adverseeffect
to	Adverseeffect
enflurane	Adverseeffect
or	O
,	O
probably	O
,	O
halothane	O
as	O
volatile	O
supplements	O
during	O
general	O
anaesthesia	O
.	O

The	O
economic	O
impact	O
of	O
esophageal	O
variceal	O
hemorrhage	O
:	O
cost-effectiveness	O
implications	O
of	O
endoscopic	O
therapy	O
.	O

Esophageal	O
variceal	O
hemorrhage	O
(	O
EVH	O
)	O
is	O
a	O
serious	O
and	O
expensive	O
sequela	O
of	O
chronic	O
liver	O
disease	O
,	O
leading	O
to	O
increased	O
utilization	O
of	O
resources	O
.	O

Today	O
,	O
endoscopic	O
sclerotherapy	O
(	O
ES	O
)	O
and	O
endoscopic	O
ligation	O
(	O
EL	O
)	O
are	O
the	O
accepted	O
,	O
community	O
standards	O
of	O
endoscopic	O
treatment	O
of	O
patients	O
with	O
EVH	O
.	O

However	O
,	O
there	O
are	O
no	O
published	O
studies	O
comparing	O
the	O
economic	O
costs	O
of	O
treating	O
EVH	O
using	O
these	O
interventions	O
.	O

As	O
part	O
of	O
a	O
prospective	O
,	O
randomized	O
trial	O
comparing	O
ES	O
and	O
EL	O
for	O
the	O
treatment	O
of	O
EVH	O
,	O
we	O
estimated	O
the	O
direct	Others
costs	Others
of	Others
health	Others
care	Others
utilization	Others
and	Others
cost-effectiveness	Others
for	O
the	O
prevention	O
of	O
variceal	O
rebleeding	O
and	O
patient	O
survival	O
at	O
1-year	O
follow-up	O
.	O

Treatment	O
groups	O
were	O
similar	O
in	O
incidence	O
of	O
variceal	Physical
rebleeding	Physical
(	O
41.9	O
%	O
vs.	O
42.9	O
%	O
)	O
,	O
variceal	Physical
obliteration	Physical
(	O
41.9	O
%	O
vs.	O
40.0	O
%	O
)	O
,	O
hospital	Others
days	Others
,	Others
blood	Others
transfusions	Others
,	Others
shunt	Others
requirements	Others
,	O
and	O
survival	Mortality
(	O
71.0	O
%	O
vs.	O
60.0	O
%	O
)	O
.	O

There	O
were	O
significantly	O
more	O
treatment	O
failures	O
for	O
active	Physical
bleeding	Physical
using	O
EL	O
(	O
42	O
%	O
vs.	O
0	O
%	O
;	O
P	O
=.027	O
)	O
and	O
esophageal	Physical
stricture	Physical
formation	Physical
in	O
the	O
ES-treated	O
patients	O
(	O
19.4	O
%	O
vs.	O
2.9	O
%	O
;	O
P	O
=	O
0.03	O
)	O
.	O

Median	O
total	O
direct	O
cost	O
outcomes	O
were	O
similar	O
between	O
groups	O
(	O
EL	O
=	O
$	O
9,696	O
and	O
ES	O
=	O
$	O
13,197	O
;	O
P	O
=.46	O
)	O
.	O

EL	O
and	O
ES	O
had	O
similar	O
cost/variceal	O
rebleeding	O
prevented	O
(	O
$	O
28,678	O
vs.	O
$	O
29,093	O
)	O
and	O
cost/survival	Others
(	O
$	O
27,313	O
vs.	O
$	O
23,804	O
)	O
.	O

In	O
the	O
subgroup	O
of	O
active	O
bleeders	O
,	O
ES	O
had	O
a	O
substantially	O
lower	O
cost/survival	O
(	O
$	O
28,523	O
vs.	O
$	O
51,696	O
)	O
.	O

We	O
conclude	O
that	O
resource	O
utilization	O
was	O
similar	O
between	O
treatment	O
groups	O
and	O
that	O
the	O
choice	O
of	O
endoscopic	O
therapy	O
for	O
EVH	O
must	O
still	O
rely	O
on	O
clinical	O
grounds	O
.	O

Further	O
studies	O
comparing	O
costs	O
and	O
resource	O
utilization	O
in	O
this	O
patient	O
population	O
are	O
needed	O
.	O

A	O
comparative	O
study	O
of	O
ofloxacin	O
and	O
cefixime	O
for	O
treatment	O
of	O
typhoid	O
fever	O
in	O
children	O
.	O

The	O
Dong	O
Nai	O
Pediatric	O
Center	O
Typhoid	O
Study	O
Group	O
.	O

BACKGROUND	O
Despite	O
concerns	O
about	O
safety	O
in	O
children	O
,	O
fluoroquinolone	O
antibiotics	O
have	O
become	O
the	O
treatment	O
of	O
choice	O
in	O
patients	O
with	O
multidrug-resistant	O
typhoid	O
fever	O
in	O
Vietnam	O
.	O

However	O
,	O
quinolone-resistant	O
strains	O
of	O
Salmonella	O
typhi	O
have	O
recently	O
been	O
reported	O
from	O
Vietnam	O
;	O
and	O
if	O
quinolone	O
resistance	O
becomes	O
established	O
,	O
alternative	O
oral	O
treatment	O
options	O
will	O
be	O
needed	O
.	O

OBJECTIVE	O
Cefixime	O
,	O
an	O
orally	O
administered	O
third	O
generation	O
cephalosporin	O
,	O
was	O
compared	O
with	O
ofloxacin	O
for	O
the	O
treatment	O
of	O
uncomplicated	O
typhoid	O
fever	O
in	O
children	O
.	O

METHODS	O
In	O
an	O
open	O
trial	O
children	O
with	O
suspected	O
typhoid	O
fever	O
were	O
randomized	O
to	O
receive	O
either	O
ofloxacin	O
(	O
10	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
)	O
for	O
5	O
days	O
or	O
cefixime	O
(	O
20	O
mg/kg/day	O
in	O
two	O
divided	O
doses	O
)	O
for	O
7	O
days	O
.	O

RESULTS	O
S.	O
typhi	O
was	O
isolated	O
from	O
82	O
patients	O
(	O
44	O
in	O
the	O
cefixime	O
group	O
,	O
38	O
in	O
the	O
ofloxacin	O
group	O
)	O
and	O
70	O
(	O
85	O
%	O
)	O
of	O
the	O
isolates	O
were	O
multidrug-resistant	O
.	O

Median	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
range	O
)	O
fever	Physical
clearance	Physical
times	Physical
were	O
4.4	O
(	O
4	O
to	O
5.2	O
,	O
0.2	O
to	O
9.9	O
)	O
days	O
for	O
ofloxacin	O
recipients	O
and	O
8.5	O
(	O
4.2	O
to	O
9	O
,	O
1.8	O
to	O
15.2	O
)	O
days	O
for	O
cefixime-treated	O
patients	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

There	O
were	O
11	O
treatment	Others
failures	Others
(	O
10	O
acute	O
and	O
one	O
relapse	O
)	O
in	O
the	O
cefixime	O
group	O
and	O
1	O
acute	Others
treatment	Others
failure	Others
in	O
the	O
ofloxacin	O
group	O
(	O
mean	O
difference	O
,	O
22	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
9	O
to	O
36	O
%	O
)	O
.	O

CONCLUSION	O
Short	O
course	O
treatment	O
with	O
cefixime	O
may	O
provide	O
a	O
useful	O
alternative	O
treatment	O
in	O
cases	O
of	O
uncomplicated	O
typhoid	O
fever	O
in	O
children	O
,	O
but	O
it	O
is	O
less	O
effective	O
than	O
short	O
course	O
treatment	O
with	O
ofloxacin	O
.	O

Evaluation	O
of	O
nonpharmacologic	O
methods	O
of	O
pain	O
and	O
anxiety	O
management	O
for	O
laceration	O
repair	O
in	O
the	O
pediatric	O
emergency	O
department	O
.	O

BACKGROUND	O
Nonpharmacologic	O
interventions	O
,	O
such	O
as	O
distraction	O
,	O
have	O
been	O
shown	O
to	O
be	O
powerful	O
adjuncts	O
in	O
reducing	O
pain	O
and	O
anxiety	O
in	O
children	O
with	O
both	O
acute	O
and	O
chronic	O
painful	O
conditions	O
.	O

There	O
are	O
no	O
controlled	O
studies	O
evaluating	O
these	O
interventions	O
as	O
adjuncts	O
to	O
facilitate	O
completion	O
of	O
painful	O
procedures	O
in	O
the	O
pediatric	O
emergency	O
department	O
(	O
ED	O
)	O
.	O

OBJECTIVE	O
We	O
assessed	O
the	O
effectiveness	O
of	O
distraction	O
techniques	O
in	O
reducing	O
the	O
sensory	O
and	O
affective	O
components	O
of	O
pain	O
among	O
pediatric	O
patients	O
undergoing	O
laceration	O
repair	O
in	O
the	O
ED	O
.	O

METHODS	O
Eligible	O
children	O
between	O
6	O
and	O
18	O
years	O
of	O
age	O
(	O
N	O
=	O
240	O
)	O
presenting	O
to	O
the	O
ED	O
for	O
laceration	O
repair	O
were	O
randomly	O
assigned	O
to	O
an	O
intervention	O
or	O
control	O
arm	O
.	O

Those	O
assigned	O
to	O
the	O
intervention	O
arm	O
were	O
given	O
a	O
choice	O
of	O
age-appropriate	O
distracters	O
during	O
laceration	O
repair	O
.	O

Quantitative	O
measures	O
of	O
pain	Pain
intensity	Pain
,	Pain
situational	Pain
anxiety	Pain
,	Pain
and	Pain
pain	Pain
distress	Pain
(	Pain
as	Pain
perceived	Pain
by	Pain
the	Pain
parent	Pain
)	Pain
were	O
assessed	O
by	O
using	O
the	O
7-point	O
Facial	O
Pain	O
Scale	O
,	O
State	Mental
Trait	Mental
Anxiety	Mental
Inventory	Mental
for	O
Children	O
,	O
and	O
a	O
visual	O
analog	O
scale	O
,	O
respectively	O
,	O
before	O
and	O
after	O
laceration	O
repair	O
.	O

The	O
State	O
Trait	O
Anxiety	O
Inventory	O
for	O
Children	O
was	O
performed	O
in	O
children	O
>	O
or	O
=	O
10	O
years	O
of	O
age	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
in	O
mean	Pain
change	Pain
in	Pain
Facial	Pain
Pain	Pain
Scale	Pain
scores	O
between	O
the	O
control	O
and	O
the	O
intervention	O
groups	O
in	O
children	O
<	O
10	O
years	O
of	O
age	O
.	O

Multivariate	O
analysis	O
in	O
this	O
same	O
age	O
group	O
showed	O
that	O
the	O
intervention	O
was	O
independently	O
associated	O
with	O
a	O
reduction	Pain
in	Pain
pain	Pain
distress	Pain
as	O
perceived	O
by	O
parents	O
based	O
on	O
the	O
mean	O
change	O
in	O
visual	O
analog	O
scale	O
scores	O
.	O

In	O
older	O
children	O
,	O
the	O
intervention	O
was	O
independently	O
associated	O
with	O
reduction	O
in	O
situational	Mental
anxiety	Mental
but	O
not	O
in	O
pain	Pain
intensity	Pain
or	Pain
in	Pain
parental	Pain
perception	Pain
of	O
pain	O
distress	O
.	O

CONCLUSIONS	O
The	O
use	O
of	O
distraction	O
techniques	O
is	O
effective	O
in	O
reducing	O
situational	O
anxiety	O
in	O
older	O
children	O
and	O
lowering	O
parental	O
perception	O
of	O
pain	O
distress	O
in	O
younger	O
children	O
.	O

This	O
technique	O
may	O
have	O
a	O
role	O
in	O
improving	O
the	O
quality	O
of	O
management	O
of	O
procedural	O
pain	O
in	O
a	O
pediatric	O
ED	O
setting	O
.	O

A	O
randomized	O
placebo-controlled	O
prevention	O
trial	O
of	O
aspirin	O
and/or	O
resistant	O
starch	O
in	O
young	O
people	O
with	O
familial	Physical
adenomatous	Physical
polyposis	Physical
.	Physical

Evidence	O
supporting	O
aspirin	O
and	O
resistant	O
starch	O
(	O
RS	O
)	O
for	O
colorectal	O
cancer	O
prevention	O
comes	O
from	O
epidemiologic	O
and	O
laboratory	O
studies	O
(	O
aspirin	O
and	O
RS	O
)	O
and	O
randomized	O
controlled	O
clinical	O
trials	O
(	O
aspirin	O
)	O
.	O

Familial	O
adenomatous	O
polyposis	O
(	O
FAP	O
)	O
strikes	O
young	O
people	O
and	O
,	O
untreated	O
,	O
confers	O
virtually	O
a	O
100	O
%	O
risk	O
of	O
colorectal	O
cancer	O
and	O
early	O
death	O
.	O

We	O
conducted	O
an	O
international	O
,	O
multicenter	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
of	O
aspirin	O
(	O
600	O
mg/d	O
)	O
and/or	O
RS	O
(	O
30	O
g/d	O
)	O
for	O
from	O
1	O
to	O
12	O
years	O
to	O
prevent	O
disease	O
progression	O
in	O
FAP	O
patients	O
from	O
10	O
to	O
21	O
years	O
of	O
age	O
.	O

In	O
a	O
2	O
?	O
2	O
factorial	O
design	O
,	O
patients	O
were	O
randomly	O
assigned	O
to	O
the	O
following	O
four	O
study	O
arms	O
:	O
aspirin	O
plus	O
RS	O
placebo	O
;	O
RS	O
plus	O
aspirin	O
placebo	O
;	O
aspirin	O
plus	O
RS	O
;	O
RS	O
placebo	O
plus	O
aspirin	O
placebo	O
;	O
they	O
were	O
followed	O
with	O
standard	O
annual	O
clinical	O
examinations	O
including	O
endoscopy	O
.	O

The	O
primary	O
endpoint	O
was	O
polyp	O
number	O
in	O
the	O
rectum	O
and	O
sigmoid	O
colon	O
(	O
at	O
the	O
end	O
of	O
intervention	O
)	O
,	O
and	O
the	O
major	O
secondary	O
endpoint	O
was	O
size	O
of	O
the	O
largest	O
polyp	O
.	O

A	O
total	O
of	O
206	O
randomized	O
FAP	O
patients	O
commenced	O
intervention	O
,	O
of	O
whom	O
133	O
had	O
at	O
least	O
one	O
follow-up	O
endoscopy	O
and	O
were	O
therefore	O
included	O
in	O
the	O
primary	O
analysis	O
.	O

Neither	O
intervention	O
significantly	O
reduced	O
polyp	O
count	O
in	O
the	O
rectum	O
and	O
sigmoid	O
colon	O
:	O
aspirin	O
relative	O
risk	O
=	O
0.77	O
(	O
95	O
%	O
CI	O
,	O
0.54-1.10	O
;	O
versus	O
nonaspirin	O
arms	O
)	O
;	O
RS	O
relative	O
risk	O
=	O
1.05	O
(	O
95	O
%	O
CI	O
,	O
0.73-1.49	O
;	O
versus	O
non-RS	O
arms	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
a	O
smaller	O
size	O
of	O
largest	O
polyp	O
in	O
patients	O
treated	O
with	O
aspirin	O
versus	O
nonaspirin	O
--	O
mean	O
3.8	O
mm	O
versus	O
5.5	O
mm	O
for	O
patients	O
treated	O
1	O
or	O
more	O
years	O
(	O
adjusted	O
P	O
=	O
0.09	O
)	O
and	O
mean	O
3.0	O
mm	O
versus	O
6.0	O
mm	O
for	O
patients	O
treated	O
more	O
than	O
1	O
year	O
(	O
P	O
=	O
0.02	O
)	O
;	O
there	O
were	O
similar	O
weaker	O
trends	O
with	O
RS	O
versus	O
non-RS	O
.	O

Exploratory	O
translational	O
endpoints	O
included	O
crypt	O
length	O
(	O
which	O
was	O
significantly	O
shorter	O
in	O
normal-appearing	O
mucosa	O
in	O
the	O
RS	O
group	O
over	O
time	O
)	O
and	O
laboratory	O
measures	O
of	O
proliferation	O
(	O
including	O
Ki67	O
)	O
.	O

This	O
clinical	O
trial	O
is	O
the	O
largest	O
ever	O
conducted	O
in	O
the	O
setting	O
of	O
FAP	O
and	O
found	O
a	O
trend	O
of	O
reduced	O
polyp	O
load	O
(	O
number	O
and	O
size	O
)	O
with	O
600	O
mg	O
of	O
aspirin	O
daily	O
.	O

RS	O
had	O
no	O
clinical	O
effect	O
on	O
adenomas	O
.	O

A	O
controlled	O
,	O
randomized	O
,	O
double-blind	O
trial	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
supplement	O
of	O
cocoa	O
husk	O
that	O
is	O
rich	O
in	O
dietary	O
fiber	O
on	O
colonic	Physical
transit	Physical
in	O
constipated	O
pediatric	O
patients	O
.	O

OBJECTIVE	O
Although	O
a	O
diet	O
that	O
is	O
rich	O
in	O
fiber	O
is	O
widely	O
recommended	O
for	O
preventing	O
and	O
treating	O
constipation	O
,	O
the	O
efficacy	O
of	O
fiber	O
supplements	O
have	O
not	O
been	O
tested	O
sufficiently	O
in	O
children	O
.	O

Our	O
aim	O
with	O
this	O
pilot	O
study	O
was	O
to	O
evaluate	O
if	O
fiber	O
supplementation	O
is	O
beneficial	O
for	O
the	O
treatment	O
of	O
children	O
with	O
idiopathic	Physical
chronic	Physical
constipation	Physical
.	O

METHODS	O
Using	O
a	O
parallel	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
trial	O
,	O
we	O
conducted	O
an	O
interventional	O
study	O
to	O
evaluate	O
the	O
efficacy	O
of	O
a	O
supplement	O
of	O
cocoa	O
husk	O
rich	O
in	O
dietary	O
fiber	O
on	O
intestinal	O
transit	O
time	O
and	O
other	O
indices	O
of	O
constipation	Physical
in	O
children	O
with	O
constipation	O
.	O

After	O
screening	O
,	O
the	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
,	O
for	O
a	O
period	O
of	O
4	O
weeks	O
,	O
either	O
a	O
cocoa	O
husk	O
supplement	O
or	O
placebo	O
plus	O
standardized	O
toilet	O
training	O
procedures	O
.	O

Before	O
and	O
after	O
4	O
weeks	O
of	O
treatment	O
,	O
we	O
(	O
1	O
)	O
performed	O
anthropometry	O
,	O
a	O
physical	O
examination	O
,	O
and	O
routine	O
laboratory	O
measurements	O
,	O
(	O
2	O
)	O
determined	O
total	O
and	O
segmental	O
colonic	O
transit	O
time	O
,	O
(	O
3	O
)	O
evaluated	O
bowel	O
movement	O
habits	O
and	O
stool	O
consistency	O
using	O
a	O
diary	O
,	O
and	O
(	O
4	O
)	O
received	O
a	O
subjective	O
evaluation	O
from	O
the	O
parents	O
regarding	O
the	O
efficacy	O
of	O
the	O
treatment	O
.	O

The	O
main	O
variable	O
for	O
verifying	O
the	O
efficacy	O
of	O
the	O
treatment	O
was	O
the	O
total	Physical
colonic	Physical
transit	Physical
time	Physical
.	O

RESULTS	O
Fifty-six	O
chronically	O
constipated	O
children	O
were	O
randomly	O
assigned	O
into	O
the	O
study	O
,	O
but	O
only	O
48	O
children	O
completed	O
it	O
.	O

These	O
children	O
,	O
who	O
were	O
aged	O
between	O
3	O
and	O
10	O
years	O
,	O
had	O
a	O
diagnosis	O
of	O
chronic	O
idiopathic	O
constipation	O
.	O

With	O
respect	O
to	O
total	Physical
,	Physical
partial	Physical
colon	Physical
,	Physical
and	Physical
rectum	Physical
transit	Physical
time	Physical
,	O
there	O
seemed	O
to	O
be	O
a	O
trend	O
,	O
although	O
statistically	O
nonsignificant	O
,	O
toward	O
faster	O
transit	Physical
times	Physical
in	O
the	O
cocoa	O
husk	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

When	O
we	O
analyzed	O
the	O
evolution	O
of	O
the	O
intestinal	Physical
transit	Physical
time	O
throughout	O
the	O
study	O
of	O
children	O
whose	O
total	O
basal	Physical
intestinal	Physical
transit	Physical
time	Physical
was	O
>	O
50th	O
percentile	O
,	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
groups	O
.	O

The	O
total	Physical
transit	Physical
time	Physical
decreased	O
by	O
45.4	O
+/-	O
38.4	O
hours	O
in	O
the	O
cocoa	O
husk	O
group	O
and	O
by	O
8.7	O
+/-	O
28.9	O
hours	O
in	O
the	O
placebo	O
group	O
(	O
-38.1	O
hours	O
)	O
.	O

In	O
the	O
case	O
of	O
the	O
right	O
colon	O
,	O
changes	Physical
in	Physical
transit	Physical
time	Physical
also	O
were	O
significant	O
between	O
groups	O
.	O

Mean	Physical
changes	Physical
tended	O
toward	O
faster	O
transit	O
times	O
in	O
the	O
left	O
colon	O
and	O
the	O
rectum	O
,	O
although	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

The	O
children	O
who	O
received	O
cocoa	O
husk	O
supplements	O
tended	O
to	O
increase	O
the	O
number	Physical
of	Physical
bowel	Physical
movements	Physical
by	O
more	O
than	O
that	O
of	O
the	O
children	O
of	O
the	O
placebo	O
group	O
.	O

We	O
also	O
observed	O
a	O
reduction	O
in	O
the	O
percentage	O
of	O
patients	O
who	O
reported	O
hard	O
stools	O
(	O
hard	Physical
scybalous	Physical
or	Physical
pebble-like	Physical
stools	Physical
)	O
,	O
although	O
this	O
reduction	O
was	O
significantly	O
greater	O
in	O
the	O
cocoa	O
husk	O
group	O
.	O

At	O
the	O
end	O
of	O
the	O
intervention	O
,	O
41.7	O
%	O
and	O
75.0	O
%	O
of	O
the	O
patients	O
who	O
received	O
cocoa	O
husk	O
supplementation	O
or	O
placebo	O
,	O
respectively	O
,	O
reported	Physical
having	Physical
hard	Physical
stools	Physical
.	O

Moreover	O
,	O
a	O
significantly	O
higher	O
number	O
of	O
children	O
(	O
or	O
their	O
parents	O
)	O
reported	O
a	O
subjective	O
improvement	Physical
in	Physical
stool	Physical
consistency	Physical
.	O

No	Adverseeffect
significant	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
were	O
reported	O
during	O
the	O
study	O
.	O

CONCLUSIONS	O
This	O
study	O
confirms	O
the	O
beneficial	O
effect	O
of	O
a	O
supplement	O
of	O
cocoa	O
husk	O
that	O
is	O
rich	O
in	O
dietary	O
fiber	O
on	O
chronic	Physical
idiopathic	Physical
constipation	Physical
in	O
children	O
.	O

These	O
benefits	O
seem	O
to	O
be	O
more	O
evident	O
in	O
pediatric	O
constipated	O
patients	O
with	O
slow	O
colonic	O
transit	O
time	O
.	O

Prospectively	O
randomized	O
toxicity	Adverseeffect
study	O
of	O
high-dose	O
versus	O
low-dose	O
treatment	O
strategies	O
for	O
lymphoblastoid	O
interferon	O
.	O

It	O
is	O
unclear	O
from	O
preliminary	O
laboratory	O
studies	O
whether	O
a	O
high-	O
or	O
a	O
low-dose	O
interferon	O
treatment	O
strategy	O
is	O
optimal	O
.	O

As	O
part	O
of	O
an	O
ongoing	O
study	O
of	O
mechanisms	O
of	O
interferon	O
action	O
,	O
we	O
have	O
evaluated	O
toxicity	O
in	O
a	O
two-arm	O
protocol	O
in	O
which	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
lymphoblastoid	O
interferon	O
by	O
either	O
a	O
low-dose	O
treatment	O
strategy	O
(	O
2	O
X	O
10	O
(	O
6	O
)	O
units/m2	O
daily	O
X	O
28	O
days	O
then	O
daily	O
X	O
5	O
days	O
every	O
other	O
week	O
by	O
im	O
injection	O
)	O
or	O
a	O
high-dose	O
treatment	O
strategy	O
(	O
5	O
X	O
10	O
(	O
6	O
)	O
units/m2	O
by	O
continuous	O
iv	O
infusion	O
over	O
24	O
hours	O
,	O
escalating	O
by	O
5	O
X	O
10	O
(	O
6	O
)	O
units/m2/day	O
as	O
tolerated	O
over	O
10	O
days	O
,	O
repeated	O
every	O
28	O
days	O
)	O
.	O

The	O
main	Adverseeffect
toxic	Adverseeffect
effects	Adverseeffect
in	O
both	O
arms	O
were	O
fever	Adverseeffect
,	Adverseeffect
fatigue	Adverseeffect
,	Adverseeffect
and	Adverseeffect
anorexia	Adverseeffect
.	Adverseeffect

Marked	O
interpatient	O
differences	O
within	O
each	O
dose	O
arm	O
were	O
greater	O
than	O
differences	O
between	O
arms	O
.	O

Additional	O
significant	Adverseeffect
toxic	Adverseeffect
effects	Adverseeffect
included	Adverseeffect
nausea	Adverseeffect
and	Adverseeffect
vomiting	Adverseeffect
,	Adverseeffect
hypotension	Adverseeffect
,	Adverseeffect
leukopenia	Adverseeffect
,	Adverseeffect
thrombocytopenia	Adverseeffect
,	Adverseeffect
and	Adverseeffect
evidence	Adverseeffect
of	Adverseeffect
hepatic	Adverseeffect
toxicity	Adverseeffect
.	O

Minor	O
changes	Adverseeffect
in	Adverseeffect
serum	Adverseeffect
electrolytes	Adverseeffect
were	O
noted	O
.	O

Coagulation	Physical
studies	Physical
were	O
normal	O
.	O

The	O
dose-limiting	O
toxic	Adverseeffect
effect	Adverseeffect
for	O
the	O
high-dose	O
arm	O
was	O
myelosuppression	Adverseeffect
.	O

Median	O
maximum	Others
tolerated	Others
dose	Others
among	O
high-dose	O
strategy	O
patients	O
was	O
18	O
X	O
10	O
(	O
6	O
)	O
units/m2	O
,	O
but	O
there	O
was	O
marked	O
interpatient	O
variation	O
.	O

We	O
conclude	O
that	O
both	O
dose	O
schedules	O
were	O
relatively	Others
well-tolerated	Others
.	Others

Because	O
of	O
individual	O
variation	O
in	O
tolerance	Others
,	O
high-dose	O
treatment	O
should	O
include	O
a	O
dose	O
escalation	O
strategy	O
.	O

Is	O
Na+	O
modeling	O
necessary	O
in	O
high	O
flux	O
dialysis	O
?	O
One	O
important	O
pathogenic	O
factor	O
in	O
dialysis	O
hypotension	O
is	O
the	O
drop	O
in	O
plasma	O
osmolality	O
.	O

Increasing	O
the	O
dialysate	O
Na+	O
concentration	O
decreases	O
hypotensive	O
episodes	O
.	O

The	O
authors	O
studied	O
39	O
patients	O
being	O
treated	O
with	O
high	O
flux	O
dialysis	O
.	O

During	O
a	O
9	O
week	O
period	O
,	O
the	O
patients	O
were	O
on	O
a	O
standard	O
Na+	O
dialysate	O
(	O
Na+	O
=	O
140	O
meq/L	O
)	O
basal	O
period	O
(	O
B	O
)	O
;	O
9	O
%	O
(	O
Na+	O
=	O
149	O
meq/L	O
)	O
linear	O
(	O
L	O
)	O
;	O
step	O
drop	O
(	O
S	O
)	O
;	O
and	O
exponential	O
drop	O
(	O
E	O
)	O
.	O

The	O
Na+	O
program	O
was	O
changed	O
weekly	O
at	O
random	O
.	O

The	O
results	O
obtained	O
with	O
the	O
three	O
Na+	O
modeling	O
programs	O
were	O
similar	O
.	O

We	O
compared	O
the	O
periods	O
with	O
and	O
without	O
Na+	O
modeling	O
:	O
no	O
differences	O
were	O
found	O
in	O
weight	Physical
gained	Physical
interdialysis	Physical
,	O
mean	Physical
blood	Physical
pressure	Physical
predialysis	Physical
and	Physical
postdialysis	Physical
,	O
and	O
hemoconcentration	Physical
.	O

Serum	Physical
Na+	Physical
levels	Physical
were	O
significantly	O
higher	O
predialysis	O
and	O
postdialysis	O
for	O
those	O
patients	O
on	O
Na+	O
modeling	O
.	O

Hypotensive	Physical
episodes	Physical
and	Physical
cramps	Physical
decreased	O
50	O
%	O
with	O
Na+	O
modeling	O
.	O

The	O
amount	Physical
of	Physical
hypertonic	Physical
and	Physical
normal	Physical
saline	Physical
given	O
during	O
dialysis	O
was	O
markedly	O
reduced	O
.	O

Na+	O
modeling	O
should	O
always	O
be	O
used	O
in	O
patients	O
being	O
maintained	O
on	O
high	O
flux	O
dialysis	O
.	O

The	O
effect	O
of	O
oral	O
steroids	O
with	O
and	O
without	O
vitamin	O
D3	O
on	O
early	O
efficacy	O
of	O
immunotherapy	O
in	O
asthmatic	O
children	O
.	O

BACKGROUND	O
The	O
possibility	O
of	O
additional	O
strategies	O
to	O
enhance	O
the	O
effectiveness	O
of	O
specific	O
immunotherapy	O
(	O
SIT	O
)	O
is	O
highly	O
attractive	O
.	O

AIM	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
influence	O
of	O
oral	O
corticosteroids	O
and	O
oral	O
corticosteroids	O
combined	O
with	O
vitamin	O
D	O
(	O
3	O
)	O
on	O
the	O
early	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
.	O

METHODS	O
It	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
conducted	O
in	O
54	O
asthmatic	O
children	O
allergic	O
to	O
house	O
dust	O
mites	O
.	O

Intervention	O
was	O
based	O
on	O
receiving	O
a	O
single	O
dose	O
of	O
oral	O
steroid	O
,	O
with	O
or	O
without	O
vitamin	O
D	O
(	O
3	O
)	O
,	O
or	O
placebo	O
only	O
on	O
the	O
day	O
of	O
the	O
build-up	O
phase	O
of	O
SIT	O
.	O

RESULTS	O
After	O
12	O
months	O
of	O
SIT	O
,	O
the	O
median	Physical
daily	Physical
inhaled	Physical
corticosteroid	Physical
(	Physical
ICS	Physical
)	Physical
dose	Physical
,	O
which	O
controls	O
the	O
symptoms	O
of	O
asthma	O
,	O
was	O
reduced	O
by	O
25	O
%	O
in	O
the	O
steroid	O
group	O
.	O

However	O
,	O
a	O
50	O
%	O
reduction	O
of	O
the	O
median	Physical
daily	Physical
ICS	Physical
dose	Physical
was	O
observed	O
in	O
the	O
control	O
group	O
.	O

The	O
clinical	O
effects	O
of	O
SIT	O
were	O
not	O
affected	O
in	O
the	O
steroid+D	O
(	O
3	O
)	O
group	O
.	O

Concomitantly	O
,	O
we	O
found	O
that	O
intervention	O
with	O
prednisone	O
significantly	O
impaired	O
the	O
induction	Physical
of	Physical
T	Physical
regulatory	Physical
lymphocytes	Physical
.	O

Importantly	O
,	O
the	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
were	O
not	O
affected	O
by	O
intervention	O
with	O
steroids	O
administered	O
with	O
vitamin	O
D	O
(	O
3	O
)	O
.	O

CONCLUSIONS	O
Our	O
study	O
failed	O
to	O
show	O
a	O
beneficial	O
effect	O
of	O
oral	O
corticosteroids	O
on	O
allergen-specific	O
immunotherapy	O
.	O

We	O
observed	O
that	O
the	O
combined	O
administration	O
of	O
a	O
corticosteroid	O
drug	O
and	O
allergen	O
extract	O
suppressed	O
the	O
early	O
clinical	O
and	O
immunological	O
effects	O
of	O
SIT	O
and	O
that	O
vitamin	O
D	O
(	O
3	O
)	O
prevented	O
this	O
'adverse	O
'	O
influence	O
of	O
steroids	O
.	O

The	O
cumulative	O
dose	O
response	O
effect	O
of	O
eicosapentaenoic	O
and	O
docosahexaenoic	O
acid	O
on	O
blood	Physical
pressure	Physical
,	Physical
plasma	Physical
lipid	Physical
profile	Physical
and	Physical
diet	Physical
pattern	Physical
in	O
mild	O
to	O
moderate	O
essential	O
hypertensive	O
black	O
patients	O
.	O

In	O
this	O
study	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
and	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
were	O
given	O
in	O
a	O
cumulative	O
manner	O
,	O
every	O
6	O
weeks	O
,	O
starting	O
with	O
10	O
mg	O
,	O
then	O
100	O
mg	O
,	O
1000	O
mg	O
and	O
10,000	O
mg	O
EPA	O
daily	O
to	O
mild	O
to	O
moderate	O
essential	O
hypertensive	O
black	O
patients	O
.	O

The	O
corresponding	O
DHA	O
doses	O
were	O
3	O
,	O
33	O
,	O
333	O
and	O
3333	O
mg.	O
A	O
control	O
group	O
was	O
given	O
olive	O
oil	O
as	O
placebo	O
for	O
the	O
entire	O
24	O
weeks	O
.	O

The	O
placebo	O
group	O
had	O
lower	Physical
diastolic	Physical
and	Physical
systolic	Physical
blood	Physical
pressures	Physical
after	O
24	O
weeks	O
than	O
the	O
EPA	O
and	O
DHA	O
group	O
.	O

No	O
effect	Others
was	O
seen	O
on	O
plasma	Physical
triglycerides	Physical
,	Physical
cholesterol	Physical
,	Physical
HDL-cholesterol	Physical
and	Physical
gamma-glutamyltranspeptidase	Physical
at	O
any	O
stage	O
of	O
the	O
trial	O
.	O

In	O
the	O
EPA	O
group	O
plasma	Physical
free-EPA	Physical
increased	O
significantly	O
from	O
1000	O
mg	O
onwards	O
and	O
plasma	Physical
free-arachidonic	Physical
acid	Physical
(	Physical
AA	Physical
)	Physical
decreased	O
after	O
1000	O
mg	O
EPA	O
.	O

No	O
other	O
plasma	Physical
free	Physical
essential	Physical
fatty	Physical
acid	Physical
changed	O
during	O
the	O
trial	O
,	O
although	O
the	O
HDL	Physical
:	Physical
cholesterol	Physical
increased	O
slightly	O
but	O
non-significantly	O
with	O
an	O
increase	O
in	O
EPA	Physical
and	Physical
DHA	Physical
.	O

No	O
significant	O
changes	O
in	O
diet	Physical
pattern	Physical
or	Physical
body	Physical
mass	Physical
was	O
observed	O
.	O

It	O
is	O
therefore	O
concluded	O
that	O
EPA	O
and	O
DHA	O
supplementation	O
had	O
no	O
beneficial	O
effects	O
in	O
mild	O
to	O
moderate	O
essential	O
hypertensive	O
black	O
patients	O
except	O
for	O
a	O
lowering	Physical
of	Physical
plasma	Physical
AA	Physical
.	O

Association	O
of	O
race	O
with	O
complications	O
and	O
prognosis	O
following	O
acute	O
coronary	O
syndromes	O
.	O

The	O
baseline	O
characteristics	Mortality
,	O
complications	Adverseeffect
,	O
and	O
survival	Mortality
of	O
489	O
black	O
and	O
6,890	O
non-black	O
patients	O
with	O
acute	O
coronary	O
syndromes	O
were	O
studied	O
.	O

Important	O
racial	Others
differences	Others
were	O
observed	O
in	O
demographic	Physical
features	Physical
,	Physical
atherosclerosis	Physical
risk	Physical
factors	Physical
,	Physical
and	Physical
treatment	Others
strategies	Others
;	Physical
however	O
,	O
despite	O
these	O
differences	O
,	O
no	O
independent	O
difference	O
was	O
observed	O
in	O
clinical	O
outcomes	O
according	O
to	O
race	O
.	O

The	O
1-year	O
mortality	Mortality
rate	Mortality
was	O
2.9	O
%	O
for	O
black	O
patients	O
and	O
2.5	O
%	O
for	O
non-black	O
patients	O
(	O
p	O
=	O
0.93	O
)	O
.	O

14	O
day	O
endoscopy	O
study	O
comparing	O
risedronate	O
and	O
alendronate	O
in	O
postmenopausal	O
women	O
stratified	O
by	O
Helicobacter	O
pylori	O
status	O
.	O

OBJECTIVE	O
Bisphosphonates	O
are	O
effective	O
treatment	O
for	O
osteoporosis	O
but	O
have	O
been	O
associated	O
with	O
gastrointestinal	O
(	O
GI	O
)	O
mucosal	O
injury	O
.	O

This	O
study	O
compared	O
the	O
incidence	O
of	O
gastric	O
ulcers	O
after	O
treatment	O
with	O
risedronate	O
,	O
a	O
pyridinyl	O
bisphosphonate	O
,	O
or	O
alendronate	O
,	O
a	O
primary	O
amino	O
bisphosphonate	O
,	O
in	O
healthy	O
postmenopausal	O
women	O
stratified	O
by	O
Helicobacter	O
pylori	O
status	O
.	O

METHODS	O
Subjects	O
were	O
randomized	O
to	O
receive	O
risedronate	O
5	O
mg	O
(	O
n	O
=	O
318	O
)	O
or	O
alendronate	O
10	O
mg	O
(	O
n	O
=	O
317	O
)	O
daily	O
for	O
14	O
days	O
.	O

Endoscopy	O
and	O
evaluator-blind	O
assessments	O
of	O
the	O
esophageal	O
,	O
gastric	O
,	O
and	O
duodenal	O
mucosa	O
were	O
performed	O
at	O
baseline	O
and	O
on	O
Days	O
8	O
and	O
15	O
.	O

RESULTS	O
Overall	O
,	O
gastric	Physical
ulcers	Physical
>	O
or	O
=	O
3	O
mm	O
were	O
observed	O
in	O
18	O
(	O
6.0	O
%	O
)	O
of	O
300	O
evaluable	O
subjects	O
in	O
the	O
risedronate	O
group	O
and	O
36	O
(	O
12.1	O
%	O
)	O
of	O
297	O
in	O
the	O
alendronate	O
group	O
during	O
treatment	O
(	O
p	O
=	O
0.013	O
)	O
.	O

On	O
Day	O
8	O
,	O
the	O
incidences	Physical
of	Physical
gastric	Physical
ulcers	Physical
in	O
the	O
risedronate	O
and	O
alendronate	O
groups	O
were	O
3.6	O
%	O
and	O
6.6	O
%	O
,	O
respectively	O
(	O
p	O
=	O
0.133	O
)	O
,	O
and	O
on	O
Day	O
15	O
,	O
they	O
were	O
3.3	O
%	O
and	O
8.7	O
%	O
(	O
p	O
=	O
0.008	O
)	O
.	O

The	O
incidence	Physical
of	Physical
gastric	Physical
ulcers	Physical
was	O
not	O
affected	O
by	O
H.	O
pylori	O
status	O
.	O

Mean	Others
gastric	Others
endoscopy	Others
scores	Others
at	O
Days	O
8	O
and	O
15	O
were	O
significantly	O
lower	O
in	O
the	O
risedronate	O
group	O
than	O
in	O
the	O
alendronate	O
group	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Mean	Others
esophageal	Others
and	Others
duodenal	Others
endoscopy	Others
scores	Others
were	O
similar	O
in	O
the	O
2	O
groups	O
at	O
Days	O
8	O
and	O
15	O
.	O

When	O
the	O
treatment	O
groups	O
were	O
combined	O
,	O
gastric	Others
endoscopy	Others
scores	Others
were	O
significantly	O
higher	O
among	O
H.	O
pylori	O
negative	O
than	O
H.	O
pylori	O
positive	O
subjects	O
at	O
Days	O
8	O
and	O
15	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Upper	Adverseeffect
GI	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
were	O
reported	O
by	O
18	O
(	O
5.7	O
%	O
)	O
subjects	O
in	O
the	O
risedronate	O
group	O
(	O
19	O
events	O
)	O
and	O
28	O
(	O
8.8	O
%	O
)	O
subjects	O
in	O
the	O
alendronate	O
group	O
(	O
32	O
events	O
)	O
.	O

Symptoms	O
did	O
not	O
predict	O
the	O
presence	O
of	O
mucosal	O
damage	O
.	O

CONCLUSION	O
Risedronate	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
incidence	O
of	O
gastric	O
ulcers	O
than	O
alendronate	O
.	O

H.	O
pylori	O
infection	O
did	O
not	O
increase	O
the	O
incidence	O
of	O
bisphosphonate	O
related	O
gastric	O
ulcers	O
.	O

The	O
findings	O
from	O
this	O
14	O
day	O
study	O
in	O
healthy	O
volunteers	O
support	O
the	O
hypothesis	O
that	O
bisphosphonates	O
may	O
differ	O
from	O
one	O
another	O
in	O
their	O
potential	O
to	O
produce	O
upper	O
GI	O
mucosal	O
damage	O
.	O

Cost	O
effectiveness	O
of	O
training	O
incontinent	O
elderly	O
in	O
nursing	O
homes	O
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

This	O
study	O
used	O
a	O
randomized	O
clinical	O
trial	O
with	O
133	O
incontinent	O
elderly	O
in	O
seven	O
nursing	O
homes	O
to	O
evaluate	O
the	O
effectiveness	Others
of	O
a	O
behavioral	O
training	O
therapy	O
and	O
its	O
cost	O
implications	O
.	O

The	O
training	O
program	O
lasted	O
three	O
months	O
,	O
and	O
a	O
22-week	O
follow-up	O
period	O
examined	O
the	O
durability	O
of	O
the	O
treatment	O
effect	O
.	O

The	O
therapy	O
became	O
effective	O
after	O
six	O
weeks	O
of	O
training	O
.	O

By	O
the	O
final	O
months	O
of	O
training	O
,	O
the	O
treatment	O
participants	O
'	O
wet	Physical
episodes	Physical
had	O
been	O
reduced	O
by	O
0.6	O
episode	O
per	O
day	O
,	O
or	O
a	O
26	O
percent	O
reduction	O
over	O
baseline	O
,	O
and	O
improvement	O
was	O
maintained	O
during	O
the	O
follow-up	O
period	O
.	O

Trainees	O
with	O
a	O
high	O
frequency	O
of	O
incontinence	O
during	O
baseline	O
,	O
relatively	O
more	O
cognitive	O
residents	O
,	O
and	O
residents	O
with	O
a	O
normal	O
bladder	O
capacity	O
responded	O
better	O
to	O
this	O
behavioral	O
program	O
.	O

The	O
cost	Others
of	Others
training	Others
was	O
the	O
equivalent	O
of	O
about	O
one	O
hour	O
of	O
nursing	O
aide	O
time	O
per	O
patient	O
day	O
.	O

The	O
reduction	O
in	O
incontinence	Physical
during	O
the	O
follow-up	O
period	O
resulted	O
in	O
some	O
small	Others
savings	Others
in	Others
laundry	Others
costs	Others
and	Others
supplies	Others
used	Others
,	O
and	O
some	O
quantitatively	O
unmeasurable	O
but	O
detectable	O
improvement	Mental
in	Mental
psychosocial	Mental
well-being	Mental
among	O
the	O
trainees	O
.	O

Since	O
the	O
central	O
figure	O
in	O
implementing	O
this	O
training	O
protocol	O
is	O
the	O
nursing	O
aide	O
,	O
it	O
is	O
important	O
to	O
find	O
an	O
organizational	O
management	O
scheme	O
that	O
will	O
stimulate	O
nursing	O
aides	O
to	O
reduce	O
incontinence	O
among	O
nursing	O
home	O
residents	O
.	O

Fluvoxamine	O
as	O
effective	O
as	O
clomipramine	O
against	O
symptoms	O
of	O
severe	Mental
depression	Mental
:	O
results	O
from	O
a	O
multicentre	O
,	O
double-blind	O
study	O
.	O

BACKGROUND	O
Although	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
are	O
better	O
tolerated	O
than	O
tricyclic	O
antidepressants	O
,	O
their	O
efficacy	Others
in	O
severe	O
depression	O
remains	O
to	O
be	O
further	O
elucidated	O
.	O

METHOD	O
A	O
double-blind	O
,	O
multicentre	O
study	O
was	O
conducted	O
in	O
86	O
severely	O
depressed	O
inpatients	O
(	O
>	O
or=	O
25	O
on	O
the	O
17-item	Mental
Hamilton	Mental
depression	Mental
rating	Mental
scale	Mental
[	Mental
HAMD	Mental
]	Mental
total	Mental
score	Mental
)	Mental
to	O
compare	O
the	O
efficacy	Others
and	O
safety	Others
of	O
fluvoxamine	O
with	O
that	O
of	O
clomipramine	O
.	O

Following	O
placebo	O
run-in	O
,	O
86	O
patients	O
were	O
randomised	O
to	O
receive	O
fluvoxamine	O
or	O
clomipramine	O
(	O
100-250	O
mg/day	O
)	O
for	O
8	O
weeks	O
.	O

RESULTS	O
Fluvoxamine	O
and	O
clomipramine	O
both	O
resulted	O
in	O
marked	O
improvements	Others
;	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
them	O
on	O
the	O
17-item	Mental
HAMD	Mental
total	Mental
score	Mental
,	O
the	O
clinical	Mental
global	Mental
impression	Mental
severity	Mental
of	Mental
illness	Mental
or	O
global	Mental
improvement	Mental
items	Mental
or	Mental
the	Mental
Montgomery-Asberg	Mental
depression	Mental
rating	Mental
scale	Mental
,	O
at	O
any	O
visit	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
71	O
%	O
in	O
the	O
fluvoxamine	O
group	O
and	O
69	O
%	O
in	O
the	O
clomipramine	O
group	O
were	O
responders	O
(	O
>	O
or=	O
50	O
%	O
decrease	O
in	O
17-item	Mental
HAMD	Mental
total	Mental
score	Mental
)	Mental
.	O

However	O
,	O
fluvoxamine	O
was	O
better	O
tolerated	Others
than	O
clomipramine	O
.	O

Clomipramine	O
was	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
overall	O
and	O
treatment-related	O
adverse	Adverseeffect
events	Adverseeffect
.	O

In	O
addition	O
,	O
the	O
percentage	O
of	O
patients	O
discontinued	Others
prematurely	Others
due	O
to	O
adverse	Adverseeffect
events	Adverseeffect
was	O
more	O
than	O
twice	O
as	O
high	O
with	O
clomipramine	O
than	O
with	O
fluvoxamine	O
(	O
24	O
%	O
vs	O
11	O
%	O
)	O
.	O

CONCLUSION	O
Fluvoxamine	O
and	O
clomipramine	O
are	O
equally	O
effective	O
in	O
severe	O
depression	O
,	O
but	O
fluvoxamine	O
has	O
a	O
better	O
safety	Others
and	O
tolerability	Others
profile	O
.	O

Acupuncture	O
versus	O
venlafaxine	O
for	O
the	O
management	O
of	O
vasomotor	Physical
symptoms	Physical
in	O
patients	O
with	O
hormone	O
receptor-positive	O
breast	O
cancer	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

PURPOSE	O
Vasomotor	Physical
symptoms	Physical
are	O
common	O
adverse	O
effects	O
of	O
antiestrogen	O
hormone	O
treatment	O
in	O
conventional	O
breast	O
cancer	O
care	O
.	O

Hormone	O
replacement	O
therapy	O
is	O
contraindicated	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Venlafaxine	O
(	O
Effexor	O
)	O
,	O
the	O
therapy	O
of	O
choice	O
for	O
these	O
symptoms	O
,	O
has	O
numerous	O
adverse	O
effects	O
.	O

Recent	O
studies	O
suggest	O
acupuncture	O
may	O
be	O
effective	O
in	O
reducing	O
vasomotor	Physical
symptoms	Physical
in	O
menopausal	O
women	O
.	O

This	O
randomized	O
controlled	O
trial	O
tested	O
whether	O
acupuncture	O
reduces	O
vasomotor	Physical
symptoms	Physical
and	O
produces	O
fewer	O
adverse	O
effects	O
than	O
venlafaxine	O
.	O

PATIENTS	O
AND	O
METHODS	O
Fifty	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
12	O
weeks	O
of	O
acupuncture	O
(	O
n	O
=	O
25	O
)	O
or	O
venlafaxine	O
(	O
n	O
=	O
25	O
)	O
treatment	O
.	O

Health	Physical
outcomes	Physical
were	O
measured	O
for	O
up	O
to	O
1	O
year	O
post-treatment	O
.	O

RESULTS	O
Both	O
groups	O
exhibited	O
significant	O
decreases	O
in	O
hot	Physical
flashes	Physical
,	Physical
depressive	Physical
symptoms	Physical
,	Physical
and	Physical
other	Physical
quality-of-life	Physical
symptoms	Physical
,	O
including	O
significant	O
improvements	O
in	O
mental	Mental
health	Mental
from	O
pre-	O
to	O
post-treatment	O
.	O

These	O
changes	O
were	O
similar	O
in	O
both	O
groups	O
,	O
indicating	O
that	O
acupuncture	O
was	O
as	O
effective	O
as	O
venlafaxine	O
.	O

By	O
2	O
weeks	O
post-treatment	O
,	O
the	O
venlafaxine	O
group	O
experienced	O
significant	O
increases	O
in	O
hot	Physical
flashes	Physical
,	O
whereas	O
hot	O
flashes	O
in	O
the	O
acupuncture	O
group	O
remained	O
at	O
low	O
levels	O
.	O

The	O
venlafaxine	O
group	O
experienced	O
18	O
incidences	O
of	O
adverse	O
effects	O
(	O
eg	O
,	O
nausea	Physical
,	Physical
dry	Physical
mouth	Physical
,	Physical
dizziness	Physical
,	Physical
anxiety	Physical
)	O
,	O
whereas	O
the	O
acupuncture	O
group	O
experienced	O
no	O
negative	O
adverse	O
effects	O
.	O

Acupuncture	O
had	O
the	O
additional	O
benefit	O
of	O
increased	O
sex	Physical
drive	Physical
in	O
some	O
women	O
,	O
and	O
most	O
reported	O
an	O
improvement	O
in	O
their	O
energy	Mental
,	Mental
clarity	Mental
of	Mental
thought	Mental
,	Mental
and	Mental
sense	Mental
of	Mental
well-being	Mental
.	O

CONCLUSION	O
Acupuncture	O
appears	O
to	O
be	O
equivalent	O
to	O
drug	O
therapy	O
in	O
these	O
patients	O
.	O

It	O
is	O
a	O
safe	O
,	O
effective	O
and	O
durable	O
treatment	O
for	O
vasomotor	O
symptoms	O
secondary	O
to	O
long-term	O
antiestrogen	O
hormone	O
use	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

Effects	O
of	O
guided	O
imagery	O
with	O
relaxation	O
training	O
on	O
anxiety	Mental
and	O
quality	Mental
of	Mental
life	Mental
among	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

BACKGROUND	O
Inflammatory	O
Bowel	O
Disease	O
(	O
IBD	O
)	O
impacts	O
quality	Others
of	Others
life	Others
(	O
QoL	O
)	O
.	O

Psychological	O
factors	O
influence	O
the	O
course	O
of	O
the	O
disease	O
and	O
should	O
be	O
targeted	O
for	O
intervention	O
.	O

METHODS	O
Our	O
study	O
was	O
a	O
prospective	O
,	O
randomised	O
control	O
trial	O
.	O

Fifty-six	O
outpatients	O
were	O
randomly	O
chosen	O
and	O
allocated	O
to	O
a	O
treatment	O
group	O
or	O
a	O
waiting-list	O
control	O
group	O
.	O

Treatment	O
group	O
patients	O
attended	O
three	O
relaxation-training	O
sessions	O
and	O
received	O
an	O
audio	O
disc	O
for	O
home	O
practice	O
.	O

Evaluations	O
performed	O
pre	O
and	O
post-treatment	O
:	O
state	Mental
anxiety	Mental
was	O
assessed	O
with	O
the	O
State-Trait	Mental
Anxiety	Mental
Inventory	Mental
,	Mental
QoL	Mental
with	Mental
the	Mental
IBD	Mental
Questionnaire	Mental
.	O

The	O
Visual	Others
Analogue	Others
Scale	Others
assessed	O
pain	Pain
,	O
depression	Mental
,	O
stress	Mental
and	O
mood	Mental
.	O

Patients	O
completed	O
a	O
symptom	O
monitoring	O
diary	O
.	O

The	O
control	O
group	O
's	O
symptoms	O
were	O
monitored	O
without	O
study-related	O
treatment	O
.	O

RESULTS	O
Thirty-nine	O
subjects	O
completed	O
the	O
study	O
and	O
were	O
included	O
in	O
the	O
data	O
analysis	O
.	O

Following	O
the	O
relaxation-training	O
intervention	O
,	O
the	O
treatment	O
group	O
's	O
(	O
n	O
=	O
18	O
)	O
measured	O
results	O
showed	O
a	O
statistically	O
significant	O
improvement	O
as	O
compared	O
to	O
the	O
control	O
group	O
(	O
n	O
=	O
21	O
)	O
(	O
time	O
by	O
treatment	O
interaction	O
)	O
:	O
anxiety	O
levels	O
decreased	O
(	O
p	O
<	O
0.01	O
)	O
,	O
QoL	O
and	O
mood	O
improved	O
(	O
p	O
<	O
0.05	O
)	O
,	O
while	O
levels	O
of	O
pain	O
and	O
stress	O
decreased	O
(	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
Findings	O
indicate	O
IBD	O
patients	O
may	O
benefit	O
from	O
relaxation	O
training	O
in	O
their	O
holistic	O
care	O
.	O

New	O
studies	O
as	O
well	O
as	O
further	O
investigation	O
of	O
the	O
subject	O
are	O
warranted	O
.	O

Ongoing	O
Telmisartan	O
Alone	O
and	O
in	O
Combination	O
With	O
Ramipril	O
Global	O
Endpoint	O
Trial	O
(	O
ONTARGET	O
)	O
:	O
implications	O
for	O
reduced	O
cardiovascular	Physical
risk	Physical
.	O

The	O
recently	O
published	O
Ongoing	O
Telmisartan	O
Alone	O
and	O
in	O
Combination	O
With	O
Ramipril	O
Global	O
Endpoint	O
Trial	O
(	O
ONTARGET	O
)	O
in	O
patients	O
with	O
vascular	O
disease	O
or	O
high-risk	O
diabetes	O
,	O
as	O
the	O
largest	O
published	O
comparative	O
trial	O
of	O
these	O
agent	O
classes	O
,	O
provides	O
further	O
evidence	O
concerning	O
the	O
comparison	O
between	O
the	O
angiotensin-receptor	O
blockers	O
(	O
ARBs	O
)	O
and	O
the	O
angiotensin-converting	O
enzyme	O
inhibitors	O
(	O
ACEIs	O
)	O
.	O

In	O
this	O
trial	O
,	O
telmisartan	O
(	O
an	O
ARB	O
)	O
was	O
non-inferior	O
to	O
ramipril	O
(	O
an	O
ACEI	O
)	O
in	O
reducing	O
fatal	Physical
and	Physical
nonfatal	Physical
cardiovascular	Physical
events	Physical
.	O

Moreover	O
,	O
ONTARGET	O
is	O
an	O
example	O
of	O
a	O
high-quality	O
noninferiority	O
trial	O
.	O

However	O
,	O
the	O
combination	O
of	O
the	O
2	O
agents	O
was	O
associated	O
with	O
more	O
adverse	Adverseeffect
effects	Adverseeffect
without	O
an	O
increase	O
in	O
benefit	O
.	O

The	O
study	O
differed	O
from	O
several	O
other	O
comparative	O
studies	O
in	O
which	O
the	O
dose	O
and	O
choice	O
of	O
ACEI	O
was	O
left	O
to	O
individual	O
physicians	O
.	O

Further	O
,	O
in	O
ONTARGET	O
,	O
the	O
ACEI	O
was	O
not	O
titrated	O
to	O
the	O
maximum	O
dose	O
and	O
patients	O
with	O
heart	O
failure	O
were	O
excluded	O
.	O

Treatment	O
effects	O
of	O
eptifibatide	O
in	O
planned	O
coronary	O
stent	O
implantation	O
in	O
patients	O
with	O
chronic	O
kidney	O
disease	O
(	O
ESPRIT	O
Trial	O
)	O
.	O

The	O
role	O
of	O
platelet	O
glycoprotein	O
IIb/IIIa	O
inhibitor	O
therapy	O
in	O
patients	O
with	O
mild	O
renal	O
impairment	O
is	O
not	O
well	O
characterized	O
.	O

Our	O
objective	O
was	O
to	O
explore	O
the	O
associations	Others
of	Others
creatinine	Others
clearance	Others
(	Others
CrCl	Others
)	Others
with	O
outcomes	O
in	O
a	O
trial	O
of	O
eptifibatide	O
therapy	O
in	O
patients	O
who	O
underwent	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

We	O
analyzed	O
48-hour	O
and	O
30-day	O
outcomes	O
of	O
patients	O
enrolled	O
in	O
the	O
Enhanced	O
Suppression	O
of	O
the	O
Platelet	O
IIb/IIIa	O
Receptor	O
with	O
Integrilin	O
Therapy	O
(	O
ESPRIT	O
)	O
trial	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
placebo	O
or	O
eptifibatide	O
as	O
an	O
adjunct	O
to	O
stent	O
implantation	O
(	O
1,755	O
with	O
CrCl	O
>	O
or	O
=60	O
ml/min	O
and	O
289	O
with	O
CrCl	O
<	O
60	O
ml/min	O
)	O
.	O

CrCl	Physical
was	O
calculated	O
using	O
the	Others
Cockcroft	Others
and	Others
Gault	Others
formula	Others
,	O
and	O
the	O
associations	O
of	O
CrCl	Physical
with	O
outcomes	O
were	O
evaluated	O
using	O
logistic	Others
regression	Others
models	Others
.	O

Patients	O
with	O
CrCl	O
<	O
60	O
ml/min	O
were	O
more	O
likely	O
to	O
be	O
older	O
,	O
women	O
,	O
hypertensive	O
,	O
and	O
have	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
surgery	O
,	O
stroke	O
,	O
or	O
peripheral	O
vascular	O
disease	O
.	O

The	O
interaction	O
of	O
eptifibatide	O
with	O
CrCl	O
had	O
borderline	O
significance	O
for	O
the	O
30-day	O
outcome	O
(	O
p	O
=	O
0.109	O
)	O
.	O

Treatment	O
effect	O
trended	O
toward	O
a	O
greater	O
magnitude	O
in	O
patients	O
with	O
lower	O
CrCl	O
(	O
60	O
ml/min	O
)	O
(	O
odds	O
ratio	O
0.53	O
,	O
confidence	O
interval	O
0.34	O
to	O
0.83	O
)	O
compared	O
with	O
those	O
with	O
higher	O
CrCl	O
(	O
90	O
ml/min	O
)	O
(	O
odds	O
ratio	O
0.68	O
,	O
confidence	O
interval	O
0.49	O
to	O
0.94	O
)	O
.	O

An	O
accompanying	O
increase	O
in	O
bleeding	Adverseeffect
risk	Adverseeffect
also	O
was	O
not	O
apparent	O
with	O
lower	O
CrCl	O
.	O

The	O
treatment	O
effect	O
of	O
eptifibatide	O
is	O
realized	O
regardless	O
of	O
renal	O
function	O
and	O
trends	O
toward	O
being	O
greater	O
in	O
patients	O
with	O
mild	O
renal	Physical
impairment	Physical
.	O

[	O
Clinical	O
observation	O
on	O
effect	O
of	O
fuzheng	O
yiliu	O
granule	O
on	O
cell	O
cycle	O
and	O
nuclear	O
transcription	O
factor-kappa	O
B	O
in	O
tissue	O
of	O
esophageal-gastric	O
carcinoma	O
]	O
.	O

OBJECTIVE	O
To	O
observe	O
the	O
effect	O
of	O
Fuzheng	O
Yiliu	O
Granule	O
(	O
FZYLG	O
)	O
on	O
cell	O
cycle	O
and	O
nuclear	O
transcription	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
in	O
tissue	O
of	O
esophageal-gastric	O
carcinoma	O
.	O

METHODS	O
Seventy-six	O
patients	O
with	O
esophageal	O
gastric	O
carcinoma	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
,	O
the	O
FZYLG	O
group	O
and	O
the	O
control	O
group	O
.	O

FZYLG	O
was	O
given	O
to	O
the	O
former	O
for	O
15	O
days	O
.	O

The	O
tumor	O
tissue	O
in	O
both	O
groups	O
was	O
resected	O
and	O
cell	Physical
cycle	Physical
and	O
apoptosis	Physical
rate	Physical
as	O
well	O
as	O
NF-kappa	O
B	O
were	O
determined	O
by	O
flowcytometry	O
.	O

RESULTS	O
Level	Physical
of	Physical
NF-kappa	Physical
B	Physical
in	O
the	O
treated	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

In	O
the	O
treated	O
group	O
,	O
the	O
percentage	Physical
of	Physical
G0/G1	Physical
stage	Physical
cells	Physical
were	O
significantly	O
increased	O
and	O
that	O
of	O
S	Physical
stage	Physical
significantly	O
decreased	O
(	O
both	O
P	O
<	O
0.05	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
obvious	O
cell	Physical
apoptosis	Physical
was	O
found	O
in	O
the	O
treated	O
group	O
,	O
the	O
apoptosis	Physical
rate	O
of	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
FZYLG	O
can	O
increase	O
the	O
NF-kappa	O
B	O
expression	O
,	O
block	O
the	O
proliferation	O
to	O
promote	O
the	O
apoptosis	Physical
of	O
tumor	O
cells	O
.	O

The	O
influence	O
of	O
fidelity	Others
of	Others
implementation	Others
on	O
teacher-student	Mental
interaction	Mental
quality	Mental
in	O
the	O
context	O
of	O
a	O
randomized	O
controlled	O
trial	O
of	O
the	O
Responsive	O
Classroom	O
approach	O
.	O

This	O
study	O
examined	O
the	O
direct	Others
and	Others
indirect	Others
effects	Others
between	O
training	O
in	O
the	O
Responsive	O
Classroom?	O
(	O
RC	O
)	O
approach	O
,	O
teachers	O
'	O
uptake	O
of	O
RC	O
practices	O
,	O
and	O
teacher-student	O
interaction	O
quality	O
,	O
using	O
a	O
structural	O
equation	O
modeling	O
framework	O
.	O

A	O
total	O
of	O
24	O
schools	O
were	O
randomly	O
assigned	O
to	O
experimental	O
or	O
control	O
conditions	O
.	O

Third-	O
and	O
fourth-grade	O
teachers	O
in	O
treatment	O
schools	O
(	O
n=132	O
)	O
received	O
training	O
in	O
the	O
RC	O
approach	O
,	O
whereas	O
teachers	O
in	O
control	O
schools	O
(	O
n=107	O
)	O
continued	O
business	O
as	O
usual	O
.	O

Observers	O
rated	O
teachers	O
'	O
fidelity	O
of	O
implementation	O
(	O
FOI	O
)	O
of	O
RC	O
practices	O
5	O
times	O
throughout	O
the	O
year	O
using	O
the	O
Classroom	O
Practices	O
Observation	O
Measure	O
.	O

In	O
addition	O
,	O
teachers	O
completed	O
self-report	O
measures	O
of	O
FOI	O
,	O
the	O
Classroom	O
Practices	O
Teacher	O
Survey	O
and	O
Classroom	O
Practices	O
Frequency	O
Survey	O
,	O
at	O
the	O
end	O
of	O
the	O
school	O
year	O
.	O

Teacher-student	O
interactions	O
were	O
rated	O
during	O
classroom	O
observations	O
using	O
the	O
Classroom	O
Assessment	O
Scoring	O
System	O
.	O

Controlling	O
for	O
teachers	O
'	O
grade	O
level	O
and	O
teacher-student	O
interaction	O
quality	O
at	O
pretest	O
,	O
RC	O
training	O
was	O
expected	O
to	O
predict	O
posttest	O
teacher-student	O
interaction	O
quality	O
directly	O
and	O
indirectly	O
through	O
FOI	O
.	O

Results	O
supported	O
only	O
a	O
significant	O
indirect	O
effect	O
,	O
?=0.85	O
,	O
p=.002	O
.	O

Specifically	O
,	O
RC	O
teachers	O
had	O
higher	O
levels	O
of	O
FOI	O
of	O
RC	O
practices	O
,	O
?=1.62	O
,	O
p	O
<	O
.001	O
,	O
R2=.69	O
.	O

In	O
turn	O
,	O
FOI	O
related	O
to	O
greater	O
improvement	O
in	O
teacher-student	O
interaction	O
quality	O
,	O
?=0.52	O
,	O
p=.001	O
,	O
R2=.32	O
.	O

Discussion	O
highlights	O
factors	O
contributing	O
to	O
variability	O
in	O
FOI	O
and	O
school	O
administrators	O
roles	O
in	O
supporting	O
FOI	O
.	O

Effect	O
of	O
ginseng	O
extract	O
supplementation	O
on	O
testicular	Physical
functions	Physical
in	O
diabetic	O
rats	O
.	O

OBJECTIVE	O
It	O
was	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
standardized	O
ginseng	O
extract	O
on	O
fertility	Physical
parameters	Physical
in	O
diabetic	O
rats	O
.	O

METHODS	O
Thirty	O
male	O
rats	O
were	O
randomly	O
allocated	O
into	O
three	O
groups	O
of	O
10	O
rats	O
each	O
:	O
1.	O
controls	O
,	O
2.	O
diabetes	O
(	O
D	O
)	O
and	O
3.	O
diabetes	O
+	O
ginseng	O
(	O
DG	O
)	O
.	O

The	O
latter	O
two	O
groups	O
were	O
rendered	O
diabetic	O
by	O
i.p	O
.	O

injection	O
of	O
streptozotocin	O
(	O
STZ	O
;	O
50	O
mg/kg	O
)	O
.	O

Standardized	O
ginseng	O
extract	O
(	O
Dansk	O
Droge	O
A/S	O
,	O
Copenhagen	O
,	O
Denmark	O
)	O
was	O
administered	O
per	O
os	O
(	O
100	O
mg/kg	O
BW	O
)	O
by	O
stomach	O
tube	O
daily	O
for	O
90	O
days	O
starting	O
one	O
week	O
after	O
STZ	O
.	O

Ninety	O
days	O
post	O
STZ	O
the	O
rats	O
were	O
sacrificed	O
,	O
and	O
testis	Physical
,	Physical
epididymis	Physical
,	Physical
prostate	Physical
,	Physical
and	Physical
seminal	Physical
vesicles	Physical
were	Physical
weighed	Physical
and	Physical
subjected	Physical
to	Physical
histological	Physical
examination	Physical
.	Physical

In	O
addition	O
,	O
spermiogram	Physical
,	Physical
testicular	Physical
enzyme	Physical
markers	Physical
,	Physical
intratesticular	Physical
steroid	Physical
hormonal	Physical
profile	Physical
and	Physical
testicular	Physical
antioxidant	Physical
status	Physical
were	O
estimated	O
.	O

RESULTS	O
The	O
administration	O
of	O
ginseng	O
extract	O
resulted	O
in	O
a	O
significant	O
improvement	O
of	O
fertility	Physical
parameters	Physical
and	Physical
testicular	Physical
antioxidants	Physical
together	Physical
with	O
a	O
decrease	Physical
in	Physical
malondialdehyde	Physical
and	Physical
testicular	Physical
pathological	Physical
signs	Physical
including	Physical
degenerative	Physical
changes	Physical
of	Physical
the	Physical
seminiferous	Physical
tubules	Physical
.	Physical

CONCLUSION	O
Ginseng	O
extract	O
may	O
be	O
a	O
beneficial	O
adjuvant	O
therapy	O
for	O
diabetics	O
suffering	O
from	O
infertility	Physical
as	O
a	O
complication	O
.	O

Effect	O
of	O
treatment	O
with	O
paromomycin	O
on	O
endotoxemia	Physical
in	O
patients	O
with	O
alcoholic	O
liver	O
disease	O
--	O
a	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

The	O
results	O
of	O
experimental	O
and	O
clinical	O
studies	O
support	O
the	O
hypothesis	O
that	O
gut-derived	O
endotoxins	O
might	O
be	O
of	O
relevance	O
for	O
the	O
development	O
and	O
course	O
of	O
alcoholic	O
liver	O
disease	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
the	O
effect	O
of	O
a	O
nonabsorbable	O
,	O
broad-spectrum	O
antibiotic	O
on	O
endotoxemia	Physical
in	O
patients	O
with	O
alcoholic	O
liver	O
disease	O
.	O

Fifty	O
patients	O
with	O
alcoholic	O
liver	O
disease	O
(	O
27	O
with	O
cirrhosis	O
,	O
23	O
without	O
cirrhosis	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
paromomycin	O
sulfate	O
(	O
3	O
x	O
1	O
g/day	O
)	O
or	O
placebo	O
in	O
a	O
double-blind	O
fashion	O
for	O
at	O
least	O
3	O
weeks	O
,	O
and	O
if	O
possible	O
4	O
weeks	O
.	O

Endotoxin	Physical
concentration	Physical
,	O
liver	Physical
function	Physical
tests	Physical
,	O
and	O
other	O
laboratory	O
parameters	O
were	O
determined	O
in	O
weekly	O
intervals	O
.	O

Endotoxin	Physical
concentration	Physical
was	O
also	O
determined	O
in	O
15	O
healthy	O
controls	O
.	O

Groups	O
receiving	O
paromomycin	O
or	O
placebo	O
were	O
similar	O
for	O
clinical	O
and	O
biological	O
items	O
collected	O
initially	O
.	O

Mean	Physical
initial	Physical
endotoxin	Physical
concentrations	Physical
were	O
significantly	O
elevated	O
in	O
both	O
groups	O
(	O
mean	O
+/-	O
SEM	O
;	O
paromomycin	O
,	O
16.7	O
+/-	O
5.3	O
pg/ml	O
;	O
placebo	O
,	O
17.5	O
+/-	O
6.9	O
pg/ml	O
;	O
healthy	O
controls	O
,	O
2.3	O
+/-	O
0.4	O
pg/ml	O
)	O
.	O

Although	O
the	O
mean	Physical
endotoxin	Physical
concentration	Physical
was	O
lower	O
in	O
the	O
verum	O
group	O
after	O
1	O
week	O
(	O
paromomycin	O
,	O
8.0	O
+/-	O
1.9	O
pg/ml	O
;	O
placebo	O
,	O
14.6	O
+/-	O
3.5	O
pg/ml	O
;	O
p	O
>	O
0.05	O
)	O
,	O
paromomycin	O
treatment	O
had	O
no	O
significant	O
effect	O
on	O
endotoxin	Physical
concentration	Physical
or	O
liver	Physical
function	Physical
tests	Physical
during	O
the	O
4-week	O
period	O
.	O

The	O
beneficial	O
effect	O
of	O
paromomycin	O
treatment	O
on	O
endotoxemia	Physical
in	O
cirrhotics	O
reported	O
in	O
earlier	O
studies	O
could	O
not	O
be	O
reproduced	O
under	O
the	O
conditions	O
of	O
this	O
trial	O
in	O
patients	O
with	O
alcoholic	O
liver	O
disease	O
.	O

Effects	O
of	O
statins	O
on	O
progression	O
of	O
subclinical	Physical
brain	Physical
infarct	Physical
.	O

BACKGROUND	O
Subclinical	Physical
brain	Physical
infarct	Physical
(	Physical
SBI	Physical
)	Physical
is	O
associated	O
with	O
subsequent	O
stroke	O
and	O
cognitive	O
decline	O
.	O

A	O
longitudinal	O
epidemiological	O
study	O
suggests	O
that	O
statins	O
may	O
prevent	O
development	O
of	O
SBI	Physical
.	O

We	O
investigated	O
the	O
effects	O
of	O
statins	O
upon	O
development	Physical
of	Physical
brain	Physical
infarct	Physical
by	O
performing	O
a	O
post-hoc	O
analysis	O
of	O
the	O
Regression	O
of	O
Cerebral	O
Artery	O
Stenosis	O
(	O
ROCAS	O
)	O
study	O
.	O

METHODS	O
The	O
ROCAS	O
study	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
evaluating	O
the	O
effects	O
of	O
simvastatin	O
20	O
mg	O
daily	O
upon	O
progression	O
of	O
asymptomatic	O
middle	O
cerebral	O
artery	O
stenosis	O
among	O
stroke-free	O
individuals	O
over	O
2	O
years	O
.	O

A	O
total	O
of	O
227	O
subjects	O
were	O
randomized	O
to	O
either	O
placebo	O
(	O
n	O
=	O
114	O
)	O
or	O
simvastatin	O
20	O
mg	O
daily	O
(	O
n	O
=	O
113	O
)	O
.	O

The	O
number	Physical
of	Physical
brain	Physical
infarcts	Physical
as	O
detected	O
by	O
MRI	O
was	O
recorded	O
at	O
baseline	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
number	Physical
of	Physical
new	Physical
brain	Physical
infarcts	Physical
at	O
the	O
end	O
of	O
the	O
study	O
.	O

RESULTS	O
Among	O
the	O
227	O
randomized	O
subjects	O
,	O
33	O
(	O
14.5	O
%	O
)	O
had	O
SBI	O
at	O
baseline	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
significantly	O
fewer	O
subjects	O
in	O
the	O
active	O
group	O
(	O
n	O
=	O
1	O
)	O
had	O
new	Physical
brain	Physical
infarcts	Physical
compared	O
with	O
the	O
placebo	O
group	O
(	O
n	O
=	O
8	O
;	O
p	O
=	O
0.018	O
)	O
.	O

The	O
new	O
brain	Physical
infarcts	Physical
of	O
subjects	O
in	O
the	O
active	O
group	O
were	O
subclinical	O
.	O

Among	O
the	O
placebo	O
group	O
,	O
the	O
new	O
brain	Physical
infarcts	Physical
of	O
3	O
subjects	O
were	O
symptomatic	O
while	O
those	O
of	O
the	O
remaining	O
5	O
subjects	O
were	O
subclinical	O
.	O

Among	O
putative	O
variables	O
,	O
multivariate	O
regression	O
analysis	O
showed	O
that	O
only	O
the	O
baseline	O
number	O
of	O
SBIs	Physical
(	O
OR	O
=	O
6.27	O
,	O
95	O
%	O
CI	O
2.4-16.5	O
)	O
and	O
simvastatin	O
treatment	O
(	O
OR	O
=	O
0.09	O
,	O
95	O
%	O
CI	O
0.01-0.82	O
)	O
independently	O
predicted	O
the	O
development	O
of	O
new	O
brain	O
infarcts	O
.	O

CONCLUSIONS	O
Consistent	O
with	O
findings	O
of	O
the	O
epidemiological	O
study	O
,	O
our	O
study	O
suggests	O
that	O
statins	O
may	O
prevent	O
the	O
development	O
of	O
a	O
new	O
brain	Physical
infarct	Physical
.	O

A	O
pilot	O
study	O
of	O
a	O
low-tilt	O
biphasic	O
waveform	O
for	O
transvenous	O
cardioversion	O
of	O
atrial	O
fibrillation	O
:	O
improved	O
efficacy	Others
compared	O
with	O
conventional	O
capacitor-based	O
waveforms	O
in	O
patients	O
.	O

BACKGROUND	O
The	O
optimal	O
waveform	O
tilt	O
for	O
defibrillation	O
is	O
not	O
known	O
.	O

Most	O
modern	O
defibrillators	O
used	O
for	O
the	O
cardioversion	O
of	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
employ	O
high-tilt	O
,	O
capacitor-based	O
biphasic	O
waveforms	O
.	O

METHODS	O
We	O
have	O
developed	O
a	O
low-tilt	O
biphasic	O
waveform	O
for	O
defibrillation	O
.	O

This	O
low-tilt	O
waveform	O
was	O
compared	O
with	O
a	O
conventional	O
waveform	O
of	O
equivalent	O
duration	O
and	O
voltage	O
in	O
patients	O
with	O
AF	O
.	O

Patients	O
with	O
persistent	O
AF	O
or	O
AF	O
induced	O
during	O
a	O
routine	O
electrophysiology	O
study	O
(	O
EPS	O
)	O
were	O
randomized	O
to	O
receive	O
either	O
the	O
low-tilt	O
waveform	O
or	O
a	O
conventional	O
waveform	O
.	O

Defibrillation	O
electrodes	O
were	O
positioned	O
in	O
the	O
right	O
atrial	O
appendage	O
and	O
distal	O
coronary	O
sinus	O
.	O

Phase	O
1	O
peak	O
voltage	O
was	O
increased	O
in	O
a	O
stepwise	O
progression	O
from	O
50	O
V	O
to	O
300V	O
.	O

Shock	O
success	O
was	O
defined	O
as	O
return	Physical
of	Physical
sinus	Physical
rhythm	Physical
for	O
>	O
/=30	O
seconds	O
.	O

RESULTS	O
The	O
low-tilt	O
waveform	O
produced	O
successful	O
termination	Physical
of	Physical
persistent	Physical
AF	Physical
at	O
a	O
mean	O
voltage	O
of	O
223	O
V	O
(	O
8.2	O
J	O
)	O
versus	O
270	O
V	O
(	O
6.7	O
J	O
)	O
with	O
the	O
conventional	O
waveform	O
(	O
P	O
=	O
0.002	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O

In	O
patients	O
with	O
induced	O
AF	O
the	O
mean	Others
voltage	Others
for	O
the	O
low-tilt	O
waveform	O
was	O
91V	O
(	O
1.6	O
J	O
)	O
and	O
for	O
the	O
conventional	O
waveform	O
was	O
158	O
V	O
(	O
2.0	O
J	O
)	O
(	O
P	O
=	O
0.005	O
for	O
voltage	O
,	O
P	O
=	O
ns	O
for	O
energy	O
)	O
.	O

The	O
waveform	O
was	O
much	O
more	O
successful	O
at	O
very	O
low	O
voltages	O
(	O
less	O
than	O
or	O
equal	O
to	O
100	O
V	O
)	O
compared	O
with	O
the	O
conventional	O
waveform	O
(	O
Novel	O
:	O
82	O
%	O
vs	O
Conventional	O
22	O
%	O
,	O
P	O
=	O
0.008	O
)	O
.	O

CONCLUSION	O
The	O
low-tilt	O
biphasic	O
waveform	O
was	O
more	O
successful	O
for	O
the	O
internal	O
cardioversion	O
of	O
both	O
persistent	O
and	O
induced	O
AF	O
in	O
patients	O
(	O
in	O
terms	O
of	O
leading	O
edge	O
voltage	O
)	O
.	O

Comparison	O
of	O
neurocognitive	Mental
functioning	Mental
in	O
children	O
previously	O
randomly	O
assigned	O
to	O
intrathecal	O
methotrexate	O
compared	O
with	O
triple	O
intrathecal	O
therapy	O
for	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
.	O

PURPOSE	O
For	O
the	O
majority	O
of	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
CNS	O
prophylaxis	O
consists	O
of	O
either	O
intrathecal	O
(	O
IT	O
)	O
methotrexate	O
or	O
triple	O
IT	O
therapy	O
(	O
ie	O
,	O
methotrexate	O
with	O
both	O
cytarabine	O
and	O
hydrocortisone	O
)	O
.	O

The	O
long-term	O
neurotoxicities	O
of	O
these	O
two	O
IT	O
strategies	O
have	O
not	O
yet	O
been	O
directly	O
compared	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
multisite	O
study	O
,	O
171	O
children	O
with	O
standard-risk	O
ALL	O
,	O
age	O
1	O
to	O
9.99	O
years	O
at	O
diagnosis	O
,	O
previously	O
randomly	O
assigned	O
to	O
IT	O
methotrexate	O
(	O
n	O
=	O
82	O
)	O
or	O
to	O
triple	O
IT	O
therapy	O
(	O
n	O
=	O
89	O
)	O
on	O
CCG	O
1952	O
,	O
underwent	O
neurocognitive	O
evaluation	O
by	O
a	O
licensed	O
psychologist	O
at	O
a	O
mean	O
of	O
5.9	O
years	O
after	O
random	O
assignment	O
.	O

RESULTS	O
Patients	O
who	O
received	O
IT	O
methotrexate	O
had	O
a	O
mean	Mental
Processing	Mental
Speed	Mental
Index	Mental
that	O
was	O
3.6	O
points	O
lower	O
,	O
about	O
one	O
fourth	O
of	O
a	O
standard	O
deviation	O
,	O
than	O
those	O
who	O
received	O
triple	O
IT	O
therapy	O
(	O
P	O
=	O
.04	O
)	O
after	O
analysis	O
was	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
and	O
time	O
since	O
diagnosis	O
.	O

Likewise	O
,	O
19.5	O
%	O
of	O
children	O
in	O
the	O
IT	O
methotrexate	O
group	O
had	O
a	O
Processing	Mental
Speed	Mental
Index	Mental
score	Mental
in	O
the	O
below-average	O
range	O
compared	O
with	O
6.9	O
%	O
in	O
the	O
triple	O
IT	O
therapy	O
group	O
(	O
P	O
=	O
.02	O
)	O
.	O

Otherwise	O
,	O
the	O
groups	O
performed	O
similarly	O
on	O
tests	Mental
of	Mental
full-scale	Mental
intelligence	Mental
quotient	Mental
,	O
academic	Mental
achievement	Mental
,	O
attention/concentration	Mental
,	O
memory	Mental
,	O
and	O
visual	Mental
motor	Mental
integration	Mental
.	O

The	O
association	O
of	O
treatment	O
with	O
measures	Mental
of	Mental
cognitive	Mental
functioning	Mental
was	O
not	O
modified	O
by	O
sex	O
or	O
age	O
at	O
diagnosis	O
.	O

In	O
the	O
post-therapy	O
period	O
,	O
there	O
were	O
no	O
group	O
differences	O
in	O
special	Mental
education	Mental
services	Mental
,	O
neurologic	Mental
events	Mental
,	O
or	O
use	Mental
of	Mental
psychotropic	Mental
medications	Mental
.	O

CONCLUSION	O
This	O
study	O
did	O
not	O
show	O
any	O
clinically	O
meaningful	O
differences	O
in	O
neurocognitive	Mental
functioning	Mental
between	O
patients	O
previously	O
randomly	O
assigned	O
to	O
IT	O
methotrexate	O
or	O
triple	O
IT	O
therapy	O
except	O
for	O
a	O
small	O
difference	O
in	O
processing	Mental
speed	Mental
in	O
the	O
IT	O
methotrexate	O
group	O
.	O

Effect	O
of	O
acarbose	O
on	O
additional	O
insulin	O
therapy	O
in	O
type	O
2	O
diabetic	O
patients	O
with	O
late	O
failure	O
of	O
sulphonylurea	O
therapy	O
.	O

AIM	O
The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
acarbose	O
on	O
insulin	Physical
requirements	Physical
and	O
glycaemic	Physical
control	Physical
in	O
patients	O
with	O
type	O
2	O
diabetes	O
receiving	O
exogenous	O
insulin	O
due	O
to	O
secondary	O
failure	O
of	O
maximum	O
dose	O
sulphonylurea	O
therapy	O
.	O

METHODS	O
A	O
single-centre	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
study	O
was	O
performed	O
in	O
48	O
type	O
2	O
diabetic	O
patients	O
with	O
late-term	O
failure	O
following	O
at	O
least	O
3	O
years	O
of	O
sulphonylurea	O
therapy	O
requiring	O
additional	O
insulin	O
therapy	O
to	O
determine	O
the	O
impact	O
of	O
acarbose	O
on	O
glycaemic	O
control	O
and	O
insulin	O
requirements	O
.	O

The	O
primary	O
end	O
points	O
were	O
glycaemic	Physical
response	Physical
rate	Physical
(	O
responders	O
being	O
predefined	O
as	O
patients	O
who	O
achieve	O
a	O
decrease	O
in	O
HbA1c	O
to	O
less	O
than	O
8	O
%	O
or	O
a	O
reduction	O
by	O
at	O
least	O
15	O
%	O
as	O
compared	O
to	O
the	O
baseline	O
values	O
)	O
and	O
the	O
daily	Physical
insulin	Physical
dose	Physical
at	O
6	O
months	O
.	O

Secondary	O
parameters	O
assessed	O
included	O
postprandial	Physical
changes	Physical
in	Physical
blood	Physical
glucose	Physical
,	Physical
serum	Physical
insulin	Physical
and	Physical
C-peptide	Physical
during	O
the	O
treatment	O
period	O
.	O

RESULTS	O
There	O
were	O
significantly	O
more	O
responders	O
in	O
the	O
acarbose-treated	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
20/24	O
patients	O
vs.	O
10/19	O
patients	O
;	O
p	O
<	O
0.05	O
)	O
.	O

The	O
mean	Physical
daily	Physical
insulin	Physical
dose	Physical
after	O
24	O
weeks	O
of	O
treatment	O
was	O
16.4	O
+/-	O
10.1	O
IU	O
in	O
the	O
acarbose	O
group	O
and	O
22.4	O
+/-	O
12.2	O
IU	O
in	O
the	O
placebo	O
group	O
(	O
mean	O
+/-	O
s.d	O
.	O

;	O
p	O
<	O
0.07	O
)	O
.	O

Postprandial	Physical
increases	Physical
in	Physical
blood	Physical
glucose	Physical
,	O
insulin	Physical
and	O
C-peptide	Physical
were	O
consistently	O
lower	O
in	O
the	O
acarbose-treated	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

For	O
example	O
,	O
the	O
mean	Physical
increase	Physical
in	Physical
2-h	Physical
postprandial	Physical
serum	Physical
insulin	Physical
remained	O
almost	O
unchanged	O
in	O
the	O
acarbose	O
group	O
at	O
the	O
end	O
of	O
24	O
weeks	O
of	O
treatment	O
compared	O
to	O
an	O
increase	O
to	O
43	O
+/-	O
29	O
microU/ml	O
(	O
mean	O
+/-	O
s.d	O
.	O

)	O
at	O
the	O
end	O
of	O
the	O
study	O
period	O
for	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
the	O
addition	O
of	O
acarbose	O
to	O
sulphonylurea/insulin	O
combination	O
therapy	O
can	O
improve	O
glycaemic	Physical
control	Physical
in	O
type	O
2	O
diabetic	O
patients	O
.	O

Acarbose	O
may	O
also	O
reduce	O
insulin	Physical
resistance	Physical
and	Physical
hyperinsulinaemia	Physical
.	Physical

Clozapine	O
versus	O
placebo	O
in	O
Huntington	O
's	O
disease	O
:	O
a	O
double	O
blind	O
randomised	O
comparative	O
study	O
.	O

OBJECTIVES	O
To	O
establish	O
the	O
effect	O
of	O
the	O
atypical	O
neuroleptic	O
clozapine	O
on	O
chorea	O
,	O
voluntary	O
motor	O
performance	O
,	O
and	O
functional	O
disability	O
in	O
patients	O
with	O
Huntington	O
's	O
disease	O
.	O

METHODS	O
Thirty	O
three	O
patients	O
with	O
Huntington	O
's	O
disease	O
participated	O
in	O
a	O
double	O
blind	O
randomised	O
trial	O
.	O

A	O
maximum	O
of	O
150	O
mg/day	O
clozapine	O
or	O
placebo	O
equivalent	O
was	O
given	O
for	O
a	O
period	O
of	O
31	O
days	O
.	O

Assessments	O
were	O
performed	O
in	O
the	O
week	O
before	O
and	O
at	O
the	O
last	O
day	O
of	O
the	O
trial	O
.	O

Chorea	O
was	O
scored	O
using	O
the	O
abnormal	O
involuntary	O
movement	O
scale	O
(	O
AIMS	O
)	O
,	O
the	O
chorea	O
score	O
of	O
the	O
unified	O
Huntington	O
's	O
disease	O
rating	O
scale	O
(	O
UHDRS	O
)	O
,	O
and	O
judgement	O
of	O
video	O
recordings	O
.	O

Voluntary	O
motor	O
performance	O
was	O
assessed	O
using	O
the	O
UHDRS	O
motor	O
scale	O
.	O

Patients	O
and	O
their	O
partners	O
completed	O
a	O
questionnaire	O
regarding	O
functional	O
disability	O
.	O

Twelve	O
patients	O
already	O
used	O
other	O
neuroleptic	O
medication	O
,	O
which	O
was	O
kept	O
unchanged	O
during	O
the	O
trial	O
period	O
.	O

Results	O
of	O
neuroleptic	O
naive	O
and	O
neuroleptic	O
treated	O
patients	O
were	O
analysed	O
separately	O
.	O

RESULTS	O
Clozapine	O
tended	O
to	O
reduce	O
chorea	Physical
in	O
neuroleptic	O
naive	O
patients	O
only	O
(	O
AIMS	O
)	O
;	O
improvement	O
seemed	O
more	O
pronounced	O
in	O
patients	O
receiving	O
higher	O
doses	O
of	O
clozapine	O
.	O

Other	O
measures	Physical
of	Physical
chorea	Physical
(	Physical
UHDRS	Physical
chorea	Physical
score	Physical
,	Physical
video	Physical
ratings	Physical
)	Physical
showed	O
no	O
improvement	O
.	O

Clozapine	O
had	O
no	O
beneficial	O
effect	O
on	O
chorea	Physical
in	O
patients	O
already	O
receiving	O
neuroleptic	O
medication	O
.	O

Voluntary	Physical
motor	Physical
performance	Physical
did	O
not	O
improve	O
with	O
clozapine	O
.	O

Neuroleptic	O
naive	O
patients	O
reported	O
aggravation	O
of	O
functional	Physical
disability	Physical
,	O
possibly	O
reflecting	O
the	O
frequent	O
occurrence	O
of	O
side	O
effects	O
.	O

Adverse	O
reactions	O
forced	O
trial	O
termination	O
in	O
six	O
patients	O
and	O
dose	O
reduction	O
in	O
another	O
eight	O
,	O
and	O
consisted	O
mainly	O
of	O
drowsiness	Adverseeffect
,	Adverseeffect
fatigue	Adverseeffect
,	Adverseeffect
anticholinergic	Adverseeffect
symptoms	Adverseeffect
,	Adverseeffect
and	Adverseeffect
walking	Adverseeffect
difficulties	Adverseeffect
.	O

CONCLUSIONS	O
Clozapine	O
has	O
little	O
beneficial	O
effect	O
in	O
patients	O
with	O
Huntington	O
's	O
disease	O
,	O
although	O
individual	O
patients	O
may	O
tolerate	O
doses	O
high	O
enough	O
to	O
reduce	O
chorea	O
.	O

Because	O
adverse	O
reactions	O
are	O
often	O
encountered	O
,	O
clozapine	O
should	O
be	O
used	O
with	O
restraint	O
in	O
this	O
patient	O
group	O
.	O

Combined	O
action	O
of	O
enalapril	O
or	O
timolol	O
with	O
hydrochlorothiazide	O
plus	O
amiloride	O
in	O
hypertension	O
.	O

59	O
mild	O
to	O
moderate	O
hypertensives	O
were	O
treated	O
for	O
four	O
weeks	O
with	O
50	O
mg	O
hydrochlorothiazide	O
plus	O
5	O
mg	O
of	O
amiloride	O
,	O
then	O
concomitantly	O
with	O
these	O
diuretics	O
with	O
either	O
enalapril	O
(	O
10-20	O
mg	O
)	O
or	O
timolol	O
(	O
10-20	O
mg	O
)	O
in	O
two	O
parallel	O
treatment	O
groups	O
for	O
an	O
additional	O
12	O
weeks	O
in	O
an	O
open	O
study	O
.	O

Addition	O
of	O
these	O
drugs	O
lowered	O
the	O
blood	Physical
pressure	Physical
by	O
25	O
+/-	O
3/16	O
+/-	O
2	O
mm	O
Hg	O
and	O
15	O
+/-	O
3/14	O
+/-	O
1	O
mm	O
Hg	O
,	O
respectively	O
.	O

The	O
difference	O
of	O
the	O
reduction	O
of	O
the	O
systolic	Physical
blood	Physical
pressure	Physical
between	O
enalapril	O
and	O
timolol	O
group	O
at	O
the	O
end	O
of	O
the	O
combined	O
treatment	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

The	O
mean	Physical
serum	Physical
potassium	Physical
was	O
elevated	O
by	O
0.3	O
mmol/l	O
after	O
addition	O
of	O
enalapril	O
to	O
the	O
diuretic	O
treatment	O
,	O
but	O
none	O
of	O
the	O
patients	O
developed	O
hyperkalaemia	Physical
.	O

No	O
adverse	Adverseeffect
effects	Adverseeffect
on	O
other	O
routine	O
laboratory	O
values	O
were	O
observed	O
.	O

Both	O
drug	O
combinations	O
can	O
be	O
considered	O
efficient	O
,	O
well	O
tolerated	Others
and	Others
safe	Others
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	O
.	O

A	O
comparison	O
of	O
the	O
laryngeal	O
tube-S	O
and	O
Proseal	O
laryngeal	O
mask	O
during	O
outpatient	O
surgical	O
procedures	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
The	O
Laryngeal	O
Tube	O
Sonda	O
(	O
LTS	O
)	O
and	O
the	O
ProSeal	O
Laryngeal	O
Mask	O
Airway	O
(	O
PLMA	O
)	O
are	O
two	O
new	O
devices	O
introduced	O
for	O
maintaining	O
the	O
airway	O
during	O
controlled	O
ventilation	O
under	O
general	O
anaesthesia	O
.	O

The	O
present	O
investigation	O
compared	O
their	O
performance	O
in	O
a	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
One	O
hundred	O
ASA	O
I-II	O
patients	O
,	O
aged	O
18-60	O
yr	O
undergoing	O
elective	O
minor	O
surgery	O
,	O
were	O
randomized	O
to	O
receive	O
either	O
an	O
LTS	O
(	O
n	O
=	O
50	O
)	O
or	O
PLMA	O
(	O
n	O
=	O
50	O
)	O
for	O
airway	O
management	O
.	O

After	O
induction	O
of	O
general	O
anaesthesia	O
,	O
the	O
devices	O
were	O
inserted	O
,	O
its	O
correct	O
placement	O
was	O
verified	O
and	O
airway	O
leak	O
pressure	O
was	O
measured	O
.	O

Ease	Others
of	Others
insertion	Others
,	Physical
quality	Others
of	Others
airway	Others
seal	Others
,	Physical
fibre-optic	Others
view	Others
and	Physical
postoperative	Physical
pharyngeal	Physical
morbidity	Physical
were	O
examined	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
in	O
patient	O
characteristics	O
for	O
both	O
groups	O
.	O

First-time	Others
and	Others
second-time	Others
success	Others
rates	Others
were	O
comparable	O
for	O
both	O
groups	O
(	O
86	O
vs.	O
88	O
%	O
and	O
96	O
vs.	O
98	O
%	O
in	O
LTS	O
and	O
PLMA	O
groups	O
,	O
respectively	O
)	O
.	O

The	O
airway	Physical
of	O
one	O
patient	O
in	O
each	O
group	O
could	O
not	O
be	O
managed	O
with	O
these	O
devices	O
after	O
three	O
attempts	O
.	O

Time	Others
until	Others
delivery	Others
of	Others
first	Others
tidal	Others
volume	Others
for	O
LTS	O
and	O
PLMA	O
was	O
24.5	O
+/-	O
6.9	O
and	O
28.8	O
+/-	O
10.3	O
s.	O
Fixation	Others
and	Physical
manipulation	Others
time	Physical
was	O
54.9	O
+/-	O
15.2	O
and	O
73.2	O
+/-	O
25	O
s	O
,	O
respectively	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Airway	Physical
seal	Physical
pressure	Physical
(	O
cm	O
H	O
(	O
2	O
)	O
O	O
)	O
for	O
LTS	O
and	O
PLMA	O
was	O
20	O
+/-	O
8.6	O
and	O
24.1	O
+/-	O
10.8	O
,	O
respectively	O
(	O
P	O
=	O
0.04	O
)	O
.	O

Patients	O
were	O
questioned	O
on	O
a	O
variety	O
of	O
postoperative	Physical
pharyngeal	Physical
morbidities	Physical
.	Adverseeffect

Only	O
hoarseness	Adverseeffect
was	O
more	O
frequent	O
in	O
the	O
LTS	O
group	O
.	O

CONCLUSIONS	O
Both	O
devices	O
provide	O
a	O
secure	O
airway	O
,	O
are	O
similar	O
in	O
clinical	O
utility	O
and	O
are	O
easy	O
to	O
insert	O
.	O

Better	O
airway	Physical
seal	Physical
was	O
detected	O
in	O
the	O
PLMA	O
group	O
.	O

Cefprozil	O
versus	O
penicillin	O
V	O
in	O
treatment	O
of	O
streptococcal	O
tonsillopharyngitis	O
.	O

In	O
a	O
randomized	O
multicenter	O
study	O
,	O
the	O
efficacy	Others
and	Others
safety	Others
of	O
cefprozil	O
were	O
compared	O
with	O
those	O
of	O
penicillin	O
in	O
the	O
treatment	O
of	O
group	O
A	O
streptococcal	O
tonsillopharyngitis	O
in	O
children	O
.	O

Of	O
the	O
409	O
patients	O
enrolled	O
,	O
323	O
were	O
evaluable	O
for	O
their	O
clinical	O
and	O
bacteriological	O
responses	O
;	O
of	O
these	O
323	O
children	O
,	O
172	O
received	O
cefprozil	O
and	O
151	O
received	O
penicillin	O
V.	O
The	O
clinical	Physical
responses	Physical
in	O
patients	O
treated	O
with	O
cefprozil	O
were	O
significantly	O
better	O
than	O
those	O
in	O
patients	O
who	O
received	O
penicillin	O
(	O
95.3	O
versus	O
88.1	O
%	O
;	O
P	O
=	O
0.023	O
)	O
.	O

Eradication	Physical
of	Physical
the	Physical
original	Physical
serotype	Physical
of	Physical
group	Physical
A	Physical
streptococci	Physical
was	O
achieved	O
in	O
91.3	O
%	O
of	O
patients	O
treated	O
with	O
cefprozil	O
and	O
87.4	O
%	O
of	O
patients	O
treated	O
with	O
penicillin	O
,	O
the	O
difference	O
not	O
being	O
statistically	O
significant	O
(	O
P	O
=	O
0.125	O
)	O
.	O

However	O
,	O
there	O
were	O
significantly	O
more	O
symptomatic	Physical
patients	O
among	O
the	O
bacteriological	O
failures	O
in	O
the	O
penicillin	O
group	O
(	O
68.4	O
%	O
)	O
than	O
in	O
the	O
cefprozil	O
group	O
(	O
26.7	O
%	O
)	O
.	O

beta-Lactamase-producing	O
Staphylococcus	Physical
aureus	Physical
was	Physical
more	O
frequently	O
isolated	Physical
from	Physical
the	Physical
throat	Physical
flora	Physical
during	O
penicillin	O
therapy	O
than	O
during	O
cefprozil	O
treatment	O
.	O

No	O
difference	O
in	O
the	O
incidence	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
probably	O
related	O
or	O
of	O
unknown	O
relationship	O
to	O
the	O
study	O
drugs	O
was	O
observed	O
in	O
the	O
two	O
treatment	O
groups	O
(	O
5.2	O
%	O
of	O
those	O
treated	O
with	O
cefprozil	O
and	O
6.0	O
%	O
of	O
those	O
treated	O
with	O
penicillin	O
)	O
.	O

Cefprozil	O
can	O
be	O
considered	O
a	O
safe	O
and	O
reliable	O
drug	O
for	O
the	O
treatment	O
of	O
streptococcal	O
pharyngitis	O
in	O
children	O
.	O

Influence	O
of	O
bony	O
defects	O
on	O
implant	O
stability	O
.	O

INTRODUCTION	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
evolution	O
of	O
implant	O
mechanical	O
stability	O
in	O
different	O
types/sizes	O
of	O
bony	O
defects	O
using	O
both	O
Periotest	O
and	O
Osstell	O
devices	O
as	O
objective	O
tools	O
.	O

MATERIALS	O
AND	O
METHODS	O
Thirty-two	O
implants	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
the	O
four	O
types	O
of	O
bone	O
defects	O
:	O
marginal	O
bone	O
loss	O
,	O
peri-apical	O
bone	O
defect	O
,	O
constant	O
width	O
dehiscence	O
and	O
constant	O
length	O
dehiscences	O
.	O

Periotest/Osstell	Physical
measurements	Physical
were	O
completed	O
before	O
and	O
during	O
staged	O
bone	O
removal	O
(	O
to	O
enlarge	O
defect	O
size	O
)	O
.	O

RESULTS	O
Significant	O
differences	O
(	O
P	O
<	O
0.05	O
)	O
with	O
initial	O
values	O
were	O
found	O
after	O
a	O
2	O
mm	O
marginal	O
bone	O
removal	O
(	O
Osstell/Periotest	O
)	O
;	O
for	O
a	O
peri-apical	Physical
bone	Physical
lesion	Physical
,	O
after	O
removal	O
of	O
5	O
mm	O
(	O
Osstell	O
)	O
or	O
8	O
mm	O
(	O
Periotest	O
)	O
;	O
for	O
a	O
6-mm-long	O
dehiscence	O
,	O
after	O
removal	O
up	O
to	O
180	O
degrees	O
of	O
the	O
implant	O
perimeter	O
(	O
Osstell/Periotest	O
)	O
;	O
for	O
a	O
3-mm-wide	O
dehiscence	O
,	O
after	O
removal	O
of	O
10	O
mm	O
(	O
Osstell	O
)	O
or	O
6	O
mm	O
(	O
Periotest	O
)	O
.	O

CONCLUSION	O
Periotest	Physical
and	O
Osstell	Physical
are	O
in	O
general	O
not	O
very	O
sensitive	O
in	O
the	O
identification	O
of	O
peri-implant	O
bone	O
destruction	O
,	O
except	O
for	O
marginal	O
bone	O
loss	O
.	O

Effect	O
of	O
explicit	O
instruction	O
on	O
Japanese	O
Verbal	O
Learning	O
Test	O
in	O
schizophrenia	O
patients	O
.	O

After	O
random	O
assignment	O
of	O
20	O
schizophrenia	O
patients	O
to	O
either	O
an	O
explicit	O
or	O
normal	O
instruction	O
group	O
,	O
the	O
Japanese	O
Verbal	O
Learning	O
Test	O
was	O
administered	O
to	O
them	O
.	O

Results	O
reveal	O
that	O
explicit	O
instruction	O
group	O
patients	O
demonstrated	O
more	O
improved	Mental
memory	Mental
performance	Mental
using	O
semantic	O
clustering	O
,	O
suggesting	O
that	O
explicit	O
and	O
direct	O
teaching	O
facilitates	O
patients	O
'	O
learning	O
of	O
information	O
.	O

Double-blind	O
comparison	O
of	O
liquid	O
antacid	O
and	O
placebo	O
in	O
the	O
treatment	O
of	O
symptomatic	O
reflux	O
esophagitis	O
.	O

Although	O
antacids	O
have	O
been	O
the	O
mainstay	O
of	O
pharmacologic	O
therapy	O
for	O
reflux	O
esophagitis	O
,	O
their	O
effectiveness	O
has	O
not	O
been	O
tested	O
in	O
a	O
placebo-controlled	O
double-blind	O
trial	O
.	O

We	O
report	O
a	O
double-blind	O
comparison	O
of	O
liquid	O
antacid	O
vs	O
placebo	O
in	O
the	O
treatment	O
of	O
reflux	O
esophagitis	O
in	O
32	O
patients	O
with	O
chronic	O
heartburn	O
.	O

Entry	O
criteria	O
included	O
the	O
presence	O
of	O
symptomatic	O
gastroesophageal	O
reflux	O
confirmed	O
by	O
both	O
an	O
acid	O
perfusion	O
(	O
Bernstein	O
)	O
test	O
and	O
by	O
intraesophageal	O
pH	O
probe	O
.	O

Drug	O
treatment	O
consisted	O
of	O
15	O
ml	O
(	O
80	O
mEq	O
)	O
doses	O
of	O
antacid	O
(	O
Maalox	O
Therapeutic	O
Concentration	O
,	O
William	O
H.	O
Rorer	O
)	O
or	O
placebo	O
taken	O
7	O
times	O
daily	O
,	O
ie	O
,	O
1	O
and	O
3	O
hr	O
after	O
meals	O
and	O
at	O
bedtime	O
.	O

Both	O
groups	O
showed	O
significant	O
improvement	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
both	O
frequency	Physical
and	Physical
severity	Physical
of	Physical
heartburn	Physical
.	Physical

The	O
time	Physical
to	Physical
reproduce	Physical
heartburn	Physical
with	O
the	O
timed	O
Bernstein	O
test	O
was	O
increased	O
with	O
both	O
active	O
drug	O
and	O
placebo	O
therapy	O
.	O

The	O
mean	O
increase	O
was	O
402	O
%	O
(	O
41	O
+/-	O
20	O
sec	O
to	O
169	O
+/-	O
66	O
sec	O
)	O
for	O
the	O
placebo	O
group	O
and	O
286	O
%	O
(	O
42	O
+/-	O
16	O
to	O
120	O
+/-	O
57	O
sec	O
)	O
in	O
the	O
antacid	O
group	O
.	O

Both	O
the	O
antacid	O
and	O
placebo	O
groups	O
showed	O
improvement	O
in	O
the	O
degree	Physical
of	Physical
esophagitis	Physical
as	O
assessed	O
endoscopically	O
.	O

The	O
current	O
study	O
asked	O
:	O
does	O
regular	O
antacid	O
therapy	O
have	O
a	O
favorable	O
influence	O
on	O
the	O
natural	O
history	O
of	O
symptomatic	Physical
reflux	Physical
esophagitis	Physical
,	O
ie	O
,	O
does	O
therapy	O
heal	O
or	O
otherwise	O
change	O
esophagitis	O
so	O
that	O
painful	O
episodes	O
are	O
either	O
less	O
frequent	O
,	O
less	O
severe	O
,	O
or	O
both	O
?	O
We	O
found	O
that	O
the	O
natural	Physical
history	Physical
of	Physical
symptomatic	Physical
reflux	Physical
esophagitis	Physical
was	O
to	O
improve	O
with	O
either	O
antacid	O
or	O
placebo	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
antacid	O
or	O
placebo	O
on	O
the	O
(	O
short-term	O
)	O
natural	Physical
history	Physical
of	Physical
the	Physical
disease	Physical
.	O

A	O
phase	O
IIb	O
dose-ranging	O
study	O
of	O
the	O
oral	O
JAK	O
inhibitor	O
tofacitinib	O
(	O
CP-690,550	O
)	O
versus	O
placebo	O
in	O
combination	O
with	O
background	O
methotrexate	O
in	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
and	O
an	O
inadequate	O
response	O
to	O
methotrexate	O
alone	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
efficacy	Others
,	Others
safety	Others
,	Others
and	Others
tolerability	Others
of	O
6	O
dosages	O
of	O
oral	O
tofacitinib	O
(	O
CP-690,550	O
)	O
with	O
placebo	O
for	O
the	O
treatment	O
of	O
active	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
in	O
patients	O
receiving	O
a	O
stable	O
background	O
regimen	O
of	O
methotrexate	O
(	O
MTX	O
)	O
who	O
have	O
an	O
inadequate	O
response	O
to	O
MTX	O
monotherapy	O
.	O

METHODS	O
In	O
this	O
24-week	O
,	O
double-blind	O
,	O
phase	O
IIb	O
study	O
,	O
patients	O
with	O
active	O
RA	O
(	O
n	O
=	O
507	O
)	O
were	O
randomized	O
to	O
receive	O
placebo	O
or	O
tofacitinib	O
(	O
20	O
mg/day	O
,	O
1	O
mg	O
twice	O
daily	O
,	O
3	O
mg	O
twice	O
daily	O
,	O
5	O
mg	O
twice	O
daily	O
,	O
10	O
mg	O
twice	O
daily	O
,	O
or	O
15	O
mg	O
twice	O
daily	O
)	O
.	O

All	O
patients	O
continued	O
to	O
receive	O
a	O
stable	O
dosage	O
of	O
MTX	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
American	Physical
College	Physical
of	Physical
Rheumatology	Physical
20	Physical
%	Physical
improvement	Physical
criteria	Physical
(	Physical
ACR20	Physical
)	Physical
response	Physical
rate	Physical
at	O
week	O
12	O
.	O

RESULTS	O
At	O
week	O
12	O
,	O
ACR20	Physical
response	O
rates	O
for	O
patients	O
receiving	O
all	O
tofacitinib	O
dosages	O
?3	O
mg	O
twice	O
daily	O
(	O
52.9	O
%	O
for	O
3	O
mg	O
twice	O
daily	O
,	O
50.7	O
%	O
for	O
5	O
mg	O
twice	O
daily	O
,	O
58.1	O
%	O
for	O
10	O
mg	O
twice	O
daily	O
,	O
56.0	O
%	O
for	O
15	O
mg	O
twice	O
daily	O
,	O
and	O
53.8	O
%	O
for	O
20	O
mg/day	O
)	O
were	O
significantly	O
(	O
P	O
?	O
0.05	O
)	O
greater	O
than	O
those	O
for	O
placebo	O
(	O
33.3	O
%	O
)	O
.	O

Improvements	O
were	O
sustained	O
at	O
week	O
24	O
for	O
the	O
ACR20	O
,	O
ACR50	O
,	O
and	O
ACR70	O
responses	O
,	O
scores	O
for	O
the	O
Health	O
Assessment	O
Questionnaire	O
disability	O
index	O
,	O
the	O
3-variable	O
Disease	O
Activity	O
Score	O
in	O
28	O
joints	O
using	O
the	O
C-reactive	O
protein	O
level	O
(	O
DAS28-CRP	O
)	O
,	O
and	O
a	O
3-variable	O
DAS28-CRP	O
of	O
<	O
2.6	O
.	O

The	O
most	O
common	O
treatment-emergent	O
adverse	O
events	O
occurring	O
in	O
>	O
10	O
%	O
of	O
patients	O
in	O
any	O
tofacitinib	O
group	O
were	O
diarrhea	O
,	O
upper	O
respiratory	O
tract	O
infection	O
,	O
and	O
headache	O
;	O
21	O
patients	O
(	O
4.1	O
%	O
)	O
experienced	O
serious	O
adverse	O
events	O
.	O

Sporadic	O
increases	O
in	O
transaminase	O
levels	O
,	O
increases	O
in	O
cholesterol	O
and	O
serum	O
creatinine	O
levels	O
,	O
and	O
decreases	O
in	O
neutrophil	O
and	O
hemoglobin	O
levels	O
were	O
observed	O
.	O

CONCLUSION	O
In	O
patients	O
with	O
active	O
RA	O
in	O
whom	O
the	O
response	O
to	O
MTX	O
has	O
been	O
inadequate	O
,	O
the	O
addition	O
of	O
tofacitinib	O
at	O
a	O
dosage	O
?3	O
mg	O
twice	O
daily	O
showed	O
sustained	O
efficacy	O
and	O
a	O
manageable	O
safety	O
profile	O
over	O
24	O
weeks	O
.	O

Comparison	O
of	O
0.25	O
%	O
S	O
(	O
-	O
)	O
-bupivacaine	O
with	O
0.25	O
%	O
RS-bupivacaine	O
for	O
epidural	O
analgesia	Pain
in	O
labour	O
.	O

We	O
have	O
compared	O
the	O
efficacy	O
of	O
0.25	O
%	O
S	O
(	O
-	O
)	O
-bupivacaine	O
with	O
0.25	O
%	O
RS-bupivacaine	O
in	O
providing	O
epidural	Pain
analgesia	Pain
for	O
labour	O
in	O
a	O
randomized	O
,	O
multicentre	O
,	O
double-blind	O
study	O
.	O

Analgesia	O
was	O
initiated	O
with	O
10	O
ml	O
of	O
the	O
study	O
solution	O
and	O
maintained	O
with	O
10-ml	O
top-ups	O
.	O

We	O
studied	O
137	O
women	O
and	O
treatments	O
were	O
found	O
to	O
be	O
equivalent	O
for	O
onset	O
,	O
duration	O
and	O
quality	O
of	O
block	O
.	O

Median	Pain
onset	Pain
of	Pain
pain	Pain
relief	Pain
was	O
12	O
min	O
for	O
both	O
drugs	O
and	O
median	O
duration	O
was	O
49	O
(	O
range	O
3-129	O
)	O
min	O
and	O
51	O
(	O
7-157	O
)	O
min	O
for	O
S	O
(	O
-	O
)	O
-bupivacaine	O
and	O
RS	O
bupivacaine	O
,	O
respectively	O
.	O

The	O
estimated	O
treatment	O
difference	O
for	O
duration	Pain
of	Pain
pain	Pain
relief	Pain
was	O
-4	O
(	O
90	O
%	O
CI	O
-13	O
,	O
6	O
)	O
min	O
.	O

Thirty	O
patients	O
failed	O
to	O
achieve	Pain
pain	Pain
relief	Pain
after	O
the	O
first	O
injection	O
(	O
20	O
patients	O
after	O
S	O
(	O
-	O
)	O
-bupivacaine	O
and	O
10	O
after	O
RS-bupivacaine	O
;	O
P	O
=	O
0.039	O
)	O
.	O

However	O
,	O
median	Pain
duration	Pain
of	Pain
pain	Pain
relief	Pain
from	O
the	O
first	O
top-up	O
was	O
82	O
(	O
range	O
3-164	O
)	O
min	O
for	O
S	O
(	O
-	O
)	O
-bupivacaine	O
and	O
76	O
(	O
22-221	O
)	O
min	O
for	O
RS-bupivacaine	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
quality	Pain
of	Pain
analgesia	Pain
,	O
as	O
assessed	O
by	O
the	O
investigators	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
extent	O
of	O
sensory	Physical
block	Physical
,	Physical
percentage	Physical
of	Physical
patients	Physical
with	Physical
motor	Physical
block	Physical
or	O
incidence	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
.	O

Symptomatic	O
and	O
functional	O
improvement	O
in	O
employed	O
depressed	O
patients	O
:	O
a	O
double-blind	O
clinical	O
trial	O
of	O
desvenlafaxine	O
versus	O
placebo	O
.	O

OBJECTIVE	O
This	O
is	O
the	O
first	O
study	O
to	O
assess	O
the	O
efficacy	O
of	O
desvenlafaxine	O
(	O
administered	O
as	O
desvenlafaxine	O
succinate	O
)	O
for	O
improving	O
depressive	Mental
symptoms	Mental
and	Mental
functioning	Mental
exclusively	O
in	O
employed	O
patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

METHODS	O
Gainfully	O
employed	O
(	O
?20	O
h/wk	O
)	O
male	O
and	O
female	O
outpatients	O
with	O
MDD	O
were	O
randomly	O
assigned	O
(	O
2:1	O
ratio	O
)	O
to	O
12	O
weeks	O
of	O
double-blind	O
treatment	O
with	O
desvenlafaxine	O
50	O
mg/d	O
or	O
placebo	O
.	O

Analysis	O
of	O
covariance	O
was	O
used	O
to	O
compare	O
differences	O
in	O
week	O
12	O
adjusted	O
mean	O
changes	O
from	O
baseline	O
on	O
the	O
17-item	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAM-D??	O
)	O
(	O
primary	O
outcome	O
)	O
and	O
Sheehan	O
Disability	O
Scale	O
(	O
SDS	O
)	O
(	O
key	O
secondary	O
outcome	O
)	O
in	O
the	O
intent-to-treat	O
(	O
ITT	O
)	O
population	O
.	O

A	O
predefined	O
,	O
modified	O
ITT	O
population	O
(	O
ie	O
,	O
those	O
in	O
the	O
ITT	O
population	O
with	O
baseline	O
HAM-D??	O
?20	O
)	O
was	O
also	O
analyzed	O
.	O

Tolerability	O
was	O
assessed	O
by	O
recording	O
adverse	O
events	O
and	O
change	O
on	O
the	O
Arizona	O
Sexual	O
Experience	O
Scale	O
.	O

RESULTS	O
Baseline	O
HAM-D??	O
scores	O
for	O
desvenlafaxine	O
(	O
n	O
=	O
285	O
)	O
and	O
placebo	O
(	O
n	O
=	O
142	O
)	O
were	O
22.0	O
and	O
21.8	O
,	O
whereas	O
baseline	O
SDS	O
scores	O
were	O
19.8	O
and	O
20.4	O
.	O

Adjusted	O
mean	O
differences	O
between	O
desvenlafaxine	O
and	O
placebo	O
were	O
2.1	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.78-3.46	O
;	O
P	O
=	O
0.002	O
)	O
on	O
the	O
HAM-D??	O
and	O
1.3	O
(	O
95	O
%	O
CI	O
,	O
-0.09	O
to	O
2.76	O
;	O
P	O
=	O
0.067	O
)	O
on	O
the	O
SDS	O
.	O

For	O
the	O
modified	O
ITT	O
sample	O
,	O
desvenlafaxine	O
(	O
n	O
=	O
208	O
)	O
and	O
placebo	O
(	O
n	O
=	O
102	O
)	O
,	O
baseline	O
HAM-D??	O
scores	O
were	O
23.8	O
and	O
23.9	O
;	O
the	O
SDS	O
baseline	O
scores	O
were	O
20.1	O
and	O
20.8	O
.	O

Mean	O
differences	O
were	O
2.6	O
(	O
95	O
%	O
CI	O
,	O
0.93-4.22	O
;	O
P	O
=	O
0.002	O
)	O
on	O
the	O
HAM-D??	O
and	O
2.1	O
(	O
95	O
%	O
CI	O
,	O
0.36-3.76	O
;	O
P	O
=	O
0.017	O
)	O
on	O
the	O
SDS	O
.	O

Adverse	O
events	O
and	O
Arizona	O
Sexual	O
Experience	O
Scale	O
scores	O
were	O
comparable	O
between	O
groups	O
.	O

CONCLUSIONS	O
Desvenlafaxine	O
50	O
mg/d	O
was	O
efficacious	O
for	O
treating	O
MDD	O
in	O
gainfully	O
employed	O
adults	O
.	O

Between-group	O
differences	O
on	O
the	O
SDS	O
narrowly	O
missed	O
statistical	O
significance	O
in	O
the	O
ITT	O
population	O
alone	O
,	O
but	O
the	O
totality	O
of	O
data	O
suggests	O
functional	O
improvements	O
with	O
active	O
treatment	O
.	O

National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
's	O
Breast	O
Cancer	O
Prevention	O
Trial	O
.	O

The	O
Breast	O
Cancer	O
Prevention	O
Trial	O
is	O
the	O
largest	O
breast	O
cancer	O
prevention	O
study	O
ever	O
undertaken	O
.	O

Administered	O
by	O
the	O
National	O
Surgical	O
Adjuvant	O
Breast	O
and	O
Bowel	O
Project	O
,	O
it	O
is	O
the	O
first	O
trial	O
seeking	O
to	O
demonstrate	O
whether	O
a	O
drug	O
,	O
tamoxifen	O
,	O
can	O
prevent	O
breast	O
cancer	O
in	O
high-risk	O
women	O
.	O

The	O
objectives	O
of	O
this	O
trial	O
are	O
to	O
determine	O
whether	O
tamoxifen	O
is	O
effective	O
in	O
1	O
)	O
reducing	Physical
the	Physical
incidence	Physical
of	Physical
invasive	Physical
breast	Physical
cancer	Physical
,	O
2	O
)	O
reducing	Mortality
breast	Mortality
cancer	Mortality
mortality	Mortality
,	O
3	O
)	O
reducing	Mortality
deaths	Mortality
from	Mortality
cardiovascular	Mortality
disease	Mortality
,	O
and	O
4	O
)	O
reducing	Physical
bone	Physical
fractures	Physical
.	O

In	O
addition	O
,	O
the	O
study	O
will	O
evaluate	O
side	Adverseeffect
effects	Adverseeffect
,	O
toxicity	Mortality
,	O
and	O
the	O
quality	Others
of	Others
life	Others
of	O
all	O
study	O
participants	O
.	O

Intrathecal	Physical
immunoactivation	Physical
in	O
patients	O
with	O
HIV-1	O
infection	O
is	O
reduced	O
by	O
zidovudine	O
but	O
not	O
by	O
didanosine	O
.	O

The	O
effect	O
of	O
zidovudine	O
and	O
didanosine	O
on	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
of	O
neopterin	O
was	O
studied	O
in	O
12	O
patients	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
infection	O
3-12	O
months	O
after	O
initiation	O
of	O
antiretroviral	O
therapy	O
.	O

Ten	O
treatment	O
periods	O
on	O
zidovudine	O
and	O
7	O
on	O
didanosine	O
were	O
analysed	O
.	O

The	O
CSF	Physical
concentrations	Physical
of	Physical
neopterin	Physical
decreased	O
by	O
63	O
%	O
(	O
from	O
29.6	O
to	O
12.9	O
nmol/l	O
,	O
p	O
<	O
0.01	O
)	O
during	O
zidovudine	O
but	O
increased	O
by	O
15	O
%	O
(	O
from	O
22.6	O
to	O
25.9	O
nmol/l	O
,	O
not	O
significant	O
during	O
didanosine	O
treatment	O
.	O

The	O
CSF	Physical
monocytic	Physical
cell	Physical
count	Physical
decreased	O
during	O
zidovudine	O
but	O
increased	O
during	O
didanosine	O
treatment	O
.	O

The	O
results	O
suggest	O
that	O
zidovudine	O
but	O
not	O
didanosine	O
reduces	O
intrathecal	Physical
immunoactivation	Physical
during	Physical
HIV-1	Physical
infection	Physical
.	O

Effects	O
of	O
ORG-2766	O
on	O
brain	O
event-related	O
potentials	O
of	O
autistic	O
children	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
study	O
examined	O
the	O
effects	O
of	O
6	O
weeks	O
of	O
treatment	O
with	O
the	O
adrenocorticotropin4-9	O
analogue	O
ORG-2766	O
(	O
40	O
mg/day	O
)	O
on	O
brain	O
event-related	O
potentials	O
(	O
ERPs	O
)	O
of	O
autistic	O
children	O
.	O

In	O
visual	O
and	O
auditory	O
oddball	O
paradigms	O
(	O
with	O
task	O
and	O
nontask	O
conditions	O
)	O
,	O
standard	O
(	O
80	O
%	O
)	O
,	O
target	O
(	O
10	O
%	O
)	O
,	O
and	O
unexpected	O
novel	O
stimuli	O
(	O
10	O
%	O
)	O
were	O
presented	O
.	O

ORG-2766	O
(	O
a	O
)	O
increased	Physical
the	Physical
occipital	Physical
P3	Physical
component	Physical
of	Physical
the	Physical
ERP	Physical
to	Physical
visual	Physical
targets	Physical
,	O
(	Physical
b	Physical
)	Physical
decreased	Physical
the	Physical
occipital	Physical
P3	Physical
component	Physical
of	Physical
the	Physical
ERP	Physical
to	Physical
auditory	Physical
targets	Physical
,	O
(	Physical
c	Physical
)	Physical
did	Physical
not	Physical
affect	Physical
visual	Physical
and	Physical
auditory	Physical
parietal	Physical
target	Physical
P3	Physical
components	Physical
,	O
and	O
(	O
d	O
)	O
also	O
did	O
not	O
affect	O
the	O
A/Pcz/300	O
to	O
auditory	O
novel	O
stimuli	O
.	O

In	O
addition	O
,	O
ORG-2766	O
treatment	O
increased	Physical
the	Physical
N1	Physical
component	Physical
of	Physical
the	Physical
ERP	Physical
to	Physical
task-irrelevant	Physical
auditory	Physical
stimuli	Physical
.	O

Effectiveness	O
of	O
Dader	O
Method	O
for	O
pharmaceutical	O
care	O
on	O
control	Physical
of	Physical
blood	Physical
pressure	Physical
and	O
total	Physical
cholesterol	Physical
in	O
outpatients	O
with	O
cardiovascular	O
disease	O
or	O
cardiovascular	O
risk	O
:	O
EMDADER-CV	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Although	O
some	O
studies	O
have	O
demonstrated	O
that	O
pharmacist	O
intervention	O
can	O
improve	O
drug	O
therapy	O
among	O
patients	O
with	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
,	O
more	O
evidence	O
derived	O
from	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
is	O
needed	O
,	O
including	O
assessment	O
of	O
the	O
effect	O
of	O
community	O
pharmacist	O
interventions	O
in	O
patients	O
with	O
CVD	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
effectiveness	O
of	O
the	O
Dader	O
Method	O
for	O
pharmaceutical	O
care	O
on	O
achieving	O
therapeutic	O
goals	O
for	O
blood	Physical
pressure	Physical
(	Physical
BP	Physical
)	Physical
,	O
total	Physical
cholesterol	Physical
(	Physical
TC	Physical
)	Physical
,	O
and	O
both	Physical
BP	Physical
and	O
TC	Physical
(	Physical
BP/TC	Physical
)	Physical
in	O
patients	O
with	O
CVD	O
and/or	O
high	O
or	O
intermediate	O
cardiovascular	O
(	O
CV	O
)	O
risk	O
attending	O
community	O
pharmacies	O
in	O
Spain	O
.	O

METHODS	O
Patients	O
aged	O
25	O
to	O
74	O
years	O
attending	O
community	O
pharmacies	O
with	O
a	O
prescription	O
for	O
at	O
least	O
1	O
drug	O
indicated	O
for	O
CVD	O
or	O
CV	O
risk	O
factors	O
were	O
randomized	O
to	O
2	O
groups	O
:	O
an	O
intervention	O
group	O
that	O
received	O
pharmaceutical	O
care	O
,	O
which	O
was	O
provided	O
by	O
specially	O
trained	O
pharmacists	O
working	O
in	O
collaboration	O
with	O
physicians	O
,	O
and	O
a	O
control	O
group	O
that	O
received	O
usual	O
care	O
(	O
routine	O
dispensing	O
counseling	O
)	O
and	O
verbal	O
and	O
written	O
counseling	O
regarding	O
CVD	O
prevention	O
.	O

Patients	O
were	O
recruited	O
from	O
December	O
2005	O
to	O
September	O
2006	O
,	O
and	O
both	O
groups	O
were	O
followed	O
for	O
8	O
months	O
.	O

Study	O
outcomes	O
were	O
assessed	O
at	O
baseline	O
and	O
at	O
16	O
and	O
32	O
weeks	O
after	O
randomization	O
.	O

The	O
primary	O
outcome	O
measures	O
were	O
the	O
proportions	Physical
of	Physical
patients	Physical
achieving	Physical
BP	Physical
,	O
TC	Physical
,	O
and	O
BP/TC	Physical
therapeutic	Physical
goals	Physical
(	O
BP	O
lower	O
than	O
140/90	O
mm	O
Hg	O
for	O
patients	O
with	O
uncomplicated	O
hypertension	O
and	O
lower	O
than	O
130/80	O
mm	O
Hg	O
for	O
patients	O
with	O
diabetes	O
,	O
chronic	O
kidney	O
disease	O
,	O
or	O
history	O
of	O
myocardial	O
infarction	O
or	O
stroke	O
;	O
TC	O
lower	O
than	O
200	O
mg	O
per	O
dL	O
for	O
patients	O
without	O
CVD	O
and	O
lower	O
than	O
175	O
mg	O
per	O
dL	O
for	O
patients	O
with	O
CVD	O
)	O
.	O

Secondary	O
outcomes	O
were	O
mean	Physical
BP	Physical
and	O
TC	Physical
values	Physical
.	O

BP	Physical
was	O
assessed	O
manually	O
by	O
the	O
pharmacist	O
after	O
a	O
10-minute	O
rest	O
in	O
the	O
supine	O
position	O
.	O

This	O
measurement	O
was	O
performed	O
twice	O
for	O
every	O
participant	O
,	O
and	O
the	O
average	O
of	O
the	O
2	O
measurements	O
was	O
calculated	O
.	O

TC	Physical
was	O
measured	O
by	O
the	O
pharmacist	O
during	O
the	O
study	O
visit	O
using	O
the	O
enzymatic	O
dry	O
method	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
2-tailed	O
McNemar	O
tests	O
,	O
Pearson	O
chi-square	O
tests	O
,	O
and	O
Student	O
's	O
t-tests	O
;	O
P	O
<	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

RESULTS	O
714	O
patients	O
were	O
included	O
in	O
the	O
study	O
(	O
356	O
intervention	O
,	O
358	O
control	O
)	O
,	O
and	O
the	O
mean	O
[	O
SD	O
]	O
age	O
was	O
62.8	O
[	O
8.1	O
]	O
years	O
.	O

The	O
2	O
groups	O
were	O
similar	O
at	O
baseline	O
in	O
clinical	O
and	O
demographic	O
characteristics	O
,	O
including	O
the	O
proportion	O
of	O
patients	O
at	O
therapeutic	O
goals	O
for	O
BP	Physical
,	O
TC	Physical
,	O
and	O
BP/TC	Physical
.	O

After	O
8	O
months	O
of	O
follow-up	O
,	O
there	O
were	O
statistically	O
significant	O
differences	O
in	O
favor	O
of	O
pharmaceutical	O
care	O
in	O
the	O
proportions	O
of	O
patients	O
who	O
achieved	O
therapeutic	O
goals	O
for	O
BP	Physical
(	O
52.5	O
%	O
vs.	O
43.0	O
%	O
,	O
P=0.017	O
)	O
,	O
TC	Physical
(	O
56.5	O
%	O
vs.	O
44.1	O
%	O
,	O
P=0.001	O
)	O
,	O
and	O
BP/TC	Physical
(	O
37.1	O
%	O
vs.	O
21.8	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
Compared	O
with	O
usual	O
care	O
plus	O
written	O
education	O
,	O
pharmaceutical	O
care	O
focused	O
on	O
patient	O
evaluation	O
and	O
follow-up	O
in	O
collaboration	O
with	O
physicians	O
improved	O
the	O
achievement	O
of	O
BP	Physical
,	O
TC	Physical
,	O
and	O
BP/TC	Physical
treatment	O
goals	O
in	O
patients	O
with	O
CVD	O
and/or	O
high	O
or	O
intermediate	O
CV	O
risk	O
attending	O
community	O
pharmacies	O
in	O
Spain	O
.	O

Superior	O
modulation	O
of	O
activation	O
levels	O
of	O
stimulus	O
representations	O
does	O
not	O
underlie	O
superior	O
discrimination	O
in	O
autism	O
.	O

The	O
performance	O
of	O
children	O
with	O
and	O
without	O
autism	O
was	O
compared	O
in	O
object-based	O
positive	O
and	O
negative	O
priming	O
tasks	O
within	O
a	O
visual	O
search	O
procedure	O
.	O

Object-based	O
positive	Others
and	Others
negative	Others
priming	Others
effects	Others
were	O
found	O
in	O
both	O
groups	O
of	O
children	O
.	O

This	O
result	O
provides	O
the	O
first	O
evidence	O
for	O
the	O
activation	O
of	O
object-based	Others
representations	Others
during	O
visual	O
search	O
task	O
performance	O
and	O
further	O
supports	O
the	O
notion	O
that	O
both	O
excitatory	Others
and	Others
inhibitory	Others
guidance	Others
mechanisms	Others
are	O
involved	O
in	O
target	O
location	O
in	O
visual	O
search	O
.	O

The	O
children	O
with	O
autism	O
were	O
overall	O
better	O
than	O
the	O
typically	O
developing	O
children	O
at	O
visual	Physical
search	Physical
,	O
thus	O
replicating	O
demonstrations	O
of	O
superior	O
discrimination	O
in	O
autism	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
difference	O
between	O
the	O
magnitude	O
of	O
the	O
positive	O
nor	O
the	O
negative	O
priming	Others
effects	Others
of	O
the	O
groups	O
.	O

This	O
finding	O
suggests	O
that	O
excitatory	Others
and	Others
inhibitory	Others
control	Others
operate	Others
comparably	Others
in	O
autism	O
and	O
normal	Physical
development	Physical
.	Physical

These	O
results	O
are	O
discussed	O
in	O
the	O
light	O
of	O
the	O
superior	O
ability	O
of	O
individuals	O
with	O
autism	O
to	O
discriminate	O
between	O
items	O
.	O

More	O
specifically	O
,	O
it	O
is	O
argued	O
that	O
superior	O
discrimination	O
in	O
autism	O
does	O
not	O
result	O
from	O
enhanced	O
top-down	O
excitatory	O
and	O
inhibitory	O
control	O
.	O

A	O
prospective	O
randomised	O
comparison	O
of	O
the	O
dynamic	O
hip	O
screw	O
and	O
the	O
gamma	O
locking	O
nail	O
.	O

We	O
made	O
a	O
randomised	O
prospective	O
comparison	O
of	O
the	O
Dynamic	O
Hip	O
Screw	O
and	O
the	O
Gamma	O
locking	O
nail	O
for	O
the	O
internal	O
fixation	O
of	O
200	O
petrochanteric	O
femoral	O
fractures	O
in	O
elderly	O
patients	O
.	O

There	O
was	O
less	O
intraoperative	Physical
blood	Physical
loss	Physical
and	Physical
a	Physical
lower	Physical
rate	Physical
of	Physical
wound	Physical
complications	Physical
in	O
the	O
patients	O
treated	O
by	O
the	O
Gamma	O
nail	O
.	O

They	O
had	O
,	O
however	O
,	O
a	O
high	O
incidence	O
of	O
femoral	Physical
shaft	Physical
fracture	Physical
which	O
we	O
relate	O
in	O
part	O
to	O
implant	O
design	O
.	O

We	O
do	O
not	O
recommend	O
the	O
use	O
of	O
the	O
Gamma	O
nail	O
for	O
these	O
fractures	O
.	O

Continuous	O
pralidoxime	O
infusion	O
versus	O
repeated	O
bolus	O
injection	O
to	O
treat	O
organophosphorus	O
pesticide	O
poisoning	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
The	O
role	O
of	O
oximes	O
for	O
the	O
treatment	O
of	O
organophosphorus	O
pesticide	O
poisoning	O
has	O
not	O
been	O
conclusively	O
established	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
effectiveness	O
of	O
a	O
constant	O
pralidoxime	O
infusion	O
compared	O
with	O
repeated	O
bolus	O
doses	O
to	O
treat	O
patients	O
with	O
moderately	O
severe	O
poisoning	O
from	O
organophosphorus	O
pesticides	O
.	O

METHODS	O
200	O
patients	O
were	O
recruited	O
to	O
our	O
single-centre	O
,	O
open	O
randomised	O
controlled	O
trial	O
after	O
moderately	O
severe	O
poisoning	O
by	O
anticholinesterase	O
pesticide	O
.	O

All	O
were	O
given	O
a	O
2	O
g	O
loading	O
dose	O
of	O
pralidoxime	O
over	O
30	O
min	O
.	O

Patients	O
were	O
then	O
randomly	O
assigned	O
to	O
control	O
and	O
study	O
groups	O
.	O

Controls	O
were	O
given	O
a	O
bolus	O
dose	O
of	O
1	O
g	O
pralidoxime	O
over	O
1	O
h	O
every	O
4	O
h	O
for	O
48	O
h.	O
The	O
study	O
group	O
had	O
a	O
constant	O
infusion	O
of	O
1	O
g	O
over	O
an	O
hour	O
every	O
hour	O
for	O
48	O
h.	O
Thereafter	O
,	O
all	O
patients	O
were	O
given	O
1	O
g	O
every	O
4	O
h	O
until	O
they	O
could	O
be	O
weaned	O
from	O
ventilators	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

Primary	O
outcome	O
measures	O
were	O
median	Others
atropine	Others
dose	Others
needed	Others
within	Others
24	Others
h	Others
,	Others
proportion	Others
of	Others
patients	Others
who	Others
needed	Others
intubation	Others
,	O
and	O
number	Mental
of	Mental
days	Mental
on	Mental
ventilation	Mental
.	O

The	O
study	O
is	O
registered	O
at	O
http	O
:	O
//www.clinicaltrials.gov	O
with	O
the	O
identifier	O
NCT00333944	O
.	O

FINDINGS	O
100	O
patients	O
were	O
assigned	O
the	O
high-dose	O
regimen	O
,	O
and	O
100	O
the	O
control	O
regimen	O
.	O

There	O
were	O
no	O
drop-outs	O
.	O

Patients	O
receiving	O
the	O
high-dose	O
pralidoxime	O
regimen	O
required	O
less	O
atropine	Physical
during	O
the	O
first	O
24	O
h	O
than	O
controls	O
(	O
median	O
6	O
mg	O
vs	O
30	O
mg	O
;	O
difference	O
24	O
mg	O
[	O
95	O
%	O
CI	O
24-26	O
,	O
p	O
<	O
0.0001	O
]	O
)	O
.	O

88	O
(	O
88	O
%	O
)	O
and	O
64	O
(	O
64	O
%	O
)	O
of	O
controls	O
and	O
high-dose	O
patients	O
,	O
respectively	O
,	O
needed	O
intubation	Others
during	Others
admission	Others
to	Others
hospital	Others
(	O
relative	O
risk=0.72	O
,	O
0.62-0.86	O
,	O
p=0.0001	O
)	O
.	O

Control	O
patients	O
required	O
ventilatory	Physical
support	Physical
for	O
longer	O
(	O
median	O
10	O
days	O
vs	O
5	O
days	O
;	O
difference	O
5	O
days	O
[	O
5-6	O
,	O
p	O
<	O
0.0001	O
]	O
)	O
.	O

INTERPRETATION	O
A	O
high-dose	O
regimen	O
of	O
pralidoxime	O
,	O
consisting	O
of	O
a	O
constant	O
infusion	O
of	O
1	O
g/h	O
for	O
48	O
h	O
after	O
a	O
2	O
g	O
loading	O
dose	O
,	O
reduces	O
morbidity	Mortality
and	Mortality
mortality	Mortality
in	O
moderately	O
severe	O
cases	O
of	O
acute	O
organophosphorus-pesticide	O
poisoning	O
.	O

Clinical	O
implications	O
of	O
a	O
reduction	O
in	O
psychological	O
distress	O
on	O
cardiac	O
prognosis	O
in	O
patients	O
participating	O
in	O
a	O
psychosocial	O
intervention	O
program	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
this	O
secondary	O
analysis	O
was	O
to	O
examine	O
the	O
relationships	O
between	O
a	O
reduction	O
in	O
psychological	O
distress	O
and	O
long-term	O
cardiac	O
and	O
psychological	O
outcomes	O
in	O
post-myocardial	O
infarction	O
patients	O
who	O
participated	O
in	O
a	O
randomized	O
trial	O
of	O
home-based	O
psychosocial	O
nursing	O
interventions	O
(	O
the	O
Montreal	O
Heart	O
Attack	O
Readjustment	O
Trial	O
[	O
M-HART	O
]	O
)	O
.	O

Gender	O
differences	O
were	O
considered	O
.	O

METHODS	O
We	O
studied	O
433	O
patients	O
(	O
36.0	O
%	O
women	O
)	O
from	O
the	O
M-HART	O
treatment	O
group	O
who	O
received	O
two	O
home	O
visits	O
after	O
achieving	O
a	O
high	O
psychological	O
distress	O
score	O
(	O
ie	O
,	O
>	O
or	O
=5	O
)	O
on	O
the	O
General	O
Health	O
Questionnaire	O
(	O
GHQ	O
)	O
.	O

Short-term	O
GHQ	Physical
success	Physical
was	O
determined	O
by	O
a	O
return	O
to	O
a	O
normal	O
GHQ	Physical
score	Physical
(	O
<	O
5	O
)	O
or	O
a	O
reduction	O
of	O
>	O
or	O
=50	O
%	O
after	O
the	O
two	O
visits	O
.	O

Patients	O
with	O
short-term	O
successful	O
and	O
unsuccessful	O
GHQ	O
outcomes	O
were	O
compared	O
for	O
mid-term	O
maintenance	O
of	O
success	O
,	O
1-year	O
death	O
and	O
readmission	O
rates	O
,	O
and	O
1-year	O
depression	O
and	O
anxiety	O
symptoms	O
.	O

RESULTS	O
Patients	O
with	O
short-term	O
GHQ	O
success	O
were	O
more	O
likely	O
to	O
show	O
mid-term	Physical
GHQ	Physical
success	Physical
(	O
p	O
<	O
.001	O
)	O
,	O
marginally	O
less	O
likely	O
to	O
die	Mortality
of	Mortality
any	Mortality
causes	Mortality
(	O
p	O
=	O
.087	O
)	O
,	O
less	O
likely	O
to	O
die	Mortality
of	Mortality
cardiac	Mortality
causes	Mortality
(	O
p	O
=	O
.043	O
)	O
,	O
less	O
likely	O
to	O
be	O
readmitted	Physical
for	O
any	O
reason	O
(	O
p	O
<	O
.001	O
)	O
and	O
for	O
cardiac	O
reasons	O
(	O
p	O
<	O
.001	O
)	O
,	O
and	O
less	O
likely	O
to	O
have	O
high	Physical
depression	Mental
(	O
p	O
<	O
.001	O
)	O
and	O
anxiety	Mental
(	O
p	O
<	O
.001	O
)	O
at	O
1-year	O
than	O
patients	O
with	O
short-term	O
unsuccessful	O
GHQ	Physical
outcomes	Physical
.	O

Results	O
held	O
for	O
men	O
and	O
women	O
and	O
were	O
not	O
altered	O
by	O
controlling	O
for	O
potential	O
confounders	O
.	O

However	O
,	O
the	O
number	O
of	O
deaths	Mortality
prevented	O
analysis	O
with	O
statistical	O
controls	O
.	O

CONCLUSIONS	O
Post-myocardial	O
infarction	O
interventions	O
that	O
reduce	O
psychological	O
distress	O
have	O
the	O
potential	O
to	O
improve	O
long-term	Others
prognosis	Others
and	O
psychological	Others
status	Others
for	O
both	O
men	O
and	O
women	O
.	O

Measuring	O
social	Mental
cognition	Mental
in	O
adolescents	O
:	O
implications	O
for	O
students	O
with	O
TBI	O
returning	O
to	O
school	O
.	O

In	O
everyday	O
adolescent	O
communication	O
,	O
the	O
ability	O
to	O
empathise	O
with	O
the	O
mental	O
state	O
of	O
others	O
,	O
recognise	O
or	O
infer	O
intentions	O
,	O
or	O
make	O
judgements	O
about	O
emotional	O
state	O
,	O
is	O
a	O
non-conscious	O
but	O
vital	O
prerequisite	O
of	O
relating	O
.	O

Execution	O
of	O
these	O
skills	O
in	O
social	O
interactions	O
supports	O
both	O
the	O
exchange	O
of	O
social	O
knowledge	O
and	O
also	O
the	O
development	O
and	O
maintenance	O
of	O
personal	O
relationships	O
.	O

Thus	O
,	O
adolescents	O
with	O
impairments	O
in	O
these	O
skills	O
are	O
at	O
risk	O
for	O
a	O
variety	O
of	O
negative	O
outcomes	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
data	O
to	O
illustrate	O
that	O
adolescents	O
with	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
are	O
likely	O
to	O
have	O
impairments	Mental
in	Mental
processes	Mental
such	Mental
as	Mental
emotion	Mental
recognition	Mental
and	Mental
mental	Mental
state	Mental
attribution	Mental
,	O
and	O
that	O
these	O
might	O
not	O
be	O
identified	O
on	O
standardised	O
tests	O
.	O

This	O
is	O
considered	O
from	O
the	O
perspective	O
of	O
clinical	O
assessment	O
and	O
intervention	O
in	O
school	O
contexts	O
.	O

Anabolic	O
steroids	O
in	O
athelics	O
:	O
crossover	O
double-blind	O
trial	O
on	O
weightlifters	O
.	O

Thirteen	O
experienced	O
male	O
weightlifters	O
taking	O
high-protein	O
diets	O
and	O
regular	O
exercise	O
took	O
part	O
in	O
a	O
double-blind	O
crossover	O
trial	O
of	O
methandienone	O
10	O
or	O
25	O
mg/day	O
to	O
seeif	O
the	O
drug	O
improved	O
athletic	Mental
performance	Mental
.	O

Their	O
improvemments	O
were	O
significantly	O
greater	Others
on	O
methandienone	O
than	O
on	O
placebo	O
;	O
their	O
body	Physical
weights	Physical
rose	Physical
(	O
though	O
this	O
seemed	O
to	O
be	O
associated	O
with	O
water	O
retention	O
)	O
;	O
and	O
systolic	Physical
blood	Physical
pressure	Physical
rose	Physical
significantly	O
.	O

Methandienone	O
caused	O
many	O
side	Adverseeffect
effects	Adverseeffect
,	O
and	O
three	O
men	O
had	O
to	O
withdraw	O
because	O
of	O
them	O
.	O

All	O
side	Adverseeffect
effects	Adverseeffect
disappeared	O
after	O
the	O
drug	O
was	O
stopped	O
.	O

Anabolic	O
steroids	O
are	O
effective	O
only	O
when	O
given	O
combination	O
with	O
exercise	O
and	O
high-protein	O
diet	O
.	O

We	O
deprecate	O
their	O
use	O
in	O
athletics	O
but	O
can	O
suggest	O
no	O
way	O
of	O
stopping	O
it	O
.	O

[	O
Metastatic	Physical
breast	Physical
cancer	Physical
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
of	O
tamoxifen	O
and	O
the	O
sequential	O
administration	O
of	O
tamoxifen	O
and	O
medroxyprogesterone	O
acetate	O
]	O
.	O

Seventy-nine	O
patients	O
with	O
an	O
histologically	O
proven	O
disseminated	O
breast	O
cancer	O
,	O
never	O
treated	O
before	O
with	O
additive	O
hormonal	O
therapy	O
,	O
entered	O
into	O
a	O
randomized	O
trial	O
between	O
june	O
1981	O
and	O
december	O
1982	O
.	O

In	O
the	O
first	O
group	O
44	O
patients	O
were	O
given	O
continually	O
a	O
daily	O
dose	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
of	O
20	O
mg/m2	O
.	O

In	O
the	O
2nd	O
group	O
35	O
patients	O
were	O
given	O
a	O
daily	O
dose	O
of	O
TAM	O
of	O
20	O
mg/m2	O
for	O
15	O
days	O
and	O
then	O
an	O
oral	O
daily	O
dose	O
of	O
medroxyprogesterone	O
acetate	O
of	O
350	O
mg/m2	O
for	O
the	O
next	O
15	O
days	O
.	O

In	O
both	O
groups	O
I	O
and	O
II	O
,	O
the	O
treatment	O
was	O
stopped	O
at	O
the	O
first	O
manifestation	O
of	O
progression	O
of	O
the	O
disease	O
.	O

The	O
hormonal	O
receptor	O
status	O
was	O
determined	O
in	O
30	O
patients	O
of	O
the	O
group	O
I	O
and	O
23	O
patients	O
of	O
the	O
group	O
II	O
.	O

An	O
objective	O
response	O
to	O
treatment	O
was	O
observed	O
in	O
48	O
per	O
cent	O
of	O
the	O
patients	O
of	O
the	O
group	O
I	O
and	O
60	O
per	O
cent	O
of	O
the	O
group	O
II	O
.	O

This	O
difference	O
is	O
not	O
significant	O
(	O
X2	O
=	O
1,05	O
)	O
.	O

However	O
,	O
the	O
mean	Physical
duration	Others
of	Others
therapeutic	Others
response	Others
is	O
significantly	O
higher	O
in	O
the	O
group	O
II	O
(	O
p	O
=	O
0,01	O
)	O
.	O

Active	O
treatment	O
programs	O
for	O
patients	O
with	O
chronic	O
low	O
back	O
pain	O
:	O
a	O
prospective	O
,	O
randomized	O
,	O
observer-blinded	O
study	O
.	O

Several	O
new	O
studies	O
have	O
indicated	O
that	O
an	O
active	O
approach	O
to	O
patients	O
with	O
chronic	O
disabling	O
low	O
back	O
pain	O
(	O
LBP	O
)	O
seems	O
effective	O
.	O

Some	O
of	O
these	O
studies	O
emphasize	O
the	O
importance	O
of	O
dealing	O
with	O
the	O
patient	O
's	O
total	O
situation	O
in	O
comprehensive	O
multidisciplinary	O
programs	O
--	O
the	O
bio-psycho-social	O
model	O
.	O

However	O
,	O
these	O
programs	O
are	O
expensive	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
rehabilitation	O
outcome	O
from	O
three	O
different	O
active	O
programs	O
in	O
terms	O
of	O
:	O
(	O
1	O
)	O
return-to-work	Others
rate	Others
,	O
(	O
2	O
)	O
days	Others
of	Others
sick	Others
leave	Others
,	O
(	O
3	O
)	O
health-care	Others
contacts	Others
,	O
(	O
4	O
)	O
pain	Pain
and	Pain
disability	Physical
scores	Physical
,	O
and	O
(	O
5	O
)	O
staying	Physical
physically	Physical
active	Physical
.	O

The	O
subjects	O
included	O
132	O
patients	O
randomized	O
to	O
the	O
study	O
,	O
of	O
whom	O
123	O
started	O
one	O
of	O
the	O
treatment	O
programs	O
.	O

They	O
had	O
all	O
had	O
at	O
least	O
6	O
months	O
of	O
chronic	O
LBP	O
.	O

The	O
patients	O
were	O
randomized	O
into	O
one	O
of	O
three	O
programs	O
:	O
group	O
1	O
--	O
a	O
full-time	O
,	O
intensive	O
3-week	O
multidisciplinary	O
program	O
,	O
including	O
active	O
physical	O
and	O
ergonomic	O
training	O
and	O
psychological	O
pain	O
management	O
,	O
followed	O
by	O
1	O
day	O
weekly	O
for	O
the	O
subsequent	O
3	O
weeks	O
;	O
group	O
2	O
--	O
active	O
physical	O
training	O
,	O
twice	O
a	O
week	O
for	O
6	O
weeks	O
,	O
for	O
a	O
total	O
of	O
24h	O
;	O
group	O
3	O
--	O
psychological	O
pain	O
management	O
combined	O
with	O
active	O
physical	O
training	O
,	O
twice	O
a	O
week	O
for	O
6	O
weeks	O
,	O
also	O
for	O
a	O
total	O
of	O
24h	O
.	O

The	O
results	O
presented	O
here	O
are	O
based	O
on	O
data	O
collected	O
4	O
months	O
following	O
treatment	O
,	O
which	O
shows	O
an	O
86	O
%	O
response	O
rate	O
.	O

The	O
initial	O
examination	O
and	O
the	O
follow-up	O
evaluation	O
were	O
performed	O
by	O
a	O
blinded	O
observer	O
.	O

The	O
results	O
show	O
that	O
4	O
months	O
after	O
treatment	O
,	O
the	O
intensive	O
multidisciplinary	O
program	O
is	O
superior	O
to	O
the	O
less	O
intensive	O
programs	O
in	O
terms	O
of	O
return-to-work	O
rate	O
,	O
health-care	O
contacts	O
,	O
pain	O
and	O
disability	O
scores	O
,	O
and	O
staying	O
physically	O
active	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Efficacy	Others
and	Others
safety	Others
of	O
bexarotene	O
combined	O
with	O
psoralen-ultraviolet	O
A	O
(	O
PUVA	O
)	O
compared	O
with	O
PUVA	O
treatment	O
alone	O
in	O
stage	O
IB-IIA	O
mycosis	O
fungoides	O
:	O
final	O
results	O
from	O
the	O
EORTC	O
Cutaneous	O
Lymphoma	O
Task	O
Force	O
phase	O
III	O
randomized	O
clinical	O
trial	O
(	O
NCT00056056	O
)	O
.	O

BACKGROUND	O
Psoralen	O
plus	O
ultraviolet	O
A	O
(	O
PUVA	O
)	O
is	O
the	O
standard	O
treatment	O
for	O
early	O
stages	O
of	O
mycosis	O
fungoides	O
.	O

There	O
have	O
been	O
no	O
adequate	O
randomized	O
controlled	O
trials	O
with	O
sufficient	O
power	O
comparing	O
this	O
modality	O
with	O
other	O
therapies	O
.	O

OBJECTIVE	O
To	O
assess	O
disease	Physical
response	Physical
and	O
to	O
compare	O
the	O
response	Physical
rates	Physical
of	O
patients	O
treated	O
with	O
PUVA	O
alone	O
or	O
PUVA	O
and	O
bexarotene	O
.	O

METHODS	O
EORTC	O
21011	O
(	O
NCT	O
00056056	O
)	O
was	O
a	O
randomized	O
phase	O
III	O
study	O
comparing	O
combined	O
bexarotene	O
(	O
Targretin	O
(	O
?	O
)	O
)	O
and	O
PUVA	O
vs.	O
PUVA	O
alone	O
in	O
patients	O
with	O
stage	O
IB	O
and	O
IIA	O
mycosis	O
fungoides	O
(	O
MF	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
overall	O
response	O
rate	O
[	O
complete	O
clinical	O
response	O
(	O
CCR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
.	O

RESULTS	O
The	O
study	O
was	O
prematurely	O
closed	O
due	O
to	O
low	O
accrual	O
after	O
93	O
of	O
145	O
required	O
patients	O
(	O
65	O
%	O
)	O
were	O
randomized	O
.	O

Of	O
the	O
93	O
randomized	O
patients	O
,	O
87	O
started	O
treatment	O
,	O
41	O
received	O
PUVA	O
and	O
46	O
received	O
PUVA	O
+	O
bexarotene	O
.	O

Total	O
UVA	O
doses	O
received	O
were	O
107	O
J	O
cm	O
(	O
-2	O
)	O
(	O
range	O
1?4-489?9	O
)	O
in	O
the	O
PUVA	O
arm	O
vs.	O
101?7	O
J	O
cm	O
(	O
-2	O
)	O
(	O
0?2-529?9	O
)	O
in	O
the	O
combination	O
arm	O
.	O

The	O
safety	O
profile	O
was	O
acceptable	O
with	O
few	O
grade	O
3-4	O
toxicities	O
observed	O
in	O
either	O
arm	O
.	O

More	O
drop-outs	O
due	O
to	O
toxicity	O
were	O
observed	O
in	O
the	O
combination	O
arm	O
compared	O
with	O
the	O
PUVA-alone	O
arm	O
.	O

The	O
best	O
overall	O
response	O
(	O
CCR	O
+	O
PR	O
)	O
rate	O
was	O
71	O
%	O
for	O
PUVA	O
alone	O
and	O
77	O
%	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0?57	O
)	O
.	O

The	O
median	O
duration	O
of	O
response	O
was	O
9?7	O
months	O
for	O
PUVA	O
vs.	O
5?8	O
months	O
for	O
the	O
combination	O
arm	O
(	O
P	O
=	O
0?33	O
)	O
.	O

CCR	O
was	O
seen	O
in	O
25	O
patients	O
of	O
whom	O
10	O
received	O
PUVA	O
alone	O
(	O
CCR	O
22	O
%	O
)	O
and	O
15	O
received	O
combination	O
therapy	O
(	O
CCR	O
31	O
%	O
)	O
(	O
P	O
=	O
0?45	O
)	O
.	O

CCR	O
was	O
sustained	O
in	O
25	O
%	O
of	O
patients	O
regardless	O
of	O
therapy	O
.	O

There	O
was	O
a	O
trend	O
towards	O
fewer	O
PUVA	O
sessions	O
needed	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
22	O
)	O
compared	O
with	O
the	O
PUVA	O
arm	O
(	O
median	O
27?5	O
)	O
(	O
P	O
=	O
0?11	O
)	O
.	O

Similarly	O
,	O
a	O
trend	O
towards	O
lower	O
UVA	O
dose	O
required	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
median	O
55?8	O
J	O
cm	O
(	O
-2	O
)	O
)	O
compared	O
with	O
the	O
PUVA	O
arm	O
alone	O
(	O
median	O
117?5	O
J	O
cm	O
(	O
-2	O
)	O
)	O
(	O
P	O
=	O
0?5	O
)	O
was	O
observed	O
.	O

CONCLUSIONS	O
No	O
significant	O
difference	O
in	O
response	O
rate	O
or	O
response	O
duration	O
was	O
observed	O
in	O
this	O
study	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
towards	O
fewer	O
PUVA	O
sessions	O
and	O
lower	O
UVA	O
dose	O
required	O
to	O
achieve	O
CCR	O
in	O
the	O
combination	O
arm	O
(	O
PUVA	O
+	O
bexarotene	O
)	O
but	O
this	O
did	O
not	O
achieve	O
statistical	O
significance	O
due	O
to	O
insufficient	O
power	O
.	O

Azelnidipine	O
and	O
amlodipine	O
anti-coronary	O
atherosclerosis	O
trial	O
in	O
hypertensive	O
patients	O
undergoing	O
coronary	O
intervention	O
by	O
serial	O
volumetric	O
intravascular	O
ultrasound	O
analysis	O
in	O
Juntendo	O
university	O
(	O
ALPS-J	O
)	O
.	O

PURPOSE	O
Many	O
trials	O
have	O
shown	O
that	O
calcium	O
channel	O
blockers	O
(	O
CCBs	O
)	O
can	O
reduce	O
the	O
cardiovascular	Physical
(	Physical
CV	Physical
)	Physical
events	Physical
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

The	O
mechanisms	O
of	O
this	O
effect	O
could	O
be	O
associated	O
with	O
plaque	O
regression	O
due	O
to	O
the	O
anti-atherosclerotic	O
properties	O
of	O
CCBs	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
effects	O
of	O
CCB	O
on	O
volumetric	O
quantitative	O
changes	O
of	O
coronary	O
plaques	O
accessed	O
by	O
intravascular	O
ultrasound	O
(	O
IVUS	O
)	O
.	O

To	O
confirm	O
this	O
hypothesis	O
,	O
a	O
multicenter	O
randomized	O
trial	O
of	O
CCBs	O
treatment	O
with	O
azelnidipine	O
or	O
amlodipine	O
will	O
be	O
conducted	O
in	O
hypertensive	O
CAD	O
patients	O
undergoing	O
elective	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
Patients	O
who	O
have	O
hypertension	O
and	O
are	O
scheduled	O
for	O
PCI	O
will	O
be	O
enrolled	O
.	O

Subjects	O
will	O
be	O
randomized	O
to	O
azelnidipine	O
or	O
amlodipine	O
and	O
observed	O
for	O
48	O
weeks	O
.	O

The	O
primary	O
endpoint	O
will	O
be	O
the	O
percent	Physical
change	Physical
of	Physical
coronary	Physical
plaque	Physical
volume	Physical
.	O

The	O
secondary	O
endpoint	O
will	O
include	O
inflammatory	Physical
markers	Physical
,	Physical
antioxidant	Physical
activity	Physical
,	Physical
and	Physical
incidence	Physical
of	Physical
composite	Physical
cardiovascular	Physical
events	Physical
.	O

CONCLUSIONS	O
In	O
this	O
study	O
,	O
we	O
will	O
investigate	O
the	O
improvement	O
of	O
coronary	Physical
plaque	Physical
with	O
IVUS	O
by	O
treatment	O
with	O
two	O
dihydropyridine	O
CCBs	O
in	O
hypertensive	O
patients	O
undergoing	O
elective	O
PCI	O
.	O

This	O
result	O
will	O
lead	O
to	O
the	O
discovery	O
of	O
more	O
effective	O
drug	O
therapy	O
for	O
inhibition	O
of	O
coronary	Physical
events	Physical
.	O

Adherence	Mental
to	Mental
lifestyle	Mental
recommendations	Mental
by	O
patients	O
with	O
depression	O
.	O

INTRODUCTION	O
There	O
is	O
an	O
increasing	O
amount	O
of	O
evidence	O
showing	O
that	O
physical	Mental
activity	Mental
and	O
sun	Mental
exposure	Mental
are	O
effective	O
coadjuvant	O
treatments	O
for	O
patients	O
with	O
mild	O
to	O
moderate	O
depression	O
.	O

However	O
,	O
there	O
is	O
a	O
lack	O
of	O
information	O
regarding	O
patient	O
's	O
adherence	Mental
to	O
these	O
recommendations	O
in	O
daily	O
clinical	O
practice	O
.	O

METHODS	O
We	O
conducted	O
a	O
study	O
including	O
15	O
depressive	O
patients	O
who	O
had	O
been	O
under	O
antidepressant	O
treatment	O
for	O
at	O
least	O
one	O
month	O
.	O

They	O
wore	O
a	O
wrist-watch-like	O
actimetry	O
sensor	O
to	O
measure	O
physical	Mental
activity	Mental
and	O
sun	Mental
exposure	Mental
24	O
hours	O
a	O
day	O
.	O

After	O
one	O
week	O
of	O
baseline	O
assessment	O
,	O
patients	O
were	O
randomised	O
into	O
one	O
of	O
the	O
two	O
arms	O
of	O
the	O
study	O
.	O

Patients	O
in	O
the	O
experimental	O
group	O
received	O
a	O
brief	O
note	O
in	O
which	O
they	O
were	O
explicitly	O
asked	O
to	O
increase	O
both	O
their	O
physical	Mental
activity	Mental
level	Mental
and	O
time	Mental
of	Mental
sun	Mental
exposure	Mental
,	O
while	O
control	O
group	O
patients	O
did	O
not	O
receive	O
these	O
explicit	O
recommendations	O
.	O

RESULTS	O
One	O
week	O
after	O
recommendations	O
were	O
delivered	O
,	O
only	O
patients	O
in	O
the	O
experimental	O
group	O
had	O
increased	O
time	Mental
of	Mental
sun	Mental
exposure	Mental
and	O
physical	Mental
activity	Mental
(	O
25.8	O
%	O
and	O
14.3	O
%	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
Depressive	O
patients	O
are	O
able	Mental
to	Mental
follow	Mental
prescribed	Mental
lifestyle	Mental
recommendations	Mental
in	Mental
the	Mental
short-term	Mental
.	O

Assessment	O
of	O
elementary	O
school	O
students	O
'	O
sun	Physical
protection	Physical
behaviors	Physical
.	Physical

BACKGROUND/OBJECTIVES	O
Studies	O
suggest	O
that	O
excessive	O
sun	O
exposure	O
in	O
childhood	O
contributes	O
to	O
the	O
development	O
of	O
skin	O
cancer	O
later	O
in	O
life	O
.	O

METHODS	O
This	O
study	O
explores	O
4th	O
grade	O
student	O
assessment	O
of	O
their	O
sun	O
protection	O
behaviors	O
.	O

This	O
study	O
used	O
baseline	O
data	O
collected	O
in	O
the	O
Fall	O
of	O
2006	O
for	O
the	O
Sun	O
Protection	O
for	O
Florida	O
's	O
Children	O
(	O
SPF	O
)	O
project	O
.	O

In	O
brief	O
,	O
the	O
SPF	O
project	O
is	O
a	O
group	O
randomized	O
trial	O
to	O
test	O
the	O
effectiveness	O
of	O
a	O
school	O
based	O
intervention	O
promoting	O
sun	O
protection	O
in	O
general	O
,	O
and	O
hat	O
use	O
in	O
particular	O
,	O
in	O
Hillsborough	O
County	O
Schools	O
,	O
Florida	O
.	O

The	O
data	O
reported	O
in	O
this	O
study	O
were	O
collected	O
at	O
baseline	O
before	O
any	O
intervention	O
activities	O
was	O
initiated	O
.	O

RESULTS	O
The	O
self-reported	Mental
use	Mental
of	Mental
various	Mental
methods	Mental
of	Mental
sun	Mental
protection	Mental
was	O
low	O
.	O

Only	O
a	O
small	O
percentage	O
of	O
students	O
wore	O
long	Physical
sleeves	Physical
or	Physical
a	Physical
hat	Physical
with	Physical
a	Physical
brim	Physical
before	O
leaving	O
for	O
school	O
.	O

In	O
addition	O
,	O
few	O
students	O
wore	O
a	O
hat	Physical
with	Physical
a	Physical
wide	Physical
brim	Physical
when	Physical
outside	Physical
but	O
not	O
at	O
school	O
.	O

Students	O
spent	O
an	O
average	O
of	O
59.1	O
minutes	O
per	O
week	O
outdoors	O
while	O
attending	O
school	O
and	O
35.5	O
minutes	O
during	O
peak	Physical
sun	Physical
exposure	Physical
.	Physical

CONCLUSION	O
Sun	O
exposure	O
at	O
school	O
poses	O
a	O
significant	O
risk	O
to	O
student	O
health	O
and	O
more	O
needs	O
to	O
be	O
carried	O
out	O
to	O
promote	O
the	O
use	O
of	O
a	O
wide-brimmed	O
hat	O
and	O
limiting	O
student	Others
sun	Others
exposure	Others
.	Others

Evaluation	O
of	O
mood	O
profiles	O
during	O
malaria	O
chemoprophylaxis	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
four-arm	O
study	O
.	O

BACKGROUND	O
To	O
objectively	O
compare	O
the	O
mood	O
profiles	O
of	O
users	O
of	O
malaria	O
chemoprophylaxis	O
regimens	O
(	O
atovaquone-proguanil	O
,	O
chloroquine-proguanil	O
,	O
doxycycline	O
,	O
or	O
mefloquine	O
)	O
in	O
a	O
group	O
of	O
nonimmune	O
tourists	O
to	O
sub-Saharan	O
Africa	O
.	O

METHODS	O
In	O
a	O
randomized	O
,	O
double-blind	O
,	O
four-arm	O
study	O
with	O
placebo	O
run-in	O
phase	O
conducted	O
at	O
travel	O
clinics	O
in	O
Switzerland	O
,	O
Germany	O
,	O
and	O
Israel	O
,	O
we	O
compared	O
moods	O
and	O
feelings	O
in	O
chemoprophylaxis	O
users	O
(	O
n=	O
547	O
)	O
by	O
administering	O
the	O
standardized	O
Profile	O
of	O
Mood	O
States	O
(	O
POMS	O
)	O
questionnaire	O
.	O

This	O
is	O
designed	O
to	O
provide	O
data	O
on	O
six	O
categories	O
of	O
feelings	O
:	O
tension	O
,	O
depression	O
,	O
anger	O
,	O
vigor	O
,	O
fatigue	O
,	O
and	O
confusion	O
.	O

The	O
questionnaire	O
was	O
administered	O
at	O
four	O
time	O
points	O
:	O
recruitment	O
(	O
T1	O
)	O
,	O
13	O
to	O
11	O
days	O
before	O
departure	O
(	O
T2	O
)	O
,	O
6	O
to	O
4	O
days	O
before	O
departure	O
(	O
T3	O
)	O
,	O
and	O
7	O
to	O
14	O
days	O
after	O
return	O
from	O
Africa	O
(	O
T4	O
)	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
with	O
respect	O
to	O
overall	O
mood	Mental
impact	O
between	O
the	O
medication	O
arms	O
.	O

All	O
scores	O
were	O
in	O
the	O
normal	O
range	O
,	O
and	O
no	O
means	O
were	O
more	O
than	O
1	O
SD	O
from	O
the	O
norm	O
.	O

The	O
POMS	O
data	O
were	O
reanalyzed	O
with	O
respect	O
to	O
sex	O
,	O
age	O
,	O
medication	O
group	O
,	O
and	O
control	O
time	O
points	O
(	O
T1-T4	O
)	O
.	O

There	O
were	O
significant	O
interaction	O
effects	O
between	O
sex	O
and	O
medication	O
group	O
--	O
women	O
in	O
the	O
mefloquine	O
group	O
showed	O
more	O
fatigue	Mental
(	O
p=	O
.011	O
)	O
and	O
confusion	Mental
(	O
p=	O
.011	O
)	O
than	O
men	O
.	O

Significant	O
effects	O
of	O
age	O
group	O
(	O
below	O
median	O
age	O
34	O
y	O
vs	O
median	O
age	O
and	O
above	O
)	O
were	O
noted	O
on	O
the	O
tension	Mental
and	Mental
fatigue	Mental
scales	O
in	O
that	O
less	O
tension	Mental
(	O
p=	O
.045	O
)	O
and	O
less	O
fatigue	Mental
(	O
p=	O
.000	O
)	O
were	O
noted	O
in	O
those	O
aged	O
34	O
years	O
and	O
older	O
.	O

Younger	O
participants	O
,	O
aged	O
<	O
34	O
years	O
,	O
reported	O
more	O
confusion	Mental
(	O
p=	O
.013	O
)	O
at	O
T2	O
than	O
at	O
T1	O
and	O
T4	O
.	O

CONCLUSIONS	O
Although	O
the	O
overall	O
mood	O
profiles	O
were	O
similar	O
for	O
the	O
users	O
of	O
any	O
of	O
the	O
standard	O
malaria	O
chemoprophylaxis	O
regimens	O
,	O
we	O
found	O
that	O
women	O
using	O
mefloquine	O
showed	O
more	O
fatigue	O
and	O
confusion	O
than	O
men	O
and	O
that	O
younger	O
persons	O
aged	O
less	O
than	O
34	O
years	O
,	O
regardless	O
of	O
chemoprophylaxis	O
used	O
,	O
reported	O
more	O
tension	O
and	O
fatigue	O
than	O
their	O
older	O
counterparts	O
.	O

Similar	O
effects	O
of	O
rofecoxib	O
and	O
indomethacin	O
on	O
the	O
incidence	O
of	O
heterotopic	O
ossification	O
after	O
hip	O
arthroplasty	O
.	O

BACKGROUND	O
Although	O
indomethacin	O
is	O
effective	O
in	O
preventing	O
heterotopic	Physical
ossification	Physical
(	O
HO	O
)	O
after	O
primary	O
total	O
hip	O
arthroplasty	O
,	O
side	Adverseeffect
effects	Adverseeffect
are	O
frequently	O
observed	O
.	O

In	O
the	O
last	O
decade	O
a	O
new	O
class	O
of	O
drugs	O
--	O
the	O
COX-2	O
selective	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
--	O
has	O
been	O
developed	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
these	O
COX-2	O
selective	O
NSAIDs	Others
on	O
heterotopic	Physical
ossification	Physical
(	O
HO	O
)	O
after	O
primary	O
total	O
hip	O
arthroplasty	O
(	O
THA	O
)	O
,	O
we	O
conducted	O
a	O
randomized	O
controlled	O
trial	O
using	O
either	O
indomethacin	O
or	O
rofecoxib	O
for	O
7	O
days	O
.	O

METHODS	O
186	O
patients	O
received	O
either	O
indomethacin	O
3	O
times	O
daily	O
,	O
or	O
rofecoxib	O
twice	O
,	O
and	O
1	O
placebo	O
,	O
daily	O
for	O
7	O
days	O
.	O

HO	Physical
was	O
graded	O
according	O
to	O
the	O
1-year	O
postoperative	O
radiographs	O
according	O
to	O
the	O
Brooker	O
classification	O
.	O

RESULTS	O
12	O
of	O
the	O
186	O
patients	O
included	O
discontinued	Others
their	O
medication	O
before	O
the	O
end	O
of	O
the	O
trial	O
due	O
to	O
side	Adverseeffect
effects	Adverseeffect
.	O

The	O
remaining	O
174	O
patients	O
were	O
included	O
in	O
the	O
analysis	O
.	O

In	O
the	O
indomethacin	O
group	O
(	O
n	O
=	O
89	O
)	O
,	O
77	O
patients	O
(	O
87	O
%	O
)	O
showed	Physical
no	Physical
HO	Physical
,	O
9	O
showed	Physical
HO	Physical
of	Physical
grade	Physical
1	Physical
and	O
3	O
showed	Physical
HO	Physical
of	Physical
grade	Physical
2	Physical
according	O
to	O
the	O
Brooker	O
classification	O
.	O

In	O
the	O
rofecoxib	O
group	O
(	O
n	O
=	O
85	O
)	O
73	O
patients	O
(	O
86	O
%	O
)	O
showed	Physical
no	Physical
ossification	Physical
,	O
9	O
showed	Physical
grade	Physical
1	Physical
,	O
and	O
3	O
showed	Physical
grade	Physical
2	Physical
.	O

INTERPRETATION	O
The	O
prophylactic	O
effect	O
of	O
rofecoxib	O
for	O
7	O
days	O
in	O
preventing	O
heterotopic	O
ossification	O
after	O
primary	O
total	O
hip	O
arthroplasty	O
is	O
comparable	O
to	O
the	O
effect	O
of	O
indomethacin	O
given	O
for	O
7	O
days	O
.	O

These	O
results	O
indicate	O
that	O
the	O
development	O
of	O
HO	O
follows	O
a	O
COX-2	O
pathway	O
.	O

Stress	O
reduction	O
prolongs	O
life	O
in	O
women	O
with	O
coronary	O
disease	O
:	O
the	O
Stockholm	O
Women	O
's	O
Intervention	O
Trial	O
for	O
Coronary	O
Heart	O
Disease	O
(	O
SWITCHD	O
)	O
.	O

BACKGROUND	O
Psychosocial	O
stress	O
may	O
increase	O
risk	O
and	O
worsen	O
prognosis	O
of	O
coronary	O
heart	O
disease	O
in	O
women	O
.	O

Interventions	O
that	O
counteract	O
women	O
's	O
psychosocial	O
stress	O
have	O
not	O
previously	O
been	O
presented	O
.	O

This	O
study	O
implemented	O
a	O
stress	O
reduction	O
program	O
for	O
women	O
and	O
investigated	O
its	O
ability	O
to	O
improve	O
survival	Mortality
in	Mortality
women	Mortality
coronary	Mortality
patients	Mortality
.	Mortality

METHODS	O
AND	O
RESULTS	O
Two	O
hundred	O
thirty-seven	O
consecutive	O
women	O
patients	O
,	O
aged	O
75	O
years	O
or	O
younger	O
,	O
hospitalized	O
for	O
acute	O
myocardial	O
infarction	O
,	O
coronary	O
artery	O
bypass	O
grafting	O
,	O
or	O
percutaneous	O
coronary	O
intervention	O
were	O
randomized	O
to	O
a	O
group-based	O
psychosocial	O
intervention	O
program	O
or	O
usual	O
care	O
.	O

Initiated	O
4	O
months	O
after	O
hospitalization	O
,	O
intervention	O
groups	O
of	O
4	O
to	O
8	O
women	O
met	O
for	O
a	O
total	O
of	O
20	O
sessions	O
that	O
were	O
spread	O
over	O
a	O
year	O
.	O

We	O
provided	O
education	O
about	O
risk	O
factors	O
,	O
relaxation	O
training	O
techniques	O
,	O
methods	O
for	O
self-monitoring	O
and	O
cognitive	O
restructuring	O
,	O
with	O
an	O
emphasis	O
on	O
coping	O
with	O
stress	O
exposure	O
from	O
family	O
and	O
work	O
,	O
and	O
self-care	O
and	O
compliance	O
with	O
clinical	O
advice	O
.	O

From	O
randomization	O
until	O
end	O
of	O
follow-up	O
(	O
mean	O
duration	O
,	O
7.1	O
years	O
)	O
,	O
25	O
women	O
(	O
20	O
%	O
)	O
in	O
the	O
usual	O
care	O
and	O
8	O
women	O
(	O
7	O
%	O
)	O
in	O
the	O
stress	Physical
reduction	Physical
died	O
,	O
yielding	O
an	O
almost	O
3-fold	O
protective	O
effect	O
of	O
the	O
intervention	O
(	O
odds	O
ratio	O
,	O
0.33	O
;	O
95	O
%	O
CI	O
,	O
0.15	O
to	O
0.74	O
;	O
P=0.007	O
)	O
.	O

Introducing	O
baseline	O
measures	O
of	O
clinical	O
prognostic	O
factors	O
,	O
including	O
use	Physical
of	Physical
aspirin	Physical
,	Physical
beta-blockers	Physical
,	Physical
angiotensin-converting	Physical
enzyme	Physical
inhibitors	Physical
,	Physical
calcium-channel	Physical
blockers	Physical
,	Physical
and	Physical
statins	Physical
into	O
multivariate	O
models	O
confirmed	O
the	O
unadjusted	O
results	O
(	O
P=0.009	O
)	O
.	O

CONCLUSIONS	O
Although	O
mechanisms	O
remain	O
unclear	O
,	O
a	O
group-based	O
psychosocial	O
intervention	O
program	O
for	O
women	O
with	O
coronary	O
heart	O
disease	O
may	O
prolong	O
lives	O
independent	O
of	O
other	O
prognostic	O
factors	O
.	O

A	O
comparison	O
of	O
high	O
and	O
low	O
fat	O
meals	O
on	O
postprandial	O
esophageal	O
acid	O
exposure	O
.	O

Fatty	O
foods	O
have	O
been	O
identified	O
as	O
precipitating	O
factors	O
in	O
symptomatic	O
gastroesophageal	O
reflux	O
(	O
GER	O
)	O
.	O

A	O
fat	O
meal	O
has	O
also	O
been	O
found	O
to	O
decrease	O
lower	O
esophageal	Physical
sphincter	Physical
pressure	Physical
(	Physical
LESP	Physical
)	Physical
in	O
normal	O
subjects	O
.	O

We	O
used	O
the	O
ambulatory	O
24-h	O
pH	O
monitor	O
to	O
assess	O
esophageal	O
acid	O
exposure	O
in	O
10	O
normal	O
subjects	O
and	O
10	O
GER	O
patients	O
following	O
low	O
and	O
high	O
fat	O
meals	O
eaten	O
in	O
two	O
body	O
positions	O
.	O

The	O
meals	O
had	O
nearly	O
identical	O
protein	O
content	O
,	O
volumes	O
,	O
and	O
calories	O
.	O

On	O
successive	O
days	O
,	O
patients	O
ingested	O
one	O
of	O
the	O
meals	O
twice	O
,	O
followed	O
by	O
random	O
assignment	O
to	O
3	O
h	O
upright	O
and	O
3	O
h	O
recumbent	O
position	O
.	O

Acid	Physical
exposure	Physical
for	Physical
each	Physical
hour	Physical
over	O
a	O
3-h	O
postprandial	O
(	O
PP	O
)	O
period	O
was	O
assessed	O
as	O
the	O
percent	O
time	O
pH	O
less	O
than	O
4.0	O
.	O

Increased	O
upright	Physical
acid	Physical
exposure	Physical
occurred	O
in	O
normals	O
after	O
the	O
high	O
fat	O
(	O
6.2	O
+/-	O
2.1	O
%	O
;	O
mean	O
+/-	O
SE	O
)	O
compared	O
with	O
the	O
low	O
fat	O
meal	O
(	O
1.5	O
+/-	O
0.5	O
%	O
;	O
p	O
less	O
than	O
0.05	O
)	O
.	O

GER	O
patients	O
had	O
greater	O
(	O
p	O
less	O
than	O
0.05	O
)	O
acid	Physical
exposure	Physical
than	O
normals	O
in	O
all	O
study	O
periods	O
,	O
but	O
no	O
differences	O
were	O
found	O
between	O
low	O
and	O
high	O
fat	O
meals	O
in	O
either	O
study	O
position	O
.	O

High	O
fat	O
meals	O
induce	O
upright	Physical
GER	Physical
in	O
normals	O
,	O
but	O
do	O
not	O
significantly	O
affect	O
the	O
abnormal	O
amount	O
of	O
GER	O
in	O
patients	O
.	O

In	O
addition	O
,	O
progressive	O
increases	O
in	O
acid	Physical
exposure	Physical
were	O
found	O
over	O
the	O
3	O
postprandial	O
hours	O
in	O
GER	O
patients	O
in	O
a	O
recumbent	O
position	O
.	O

The	O
findings	O
are	O
consistent	O
with	O
prior	O
data	O
showing	O
decreased	O
LESP	Physical
with	O
a	O
fat	O
meal	O
in	O
normals	O
.	O

A	O
randomized	O
breast-feeding	O
promotion	O
intervention	O
did	O
not	O
reduce	O
child	O
obesity	O
in	O
Belarus	O
.	O

The	O
evidence	O
that	O
breast-feeding	O
protects	O
against	O
obesity	O
is	O
based	O
on	O
observational	O
studies	O
,	O
with	O
potential	O
for	O
confounding	O
and	O
selection	O
bias	O
.	O

This	O
article	O
summarizes	O
a	O
previously	O
published	O
study	O
in	O
which	O
we	O
assessed	O
whether	O
an	O
intervention	O
designed	O
to	O
promote	O
exclusive	O
and	O
prolonged	O
breast-feeding	O
affects	O
children	O
's	O
height	O
,	O
weight	O
,	O
adiposity	O
,	O
and	O
blood	O
pressure	O
(	O
BP	O
)	O
at	O
age	O
6.5	O
y	O
.	O

The	O
Promotion	O
of	O
Breastfeeding	O
Intervention	O
Trial	O
(	O
PROBIT	O
)	O
is	O
a	O
cluster-randomized	O
trial	O
of	O
a	O
breast-feeding	O
promotion	O
intervention	O
based	O
on	O
the	O
WHO/UNICEF	O
Baby-Friendly	O
Hospital	O
Initiative	O
.	O

A	O
total	O
of	O
17,046	O
healthy	O
breast-fed	O
infants	O
were	O
enrolled	O
from	O
31	O
Belarussian	O
maternity	O
hospitals	O
and	O
affiliated	O
clinics	O
,	O
of	O
whom	O
13,889	O
(	O
81.5	O
%	O
)	O
were	O
followed	O
up	O
at	O
6.5	O
y	O
with	O
duplicate	O
measurements	O
of	O
height	O
,	O
weight	O
,	O
waist	O
circumference	O
,	O
triceps	O
and	O
subscapular	O
skinfold	O
thicknesses	O
,	O
systolic	O
and	O
diastolic	O
BP	O
.	O

Analysis	O
was	O
based	O
on	O
intention	O
to	O
treat	O
,	O
with	O
statistical	O
adjustment	O
for	O
clustering	O
within	O
hospitals/clinics	O
to	O
permit	O
inferences	O
at	O
the	O
individual	O
level	O
.	O

The	O
experimental	O
intervention	O
led	O
to	O
a	O
large	O
increase	O
in	O
exclusive	Others
breast-feeding	Others
at	Others
3	Others
mo	Others
(	O
43.3	O
%	O
vs.	O
6.4	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
a	O
significantly	O
higher	O
prevalence	O
of	O
any	O
breast-feeding	O
throughout	O
infancy	O
.	O

No	O
significant	O
intervention	O
effects	O
were	O
observed	O
on	O
height	Physical
,	Physical
BMI	Physical
,	Physical
adiposity	Physical
measures	Physical
,	Physical
or	Physical
BP	Physical
.	Physical

The	O
breast-feeding	O
promotion	O
intervention	O
resulted	O
in	O
substantial	O
increases	Physical
in	Physical
the	Physical
duration	Physical
and	Physical
exclusivity	Physical
of	Physical
breast-feeding	Physical
yet	Physical
did	Physical
not	Physical
reduce	Physical
measures	Physical
of	Physical
adiposity	Physical
at	O
age	O
6.5	O
y	O
.	O

Previous	O
reports	O
of	O
protective	O
effects	O
against	O
obesity	O
may	O
reflect	O
uncontrolled	O
bias	O
caused	O
by	O
confounding	O
and	O
selection	O
.	O

Engagement	O
with	O
electronic	O
screen	O
media	O
among	O
students	O
with	O
autism	O
spectrum	O
disorders	O
.	O

This	O
study	O
investigated	O
the	O
relative	O
engagement	O
potential	O
of	O
four	O
types	O
of	O
electronic	O
screen	O
media	O
(	O
ESM	O
)	O
:	O
animated	O
video	O
,	O
video	O
of	O
self	O
,	O
video	O
of	O
a	O
familiar	O
person	O
engaged	O
with	O
an	O
immersive	O
virtual	O
reality	O
(	O
VR	O
)	O
game	O
,	O
and	O
immersion	O
of	O
self	O
in	O
the	O
VR	O
game	O
.	O

Forty-two	O
students	O
with	O
autism	O
,	O
varying	O
in	O
age	O
and	O
expressive	O
communication	O
ability	O
,	O
were	O
randomly	O
assigned	O
to	O
the	O
experimental	O
conditions	O
.	O

Gaze	Mental
duration	Mental
and	O
vocalization	Mental
served	O
as	O
dependent	O
measures	O
of	O
engagement	O
.	O

The	O
results	O
reveal	O
differential	O
responding	O
across	O
ESM	Physical
,	O
with	O
some	O
variation	O
related	O
to	O
the	O
engagement	O
metric	O
employed	O
.	O

Preferences	O
for	O
seeing	Mental
themselves	Mental
on	Mental
the	Mental
screen	Mental
,	Mental
as	Mental
well	Mental
as	Mental
for	Mental
viewing	Mental
the	Mental
VR	Mental
scenarios	Mental
,	O
emerged	O
from	O
the	O
data	O
.	O

While	O
the	O
study	O
did	O
not	O
yield	O
definitive	O
data	O
about	O
the	O
relative	O
engagement	O
potential	O
of	O
ESM	O
alternatives	O
,	O
it	O
does	O
provide	O
a	O
foundation	O
for	O
future	O
research	O
,	O
including	O
guidance	O
related	O
to	O
participant	O
profiles	O
,	O
stimulus	O
characteristics	O
,	O
and	O
data	O
coding	O
challenges	O
.	O

Improving	O
patient	O
involvement	O
in	O
chronic	O
disease	O
management	O
:	O
the	O
views	O
of	O
patients	O
,	O
GPs	O
and	O
specialists	O
on	O
a	O
guidebook	O
for	O
ulcerative	O
colitis	O
.	O

Patient	O
information	O
,	O
shared	O
care	O
and	O
decision-making	O
are	O
recognised	O
as	O
beneficial	O
to	O
chronic	O
disease	O
management	O
.	O

As	O
part	O
of	O
an	O
RCT	O
,	O
opinions	O
of	O
ulcerative	O
colitis	O
patients	O
and	O
their	O
doctors	O
were	O
sought	O
on	O
a	O
guidebook	O
designed	O
to	O
support	O
self-care	O
and	O
mediate	O
doctor/patient	O
interaction	O
during	O
consultations	O
.	O

Semi-structured	O
interviews	O
were	O
conducted	O
with	O
6	O
specialists	O
and	O
16	O
GPs	O
.	O

Patients	O
'	O
views	O
were	O
obtained	O
from	O
written	O
responses	O
to	O
a	O
postal	O
questionnaire	O
(	O
136	O
replies	O
)	O
.	O

Inclusion	O
of	O
lay	O
knowledge	O
and	O
clarification	O
of	O
treatment	O
decision	O
processes	O
increased	O
patients	O
'	O
perception	O
of	O
involvement	O
in	O
disease	O
management	O
through	O
increased	O
identification	O
and	O
awareness	O
of	O
others	O
'	O
self-management	O
experiences	O
.	O

Doctors	O
focused	O
on	O
the	O
importance	O
of	O
improving	O
patients	O
'	O
compliance	O
and	O
use	O
of	O
services	O
.	O

However	O
,	O
the	O
guidebook	O
was	O
seldom	O
used	O
as	O
it	O
had	O
been	O
intended	O
during	O
consultations	O
.	O

Patients	O
felt	O
constrained	O
by	O
time	O
limits	O
and	O
consultants	O
did	O
not	O
actively	O
encourage	O
guidebook	O
use	O
.	O

Based	O
on	O
the	O
findings	O
,	O
we	O
suggest	O
an	O
approach	O
utilising	Others
the	Others
guidebook	Others
to	O
improve	O
patient	Mental
participation	Mental
in	O
disease	O
management	O
.	O

How	O
well	O
do	O
blood	Physical
folate	Physical
concentrations	Physical
predict	O
dietary	O
folate	O
intakes	O
in	O
a	O
sample	O
of	O
Canadian	O
lactating	O
women	O
exposed	O
to	O
high	O
levels	O
of	O
folate	O
?	O
An	O
observational	O
study	O
.	O

BACKGROUND	O
In	O
1998	O
,	O
mandatory	O
folic	O
acid	O
fortification	O
of	O
white	O
flour	O
and	O
select	O
cereal	O
grain	O
products	O
was	O
implemented	O
in	O
Canada	O
with	O
the	O
intention	O
to	O
increase	O
dietary	O
folate	O
intakes	O
of	O
reproducing	O
women	O
.	O

Folic	O
acid	O
fortification	O
has	O
produced	O
a	O
dramatic	O
increase	O
in	O
blood	O
folate	O
concentrations	O
among	O
reproductive	O
age	O
women	O
,	O
and	O
a	O
reduction	O
in	O
neural	O
tube	O
defect	O
(	O
NTD	O
)	O
-affected	O
pregnancies	O
.	O

In	O
response	O
to	O
improved	O
blood	O
folate	O
concentrations	O
,	O
many	O
health	O
care	O
professionals	O
are	O
asking	O
whether	O
a	O
folic	O
acid	O
supplement	O
is	O
necessary	O
for	O
NTD	O
prevention	O
among	O
women	O
with	O
high	O
blood	O
folate	O
values	O
,	O
and	O
how	O
reliably	O
high	O
RBC	O
folate	O
concentrations	O
predict	O
folate	O
intakes	O
shown	O
in	O
randomized	O
controlled	O
trials	O
to	O
be	O
protective	O
against	O
NTDs	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
how	O
predictive	O
blood	Physical
folate	Physical
concentrations	Physical
and	O
folate	Physical
intakes	Physical
are	O
of	O
each	O
other	O
in	O
a	O
sample	O
of	O
well-educated	O
lactating	O
Canadian	O
women	O
exposed	O
to	O
high	O
levels	O
of	O
synthetic	O
folate	O
.	O

METHODS	O
The	O
relationship	O
between	O
blood	Physical
folate	Physical
concentrations	Physical
and	O
dietary	Physical
folate	Physical
intakes	Physical
,	O
determined	O
by	O
weighed	O
food	O
records	O
,	O
were	O
assessed	O
in	O
a	O
sample	O
of	O
predominantly	O
university-educated	O
lactating	O
women	O
(	O
32	O
+/-	O
4	O
yr	O
)	O
at	O
4-	O
(	O
n	O
=	O
53	O
)	O
and	O
16-wk	O
postpartum	O
(	O
n	O
=	O
55	O
)	O
.	O

RESULTS	O
Median	O
blood	Physical
folate	Physical
concentrations	Physical
of	O
all	O
participants	O
were	O
well	O
above	O
plasma	O
and	O
RBC	O
folate	O
cut-off	O
levels	O
indicative	O
of	O
deficiency	O
(	O
6.7	O
and	O
317	O
nmol/L	O
,	O
respectively	O
)	O
and	O
all	O
,	O
except	O
for	O
2	O
subjects	O
,	O
were	O
above	O
the	O
cut-off	O
for	O
NTD-risk	O
reduction	O
(	O
>	O
906	O
nmol/L	O
)	O
.	O

Only	O
modest	O
associations	O
existed	O
between	O
total	Physical
folate	Physical
intakes	Physical
and	O
plasma	Physical
(	O
r	O
=	O
0.46	O
,	O
P	O
<	O
0.001	O
)	O
and	O
RBC	O
(	O
r	O
=	O
0.36	O
,	O
P	O
<	O
0.01	O
)	O
folate	Physical
concentrations	Physical
at	O
16-wk	O
postpartum	O
.	O

Plasma	Physical
and	Physical
RBC	Physical
folate	Physical
values	Physical
at	O
16-wk	O
postpartum	O
correctly	O
identified	O
the	O
quartile	O
of	O
folate	O
intake	O
of	O
only	O
26	O
of	O
55	O
(	O
47	O
%	O
)	O
and	O
18	O
of	O
55	O
(	O
33	O
%	O
)	O
of	O
subjects	O
,	O
respectively	O
.	O

The	O
mean	O
RBC	Physical
folate	Physical
concentration	Physical
of	O
women	O
consuming	O
151-410	O
microg/d	O
of	O
synthetic	O
folate	O
(	O
2nd	O
quartile	O
of	O
intake	O
)	O
did	O
not	O
differ	O
from	O
that	O
of	O
women	O
consuming	O
>	O
410	O
microg/d	O
(	O
3rd	O
and	O
4th	O
quartile	O
)	O
.	O

CONCLUSION	O
Folate	Physical
intakes	Physical
,	O
estimated	O
by	O
food	O
composition	O
tables	O
,	O
and	O
blood	Physical
folate	Physical
concentrations	Physical
are	O
not	O
predictive	O
of	O
each	O
other	O
in	O
Canadian	O
lactating	O
women	O
exposed	O
to	O
high	O
levels	O
of	O
folate	Physical
.	O

Synthetic	O
intakes	O
>	O
151-410	O
microg/d	O
in	O
these	O
women	O
produced	O
little	O
additional	O
benefit	O
in	O
terms	O
of	O
maximizing	O
RBC	O
content	O
.	O

More	O
studies	O
are	O
needed	O
to	O
examine	O
the	O
relationship	O
between	O
blood	Physical
folate	Physical
concentration	Physical
and	O
NTD	O
risk	O
.	O

Until	O
data	O
from	O
such	O
studies	O
are	O
available	O
,	O
women	O
planning	O
a	O
pregnancy	O
should	O
continue	O
to	O
consume	O
a	O
daily	O
folic	O
acid	O
supplement	O
of	O
400	O
microg	O
.	O

Propranolol	O
in	O
acute	O
myocardial	O
infarction	O
:	O
the	O
MILIS	O
experience	O
.	O

The	O
results	O
of	O
the	O
propranolol	O
limb	O
of	O
the	O
Multicenter	O
Investigation	O
of	O
the	O
Limitation	O
of	O
Infarct	O
Size	O
are	O
reviewed	O
.	O

A	O
total	O
of	O
269	O
patients	O
,	O
who	O
presented	O
with	O
symptoms	O
and	O
electrocardiographic	O
signs	O
suggesting	O
acute	O
myocardial	O
infarction	O
were	O
randomized	O
to	O
acute	O
intravenous	O
and	O
subsequent	O
oral	O
therapy	O
with	O
propranolol	O
(	O
n	O
=	O
134	O
)	O
or	O
placebo	O
(	O
n	O
=	O
135	O
)	O
.	O

Eligibility	O
for	O
acute	O
beta-blocker	O
therapy	O
was	O
determined	O
on	O
the	O
basis	O
of	O
readily	O
available	O
,	O
noninvasive	O
tests	O
.	O

Therapy	O
was	O
started	O
at	O
an	O
average	O
time	O
of	O
8.5	O
hours	O
after	O
onset	O
of	O
symptoms	O
.	O

The	O
full	O
induction	O
dose	O
of	O
intravenous	O
propranolol	O
(	O
0.1	O
mg/kg	O
)	O
was	O
tolerated	O
by	O
90	O
%	O
of	O
treated	O
patients	O
,	O
and	O
oral	O
maintenance	O
therapy	O
was	O
being	O
continued	O
in	O
82	O
%	O
of	O
treated	O
patients	O
on	O
the	O
second	O
hospital	O
day	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
heart	Physical
rate	Physical
throughout	O
maintenance	O
therapy	O
with	O
propranolol	O
,	O
which	O
continued	O
through	O
the	O
tenth	O
hospital	O
day	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	Physical
of	Physical
congestive	Physical
heart	Physical
failure	Physical
between	O
propranolol-	O
and	O
placebo-treated	O
groups	O
.	O

There	O
was	O
also	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
in	O
infarct	Physical
size	Physical
estimated	O
by	O
measurement	O
of	O
serum	Physical
CK-MB	Physical
,	Physical
planimetry	Physical
of	Physical
infarct	Physical
area	Physical
on	Physical
technetium	Physical
pyrophosphate	Physical
myocardial	Physical
scintigrams	Physical
or	Physical
R-wave	Physical
measurements	Physical
in	O
patients	O
with	O
transmural	O
anterior	O
and	O
inferior	O
infarcts	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
mortality	Mortality
between	O
the	O
2	O
groups	O
during	O
an	O
average	O
of	O
36	O
months	O
'	O
follow-up	O
.	O

Although	O
propranolol	O
can	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
acute	O
myocardial	O
infarction	O
who	O
are	O
selected	O
on	O
the	O
basis	O
of	O
simple	O
clinical	O
criteria	O
,	O
there	O
is	O
no	O
evidence	O
of	O
reduction	O
of	O
infarct	Physical
size	Physical
when	O
beta	O
blockade	O
is	O
begun	O
8.5	O
hours	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O

Severe	O
enteropathy	O
among	O
patients	O
with	O
stage	O
II/III	O
colon	O
cancer	O
treated	O
on	O
a	O
randomized	O
trial	O
of	O
bolus	O
5-fluorouracil/leucovorin	O
plus	O
or	O
minus	O
oxaliplatin	O
:	O
a	O
prospective	O
analysis	O
.	O

BACKGROUND	O
Cases	O
of	O
severe	O
gastrointestinal	O
toxicity	O
were	O
monitored	O
prospectively	O
during	O
NSABP	O
C-07	O
,	O
a	O
randomized	O
clinical	O
trial	O
of	O
adjuvant	O
therapy	O
for	O
patients	O
with	O
stage	O
II/III	O
colon	O
cancer	O
.	O

METHODS	O
Patients	O
were	O
treated	O
with	O
weekly	O
bolus	O
5-fluorouracil	O
(	O
5-FU	O
)	O
and	O
leucovorin	O
(	O
FL	O
;	O
Roswell	O
Park	O
Regimen	O
)	O
or	O
the	O
same	O
regimen	O
plus	O
oxaliplatin	O
(	O
FLOX	O
)	O
.	O

RESULTS	O
Of	O
1857	O
patients	O
,	O
79	O
(	O
4.3	O
%	O
)	O
developed	O
a	O
syndrome	Physical
of	Physical
bowel	Physical
wall	Physical
injury	Physical
(	Physical
BWI	Physical
,	Physical
small	Physical
or	Physical
large	Physical
)	Physical
characterized	O
by	O
hospitalization	O
for	O
the	O
management	O
of	O
severe	Physical
diarrhea	Physical
or	Physical
dehydration	Physical
and	Physical
radiographic	Physical
or	Physical
endoscopic	Physical
evidence	Physical
of	Physical
bowel	Physical
wall	Physical
thickening	Physical
or	Physical
ulceration	Physical
.	O

Fifty-one	O
(	O
64.6	O
%	O
)	O
of	O
these	O
adverse	Adverseeffect
events	Adverseeffect
occurred	O
in	O
patients	O
treated	O
with	O
FLOX	O
and	O
28	O
(	O
35.4	O
%	O
)	O
in	O
those	O
treated	O
with	O
FL	O
(	O
P	O
<	O
.01	O
)	O
.	O

Enteric	Physical
sepsis	Physical
(	Physical
ES	Physical
)	Physical
,	O
characterized	O
by	O
grade	Physical
3	Physical
or	Physical
greater	Physical
diarrhea	Physical
and	Physical
grade	Physical
4	Physical
neutropenia	Physical
with	Physical
or	Physical
without	Physical
proven	Physical
bacteremia	Physical
occurred	O
in	O
22	O
patients	O
treated	O
with	O
FLOX	O
,	O
versus	O
8	O
in	O
those	O
treated	O
with	O
FL	O
(	O
P	O
=	O
.01	O
)	O
.	O

Patients	O
>	O
60	O
years	O
were	O
at	O
higher	Physical
risk	Physical
for	Physical
BWI	Physical
after	O
treatment	O
with	O
FLOX	O
(	O
6.7	O
%	O
)	O
versus	O
treatment	O
with	O
FL	O
(	O
2.9	O
%	O
,	O
P	O
<	O
.01	O
)	O
.	O

Female	O
patients	O
had	O
a	O
higher	Physical
incidence	Physical
of	Physical
BWI	Physical
with	O
FLOX	O
(	O
9.1	O
%	O
)	O
than	O
with	O
FL	O
(	O
3.9	O
%	O
,	O
P	O
<	O
.01	O
)	O
.	O

Severe	Physical
gastrointestinal	Physical
toxicity	Physical
usually	O
occurred	O
during	O
the	O
third	O
or	O
fourth	O
week	O
on	O
the	O
first	O
cycle	O
of	O
therapy	O
,	O
required	O
hospitalization	O
,	O
and	O
was	O
managed	O
with	O
fluids	O
,	O
antidiarrheals	O
,	O
and	O
antibiotics	O
.	O

There	O
were	O
5	O
deaths	Mortality
(	O
0.3	O
%	O
)	O
due	O
to	O
enteropathy	O
,	O
2	O
related	O
to	O
ES	O
and	O
3	O
related	O
to	O
both	O
BWI	O
and	O
ES	O
.	O

Seventy-one	O
percent	O
of	O
patients	O
resumed	O
treatment	O
with	O
FL	O
after	O
recovery	O
.	O

CONCLUSIONS	O
Patients	O
treated	O
with	O
adjuvant	O
FL	O
should	O
be	O
closely	O
monitored	O
for	O
diarrhea	Adverseeffect
and	O
aggressively	O
managed	O
,	O
especially	O
if	O
oxaliplatin	O
has	O
been	O
added	O
to	O
the	O
regimen	O
.	O

Society	O
.	O

[	O
Intraoperative	O
continuous	O
epidural	O
block	O
influences	O
postoperative	O
changes	O
in	O
breathing	O
pattern	O
and	O
thoracoabdominal	O
movement	O
associated	O
with	O
upper	O
abdominal	O
surgery	O
]	O
.	O

We	O
have	O
examined	O
the	O
changes	O
in	O
breathing	O
pattern	O
and	O
thoracoabdominal	O
movement	O
associated	O
with	O
upper	O
abdominal	O
surgery	O
in	O
order	O
to	O
evaluate	O
the	O
possible	O
influences	O
of	O
nociceptive	O
input	O
on	O
respiration	O
.	O

Sixteen	O
patients	O
scheduled	O
for	O
gastrectomy	O
were	O
studied	O
.	O

Continuous	O
epidural	O
block	O
was	O
instituted	O
prior	O
to	O
the	O
induction	O
of	O
anesthesia	O
and	O
maintained	O
throughout	O
the	O
surgery	O
in	O
8	O
of	O
16	O
patients	O
(	O
Group	O
1	O
)	O
while	O
it	O
was	O
instituted	O
upon	O
the	O
peritoneal	O
closure	O
and	O
maintained	O
thereafter	O
in	O
the	O
remaining	O
8	O
patients	O
(	O
Group	O
2	O
)	O
.	O

Breathing	Physical
pattern	Physical
and	Physical
thoracoabdominal	Physical
motion	Physical
were	O
determined	O
before	O
and	O
after	O
surgery	O
while	O
the	O
patients	O
awake	O
by	O
respiratory	O
inductance	O
plethysmography	O
(	O
Respisomnography	O
,	O
Chest	O
MI	O
)	O
.	O

Breathing	Physical
frequency	Physical
and	Physical
minute	Physical
ventilation	Physical
increased	O
significantly	O
while	O
tidal	O
volume	O
was	O
unchanged	O
after	O
the	O
operation	O
regardless	O
of	O
the	O
intraoperative	O
epidural	O
block	O
.	O

Furthermore	O
,	O
there	O
were	O
identical	O
shortening	O
of	O
inspiratory	Physical
time	Physical
and	Physical
prolongation	Physical
of	Physical
duty	Physical
ratio	Physical
(	O
inspiratory	O
time/duration	O
of	O
a	O
breath	O
)	O
in	O
the	O
two	O
groups	O
.	O

Contribution	Physical
of	Physical
rib	Physical
cage	Physical
movement	Physical
on	Physical
tidal	Physical
volume	Physical
increased	O
significantly	O
postoperatively	O
in	O
all	O
the	O
patients	O
.	O

However	O
,	O
the	O
changes	O
were	O
significantly	O
smaller	O
in	O
patients	O
receiving	O
intraoperative	O
epidural	O
block	O
.	O

These	O
results	O
indicate	O
that	O
the	O
causes	O
of	O
tachypnea	O
and	O
increased	O
minute	O
ventilation	O
are	O
different	O
from	O
the	O
mechanism	O
responsible	O
for	O
the	O
alteration	O
of	O
thoracoabdominal	O
partitioning	O
of	O
ventilation	O
after	O
upper	O
abdominal	O
surgery	O
.	O

The	O
former	O
may	O
be	O
related	O
to	O
the	O
metabolic	O
changes	O
and	O
,	O
conceivably	O
,	O
unaffected	O
by	O
continuous	O
epidural	O
block	O
.	O

While	O
the	O
latter	O
may	O
be	O
the	O
consequence	O
of	O
the	O
reflex	O
inhibition	O
of	O
the	O
diaphragmatic	O
function	O
that	O
can	O
be	O
,	O
at	O
least	O
partially	O
,	O
modified	O
by	O
continuous	O
epidural	O
block	O
.	O

A	O
randomized	O
crossover	O
study	O
investigating	O
the	O
influence	O
of	O
ranitidine	O
or	O
omeprazole	O
on	O
the	O
pharmacokinetics	Physical
of	Physical
cephalexin	Physical
monohydrate	Physical
.	Physical

Limited	O
data	O
characterize	O
pharmacokinetic	O
interactions	O
between	O
cephalexin	O
and	O
ranitidine	O
,	O
and	O
no	O
data	O
exist	O
for	O
an	O
interaction	O
with	O
proton	O
pump	O
inhibitors	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
ranitidine	O
or	O
omeprazole	O
administration	O
on	O
the	O
pharmacokinetics	Physical
and	Physical
pharmacodynamics	Physical
of	Physical
cephalexin	Physical
.	O

A	O
randomized	O
single-	O
and	O
multiple-dose	O
crossover	O
study	O
was	O
conducted	O
in	O
healthy	O
subjects	O
ingesting	O
cephalexin	O
before	O
and	O
after	O
steady-state	O
administration	O
of	O
ranitidine	O
or	O
omeprazole	O
.	O

Time-concentration	Others
profiles	O
were	O
determined	O
and	O
pharmacokinetic	Physical
parameters	Physical
were	O
characterized	O
using	O
noncompartmental	O
methods	O
.	O

Pharmacokinetic	O
data	O
were	O
analyzed	O
in	O
accordance	O
with	O
the	O
two	O
1-sided	O
test	O
for	O
bioequivalence	O
.	O

The	O
percentage	Physical
of	Physical
time	Physical
that	Physical
serum	Physical
concentrations	Physical
remain	Physical
above	Physical
the	Physical
MIC	Physical
(	Physical
90	Physical
)	Physical
during	Physical
the	Physical
dosing	Physical
interval	Physical
(	Physical
T	Physical
>	Physical
MIC	Physical
(	Physical
90	Physical
)	Physical
)	Physical
for	O
Streptococcus	Physical
pyogenes	Physical
and	O
Staphylococcus	O
aureus	O
associated	O
with	O
the	O
pharmacokinetic	O
profiles	O
was	O
calculated	O
.	O

The	O
coadministration	O
of	O
cephalexin	O
with	O
ranitidine	O
or	O
omeprazole	O
resulted	O
in	O
relatively	O
minor	O
changes	O
in	O
C	Others
(	Others
max	Others
)	Others
,	Physical
AUC	Others
(	Others
infinity	Others
)	Others
,	Physical
t	Others
(	Others
1/2	Others
)	Others
,	Physical
or	Physical
CL/F	Others
.	O

t	Physical
(	Physical
max	Physical
)	Physical
was	O
significantly	O
prolonged	O
when	O
cephalexin	O
was	O
administered	O
with	O
ranitidine	O
or	O
omeprazole	O
.	O

Suboptimal	Physical
T	Physical
>	Physical
MIC	Physical
(	Physical
90	Physical
)	Physical
was	O
observed	O
for	O
cephalexin	O
irrespective	O
of	O
acid	O
suppression	O
.	O

Delay	O
in	O
absorption	O
of	O
cephalexin	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
percentage	O
of	O
T	Physical
>	Physical
MIC	Physical
(	Physical
90	Physical
)	Physical
for	O
certain	O
acid-suppressive	O
regimens	O
and	O
pathogen	O
combinations	O
.	O

With	O
the	O
exception	O
of	O
an	O
increase	O
in	O
t	Physical
(	Physical
max	Physical
)	Physical
,	O
there	O
were	O
no	O
significant	O
pharmacokinetic	O
interactions	O
between	O
cephalexin	O
and	O
ranitidine	O
or	O
omeprazole	O
.	O

Delayed	O
t	Physical
(	Physical
max	Physical
)	Physical
associated	O
with	O
acid	O
suppression	O
may	O
result	O
in	O
a	O
diminished	O
T	O
>	O
MIC	O
(	O
90	O
)	O
.	O

Lengthening	O
the	O
moment	O
arm	O
of	O
the	O
patella	O
confers	O
enhanced	O
extensor	Physical
mechanism	Physical
power	Physical
following	O
total	O
knee	O
arthroplasty	O
.	O

We	O
investigated	O
whether	O
a	O
postulated	O
biomechanical	O
advantage	O
conferred	O
to	O
the	O
extensor	O
mechanism	O
by	O
a	O
change	O
in	O
knee	O
implant	O
design	O
was	O
detectable	O
in	O
patients	O
by	O
direct	O
physical	O
testing	O
.	O

212	O
TKA	O
patients	O
were	O
enrolled	O
in	O
a	O
double	O
blind	O
randomized	O
controlled	O
trial	O
to	O
receive	O
either	O
a	O
traditional	O
implant	O
or	O
one	O
which	O
incorporated	O
new	O
design	O
features	O
.	O

Extensor	Physical
mechanism	Physical
power	Physical
output	Physical
and	O
physical	Physical
performance	Physical
on	Physical
a	Physical
battery	Physical
of	Physical
timed	Physical
functional	Physical
activities	Physical
was	O
assessed	O
pre-operatively	O
and	O
then	O
at	O
6	O
,	O
26	O
,	O
and	O
52	O
weeks	O
post-operatively	O
.	O

Significantly	O
enhanced	O
power	Physical
output	Physical
was	O
observed	O
in	O
both	O
groups	O
post-arthroplasty	O
;	O
however	O
,	O
the	O
new	O
design	O
implant	O
group	O
demonstrated	O
a	O
greater	O
change	O
in	O
power	Physical
output	Physical
than	O
the	O
traditional	O
implant	O
group	O
.	O

Posthoc	Physical
testing	Physical
of	O
between	O
group	O
differences	O
highlighted	O
greater	O
improvement	O
at	O
all	O
post-operative	Mental
assessments	Mental
.	O

At	O
52	O
weeks	O
,	O
patients	O
receiving	O
the	O
implant	O
with	O
the	O
postulated	O
biomechanical	O
advantage	O
achieved	O
116	O
%	O
of	O
the	O
power	Physical
output	Physical
of	Physical
their	Physical
contralateral	Physical
limb	Physical
,	O
whereas	O
patients	O
with	O
the	O
traditional	O
design	O
achieved	O
90	O
%	O
.	O

No	O
between	O
group	O
difference	O
was	O
detected	O
in	O
the	O
patient	O
's	O
time	O
to	O
complete	O
functional	O
tasks	O
.	O

Thus	O
,	O
patients	O
receiving	O
a	O
knee	O
implant	O
of	O
a	O
modern	O
design	O
(	O
theoretically	O
able	O
to	O
confer	O
a	O
mechanical	O
advantage	O
to	O
the	O
extensor	O
mechanism	O
)	O
were	O
found	O
to	O
generate	O
significantly	O
greater	O
extensor	Physical
power	Physical
than	O
those	O
receiving	O
a	O
traditional	O
implant	O
without	O
the	O
postulated	O
mechanical	O
advantage	O
.	O

Extra	O
prompts	O
versus	O
no	O
extra	O
prompts	O
in	O
self-care	O
training	O
of	O
autistic	O
children	O
and	O
adolescents	O
.	O

A	O
color-coded	O
extra	O
prompt	O
procedure	O
was	O
compared	O
to	O
a	O
no	O
extra	O
prompt	O
procedure	O
in	O
teaching	O
autistic	O
children	O
and	O
adolescents	O
how	O
to	O
lace	O
shoes	O
.	O

One	O
randomly	O
assigned	O
group	O
of	O
10	O
autistic	O
subjects	O
first	O
learned	O
to	O
lace	O
shoes	O
whose	O
laces	O
and	O
eyelets	O
were	O
color-coded	O
red	O
and	O
white	O
,	O
and	O
then	O
encountered	O
the	O
no	O
extra	O
prompt	O
condition	O
in	O
which	O
color	O
codes	O
could	O
no	O
longer	O
be	O
depended	O
upon	O
to	O
solve	O
the	O
position	O
discriminations	O
required	O
to	O
lace	O
properly	O
.	O

In	O
a	O
counterbalanced	O
fashion	O
,	O
the	O
other	O
group	O
of	O
10	O
autistic	O
subjects	O
reached	O
criterion	O
on	O
the	O
non-color-coded	O
,	O
naturalistic	O
shoe	O
before	O
experiencing	O
the	O
extra	O
prompt	O
condition	O
.	O

Analysis	O
of	O
variance	O
and	O
post-hoc	O
analyses	O
suggest	O
that	O
subjects	O
who	O
first	O
learned	O
under	O
the	O
color-coded	O
,	O
extra	O
prompt	O
condition	O
encountered	O
significant	O
difficulty	O
in	O
transferring	O
their	O
newly	O
acquired	O
skill	O
to	O
the	O
naturalistic	O
,	O
non-color-coded	O
condition	O
,	O
whereas	O
subjects	O
who	O
learned	O
initially	O
without	O
the	O
extra	O
prompts	O
had	O
little	O
difficulty	O
with	O
the	O
subsequent	O
color-coded	O
condition	O
.	O

A	O
follow-up	O
procedure	O
requiring	O
all	O
subjects	O
to	O
choose	O
between	O
the	O
color	O
prompt	O
and	O
the	O
position	O
cue	O
revealed	O
that	O
11	O
of	O
20	O
subjects	O
consistently	O
chose	O
the	O
color	O
cue	O
,	O
even	O
though	O
it	O
resulted	O
in	O
improper	O
lacing	O
.	O

It	O
is	O
recommended	O
that	O
clinicians	O
avoid	O
the	O
use	O
of	O
highly	O
salient	O
,	O
non-criterion-related	O
prompts	O
in	O
teaching	O
certain	O
types	O
of	O
adaptive	O
skills	O
to	O
autistic	O
children	O
.	O

Randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
clinical	O
trial	O
evaluating	O
the	O
treatment	O
of	O
plantar	O
fasciitis	O
with	O
an	O
extracoporeal	O
shockwave	O
therapy	O
(	O
ESWT	O
)	O
device	O
:	O
a	O
North	O
American	O
confirmatory	O
study	O
.	O

Despite	O
numerous	O
publications	O
and	O
clinical	O
trials	O
,	O
the	O
results	O
of	O
treatment	O
of	O
recalcitrant	O
chronic	O
plantar	O
fasciitis	O
with	O
extracorporeal	O
shockwave	O
therapy	O
(	O
ESWT	O
)	O
still	O
remain	O
equivocal	O
as	O
to	O
whether	O
or	O
not	O
this	O
treatment	O
provides	O
relief	Others
from	O
the	Pain
pain	Pain
associated	O
with	O
this	O
condition	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
extracorporeal	O
shock	O
wave	O
therapy	O
can	O
safely	Others
and	O
effectively	Others
relieve	Others
the	Others
pain	Others
associated	O
with	O
chronic	O
plantar	O
fasciitis	O
compared	O
to	O
placebo	O
treatment	O
,	O
as	O
demonstrated	O
by	O
pain	O
with	O
walking	O
in	O
the	O
morning	O
.	O

This	O
was	O
set	O
in	O
a	O
multicenter	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
,	O
confirmatory	O
clinical	O
study	O
undertaken	O
in	O
four	O
outpatient	O
orthopedic	O
clinics	O
.	O

The	O
patients	O
,	O
114	O
adult	O
subjects	O
with	O
chronic	O
plantar	O
fasciitis	O
,	O
recalcitrant	O
to	O
conservative	O
therapies	O
for	O
at	O
least	O
6	O
months	O
,	O
were	O
randomized	O
to	O
two	O
groups	O
.	O

Treatment	O
consisted	O
of	O
approximately	O
3,800	O
total	O
shock	O
waves	O
(	O
+/-10	O
)	O
reaching	O
an	O
approximated	O
total	O
energy	O
delivery	O
of	O
1,300	O
mJ/mm	O
(	O
2	O
)	O
(	O
ED+	O
)	O
in	O
a	O
single	O
session	O
versus	O
placebo	O
treatment	O
.	O

This	O
study	O
demonstrated	O
a	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
the	O
change	O
from	O
baseline	O
to	O
3	O
months	O
in	O
the	O
primary	O
efficacy	O
outcome	O
of	O
pain	Pain
during	O
the	Others
first	Others
few	Others
minutes	Others
of	O
walking	O
measured	O
by	O
a	O
visual	Pain
analog	Pain
scale	Pain
.	O

There	O
was	O
also	O
a	O
statistically	O
significant	O
difference	O
between	O
treatments	O
in	O
the	O
number	O
of	O
participants	O
whose	O
changes	O
in	O
Visual	Pain
Analog	Pain
Scale	Pain
scores	Pain
met	O
the	O
study	O
definition	O
of	O
success	O
at	O
both	O
6	O
weeks	O
and	O
3	O
months	O
posttreatment	O
;	O
and	O
between	O
treatment	O
groups	O
in	O
the	O
change	O
from	O
baseline	O
to	O
3	O
months	O
posttreatment	O
in	O
the	O
Roles	Pain
and	Pain
Maudsley	Pain
Score	Pain
.	O

The	O
results	O
of	O
this	O
study	O
confirm	O
that	O
ESWT	O
administered	O
with	O
the	O
Dornier	O
Epos	O
Ultra	O
is	O
a	O
safe	Others
and	O
effective	Others
treatment	O
for	O
recalcitrant	O
plantar	O
fasciitis	O
.	O

Calcium	O
acetate	O
versus	O
calcium	O
carbonate	O
as	O
phosphate	O
binders	O
in	O
hemodialysis	O
patients	O
.	O

We	O
conducted	O
a	O
randomized	O
unblinded	O
parallel	O
clinical	O
trial	O
to	O
compare	O
the	O
effectiveness	Others
,	O
side	Adverseeffect
effects	Adverseeffect
and	O
tolerance	Physical
between	Physical
calcium	Physical
acetate	Physical
(	Physical
CA	Physical
)	Physical
and	Physical
calcium	Physical
carbonate	Physical
(	Physical
CC	Physical
)	Physical
in	O
80	O
stable	O
chronic	O
hemodialysis	O
patients	O
selected	O
on	O
the	O
basis	O
of	O
their	O
acceptable	O
control	O
of	O
serum	O
phosphorus	O
(	O
P	O
)	O
levels	O
with	O
aluminum	O
hydroxide	O
(	O
AH	O
)	O
.	O

All	O
patients	O
were	O
dialyzed	O
against	O
the	O
same	O
calcium	O
dialyzate	O
(	O
1.62	O
mmol/l	O
)	O
.	O

The	O
serum	O
analytical	O
tests	O
included	O
:	O
calcium	Physical
corrected	Physical
to	Physical
total	Physical
protein	Physical
,	Physical
P	Physical
,	Physical
PTH	Physical
(	Physical
intact	Physical
molecule	Physical
)	Physical
and	Physical
bicarbonate	Physical
.	O

The	O
study	O
was	O
divided	O
into	O
the	O
following	O
periods	O
:	O
P0	O
:	O
baseline	O
measurements	O
;	O
P1	O
:	O
washout	O
(	O
withdrawal	O
of	O
AH	O
for	O
15	O
days	O
)	O
;	O
P2	O
:	O
random	O
allocation	O
to	O
CA	O
and	O
CC	O
treatment	O
at	O
doses	O
equivalent	O
to	O
75	O
mEq	O
of	O
elemental	O
calcium	O
,	O
stratified	O
according	O
to	O
previous	O
doses	O
of	O
AH	O
(	O
2	O
months	O
)	O
;	O
P3	O
:	O
adjustment	O
of	O
doses	O
until	O
control	O
P	O
(	O
2	O
months	O
)	O
.	O

CA	Others
was	Others
poorly	Others
tolerated	Others
in	O
7	O
patients	O
and	O
CC	O
in	O
2	O
(	O
NS	O
)	O
.	O

The	O
changes	Physical
in	Physical
serum	Physical
P	Physical
levels	Physical
between	O
P0	O
and	O
P2	O
periods	O
were	O
lower	O
in	O
the	O
CA	O
group	O
(	O
1.73	O
+/-	O
0.25	O
vs.	O
1.80	O
+/-	O
0.50	O
mmol/l	O
;	O
p	O
=	O
0.26	O
)	O
than	O
in	O
the	O
CC	O
group	O
(	O
1.77	O
+/-	O
0.35	O
vs.	O
1.93	O
+/-	O
0.48	O
mmol/l	O
;	O
p	O
=	O
0.03	O
,	O
paired	O
t	O
test	O
)	O
.	O

Serum	Physical
calcium	Physical
was	O
hardly	O
modified	O
by	O
CA	O
(	O
2.42	O
+/-	O
0.20	O
vs.	O
2.47	O
+/-	O
0.17	O
mmol/l	O
;	O
NS	O
)	O
while	O
in	O
the	O
CC	O
group	O
,	O
it	O
rose	O
significantly	O
(	O
2.40	O
+/-	O
0.12	O
vs.	O
2.55	O
+/-	O
0.22	O
mmol/l	O
;	O
p	O
=	O
0.0004	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
control	O
of	O
PTH	O
or	O
bicarbonate	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Overexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
cellular	O
receptor	O
KDR	O
(	O
VEGFR-2	O
)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
cellular	O
receptor	O
VEGFR-2	O
have	O
been	O
implicated	O
as	O
the	O
main	O
endothelial	O
pathway	O
required	O
for	O
tumor	O
neovascularization	O
.	O

However	O
,	O
the	O
importance	O
of	O
the	O
VEGF/VEGFR-2	O
system	O
for	O
angiogenesis	O
in	O
hematologic	O
malignancies	O
such	O
as	O
AML	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
32	O
patients	O
with	O
newly	O
diagnosed	O
untreated	O
AML	O
,	O
we	O
observed	O
by	O
immunohistochemical	O
analysis	O
of	O
bone	O
marrow	O
biopsies	O
significantly	O
higher	O
levels	O
of	O
VEGF	O
and	O
VEGFR-2	O
expression	O
than	O
in	O
10	O
control	O
patients	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
contrast	O
,	O
VEGFR-1	O
staining	O
levels	O
in	O
AML	O
patients	O
were	O
in	O
the	O
same	O
range	O
as	O
in	O
the	O
controls	O
.	O

Expression	Physical
of	Physical
VEGF	Physical
and	Physical
VEGFR-2	Physical
was	O
significantly	O
higher	O
in	O
patients	O
with	O
a	O
high	O
degree	O
of	O
microvessel	O
density	O
compared	O
to	O
those	O
with	O
a	O
low	O
degree	O
(	O
VEGF	O
:	O
P	O
=0.024	O
;	O
VEGFR-2	O
:	O
P	O
=0.040	O
)	O
and	O
correlated	O
well	O
with	O
bone	O
marrow	O
microvessel	O
density	O
(	O
r	O
(	O
s	O
)	O
=0.566	O
and	O
0.609	O
,	O
respectively	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Furthermore	O
,	O
in	O
patients	O
who	O
achieved	O
a	O
complete	O
remission	Physical
following	O
induction	O
chemotherapy	O
VEGFR-2	Physical
staining	Physical
levels	Physical
decreased	O
into	O
the	O
normal	O
range	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
provide	O
evidence	O
for	O
increased	O
expression	O
of	O
VEGF/VEGFR-2	Physical
of	Physical
leukemic	Physical
blasts	Physical
and	O
correlation	O
with	O
angiogenesis	O
in	O
the	O
bone	O
marrow	O
of	O
AML	O
patients	O
.	O

Thus	O
,	O
VEGF/VEGFR-2	O
might	O
constitute	O
promising	O
targets	O
for	O
antiangiogenic	O
and	O
antileukemic	O
treatment	O
strategies	O
in	O
AML	O
.	O

Olanzapine	O
versus	O
haloperidol	O
in	O
children	O
with	O
autistic	Physical
disorder	Physical
:	O
an	O
open	O
pilot	O
study	O
.	O

OBJECTIVES	O
Conventional	O
neuroleptics	O
ameliorate	O
symptoms	O
in	O
children	O
with	O
autistic	O
disorder	O
;	O
however	O
,	O
they	O
are	O
known	O
to	O
cause	O
dyskinesias	O
.	O

Atypical	O
neuroleptics	O
,	O
including	O
olanzapine	O
,	O
may	O
have	O
less	O
risk	O
for	O
dyskinesia	O
,	O
but	O
their	O
efficacy	O
in	O
autistic	O
disorder	O
is	O
not	O
established	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
safety	O
and	O
effectiveness	O
of	O
open-label	O
olanzapine	O
as	O
a	O
treatment	O
for	O
children	O
with	O
autistic	O
disorder	O
by	O
using	O
haloperidol	O
as	O
a	O
standard	O
comparator	O
treatment	O
.	O

METHOD	O
In	O
a	O
parallel	O
groups	O
design	O
,	O
12	O
children	O
with	O
DSM-IV	O
autistic	O
disorder	O
(	O
mean	O
age	O
7.8+/-2.1	O
years	O
)	O
were	O
randomized	O
to	O
6	O
weeks	O
of	O
open	O
treatment	O
with	O
olanzapine	O
or	O
haloperidol	O
.	O

Mean	O
final	O
dosages	O
were	O
7.9+/-2.5	O
mg/day	O
for	O
olanzapine	O
and	O
1.4+/-0.7	O
mg/day	O
for	O
haloperidol	O
.	O

Outcome	O
measures	O
included	O
the	O
Clinical	Mental
Global	Mental
Impressions	Mental
(	Mental
CGI	Mental
)	Mental
and	O
the	Mental
Children	Mental
's	Mental
Psychiatric	Mental
Rating	Mental
Scale	Mental
(	Mental
CPRS	Mental
)	Mental
.	O

RESULTS	O
Both	O
groups	O
had	O
symptom	Mental
reduction	Mental
.	O

Five	O
of	O
six	O
in	O
the	O
olanzapine	O
group	O
and	O
three	O
of	O
six	O
in	O
the	O
haloperidol	O
group	O
were	O
rated	O
as	O
responders	O
according	O
to	O
the	O
CGI	Mental
Improvement	O
item	O
.	O

Subjects	O
showed	O
improvement	O
on	O
the	O
CPRS	Mental
Autism	Mental
Factor	Mental
(	O
F1,9	O
=	O
24.4	O
,	O
p	O
=	O
.0008	O
)	O
.	O

Side	O
effects	O
included	O
drowsiness	Adverseeffect
and	Adverseeffect
weight	Adverseeffect
gain	Adverseeffect
.	O

CONCLUSIONS	O
The	O
findings	O
suggest	O
that	O
olanzapine	O
is	O
a	O
promising	O
treatment	O
for	O
children	O
with	O
autistic	O
disorder	O
.	O

Further	O
placebo-controlled	O
and	O
long-term	O
studies	O
of	O
olanzapine	O
in	O
autistic	O
disorder	O
are	O
required	O
.	O

Components	O
of	O
working	O
memory	O
and	O
visual	O
selective	O
attention	O
.	O

Load	O
theory	O
(	O
Lavie	O
,	O
N.	O
,	O
Hirst	O
,	O
A.	O
,	O
De	O
Fockert	O
,	O
J.	O
W.	O
,	O
&	O
Viding	O
,	O
E.	O
[	O
2004	O
]	O
.	O

Load	O
theory	O
of	O
selective	O
attention	O
and	O
cognitive	O
control	O
.	O

Journal	O
of	O
Experimental	O
Psychology	O
:	O
General	O
,	O
133	O
,	O
339-354	O
.	O

)	O
proposes	O
that	O
control	Mental
of	Mental
attention	Mental
depends	O
on	O
the	O
amount	Mental
and	Mental
type	Mental
of	Mental
load	Mental
that	O
is	O
imposed	O
by	O
current	O
processing	O
.	O

Specifically	O
,	O
perceptual	O
load	O
should	O
lead	O
to	O
efficient	O
distractor	O
rejection	O
,	O
whereas	O
working	O
memory	O
load	O
(	O
dual-task	O
coordination	O
)	O
should	O
hinder	O
distractor	Mental
rejection	Mental
.	Mental

Studies	O
support	O
load	O
theory	O
's	O
prediction	O
that	O
working	O
memory	O
load	O
will	O
lead	O
to	O
larger	O
distractor	Mental
effects	Mental
;	Mental
however	O
,	O
these	O
studies	O
used	O
secondary	O
tasks	O
that	O
required	O
only	O
verbal	O
working	O
memory	O
and	O
the	O
central	O
executive	O
.	O

The	O
present	O
study	O
examined	O
which	O
other	O
working	O
memory	O
components	O
(	O
visual	O
,	O
spatial	O
,	O
and	O
phonological	O
)	O
influence	O
visual	Mental
selective	Mental
attention	Mental
.	Mental

Subjects	O
completed	O
an	O
attentional	Mental
capture	Mental
task	Mental
alone	O
(	O
single-task	O
)	O
or	O
while	O
engaged	O
in	O
a	O
working	O
memory	O
task	O
(	O
dual-task	O
)	O
.	O

Results	O
showed	O
that	O
along	O
with	O
the	O
central	O
executive	O
,	O
visual	O
and	O
spatial	O
working	O
memory	O
influenced	O
selective	Mental
attention	Mental
,	O
but	O
phonological	O
working	O
memory	O
did	O
not	O
.	O

Specifically	O
,	O
attentional	Mental
capture	Mental
was	O
larger	O
when	O
visual	O
or	O
spatial	O
working	O
memory	O
was	O
loaded	O
,	O
but	O
phonological	O
working	O
memory	O
load	O
did	O
not	O
affect	O
attentional	Mental
capture	Mental
.	O

The	O
results	O
are	O
consistent	O
with	O
load	O
theory	O
and	O
suggest	O
specific	O
components	O
of	O
working	O
memory	O
influence	O
visual	Mental
selective	Mental
attention	Mental
.	O

A	O
multi-center	O
,	O
randomized	O
,	O
controlled	O
trial	O
of	O
parenteral	O
nutrition	O
titrated	O
to	O
resting	O
energy	O
expenditure	O
in	O
children	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
PNTREE	O
)	O
:	O
rationale	O
and	O
design	O
.	O

BACKGROUND	O
Children	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
frequently	O
require	O
prolonged	O
courses	O
of	O
parenteral	O
nutrition	O
(	O
PN	O
)	O
as	O
a	O
consequence	O
of	O
gastrointestinal	O
dysfunction	O
related	O
to	O
preparative	O
chemotherapy	O
and	O
radiation	O
.	O

PN	O
has	O
been	O
associated	O
with	O
shorter	O
engraftment	O
time	O
and	O
decreased	O
mortality	O
during	O
HSCT	O
,	O
however	O
,	O
it	O
is	O
also	O
linked	O
with	O
complications	O
,	O
including	O
infections	Physical
,	Adverseeffect
liver	Physical
disease	Physical
,	Adverseeffect
and	Adverseeffect
metabolic	Physical
disturbances	Physical
.	Adverseeffect

Some	O
of	O
these	O
complications	O
may	O
be	O
a	O
result	O
of	O
providing	O
PN	O
in	O
excess	O
of	O
nutrient	O
requirements	O
.	O

We	O
previously	O
described	O
significant	O
reductions	O
in	O
resting	O
energy	O
expenditure	O
(	O
REE	O
)	O
,	O
as	O
measured	O
by	O
indirect	O
calorimetry	O
,	O
over	O
the	O
course	O
of	O
HSCT	O
.	O

We	O
also	O
documented	O
a	O
decline	O
in	O
mid-arm	O
muscle	O
area	O
,	O
suggesting	O
depletion	O
of	O
muscle	O
mass	O
,	O
while	O
triceps	O
skinfold	O
,	O
a	O
marker	O
of	O
fat	O
stores	O
,	O
was	O
unchanged	O
.	O

These	O
results	O
suggested	O
the	O
need	O
for	O
further	O
study	O
of	O
energy	O
expenditure	O
,	O
body	O
composition	O
and	O
nutritional	O
intake	O
in	O
this	O
group	O
of	O
high	O
risk	O
patients	O
.	O

DESIGN	O
AND	O
HYPOTHESIS	O
We	O
hypothesize	O
that	O
changes	O
in	O
body	O
composition	O
affect	O
REE	O
during	O
HSCT	O
,	O
and	O
that	O
standard	O
nutritional	O
support	O
may	O
lead	O
to	O
overfeeding	O
.	O

We	O
are	O
performing	O
a	O
randomized	O
controlled	O
trial	O
of	O
parenteral	O
nutrition	O
among	O
children	O
undergoing	O
allogeneic	O
HSCT	O
.	O

Subjects	O
are	O
randomized	O
to	O
receive	O
PN	O
designed	O
to	O
provide	O
100	O
%	O
of	O
measured	O
REE	O
,	O
or	O
standard	O
PN	O
,	O
i.e.	O
,	O
140	O
%	O
of	O
estimated	O
energy	O
expenditure	O
.	O

The	O
primary	O
outcome	O
variable	O
is	O
change	Physical
in	Physical
percent	Physical
body	Physical
fat	Physical
.	Physical

Secondary	O
outcomes	O
include	O
glycemic	Physical
control	Physical
and	Physical
frequency	Physical
of	Physical
infections	Physical
,	Physical
changes	Physical
in	Physical
REE	Physical
and	Physical
body	Physical
composition	Physical
.	Physical

CONCLUSION	O
This	O
study	O
will	O
provide	O
unique	O
and	O
comprehensive	O
nutritional	O
data	O
and	O
its	O
results	O
will	O
guide	O
nutritional	O
therapy	O
for	O
children	O
undergoing	O
HSCT	O
and	O
possibly	O
other	O
catabolic	O
patients	O
.	O

Lowering	O
the	O
triglyceride/high-density	Physical
lipoprotein	Physical
cholesterol	Physical
ratio	Physical
is	O
associated	O
with	O
the	O
beneficial	O
impact	O
of	O
pioglitazone	O
on	O
progression	O
of	O
coronary	Physical
atherosclerosis	Physical
in	O
diabetic	O
patients	O
:	O
insights	O
from	O
the	O
PERISCOPE	O
(	O
Pioglitazone	O
Effect	O
on	O
Regression	O
of	O
Intravascular	O
Sonographic	O
Coronary	O
Obstruction	O
Prospective	O
Evaluation	O
)	O
study	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
factors	O
associated	O
with	O
the	O
favorable	O
effect	O
of	O
pioglitazone	O
on	O
atheroma	O
progression	O
.	O

BACKGROUND	O
Diabetes	O
mellitus	O
is	O
associated	O
with	O
accelerated	O
coronary	O
atheroma	O
progression	O
.	O

Pioglitazone	O
slowed	O
progression	O
compared	O
with	O
glimepiride	O
in	O
this	O
population	O
.	O

METHODS	O
In	O
all	O
,	O
360	O
diabetic	O
patients	O
with	O
coronary	O
artery	O
disease	O
were	O
treated	O
with	O
pioglitazone	O
or	O
glimepiride	O
for	O
18	O
months	O
in	O
the	O
PERISCOPE	O
(	O
Pioglitazone	O
Effect	O
on	O
Regression	O
of	O
Intravascular	O
Sonographic	O
Coronary	O
Obstruction	O
Prospective	O
Evaluation	O
)	O
study	O
.	O

Coronary	Physical
atheroma	Physical
progression	Physical
was	O
evaluated	O
by	O
serial	O
intravascular	O
ultrasound	O
.	O

The	O
relationship	Physical
between	Physical
changes	Physical
in	Physical
biochemical	Physical
parameters	Physical
,	O
percent	Physical
atheroma	Physical
volume	Physical
,	O
and	O
total	Physical
atheroma	Physical
volume	Physical
was	O
investigated	O
.	O

RESULTS	O
Pioglitazone-treated	O
patients	O
demonstrated	O
greater	O
increases	O
in	O
high-density	Physical
lipoprotein	Physical
cholesterol	Physical
(	Physical
HDL-C	Physical
)	Physical
and	O
reductions	Physical
in	Physical
glycated	Physical
hemoglobin	Physical
,	Physical
triglycerides	Physical
,	Physical
and	Physical
C-reactive	Physical
protein	Physical
.	O

Significant	O
correlations	O
were	O
observed	O
between	O
changes	Physical
in	Physical
percent	Physical
atheroma	Physical
volume	Physical
and	Physical
triglycerides	Physical
(	O
r	O
=	O
0.15	O
,	O
p	O
=	O
0.04	O
)	O
,	O
triglyceride/HDL-C	Physical
ratio	Physical
(	O
r	O
=	O
0.16	O
,	O
p	O
=	O
0.03	O
)	O
,	O
and	O
glycated	Physical
hemoglobin	Physical
(	O
r	O
=	O
0.16	O
,	O
p	O
=	O
0.03	O
)	O
with	O
pioglitazone	O
,	O
and	O
changes	Physical
in	Physical
low-density	Physical
lipoprotein	Physical
cholesterol	Physical
(	O
r	O
=	O
-0.15	O
,	O
p	O
=	O
0.05	O
)	O
,	O
apolipoprotein	Physical
B	Physical
(	O
r	O
=	O
-0.16	O
,	O
p	O
=	O
0.04	O
)	O
,	O
and	O
apolipoprotein	Physical
A-I	Physical
(	O
r	O
=	O
-0.20	O
,	O
p	O
=	O
0.01	O
)	O
with	O
glimepiride	O
.	O

Substantial	O
atheroma	O
regression	O
,	O
compared	O
to	O
progression	O
,	O
was	O
associated	O
with	O
greater	O
relative	O
increases	O
in	O
HDL-C	Physical
(	O
14.2	O
%	O
vs.	O
7.8	O
%	O
,	O
p	O
=	O
0.04	O
)	O
,	O
relative	O
decreases	O
in	O
triglycerides	Physical
(	O
-13.3	O
%	O
vs.	O
-1.9	O
%	O
,	O
p	O
=	O
0.045	O
)	O
,	O
triglyceride/HDL-C	Physical
ratio	Physical
(	O
-22.5	O
vs.	O
-9.9	O
%	O
,	O
p	O
=	O
0.05	O
)	O
,	O
and	O
decrease	O
in	O
glycated	Physical
hemoglobin	Physical
(	O
-0.6	O
%	O
vs.	O
-0.3	O
%	O
,	O
p	O
=	O
0.01	O
)	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
pioglitazone-induced	O
effects	O
on	O
triglyceride/HDL-C	Physical
were	O
associated	O
with	O
changes	O
in	O
percent	Physical
atheroma	Physical
volume	Physical
(	O
p	O
=	O
0.03	O
)	O
and	O
total	Physical
atheroma	Physical
volume	Physical
(	O
p	O
=	O
0.02	O
)	O
.	O

CONCLUSIONS	O
Favorable	O
effects	O
of	O
pioglitazone	O
on	O
the	O
triglyceride/HDL-C	Physical
ratio	Physical
correlated	O
with	O
delayed	O
atheroma	Physical
progression	Physical
in	O
diabetic	O
patients	O
.	O

This	O
finding	O
highlights	O
the	O
potential	O
importance	O
of	O
targeting	O
atherogenic	O
dyslipidemia	O
in	O
diabetic	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

[	O
A	O
multicenter	O
,	O
randomized	O
clinical	O
trial	O
of	O
intravenous	O
diltiazem	O
in	O
treatment	O
of	O
unstable	O
angina	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
intravenous	O
diltiazem	O
compared	O
with	O
nitroglycerin	O
in	O
the	O
patients	O
with	O
unstable	O
angina	O
pectoris	O
.	O

METHODS	O
A	O
multicenter	O
,	O
randomized	O
,	O
open-label	O
,	O
parallel	O
group	O
trial	O
was	O
conducted	O
.	O

A	O
total	O
of	O
213	O
eligible	O
patients	O
were	O
enrolled	O
.	O

They	O
were	O
randomized	O
either	O
to	O
diltiazem	O
or	O
nitroglycerin	O
treatment	O
.	O

The	O
diltiazem	O
was	O
administered	O
from	O
100	O
microg/min	O
at	O
the	O
initiation	O
of	O
treatment	O
,	O
the	O
largest	O
dosage	O
was	O
200	O
-	O
300	O
microg/min	O
;	O
the	O
nitroglycerin	O
was	O
administered	O
from	O
20	O
microg/min	O
at	O
the	O
initiation	O
of	O
treatment	O
.	O

The	O
largest	O
dosage	O
was	O
80	O
-	O
100	O
microg/min	O
.	O

Intravenous	O
infusion	O
was	O
kept	O
over	O
48	O
hours	O
.	O

The	O
endpoints	O
included	O
refractory	Physical
angina	Physical
pectoris	Physical
,	O
acute	Physical
myocardial	Physical
infarction	Physical
,	O
death	Mortality
,	O
emergency	Physical
PTCA	Physical
and	O
CABG	Physical
.	O

RESULTS	O
(	O
1	O
)	O
Intravenous	O
diltiazem	O
was	O
effective	O
on	O
the	O
improvement	O
of	O
symptom	Physical
and	Physical
electrocardiogram	Physical
,	O
and	O
its	O
effects	O
were	O
similar	O
to	O
intravenous	O
nitroglycerin	O
.	O

(	O
2	O
)	O
Compared	O
with	O
nitroglycerin	O
,	O
intravenous	O
diltiazem	O
lowered	Physical
heart	Physical
rate	Physical
and	O
myocardial	Others
oxygen	Others
consumption	Others
index	Others
(	O
systolic	O
pressure	O
x	O
heart	O
rate	O
)	O
to	O
more	O
extent	O
significantly	O
.	O

(	O
3	O
)	O
After	O
treatment	O
,	O
the	O
onsets	Physical
of	Physical
refractory	Physical
angina	Physical
pectoris	Physical
were	O
reduced	Others
more	Others
significantly	Others
in	O
the	O
diltiazem	O
group	O
than	O
in	O
nitroglycerin	O
group	O
[	O
4	O
(	O
3.8	O
%	O
)	O
vs	O
13	O
(	O
11.9	O
%	O
)	O
,	O
RR	O
0.32	O
(	O
95	O
%	O
CI	O
0.11	O
-	O
0.96	O
)	O
,	O
P	O
<	O
0.05	O
]	O
.	O

(	O
4	O
)	O
The	O
patients	O
whose	O
heart	Physical
rate	Physical
were	O
reduced	Others
significantly	Others
(	O
<	O
or=	O
50	O
beats	O
per	O
minute	O
)	O
in	O
the	O
diltiazem	O
group	O
were	O
more	O
than	O
in	O
the	O
nitroglycerin	O
group	O
[	O
8	O
(	O
7.7	O
%	O
)	O
vs	O
0	O
(	O
0	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O

But	O
these	O
patients	O
could	O
tolerate	O
the	O
lower	O
heart	Physical
rate	Physical
very	O
well	O
in	O
the	O
diltiazem	O
group	O
.	O

(	O
5	O
)	O
The	O
needs	O
of	O
beta	O
receptor	O
blocker	O
or	O
calcium	O
antagonists	O
were	O
reduced	O
more	O
significantly	O
in	O
the	O
diltiazem	O
group	O
compared	O
with	O
those	O
in	O
the	O
nitroglycerin	O
group	O
[	O
2	O
(	O
1.9	O
%	O
)	O
vs	O
13	O
(	O
11.9	O
%	O
)	O
,	O
P	O
<	O
0.01	O
]	O
.	O

CONCLUSION	O
Intravenous	O
diltiazem	O
therapy	O
is	O
effective	O
and	O
safe	O
for	O
patients	O
with	O
unstable	O
angina	O
pectoris	O
.	O

It	O
may	O
significantly	O
lower	O
the	O
risk	O
of	O
refractory	O
angina	O
pectoris	O
compared	O
with	O
intravenous	O
nitroglycerin	O
.	O

Inflammatory	O
response	O
in	O
humans	O
exposed	O
to	O
2.0	O
ppm	O
nitrogen	O
dioxide	O
.	O

Nitrogen	O
dioxide	O
(	O
NO2	O
)	O
is	O
a	O
common	O
indoor	O
air	O
pollutant	O
,	O
especially	O
in	O
homes	O
with	O
unvented	O
combustion	O
appliances	O
.	O

Epidemiological	O
studies	O
suggest	O
that	O
children	O
living	O
in	O
homes	O
with	O
unvented	O
heating	O
sources	O
are	O
more	O
prone	O
to	O
respiratory	O
infections	O
than	O
children	O
living	O
in	O
homes	O
with	O
lower	O
levels	O
of	O
NO2	O
.	O

However	O
,	O
experimental	O
studies	O
in	O
which	O
human	O
volunteers	O
were	O
exposed	O
acutely	O
to	O
moderate	O
levels	O
of	O
NO2	O
(	O
0.5-2.0	O
ppm	O
)	O
have	O
shown	O
little	O
evidence	O
of	O
lung	O
inflammation	O
or	O
decreased	O
host	O
resistance	O
capacity	O
.	O

In	O
the	O
study	O
reported	O
here	O
,	O
8	O
healthy	O
volunteers	O
were	O
exposed	O
to	O
2.0	O
ppm	O
NO2	O
and	O
to	O
filtered	O
air	O
for	O
4	O
h	O
while	O
undergoing	O
intermittent	O
moderate	O
exercise	O
.	O

Bronchoalveolar	O
lavage	O
was	O
performed	O
the	O
following	O
morning	O
.	O

The	O
lavage	O
was	O
divided	O
into	O
a	O
predominantly	O
bronchial	O
washing	O
(	O
first	O
20	O
ml	O
of	O
lavage	O
;	O
BL	O
)	O
and	O
a	O
predominantly	O
alveolar	O
washing	O
(	O
BAL	O
)	O
.	O

In	O
the	O
BL	O
,	O
NO2	Physical
exposure	Physical
caused	O
increases	O
in	O
polymorphonuclear	Physical
neutrophils	Physical
(	Physical
PMNs	Physical
)	Physical
,	Physical
interleukin	Physical
6	Physical
(	Physical
IL-6	Physical
)	Physical
,	Physical
IL-8	Physical
,	Physical
alpha1-antitrypsin	Physical
,	Physical
and	Physical
tissue	Physical
plasminogen	Physical
activator	Physical
,	O
and	O
decreases	O
in	O
epithelial	Physical
cells	Physical
.	Physical

In	O
the	O
BAL	O
,	O
there	O
were	O
no	O
NO2-induced	O
changes	O
in	O
either	O
cell	Physical
numbers	Physical
or	Physical
soluble	Physical
mediators	Physical
.	Physical

On	O
the	O
other	O
hand	O
,	O
alveolar	O
macrophages	O
from	O
BAL	O
showed	O
a	O
decrease	O
in	O
the	O
ability	O
to	O
phagocytose	Physical
unopsonized	Physical
Candida	Physical
albicans	Physical
and	O
a	O
decrease	O
in	O
superoxide	Physical
production	Physical
.	Physical

No	O
difference	O
in	O
susceptibility	Physical
to	Physical
virus	Physical
infection	Physical
was	O
found	O
between	O
the	O
NO2-	O
and	O
air-exposed	O
macrophages	O
.	O

No	O
changes	O
in	O
lung	O
function	O
were	O
observed	O
,	O
but	O
the	O
aerosol	O
bolus	O
recovery	O
technique	O
revealed	O
a	O
statistically	O
significant	O
(	O
p	O
<	O
.05	O
)	O
decrease	O
in	O
the	O
fraction	O
of	O
aerosol	O
recovered	O
following	O
nitrogen	O
dioxide	O
exposure	O
,	O
which	O
is	O
suggestive	O
of	O
small	O
obstructive	O
changes	O
induced	O
by	O
NO2	O
.	O

Cardiac	O
failure	O
:	O
symptoms	O
and	O
functional	O
status	O
.	O

The	O
associations	O
between	O
exercise	O
capacity	O
,	O
symptoms	O
and	O
specific	O
aspects	O
of	O
quality	O
of	O
life	O
were	O
examined	O
in	O
subjects	O
participating	O
in	O
a	O
trial	O
of	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O

Patients	O
were	O
assessed	O
on	O
entry	O
and	O
after	O
three	O
months	O
treatment	O
.	O

The	O
principle	O
symptoms	O
were	O
fatigue	O
,	O
breathlessness	O
and	O
chest	O
pain	O
.	O

These	O
limited	O
the	O
extent	O
and	O
speed	O
of	O
physical	O
activities	O
,	O
restricted	O
social	O
,	O
leisure	O
and	O
family	O
life	O
and	O
were	O
associated	O
with	O
emotional	O
distress	O
.	O

There	O
were	O
associations	O
between	O
baseline	Others
exercise	Others
capacity	Others
and	O
measures	Others
of	Others
quality	Others
of	Others
life	Others
.	O

Change	O
in	O
exercise	O
capacity	O
during	O
three	O
months	O
treatment	O
was	O
correlated	O
with	O
changes	O
in	O
measures	Others
of	Others
symptoms	Others
,	O
limitation	Others
of	Others
activity	Others
and	Others
quality	Others
of	Others
life	Others
.	O

The	O
findings	O
confirm	O
the	O
value	O
of	O
change	O
in	O
exercise	Others
capacity	Others
as	O
a	O
measure	O
of	O
functional	O
status	O
and	O
suggest	O
that	O
it	O
should	O
be	O
supported	O
by	O
a	O
limited	O
number	O
of	O
specific	O
measures	O
of	O
quality	Others
of	Others
life	Others
.	O

Pharmacokinetic-pharmacodynamic	O
relationship	O
of	O
rocuronium	O
under	O
stable	O
nitrous	O
oxide-fentanyl	O
or	O
nitrous	O
oxide-sevoflurane	O
anesthesia	O
in	O
children	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
pharmacokinetics	O
and	O
pharmacokinetic-pharmacodynamic	O
(	O
PK-PD	O
)	O
relationship	O
of	O
rocuronium	O
in	O
children	O
anesthetized	O
with	O
nitrous	O
oxide	O
(	O
N2O	O
)	O
and	O
fentanyl	O
or	O
with	O
N2O	O
and	O
sevoflurane	O
.	O

METHODS	O
Twenty-four	O
children	O
(	O
3-11	O
years	O
old	O
,	O
ASA	O
PS	O
I	O
or	O
II	O
)	O
were	O
randomized	O
to	O
receive	O
N2O/O2-fentanyl	O
or	O
N2O/O2-sevoflurane	O
(	O
one	O
MAC	O
)	O
anesthesia	O
.	O

Neuromuscular	O
transmission	O
was	O
monitored	O
electromyographically	O
.	O

Initial	O
bolus	O
dose	O
of	O
rocuronium	O
,	O
0.6	O
mg	O
x	O
kg	O
(	O
-1	O
)	O
was	O
followed	O
by	O
continuous	O
infusion	O
,	O
targeting	O
at	O
steady-state	O
95	O
%	O
T1	O
depression	O
.	O

Neuromuscular	O
transmission	O
was	O
allowed	O
to	O
recover	O
spontaneously	O
.	O

Plasma	O
samples	O
were	O
collected	O
at	O
the	O
moment	O
of	O
discontinuation	O
of	O
infusion	O
,	O
and	O
10	O
,	O
20	O
,	O
30	O
,	O
50	O
,	O
60	O
and	O
75	O
min	O
afterwards	O
.	O

Concentrations	O
of	O
rocuronium	O
were	O
measured	O
using	O
high-performance	O
liquid	O
chromatography	O
with	O
electrochemical	O
detection	O
(	O
HPLC-EC	O
)	O
.	O

Rocuronium	O
PK	O
was	O
described	O
by	O
a	O
two-compartment	O
model	O
and	O
PD	O
parameters	O
were	O
estimated	O
using	O
effect	O
compartment	O
and	O
sigmoidal	O
E	O
(	O
max	O
)	O
models	O
.	O

RESULTS	O
No	O
differences	O
in	O
rocuronium	Others
PK	Others
parameters	Others
were	O
observed	O
between	O
study	O
groups	O
.	O

Clearance	Others
was	O
3.91	O
+/-	O
2.07	O
and	O
3.62	O
+/-	O
0.80	O
ml	O
x	O
min	O
(	O
-1	O
)	O
x	O
kg	O
(	O
-1	O
)	O
in	O
sevoflurane	O
and	O
fentanyl	O
groups	O
,	O
respectively	O
(	O
P	O
<	O
0.65	O
)	O
.	O

Effect	Others
compartment	Others
concentrations	Others
corresponding	Others
to	Others
50	Others
%	Others
inhibition	Others
of	Others
T1	Others
(	O
EC50	O
)	O
were	O
1.41	O
+/-	O
0.45	O
and	O
2.32	O
+/-	O
1.00	O
microg	O
x	O
ml	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.02	O
)	O
,	O
and	O
rate	Others
constants	Others
for	Others
equilibration	Others
between	Others
plasma	Others
and	Others
effect	Others
compartment	Others
(	Others
k	Others
(	Others
e0	Others
)	Others
)	Others
values	O
were	O
0.10	O
+/-	O
0.04	O
and	O
0.24	O
+/-	O
0.14	O
min	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.009	O
)	O
in	O
sevoflurane	O
and	O
fentanyl	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
Disposition	Others
of	Others
rocuronium	Others
was	O
similar	O
under	O
stable	O
N2O-fentanyl	O
and	O
N2O-sevoflurane	O
anesthesia	O
.	O

Sevoflurane	O
reduced	O
rocuronium	O
requirements	O
as	O
well	O
as	O
decreased	O
EC50	O
relevant	O
to	O
inhibition	O
of	O
T1	O
and	O
rocuronium	Others
transfer	Others
to	O
effect	O
compartment	O
.	O

Therefore	O
,	O
the	O
potentiating	O
effect	O
of	O
sevoflurane	O
seems	O
to	O
be	O
mainly	O
of	O
PD	O
origin	O
,	O
probably	O
due	O
to	O
an	O
increased	O
sensitivity	O
of	O
the	O
neuromuscular	O
junction	O
.	O

Design	O
of	O
a	O
cost-effectiveness	O
study	O
within	O
a	O
randomized	O
trial	O
:	O
the	O
LIPID	O
Trial	O
for	O
Secondary	O
Prevention	O
of	O
IHD	O
.	O

Long-term	O
Intervention	O
with	O
Pravastatin	O
in	O
Ischemic	O
Heart	O
disease	O
.	O

The	O
Long-term	O
Intervention	O
with	O
Pravastatin	O
in	O
Ischemic	O
Heart	O
Disease	O
(	O
LIPID	O
)	O
trial	O
is	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
evaluating	O
the	O
long-term	O
effect	O
of	O
pravastatin	O
on	O
coronary	O
mortality	O
in	O
patients	O
with	O
a	O
previous	O
myocardial	O
infarction	O
or	O
unstable	O
angina-ischemic	O
heart	O
disease	O
(	O
IHD	O
)	O
.	O

It	O
is	O
planned	O
to	O
run	O
for	O
at	O
least	O
five	O
years	O
with	O
9014	O
patients	O
from	O
85	O
centers	O
in	O
Australia	O
and	O
New	O
Zealand	O
.	O

The	O
trial	O
will	O
monitor	O
cause-specific	O
mortality	O
and	O
major	O
clinical	O
events	O
associated	O
with	O
each	O
treatment	O
.	O

Running	O
in	O
parallel	O
with	O
the	O
main	O
study	O
is	O
a	O
prospective	O
economic	O
analysis	O
,	O
the	O
objectives	O
of	O
which	O
are	O
(	O
1	O
)	O
to	O
estimate	O
the	O
effectiveness	O
of	O
pravastatin	O
compared	O
with	O
placebo	O
in	O
terms	O
of	O
survival	Mortality
,	O
quality	Others
of	Others
life	Others
(	Others
QOL	Others
)	Others
,	O
and	O
quality-adjusted	Others
life-years	Others
(	Others
QALY	Others
)	Others
;	O
(	O
2	O
)	O
to	O
estimate	O
the	O
resource	O
usage	O
associated	O
with	O
pravastatin	O
compared	O
with	O
placebo-in	O
particular	O
,	O
to	O
study	O
whether	O
it	O
alters	O
resource	O
usage	O
through	O
prevention	O
of	O
disease	O
progression	O
;	O
and	O
(	O
3	O
)	O
to	O
use	O
this	O
information	O
for	O
a	O
cost-utility	O
analysis	O
with	O
cost	O
per	O
quality-adjusted	O
life-year	O
as	O
the	O
unit	O
of	O
analysis	O
.	O

A	O
novel	O
aspect	O
of	O
the	O
design	O
is	O
the	O
use	O
of	O
a	O
preliminary	O
cost-effectiveness	O
analysis	O
,	O
based	O
on	O
best-guess	O
values	O
,	O
and	O
a	O
sensitivity	O
analysis	O
over	O
plausible	O
ranges	O
to	O
guide	O
the	O
choice	O
of	O
subsample	O
size	O
.	O

Some	O
data	O
,	O
such	O
a	O
mortality	Mortality
,	O
days	Others
spent	Others
in	Others
hospital	Others
,	O
major	Physical
clinical	Physical
events	Physical
,	O
and	O
drug	Mental
use	Mental
,	O
are	O
being	O
collected	O
within	O
the	O
main	O
LIPID	O
trial	O
.	O

However	O
,	O
additional	O
subsamples	O
for	O
the	O
cost-effectiveness	Others
study	O
will	O
include	O
information	O
on	O
quality	Others
of	Others
life	Others
,	O
time	Others
off	Others
work	Others
,	O
and	O
resources	Others
used	Others
,	O
such	O
as	O
time	Others
in	Others
hospital	Others
,	O
procedures	Others
,	O
and	O
medications	Others
taken	Others
.	O

The	O
methods	O
and	O
sample	O
sizes	O
for	O
these	O
substudies	O
have	O
been	O
a	O
crucial	O
issue	O
in	O
validity	O
and	O
feasibility	O
.	O

Heat-exercise	O
performance	O
of	O
pyridostigmine-treated	O
subjects	O
wearing	O
chemical	O
protective	O
clothing	O
.	O

Pyridostigmine	O
bromide	O
is	O
currently	O
the	O
pretreatment	O
of	O
choice	O
for	O
operation	O
in	O
a	O
chemical	O
warfare	O
(	O
CW	O
)	O
environment	O
.	O

Under	O
CW	O
conditions	O
,	O
subjects	O
are	O
exposed	O
to	O
thermal	O
stress	O
caused	O
by	O
CW	O
protective	O
clothing	O
.	O

This	O
investigation	O
was	O
conducted	O
to	O
determine	O
if	O
pyridostigmine	O
affects	O
various	O
physiological	O
and	O
biophysical	O
parameters	O
of	O
human	O
temperature	O
regulation	O
in	O
subjects	O
wearing	O
CW	O
protective	O
clothing	O
.	O

Pyridostigmine	O
was	O
administered	O
orally	O
in	O
a	O
randomized	O
double-blind	O
cross-over	O
study	O
in	O
four	O
doses	O
of	O
30	O
mg	O
every	O
8	O
h.	O
An	O
average	O
of	O
33	O
%	O
whole	O
blood	O
cholinesterase	O
inhibition	O
was	O
induced	O
in	O
the	O
pyridostigmine	O
treated	O
group	O
4	O
h	O
after	O
ingestion	O
of	O
last	O
tablet	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
170	O
min	O
exercise-heat	O
stress	O
(	O
Tdb	O
=	O
33	O
degrees	O
C	O
;	O
rh	O
=	O
60	O
%	O
)	O
consisting	O
of	O
60	O
min	O
in	O
a	O
sitting	O
position	O
and	O
two	O
50-min	O
walks	O
(	O
1.39	O
m.s-1	O
,	O
5	O
%	O
grade	O
)	O
separated	O
by	O
10	O
min	O
of	O
rest	O
.	O

Non-evaporative	Physical
heat	Physical
exchange	Physical
was	O
significantly	O
higher	O
,	O
-14.0	O
and	O
-10.6	O
W.m-2	O
(	O
p	O
less	O
than	O
0.03	O
)	O
,	O
for	O
the	O
pyridostigmine-treated	O
subjects	O
.	O

No	O
additional	O
differences	O
were	O
found	O
between	O
treatments	O
in	O
the	O
physiological	O
responses	O
and	O
heat	O
balance	O
parameters	O
at	O
the	O
end	O
of	O
exposure	O
:	O
heart	O
rate	O
(	O
HR	O
)	O
was	O
(	O
mean	O
+/-	O
S.D	O
.	O

)	O
154	O
+/-	O
16	O
and	O
151	O
+/-	O
24	O
bpm	O
,	O
rectal	O
temperature	O
(	O
Tre	O
)	O
was	O
39.0	O
+/-	O
0.4	O
and	O
38.9	O
+/-	O
0.2	O
degrees	O
C	O
,	O
heat	O
storage	O
over	O
the	O
2	O
h	O
of	O
exercise	O
was	O
62	O
+/-	O
15	O
and	O
70	O
+/-	O
15	O
W.m-2	O
,	O
and	O
sweat	O
rate	O
was	O
832	O
+/-	O
185	O
and	O
748	O
+/-	O
52	O
g.h-1	O
,	O
in	O
the	O
pyridostigmine	O
and	O
placebo	O
treatments	O
,	O
respectively	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Relief	O
of	O
periorbital	O
pain	O
after	O
acute	O
angle	O
closure	O
glaucoma	O
attack	O
by	O
botulinum	O
toxin	O
type	O
A	O
.	O

PURPOSE	O
To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
botulinum	O
toxin	O
type	O
A	O
(	O
BoNT-A	O
)	O
injection	O
in	O
patients	O
suffering	O
from	O
intractable	O
periorbital	O
pain	O
after	O
acute	O
angle	O
closure	O
glaucoma	O
(	O
AACG	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
In	O
this	O
prospective	O
randomized	O
intervention	O
study	O
,	O
19	O
patients	O
suffering	O
from	O
periorbital	O
pain	O
after	O
an	O
AACG	O
attack	O
were	O
injected	O
with	O
BoNT-A	O
or	O
placebo	O
for	O
pain	O
relief	O
.	O

Patients	O
were	O
assessed	O
on	O
days	O
1	O
,	O
2	O
,	O
7	O
,	O
14	O
,	O
30	O
,	O
60	O
,	O
and	O
90	O
.	O

The	O
main	O
outcomes	O
were	O
mean	O
change	O
of	O
visual	O
analog	O
rating	O
scale	O
(	O
VARS	O
)	O
and	O
index	O
scores	O
measured	O
through	O
a	O
quality-of-life	O
questionnaire	O
(	O
EQ-5D	O
)	O
,	O
and	O
changes	O
in	O
the	O
visual	Physical
analog	Physical
scale	Physical
(	O
VAS	O
)	O
,	O
all	O
of	O
which	O
were	O
assessed	O
at	O
each	O
visit	O
.	O

A	O
secondary	O
outcome	O
was	O
the	O
frequency	O
and	O
nature	O
of	O
adverse	O
events	O
and	O
the	O
number	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
as	O
a	O
result	O
.	O

RESULTS	O
In	O
the	O
treatment	O
group	O
(	O
n=10	O
)	O
,	O
the	O
mean	Physical
index	Physical
score	Physical
of	Physical
EQ-5D	Physical
and	O
VAS	Physical
changed	O
significantly	O
from	O
the	O
placebo	O
group	O
(	O
by	O
0.299	O
and	O
2.61	O
,	O
respectively	O
)	O
from	O
day	O
2	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
VARS	Physical
of	Physical
EQ-5D	Physical
also	O
disclosed	O
significant	O
changes	O
from	O
day	O
2	O
(	O
17	O
,	O
P	O
<	O
0.01	O
)	O
.	O

In	O
addition	O
,	O
efficacy	Others
was	O
maintained	O
mainly	O
between	O
days	O
2	O
and	O
60	O
but	O
declined	O
slightly	O
by	O
day	O
90	O
.	O

The	O
most	O
frequently	O
reported	O
treatment-related	O
adverse	O
events	O
in	O
the	O
treatment	O
and	O
placebo	O
groups	O
were	O
local	Physical
tenderness	Physical
(	O
21	O
%	O
)	O
,	O
subcutaneous	Physical
hemorrhage	Physical
(	O
10.5	O
%	O
)	O
,	O
and	O
conjunctivitis	Physical
(	O
10.5	O
%	O
)	O
.	O

No	O
severe	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
were	O
reported	O
during	O
the	O
study	O
or	O
follow-up	O
period	O
.	O

CONCLUSIONS	O
BoNT-A	O
is	O
effective	O
and	O
well	O
tolerated	O
for	O
the	O
treatment	O
of	O
periorbital	O
pain	O
after	O
an	O
AACG	O
attack	O
.	O

Its	O
effects	O
may	O
be	O
maintained	O
for	O
3	O
months	O
.	O

The	O
specific	O
role	O
of	O
isoflavones	O
on	O
estrogen	O
metabolism	O
in	O
premenopausal	O
women	O
.	O

BACKGROUND	O
There	O
is	O
increasing	O
evidence	O
that	O
dietary	O
factors	O
may	O
play	O
a	O
role	O
in	O
the	O
production	O
,	O
metabolism	O
,	O
and	O
bioavailability	O
of	O
sex	O
hormones	O
and	O
their	O
impact	O
on	O
target	O
tissues	O
.	O

The	O
specific	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
supplementing	O
a	O
group	O
of	O
premenopausal	O
women	O
who	O
were	O
free	O
of	O
breast	O
carcinoma	O
with	O
a	O
dietary	O
supplement	O
of	O
isoflavones	O
(	O
40	O
mg	O
per	O
day	O
)	O
in	O
producing	O
a	O
change	O
in	O
steroid	O
hormones	O
and	O
menstrual	O
cycle	O
length	O
.	O

METHODS	O
Sixty-eight	O
consecutively	O
recruited	O
,	O
premenopausal	O
,	O
omnivorous	O
women	O
of	O
all	O
races	O
and	O
ethnicities	O
between	O
the	O
ages	O
of	O
25	O
years	O
and	O
55	O
years	O
were	O
admitted	O
to	O
the	O
study	O
and	O
randomized	O
to	O
an	O
experimental	O
group	O
supplemented	O
with	O
soy	O
(	O
40	O
mg	O
genistein	O
per	O
day	O
)	O
or	O
to	O
a	O
control	O
group	O
that	O
consumed	O
a	O
placebo	O
for	O
a	O
12-week	O
period	O
.	O

Changes	O
in	O
their	O
anthropometric	Physical
,	O
nutritional	Physical
,	O
and	O
hormonal	Physical
biomarkers	Physical
from	O
early	O
follicular	O
phase	O
were	O
analyzed	O
at	O
baseline	O
and	O
post-intervention	O
.	O

RESULTS	O
Serum-free	Physical
estradiol	Physical
and	O
estrone	Physical
levels	Physical
decreased	O
moderately	O
in	O
the	O
experimental	O
group	O
.	O

Serum	Physical
hormone-binding	Physical
globulin	Physical
levels	Physical
increased	O
in	O
41.4	O
%	O
of	O
women	O
in	O
the	O
experimental	O
group	O
compared	O
with	O
37.5	O
%	O
of	O
women	O
in	O
the	O
placebo	O
group	O
.	O

Free	Physical
estradiol	Physical
decreased	O
in	O
53.85	O
%	O
of	O
women	O
in	O
the	O
experimental	O
group	O
compared	O
with	O
37.5	O
%	O
of	O
women	O
in	O
the	O
placebo	O
group	O
.	O

Estrone	O
decreased	O
in	O
55.56	O
%	O
of	O
women	O
in	O
the	O
experimental	O
group	O
compared	O
with	O
42.86	O
%	O
in	O
the	O
placebo	O
group	O
.	O

Those	O
women	O
in	O
the	O
experimental	O
group	O
who	O
were	O
consuming	O
soy	O
had	O
their	O
mean	Physical
menstrual	Physical
cycle	Physical
length	Physical
increased	O
by	O
3.52	O
days	O
compared	O
with	O
a	O
mean	O
decrease	O
of	O
0.06	O
days	O
for	O
women	O
in	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0.04	O
)	O
from	O
baseline	O
to	O
the	O
third	O
menstrual	O
cycle	O
.	O

In	O
addition	O
,	O
women	O
who	O
were	O
taking	O
soy	O
had	O
their	O
mean	Physical
follicular	Physical
phase	Physical
increase	Physical
by	O
1.46	O
days	O
compared	O
with	O
a	O
mean	O
increase	O
of	O
0.14	O
days	O
for	O
women	O
who	O
were	O
taking	O
the	O
placebo	O
(	O
P	O
=	O
0.08	O
)	O
.	O

CONCLUSIONS	O
These	O
data	O
suggest	O
that	O
increased	O
isoflavone	O
intake	O
affects	O
estrogen	O
metabolism	O
by	O
altering	O
the	O
steroid	O
hormone	O
concentrations	O
and	O
menstrual	O
cycle	O
length	O
,	O
thereby	O
demonstrating	O
a	O
potential	O
to	O
reduce	O
the	O
risk	O
for	O
breast	O
carcinoma	O
.	O

Effectiveness	Others
of	O
norgestimate	O
and	O
ethinyl	O
estradiol	O
in	O
treating	O
moderate	O
acne	O
vulgaris	O
.	O

BACKGROUND	O
An	O
excess	O
of	O
androgen	O
is	O
believed	O
to	O
contribute	O
to	O
development	O
of	O
acne	O
in	O
some	O
patients	O
.	O

Because	O
oral	O
contraceptives	O
(	O
OCs	O
)	O
may	O
reduce	O
the	O
active	Physical
androgen	Physical
level	Physical
,	O
hormonal	O
therapy	O
with	O
OCs	O
has	O
been	O
used	O
successfully	O
to	O
treat	O
patients	O
with	O
acne	O
,	O
although	O
this	O
treatment	O
has	O
previously	O
not	O
been	O
studied	O
in	O
placebo-controlled	O
trials	O
.	O

OBJECTIVE	O
Our	O
purpose	O
was	O
to	O
evaluate	O
the	O
efficacy	Others
of	O
a	O
triphasic	O
,	O
combination	O
OC	O
(	O
ORTHO	O
TRI-CYCLEN	O
[	O
Ortho-McNeil	O
Pharmaceutical	O
,	O
Raritan	O
,	O
N.J.	O
]	O
,	O
norgestimate/ethinyl	O
estradiol	O
)	O
compared	O
with	O
placebo	O
in	O
the	O
treatment	O
of	O
moderate	O
acne	O
vulgaris	O
.	O

METHODS	O
Two	O
hundred	O
fifty-seven	O
healthy	O
female	O
subjects	O
,	O
15	O
to	O
49	O
years	O
of	O
age	O
with	O
moderate	O
acne	O
vulgaris	O
,	O
were	O
enrolled	O
in	O
a	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
.	O

Each	O
month	O
for	O
6	O
months	O
,	O
subjects	O
received	O
either	O
3	O
consecutive	O
weeks	O
of	O
the	O
OC	O
(	O
i.e.	O
,	O
tablets	O
containing	O
a	O
fixed	O
dose	O
of	O
ethinyl	O
estradiol	O
[	O
0.035	O
mg	O
]	O
and	O
increasing	O
doses	O
of	O
norgestimate	O
[	O
0.180	O
mg	O
,	O
0.215	O
mg	O
,	O
0.250	O
mg	O
]	O
)	O
followed	O
by	O
7	O
days	O
of	O
inactive	O
drug	O
or	O
placebo	O
(	O
color-matched	O
tablets	O
)	O
.	O

Efficacy	Others
was	O
assessed	O
by	O
facial	Physical
acne	Physical
lesion	Physical
counts	Physical
,	O
an	O
investigator	O
's	O
global	Physical
assessment	Physical
,	O
a	O
subject	Others
's	Others
self-assessment	Others
,	O
and	O
an	O
analysis	O
of	O
within-cycle	Physical
variation	Physical
(	Physical
cycle	Physical
6	Physical
)	Physical
in	Physical
lesion	Physical
counts	Physical
.	Physical

RESULTS	O
Of	O
the	O
160	O
subjects	O
in	O
whom	O
efficacy	O
could	O
be	O
evaluated	O
,	O
the	O
OC	O
group	O
showed	O
a	O
statistically	O
significantly	O
greater	O
improvement	Physical
than	O
the	O
placebo	O
group	O
for	O
all	O
primary	O
efficacy	O
measures	O
.	O

The	O
mean	Physical
decrease	Physical
in	Physical
inflammatory	Physical
lesion	Physical
count	Physical
from	O
baseline	O
to	O
cycle	O
6	O
was	O
11.8	O
(	O
62.0	O
%	O
)	O
versus	O
7.6	O
(	O
38.6	O
%	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
,	O
and	O
the	O
mean	Physical
decrease	Physical
in	Physical
total	Physical
lesion	Physical
count	Physical
was	O
29.1	O
(	O
53.1	O
%	O
)	O
versus	O
14.1	O
(	O
26.8	O
%	O
)	O
(	O
p	O
=	O
0.0001	O
)	O
in	O
the	O
OC	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

In	O
the	O
investigator	Physical
's	Physical
global	Physical
assessment	Physical
,	O
93.7	O
%	O
of	O
the	O
active	O
treatment	O
group	O
versus	O
65.4	O
%	O
of	O
the	O
placebo	O
group	O
were	O
rated	O
as	O
improved	O
at	O
the	O
end	O
of	O
the	O
study	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Six	O
of	O
the	O
seven	O
secondary	Physical
efficacy	Physical
measures	Physical
(	Physical
total	Physical
comedones	Physical
,	Physical
open	Physical
comedones	Physical
,	Physical
closed	Physical
comedones	Physical
,	Physical
papules	Physical
,	Physical
pustules	Physical
,	Physical
and	Physical
the	Physical
subject	Physical
's	Physical
self-assessment	Physical
of	Physical
study	Physical
treatment	Physical
)	Physical
were	O
also	O
significantly	O
more	O
favorable	O
in	O
the	O
OC	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

CONCLUSION	O
An	O
OC	O
containing	O
0.035	O
mg	O
of	O
ethinyl	O
estradiol	O
combined	O
with	O
the	O
triphasic	O
regimen	O
of	O
norgestimate	O
is	O
a	O
safe	Others
and	Others
effective	Others
treatment	Others
of	Others
moderate	Others
acne	Others
vulgaris	Others
in	O
women	O
with	O
no	O
known	O
contraindication	O
to	O
OC	O
therapy	O
.	O

Sulfadoxine/pyrimethamine	O
alone	O
or	O
with	O
amodiaquine	O
or	O
artesunate	O
for	O
treatment	O
of	O
uncomplicated	Physical
malaria	Physical
:	O
a	O
longitudinal	O
randomised	O
trial	O
.	O

BACKGROUND	O
New	O
antimalarial	O
treatments	O
are	O
urgently	O
needed	O
in	O
sub-Saharan	O
Africa	O
.	O

Improved	O
therapies	O
should	O
decrease	O
failure	Others
rates	Others
in	O
the	O
short	O
term	O
,	O
but	O
their	O
effect	O
on	O
incidence	O
of	O
subsequent	O
episodes	O
of	O
malaria	O
is	O
little	O
studied	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
short-term	O
and	O
long-term	O
effectiveness	O
of	O
three	O
antimalarial	O
regimens	O
in	O
children	O
from	O
Kampala	O
,	O
Uganda	O
.	O

METHODS	O
We	O
randomly	O
allocated	O
healthy	O
children	O
aged	O
6	O
months	O
to	O
5	O
years	O
to	O
receive	O
25	O
mg/kg	O
sulfadoxine	O
and	O
1.25	O
mg/kg	O
pyrimethamine	O
plus	O
either	O
placebo	O
,	O
25	O
mg/kg	O
amodiaquine	O
,	O
or	O
12	O
mg/kg	O
artesunate	O
.	O

Participants	O
were	O
followed	O
up	O
for	O
1	O
year	O
and	O
received	O
the	O
same	O
preassigned	O
treatment	O
for	O
every	O
new	O
episode	O
of	O
uncomplicated	O
malaria	O
diagnosed	O
during	O
follow-up	O
.	O

Recrudescent	O
and	O
new	O
infections	O
were	O
distinguished	O
by	O
comparison	O
of	O
polymorphisms	O
in	O
merozoite	O
surface	O
protein	O
2	O
(	O
MSP2	O
)	O
.	O

Our	O
primary	O
endpoint	O
was	O
the	O
total	Physical
number	Physical
of	Physical
treatments	Physical
for	Physical
malaria	Physical
per	O
time	O
at	O
risk	O
.	O

Analyses	O
were	O
done	O
per	O
protocol	O
.	O

FINDINGS	O
183	O
(	O
61	O
%	O
)	O
of	O
316	O
participants	O
were	O
diagnosed	O
with	O
at	O
least	O
one	O
episode	O
of	O
uncomplicated	O
malaria	O
.	O

A	O
total	O
of	O
577	O
episodes	O
of	O
uncomplicated	O
Plasmodium	O
falciparum	O
malaria	O
were	O
treated	O
with	O
study	O
drugs	O
;	O
all	O
regimens	O
were	O
safe	Others
and	O
well	O
tolerated	Others
.	O

Clinical	Physical
treatment	Physical
failure	Physical
after	O
14	O
days	O
was	O
significantly	O
more	O
frequent	O
in	O
the	O
sulfadoxine/pyrimethamine	O
group	O
(	O
38	O
of	O
215	O
,	O
18	O
%	O
)	O
compared	O
with	O
either	O
the	O
sulfadoxine/pyrimethamine	O
plus	O
amodiaquine	O
group	O
(	O
two	O
of	O
164	O
,	O
1	O
%	O
;	O
p	O
<	O
0.0001	O
)	O
or	O
sulfadoxine/pyrimethamine	O
plus	O
artesunate	O
group	O
(	O
one	O
of	O
198	O
,	O
1	O
%	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

After	O
28	O
and	O
42	O
days	O
,	O
patients	O
in	O
the	O
sulfadoxine/pyrimethamine	O
plus	O
amodiaquine	O
group	O
were	O
significantly	O
less	O
likely	O
to	O
develop	O
malaria	Physical
than	O
were	O
those	O
in	O
the	O
other	O
groups	O
.	O

Overall	O
,	O
sulfadoxine/pyrimethamine	O
plus	O
amodiaquine	O
reduced	O
the	O
rate	Physical
of	Physical
subsequent	Physical
treatments	Physical
for	Physical
malaria	Physical
by	O
54	O
%	O
(	O
95	O
%	O
CI	O
36-66	O
,	O
p	O
<	O
0.0001	O
)	O
compared	O
with	O
sulfadoxine/	O
pyrimethamine	O
alone	O
and	O
by	O
37	O
%	O
(	O
12-54	O
,	O
p=0.007	O
)	O
compared	O
with	O
sulfadoxine/pyrimethamine	O
plus	O
artesunate	O
.	O

INTERPRETATION	O
Sulfadoxine/pyrimethamine	O
plus	O
amodiaquine	O
could	O
be	O
used	O
as	O
an	O
inexpensive	O
regimen	O
to	O
decrease	Physical
the	Physical
rate	Physical
of	Physical
subsequent	Physical
episodes	Physical
of	Physical
malaria	Physical
.	O

A	O
multifactorial	O
strategy	O
of	O
pain	O
management	O
is	O
associated	O
with	O
less	O
pain	O
in	O
scheduled	O
vaccination	O
of	O
children	O
.	O

A	O
study	O
realized	O
by	O
family	O
practitioners	O
in	O
239	O
children	O
aged	O
4-12	O
years	O
old	O
.	O

BACKGROUND	O
AND	O
AIMS	O
The	O
multiplicity	O
of	O
vaccine	O
injections	O
during	O
childhood	O
leads	O
to	O
iterative	O
painful	O
and	O
stressful	O
experiences	O
which	O
may	O
lead	O
in	O
turn	O
to	O
anticipated	O
pain	O
and	O
then	O
possibly	O
to	O
a	O
true	O
needle	O
phobia	O
.	O

We	O
aimed	O
at	O
evaluating	O
a	O
multifactorial	O
strategy	O
of	O
pain	O
management	O
combining	O
pharmacological	O
and	O
non-pharmacological	O
approaches	O
during	O
vaccination	O
,	O
as	O
compared	O
to	O
usual	O
care	O
,	O
in	O
4-	O
to	O
12-year-old	O
children	O
.	O

METHODS	O
In	O
all	O
,	O
239	O
children	O
were	O
enrolled	O
by	O
25	O
family	O
practitioners	O
in	O
an	O
open-label	O
study	O
.	O

After	O
a	O
pseudo-randomization	O
,	O
usual	O
pain	O
management	O
(	O
n	O
=	O
132	O
)	O
was	O
compared	O
to	O
a	O
multifactorial	O
strategy	O
(	O
n	O
=	O
107	O
)	O
associating	O
preliminary	O
application	O
of	O
an	O
anesthesic	O
patch	O
,	O
preferential	O
use	O
of	O
specified	O
vaccines	O
,	O
child	O
education	O
by	O
the	O
parents	O
and	O
the	O
doctor	O
,	O
parental	O
accompaniment	O
and	O
child	O
distraction	O
with	O
soap	O
bubbles	O
during	O
the	O
procedure	O
.	O

The	O
primary	O
outcome	O
(	O
i.e	O
.	O

child	Pain
pain	Pain
)	Pain
was	O
assessed	O
with	O
a	O
self-report	Pain
scale	Pain
named	Pain
visual	Pain
analog	Pain
scale	Pain
(	Pain
VAS	Pain
)	Pain
of	Pain
pain	Pain
.	Others

RESULTS	O
A	O
significant	O
decrease	O
in	O
pain	Pain
was	O
obtained	O
using	O
the	O
multifactorial	O
strategy	O
,	O
as	O
assessed	O
by	O
self-reported	O
VAS	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
another	O
self-report	O
scale	O
(	O
the	O
facial	Pain
pain	Pain
scale	Pain
revised	O
:	O
P	O
=	O
0.005	O
)	O
,	O
as	O
well	O
as	O
with	O
hetero-evaluations	O
by	O
GPs	O
and	O
parents	O
[	Others
Children	Pain
's	Pain
Hospital	Pain
of	Pain
Eastern	Pain
Ontario	Pain
Pain	Pain
Scale	Pain
:	Others
P	O
=	O
0.0007	O
;	O
GPs	O
VAS	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
parents	Pain
VAS	Pain
(	O
P	O
<	O
0.0001	O
)	O
]	O
,	O
which	O
were	O
secondary	O
outcome	O
criteria	O
.	O

CONCLUSIONS	O
This	O
multifactorial	O
method	O
significantly	O
decreases	O
vaccination	O
pain	Pain
in	O
4-	O
to	O
12-year-old	O
children	O
.	O

This	O
strategy	O
could	O
make	O
vaccines	O
more	O
acceptable	O
to	O
children	O
and	O
may	O
improve	O
child-doctor	O
relationships	O
and	O
contribute	O
to	O
a	O
decrease	O
in	O
child	O
fear	O
about	O
health	O
care	O
.	O

Prospective	O
evaluation	O
of	O
the	O
macrolide	O
antibiotic	O
dirithromycin	O
for	O
the	O
treatment	O
of	O
Helicobacter	O
pylori	O
.	O

BACKGROUND	O
Macrolide	O
antibiotics	O
are	O
active	O
in	O
vitro	O
and	O
in	O
vivo	O
against	O
Helicobacter	O
pylori	O
.	O

We	O
assessed	O
a	O
newer	O
macrolide	O
,	O
dirithromycin	O
,	O
for	O
the	O
treatment	O
of	O
H.	O
pylori	O
in	O
two	O
separate	O
studies	O
.	O

METHODS	O
Volunteers	O
with	O
H.	O
pylori	O
infection	O
(	O
by	O
13C-urea	O
breath	O
test	O
)	O
were	O
randomly	O
assigned	O
to	O
2-week	O
treatment	O
regimens	O
.	O

Study	O
1	O
:	O
dirithromycin	O
500	O
mg	O
q.d.s.	O
,	O
dirithromycin	O
500	O
mg	O
q.d.s	O
.	O

plus	O
omeprazole	O
40	O
mg	O
q.d.s.	O
,	O
or	O
dirithromycin	O
500	O
mg	O
q.d.s	O
.	O

plus	O
metronidazole	O
500	O
mg	O
t.d.s	O
.	O

Study	O
2	O
:	O
dirithromycin	O
500	O
mg	O
q.d.s	O
.	O

plus	O
omeprazole	O
20	O
mg	O
b.d.	O
,	O
dirithromycin	O
1000	O
mg	O
q.d.s	O
.	O

plus	O
omeprazole	O
20	O
mg	O
b.d.	O
,	O
or	O
amoxycillin	O
500	O
mg	O
q.d.s	O
.	O

plus	O
omepirazole	O
20	O
mg	O
b.d	O
.	O

Four	O
weeks	O
after	O
the	O
completion	O
of	O
therapy	O
a	O
repeat	O
13C-urea	O
breath	O
test	O
was	O
done	O
to	O
assess	O
for	O
cure	O
.	O

RESULTS	O
No	O
patient	O
taking	O
dirithromycin	O
alone	O
(	O
n	O
=	O
6	O
)	O
or	O
in	O
combination	O
with	O
omeprazole	O
(	O
n	O
=	O
26	O
)	O
achieved	O
cure	Physical
of	Physical
their	Physical
infection	Physical
.	O

Eradication	Others
of	Others
H.	Others
pylori	Others
was	O
seen	O
in	O
one	O
of	O
seven	O
patients	O
taking	O
dirithromycin	O
plus	O
metronidazole	O
.	O

Five	O
of	O
10	O
patients	O
taking	O
omeprazole-amoxycillin	O
dual	O
therapy	O
had	O
their	O
H.	O
pylori	O
infection	O
cured	O
(	O
P	O
=	O
0.0007	O
vs.	O
patients	O
taking	O
dirithromycin	O
plus	O
omeprazole	O
)	O
.	O

Eleven	O
(	O
47	O
%	O
)	O
of	O
32	O
patients	O
taking	O
dirithromycin	O
alone	O
or	O
combined	O
with	O
omeprazole	O
reported	Adverseeffect
side-effects	Adverseeffect
,	O
but	O
only	O
two	O
(	O
6	O
%	O
)	O
stopped	O
therapy	O
prematurely	O
as	O
a	O
result	O
of	O
side-effects	Adverseeffect
.	O

CONCLUSION	O
No	O
subject	O
taking	O
dirithromycin	O
alone	O
or	O
in	O
combination	O
with	O
omeprazole	O
had	O
their	O
H.	O
pylori	O
infection	O
cured	Others
.	O

Dirithromycin	O
,	O
in	O
the	O
regimen	O
used	O
,	O
shows	O
little	O
promise	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
H.	O
pylori	O
infection	O
.	O

[	O
Sublingually	O
administered	O
captopril	O
versus	O
nifedipine	O
in	O
hypertension	O
emergencies	O
]	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
assess	O
the	O
effectiveness	Others
and	Others
tolerability	Others
of	O
sublingual	O
captopril	O
(	O
SLC	O
)	O
versus	O
sublingual	O
nifedipine	O
(	O
SLN	O
)	O
in	O
treating	O
hypertensive	O
emergencies	O
.	O

During	O
hypertensive	O
crises	O
(	O
systolic	O
blood	O
pressure	O
exceeding	O
200	O
mmHg	O
and	O
diastolic	O
blood	O
pressure	O
exceeding	O
115	O
mmHg	O
)	O
forty	O
hypertensive	O
patients	O
received	O
either	O
25	O
mg	O
of	O
SLC	O
or	O
10	O
mg	O
of	O
SLN	O
in	O
a	O
randomized	O
single	O
blind	O
fashion	O
.	O

Blood	Physical
pressure	Physical
and	Physical
heart	Physical
rate	Physical
were	O
then	O
controlled	O
after	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
120	O
min	O
.	O

and	O
,	O
in	O
18	O
cases	O
,	O
up	O
to	O
the	O
8th	O
hour	O
from	O
the	O
administration	O
.	O

Our	O
results	O
showed	O
:	O
1	O
)	O
a	O
satisfactory	O
control	Physical
of	Physical
the	Physical
hypertensive	Physical
crises	Physical
in	O
80	O
%	O
of	O
patients	O
treated	O
with	O
SLC	O
with	O
a	O
significant	O
blood	Physical
pressure	Physical
reduction	O
after	O
10	O
min	O
.	O

(	O
13/8	O
mmHg	O
,	O
p	O
less	O
than	O
0.02	O
)	O
,	O
while	O
the	O
maximum	O
hypotensive	Physical
effect	Physical
was	O
achieved	O
after	O
30	O
min	O
.	O

(	O
52/36	O
mmHg	O
,	O
p	O
less	O
than	O
0.001	O
)	O
;	O
SLN	O
was	O
able	O
to	O
reduce	O
blood	Physical
pressure	Physical
in	O
90	O
%	O
of	O
all	O
the	O
cases	O
,	O
with	O
a	O
significant	O
reduction	O
after	O
5	O
min	O
.	O

(	O
15/11	O
mmHg	O
,	O
p	O
less	O
than	O
0.02	O
)	O
and	O
hypotensive	Physical
peak	Physical
after	O
20	O
min	O
(	O
57/38	O
mmHg	O
,	O
p	O
greater	O
than	O
0.001	O
)	O
;	O
2	O
)	O
no	O
significant	O
differences	O
for	O
hypotensive	Physical
effectiveness	Physical
between	O
the	O
two	O
groups	O
,	O
but	O
with	O
SLC	O
having	O
a	O
mildly	O
delayed	O
onset	Physical
of	Physical
action	Physical
when	O
compared	O
to	O
SLN	O
;	O
3	O
)	O
antihypertensive	Physical
effect	Physical
lasting	O
for	O
about	O
6	O
hours	O
in	O
patients	O
treated	O
with	O
SLC	O
and	O
blood	Physical
pressure	Physical
progressively	O
raising	O
after	O
4	O
hours	O
in	O
patients	O
who	O
received	O
SLN	O
;	O
4	O
)	O
a	O
significant	O
correlation	O
between	O
blood	Physical
pressure	Physical
reduction	O
and	O
blood	Physical
pressure	Physical
before	O
drug	O
administration	O
in	O
both	O
groups	O
;	O
a	O
significant	O
correlation	O
between	O
pretreatment	O
PRA	O
and	O
antihypertensive	O
effect	O
in	O
the	O
SLC	O
group	O
.	O

We	O
conclude	O
that	O
both	O
drugs	O
are	O
effective	O
and	O
useful	O
in	O
treating	Physical
hypertensive	Physical
emergencies	Physical
.	O

Anyway	O
we	O
think	O
that	O
in	O
severe	O
forms	O
SLN	O
should	O
be	O
preferred	O
for	O
the	O
shorter	O
time	O
preceding	O
onset	Physical
of	Physical
action	Physical
.	O

Phase	O
III	O
trial	O
comparing	O
whole-pelvic	O
versus	O
prostate-only	O
radiotherapy	O
and	O
neoadjuvant	O
versus	O
adjuvant	O
combined	O
androgen	O
suppression	O
:	O
Radiation	O
Therapy	O
Oncology	O
Group	O
9413	O
.	O

PURPOSE	O
This	O
trial	O
tested	O
the	O
hypothesis	O
that	O
combined	O
androgen	O
suppression	O
(	O
CAS	O
)	O
and	O
whole-pelvic	O
(	O
WP	O
)	O
radiotherapy	O
(	O
RT	O
)	O
followed	O
by	O
a	O
boost	O
to	O
the	O
prostate	O
improves	O
progression-free	Mortality
survival	Mortality
(	Mortality
PFS	Mortality
)	Mortality
by	O
10	O
%	O
compared	O
with	O
CAS	O
and	O
prostate-only	O
(	O
PO	O
)	O
RT	O
.	O

This	O
trial	O
also	O
tested	O
the	O
hypothesis	O
that	O
neoadjuvant	O
and	O
concurrent	O
hormonal	O
therapy	O
(	O
NCHT	O
)	O
improves	O
PFS	O
compared	O
with	O
adjuvant	O
hormonal	O
therapy	O
(	O
AHT	O
)	O
by	O
10	O
%	O
.	O

MATERIALS	O
AND	O
METHODS	O
Eligibility	O
included	O
localized	O
prostate	O
cancer	O
with	O
an	O
elevated	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
<	O
or	O
=	O
100	O
ng/mL	O
and	O
an	O
estimated	O
risk	O
of	O
lymph	O
node	O
(	O
LN	O
)	O
involvement	O
of	O
15	O
%	O
.	O

Between	O
April	O
1	O
,	O
1995	O
,	O
and	O
June	O
1	O
,	O
1999	O
,	O
1,323	O
patients	O
were	O
accrued	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
WP	O
+	O
NCHT	O
,	O
PO	O
+	O
NCHT	O
,	O
WP	O
+	O
AHT	O
,	O
or	O
PO	O
+	O
AHT	O
.	O

Failure	Mortality
for	Mortality
PFS	Mortality
was	O
defined	O
as	O
the	O
first	O
occurrence	O
of	O
local	Physical
,	Physical
regional	Physical
,	Physical
or	Physical
distant	Physical
disease	Physical
;	Physical
PSA	Physical
failure	Physical
;	O
or	O
death	Mortality
for	O
any	O
cause	O
.	O

RESULTS	O
With	O
a	O
median	O
follow-up	O
of	O
59.5	O
months	O
,	O
WP	O
RT	O
was	O
associated	O
with	O
a	O
4-year	Mortality
PFS	Mortality
of	O
54	O
%	O
compared	O
with	O
47	O
%	O
in	O
patients	O
treated	O
with	O
PO	O
RT	O
(	O
P	O
=.022	O
)	O
.	O

Patients	O
treated	O
with	O
NCHT	O
experienced	O
a	O
4-year	Mortality
PFS	Mortality
of	O
52	O
%	O
versus	O
49	O
%	O
for	O
AHT	O
(	O
P	O
=.56	O
)	O
.	O

When	O
comparing	O
all	O
four	O
arms	O
,	O
there	O
was	O
a	O
progression-free	Mortality
difference	Mortality
among	O
WP	O
RT	O
+	O
NCHT	O
,	O
PO	O
RT	O
+	O
NCHT	O
,	O
WP	O
RT	O
+	O
AHT	O
,	O
and	O
PO	O
RT	O
+	O
AHT	O
(	O
60	O
%	O
v	O
44	O
%	O
v	O
49	O
%	O
v	O
50	O
%	O
,	O
respectively	O
;	O
P	O
=.008	O
)	O
.	O

No	O
survival	Mortality
advantage	Mortality
has	O
yet	O
been	O
seen	O
.	O

CONCLUSION	O
WP	O
RT	O
+	O
NCHT	O
improves	O
PFS	Mortality
compared	O
with	O
PO	O
RT	O
and	O
NCHT	O
or	O
PO	O
RT	O
and	O
AHT	O
,	O
and	O
compared	O
with	O
WP	O
RT	O
+	O
AHT	O
in	O
patients	O
with	O
a	O
risk	O
of	O
LN	O
involvement	O
of	O
15	O
%	O
.	O

Effectiveness	O
of	O
erythromycin	O
in	O
the	O
treatment	O
of	O
acute	O
bronchitis	O
.	O

BACKGROUND	O
Clinical	O
trials	O
have	O
not	O
shown	O
a	O
consistent	O
benefit	O
of	O
treating	O
bronchitis	O
with	O
antibiotics	O
.	O

Many	O
physicians	O
,	O
however	O
,	O
treat	O
acute	O
bronchitis	O
with	O
antibiotics	O
because	O
of	O
the	O
possibility	O
of	O
Mycoplasma	O
pneumoniae	O
or	O
other	O
pathogens	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
effectiveness	O
of	O
erythromycin	O
treatment	O
in	O
patients	O
with	O
acute	O
bronchitis	O
and	O
to	O
determine	O
whether	O
a	O
newly	O
developed	O
rapid	O
M	O
pneumoniae	O
antibody	O
test	O
is	O
useful	O
in	O
predicting	O
which	O
patients	O
will	O
respond	O
to	O
therapy	O
.	O

METHODS	O
We	O
conducted	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
at	O
three	O
primary	O
care	O
centers	O
in	O
North	O
Carolina	O
.	O

A	O
convenience	O
sample	O
of	O
140	O
patients	O
presenting	O
with	O
acute	O
bronchitis	O
were	O
tested	O
for	O
M	O
pneumoniae	O
,	O
91	O
of	O
whom	O
were	O
treated	O
with	O
either	O
erythromycin	O
250	O
mg	O
four	O
times	O
daily	O
for	O
10	O
days	O
or	O
an	O
identical-appearing	O
placebo	O
.	O

RESULTS	O
Patients	O
treated	O
with	O
erythromycin	O
missed	O
an	O
average	O
of	O
only	O
0.81	O
+/-	O
1.1	O
days	Others
of	Others
work	Others
compared	O
with	O
2.16	O
+/-	O
3.2	O
days	O
for	O
placebo-treated	O
patients	O
(	O
P	O
<	O
.02	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
cough	Physical
,	O
use	Physical
of	Physical
cough	Physical
medicine	Physical
,	O
general	Mental
feeling	Mental
of	Mental
well-being	Mental
,	O
or	O
chest	Physical
congestion	Physical
between	O
the	O
erythromycin	O
and	O
placebo	O
groups	O
.	O

Twenty-five	O
percent	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
M	O
pneumoniae	O
.	O

There	O
were	O
no	O
differences	O
in	O
response	O
to	O
erythromycin	O
based	O
on	O
whether	O
the	O
patient	O
had	O
a	O
positive	O
test	O
for	O
M	O
pneumoniae	O
.	O

CONCLUSIONS	O
Erythromycin	O
is	O
effective	O
in	O
significantly	O
reducing	O
lost	O
time	O
from	O
work	O
,	O
but	O
it	O
is	O
not	O
effective	O
in	O
reducing	O
cough	O
or	O
other	O
symptoms	O
in	O
patients	O
with	O
acute	O
bronchitis	O
,	O
regardless	O
of	O
the	O
outcome	O
of	O
the	O
M	O
pneumoniae	O
antibody	O
test	O
.	O

ApoA-I	O
induction	O
as	O
a	O
potential	O
cardioprotective	O
strategy	O
:	O
rationale	O
for	O
the	O
SUSTAIN	O
and	O
ASSURE	O
studies	O
.	O

BACKGROUND	O
Considerable	O
interest	O
has	O
focused	O
on	O
the	O
development	O
of	O
therapies	O
that	O
target	O
the	O
functionality	O
of	O
high-density	O
lipoproteins	O
(	O
HDL	O
)	O
.	O

Upregulation	O
of	O
endogenous	O
synthesis	O
of	O
the	O
major	O
protein	O
on	O
HDL	O
particles	O
,	O
apolipoprotein	O
A-I	O
(	O
apoA-I	O
)	O
,	O
represents	O
a	O
novel	O
approach	O
to	O
generation	O
of	O
new	O
HDL	O
particles	O
.	O

The	O
Study	O
of	O
Quantitative	O
Serial	O
Trends	O
in	O
Lipids	O
with	O
Apolipoprotein	O
A-I	O
Stimulation	O
(	O
SUSTAIN	O
,	O
NCT01423188	O
)	O
study	O
aims	O
to	O
evaluate	O
the	O
lipid	Others
efficacy	Others
,	Others
safety	Others
and	O
tolerability	Others
of	O
an	O
apoA-I	O
inducer	O
(	O
RVX-208	O
)	O
.	O

The	O
ApoA-I	O
Synthesis	O
Stimulation	O
and	O
Intravascular	O
Ultrasound	O
for	O
Coronary	O
Atheroma	O
Regression	O
Evaluation	O
(	O
ASSURE	O
,	O
NCT01067820	O
)	O
study	O
aims	O
to	O
evaluate	O
the	O
effect	O
of	O
RVX-208	O
on	O
plaque	O
burden	O
.	O

METHODS	O
In	O
SUSTAIN	O
,	O
172	O
patients	O
with	O
low	O
levels	O
of	O
HDL-C	O
will	O
be	O
randomized	O
to	O
receive	O
RVX-208	O
100	O
mg	O
bid	O
or	O
placebo	O
for	O
24	O
weeks	O
.	O

The	O
primary	O
efficacy	O
parameter	O
will	O
be	O
the	O
percentage	Physical
change	Physical
in	Physical
HDL-C	Physical
levels	Physical
.	O

In	O
ASSURE	O
,	O
310	O
patients	O
with	O
angiographic	O
coronary	O
artery	O
disease	O
and	O
low	O
HDL-C	O
levels	O
will	O
be	O
randomized	O
to	O
receive	O
RVX-208	O
100	O
mg	O
bid	O
or	O
placebo	O
for	O
26	O
weeks	O
.	O

The	O
primary	O
efficacy	O
parameter	O
will	O
be	O
the	O
nominal	O
change	O
in	O
percent	Physical
atheroma	Physical
volume	Physical
(	Physical
PAV	Physical
)	Physical
,	O
determined	O
by	O
analysis	O
of	O
intravascular	O
ultrasound	O
(	O
IVUS	O
)	O
images	O
of	O
matched	O
coronary	O
artery	O
segments	O
acquired	O
at	O
baseline	O
and	O
at	O
26-week	O
follow-up	O
.	O

The	O
effect	O
of	O
RVX-208	O
on	O
other	O
lipid	Physical
and	Physical
inflammatory	Physical
markers	Physical
,	O
safety	Others
and	Others
tolerability	Others
will	O
also	O
be	O
assessed	O
in	O
both	O
studies	O
.	O

CONCLUSION	O
ApoA-I	O
induction	O
represents	O
a	O
potential	O
novel	O
strategy	O
to	O
reduce	O
cardiovascular	Physical
risk	Physical
,	O
by	O
generating	O
nascent	O
HDL	O
particles	O
.	O

These	O
studies	O
will	O
provide	O
early	O
evaluation	O
of	O
the	O
effects	O
of	O
RVX-208	O
on	O
lipids	O
and	O
atherosclerotic	O
plaque	O
.	O

The	O
impact	O
of	O
patient	O
and	O
physician	O
computer	O
mediated	O
communication	O
skill	O
training	O
on	O
reported	O
communication	O
and	O
patient	O
satisfaction	O
.	O

OBJECTIVE	O
The	O
objective	O
was	O
to	O
evaluate	O
parallel	Mental
patient	Mental
and	Mental
physician	Mental
computer-mediated	Mental
communication	Mental
skill	Mental
training	Mental
on	O
participants	O
'	O
report	O
of	O
skill	O
use	O
and	O
patient	O
satisfaction	O
.	O

METHODS	O
Separate	O
patient	O
and	O
clinician	O
web-tools	O
comprised	O
of	O
over	O
500	O
,	O
10-s	O
video	O
clips	O
demonstrating	O
patient-centered	Mental
skills	Mental
in	O
various	O
ways	O
.	O

Four	O
clinician	O
members	O
of	O
the	O
American	O
Academy	O
of	O
Family	O
Physicians	O
National	O
Research	O
Network	O
participated	O
by	O
enrolling	O
194	O
patients	O
into	O
a	O
randomized	O
patient	O
trial	O
and	O
29	O
physicians	O
into	O
a	O
non-randomized	O
clinician	O
trial	O
of	O
respective	O
interventions	O
.	O

All	O
participants	O
completed	O
baseline	O
and	O
follow-up	O
self-report	O
measures	O
of	O
visit	O
communication	Others
and	O
satisfaction	Others
.	O

RESULTS	O
Intervention	O
patients	O
reported	O
using	O
more	O
skills	Mental
than	O
controls	O
in	O
five	O
of	O
six	O
skill	O
areas	O
,	O
including	O
identification	Mental
of	Mental
problems/concerns	Mental
,	Mental
information	Mental
exchange	Mental
,	Mental
treatment	Mental
adherence	Mental
,	Mental
shared	Mental
decision-making	Mental
and	Mental
interpersonal	Mental
rapport	Mental
(	O
all	O
p	O
<	O
.05	O
)	O
;	O
post	O
intervention	O
,	O
physicians	O
reported	O
using	O
more	O
skills	O
in	O
the	O
same	O
5	O
areas	O
(	O
all	O
p	O
<	O
.01	O
)	O
.	O

Intervention	O
group	O
patients	O
reported	O
higher	Others
levels	Others
of	Others
satisfaction	Others
than	O
controls	O
in	O
five	O
of	O
six	O
domains	O
(	O
all	O
p	O
<	O
.05	O
)	O
.	O

CONCLUSION	O
Communication	O
skill	O
training	O
delivered	O
in	O
a	O
computer	O
mediated	O
format	O
had	O
a	O
positive	Others
and	Others
parallel	Others
impact	Others
on	O
both	O
patient	O
and	O
clinician	O
reported	O
use	O
of	O
patient-centered	Mental
communication	Mental
and	O
in	O
patient	Others
satisfaction	Others
.	O

PRACTICE	O
IMPLICATIONS	O
Computer-mediated	O
interventions	O
are	O
cost	Others
and	Others
time	Others
effective	Others
thereby	O
increasing	O
patient	O
and	O
clinician	O
willingness	O
to	O
undertake	O
training	O
.	O

Oral	O
desensitization	O
in	O
papular	O
urticaria	O
in	O
children	O
.	O

Papular	O
urticaria	O
(	O
PU	O
)	O
is	O
among	O
the	O
commonest	O
skin	O
ailments	O
in	O
children	O
.	O

Induced	O
specific	O
desensitization	O
to	O
insect	O
bites	O
is	O
theoretically	O
an	O
effective	O
means	O
of	O
prevention	O
of	O
PU	O
.	O

In	O
this	O
double	O
blind	O
placebo	O
controlled	O
study	O
,	O
an	O
oral	O
vaccine	O
prepared	O
from	O
insect	O
saliva	O
was	O
compared	O
with	O
placebo	O
(	O
stable	O
vaccine	O
solvent	O
)	O
.	O

Vaccine	O
and	O
placebo	O
effectiveness	O
were	O
tested	O
by	O
counting	Physical
active	Physical
PU	Physical
lesions	Physical
,	O
serum	Physical
eosinophils	Physical
,	O
and	O
IgE	Physical
,	O
before	O
and	O
after	O
4	O
months	O
of	O
treatment	O
.	O

Statistically	O
significant	O
differences	O
between	O
oral	O
vaccine	O
and	O
placebo	O
were	O
not	O
found	O
in	O
the	O
clinical	O
or	O
the	O
immunological	O
variables	O
tested	O
.	O

We	O
conclude	O
that	O
,	O
although	O
a	O
lack	O
of	O
oral	O
vaccine	O
efficacy	O
was	O
suspected	O
,	O
larger	O
study	O
samples	O
are	O
needed	O
to	O
strengthen	O
our	O
conclusion	O
.	O

Sustained	O
augmentation	O
of	O
parasympathetic	O
tone	O
with	O
angiotensin-converting	O
enzyme	O
inhibition	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

OBJECTIVES	O
The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
the	O
changes	O
in	O
parasympathetic	O
tone	O
associated	O
with	O
long-term	O
angiotensin-converting	O
enzyme	O
inhibitor	O
therapy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

BACKGROUND	O
Angiotensin-converting	O
enzyme	O
inhibitors	O
provide	O
hemodynamic	O
and	O
symptomatic	O
benefit	O
and	O
are	O
associated	O
with	O
improved	O
survival	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

Angiotensin	O
II	O
,	O
whose	O
production	O
is	O
ultimately	O
inhibited	O
by	O
these	O
agents	O
,	O
exerts	O
significant	O
regulatory	O
influence	O
on	O
a	O
variety	O
of	O
target	O
organs	O
including	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
.	O

Accordingly	O
,	O
it	O
would	O
be	O
anticipated	O
that	O
angiotensin-converting	O
enzyme	O
inhibitors	O
would	O
significantly	O
alter	O
the	O
autonomic	O
imbalance	O
characteristic	O
of	O
patients	O
with	O
congestive	O
heart	O
failure	O
and	O
that	O
this	O
influence	O
over	O
neural	O
mechanisms	O
of	O
cardiovascular	O
control	O
may	O
significantly	O
contribute	O
to	O
the	O
hemodynamic	O
benefit	O
and	O
improved	O
survival	O
associated	O
with	O
angiotensin-converting	O
enzyme	O
inhibitor	O
therapy	O
.	O

METHODS	O
In	O
the	O
current	O
investigation	O
,	O
changes	O
in	O
autonomic	O
tone	O
associated	O
with	O
long-term	O
administration	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
were	O
measured	O
using	O
spectral	O
analysis	O
of	O
heart	O
rate	O
variability	O
in	O
13	O
patients	O
with	O
congestive	O
heart	O
failure	O
who	O
were	O
enrolled	O
in	O
a	O
double-blind	O
randomized	O
placebo-controlled	O
trial	O
of	O
the	O
angiotensin-converting	O
enzyme	O
inhibitor	O
zofenopril	O
.	O

Both	O
placebo	O
and	O
treatment	O
groups	O
were	O
balanced	O
at	O
baseline	O
study	O
in	O
terms	O
of	O
functional	O
class	O
,	O
ventricular	O
performance	O
and	O
autonomic	O
tone	O
.	O

RESULTS	O
After	O
12	O
weeks	O
of	O
therapy	O
with	O
placebo	O
,	O
there	O
was	O
no	O
change	O
in	O
total	Physical
heart	Physical
rate	Physical
variability	Physical
,	O
parasympathetically	Physical
governed	Physical
high	Physical
frequency	Physical
heart	Physical
rate	Physical
variability	Physical
or	O
sympathetically	Physical
influenced	Physical
low	Physical
frequency	Physical
heart	Physical
rate	Physical
variability	Physical
.	O

In	O
contrast	O
,	O
therapy	O
with	O
zofenopril	O
was	O
associated	O
with	O
a	O
50	O
%	O
increase	Physical
in	Physical
total	Physical
heart	Physical
rate	Physical
variability	Physical
(	O
p	O
=	O
0.09	O
)	O
and	O
a	O
significant	O
(	O
p	O
=	O
0.03	O
)	O
twofold	O
increase	Physical
in	Physical
high	Physical
frequency	Physical
heart	Physical
rate	Physical
variability	Physical
,	O
indicating	O
a	O
significant	O
augmentation	O
of	O
parasympathetic	O
tone	O
.	O

CONCLUSIONS	O
These	O
results	O
demonstrate	O
that	O
long-term	O
treatment	O
of	O
patients	O
having	O
congestive	O
heart	O
failure	O
with	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
is	O
associated	O
with	O
a	O
restoration	O
of	O
autonomic	O
balance	O
,	O
which	O
derives	O
in	O
part	O
from	O
a	O
sustained	O
augmentation	O
of	O
parasympathetic	O
tone	O
.	O

Such	O
augmentation	O
of	O
vagal	O
tone	O
is	O
known	O
to	O
be	O
protective	O
against	O
malignant	O
ventricular	O
arrhythmias	O
in	O
patients	O
with	O
ischemic	O
heart	O
disease	O
and	O
therefore	O
may	O
have	O
similar	O
benefit	O
in	O
the	O
setting	O
of	O
ventricular	O
failure	O
,	O
thus	O
contributing	O
to	O
the	O
improved	O
survival	O
associated	O
with	O
angiotensin-converting	O
enzyme	O
inhibitor	O
therapy	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

The	O
A-V	O
Impulse	O
System	O
reduces	O
deep-vein	O
thrombosis	O
and	O
swelling	O
after	O
hemiarthroplasty	O
for	O
hip	O
fracture	O
.	O

We	O
performed	O
a	O
prospective	O
randomised	O
controlled	O
trial	O
of	O
the	O
A-V	O
Impulse	O
System	O
in	O
82	O
patients	O
treated	O
by	O
hemiarthroplasty	O
for	O
subcapital	O
fracture	O
of	O
the	O
femoral	O
neck	O
.	O

The	O
incidence	O
of	O
proximal	O
deep-vein	O
thrombosis	O
as	O
assessed	O
by	O
Doppler	O
ultrasonography	O
was	O
23	O
%	O
in	O
the	O
control	O
group	O
and	O
0	O
%	O
in	O
those	O
using	O
the	O
device	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Calf	O
and	O
thigh	O
circumferences	O
were	O
measured	O
in	O
both	O
groups	O
at	O
seven	O
to	O
ten	O
days	O
after	O
operation	O
.	O

In	O
the	O
treatment	O
group	O
there	O
was	O
a	O
mean	Others
relative	Others
reduction	Others
of	Others
postoperative	Others
swelling	Others
of	Others
the	Others
thigh	Others
by	O
3.27	O
cm	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
of	O
the	O
calf	O
by	O
1.55	O
cm	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

The	O
A-V	O
Impulse	O
System	O
appears	O
to	O
be	O
a	O
safe	Others
and	O
effective	O
method	O
of	O
reducing	O
the	O
incidence	Physical
of	Physical
proximal	Physical
deep-vein	Physical
thrombosis	Physical
,	O
and	O
of	O
postoperative	Adverseeffect
swelling	Adverseeffect
.	O

Angiotensin-converting	O
enzyme	O
inhibition	O
does	O
not	O
suppress	O
plasma	O
angiotensin	O
II	O
increase	O
during	O
exercise	O
in	O
humans	O
.	O

Physical	O
effort	O
stimulates	O
the	O
reninangiotensin	O
system	O
(	O
RAS	O
)	O
.	O

We	O
studied	O
the	O
effect	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
ACE	O
inhibitor	O
)	O
in	O
a	O
double-blind	O
placebo-controlled	O
study	O
,	O
on	O
eight	O
volunteers	O
undergoing	O
physical	O
stress	O
on	O
an	O
ergometric	O
bicycle	O
.	O

The	O
effects	O
of	O
captopril	O
(	O
C	O
)	O
(	O
50	O
mg	O
,	O
three	O
times	O
daily	O
for	O
3	O
days	O
)	O
on	O
arterial	Physical
pressure	Physical
(	Physical
AP	Physical
)	Physical
,	Physical
O2	Physical
consumption	Physical
(	Physical
VO2	Physical
)	Physical
,	Physical
variations	Physical
in	Physical
auricular	Physical
natriuretic	Physical
factor	Physical
(	Physical
ANF	Physical
)	Physical
,	Physical
renin	Physical
,	Physical
angiotensin	Physical
II	Physical
(	Physical
AII	Physical
)	Physical
plasma	Physical
levels	Physical
,	Physical
as	Physical
well	Physical
as	Physical
glomerular	Physical
filtration	Physical
rate	Physical
(	Physical
GFR	Physical
)	Physical
and	Physical
microalbuminuria	Physical
(	Physical
MA	Physical
)	Physical
were	O
evaluated	O
.	O

The	O
different	O
parameters	O
were	O
compared	O
by	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

The	O
pressure	O
profile	O
and	O
VO2	O
were	O
not	O
modified	O
by	O
ACE	O
inhibitor	O
.	O

Exercise	O
stimulates	O
release	O
of	O
renin	O
;	O
this	O
action	O
was	O
greater	O
with	O
captopril	O
administration	O
(	O
treatment	O
effect	O
:	O
p	O
<	O
10	O
(	O
-4	O
)	O
,	O
indicating	O
blockade	O
of	O
the	O
RAS	O
.	O

This	O
inhibition	O
was	O
incomplete	O
because	O
AII	O
levels	O
increased	O
markedly	O
when	O
captopril	O
was	O
given	O
(	O
no	O
treatment	O
effect	O
:	O
p	O
<	O
0.37	O
)	O
.	O

Finally	O
,	O
ACE	O
inhibitor	O
resulted	O
in	O
decreased	O
GFR	Physical
(	O
p	O
=	O
115	O
+/-	O
5.8	O
ml/mn-1	O
,	O
C	O
=	O
91.1	O
+/-	O
4	O
,	O
p	O
<	O
0.05	O
)	O
with	O
exercise	O
without	O
modification	O
of	O
MA	O
.	O

ACE	O
inhibitor	O
administration	O
does	O
not	O
modify	O
the	O
physical	O
performance	O
of	O
nonathletic	O
subjects	O
;	O
AII	O
is	O
significantly	O
increased	O
with	O
exercise	O
despite	O
captopril	O
treatment	O
;	O
ACE	O
inhibitor	O
decreases	O
GFR	Physical
significantly	O
but	O
does	O
not	O
influence	O
MA	O
with	O
prolonged	O
physical	O
effort	O
.	O

Esomeprazole	O
resolves	O
chronic	Physical
heartburn	Physical
in	O
patients	O
without	O
erosive	O
oesophagitis	O
.	O

BACKGROUND	O
Patients	O
with	O
chronic	Physical
heartburn	Physical
but	O
with	O
no	O
endoscopic	O
evidence	O
of	O
erosive	O
oesophagitis	O
require	O
gastric	O
acid	O
suppression	O
to	O
relieve	Physical
symptoms	Physical
.	Physical

AIM	O
To	O
assess	O
the	O
efficacy	Others
and	Others
safety	Others
of	O
esomeprazole	O
in	O
patients	O
with	O
frequent	Physical
heartburn	Physical
for	O
>	O
or	O
=	O
6	O
months	O
and	O
no	O
evidence	O
of	O
erosive	O
oesophagitis	O
on	O
endoscopy	O
.	O

METHODS	O
Two	O
randomized	O
,	O
double-blind	O
,	O
4-week	O
,	O
multi-centre	O
trials	O
with	O
identical	O
methodology	O
compared	O
once-daily	O
esomeprazole	O
,	O
40	O
mg	O
(	O
n	O
=	O
241	O
)	O
or	O
20	O
mg	O
(	O
n	O
=	O
234	O
)	O
,	O
with	O
placebo	O
(	O
n	O
=	O
242	O
)	O
for	O
the	O
rigorous	O
end-point	O
of	O
complete	Physical
resolution	Physical
of	Physical
heartburn	Physical
.	O

Secondary	O
end-points	O
included	O
the	O
percentage	Physical
of	Physical
heartburn-free	Physical
days	Physical
and	O
the	O
time	Physical
to	Physical
first	Physical
and	Physical
sustained	Physical
resolution	Physical
of	Physical
heartburn	Physical
.	O

RESULTS	O
Patients	O
treated	O
with	O
either	O
dose	O
of	O
esomeprazole	O
were	O
two	O
to	O
three	O
times	O
more	O
likely	O
to	O
achieve	O
complete	Physical
resolution	Physical
of	Physical
heartburn	Physical
than	O
patients	O
treated	O
with	O
placebo	O
(	O
P	O
<	O
0.001	O
)	O
.	O

The	O
percentage	Physical
of	Physical
heartburn-free	Physical
days	Physical
was	O
significantly	O
higher	O
with	O
esomeprazole	O
40	O
mg	O
(	O
63	O
%	O
,	O
66	O
%	O
)	O
or	O
20	O
mg	O
(	O
63	O
%	O
,	O
68	O
%	O
)	O
than	O
with	O
placebo	O
(	O
46	O
%	O
,	O
36	O
%	O
;	O
P	O
<	O
or	O
=	O
0.001	O
)	O
in	O
each	O
of	O
the	O
two	O
studies	O
.	O

Esomeprazole	O
was	O
associated	O
with	O
a	O
significantly	O
shorter	O
mean	O
time	O
to	O
first	O
(	O
6-7	O
days	O
)	O
and	O
sustained	O
(	O
12-17	O
days	O
)	O
resolution	Physical
of	Physical
heartburn	Physical
compared	O
with	O
placebo	O
(	O
first	O
,	O
10-12	O
days	O
;	O
sustained	O
,	O
21-22	O
days	O
;	O
P	O
<	O
or	O
=	O
0.008	O
)	O
.	O

The	O
spectrum	Adverseeffect
and	Adverseeffect
frequency	Adverseeffect
of	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
with	O
esomeprazole	O
were	O
similar	O
to	O
those	O
with	O
placebo	O
.	O

CONCLUSIONS	O
Esomeprazole	O
,	O
at	O
daily	O
doses	O
of	O
40	O
mg	O
or	O
20	O
mg	O
,	O
is	O
effective	Others
and	Others
safe	Others
for	O
the	O
treatment	O
of	O
chronic	Physical
heartburn	Physical
in	O
patients	O
without	O
erosive	O
oesophagitis	O
.	O

Intravenous	O
adenosine	O
activates	O
diffuse	O
nociceptive	O
inhibitory	O
controls	O
in	O
humans	O
.	O

Experimentally	O
induced	O
pain	O
can	O
be	O
attenuated	O
by	O
concomitant	O
heterotopic	O
nociceptive	O
stimuli	O
(	O
counterirritation	O
)	O
.	O

Animal	O
data	O
indicate	O
that	O
this	O
stems	O
from	O
supraspinal	Physical
diffuse	Physical
noxious	Physical
inhibitory	Physical
controls	Physical
(	Physical
DNICs	Physical
)	Physical
triggered	O
by	O
C	O
and	O
A?	O
fibers	O
.	O

In	O
humans	O
,	O
only	O
noxious	O
stimuli	O
induce	O
counterirritation	O
.	O

This	O
points	O
at	O
C	O
fibers	O
,	O
but	O
the	O
effects	O
of	O
pharmacologically	O
stimulating	O
C	O
fibers	O
have	O
not	O
been	O
studied	O
.	O

Intravenous	O
adenosine	O
activates	O
pulmonary	O
C	O
fibers	O
and	O
induces	O
dyspnea	O
.	O

This	O
study	O
tests	O
the	O
hypothesis	O
that	O
putative	O
activation	O
of	O
pulmonary	O
C	O
fibers	O
by	O
adenosine	O
would	O
trigger	O
DNICs	O
in	O
humans	O
and	O
induce	O
counterirritation	O
.	O

Twelve	O
healthy	O
volunteers	O
were	O
included	O
(	O
with	O
valid	O
results	O
available	O
in	O
9	O
)	O
and	O
studied	O
according	O
to	O
a	O
double-blind	O
,	O
randomized	O
,	O
cross-over	O
design	O
(	O
intravenous	O
adenosine	O
,	O
140	O
?g?kg	O
(	O
-1	O
)	O
?min	O
(	O
-1	O
)	O
,	O
during	O
5	O
min	O
vs.	O
placebo	O
)	O
.	O

We	O
measured	O
ventilatory	O
variables	O
and	O
end-tidal	O
CO2	O
tension	O
,	O
dyspnea	O
intensity	O
by	O
visual	O
analog	O
scale	O
,	O
and	O
the	O
intensity	O
of	O
putative	O
chest	O
pain	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
amplitude	O
of	O
the	O
RIII	O
component	O
of	O
the	O
nociceptive	O
flexor	O
reflex	O
recorded	O
by	O
biceps	O
femoris	O
electromyogram	O
in	O
response	O
to	O
painful	O
electrical	O
sural	O
nerve	O
stimulation	O
(	O
RIII	O
)	O
,	O
taken	O
as	O
a	O
substitute	O
for	O
pain	O
perception	O
.	O

Placebo	O
did	O
not	O
induce	O
any	O
significant	O
effect	O
.	O

Adenosine	O
induced	O
dyspnea	O
,	O
hyperpnea	O
,	O
tachycardia	O
,	O
and	O
significant	O
RIII	O
inhibition	O
(	O
24	O
?	O
8	O
%	O
at	O
the	O
4th	O
min	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

The	O
temporal	O
dynamics	O
of	O
adenosine-induced	O
dyspnea	O
and	O
RIII	O
inhibition	O
differed	O
(	O
immediate	O
onset	O
followed	O
by	O
a	O
slow	O
decrease	O
for	O
dyspnea	O
,	O
slower	O
onset	O
for	O
RIII	O
inhibition	O
)	O
.	O

Intravenous	O
adenosine	O
in	O
normal	O
humans	O
induces	O
counterirritation	O
,	O
fueling	O
the	O
notion	O
that	O
C-fiber	O
stimulation	O
trigger	O
DNICs	O
in	O
humans	O
.	O

The	O
temporal	O
dissociation	O
between	O
adenosine-induced	O
dyspnea	O
and	O
RIII	O
inhibition	O
suggests	O
that	O
C	O
fibers	O
other	O
than	O
pulmonary	O
ones	O
might	O
be	O
involved	O
.	O

A	O
randomised	O
,	O
double-blind	O
,	O
parallel	O
design	O
,	O
multi-institutional	O
,	O
non-inferiority	O
phase	O
IV	O
trial	O
of	O
imidafenacin	O
versus	O
fesoterodine	O
for	O
overactive	O
bladder	O
.	O

AIMS	O
Our	O
objective	O
was	O
to	O
compare	O
the	O
efficacy	Others
and	Others
safety	Others
of	O
imidafenacin	O
over	O
fesoterodine	O
in	O
patients	O
with	O
overactive	O
bladder	O
(	O
OAB	O
)	O
.	O

METHODS	O
This	O
study	O
is	O
a	O
randomised	O
,	O
double-blind	O
,	O
parallel-group	O
,	O
fesoterodine-controlled	O
study	O
in	O
patients	O
with	O
continuous	O
OAB	O
symptoms	O
for	O
?	O
3	O
months	O
,	O
daily	O
mean	O
voiding	O
frequency	O
(	O
DMVF	O
)	O
?	O
8	O
,	O
and	O
daily	O
mean	O
urgency	O
or	O
urgency	O
incontinence	O
frequency	O
?	O
2	O
.	O

A	O
twice-daily	O
0.1	O
mg	O
imidafenacin	O
with	O
placebo	O
,	O
or	O
once-daily	O
4	O
mg	O
fesoterodine	O
with	O
placebo	O
were	O
administered	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
end-point	O
was	O
the	O
difference	O
in	O
DMVF	O
at	O
12	O
weeks	O
.	O

The	O
secondary	O
efficacy	O
end-points	O
were	O
differences	O
in	O
daily	O
mean	O
:	O
(	O
i	O
)	O
voiding	O
frequency	O
at	O
4	O
and	O
8	O
weeks	O
;	O
(	O
ii	O
)	O
urgency	O
frequency	O
;	O
(	O
iii	O
)	O
urgency	O
incontinence	O
frequency	O
;	O
(	O
iv	O
)	O
incontinence	O
frequency	O
;	O
(	O
v	O
)	O
nocturia	O
frequency	O
;	O
and	O
(	O
vi	O
)	O
quality	O
of	O
life	O
score	O
.	O

The	O
variables	O
for	O
safety	O
analysis	O
were	O
adverse	O
events	O
,	O
vital	O
signs	O
,	O
residual	O
urine	O
volume	O
and	O
clinical	Others
laboratory	Others
tests	Others
.	O

An	O
efficacy	O
analysis	O
was	O
conducted	O
in	O
per-protocol	O
patients	O
and	O
the	O
safety	O
analysis	O
was	O
conducted	O
in	O
all	O
randomised	O
patients	O
.	O

RESULTS	O
The	O
differences	O
in	O
DMVF	O
at	O
12	O
weeks	O
were	O
-3.38	O
?	O
3.63	O
and	O
-2.45	O
?	O
3.73	O
in	O
the	O
imidafenacin	O
and	O
fesoterodine	O
groups	O
,	O
respectively	O
,	O
and	O
the	O
difference	O
was	O
not	O
significant	O
between	O
the	O
two	O
groups	O
.	O

Imidafenacin	O
was	O
non-inferior	O
to	O
fesoterodine	O
,	O
and	O
the	O
lower	O
limit	O
of	O
95	O
%	O
two-sided	O
confidence	O
intervals	O
was	O
-0.53	O
.	O

The	O
other	O
six	O
secondary	O
end-points	O
and	O
variables	O
for	O
safety	O
analysis	O
showed	O
no	O
difference	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
Imidafenacin	O
was	O
non-inferior	O
to	O
fesoterodine	O
in	O
terms	O
of	O
efficacy	O
,	O
and	O
showed	O
no	O
significant	O
difference	O
in	O
terms	O
of	O
safety	O
.	O

Effects	O
of	O
a	O
videotape	O
information	O
intervention	O
at	O
discharge	O
on	O
diet	O
and	O
exercise	O
compliance	O
after	O
coronary	O
bypass	O
surgery	O
.	O

BACKGROUND	O
This	O
study	O
evaluated	O
the	O
relative	O
effects	O
on	O
compliance	O
with	O
recommended	O
lifestyle	O
changes	O
of	O
two	O
experimental	O
videotapes	O
that	O
involved	O
different	O
approaches	O
for	O
preparing	O
coronary	O
artery	O
bypass	O
graft	O
(	O
CABG	O
)	O
patients	O
for	O
the	O
posthospital	O
recovery	O
period	O
.	O

The	O
tapes	O
differed	O
in	O
the	O
extent	O
to	O
which	O
they	O
portrayed	O
the	O
recovery	O
period	O
as	O
a	O
steady	O
,	O
forward	O
progression	O
versus	O
a	O
series	O
of	O
ups	O
and	O
downs	O
.	O

METHODS	O
Two	O
hundred	O
sixteen	O
male	O
and	O
female	O
CABG	O
patients	O
were	O
assigned	O
randomly	O
either	O
to	O
view	O
one	O
of	O
the	O
two	O
videotapes	O
before	O
discharge	O
from	O
the	O
hospital	O
or	O
to	O
receive	O
only	O
the	O
standard	O
discharge	O
preparation	O
provided	O
by	O
the	O
hospital	O
.	O

All	O
patients	O
completed	O
measures	Others
of	Others
anxiety	Others
and	Others
self-efficacy	Others
at	O
discharge	O
,	O
1	O
month	O
and	O
3	O
months	O
after	O
discharge	O
from	O
the	O
hospital	O
.	O

Patients	O
also	O
completed	O
measures	O
of	O
dietary	Mental
fat	Mental
consumption	Mental
and	O
activity	Mental
level	Mental
1	Mental
and	Mental
3	Mental
months	O
after	O
discharge	O
.	O

RESULTS	O
Relative	O
to	O
controls	O
,	O
patients	O
who	O
viewed	O
either	O
of	O
the	O
videotapes	O
before	O
hospital	O
release	O
reported	O
higher	O
self-efficacy	Mental
for	Mental
adhering	Mental
to	Mental
the	Mental
recommended	Mental
low-fat	Mental
diet	Mental
both	O
at	O
discharge	O
and	O
1	O
month	O
after	O
surgery	O
.	O

Viewing	O
either	O
of	O
the	O
videotapes	O
also	O
resulted	O
in	O
significantly	Mental
less	Mental
dietary	Mental
fat	Mental
intake	Mental
1	Mental
month	Mental
after	Mental
hospital	Mental
release	Mental
compared	O
with	O
controls	O
.	O

Patients	O
who	O
viewed	O
the	O
tape	O
that	O
portrayed	O
the	O
recovery	O
period	O
as	O
consisting	O
of	O
ups	O
and	O
downs	O
also	O
reported	O
significantly	O
more	O
frequent	O
moderate	Mental
exercise	Mental
at	Mental
1	Mental
month	Mental
and	O
more	O
frequent	O
strenuous	Mental
exercise	Mental
3	O
months	O
after	O
discharge	O
.	O

CONCLUSIONS	O
The	O
experimental	O
videotapes	O
proved	O
to	O
be	O
an	O
effective	O
method	O
for	O
increasing	O
dietary	Mental
and	Mental
exercise	Mental
compliance	Mental
during	O
the	O
first	O
3	O
months	O
after	O
CABG	O
.	O

Hepatorenal	O
syndrome	O
.	O

Studies	O
of	O
the	O
effect	O
of	O
vascular	O
volume	O
and	O
intraperitoneal	O
pressure	O
on	O
renal	Physical
and	Physical
hepatic	Physical
function	Physical
.	O

Eleven	O
patients	O
with	O
well-documented	O
hepatorenal	O
syndrome	O
were	O
studied	O
by	O
measurement	O
of	O
blood	Physical
volume	Physical
,	O
glomerular	Physical
filtration	Physical
rate	Physical
,	O
renal	Physical
plasma	Physical
flow	Physical
,	O
plasma	Physical
aldosterone	Physical
concentration	Physical
,	O
renin	Physical
substrate	Physical
concentration	Physical
,	O
and	O
plasma	Physical
renin	Physical
activity	Physical
.	O

They	O
were	O
then	O
given	O
750	O
ml	O
of	O
stored	O
plasma	O
,	O
750	O
ml	O
of	O
fresh	O
frozen	O
plasma	O
,	O
and	O
then	O
an	O
infusion	O
of	O
angiotensin	O
II	O
,	O
in	O
random	O
order	O
on	O
successive	O
days	O
.	O

Infusion	O
of	O
fresh	O
frozen	O
plasma	O
improved	O
function	O
more	O
than	O
did	O
stored	O
plasma	O
and	O
in	O
addition	O
returned	O
a	O
very	O
low	O
filtration	O
fraction	O
toward	O
normal	O
.	O

Angiotensin	O
II	O
infusion	O
increased	O
filtration	Physical
fraction	Physical
,	O
but	O
decreased	O
glomerular	Physical
filtration	Physical
rate	Physical
,	O
renal	Physical
plasma	Physical
flow	Physical
,	O
and	O
urine	Physical
flow	Physical
sharply	O
.	O

Patients	O
were	O
then	O
given	O
a	O
daily	O
infusion	O
of	O
1,000	O
ml	O
of	O
fresh	O
frozen	O
plasma	O
for	O
seven	O
to	O
18	O
days	O
to	O
expand	O
the	O
blood	O
volume	O
to	O
supranormal	O
levels	O
as	O
assayed	O
by	O
serial	O
measurement	O
of	O
blood	O
volume	O
.	O

Plasma	Physical
aldosterone	Physical
levels	Physical
decreased	O
to	O
a	O
normal	O
range	O
,	O
glomerular	Physical
filtration	Physical
rate	Physical
and	O
renal	Physical
plasma	Physical
flow	Physical
both	O
increased	O
,	O
and	O
urinary	Physical
excretion	Physical
of	Physical
sodium	Physical
and	Physical
potassium	Physical
both	O
returned	O
toward	O
normal	O
.	O

The	O
effect	O
of	O
intraperitoneal	O
pressure	O
was	O
then	O
studied	O
by	O
measuring	O
glomerular	Physical
filtration	Physical
rate	Physical
,	O
renal	Physical
plasma	Physical
flow	Physical
,	O
pressure	Physical
in	Physical
the	Physical
vena	Physical
cava	Physical
,	O
hepatic	Physical
vein	Physical
free	Physical
flow	Physical
,	O
and	O
hepatic	Physical
vein	Physical
wedged	Physical
pressure	Physical
before	O
,	O
during	O
,	O
and	O
after	O
paracentesis	O
to	O
reduce	O
the	O
intraperitoneal	O
pressure	O
from	O
30	O
to	O
40	O
cm	O
H2O	O
to	O
12	O
to	O
17	O
cm	O
H2O	O
.	O

Venous	Physical
pressures	Physical
moved	O
parallel	O
to	O
ascitic	Physical
fluid	Physical
pressures	Physical
,	O
and	O
glomerular	Physical
filtration	Physical
rate	Physical
,	O
renal	Physical
plasma	Physical
flow	Physical
,	O
and	O
urine	Physical
flow	Physical
all	O
improved	O
sharply	O
;	O
then	O
,	O
as	O
ascitic	O
fluid	O
continued	O
to	O
form	O
,	O
reducing	O
vascular	Physical
volume	Physical
,	O
urine	Physical
flow	Physical
,	Physical
glomerular	Physical
filtration	Physical
rate	Physical
,	O
and	O
renal	Physical
plasma	Physical
flow	Physical
all	O
decreased	O
slowly	O
.	O

Six	O
patients	O
then	O
underwent	O
placement	O
of	O
a	O
LeVeen	O
shunt	O
.	O

Improvement	O
in	O
glomerular	Physical
filtration	Physical
rate	Physical
and	O
renal	Physical
plasma	Physical
flow	Physical
and	O
clinical	Physical
condition	Physical
was	O
dramatic	O
.	O

During	O
postoperative	O
observation	O
of	O
up	O
to	O
two	O
years	O
,	O
progressive	O
improvement	O
in	O
hepatic	Physical
function	Physical
has	O
occurred	O
.	O

Phonophoresis	O
versus	O
topical	O
application	O
of	O
ketoprofen	O
:	O
comparison	O
between	O
tissue	O
and	O
plasma	O
levels	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
Over	O
the	O
last	O
few	O
decades	O
,	O
application	O
of	O
ultrasound	O
has	O
been	O
attempted	O
to	O
enhance	O
transdermal	O
transport	O
of	O
several	O
drugs	O
,	O
a	O
method	O
referred	O
to	O
as	O
phonophoresis	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
examine	O
the	O
influence	O
of	O
ultrasound	O
on	O
the	O
transdermal	O
delivery	O
of	O
ketoprofen	O
in	O
humans	O
and	O
to	O
compare	O
the	O
concentrations	O
found	O
after	O
continuous	O
and	O
pulsed	O
application	O
.	O

SUBJECTS	O
AND	O
METHODS	O
Twenty-six	O
patients	O
with	O
knee	O
disorders	O
requiring	O
arthroscopy	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
3	O
groups	O
.	O

Just	O
before	O
surgery	O
,	O
phonophoresis	O
of	O
a	O
ketoprofen	O
gel	O
(	O
Fastum	O
gel	O
)	O
was	O
given	O
to	O
group	O
A	O
using	O
continuous	O
ultrasound	O
(	O
1	O
MHz	O
,	O
1.5	O
W/cm2	O
,	O
for	O
5	O
minutes	O
)	O
.	O

Group	O
B	O
received	O
the	O
same	O
treatment	O
but	O
with	O
pulsed	O
ultrasound	O
(	O
100	O
Hz	O
,	O
20	O
%	O
duty	O
cycle	O
)	O
.	O

Group	O
C	O
received	O
5	O
minutes	O
of	O
sham	O
ultrasound	O
with	O
the	O
ketoprofen	O
gel	O
.	O

The	O
ultrasound	O
head	O
was	O
moved	O
over	O
a	O
10-cm2	O
area	O
using	O
small	O
,	O
continuous	O
,	O
circular	O
movements	O
.	O

Biopsies	O
of	O
adipose	O
tissue	O
and	O
synovial	O
tissue	O
were	O
taken	O
during	O
surgery	O
to	O
evaluate	Physical
the	Physical
local	Physical
penetration	Physical
of	Physical
the	Physical
drug	Physical
.	O

Blood	O
samples	O
also	O
were	O
collected	O
to	O
determine	Others
whether	Others
ketoprofen	Others
entered	Others
the	Others
systemic	Others
circulation	Others
.	O

RESULTS	O
The	O
concentration	Physical
of	Physical
ketoprofen	Physical
in	O
plasma	O
was	O
negligible	O
in	O
all	O
3	O
groups	O
.	O

The	O
concentration	Physical
of	Physical
ketoprofen	Physical
in	O
synovial	O
tissue	O
differed	O
from	O
that	O
in	O
fat	O
tissue	O
.	O

A	O
difference	O
in	O
concentration	Physical
of	Physical
ketoprofen	Physical
in	O
synovial	O
tissue	O
was	O
found	O
between	O
group	O
C	O
and	O
groups	O
A	O
and	O
B	O
.	O

The	O
concentration	Physical
of	Physical
ketoprofen	Physical
in	Physical
fat	Physical
tissue	Physical
and	Physical
synovial	Physical
tissue	Physical
was	O
consistently	O
higher	O
in	O
group	O
B	O
than	O
in	O
group	O
A	O
.	O

DISCUSSION	O
AND	O
CONCLUSION	O
This	O
study	O
confirms	O
that	O
phonophoresis	O
of	O
ketoprofen	O
allows	O
the	O
attainment	O
of	O
higher	O
local	O
concentrations	O
,	O
whereas	O
systemic	O
exposure	O
is	O
lower	O
.	O

The	O
results	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
sham	O
phonopheresis	O
,	O
ultrasound	O
can	O
increase	O
the	O
transdermal	O
delivery	O
of	O
ketoprofen	O
.	O

Short-term	O
metabolic	O
effects	Others
of	O
prednisone	O
administration	O
in	O
healthy	O
subjects	O
.	O

AIMS	O
Supraphysiologic	O
glucocorticoid	O
activity	O
is	O
well	O
established	O
to	O
cause	O
impaired	O
glucose	Physical
tolerance	Physical
and	Physical
insulin	Physical
resistance	Physical
,	O
yet	O
no	O
study	O
has	O
evaluated	O
dose-dependent	O
effects	O
of	O
low-dose	O
prednisone	O
during	O
short-term	O
oral	O
administration	O
.	O

METHODS	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
quantify	O
the	O
effects	O
of	O
daily	O
10	O
or	O
25	O
mg	O
prednisone	O
administration	O
for	O
one	O
week	O
on	O
insulin	O
sensitivity	O
by	O
employing	O
a	O
two-step	O
hyperinsulinemic	O
euglycemic	O
glucose	O
clamp	O
(	O
Step	O
1	O
:	O
insulin	O
infusion	O
=	O
20	O
mU/m?/min	O
;	O
Step	O
2	O
:	O
insulin	O
infusion	O
=	O
80	O
mU/m?/min	O
)	O
in	O
healthy	O
,	O
lean	O
males	O
.	O

The	O
amount	O
of	O
glucose	O
infused	O
at	O
steady-state	O
to	O
maintain	O
stable	O
blood	O
glucose	O
[	O
90	O
mg/dl	O
(	O
4.95	O
mmol/l	O
)	O
]	O
was	O
used	O
to	O
calculate	O
several	O
indices	O
of	O
insulin	O
sensitivity	O
.	O

RESULTS	O
During	O
Step	O
1	O
of	O
the	O
clamp	O
,	O
whole	O
body	O
glucose	O
disposal	O
(	O
M	O
)	O
was	O
reduced	O
by	O
35	O
%	O
(	O
p	O
=	O
0.003	O
)	O
and	O
M/I	O
was	O
reduced	O
by	O
29	O
%	O
(	O
p	O
=	O
0.025	O
)	O
for	O
25	O
mg	O
prednisone	O
compared	O
to	O
placebo	O
.	O

No	O
appreciable	O
effect	O
of	O
10	O
mg	O
prednisone	O
was	O
observed	O
.	O

During	O
Step	O
2	O
,	O
M	O
was	O
reduced	O
by	O
33	O
%	O
(	O
p	O
=	O
0.001	O
)	O
and	O
15	O
%	O
(	O
p	O
=	O
0.006	O
)	O
for	O
25	O
and	O
10	O
mg	O
prednisone	O
compared	O
to	O
placebo	O
;	O
and	O
M/I	O
ratio	O
was	O
reduced	O
by	O
31	O
%	O
(	O
p	O
<	O
0.001	O
)	O
and	O
13	O
%	O
(	O
p	O
=	O
0.026	O
)	O
,	O
respectively	O
.	O

The	O
insulin	O
sensitivity	O
index	O
,	O
Si	O
,	O
calculated	O
as	O
the	O
quotient	O
of	O
augmentation	O
of	O
M/I	O
between	O
Step	O
1	O
and	O
2	O
,	O
was	O
reduced	O
by	O
35.3	O
%	O
(	O
p	O
<	O
0.01	O
)	O
and	O
23.5	O
%	O
(	O
p	O
<	O
0.05	O
)	O
for	O
25	O
and	O
10	O
mg	O
prednisone	O
,	O
respectively	O
.	O

CONCLUSION	O
Administration	O
of	O
relatively	O
low	O
pharmacological	O
doses	O
of	O
prednisone	O
for	O
one	O
week	O
impaired	O
insulin	O
sensitivity	O
in	O
a	O
dose-dependent	O
manner	O
in	O
healthy	O
males	O
.	O

These	O
observed	O
changes	O
in	O
insulin	O
sensitivity	O
are	O
likely	O
to	O
be	O
clinically	O
relevant	O
,	O
especially	O
in	O
individuals	O
predisposed	O
to	O
develop	O
glucose	O
intolerance	O
.	O

Evaluation	O
of	O
the	O
effect	O
of	O
acetazolamide	O
on	O
cystoid	O
macular	O
oedema	O
in	O
patients	O
with	O
Behcet	O
's	O
disease	O
.	O

AIM	O
To	O
study	O
the	O
effect	O
of	O
acetazolamide	O
on	O
cystoid	O
macular	O
oedema	O
(	O
CMO	O
)	O
in	O
patients	O
with	O
Behcet	O
's	O
disease	O
.	O

PATIENTS	O
AND	O
METHODS	O
A	O
total	O
of	O
67	O
eyes	O
of	O
35	O
Behcet	O
's	O
patients	O
with	O
chronic	O
,	O
but	O
well-controlled	O
uveitis	O
,	O
and	O
CMO	O
were	O
randomised	O
into	O
a	O
double-masked	O
,	O
crossover	O
trial	O
comparing	O
the	O
effect	O
of	O
acetazolamide	O
vs	O
placebo	O
.	O

The	O
patients	O
received	O
an	O
initial	O
4-week	O
course	O
of	O
either	O
250	O
mg	O
acetazolamide	O
twice	O
daily	O
(	O
b.i.d	O
.	O

)	O
or	O
placebo	O
,	O
followed	O
by	O
a	O
4-week	O
washout	O
period	O
.	O

They	O
then	O
received	O
a	O
4-week	O
course	O
of	O
the	O
reverse	O
study	O
medication	O
.	O

An	O
improvement	O
in	O
visual	Physical
acuity	Physical
and	O
fundus	Physical
fluorescein	Physical
angiographic	Physical
findings	Physical
was	O
assessed	O
.	O

RESULTS	O
In	O
total	O
,	O
29	O
patients	O
(	O
55	O
eyes	O
)	O
completed	O
the	O
trial	O
and	O
were	O
available	O
for	O
analysis	O
.	O

Of	O
the	O
29	O
,	O
16	O
men	O
and	O
13	O
were	O
women	O
.	O

The	O
age	O
range	O
was	O
13-50	O
years	O
(	O
mean	O
33.6	O
years	O
)	O
.	O

Patients	O
on	O
acetazolamide	O
showed	O
a	O
slightly	O
better	O
improvement	O
of	O
angiographic	Physical
signs	Physical
(	O
at	O
least	O
by	O
one	O
grade	O
improvement	O
)	O
over	O
that	O
of	O
placebo	O
(	O
12	O
vs	O
five	O
eyes	O
)	O
.	O

They	O
also	O
had	O
less	O
deterioration	Physical
of	Physical
angiographic	Physical
signs	Physical
over	O
that	O
of	O
placebo	O
(	O
three	O
vs	O
seven	O
eyes	O
)	O
.	O

However	O
,	O
these	O
findings	O
were	O
not	O
statistically	O
significant	O
(	O
P=0.99	O
)	O
.	O

Acetazolamide	O
had	O
no	O
statistically	O
significant	O
effect	O
(	O
P=0.53	O
)	O
on	O
the	O
improvement	O
of	O
visual	Physical
acuity	Physical
of	O
patients	O
over	O
that	O
of	O
placebo	O
(	O
13	O
vs	O
eight	O
eyes	O
)	O
,	O
nor	O
on	O
the	O
deterioration	O
of	O
visual	Physical
acuity	Physical
(	O
three	O
vs	O
11	O
eyes	O
)	O
.	O

CONCLUSION	O
Despite	O
seemingly	O
favourable	O
results	O
,	O
the	O
4-week	O
course	O
of	O
acetazolamide	O
(	O
250	O
mg	O
b.i.d	O
.	O

)	O
has	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
improvement	O
of	O
the	O
visual	Physical
acuity	Physical
and	O
the	O
fluorescein	Physical
angiographic	Physical
findings	Physical
in	O
Behcet	O
's	O
patients	O
with	O
CMO	O
.	O

Effects	O
of	O
diet	O
and	O
Aspergillus	O
oryzae	O
extract	O
or	O
Saccharomyces	O
cervisiae	O
on	O
growth	O
and	O
carcass	O
characteristics	O
of	O
lambs	O
and	O
steers	O
fed	O
to	O
meet	O
requirements	O
of	O
natural	O
markets	O
.	O

Two	O
studies	O
were	O
conducted	O
to	O
determine	O
the	O
effects	O
of	O
diet	O
and	O
feed	O
additive	O
on	O
growth	O
and	O
carcass	O
characteristics	O
of	O
lambs	O
and	O
cattle	O
destined	O
for	O
all	O
natural	O
markets	O
.	O

In	O
Exp	O
.	O

1	O
,	O
48	O
Dorset	O
?	O
Hampshire	O
lambs	O
(	O
initial	O
BW	O
29.4	O
?	O
0.1	O
kg	O
)	O
were	O
used	O
in	O
a	O
randomized	O
complete	O
block	O
experiment	O
to	O
determine	O
the	O
effects	O
of	O
Aspergillus	O
oryzae	O
extract	O
,	O
Amaferm	O
(	O
AMF	O
)	O
supplementation	O
(	O
1	O
g/d	O
)	O
in	O
an	O
85	O
%	O
concentrate	O
diet	O
on	O
growth	O
and	O
carcass	O
characteristics	O
.	O

Lambs	O
were	O
allotted	O
to	O
12	O
pens	O
(	O
4	O
lambs	O
per	O
pen	O
)	O
,	O
and	O
blocked	O
by	O
sex	O
and	O
BW	O
.	O

Lambs	O
were	O
fed	O
until	O
the	O
average	O
BW	O
of	O
each	O
pen	O
reached	O
a	O
target	O
BW	O
(	O
55.4	O
kg	O
for	O
wethers	O
and	O
50.0	O
kg	O
for	O
ewes	O
)	O
,	O
at	O
which	O
time	O
the	O
entire	O
pen	O
of	O
lambs	O
was	O
slaughtered	O
.	O

Amaferm	O
resulted	O
in	O
a	O
greater	O
(	O
P=0.07	O
)	O
G	O
:	O
F.	O
In	O
Exp	O
.	O

2	O
,	O
168	O
crossbred	O
steers	O
(	O
initial	O
BW	O
300	O
?	O
0.7	O
kg	O
)	O
were	O
used	O
in	O
a	O
trial	O
with	O
a	O
3	O
?	O
2	O
factorial	O
arrangement	O
of	O
treatments	O
to	O
examine	O
the	O
effects	O
of	O
0.5	O
g/d	O
of	O
Saccaromyces	O
cervisiae	O
boulardii	O
CNCM	O
1079-Levucell	O
SB	O
(	O
LEV	O
)	O
,	O
or	O
3	O
g/d	O
of	O
AMF	O
with	O
2	O
corn	O
sources	O
,	O
dry	O
whole-shelled	O
corn	O
or	O
high	O
moisture	O
corn	O
,	O
on	O
growth	O
and	O
carcass	O
characteristics	O
.	O

Neither	O
LEV	O
nor	O
AMF	O
improved	O
(	O
P	O
>	O
0.10	O
)	O
carcass	Physical
characteristics	Physical
compared	O
with	O
control	O
or	O
non-feed-supplemented	O
steers	O
.	O

Addition	O
of	O
LEV	O
to	O
high-concentrate	O
,	O
corn-based	O
diets	O
did	O
not	O
improve	O
(	O
P	O
>	O
0.10	O
)	O
growth	Physical
performance	Physical
of	O
feedlot	O
steers	O
.	O

However	O
,	O
addition	O
of	O
AMF	O
to	O
a	O
diet	O
composed	O
of	O
dry	O
whole-shelled	O
corn	O
resulted	O
in	O
an	O
improvement	O
(	O
P	O
<	O
0.05	O
)	O
in	O
G	Physical
:	Physical
F	Physical
(	O
0.208	O
vs.	O
0.194	O
)	O
.	O

Results	O
indicate	O
that	O
at	O
the	O
amounts	O
fed	O
,	O
AMF	O
may	O
improve	O
G	Physical
:	Physical
F	Physical
for	O
lambs	O
and	O
steers	O
fed	O
dry	O
corn-based	O
finishing	O
diets	O
.	O

Does	O
aerobic	O
training	O
lead	O
to	O
a	O
more	O
active	Mental
lifestyle	Mental
and	O
improved	Others
quality	Others
of	Others
life	Others
in	O
patients	O
with	O
chronic	O
heart	O
failure	O
?	O
BACKGROUND	O
Due	O
to	O
dyspnea	O
and	O
fatigue	O
,	O
patients	O
with	O
chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
are	O
often	O
restricted	O
in	O
the	O
performance	O
of	O
everyday	O
activities	O
,	O
which	O
gradually	O
may	O
lead	O
to	O
hypoactivity	O
.	O

AIMS	O
To	O
assess	O
whether	O
aerobic	O
training	O
leads	O
to	O
a	O
more	O
active	Mental
lifestyle	Mental
and	O
improved	O
quality	Physical
of	Physical
life	Physical
(	Physical
QoL	Physical
)	Physical
in	O
patients	O
with	O
CHF	O
.	O

METHODS	O
Patients	O
with	O
stable	O
CHF	O
(	O
NYHA	O
II/III	O
;	O
59	O
(	O
11	O
)	O
years	O
)	O
were	O
randomly	O
assigned	O
to	O
a	O
training	O
group	O
(	O
n=18	O
;	O
3-month	O
aerobic	O
program	O
above	O
standard	O
treatment	O
)	O
or	O
control	O
group	O
(	O
n=16	O
;	O
standard	O
treatment	O
without	O
special	O
advice	O
for	O
exercise	O
)	O
.	O

Measurements	O
were	O
performed	O
on	O
level	O
of	O
everyday	Mental
physical	Mental
activity	Mental
(	Mental
PA	Mental
,	Mental
novel	Mental
accelerometry-based	Mental
activity	Mental
monitor	Mental
)	Mental
and	O
QoL	Physical
,	O
and	O
on	O
several	Others
related	Others
parameters	Others
.	O

RESULTS	O
Training	O
did	O
not	O
result	O
in	O
a	O
more	O
active	Mental
lifestyle	Mental
or	O
improved	O
QoL	Physical
,	O
but	O
improved	O
(	O
P	O
<	O
0.05	O
)	O
peak	Physical
power	Physical
(	O
17	O
%	O
)	O
,	O
6-min	Physical
walk	Physical
distance	Physical
(	O
10	O
%	O
)	O
,	O
muscle	Physical
strength	Physical
(	O
13-15	O
%	O
)	O
and	O
depression	Mental
(	O
-1.3	O
unit	O
)	O
.	O

Changes	O
in	O
level	O
of	O
everyday	O
PA	O
were	O
related	O
to	O
changes	O
in	O
peak	Physical
Vo	Physical
(	Physical
2	Physical
)	Physical
(	O
r=0.58	O
,	O
P=0.01	O
)	O
and	O
knee	Physical
extension	Physical
strength	Physical
(	O
r=0.48	O
,	O
P=0.05	O
)	O
.	O

CONCLUSIONS	O
At	O
group	O
level	O
training	O
did	O
not	O
result	O
in	O
a	O
more	O
active	Mental
lifestyle	Mental
or	O
improved	O
QoL	Physical
.	O

However	O
,	O
correlations	O
between	O
training-related	O
changes	O
in	O
parameters	O
suggest	O
that	O
aerobic	O
training	O
has	O
the	O
potential	O
to	O
increase	O
levels	O
of	O
everyday	O
PA	O
in	O
CHF	O
.	O

Tacrolimus/sirolimus	O
vs	O
tacrolimus/methotrexate	O
as	O
GVHD	O
prophylaxis	O
after	O
matched	O
,	O
related	O
donor	O
allogeneic	O
HCT	O
.	O

Grades	O
2-4	O
acute	O
graft-versus-host	O
disease	O
(	O
GVHD	O
)	O
occurs	O
in	O
approximately	O
35	O
%	O
of	O
matched	O
,	O
related	O
donor	O
(	O
MRD	O
)	O
allogeneic	O
hematopoietic	O
cell	O
transplantation	O
(	O
HCT	O
)	O
recipients	O
.	O

We	O
sought	O
to	O
determine	O
if	O
the	O
combination	O
of	O
tacrolimus	O
and	O
sirolimus	O
(	O
Tac/Sir	O
)	O
was	O
more	O
effective	O
than	O
tacrolimus	O
and	O
methotrexate	O
(	O
Tac/Mtx	O
)	O
in	O
preventing	O
acute	O
GVHD	O
and	O
early	O
mortality	O
after	O
allogeneic	O
MRD	O
HCT	O
in	O
a	O
phase	O
3	O
,	O
multicenter	O
trial	O
.	O

The	O
primary	O
end	O
point	O
of	O
the	O
trial	O
was	O
to	O
compare	O
114-day	Mortality
grades	Mortality
2-4	Mortality
acute	Mortality
GVHD-free	Mortality
survival	Mortality
using	O
an	O
intention-to-treat	O
analysis	O
of	O
304	O
randomized	O
subjects	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
probability	O
of	O
day	O
114	O
grades	O
2-4	O
acute	O
GVHD-free	O
survival	O
(	O
67	O
%	O
vs	O
62	O
%	O
,	O
P	O
=	O
.38	O
)	O
.	O

Grades	Mortality
2-4	Mortality
GVHD	Mortality
was	O
similar	O
in	O
the	O
Tac/Sir	O
and	O
Tac/Mtx	O
arms	O
(	O
26	O
%	O
vs	O
34	O
%	O
,	O
P	O
=	O
.48	O
)	O
.	O

Neutrophil	Physical
and	Physical
platelet	Physical
engraftment	Physical
were	O
more	O
rapid	O
in	O
the	O
Tac/Sir	O
arm	O
(	O
14	O
vs	O
16	O
days	O
,	O
P	O
<	O
.001	O
;	O
16	O
vs	O
19	O
days	O
,	O
P	O
=	O
.03	O
)	O
.	O

Oropharyngeal	Physical
mucositis	Physical
was	O
less	O
severe	O
in	O
the	O
Tac/Sir	O
arm	O
(	O
peak	O
Oral	Physical
Mucositis	Physical
Assessment	Physical
Scale	Physical
score	Physical
0.70	O
vs	O
0.96	O
,	O
P	O
<	O
.001	O
)	O
,	O
but	O
otherwise	O
toxicity	Adverseeffect
was	O
similar	O
.	O

Chronic	Mortality
GVHD	Mortality
,	Mortality
relapse-free	Mortality
survival	Mortality
,	Mortality
and	Mortality
overall	Mortality
survival	Mortality
at	Mortality
2	Mortality
years	Mortality
were	O
no	O
different	O
between	O
study	O
arms	O
(	O
53	O
%	O
vs	O
45	O
%	O
,	O
P	O
=	O
.06	O
;	O
53	O
%	O
vs	O
54	O
%	O
,	O
P	O
=	O
.77	O
;	O
and	O
59	O
%	O
vs	O
63	O
%	O
,	O
P	O
=	O
.36	O
)	O
.	O

Based	O
on	O
similar	O
long-term	O
outcomes	O
,	O
more	O
rapid	O
engraftment	O
,	O
and	O
less	O
oropharyngeal	O
mucositis	O
,	O
the	O
combination	O
of	O
Tac/Sir	O
is	O
an	O
acceptable	O
alternative	O
to	O
Tac/Mtx	O
after	O
MRD	O
HCT	O
.	O

This	O
study	O
was	O
funded	O
by	O
the	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
and	O
the	O
National	O
Cancer	O
Institute	O
;	O
and	O
the	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT00406393	O
.	O

A	O
randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
parallel	O
study	O
of	O
loteprednol	O
etabonate	O
0.2	O
%	O
in	O
patients	O
with	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
loteprednol	O
etabonate	O
(	O
LE	O
)	O
0.2	O
%	O
in	O
reducing	O
the	O
signs	O
and	O
symptoms	O
of	O
seasonal	Physical
allergic	Physical
conjunctivitis	Physical
.	Physical

DESIGN	O
Randomized	O
,	O
double-masked	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
multicenter	O
study	O
of	O
6	O
weeks	O
duration	O
.	O

PARTICIPANTS	O
A	O
total	O
of	O
135	O
patients	O
with	O
signs	O
and	O
symptoms	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
participated	O
.	O

INTERVENTION	O
All	O
patients	O
received	O
either	O
LE	O
0.2	O
%	O
or	O
placebo	O
(	O
vehicle	O
)	O
four	O
times	O
a	O
day	O
in	O
both	O
eyes	O
for	O
42	O
days	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Bulbar	Physical
conjunctival	Physical
injection	Physical
(	Physical
primary	Physical
sign	Physical
)	Physical
and	Physical
itching	Physical
(	Physical
primary	Physical
symptom	Physical
)	Physical
over	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
was	O
measured	O
.	O

RESULTS	O
A	O
reduction	Physical
in	Physical
severity	Physical
was	O
seen	O
in	O
both	O
LE	O
and	O
placebo	O
groups	O
for	O
bulbar	Physical
conjunctival	Physical
injection	Physical
(	O
1.5	O
vs.	O
1.0	O
units	O
on	O
a	O
0-3	O
scale	O
)	O
and	O
itching	O
(	O
3.4	O
vs.	O
3.0	O
units	O
on	O
a	O
0-4	O
scale	O
)	O
over	O
the	O
first	O
2	O
weeks	O
.	O

The	O
treatment	O
effect	O
by	O
these	O
measures	O
was	O
-0.5	O
and	O
-0.4	O
units	O
in	O
favor	O
of	O
LE	O
(	O
P	O
<	O
or	O
=	O
0.008	O
)	O
.	O

Resolution	O
(	O
i.e.	O
,	O
the	O
proportion	Others
of	Others
patients	Others
with	Others
signs	Others
or	Others
symptoms	Others
no	Others
longer	Others
present	Others
)	Others
at	O
day	O
14	O
strongly	O
favored	O
LE-treated	O
patients	O
(	O
36	O
%	O
and	O
15	O
%	O
;	O
58	O
%	O
and	O
38	O
%	O
,	O
for	O
injection	O
and	O
itching	O
,	O
respectively	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	Others
.	O

One	O
patient	O
in	O
each	O
treatment	O
group	O
(	O
1	O
of	O
67	O
and	O
1	O
of	O
68	O
,	O
respectively	O
)	O
had	O
an	O
elevation	Physical
of	Physical
intraocular	Physical
pressure	Physical
of	O
10	O
mmHg	O
or	O
greater	O
during	O
the	O
6	O
weeks	O
of	O
treatment	O
.	O

CONCLUSIONS	O
Loteprednol	O
etabonate	O
0.2	O
%	O
was	O
more	O
effective	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

Loteprednol	O
etabonate	O
0.2	O
%	O
had	O
a	O
safety	O
profile	O
comparable	O
to	O
placebo	O
.	O

A	O
preliminary	O
study	O
of	O
the	O
optimal	O
anesthesia	O
positioning	O
for	O
the	O
morbidly	O
obese	O
patient	O
.	O

BACKGROUND	O
Hypoxemia	O
during	O
the	O
induction	O
of	O
general	O
anesthesia	O
for	O
the	O
morbidly	O
obese	O
patient	O
is	O
a	O
major	O
concern	O
of	O
anesthesiologists	O
.	O

The	O
etiology	O
of	O
this	O
pathophysiological	O
problem	O
is	O
multifactorial	O
,	O
and	O
patient	O
positioning	O
may	O
be	O
a	O
contributing	O
factor	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
identify	O
optimal	O
patient	O
positioning	O
for	O
the	O
induction	O
of	O
general	O
anesthesia	O
that	O
minimizes	O
the	O
risk	O
of	O
hypoxemia	O
in	O
these	O
patients	O
.	O

METHODS	O
26	O
morbidly	O
obese	O
patients	O
(	O
body	O
mass	O
index-BMI	O
56	O
+/-	O
3	O
)	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
positions	O
for	O
induction	O
of	O
anesthesia	O
:	O
1	O
)	O
30	O
degrees	O
Reverse	O
Trendelenburg	O
;	O
2	O
)	O
Supine-Horizontal	O
;	O
3	O
)	O
30	O
degrees	O
Back	O
Up	O
Fowler	O
.	O

Mask	O
ventilation	O
,	O
full	O
neuromuscular	O
paralysis	O
and	O
direct	O
laryngoscopy	O
were	O
performed	O
.	O

Any	O
airway	Physical
difficulties	Physical
were	O
noted	O
.	O

After	O
endotracheal	O
tube	O
placement	O
,	O
subjects	O
were	O
ventilated	O
for	O
5	O
minutes	O
with	O
1	O
%	O
isoflurane	O
in	O
a	O
mixture	O
of	O
50	O
%	O
oxygen/50	O
%	O
air	O
and	O
then	O
disconnected	O
from	O
the	O
ventilation	O
circuit	O
.	O

The	O
time	Physical
required	Physical
for	Physical
capillary	Physical
oxygen	Physical
saturation	Physical
(	Physical
SaO2	Physical
)	Physical
,	O
as	O
measured	O
by	O
pulse	O
oximeter	O
,	O
to	O
decline	O
from	O
100	O
%	O
to	O
92	O
%	O
was	O
noted	O
and	O
identified	O
as	O
the	O
safe	Physical
apnea	Physical
period	Physical
(	Physical
SAP	Physical
)	Physical
.	O

Ventilation	O
was	O
then	O
immediately	O
re-established	O
.	O

The	O
lowest	O
SaO2	Physical
after	O
resuming	O
ventilation	O
and	O
the	O
time	O
from	O
that	O
nadir	O
to	O
an	O
SaO2	O
of	O
97	O
%	O
were	O
also	O
recorded	O
.	O

RESULTS	O
BMI	Physical
and	Physical
hip-waist	Physical
ratios	Physical
of	Physical
patients	Physical
in	O
groups	O
1	O
,	O
2	O
and	O
3	O
did	O
not	O
significantly	O
differ	O
.	O

There	O
were	O
no	O
differences	O
in	O
airway	Physical
difficulties	Physical
between	O
the	O
different	O
groups	O
.	O

The	O
SAP	Physical
in	O
groups	O
1	O
,	O
2	O
and	O
3	O
was	O
178	O
+/-	O
55	O
,	O
123	O
+/-	O
24	O
and	O
153	O
+/-	O
63	O
seconds	O
,	O
respectively	O
.	O

The	O
SaO2	Physical
of	O
patients	O
in	O
the	O
reverse	O
Trendelenburg	O
position	Mental
dropped	O
the	O
least	O
and	O
took	O
the	O
shortest	O
time	Physical
to	Physical
recover	Physical
to	O
97	O
%	O
.	O

CONCLUSIONS	O
In	O
morbidly	O
obese	O
patients	O
,	O
the	O
30	O
degrees	O
Reverse	O
Trendelenburg	O
position	O
provided	O
the	O
longest	O
SAP	O
when	O
compared	O
to	O
the	O
30	O
degrees	O
Back	O
Up	O
Fowler	O
and	O
Horizontal-Supine	O
positions	O
.	O

Since	O
on	O
induction	O
of	O
general	O
anesthesia	O
morbidly	O
obese	O
patients	O
may	O
be	O
difficult	O
to	O
mask	O
ventilate	O
and/or	O
intubate	O
,	O
this	O
extra	O
time	O
may	O
preclude	O
adverse	O
sequelae	O
resulting	O
from	O
hypoxemia	O
.	O

Therefore	O
,	O
Reverse	O
Trendelenburg	O
is	O
recommended	O
as	O
the	O
optimal	O
position	O
for	O
induction	O
.	O

Evaluation	O
of	O
an	O
intervention	O
to	O
change	O
benzodiazepine-prescribing	O
behavior	O
in	O
a	O
prepaid	O
group	O
practice	O
setting	O
.	O

To	O
determine	O
the	O
effect	O
of	O
two	O
levels	O
of	O
educational	O
intervention	O
on	O
benzodiazepine-prescribing	O
behavior	O
in	O
an	O
elderly	O
population	O
in	O
a	O
controlled	O
prepaid	O
group	O
practice	O
(	O
PPGP	O
)	O
setting	O
,	O
we	O
designed	O
a	O
prospective	O
controlled	O
trial	O
,	O
with	O
six-month	O
follow-up	O
.	O

Our	O
setting	O
was	O
a	O
270,000	O
member	O
group-model	O
PPGP	O
in	O
Colorado	O
,	O
from	O
1990	O
to	O
1991	O
.	O

Participants	O
included	O
91	O
physicians	O
,	O
62	O
men	O
and	O
29	O
women	O
;	O
median	O
age	O
was	O
38.7	O
years	O
.	O

Group	O
1	O
received	O
a	O
one-on-one	O
educational	O
presentation	O
by	O
a	O
clinical	O
pharmacist	O
,	O
written	O
educational	O
materials	O
,	O
a	O
brief	O
follow-up	O
visit	O
,	O
and	O
feedback	O
with	O
recommendations	O
.	O

Group	O
2	O
received	O
only	O
a	O
face-to-face	O
presentation	O
,	O
given	O
to	O
departmental	O
groups	O
,	O
as	O
well	O
as	O
the	O
same	O
written	O
educational	O
materials	O
used	O
in	O
group	O
1	O
.	O

Controls	O
received	O
no	O
intervention	O
.	O

Our	O
primary	O
outcome	O
measure	O
was	O
the	O
benzodiazepine	Others
on/off	Others
status	Others
of	Others
the	Others
elderly	Others
PPGP	Others
members	Others
.	O

The	O
secondary	O
outcome	O
measure	O
was	O
the	O
median	Others
change	Others
(	Others
preintervention	Others
minus	Others
postintervention	Others
)	Others
in	Others
a	Others
standardized	Others
amount	Others
of	Others
benzodiazepines	Others
prescribed	Others
per	Others
physician	Others
.	O

Logistic	O
regression	O
analysis	O
failed	O
to	O
show	O
a	O
significant	O
effect	O
on	O
postintervention	O
benzodiazepine	Others
on/off	Others
status	Others
between	O
study	O
groups	O
,	O
when	O
controlling	O
for	O
preintervention	O
on/off	O
status	O
,	O
PPGP-member	O
age	O
,	O
PPGP-member	O
gender	O
,	O
and	O
all	O
possible	O
interactions	O
.	O

Analysis	O
of	O
variance	O
failed	O
to	O
demonstrate	O
an	O
effect	O
of	O
either	O
intervention	O
on	O
the	O
median	Others
change	Others
in	Others
standardized	Others
amount	Others
of	Others
benzodiazepines	Others
prescribed	O
per	O
physician	O
,	O
with	O
groups	O
1	O
,	O
2	O
,	O
and	O
controls	O
yielding	O
values	O
of	O
-278	O
(	O
range	O
:	O
-4,137	O
,	O
2,844	O
)	O
,	O
-330	O
(	O
-1,531	O
,	O
1,358	O
)	O
,	O
and	O
-541	O
(	O
range	O
:	O
-3,716	O
,	O
2,185	O
)	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
strategies	O
effective	O
in	O
changing	O
physician	O
prescribing	O
behavior	O
in	O
other	O
settings	O
may	O
not	O
be	O
effective	O
in	O
a	O
PPGP	O
setting	O
with	O
benzodiazepines	O
in	O
the	O
elderly	O
as	O
the	O
target	O
for	O
change	O
.	O

Prognostic	O
value	O
of	O
postoperative	O
CEA	O
clearance	O
in	O
rectal	O
cancer	O
patients	O
with	O
high	O
preoperative	O
CEA	O
levels	O
.	O

PURPOSE	O
We	O
determined	O
the	O
prognostic	O
value	O
of	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
clearance	O
after	O
tumor	O
resection	O
with	O
serial	O
evaluation	O
of	O
postoperative	O
CEA	O
levels	O
in	O
rectal	O
cancer	O
.	O

METHODS	O
Between	O
1994	O
and	O
2004	O
,	O
we	O
retrospectively	O
reviewed	O
122	O
patients	O
with	O
rectal	O
cancer	O
whose	O
serum	Physical
CEA	Physical
levels	Physical
were	O
measured	O
on	O
the	O
preoperative	O
day	O
and	O
postoperative	O
days	O
7	O
and	O
30	O
.	O

Patients	O
with	O
preoperative	O
CEA	O
levels	O
<	O
5.0	O
ng/ml	O
were	O
excluded	O
.	O

An	O
exponential	O
trend	O
line	O
was	O
drawn	O
using	O
the	O
three	O
CEA	O
values	O
.	O

Patients	O
were	O
categorized	O
into	O
three	O
groups	O
based	O
on	O
R	O
(	O
2	O
)	O
values	O
calculated	O
through	O
trend	O
line	O
,	O
which	O
indicates	O
the	O
correlation	O
coefficient	O
between	O
exponential	O
graph	O
and	O
measured	O
CEA	Physical
values	Physical
:	O
exponential	O
decrease	O
group	O
(	O
group	O
1	O
:	O
0.9	O
<	O
R	O
(	O
2	O
)	O
<	O
or	O
=	O
1.0	O
)	O
,	O
nearly	O
exponential	O
decrease	O
group	O
(	O
group	O
2	O
:	O
0.5	O
<	O
R	O
(	O
2	O
)	O
<	O
or	O
=	O
0.9	O
)	O
,	O
and	O
randomized	O
clearance	O
group	O
(	O
group	O
3	O
:	O
0.5	O
<	O
or	O
=	O
R	O
(	O
2	O
)	O
)	O
.	O

We	O
then	O
analyzed	O
the	O
CEA	O
clearance	O
pattern	O
as	O
a	O
prognostic	O
indicator	O
.	O

RESULTS	O
With	O
a	O
median	O
follow-up	O
of	O
57	O
months	O
,	O
the	O
5-year	Mortality
overall	Mortality
survival	Mortality
was	O
62.3	O
%	O
vs.	O
48.1	O
%	O
vs.	O
25	O
%	O
and	O
the	O
5-year	Mortality
disease-free	Mortality
survival	Mortality
was	O
58.6	O
%	O
vs.	O
52.7	O
%	O
vs.	O
25	O
%	O
among	O
groups	O
1	O
,	O
2	O
,	O
and	O
3	O
(	O
P	O
=	O
0.014	O
,	O
P	O
=	O
0.027	O
,	O
respectively	O
)	O
in	O
patients	O
with	O
stage	O
III	O
rectal	O
cancer	O
.	O

For	O
those	O
with	O
stage	O
II	O
rectal	O
cancer	O
,	O
the	O
5-year	Mortality
overall	Mortality
survival	Mortality
rate	Mortality
of	O
group	O
1	O
was	O
significantly	O
better	O
than	O
groups	O
2	O
and	O
3	O
(	O
88.8	O
%	O
vs.	O
74.1	O
%	O
,	O
respectively	O
,	O
P	O
=	O
0.021	O
)	O
.	O

CONCLUSIONS	O
The	O
postoperative	O
pattern	O
of	O
CEA	O
clearance	O
is	O
a	O
useful	O
prognostic	O
determinant	O
in	O
patients	O
with	O
rectal	O
cancer	O
.	O

Patients	O
with	O
a	O
randomized	O
pattern	O
of	O
CEA	Physical
clearance	Physical
after	O
tumor	O
resection	O
should	O
be	O
regarded	O
as	O
having	O
the	O
possibility	O
of	O
a	O
persistent	O
CEA	O
source	O
and	O
may	O
require	O
consideration	O
of	O
intensive	O
follow-up	O
or	O
adjuvant	O
therapy	O
.	O

Randomized	O
,	O
controlled	O
,	O
crossover	O
trial	O
of	O
methylphenidate	O
in	O
pervasive	O
developmental	O
disorders	O
with	O
hyperactivity	O
.	O

CONTEXT	O
Hyperactivity	O
and	O
inattention	O
are	O
common	O
symptoms	O
in	O
children	O
with	O
autistic	O
disorder	O
and	O
related	O
pervasive	O
developmental	O
disorders	O
,	O
but	O
studies	O
of	O
stimulants	O
in	O
these	O
conditions	O
have	O
been	O
inconclusive	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
and	O
safety	O
of	O
methylphenidate	O
hydrochloride	O
in	O
children	O
with	O
pervasive	O
developmental	O
disorders	O
and	O
hyperactivity	O
.	O

DESIGN	O
Double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
trial	O
followed	O
by	O
open-label	O
continuation	O
.	O

SETTING	O
Five	O
academic	O
outpatient	O
clinics	O
.	O

PARTICIPANTS	O
Seventy-two	O
drug-free	O
children	O
,	O
aged	O
5	O
to	O
14	O
years	O
,	O
with	O
pervasive	O
developmental	O
disorders	O
accompanied	O
by	O
moderate	O
to	O
severe	O
hyperactivity	O
.	O

INTERVENTIONS	O
Prior	O
to	O
randomization	O
,	O
subjects	O
entered	O
a	O
1-week	O
test-dose	O
phase	O
in	O
which	O
each	O
subject	O
received	O
placebo	O
for	O
1	O
day	O
followed	O
by	O
increasing	O
doses	O
of	O
methylphenidate	O
(	O
low	O
,	O
medium	O
,	O
and	O
high	O
doses	O
)	O
that	O
were	O
each	O
given	O
for	O
2	O
days	O
.	O

The	O
low	O
,	O
medium	O
,	O
and	O
high	O
doses	O
of	O
methylphenidate	O
hydrochloride	O
were	O
based	O
on	O
weight	O
,	O
and	O
they	O
ranged	O
from	O
7.5	O
mg/d	O
to	O
50.0	O
mg/d	O
in	O
divided	O
doses	O
.	O

Subjects	O
who	O
tolerated	O
the	O
test	O
dose	O
(	O
n	O
=	O
66	O
)	O
were	O
assigned	O
to	O
receive	O
placebo	O
for	O
1	O
week	O
and	O
then	O
3	O
methylphenidate	O
doses	O
in	O
random	O
order	O
during	O
a	O
double-blind	O
,	O
crossover	O
phase	O
.	O

Children	O
responding	O
to	O
methylphenidate	O
then	O
entered	O
8	O
weeks	O
of	O
open-label	O
treatment	O
at	O
the	O
individually	O
determined	O
best	O
dose	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
The	O
primary	O
outcome	O
measure	O
was	O
the	O
teacher-rated	Mental
hyperactivity	Mental
subscale	Mental
of	Mental
the	Mental
Aberrant	Mental
Behavior	Mental
Checklist	Mental
.	O

Response	O
was	O
defined	O
as	O
much	Others
improved	Others
or	O
very	Others
much	Others
improved	Others
on	O
the	O
Clinical	Mental
Global	Mental
Impressions	Mental
Improvement	Mental
item	Mental
coupled	O
with	O
considerable	O
reductions	O
in	O
the	O
parent-rated	Mental
and/or	Mental
teacher-rated	Mental
Aberrant	Mental
Behavior	Mental
Checklist	Mental
hyperactivity	Mental
subscale	Mental
score	Mental
.	O

RESULTS	O
Methylphenidate	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
primary	O
outcome	O
measure	O
,	O
with	O
effect	Others
sizes	Others
ranging	O
from	O
0.20	O
to	O
0.54	O
depending	O
on	O
dose	O
and	O
rater	O
.	O

Thirty-five	O
(	O
49	O
%	O
)	O
of	O
72	O
enrolled	O
subjects	O
were	O
classified	O
as	O
methylphenidate	O
responders	O
.	O

Adverse	Adverseeffect
effects	Adverseeffect
led	O
to	O
the	O
discontinuation	O
of	O
study	O
medication	O
in	O
13	O
(	O
18	O
%	O
)	O
of	O
72	O
subjects	O
.	O

CONCLUSIONS	O
Methylphenidate	O
was	O
often	O
efficacious	O
in	O
treating	O
hyperactivity	O
associated	O
with	O
pervasive	O
developmental	O
disorders	O
,	O
but	O
the	O
magnitude	O
of	O
response	O
was	O
less	O
than	O
that	O
seen	O
in	O
typically	O
developing	O
children	O
with	O
attention-deficit/hyperactivity	O
disorder	O
.	O

Adverse	O
effects	O
were	O
more	O
frequent	O
.	O

[	O
The	O
value	O
of	O
local	O
administration	O
of	O
antibiotics	O
in	O
treatment	O
of	O
bone	O
infections	O
]	O
.	O

An	O
open	O
,	O
controlled	O
,	O
randomized	O
clinical	O
investigation	O
was	O
carried	O
out	O
in	O
33	O
patients	O
suffering	O
from	O
osteomyelitis	O
.	O

In	O
the	O
first	O
group	O
,	O
17	O
patients	O
,	O
a	O
through	O
drainage	O
with	O
sterile	O
physiologic	O
solution	O
was	O
applied	O
,	O
while	O
in	O
the	O
second	O
group	O
,	O
16	O
patients	O
,	O
antibiotic	O
was	O
added	O
to	O
the	O
sterile	O
physiologic	O
solution	O
.	O

In	O
all	O
patients	O
values	O
of	O
C	O
reactive	O
protein	O
(	O
CRP	O
)	O
in	O
the	O
blood	O
were	O
examined	O
,	O
and	O
later	O
on	O
every	O
third	O
day	O
after	O
the	O
operation	O
.	O

A	Others
significant	Others
difference	Others
of	Others
average	Physical
values	Physical
of	Physical
CRP	Physical
between	Others
the	Others
3rd	Others
and	Others
21st	Others
day	Others
in	Others
both	Others
groups	Others
of	Others
patients	Others
was	Others
established	Others
,	O
as	O
well	O
as	O
the	O
similarity	Others
in	Others
average	Physical
values	Physical
of	Physical
CRP	Physical
,	O
which	O
points	O
to	O
the	O
fact	O
that	O
the	O
mechanical	O
effect	O
of	O
through	O
drainage	O
is	O
dominant	O
,	O
speaking	O
about	O
rinsing	O
focus	O
of	O
infection	Physical
and	O
eliminating	O
necrotic	O
tissues	O
and	O
small	O
sequesters	O
.	O

Evaluation	O
of	O
electrofunctional	O
data	O
following	O
argon-laser	O
trabeculoplasty	O
in	O
primary	O
open-angle	O
glaucoma	O
.	O

To	O
establish	O
whether	O
or	O
not	O
glaucomatous	Physical
damage	Physical
is	O
reversible	O
,	O
we	O
obtained	O
pattern-reversal	Others
electroretinograms	Others
(	Others
PERGs	Others
)	Others
and	O
visual	Others
evoked	Others
potentials	Others
(	Others
VEPs	Others
)	Others
in	O
25	O
eyes	O
of	O
25	O
patients	O
suffering	O
from	O
bilateral	O
primary	O
open-angle	O
glaucoma	O
(	O
POAG	O
)	O
before	O
and	O
after	O
argon-laser	O
trabeculoplasty	O
.	O

The	O
laser	O
treatment	O
was	O
carried	O
out	O
in	O
only	O
one	O
eye	O
chosen	O
at	O
random	O
,	O
and	O
the	O
fellow	O
eye	O
was	O
used	O
as	O
a	O
control	O
.	O

In	O
the	O
present	O
study	O
we	O
intended	O
to	O
verify	O
the	O
possibility	O
of	O
using	O
electrofunctional	O
techniques	O
to	O
determine	O
the	O
two	O
distinct	O
and	O
,	O
probably	O
,	O
consecutive	O
glaucomatous	Physical
alterations	Physical
occurring	Physical
in	Physical
ganglion	Physical
cells	Physical
:	Physical
functional	Physical
(	Physical
reversible	Physical
)	Physical
and	Physical
anatomical	Physical
(	Physical
irreversible	Physical
)	Physical
.	Physical

The	O
results	O
obtained	O
indicate	O
that	O
glaucomatous	Physical
damage	Physical
is	O
irreversible	O
.	O

We	O
propose	O
that	O
such	O
alterations	O
differ	O
very	O
slightly	O
and	O
that	O
the	O
current	O
electrofunctional	O
techniques	O
may	O
not	O
be	O
sufficiently	O
sophisticated	O
to	O
distinguish	O
between	O
them	O
.	O

The	O
effects	O
of	O
strength	O
training	O
on	O
central	Physical
arterial	Physical
compliance	Physical
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

BACKGROUND	O
Contrary	O
to	O
aerobic	O
exercise	O
,	O
strength	O
training	O
(	O
ST	O
)	O
is	O
associated	O
with	O
decreased	O
central	Physical
arterial	Physical
compliance	Physical
in	O
young	O
men	O
.	O

It	O
is	O
unknown	O
whether	O
ST	O
,	O
with	O
or	O
without	O
concurrent	O
endurance	O
training	O
,	O
would	O
have	O
a	O
similar	O
effect	O
in	O
older	O
adults	O
with	O
reduced	O
baseline	O
arterial	Physical
compliance	Physical
.	Physical

OBJECTIVE	O
The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
a	O
ST	O
program	O
on	O
central	Physical
arterial	Physical
compliance	Physical
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

DESIGN	O
Randomized	O
,	O
controlled	O
intervention	O
study	O
in	O
which	O
37	O
healthy	O
,	O
sedentary	O
men	O
and	O
women	O
(	O
52+/-2	O
years	O
)	O
performed	O
13	O
weeks	O
of	O
ST	O
(	O
n=13	O
)	O
,	O
ST+aerobic	O
exercise	O
(	O
n=12	O
)	O
or	O
stretching	O
exercises	O
as	O
a	O
control	O
group	O
(	O
n=12	O
)	O
.	O

METHODS	O
Participants	O
were	O
rigorously	O
screened	O
for	O
cardiovascular	O
disease	O
and	O
underwent	O
pre-post	O
testing	O
for	O
carotid	Physical
arterial	Physical
compliance	Physical
(	O
via	O
simultaneous	O
ultrasound	O
and	O
applanation	O
tonometry	O
)	O
,	O
carotid-femoral	Physical
pulse	Physical
wave	Physical
velocity	Physical
,	Physical
plasma	Physical
endothelin-1	Physical
and	O
angiotensin	Physical
II	Physical
concentrations	Physical
and	O
carotid	Physical
artery	Physical
vasoreactivity	Physical
(	O
cold	O
pressor	O
test	O
)	O
.	O

RESULTS	O
ST	O
performed	O
alone	O
,	O
or	O
in	O
conjunction	O
with	O
aerobic	O
exercise	O
,	O
improved	O
maximal	Physical
muscle	Physical
strength	Physical
and	Physical
increased	Physical
total	Physical
lean	Physical
body	Physical
mass	Physical
(	O
both	O
P	O
<	O
0.01	O
)	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
carotid	Others
artery	Others
compliance	Others
or	O
carotid-femoral	Physical
pulse	Physical
wave	Physical
velocity	Physical
following	O
ST	Others
or	Others
ST+aerobic	Others
exercise	Others
.	O

Carotid	Physical
artery	Physical
compliance	Physical
increased	O
significantly	O
(	O
23	O
%	O
)	O
following	O
stretching	O
which	O
may	O
be	O
attributed	O
to	O
a	O
reduction	O
in	O
carotid	O
pulse	O
pressure	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
in	O
plasma	Physical
vasoconstrictor	Physical
hormones	Physical
or	Physical
carotid	Physical
artery	Physical
vasoreactivity	Physical
following	O
the	O
interventions	O
.	O

CONCLUSION	O
Thirteen	O
weeks	O
of	O
moderate	O
ST	O
two	O
or	O
three	O
times	O
per	O
week	O
does	O
not	O
reduce	O
central	Physical
arterial	Physical
compliance	Physical
in	O
middle-aged	O
and	O
older	O
adults	O
.	O

Local	O
anaesthetic	O
use	O
for	O
the	O
iliac	O
crest-donor	O
site	O
:	O
pharmacokinetic	O
and	O
pharmacodynamic	O
evaluations	O
.	O

During	O
orthopaedic	O
surgery	O
of	O
the	O
limb	O
,	O
we	O
performed	O
a	O
prospective	O
,	O
double	O
blind	O
controlled	O
study	O
on	O
three	O
parallel	O
groups	O
in	O
30	O
patients	O
to	O
evaluate	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
effect	O
of	O
infiltration	O
of	O
the	O
iliac	O
crest	O
bone	O
graft	O
harvest	O
site	O
with	O
20	O
ml	O
of	O
bupivacaine	O
(	O
100	O
mg	O
)	O
,	O
ropivacaine	O
(	O
150	O
mg	O
)	O
or	O
saline	O
as	O
control	O
group	O
(	O
n	O
=	O
10	O
in	O
each	O
group	O
)	O
.	O

Then	O
,	O
in	O
a	O
sheep	O
model	O
of	O
iliac	O
crest	O
infiltration	O
,	O
we	O
compared	O
the	O
pharmacokinetics	O
of	O
single	O
administration	O
of	O
plain	O
bupivacaine	O
(	O
100	O
mg	O
)	O
and	O
bupivacaine	O
(	O
500	O
mg	O
)	O
-loaded	O
microspheres	O
.	O

In	O
the	O
clinical	O
control	O
group	O
,	O
pain	O
from	O
the	O
iliac	O
crest	O
was	O
worse	O
than	O
pain	O
from	O
the	O
primary	O
surgical	O
site	O
.	O

Pain	Pain
from	Pain
the	Pain
iliac	Pain
crest	Pain
was	O
significantly	Others
reduced	Others
during	O
the	O
first	O
12	O
postoperative	O
hours	O
in	O
local	O
anaesthetic	O
groups	O
compared	O
to	O
the	O
control	O
group	O
.	O

However	O
,	O
during	O
this	O
period	O
,	O
pain	Pain
from	Pain
the	Pain
primary	Pain
surgical	Pain
site	Pain
was	Pain
increased	Pain
compared	O
to	O
the	O
control	O
group	O
.	O

Finally	O
,	O
there	O
was	O
no	Others
difference	Others
between	O
the	O
three	O
groups	O
in	O
the	O
average	O
intake	O
of	O
PCA	O
morphine	O
.	O

There	O
was	O
no	Others
significant	Others
pharmacokinetic	Physical
and	Physical
pharmacodynamic	Physical
difference	Others
between	O
plain	O
bupivacaine	O
and	O
ropivacaine	O
.	O

The	O
maximal	Physical
plasma	Physical
concentration	Physical
(	Physical
Cmax	Physical
)	Physical
of	O
ropivacaine	O
and	O
bupivacaine	O
were	O
964	O
(	O
282	O
)	O
ng	O
ml	O
(	O
-1	O
)	O
and	O
638	O
(	O
366	O
)	O
ng	O
ml	O
(	O
-1	O
)	O
,	O
respectively	O
.	O

In	O
the	O
sheep	O
model	O
,	O
it	O
was	O
clearly	O
shown	O
that	O
the	O
release	O
of	O
bupivacaine	O
from	O
microspheres	O
was	O
controlled	O
and	O
prolonged	O
despite	O
the	O
largest	O
dose	O
of	O
bupivacaine	O
used	O
(	O
500	O
mg	O
;	O
n	O
=	O
4	O
)	O
.	O

Wound	O
infiltration	O
of	O
iliac	O
crest	O
harvest	O
site	O
with	O
local	O
anaesthetic	O
is	O
an	O
easy	O
technique	O
for	O
postoperative	O
analgesia	O
.	O

However	O
,	O
this	O
effect	O
lasts	O
only	O
12	O
hours	O
without	O
reducing	O
the	O
morphine	Mental
consumption	Mental
due	O
to	O
an	O
increase	O
of	O
pain	O
from	O
the	O
primary	O
surgical	O
site	O
.	O

The	O
local	O
anaesthetic	O
infiltration	O
produced	O
a	O
significant	Physical
peak	Physical
of	Physical
plasma	Physical
level	Physical
,	O
which	O
could	O
be	O
dangerous	O
if	O
another	O
infiltration	O
or	O
regional	O
anaesthetic	O
technique	O
was	O
associated	O
with	O
it	O
.	O

Experimentally	O
,	O
as	O
a	O
drug	O
delivery	O
system	O
,	O
the	O
use	O
of	O
local	O
anaesthetic-loaded	O
microspheres	O
could	O
be	O
an	O
interesting	O
alternative	O
.	O

The	O
effects	O
of	O
treatment	O
of	O
urinary	O
incontinence	O
in	O
general	O
practice	O
.	O

A	O
total	O
of	O
110	O
women	O
who	O
had	O
reported	O
urinary	O
incontinence	O
to	O
their	O
general	O
practitioners	O
were	O
randomly	O
assigned	O
to	O
a	O
treatment	O
or	O
control	O
group	O
.	O

Treatment	O
consisted	O
of	O
pelvic	O
floor	O
exercises	O
in	O
the	O
case	O
of	O
stress	O
incontinence	O
and	O
bladder	O
training	O
in	O
the	O
case	O
of	O
urge	O
incontinence	O
.	O

The	O
results	O
were	O
measured	O
after	O
3	O
and	O
12	O
months	O
by	O
a	O
research	O
assistant	O
on	O
the	O
basis	O
of	O
a	O
constructed	O
severity	O
scale	O
,	O
an	O
incontinence	O
diary	O
,	O
and	O
a	O
comparison	O
by	O
the	O
patients	O
themselves	O
of	O
their	O
previous	O
and	O
current	O
conditions	O
.	O

After	O
3	O
months	O
the	O
control	O
group	O
were	O
given	O
the	O
same	O
treatment	O
.	O

After	O
a	O
further	O
3	O
and	O
12	O
months	O
,	O
they	O
were	O
assessed	O
in	O
exactly	O
the	O
same	O
way	O
as	O
the	O
treatment	O
group	O
.	O

After	O
3	O
months	O
about	O
60	O
%	O
of	O
the	O
patients	O
were	O
either	O
dry	Physical
or	Physical
only	Physical
mildly	Physical
incontinent	Physical
;	Physical
the	O
mean	Physical
number	Physical
of	Physical
wet	Physical
episodes	Physical
had	O
gone	O
down	O
from	O
20	O
to	O
7	O
,	O
and	O
74	O
%	O
of	O
the	O
women	O
felt	O
improved	Others
or	Others
cured	Others
.	Others

These	O
results	O
were	O
later	O
corroborated	O
by	O
the	O
control	O
group	O
.	O

After	O
12	O
months	O
this	O
successful	O
outcome	O
was	O
improved	O
slightly	O
further	O
.	O

It	O
may	O
be	O
concluded	O
that	O
the	O
majority	O
of	O
women	O
with	O
incontinence	O
can	O
be	O
successfully	O
treated	Others
by	O
the	O
general	O
practitioner	O
.	O

The	O
effect	O
of	O
this	O
treatment	O
continues	O
after	O
one	O
year	O
.	O

[	O
Treatment	O
of	O
primary	O
osteoporosis	O
with	O
calcium	O
and	O
salmon	O
calcitonin	O
]	O
.	O

Fifty-nine	O
consecutive	O
patients	O
(	O
19	O
men	O
,	O
40	O
women	O
,	O
mean	O
age	O
60.8	O
[	O
27-80	O
]	O
years	O
)	O
with	O
primary	O
osteoporosis	O
were	O
studied	O
to	O
see	O
if	O
there	O
was	O
any	O
significant	O
gain	O
in	O
bone	O
mass	O
after	O
treatment	O
with	O
salmon	O
calcitonin	O
.	O

All	O
the	O
patients	O
were	O
given	O
1	O
g	O
calcium	O
by	O
mouth	O
every	O
morning	O
.	O

Group	O
1	O
(	O
n	O
=	O
20	O
)	O
received	O
no	O
other	O
specific	O
medication	O
while	O
group	O
2	O
(	O
n	O
=	O
19	O
)	O
were	O
given	O
100	O
I.U	O
.	O

calcitonin	O
subcutaneously	O
every	O
second	O
evening	O
and	O
group	O
3	O
(	O
n	O
=	O
20	O
)	O
received	O
the	O
same	O
dose	O
every	O
evening	O
.	O

The	O
pain	Pain
reported	O
by	O
the	O
patients	O
was	O
subdivided	O
into	O
four	O
severity	O
grades	O
,	O
and	O
analgesic	Others
consumption	Others
was	O
recorded	O
.	O

In	O
group	O
1	O
there	O
was	O
a	O
nonsignificant	O
decrease	O
in	O
pain	Pain
,	O
but	O
in	O
groups	O
2	O
and	O
3	O
there	O
was	O
a	O
highly	O
significant	O
diminution	O
in	O
pain	Pain
(	O
P	O
less	O
than	O
0.005	O
)	O
and	O
in	O
analgesic	Others
intake	Others
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Measurements	O
of	O
bone	Physical
density	Physical
carried	O
out	O
by	O
photon	O
absorption	O
at	O
the	O
end	O
of	O
12	O
months	O
showed	O
a	O
5.5	O
%	O
increase	O
in	O
the	O
distal	Physical
radius	Physical
in	O
group	O
2	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
a	O
7.1	O
%	O
increase	O
in	O
group	O
3	O
(	O
P	O
=	O
0.0001	O
)	O
,	O
while	O
in	O
group	O
1	O
mineral	O
content	O
had	O
decreased	O
by	O
4.3	O
%	O
(	O
nonsignificant	O
)	O
.	O

These	O
results	O
show	O
that	O
a	O
significant	O
gain	O
in	O
bone	Physical
mass	Physical
can	O
be	O
achieved	O
by	O
administration	O
of	O
calcitonin	O
,	O
either	O
daily	O
or	O
on	O
alternate	O
days	O
.	O

The	O
incidence	O
of	O
extravertebral	O
fractures	O
and	O
of	O
new	O
or	O
progressive	O
vertebral	O
deformity	O
tended	O
to	O
be	O
lower	O
in	O
groups	O
2	O
and	O
3	O
than	O
in	O
group	O
1	O
.	O

Comparing	O
the	O
effectiveness	O
of	O
copper	O
intrauterine	O
devices	O
available	O
in	O
Canada	O
.	O

Is	O
FlexiT	O
non-inferior	O
to	O
NovaT	O
when	O
inserted	O
immediately	O
after	O
first-trimester	O
abortion	O
?	O
Study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
We	O
describe	O
the	O
rationale	O
and	O
protocol	O
for	O
a	O
randomized	O
noninferiority	O
controlled	O
trial	O
(	O
RCT	O
)	O
to	O
determine	O
if	O
the	O
Flexi-T380	O
(	O
+	O
)	O
copper	O
intrauterine	O
contraceptive	O
device	O
(	O
IUD	O
)	O
is	O
comparable	O
in	O
terms	O
of	O
effectiveness	O
and	O
expulsion	O
rates	O
to	O
the	O
most	O
common	O
Canadian	O
IUD	O
currently	O
in	O
use	O
,	O
NovaT-200	O
,	O
when	O
placed	O
immediately	O
after	O
a	O
first-trimester	O
abortion	O
.	O

METHODS/DESIGN	O
Consenting	O
women	O
choosing	O
to	O
use	O
an	O
IUD	O
after	O
an	O
abortion	O
for	O
a	O
pregnancy	O
of	O
less	O
than	O
12	O
weeks	O
of	O
gestation	O
will	O
be	O
randomized	O
to	O
device-type	O
groups	O
to	O
receive	O
immediate	O
post-abortion	O
placement	O
of	O
either	O
a	O
Flexi-T380	O
(	O
+	O
)	O
IUD	O
,	O
a	O
device	O
for	O
which	O
no	O
current	O
evidence	O
on	O
expulsion	O
or	O
effectiveness	O
rates	O
is	O
available	O
,	O
or	O
the	O
Nova-T200	O
IUD	O
,	O
the	O
only	O
other	O
brand	O
of	O
copper	O
IUD	O
available	O
in	O
Canada	O
at	O
the	O
time	O
of	O
study	O
initiation	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
IUD	Mental
expulsion	Mental
rate	Mental
at	Mental
1	Mental
year	Mental
.	Physical

Secondary	O
outcomes	O
include	O
:	O
pregnancy	Mental
rate	Mental
,	Physical
method	Mental
continuation	Mental
rate	Mental
,	Physical
complication	Physical
rates	Physical
(	Physical
infection	Physical
,	Physical
perforation	Physical
)	Physical
,	Physical
and	Physical
satisfaction	Others
with	Physical
contraceptive	Physical
method	Physical
.	Physical

A	O
non-intervention	O
group	O
of	O
consenting	O
women	O
choosing	O
a	O
range	O
of	O
other	O
post-abortion	O
contraception	O
methods	O
,	O
including	O
no	O
contraception	O
,	O
will	O
be	O
included	O
for	O
comparison	O
of	O
secondary	O
outcomes	O
.	O

Web-based	O
contraception	O
satisfaction	O
questionnaires	O
,	O
clinical	O
records	O
,	O
and	O
government-linked	O
health	O
administrative	O
databases	O
will	O
be	O
used	O
to	O
assess	O
primary	O
and	O
secondary	O
outcomes	O
.	O

DISCUSSION	O
The	O
RCT	O
design	O
,	O
combined	O
with	O
access	O
to	O
clinical	O
records	O
at	O
all	O
provincial	O
abortion	O
clinics	O
,	O
and	O
to	O
information	O
in	O
provincial	O
single-payer	O
linked	O
administrative	O
health	O
databases	O
,	O
birth	O
registry	O
,	O
and	O
hospital	O
records	O
,	O
offers	O
a	O
unique	O
opportunity	O
to	O
determine	O
if	O
a	O
novel	O
IUD	O
has	O
a	O
comparable	O
expulsion	Mental
rate	Mental
to	O
that	O
of	O
the	O
current	O
standard	O
IUD	O
in	O
Canada	O
,	O
in	O
addition	O
to	O
the	O
first	O
opportunity	O
to	O
determine	O
pregnancy	Others
rate	Others
and	O
method	Others
satisfaction	Others
at	O
1	O
year	O
post-abortion	O
for	O
women	O
choosing	O
a	O
range	O
of	O
post-abortion	O
contraceptive	O
options	O
.	O

We	O
highlight	O
considerations	O
of	O
design	O
,	O
implementation	O
,	O
and	O
evaluation	O
of	O
the	O
first	O
trial	O
to	O
provide	O
rigorous	O
evidence	O
for	O
the	O
effectiveness	O
of	O
current	O
Canadian	O
IUDs	O
when	O
inserted	O
after	O
first-trimester	O
abortion	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
NCT01174225	O
.	O

Randomized	O
clinical	O
trial	O
of	O
radiofrequency	O
ablation	O
or	O
conventional	O
high	O
ligation	O
and	O
stripping	O
for	O
great	O
saphenous	O
varicose	O
veins	O
.	O

BACKGROUND	O
This	O
randomized	O
clinical	O
trial	O
compared	O
early	O
outcomes	O
after	O
radiofrequency	O
ablation	O
(	O
RFA	O
)	O
and	O
conventional	O
surgery	O
for	O
varicose	O
veins	O
.	O

METHODS	O
Consecutive	O
patients	O
with	O
symptomatic	O
varicose	O
veins	O
due	O
to	O
isolated	O
great	O
saphenous	O
vein	O
(	O
GSV	O
)	O
incompetence	O
and	O
suitable	O
for	O
RFA	O
were	O
randomized	O
to	O
either	O
RFA	O
or	O
conventional	O
surgery	O
(	O
saphenofemoral	O
disconnection	O
and	O
stripping	O
)	O
.	O

Clinical	O
,	O
radiological	O
and	O
patient-based	Physical
outcomes	Physical
were	O
recorded	O
at	O
1	O
and	O
5	O
weeks	O
after	O
intervention	O
.	O

RESULTS	O
RFA	O
resulted	O
in	O
successful	O
obliteration	O
of	O
the	O
GSV	O
in	O
all	O
47	O
patients	O
.	O

Complete	Physical
above-knee	Physical
stripping	Physical
was	O
unsuccessful	O
in	O
seven	O
of	O
41	O
patients	O
.	O

RFA	O
took	O
longer	O
than	O
conventional	O
surgery	O
:	O
median	O
interquartile	O
range	O
76	O
(	O
67-84	O
)	O
versus	O
48	O
(	O
39-54	O
)	O
min	O
;	O
P	O
<	O
0.001	O
.	O

Patients	O
returned	Physical
to	Physical
their	Physical
normal	Physical
activities	Physical
significantly	O
earlier	O
after	O
RFA	O
(	O
median	O
3	O
(	O
2-5	O
)	O
versus	O
12.5	O
(	O
4-21	O
)	O
days	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Postoperative	Pain
pain	Pain
was	O
significantly	O
less	O
after	O
RFA	O
(	O
median	O
score	O
on	O
visual	O
analogue	O
scale	O
1.70	O
(	O
0.50-4.30	O
)	O
versus	O
4.0	O
(	O
2.35-6.05	O
)	O
;	O
P	O
=	O
0.001	O
)	O
.	O

Patient	Others
satisfaction	Others
,	O
quality	Mental
of	Mental
life	Mental
improvement	Mental
and	Mental
analgesic	Others
requirements	Others
significantly	O
favoured	O
RFA	O
.	O

CONCLUSION	O
RFA	O
took	O
longer	O
to	O
perform	O
but	O
resulted	O
in	O
a	O
significantly	O
better	O
early	O
outcome	O
than	O
conventional	O
surgery	O
in	O
suitable	O
patients	O
with	O
great	O
saphenous	O
varicose	O
veins	O
.	O

Implementing	O
a	O
simplified	O
neonatal	O
resuscitation	O
protocol-helping	O
babies	O
breathe	O
at	O
birth	O
(	O
HBB	O
)	O
-	O
at	O
a	O
tertiary	O
level	O
hospital	O
in	O
Nepal	O
for	O
an	O
increased	O
perinatal	Mortality
survival	Mortality
.	Mortality

BACKGROUND	O
Reducing	O
neonatal	Mortality
death	Mortality
has	O
been	O
an	O
emerging	O
challenge	O
in	O
low	O
and	O
middle	O
income	O
countries	O
in	O
the	O
past	O
decade	O
.	O

The	O
development	O
of	O
the	O
low	O
cost	O
interventions	O
and	O
their	O
effective	O
delivery	O
are	O
needed	O
to	O
reduce	O
deaths	Mortality
from	O
birth	O
asphyxia	O
.	O

This	O
study	O
will	O
assess	O
the	O
impact	O
of	O
a	O
simplified	O
neonatal	O
resuscitation	O
protocol	O
provided	O
by	O
Helping	O
Babies	O
Breathe	O
(	O
HBB	O
)	O
at	O
a	O
tertiary	O
hospital	O
in	O
Nepal	O
.	O

Perinatal	O
outcomes	O
and	O
performance	O
of	O
skilled	O
birth	O
attendants	O
on	O
management	Others
of	Others
intrapartum-related	Others
neonatal	Others
hypoxia	Others
will	O
be	O
the	O
main	O
measurements	O
.	O

METHODS/DESIGN	O
The	O
study	O
will	O
be	O
carried	O
out	O
at	O
a	O
tertiary	O
level	O
maternity	O
hospital	O
in	O
Nepal	O
.	O

A	O
prospective	O
cohort-study	O
will	O
include	O
a	O
six-month	O
baseline	O
a	O
six	O
month	O
intervention	O
period	O
and	O
a	O
three-month	O
post	O
intervention	O
period	O
.	O

A	O
quality	O
improvement	O
process	O
cycle	O
will	O
introduce	O
the	O
neonatal	O
resuscitation	O
protocol	O
.	O

A	O
surveillance	O
system	O
,	O
including	O
CCD	O
cameras	O
and	O
pulse	O
oximeters	O
,	O
will	O
be	O
set	O
up	O
to	O
evaluate	O
the	O
intervention	O
.	O

DISCUSSION	O
Along	O
with	O
a	O
technique	O
to	O
improve	O
health	Others
workers	Others
performance	Others
on	O
the	O
protocol	O
,	O
the	O
study	O
will	O
generate	O
evidence	O
on	O
the	O
research	O
gap	O
on	O
the	O
effectiveness	O
of	O
the	O
simplified	O
neonatal	O
resuscitation	O
protocol	O
on	O
intrapartum	Mortality
outcome	Mortality
and	Mortality
early	Mortality
neonatal	Mortality
survival	Mortality
.	Mortality

This	O
will	O
generate	O
a	O
global	O
interest	O
and	O
inform	O
policymaking	O
in	O
relation	O
to	O
delivery	O
care	O
in	O
all	O
income	O
settings	O
.	O

TRIAL	O
REGISTRATION	O
ISRCTN97846009	O
.	O

Expectant	O
management	O
of	O
functional	O
ovarian	O
cysts	O
:	O
an	O
alternative	O
to	O
hormonal	O
therapy	O
.	O

OBJECTIVE	O
We	O
studied	O
whether	O
the	O
administration	O
of	O
oral	O
contraceptives	O
facilitates	O
the	O
disappearance	O
of	O
spontaneously	O
formed	O
functional	O
ovarian	O
cysts	O
.	O

METHODS	O
Eighty	O
patients	O
in	O
whom	O
ultrasonography	O
revealed	O
unilateral	O
,	O
mobile	O
,	O
unilocular	O
,	O
thin-walled	O
ovarian	O
cysts	O
without	O
internal	O
echoes	O
and	O
greater	O
than	O
30	O
mm	O
but	O
not	O
exceeding	O
60	O
mm	O
in	O
diameter	O
were	O
enrolled	O
into	O
the	O
study	O
.	O

Patients	O
were	O
randomized	O
by	O
stratification	O
to	O
receive	O
a	O
low-dose	O
monophasic	O
pill	O
,	O
a	O
high-dose	O
monophasic	O
pill	O
,	O
a	O
multiphasic	O
pill	O
or	O
no	O
therapy	O
.	O

Patients	O
were	O
re-evaluated	O
after	O
5	O
weeks	O
of	O
therapy	O
and	O
at	O
the	O
end	O
of	O
therapy	O
(	O
10	O
weeks	O
)	O
.	O

RESULTS	O
The	O
mean	Physical
ages	Physical
and	Physical
the	Physical
mean	Physical
cyst	Physical
diameters	Physical
of	O
the	O
patients	O
for	O
each	O
group	O
were	O
not	O
significantly	O
different	O
.	O

We	O
did	O
not	O
find	O
a	O
significant	O
effect	O
of	O
oral	O
contraceptive	O
administration	O
on	O
the	O
disappearance	Physical
rate	Physical
of	Physical
functional	Physical
ovarian	Physical
cysts	Physical
over	O
that	O
of	O
expectant	O
management	O
.	O

CONCLUSION	O
We	O
conclude	O
that	O
oral	O
contraceptive	O
therapy	O
even	O
with	O
multiphasic	O
pills	O
is	O
very	O
effective	O
in	O
the	O
management	O
of	O
functional	Physical
ovarian	Physical
cysts	Physical
but	O
expectant	O
management	O
achieves	O
similar	O
success	O
rates	O
and	O
may	O
be	O
a	O
good	O
alternative	O
to	O
oral	O
contraceptive	O
therapy	O
.	O

Phenobarbital	O
compared	O
with	O
phenytoin	O
for	O
the	O
treatment	O
of	O
neonatal	O
seizures	O
.	O

BACKGROUND	O
Seizures	O
occur	O
in	O
1	O
to	O
2	O
percent	O
of	O
neonates	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
.	O

The	O
treatment	O
is	O
usually	O
with	O
either	O
phenobarbital	O
or	O
phenytoin	O
,	O
but	O
the	O
efficacy	Others
of	O
the	O
two	O
drugs	O
has	O
not	O
been	O
compared	O
directly	O
.	O

METHODS	O
From	O
1990	O
to	O
1995	O
,	O
we	O
studied	O
59	O
neonates	O
with	O
seizures	O
that	O
were	O
confirmed	O
by	O
electroencephalography	O
.	O

The	O
neonates	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
phenobarbital	O
or	O
phenytoin	O
intravenously	O
,	O
at	O
doses	O
sufficient	O
to	O
achieve	O
free	O
plasma	O
concentrations	O
of	O
25	O
microg	O
per	O
milliliter	O
for	O
phenobarbital	O
and	O
3	O
microg	O
per	O
milliliter	O
for	O
phenytoin	O
.	O

Neonates	O
whose	O
seizures	O
were	O
not	O
controlled	O
by	O
the	O
assigned	O
drug	O
were	O
then	O
treated	O
with	O
both	O
drugs	O
.	O

Seizure	Others
control	Others
was	O
assessed	O
by	O
electroencephalographic	O
criteria	O
.	O

RESULTS	O
Seizures	Physical
were	O
controlled	O
in	O
13	O
of	O
the	O
30	O
neonates	O
assigned	O
to	O
receive	O
phenobarbital	O
(	O
43	O
percent	O
)	O
and	O
13	O
of	O
the	O
29	O
neonates	O
assigned	O
to	O
receive	O
phenytoin	O
(	O
45	O
percent	O
;	O
P=1.00	O
)	O
.	O

When	O
combined	O
treatment	O
is	O
considered	O
,	O
seizure	Others
control	Others
was	O
achieved	O
in	O
17	O
(	O
57	O
percent	O
)	O
of	O
the	O
neonates	O
assigned	O
to	O
receive	O
phenobarbital	O
first	O
and	O
18	O
(	O
62	O
percent	O
)	O
of	O
those	O
assigned	O
to	O
receive	O
phenytoin	O
first	O
(	O
P=0.67	O
)	O
.	O

The	O
severity	Physical
of	Physical
the	Physical
seizures	Physical
was	O
a	O
stronger	O
predictor	O
of	O
the	O
success	O
of	O
treatment	O
than	O
was	O
the	O
assigned	O
agent	O
.	O

Neonates	O
with	O
mild	Physical
seizures	Physical
or	O
with	O
seizures	Physical
that	O
were	O
decreasing	O
in	O
severity	O
before	O
treatment	O
were	O
more	O
likely	O
to	O
have	O
their	O
seizures	Physical
end	O
,	O
regardless	O
of	O
the	O
treatment	O
assignment	O
.	O

CONCLUSIONS	O
Phenobarbital	O
and	O
phenytoin	O
are	O
equally	O
but	O
incompletely	O
effective	O
as	O
anticonvulsants	Others
in	O
neonates	O
.	O

With	O
either	O
drug	O
given	O
alone	O
,	O
the	O
seizures	Physical
were	O
controlled	Others
in	O
fewer	O
than	O
half	O
of	O
the	O
neonates	O
.	O

Effects	O
of	O
cuff	O
inflation	O
on	O
self-recorded	Physical
blood	Physical
pressure	Physical
.	O

Changes	O
in	O
continuously	O
recorded	O
'Finapres	Physical
'	Physical
finger	Physical
blood	Physical
pressure	Physical
in	O
ten	O
normotensive	O
and	O
seven	O
hypertensive	O
subjects	O
induced	O
by	O
self-inflation	O
of	O
the	O
cuff	O
or	O
just	O
wearing	O
the	O
inflated	O
cuff	O
were	O
studied	O
.	O

Inflating	O
the	O
cuff	O
caused	O
an	O
instantaneous	O
rise	O
in	O
systolic	Physical
blood	Physical
pressure	Physical
of	O
13	O
and	O
12	O
mm	O
Hg	O
(	O
hypertensive	O
and	O
normotensive	O
subjects	O
,	O
respectively	O
)	O
.	O

Wearing	O
the	O
inflated	O
cuff	O
did	O
not	O
change	O
blood	Physical
pressure	Physical
.	O

Thus	O
the	O
rise	O
in	O
pressure	Physical
was	O
related	O
to	O
the	O
muscular	O
activity	O
required	O
for	O
cuff	O
inflation	O
.	O

Systolic	Physical
blood	Physical
pressure	Physical
took	O
on	O
average	O
7	O
s	O
and	O
at	O
most	O
21	O
s	O
to	O
return	O
to	O
baseline	O
level	O
after	O
stopping	O
cuff	O
inflation	O
.	O

Since	O
first	O
Korotkoff	O
sounds	O
may	O
already	O
be	O
heard	O
after	O
10-15	O
s	O
when	O
following	O
recommended	O
procedures	O
,	O
self-recorded	Physical
systolic	Physical
blood	Physical
pressure	Physical
may	O
be	O
recorded	O
as	O
too	O
high	O
when	O
subjects	O
inflate	O
their	O
cuff	O
at	O
too	O
low	O
a	O
pressure	O
or	O
deflate	O
it	O
too	O
fast	O
.	O

Less	O
tachycardia	Physical
in	O
adults	O
when	O
using	O
atropine	O
0.9	O
mg	O
compared	O
with	O
1.2	O
mg	O
plus	O
neostigmine	O
2.5	O
mg	O
.	O

OBJECTIVE	O
Compare	O
the	O
increase	O
in	O
heart	Physical
rate	Physical
in	O
adults	O
after	O
0.9	O
vs.	O
1.2	O
mg	O
of	O
atropine	O
plus	O
neostigmine	O
2.5	O
mg	O
as	O
the	O
non-depolarizing	O
muscle	O
relaxant	O
reversal	O
agent	O
.	O

MATERIAL	O
AND	O
METHOD	O
A	O
randomized	O
,	O
double	O
blind	O
,	O
controlled	O
trial	O
on	O
46	O
adults	O
ASA	O
I-II	O
,	O
undergoing	O
elective	O
gynecological	O
or	O
general	O
surgery	O
with	O
balanced	O
general	O
anesthesia	O
was	O
performed	O
.	O

The	O
subjects	O
were	O
randomized	O
into	O
two	O
groups	O
,	O
After	O
surgery	O
,	O
the	O
study	O
group	O
received	O
0.9	O
mg	O
of	O
atropine	O
,	O
while	O
the	O
control	O
group	O
received	O
1.2	O
mg	O
of	O
atropine	O
.	O

Both	O
groups	O
received	O
2.5	O
mg	O
of	O
neostigmine	O
simultaneously	O
.	O

RESULTS	O
The	O
heart	Physical
rate	Physical
and	O
blood	Physical
pressure	Physical
were	O
taken	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
and	O
30	O
min	O
after	O
the	O
injection	O
.	O

The	O
increase	O
in	O
heart	Physical
rate	Physical
and	O
blood	Physical
pressure	Physical
between	O
the	O
two	O
groups	O
were	O
compared	O
.	O

The	O
heart	Physical
rate	Physical
(	O
at	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
min	O
)	O
of	O
patients	O
in	O
the	O
study	O
group	O
increased	O
significantly	O
less	O
than	O
that	O
of	O
patients	O
in	O
the	O
control	O
group	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
blood	Physical
pressure	Physical
between	O
groups	O
and	O
no	O
side	O
effects	O
occurred	O
.	O

CONCLUSION	O
The	O
authors	O
conclude	O
that	O
0.9	O
mg	O
of	O
atropine	O
with	O
2.5	O
mg	O
neostigmine	O
can	O
be	O
safely	O
used	O
as	O
the	O
reversal	O
agent	O
for	O
a	O
non-depolarizing	O
muscle	O
relaxant	O
,	O
particularly	O
in	O
patients	O
for	O
whom	O
any	O
increase	O
in	O
heart	Physical
rate	Physical
would	O
be	O
harmful	O
.	O

The	O
effect	O
of	O
splinting	O
of	O
teeth	O
in	O
combination	O
with	O
reconstructive	O
periodontal	O
surgery	O
in	O
humans	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
splinting	O
teeth	O
on	O
the	O
results	O
of	O
periodontal	O
reconstructive	O
surgery	O
using	O
a	O
specific	O
carbonate	O
bone	O
replacement	O
graft	O
(	O
BRG	O
)	O
material	O
.	O

Forty-five	O
patients	O
were	O
randomly	O
treated	O
with	O
a	O
periodontal	O
surgery	O
approach	O
.	O

Natural	O
coral	O
calcium	O
BRG	O
was	O
utilised	O
in	O
33	O
patients	O
.	O

This	O
33-patient	O
group	O
was	O
divided	O
into	O
three	O
equal	O
groups	O
.	O

In	O
the	O
presplint	O
group	O
,	O
teeth	O
were	O
splinted	O
to	O
at	O
least	O
two	O
rigid	O
teeth	O
before	O
surgery	O
,	O
in	O
the	O
postsplint	O
group	O
,	O
teeth	O
were	O
splinted	O
at	O
suture	O
removal	O
,	O
and	O
in	O
the	O
nonsplint	O
group	O
,	O
the	O
treated	O
teeth	O
were	O
not	O
splinted	O
at	O
all	O
.	O

In	O
12	O
patients	O
,	O
teeth	O
were	O
treated	O
with	O
surgical	O
debridement	O
(	O
DEBR	O
)	O
alone	O
and	O
not	O
splinted	O
.	O

Periodontal	Physical
probing	Physical
depth	Physical
(	Physical
PPD	Physical
)	Physical
,	Physical
clinical	Physical
probing	Physical
attachment	Physical
level	Physical
(	Physical
CPAL	Physical
)	Physical
,	Physical
and	Physical
tooth	Physical
mobility	Physical
were	O
measured	O
using	O
desmodontometry	O
(	O
DDM	O
)	O
and	O
periotest	O
(	O
PTV	O
)	O
with	O
reproducible	O
methods	O
before	O
surgery	O
and	O
at	O
various	O
periods	O
up	O
to	O
1	O
year	O
afterwards	O
.	O

A	O
decrease	Others
in	Others
PPD	Others
(	O
5.4	O
mm	O
,	O
SD	O
1.4	O
mm	O
)	O
and	O
tooth	Physical
mobility	Physical
(	O
DDM-horizontal	O
257	O
microns	O
,	O
SD	O
60	O
microns	O
)	O
and	O
a	O
gain	Others
of	Others
CPAL	Others
(	O
5.1	O
mm	O
,	O
SD	O
1.4	O
mm	O
)	O
were	O
seen	O
following	O
the	O
use	O
of	O
BRG	O
in	O
presplint	O
teeth	O
.	O

In	O
the	O
same	O
group	O
,	O
PPD	Others
and	O
tooth	Physical
mobility	Physical
were	O
significantly	O
reduced	O
compared	O
to	O
nonsplint	O
teeth	O
.	O

DEBR	O
alone	O
showed	O
reductions	O
in	O
tooth	Physical
mobility	Physical
and	O
PPD	Others
and	O
a	O
significantly	O
smaller	O
gain	O
in	O
CPAL	Others
than	O
in	O
presplint	O
teeth	O
treated	O
with	O
BRG	O
.	O

The	O
less	O
favourable	O
improvement	O
in	O
periodontal	O
function	O
of	O
postsplint	O
or	O
nonsplint	O
teeth	O
seemed	O
to	O
be	O
due	O
to	O
the	O
loss	Physical
of	Physical
BRG	Physical
material	Physical
caused	O
by	O
tooth	Physical
mobility	Physical
.	O

These	O
results	O
indicate	O
that	O
an	O
undisturbed	O
wound	O
healing	O
process	O
using	O
BRG	O
together	O
with	O
tooth	O
stability	O
is	O
beneficial	O
to	O
overall	Physical
clinical	Physical
success	Physical
.	Physical

Study	O
design	O
and	O
rationale	O
of	O
a	O
dose-ranging	O
trial	O
of	O
LX4211	O
,	O
a	O
dual	O
inhibitor	O
of	O
SGLT1	O
and	O
SGLT2	O
,	O
in	O
type	O
2	O
diabetes	O
inadequately	O
controlled	O
on	O
metformin	O
monotherapy	O
.	O

Sodium-glucose	O
cotransporters	O
1	O
(	O
SGLT1	O
)	O
and	O
2	O
(	O
SGLT2	O
)	O
are	O
the	O
major	O
cellular	O
transporters	O
responsible	O
for	O
gastrointestinal	O
(	O
GI	O
)	O
glucose	O
absorption	O
and	O
renal	O
glucose	O
reabsorption	O
,	O
respectively	O
.	O

LX4211	O
,	O
a	O
dual	O
inhibitor	O
of	O
SGLT1	O
and	O
SGLT2	O
,	O
reduces	O
glucose	O
absorption	O
from	O
the	O
GI	O
tract	O
and	O
enhances	O
urinary	O
glucose	O
excretion	O
.	O

Although	O
several	O
SGLT2-selective	O
inhibitors	O
have	O
been	O
tested	O
in	O
large	O
phase	O
2	O
studies	O
,	O
dual	O
inhibition	O
of	O
SGLT1	O
and	O
SGLT2	O
is	O
novel	O
at	O
this	O
stage	O
of	O
drug	O
development	O
,	O
and	O
it	O
has	O
implications	O
for	O
clinical-trial	O
design	O
.	O

In	O
this	O
article	O
,	O
we	O
describe	O
the	O
design	O
and	O
rationale	O
of	O
a	O
phase	O
2	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
study	O
to	O
evaluate	O
the	O
safety	Others
and	Others
efficacy	Others
of	Physical
LX4211	Physical
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
mellitus	O
who	O
have	O
inadequate	O
glycemic	Physical
control	Physical
on	O
metformin	O
monotherapy	O
.	O

The	O
primary	O
endpoint	O
is	O
the	O
change	O
in	O
glycated	Physical
hemoglobin	Physical
A1c	Physical
from	O
baseline	O
to	O
week	O
12	O
.	O

Secondary	O
endpoints	O
include	O
the	O
proportion	Physical
of	Physical
subjects	Physical
achieving	Physical
a	Physical
glycated	Physical
hemoglobin	Physical
A1c	Physical
value	Physical
of	Physical
<	Physical
7	Physical
%	Physical
,	Physical
change	Physical
from	Physical
baseline	Physical
in	Physical
fasting	Physical
plasma	Physical
glucose	Physical
and	Physical
postprandial	Physical
glucose	Physical
(	Physical
as	Physical
part	Physical
of	Physical
an	Physical
oral	Physical
glucose	Physical
tolerance	Physical
test	Physical
)	Physical
,	Physical
body	Physical
weight	Physical
,	Physical
and	Physical
blood	Physical
pressure	Physical
.	Physical

Safety	Others
is	O
evaluated	O
with	O
particular	O
focus	O
on	O
hypoglycemia	Physical
,	Physical
GI	Physical
symptoms	Physical
,	Physical
and	Physical
incidence	Physical
of	Physical
genitourinary	Physical
tract	Physical
infections	Physical
.	O

Treatment	O
of	O
acute	O
otitis	O
media	O
in	O
children	O
under	O
2	O
years	O
of	O
age	O
.	O

BACKGROUND	O
Recommendations	O
vary	O
regarding	O
immediate	O
antimicrobial	O
treatment	O
versus	O
watchful	O
waiting	O
for	O
children	O
younger	O
than	O
2	O
years	O
of	O
age	O
with	O
acute	O
otitis	O
media	O
.	O

METHODS	O
We	O
randomly	O
assigned	O
291	O
children	O
6	O
to	O
23	O
months	O
of	O
age	O
,	O
with	O
acute	O
otitis	O
media	O
diagnosed	O
with	O
the	O
use	O
of	O
stringent	O
criteria	O
,	O
to	O
receive	O
amoxicillin-clavulanate	O
or	O
placebo	O
for	O
10	O
days	O
.	O

We	O
measured	O
symptomatic	Physical
response	Physical
and	O
rates	Physical
of	Physical
clinical	Physical
failure	Physical
.	O

RESULTS	O
Among	O
the	O
children	O
who	O
received	O
amoxicillin-clavulanate	O
,	O
35	O
%	O
had	O
initial	Physical
resolution	Physical
of	Physical
symptoms	Physical
by	O
day	O
2	O
,	O
61	O
%	O
by	O
day	O
4	O
,	O
and	O
80	O
%	O
by	O
day	O
7	O
;	O
among	O
children	O
who	O
received	O
placebo	O
,	O
28	O
%	O
had	O
initial	O
resolution	O
of	O
symptoms	O
by	O
day	O
2	O
,	O
54	O
%	O
by	O
day	O
4	O
,	O
and	O
74	O
%	O
by	O
day	O
7	O
(	O
P=0.14	O
for	O
the	O
overall	O
comparison	O
)	O
.	O

For	O
sustained	O
resolution	O
of	O
symptoms	O
,	O
the	O
corresponding	O
values	O
were	O
20	O
%	O
,	O
41	O
%	O
,	O
and	O
67	O
%	O
with	O
amoxicillin-clavulanate	O
,	O
as	O
compared	O
with	O
14	O
%	O
,	O
36	O
%	O
,	O
and	O
53	O
%	O
with	O
placebo	O
(	O
P=0.04	O
for	O
the	O
overall	O
comparison	O
)	O
.	O

Mean	Physical
symptom	Physical
scores	Physical
over	O
the	O
first	O
7	O
days	O
were	O
lower	O
for	O
the	O
children	O
treated	O
with	O
amoxicillin-clavulanate	O
than	O
for	O
those	O
who	O
received	O
placebo	O
(	O
P=0.02	O
)	O
.	O

The	O
rate	Physical
of	Physical
clinical	Physical
failure	Physical
--	Physical
defined	Physical
as	O
the	O
persistence	O
of	O
signs	O
of	O
acute	Physical
infection	Physical
on	Physical
otoscopic	Physical
examination	Physical
--	O
was	O
also	O
lower	O
among	O
the	O
children	O
treated	O
with	O
amoxicillin-clavulanate	O
than	O
among	O
those	O
who	O
received	O
placebo	O
:	O
4	O
%	O
versus	O
23	O
%	O
at	O
or	O
before	O
the	O
visit	O
on	O
day	O
4	O
or	O
5	O
(	O
P	O
<	O
0.001	O
)	O
and	O
16	O
%	O
versus	O
51	O
%	O
at	O
or	O
before	O
the	O
visit	O
on	O
day	O
10	O
to	O
12	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Mastoiditis	Adverseeffect
developed	O
in	O
one	O
child	O
who	O
received	O
placebo	O
.	O

Diarrhea	Adverseeffect
and	Adverseeffect
diaper-area	Adverseeffect
dermatitis	Adverseeffect
were	O
more	O
common	O
among	O
children	O
who	O
received	O
amoxicillin-clavulanate	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
either	O
group	O
in	O
the	O
rates	O
of	O
nasopharyngeal	Physical
colonization	Physical
with	O
nonsusceptible	O
Streptococcus	O
pneumoniae	O
.	O

CONCLUSIONS	O
Among	O
children	O
6	O
to	O
23	O
months	O
of	O
age	O
with	O
acute	O
otitis	O
media	O
,	O
treatment	O
with	O
amoxicillin-clavulanate	O
for	O
10	O
days	O
tended	O
to	O
reduce	O
the	O
time	O
to	O
resolution	O
of	O
symptoms	O
and	O
reduced	O
the	O
overall	O
symptom	O
burden	O
and	O
the	O
rate	O
of	O
persistent	O
signs	O
of	O
acute	O
infection	O
on	O
otoscopic	O
examination	O
.	O

(	O
Funded	O
by	O
the	O
National	O
Institute	O
of	O
Allergy	O
and	O
Infectious	O
Diseases	O
;	O
ClinicalTrials.gov	O
number	O
,	O
NCT00377260	O
.	O

)	O
.	O

Effectiveness	O
of	O
education	O
for	O
gastric	O
cancer	O
patients	O
:	O
a	O
controlled	O
prospective	O
trial	O
comparing	O
interactive	O
vs.	O
lecture-based	O
programs	O
.	O

OBJECTIVE	O
Although	O
patient	O
education	O
may	O
enhance	O
knowledge	O
,	O
coping	O
with	O
illness	O
,	O
and	O
quality	O
of	O
life	O
among	O
cancer	O
patients	O
,	O
it	O
is	O
uncertain	O
which	O
didactic	O
method	O
is	O
most	O
effective	O
.	O

We	O
compared	O
the	O
impact	O
of	O
an	O
interactive	O
,	O
patient-oriented	O
group	O
program	O
to	O
a	O
lecture-based	O
,	O
information-only	O
program	O
in	O
gastric	O
cancer	O
patients	O
.	O

METHODS	O
In	O
this	O
prospective	O
,	O
controlled	O
trial	O
,	O
121	O
gastric	O
cancer	O
patients	O
attending	O
inpatient	O
rehabilitation	O
after	O
surgical	O
treatment	O
received	O
either	O
the	O
interactive	O
intervention	O
or	O
lectures	O
providing	O
information	O
.	O

The	O
outcomes	O
were	O
patients	Mental
'	Mental
disease-related	Mental
knowledge	Mental
,	Others
active	Mental
coping	Mental
with	Mental
illness	Mental
,	Others
and	Others
quality	Mental
of	Mental
life	Mental
(	Mental
QoL	Mental
)	Mental
at	O
the	O
end	O
of	O
their	O
stay	O
and	O
6	O
and	O
12	O
months	O
thereafter	O
.	O

RESULTS	O
Both	O
groups	O
improved	Mental
their	Mental
knowledge	Mental
and	Others
QoL	Others
during	Others
rehabilitation	Others
;	O
however	O
,	O
knowledge	Mental
was	O
significantly	O
higher	O
in	O
the	O
interactive	O
group	O
compared	O
to	O
the	O
lecture	O
group	O
.	O

This	O
difference	O
was	O
maintained	O
at	O
the	O
6-	O
and	O
12-months	O
follow-ups	O
.	O

In	O
addition	O
,	O
the	O
interactive	O
group	O
proved	O
superior	O
to	O
the	O
lecture	O
group	O
regarding	O
active	Mental
coping	Mental
with	Mental
illness	Mental
and	O
QoL	Mental
at	O
the	O
end	O
of	O
rehabilitation	O
,	O
but	O
not	O
during	O
follow-up	O
.	O

CONCLUSIONS	O
A	O
structured	O
,	O
interactive	O
patient	O
education	O
program	O
proved	O
superior	O
to	O
lecture-based	O
provision	O
of	O
information	O
in	O
regards	O
to	O
short-term	O
and	O
long-term	O
knowledge	O
as	O
well	O
as	O
short-term	O
coping	O
and	O
QoL	O
.	O

PRACTICE	O
IMPLICATIONS	O
In	O
gastric	O
cancer	O
patients	O
,	O
interactive	O
patient	O
education	O
seems	O
preferable	O
over	O
lectures	O
.	O

Amisulpride	O
versus	O
bromocriptine	O
in	O
infantile	O
autism	O
:	O
a	O
controlled	O
crossover	O
comparative	O
study	O
of	O
two	O
drugs	O
with	O
opposite	O
effects	O
on	O
dopaminergic	O
function	O
.	O

An	O
alteration	O
of	O
dopaminergic	Physical
(	Physical
DA	Physical
)	Physical
function	Physical
much	O
more	O
complex	O
than	O
simple	O
hyperactivity	O
has	O
been	O
evoked	O
in	O
infantile	O
autism	O
.	O

We	O
therefore	O
compared	O
the	O
clinical	Others
efficacy	Others
of	O
a	O
DA	O
antagonist	O
(	O
amisulpride	O
)	O
and	O
a	O
DA	O
agonist	O
(	O
bromocriptine	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
trial	O
in	O
9	O
children	O
with	O
autism	O
,	O
likely	O
severely	O
mentally	O
retarded	O
.	O

Amisulpride	O
acts	O
preferentially	O
on	O
specific	O
autistic	O
symptoms	O
whereas	O
bromocriptine	O
acts	O
more	O
on	O
motor	Physical
hyperactivity	Physical
and	Physical
attention	Physical
symptoms	Physical
.	O

These	O
findings	O
raise	O
the	O
specificity	O
of	O
these	O
two	O
drugs	O
which	O
appear	O
to	O
act	O
preferentially	O
on	O
some	O
target	O
symptoms	O
and	O
are	O
consistent	O
with	O
some	O
clinical	O
and	O
pharmacological	O
observations	O
showing	O
a	O
sedative	Physical
effect	Physical
with	O
low	O
doses	O
of	O
DA	O
agonists	O
and	O
a	O
stimulant	Physical
effect	Physical
with	O
low	O
doses	O
of	O
DA	O
antagonists	O
such	O
as	O
the	O
benzamides	O
.	O

Changes	O
in	O
selected	O
fitness	Physical
parameters	Physical
following	O
six	O
weeks	O
of	O
snowshoe	O
training	O
.	O

BACKGROUND	O
Recently	O
,	O
there	O
has	O
been	O
an	O
increase	O
in	O
popularity	O
and	O
participation	O
in	O
the	O
sport	O
of	O
snowshoeing	O
.	O

While	O
the	O
sport	O
has	O
gained	O
considerable	O
recognition	O
,	O
to	O
date	O
there	O
is	O
little	O
or	O
no	O
scientific	O
research	O
regarding	O
training	Others
responses	Others
to	O
snowshoeing	O
as	O
a	O
form	O
of	O
exercise	O
.	O

Therefore	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
snowshoe	O
training	O
could	O
improve	O
fitness	Physical
measures	Physical
.	Physical

A	O
further	O
purpose	O
was	O
to	O
compare	O
responses	O
from	O
a	O
snowshoe	O
training	O
program	O
to	O
a	O
similarly	O
designed	O
run	O
training	O
program	O
.	O

METHODS	O
This	O
prospective	O
,	O
comparative	O
study	O
was	O
conducted	O
with	O
healthy	O
males	O
and	O
females	O
between	O
the	O
ages	O
of	O
19	O
and	O
24	O
.	O

These	O
subjects	O
were	O
recruited	O
from	O
the	O
University	O
of	O
Vermont	O
population	O
and	O
surrounding	O
community	O
.	O

Following	O
baseline	O
measurements	O
in	O
VO2max	Physical
,	Physical
running	Others
time	Others
to	Others
exhaustion	Others
(	Others
RTE	Others
)	Others
,	Physical
and	Physical
anthropometry	Physical
,	O
17	O
subjects	O
(	O
10	O
snowshoers	O
and	O
7	O
runners	O
)	O
participated	O
in	O
a	O
six	O
week	O
conditioning	O
program	O
.	O

Both	O
groups	O
exercised	O
for	O
30	O
min	O
at	O
75-85	O
%	O
age	O
predicted	O
maximum	O
heart	O
rate	O
,	O
3-4	O
times	O
per	O
week	O
,	O
for	O
a	O
total	O
of	O
18	O
sessions	O
.	O

RESULTS	O
VO2max	Physical
improved	O
significantly	O
in	O
both	O
running	O
and	O
snowshoeing	O
groups	O
,	O
6.3	O
and	O
8.5	O
%	O
,	O
respectively	O
.	O

Run	Physical
time	Physical
to	Physical
exhaustion	Physical
also	O
improved	O
significantly	O
in	O
both	O
groups	O
,	O
23.3	O
and	O
33.5	O
%	O
,	O
respectively	O
.	O

There	O
were	O
no	O
changes	O
in	O
anthropometry	Physical
for	O
either	O
group	O
.	O

With	O
the	O
exception	O
of	O
RTE	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
groups	O
in	O
any	O
other	O
measurements	O
at	O
baseline	O
.	O

CONCLUSIONS	O
These	O
results	O
support	O
the	O
acceptability	O
of	O
snowshoeing	O
as	O
a	O
valid	O
means	O
to	O
improve	O
or	O
maintain	O
cardiovascular	Physical
endurance	Physical
.	Physical

Double-blind	O
,	O
placebo-controlled	O
study	O
of	O
azelastine	O
and	O
fluticasone	O
in	O
a	O
single	O
nasal	O
spray	O
delivery	O
device	O
.	O

BACKGROUND	O
A	O
proof-of-concept	O
study	O
suggested	O
that	O
combination	O
therapy	O
with	O
commercial	O
azelastine	O
hydrochloride	O
nasal	O
spray	O
and	O
fluticasone	O
propionate	O
nasal	O
spray	O
significantly	O
improved	O
nasal	Physical
symptoms	Physical
of	Physical
seasonal	Physical
allergic	Physical
rhinitis	Physical
compared	O
with	O
either	O
agent	O
alone	O
.	O

OBJECTIVE	O
To	O
compare	O
an	O
azelastine-fluticasone	O
combination	O
nasal	O
spray	O
administered	O
in	O
a	O
single-delivery	O
device	O
with	O
a	O
commercially	O
available	O
azelastine	O
nasal	O
spray	O
and	O
fluticasone	O
nasal	O
spray	O
.	O

METHODS	O
This	O
14-day	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
study	O
was	O
conducted	O
during	O
the	O
Texas	O
mountain	O
cedar	O
season	O
.	O

After	O
a	O
5-day	O
placebo	O
lead-in	O
,	O
610	O
patients	O
with	O
moderate-to-severe	O
nasal	O
symptoms	O
were	O
randomized	O
to	O
treatment	O
with	O
(	O
1	O
)	O
azelastine	O
nasal	O
spray	O
,	O
(	O
2	O
)	O
fluticasone	O
nasal	O
spray	O
,	O
(	O
3	O
)	O
combination	O
azelastine	O
and	O
fluticasone	O
nasal	O
spray	O
,	O
or	O
(	O
4	O
)	O
placebo	O
nasal	O
spray	O
.	O

All	O
treatments	O
were	O
given	O
as	O
1	O
spray	O
per	O
nostril	O
twice	O
daily	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
the	O
change	O
from	O
baseline	O
in	O
the	O
total	Physical
nasal	Physical
symptom	Physical
score	Physical
(	Physical
TNSS	Physical
)	Physical
,	Physical
consisting	Physical
of	Physical
nasal	Physical
congestion	Physical
,	Physical
runny	Physical
nose	Physical
,	Physical
itchy	Physical
nose	Physical
,	Physical
and	Physical
sneezing	Physical
.	O

RESULTS	O
All	O
3	O
active	O
groups	O
were	O
statistically	O
superior	O
(	O
P	O
<	O
or=	O
.02	O
)	O
to	O
placebo	O
,	O
and	O
the	O
combination	O
was	O
statistically	O
superior	O
(	O
P	O
<	O
or=	O
.003	O
)	O
to	O
either	O
agent	O
alone	O
.	O

The	O
TNSS	Physical
improved	O
by	O
28.4	O
%	O
with	O
combination	O
azelastine-fluticasone	O
,	O
20.4	O
%	O
with	O
fluticasone	O
,	O
16.4	O
%	O
with	O
azelastine	O
,	O
and	O
11.2	O
%	O
with	O
placebo	O
.	O

All	O
3	O
treatments	O
were	O
well	O
tolerated	O
.	O

CONCLUSIONS	O
The	O
combination	O
azelastine-fluticasone	O
nasal	O
spray	O
provided	O
statistically	O
significant	O
improvement	O
in	O
the	O
TNSS	Physical
and	O
additive	O
clinical	O
benefit	O
compared	O
with	O
either	O
agent	O
alone	O
in	O
patients	O
with	O
moderate-to-severe	O
seasonal	O
allergic	O
rhinitis	O
.	O

TRIAL	O
REGISTRATION	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00660517	O
.	O

Evaluating	O
online	O
continuing	O
medical	O
education	O
seminars	O
:	O
evidence	O
for	O
improving	O
clinical	O
practices	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
for	O
online	O
continuing	O
medical	O
education	O
(	O
CME	O
)	O
seminars	O
to	O
improve	Others
quality	Others
of	Others
care	Others
.	Others

Primary	O
care	O
physicians	O
(	O
113	O
)	O
participated	O
in	O
a	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
an	O
online	O
CME	O
series	O
.	O

Physicians	O
were	O
randomized	O
to	O
view	O
either	O
a	O
seminar	O
about	O
type	O
2	O
diabetes	O
or	O
a	O
seminar	O
about	O
systolic	O
heart	O
failure	O
.	O

Following	O
the	O
seminar	O
,	O
physicians	O
were	O
presented	O
with	O
4	O
clinical	O
vignettes	O
and	O
asked	O
to	O
describe	O
what	O
tests	O
,	O
treatments	O
,	O
counseling	O
,	O
or	O
referrals	O
they	O
would	O
recommend	O
.	O

Physicians	O
who	O
viewed	O
the	O
seminars	O
were	O
significantly	O
more	O
likely	O
to	O
recommend	Mental
guideline-consistent	Mental
care	Mental
to	O
patients	O
in	O
the	O
vignettes	O
.	O

For	O
example	O
,	O
physicians	O
who	O
viewed	O
the	O
diabetes	O
seminar	O
were	O
significantly	O
more	O
likely	O
to	O
order	Mental
an	Mental
eye	Mental
exam	Mental
for	Mental
diabetes	Mental
patients	Mental
(	O
63	O
%	O
)	O
compared	O
with	O
physicians	O
in	O
the	O
control	O
group	O
(	O
27	O
%	O
)	O
.	O

For	O
some	O
guidelines	O
there	O
were	O
no	O
group	O
differences	O
.	O

These	O
results	O
provide	O
early	O
evidence	O
of	O
the	O
effectiveness	O
of	O
online	O
CME	O
programs	O
to	O
improve	Others
physician	Others
clinical	Others
practice	Others
.	Others

Effects	O
of	O
pioglitazone	O
and	O
glimepiride	O
on	O
glycemic	O
control	O
and	O
insulin	O
sensitivity	O
in	O
Mexican	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
:	O
A	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel-group	O
trial	O
.	O

BACKGROUND	O
Pioglitazone	O
and	O
glimepiride	O
improve	O
glycemic	O
control	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
by	O
different	O
mechanisms	O
.	O

Pioglitazone	O
is	O
a	O
thiazolidinedione	O
that	O
reduces	O
insulin	O
resistance	O
,	O
and	O
glimepiride	O
is	O
a	O
sulfonylurea	O
insulin	O
secretagogue	O
.	O

OBJECTIVE	O
The	O
goals	O
of	O
this	O
study	O
were	O
to	O
compare	O
changes	O
in	O
measures	O
of	O
glycemic	O
control	O
and	O
insulin	O
sensitivity	O
in	O
Mexican	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
received	O
pioglitazone	O
or	O
glimepiride	O
for	O
1	O
year	O
.	O

METHODS	O
This	O
was	O
a	O
multicenter	O
,	O
52-week	O
,	O
double-blind	O
,	O
parallel-group	O
trial	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
monotherapy	O
with	O
either	O
glimepiride	O
(	O
2	O
mg	O
QD	O
initially	O
)	O
or	O
pioglitazone	O
(	O
15	O
mg	O
QD	O
initially	O
)	O
.	O

Doses	O
were	O
titrated	O
(	O
maximal	O
doses	O
:	O
pioglitazone	O
45	O
mg	O
,	O
glimepiride	O
8	O
mg	O
)	O
to	O
achieve	O
glycemic	O
targets	O
(	O
fasting	O
blood	O
glucose	O
<	O
or	O
=7	O
mmol/L	O
and	O
1-hour	O
postprandial	O
blood	O
glucose	O
<	O
or	O
=10	O
mmol/L	O
)	O
.	O

Insulin	O
sensitivity	O
(	O
primary	O
end	O
point	O
)	O
was	O
evaluated	O
in	O
terms	O
of	O
the	O
Homeostasis	O
Model	O
Assessment	O
for	O
Insulin	O
Sensitivity	O
(	O
HOMA-S	O
)	O
,	O
the	O
Quantitative	O
Insulin	O
Sensitivity	O
Check	O
Index	O
(	O
QUICKI	O
)	O
,	O
and	O
fasting	O
serum	O
insulin	O
(	O
FSI	O
)	O
concentrations	O
.	O

Glycemic	O
control	O
was	O
evaluated	O
in	O
terms	O
of	O
glycosylated	O
hemoglobin	O
(	O
HbA	O
(	O
1c	O
)	O
)	O
values	O
and	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
concentrations	O
.	O

Patients	O
were	O
encouraged	O
to	O
maintain	O
their	O
individual	O
diet	O
and	O
exercise	O
regimens	O
throughout	O
the	O
study	O
.	O

RESULTS	O
Two	O
hundred	O
forty-four	O
patients	O
(	O
125	O
women	O
,	O
119	O
men	O
;	O
all	O
but	O
1	O
Hispanic	O
)	O
were	O
randomized	O
to	O
receive	O
pioglitazone	O
(	O
n	O
=	O
121	O
)	O
or	O
glimepiride	O
(	O
n	O
=	O
123	O
)	O
.	O

In	O
the	O
intent-to-treat	O
sample	O
,	O
pioglitazone	O
and	O
glimepirede	O
produced	O
comparable	O
reductions	Physical
in	Physical
HbA	Physical
(	Physical
1c	Physical
)	Physical
from	O
baseline	O
to	O
the	O
end	O
of	O
the	O
study	O
(	O
-0.78	O
%	O
and	O
-0.68	O
%	O
,	O
respectively	O
)	O
.	O

The	O
pioglitazone	O
group	O
had	O
significantly	O
higher	O
HbA	Physical
(	Physical
1c	Physical
)	Physical
values	O
compared	O
with	O
the	O
glimepiride	O
group	O
after	O
12	O
weeks	O
of	O
therapy	O
(	O
8.66	O
%	O
vs	O
7.80	O
%	O
;	O
P	O
=	O
0.007	O
)	O
but	O
had	O
significantly	O
lower	O
values	O
after	O
52	O
weeks	O
(	O
7.46	O
%	O
vs	O
7.77	O
%	O
;	O
P	O
=	O
0.027	O
)	O
.	O

Pioglitazone	O
significantly	O
reduced	O
FPG	Physical
compared	O
with	O
glimepiride	O
(	O
-0.6	O
vs	O
0.6	O
mmol/L	O
;	O
P	O
=	O
0.01	O
)	O
.	O

Pioglitazone	O
therapy	O
was	O
associated	O
with	O
significant	O
increases	O
in	O
insulin	Physical
sensitivity	Physical
(	Physical
reduced	Physical
insulin	Physical
resistance	Physical
)	Physical
,	O
whereas	O
glimepiride	O
had	O
no	O
effect	O
.	O

HOMA-S	Physical
values	Physical
changed	O
18.0	O
%	O
for	O
pioglitazone	O
and	O
-7.9	O
%	O
for	O
glimepiride	O
(	O
P	O
<	O
0.001	O
)	O
,	O
QUICKI	O
values	O
changed	O
a	O
respective	O
0.013	O
and	O
-0.007	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
FSI	O
values	O
were	O
-21.1	O
and	O
15.1	O
pmol/L	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Both	O
drugs	O
were	O
well	O
tolerated	Others
,	O
with	O
pioglitazone	O
associated	O
with	O
more	O
peripheral	Physical
edema	Physical
(	O
number	O
of	O
treatment-emergent	O
cases	O
:	O
35/121	O
[	O
28.9	O
%	O
]	O
vs	O
17/123	O
[	O
13.8	O
%	O
]	O
;	O
P	O
=	O
0.005	O
)	O
and	O
fewer	O
hypoglycemic	Physical
episodes	Physical
(	O
19	O
[	O
15.7	O
%	O
]	O
vs	O
38	O
[	O
30.9	O
%	O
]	O
;	O
P	O
=	O
0.024	O
)	O
.	O

The	O
incidence	O
of	O
weight	Physical
gain	Physical
was	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O

CONCLUSIONS	O
These	O
data	O
suggest	O
that	O
long-term	O
treatment	O
with	O
pioglitazone	O
enhances	O
insulin	O
sensitivity	O
relative	O
to	O
glimepiride	O
in	O
Mexican	O
patients	O
with	O
type	O
2	O
diabetes	O
and	O
that	O
pioglitazone	O
may	O
have	O
a	O
more	O
sustained	O
antihyperglycemic	O
effect	O
.	O

A	O
double-blind	O
comparison	O
of	O
oral	O
ketoprofen	O
'controlled	O
release	O
'	O
and	O
indomethacin	O
suppository	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
with	O
special	O
regard	O
to	O
morning	O
stiffness	O
and	O
pain	O
on	O
awakening	O
.	O

A	O
double-blind	O
,	O
double-dummy	O
,	O
crossover	O
study	O
was	O
carried	O
out	O
in	O
8	O
centres	O
to	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
'controlled-release	O
'	O
ketoprofen	O
tablets	O
(	O
200	O
mg	O
)	O
with	O
that	O
of	O
indomethacin	O
suppositories	O
(	O
100	O
mg	O
)	O
in	O
out-patients	O
with	O
definite	O
or	O
classical	O
rheumatoid	O
arthritis	O
.	O

Patients	O
were	O
allocated	O
at	O
random	O
to	O
receive	O
a	O
daily	O
bedtime	O
dose	O
of	O
either	O
1	O
ketoprofen	O
tablet	O
or	O
1	O
indomethacin	O
suppository	O
plus	O
the	O
dummy	O
of	O
the	O
other	O
formulation	O
for	O
a	O
period	O
of	O
3	O
weeks	O
.	O

They	O
were	O
then	O
crossed	O
over	O
to	O
the	O
alternative	O
treatment	O
for	O
a	O
further	O
3	O
weeks	O
.	O

Daily	O
diary	O
records	O
were	O
kept	O
by	O
patients	O
of	O
the	O
number	O
of	O
night-time	O
awakenings	O
due	O
to	O
pain	O
,	O
pain	O
severity	O
at	O
awakening	O
in	O
the	O
morning	O
and	O
the	O
duration	O
of	O
early	O
morning	O
stiffness	O
.	O

Treatment	O
efficacy	O
was	O
also	O
assessed	O
at	O
the	O
end	O
of	O
each	O
trial	O
period	O
by	O
means	O
of	O
an	O
articular	O
index	O
and	O
by	O
physician	O
's	O
and	O
patient	O
's	O
overall	O
evaluation	O
of	O
response	O
.	O

Adverse	O
effects	O
spontaneously	O
mentioned	O
by	O
the	O
patients	O
or	O
elicited	O
by	O
direct	O
questioning	O
using	O
a	O
symptom	O
check-list	O
were	O
recorded	O
.	O

Statistical	O
analysis	O
of	O
the	O
results	O
from	O
83	O
evaluable	O
patients	O
showed	O
that	O
the	O
'controlled-release	Others
'	Others
tablet	Others
formulation	Others
of	Others
200	Others
mg	Others
ketoprofen	O
was	O
equally	O
as	O
effective	O
as	O
the	O
100	O
mg	O
indomethacin	Others
suppository	Others
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
,	O
especially	O
with	O
regard	O
to	O
pain	Pain
at	Pain
awakening	Pain
and	Pain
morning	Pain
stiffness	Pain
.	O

Side-effects	O
in	O
both	O
groups	O
were	O
those	O
commonly	O
seen	O
with	O
non-steroidal	O
anti-inflammatory	O
drugs	O
and	O
,	O
as	O
expected	O
,	O
gastro-intestinal	Adverseeffect
and	Adverseeffect
CNS	Adverseeffect
disturbances	Adverseeffect
predominated	O
.	O

Overall	O
,	O
side-effects	Adverseeffect
were	O
fewer	O
with	O
ketoprofen	Others
than	O
with	O
indomethacin	Others
.	O

The	O
peroxisome	O
proliferator	O
activated	O
receptor-?	O
pioglitazone	O
improves	O
vascular	O
function	O
and	O
decreases	O
disease	O
activity	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

BACKGROUND	O
Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
is	O
associated	O
with	O
heightened	O
mortality	O
due	O
to	O
atherosclerotic	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

Inflammatory	O
pathways	O
in	O
RA	O
negatively	O
affect	O
vascular	O
physiology	O
and	O
promote	O
metabolic	O
disturbances	O
that	O
contribute	O
to	O
CVD	O
.	O

We	O
hypothesized	O
that	O
the	O
peroxisome	O
proliferator	O
activated	O
receptor-?	O
(	O
PPAR-?	O
)	O
pioglitazone	O
could	O
promote	O
potent	O
vasculoprotective	O
and	O
anti-inflammatory	O
effects	O
in	O
RA	O
.	O

METHODS	O
AND	O
RESULTS	O
One	O
hundred	O
forty-three	O
non-diabetic	O
adult	O
RA	O
patients	O
(	O
76.2	O
%	O
female	O
,	O
age	O
55.2	O
?	O
12.1	O
[	O
mean	O
?	O
SD	O
]	O
)	O
on	O
stable	O
RA	O
standard	O
of	O
care	O
treatment	O
were	O
enrolled	O
in	O
a	O
randomized	O
,	O
double-blind	O
placebo	O
controlled	O
crossover	O
trial	O
of	O
45	O
mg	O
daily	O
pioglitazone	O
versus	O
placebo	O
,	O
with	O
a	O
3-month	O
duration/arm	O
and	O
a	O
2-month	O
washout	O
period	O
.	O

Pulse	O
wave	O
velocity	O
of	O
the	O
aorta	O
(	O
PWV	O
)	O
,	O
brachial	O
artery	O
flow	O
mediated	O
dilatation	O
(	O
FMD	O
)	O
,	O
nitroglycerin	O
mediated	O
dilatation	O
(	O
NMD	O
)	O
,	O
microvascular	O
endothelial	O
function	O
(	O
reactive	O
hyperemia	O
index	O
[	O
RHI	O
]	O
)	O
,	O
and	O
circulating	O
biomarkers	O
of	O
inflammation	O
,	O
insulin	O
resistance	O
,	O
and	O
atherosclerosis	O
risk	O
all	O
were	O
quantified	O
.	O

RA	O
disease	O
activity	O
was	O
assessed	O
with	O
the	O
28-Joint	O
Count	O
Disease	O
Activity	O
Score	O
(	O
DAS-28	O
)	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
and	O
the	O
Short	O
Form	O
(	O
36	O
)	O
Health	O
Survey	O
quality	O
of	O
life	O
questionnaire	O
.	O

When	O
added	O
to	O
standard	O
of	O
care	O
RA	O
treatment	O
,	O
pioglitazone	O
significantly	O
decreased	O
pulse	O
wave	O
velocity	O
(	O
ie	O
,	O
aortic	O
stiffness	O
)	O
(	O
P=0.01	O
)	O
,	O
while	O
FMD	O
and	O
RHI	O
remained	O
unchanged	O
when	O
compared	O
to	O
treatment	O
with	O
placebo	O
.	O

Further	O
,	O
pioglitazone	O
significantly	O
reduced	O
RA	O
disease	O
activity	O
(	O
P=0.02	O
)	O
and	O
CRP	O
levels	O
(	O
P=0.001	O
)	O
,	O
while	O
improving	O
lipid	O
profiles	O
.	O

The	O
drug	O
was	O
well	O
tolerated	O
.	O

CONCLUSIONS	O
Addition	O
of	O
pioglitazone	O
to	O
RA	O
standard	O
of	O
care	O
significantly	O
improves	O
aortic	O
elasticity	O
and	O
decreases	O
inflammation	O
and	O
disease	O
activity	O
with	O
minimal	O
safety	O
issues	O
.	O

The	O
clinical	O
implications	O
of	O
these	O
findings	O
remain	O
to	O
be	O
established	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
URL	O
ClinicalTrials.gov	O
Unique	O
Identifier	O
:	O
NCT00554853	O
.	O

Osteoporosis	O
and	O
gait	O
and	O
balance	O
disturbances	O
in	O
older	O
sarcopenic	O
obese	O
New	O
Zealanders	O
.	O

UNLABELLED	O
Bone	O
,	O
muscle	O
,	O
and	O
fat	O
may	O
affect	O
gait	O
and	O
balance	O
in	O
older	O
adults	O
.	O

Osteoporosis	O
was	O
prevalent	O
in	O
low	O
muscle	O
mass	O
participants	O
and	O
related	O
to	O
gait	O
and	O
balance	O
deficits	O
.	O

Low	O
muscle	O
combined	O
with	O
high	O
fat	O
mass	O
had	O
more	O
functional	O
deficits	O
and	O
poorer	O
bone	O
health	O
,	O
which	O
has	O
implications	O
for	O
falls	O
risk	O
and	O
fractures	O
.	O

INTRODUCTION	O
Decreasing	O
bone	O
density	O
and	O
muscle	O
mass	O
and	O
increasing	O
fat	O
mass	O
may	O
act	O
synergistically	O
to	O
affect	O
gait	O
and	O
balance	O
in	O
older	O
adults	O
.	O

METHODS	O
One	O
hundred	O
eighty-three	O
older	O
adults	O
(	O
age	O
72.7	O
+/-	O
6	O
years	O
,	O
range	O
56-93	O
;	O
body	O
mass	O
index	O
28.2	O
+/-	O
4.9	O
,	O
range	O
16.6-46.0	O
)	O
were	O
recruited	O
from	O
a	O
New	O
Zealand	O
falls	O
prevention	O
intervention	O
trial	O
.	O

Total	Physical
and	Physical
appendicular	Physical
skeletal	Physical
muscle	Physical
mass	Physical
(	Physical
ASM	Physical
)	Physical
,	O
percent	Physical
fat	Physical
,	O
and	O
bone	Physical
mineralization	Physical
were	O
assessed	O
by	O
dual	O
energy	O
X-ray	O
absorptiometry	O
and	O
used	O
to	O
characterize	O
normal	O
lean	O
(	O
NL	O
,	O
n	O
=	O
51	O
)	O
,	O
sarcopenic	O
(	O
SS	O
,	O
n	O
=	O
18	O
)	O
,	O
sarcopenic	O
obese	O
(	O
SO	O
,	O
n	O
=	O
29	O
)	O
,	O
and	O
obese	O
(	O
OO	O
,	O
n	O
=	O
85	O
)	O
phenotypes	O
.	O

Functional	O
performance	O
was	O
assessed	O
using	O
timed	O
up	O
and	O
go	O
,	O
chair	O
stand	O
,	O
single	O
leg	O
stand	O
,	O
and	O
step	O
test	O
.	O

Regression	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
medications	O
,	O
and	O
physical	O
activity	O
.	O

RESULTS	O
Femoral	Physical
neck	Physical
osteoporosis	Physical
was	O
present	O
in	O
22	O
%	O
SS	O
,	O
17	O
%	O
SO	O
,	O
12	O
%	O
NL	O
,	O
and	O
7	O
%	O
OO	O
.	O

Femoral	O
neck	O
osteoporosis	O
with	O
low	O
ASM	Physical
predicted	O
poor	O
chair	Physical
stand	Physical
performance	Physical
(	O
beta	O
-3.3	O
,	O
standard	O
error	O
1.6	O
,	O
p	O
=	O
0.04	O
)	O
.	O

SO	O
scored	O
lowest	O
on	O
the	O
chair	O
stand	O
(	O
p	O
=	O
0.03	O
)	O
and	O
step	O
test	O
(	O
p	O
=	O
0.03	O
)	O
.	O

Higher	Physical
ASM	Physical
predicted	O
faster	O
timed	O
up	O
and	O
go	O
performance	O
(	O
p	O
=	O
0.001	O
)	O
.	O

CONCLUSIONS	O
Osteoporosis	O
was	O
prevalent	O
in	O
low	O
ASM	O
groups	O
(	O
SS	O
and	O
SO	O
)	O
and	O
related	O
to	O
gait	O
and	O
balance	O
deficits	O
,	O
particularly	O
in	O
the	O
SO	O
.	O

This	O
has	O
implications	O
for	O
falls	O
risk	O
,	O
fractures	O
,	O
and	O
interventions	O
.	O

The	O
European	O
Myocardial	O
Infarction	O
Project	O
:	O
an	O
assessment	O
of	O
pre-hospital	O
thrombolysis	O
.	O

The	O
use	O
of	O
thrombolytic	O
agents	O
in	O
patients	O
with	O
suspected	O
myocardial	O
infarction	O
has	O
been	O
shown	O
to	O
reduce	O
early	O
and	O
long-term	O
mortality	O
by	O
about	O
20	O
%	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
since	O
time	O
is	O
an	O
important	O
factor	O
,	O
pre-hospital	O
treatment	O
would	O
give	O
better	O
results	O
.	O

However	O
,	O
health	O
deciders	O
need	O
reliable	O
data	O
on	O
which	O
to	O
base	O
future	O
policies	O
concerning	O
this	O
.	O

The	O
European	O
Myocardial	O
Infarction	O
Project	O
was	O
a	O
European	O
Economic	O
Community-supported	O
double-blind	O
study	O
designed	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
pre-hospital	O
early	O
thrombolytic	O
treatment	O
in	O
patients	O
with	O
suspected	O
myocardial	O
infarction	O
compared	O
with	O
the	O
same	O
treatment	O
given	O
later	O
in	O
a	O
hospital	O
setting	O
.	O

A	O
total	O
of	O
5469	O
patients	O
in	O
16	O
countries	O
were	O
randomised	O
by	O
198	O
mobile	O
emergency	O
units	O
to	O
receive	O
either	O
pre-hospital	O
treatment	O
with	O
anistreplase	O
,	O
the	O
thrombolytic	O
agent	O
used	O
,	O
followed	O
by	O
placebo	O
after	O
hospital	O
admission	O
(	O
pre-hospital	O
group	O
;	O
2750	O
patients	O
)	O
,	O
or	O
placebo	O
followed	O
by	O
anistreplase	O
(	O
hospital	O
group	O
;	O
2719	O
patients	O
)	O
.	O

The	O
median	Others
time	Others
delay	Others
between	O
the	O
injections	O
was	O
55	O
min	O
.	O

A	O
non-significant	O
decrease	O
in	O
30-day	Mortality
mortality	Mortality
was	O
observed	O
in	O
favour	O
of	O
the	O
pre-hospital	O
group	O
(	O
13	O
%	O
:	O
P	O
=	O
0.08	O
)	O
,	O
whereas	O
the	O
decrease	Mortality
in	Mortality
cardiac	Physical
death	Physical
observed	O
,	O
also	O
in	O
favour	O
of	O
the	O
pre-hospital	O
group	O
,	O
was	O
on	O
the	O
borderline	O
of	O
significance	O
(	O
16	O
%	O
;	O
P	O
=	O
0.049	O
)	O
.	O

Although	O
some	Adverseeffect
complications	Adverseeffect
occurred	O
more	O
frequently	O
in	O
the	O
pre-hospital	O
group	O
in	O
the	O
pre-hospital	O
period	O
,	O
the	O
overall	O
incidence	O
for	O
serious	Adverseeffect
complications	Adverseeffect
was	O
similar	O
for	O
both	O
groups	O
.	O

These	O
results	O
show	O
that	O
the	O
pre-hospital	Others
thrombolytic	Others
strategy	Others
in	O
patients	O
with	O
suspected	O
myocardial	Physical
infarction	Physical
is	O
both	O
effective	Others
and	Others
safe	Others
when	O
performed	O
by	O
well-equipped	Others
well-staffed	Others
mobile	Others
emergency	Others
units	Others
.	O

Effect	O
of	O
ozone	O
application	O
on	O
the	O
resin-dentin	Others
microtensile	Others
bond	Others
strength	Others
.	O

When	O
ozone	O
is	O
used	O
during	O
caries	O
treatment	O
,	O
bond	O
strength	O
can	O
be	O
compromised	O
by	O
the	O
release	O
of	O
oxygen	O
.	O

The	O
use	O
of	O
antioxidant	O
agents	O
neutralizes	O
the	O
free	O
oxygen	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
ozone	O
and	O
sodium	O
ascorbate	O
on	O
resin-dentin	O
microtensile	O
bond	O
strength	O
(	O
?TBS	O
)	O
.	O

Forty	O
human	O
third	O
molars	O
were	O
divided	O
into	O
four	O
groups	O
:	O
Group	O
1	O
,	O
not	O
treated	O
with	O
ozone	O
;	O
Group	O
2	O
,	O
ozone	O
application	O
followed	O
by	O
acid	O
etching	O
;	O
Group	O
3	O
,	O
acid	O
etching	O
followed	O
by	O
ozone	O
application	O
;	O
and	O
Group	O
4	O
,	O
ozone	O
and	O
application	O
of	O
sodium	O
ascorbate	O
.	O

Bonded	O
beams	O
(	O
1.0	O
mm	O
(	O
2	O
)	O
)	O
were	O
tested	O
under	O
tension	O
(	O
0.5	O
mm	O
min	O
(	O
-1	O
)	O
)	O
.	O

The	O
?TBS	O
values	O
were	O
analyzed	O
using	O
one-way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	O
Tukey	O
test	O
(	O
p=0.05	O
)	O
.	O

All	O
beams	O
that	O
fractured	O
were	O
analyzed	O
under	O
stereomicroscopy	O
(	O
40?	O
)	O
.	O

Group	O
1	O
had	O
significantly	O
higher	O
?TBS	O
values	O
than	O
Group	O
2	O
or	O
3	O
.	O

The	O
?TBS	O
values	O
of	O
Groups	O
1	O
and	O
4	O
were	O
similar	O
and	O
higher	O
than	O
those	O
of	O
Group	O
2	O
.	O

The	O
use	O
of	O
ozone	O
in	O
Group	O
2	O
resulted	O
in	O
lower	O
values	O
of	O
?TBS	O
in	O
all	O
conditions	O
evaluated	O
.	O

The	O
predominant	O
failure	O
mode	O
was	O
adhesive	O
.	O

The	O
application	O
of	O
ozone	O
decreased	O
the	O
?TBS	O
of	O
the	O
dentin-composite	O
resin	O
interface	O
.	O

These	O
values	O
were	O
reversed	O
when	O
compared	O
with	O
Groups	O
1	O
and	O
2	O
when	O
sodium	O
ascorbate	O
was	O
used	O
.	O

Measuring	O
adherence	O
in	O
a	O
hypertension	O
clinical	O
trial	O
.	O

BACKGROUND	O
Non-adherence	O
in	O
hypertension	O
is	O
a	O
global	O
problem	O
and	O
promoting	O
adherence	O
is	O
necessary	O
to	O
decrease	O
cardiovascular	O
mortality	O
.	O

AIMS	O
The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
examine	O
the	O
measurement	O
of	O
adherence	Mental
to	O
medication	O
taking	O
in	O
hypertensive	O
patients	O
.	O

Adherence	O
was	O
evaluated	O
primarily	O
by	O
means	O
of	O
MEMS	Mental
(	Mental
Medication	Mental
Event	Mental
Monitoring	Mental
System	Mental
,	O
Aprex	O
Corporation	O
,	O
Fremont	O
,	O
California	O
)	O
an	O
electronic	O
system	O
that	O
records	O
the	O
date	O
and	O
time	O
of	O
opening	O
of	O
the	O
study	O
medication	O
container	O
.	O

Additional	O
measurements	O
such	O
as	O
change	O
in	O
urinary	Physical
potassium	Physical
level	Physical
,	Mental
capsule	Physical
count	Physical
,	Mental
client	Mental
self	Mental
report	Mental
and	Mental
physician	Mental
estimate	Mental
of	Mental
adherence	Mental
were	O
recorded	O
.	O

METHODS	O
A	O
randomised	O
clinical	O
trial	O
was	O
used	O
to	O
assign	O
patients	O
to	O
receive	O
the	O
study	O
medication	O
(	O
potassium	O
)	O
or	O
placebo	O
.	O

Descriptive	O
statistics	O
were	O
used	O
to	O
answer	O
the	O
research	O
questions	O
.	O

Frequency	O
and	O
percentage	O
of	O
responses	O
to	O
different	O
measures	O
of	O
adherence	O
were	O
carried	O
out	O
as	O
well	O
as	O
correlation	O
between	O
the	O
measures	O
.	O

RESULTS	O
One	O
hundred	O
and	O
seven	O
subjects	O
between	O
the	O
ages	O
of	O
26	O
and	O
80	O
participated	O
in	O
the	O
clinical	O
trial	O
.	O

The	O
results	O
showed	O
that	O
adherence	O
measures	O
varied	O
with	O
lowest	O
adherence	Physical
from	O
two	O
items	O
of	O
self-report	Physical
related	Physical
to	Physical
forgetfulness	Physical
(	O
46	O
and	O
55	O
%	O
)	O
and	O
stringent	O
electronic	Physical
monitoring	Physical
with	Physical
the	Physical
MEMS	Physical
(	O
58	O
%	O
)	O
to	O
percentages	O
in	O
the	O
80-90	O
range	O
for	O
other	O
self-report	O
items	O
and	O
the	O
general	O
adherence	O
scale	O
.	O

Electronic	O
monitoring	O
correlated	O
best	O
with	O
capsule	Physical
count	Physical
at	O
visit	O
5	O
.	O

Implications	O
for	O
health	O
care	O
providers	O
are	O
discussed	O
.	O

Predictors	O
of	O
smoking	O
cessation	O
among	O
cancer	O
patients	O
enrolled	O
in	O
a	O
smoking	O
cessation	O
program	O
.	O

UNLABELLED	O
Many	O
cancer	O
patients	O
continue	O
to	O
smoke	O
postdiagnosis	O
,	O
which	O
is	O
associated	O
with	O
poorer	O
clinical	O
outcomes	O
.	O

Identifying	O
prospective	O
predictors	O
of	O
smoking	O
cessation	O
among	O
patients	O
currently	O
receiving	O
smoking	O
cessation	O
treatment	O
can	O
help	O
guide	O
the	O
development	O
and	O
implementation	O
of	O
smoking	O
cessation	O
programs	O
with	O
this	O
population	O
.	O

MATERIAL	O
AND	O
METHODS	O
Data	O
from	O
246	O
cancer	O
patients	O
participating	O
in	O
a	O
randomized	O
placebo-controlled	O
smoking	O
cessation	O
clinical	O
trial	O
were	O
used	O
to	O
examine	O
baseline	O
predictors	O
of	O
end-of-treatment	O
and	O
six-month	O
postbaseline	O
smoking	O
cessation	O
outcomes	O
.	O

Baseline	O
demographic	O
,	O
smoking-related	O
,	O
disease-related	O
,	O
and	O
psychological	O
variables	O
were	O
examined	O
as	O
predictors	O
of	O
biochemically-confirmed	O
point-prevalence	O
abstinence	O
.	O

RESULTS	O
Multivariate	Others
analysis	O
indicated	O
that	O
,	O
for	O
end-of-treatment	Mental
abstinence	Mental
,	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
quit	Mental
smoking	Mental
if	O
they	O
were	O
older	O
(	O
OR	O
=	O
1.06	O
,	O
95	O
%	O
CI	O
:	O
1.03-1.10	O
,	O
p	O
<	O
0.05	O
)	O
and	O
were	O
diagnosed	O
with	O
a	O
non-tobacco	O
related	O
cancer	O
(	O
OR	O
=	O
2.54	O
,	O
95	O
%	O
CI	O
:	O
1.24-5.20	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Likewise	O
,	O
for	O
six-month	Mental
abstinence	Mental
,	O
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
quit	Mental
smoking	Mental
if	O
they	O
were	O
older	O
(	O
OR	O
=	O
1.04	O
,	O
95	O
%	O
CI	O
:	O
1.01-1.08	O
,	O
p	O
<	O
0.05	O
)	O
and	O
were	O
significantly	O
less	O
likely	O
to	O
have	O
quit	O
smoking	O
if	O
they	O
were	O
female	O
(	O
OR	O
=	O
0.47	O
,	O
95	O
%	O
CI	O
:	O
0.22-0.97	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Patients	O
with	O
tobacco-related	O
cancers	O
and	O
female	O
patients	O
reported	O
significantly	O
higher	O
levels	Mental
of	Mental
depression	Mental
symptoms	Mental
(	O
p	O
<	O
0.05	O
)	O
,	O
which	O
proved	O
predictive	Mental
of	Mental
smoking	Mental
relapse	Mental
.	Mental

CONCLUSIONS	O
Patient	O
age	O
,	O
gender	O
,	O
and	O
cancer-type	O
may	O
be	O
important	O
factors	O
to	O
consider	O
when	O
developing	O
and	O
implementing	O
smoking	O
cessation	O
interventions	O
for	O
cancer	O
patients	O
.	O

Covariation	O
of	O
adolescent	Physical
physical	Physical
activity	Physical
and	O
dietary	Mental
behaviors	Mental
over	O
12	O
months	O
.	O

PURPOSE	O
This	O
study	O
examined	O
covariation	O
among	O
changes	O
in	O
dietary	O
,	O
physical	O
activity	O
,	O
and	O
sedentary	O
behaviors	O
over	O
12	O
months	O
among	O
adolescents	O
participating	O
in	O
a	O
health	O
behavior	O
intervention	O
.	O

Evidence	O
of	O
covariation	O
among	O
behaviors	O
would	O
suggest	O
multi-behavior	O
interventions	O
could	O
have	O
synergistic	O
effects	O
.	O

METHODS	O
Prospective	O
analyses	O
were	O
conducted	O
with	O
baseline	O
and	O
12-month	O
assessments	O
from	O
a	O
randomized	O
controlled	O
trial	O
to	O
promote	O
improved	O
diet	Mental
,	O
physical	Mental
activity	Mental
,	O
and	O
sedentary	Mental
behaviors	Mental
(	O
experimental	O
condition	O
)	O
or	O
SUN	Mental
protection	Mental
behaviors	Mental
(	O
comparison	O
condition	O
)	O
.	O

Participants	O
were	O
adolescent	O
girls	O
and	O
boys	O
(	O
N	O
=	O
878	O
)	O
aged	O
11-15	O
years	O
on	O
entry	O
.	O

The	O
main	O
outcomes	O
were	O
:	O
diet	Mental
,	O
based	O
on	O
multiple	O
24-hour	O
recalls	O
(	O
total	O
fat	O
,	O
grams	O
of	O
fiber	O
,	O
servings	O
of	O
fruit	O
and	O
vegetables	O
,	O
total	O
calories	O
)	O
;	O
average	Mental
daily	Mental
energy	Mental
expenditure	Mental
(	O
kcals/kg	O
)	O
based	O
on	O
7-day	O
physical	O
activity	O
recall	O
interviews	O
;	O
daily	Mental
minutes	Mental
of	Mental
moderate-vigorous	Mental
physical	Mental
activity	Mental
minutes	O
from	O
accelerometery	O
;	O
and	O
self-reported	Mental
daily	Mental
hours	Mental
of	Mental
sedentary	Mental
behavior	Mental
.	O

RESULTS	O
Covariation	O
was	O
found	O
between	O
fat	O
and	O
calories	O
(	O
r	O
=	O
.16	O
)	O
,	O
fiber	O
and	O
calories	O
(	O
r	O
=	O
.53	O
)	O
,	O
fiber	Physical
and	Physical
fruit/vegetables	Physical
(	O
r	O
=	O
.53	O
)	O
,	O
calories	Physical
and	Physical
fruit/vegetables	Physical
(	O
r	O
=	O
.34	O
)	O
,	O
and	O
fruit	Physical
and	Physical
vegetables	Physical
and	O
sedentary	Mental
behavior	Mental
(	O
r	O
=	O
-.12	O
)	O
for	O
the	O
total	O
sample	O
(	O
all	O
p	O
values	O
<	O
.01	O
)	O
.	O

The	O
pattern	O
of	O
findings	O
was	O
similar	O
for	O
most	O
subgroups	O
defined	O
by	O
gender	O
and	O
study	O
condition	O
.	O

CONCLUSIONS	O
The	O
strongest	O
covariation	O
was	O
observed	O
for	O
diet	Mental
variables	Mental
that	O
are	O
inherently	O
related	O
(	O
calories	O
and	O
fat	O
,	O
fiber	O
,	O
and	O
fruit/vegetables	O
)	O
.	O

Little	O
covariation	O
was	O
detected	O
within	O
or	O
between	O
other	O
diet	Mental
,	O
physical	Mental
activity	Mental
and	O
sedentary	Mental
behavior	Mental
domains	O
suggesting	O
that	O
interventions	O
to	O
improve	O
these	O
behaviors	O
in	O
adolescents	O
need	O
to	O
include	O
specific	O
program	O
components	O
for	O
each	O
target	O
behavior	O
of	O
interest	O
.	O

Evaluation	O
of	O
reducing	O
postoperative	O
hip	O
precautions	O
in	O
total	O
hip	O
replacement	O
:	O
a	O
randomized	O
prospective	O
study	O
.	O

Currently	O
,	O
many	O
rehabilitation	O
protocols	O
for	O
total	O
hip	O
replacements	O
(	O
THRs	O
)	O
include	O
activity	O
restrictions	O
to	O
prevent	O
postoperative	O
dislocation	O
.	O

There	O
is	O
increasing	O
demand	O
for	O
more	O
efficient	O
and	O
safe	O
rehabilitation	O
protocols	O
.	O

This	O
randomized	O
prospective	O
study	O
evaluates	O
the	O
need	O
for	O
hip	O
restrictions	O
following	O
a	O
modified	O
anterolateral	O
procedure	O
.	O

From	O
2004	O
to	O
2008	O
,	O
81	O
patients	O
seeking	O
elective	O
THRs	O
were	O
randomly	O
assigned	O
into	O
a	O
standard	O
rehabilitation	O
group	O
or	O
an	O
early	O
rehabilitation	O
group	O
.	O

The	O
standard	O
group	O
included	O
restrictions	O
to	O
avoid	O
hip	O
flexion	O
>	O
90	O
degrees	O
and	O
avoidance	O
of	O
riding	O
in	O
a	O
car	O
for	O
the	O
first	O
postoperative	O
month	O
.	O

The	O
early	O
group	O
had	O
no	O
flexion	O
or	O
car	O
riding	O
restrictions	O
.	O

Forty-three	O
patients	O
were	O
in	O
the	O
standard	O
group	O
and	O
38	O
patients	O
were	O
in	O
the	O
early	O
group	O
.	O

There	O
were	O
no	O
significant	O
demographic	O
differences	O
between	O
the	O
2	O
groups	O
.	O

All	O
patients	O
completed	O
the	O
Short	O
Form	O
12-question	O
Health	O
Survey	O
and	O
Harris	O
Hip	O
Score	O
preoperatively	O
and	O
at	O
4	O
weeks	O
,	O
1	O
month	O
,	O
3	O
months	O
,	O
and	O
1	O
year	O
postoperatively	O
.	O

The	O
time-points	Others
at	Others
which	Others
the	Others
patient	Others
first	Others
drove	Others
and	Others
ambulated	Others
with	O
a	O
cane	O
,	O
without	O
a	O
cane	O
,	O
and	O
without	O
a	O
limp	O
were	O
also	O
collected	O
.	O

No	O
incidents	O
of	O
dislocation	Physical
occurred	O
.	O

Patients	O
in	O
the	O
early	O
group	O
were	O
faster	O
to	O
ambulate	Physical
with	Physical
only	Physical
a	Physical
cane	Physical
(	O
P=.03	O
)	O
,	O
without	Others
a	Others
cane	Others
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
without	Others
a	Others
limp	Others
(	O
P=.003	O
)	O
.	O

They	O
also	O
drove	Others
earlier	O
(	O
P=.02	O
)	O
.	O

Pace	Physical
of	Physical
recovery	Physical
was	O
the	O
only	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
.	O

The	O
early	O
rehabilitation	O
protocol	O
increases	O
the	O
pace	O
of	O
recovery	O
compared	O
to	O
a	O
pathway	O
with	O
hip	O
precautions	O
without	O
increasing	O
complications	Adverseeffect
.	O

Evaluation	O
of	O
lidocaine	O
in	O
human	O
inferior	O
alveolar	O
nerve	O
block	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
measure	O
the	O
degree	Physical
of	Physical
anesthesia	Physical
following	O
the	O
administration	O
of	O
3.6	O
ml	O
of	O
2	O
%	O
lidocaine	O
solutions	O
with	O
either	O
1:50,000	O
,	O
1:80,000	O
,	O
or	O
1:100,000	O
for	O
inferior	O
alveolar	O
nerve	O
block	O
and	O
to	O
compare	O
the	O
results	O
with	O
those	O
obtained	O
following	O
the	O
administration	O
of	O
1.8	O
ml	O
of	O
the	O
same	O
solutions	O
(	O
1	O
)	O
.	O

With	O
the	O
use	O
of	O
a	O
repeated	O
measures	O
design	O
,	O
30	O
subjects	O
randomly	O
received	O
an	O
inferior	O
alveolar	O
injection	O
at	O
three	O
successive	O
appointments	O
.	O

The	O
first	O
molar	O
,	O
first	O
premolar	O
,	O
lateral	O
incisor	O
,	O
and	O
contralateral	O
canine	O
(	O
control	O
)	O
were	O
blindly	O
tested	O
with	O
an	O
Analytic	O
Technology	O
pulp	O
tester	O
at	O
3-min	O
cycles	O
for	O
50	O
min	O
.	O

The	O
degree	Physical
of	Physical
anesthesia	Physical
was	O
comparable	O
for	O
the	O
three	O
solutions	O
following	O
the	O
administration	O
of	O
3.6	O
ml	O
of	O
each	O
solution	O
.	O

Retrospective	O
evaluation	O
showed	O
that	O
the	O
volume	O
of	O
the	O
solution	O
influenced	O
the	O
degree	O
of	O
anesthesia	O
.	O

Efficacy	Others
of	O
latanoprost	O
when	O
stored	O
at	O
room	O
temperature	O
.	O

We	O
compared	O
the	O
ocular	O
hypotensive	O
effect	Physical
for	O
24	O
hours	O
and	O
the	O
tolerability	O
of	O
latanoprost	O
stored	O
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C.	O
Seventeen	O
healthy	O
volunteers	O
were	O
included	O
in	O
this	O
crossover	O
trial	O
.	O

Latanoprost	O
0.005	O
%	O
(	O
Xalatan	O
)	O
was	O
stored	O
at	O
4	O
degrees	O
C	O
or	O
30	O
degrees	O
C	O
for	O
4	O
weeks	O
in	O
the	O
dark	O
.	O

The	O
subjects	O
enrolled	O
to	O
the	O
study	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
latanoprost	O
stored	O
at	O
4	O
degrees	O
C	O
or	O
that	O
stored	O
at	O
30	O
degrees	O
C.	O
The	O
eye	O
drop	O
was	O
applied	O
to	O
the	O
right	O
eye	O
of	O
each	O
subject	O
for	O
3	O
days	O
.	O

The	O
left	O
eye	O
served	O
as	O
a	O
control	O
without	O
administration	O
.	O

Slit-lamp	O
biomicroscopy	O
and	O
circadian	O
intra	O
ocular	O
pressure	O
(	O
IOP	O
)	O
curve	O
was	O
performed	O
at	O
Day	O
3	O
,	O
every	O
3	O
hours	O
from	O
6	O
pm	O
.	O

This	O
procedure	O
was	O
repeated	O
7	O
days	O
after	O
changing	O
the	O
drug	O
from	O
4	O
degrees	O
C	O
to	O
30	O
degrees	O
C	O
or	O
vice	O
versa	O
,	O
and	O
application	O
to	O
the	O
left	O
eye	O
for	O
3	O
days	O
.	O

Eyes	O
treated	O
with	O
latanoprost	O
,	O
stored	O
both	O
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C	O
,	O
achieved	O
statistically	Physical
significantly	Physical
lower	Physical
mean	Physical
IOPs	Physical
than	O
untreated	O
eyes	O
at	O
all	O
time	O
points	O
,	O
except	O
at	O
21	O
hours	O
treated	O
by	O
the	O
drug	O
stored	O
at	O
30	O
degrees	O
C.	O
We	O
subtracted	O
the	O
IOP	O
of	O
eyes	O
receiving	O
latanoprost	O
from	O
the	O
IOP	O
of	O
untreated	O
eyes	O
for	O
each	O
time	O
point	O
to	O
evaluate	O
the	O
efficacy	Others
of	O
the	O
eye	O
drops	O
(	O
delta	O
IOP	O
)	O
.	O

There	O
were	O
no	Physical
statistically	Physical
significant	Physical
differences	Physical
between	Physical
the	Physical
delta	Physical
IOPs	Physical
with	Physical
the	Physical
drug	Physical
stored	Physical
at	O
4	O
degrees	O
C	O
and	O
30	O
degrees	O
C.	O
During	O
the	O
study	O
,	O
no	Adverseeffect
subject	Adverseeffect
developed	Adverseeffect
a	Adverseeffect
serious	Adverseeffect
adverse	Adverseeffect
event	Adverseeffect
.	Adverseeffect

These	O
results	O
suggest	O
that	O
latanoprost	O
stored	O
at	O
30	O
degrees	O
C	O
for	O
4	Others
weeks	Others
after	Others
opening	Others
the	Others
bottle	Others
remains	Others
as	Others
effective	Others
and	Others
safe	Others
as	O
latanoprost	O
stored	O
under	O
cold	O
conditions	O
.	O

Controlled	O
study	O
on	O
the	O
therapeutic	Others
efficacy	Others
of	O
propionyl-L-carnitine	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

A	O
double-blind	O
phase	O
II	O
study	O
of	O
propionyl-L-carnitine	O
(	O
CAS	O
17298-37-2	O
)	O
versus	O
placebo	O
was	O
carried	O
out	O
on	O
a	O
group	O
of	O
60	O
patients	O
with	O
mild	O
to	O
moderate	O
(	O
II	O
and	O
III	O
NYHA	O
class	O
)	O
congestive	O
heart	O
failure	O
.	O

The	O
group	O
was	O
made	O
up	O
of	O
men	O
and	O
women	O
aged	O
between	O
48	O
and	O
73	O
years	O
in	O
chronic	O
treatment	O
with	O
digitalis	O
and	O
diuretics	O
for	O
at	O
least	O
3	O
months	O
and	O
who	O
still	O
displayed	O
symptoms	O
.	O

Thirty	O
of	O
these	O
patients	O
were	O
chosen	O
randomly	O
and	O
for	O
180	O
days	O
,	O
500	O
mg	O
of	O
propionyl-L-carnitine	O
was	O
orally	O
administered	O
,	O
3	O
times	O
a	O
day	O
in	O
addition	O
to	O
their	O
usual	O
treatment	O
.	O

At	O
basal	O
conditions	O
and	O
after	O
30	O
,	O
90	O
and	O
180	O
days	O
the	O
maximum	Physical
exercise	Physical
time	Physical
was	O
evaluated	O
using	O
an	O
exercise	Others
tolerance	Others
test	Others
performed	O
on	O
an	O
ergometer	O
bicycle	O
and	O
the	O
left	Physical
ventricular	Physical
ejection	Physical
fraction	Physical
was	O
tested	O
by	O
means	O
of	O
bidimensional	Others
echocardiography	Others
.	O

After	O
one	O
month	O
of	O
treatment	O
,	O
the	O
patients	O
treated	O
with	O
propionyl-L-carnitine	O
,	O
compared	O
to	O
the	O
control	O
group	O
,	O
showed	O
significant	O
increases	O
in	O
the	O
values	Others
of	Others
both	Others
tests	Others
,	O
increases	O
which	O
became	O
even	O
more	O
evident	O
after	O
90	O
and	O
180	O
days	O
.	O

At	O
the	O
stated	O
times	O
the	O
increases	O
in	O
the	O
maximum	Physical
exercise	Physical
time	Physical
were	O
16.4	O
%	O
,	O
22.9	O
%	O
,	O
and	O
25.9	O
%	O
,	O
respectively	O
.	O

The	O
ventricular	Physical
ejection	Physical
fraction	Physical
increased	O
by	O
8.4	O
%	O
,	O
11.6	O
%	O
and	O
13.6	O
%	O
,	O
respectively	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
having	O
studied	O
the	O
particular	O
mechanism	O
of	O
action	O
of	O
propionyl-L-carnitine	O
the	O
authors	O
conclude	O
that	O
it	O
represents	O
a	O
drug	O
of	O
undoubted	O
therapeutic	O
interest	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
in	O
whom	O
it	O
could	O
be	O
efficaciously	Others
administered	O
along	O
with	O
a	O
standard	O
pharmacological	O
therapy	O
.	O

Oral	O
magnesium	O
supplementation	O
in	O
children	O
with	O
cystic	O
fibrosis	O
improves	O
clinical	Physical
and	Physical
functional	Physical
variables	Physical
:	Physical
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
crossover	O
trial	O
.	O

BACKGROUND	O
Magnesium	O
is	O
one	O
of	O
the	O
most	O
important	O
minerals	O
in	O
the	O
body	O
.	O

Although	O
some	O
studies	O
reported	O
that	O
patients	O
with	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
lack	O
magnesium	O
,	O
no	O
international	O
study	O
has	O
assessed	O
the	O
importance	O
of	O
oral	O
magnesium	O
supplementation	O
in	O
CF	O
patients	O
.	O

OBJECTIVE	O
We	O
prospectively	O
investigated	O
the	O
long-term	O
effect	O
of	O
oral	O
magnesium	O
supplementation	O
on	O
respiratory	Physical
muscle	Physical
strength	Physical
by	O
using	O
manuvacuometry	O
and	O
the	O
Shwachman-Kulczycki	Physical
(	Physical
SK	Physical
)	Physical
score	Physical
among	O
children	O
and	O
adolescents	O
with	O
CF	O
.	O

DESIGN	O
This	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
crossover	O
study	O
included	O
44	O
CF	O
patients	O
(	O
aged	O
7-19	O
y	O
;	O
20	O
males	O
)	O
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
magnesium	O
(	O
n	O
=	O
22	O
;	O
300	O
mg/d	O
)	O
or	O
placebo	O
(	O
n	O
=	O
22	O
)	O
for	O
8	O
wk	O
with	O
a	O
4-wk	O
washout	O
period	O
between	O
trials	O
.	O

All	O
patients	O
were	O
undergoing	O
conventional	O
treatment	O
of	O
CF	O
.	O

The	O
experimental	O
protocol	O
included	O
clinical	O
evaluation	O
,	O
assessment	O
of	O
urinary	O
concentration	O
of	O
magnesium	O
,	O
and	O
manuvacuometric	O
measurements	O
[	Physical
maximal	Physical
inspiratory	Physical
pressure	Physical
(	Physical
MIP	Physical
)	Physical
and	O
maximal	Physical
expiratory	Physical
pressure	Physical
(	Physical
MEP	Physical
)	Physical
]	Physical
.	O

MIP	Physical
was	O
the	O
primary	O
outcome	O
.	O

RESULTS	O
Urinary	Physical
magnesium	Physical
increased	O
after	O
the	O
administration	O
of	O
magnesium	O
(	O
change	O
:	O
36.38	O
mg/d	O
after	O
magnesium	O
compared	O
with	O
0.72	O
mg/d	O
after	O
placebo	O
;	O
P	O
<	O
0.001	O
)	O
.	O

Moreover	O
,	O
MIP	Physical
and	O
MEP	Physical
significantly	O
improved	O
only	O
after	O
magnesium	O
administration	O
(	O
change	O
in	O
MIP	O
:	O
11	O
%	O
predicted	O
after	O
magnesium	O
compared	O
with	O
0.5	O
%	O
predicted	O
after	O
placebo	O
;	O
change	O
in	O
MEP	O
:	O
11.9	O
%	O
predicted	O
after	O
magnesium	O
compared	O
with	O
0.8	O
%	O
predicted	O
after	O
placebo	O
;	O
P	O
<	O
0.001	O
for	O
both	O
)	O
.	O

Magnesium	O
administration	O
had	O
a	O
beneficial	O
effect	O
on	O
clinical	O
variables	O
assessed	O
by	O
the	O
SK	Physical
score	Physical
(	O
change	O
:	O
4.48	O
points	O
after	O
magnesium	O
compared	O
with	O
-1.30	O
points	O
after	O
placebo	O
;	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
Oral	O
magnesium	O
supplementation	O
helped	O
improve	O
both	O
the	O
SK	Others
score	Others
and	Others
respiratory	Others
muscle	Others
strength	Others
in	O
pediatric	O
patients	O
with	O
CF	O
.	O

Wheelchair	O
skills	O
training	O
to	O
improve	O
confidence	Mental
with	O
using	O
a	O
manual	O
wheelchair	O
among	O
older	O
adults	O
:	O
a	O
pilot	O
study	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
effects	O
of	O
wheelchair	O
skills	O
training	O
on	O
confidence	Mental
in	O
older	O
adults	O
who	O
are	O
inexperienced	O
wheelchair	O
users	O
.	O

DESIGN	O
Parallel	O
group	O
,	O
single-blind	O
randomized	O
controlled	O
trial	O
.	O

SETTING	O
Research	O
laboratory	O
in	O
a	O
rehabilitation	O
hospital	O
.	O

PARTICIPANTS	O
Participants	O
(	O
N=20	O
)	O
who	O
were	O
community-living	O
older	O
adults	O
at	O
least	O
65	O
years	O
old	O
(	O
mean	O
age	O
,	O
70y	O
)	O
,	O
50	O
%	O
women	O
,	O
and	O
who	O
had	O
no	O
experience	O
of	O
using	O
a	O
wheelchair	O
were	O
randomly	O
allocated	O
to	O
an	O
intervention	O
(	O
n=10	O
)	O
or	O
control	O
(	O
n=10	O
)	O
group	O
.	O

INTERVENTIONS	O
The	O
intervention	O
group	O
received	O
two	O
1-hour	O
training	O
sessions	O
that	O
followed	O
the	O
Wheelchair	O
Skills	O
Training	O
Program	O
(	O
WSTP	O
)	O
protocol	O
.	O

The	O
control	O
group	O
received	O
a	O
single	O
socialization	O
contact	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
The	O
Wheelchair	Mental
Use	Mental
Confidence	Mental
Scale-Manual	Mental
(	Mental
WheelCon-M	Mental
)	Mental
was	O
used	O
to	O
evaluate	Mental
confidence	Mental
with	O
using	O
a	O
manual	O
wheelchair	O
.	O

The	O
WheelCon-M	O
is	O
a	O
self-report	O
questionnaire	O
that	O
comprises	O
65	O
items	O
in	O
6	O
conceptual	O
areas	O
.	O

RESULTS	O
A	O
1-way	O
between-groups	O
analysis	O
of	O
covariance	O
revealed	O
a	O
significant	Mental
difference	Mental
in	O
postintervention	Others
WheelCon-M	Others
scores	Others
between	O
the	O
intervention	O
and	O
control	O
groups	O
(	O
F1,17=10.9	O
,	O
P=.004	O
)	O
after	O
controlling	O
for	O
baseline	O
WheelCon-M	O
scores	O
.	O

A	O
large	O
effect	Mental
size	Mental
was	O
also	O
observed	O
(	O
partial	O
?	O
(	O
2	O
)	O
=.39	O
)	O
.	O

Secondary	O
analyses	O
revealed	O
that	O
the	O
WSTP	O
had	O
greater	O
effects	O
on	O
confidence	O
in	O
areas	O
related	O
to	O
maneuvering	O
around	O
the	O
physical	O
environment	O
,	O
knowledge	O
and	O
problem	O
solving	O
,	O
advocacy	O
,	O
and	O
managing	O
emotions	O
than	O
in	O
areas	O
related	O
to	O
performing	O
activities	O
and	O
behaving	O
in	O
social	O
situations	O
.	O

CONCLUSION	O
Two	O
1-hour	O
WSTP	O
sessions	O
improve	O
confidence	O
with	O
using	O
a	O
manual	O
wheelchair	O
among	O
older	O
adults	O
who	O
are	O
inexperienced	O
wheelchair	O
users	O
.	O

Improved	O
local	O
control	O
of	O
invasive	O
bladder	O
cancer	O
by	O
concurrent	O
cisplatin	O
and	O
preoperative	O
or	O
definitive	O
radiation	O
.	O

The	O
National	O
Cancer	O
Institute	O
of	O
Canada	O
Clinical	O
Trials	O
Group	O
.	O

PURPOSE	O
A	O
prospective	O
randomized	O
trial	O
was	O
conducted	O
to	O
determine	O
whether	O
the	O
addition	O
of	O
concurrent	O
cisplatin	O
to	O
preoperative	O
or	O
definitive	O
radiation	O
therapy	O
in	O
patients	O
with	O
muscle-invasive	O
bladder	O
cancer	O
improved	O
local	Mortality
control	Mortality
or	Mortality
survival	Mortality
.	O

PATIENTS	O
AND	O
METHODS	O
Ninety-nine	O
eligible	O
patients	O
with	O
T2	O
to	O
T4b	O
transitional	O
cell	O
bladder	O
cancer	O
participated	O
,	O
64	O
%	O
with	O
cT3b	O
or	O
cT4	O
.	O

Patients	O
and	O
their	O
physicians	O
selected	O
either	O
definitive	O
radiotherapy	O
or	O
precystectomy	O
radiotherapy	O
;	O
patients	O
were	O
then	O
randomly	O
allocated	O
to	O
receive	O
intravenous	O
cisplatin	O
100	O
mg/m2	O
at	O
2-week	O
intervals	O
for	O
three	O
cycles	O
concurrent	O
with	O
pelvic	O
radiation	O
,	O
or	O
to	O
receive	O
radiation	O
without	O
chemotherapy	O
.	O

Patients	O
were	O
stratified	O
by	O
clinical	O
tumor	O
stage	O
and	O
by	O
radiation	O
plan	O
.	O

The	O
median	O
follow-up	O
duration	O
is	O
6.5	O
years	O
.	O

RESULTS	O
The	O
occurrence	Physical
of	Physical
distant	Physical
metastases	Physical
was	O
the	O
same	O
in	O
both	O
study	O
arms	O
.	O

However	O
,	O
25	O
of	O
48	O
control	O
patients	O
have	O
had	O
a	O
first	Physical
recurrence	Physical
in	O
the	O
pelvis	O
,	O
compared	O
with	O
15	O
of	O
51	O
cisplatin-treated	O
patients	O
(	O
P	O
=	O
.036	O
)	O
.	O

The	O
pelvic	Physical
relapse	Physical
rate	Physical
in	O
the	O
two	O
groups	O
was	O
significantly	O
reduced	O
by	O
concurrent	O
cisplatin	O
(	O
P	O
=	O
.038	O
,	O
log-rank	O
test	O
)	O
and	O
this	O
effect	O
was	O
preserved	O
in	O
a	O
stepwise	O
Cox	O
regression	O
model	O
of	O
prognostic	O
factors	O
(	O
hazards	O
ratio	O
,	O
0.50	O
;	O
90	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0.29	O
to	O
0.86	O
;	O
P	O
=	O
.036	O
)	O
.	O

The	O
hazard	Others
reduction	Others
was	O
similar	O
for	O
both	O
radiation	O
plans	O
.	O

Pretreatment	O
leukocytosis	O
and	O
high	O
clinical	O
stage	O
were	O
independent	O
adverse	O
factors	O
in	O
a	O
Cox	O
model	O
of	O
overall	Mortality
survival	Mortality
,	O
but	O
the	O
effect	Physical
of	O
cisplatin	O
was	O
not	O
significant	O
.	O

CONCLUSION	O
Concurrent	O
cisplatin	O
may	O
improve	O
pelvic	Physical
control	Physical
of	O
locally	O
advanced	O
bladder	O
cancer	O
with	O
preoperative	O
or	O
definitive	O
radiation	O
,	O
but	O
has	O
not	O
been	O
shown	O
to	O
improve	O
overall	Mortality
survival	Mortality
.	O

The	O
use	O
of	O
concurrent	O
cisplatin	O
had	O
no	O
detectable	O
effect	Physical
on	O
distant	O
metastases	O
.	O

Pilot	O
study	O
of	O
the	O
effectiveness	O
of	O
weighted	O
vests	O
.	O

OBJECTIVE	O
In	O
this	O
pilot	O
study	O
,	O
we	O
determined	O
the	O
effectiveness	O
of	O
a	O
weighted	O
vest	O
on	O
attention	O
to	O
task	O
for	O
second-grade	O
general	O
education	O
students	O
with	O
difficulty	O
attending	O
.	O

METHOD	O
We	O
used	O
an	O
intervention	O
and	O
a	O
control	O
group	O
and	O
an	O
ABA	O
design	O
to	O
compare	O
participants	O
'	O
percentage	O
of	O
time	O
on	O
task	O
with	O
and	O
without	O
a	O
vest	O
.	O

Ten	O
participants	O
from	O
nine	O
elementary	O
schools	O
in	O
a	O
suburban	O
Texas	O
school	O
district	O
were	O
randomly	O
assigned	O
to	O
an	O
intervention	O
or	O
a	O
control	O
group	O
.	O

Control	O
group	O
participants	O
wore	O
a	O
nonweighted	O
vest	O
.	O

Participants	O
,	O
classroom	O
teachers	O
,	O
and	O
research	O
assistants	O
who	O
coded	O
the	O
data	O
were	O
blind	O
as	O
to	O
the	O
group	O
to	O
which	O
the	O
participants	O
were	O
assigned	O
.	O

RESULTS	O
A	O
repeated	O
measures	O
analysis	O
of	O
variance	O
indicated	O
no	O
significant	O
differences	O
between	O
groups	O
or	O
between	O
baseline	O
,	O
intervention	O
,	O
and	O
withdrawal	O
conditions	O
.	O

CONCLUSION	O
Our	O
results	O
indicated	O
that	O
the	O
weighted	O
vests	O
were	O
not	O
effective	O
in	O
increasing	O
time	Mental
on	Mental
task	Mental
.	O

These	O
results	O
should	O
be	O
generalized	O
cautiously	O
owing	O
to	O
the	O
small	O
sample	O
size	O
and	O
participant	O
selection	O
process	O
.	O

Rizatriptan	O
5	O
mg	O
for	O
the	O
acute	O
treatment	O
of	O
migraine	Physical
in	O
adolescents	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
tolerability	Others
and	Others
efficacy	Others
of	O
rizatriptan	O
5	O
mg	O
in	O
adolescent	O
migraineurs	O
.	O

METHODS	O
Randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

Patients	O
aged	O
12	O
to	O
17	O
years	O
received	O
rizatriptan	O
5	O
mg	O
(	O
n	O
=	O
149	O
)	O
or	O
placebo	O
(	O
n	O
=	O
147	O
)	O
for	O
a	O
moderate	O
or	O
severe	O
headache	O
and	O
for	O
up	O
to	O
two	O
recurrences	O
.	O

Headache	Physical
severity	Physical
,	O
presence	Physical
or	Physical
absence	Physical
of	Physical
associated	Physical
symptoms	Physical
,	O
and	O
functional	Physical
disability	Physical
were	O
assessed	O
over	O
a	O
4-hour	O
postdose	O
period	O
,	O
and	O
any	O
adverse	Adverseeffect
events	Adverseeffect
were	O
recorded	O
.	O

The	O
primary	O
efficacy	O
measure	O
was	O
pain-free	Pain
status	Pain
at	Pain
2	Pain
hours	Pain
postdose	Pain
.	O

RESULTS	O
Rizatriptan	O
5	O
mg	O
was	O
well	O
tolerated	O
.	O

The	O
most	O
commonly	O
reported	O
adverse	Adverseeffect
events	Adverseeffect
(	O
all	O
with	O
incidence	O
of	O
5	O
%	O
or	O
less	O
)	O
among	O
patients	O
receiving	O
rizatriptan	O
were	O
dry	Adverseeffect
mouth	Adverseeffect
,	Adverseeffect
dizziness	Adverseeffect
,	Adverseeffect
asthenia/fatigue	Adverseeffect
,	Adverseeffect
nausea	Adverseeffect
,	Adverseeffect
and	Adverseeffect
somnolence	Adverseeffect
.	O

The	O
percentage	O
of	O
patients	O
pain-free	Pain
at	O
2	O
hours	O
was	O
32	O
%	O
for	O
rizatriptan	O
5	O
mg	O
versus	O
28	O
%	O
for	O
placebo	O
(	O
P=.474	O
)	O
.	O

The	O
percentage	Pain
of	Pain
patients	Pain
with	Pain
pain	Pain
relief	Pain
(	O
reduction	O
of	O
predose	Pain
pain	Pain
intensity	Pain
to	O
mild	O
or	O
none	O
)	O
at	O
2	O
hours	O
was	O
66	O
%	O
for	O
rizatriptan	O
versus	O
56	O
%	O
for	O
placebo	O
(	O
P=.079	O
)	O
.	O

Placebo	Physical
response	Physical
rates	Physical
were	O
higher	O
than	O
those	O
typically	O
observed	O
in	O
previous	O
studies	O
of	O
rizatriptan	O
in	O
adults	O
.	O

Compared	O
with	O
placebo	O
,	O
rizatriptan	O
significantly	O
improved	O
functional	Physical
disability	Physical
at	O
1.5	O
and	O
2	O
hours	O
,	O
and	O
nausea	Adverseeffect
at	O
1	O
and	O
1.5	O
hours	O
.	O

Post	O
hoc	O
analysis	O
showed	O
a	O
significant	O
benefit	O
of	O
rizatriptan	O
versus	O
placebo	O
in	O
the	O
percentage	O
of	O
patients	O
who	O
had	O
pain	Pain
relief	Pain
when	O
their	O
migraine	O
attacks	O
were	O
treated	O
on	O
weekends	O
(	O
65	O
%	O
versus	O
36	O
%	O
,	O
P=.046	O
)	O
compared	O
with	O
weekdays	O
(	O
66	O
%	O
versus	O
61	O
%	O
,	O
P=.365	O
)	O
,	O
and	O
the	O
weekend	O
placebo	O
response	Physical
rate	Physical
was	O
similar	O
to	O
that	O
seen	O
in	O
adults	O
.	O

CONCLUSIONS	O
Rizatriptan	O
5	O
mg	O
was	O
well	O
tolerated	Others
and	Others
effective	Others
on	O
some	O
measures	O
when	O
used	O
in	O
adolescents	O
for	O
the	O
treatment	O
of	O
a	O
migraine	O
attack	O
.	O

Vilazodone	O
lacks	O
proarrhythmogenic	O
potential	O
in	O
healthy	O
participants	O
:	O
a	O
thorough	O
ECG	O
study	O
.	O

OBJECTIVE	O
Vilazodone	O
is	O
a	O
potent	O
serotonin	O
reuptake	O
inhibitor	O
and	O
5-HT1A	O
receptor	O
partial	O
agonist	O
approved	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adults	O
.	O

The	O
effect	O
of	O
clinical	O
and	O
supratherapeutic	O
doses	O
of	O
vilazodone	O
on	O
cardiac	O
repolarization	O
was	O
determined	O
in	O
healthy	O
volunteers	O
.	O

METHODS	O
In	O
this	O
Phase	O
1	O
,	O
randomized	O
,	O
doubleblind	O
,	O
placebo-	O
and	O
active-controlled	O
,	O
3-arm	O
,	O
parallel	O
,	O
single-center	O
study	O
,	O
healthy	O
subjects	O
received	O
placebo	O
;	O
moxifloxacin	O
400	O
mg	O
;	O
or	O
vilazodone	O
(	O
sequentially	O
escalated	O
every	O
3	O
days	O
)	O
10	O
,	O
20	O
,	O
40	O
,	O
60	O
,	O
and	O
80	O
mg/day	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
time-matched	O
change	O
from	O
baseline	O
in	O
the	O
QT	Physical
interval	Physical
corrected	Physical
for	Physical
heart	Physical
rate	Physical
(	Physical
QTc	Physical
)	Physical
using	O
an	O
individual	O
correction	O
method	O
(	O
QTcI	O
)	O
.	O

RESULTS	O
Placebo-corrected	O
time-matched	O
analysis	O
of	O
the	O
QTcI	Physical
duration	Physical
for	O
the	O
vilazodone	O
treatment	O
effect	O
indicated	O
that	O
no	O
vilazodone	O
dose	O
had	O
an	O
upper	O
bound	O
that	O
approached	O
or	O
exceeded	O
10	O
ms	O
,	O
demonstrating	O
no	O
signal	O
for	O
a	O
significant	O
vilazodone	O
effect	O
on	O
cardiac	Physical
repolarization	Physical
.	Physical

Vilazodone	O
had	O
no	O
significant	O
effect	O
on	O
heart	Physical
rate	Physical
,	O
PR	Physical
,	O
or	O
QRS	Physical
interval	Physical
duration	Physical
.	Physical

The	O
pharmacokinetic/pharmacodynamic	O
model	O
showed	O
that	O
the	O
QTcI	Physical
slope	O
for	O
vilazodone	O
was	O
not	O
different	O
from	O
0.0	O
and	O
that	O
the	O
predicted	O
increase	O
from	O
baseline	O
in	O
the	O
QTc	Physical
at	Physical
Cmax	Physical
for	O
the	O
highest	O
therapeutic	O
dose	O
(	O
156	O
ng/ml	O
after	O
40	O
mg/day	O
)	O
was	O
<	O
1	O
ms	O
.	O

The	O
incidence	O
of	O
adverse	Adverseeffect
events	Adverseeffect
(	Adverseeffect
AEs	Adverseeffect
)	Adverseeffect
was	O
higher	O
in	O
the	O
vilazodone	O
group	O
(	O
57.6	O
%	O
)	O
than	O
in	O
the	O
moxifloxacin	O
(	O
37.0	O
%	O
)	O
and	O
placebo	O
(	O
35.6	O
%	O
)	O
groups	O
,	O
though	O
AEs	Adverseeffect
were	O
generally	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resulted	O
in	O
few	O
discontinuations	O
.	O

CONCLUSIONS	O
Vilazodone	O
had	O
no	O
significant	O
effect	O
on	O
cardiac	Physical
repolarization	Physical
,	O
heart	Physical
rate	Physical
,	O
PR	Physical
or	O
QRS	Physical
interval	Physical
duration	Physical
,	O
or	O
ECG	Physical
morphology	Physical
in	O
healthy	O
adult	O
participants	O
.	O

Bayesian	O
adaptive	O
trials	O
offer	O
advantages	O
in	O
comparative	O
effectiveness	O
trials	O
:	O
an	O
example	O
in	O
status	O
epilepticus	O
.	O

OBJECTIVE	O
We	O
present	O
a	O
novel	O
Bayesian	O
adaptive	O
comparative	O
effectiveness	O
trial	O
comparing	O
three	O
treatments	O
for	O
status	O
epilepticus	O
that	O
uses	O
adaptive	O
randomization	O
with	O
potential	O
early	O
stopping	O
.	O

STUDY	O
DESIGN	O
AND	O
SETTING	O
The	O
trial	O
will	O
enroll	O
720	O
unique	O
patients	O
in	O
emergency	O
departments	O
and	O
uses	O
a	O
Bayesian	O
adaptive	O
design	O
.	O

RESULTS	O
The	O
trial	O
design	O
is	O
compared	O
to	O
a	O
trial	O
without	O
adaptive	O
randomization	O
and	O
produces	O
an	O
efficient	O
trial	O
in	O
which	O
a	O
higher	O
proportion	O
of	O
patients	O
are	O
likely	O
to	O
be	O
randomized	O
to	O
the	O
most	O
effective	O
treatment	O
arm	O
while	O
generally	O
using	O
fewer	O
total	O
patients	O
and	O
offers	O
higher	O
power	O
than	O
an	O
analogous	O
trial	O
with	O
fixed	O
randomization	O
when	O
identifying	O
a	O
superior	O
treatment	O
.	O

CONCLUSION	O
When	O
one	O
treatment	O
is	O
superior	O
to	O
the	O
other	O
two	O
,	O
the	O
trial	O
design	O
provides	O
better	O
patient	Others
care	Others
,	O
higher	Others
power	Others
,	O
and	O
a	O
lower	Others
expected	Others
sample	Others
size	Others
.	O

Automatic	O
detection	O
of	O
red	O
lesions	O
in	O
digital	O
color	O
fundus	O
photographs	O
.	O

The	O
robust	O
detection	O
of	O
red	Others
lesions	Others
in	O
digital	O
color	O
fundus	O
photographs	O
is	O
a	O
critical	O
step	O
in	O
the	O
development	O
of	O
automated	O
screening	O
systems	O
for	O
diabetic	O
retinopathy	O
.	O

In	O
this	O
paper	O
,	O
a	O
novel	O
red	O
lesion	O
detection	O
method	O
is	O
presented	O
based	O
on	O
a	O
hybrid	O
approach	O
,	O
combining	O
prior	O
works	O
by	O
Spencer	O
et	O
al	O
.	O

(	O
1996	O
)	O
and	O
Frame	O
et	O
al	O
.	O

(	O
1998	O
)	O
with	O
two	O
important	O
new	O
contributions	O
.	O

The	O
first	O
contribution	O
is	O
a	O
new	O
red	O
lesion	O
candidate	O
detection	O
system	O
based	O
on	O
pixel	O
classification	O
.	O

Using	O
this	O
technique	O
,	O
vasculature	Others
and	Others
red	Others
lesions	Others
are	O
separated	O
from	O
the	O
background	O
of	O
the	O
image	O
.	O

After	O
removal	O
of	O
the	O
connected	O
vasculature	O
the	O
remaining	O
objects	O
are	O
considered	O
possible	O
red	O
lesions	O
.	O

Second	O
,	O
an	O
extensive	O
number	O
of	O
new	O
features	O
are	O
added	O
to	O
those	O
proposed	O
by	O
Spencer-Frame	O
.	O

The	O
detected	O
candidate	O
objects	O
are	O
classified	O
using	O
all	O
features	O
and	O
a	O
k-nearest	O
neighbor	O
classifier	O
.	O

An	O
extensive	O
evaluation	O
was	O
performed	O
on	O
a	O
test	O
set	O
composed	O
of	O
images	O
representative	O
of	O
those	O
normally	O
found	O
in	O
a	O
screening	O
set	O
.	O

When	O
determining	O
whether	O
an	O
image	O
contains	O
red	Physical
lesions	Physical
the	O
system	O
achieves	O
a	O
sensitivity	Others
of	O
100	O
%	O
at	O
a	O
specificity	O
of	O
87	O
%	O
.	O

The	O
method	O
is	O
compared	O
with	O
several	O
different	O
automatic	O
systems	O
and	O
is	O
shown	O
to	O
outperform	O
them	O
all	O
.	O

Performance	Others
is	O
close	O
to	O
that	O
of	O
a	O
human	O
expert	O
examining	O
the	O
images	O
for	O
the	O
presence	O
of	O
red	O
lesions	O
.	O

Efficacy	Others
of	O
azithromycin	O
for	O
the	O
treatment	O
of	O
feline	O
chlamydophilosis	O
.	O

The	O
current	O
recommended	O
treatment	O
for	O
feline	O
chlamydophilosis	O
involves	O
daily	O
oral	O
administration	O
of	O
antimicrobials	O
to	O
all	O
cats	O
within	O
an	O
affected	O
group	O
for	O
a	O
prolonged	O
period	O
of	O
time	O
(	O
4-6	O
weeks	O
)	O
.	O

Not	O
surprisingly	O
,	O
owner	O
compliance	O
can	O
be	O
poor	O
resulting	O
in	O
apparent	O
treatment	O
failure	O
.	O

Recent	O
anecdotal	O
evidence	O
,	O
supported	O
by	O
its	O
efficacy	Others
in	O
the	O
treatment	O
of	O
Chlamydia	O
trachomatis	O
infection	O
in	O
humans	O
,	O
has	O
suggested	O
that	O
azithromycin	O
may	O
offer	O
an	O
alternative	O
by	O
allowing	O
less	O
frequent	O
dosing	O
for	O
a	O
shorter	O
duration	O
.	O

A	O
clinical	O
trial	O
was	O
designed	O
to	O
evaluate	O
the	O
efficacy	Others
of	O
azithromycin	O
for	O
the	O
treatment	O
of	O
chlamydia	O
(	O
Chlamydophila	O
felis	O
)	O
infection	O
in	O
cats	O
.	O

Whilst	O
azithromycin	O
,	O
given	O
at	O
10-15	O
mg/kg	O
daily	O
for	O
3	O
days	O
and	O
then	O
twice	O
weekly	O
,	O
provided	O
a	O
similar	Others
,	Others
rapid	Others
resolution	Others
of	Others
clinical	Others
signs	Others
and	Others
negative	Others
isolation	Others
scores	Others
as	O
doxycycline	O
,	O
C	O
felis	O
was	O
re-isolated	O
in	O
four	O
out	O
of	O
the	O
five	O
cats	O
treated	O
.	O

Furthermore	O
,	O
even	O
daily	O
administration	O
of	O
azithromycin	O
to	O
chronically	O
infected	O
cats	O
was	O
ineffective	Physical
in	Physical
clearing	Physical
infection	Physical
.	Physical

The	O
azithromycin	O
protocols	O
used	O
here	O
were	O
therefore	O
found	O
to	O
be	O
unsuccessful	Physical
in	Physical
eliminating	Physical
the	Physical
carriage	Physical
of	Physical
this	Physical
strain	Physical
of	Physical
C	Physical
felis	Physical
.	Physical

Untoward	O
effects	O
of	O
fenfluramine	O
in	O
autistic	O
children	O
.	O

Several	O
recent	O
studies	O
have	O
described	O
the	O
benefits	O
of	O
fenfluramine	O
for	O
the	O
symptomatic	O
treatment	O
of	O
infantile	O
autism	O
.	O

No	O
large	O
surveys	O
of	O
side	O
effects	O
of	O
this	O
drug	O
have	O
been	O
reported	O
in	O
autistic	O
children	O
.	O

To	O
evaluate	O
the	O
untoward	O
effects	O
of	O
fenfluramine	O
in	O
children	O
with	O
autism	O
,	O
12	O
subjects	O
were	O
systematically	O
studied	O
.	O

Medication	O
was	O
administered	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
cross-over	O
study	O
.	O

Parents	O
were	O
trained	O
in	O
monitoring	O
untoward	O
effects	O
.	O

These	O
observations	O
were	O
compiled	O
in	O
detailed	O
daily	O
notes	O
.	O

In	O
addition	O
,	O
four	O
cases	O
describing	O
unusual	O
effects	O
found	O
in	O
a	O
sample	O
of	O
170	O
patients	O
treated	O
with	O
fenfluramine	O
are	O
also	O
reported	O
.	O

In	O
the	O
initial	O
2	O
weeks	O
of	O
active	O
drug	O
listlessness	O
,	O
food	Mental
refusal	Mental
,	O
and	O
stomach	Physical
upset	Physical
were	O
frequently	O
seen	O
.	O

A	O
different	O
pattern	O
of	O
untoward	Adverseeffect
effects	Adverseeffect
was	O
seen	O
in	O
the	O
final	O
14	O
weeks	O
of	O
treatment	O
.	O

Irritability	Mental
,	Mental
agitation	Mental
,	Mental
and	Mental
crying	Mental
along	Mental
with	Mental
continued	Mental
food	Mental
refusal	Mental
were	O
noted	O
.	O

The	O
subjects	O
lost	O
2.1	O
%	O
of	O
body	Physical
weight	Physical
during	O
active	O
drug	O
phase	O
,	O
but	O
there	O
was	O
a	O
rebound	Physical
weight	Physical
gain	Physical
during	O
the	O
subsequent	O
placebo	O
phase	O
.	O

A	O
thorough	O
understanding	O
of	O
fenfluramine	O
's	O
side	O
effects	O
and	O
adverse	O
reactions	O
is	O
necessary	O
so	O
as	O
to	O
differentiate	O
them	O
from	O
the	O
multiple	O
symptoms	O
inherent	O
in	O
the	O
syndrome	O
of	O
autism	O
.	O

Baseline	O
characteristics	O
of	O
participants	O
in	O
the	O
Appropriate	O
Blood	O
Pressure	O
Control	O
in	O
Diabetes	O
trial	O
.	O

The	O
ABCD	O
(	O
Appropriate	O
Blood	O
Pressure	O
Control	O
in	O
Diabetes	O
)	O
trial	O
is	O
a	O
large	O
,	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
intensive	O
with	O
moderate	O
blood	O
pressure	O
control	O
on	O
the	O
prevention	O
and	O
progression	O
of	O
diabetic	O
nephropathy	O
,	O
retinopathy	O
,	O
cardiovascular	O
disease	O
,	O
and	O
neuropathy	O
in	O
non-insulin-dependent	O
diabetes	O
(	O
NIDDM	O
)	O
.	O

The	O
secondary	O
objective	O
is	O
to	O
determine	O
equivalency	O
of	O
the	O
effects	O
of	O
a	O
calcium	O
channel	O
blocker	O
(	O
nisoldipine	O
)	O
and	O
of	O
an	O
angiotensin-converting	O
enzyme	O
inhibitor	O
(	O
enalapril	O
)	O
as	O
a	O
first-line	O
antihypertensive	O
agent	O
in	O
the	O
prevention	O
and/or	O
progression	O
of	O
these	O
diabetic	O
vascular	O
complications	O
.	O

The	O
study	O
consists	O
of	O
two	O
study	O
populations	O
:	O
a	O
hypertensive	O
one	O
(	Physical
diastolic	Physical
blood	Physical
pressure	Physical
of	O
>	O
or	O
=	O
90.0	O
mm	O
Hg	O
at	O
the	O
time	O
of	O
randomization	O
)	O
and	O
a	O
normotensive	O
one	O
(	Physical
diastolic	Physical
blood	Physical
pressure	Physical
of	O
80.0-89.0	O
mm	O
Hg	O
at	O
the	O
time	O
of	O
randomization	O
)	O
.	O

A	O
total	O
of	O
950	O
men	O
and	O
women	O
aged	O
40-74	O
years	O
were	O
randomized	O
and	O
are	O
being	O
followed	O
for	O
5	O
years	O
at	O
a	O
single	O
center	O
.	O

There	O
were	O
470	O
randomized	O
participants	O
in	O
the	O
hypertensive	O
population	O
and	O
480	O
randomized	O
participants	O
in	O
the	O
normotensive	O
population	O
.	O

This	O
report	O
summarizes	O
the	O
demographic	Physical
,	Physical
biochemical	Physical
,	O
and	O
clinical	Physical
characteristics	Physical
of	O
the	O
randomized	O
patients	O
at	O
the	O
time	O
of	O
entry	O
into	O
the	O
trial	O
and	O
evaluates	O
the	O
balance	O
between	O
the	O
treatment	O
groups	O
within	O
each	O
population	O
.	O

Japan	O
useful	O
medication	O
program	O
for	O
schizophrenia	O
(	O
JUMPs	O
)	O
-long-term	O
study	O
on	O
discontinuation	O
rate	O
,	O
resolution	O
and	O
remission	O
,	O
and	O
improvement	O
in	O
social	O
functioning	O
rate	O
associated	O
with	O
atypical	O
antipsychotic	O
medications	O
in	O
patients	O
with	O
schizophrenia	O
.	O

BACKGROUND	O
It	O
is	O
desirable	O
to	O
establish	O
evidence	O
for	O
the	O
selection	O
of	O
antipsychotics	O
from	O
the	O
viewpoint	O
of	O
recovery	O
of	O
social	O
activity	O
in	O
individual	O
patient	O
with	O
schizophrenia	O
receiving	O
medication	O
.	O

From	O
this	O
perspective	O
,	O
awareness	O
of	O
the	O
importance	O
of	O
studies	O
about	O
drug	O
effectiveness	O
on	O
treatment	O
discontinuation	O
rate	O
,	O
remission	O
rate	O
,	O
and	O
improvement	O
in	O
QOL	O
has	O
grown	O
recently	O
.	O

In	O
Western	O
countries	O
,	O
numerous	O
reports	O
are	O
available	O
in	O
effectiveness	O
studies	O
,	O
which	O
are	O
related	O
to	O
olanzapine	O
and	O
risperidone	O
primarily	O
,	O
whereas	O
evidence	O
for	O
other	O
second-generation	O
antipsychotics	O
(	O
SGAs	O
)	O
is	O
poor	O
.	O

In	O
Japan	O
,	O
no	O
effectiveness	O
study	O
has	O
been	O
reported	O
:	O
thus	O
,	O
it	O
is	O
desirable	O
to	O
collect	O
data	O
that	O
will	O
serve	O
as	O
evidence	O
for	O
selection	O
of	O
the	O
3	O
SGAs	O
approved	O
after	O
olanzapine	O
.	O

METHODS	O
The	O
present	O
study	O
was	O
a	O
long-term	O
effectiveness	O
study	O
under	O
healthcare	O
setting	O
in	O
Japan	O
.	O

It	O
was	O
designed	O
as	O
an	O
open-label	O
,	O
multicenter	O
,	O
randomized	O
,	O
comparative	O
study	O
involving	O
104-week	O
oral	O
treatment	O
with	O
1	O
of	O
the	O
3	O
drugs	O
(	O
aripiprazole	O
,	O
blonanserin	O
,	O
and	O
paliperidone	O
)	O
in	O
patients	O
with	O
schizophrenia	O
aged	O
20	O
years	O
or	O
over	O
who	O
required	O
antipsychotic	O
medication	O
or	O
switching	O
of	O
the	O
current	O
medication	O
to	O
others	O
for	O
reasons	O
such	O
as	O
lack	O
of	O
efficacy	O
and	O
intolerability	O
.	O

The	O
primary	O
endpoint	O
is	O
treatment	Mental
discontinuation	Mental
rate	Mental
for	Mental
any	Mental
causes	Mental
.	O

The	O
secondary	O
endpoints	O
include	O
remission	Physical
rate	Physical
,	O
improvement	Mental
of	Mental
social	Mental
activity	Mental
,	O
alleviation	Physical
,	O
aggravation	Mental
or	Mental
recurrence	Mental
of	Mental
psychiatric	Mental
symptoms	Mental
,	O
and	O
safety	Others
.	O

The	O
target	O
number	O
of	O
subjects	O
was	O
set	O
at	O
300	O
.	O

DISCUSSION	O
Because	O
this	O
study	O
is	O
expected	O
to	O
yield	O
evidence	O
regarding	O
the	O
selection	O
of	O
antipsychotics	O
for	O
facilitating	O
the	O
recovery	O
of	O
social	O
activity	O
in	O
patients	O
with	O
schizophrenia	O
,	O
it	O
is	O
considered	O
highly	O
valuable	O
to	O
perform	O
this	O
effectiveness	O
study	O
under	O
ordinary	O
healthcare	O
setting	O
in	O
Japan	O
.	O

TRIAL	O
REGISTRATION	O
UMIN	O
Clinical	O
Trials	O
Registry	O
000007942	O
.	O

Chronology	O
of	O
panic	O
and	O
avoidance	O
,	O
age	O
of	O
onset	O
in	O
panic	O
disorder	O
,	O
and	O
prediction	O
of	O
treatment	O
response	O
.	O

A	O
report	O
from	O
the	O
Cross-National	O
Collaborative	O
Panic	O
Study	O
.	O

The	O
relevance	O
of	O
the	O
chronology	O
between	O
panic	O
disorder	O
and	O
avoidance	O
behavior	O
and	O
of	O
an	O
early	O
,	O
medium	O
or	O
late	O
onset	O
of	O
panic	O
disorder	O
was	O
tested	O
.	O

Groups	O
from	O
the	O
sample	O
of	O
the	O
cross-national	O
collaborative	O
panic	O
study	O
(	O
CNCPS	O
)	O
were	O
compared	O
for	O
differences	O
in	O
basic	O
characteristics	O
and	O
for	O
the	O
ability	O
to	O
predict	O
treatment	O
response	O
.	O

Patients	O
who	O
developed	O
avoidance	Mental
behavior	Mental
before	O
the	O
full	O
syndrome	O
of	O
panic	Mental
disorder	Mental
had	O
less	O
often	O
a	O
full	O
agoraphobia	Mental
but	O
were	O
not	O
different	O
in	O
their	O
response	O
to	O
treatment	O
.	O

Patients	O
with	O
an	O
early	Mental
onset	Mental
of	Mental
panic	Mental
disorder	Mental
suffered	O
more	O
often	O
from	O
agoraphobia	Mental
.	O

The	O
treatment	Others
response	Others
was	O
similar	Others
in	O
the	O
groups	O
with	O
early	Mental
,	Mental
medium	Mental
or	Mental
late	Mental
onset	Mental
of	Mental
panic	Mental
disorder	Mental
.	O

Neither	O
the	O
chronology	O
between	O
panic	Mental
disorder	Mental
and	Mental
avoidance	Mental
behavior	Mental
nor	O
the	O
age	Mental
of	Mental
onset	Mental
of	Mental
panic	Mental
disorder	Mental
predicted	O
outcome	O
in	O
short-term	O
treatment	O
with	O
alprazolam	O
or	O
imipramine	O
.	O

The	O
effect	O
of	O
venlafaxine	O
on	O
ongoing	O
and	O
experimentally	O
induced	O
pain	O
in	O
neuropathic	O
pain	O
patients	O
:	O
a	O
double	O
blind	O
,	O
placebo	O
controlled	O
study	O
.	O

BACKGROUND	O
AND	O
AIM	O
The	O
aim	O
of	O
this	O
randomized	O
double	O
blind	O
placebo	O
controlled	O
study	O
was	O
to	O
investigate	O
the	O
effectiveness	O
and	O
the	O
safety	O
of	O
venlafaxine	O
XR	O
75	O
and	O
150	O
mg	O
on	O
ongoing	O
pain	O
and	O
on	O
quantitative	O
sensory	O
tests	O
in	O
60	O
patients	O
with	O
neuropathic	O
pain	O
for	O
8	O
weeks	O
.	O

METHODS	O
Evaluation	O
parameters	O
consisted	O
of	O
ongoing	O
pain	O
intensity	O
(	O
VAS	O
)	O
,	O
patient	O
satisfaction	O
,	O
side	O
effects	O
,	O
global	O
efficacy	O
and	O
tolerance	O
.	O

Quantitative	O
sensory	O
measurements	O
taken	O
from	O
the	O
affected	O
area	O
before	O
and	O
after	O
the	O
drug	O
treatment	O
included	O
pin-prick	O
hyperalgesia	O
,	O
allodynia	O
,	O
detection	O
and	O
pain	O
thresholds	O
to	O
electrical	O
and	O
heat	O
stimuli	O
,	O
temporal	O
summation	O
of	O
repetitive	O
electrical	O
and	O
heat	O
stimuli	O
.	O

RESULTS	O
A	O
total	O
of	O
55	O
patients	O
completed	O
the	O
study	O
.	O

VAS	Pain
scores	Pain
decreased	O
significantly	O
compared	O
to	O
the	O
baseline	O
measurements	O
in	O
all	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
regarding	O
pain	Pain
intensity	Pain
and	Pain
escape	Pain
medication	Pain
.	Pain

The	O
areas	Physical
of	Physical
allodynia	Physical
and	Physical
pin-prick	Physical
hyperalgesia	Physical
decreased	O
significantly	O
in	O
venlafaxine	O
groups	O
compared	O
to	O
the	O
placebo	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
regarding	O
the	O
detection	O
thresholds	O
(	O
electrical	O
and	O
heat	O
)	O
.	O

The	O
pain	Pain
threshold	Pain
and	O
the	O
summation	Others
threshold	Others
to	Others
electrical	Others
stimuli	Others
and	Physical
the	Physical
summation	Others
threshold	Others
to	Others
heat	Others
stimuli	Others
increased	O
significantly	O
following	O
treatment	O
in	O
both	O
venlafaxine	O
groups	O
.	O

In	O
addition	O
,	O
the	O
degree	Physical
of	Physical
the	Physical
temporal	Physical
summation	Physical
to	Physical
electrical	Physical
and	Physical
heat	Physical
stimuli	Physical
decreased	O
significantly	O
following	O
treatment	O
in	O
both	O
venlafaxine	O
groups	O
compared	O
to	O
the	O
placebo	O
.	O

CONCLUSION	O
The	O
study	O
showed	O
significant	O
effect	O
of	O
venlafaxine	O
in	O
the	O
manifestations	O
of	O
hyperalgesia	O
and	O
temporal	O
summation	O
,	O
but	O
not	O
on	O
the	O
ongoing	O
pain	O
intensity	O
.	O

Furthermore	O
,	O
the	O
quantitative	O
sensory	O
tests	O
provided	O
complementing	O
information	O
to	O
the	O
clinical	O
measures	O
.	O

Nitrous	O
oxide	O
does	O
not	O
increase	O
the	O
incidence	O
of	O
nausea	O
and	O
vomiting	O
after	O
isoflurane	O
anesthesia	O
.	O

A	O
total	O
of	O
110	O
patients	O
undergoing	O
elective	O
abdominal	O
hysterectomy	O
were	O
anesthetized	O
in	O
random	O
order	O
with	O
either	O
isoflurane	O
in	O
nitrous	O
oxide	O
and	O
oxygen	O
or	O
isoflurane	O
in	O
air	O
and	O
oxygen	O
.	O

Fentanyl	O
was	O
used	O
as	O
an	O
adjunct	O
to	O
isoflurane	O
in	O
all	O
patients	O
,	O
0.05	O
mg	O
every	O
45	O
min	O
.	O

No	O
difference	O
was	O
found	O
between	O
the	O
two	O
anesthetic	O
techniques	O
in	O
the	O
incidence	Adverseeffect
of	Adverseeffect
nausea	Adverseeffect
,	Adverseeffect
vomiting	Adverseeffect
,	Adverseeffect
or	Adverseeffect
both	Adverseeffect
during	O
the	O
first	O
24	O
hr	O
after	O
operation	O
.	O

The	O
overall	O
incidence	Adverseeffect
was	O
62	O
and	O
67	O
%	O
for	O
air-O2	O
and	O
N2O-O2	O
groups	O
,	O
respectively	O
.	O

Patients	O
who	O
had	O
had	O
nausea	Adverseeffect
or	Adverseeffect
vomiting	Adverseeffect
after	O
previous	O
anesthetics	O
had	O
nausea	Adverseeffect
or	Adverseeffect
vomiting	Adverseeffect
significantly	O
more	O
frequently	O
than	O
patients	O
who	O
did	O
not	O
.	O

It	O
is	O
concluded	O
that	O
nitrous	O
oxide	O
does	O
not	O
contribute	O
to	O
the	O
occurrence	O
of	O
nausea	Adverseeffect
or	Adverseeffect
vomiting	Adverseeffect
after	O
isoflurane	O
anesthesia	O
for	O
gynecologic	O
laparotomies	O
.	O

Effects	O
of	O
nifedipine	O
on	O
gastric	Physical
acid	Physical
secretion	Physical
and	O
gastrin	Physical
release	Physical
in	O
man	O
.	O

As	O
calcium	O
is	O
important	O
in	O
the	O
regulation	O
of	O
gastric	O
acid	O
secretion	O
and	O
gastrin	O
release	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
calcium	O
antagonist	O
nifedipine	O
on	O
these	O
processes	O
in	O
man	O
.	O

Nifedipine	O
30	O
mg	O
orally	O
inhibited	O
basal	O
acid	O
output	O
by	O
37	O
%	O
(	O
p	O
less	O
than	O
0.025	O
)	O
and	O
that	O
stimulated	O
by	O
low	O
infusion	O
rates	O
of	O
pentagastrin	O
--	O
that	O
is	O
,	O
0.031	O
and	O
0.062	O
microgram/kg/h	O
by	O
44	O
%	O
(	O
p	O
=	O
0.05	O
)	O
and	O
39	O
%	O
(	O
p	O
less	O
than	O
0.02	O
)	O
respectively	O
.	O

On	O
increasing	O
the	O
pentagastrin	O
infusion	O
rate	O
the	O
inhibition	O
was	O
surmounted	O
suggesting	O
it	O
was	O
competitive	O
in	O
type	O
.	O

Nifedipine	O
did	O
not	O
affect	O
basal	Physical
or	Physical
Oxo	Physical
meal	Physical
stimulated	Physical
gastrin	Physical
concentrations	Physical
in	O
normal	O
volunteers	O
nor	O
did	O
it	O
affect	O
resting	Physical
serum	Physical
gastrin	Physical
or	O
calcium	Physical
stimulated	Physical
increase	Physical
in	Physical
gastrin	Physical
in	O
a	O
single	O
patient	O
with	O
Zollinger-Ellison	O
syndrome	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
transmembrane	O
flux	O
of	O
calcium	O
ions	O
being	O
involved	O
in	O
basal	O
and	O
pentagastrin	O
stimulated	O
acid	O
secretion	O
in	O
man	O
.	O

Midlife	O
women	O
online	O
:	O
evaluation	O
of	O
an	O
internet-based	O
program	O
to	O
prevent	O
unintended	O
pregnancy	O
&	O
STIs	O
.	O

BACKGROUND	O
Midlife	O
women	O
are	O
an	O
underserved	O
population	O
in	O
the	O
areas	O
of	O
unintended	O
pregnancy	O
and	O
STI	O
prevention	O
yet	O
remain	O
at	O
risk	O
for	O
both	O
health	O
conditions	O
.	O

METHODS	O
A	O
randomized	O
controlled	O
trial	O
of	O
an	O
Internet-based	O
multimedia	O
program	O
to	O
reduce	O
risk	O
of	O
unintended	O
pregnancy	O
and	O
STIs	O
among	O
midlife	O
women	O
was	O
conducted	O
with	O
164	O
women	O
ages	O
40-55	O
years	O
of	O
age	O
.	O

RESULTS	O
Women	O
in	O
the	O
treatment	O
condition	O
compared	O
to	O
the	O
control	O
condition	O
reported	O
significant	O
gains	O
in	O
attitudes	Mental
,	Mental
self-efficacy	Mental
,	Mental
and	Mental
behavioral	Mental
intentions	Mental
at	O
posttest	O
.	O

CONCLUSION	O
Interventions	O
specifically	O
targeted	O
to	O
midlife	O
women	O
can	O
impact	O
constructs	O
known	O
to	O
reduce	O
risk	O
.	O

Implications	O
for	O
future	O
research	O
and	O
intervention	O
development	O
are	O
presented	O
.	O

Improvement	O
of	O
pain	O
related	O
self	O
management	O
for	O
oncologic	O
patients	O
through	O
a	O
trans	O
institutional	O
modular	O
nursing	O
intervention	O
:	O
protocol	O
of	O
a	O
cluster	O
randomized	O
multicenter	O
trial	O
.	O

BACKGROUND	O
Pain	O
is	O
one	O
of	O
the	O
most	O
frequent	O
and	O
distressing	O
symptoms	O
in	O
cancer	O
patients	O
.	O

For	O
the	O
majority	O
of	O
the	O
patients	O
,	O
sufficient	O
pain	O
relief	O
can	O
be	O
obtained	O
if	O
adequate	O
treatment	O
is	O
provided	O
.	O

However	O
,	O
pain	O
remains	O
often	O
undertreated	O
due	O
to	O
institutional	O
,	O
health	O
care	O
professional	O
and	O
patient	O
related	O
barriers	O
.	O

Patients	O
self	O
management	O
skills	O
are	O
affected	O
by	O
the	O
patients	O
'	O
knowledge	O
,	O
activities	O
and	O
attitude	O
to	O
pain	O
management	O
.	O

This	O
trial	O
protocol	O
is	O
aimed	O
to	O
test	O
the	O
SCION-PAIN	O
program	O
,	O
a	O
multi	O
modular	O
structured	O
intervention	O
to	O
improve	O
self	O
management	O
in	O
cancer	O
patients	O
with	O
pain	O
.	O

METHODS	O
240	O
patients	O
with	O
diagnosed	O
malignancy	O
and	O
pain	O
>	O
3	O
days	O
and	O
average	O
pain	O
>	O
or=	O
3/10	O
will	O
participate	O
in	O
a	O
cluster	O
randomized	O
trial	O
on	O
18	O
wards	O
in	O
2	O
German	O
university	O
hospitals	O
.	O

Patients	O
from	O
the	O
intervention	O
wards	O
will	O
receive	O
,	O
additionally	O
to	O
standard	O
pain	O
treatment	O
,	O
the	O
SCION-PAIN	O
program	O
consisting	O
of	O
3	O
modules	O
:	O
pharmacologic	O
pain	O
management	O
,	O
nonpharmacologic	O
pain	O
management	O
and	O
discharge	O
management	O
.	O

The	O
intervention	O
will	O
be	O
conducted	O
by	O
specially	O
trained	O
oncology	O
nurses	O
and	O
includes	O
components	O
of	O
patient	O
education	O
,	O
skills	O
training	O
and	O
counseling	O
to	O
improve	O
self	O
care	O
regarding	O
pain	O
management	O
beginning	O
with	O
admission	O
followed	O
by	O
booster	O
session	O
every	O
3rd	O
day	O
and	O
one	O
follow	O
up	O
telephone	O
counseling	O
within	O
2	O
to	O
3	O
days	O
after	O
discharge	O
.	O

Patients	O
in	O
the	O
control	O
group	O
will	O
receive	O
standard	O
care	O
.	O

Primary	O
endpoint	O
is	O
the	O
group	Mental
difference	Mental
in	Mental
patient	Mental
related	Mental
barriers	Pain
to	Pain
management	Pain
of	Pain
cancer	Pain
pain	Pain
(	O
BQII	O
)	O
,	O
7	O
days	O
after	O
discharge	O
.	O

Secondary	O
endpoints	O
are	O
:	O
pain	Pain
intensity	Pain
&	O
interference	Pain
,	O
adherence	Pain
,	O
coping	Pain
and	O
HRQoL	Pain
.	O

DISCUSSION	O
The	O
study	O
will	O
determine	O
if	O
the	O
acquired	O
self	O
management	O
skills	O
of	O
the	O
patients	O
continue	O
to	O
be	O
used	O
after	O
discharge	O
from	O
hospital	O
.	O

It	O
is	O
hypothesized	O
that	O
patients	O
who	O
receive	O
the	O
multi	O
modular	O
structured	O
intervention	O
will	O
have	O
less	O
patient	O
related	O
barriers	O
and	O
a	O
better	O
self	O
management	O
of	O
cancer	Pain
pain	Pain
.	Pain

TRIAL	O
REGISTRATION	O
ClinicalTrials	O
NCT00779597	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
R-salbutamol	O
for	O
topical	O
treatment	O
of	O
discoid	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
In	O
a	O
recent	O
open	O
pilot	O
trial	O
,	O
R-salbutamol	O
sulphate	O
,	O
a	O
well-known	O
molecule	O
with	O
anti-inflammatory	O
effects	O
,	O
was	O
tested	O
successfully	O
on	O
patients	O
with	O
therapy-resistant	O
discoid	O
lupus	O
erythematosus	O
(	O
DLE	O
)	O
.	O

OBJECTIVES	O
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
R-salbutamol	O
cream	O
0.5	O
%	O
vs.	O
placebo	O
on	O
DLE	O
lesions	O
in	O
a	O
multicentre	O
,	O
double-blinded	O
,	O
randomized	O
,	O
placebo-controlled	O
phase	O
II	O
trial	O
.	O

METHODS	O
Thirty-seven	O
patients	O
with	O
at	O
least	O
one	O
newly	O
developed	O
DLE	O
lesion	O
were	O
randomized	O
-	O
19	O
to	O
the	O
R-salbutamol	O
cream	O
0.5	O
%	O
and	O
18	O
to	O
placebo	O
-	O
and	O
treated	O
twice	O
daily	O
for	O
8	O
weeks	O
.	O

Efficacy	Others
was	O
evaluated	O
through	O
scores	Physical
of	Physical
erythema	Physical
,	O
scaling/hypertrophy	Physical
and	Physical
induration	Physical
as	O
well	O
as	O
pain	Pain
and	Physical
itching	Physical
;	O
general	Others
improvement	Others
scored	Physical
by	Physical
the	Physical
investigator	Physical
and	Physical
global	Physical
improvement	Physical
scored	Physical
by	Physical
patients	Physical
'	Physical
assessment	Physical
were	Physical
also	Physical
evaluated	Physical
.	O

RESULTS	O
The	O
mean	O
area	O
under	O
the	O
curve	O
of	O
improvement	O
for	O
scaling/hypertrophy	Physical
,	O
pain	Physical
,	O
itching	O
and	O
global	Physical
patient	Physical
assessment	Physical
was	O
significantly	O
better	O
for	O
the	O
actively	O
treated	O
patients	O
as	O
compared	O
with	O
placebo	O
(	O
scaling/hypertrophy	O
,	O
P	O
=	O
0.0262	O
;	O
pain	O
,	O
P	O
=	O
0.0238	O
;	O
itching	O
,	O
P	O
=	O
0.0135	O
;	O
global	O
patient	O
assessment	O
,	O
P	O
=	O
0.045	O
)	O
.	O

Moreover	O
,	O
the	O
percentage	O
of	O
patients	O
without	O
induration	Physical
was	O
significantly	O
higher	O
in	O
the	O
active	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
(	O
P	O
=	O
0.013	O
)	O
,	O
and	O
a	O
statistically	O
significantly	O
greater	O
decrease	O
in	O
the	O
size	Physical
of	Physical
the	Physical
lesional	Physical
area	Physical
was	O
also	O
seen	O
in	O
the	O
overall	O
analysis	O
of	O
the	O
R-salbutamol-treated	O
patients	O
(	O
P	O
=	O
0.0197	O
)	O
.	O

No	O
serious	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
were	O
reported	O
.	O

CONCLUSIONS	O
Application	O
of	O
R-salbutamol	O
cream	O
0.5	O
%	O
was	O
safe	O
and	O
well	O
tolerated	O
.	O

Statistically	O
significant	O
effects	O
were	O
seen	O
on	O
scaling/hypertrophy	O
,	O
induration	O
,	O
pain	O
and	O
itching	O
as	O
well	O
as	O
patient	O
global	O
assessment	O
,	O
suggesting	O
that	O
R-salbutamol	O
could	O
be	O
a	O
promising	O
new	O
topical	O
therapy	O
alternative	O
for	O
DLE	O
.	O

Effect	O
of	O
clinical	O
context	O
on	O
simulator-based	O
assessment	O
of	O
blood	Physical
pressure	Physical
taking	O
-	O
a	O
pilot	O
randomized	O
study	O
.	O

BACKGROUND	O
Blood	O
pressure	O
measurement	O
is	O
an	O
essential	O
clinical	O
skill	O
that	O
can	O
readily	O
be	O
assessed	O
in	O
objective	O
structured	O
clinical	O
examination	O
(	O
OSCE	O
)	O
.	O

While	O
the	O
use	O
of	O
simulators	O
can	O
enhance	O
test	O
validity	O
and	O
reliability	O
,	O
the	O
given	O
clinical	O
context	O
may	O
also	O
affect	O
student	O
performance	O
.	O

AIMS	O
To	O
investigate	O
the	O
impact	O
of	O
variations	O
in	O
clinical	O
context	O
on	O
blood	O
pressure	O
measurement	O
in	O
a	O
simulator-based	O
OSCE	O
.	O

METHOD	O
We	O
randomized	O
162	O
first-year	O
medical	O
students	O
into	O
four	O
groups	O
that	O
received	O
different	O
lead-in	O
statements	O
before	O
measuring	O
blood	Physical
pressure	Physical
on	O
a	O
manikin	O
simulator	O
.	O

These	O
statements	O
described	O
hypothetical	O
patients	O
with	O
different	O
likelihoods	O
of	O
having	O
systemic	Physical
hypertension	Physical
.	O

RESULTS	O
The	O
lead-in	O
that	O
described	O
the	O
highest	O
likelihood	Physical
of	Physical
hypertension	Physical
was	O
associated	O
with	O
significantly	O
higher	O
reported	Others
readings	Others
and	Others
lower	Others
accuracy	Others
.	O

The	O
lead-in	O
that	O
suggested	O
normality	O
yielded	O
the	O
best	O
performance	O
.	O

CONCLUSION	O
Student	O
performance	O
in	O
simulator-based	O
OSCE	O
may	O
be	O
affected	O
by	O
the	O
clinical	O
context	O
provided	O
.	O

However	O
,	O
we	O
argue	O
that	O
construct	O
validity	O
should	O
be	O
viewed	O
in	O
light	O
of	O
the	O
application	O
of	O
a	O
test	O
,	O
in	O
that	O
patients	O
may	O
also	O
present	O
with	O
different	O
cues	O
and	O
likelihoods	O
of	O
having	O
hypertension	O
.	O

Variations	O
in	O
construct	O
design	O
should	O
be	O
further	O
explored	O
to	O
enhance	O
the	O
training	O
and	O
assessment	O
of	O
clinical	O
competence	O
that	O
reflects	O
the	O
unpredictability	O
encountered	O
in	O
daily	O
clinical	O
practice	O
.	O

Cyclosporine	O
inhibition	O
of	O
P-glycoprotein	O
in	O
chronic	O
myeloid	O
leukemia	O
blast	O
phase	O
.	O

Chronic	O
myeloid	O
leukemia	O
blast	O
phase	O
(	O
CML-BP	O
)	O
cells	O
commonly	O
express	O
the	O
multidrug	O
transporter	O
,	O
P-glycoprotein	O
(	O
Pgp	O
)	O
.	O

To	O
determine	O
whether	O
Pgp	O
inhibition	O
improves	O
treatment	O
outcome	O
in	O
CML-BP	O
,	O
the	O
Southwest	O
Oncology	O
Group	O
performed	O
a	O
randomized	O
,	O
controlled	O
trial	O
testing	O
the	O
benefit	O
of	O
the	O
Pgp	O
modulator	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Seventy-three	O
eligible	O
patients	O
were	O
assigned	O
to	O
treatment	O
with	O
cytarabine	O
and	O
infusional	O
daunorubicin	O
with	O
or	O
without	O
intravenous	O
CsA	O
.	O

Treatment	O
with	O
CsA	O
yielded	O
no	Others
improvement	Others
in	O
treatment	O
outcome	O
as	O
measured	O
by	O
the	O
frequency	Physical
of	Physical
induction	Physical
resistance	Physical
(	O
68	O
%	O
vs	O
53	O
%	O
)	O
,	O
rate	Physical
of	Physical
complete	Physical
remission	Physical
or	O
restored	Physical
chronic	Physical
phase	Physical
(	O
CR/CP	O
,	O
8	O
%	O
vs	O
30	O
%	O
)	O
,	O
and	O
survival	Mortality
(	O
3	O
vs	O
5	O
months	O
)	O
.	O

Blast	Physical
expression	Physical
of	Physical
Pgp	Physical
(	O
63	O
%	O
)	O
and	O
LRP	Physical
(	O
71	O
%	O
)	O
was	O
common	O
,	O
whereas	O
only	O
Pgp	O
adversely	O
impacted	O
the	O
rate	Physical
of	Physical
CR/CP	Physical
(	O
P	O
=.025	O
)	O
.	O

We	O
conclude	O
that	O
Pgp	O
has	O
prognostic	O
relevance	O
in	O
CML-BP	O
but	O
that	O
the	O
modulation	O
of	O
Pgp	O
function	O
with	O
CsA	O
as	O
applied	O
in	O
this	O
trial	O
is	O
ineffective	O
.	O

Effect	O
of	O
nitric-oxide-generating	O
system	O
on	O
microcirculatory	Others
blood	Others
flow	Others
in	O
skin	O
of	O
patients	O
with	O
severe	O
Raynaud	O
's	O
syndrome	O
:	O
a	O
randomised	O
trial	O
.	O

BACKGROUND	O
Patients	O
with	O
Raynaud	O
's	O
syndrome	O
have	O
abnormal	O
digital	O
vasoconstriction	O
,	O
which	O
may	O
be	O
secondary	O
to	O
impaired	O
synthesis	O
of	O
,	O
or	O
impaired	O
sensitivity	O
to	O
,	O
nitric	O
oxide	O
.	O

We	O
studied	O
the	O
effect	O
on	O
microcirculation	O
of	O
a	O
nitric-oxide-generating	O
system	O
applied	O
topically	O
to	O
the	O
finger	O
and	O
forearm	O
of	O
healthy	O
volunteers	O
and	O
patients	O
with	O
primary	O
Raynaud	O
's	O
syndrome	O
.	O

METHODS	O
We	O
did	O
a	O
single-blind	O
,	O
randomised	O
,	O
placebo	O
controlled	O
,	O
cross-over	O
study	O
of	O
the	O
microcirculatory	Physical
response	Physical
to	O
topical	O
application	O
of	O
a	O
nitric-oxidegenerating	O
gel	O
in	O
20	O
patients	O
with	O
severe	O
Raynaud	O
's	O
syndrome	O
,	O
and	O
ten	O
healthy	O
volunteers	O
.	O

We	O
prepared	O
the	O
nitric-oxide-generating	O
system	O
by	O
mixing	O
a	O
solution	O
of	O
KY	O
jelly	O
and	O
sodium	O
nitrite	O
(	O
5	O
%	O
weight/volume	O
)	O
,	O
with	O
a	O
solution	O
of	O
KY	O
jelly	O
and	O
ascorbic	O
acid	O
(	O
5	O
%	O
weight/volume	O
)	O
.	O

About	O
0.5	O
mL	O
of	O
each	O
solution	O
was	O
separately	O
applied	O
to	O
the	O
skin	O
of	O
the	O
forearm	O
(	O
3	O
cm2	O
)	O
,	O
and	O
then	O
mixed	O
with	O
a	O
sterile	O
cotton	O
bud	O
.	O

A	O
similar	O
procedure	O
was	O
done	O
simultaneously	O
on	O
the	O
other	O
arm	O
with	O
KY	O
jelly	O
only	O
(	O
placebo	O
)	O
.	O

The	O
procedure	O
was	O
then	O
repeated	O
on	O
the	O
finger	O
pulps	O
.	O

Changes	Mortality
in	Mortality
skin	Mortality
microcirculatory	Mortality
volume	Mortality
and	Mortality
flux	Mortality
were	O
measured	O
bilaterally	O
by	O
infrared	O
photoplethysmography	O
and	O
laser	O
doppler	O
fluxmetry	O
,	O
respectively	O
.	O

FINDINGS	O
In	O
the	O
forearm	O
,	O
blood	Mental
flow	Mental
increased	O
significantly	O
after	O
application	O
of	O
the	O
active	O
gel	O
both	O
in	O
patients	O
with	O
Raynaud	O
's	O
syndrome	O
(	O
microcirculatory	O
volume	O
from	O
mean	O
area	O
under	O
the	O
curve	O
98	O
[	O
SE	O
14	O
]	O
to	O
1024	O
[	O
130	O
]	O
;	O
microcirculatory	O
flux	O
from	O
5060	O
[	O
462	O
]	O
to	O
74,800	O
[	O
3940	O
]	O
)	O
and	O
in	O
healthy	O
controls	O
(	O
volume	O
from	O
85	O
[	O
19	O
]	O
to	O
1020	O
[	O
60	O
]	O
;	O
flux	O
from	O
4420	O
[	O
435	O
]	O
to	O
84,500	O
[	O
7000	O
]	O
)	O
.	O

In	O
the	O
fingers	O
,	O
although	O
baseline	Mental
blood	Mental
flow	Mental
was	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
,	O
both	O
groups	O
showed	O
increases	O
with	O
application	O
of	O
active	O
gel	O
(	O
volume	O
from	O
1100	O
[	O
194	O
]	O
to	O
3280	O
[	O
672	O
]	O
and	O
2380	O
[	O
441	O
]	O
to	O
6160	O
[	O
1160	O
]	O
,	O
respectively	O
;	O
flux	Mental
from	O
33,400	O
[	O
4200	O
]	O
to	O
108,000	O
[	O
13,600	O
]	O
and	O
52,000	O
[	O
8950	O
]	O
to	O
185,000	O
[	O
19,500	O
]	O
)	O
.	O

Increases	O
in	O
blood	Others
flow	Others
with	O
placebo	O
gel	O
were	O
not	O
significant	O
.	O

No	O
adverse	O
effects	O
were	O
reported	O
.	O

INTERPRETATION	O
In	O
primary	O
Raynaud	O
's	O
syndrome	O
,	O
topical	O
application	O
of	O
a	O
nitric-oxide-generating	O
system	O
can	O
stimulate	O
an	O
increase	O
in	O
both	O
microcirculatory	Others
volume	Others
and	Others
flux	Others
.	Others

Impact	O
of	O
pentoxifylline	O
on	O
platelet	Physical
function	Physical
profiles	Physical
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
and	O
coronary	O
artery	O
disease	O
on	O
dual	O
antiplatelet	O
therapy	O
with	O
aspirin	O
and	O
clopidogrel	O
.	O

OBJECTIVES	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
the	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibitor	O
pentoxifylline	O
on	O
platelet	Physical
function	Physical
profiles	Physical
in	O
patients	O
receiving	O
dual	O
antiplatelet	O
therapy	O
(	O
DAPT	O
)	O
.	O

BACKGROUND	O
Previous	O
studies	O
have	O
shown	O
that	O
,	O
in	O
patients	O
receiving	O
DAPT	O
,	O
the	O
adjunctive	O
use	O
of	O
a	O
PDE	O
inhibitor	O
enhances	O
platelet	Physical
inhibition	Physical
,	O
particularly	O
in	O
those	O
presenting	O
with	O
diabetes	O
mellitus	O
(	O
DM	O
)	O
.	O

However	O
,	O
the	O
pharmacodynamic	O
(	O
PD	O
)	O
effects	O
of	O
the	O
PDE	O
inhibitor	O
pentoxifylline	O
on	O
platelet	Physical
function	Physical
profiles	Physical
in	O
DM	O
patients	O
receiving	O
DAPT	O
are	O
unknown	O
.	O

METHODS	O
This	O
was	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel	O
design	O
study	O
conducted	O
in	O
DM	O
patients	O
with	O
stable	O
coronary	O
artery	O
disease	O
receiving	O
DAPT	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
either	O
pentoxifylline	O
400	O
mg	O
or	O
placebo	O
3	O
times	O
daily	O
for	O
14	O
days	O
.	O

The	O
PD	O
effects	O
were	O
assessed	O
by	O
vasodilator-stimulated	Others
phosphoprotein	Others
phosphorylation	Others
assay	Others
,	O
light	Others
transmittance	Others
aggregometry	Others
,	O
VerifyNow	Physical
P2Y12	Physical
assay	Physical
(	O
Accumetric	O
,	O
Inc.	O
,	O
San	O
Diego	O
,	O
California	O
)	O
,	O
and	O
multiple	Others
electrode	Others
aggregometry	Others
at	O
baseline	O
and	O
14	O
days	O
.	O

The	O
PD	O
effects	O
were	O
also	O
assessed	O
according	O
the	O
presence	O
or	O
absence	O
of	O
high	Physical
on-treatment	Physical
platelet	Physical
reactivity	Physical
status	Physical
.	O

RESULTS	O
A	O
total	O
of	O
40	O
patients	O
were	O
available	O
for	O
analysis	O
.	O

At	O
14	O
days	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
P2Y	Physical
(	Physical
12	Physical
)	Physical
reactivity	Physical
index	Physical
as	O
assessed	O
by	O
vasodilator-stimulated	O
phosphoprotein	O
phosphorylation	O
between	O
treatment	O
groups	O
(	O
primary	O
endpoint	O
;	O
p	O
=	O
0.93	O
)	O
.	O

Intra-group	O
comparisons	O
also	O
failed	O
to	O
show	O
any	O
differences	O
between	O
baseline	O
and	O
14-day	Physical
P2Y	Physical
(	Physical
12	Physical
)	Physical
reactivity	Physical
index	Physical
assessment	Physical
in	O
the	O
placebo	O
and	O
pentoxifylline	O
arms	O
(	O
p	O
=	O
0.61	O
)	O
.	O

There	O
were	O
no	O
significant	O
inter-	O
and	O
intra-group	O
differences	O
in	O
all	O
other	O
PD	Physical
measures	Physical
.	O

The	O
PD	O
effects	O
did	O
not	O
vary	O
according	O
the	O
presence	O
or	O
absence	O
of	O
high	O
on-treatment	O
platelet	O
reactivity	O
.	O

CONCLUSIONS	O
Adjunctive	O
treatment	O
with	O
pentoxifylline	O
is	O
not	O
associated	O
with	O
increased	O
platelet	Physical
inhibitory	Physical
effects	Physical
in	O
DM	O
patients	O
with	O
coronary	O
artery	O
disease	O
receiving	O
DAPT	O
.	O

Anti-IgG	O
antibodies	O
during	O
immunotherapy	O
with	O
purified	O
grass	O
pollen	O
extracts	O
.	O

In	O
a	O
double	O
blind	O
study	O
40	O
patients	O
were	O
allocated	O
specific	O
immunotherapy	O
(	O
hyposensitization	O
)	O
with	O
partially	O
purified	O
timothy	O
extract	O
or	O
two	O
timothy	O
major	O
allergens	O
19	O
,	O
25	O
.	O

All	O
patients	O
had	O
typical	O
grass	O
pollen	O
hay	O
fever	O
,	O
in	O
27	O
%	O
associated	O
with	O
grass	O
pollen	O
asthma	O
and	O
in	O
13	O
%	O
with	O
birch	O
pollen	O
allergy	O
.	O

Serum	Physical
IgG	Physical
anti-IgG	Physical
antibodies	Physical
were	O
determined	O
after	O
dithiothreitol	O
treatment	O
.	O

Before	O
hyposensitization	O
,	O
IgG	Physical
anti-IgG	Physical
titres	Physical
greater	O
than	O
or	O
equal	O
to	O
9	O
were	O
demonstrated	O
in	O
45	O
%	O
of	O
the	O
patients	O
.	O

During	O
hyposensitization	O
IgG	Physical
anti-IgG	Physical
titres	Physical
showed	O
a	O
slight	O
initial	O
increase	O
followed	O
by	O
a	O
decrease	O
below	O
pretreatment	O
level	O
.	O

Neither	O
increase	O
nor	O
decrease	O
was	O
statistically	O
significant	O
.	O

Reactions	Physical
to	Physical
rabbit	Physical
IgG	Physical
F	Physical
(	Physical
ab	Physical
'	Physical
)	Physical
2	Physical
fractions	O
were	O
only	O
obtained	O
during	O
hyposensitization	O
.	O

The	O
occurrence	O
of	O
anti-IgG	Physical
antibodies	Physical
did	O
no	O
correlate	O
with	O
symptoms	Physical
,	O
side	Adverseeffect
effects	Adverseeffect
,	Adverseeffect
or	O
the	Physical
level	Physical
of	Physical
allergen-specific	Physical
IgG	Physical
.	O

In	O
a	O
previous	O
study	O
it	O
was	O
demonstrated	O
that	O
patients	O
with	O
multiallergy	O
hyposensitized	O
with	O
combined	O
allergen	O
extracts	O
showed	O
a	O
statistically	O
significant	O
increase	O
in	O
IgG	Physical
anti-IgG	Physical
titres	Physical
during	O
treatment	O
.	O

The	O
increase	O
failed	O
to	O
appear	O
in	O
the	O
present	O
patients	O
allergic	O
only	O
to	O
pollen	O
and	O
treated	O
with	O
purified	O
allergen	O
extracts	O
.	O

It	O
is	O
therefore	O
suggested	O
that	O
a	O
multiallergic	O
condition	O
and	O
the	O
combination	O
and/or	O
purification	O
of	O
allergen	O
extracts	O
administered	O
during	O
hyposensitization	O
may	O
influence	O
the	O
production	O
of	O
IgG	Physical
anti-	Physical
IgG	Physical
antibodies	Physical
.	O

Reaching	O
out	O
,	O
inviting	O
back	O
:	O
using	O
Interactive	O
voice	O
response	O
(	O
IVR	O
)	O
technology	O
to	O
recycle	O
relapsed	O
smokers	O
back	O
to	O
Quitline	O
treatment	O
--	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
Tobacco	O
dependence	O
is	O
a	O
chronic	O
,	O
relapsing	O
condition	O
that	O
typically	O
requires	O
multiple	O
quit	O
attempts	O
and	O
extended	O
treatment	O
.	O

When	O
offered	O
the	O
opportunity	O
,	O
relapsed	O
smokers	O
are	O
interested	O
in	O
recycling	O
back	O
into	O
treatment	O
for	O
a	O
new	O
,	O
assisted	O
quit	O
attempt	O
.	O

This	O
manuscript	O
presents	O
the	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
testing	O
the	O
efficacy	O
of	O
interactive	O
voice	O
response	O
(	O
IVR	O
)	O
in	O
recycling	O
low	O
income	O
smokers	O
who	O
had	O
previously	O
used	O
quitline	O
(	O
QL	O
)	O
support	O
back	O
to	O
QL	O
support	O
for	O
a	O
new	O
quit	O
attempt	O
.	O

METHODS	O
A	O
sample	O
of	O
2985	O
previous	O
QL	O
callers	O
were	O
randomized	O
to	O
either	O
receive	O
IVR	O
screening	O
for	O
current	O
smoking	O
(	O
control	O
group	O
)	O
or	O
IVR	O
screening	O
plus	O
an	O
IVR	O
intervention	O
.	O

The	O
IVR	O
intervention	O
consists	O
of	O
automated	O
questions	O
to	O
identify	O
and	O
address	O
barriers	O
to	O
re-cycling	O
in	O
QL	O
support	O
,	O
followed	O
by	O
an	O
offer	O
to	O
be	O
transferred	O
to	O
the	O
QL	O
and	O
reinitiate	O
treatment	O
.	O

Re-enrollment	O
in	O
QL	O
services	O
for	O
both	O
groups	O
was	O
documented	O
.	O

RESULTS	O
The	O
IVR	O
system	O
successfully	Others
reached	Others
715	O
(	O
23.9	O
%	O
)	O
former	O
QL	O
participants	O
.	O

Of	O
those	O
,	O
27	O
%	O
(	O
194/715	O
)	O
reported	O
to	O
the	O
IVR	O
system	O
that	O
they	O
had	O
quit	Mental
smoking	Mental
and	O
were	O
therefore	O
excluded	O
from	O
the	O
study	O
and	O
analysis	O
.	O

The	O
trial	O
's	O
final	O
sample	O
was	O
composed	O
of	O
521	O
current	O
smokers	O
.	O

The	O
re-enrollment	Others
rate	Others
was	O
3.3	O
%	O
for	O
the	O
control	O
group	O
and	O
28.2	O
%	O
for	O
the	O
intervention	O
group	O
(	O
p	O
<	O
.001	O
)	O
.	O

Logistic	O
regression	O
results	O
indicated	O
an	O
11.2	O
times	O
higher	O
odds	O
for	O
re-enrollment	O
of	O
the	O
intervention	O
group	O
than	O
the	O
control	O
group	O
(	O
p	O
<	O
.001	O
)	O
.	O

Results	Others
did	Others
not	Others
vary	Others
by	Others
gender	Others
,	Others
race	Others
,	Others
ethnicity	Others
,	Others
or	Others
level	Others
of	Others
education	Others
,	O
however	O
recycled	Others
smokers	Mental
were	Others
older	Others
(	O
Mean	O
=	O
45.2	O
;	O
SD	O
=	O
11.7	O
)	O
than	O
smokers	O
who	O
declined	O
a	O
new	O
treatment	O
cycle	O
(	O
Mean	O
=	O
41.8	O
;	O
SD	O
=	O
13.2	O
)	O
;	O
(	O
p	O
=	O
0.013	O
)	O
.	O

The	O
main	O
barriers	O
reported	O
for	O
not	O
engaging	O
in	O
a	O
new	O
treatment	O
cycle	O
were	O
low	O
self-efficacy	Mental
and	O
lack	Mental
of	Mental
interest	Mental
in	O
quitting	O
.	O

After	O
delivering	O
IVR	O
messages	O
targeting	O
these	O
reported	O
barriers	O
,	O
32	O
%	O
of	O
the	O
smokers	O
reporting	O
low	Mental
self-efficacy	Mental
and	O
4.8	O
%	O
of	O
those	O
reporting	O
lack	O
of	O
interest	O
in	O
quitting	O
re-engaged	O
in	O
a	O
new	O
QL	O
treatment	O
cycle	O
.	O

CONCLUSION	O
Proactive	O
IVR	O
outreach	O
is	O
a	O
promising	O
tool	O
to	O
engage	O
low	O
income	O
,	O
relapsed	O
smokers	O
back	O
into	O
a	O
new	O
cycle	O
of	O
treatment	O
.	O

Integration	O
of	O
IVR	O
intervention	O
for	O
recycling	O
smokers	O
with	O
previous	O
QL	O
treatment	O
has	O
the	O
potential	O
to	O
decrease	O
tobacco-related	O
disparities	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT01260597	O
.	O

Effects	O
of	O
irrigation	O
fluid	O
temperature	O
on	O
core	O
body	O
temperature	O
during	O
transurethral	O
resection	O
of	O
the	O
prostate	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
effect	O
irrigation	O
fluid	O
temperature	O
has	O
on	O
core	O
body	O
temperature	O
changes	O
in	O
patients	O
undergoing	O
transurethral	O
resection	O
of	O
the	O
prostate	O
(	O
TURP	O
)	O
.	O

METHODS	O
Fifty-six	O
male	O
patients	O
(	O
mean	O
age	O
71.2	O
+/-	O
8.2	O
years	O
)	O
scheduled	O
for	O
TURP	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Patients	O
were	O
randomized	O
to	O
one	O
of	O
two	O
groups	O
.	O

Group	O
1	O
consisted	O
of	O
27	O
patients	O
who	O
received	O
room	O
temperature	O
irrigation	O
fluid	O
(	O
70	O
degrees	O
F	O
)	O
throughout	O
TURP	O
;	O
group	O
2	O
consisted	O
of	O
29	O
patients	O
whose	O
procedure	O
was	O
performed	O
with	O
warmed	O
irrigation	O
fluid	O
(	O
91.5	O
degrees	O
F	O
)	O
.	O

The	O
irrigation	O
fluid	O
used	O
for	O
both	O
groups	O
was	O
glycine	O
.	O

The	O
baseline	O
temperature	O
,	O
final	O
temperature	O
,	O
total	O
time	O
in	O
the	O
operating	O
room	O
,	O
and	O
amount	O
of	O
irrigation	O
fluid	O
used	O
during	O
the	O
procedure	O
were	O
recorded	O
for	O
each	O
patient	O
.	O

RESULTS	O
No	O
significant	O
difference	O
in	O
the	O
average	Others
time	Others
spent	Others
in	Others
the	Others
operating	Others
room	Others
or	O
in	O
the	Others
total	Others
irrigation	Others
fluid	Others
used	O
between	O
the	O
two	O
groups	O
was	O
observed	O
.	O

Of	O
the	O
27	O
patients	O
who	O
received	O
room	Physical
temperature	Physical
irrigation	Physical
fluid	Physical
,	O
15	O
(	O
55.6	O
%	O
)	O
had	O
a	O
decrease	O
in	O
body	Physical
temperature	Physical
.	O

A	O
decrease	O
in	O
temperature	Physical
was	O
observed	O
in	O
21	O
(	O
72.4	O
%	O
)	O
of	O
the	O
29	O
patients	O
who	O
received	O
warm	O
irrigation	Others
fluid	Others
.	O

Groups	O
1	O
and	O
2	O
had	O
12	O
(	O
44.4	O
%	O
)	O
of	O
27	O
and	O
8	O
(	O
27.6	O
%	O
)	O
of	O
29	O
patients	O
,	O
respectively	O
,	O
who	O
demonstrated	O
an	O
elevation	O
in	O
their	O
core	Physical
body	Physical
temperature	Physical
.	O

CONCLUSIONS	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
irrigation	O
fluid	O
temperature	O
is	O
not	O
a	O
factor	O
responsible	O
for	O
altering	O
the	O
core	O
body	Physical
temperature	Physical
in	O
patients	O
undergoing	O
TURP	O
.	O

[	O
Pilot	O
results	O
of	O
using	O
tamsulone-FS	O
in	O
patients	O
with	O
prostatic	O
adenoma	O
according	O
to	O
the	O
results	O
of	O
a	O
randomized	O
multicenter	O
comparative	O
trial	O
]	O
.	O

Tamsulone-FS	O
--	O
a	O
novel	O
Russian	O
alpha1A/D-adrenoblocker	O
(	O
Farm-Syntez	O
)	O
--	O
was	O
studied	O
in	O
a	O
randomized	O
multicenter	O
comparative	O
trial	O
in	O
patients	O
with	O
prostatic	O
adenoma	O
.	O

Pilot	O
results	O
agreed	O
with	O
other	O
trials	O
published	O
in	O
the	O
literature	O
and	O
demonstrated	O
tamsulone-FS	O
efficacy	Others
and	Others
safety	Others
for	Others
management	Others
of	Others
lower	Others
urinary	Others
tract	Others
symptoms	Others
caused	O
by	O
prostatic	O
adenoma	O
.	O

The	Others
efficacy	Others
and	Others
safety	Others
of	Others
tamsulone-FS	Others
was	Others
comparable	Others
to	Others
those	Others
of	Others
omnik	Others
.	Others

This	O
drug	O
can	O
be	O
recommended	O
for	O
wide	O
clinical	O
practice	O
in	O
prostatic	Physical
adenoma	Physical
.	Physical

It	O
is	O
registered	O
by	O
Roszdravnadzor	O
(	O
certificate	O
N	O
LC-000859	O
of	O
03.11.2005	O
)	O
and	O
allowed	O
for	O
production	O
and	O
sale	O
.	O

Double-blind	O
placebo-controlled	O
administration	O
of	O
fluoxetine	O
in	O
restricting-	O
and	O
restricting-purging-type	O
anorexia	O
nervosa	O
.	O

BACKGROUND	O
Anorexia	O
nervosa	O
is	O
an	O
often	O
chronic	O
disorder	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

Many	O
people	O
relapse	O
after	O
weight	O
restoration	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
a	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
would	O
improve	O
outcome	O
and	O
reduce	O
relapse	O
after	O
weight	Physical
restoration	Physical
by	Physical
contributing	Physical
to	Physical
maintenance	Physical
of	Physical
a	Physical
healthy	Physical
normal	Physical
weight	Physical
and	Physical
a	Physical
reduction	Physical
of	Physical
symptoms	Physical
.	Physical

METHODS	O
We	O
administered	O
a	O
double-blind	O
placebo-controlled	O
trial	O
of	O
fluoxetine	O
to	O
35	O
patients	O
with	O
restricting-type	O
anorexia	O
nervosa	O
.	O

Anorexics	O
were	O
randomly	O
assigned	O
to	O
fluoxetine	O
(	O
n	O
=	O
16	O
)	O
or	O
a	O
placebo	O
(	O
n	O
=	O
19	O
)	O
after	O
inpatient	O
weight	O
gain	O
and	O
then	O
were	O
observed	O
as	O
outpatients	O
for	O
1	O
year	O
.	O

RESULTS	O
Ten	O
of	O
16	O
(	O
63	O
%	O
)	O
subjects	O
remained	O
on	O
fluoxetine	O
for	O
a	O
year	O
,	O
whereas	O
only	O
three	O
of	O
19	O
(	O
16	O
%	O
)	O
remained	O
on	O
the	O
placebo	O
for	O
a	O
year	O
(	O
p	O
=.006	O
)	O
.	O

Those	O
subjects	O
remaining	O
on	O
fluoxetine	O
for	O
a	O
year	O
had	O
reduced	Mental
relapse	Mental
as	O
determined	O
by	O
a	O
significant	Physical
increase	Physical
in	Physical
weight	Physical
and	Physical
reduction	Physical
in	Physical
symptoms	Physical
.	Physical

CONCLUSIONS	O
This	O
study	O
offers	O
preliminary	O
evidence	O
that	O
fluoxetine	O
may	O
be	O
useful	O
in	O
improving	O
outcome	O
and	O
preventing	O
relapse	Physical
of	O
patients	O
with	O
anorexia	O
nervosa	O
after	O
weight	O
restoration	O
.	O

Metformin	O
does	O
not	O
enhance	O
ovulation	O
induction	O
in	O
clomiphene	O
resistant	O
polycystic	O
ovary	O
syndrome	O
in	O
clinical	O
practice	O
.	O

AIMS	O
To	O
determine	O
whether	O
metformin	O
pretreatment	O
has	O
beneficial	O
effects	O
in	O
clomiphene	O
resistant	O
infertile	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
in	O
an	O
infertility	O
clinic	O
.	O

METHODS	O
This	O
was	O
a	O
randomized	O
placebo	O
controlled	O
double-blind	O
crossover	O
study	O
of	O
3	O
months	O
metformin	O
(	O
1500	O
mg	O
day-1	O
)	O
/placebo	O
,	O
followed	O
by	O
3	O
months	O
metformin/placebo	O
together	O
with	O
clomiphene	O
(	O
50-100	O
mg	O
for	O
5	O
days	O
)	O
for	O
three	O
cycles	O
in	O
clomiphene	O
resistant	O
women	O
with	O
PCOS	O
.	O

The	O
primary	O
outcomes	O
were	O
restoration	Physical
of	Physical
spontaneous	Physical
menses	Physical
,	Physical
ovulation	Physical
induction	Physical
(	Physical
spontaneous	Physical
or	Physical
clomiphene	Physical
induced	Physical
)	Physical
and	Physical
pregnancy	Physical
.	Physical

Secondary	Physical
endpoints	Physical
were	O
changes	O
in	O
biochemical	O
parameters	O
related	O
to	O
androgens	O
and	O
insulin	O
.	O

RESULTS	O
Twelve	O
women	O
completed	O
the	O
metformin	O
arm	O
and	O
14	O
the	O
placebo	O
arm	O
.	O

Spontaneous	Physical
menstruation	Physical
resumed	O
in	O
five	O
metformin	O
treated	O
patients	O
and	O
in	O
six	O
placebo	O
treated	O
women	O
,	O
P=0.63	O
.	O

No	O
women	O
given	O
metformin	O
spontaneously	Physical
ovulated	Physical
,	O
although	O
one	O
patient	O
given	O
placebo	O
did	O
,	O
P=0.30	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
efficacy	Physical
of	Physical
clomiphene	Physical
between	O
the	O
two	O
groups	O
with	O
ovulation	Physical
being	Physical
induced	Physical
in	O
five	O
(	O
out	O
of	O
12	O
)	O
metformin	O
treated	O
women	O
and	O
four	O
(	O
out	O
of	O
14	O
)	O
placebo	O
treated	O
women	O
,	O
P=0.63	O
.	O

Pregnancy	Physical
occurred	O
in	O
three	O
(	O
out	O
of	O
12	O
)	O
women	O
given	O
metformin	O
and	O
two	O
(	O
out	O
of	O
14	O
)	O
women	O
given	O
placebo	O
,	O
P=0.59	O
.	O

CONCLUSIONS	O
Metformin	O
is	O
not	O
always	O
beneficial	O
when	O
given	O
to	O
clomiphene	O
resistant	O
infertile	O
women	O
with	O
PCOS	O
in	O
clinical	O
practice	O
.	O

A	O
prospective	O
,	O
randomized	O
trial	O
of	O
nerve	O
monitoring	O
of	O
the	O
external	O
branch	O
of	O
the	O
superior	O
laryngeal	O
nerve	O
during	O
thyroidectomy	O
under	O
local/regional	O
anesthesia	O
and	O
IV	O
sedation	O
.	O

BACKGROUND	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
impact	O
of	O
the	O
neuromonitoring	O
of	O
the	O
external	O
branch	O
of	O
the	O
superior	O
laryngeal	O
nerve	O
(	O
EBSLN	O
)	O
on	O
the	O
voice	Others
quality	Others
after	O
mini-incision	O
thyroidectomy	O
under	O
local/regional	O
anesthesia	O
and	O
intravenous	O
sedation	O
.	O

METHODS	O
Patients	O
undergoing	O
mini-incision	O
thyroidectomy	O
under	O
local	O
anesthesia	O
were	O
prospectively	O
randomized	O
for	O
either	O
nerve	O
monitoring	O
of	O
the	O
EBSLN	O
(	O
group	O
1	O
)	O
or	O
no	O
nerve	O
monitoring	O
(	O
group	O
2	O
)	O
.	O

Voice	Others
and	Physical
swallowing	Others
assessment	O
were	O
obtained	O
by	O
using	O
the	O
Voice	Others
Handicap	Others
Index-10	Others
(	Others
VHI-10	Others
)	Others
and	Physical
the	Others
Reflux	Others
Symptom	Others
Index	Others
questionnaires	Others
(	Others
RSI	Others
)	Others
before	O
surgery	O
and	O
at	O
3	O
weeks	O
and	O
3	O
months	O
after	O
surgery	O
.	O

RESULTS	O
Recruitment	O
led	O
to	O
22	O
patients	O
in	O
group	O
1	O
and	O
25	O
patients	O
in	O
group	O
2	O
.	O

The	O
rate	Mental
of	Mental
visualized	Mental
EBSLN	Mental
was	O
higher	O
in	O
group	O
1	O
(	O
66	O
%	O
vs	O
21	O
%	O
;	O
P	O
=	O
.003	O
)	O
.	O

Contrary	O
to	O
group	O
1	O
,	O
in	O
group	O
2	O
,	O
the	O
median	Physical
total	Physical
VHI-10	Physical
score	Physical
was	O
significantly	O
higher	O
3	O
months	O
after	O
surgery	O
(	O
P	O
=	O
.034	O
)	O
compared	O
with	O
preoperatively	O
,	O
indicating	O
a	O
subjective	O
voice	O
handicap	O
.	O

In	O
both	O
groups	O
,	O
there	O
was	O
no	O
difference	O
in	O
median	Physical
total	Physical
RSI	Physical
score	Physical
before	O
surgery	O
or	O
at	O
3	O
weeks	O
and	O
3	O
months	O
after	O
surgery	O
.	O

CONCLUSION	O
Nerve	O
monitoring	O
aids	O
in	O
the	O
visualization	O
of	O
the	O
EBSLN	Physical
during	O
mini-incision	O
thyroidectomy	O
under	O
local/regional	O
anesthesia	O
and	O
leads	O
to	O
an	O
improvement	O
in	O
patient-assessed	O
voice	Others
quality	Others
after	O
surgery	O
but	O
does	O
not	O
impact	O
swallowing	Physical
.	Physical

Antibiotic	O
strategy	O
after	O
the	O
empiric	O
phase	O
in	O
patients	O
treated	O
for	O
a	O
hematological	O
malignancy	O
.	O

Empiric	O
broad-spectrum	O
antibiotic	O
therapy	O
has	O
become	O
a	O
generally	O
accepted	O
strategy	O
in	O
the	O
treatment	O
of	O
febrile	O
neutropenic	O
patients	O
.	O

Particularly	O
in	O
patients	O
with	O
prolonged	O
neutropenia	O
,	O
subsequent	O
adaptation	O
of	O
such	O
a	O
regimen	O
will	O
be	O
the	O
rule	O
rather	O
than	O
exception	O
.	O

Since	O
there	O
are	O
no	O
uniformly	O
accepted	O
guidelines	O
for	O
the	O
modification	O
of	O
antibiotic	O
therapy	O
during	O
the	O
post-empiric	O
phase	O
,	O
we	O
assessed	O
the	O
impact	O
of	O
a	O
set	O
of	O
rules	O
that	O
evolved	O
during	O
the	O
first	O
randomized	O
trials	O
.	O

Evaluation	O
of	O
the	O
clinician	O
's	O
compliance	O
with	O
these	O
rules	O
in	O
1951	O
febrile	O
neutropenic	O
episodes	O
was	O
the	O
subject	O
of	O
the	O
present	O
analysis	O
.	O

Treatment	O
was	O
modified	O
in	O
761	O
(	O
39	O
%	O
)	O
cases	O
,	O
and	O
these	O
changes	O
were	O
made	O
according	O
to	O
the	O
rules	O
in	O
76	O
%	O
.	O

For	O
75	O
%	O
of	O
the	O
alterations	O
in	O
treatment	O
during	O
the	O
evening	O
and	O
night	O
shifts	O
,	O
no	O
reasonable	O
explanation	O
was	O
established	O
,	O
while	O
93	O
%	O
of	O
the	O
modifications	O
during	O
the	O
normal	O
working	O
hours	O
were	O
made	O
for	O
objective	O
reasons	O
.	O

The	O
empiric	O
regimen	O
was	O
more	O
frequently	O
changed	O
in	O
patients	O
with	O
a	O
clinical	O
focus	O
of	O
infection	O
at	O
the	O
onset	O
of	O
fever	O
than	O
in	O
patients	O
who	O
showed	O
fever	O
as	O
the	O
only	O
symptom	O
of	O
a	O
possible	O
infection	O
.	O

The	O
perceived	O
need	O
for	O
modification	O
amounted	O
to	O
69	O
%	O
in	O
pulmonary	O
infections	O
,	O
to	O
51	O
%	O
in	O
skin	O
and	O
soft-tissue	O
infections	O
,	O
to	O
44	O
%	O
in	O
patients	O
with	O
abdominal	O
complaints	O
,	O
and	O
to	O
37	O
%	O
in	O
upper	O
respiratory	O
tract	O
infections	O
.	O

Glycopeptides	O
constituted	O
22	O
%	O
of	O
modifications	O
,	O
particularly	O
in	O
patients	O
with	O
a	O
central	O
venous	O
catheter	O
,	O
and	O
systemically	O
active	O
antifungals	O
were	O
administered	O
in	O
16	O
%	O
of	O
cases	O
.	O

Especially	O
inexperienced	O
clinicians	O
tend	O
to	O
adjust	O
antibiotic	O
therapy	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
persistence	O
of	O
fever	O
alone	O
seldom	O
reflects	O
inadequate	O
treatment	O
when	O
the	O
clinical	O
condition	O
of	O
the	O
patient	O
is	O
stable	O
or	O
improving	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
development	O
of	O
subsequent	O
infectious	O
events	O
emphasizes	O
that	O
a	O
genuine	O
need	O
for	O
modification	O
does	O
frequently	O
exist	O
.	O

Rapid	O
tightening	O
of	O
blood	O
glucose	O
control	O
leads	O
to	O
transient	O
deterioration	O
of	O
retinopathy	Physical
in	O
insulin	O
dependent	O
diabetes	O
mellitus	O
:	O
the	O
Oslo	O
study	O
.	O

In	O
a	O
study	O
of	O
retinopathy	O
during	O
one	O
year	O
of	O
tight	O
blood	O
glucose	O
control	O
45	O
type	O
I	O
(	O
insulin	O
dependent	O
)	O
diabetics	O
without	O
proliferative	O
retinopathy	O
were	O
randomised	O
to	O
receive	O
either	O
continuous	O
subcutaneous	O
insulin	O
infusion	O
,	O
multiple	O
insulin	O
injections	O
,	O
or	O
conventional	O
insulin	O
treatment	O
(	O
controls	O
)	O
.	O

Near	O
normoglycaemia	O
was	O
achieved	O
with	O
continuous	O
infusion	O
and	O
multiple	O
injections	O
but	O
not	O
with	O
conventional	O
treatment	O
.	O

Blind	O
evaluation	O
of	O
fluorescein	Physical
angiograms	Physical
performed	O
three	O
monthly	O
showed	O
progression	Physical
of	Physical
retinopathy	Physical
in	O
the	O
control	O
group	O
,	O
transient	O
deterioration	O
in	O
the	O
continuous	O
infusion	O
group	O
,	O
and	O
no	O
change	O
in	O
the	O
multiple	O
injection	O
group	O
.	O

Half	O
the	O
patients	O
receiving	O
continuous	O
infusion	O
and	O
multiple	O
injections	O
developed	O
retinal	Physical
cotton	Physical
wool	Physical
spots	Physical
after	O
three	O
to	O
six	O
months	O
.	O

These	O
changes	O
regressed	O
in	O
all	O
but	O
four	O
patients	O
after	O
12	O
months	O
.	O

Control	O
patients	O
did	O
not	O
develop	O
cotton	Physical
wool	Physical
spots	Physical
.	O

Patients	O
who	O
developed	O
cotton	O
wool	O
spots	O
are	O
characterised	O
by	O
a	O
larger	O
decrement	O
in	O
glycosylated	Physical
haemoglobin	Physical
and	O
blood	Physical
glucose	Physical
values	Physical
,	O
more	O
frequent	O
episodes	Physical
of	Physical
hypoglycaemia	Physical
,	O
a	O
longer	Physical
duration	Physical
of	Physical
diabetes	Physical
,	O
and	O
more	Physical
severe	Physical
retinopathy	Physical
at	O
onset	O
.	O

A	O
large	O
and	O
rapid	O
fall	O
in	O
blood	Physical
glucose	Physical
concentration	Physical
may	O
promote	O
transient	O
deterioration	O
of	O
diabetic	O
retinopathy	O
.	O

HOXB13	O
G84E	O
mutation	O
in	O
Finland	O
:	O
population-based	O
analysis	O
of	O
prostate	O
,	O
breast	O
,	O
and	O
colorectal	O
cancer	O
risk	O
.	O

BACKGROUND	O
A	O
recently	O
identified	O
germline	O
mutation	O
G84E	O
in	O
HOXB13	O
was	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
prostate	O
cancer	O
.	O

In	O
a	O
family-based	O
analysis	O
by	O
The	O
International	O
Consortium	O
for	O
Prostate	O
Cancer	O
Genetics	O
(	O
ICPCG	O
)	O
,	O
the	O
G84E	O
mutation	O
was	O
most	O
prevalent	O
in	O
families	O
from	O
the	O
Nordic	O
countries	O
of	O
Finland	O
(	O
22.4	O
%	O
)	O
and	O
Sweden	O
(	O
8.2	O
%	O
)	O
.	O

METHODS	O
To	O
further	O
investigate	O
the	O
importance	O
of	O
G84E	O
in	O
the	O
Finns	O
,	O
we	O
determined	O
its	O
frequency	O
in	O
more	O
than	O
4,000	O
prostate	O
cancer	O
cases	O
and	O
5,000	O
controls	O
.	O

In	O
addition	O
,	O
986	O
breast	O
cancer	O
and	O
442	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
cases	O
were	O
studied	O
.	O

Genotyping	O
was	O
conducted	O
using	O
TaqMan	O
,	O
MassARRAY	O
iPLEX	O
,	O
and	O
sequencing	O
.	O

Statistical	O
analyses	O
were	O
conducted	O
using	O
Fisher	O
exact	O
test	O
,	O
and	O
overall	Mortality
survival	Mortality
was	O
analyzed	O
using	O
Cox	O
modeling	O
.	O

RESULTS	O
The	O
frequency	Physical
of	Physical
the	Physical
G84E	Physical
mutation	Physical
was	O
significantly	O
higher	O
among	O
patients	O
with	O
prostate	O
cancer	O
and	O
highest	O
among	O
patients	O
with	O
a	O
family	O
history	O
of	O
the	O
disease	O
,	O
hereditary	O
prostate	O
cancer	O
[	O
8.4	O
%	O
vs.	O
1.0	O
%	O
in	O
controls	O
;	O
OR	O
8.8	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
4.9-15.7	O
]	O
.	O

The	O
mutation	Physical
contributed	O
significantly	O
to	O
younger	O
age	O
(	O
?55	O
years	O
)	O
at	O
onset	O
and	O
high	O
prostate-specific	O
antigen	O
(	O
PSA	O
;	O
?20	O
ng/mL	O
)	O
at	O
diagnosis	O
.	O

An	O
association	O
with	O
increased	Physical
prostate	Physical
cancer	Physical
risk	Physical
in	O
patients	O
with	O
prior	O
benign	O
prostate	O
hyperplasia	O
(	O
BPH	O
)	O
diagnosis	O
was	O
also	O
revealed	O
.	O

No	O
statistically	O
significant	O
evidence	O
for	O
a	O
contribution	O
in	O
CRC	O
risk	O
was	O
detected	O
,	O
but	O
a	O
suggestive	O
role	O
for	O
the	O
mutation	O
was	O
observed	O
in	O
familial	O
BRCA1/2-negative	O
breast	O
cancer	O
.	O

CONCLUSIONS	O
These	O
findings	O
confirm	O
an	O
increased	O
cancer	O
risk	O
associated	O
with	O
the	O
G84E	O
mutation	O
in	O
the	O
Finnish	O
population	O
,	O
particularly	O
for	O
early-onset	O
prostate	O
cancer	O
and	O
cases	O
with	O
substantially	O
elevated	O
PSA	O
.	O

IMPACT	O
This	O
study	O
confirms	O
the	O
overall	O
importance	O
of	O
the	O
HOXB13	O
G84E	O
mutation	O
in	O
prostate	O
cancer	O
susceptibility	O
.	O

[	O
The	O
effect	O
of	O
thoracic	O
peridural	O
analgesia	O
on	O
the	O
cortisol	Physical
and	Physical
glucose	Physical
response	Physical
in	O
surgery	O
of	O
the	O
abdominal	O
aorta	O
]	O
.	O

UNLABELLED	O
It	O
has	O
been	O
shown	O
that	O
the	O
stress	O
response	O
to	O
lower	O
abdominal	O
surgery	O
can	O
be	O
inhibited	O
by	O
epidural	O
analgesia	O
(	O
EA	O
)	O
.	O

But	O
EA	O
seems	O
to	O
have	O
little	O
influence	O
on	O
the	O
stress	O
reaction	O
to	O
major	O
abdominal	O
surgery	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
find	O
out	O
whether	O
EA	O
is	O
able	O
to	O
diminish	O
the	O
cortisol	Mental
and	Mental
glucose	Mental
response	Mental
to	O
major	O
transabdominal	O
surgery	O
.	O

METHODS	O
31	O
patients	O
undergoing	O
elective	O
surgery	O
of	O
the	O
abdominal	O
aorta	O
were	O
subdivided	O
at	O
random	O
into	O
3	O
different	O
anaesthesia	O
groups	O
:	O
1.	O
halothane	O
anesthesia	O
,	O
2.	O
neuroleptanalgesia	O
(	O
NLA	O
)	O
and	O
3.	O
thoracic	O
EA	O
with	O
bupivacaine	O
(	O
0.5	O
%	O
)	O
in	O
combination	O
with	O
a	O
light	O
general	O
anesthesia	O
.	O

Some	O
patients	O
of	O
each	O
group	O
received	O
an	O
intravenous	O
infusion	O
of	O
5	O
%	O
glucose	O
.	O

Blood	O
samples	O
were	O
drawn	O
before	O
anesthesia	O
,	O
after	O
intubation	O
,	O
5	O
times	O
during	O
surgery	O
and	O
at	O
the	O
end	O
of	O
the	O
operation	O
and	O
were	O
analysed	O
for	O
cortisol	O
and	O
glucose	O
.	O

During	O
the	O
early	O
postoperative	O
period	O
,	O
1	O
,	O
2	O
and	O
24	O
h	O
after	O
surgery	O
,	O
only	O
cortisol	Mental
was	O
measured	O
.	O

RESULTS	O
Only	O
the	O
glucose	Physical
levels	Physical
of	O
patients	O
who	O
received	O
no	O
carbohydrate-containing	O
infusion	O
fluids	O
were	O
used	O
for	O
evaluation	O
of	O
the	O
stress	O
response	O
.	O

In	O
the	O
halothane	O
group	O
,	O
there	O
was	O
a	O
significant	O
increase	O
of	O
the	O
mean	Physical
cortisol	Physical
and	Physical
glucose	Physical
levels	Physical
after	O
the	O
start	O
of	O
surgery	O
.	O

No	O
intraoperative	O
elevations	O
of	O
blood	Physical
glucose	Physical
and	O
cortisol	Physical
were	O
seen	O
in	O
the	O
EA	O
group	O
.	O

Patients	O
of	O
the	O
NLA	O
group	O
showed	O
no	O
hyperglycaemia	O
and	O
only	O
mild	O
elevations	O
of	O
the	O
cortisol	O
levels	O
during	O
the	O
intraoperative	O
period	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Zoledronic	O
acid	O
significantly	O
reduces	O
skeletal	O
complications	O
compared	O
with	O
placebo	O
in	O
Japanese	O
women	O
with	O
bone	O
metastases	O
from	O
breast	O
cancer	O
:	O
a	O
randomized	O
,	O
placebo-controlled	O
trial	O
.	O

PURPOSE	O
To	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
zoledronic	O
acid	O
for	O
the	O
treatment	O
of	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
Women	O
with	O
bone	O
metastases	O
(	O
N	O
=	O
228	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
4	O
mg	O
zoledronic	O
acid	O
(	O
n	O
=	O
114	O
)	O
or	O
placebo	O
(	O
n	O
=	O
114	O
)	O
via	O
15-minute	O
infusions	O
every	O
4	O
weeks	O
for	O
1	O
year	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
skeletal-related	O
event	O
(	O
SRE	O
)	O
rate	O
ratio	O
between	O
treatment	O
groups	O
.	O

An	O
SRE	O
was	O
defined	O
as	O
pathologic	O
fracture	O
,	O
spinal	O
cord	O
compression	O
,	O
and	O
radiation	O
or	O
surgery	O
to	O
bone	O
.	O

Secondary	O
end	O
points	O
included	O
percentage	O
of	O
patients	O
with	O
at	O
least	O
one	O
SRE	O
,	O
time-to-first	O
SRE	O
,	O
and	O
Andersen-Gill	O
multiple-event	O
analysis	O
.	O

RESULTS	O
The	O
SRE	Physical
rate	Physical
ratio	Physical
at	O
1	O
year	O
(	O
excluding	O
HCM	O
and	O
adjusted	O
for	O
prior	O
fracture	O
)	O
was	O
0.61	O
(	O
permutation	O
test	O
;	O
P	O
=	O
.027	O
)	O
,	O
indicating	O
that	O
zoledronic	O
acid	O
reduced	O
the	O
rate	Physical
of	Physical
SRE	Physical
by	O
39	O
%	O
compared	O
with	O
placebo	O
.	O

The	O
percentage	Physical
of	Physical
patients	Physical
with	Physical
at	Physical
least	Physical
one	Physical
SRE	Physical
(	Physical
excluding	Physical
HCM	Physical
)	Physical
was	O
significantly	O
reduced	O
by	O
20	O
%	O
by	O
zoledronic	O
acid	O
(	O
29.8	O
%	O
v	O
49.6	O
%	O
for	O
placebo	O
;	O
P	O
=	O
.003	O
)	O
.	O

Zoledronic	O
acid	O
significantly	Physical
delayed	Physical
time-to-first	Physical
SRE	Physical
(	O
median	O
not	O
reached	O
v	O
364	O
days	O
;	O
Cox	O
regression	O
;	O
P	O
=	O
.007	O
)	O
and	O
reduced	Physical
the	Physical
risk	Physical
of	Physical
SREs	Physical
by	O
41	O
%	O
in	O
multiple	O
event	O
analysis	O
(	O
risk	O
ratio	O
=	O
0.59	O
;	O
P	O
=	O
.019	O
)	O
compared	O
with	O
placebo	O
.	O

Zoledronic	O
acid	O
was	O
well	O
tolerated	Others
with	O
a	O
safety	O
profile	O
similar	O
to	O
placebo	O
.	O

No	O
patient	O
treated	O
with	O
zoledronic	O
acid	O
had	O
grade	O
3	O
or	O
4	O
serum	O
creatinine	O
increase	O
.	O

CONCLUSION	O
Zoledronic	O
acid	O
significantly	O
reduced	O
skeletal	O
complications	O
compared	O
with	O
placebo	O
across	O
multiple	O
end	O
points	O
in	O
Japanese	O
women	O
with	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O

Uncomplicated	O
moderate	O
coronary	O
artery	O
dissections	O
after	O
balloon	O
angioplasty	O
:	O
good	O
outcome	O
without	O
stenting	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
relation	O
between	O
moderate	O
coronary	O
dissections	O
,	O
coronary	O
flow	O
velocity	O
reserve	O
(	O
CFVR	O
)	O
,	O
and	O
long	O
term	O
outcome	O
.	O

METHODS	O
523	O
patients	O
undergoing	O
balloon	O
angioplasty	O
and	O
sequential	O
intracoronary	O
Doppler	O
measurements	O
were	O
examined	O
as	O
part	O
of	O
the	O
DEBATE	O
II	O
trial	O
(	O
Doppler	O
endpoints	O
balloon	O
angioplasty	O
trial	O
Europe	O
)	O
.	O

After	O
successful	O
balloon	O
angioplasty	O
,	O
patients	O
were	O
randomised	O
to	O
stenting	O
or	O
no	O
further	O
treatment	O
.	O

Dissections	O
were	O
graded	O
at	O
the	O
core	O
laboratory	O
by	O
two	O
observers	O
and	O
divided	O
into	O
four	O
categories	O
:	O
none	O
,	O
mild	O
(	O
type	O
A-B	O
)	O
,	O
moderate	O
(	O
type	O
C	O
)	O
,	O
severe	O
(	O
types	O
D	O
to	O
F	O
)	O
.	O

Patients	O
with	O
severe	O
dissections	O
(	O
n	O
=	O
128	O
)	O
or	O
without	O
available	O
reference	O
vessel	O
CFVR	O
(	O
n	O
=	O
139	O
)	O
were	O
excluded	O
.	O

The	O
remaining	O
256	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
according	O
to	O
the	O
presence	O
(	O
group	O
A	O
,	O
n	O
=	O
45	O
)	O
or	O
absence	O
(	O
group	O
B	O
,	O
n	O
=	O
211	O
)	O
of	O
moderate	O
dissection	O
.	O

RESULTS	O
Following	O
balloon	O
angioplasty	O
,	O
there	O
was	O
no	O
difference	O
in	O
CFVR	Physical
between	O
the	O
two	O
groups	O
.	O

At	O
12	O
months	O
follow	O
up	O
,	O
a	O
higher	O
rate	O
of	O
major	Adverseeffect
adverse	Adverseeffect
cardiac	Adverseeffect
events	Adverseeffect
was	O
observed	O
overall	O
in	O
group	O
A	O
than	O
in	O
group	O
B	O
(	O
10	O
(	O
22	O
%	O
)	O
v	O
23	O
(	O
11	O
%	O
)	O
,	O
p	O
=	O
0.041	O
)	O
.	O

However	O
,	O
the	O
risk	Adverseeffect
of	Adverseeffect
major	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
was	O
similar	O
in	O
the	O
subgroups	O
receiving	O
balloon	O
angioplasty	O
(	O
group	O
A	O
,	O
6	O
(	O
19	O
%	O
)	O
v	O
group	O
B	O
,	O
16	O
(	O
16	O
%	O
)	O
,	O
NS	O
)	O
.	O

Among	O
group	O
A	O
patients	O
,	O
the	O
adverse	Adverseeffect
events	Adverseeffect
risk	Adverseeffect
was	O
greater	O
in	O
those	O
randomised	O
to	O
stenting	O
(	O
odds	O
ratios	O
6.603	O
v	O
1.197	O
,	O
p	O
=	O
0.046	O
)	O
,	O
whereas	O
there	O
was	O
no	O
difference	O
in	O
risk	O
if	O
the	O
group	O
was	O
analysed	O
according	O
to	O
whether	O
the	O
CFVR	O
was	O
<	O
2.5	O
or	O
>	O
/=	O
2.5	O
after	O
balloon	O
angioplasty	O
.	O

CONCLUSIONS	O
Moderate	O
dissections	O
left	O
untreated	O
result	O
in	O
no	O
increased	O
risk	Adverseeffect
of	Adverseeffect
major	Adverseeffect
adverse	Adverseeffect
cardiac	Adverseeffect
events	Adverseeffect
.	O

Additional	O
stenting	O
does	O
not	O
improve	O
the	O
long	O
term	O
outcome	O
.	O

A	O
randomized	O
controlled	O
trial	O
to	O
evaluate	O
the	O
efficacy	Others
of	O
ultrasound-guided	O
laser	O
photocoagulation	O
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
.	O

This	O
randomized	O
controlled	O
study	O
was	O
designed	O
to	O
test	O
the	O
efficacy	O
and	O
safety	O
of	O
percutaneous	O
ultrasound	O
(	O
US	O
)	O
-guided	O
laser	O
photocoagulation	O
(	O
PLP	O
)	O
for	O
treatment	O
of	O
subjects	O
with	O
compressive	O
symptoms	O
due	O
to	O
benign	Physical
thyroid	Physical
nodules	Physical
and/or	O
at	O
high	O
surgical	O
risk	O
.	O

Twenty	O
six	O
subjects	O
were	O
randomized	O
to	O
the	O
intervention	O
(	O
no	O
.	O

13	O
,	O
age	O
68+/-3	O
yr	O
,	O
mean+/-SEM	O
)	O
or	O
observation	O
(	O
no	O
.	O

13	O
,	O
age	O
71+/-2	O
yr	O
)	O
groups	O
.	O

In	O
the	O
control	O
group	O
,	O
the	O
volume	Physical
of	Physical
nodules	Physical
did	O
not	O
significantly	O
change	O
over	O
the	O
30	O
week	O
period	O
of	O
observation	O
.	O

In	O
the	O
intervention	O
group	O
,	O
median	O
nodule	Physical
volume	Physical
at	O
baseline	O
was	O
8.2	O
ml	O
(	O
range	O
2.8-26.9	O
)	O
and	O
was	O
not	O
significantly	O
different	O
from	O
that	O
of	O
the	O
control	O
group	O
.	O

Nodules	Physical
decreased	O
significantly	O
(	O
p	O
<	O
0.0001	O
)	O
by	O
22	O
%	O
after	O
2	O
weeks	O
(	O
6.5	O
ml	O
;	O
range	O
2.4-16.7	O
)	O
and	O
by	O
44	O
%	O
after	O
30	O
weeks	O
(	O
4.6	O
ml	O
;	O
range	O
0.69-14.2	O
)	O
.	O

Energy	O
given	O
was	O
correlated	O
(	O
p	O
<	O
0.05	O
)	O
with	O
the	O
reduction	O
of	O
thyroid	Physical
nodule	Physical
volume	Physical
.	O

All	O
patients	O
tolerated	O
the	O
treatment	O
well	O
and	O
reported	O
relief	O
from	O
compressive	Physical
and	Physical
cosmetic	Physical
complaints	Physical
(	O
p	O
<	O
0.05	O
)	O
.	O

At	O
the	O
time	O
of	O
enrolment	O
7/13	O
(	O
54	O
%	O
)	O
and	O
6/13	O
(	O
46	O
%	O
)	O
of	O
patients	O
in	O
the	O
intervention	O
and	O
control	O
groups	O
,	O
respectively	O
,	O
had	O
sub	Physical
clinical	Physical
hyperthyroidism	Physical
.	O

PLP	O
normalized	O
thyroid	Physical
function	Physical
at	O
6	O
and	O
30	O
weeks	O
after	O
treatment	O
.	O

In	O
conclusion	O
,	O
PLP	O
is	O
a	O
promising	O
safe	Others
and	O
effective	Others
procedure	O
for	O
treatment	O
of	O
benign	O
thyroid	O
nodules	O
in	O
patients	O
at	O
high	O
surgical	O
risk	O
.	O

Preliminary	O
findings	O
of	O
the	O
minimally-invasive	O
surgery	O
plus	O
rtPA	O
for	O
intracerebral	Physical
hemorrhage	Physical
evacuation	Physical
(	O
MISTIE	O
)	O
clinical	O
trial	O
.	O

INTRODUCTION	O
Compared	O
to	O
ischemic	O
stroke	O
,	O
intracerebral	O
hemorrhage	O
(	O
ICH	O
)	O
is	O
easily	O
and	O
rapidly	O
identified	O
,	O
occurs	O
in	O
younger	O
patients	O
,	O
and	O
produces	O
relatively	O
small	O
initial	O
injury	O
to	O
cerebral	O
tissues	O
--	O
all	O
factors	O
suggesting	O
that	O
interventional	O
amelioration	O
is	O
possible	O
.	O

Investigations	O
from	O
the	O
last	O
decade	O
established	O
that	O
extent	O
of	O
ICH-mediated	O
brain	O
injury	O
relates	O
directly	O
to	O
blood	O
clot	O
volume	O
and	O
duration	O
of	O
blood	O
exposure	O
to	O
brain	O
tissue	O
.	O

Using	O
minimally-invasive	O
surgery	O
plus	O
recombinant	O
tissue	O
plasminogen	O
activator	O
(	O
rtPA	O
)	O
,	O
MISTIE	O
investigators	O
explored	O
aggressive	O
avenues	O
to	O
treat	O
ICH	O
.	O

METHODS	O
We	O
investigated	O
the	O
difference	O
between	O
surgical	O
intervention	O
plus	O
rtPA	O
and	O
standard	O
medical	O
management	O
for	O
ICH	O
.	O

Subjects	O
in	O
both	O
groups	O
were	O
medically	O
managed	O
according	O
to	O
standard	O
ICU	O
protocols	O
.	O

Subjects	O
randomized	O
to	O
surgery	O
underwent	O
stereotactic	O
catheter	O
placement	O
and	O
clot	O
aspiration	O
.	O

Injections	O
of	O
rtPA	O
were	O
then	O
given	O
through	O
hematoma	O
catheter	O
every	O
8	O
h	O
,	O
up	O
to	O
9	O
doses	O
,	O
or	O
until	O
a	O
clot-reduction	O
endpoint	O
.	O

After	O
each	O
injection	O
the	O
system	O
was	O
flushed	O
with	O
sterile	O
saline	O
and	O
closed	O
for	O
60	O
min	O
before	O
opening	O
to	O
spontaneous	O
drainage	O
.	O

RESULTS	O
Average	Physical
aspiration	Physical
of	Physical
clots	Physical
for	O
all	O
patients	O
randomized	O
to	O
surgery	O
plus	O
rtPA	O
was	O
20	O
%	O
of	O
mean	O
initial	O
clot	O
size	O
.	O

After	O
acute	O
treatment	O
phase	O
(	O
aspiration	O
plus	O
rtPA	O
)	O
,	O
clot	Physical
was	O
reduced	O
an	O
average	O
of	O
46	O
%	O
.	O

Recorded	O
adverse	O
events	O
were	O
within	O
safety	O
limits	O
,	O
including	O
30-day	Mortality
mortality	Mortality
,	O
8	O
%	O
;	O
symptomatic	Physical
re-bleeding	Physical
,	O
8	O
%	O
;	O
and	O
bacterial	Physical
ventriculitis	Physical
,	O
0	O
%	O
.	O

Patients	O
randomized	O
to	O
medical	O
management	O
showed	O
4	O
%	O
clot	Physical
resolution	Physical
in	O
a	O
similar	O
time	O
window	O
.	O

Preliminary	O
analysis	O
indicates	O
that	O
clot	Physical
resolution	Physical
rates	Physical
are	O
greatly	O
dependent	O
on	O
catheter	O
placement	O
.	O

Location	O
of	O
ICH	O
also	O
affects	O
efficacy	O
of	O
aggressive	O
treatment	O
of	O
ICH	O
.	O

CONCLUSION	O
There	O
is	O
tentative	O
indication	O
that	O
minimally-invasive	O
surgery	O
plus	O
rtPA	O
shows	O
greater	Physical
clot	Physical
resolution	Physical
than	O
traditional	O
medical	O
management	O
.	O

Final	Physical
height	Physical
in	Physical
girls	Physical
with	O
turner	O
syndrome	O
after	O
long-term	O
growth	O
hormone	O
treatment	O
in	O
three	O
dosages	O
and	O
low	O
dose	O
estrogens	O
.	O

Although	O
GH	O
treatment	O
for	O
short	O
stature	O
in	O
Turner	O
syndrome	O
is	O
an	O
accepted	O
treatment	O
in	O
many	O
countries	O
,	O
which	O
GH	O
dosage	O
to	O
use	O
and	O
which	O
age	O
to	O
start	O
puberty	O
induction	O
are	O
issues	O
of	O
debate	O
.	O

This	O
study	O
shows	O
final	Physical
height	Physical
(	Physical
FH	Physical
)	Physical
in	O
60	O
girls	O
with	O
Turner	O
syndrome	O
treated	O
in	O
a	O
randomized	O
dose-response	O
trial	O
,	O
combining	O
GH	O
treatment	O
with	O
low	O
dose	O
estrogens	O
at	O
a	O
relatively	O
young	O
age	O
.	O

Girls	O
were	O
randomly	O
assigned	O
to	O
group	O
A	O
(	O
4	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
approximately	O
0.045	O
mg/kg/d	O
)	O
,	O
group	O
B	O
(	O
first	O
year	O
,	O
4	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
thereafter	O
6	O
IU/m	O
(	O
2	O
)	O
.d	O
)	O
,	O
or	O
group	O
C	O
(	O
first	O
year	O
,	O
4	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
second	O
year	O
,	O
6	O
IU/m	O
(	O
2	O
)	O
.d	O
;	O
thereafter	O
,	O
8	O
IU/m	O
(	O
2	O
)	O
.d	O
)	O
.	O

After	O
a	O
minimum	O
of	O
4	O
yr	O
of	O
GH	O
treatment	O
,	O
at	O
a	O
mean	O
age	O
of	O
12.7	O
+/-	O
0.7	O
yr	O
,	O
low	O
dose	O
micronized	O
17beta-estradiol	O
was	O
given	O
orally	O
.	O

After	O
a	O
mean	O
duration	Others
of	Others
GH	Others
treatment	Others
of	O
8.6	O
+/-	O
1.9	O
yr	O
,	O
FH	O
was	O
reached	O
at	O
a	O
mean	O
age	O
of	O
15.8	O
+/-	O
0.9	O
yr.	O
FH	Physical
,	O
expressed	O
in	O
centimeters	O
or	O
SD	O
score	O
,	O
was	O
157.6	O
+/-	O
6.5	O
or	O
-1.6	O
+/-	O
1.0	O
in	O
group	O
A	O
,	O
162.9	O
+/-	O
6.1	O
or	O
-0.7	O
+/-	O
1.0	O
in	O
group	O
B	O
,	O
and	O
163.6	O
+/-	O
6.0	O
or	O
-0.6	O
+/-	O
1.0	O
in	O
group	O
C.	O
The	O
difference	O
in	O
FH	Physical
in	Physical
centimeters	Physical
,	O
corrected	O
for	O
height	O
SD	O
score	O
and	O
age	O
at	O
start	O
of	O
treatment	O
,	O
was	O
significant	O
between	O
groups	O
A	O
and	O
B	O
[	O
regression	O
coefficient	O
,	O
4.1	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
1.4	O
,	O
6.9	O
;	O
P	O
<	O
0.01	O
]	O
,	O
and	O
groups	O
A	O
and	O
C	O
(	O
coefficient	O
,	O
5.0	O
;	O
95	O
%	O
CI	O
,	O
2.3	O
,	O
7.7	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
between	O
groups	O
B	O
and	O
C	O
(	O
coefficient	O
,	O
0.9	O
;	O
95	O
%	O
CI	O
,	O
-1.8	O
,	O
3.6	O
)	O
.	O

Fifty	O
of	O
the	O
60	O
girls	O
(	O
83	O
%	O
)	O
had	O
reached	O
a	O
normal	Physical
FH	Physical
(	O
FH	O
SD	O
score	O
,	O
more	O
than	O
-2	O
)	O
.	O

After	O
starting	O
estrogen	O
treatment	O
,	O
the	O
decrease	Others
in	Others
height	Others
velocity	Others
(	Others
HV	Others
)	Others
changed	Others
significantly	Others
to	Others
a	Others
stable	Others
HV	Others
,	O
without	O
affecting	O
bone	Physical
maturation	Physical
(	O
change	O
in	O
bone	O
age/change	O
in	O
chronological	O
age	O
)	O
.	O

The	O
following	O
variables	O
contributed	O
significantly	O
to	O
predicting	O
FH	Physical
SD	Physical
score	Physical
:	O
GH	Physical
dose	Physical
,	O
height	Physical
SD	Physical
score	Physical
(	O
ref	O
.	O

normal	O
girls	O
)	O
,	O
chronological	Physical
age	Physical
at	Physical
start	Physical
of	Physical
treatment	Physical
,	O
and	O
HV	Physical
in	O
the	O
first	O
year	O
of	O
GH	O
treatment	O
.	O

GH	O
treatment	O
was	O
well	Others
tolerated	Others
.	O

In	O
conclusion	O
,	O
GH	O
treatment	O
leads	O
to	O
a	O
normalization	O
of	O
FH	Physical
in	O
most	O
girls	O
,	O
even	O
when	O
puberty	O
is	O
induced	O
at	O
a	O
normal	O
pubertal	O
age	O
.	O

The	O
optimal	O
GH	O
dosage	O
depends	O
on	O
height	O
and	O
age	O
at	O
the	O
start	O
of	O
treatment	O
and	O
first	O
year	O
HV	O
.	O

Closure	O
of	O
the	O
femoral	O
artery	O
after	O
cardiac	O
catheterization	O
:	O
a	O
comparison	O
of	O
Angio-Seal	O
,	O
StarClose	O
,	O
and	O
manual	O
compression	O
.	O

OBJECTIVES	O
To	O
compare	O
Angio-Seal	O
(	O
AS	O
)	O
and	O
StarClose	O
(	O
SC	O
)	O
and	O
manual	O
compression	O
(	O
MC	O
)	O
on	O
efficacy	Physical
of	Physical
hemostasis	Physical
,	O
complication	Adverseeffect
rate	Adverseeffect
,	O
safety	Others
of	Others
early	Others
mobilization	Others
,	O
and	O
patient	Others
comfort	Others
.	O

BACKGROUND	O
Closure	O
of	O
the	O
femoral	O
artery	O
after	O
cardiac	O
catheterization	O
can	O
be	O
obtained	O
through	O
different	O
methods	O
.	O

Today	O
,	O
physicians	O
can	O
choose	O
from	O
a	O
number	O
of	O
different	O
devices	O
to	O
achieve	O
arterial	O
closure	O
.	O

METHODS	O
In	O
a	O
prospective	O
trial	O
450	O
patients	O
were	O
randomized	O
to	O
AS	O
,	O
SC	O
,	O
or	O
MC	O
.	O

Patients	O
were	O
mobilized	O
1	O
to	O
2	O
hr	O
after	O
device	O
placement	O
,	O
and	O
6	O
hr	O
after	O
MC	O
.	O

Data	O
were	O
collected	O
during	O
hospital	O
admission	O
and	O
by	O
telephone	O
at	O
one	O
month	O
after	O
hospital	O
discharge	O
.	O

RESULTS	O
Devices	O
were	O
used	O
in	O
138/150	O
allocated	O
to	O
AS	O
and	O
124/150	O
allocated	O
to	O
SC	O
patients	O
(	O
92	O
%	O
vs.	O
83	O
%	O
,	O
P	O
=	O
0.015	O
)	O
Patients	O
with	O
MC	O
experienced	O
more	O
pain	Pain
during	Pain
sheath	Pain
removal	Pain
than	O
patients	O
receiving	O
a	O
device	O
,	O
and	O
rated	O
their	O
period	Others
of	Others
bed	Others
rest	Others
as	O
less	O
comfortable	O
.	O

Oozing	Others
and	Others
need	Others
for	Others
pressure	Others
bandage	Others
at	Others
the	Others
puncture	Others
site	Others
were	O
observed	O
in	O
37	O
AS	O
patients	O
and	O
57	O
SC	O
patients	O
(	O
25	O
%	O
vs.	O
38	O
%	O
,	O
P	O
=	O
0.002	O
)	O
.	O

Hematoma	Adverseeffect
occurred	O
in	O
15	O
AS	O
patients	O
,	O
in	O
17	O
SC	O
patients	O
,	O
and	O
in	O
14	O
MC	O
patients	O
(	O
11	O
vs.	O
14	O
vs.	O
9	O
%	O
,	O
ns	O
)	O
.	O

CONCLUSION	O
There	O
is	O
no	O
difference	O
in	O
safety	Others
between	O
the	O
three	O
methods	O
of	O
arterial	O
closure	O
.	O

SC	O
was	O
more	O
often	O
not	O
used	O
or	O
successfully	O
deployed	O
.	O

SC	O
patients	O
more	O
often	O
had	O
continuing	O
oozing	Physical
.	O

On	O
patient	Others
comfort	Others
,	O
closure	O
devices	O
performed	O
better	O
than	O
MC	O
.	O

Early	O
ambulation	O
in	O
patients	O
with	O
a	O
closure	O
device	O
is	O
safe	O
.	O

AS	O
is	O
the	O
preferred	O
method	O
of	O
arterial	O
closure	O
after	O
cardiac	O
catheterization	O
.	O

Injection	Pain
pain	Pain
with	O
propofol	O
.	O

Reduction	O
with	O
aspiration	O
of	O
blood	O
.	O

A	O
randomised	O
,	O
controlled	O
,	O
single-blind	O
study	O
was	O
performed	O
on	O
100	O
patients	O
to	O
investigate	O
a	O
new	O
method	O
of	O
reducing	O
pain	Pain
on	O
propofol	O
injection	O
.	O

Aspiration	O
of	O
2	O
ml	O
of	O
the	O
patient	O
's	O
blood	O
into	O
a	O
syringe	O
of	O
propofol	O
immediately	O
before	O
injection	O
was	O
compared	O
with	O
the	O
addition	O
of	O
lignocaine	O
20	O
mg	O
or	O
normal	O
saline	O
2	O
ml	O
to	O
the	O
propofol	O
before	O
injection	O
.	O

The	O
addition	O
of	O
blood	O
was	O
significantly	O
more	O
effective	O
in	O
reducing	Pain
pain	Pain
on	Pain
injection	Pain
than	O
the	O
addition	O
of	O
saline	O
(	O
p	O
<	O
0.001	O
)	O
,	O
but	O
was	O
not	O
significantly	O
more	O
effective	Others
than	O
the	O
addition	O
of	O
lignocaine	O
.	O

Vancomycin	O
added	O
to	O
empirical	O
combination	O
antibiotic	O
therapy	O
for	O
fever	O
in	O
granulocytopenic	O
cancer	O
patients	O
.	O

European	O
Organization	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
(	O
EORTC	O
)	O
International	O
Antimicrobial	O
Therapy	O
Cooperative	O
Group	O
and	O
the	O
National	O
Cancer	O
Institute	O
of	O
Canada-Clinical	O
Trials	O
Group	O
.	O

A	O
total	O
of	O
747	O
febrile	O
granulocytopenic	O
patients	O
with	O
cancer	O
were	O
randomized	O
to	O
receive	O
ceftazidime	O
plus	O
amikacin	O
(	O
CA	O
)	O
with	O
or	O
without	O
vancomycin	O
(	O
V	O
)	O
as	O
initial	O
empirical	O
therapy	O
.	O

Single	O
gram-positive	O
bacteremias	O
responded	O
in	O
29	O
(	O
43	O
%	O
)	O
of	O
68	O
patients	O
treated	O
with	O
CA	O
and	O
in	O
48	O
(	O
72	O
%	O
)	O
of	O
67	O
treated	O
with	O
CAV	O
(	O
P	O
=	O
.001	O
)	O
.	O

For	O
single	O
gram-negative	O
bacteremias	O
and	O
clinically	O
documented	O
and	O
possible	O
infections	O
the	O
response	Others
rates	Others
of	O
CA	O
and	O
CAV	O
were	O
80	O
%	O
and	O
63	O
%	O
(	O
P	O
=	O
.17	O
)	O
,	O
55	O
%	O
and	O
75	O
%	O
(	O
P	O
=	O
.009	O
)	O
,	O
and	O
74	O
%	O
and	O
81	O
%	O
(	O
P	O
=	O
.16	O
)	O
,	O
respectively	O
.	O

However	O
,	O
for	O
patients	O
with	O
gram-positive	O
bacteremia	O
and	O
for	O
all	O
other	O
patients	O
,	O
there	O
were	O
no	O
differences	O
by	O
treatment	O
regimens	O
in	O
the	O
proportion	Physical
of	Physical
febrile	Physical
patients	Physical
on	O
each	O
trial	O
day	O
(	O
P	O
=	O
.85	O
,	O
P	O
=	O
.82	O
,	O
respectively	O
)	O
or	O
in	O
the	O
duration	Physical
of	Physical
fever	Physical
(	O
P	O
=	O
.22	O
,	O
P	O
=	O
.93	O
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
no	O
patient	O
with	O
gram-positive	O
bacteremia	O
died	Mortality
during	O
the	O
first	O
3	O
days	O
of	O
true	O
empirical	O
therapy	O
.	O

Antibiotic-associated	Adverseeffect
nephrotoxicity	Adverseeffect
was	O
more	O
frequent	O
in	O
patients	O
treated	O
with	O
vancomycin	O
(	O
6	O
%	O
vs.	O
2	O
%	O
,	O
P	O
=	O
.02	O
)	O
.	O

These	O
results	O
do	O
not	O
support	O
the	O
empirical	O
addition	O
of	O
vancomycin	O
to	O
initial	O
antibiotic	O
therapy	O
in	O
cancer	O
patients	O
with	O
fever	O
and	O
granulocytopenia	O
.	O

Clonidine	Physical
clearance	Physical
matures	O
rapidly	O
during	O
the	O
early	O
postnatal	O
period	O
:	O
a	O
population	O
pharmacokinetic	O
analysis	O
in	O
newborns	O
with	O
neonatal	O
abstinence	O
syndrome	O
.	O

The	O
population	O
pharmacokinetic	Physical
(	Physical
PK	Physical
)	Physical
profile	Physical
of	O
oral	O
clonidine	O
was	O
characterized	O
in	O
newborns	O
with	O
neonatal	O
abstinence	O
syndrome	O
,	O
and	O
significant	O
covariates	O
affecting	O
its	O
PK	O
parameters	O
were	O
identified	O
.	O

Plasma	Others
clonidine	Others
concentration	Others
data	Others
were	O
obtained	O
from	O
a	O
clinical	O
trial	O
in	O
which	O
36	O
newborns	O
,	O
aged	O
1	O
to	O
25	O
days	O
(	O
postnatal	O
age	O
,	O
PNA	O
)	O
and	O
weighing	O
2.1	O
to	O
3.9	O
kg	O
,	O
were	O
enrolled	O
to	O
take	O
multiple	O
oral	O
doses	O
of	O
clonidine	O
.	O

The	O
population	O
PK	Others
model	Others
of	Others
clonidine	Others
was	O
developed	O
by	O
NONMEM	O
,	O
and	O
significant	O
covariates	O
were	O
identified	O
,	O
followed	O
by	O
nonparametric	O
bootstraps	O
(	O
2000	O
replicates	O
)	O
and	O
simulation	O
experiments	O
.	O

A	O
1-compartment	O
open	O
linear	O
PK	O
model	O
was	O
chosen	O
to	O
describe	O
plasma	Others
concentrations	Others
of	Others
clonidine	Others
,	O
and	O
body	Physical
weight	Physical
and	Physical
PNA	Physical
were	O
significant	O
covariates	O
for	O
apparent	Others
clearance	Others
(	O
CL/F	O
)	O
as	O
follows	O
:	O
CL/F	O
(	O
L/h	O
)	O
=	O
15.2	O
?	O
[	O
body	O
weight	O
(	O
kg	O
)	O
/70	O
]	O
(	O
0.75	O
)	O
?	O
[	O
PNA	O
(	O
day	O
)	O
(	O
0.441	O
)	O
/	O
(	O
4.06	O
(	O
0.441	O
)	O
+	O
PNA	O
(	O
day	O
)	O
(	O
0.441	O
)	O
)	O
]	O
.	O

Furthermore	O
,	O
CL/F	O
of	O
clonidine	O
increased	O
rapidly	O
with	O
PNA	O
during	O
the	O
first	O
month	O
of	O
life	O
after	O
body	O
weight	O
was	O
adjusted	O
.	O

Any	O
optimal	O
dosage	O
regimen	O
for	O
clonidine	O
in	O
term	O
neonates	O
should	O
be	O
based	O
on	O
infant	O
's	O
age	O
and	O
body	O
weight	O
,	O
and	O
1.5	O
?g/kg	O
every	O
4	O
hours	O
is	O
proposed	O
starting	O
the	O
second	O
week	O
of	O
life	O
based	O
on	O
the	O
simulation	O
results	O
.	O

Using	O
a	O
laryngeal	O
tube	O
suction-device	O
(	O
LTS-D	O
)	O
reduces	O
the	O
no	Others
flow	Others
time	Others
in	O
a	O
single	O
rescuer	O
manikin	O
study	O
.	O

BACKGROUND	O
In	O
2005	O
,	O
the	O
European	O
Resuscitation	O
Council	O
and	O
the	O
American	O
Heart	O
Association	O
published	O
new	O
guidelines	O
for	O
Advanced	O
Life	O
Support	O
.	O

One	O
of	O
the	O
points	O
was	O
to	O
reduce	O
the	O
time	Others
without	Others
chest	Others
compressions	Others
in	O
the	O
first	O
phase	O
of	O
cardiac	O
arrest	O
.	O

OBJECTIVE	O
We	O
evaluated	O
in	O
a	O
manikin	O
model	O
whether	O
using	O
the	O
single-use	O
laryngeal	O
tube	O
with	O
suction	O
option	O
(	O
LTS-D	O
)	O
instead	O
of	O
endotracheal	O
intubation	O
(	O
ET	O
)	O
and	O
bag-mask-valve	O
ventilation	O
(	O
BMV	O
)	O
for	O
emergency	O
airway	O
management	O
could	O
reduce	O
the	O
no-flow	Others
time	Others
(	Others
NFT	Others
)	Others
.	O

The	O
NFT	O
is	O
defined	O
as	O
the	O
time	O
during	O
resuscitation	O
when	O
no	O
chest	O
compressions	O
take	O
place	O
.	O

METHODS	O
A	O
randomized	O
,	O
prospective	O
study	O
was	O
undertaken	O
with	O
150	O
volunteers	O
who	O
performed	O
management	O
of	O
a	O
standardized	O
simulated	O
cardiac	O
arrest	O
in	O
a	O
manikin	O
.	O

Every	O
participant	O
was	O
randomized	O
to	O
one	O
of	O
three	O
different	O
airway	O
management	O
groups	O
(	O
LTS-D	O
vs	O
.	O

ET	O
vs.	O
BMV	O
)	O
.	O

RESULTS	O
The	O
LTS-D	O
was	O
inserted	O
significantly	O
faster	O
than	O
the	O
ET	O
tube	O
(	O
15	O
s	O
vs.	O
44	O
s	O
,	O
respectively	O
,	O
p	O
<	O
0.01	O
)	O
.	O

During	O
the	O
cardiac	O
arrest	O
simulation	O
,	O
establishing	Others
and	Others
performing	Others
ventilation	Others
took	O
an	O
average	O
of	O
57	O
s	O
with	O
the	O
LTS-D	O
compared	O
to	O
116	O
s	O
with	O
ET	O
and	O
111	O
s	O
with	O
the	O
BMV	O
.	O

Using	O
the	O
LTS-D	O
significantly	O
reduced	O
NFT	Others
compared	O
to	O
ET	O
and	O
the	O
BMV	O
(	O
125	O
s	O
vs.	O
207	O
s	O
vs.	O
160	O
s	O
;	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
In	O
our	O
manikin	O
study	O
,	O
NFT	Others
was	O
reduced	O
significantly	O
when	O
the	O
LTS-D	O
was	O
used	O
when	O
compared	O
to	O
ET	O
and	O
BMV	O
.	O

The	O
results	O
of	O
our	O
manikin	O
study	O
suggest	O
that	O
for	O
personnel	O
not	O
experienced	O
in	O
tracheal	O
intubation	O
,	O
the	O
LTS-D	O
offers	O
a	O
good	O
alternative	O
to	O
ET	O
and	O
BMV	O
to	O
manage	O
the	O
airway	O
during	O
resuscitation	O
,	O
and	O
to	O
avoid	O
the	O
failure	O
to	O
achieve	O
tracheal	O
intubation	O
with	O
the	O
ET	O
,	O
and	O
the	O
failure	O
to	O
achieve	O
adequate	O
ventilation	O
with	O
the	O
BMV	O
.	O

Testing	O
three	O
different	O
cancer	O
genetics	O
registry	O
recruitment	O
methods	O
with	O
Hispanic	O
cancer	O
patients	O
and	O
their	O
family	O
members	O
previously	O
registered	O
in	O
local	O
cancer	O
registries	O
in	O
Texas	O
.	O

OBJECTIVE	O
To	O
increase	O
accrual	O
among	O
Hispanics	O
to	O
the	O
Cancer	O
Genetics	O
Network	O
national	O
cancer	O
genetics	O
registry	O
.	O

METHODS	O
Drawing	O
from	O
South	O
Texas	O
cancer	O
registries	O
,	O
444	O
Hispanic	O
men	O
and	O
women	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
experimental	O
conditions	O
:	O
standard	O
direct-mailed	O
procedures	O
(	O
X1	O
)	O
,	O
X1	O
plus	O
culturally	O
tailored	O
materials	O
(	O
X2	O
)	O
,	O
and	O
X2	O
plus	O
interpersonal	O
phone	O
contact	O
(	O
X3	O
)	O
.	O

Participants	O
were	O
also	O
surveyed	O
about	O
the	O
effectiveness	O
of	O
the	O
education	O
materials	O
and	O
the	O
phone	O
contact	O
.	O

A	O
refusal	O
survey	O
was	O
provided	O
for	O
those	O
who	O
declined	O
to	O
join	O
the	O
study	O
.	O

RESULTS	O
A	O
total	O
of	O
154	O
individuals	O
joined	O
the	O
Cancer	O
Genetics	O
Network	O
.	O

The	O
X3	Others
condition	Others
yielded	Others
the	Others
greatest	Others
accrual	Others
(	O
43.2	O
%	O
)	O
compared	O
to	O
X1	O
(	O
30.9	O
%	O
)	O
and	O
X2	O
(	O
29.9	O
%	O
;	O
p	O
<	O
0.05	O
)	O
.	O

Tailored	O
materials	O
appeared	O
to	O
have	O
no	O
effect	O
but	O
were	O
highly	O
regarded	O
.	O

The	O
main	O
reasons	O
for	O
not	O
participating	O
were	O
a	O
lack	Mental
of	Mental
interest	Mental
and	Mental
time	Mental
requirements	Mental
.	O

CONCLUSION	O
Interpersonal	O
communication	O
can	O
have	O
a	O
powerful	O
effect	O
on	O
recruitment	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
to	O
determine	O
the	O
cost-efficacy	O
of	O
more	O
labor-intensive	O
approaches	O
to	O
registry	O
accrual	O
.	O

Fusidic	O
acid	O
prophylaxis	O
before	O
cataract	O
surgery	O
:	O
patient	O
self-administration	O
.	O

In	O
a	O
placebo-controlled	O
,	O
randomised	O
,	O
double-blind	O
clinical	O
trial	O
,	O
the	O
authors	O
evaluated	O
the	O
efficacy	O
of	O
patient-administered	O
1	O
%	O
fusidic	O
acid	O
viscous	O
eye	O
drops	O
in	O
clearing	O
the	O
commonest	O
organisms	O
causing	O
pseudophakic	O
endophthalmitis	O
(	O
Staphylococcus	O
epidermidis	O
and	O
aureus	O
)	O
from	O
the	O
lids	O
and	O
conjunctivae	O
of	O
79	O
patients	O
before	O
cataract	O
surgery	O
.	O

The	O
treatment	O
group	O
self-administered	O
fusidic	O
acid	O
viscous	O
eye	O
drops	O
four	O
times	O
daily	O
for	O
seven	O
days	O
before	O
surgery	O
;	O
the	O
placebo	O
group	O
received	O
inert	O
ophthalmic	O
drops	O
.	O

Fellow	O
eyes	O
of	O
both	O
groups	O
remained	O
untreated	O
as	O
a	O
natural	O
control	O
.	O

Lower	O
fornix	O
and	O
lid	O
margin	O
cultures	O
were	O
taken	O
from	O
both	O
eyes	O
before	O
and	O
after	O
treatment	O
.	O

Before	O
treatment	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
in	O
organism	Physical
counts	Physical
between	O
the	O
groups	O
.	O

After	O
treatment	O
,	O
eyes	O
receiving	O
fusidic	O
acid	O
were	O
more	O
likely	O
to	O
be	O
free	O
of	O
clinically	O
relevant	O
Staphylococcus	O
spp	O
.	O

than	O
all	O
pre-treatment	O
eyes	O
(	O
for	O
lids	O
,	O
P	O
<	O
0.001	O
;	O
conjunctivae	O
,	O
P	O
=	O
0.02	O
)	O
.	O

A	O
highly	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
number	Physical
of	Physical
lid	Physical
margins	Physical
were	O
rendered	O
'clinically	O
clean	O
'	O
(	O
i.e.	O
,	O
0-49	O
organisms/swab	O
)	O
by	O
fusidic	O
acid	O
when	O
compared	O
with	O
untreated	O
eyes	O
.	O

Treatment	O
also	O
effectively	O
(	O
P	O
<	O
0.05	O
)	O
reduced	O
the	O
numbers	Physical
of	Physical
bacteria	Physical
isolated	Physical
from	Physical
conjunctivae	Physical
.	O

This	O
study	O
indicates	O
that	O
there	O
is	O
a	O
highly	O
significant	O
reduction	O
of	O
Staphylococcus	O
spp	O
.	O

(	O
P	O
<	O
0.001	O
)	O
,	O
non-Staphylococcus	O
spp	O
.	O

(	O
P	O
<	O
0.001	O
)	O
and	O
attainment	O
of	O
sterile	O
eyes	O
(	O
P	O
<	O
0.001	O
)	O
at	O
operation	O
gained	O
by	O
patient	O
self-administration	O
of	O
1	O
%	O
fusidic	O
acid	O
four	O
times	O
daily	O
for	O
seven	O
days	O
before	O
surgery	O
.	O

[	O
Effect	O
of	O
zengjing	O
no	O
.	O

1	O
capsule	O
on	O
morphology	Others
and	Others
motility	Others
of	Others
sperm	Others
in	O
patients	O
with	O
oligospermia	O
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
effect	O
of	O
Zengjing	O
Capsule	O
No	O
.	O

1	O
(	O
ZJC1	O
)	O
on	O
morphology	O
and	O
motility	O
of	O
sperm	O
in	O
patients	O
with	O
oligospermia	O
(	O
OSM	O
)	O
.	O

METHODS	O
Seventy-two	O
OSM	O
patients	O
were	O
assigned	O
to	O
2	O
groups	O
by	O
a	O
randomizing	O
digital	O
table	O
,	O
the	O
treated	O
group	O
and	O
the	O
control	O
group	O
,	O
they	O
were	O
treated	O
respectively	O
by	O
ZJC1	O
and	O
Wuzi	O
Yanzong	O
Pill	O
(	O
WYP	O
)	O
.	O

The	O
changes	Others
of	Others
density	Others
,	Others
motility	Others
and	Others
morphology	Others
of	Others
sperm	Others
in	O
patients	O
before	O
and	O
after	O
3-month	O
treatment	O
were	O
examined	O
using	O
computerized	O
WLJY-9000	O
colour	O
semen	Others
analysis	Others
system	Others
with	O
refined	O
Papanicolaou	O
's	O
stain	O
.	O

RESULTS	O
The	O
density	Others
,	Others
motility	Others
and	Others
morphology	Others
of	Others
sperm	Others
were	O
improved	O
and	O
sperm	Others
deformity	Others
rate	Others
was	O
significantly	O
decreased	O
after	O
treatment	O
in	O
both	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
the	O
effects	O
in	O
the	O
treated	O
group	O
were	O
better	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSION	O
ZJC1	O
can	O
enhance	O
the	O
density	Others
and	Others
motility	Others
of	Others
sperm	Others
and	O
reduce	O
the	O
sperm	Others
deformity	Others
rate	Others
in	O
patients	O
with	O
OSM	O
.	O

Topical	O
anesthesia	O
during	O
infant	O
eye	O
examinations	O
:	O
does	O
it	O
reduce	O
stress	O
?	O
We	O
studied	O
the	O
effect	O
of	O
topical	O
anesthesia	O
on	O
infant	O
stress	O
and	O
corneal	O
haze	O
during	O
the	O
routine	O
eye	O
examination	O
for	O
retinopathy	O
of	O
prematurity	O
.	O

Using	O
a	O
double-blind	O
protocol	O
,	O
55	O
premature	O
infants	O
weighing	O
less	O
than	O
1501	O
g	O
at	O
birth	O
were	O
selected	O
randomly	O
to	O
receive	O
normal	O
saline	O
or	O
proparacaine	O
HCl	O
0.5	O
%	O
eye	O
drops	O
as	O
a	O
corneal	O
wetting	O
agent	O
at	O
their	O
initial	O
eye	O
examination	O
.	O

Before	O
,	O
during	O
,	O
and	O
after	O
the	O
procedure	O
,	O
infant	O
stress	O
was	O
evaluated	O
by	O
heart	Physical
rate	Physical
,	Physical
respiration	Physical
rate	Physical
,	Physical
blood	Physical
pressure	Physical
,	Physical
and	Physical
transcutaneous	Physical
oxygen	Physical
saturation	Physical
.	Physical

Subjective	Physical
assessment	Physical
of	Physical
the	Physical
infant	Physical
's	Physical
cry	Physical
intensity	Physical
and	Physical
corneal	Physical
haze	Physical
also	O
were	O
recorded	O
.	O

Adequate	O
data	O
were	O
collected	O
on	O
42	O
patients	O
.	O

Using	O
analysis	O
of	O
variance	O
and	O
chi-square	O
tests	O
,	O
we	O
found	O
no	O
difference	O
in	O
any	O
of	O
these	O
parameters	O
between	O
the	O
two	O
patients	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
topical	O
anesthetic	O
agents	O
offer	O
no	O
advantage	O
over	O
normal	O
saline	O
eye	O
drops	O
during	O
the	O
examination	O
of	O
premature	O
infants	O
.	O

Efficiency	O
of	O
anaferon	O
in	O
complex	O
therapy	O
of	O
genital	O
herpes	O
.	O

We	O
studied	O
clinical	O
efficiency	O
and	O
IFN-inducing	O
activity	O
of	O
anaferon	O
in	O
chronic	O
recurrent	O
genital	O
herpes	O
with	O
high	O
incidence	O
of	O
relapses	O
.	O

The	O
use	O
of	O
anaferon	O
in	O
complex	O
therapy	O
reduced	O
the	O
duration	Physical
of	Physical
intoxication	Physical
symptoms	Physical
and	Physical
local	Physical
symptoms	Physical
,	O
shortened	O
the	O
duration	Physical
of	Physical
the	Physical
relapse	Physical
,	Physical
activated	Physical
expression	Physical
of	Physical
IFN-gamma	Physical
mRNA	Physical
,	Physical
and	Physical
improved	Physical
IFN-gamma-producing	Physical
capacity	Physical
of	Physical
blood	Physical
leukocytes	Physical
.	Physical

Comparison	O
of	O
percutaneous	O
transmitral	O
commissurotomy	O
with	O
Inoue	O
balloon	O
technique	O
and	O
metallic	O
commissurotomy	O
:	O
immediate	O
and	O
short-term	O
follow-up	O
results	O
of	O
a	O
randomized	O
study	O
.	O

BACKGROUND	O
The	O
Inoue	O
balloon	O
technique	O
for	O
mitral	O
commissurotomy	O
is	O
well	O
established	O
and	O
carried	O
out	O
worldwide	O
.	O

Metallic	O
commissurotomy	O
is	O
reported	O
to	O
be	O
a	O
cheaper	O
and	O
effective	O
alternative	O
to	O
balloon	O
mitral	O
commissurotomy	O
.	O

METHODS	O
One	O
hundred	O
patients	O
were	O
randomized	O
into	O
2	O
groups	O
to	O
undergo	O
percutaneous	O
transmitral	O
commissurotomy	O
(	O
PTMC	O
)	O
by	O
means	O
of	O
the	O
Inoue	O
balloon	O
technique	O
(	O
IBMC	O
,	O
n	O
=	O
49	O
)	O
or	O
metallic	O
commissurotomy	O
(	O
PMMC	O
,	O
n	O
=	O
51	O
)	O
.	O

Patients	O
were	O
crossed	O
over	O
to	O
the	O
other	O
technique	O
when	O
the	O
initial	O
technique	O
was	O
a	O
failure	O
.	O

Success	Others
of	Others
valvotomy	Others
,	O
procedure-related	Adverseeffect
complications	Adverseeffect
,	O
and	O
follow-up	Physical
events	Physical
of	O
the	O
2	O
techniques	O
were	O
compared	O
.	O

RESULTS	O
Basal	Physical
echocardiographic	Physical
and	O
hemodynamic	Physical
data	Physical
were	O
similar	O
in	O
both	O
groups	O
.	O

Procedural	O
success	O
was	O
similar	O
in	O
both	O
groups	O
:	O
45	O
of	O
49	O
procedures	O
(	O
91.8	O
%	O
)	O
in	O
the	O
IBMC	O
group	O
,	O
compared	O
with	O
46	O
of	O
51	O
procedures	O
(	O
90.18	O
%	O
)	O
in	O
the	O
PMMC	O
group	O
(	O
P	O
=	O
1.0	O
)	O
.	O

Crossover	O
was	O
also	O
comparable	O
,	O
with	O
1	O
occurring	O
in	O
the	O
IBMC	O
group	O
,	O
compared	O
with	O
3	O
in	O
the	O
PMMC	O
group	O
.	O

Complications	O
such	O
as	O
cardiac	Adverseeffect
tamponade	Adverseeffect
and	Adverseeffect
mitral	Adverseeffect
regurgitation	Adverseeffect
(	O
requiring	O
or	O
not	O
requiring	O
mitral	O
valve	O
replacement	O
)	O
were	O
similar	O
in	O
both	O
groups	O
,	O
with	O
3	O
complications	O
in	O
the	O
IBMC	O
group	O
,	O
compared	O
with	O
4	O
complications	O
in	O
the	O
PMMC	O
group	O
(	O
P	O
=.29	O
)	O
.	O

After	O
a	O
follow-up	O
period	O
of	O
approximately	O
4	O
months	O
,	O
both	O
groups	O
had	O
similar	O
event	O
rates	O
and	O
comparable	O
hemodynamic	O
parameters	O
(	O
P	O
=	O
not	O
significant	O
)	O
.	O

CONCLUSIONS	O
Both	O
IBMC	O
and	O
PMMC	O
are	O
successful	O
means	O
of	O
providing	O
relief	O
from	O
severe	O
mitral	O
stenosis	O
with	O
a	O
gain	O
in	O
valve	O
area	O
and	O
reduction	O
in	O
transmitral	O
gradient	O
.	O

Both	O
techniques	O
have	O
similar	O
procedural	O
success	O
,	O
complication	O
rates	O
,	O
and	O
follow-up	O
events	O
.	O

Humoral	Physical
immune	Physical
response	Physical
to	O
tetanus-diphtheria	O
vaccine	O
given	O
during	O
extended	O
use	O
of	O
chloroquine	O
or	O
primaquine	O
malaria	O
chemoprophylaxis	O
.	O

Immune	Physical
suppression	Physical
resulting	O
from	O
prolonged	O
chemoprophylaxis	O
and	O
potential	O
drug-vaccine	O
interaction	O
were	O
investigated	O
within	O
the	O
context	O
of	O
a	O
randomized	O
placebo-controlled	O
trial	O
that	O
compared	O
daily	O
primaquine	O
or	O
weekly	O
chloroquine	O
administration	O
for	O
malaria	O
prevention	O
.	O

After	O
11	O
months	O
of	O
prophylaxis	O
,	O
adult	O
male	O
subjects	O
received	O
a	O
tetanus-diphtheria	O
(	O
Td	O
)	O
vaccination	O
.	O

Prophylaxis	O
continued	O
4	O
weeks	O
longer	O
.	O

Anti-tetanus	Physical
and	Physical
anti-diphtheria	Physical
antibody	Physical
levels	Physical
were	O
measured	O
by	O
ELISA	Physical
at	O
baseline	O
and	O
at	O
1	O
,	O
3	O
,	O
7	O
,	O
and	O
14	O
months	O
after	O
Td	O
vaccination	O
.	O

All	O
groups	O
were	O
comparable	O
at	O
baseline	O
.	O

Immunization	O
triggered	O
significant	O
increases	O
in	O
anti-tetanus	Physical
and	Physical
anti-diphtheria	Physical
IgG	Physical
levels	Physical
over	O
each	O
group	O
's	O
pre-Td	O
baseline	O
levels	O
and	O
those	O
of	O
an	O
unvaccinated	O
control	O
group	O
.	O

Geometric	Physical
mean	Physical
anti-tetanus	Physical
titers	Physical
(	Physical
GMTs	Physical
)	Physical
in	O
the	O
primaquine	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
placebo	O
group	O
at	O
1	O
,	O
3	O
,	O
and	O
14	O
months	O
.	O

Anti-tetanus	Physical
GMTs	Physical
in	O
placebo	O
and	O
chloroquine	O
groups	O
declined	O
over	O
14	O
months	O
to	O
levels	O
comparable	O
to	O
those	O
of	O
unvaccinated	O
controls	O
,	O
but	O
levels	O
in	O
the	O
primaquine	O
group	O
remained	O
significantly	O
higher	O
than	O
in	O
controls	O
.	O

Comparison	O
of	O
short-term	O
efficacy	O
of	O
diltiazem	O
and	O
propranolol	O
in	O
unstable	O
angina	O
at	O
rest	O
--	O
a	O
randomized	O
trial	O
in	O
70	O
patients	O
.	O

The	O
short-term	O
efficacy	O
of	O
diltiazem	O
(	O
D	O
)	O
has	O
been	O
compared	O
to	O
that	O
of	O
propranolol	O
(	O
P	O
)	O
,	O
in	O
a	O
group	O
of	O
70	O
patients	O
hospitalized	O
in	O
the	O
Coronary	O
Care	O
Unit	O
for	O
unstable	O
angina	O
,	O
defined	O
as	O
recent	O
(	O
less	O
than	O
one	O
month	O
)	O
appearance	O
or	O
aggravation	O
of	O
spontaneous	O
chest	O
pains	O
.	O

Among	O
the	O
70	O
patients	O
,	O
24	O
had	O
angina	O
only	O
at	O
rest	O
.	O

The	O
patients	O
have	O
been	O
divided	O
into	O
two	O
groups	O
according	O
to	O
ST-T	O
changes	O
during	O
chest	O
pain	O
:	O
29	O
with	O
ST	O
elevation	O
(	O
group	O
A	O
)	O
and	O
41	O
with	O
other	O
repolarization	O
abnormalities	O
(	O
group	O
B	O
)	O
.	O

Treatment	O
was	O
then	O
randomized	O
in	O
each	O
group	O
.	O

Treatment	O
Treatment	O
was	O
considered	O
successful	O
only	O
if	O
spontaneous	O
chest	Physical
pains	Physical
disappeared	O
completely	O
.	O

Thirty-four	O
patients	O
were	O
treated	O
with	O
D	O
(	O
282	O
+/-	O
102	O
mg/day	O
)	O
and	O
36	O
with	O
P	O
(	O
158	O
+/-	O
81	O
mg/day	O
)	O
.	O

In	O
the	O
whole	O
group	O
and	O
in	O
groups	O
A	O
and	O
B	O
considered	O
individually	O
,	O
responses	O
to	O
D	O
and	O
P	O
did	O
not	O
differ	O
.	O

Among	O
the	O
24	O
patients	O
with	O
angina	Physical
exclusively	O
at	O
rest	O
,	O
nine	O
successes	O
and	O
four	O
failures	O
were	O
observed	O
with	O
D.	O
There	O
was	O
no	Physical
symptomatic	Physical
relief	Physical
among	O
the	O
11	O
patients	O
treated	O
by	O
P	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Moreover	O
,	O
the	O
number	Physical
of	Physical
episodes	Physical
of	Physical
angina	Physical
was	O
decreased	O
by	O
D	O
and	O
unchanged	O
by	O
P	O
,	O
while	O
eight	O
out	O
of	O
the	O
11	O
failures	O
with	O
P	O
were	O
immediate	O
successes	O
when	O
treatment	O
was	O
replaced	O
with	O
D.	O
These	O
results	O
suggest	O
that	O
D	O
is	O
preferable	O
to	O
P	O
for	O
management	O
of	O
unstable	O
angina	O
in	O
patients	O
with	O
angina	O
which	O
is	O
exclusively	O
spontaneous	O
.	O

Impact	O
of	O
antisecretory	O
treatment	O
on	O
respiratory	Physical
symptoms	Physical
of	Physical
gastroesophageal	Physical
reflux	Physical
disease	Physical
in	O
children	O
.	O

The	O
effect	Others
of	O
antisecretory	O
treatment	O
on	O
extraesophageal	Physical
symptoms	Physical
of	Physical
gastroesophageal	Physical
reflux	Physical
disease	Physical
was	O
evaluated	O
.	O

Seventy-eight	O
children	O
presenting	O
with	O
typical	O
and	O
extraesophageal	O
symptoms	O
of	O
gastroesophageal	O
reflux	O
disease	O
underwent	O
a	O
multichannel	O
intraluminal	O
impedance	O
and	O
pH	O
monitoring	O
(	O
MII/pH	O
)	O
.	O

Children	O
with	O
a	O
positive	O
MII/pH	O
were	O
randomly	O
treated	O
with	O
proton	O
pump	O
inhibitors	O
(	O
PPIs	O
)	O
or	O
histamine	O
H	O
(	O
2	O
)	O
-receptor	O
antagonists	O
(	O
H	O
(	O
2	O
)	O
RAs	O
)	O
during	O
3	O
months	O
.	O

At	O
the	O
end	O
of	O
the	O
treatment	O
period	O
,	O
all	O
patients	O
were	O
recalled	O
.	O

A	O
second	O
treatment	O
period	O
of	O
3	O
months	O
was	O
given	O
to	O
those	O
patients	O
who	O
were	O
not	O
symptom-free	O
after	O
3	O
months	O
.	O

Thirty-five	O
of	O
the	O
forty-one	O
(	O
85.4	O
%	O
)	O
children	O
with	O
a	O
pathologic	O
MII/pH	O
presented	O
with	O
extraesophageal	Physical
symptoms	Physical
and	O
were	O
treated	O
with	O
PPIs	O
(	O
omeprazole	O
;	O
n:19	O
)	O
or	O
H	O
(	O
2	O
)	O
RAs	O
(	O
ranitidine	O
;	O
n:16	O
)	O
for	O
12	O
weeks	O
.	O

After	O
3	O
months	O
,	O
11/19	O
(	O
57.9	O
%	O
)	O
PPI-treated	O
patients	O
had	O
a	O
complete	O
resolution	Physical
of	Physical
symptoms	Physical
;	O
6/8	O
nonresponders	O
were	O
treated	O
with	O
PPI	O
for	O
another	O
3	O
months	O
and	O
became	O
all	O
symptom-free	Physical
.	O

The	O
other	O
two	O
underwent	O
a	O
Nissen	O
fundoplication	O
.	O

Only	O
5/16	O
(	O
31.2	O
%	O
)	O
patients	O
treated	O
with	O
H	O
(	O
2	O
)	O
RAs	O
had	O
a	O
complete	Physical
resolution	Physical
of	Physical
symptoms	Physical
after	O
3	O
months	O
;	O
1/11	O
was	O
treated	O
again	O
with	O
H	O
(	O
2	O
)	O
RAs	O
during	O
3	O
months	O
,	O
and	O
10/11	O
were	O
changed	O
to	O
PPIs	O
.	O

In	O
3/10	O
,	O
a	O
partial	Physical
resolution	Physical
of	Physical
symptoms	Physical
was	O
achieved	O
,	O
while	O
in	O
7/10	O
,	O
a	O
complete	Physical
remission	Physical
was	O
obtained	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Antisecretory	O
reflux	O
treatment	O
improves	O
extraesophageal	Physical
reflux	Physical
symptoms	Physical
.	O

The	O
efficacy	Others
of	O
PPIs	O
is	O
superior	O
to	O
that	O
of	O
H	O
(	O
2	O
)	O
RAs	O
in	O
these	O
children	O
.	O

Comparison	O
of	O
comfort	Mental
and	Others
local	Adverseeffect
complications	Adverseeffect
after	O
cardiac	O
catheterization	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
4	O
hours	O
of	O
bed	O
rest	O
versus	O
6	O
hours	O
of	O
bed	O
rest	O
on	O
patients	O
'	O
safety	Physical
,	Physical
comfort	Physical
,	Physical
and	Physical
satisfaction	Physical
levels	Physical
.	Physical

Using	O
a	O
quasi-experimental	O
design	O
,	O
the	O
authors	O
studied	O
118	O
left-heart	O
catheterization	O
patients	O
who	O
were	O
randomly	O
assigned	O
to	O
4	O
hours	O
or	O
6	O
hours	O
of	O
bed	O
rest	O
.	O

Among	O
the	O
study	O
participants	O
,	O
only	O
1	O
in	O
the	O
6-hour	O
group	O
had	O
significant	Physical
bleeding	Physical
.	Physical

There	O
were	O
no	O
complications	Physical
in	O
the	O
4-hour	O
group	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
on	O
any	O
of	O
the	O
other	O
study	O
variables	O
.	O

Given	O
the	O
lack	O
of	O
significant	O
complications	O
for	O
the	O
4-hour	O
group	O
and	O
similar	O
comfort	Physical
levels	Physical
for	O
both	O
study	O
groups	O
,	O
these	O
findings	O
suggest	O
the	O
feasibility	O
of	O
reducing	O
the	O
standard	O
period	O
of	O
postcatheterization	O
bed	O
rest	O
from	O
6	O
hours	O
to	O
4	O
hours	O
,	O
thereby	O
possibly	O
lowering	O
the	O
cost	Others
of	Others
the	Others
outpatient	Others
procedure	Others
.	Physical

Phase	O
I	O
pharmacokinetic	O
,	O
food	O
effect	O
,	O
and	O
pharmacogenetic	O
study	O
of	O
oral	O
irinotecan	O
given	O
as	O
semisolid	O
matrix	O
capsules	O
in	O
patients	O
with	O
solid	O
tumors	O
.	O

PURPOSE	O
To	O
characterize	O
the	O
maximum-tolerated	O
dose	O
,	O
recommended	O
dose	O
,	O
dose-limiting	O
toxicities	O
(	O
DLT	O
)	O
,	O
pharmacokinetic	O
profile	O
,	O
and	O
food	O
effect	O
of	O
orally	O
administered	O
irinotecan	O
formulated	O
as	O
new	O
semisolid	O
matrix	O
capsules	O
.	O

EXPERIMENTAL	O
DESIGN	O
Irinotecan	O
was	O
given	O
orally	O
in	O
fasted	O
patients	O
once	O
daily	O
for	O
5	O
consecutive	O
days	O
and	O
repeated	O
every	O
3	O
weeks	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
take	O
the	O
drug	O
along	O
with	O
a	O
high-fat	O
,	O
high-calorie	O
breakfast	O
for	O
the	O
administration	O
at	O
day	O
1	O
of	O
the	O
first	O
or	O
second	O
cycle	O
.	O

Dosages	O
tested	O
were	O
70	O
and	O
80	O
mg/m	O
(	O
2	O
)	O
/day	O
.	O

RESULTS	O
Twenty-five	O
patients	O
received	O
101	O
cycles	O
of	O
therapy	O
(	O
median	O
two	O
cycles	O
,	O
range	O
1-15	O
)	O
.	O

During	O
the	O
first	O
cycle	O
,	O
grade	Physical
3	Physical
delayed	Physical
diarrhea	Physical
and	Physical
grade	Physical
3	Physical
fever	Physical
were	O
the	O
DLTs	O
at	O
the	O
dosage	O
of	O
80	O
mg/m	O
(	O
2	O
)	O
/day	O
in	O
three	O
out	O
of	O
five	O
patients	O
.	O

Hematologic	Physical
and	Physical
nonhematologic	Physical
toxicities	Physical
were	O
mild	O
to	O
moderate	O
.	O

Exposure	Others
to	Others
the	Others
active	Others
metabolite	Others
SN-38	Others
was	O
relatively	O
high	O
compared	O
with	O
i.v	O
.	O

infusion	O
,	O
but	O
no	O
relevant	O
accumulation	O
was	O
observed	O
.	O

Food	O
had	O
no	O
significant	O
effect	O
on	O
irinotecan	O
pharmacokinetics	O
.	O

One	O
confirmed	O
partial	O
remission	O
and	O
10	O
disease	O
stabilizations	O
were	O
observed	O
in	O
previously	O
treated	O
patients	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
UGT1A1*28	O
genotype	O
and	O
the	O
risk	O
of	O
severe	Others
irinotecan-induced	Others
toxicity	Others
.	Others

CONCLUSIONS	O
For	O
oral	O
irinotecan	O
,	O
a	O
dose	O
of	O
70	O
mg/m	O
(	O
2	O
)	O
/day	O
for	O
5	O
consecutive	O
days	O
every	O
3	O
weeks	O
is	O
recommended	O
for	O
further	O
studies	O
.	O

Delayed	O
diarrhea	O
was	O
the	O
main	O
DLT	O
,	O
similar	O
to	O
that	O
observed	O
with	O
intravenously	O
administered	O
irinotecan	O
.	O

This	O
study	O
confirms	O
that	O
oral	O
administration	O
of	O
irinotecan	O
is	O
feasible	O
and	O
may	O
have	O
favorable	O
pharmacokinetic	O
characteristics	O
.	O

The	O
influence	O
of	O
nonhandicapped	O
peers	O
on	O
the	O
social	Mental
interactions	Mental
of	O
children	O
with	O
a	O
pervasive	O
development	O
disorder	O
.	O

This	O
study	O
investigated	O
whether	O
or	O
not	O
children	O
with	O
autism	O
or	O
a	O
related	O
pervasive	O
developmental	O
disorder	O
(	O
PDD	O
)	O
can	O
benefit	Others
from	O
regular	O
opportunities	O
to	O
interact	O
with	O
a	O
normally	O
developing	O
peer	O
,	O
matched	O
as	O
to	O
sex	O
and	O
age	O
.	O

An	O
experimental	O
design	O
with	O
random	O
assignment	O
of	O
subjects	O
to	O
treatment	O
and	O
control	O
groups	O
was	O
used	O
to	O
demonstrate	O
the	O
impact	Others
of	O
this	O
peer-mediated	O
intervention	O
.	O

In	O
the	O
treatment	O
group	O
,	O
we	O
found	O
significant	O
improvements	O
in	O
the	O
social	Mental
behavior	Mental
of	O
the	O
children	O
with	O
PDD	O
.	O

Several	O
gains	Others
were	O
also	O
generalized	O
to	O
interactions	Mental
with	Mental
an	Mental
unfamiliar	Mental
nonhandicapped	Mental
peer	Mental
,	O
to	O
interactions	Mental
with	Mental
another	Mental
child	Mental
with	Mental
PDD	Mental
,	Mental
and	O
to	O
the	O
large	Mental
school	Mental
setting	Mental
.	O

In	O
the	O
untreated	O
control	O
group	O
,	O
no	O
positive	Others
changes	Others
were	O
observed	O
.	O

Results	O
suggest	O
that	O
children	O
with	O
PDD	O
can	O
develop	O
peer	Mental
relations	Mental
if	O
appropriate	O
social	O
contexts	O
are	O
made	O
available	O
for	O
them	O
.	O

Evidence	O
for	O
poorer	O
outcome	O
in	O
patients	O
with	O
severe	O
negative	O
trauma-related	O
cognitions	O
receiving	O
prolonged	O
exposure	O
plus	O
cognitive	O
restructuring	O
:	O
implications	O
for	O
treatment	O
matching	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

In	O
the	O
current	O
article	O
,	O
we	O
address	O
the	O
existing	O
assumption	O
in	O
the	O
literature	O
on	O
cognitive	O
behavioral	O
treatment	O
of	O
PTSD	O
that	O
patients	O
with	O
severe	O
negative	O
trauma-related	O
cognitions	O
would	O
benefit	O
more	O
from	O
a	O
treatment	O
package	O
that	O
includes	O
exposure	O
and	O
cognitive	O
techniques	O
compared	O
with	O
a	O
treatment	O
that	O
includes	O
exposure	O
only	O
.	O

To	O
test	O
this	O
assumption	O
,	O
54	O
PTSD	O
patients	O
were	O
randomized	O
to	O
prolonged	O
exposure	O
therapy	O
or	O
prolonged	O
exposure	O
therapy	O
plus	O
cognitive	O
restructuring	O
.	O

Contrary	O
to	O
expectations	O
,	O
findings	O
revealed	O
that	O
patients	O
characterized	O
by	O
more	O
severe	O
pretreatment	O
trauma-related	O
cognitions	O
(	O
and	O
more	O
severe	O
pretreatment	O
PTSD	O
symptoms	O
)	O
fared	O
slightly	O
worse	O
in	O
treatment	O
combining	O
exposure	O
and	O
cognitive	O
restructuring	O
.	O

However	O
,	O
there	O
was	O
no	O
relationship	O
between	O
pre-	O
and	O
post-treatment	Mental
measures	Mental
of	Mental
negative	Mental
cognitions	Mental
and	Physical
PTSD	Physical
symptoms	Physical
in	O
the	O
exposure	O
alone	O
group	O
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
examining	O
Person	O
X	O
Treatment	O
interactions	O
and	O
the	O
efficacy	Others
of	O
combining	O
treatments	O
for	O
PTSD	O
are	O
discussed	O
.	O

Albendazole	O
trial	O
at	O
15	O
or	O
30	O
mg/kg/day	O
for	O
subarachnoid	O
and	O
intraventricular	O
cysticercosis	O
.	O

Thirty-six	O
patients	O
with	O
subarachnoid	O
and	O
intraventricular	O
cysticercosis	O
were	O
randomly	O
assigned	O
to	O
receive	O
albendazole	O
at	O
15	O
or	O
30	O
mg/kg/day	O
plus	O
dexamethasone	O
for	O
8	O
days	O
.	O

Results	O
favored	O
a	O
higher	O
dose	O
,	O
with	O
larger	Physical
cyst	Physical
reduction	Physical
on	O
MRI	O
at	O
90	O
and	O
180	O
days	O
and	O
higher	O
albendazole	Physical
sulfoxide	Physical
levels	Physical
in	Physical
plasma	Physical
.	O

An	O
albendazole	O
course	O
at	O
30	O
mg/kg/day	O
combined	O
with	O
corticosteroids	O
is	O
safe	Others
and	Others
more	Others
effective	Others
than	O
the	O
usual	O
dose	O
.	O

A	O
single	O
treatment	O
was	O
insufficient	Others
in	O
intraventricular	O
and	O
giant	O
cysts	O
.	O

Randomised	O
trial	O
of	O
laparoscopic	O
versus	O
open	O
cholecystectomy	O
for	O
acute	O
and	O
gangrenous	O
cholecystitis	O
.	O

BACKGROUND	O
Laparoscopic	O
cholecystectomy	O
(	O
LC	O
)	O
has	O
become	O
the	O
treatment	O
of	O
choice	O
for	O
elective	O
cholecystectomy	O
,	O
but	O
controversy	O
persists	O
over	O
use	O
of	O
this	O
approach	O
in	O
the	O
treatment	O
of	O
acute	O
cholecystitis	O
.	O

We	O
undertook	O
a	O
randomised	O
comparison	O
of	O
the	O
safety	O
and	O
outcome	O
of	O
LC	O
and	O
open	O
cholecystectomy	O
(	O
OC	O
)	O
in	O
patients	O
with	O
acute	O
cholecystitis	O
.	O

METHODS	O
63	O
of	O
68	O
consecutive	O
patients	O
who	O
met	O
criteria	O
for	O
acute	O
cholecystitis	O
were	O
randomly	O
assigned	O
OC	O
(	O
31	O
patients	O
)	O
or	O
LC	O
(	O
32	O
patients	O
)	O
.	O

The	O
primary	O
endpoints	O
were	O
hospital	Mortality
mortality	Mortality
and	O
morbidity	Mortality
,	O
length	Others
of	Others
hospital	Others
stay	Others
,	O
and	O
length	Others
of	Others
sick	Others
leave	Others
from	Others
work	Others
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

Suspected	Physical
bile-duct	Physical
stones	Physical
were	O
investigated	O
by	O
preoperative	O
endoscopic	O
retrograde	O
cholangiography	O
(	O
LC	O
group	O
)	O
or	O
intraoperative	O
cholangiography	O
(	O
OC	O
group	O
)	O
.	O

FINDINGS	O
The	O
two	O
randomised	O
groups	O
were	O
similar	O
in	O
demographic	O
,	O
physical	O
,	O
and	O
clinical	O
characteristics	O
.	O

48	O
%	O
of	O
the	O
patients	O
in	O
the	O
OC	O
group	O
and	O
59	O
%	O
in	O
the	O
LC	O
group	O
were	O
older	O
than	O
60	O
years	O
.	O

13	O
patients	O
in	O
each	O
group	O
had	O
gangrene	Physical
or	O
empyema	Physical
,	O
and	O
one	O
in	O
each	O
group	O
had	O
perforation	Physical
of	Physical
the	Physical
gallbladder	Physical
causing	Physical
diffuse	Physical
peritonitis	Physical
.	O

Five	O
(	O
16	O
%	O
)	O
patients	O
in	O
the	O
LC	O
group	O
required	O
conversion	O
to	O
OC	O
,	O
in	O
most	O
because	O
severe	Physical
inflammation	Physical
distorted	O
the	O
anatomy	O
of	O
Calot	O
's	O
triangle	O
.	O

There	O
were	O
no	O
deaths	Mortality
or	Physical
bile-duct	Physical
lesions	Physical
in	O
either	O
group	O
,	O
but	O
the	O
postoperative	Adverseeffect
complication	Adverseeffect
rate	O
was	O
significantly	O
(	O
p=0.0048	O
)	O
higher	O
in	O
the	O
OC	O
than	O
in	O
the	O
LC	O
group	O
:	O
seven	O
(	O
23	O
%	O
)	O
patients	O
had	O
major	O
and	O
six	O
(	O
19	O
%	O
)	O
minor	Physical
complications	Physical
after	O
OC	O
,	O
whereas	O
only	O
one	O
(	O
3	O
%	O
)	O
minor	O
complication	O
occurred	O
after	O
LC	O
.	O

The	O
postoperative	Others
hospital	Others
stay	Others
was	O
significantly	O
shorter	O
in	O
the	O
LC	O
than	O
the	O
OC	O
group	O
(	O
median	O
4	O
[	O
IQR	O
2-5	O
]	O
vs	O
6	O
[	O
5-8	O
]	O
days	O
;	O
p=0.0063	O
)	O
.	O

Mean	Others
length	Others
of	Others
sick	Others
leave	Others
was	O
shorter	O
in	O
the	O
LC	O
group	O
(	O
13.9	O
vs	O
30.1	O
days	O
;	O
95	O
%	O
CI	O
for	O
difference	O
10.9-21.7	O
)	O
.	O

INTERPRETATION	O
Even	O
though	O
LC	O
for	O
acute	O
and	O
gangrenous	O
cholecystitis	O
is	O
technically	O
demanding	O
,	O
in	O
experienced	O
hands	O
it	O
is	O
safe	Others
and	O
effective	Others
.	O

It	O
does	O
not	O
increase	O
the	O
mortality	Mortality
rate	Mortality
,	O
and	O
the	O
morbidity	Mortality
rate	Mortality
seems	O
to	O
be	O
even	O
lower	O
than	O
that	O
in	O
OC	O
.	O

However	O
,	O
a	O
moderately	O
high	O
conversion	O
rate	O
must	O
be	O
accepted	O
.	O

A	O
comparative	O
study	O
of	O
a	O
new	O
food	O
supplement	O
,	O
ViviScal	O
,	O
with	O
fish	O
extract	O
for	O
the	O
treatment	O
of	O
hereditary	O
androgenic	O
alopecia	O
in	O
young	O
males	O
.	O

A	O
controlled	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel-group	O
study	O
compared	O
the	O
effects	O
of	O
ViviScal	O
(	O
a	O
new	O
food	O
supplement	O
incorporating	O
special	O
marine	O
extracts	O
and	O
a	O
silica	O
compound	O
)	O
with	O
those	O
of	O
a	O
fish	O
extract	O
in	O
the	O
treatment	O
of	O
young	O
males	O
with	O
hereditary	O
androgenic	O
alopecia	O
.	O

The	O
pretreatment	O
histological	O
diagnosis	O
was	O
alopecia	O
with	O
a	O
mild	O
to	O
moderate	O
perifollicular	O
inflammation	O
zone	O
.	O

The	O
study	O
consisted	O
of	O
20	O
subjects	O
who	O
received	O
two	O
tablets	O
of	O
ViviScal	O
once	O
daily	O
and	O
20	O
who	O
received	O
two	O
tablets	O
of	O
fish	O
extract	O
once	O
daily	O
for	O
6	O
months	O
.	O

The	O
mean	O
patient	O
age	O
and	O
mean	O
duration	O
and	O
severity	O
of	O
baldness	O
compared	O
well	O
between	O
the	O
two	O
groups	O
.	O

Most	O
patients	O
had	O
been	O
treated	O
with	O
long-term	O
topical	O
2	O
%	O
minoxidil	O
for	O
1	O
year	O
or	O
more	O
prior	O
to	O
the	O
study	O
.	O

At	O
baseline	O
and	O
after	O
6	O
months	O
'	O
treatment	O
,	O
a	O
biopsy	O
was	O
taken	O
for	O
histological	O
examination	O
.	O

A	O
non-vellus	Physical
hair	Physical
count	Physical
was	O
performed	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
and	O
6	O
months	O
.	O

In	O
the	O
fish	O
extract	O
treatment	O
group	O
three	O
patients	O
withdrew	O
from	O
the	O
study	O
before	O
the	O
fourth	O
month	O
due	O
to	O
lack	Physical
of	Physical
therapeutic	Physical
effect	Physical
.	O

After	O
6	O
months	O
'	O
treatment	O
,	O
patients	O
receiving	O
ViviScal	O
showed	O
a	O
mean	Physical
increase	Physical
in	Physical
non-vellus	Physical
hair	Physical
of	O
38	O
%	O
compared	O
with	O
a	O
2	O
%	O
increase	O
in	O
the	O
fish	O
extract	O
treatment	O
group	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
the	O
ViviScal	O
group	O
,	O
19	O
(	O
95	O
%	O
)	O
subjects	O
showed	O
both	Physical
clinical	Physical
and	Physical
histological	Physical
cure	Physical
,	O
whereas	O
none	O
treated	O
with	O
fish	O
extract	O
showed	O
any	O
clinical	O
or	O
histological	O
difference	O
after	O
6	O
months	O
'	O
treatment	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
both	O
groups	O
,	O
a	O
minimal	O
decrease	O
in	O
the	O
erythemal	Others
index	Others
was	O
observed	O
.	O

In	O
conclusion	O
,	O
ViviScal	O
appears	O
to	O
be	O
the	O
first	O
highly	O
active	O
treatment	O
for	O
androgenic	O
alopecia	O
in	O
young	O
males	O
.	O

Ganitumab	O
with	O
either	O
exemestane	O
or	O
fulvestrant	O
for	O
postmenopausal	O
women	O
with	O
advanced	O
,	O
hormone-receptor-positive	O
breast	O
cancer	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
double-blind	O
,	O
phase	O
2	O
trial	O
.	O

BACKGROUND	O
Insulin-like	O
growth	O
factors	O
(	O
IGF-1	O
and	O
IGF-2	O
)	O
bind	O
to	O
the	O
IGF-1	O
receptor	O
(	O
IGF-1R	O
)	O
,	O
increasing	O
cell	Physical
proliferation	Physical
and	O
survival	Mortality
.	O

Ganitumab	O
is	O
a	O
monoclonal	O
IgG1	O
antibody	O
that	O
blocks	O
IGF-1R	O
.	O

We	O
tested	O
the	O
efficacy	Others
and	O
safety	Others
of	O
adding	O
ganitumab	O
to	O
endocrine	O
treatment	O
for	O
patients	O
with	O
hormone-receptor-positive	O
breast	O
cancer	O
.	O

METHODS	O
We	O
did	O
this	O
phase	O
2	O
trial	O
in	O
outpatient	O
clinics	O
and	O
hospitals	O
.	O

We	O
enrolled	O
postmenopausal	O
women	O
with	O
hormone-receptor-positive	O
,	O
locally	O
advanced	O
or	O
metastatic	O
breast	O
cancer	O
previously	O
treated	O
with	O
endocrine	O
treatment	O
.	O

They	O
were	O
randomly	O
assigned	O
(	O
2:1	O
)	O
with	O
a	O
central	O
randomisation	O
schedule	O
to	O
receive	O
intravenous	O
ganitumab	O
12	O
mg	O
per	O
kg	O
bodyweight	O
or	O
placebo	O
in	O
combination	O
with	O
open-label	O
intramuscular	O
fulvestrant	O
(	O
500	O
mg	O
on	O
day	O
1	O
,	O
then	O
250	O
mg	O
on	O
days	O
15	O
,	O
29	O
,	O
and	O
every	O
28	O
days	O
)	O
or	O
oral	O
exemestane	O
(	O
25	O
mg	O
once	O
daily	O
)	O
on	O
a	O
28-day	O
cycle	O
.	O

Patients	O
,	O
investigators	O
,	O
study	O
monitors	O
,	O
and	O
the	O
sponsor	O
staff	O
were	O
masked	O
to	O
treatment	O
allocation	O
.	O

Response	O
was	O
assessed	O
every	O
8	O
weeks	O
.	O

The	O
primary	O
endpoint	O
was	O
median	Mortality
progression-free	Mortality
survival	Mortality
in	O
the	O
intention-to-treat	O
population	O
.	O

We	O
analysed	O
overall	Mortality
survival	Mortality
as	O
one	O
of	O
our	O
secondary	O
endpoints	O
.	O

The	O
study	O
is	O
registered	O
at	O
ClinicalTrials.gov	O
,	O
number	O
NCT00626106	O
.	O

FINDINGS	O
We	O
screened	O
189	O
patients	O
and	O
enrolled	O
156	O
(	O
106	O
in	O
the	O
ganitumab	O
group	O
and	O
50	O
in	O
the	O
placebo	O
group	O
)	O
.	O

Median	Mortality
progression-free	Mortality
survival	Mortality
did	O
not	O
differ	O
significantly	O
between	O
the	O
ganitumab	O
and	O
placebo	O
groups	O
(	O
3?9	O
months	O
,	O
80	O
%	O
CI	O
3?6-5?3	O
vs	O
5?7	O
months	O
,	O
4?4-7?4	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
1?17	O
,	O
80	O
%	O
CI	O
0?91-1?50	O
;	O
p=0?44	O
)	O
.	O

However	O
,	O
overall	O
survival	O
was	O
worse	O
in	O
the	O
the	O
ganitumab	O
group	O
than	O
in	O
the	O
placebo	O
group	O
(	O
HR	O
1?78	O
,	O
80	O
%	O
CI	O
1?27-2?50	O
;	O
p=0?025	O
)	O
.	O

With	O
the	O
exception	O
of	O
hyperglycaemia	O
,	O
adverse	O
events	O
were	O
generally	O
similar	O
between	O
groups	O
.	O

The	O
most	O
common	O
grade	O
3	O
or	O
higher	O
adverse	O
event	O
was	O
neutropenia-reported	O
by	O
six	O
of	O
106	O
(	O
6	O
%	O
)	O
patients	O
in	O
the	O
ganitumab	O
group	O
and	O
one	O
of	O
49	O
(	O
2	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O

Hyperglycaemia	O
was	O
reported	O
by	O
12	O
of	O
106	O
(	O
11	O
%	O
)	O
patients	O
in	O
the	O
ganitumab	O
group	O
(	O
with	O
six	O
patients	O
having	O
grade	O
3	O
or	O
4	O
hyperglycaemia	O
)	O
and	O
none	O
of	O
49	O
in	O
the	O
placebo	O
group	O
.	O

Serious	O
adverse	O
events	O
were	O
reported	O
by	O
27	O
of	O
106	O
(	O
25	O
%	O
)	O
patients	O
in	O
the	O
ganitumab	O
group	O
and	O
nine	O
of	O
49	O
(	O
18	O
%	O
)	O
patients	O
in	O
the	O
placebo	O
group	O
.	O

INTERPRETATION	O
Addition	O
of	O
ganitumab	O
to	O
endocrine	O
treatment	O
in	O
women	O
with	O
previously	O
treated	O
hormone-receptor-positive	O
locally	O
advanced	O
or	O
metastatic	O
breast	O
cancer	O
did	O
not	O
improve	O
outcomes	O
.	O

Our	O
results	O
do	O
not	O
support	O
further	O
study	O
of	O
ganitumab	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O

FUNDING	O
Amgen	O
.	O

Prevalence	O
and	O
treatment	O
outcome	O
of	O
cervicitis	Physical
of	O
unknown	O
etiology	O
.	O

BACKGROUND	O
Mucopurulent	O
cervicitis	O
(	O
MPC	O
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
mucopurulent	O
discharge	O
from	O
the	O
cervix	O
and	O
other	O
signs	O
of	O
inflammation	O
.	O

This	O
was	O
a	O
phase	O
III	O
,	O
multicenter	O
study	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
placebo	O
versus	O
empiric	O
antibiotic	O
treatment	O
for	O
clinical	O
cure	O
of	O
MPC	Physical
of	O
unknown	O
etiology	O
at	O
2-month	O
follow-up	O
.	O

Unfortunately	O
,	O
enrollment	O
was	O
terminated	O
because	O
of	O
low	O
accrual	O
of	O
women	O
with	O
cervicitis	O
of	O
unknown	O
etiology	O
,	O
but	O
important	O
prevalence	O
and	O
outcome	O
data	O
were	O
obtained	O
.	O

METHODS	O
Five	O
hundred	O
seventy-seven	O
women	O
were	O
screened	O
for	O
MPC	O
.	O

Women	O
with	O
MPC	O
were	O
randomized	O
to	O
the	O
treatment	O
or	O
placebo	O
arm	O
of	O
the	O
study	O
,	O
and	O
the	O
2	O
arms	O
were	O
evaluated	O
based	O
on	O
the	O
etiology	O
,	O
clinical	Others
cure	Others
rates	Others
,	O
adverse	Physical
events	Physical
(	Physical
AEs	Physical
)	Physical
,	O
and	O
rates	Physical
of	Physical
pelvic	Physical
inflammatory	Physical
disease	Physical
.	O

RESULTS	O
One	O
hundred	O
thirty-one	O
(	O
23	O
%	O
[	O
131/577	O
]	O
)	O
screened	O
women	O
were	O
found	O
to	O
have	O
MPC	O
.	O

Eighty-seven	O
were	O
enrolled	O
and	O
randomized	O
.	O

After	O
excluding	O
women	O
with	O
sexually	O
transmitted	O
infections	O
and	O
other	O
exclusions	O
,	O
61	O
%	O
(	O
53/87	O
)	O
had	O
cervicitis	Physical
of	O
unknown	O
etiology	O
.	O

The	O
overall	Others
clinical	Others
failure	Others
rate	Others
was	O
30	O
%	O
(	O
10/33	O
)	O
,	O
and	O
the	O
clinical	Others
cure	Others
rate	Others
was	O
only	O
24	O
%	O
(	O
8/33	O
)	O
.	O

Rates	O
were	O
not	O
significantly	O
different	O
between	O
the	O
arms	O
.	O

There	O
were	O
24	O
gastrointestinal	Physical
AEs	Physical
in	O
the	O
treatment	O
arm	O
compared	O
with	O
1	O
AE	O
in	O
the	O
placebo	O
arm	O
.	O

CONCLUSIONS	O
More	O
than	O
half	O
of	O
the	O
cases	O
of	O
MPC	O
were	O
of	O
unknown	O
etiology	O
.	O

Clinical	Others
cure	Others
rates	Others
for	O
the	O
placebo	O
and	O
treatment	O
arms	O
were	O
extremely	O
low	O
,	O
with	O
most	O
women	O
concluding	O
the	O
study	O
with	O
a	O
partial	O
response	O
.	O

Gastrointestinal	Physical
AEs	Physical
were	O
higher	O
in	O
the	O
treatment	O
arm	O
.	O

Effect	O
of	O
home-based	O
nursing	O
pulmonary	O
rehabilitation	O
on	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
:	O
a	O
randomised	O
clinical	O
trial	O
.	O

Fatigue	O
is	O
a	O
common	O
symptom	O
of	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
and	O
results	O
in	O
a	O
reduction	O
of	O
daily	O
activity	O
and	O
quality	O
of	O
life	O
in	O
patients	O
with	O
the	O
disease	O
.	O

The	O
authors	O
aimed	O
to	O
identify	O
the	O
effect	O
of	O
home-based	O
nursing	O
pulmonary	O
rehabilitation	O
on	O
fatigue	O
,	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
and	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
in	O
patients	O
with	O
COPD	O
.	O

A	O
block	O
randomisation	O
method	O
was	O
used	O
to	O
randomise	O
participants	O
into	O
case	O
and	O
control	O
groups	O
.	O

Fatigue	Physical
,	O
ADL	Mental
and	O
QOL	Mental
were	O
assessed	O
before	O
and	O
after	O
the	O
intervention	O
in	O
both	O
groups	O
.	O

Independent	O
and	O
paired	O
t-tests	O
,	O
chi-squared	O
tests	O
and	O
covariance	O
analysis	O
were	O
used	O
to	O
analysing	O
data	O
.	O

Findings	O
showed	O
the	O
significant	O
decrease	O
in	O
the	O
mean	Physical
scores	Physical
of	Physical
fatigue	Physical
(	O
p	O
<	O
0.001	O
)	O
and	O
significant	O
improvement	O
in	O
mean	Physical
scores	Physical
of	Physical
ADL	Mental
(	O
p	O
<	O
0.001	O
)	O
and	O
QOL	Mental
(	O
p	O
<	O
0.001	O
)	O
after	O
home-based	O
nursing	O
pulmonary	O
rehabilitation	O
in	O
the	O
case	O
group	O
.	O

Home-based	O
nursing	O
pulmonary	O
rehabilitation	O
can	O
be	O
an	O
effective	Others
,	O
inexpensive	Others
and	O
accessible	Others
programme	O
for	O
decreasing	Physical
fatigue	Physical
and	O
improving	Physical
ADL	Mental
and	Physical
QOL	Mental
for	O
patients	O
with	O
COPD	O
.	O

Children	O
with	O
persistent	O
conduct	O
problems	O
who	O
dropout	O
of	O
treatment	O
.	O

Dropout	Others
of	O
treatment	O
is	O
one	O
of	O
the	O
key	O
issues	O
in	O
outcome	O
in	O
a	O
child	O
and	O
adolescent	O
mental	O
health	O
service	O
.	O

We	O
report	O
two	O
studies	O
focusing	O
on	O
the	O
treatment	O
process	O
and	O
the	O
dropout	Others
rate	Others
of	Others
children	Others
with	O
persistent	O
conduct	O
problems	O
presenting	O
to	O
a	O
community	O
mental	O
health	O
service	O
,	O
using	O
a	O
prospective	O
design	O
.	O

The	O
first	O
study	O
included	O
32	O
children	O
and	O
used	O
a	O
randomised	O
controlled	O
treatment	O
design	O
comparing	O
a	O
CBT	O
approach	O
with	O
conjoint	O
family	O
therapy	O
and	O
an	O
eclectic	O
approach	O
.	O

The	O
overall	Others
dropout	Others
rate	Others
was	O
36	O
%	O
.	O

Dropout	Others
occurred	O
significantly	O
less	O
frequently	O
in	O
the	O
CBT	O
group	O
.	O

The	O
dropout	O
group	O
was	O
associated	O
with	O
mothers	O
who	O
were	O
younger	O
and	O
less	O
educated	O
,	O
a	O
poorer	O
rating	O
by	O
the	O
clinicians	O
at	O
the	O
last	O
meeting	O
,	O
parental	Others
dissatisfaction	Others
with	Others
the	Others
treatment	Others
service	Others
and	O
perception	O
that	O
the	O
treatment	O
was	O
less	O
organised	O
and	O
having	O
less	O
behavioural	O
tasks	O
.	O

In	O
the	O
second	O
study	O
we	O
used	O
a	O
naturalistic	O
follow-up	O
design	O
.	O

Forty-six	O
children	O
were	O
included	O
.	O

The	O
overall	Others
dropout	Others
rate	Others
was	O
48	O
%	O
.	O

Again	O
,	O
the	O
children	O
who	O
defaulted	O
were	O
rated	O
by	O
clinicians	O
as	O
less	O
likely	O
to	O
have	O
improved	O
and	O
dropout	O
was	O
also	O
significantly	O
associated	O
with	O
parental	Others
perception	Others
of	Others
a	Others
less	Others
organised	Others
treatment	Others
.	O

In	O
both	O
studies	O
dropout	Others
usually	O
occurred	O
after	O
assessment	O
and	O
at	O
the	O
early	O
phase	O
of	O
treatment	O
.	O

Effect	O
of	O
total	O
androgen	O
ablation	O
on	O
pathologic	Physical
stage	Physical
and	Physical
resection	Physical
limit	Physical
status	Physical
of	Physical
prostate	Physical
cancer	Physical
.	O

Initial	O
results	O
of	O
the	O
Italian	O
PROSIT	O
study	O
.	O

The	O
likelihood	O
of	O
finding	O
organ-confined	O
untreated	O
prostate	O
cancer	O
(	O
PCa	O
)	O
by	O
pathological	O
examination	O
at	O
the	O
time	O
of	O
radical	O
prostatectomy	O
(	O
RP	O
)	O
is	O
only	O
50	O
%	O
in	O
patients	O
with	O
clinically	O
organ-confined	O
disease	O
.	O

In	O
addition	O
,	O
tumour	O
is	O
present	O
at	O
the	O
resection	O
margin	O
in	O
approximately	O
30	O
%	O
of	O
clinical	O
T2	O
(	O
clinical	O
stage	O
B	O
)	O
cases	O
.	O

The	O
issue	O
of	O
clinical	O
understaging	O
and	O
of	O
resection	O
limit	O
positivity	O
have	O
led	O
to	O
the	O
development	O
of	O
novel	O
management	O
practices	O
,	O
including	O
neoadjuvant	O
hormonal	O
therapy	O
(	O
NHT	O
)	O
.	O

The	O
optimal	O
duration	O
of	O
NHT	O
is	O
unknown	O
.	O

We	O
undertook	O
the	O
present	O
analysis	O
to	O
evaluate	O
the	O
effect	Physical
of	Physical
NHT	Physical
on	Physical
pathologic	Physical
stage	Physical
of	Physical
PCa	Physical
and	Physical
resection	Physical
limit	Physical
status	Physical
in	O
patients	O
with	O
prostate	O
cancer	O
and	O
treated	O
with	O
total	O
androgen	O
ablation	O
either	O
for	O
three	O
or	O
six	O
months	O
before	O
RP	O
.	O

Between	O
January	O
1996	O
and	O
February	O
1998	O
,	O
259	O
men	O
with	O
prostate	O
cancer	O
underwent	O
radical	O
retropubic	O
prostatectomy	O
and	O
bilateral	O
pelvic	O
node	O
dissection	O
in	O
the	O
26	O
centres	O
participating	O
in	O
the	O
Italian	O
randomised	O
prospective	O
PROSIT	O
study	O
.	O

Whole	O
mount	O
sectioning	O
of	O
the	O
complete	O
RP	O
specimens	O
was	O
adopted	O
in	O
each	O
centre	O
for	O
accurately	O
evaluating	O
the	O
pathologic	Physical
stage	Physical
and	Physical
resection	Physical
limit	Physical
status	Physical
.	O

By	O
February	O
1998	O
,	O
haematoxylin	O
and	O
eosin	O
stained	O
sections	O
from	O
155	O
RP	O
specimens	O
had	O
been	O
received	O
and	O
evaluated	O
by	O
the	O
reviewing	O
pathologist	O
(	O
RM	O
)	O
.	O

64	O
cases	O
had	O
not	O
been	O
treated	O
with	O
total	O
androgen	O
ablation	O
(	O
e.g	O
.	O

NHT	O
)	O
before	O
RP	O
was	O
performed	O
,	O
whereas	O
58	O
and	O
33	O
had	O
been	O
treated	O
for	O
three	O
and	O
six	O
months	O
,	O
respectively	O
.	O

114	O
patients	O
were	O
clinical	O
stage	O
B	O
whereas	O
41	O
were	O
clinical	O
stage	O
C.	O
After	O
three	O
months	O
of	O
total	O
androgen	O
ablation	O
,	O
pathological	Physical
stage	Physical
B	Physical
was	O
more	O
prevalent	O
among	O
patients	O
with	O
clinical	O
B	O
tumours	O
,	O
compared	O
with	O
untreated	O
patients	O
(	O
57	O
%	O
in	O
treated	O
patients	O
vs.	O
36	O
%	O
in	O
untreated	O
)	O
.	O

The	O
percentage	Physical
of	Physical
cancers	Physical
with	Physical
negative	Physical
margins	Physical
was	O
statistically	O
significantly	O
greater	O
in	O
patients	O
treated	O
with	O
neoadjuvant	O
therapy	O
than	O
those	O
treated	O
with	O
immediate	O
surgery	O
alone	O
(	O
69	O
%	O
vs.	O
42	O
%	O
,	O
respectively	O
)	O
.	O

After	O
six	O
months	O
of	O
NHT	O
therapy	O
the	O
proportion	Physical
of	Physical
patients	Physical
with	Physical
pathological	Physical
stage	Physical
B	Physical
(	O
67	O
%	O
vs.	O
36	O
%	O
,	O
respectively	O
)	O
and	O
negative	Physical
margins	Physical
was	O
greater	O
than	O
after	O
3	O
months	O
(	O
92	O
%	O
vs.	O
42	O
%	O
,	O
respectively	O
)	O
.	O

For	O
clinical	O
C	O
tumours	O
,	O
the	O
prevalence	O
of	O
pathological	Physical
stage	Physical
B	Physical
and	Physical
negative	Physical
margins	Physical
in	O
the	O
patients	O
treated	O
for	O
either	O
3	O
or	O
6	O
months	O
was	O
not	O
as	O
high	O
as	O
in	O
the	O
clinical	O
B	O
tumours	O
,	O
when	O
compared	O
with	O
the	O
untreated	O
group	O
(	O
pathological	O
stage	O
B	O
:	O
31	O
%	O
and	O
33	O
%	O
vs.	O
6	O
%	O
in	O
the	O
clinical	O
C	O
cases	O
,	O
respectively	O
.	O

Negative	O
margins	O
:	O
56	O
%	O
and	O
67	O
%	O
vs.	O
31	O
%	O
,	O
respectively	O
)	O
.	O

The	O
initial	O
results	O
of	O
this	O
study	O
suggest	O
that	O
total	O
androgen	O
ablation	O
before	O
RP	O
is	O
beneficial	O
in	O
men	O
with	O
clinical	O
stage	O
B	O
because	O
of	O
the	O
significant	O
pathological	Physical
downstaging	Physical
and	O
decrease	O
in	O
the	O
number	O
of	O
positive	Physical
margins	Physical
in	Physical
the	Physical
RP	Physical
specimens	Physical
.	O

These	O
two	O
effects	O
are	O
more	O
pronounced	O
after	O
six	O
months	O
of	O
NHT	O
than	O
after	O
three	O
months	O
of	O
therapy	O
.	O

The	O
same	O
degree	O
of	O
beneficial	Others
effects	Others
are	O
not	O
observed	O
in	O
clinical	O
C	O
tumours	O
.	O

Prospective	O
investigation	O
of	O
body	O
mass	O
index	O
,	O
colorectal	Physical
adenoma	Physical
,	O
and	O
colorectal	Physical
cancer	Physical
in	O
the	O
prostate	O
,	O
lung	O
,	O
colorectal	O
,	O
and	O
ovarian	O
cancer	O
screening	O
trial	O
.	O

PURPOSE	O
Obesity	O
has	O
consistently	O
been	O
linked	O
to	O
an	O
increased	O
risk	Physical
of	Physical
colorectal	Physical
cancer	Physical
,	O
particularly	O
among	O
men	O
.	O

Whether	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
differentially	O
influences	O
the	O
risk	O
across	O
the	O
stages	O
of	O
colorectal	O
cancer	O
development	O
remains	O
unclear	O
.	O

We	O
evaluated	O
the	O
associations	O
of	O
BMI	O
with	O
colorectal	Physical
adenoma	Physical
incidence	Physical
,	O
adenoma	Physical
recurrence	Physical
,	Physical
and	Physical
cancer	Physical
in	O
the	O
context	O
of	O
a	O
large	O
screening	O
trial	O
,	O
in	O
which	O
cases	O
and	O
controls	O
had	O
an	O
equal	O
chance	O
for	O
disease	O
detection	O
.	O

METHODS	O
We	O
prospectively	O
evaluated	O
the	O
association	O
between	O
baseline	O
BMI	O
and	O
the	O
risk	O
of	O
incident	Physical
distal	Physical
adenoma	Physical
(	O
1,213	O
cases	O
)	O
,	O
recurrent	Physical
adenoma	Physical
(	O
752	O
cases	O
)	O
,	O
and	O
incident	Physical
colorectal	Physical
cancer	Physical
(	O
966	O
cases	O
)	O
among	O
men	O
and	O
women	O
,	O
ages	O
55	O
to	O
74	O
years	O
,	O
randomly	O
assigned	O
to	O
receive	O
flexible	O
sigmoidoscopy	O
screening	O
as	O
part	O
of	O
the	O
Prostate	O
,	O
Lung	O
,	O
Colorectal	O
,	O
and	O
Ovarian	O
Cancer	O
Screening	O
Trial	O
.	O

We	O
calculated	O
odds	Physical
ratios	Physical
(	Physical
ORs	Physical
)	Physical
and	Physical
95	Physical
%	Physical
CIs	Physical
for	O
adenoma	Physical
incidence	Physical
and	Physical
recurrence	Physical
,	O
and	O
hazard	Physical
ratios	Physical
(	Physical
HRs	Physical
)	Physical
and	O
95	Physical
%	Physical
CIs	Physical
for	O
colorectal	Physical
cancer	Physical
incidence	Physical
,	O
using	O
multivariable-adjusted	O
models	O
.	O

RESULTS	O
Compared	O
with	O
normal-weight	O
men	O
(	O
18.5	O
to	O
24.9	O
kg/m	O
(	O
2	O
)	O
)	O
,	O
obese	O
men	O
(	O
?	O
30	O
kg/m	O
(	O
2	O
)	O
)	O
had	O
significantly	O
higher	O
risk	O
of	O
incident	O
adenoma	O
(	O
OR	O
,	O
1.32	O
;	O
95	O
%	O
CI	O
,	O
1.06	O
to	O
1.65	O
)	O
and	O
colorectal	O
cancer	O
(	O
HR	O
,	O
1.48	O
;	O
95	O
%	O
CI	O
,	O
1.16	O
to	O
1.89	O
)	O
and	O
a	O
borderline	O
increased	O
risk	O
of	O
recurrent	O
adenoma	O
(	O
OR	O
,	O
1.50	O
;	O
95	O
%	O
CI	O
,	O
0.98	O
to	O
2.30	O
)	O
.	O

No	O
associations	O
were	O
observed	O
for	O
either	O
adenoma	O
or	O
cancer	O
in	O
women	O
.	O

CONCLUSION	O
Data	O
from	O
this	O
large	O
prospective	O
study	O
suggest	O
that	O
obesity	O
is	O
important	O
throughout	O
the	O
natural	O
history	O
of	O
colorectal	O
cancer	O
,	O
at	O
least	O
in	O
men	O
,	O
and	O
colorectal	O
cancer	O
prevention	O
efforts	O
should	O
encourage	O
the	O
achievement	O
and	O
maintenance	O
of	O
a	O
healthy	O
body	O
weight	O
in	O
addition	O
to	O
regular	O
screenings	O
.	O

Mecamylamine	O
reduces	O
some	O
EEG	Physical
effects	Physical
of	O
nicotine	O
chewing	O
gum	O
in	O
humans	O
.	O

Spontaneous	Physical
EEG	Physical
was	O
recorded	O
in	O
nine	O
cigarette	O
smokers	O
who	O
had	O
been	O
abstinent	O
from	O
tobacco	O
for	O
12	O
hr	O
.	O

Subjects	O
were	O
treated	O
with	O
a	O
capsule	O
containing	O
either	O
centrally	O
acting	O
nicotine	O
blocker	O
,	O
mecamylamine	O
(	O
10	O
mg	O
)	O
,	O
or	O
placebo	O
.	O

At	O
each	O
of	O
three	O
60-min	O
intervals	O
after	O
the	O
capsule	O
was	O
ingested	O
,	O
the	O
subjects	O
chewed	O
two	O
pieces	O
of	O
gum	O
containing	O
a	O
total	O
of	O
0	O
,	O
4	O
or	O
8	O
mg	O
of	O
nicotine	O
.	O

Nicotine	O
and	O
mecamylamine	O
dose	O
combinations	O
were	O
randomized	O
across	O
subjects	O
.	O

Two	O
three-minute	O
periods	O
of	O
spontaneous	Physical
EEG	Physical
were	O
recorded	O
before	O
the	O
capsule	O
and	O
before	O
and	O
after	O
gum	O
chewing	O
from	O
bipolar	O
electrode	O
montages	O
at	O
the	O
following	O
positions	O
:	O
Cz-T5	O
,	O
Cz-T6	O
,	O
Cz-F7	O
and	O
Cz-F8	O
.	O

During	O
one	O
period	O
the	O
subjects	O
relaxed	O
with	O
eyes	O
closed	O
,	O
in	O
the	O
other	O
period	O
they	O
performed	O
a	O
math	O
task	O
with	O
eyes	O
open	O
.	O

When	O
the	O
drugs	O
were	O
given	O
individually	O
,	O
mecamylamine	O
decreased	O
beta	Physical
power	Physical
and	O
nicotine	O
gum	O
(	O
4	O
and	O
8	O
mg	O
)	O
increased	O
alpha	Physical
frequency	Physical
.	Physical

Mecamylamine	O
pretreatment	O
prevented	O
the	O
increase	O
in	O
alpha	Physical
frequency	Physical
caused	O
by	O
the	O
4	O
mg	O
gum	O
dose	O
but	O
not	O
the	O
8	O
mg	O
dose	O
.	O

Alpha	Others
power	Others
was	O
increased	O
by	O
the	O
8	O
mg	O
gum	O
dose	O
and	O
that	O
increase	O
was	O
prevented	O
by	O
mecamylamine	O
.	O

Self-reported	O
ratings	O
of	O
the	O
strength	Physical
of	O
the	O
gum	O
were	O
significantly	O
diminished	O
by	O
mecamylamine	O
pretreatment	O
.	O

The	O
data	O
are	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
studies	O
which	O
indicate	O
that	O
the	O
effects	O
of	O
tobacco	O
administration	O
and	O
withdrawal	O
are	O
mediated	O
by	O
central	O
actions	O
of	O
nicotine	O
.	O

Safety	O
and	O
immunogenicity	O
of	O
a	O
combined	O
pentavalent	O
diphtheria	O
,	O
tetanus	O
,	O
acellular	O
pertussis	O
,	O
inactivated	O
poliovirus	O
and	O
Haemophilus	O
influenzae	O
type	O
b-tetanus	O
conjugate	O
vaccine	O
in	O
infants	O
,	O
compared	O
with	O
a	O
whole	O
cell	O
pertussis	O
pentavalent	O
vaccine	O
.	O

BACKGROUND	O
We	O
compared	O
the	O
safety	O
and	O
immunogenicity	O
of	O
two	O
combined	O
diphtheria-tetanus-pertussis-inactivated	O
poliovirus	O
vaccines	O
containing	O
either	O
acellular	O
(	O
Pa	O
,	O
SmithKline	O
Beecham	O
Biologicals	O
)	O
or	O
whole	O
cell	O
(	O
Pw	O
,	O
Pasteur	O
Merieux	O
Connaught	O
)	O
pertussis	O
components	O
,	O
mixed	O
with	O
a	O
Haemophilus	O
influenzae	O
type	O
b	O
polysaccharide	O
polyribosylribitol	O
phosphate-tetanus	O
conjugate	O
vaccine	O
in	O
an	O
open	O
,	O
randomized	O
study	O
in	O
healthy	O
infants	O
.	O

DESIGN	O
The	O
combined	O
vaccines	O
were	O
given	O
at	O
2	O
,	O
4	O
,	O
6	O
and	O
12	O
months	O
of	O
age	O
,	O
and	O
serum	O
samples	O
were	O
obtained	O
at	O
ages	O
2	O
,	O
6	O
,	O
7	O
,	O
12	O
and	O
13	O
months	O
.	O

Adverse	O
events	O
were	O
obtained	O
by	O
diary	O
cards	O
.	O

RESULTS	O
The	O
Pa	O
group	O
(	O
n	O
=	O
101	O
)	O
had	O
a	O
clearly	O
lower	Adverseeffect
incidence	Adverseeffect
of	Adverseeffect
both	Adverseeffect
local	Adverseeffect
and	Adverseeffect
systemic	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
than	O
the	O
Pw	O
group	O
(	O
n	O
=	O
100	O
)	O
.	O

Immunogenicity	Physical
was	O
comparable	O
for	O
the	O
diphtheria	O
and	O
tetanus	O
components	O
,	O
but	O
significantly	O
superior	O
for	O
pertussis	Physical
toxin	Physical
,	Physical
filamentous	Physical
hemagglutinin	Physical
,	Physical
pertactin	Physical
and	Physical
polioviruses	Physical
1	Physical
,	Physical
2	Physical
and	Physical
3	Physical
in	Physical
the	Physical
Pa	Physical
group	Physical
.	Physical

Both	O
groups	O
had	O
an	O
appropriate	O
response	O
with	O
regard	O
to	O
H.	O
influenzae	O
type	O
b	O
polysaccharide	O
polyribosylribitol	O
phosphate	O
,	O
but	O
the	O
dynamics	O
of	O
the	O
response	O
were	O
significantly	O
different	O
:	O
geometric	Physical
mean	Physical
concentrations	Physical
(	O
micrograms	O
per	O
ml	O
)	O
after	O
the	O
second	O
,	O
third	O
and	O
booster	O
doses	O
were	O
1.27	O
,	O
5.06	O
and	O
23.12	O
in	O
the	O
Pa	O
group	O
and	O
2.72	O
,	O
6.66	O
and	O
13.59	O
in	O
the	O
Pw	O
group	O
,	O
respectively	O
(	O
P	O
=	O
0.0002	O
after	O
second	O
dose	O
;	O
P	O
=	O
0.0005	O
after	O
booster	O
)	O
.	O

CONCLUSION	O
The	O
presently	O
studied	O
diphtheria	O
,	O
tetanus	O
,	O
acellular	O
pertussis-H.	O
influenzae	O
b	O
vaccine	O
conjugated	O
to	O
tetanus	O
toxoid	O
combination	O
was	O
at	O
least	O
as	O
immunogenic	O
as	O
the	O
diphtheria	O
,	O
tetanus	O
,	O
whole	O
cell	O
pertussis-H.	O
influenzae	O
b	O
vaccine	O
conjugated	O
to	O
tetanus	O
toxoid	O
combination	O
,	O
with	O
a	O
significantly	O
better	O
safety	O
profile	O
.	O

This	O
is	O
of	O
obvious	O
importance	O
in	O
countries	O
where	O
inactivated	O
poliovirus	O
vaccine	O
is	O
part	O
of	O
the	O
routine	O
infant	O
immunization	O
programs	O
.	O

Differential	O
response	O
of	O
seven	O
subjects	O
with	O
autistic	O
disorder	O
to	O
clomipramine	O
and	O
desipramine	O
.	O

OBJECTIVE	O
Clomipramine	O
,	O
a	O
serotonin	O
reuptake	O
blocker	O
that	O
has	O
unique	O
antiobsessional	O
properties	O
,	O
was	O
hypothesized	O
to	O
have	O
a	O
different	O
effect	O
from	O
that	O
of	O
desipramine	O
,	O
a	O
tricyclic	O
antidepressant	O
with	O
selective	O
adrenergic	O
effects	O
,	O
for	O
the	O
stereotyped	O
,	O
repetitive	O
behaviors	O
in	O
autism	O
.	O

METHOD	O
Seven	O
subjects	O
,	O
ages	O
6-18	O
years	O
,	O
with	O
autistic	O
disorder	O
completed	O
a	O
10-week	O
double-blind	O
,	O
crossover	O
trial	O
of	O
clomipramine	O
and	O
desipramine	O
following	O
a	O
2-week	O
single-blind	O
,	O
placebo	O
phase	O
.	O

RESULTS	O
Clomipramine	O
was	O
superior	O
to	O
desipramine	O
and	O
placebo	O
,	O
as	O
indicated	O
by	O
standardized	O
ratings	Others
of	Others
autism	Others
and	Others
anger	Others
as	O
well	O
as	O
ratings	Mental
of	Mental
repetitive	Mental
and	Mental
compulsive	Mental
behaviors	Mental
.	O

Clomipramine	O
and	O
desipramine	O
were	O
equally	O
superior	O
to	O
placebo	O
for	O
ratings	Mental
of	Mental
hyperactivity	Mental
.	O

Parents	O
of	O
all	O
seven	O
subjects	O
elected	O
to	O
have	O
their	O
children	O
continue	O
to	O
take	O
clomipramine	O
after	O
the	O
study	O
.	O

CONCLUSIONS	O
Clomipramine	O
and	O
desipramine	O
are	O
differentially	O
effective	O
in	O
treating	O
the	O
obsessive-compulsive	Mental
and	O
core	Physical
symptoms	Physical
in	O
autistic	O
disorder	O
.	O

Biological	O
links	O
between	O
compulsions	O
and	O
stereotyped	O
,	O
repetitive	O
behaviors	O
in	O
autistic	O
disorder	O
should	O
be	O
explored	O
.	O

Effectiveness	O
of	O
two	O
quadruple	O
,	O
tetracycline-	O
or	O
clarithromycin-containing	O
,	O
second-line	O
,	O
Helicobacter	Physical
pylori	Physical
eradication	Physical
therapies	Physical
.	O

BACKGROUND	O
There	O
are	O
no	O
guidelines	O
on	O
second-line	O
therapies	O
for	O
Helicobacter	O
pylori	O
eradication	O
failures	O
of	O
omeprazole-clarithromycin-amoxicillin	O
triple	O
therapy	O
.	O

AIM	O
To	O
compare	O
the	O
efficacy	O
of	O
two	O
second-line	O
therapies	O
for	O
persistent	O
H.	O
pylori	O
infection	O
.	O

METHODS	O
Over	O
a	O
6-year	O
period	O
,	O
patients	O
with	O
persistent	O
H.	O
pylori	O
infection	O
following	O
omeprazole-clarithromycin-amoxicillin	O
eradication	O
therapy	O
were	O
randomized	O
to	O
receive	O
omeprazole	O
,	O
20	O
mg	O
twice	O
daily	O
,	O
bismuth	O
,	O
120	O
mg	O
four	O
times	O
daily	O
,	O
metronidazole	O
,	O
500	O
mg	O
twice	O
daily	O
,	O
and	O
either	O
tetracycline	O
,	O
500	O
mg	O
four	O
times	O
daily	O
,	O
or	O
clarithromycin	O
,	O
500	O
mg	O
twice	O
daily	O
,	O
given	O
for	O
7	O
days	O
.	O

Before	O
therapy	O
,	O
patients	O
underwent	O
endoscopy	O
with	O
biopsies	O
for	O
histology	O
,	O
culture	O
and	O
antibiotic	O
susceptibility	O
tests	O
.	O

H.	O
pylori	O
infection	O
was	O
confirmed	O
by	O
histology	O
.	O

RESULTS	O
Of	O
the	O
95	O
randomized	O
patients	O
,	O
88	O
(	O
93	O
%	O
)	O
completed	O
the	O
study	O
.	O

Age	O
,	O
sex	O
,	O
smoking	O
,	O
ulcer/non-ulcer	O
dyspepsia	O
ratio	O
and	O
antibiotic	O
resistance	O
were	O
not	O
significantly	O
different	O
between	O
the	O
treatment	O
groups	O
.	O

On	O
intention-to-treat	O
analysis	O
,	O
eradication	Physical
was	O
achieved	O
in	O
41	O
of	O
the	O
49	O
patients	O
(	O
84	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
70.4-92.7	O
%	O
)	O
and	O
27	O
of	O
the	O
46	O
patients	O
(	O
59	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
43.3-73.0	O
%	O
)	O
of	O
the	O
tetracycline-	O
and	O
clarithromycin-containing	O
groups	O
,	O
respectively	O
(	O
P=0.007	O
)	O
.	O

On	O
multivariate	O
regression	O
analysis	O
,	O
the	O
sensitivity	Others
of	Others
H.	Others
pylori	O
to	O
metronidazole	O
had	O
a	O
likelihood	O
ratio	O
of	O
5.2	O
(	O
P=0.022	O
)	O
,	O
followed	O
by	O
the	O
type	O
of	O
quadruple	O
therapy	O
(	O
likelihood	O
ratio	O
,	O
4.4	O
;	O
P=0.036	O
)	O
.	O

CONCLUSIONS	O
Tetracycline-containing	O
quadruple	O
rescue	O
therapy	O
is	O
highly	O
effective	O
in	O
treating	O
H.	O
pylori	O
eradication	O
failures	O
of	O
the	O
omeprazole-amoxicillin-clarithromycin	O
regimen	O
.	O

Active	O
symptom	O
control	O
with	O
or	O
without	O
chemotherapy	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
malignant	O
pleural	O
mesothelioma	O
(	O
MS01	O
)	O
:	O
a	O
multicentre	O
randomised	O
trial	O
.	O

BACKGROUND	O
Malignant	O
pleural	O
mesothelioma	O
is	O
almost	O
always	O
fatal	O
,	O
and	O
few	O
treatment	O
options	O
are	O
available	O
.	O

Although	O
active	O
symptom	O
control	O
(	O
ASC	O
)	O
has	O
been	O
recommended	O
for	O
the	O
management	O
of	O
this	O
disease	O
,	O
no	O
consensus	O
exists	O
for	O
the	O
role	O
of	O
chemotherapy	O
.	O

We	O
investigated	O
whether	O
the	O
addition	O
of	O
chemotherapy	O
to	O
ASC	O
improved	O
survival	Mortality
and	O
quality	Physical
of	Physical
life	Physical
.	O

METHODS	O
409	O
patients	O
with	O
malignant	O
pleural	O
mesothelioma	O
,	O
from	O
76	O
centres	O
in	O
the	O
UK	O
and	O
two	O
in	O
Australia	O
,	O
were	O
randomly	O
assigned	O
to	O
ASC	O
alone	O
(	O
treatment	O
could	O
include	O
steroids	O
,	O
analgesic	O
drugs	O
,	O
bronchodilators	O
,	O
palliative	O
radiotherapy	O
[	O
n=136	O
]	O
)	O
;	O
to	O
ASC	O
plus	O
MVP	O
(	O
four	O
cycles	O
of	O
mitomycin	O
6	O
mg/m2	O
,	O
vinblastine	O
6	O
mg/m2	O
,	O
and	O
cisplatin	O
50	O
mg/m2	O
every	O
3	O
weeks	O
[	O
n=137	O
]	O
)	O
;	O
or	O
to	O
ASC	O
plus	O
vinorelbine	O
(	O
one	O
injection	O
of	O
vinorelbine	O
30	O
mg/m2	O
every	O
week	O
for	O
12	O
weeks	O
[	O
n=136	O
]	O
)	O
.	O

Randomisation	O
was	O
done	O
by	O
minimisation	O
,	O
with	O
stratification	O
for	O
WHO	O
performance	O
status	O
,	O
histology	O
,	O
and	O
centre	O
.	O

Follow-up	O
was	O
every	O
3	O
weeks	O
to	O
21	O
weeks	O
after	O
randomisation	O
,	O
and	O
every	O
8	O
weeks	O
thereafter	O
.	O

Because	O
of	O
slow	O
accrual	O
,	O
the	O
two	O
chemotherapy	O
groups	O
were	O
combined	O
and	O
compared	O
with	O
ASC	O
alone	O
for	O
the	O
primary	O
outcome	O
of	O
overall	O
survival	O
.	O

Analysis	O
was	O
by	O
intention	O
to	O
treat	O
.	O

This	O
study	O
is	O
registered	O
,	O
number	O
ISRCTN54469112	O
.	O

FINDINGS	O
At	O
the	O
time	O
of	O
analysis	O
,	O
393	O
(	O
96	O
%	O
)	O
patients	O
had	O
died	Mortality
(	O
ASC	O
132	O
[	O
97	O
%	O
]	O
,	O
ASC	O
plus	O
MVP	O
132	O
[	O
96	O
%	O
]	O
,	O
ASC	O
plus	O
vinorelbine	O
129	O
[	O
95	O
%	O
]	O
)	O
.	O

Compared	O
with	O
ASC	O
alone	O
,	O
we	O
noted	O
a	O
small	O
,	O
non-significant	Mortality
survival	Mortality
benefit	Mortality
for	O
ASC	O
plus	O
chemotherapy	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.89	O
[	O
95	O
%	O
CI	O
0.72-1.10	O
]	O
;	O
p=0.29	O
)	O
.	O

Median	Mortality
survival	Mortality
was	O
7.6	O
months	O
in	O
the	O
ASC	O
alone	O
group	O
and	O
8.5	O
months	O
in	O
the	O
ASC	O
plus	O
chemotherapy	O
group	O
.	O

Exploratory	O
analyses	O
suggested	O
a	O
survival	Mortality
advantage	Mortality
for	O
ASC	O
plus	O
vinorelbine	O
compared	O
with	O
ASC	O
alone	O
(	O
HR	O
0.80	O
[	O
0.63-1.02	O
]	O
;	O
p=0.08	O
)	O
,	O
with	O
a	O
median	Mortality
survival	Mortality
of	O
9.5	O
months	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
survival	Mortality
benefit	Mortality
with	O
ASC	O
plus	O
MVP	O
(	O
HR	O
0.99	O
[	O
0.78-1.27	O
]	O
;	O
p=0.95	O
)	O
.	O

We	O
observed	O
no	O
between-group	O
differences	O
in	O
four	O
predefined	O
quality-of-life	Physical
subscales	Physical
(	Physical
physical	Physical
functioning	Physical
,	Physical
pain	Physical
,	Physical
dyspnoea	Physical
,	Physical
and	Physical
global	Physical
health	Physical
status	Physical
)	Physical
at	O
any	O
of	O
the	O
assessments	O
in	O
the	O
first	O
6	O
months	O
.	O

INTERPRETATION	O
The	O
addition	O
of	O
chemotherapy	O
to	O
ASC	O
offers	O
no	O
significant	O
benefits	O
in	O
terms	O
of	O
overall	O
survival	Mortality
or	Mental
quality	Physical
of	Physical
life	Physical
.	O

However	O
,	O
exploratory	O
analyses	O
suggested	O
that	O
vinorelbine	O
merits	O
further	O
investigation	O
.	O

[	O
Comparison	O
of	O
complications	Adverseeffect
after	O
intra-	O
and	O
extracapsular	O
cataract	O
extraction	O
with	O
lens	O
implantation	O
.	O

Results	O
of	O
a	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
]	O
.	O

BACKGROUND	O
The	O
postoperative	Adverseeffect
complications	Adverseeffect
of	O
ICCE	O
with	O
ACL	O
implantation	O
are	O
compared	O
with	O
those	O
of	O
ECCE	O
and	O
PCL	O
.	O

Our	O
clinical	O
experience	O
with	O
ICCE	O
and	O
ACL	O
implantation	O
can	O
not	O
confirm	O
the	O
widespread	O
rejection	O
of	O
this	O
method	O
.	O

PATIENTS	O
AND	O
METHOD	O
A	O
prospective	O
,	O
randomized	O
,	O
clinical	O
study	O
with	O
participation	O
of	O
medical	O
statisticians	O
was	O
performed	O
.	O

A	O
total	O
of	O
190	O
patients	O
with	O
ICCE	O
and	O
ACL	O
and	O
170	O
patients	O
with	O
ECCE	O
and	O
PCL	O
were	O
followed	O
up	O
for	O
2	O
years	O
.	O

The	O
follow-up	O
examinations	O
were	O
performed	O
upon	O
dismission	O
from	O
the	O
hospital	O
,	O
after	O
6	O
,	O
12	O
and	O
24	O
months	O
.	O

The	O
data	O
were	O
compiled	O
in	O
a	O
computer	O
program	O
designed	O
for	O
this	O
study	O
and	O
evaluated	O
by	O
the	O
statisticians	O
.	O

The	O
surgical	O
procedures	O
and	O
the	O
surgeons	O
were	O
defined	O
prior	O
to	O
the	O
beginning	O
of	O
patient	O
recruitment	O
.	O

RESULTS	O
ICCE	O
with	O
ACL	O
shows	O
much	O
less	O
postoperative	Adverseeffect
complications	Adverseeffect
as	O
usually	O
emphasized	O
.	O

There	O
were	O
only	O
2	O
(	O
1.2	O
%	O
)	O
of	O
retinal	Physical
detachment	Physical
and	O
no	O
case	O
of	O
corneal	Physical
decompensation	Physical
.	O

Cystoid	Adverseeffect
macular	Adverseeffect
edema	Adverseeffect
8	O
(	O
4.7	O
%	O
)	O
,	O
postoperative	Adverseeffect
vitreous	Adverseeffect
prolaps	Adverseeffect
into	Adverseeffect
the	Adverseeffect
anterior	Adverseeffect
chamber	Adverseeffect
4	O
(	O
2.3	O
%	O
)	O
and	O
spontaneous	Pain
complaints	Pain
of	Pain
pain	Pain
16	O
(	O
9.4	O
%	O
)	O
occurred	O
in	O
a	O
low	O
percentage	O
after	O
ICCE	O
with	O
ACL	O
.	O

These	O
complications	O
did	O
not	O
occur	O
after	O
ECCE	O
with	O
PCL	O
.	O

The	O
patients	O
with	O
ECCE	O
and	O
PCL	O
showed	O
capsular	Physical
fibrosis	Physical
in	O
48	O
(	O
28	O
%	O
)	O
making	O
it	O
the	O
most	O
frequent	O
complication	O
of	O
the	O
whole	O
study	O
.	O

33	O
%	O
of	O
these	O
patients	O
required	O
YAG-laser	O
capsulotomy	O
.	O

Since	O
retinal	O
detachment	O
occurs	O
in	O
2.5	O
%	O
after	O
YAG-laser	O
capsulotomy	O
we	O
can	O
not	O
regard	O
capsular	O
fibrosis	O
as	O
a	O
totally	O
harmless	O
complication	O
.	O

It	O
is	O
noteworthy	O
that	O
visual	Physical
acuity	Physical
is	O
almost	O
identical	O
1	O
year	O
after	O
surgery	O
in	O
both	O
methods	O
.	O

CONCLUSIONS	O
The	O
results	O
of	O
this	O
study	O
show	O
that	O
the	O
evaluation	O
of	O
ICCE	O
with	O
ACL	O
is	O
too	O
negative	O
.	O

The	O
elimination	O
of	O
postoperative	O
complications	O
in	O
this	O
method	O
is	O
more	O
difficult	O
.	O

ECCE	O
with	O
PCL	O
is	O
burdened	O
by	O
frequent	Physical
capsular	Physical
fibrosis	Physical
.	O

Visual	O
acuity	O
is	O
almost	O
the	O
same	O
in	O
both	O
methods	O
1	O
years	O
after	O
the	O
operation	O
.	O

ACL-implantation	O
remains	O
our	O
method	O
of	O
choice	O
for	O
secondary	O
implantation	O
in	O
patients	O
with	O
an	O
intact	O
iris	O
diaphragm	O
.	O

Drug	O
therapy	O
of	O
ventricular	O
tachycardia	O
:	O
a	O
cost	O
comparison	O
of	O
randomized	O
noninvasive	O
and	O
invasive	O
approaches	O
.	O

OBJECTIVE	O
Economic	Others
evaluation	Others
of	O
noninvasive	O
(	O
suppression	O
of	O
ventricular	O
arrhythmias	O
detected	O
by	O
ambulatory	O
monitoring	O
)	O
and	O
invasive	O
(	O
suppression	O
of	O
arrhythmias	O
induced	O
by	O
programmed	O
stimulation	O
)	O
approaches	O
to	O
antiarrhythmic	O
drug	O
selection	O
for	O
ventricular	O
tachyarrhythmias	O
.	O

DESIGN/SETTING	O
Randomized	O
clinical	O
trial/tertiary-care	O
hospital	O
.	O

PATIENTS	O
Of	O
124	O
consecutive	O
patients	O
referred	O
for	O
treatment	O
of	O
symptomatic	O
ventricular	O
tachyarrhythmias	O
,	O
57	O
consenting	O
patients	O
were	O
eligible	O
to	O
have	O
drug	O
therapy	O
selected	O
by	O
either	O
noninvasive	O
or	O
invasive	O
approaches	O
.	O

MEASUREMENTS	O
Costs	Others
of	Others
initial	Others
and	Others
follow-up	Others
(	O
26	O
+/-	O
15	O
months	O
)	O
admissions	O
for	O
the	O
two	O
groups	O
were	O
compared	O
.	O

This	O
economic	Others
evaluation	Others
also	O
considered	O
relative	O
efficacies	O
of	O
the	O
approaches	O
using	O
the	O
primary	O
outcome	O
variable	O
of	O
symptomatic	O
,	O
sustained	Physical
ventricular	Physical
tachyarrhythmia	Physical
recurrence	Physical
(	O
including	Physical
sudden	Physical
death	Physical
)	O
.	O

RESULTS	O
Initial	Others
hospitalization	Others
for	O
therapy	O
selection	O
was	O
less	O
costly	Others
by	O
the	O
noninvasive	O
approach	O
(	O
$	O
6,869	O
+/-	O
4,019	O
)	O
than	O
by	O
the	O
invasive	O
approach	O
(	O
$	O
13,164	O
+/-	O
6,740	O
)	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

However	O
,	O
the	O
noninvasive	O
approach	O
generated	O
higher	O
follow-up	Others
hospital	Others
costs	Others
(	O
$	O
9,204	O
+/-	O
9,217	O
)	O
than	O
the	O
invasive	O
approach	O
(	O
$	O
3,784	O
+/-	O
4,944	O
)	O
(	O
P	O
=	O
0.01	O
)	O
.	O

Thus	O
,	O
total	Others
hospital	Others
costs	Others
of	O
the	O
noninvasive	O
(	O
$	O
16,073	O
+/-	O
9,423	O
)	O
and	O
invasive	O
approaches	O
(	O
$	O
16,949	O
+/-	O
7,174	O
)	O
were	O
equivalent	O
.	O

The	O
two-year	O
actuarial	O
probability	O
of	O
a	O
recurrent	O
,	O
sustained	O
,	O
symptomatic	Physical
ventricular	Physical
tachyarrhythmia	Physical
was	O
greater	O
in	O
noninvasive	O
(	O
0.50	O
+/-	O
0.10	O
)	O
than	O
in	O
invasive	O
(	O
0.20	O
+/-	O
0.08	O
)	O
approach	O
patients	O
(	O
P	O
=	O
0.02	O
)	O
.	O

CONCLUSIONS	O
The	O
lower	O
initial	Others
hospital	Others
costs	Others
of	O
the	O
noninvasive	O
approach	O
are	O
offset	O
by	O
greater	O
follow-up	O
costs	O
.	O

Within	O
two	O
years	O
the	O
costs	Others
of	O
the	O
two	O
approaches	O
are	O
equivalent	O
.	O

Thus	O
,	O
greater	O
antiarrhythmic	Physical
efficacy	Physical
can	O
be	O
achieved	O
by	O
the	O
invasive	O
approach	O
to	O
drug	O
selection	O
without	O
increasing	O
total	Others
hospital	Others
costs	Others
.	O

The	O
FLT3ITD	O
mRNA	O
level	O
has	O
a	O
high	O
prognostic	O
impact	O
in	O
NPM1	O
mutated	O
,	O
but	O
not	O
in	O
NPM1	O
unmutated	O
,	O
AML	O
with	O
a	O
normal	O
karyotype	O
.	O

The	O
impact	O
of	O
a	O
FLT3-internal	O
tandem	O
duplication	O
(	O
FLT3ITD	O
)	O
on	O
prognosis	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
is	O
dependent	O
on	O
the	O
ratio	O
of	O
mutated	O
to	O
wild-type	O
allele	O
.	O

In	O
648	O
normal	O
karyotype	O
(	O
NK	O
)	O
AML	O
patients	O
,	O
we	O
found	O
a	O
significant	O
independent	O
effect	O
of	O
the	O
quantitative	Physical
FLT3ITD	Physical
mRNA	Physical
level	Physical
--	Physical
measured	Physical
as	O
(	O
FLT3ITD/wtFLT3	O
)	O
/	O
(	O
FLT3ITD/wtFLT3+1	O
)	O
--	O
on	O
outcome	O
.	O

Moreover	O
,	O
this	O
effect	O
was	O
clearly	O
seen	O
in	O
329	O
patients	O
with	O
a	O
mutated	O
NPM1	O
gene	O
(	O
NPM1+	O
)	O
,	O
but	O
not	O
in	O
319	O
patients	O
without	O
a	O
NPM1	O
mutation	O
(	O
wtNPM1	O
)	O
.	O

In	O
a	O
multivariate	O
Cox	O
regression	O
model	O
,	O
the	O
quantitative	O
FLT3ITD	O
mRNA	O
level	O
showed	O
an	O
independent	O
prognostic	O
impact	O
on	O
overall	Mortality
survival	Mortality
(	O
OS	O
)	O
and	O
relapse-free	Mortality
survival	Mortality
(	O
RFS	O
)	O
only	O
in	O
the	O
NPM1+	O
subgroup	O
(	O
OS	O
:	O
hazard	O
ratio	O
,	O
5.9	O
;	O
[	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
3.1-11.2	O
]	O
;	O
RFS	O
:	O
hazard	O
ratio	O
,	O
7.5	O
[	O
95	O
%	O
CI	O
:	O
3.4-16.5	O
]	O
)	O
.	O

The	O
FLT3ITD	O
mRNA	O
level	O
contributes	O
to	O
relapse	O
risk	O
stratification	O
and	O
might	O
help	O
to	O
guide	O
postremission	O
therapy	O
in	O
NPM1-mutated	O
AML	O
.	O

Cardiovascular	O
safety	O
of	O
degarelix	O
:	O
results	O
from	O
a	O
12-month	O
,	O
comparative	O
,	O
randomized	O
,	O
open	O
label	O
,	O
parallel	O
group	O
phase	O
III	O
trial	O
in	O
patients	O
with	O
prostate	O
cancer	O
.	O

PURPOSE	O
We	O
assessed	O
the	O
cardiovascular	O
safety	O
profile	O
of	O
degarelix	O
,	O
a	O
new	O
gonadotropin-releasing	O
hormone	O
antagonist	O
.	O

MATERIALS	O
AND	O
METHODS	O
This	O
is	O
the	O
first	O
report	O
to	O
our	O
knowledge	O
on	O
cardiovascular	O
safety	O
data	O
from	O
a	O
completed	O
1-year	O
randomized	O
controlled	O
trial	O
of	O
leuprolide	O
acetate	O
vs	O
degarelix	O
.	O

Outcomes	O
considered	O
in	O
these	O
analyses	O
included	O
the	O
QT	Physical
interval	Physical
by	Physical
central	Physical
reading	Physical
and	Physical
analysis	Physical
,	O
and	O
cardiovascular	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
.	O

On	O
multivariate	O
analyses	O
relationships	O
between	O
selected	O
baseline	O
factors	O
and	O
cardiovascular	Physical
events	Physical
were	O
evaluated	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
between	O
treatment	O
groups	O
for	O
mean	O
change	O
in	O
Fridericia	O
's	O
correction	O
of	O
QT	O
during	O
the	O
trial	O
.	O

Markedly	Physical
abnormal	Physical
Fridericia	Physical
's	Physical
correction	Physical
of	Physical
QT	Physical
values	Physical
(	O
500	O
milliseconds	O
or	O
greater	O
)	O
were	O
observed	O
in	O
only	O
a	O
small	O
number	O
of	O
subjects	O
by	O
treatment	O
group	O
,	O
that	O
is	O
2	O
(	O
less	O
than	O
1	O
%	O
)	O
in	O
the	O
pooled	O
degarelix	O
group	O
and	O
2	O
(	O
1	O
%	O
)	O
in	O
the	O
leuprolide	O
group	O
.	O

Supraventricular	Physical
arrhythmias	Physical
were	O
the	O
most	O
common	O
type	O
of	O
arrhythmias	O
,	O
affecting	O
2	O
%	O
of	O
subjects	O
in	O
the	O
pooled	O
degarelix	O
group	O
and	O
4	O
%	O
in	O
the	O
leuprolide	O
group	O
.	O

Other	Physical
arrhythmias	Physical
occurred	O
in	O
1	O
%	O
or	O
less	O
of	O
subjects	O
by	O
treatment	O
group	O
.	O

The	O
most	O
frequently	O
reported	O
cardiac	O
disorder	O
was	O
ischemic	Physical
heart	Physical
disease	Physical
,	O
which	O
occurred	O
in	O
4	O
%	O
of	O
subjects	O
treated	O
with	O
degarelix	O
and	O
10	O
%	O
of	O
those	O
on	O
leuprolide	O
.	O

Cox	O
proportional	O
hazard	O
ratio	O
estimates	O
for	O
selected	O
baseline	O
covariates	O
showed	O
a	O
significantly	O
increased	O
risk	O
of	O
cardiovascular	O
events	O
by	O
age	O
(	O
p=0.0459	O
)	O
and	O
systolic	O
blood	O
pressure	O
(	O
p=0.0061	O
)	O
.	O

CONCLUSIONS	O
In	O
men	O
with	O
prostate	O
cancer	O
degarelix	O
and	O
leuprolide	O
have	O
similar	O
cardiovascular	O
safety	O
profiles	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
cardiovascular	O
events	O
associated	O
with	O
both	O
agents	O
result	O
from	O
hypogonadism	O
rather	O
than	O
a	O
direct	O
drug	O
effect	O
.	O

Protocol	O
for	O
the	O
Multicenter	O
Acute	O
Stroke	O
Trial	O
--	O
thrombolysis	O
study	O
.	O

The	O
rationale	O
for	O
the	O
Multicenter	O
Acute	O
Stroke	O
Trial	O
(	O
MAST	O
)	O
is	O
presented	O
in	O
a	O
companion	O
article	O
appearing	O
in	O
this	O
issue	O
.	O

Acute	O
ischaemic	O
stroke	O
is	O
the	O
third	O
major	O
cause	O
of	O
death	Mortality
in	O
developed	O
countries	O
,	O
and	O
a	O
major	O
cause	O
of	O
disability	Physical
.	O

Despite	O
a	O
very	O
poor	O
prognosis	O
,	O
no	O
treatment	O
has	O
demonstrated	O
an	O
efficacy	O
in	O
lowering	O
the	O
mortality	Mortality
and	O
disability	Physical
resulting	O
from	O
stroke	O
events	O
.	O

Thrombolysis	O
has	O
been	O
proven	O
to	O
reduce	O
mortality	Mortality
in	Mortality
myocardial	Mortality
infarction	Mortality
,	O
and	O
it	O
has	O
been	O
shown	O
able	O
to	O
induce	O
recanalisation	Physical
when	O
administered	O
to	O
acute	O
stroke	O
patients	O
.	O

A	O
recent	O
meta	O
analysis	O
of	O
small-sized	O
studies	O
suggests	O
that	O
thrombolysis	O
could	O
offer	O
some	O
benefit	O
to	O
stroke	O
patients	O
,	O
by	O
reducing	O
the	O
mortality	Mortality
and	O
severe	Physical
invalidity	Physical
by	O
56	O
%	O
;	O
these	O
results	O
need	O
to	O
be	O
confirmed	O
in	O
adequately	O
designed	O
and	O
sized	O
studies	O
.	O

Effects	O
of	O
iron	O
on	O
the	O
pharmacokinetics	Physical
of	Physical
paracetamol	Physical
in	Physical
saliva	Physical
.	O

Paracetamol	O
has	O
been	O
reported	O
to	O
chelate	O
with	O
iron	O
.	O

It	O
was	O
found	O
that	O
no	O
in	Others
vitro	Others
reaction	Others
between	O
ferrous	O
ion	O
and	O
paracetamol	O
.	O

Other	O
studies	O
found	O
that	O
there	O
is	O
an	O
aerobic	O
(	O
in	O
the	O
gastrointestinal	O
tract	O
)	O
oxidation	O
of	O
ferrous	O
ion	O
to	O
ferric	O
ion	O
caused	O
in	O
iron-paracetamol	O
in	O
vivo	O
reactions	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
iron	O
interacts	O
with	O
paracetamol	O
and	O
reduces	O
paracetamol	Physical
absorption	Physical
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
cross-over	O
study	O
design	O
was	O
used	O
to	O
assess	O
the	O
in	Others
vivo	Others
interaction	Others
of	Others
paracetamol	Others
and	Others
ferrous	Others
ion	Others
.	O

Paracetamol	O
(	O
1.0	O
g	O
)	O
was	O
co-ignested	O
alone	O
or	O
with	O
(	O
300	O
mg	O
)	O
ferrous	O
sulphate	O
by	O
ten	O
healthy	O
male	O
volunteers	O
,	O
using	O
saliva	O
drug	O
levels	O
as	O
a	O
parameter	O
.	O

Concomitant	O
administration	O
of	O
ferrous	O
sulphate	O
and	O
paracetamol	O
,	O
decreased	O
AUC8	Physical
from	O
42.88	O
+/-	O
3.8-34.25	O
+/-	O
2.8	O
microg	O
h	O
mL	O
(	O
-1	O
)	O
(	O
p	O
=	O
0.04	O
)	O
and	O
Cmax	Physical
from	O
18.75	O
+/-	O
1.9	O
to	O
15.9	O
+/-	O
1.7	O
microg	O
mL	O
(	O
-1	O
)	O
(	O
p	O
=	O
0.11	O
)	O
,	O
while	O
no	O
change	O
in	O
tmax	O
(	O
p	O
=	O
0.5	O
)	O
was	O
originated	O
.	O

A	O
significant	O
difference	O
was	O
found	O
in	O
the	O
paracetamol	Others
pharmacokinetic	Others
parameter	Others
oral	Others
clearance	Others
(	Others
C1/F	Others
)	Others
(	O
p	O
=	O
0.02	O
)	O
and	O
slightly	O
increased	O
in	O
volume	Physical
of	Physical
distribution	Physical
(	O
V	O
(	O
d	O
)	O
/F	O
)	O
(	O
p	O
=	O
0.10	O
)	O
.	O

Co-administration	O
of	O
iron	O
and	O
paracetamol	O
results	O
in	O
decreased	Others
paracetamol	Physical
absorption	Physical
due	O
to	O
an	O
interaction	O
between	O
iron	O
and	O
paracetamol	O
.	O

The	O
TOM	O
test	O
:	O
a	O
new	O
instrument	O
for	O
assessing	O
theory	O
of	O
mind	O
in	O
normal	O
children	O
and	O
children	O
with	O
pervasive	O
developmental	O
disorders	O
.	O

This	O
article	O
describes	O
a	O
first	O
attempt	O
to	O
investigate	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
TOM	Others
test	Others
,	O
a	O
new	O
instrument	O
for	O
assessing	O
theory	O
of	O
mind	O
ability	O
in	O
normal	O
children	O
and	O
children	O
with	O
pervasive	O
developmental	O
disorders	O
(	O
PDDs	O
)	O
.	O

In	O
Study	O
1	O
,	O
TOM	O
test	O
scores	O
of	O
normal	O
children	O
(	O
n	O
=	O
70	O
)	O
correlated	O
positively	O
with	O
their	O
performance	O
on	O
other	O
theory	O
of	O
mind	O
tasks	O
.	O

Furthermore	O
,	O
young	O
children	O
only	O
succeeded	O
on	O
TOM	O
items	O
that	O
tap	O
the	O
basic	O
domains	O
of	O
theory	O
of	O
mind	O
(	O
e.g.	O
,	O
emotion	O
recognition	O
)	O
,	O
whereas	O
older	O
children	O
also	O
passed	O
items	O
that	O
measure	O
the	O
more	O
mature	O
areas	O
of	O
theory	O
of	O
mind	O
(	O
e.g.	O
,	O
understanding	O
of	O
humor	O
,	O
understanding	O
of	O
second-order	O
beliefs	O
)	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
Study	O
1	O
suggest	O
that	O
the	O
TOM	Others
test	Others
is	O
a	O
valid	O
measure	O
.	O

Study	O
2	O
showed	O
for	O
a	O
separate	O
sample	O
of	O
normal	O
children	O
(	O
n	O
=	O
12	O
)	O
that	O
the	O
TOM	Others
test	Others
possesses	O
sufficient	O
test-retest	O
stability	O
.	O

Study	O
3	O
demonstrated	O
for	O
a	O
sample	O
of	O
children	O
with	O
PDDs	O
(	O
n	O
=	O
10	O
)	O
that	O
the	O
interrater	Others
reliability	Others
of	O
the	O
TOM	Others
test	Others
is	O
good	O
.	O

Study	O
4	O
found	O
that	O
children	O
with	O
PDDs	O
(	O
n	O
=	O
20	O
)	O
had	O
significantly	O
lower	O
TOM	Others
test	Others
scores	Others
than	O
children	O
with	O
other	O
psychiatric	O
disorders	O
(	O
e.g.	O
,	O
children	O
with	O
Attention-deficit	O
Hyperactivity	O
Disorder	O
;	O
n	O
=	O
32	O
)	O
,	O
a	O
finding	O
that	O
underlines	O
the	O
discriminant	O
validity	O
of	O
the	O
TOM	O
test	O
.	O

Furthermore	O
,	O
Study	O
4	O
showed	O
that	O
intelligence	Mental
as	O
indexed	O
by	O
the	O
Wechsler	Others
Intelligence	Others
Scale	Others
for	Others
Children	Others
was	O
positively	O
associated	O
with	O
TOM	Others
test	Others
scores	Others
.	O

Finally	O
,	O
in	O
all	O
studies	O
,	O
the	O
TOM	Others
test	Others
was	O
found	O
to	O
be	O
reliable	O
in	O
terms	O
of	O
internal	O
consistency	O
.	O

Altogether	O
,	O
results	O
indicate	O
that	O
the	O
TOM	O
test	O
is	O
a	O
reliable	O
and	O
valid	O
instrument	O
that	O
can	O
be	O
employed	O
to	O
measure	O
various	O
aspects	O
of	O
theory	O
of	O
mind	O
.	O

[	O
Obstetrical	O
analgesia	O
with	O
tramadol	O
]	O
.	O

Parenteral	O
analgesia	O
with	O
Tramal	O
was	O
performed	O
in	O
23	O
normal	O
deliveries	O
.	O

The	O
results	O
were	O
compared	O
with	O
a	O
group	O
of	O
normal	O
deliveries	O
in	O
which	O
analgesia	Pain
was	O
achieved	O
with	O
pethidine	O
.	O

Both	O
medicaments	O
excerted	O
an	O
identical	Others
analgetic	Pain
efficiency	Pain
.	O

No	O
adverse	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
were	O
observed	O
with	O
Tramal	O
concerning	O
the	O
follow-up	O
of	O
labour	O
or	O
the	O
newborn	O
.	O

Tramal	O
can	O
be	O
recommended	O
for	O
obstetrical	Pain
analgesia	Pain
since	O
it	O
does	O
not	O
excert	O
inhibitory	Physical
effects	Physical
upon	O
the	O
respiratory	O
center	O
.	O

The	O
effect	O
of	O
intravenous	O
lidocaine	O
on	O
QT	Physical
changes	Physical
during	O
tracheal	O
intubation	O
.	O

Laryngoscopy	O
and	O
tracheal	O
intubation	O
may	O
provoke	O
changes	O
of	O
cardiac	Physical
repolarisation	Physical
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
intravenous	O
lidocaine	O
on	O
the	O
ECG	Physical
changes	Physical
induced	O
by	O
laryngoscopy	O
and	O
tracheal	O
intubation	O
.	O

Forty-three	O
female	O
patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
lidocaine	O
(	O
1.5	O
mg.kg	O
(	O
-1	O
)	O
)	O
or	O
placebo	O
immediately	O
after	O
induction	O
of	O
anaesthesia	O
and	O
changes	O
in	O
the	O
ECG	Physical
and	Physical
arterial	Physical
blood	Physical
pressure	Physical
were	O
recorded	O
.	O

Correction	O
of	O
QT	Physical
interval	Physical
was	O
calculated	O
using	O
Bazett	O
's	O
formula	O
(	O
QTcb	O
)	O
,	O
Fridericia	O
's	O
correction	O
(	O
QTcf	O
)	O
,	O
and	O
Framingham	O
formula	O
(	O
QTcF	O
)	O
.	O

Transmural	Physical
dispersion	Physical
of	Physical
repolarisation	Physical
(	Physical
TDR	Physical
)	Physical
was	O
determined	O
as	O
Tpeak-Tend	O
time	O
.	O

There	O
were	O
no	O
changes	O
in	O
the	O
QTc	Physical
value	Physical
in	O
the	O
lidocaine	O
group	O
.	O

In	O
the	O
placebo	O
group	O
,	O
significant	O
increases	O
in	O
QTcb	Physical
,	Physical
QTcf	Physical
and	Physical
QTcF	Physical
values	Physical
were	O
observed	O
after	O
intubation	O
compared	O
to	O
either	O
control	O
measurements	O
or	O
to	O
comparative	O
measurements	O
in	O
the	O
lidocaine	O
group	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
TDR	Physical
either	O
between	O
or	O
within	O
the	O
groups	O
.	O

Lidocaine	O
diminishes	O
prolongation	O
of	O
QTc	Physical
,	O
induced	O
by	O
tracheal	O
intubation	O
but	O
there	O
is	O
no	O
effect	O
of	O
intubation	O
on	O
TDR	Physical
.	O

A	O
comparative	O
trial	O
of	O
fixed	O
ratio	O
beta-adrenoceptor	O
blocker	O
and	O
diuretic	O
combination	O
products	O
in	O
moderate	O
hypertension	O
.	O

Two	O
fixed	O
ratio	O
combination	O
tablets	O
,	O
10	O
mg	O
pindolol	O
combined	O
with	O
5	O
mg	O
clopamide	O
and	O
100	O
mg	O
metoprolol	O
combined	O
with	O
12.5	O
mg	O
hydrochlorothiazide	O
,	O
were	O
compared	O
at	O
two	O
dose	O
levels	O
in	O
a	O
double-blind	O
crossover	O
trial	O
in	O
10	O
previously	O
untreated	O
hypertensive	O
patients	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
between	O
resting	Physical
blood	Physical
pressure	Physical
on	O
the	O
two	O
combinations	O
at	O
either	O
dose	O
level	O
.	O

Exercise	Physical
systolic	Physical
pressure	Physical
was	O
lower	O
after	O
the	O
pindolol/clopamide	O
combination	O
at	O
low	O
dose	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
incidence	Adverseeffect
of	Adverseeffect
side-effects	Adverseeffect
in	O
this	O
trial	O
was	O
high	O
but	O
proper	O
comparison	O
of	O
the	O
two	O
products	O
could	O
not	O
be	O
made	O
because	O
of	O
the	O
small	O
number	O
of	O
patients	O
.	O

It	O
is	O
suggested	O
that	O
combination	O
products	O
should	O
be	O
used	O
only	O
after	O
patients	O
have	O
failed	O
to	O
respond	O
adequately	O
to	O
a	O
single	O
agent	O
.	O

A	O
randomized	O
controlled	O
trial	O
for	O
reducing	O
risks	Mental
for	Mental
sexually	Mental
transmitted	Mental
infections	Mental
through	O
enhanced	O
patient-based	O
partner	O
notification	O
.	O

OBJECTIVES	O
We	O
sought	O
to	O
assess	O
the	O
effectiveness	O
of	O
approaches	O
targeting	O
improved	O
sexually	O
transmitted	O
infection	O
(	O
STI	O
)	O
sexual	O
partner	O
notification	O
through	O
patient	O
referral	O
.	O

METHODS	O
From	O
January	O
2002	O
through	O
December	O
2004	O
,	O
600	O
patients	O
with	O
Neisseria	O
gonorrhoeae	O
or	O
Chlamydia	O
trachomatis	O
were	O
recruited	O
from	O
STI	O
clinics	O
and	O
randomly	O
assigned	O
to	O
either	O
a	O
standard-of-care	O
group	O
or	O
a	O
group	O
that	O
was	O
counseled	O
at	O
the	O
time	O
of	O
diagnosis	O
and	O
given	O
additional	O
follow-up	O
contact	O
.	O

Participants	O
completed	O
an	O
interview	O
at	O
baseline	O
,	O
1	O
month	O
,	O
and	O
6	O
months	O
and	O
were	O
checked	O
at	O
6	O
months	O
for	O
gonorrhea	O
or	O
chlamydial	O
infection	O
via	O
nucleic	O
acid	O
amplification	O
testing	O
of	O
urine	O
.	O

RESULTS	O
Program	O
participants	O
were	O
more	O
likely	O
to	O
report	O
sexual	O
partner	O
notification	O
at	O
1	O
month	O
(	O
86	O
%	O
control	O
,	O
92	O
%	O
intervention	O
;	O
adjusted	O
odds	O
ratio	O
[	O
AOR	O
]	O
=	O
1.8	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
1.02	O
,	O
3.0	O
)	O
and	O
were	O
more	O
likely	O
to	O
report	O
no	O
unprotected	Mental
sexual	Mental
intercourse	Mental
at	O
6	O
months	O
(	O
38	O
%	O
control	O
,	O
48	O
%	O
intervention	O
;	O
AOR	O
=	O
1.5	O
;	O
95	O
%	O
CI	O
=	O
1.1	O
,	O
2.1	O
)	O
.	O

Gonorrhea	Physical
or	Physical
chlamydial	Physical
infection	Physical
was	O
detected	O
in	O
6	O
%	O
of	O
intervention	O
and	O
11	O
%	O
of	O
control	O
participants	O
at	O
follow-up	O
(	O
AOR	O
=	O
2.2	O
;	O
95	O
%	O
CI	O
=	O
1.1	O
,	O
4.1	O
)	O
,	O
with	O
greatest	O
benefits	O
seen	O
among	O
men	O
(	O
for	O
gender	O
interaction	O
,	O
P	O
=	O
.03	O
)	O
.	O

CONCLUSIONS	O
This	O
patient-based	O
sexual	O
partner	O
notification	O
program	O
can	O
help	O
reduce	O
risks	O
for	O
subsequent	O
STIs	O
among	O
urban	O
,	O
minority	O
patients	O
presenting	O
for	O
care	O
at	O
STI	O
clinics	O
.	O

Anticholinergic	O
drugs	O
:	O
effects	O
on	O
oxygen	Physical
consumption	Physical
and	Physical
energy	Physical
expenditure	Physical
.	O

Premedication	O
has	O
been	O
shown	O
to	O
affect	O
both	O
oxygen	Physical
consumption	Physical
(	O
VO2	O
)	O
and	O
energy	Physical
expenditure	Physical
(	O
EE	O
)	O
.	O

The	O
metabolic	O
responses	O
to	O
anticholinergic	O
drugs	O
have	O
not	O
been	O
studied	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
anticholinergic	O
drugs	O
on	O
VO2	O
and	O
EE	O
(	O
calculated	O
from	O
the	O
measured	O
rates	O
of	O
VO2	O
and	O
carbon	O
dioxide	O
production	O
[	O
VCO2	O
]	O
:	O
EE	O
[	O
kcal/d	O
]	O
=	O
3.581	O
x	O
VO2	O
[	O
L/d	O
]	O
+	O
1.448	O
x	O
VCO2	O
[	O
L/d	O
]	O
-	O
32.4	O
)	O
were	O
measured	O
in	O
six	O
healthy	O
female	O
volunteers	O
.	O

They	O
were	O
given	O
intramuscular	O
atropine	O
(	O
15	O
micrograms/kg	O
)	O
,	O
glycopyrrolate	O
(	O
8	O
micrograms/kg	O
)	O
,	O
scopolamine	O
(	O
8	O
micrograms/kg	O
)	O
,	O
and	O
placebo	O
in	O
a	O
random	O
double-blind	O
cross-over	O
design	O
.	O

The	O
consecutive	O
sessions	O
were	O
at	O
least	O
1	O
wk	O
apart	O
for	O
each	O
subject	O
.	O

VO2	Physical
and	Physical
EE	Physical
were	O
measured	O
using	O
an	O
indirect	O
calorimetry	O
(	O
Deltatrac	O
)	O
.	O

Cardiovascular	Physical
responses	Physical
were	O
assessed	O
using	O
standard	O
noninvasive	O
monitoring	O
.	O

Plasma	Physical
drug	Physical
concentrations	Physical
were	O
analyzed	O
using	O
a	O
sensitive	O
modification	O
of	O
radioreceptor	O
assay	O
.	O

Subjective	O
responses	O
were	O
measured	O
with	O
visual	Physical
analog	Physical
scale	Physical
(	Physical
VAS	Physical
)	Physical
.	O

Atropine	O
and	O
glycopyrrolate	O
induced	O
a	O
significant	O
increase	O
in	O
heart	Physical
rate	Physical
with	O
a	O
simultaneous	O
decrease	O
in	O
pressure	Physical
rate	Physical
quotient	Physical
(	Physical
PRQ	Physical
)	Physical
,	O
while	O
scopolamine	O
caused	O
a	O
significant	O
decrease	O
in	O
heart	Physical
rate	Physical
with	O
a	O
simultaneous	O
increase	Physical
in	Physical
PRQ	Physical
.	O

Scopolamine	O
significantly	O
decreased	O
both	O
VO2	Physical
and	Physical
EE	Physical
,	O
whereas	O
glycopyrrolate	O
increased	O
VO2	Physical
.	O

Atropine	O
had	O
no	O
significant	O
effect	O
on	O
metabolic	Physical
variables	Physical
.	O

Only	O
scopolamine	O
induced	O
sedation	Physical
in	O
this	O
study	O
.	O

In	O
conclusion	O
,	O
atropine	O
,	O
glycopyrrolate	O
,	O
and	O
scopolamine	O
differ	O
not	O
only	O
in	O
their	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
effects	O
,	O
but	O
also	O
in	O
their	O
effects	O
on	O
metabolism	O
.	O

Neuromuscular	O
excitability	O
changes	O
in	O
the	O
vastus	O
medialis	O
following	O
anterior	O
cruciate	O
ligament	O
reconstruction	O
.	O

PURPOSE	O
Quadriceps	O
weakness	O
following	O
anterior	O
cruciate	O
ligament	O
reconstruction	O
(	O
ACLR	O
)	O
is	O
prevalent	O
despite	O
intensive	O
rehabilitation	O
.	O

Diminished	O
neuromuscular	O
excitability	O
is	O
one	O
potential	O
factor	O
that	O
may	O
limit	O
muscular	O
recovery	O
following	O
injury	O
or	O
surgery	O
.	O

The	O
H-reflex	Physical
provides	O
a	O
measure	O
of	O
alpha	O
motorneuron	O
(	O
neuromuscular	O
)	O
excitability	O
in	O
the	O
sensory-motor	O
pathway	O
of	O
the	O
respective	O
muscle	O
and	O
nerve	O
.	O

To	O
date	O
the	O
vastus	O
medialis	O
(	O
VM	O
)	O
and	O
soleus	O
(	O
SOL	O
)	O
H-reflexes	O
have	O
been	O
examined	O
primarily	O
in	O
control	O
subjects	O
with	O
induced	O
knee	O
joint	O
effusion	O
.	O

This	O
prospective	O
,	O
randomized	O
clinical	O
trial	O
evaluated	O
the	O
affect	O
of	O
ACLR	O
,	O
utilizing	O
hamsting	Physical
(	Physical
HS	Physical
)	Physical
or	Physical
bone-patellar	Physical
tendon-bone	Physical
(	Physical
BTB	Physical
)	Physical
autograft	Physical
,	O
on	O
VM	Physical
and	Physical
SOL	Physical
H-reflex	Physical
latency	Physical
and	Physical
amplitude	Physical
in	O
twenty	O
subjects	O
.	O

METHODS	O
Preoperatively	O
bilateral	O
VM	O
and	O
SOL	O
H-reflex	O
tests	O
were	O
conducted	O
.	O

VM	Physical
and	Physical
SOL	Physical
H-reflexes	Physical
were	O
subsequently	O
conducted	O
on	O
the	O
involved	O
lower	O
extremity	O
at	O
1	O
and	O
3	O
months	O
post	O
surgery	O
.	O

At	O
each	O
test	O
session	O
subjects	O
completed	O
visual	Others
analog	Others
scales	Others
and	O
knee	Physical
girth	Physical
was	O
measured	O
.	O

RESULTS	O
The	O
VM	Physical
H-reflex	Physical
amplitude	Physical
increased	O
in	O
the	O
HS	O
group	O
at	O
3	O
months	O
compared	O
to	O
1-month	O
post	O
surgery	O
(	O
p	O
<	O
.05	O
)	O
.	O

Significant	O
changes	O
over	O
time	O
were	O
also	O
noted	O
in	O
the	O
visual	Pain
analog	Pain
pain	Pain
and	O
functional	Physical
scales	Physical
and	Physical
the	Physical
mid-patella	Physical
girth	Physical
.	O

CONCLUSIONS	O
The	O
increased	O
VM	Physical
H-reflex	Physical
amplitude	Physical
at	O
3	O
months	O
following	O
HS	O
autograft	O
ACLR	O
demonstrates	O
an	O
increase	O
in	O
VM	Physical
neuromuscular	Physical
excitability	Physical
.	O

Increased	O
VM	Physical
neuromuscular	Physical
excitability	Physical
was	O
not	O
evident	O
in	O
patients	O
following	O
BTB	O
reconstruction	O
.	O

The	O
increased	O
neuromuscular	Physical
excitability	Physical
,	O
observed	O
only	O
in	O
the	O
HS	O
group	O
,	O
warrants	O
consideration	O
when	O
selecting	O
graft	O
type	O
for	O
patients	O
with	O
extensive	O
preoperative	O
quadriceps	O
dysfunction	O
.	O

Children	O
's	O
attitudes	Mental
and	Mental
behavioral	Mental
intentions	Mental
toward	O
a	O
peer	O
with	O
autistic	O
behaviors	O
:	O
does	O
a	O
brief	O
educational	O
intervention	O
have	O
an	O
effect	O
?	O
This	O
study	O
examined	O
children	O
's	O
ratings	O
of	O
attitudes	Mental
and	Mental
behavioral	Mental
intentions	Mental
toward	O
a	O
peer	O
presented	O
with	O
or	O
without	O
autistic	O
behaviors	O
.	O

The	O
impact	O
of	O
information	O
about	O
autism	O
on	O
these	O
ratings	O
was	O
investigated	O
as	O
well	O
as	O
age	O
and	O
gender	O
effects	O
.	O

Third-	O
and	O
sixth-grade	O
children	O
(	O
N	O
=	O
233	O
)	O
were	O
randomly	O
assigned	O
to	O
view	O
a	O
video	O
of	O
the	O
same	O
boy	O
in	O
one	O
of	O
three	O
conditions	O
:	O
No	O
Autism	O
,	O
Autism	O
,	O
or	O
Autism/Information	O
.	O

Children	O
at	O
both	O
grade	O
levels	O
showed	O
less	Others
positive	Others
attitudes	Others
toward	O
the	O
child	O
in	O
the	O
two	O
autism	O
conditions	O
.	O

In	O
rating	O
their	O
own	O
behavioral	Mental
intentions	Mental
,	O
children	O
showed	O
no	O
differences	O
between	O
conditions	O
.	O

However	O
,	O
in	O
attributing	O
intentions	O
to	O
their	O
classmates	O
,	O
older	O
children	O
and	O
girls	O
gave	O
lower	Others
ratings	Others
to	O
the	O
child	O
in	O
the	O
autism	O
conditions	O
.	O

Information	O
about	O
autism	O
did	O
not	O
affect	O
ratings	O
of	O
either	O
attitudes	Mental
or	Mental
behavioral	Mental
intentions	Mental
as	O
ascribed	O
to	O
self	O
or	O
others	O
.	O

A	O
randomised	O
trial	O
comparing	O
preoperative	O
to	O
perioperative	O
chemotherapy	O
in	O
early-stage	O
non-small-cell	O
lung	O
cancer	O
(	O
IFCT	O
0002	O
trial	O
)	O
.	O

HYPOTHESIS	O
There	O
will	O
be	O
a	O
detectable	O
increase	O
in	O
overall	Mortality
survival	Mortality
(	Mortality
OS	Mortality
)	Mortality
using	O
preoperative	O
(	O
PRE	O
)	O
as	O
opposed	O
to	O
perioperative	O
(	O
PERI	O
)	O
chemotherapy	O
in	O
resectable	O
StageI-II	O
non-small-cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O

METHODS	O
This	O
multicenter	O
,	O
open-label	O
,	O
randomised	O
trial	O
with	O
a	O
2?2	O
factorial	O
design	O
first	O
compared	O
two	O
chemotherapy	O
strategies	O
(	O
PRE	O
versus	O
PERI	O
)	O
,	O
then	O
two	O
chemotherapy	O
regimens	O
(	O
gemcitabine-cisplatin	O
[	O
GP	O
]	O
versus	O
paclitaxel-carboplatin	O
[	O
TC	O
]	O
)	O
.	O

The	O
PRE	O
group	O
received	O
two	O
preoperative	O
cycles	O
followed	O
by	O
two	O
additional	O
preoperative	O
cycles	O
,	O
while	O
the	O
PERI	O
group	O
underwent	O
two	O
preoperative	O
cycles	O
followed	O
by	O
two	O
postoperative	O
cycles	O
,	O
the	O
3rd	O
and	O
4th	O
cycles	O
being	O
given	O
only	O
to	O
responders	O
in	O
both	O
cases	O
.	O

RESULTS	O
A	O
total	O
of	O
528	O
patients	O
were	O
randomised	O
,	O
267	O
of	O
which	O
were	O
assigned	O
to	O
the	O
PRE	O
group	O
and	O
261	O
to	O
the	O
PERI	O
group	O
.	O

Three-year	O
OS	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
(	O
67.4	O
%	O
and	O
67.7	O
%	O
,	O
respectively	O
;	O
hazard	O
ratio	O
(	O
HR	O
)	O
=1.01	O
[	O
0.79-1.30	O
]	O
,	O
p=0.92	O
)	O
,	O
nor	O
did	O
3-year	O
disease-free	O
survival	O
,	O
response	O
rates	O
,	O
toxicity	O
,	O
or	O
postoperative	O
mortality	O
.	O

Pathological	O
complete	O
response	O
was	O
observed	O
in	O
22	O
(	O
8.2	O
%	O
)	O
and	O
16	O
patients	O
(	O
6.1	O
%	O
)	O
,	O
respectively	O
.	O

Although	O
quality	O
of	O
life	O
did	O
not	O
differ	O
significantly	O
,	O
chemotherapy	O
compliance	O
was	O
significantly	O
higher	O
in	O
the	O
PRE	O
group	O
.	O

The	O
proportion	O
of	O
responders	O
who	O
received	O
Cycles	O
3	O
and	O
4	O
was	O
significantly	O
higher	O
in	O
the	O
PRE	O
group	O
(	O
90.4	O
%	O
versus	O
75.2	O
%	O
,	O
p=0.001	O
)	O
.	O

In	O
responders	O
,	O
the	O
dose	O
intensity	O
of	O
Cycles	O
3	O
and	O
4	O
was	O
higher	O
in	O
the	O
PRE	O
group	O
than	O
in	O
the	O
PERI	O
group	O
(	O
mean	O
relative	O
dose	O
intensity	O
of	O
90.4	O
%	O
versus	O
82.6	O
%	O
,	O
respectively	O
;	O
p=0.0007	O
)	O
.	O

There	O
was	O
no	O
difference	O
between	O
GP	O
and	O
TC	O
in	O
3-year	O
OS	O
(	O
HR=0.97	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0.76-1.25	O
]	O
,	O
p=0.80	O
)	O
or	O
response	O
rates	O
.	O

However	O
,	O
the	O
regimens	O
'	O
toxicity	O
profiles	O
differed	O
.	O

CONCLUSIONS	O
This	O
study	O
failed	O
to	O
demonstrate	O
any	O
difference	O
in	O
survival	O
between	O
patients	O
receiving	O
preoperative	O
and	O
perioperative	O
chemotherapy	O
in	O
early-stage	O
NSCLC	O
.	O

The	O
increase	O
from	O
two	O
to	O
four	O
preoperative	O
chemotherapy	O
cycles	O
did	O
not	O
increase	O
the	O
pathological	O
response	O
rate	O
.	O

Lack	O
of	O
effect	O
of	O
a	O
low-fat	O
,	O
high-fiber	O
diet	O
on	O
the	O
recurrence	Physical
of	Physical
colorectal	Physical
adenomas	Physical
.	O

Polyp	O
Prevention	O
Trial	O
Study	O
Group	O
.	O

BACKGROUND	O
We	O
tested	O
the	O
hypothesis	O
that	O
dietary	O
intervention	O
can	O
inhibit	O
the	O
development	Physical
of	Physical
recurrent	Physical
colorectal	Physical
adenomas	Physical
,	O
which	O
are	O
precursors	O
of	O
most	O
large-bowel	O
cancers	O
.	O

METHODS	O
We	O
randomly	O
assigned	O
2079	O
men	O
and	O
women	O
who	O
were	O
35	O
years	O
of	O
age	O
or	O
older	O
and	O
who	O
had	O
had	O
one	O
or	O
more	O
histologically	O
confirmed	O
colorectal	O
adenomas	O
removed	O
within	O
six	O
months	O
before	O
randomization	O
to	O
one	O
of	O
two	O
groups	O
:	O
an	O
intervention	O
group	O
given	O
intensive	O
counseling	O
and	O
assigned	O
to	O
follow	O
a	O
diet	O
that	O
was	O
low	O
in	O
fat	O
(	O
20	O
percent	O
of	O
total	O
calories	O
)	O
and	O
high	O
in	O
fiber	O
(	O
18	O
g	O
of	O
dietary	O
fiber	O
per	O
1000	O
kcal	O
)	O
and	O
fruits	O
and	O
vegetables	O
(	O
3.5	O
servings	O
per	O
1000	O
kcal	O
)	O
,	O
and	O
a	O
control	O
group	O
given	O
a	O
standard	O
brochure	O
on	O
healthy	O
eating	O
and	O
assigned	O
to	O
follow	O
their	O
usual	O
diet	O
.	O

Subjects	O
entered	O
the	O
study	O
after	O
undergoing	O
complete	O
colonoscopy	O
and	O
removal	O
of	O
adenomatous	O
polyps	O
;	O
they	O
remained	O
in	O
the	O
study	O
for	O
approximately	O
four	O
years	O
,	O
undergoing	O
colonoscopy	O
one	O
and	O
four	O
years	O
after	O
randomization	O
.	O

RESULTS	O
A	O
total	O
of	O
1905	O
of	O
the	O
randomized	O
subjects	O
(	O
91.6	O
percent	O
)	O
completed	O
the	O
study	O
.	O

Of	O
the	O
958	O
subjects	O
in	O
the	O
intervention	O
group	O
and	O
the	O
947	O
in	O
the	O
control	O
group	O
who	O
completed	O
the	O
study	O
,	O
39.7	O
percent	O
and	O
39.5	O
percent	O
,	O
respectively	O
,	O
had	O
at	O
least	O
one	Physical
recurrent	Physical
adenoma	Physical
;	O
the	O
unadjusted	Physical
risk	Physical
ratio	Physical
was	O
1.00	O
(	O
95	O
percent	O
confidence	O
interval	O
,	O
0.90	O
to	O
1.12	O
)	O
.	O

Among	O
subjects	O
with	O
recurrent	O
adenomas	O
,	O
the	O
mean	Physical
(	Physical
+/-SE	Physical
)	Physical
number	Physical
of	Physical
such	Physical
lesions	Physical
was	O
1.85+/-0.08	O
in	O
the	O
intervention	O
group	O
and	O
1.84+/-0.07	O
in	O
the	O
control	O
group	O
.	O

The	O
rate	Physical
of	Physical
recurrence	Physical
of	Physical
large	Physical
adenomas	Physical
(	O
with	O
a	O
maximal	O
diameter	O
of	O
at	O
least	O
1	O
cm	O
)	O
and	O
advanced	Physical
adenomas	Physical
(	O
defined	O
as	O
lesions	O
that	O
had	O
a	O
maximal	O
diameter	O
of	O
at	O
least	O
1	O
cm	O
or	O
at	O
least	O
25	O
percent	O
villous	O
elements	O
or	O
evidence	O
of	O
high-grade	O
dysplasia	O
,	O
including	O
carcinoma	O
)	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSIONS	O
Adopting	O
a	O
diet	O
that	O
is	O
low	O
in	O
fat	O
and	O
high	O
in	O
fiber	O
,	O
fruits	O
,	O
and	O
vegetables	O
does	O
not	O
influence	O
the	O
risk	Physical
of	Physical
recurrence	Physical
of	O
colorectal	O
adenomas	O
.	O

Bevacizumab	O
compared	O
with	O
macular	O
laser	O
grid	O
photocoagulation	O
for	O
cystoid	O
macular	O
edema	O
in	O
branch	O
retinal	O
vein	O
occlusion	O
.	O

INTRODUCTION	O
To	O
evaluate	O
the	O
outcome	O
of	O
cystoid	O
macular	O
edema	O
treated	O
with	O
intravitreal	O
injections	O
of	O
bevacizumab	O
and	O
macular	O
grid	O
laser	O
photocoagulation	O
(	O
GLP	O
)	O
,	O
in	O
patients	O
with	O
perfused	O
branch	O
retinal	O
vein	O
occlusion	O
.	O

METHODS	O
Thirty	O
eyes	O
of	O
30	O
consecutive	O
patients	O
with	O
cystoid	O
macular	O
edema	O
secondary	O
to	O
nonischemic	O
branch	O
retinal	O
vein	O
occlusion	O
were	O
assigned	O
to	O
either	O
GLP	O
group	O
or	O
to	O
intravitreal	O
bevacizumab	O
(	O
IB	O
)	O
group	O
.	O

Complete	Physical
ophthalmologic	Physical
examinations	Physical
were	O
performed	O
just	O
before	O
GLP	O
and	O
IB	O
injection	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
treatment	O
.	O

Changes	O
in	O
logarithm	Physical
of	Physical
minimum	Physical
angle	Physical
of	Physical
resolution	Physical
(	Physical
logMAR	Physical
)	Physical
best-corrected	Physical
visual	Physical
acuity	Physical
(	Physical
BCVA	Physical
)	Physical
,	Physical
central	Physical
macular	Physical
thickness	Physical
(	Physical
CMT	Physical
)	Physical
shown	Physical
by	Physical
optical	Physical
coherence	Physical
tomography-3	Physical
were	O
evaluated	O
.	O

RESULTS	O
Baseline	Physical
BCVA	Physical
(	Physical
logMAR	Physical
)	Physical
and	Physical
CMT	Physical
were	O
,	O
respectively	O
,	O
0.89	O
+/-	O
0.13	O
and	O
650	O
+/-	O
140	O
microm	O
for	O
the	O
GLP	O
group	O
,	O
0.87	O
+/-	O
0.16	O
and	O
690	O
+/-	O
120	O
microm	O
for	O
the	O
IB	O
group	O
.	O

After	O
the	O
treatment	O
,	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
in	O
the	O
GLP	O
group	O
,	O
BCVA	Physical
had	O
improved	O
by	O
0.19	O
,	O
0.22	O
,	O
0.21	O
,	O
and	O
0.20	O
logMAR	O
,	O
CMT	Physical
had	O
decreased	O
by	O
40	O
%	O
,	O
41.3	O
%	O
,	O
40.5	O
%	O
,	O
and	O
42	O
%	O
.	O

In	O
the	O
IB	O
group	O
,	O
BCVA	Physical
had	O
improved	O
by	O
0.31	O
,	O
0.32	O
,	O
0.30	O
,	O
and	O
0.31	O
logMAR	Physical
and	O
CMT	Physical
had	O
decreased	O
by	O
59.5	O
%	O
,	O
59	O
%	O
,	O
60	O
%	O
,	O
and	O
60.3	O
%	O
.	O

The	O
group	O
receiving	O
bevacizumab	O
had	O
better	O
BCVA	Physical
and	O
lower	O
CMT	Physical
values	O
at	O
all	O
time	O
points	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
Intravitreal	O
bevacizumab	O
injection	O
improves	O
BCVA	Physical
and	O
reduces	O
CMT	Physical
more	O
than	O
GLP	O
.	O

Intravitreal	O
bevacizumab	O
injection	O
was	O
well	O
tolerated	O
and	O
could	O
be	O
used	O
as	O
primary	O
treatment	O
in	O
patients	O
with	O
cystoid	O
macular	O
edema	O
secondary	O
to	O
perfused	O
branch	O
retinal	O
vein	O
occlusion	O
.	O

[	O
Intravesical	O
instillation	O
of	O
doxorubicin	O
or	O
epirubicin	O
for	O
chemoprophylaxis	O
of	O
superficial	O
bladder	O
cancer	O
--	O
the	O
fifth	O
study	O
of	O
the	O
Japanese	O
Urological	O
Cancer	O
Research	O
Group	O
for	O
Adriamycin/Farumorubicin	O
]	O
.	O

A	O
total	O
of	O
465	O
patients	O
with	O
primary	O
and	O
multiple	O
or	O
recurrent	O
,	O
stages	O
Ta	O
and	O
T1	O
superficial	O
bladder	O
cancer	O
were	O
included	O
in	O
this	O
randomized	O
multicenter	O
trial	O
to	O
compare	O
the	O
prophylactic	O
effect	O
by	O
17	O
times	O
instillation	O
of	O
40	O
mg	O
doxorubicin	O
or	O
40	O
mg	O
epirubicin	O
with	O
no	O
instillation	O
after	O
transurethral	O
resection	O
of	O
tumor	O
(	O
s	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
first	Physical
recurrence	Physical
after	O
transurethral	O
resection	O
.	O

Endoscopic	Others
examination	Others
as	O
well	O
as	O
urinary	Others
cytology	Others
was	O
performed	O
in	O
each	O
case	O
every	O
three	O
months	O
.	O

It	O
became	O
evident	O
that	O
the	O
recurrence	Physical
rate	Physical
in	O
the	O
doxorubicin	O
or	O
epirubicin	O
instillation	O
arm	O
was	O
lower	O
that	O
in	O
the	O
no	O
instillation	O
arm	O
.	O

Toxicity	Adverseeffect
was	O
mainly	O
restricted	O
to	O
bladder	Adverseeffect
irritation	Adverseeffect
in	O
about	O
10	O
%	O
of	O
patients	O
in	O
each	O
instillation	O
arm	O
.	O

Effect	O
of	O
the	O
dietary	O
approaches	O
to	O
stop	O
hypertension	O
diet	O
and	O
reduced	O
sodium	O
intake	O
on	O
blood	O
pressure	O
control	O
.	O

The	O
authors	O
hypothesized	O
that	O
the	O
Dietary	O
Approaches	O
to	O
Stop	O
Hypertension	O
(	O
DASH	O
)	O
diet	O
and	O
reduced	O
sodium	O
intake	O
would	O
control	O
stage	O
1	O
hypertension	O
and	O
reduce	O
high-normal	O
blood	Physical
pressure	Physical
(	Physical
BP	Physical
)	Physical
to	O
optimal	O
levels	O
.	O

Adults	O
with	O
systolic	O
BP	O
120-159	O
mm	O
Hg	O
and	O
diastolic	O
BP	O
80-95	O
mm	O
Hg	O
were	O
randomly	O
assigned	O
to	O
receive	O
the	O
DASH	O
diet	O
or	O
a	O
typical	O
American	O
(	O
control	O
)	O
diet	O
,	O
consuming	O
three	O
different	O
sodium	O
intakes	O
(	O
higher=142	O
mmol/d	O
,	O
intermediate=107	O
mmol/d	O
,	O
and	O
lower=65	O
mmol/d	O
)	O
for	O
30	O
days	O
each	O
.	O

BP	O
control	O
was	O
defined	O
as	O
systolic	Physical
BP	Physical
<	O
140	O
mm	O
Hg	O
and	O
diastolic	Physical
BP	Physical
<	O
90	O
mm	O
Hg	O
.	O

Among	O
subjects	O
with	O
hypertension	O
at	O
baseline	O
,	O
at	O
higher	O
sodium	O
intake	O
the	O
DASH	O
diet	O
increased	Physical
BP	Physical
control	Physical
two-fold	O
over	O
control	O
(	O
63	O
%	O
vs.	O
32	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.4-2.9	O
)	O
.	O

Reducing	O
sodium	O
intake	O
in	O
the	O
control	O
diet	O
group	O
increased	Physical
BP	Physical
control	Physical
2.3-fold	O
(	O
74	O
%	O
vs.	O
32	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.7-3.2	O
)	O
.	O

The	O
maximum	Physical
BP	Physical
control	Physical
rate	Physical
(	O
84	O
%	O
)	O
was	O
achieved	O
with	O
the	O
DASH/lower	O
sodium	O
diet	O
.	O

BP	Physical
became	Physical
normal	Physical
or	Physical
optimal	Physical
in	O
71	O
%	O
of	O
persons	O
consuming	O
the	O
control/lower	O
sodium	O
diet	O
and	O
77	O
%	O
of	O
persons	O
consuming	O
the	O
DASH/lower	O
sodium	O
diet	O
.	O

Both	O
the	O
DASH	O
diet	O
and	O
reduced	O
sodium	O
intake	O
improved	O
BP	Physical
control	Physical
.	O

Pharmacokinetic	Physical
study	O
of	O
human	O
immunodeficiency	O
virus	O
protease	O
inhibitors	O
used	O
in	O
combination	O
with	O
amprenavir	O
.	O

In	O
an	O
open-label	O
,	O
randomized	O
,	O
multicenter	O
,	O
multiple-dose	O
pharmacokinetic	O
study	O
,	O
we	O
determined	O
the	O
steady-state	Others
pharmacokinetics	Others
of	O
amprenavir	O
with	O
and	O
without	O
coadministration	O
of	O
indinavir	O
,	O
nelfinavir	O
,	O
or	O
saquinavir	O
soft	O
gel	O
formulation	O
in	O
31	O
human	O
immunodeficiency	O
virus	O
type	O
1-infected	O
subjects	O
.	O

The	O
results	O
indicated	O
that	O
amprenavir	Physical
plasma	Physical
concentrations	Physical
were	O
decreased	O
by	O
saquinavir	O
soft	O
gel	O
capsule	O
(	O
by	O
32	O
%	O
for	O
area	O
under	O
the	O
concentration-time	Physical
curve	Physical
at	Physical
steady	Physical
state	Physical
[	O
AUC	O
(	O
ss	O
)	O
]	O
and	O
37	O
%	O
for	O
peak	Physical
plasma	Physical
concentration	Physical
at	Physical
steady	Physical
state	Physical
[	O
C	O
(	O
max	O
,	O
ss	O
)	O
]	O
)	O
and	O
increased	O
by	O
indinavir	O
(	O
33	O
%	O
for	O
AUC	O
(	O
ss	O
)	O
)	O
.	O

Nelfinavir	O
significantly	O
increased	O
amprenavir	Physical
minimum	Physical
drug	Physical
concentration	Physical
at	O
steady	O
state	O
(	O
by	O
189	O
%	O
)	O
but	O
did	O
not	O
affect	O
amprenavir	O
AUC	Physical
(	Physical
ss	Physical
)	Physical
or	O
C	Physical
(	Physical
max	Physical
,	Physical
ss	Physical
)	Physical
.	O

Nelfinavir	O
and	O
saquinavir	O
steady-state	Physical
pharmacokinetics	Physical
were	O
unchanged	O
by	O
coadministration	O
with	O
amprenavir	O
compared	O
with	O
the	O
historical	O
monotherapy	O
data	O
.	O

Concentrations	Physical
of	Physical
indinavir	Physical
,	Physical
coadministered	Physical
with	Physical
amprenavir	Physical
,	Physical
in	Physical
plasma	Physical
decreased	O
in	O
both	O
single-dose	O
and	O
steady-state	O
evaluations	O
.	O

The	O
changes	O
in	O
amprenavir	O
steady-state	Physical
pharmacokinetic	Physical
parameters	Physical
,	O
relative	O
to	O
those	O
for	O
amprenavir	O
alone	O
,	O
were	O
not	O
consistent	O
among	O
protease	O
inhibitors	O
,	O
nor	O
were	O
the	O
changes	O
consistent	O
with	O
potential	O
interactions	O
in	O
CYP3A4	O
metabolism	O
or	O
P-glycoprotein	O
transport	O
.	O

No	O
dose	O
adjustment	O
of	O
either	O
protease	O
inhibitor	O
in	O
any	O
of	O
the	O
combinations	O
studied	O
is	O
needed	O
.	O

Randomized	O
crossover	O
study	O
comparing	O
efficacy	Others
of	O
transnasal	O
endoscopy	O
with	O
that	O
of	O
standard	O
endoscopy	O
to	O
detect	O
Barrett	O
's	O
esophagus	O
.	O

BACKGROUND	O
Unsedated	O
transnasal	O
endoscopy	O
(	O
TNE	O
)	O
may	O
be	O
safer	O
and	O
less	O
expensive	O
than	O
standard	O
endoscopy	O
(	O
SE	O
)	O
for	O
detecting	O
Barrett	O
's	O
esophagus	O
(	O
BE	O
)	O
.	O

Emerging	O
technologies	O
require	O
robust	O
evaluation	O
before	O
routine	O
use	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
sensitivity	Physical
,	Physical
specificity	Physical
,	Physical
and	Physical
acceptability	Physical
of	O
TNE	O
in	O
diagnosing	O
BE	O
compared	O
with	O
those	O
of	O
SE	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

SETTING	O
Single	O
,	O
tertiary-care	O
referral	O
center	O
.	O

PATIENTS	O
This	O
study	O
enrolled	O
consecutive	O
patients	O
with	O
BE	O
or	O
those	O
referred	O
for	O
diagnostic	O
assessment	O
.	O

INTERVENTION	O
All	O
patients	O
underwent	O
TNE	O
followed	O
by	O
SE	O
or	O
the	O
reverse	O
.	O

Spielberger	Mental
State-Trait	Mental
Anxiety	Mental
Inventory	Mental
short-form	Mental
questionnaires	Mental
,	O
a	Others
visual	Others
analogue	Others
scale	Others
,	O
and	O
a	O
single	Others
question	Others
addressing	Others
preference	Others
for	Others
endoscopy	Others
type	Others
were	O
administered	O
.	O

MAIN	O
OUTCOME	O
MEASUREMENTS	O
Diagnostic	Others
accuracy	Others
and	Others
tolerability	Others
of	O
TNE	O
were	O
compared	O
with	O
those	O
of	O
SE	O
.	O

RESULTS	O
Of	O
95	O
patients	O
randomized	O
,	O
82	O
completed	O
the	O
study	O
.	O

We	O
correctly	O
diagnosed	O
48	O
of	O
49	O
BE	O
cases	O
by	O
TNE	O
for	O
endoscopic	O
findings	O
of	O
columnar	O
lined	O
esophagus	O
compared	O
with	O
the	O
criterion	O
standard	O
,	O
SE	O
,	O
giving	O
a	O
sensitivity	O
and	O
specificity	O
of	O
0.98	O
and	O
1.00	O
,	O
respectively	O
.	O

The	O
BE	Physical
median	Physical
length	Physical
was	O
3	O
cm	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
1-5	O
cm	O
)	O
with	O
SE	O
and	O
3	O
cm	O
(	O
IQR	O
2-4	O
cm	O
)	O
with	O
TNE	O
,	O
giving	O
high	O
correlations	O
between	O
the	O
two	O
modalities	O
(	O
R	O
(	O
2	O
)	O
=	O
0.97	O
;	O
P	O
<	O
.001	O
)	O
.	O

The	O
sensitivity	Physical
and	Physical
specificity	Physical
for	O
detecting	O
intestinal	O
metaplasia	O
by	O
TNE	O
compared	O
with	O
those	O
by	O
SE	O
was	O
0.91	O
and	O
1.00	O
,	O
respectively	O
.	O

The	O
mean	O
(	O
?	O
standard	O
deviation	O
)	O
post-endoscopy	O
Spielberger	O
State-Trait	O
Anxiety	O
Inventory	O
short-form	O
score	O
for	O
TNE	O
(	O
30.0	O
?	O
1.10	O
standard	O
error	O
of	O
the	O
mean	O
[	O
SEM	O
]	O
)	O
was	O
lower	O
than	O
that	O
for	O
SE	O
(	O
30.7	O
?	O
1.29	O
SEM	O
)	O
,	O
(	O
P	O
=	O
.054	O
)	O
.	O

The	O
visual	O
analogue	O
scale	O
scores	O
were	O
no	O
different	O
(	O
P	O
=	O
.07	O
)	O
.	O

The	O
majority	O
of	O
patients	O
(	O
59	O
%	O
)	O
expressed	O
a	O
preference	O
for	O
TNE	O
.	O

LIMITATIONS	O
This	O
is	O
a	O
small	O
study	O
,	O
with	O
limited	O
generalizability	O
,	O
a	O
high	O
prevalence	O
of	O
patients	O
with	O
BE	O
,	O
differential	O
drop-out	O
between	O
the	O
two	O
procedures	O
,	O
and	O
use	O
of	O
sedation	O
.	O

CONCLUSION	O
TNE	O
is	O
an	O
accurate	O
and	O
well-tolerated	O
method	O
for	O
diagnosing	O
BE	O
compared	O
with	O
SE	O
.	O

TNE	O
warrants	O
further	O
evaluation	O
as	O
a	O
screening	O
tool	O
for	O
BE	O
.	O

The	O
treatment	O
of	O
senile	Physical
dementia	Physical
associated	O
with	O
cerebrovascular	O
insufficiency	O
:	O
a	O
comparative	O
study	O
of	O
buflomedil	O
and	O
dihydrogenated	O
ergot	O
alkaloids	O
.	O

Seventy-six	O
patients	O
took	O
part	O
in	O
a	O
randomized	O
,	O
comparative	O
study	O
of	O
the	O
efficacy	O
of	O
buflomedil	O
hydrochloride	O
and	O
dihydrogenated	O
ergot	O
alkaloids	O
in	O
the	O
treatment	O
of	O
senile	Physical
dementia	Physical
associated	O
with	O
cerebrovascular	O
insufficiency	O
.	O

Efficacy	Others
was	O
assessed	O
by	O
the	O
patients	O
'	O
performance	O
in	O
four	O
psychometric	Mental
tests	Mental
.	O

The	O
results	O
showed	O
that	O
a	O
trend	O
in	O
favour	O
of	O
the	O
buflomedil	O
group	O
in	O
three	O
of	O
the	O
tests	O
became	O
statistically	O
significant	O
in	O
the	O
fourth	O
.	O

Both	O
drugs	O
appeared	O
to	O
be	O
safe	Others
,	O
causing	O
no	O
marked	O
adverse	Adverseeffect
reactions	Adverseeffect
.	O

In	O
conclusion	O
,	O
buflomedil	O
is	O
as	O
effective	O
or	O
more	O
effective	O
than	O
dihydrogenated	O
ergot	O
alkaloids	O
in	O
the	O
treatment	O
of	O
senile	Physical
dementia	Physical
associated	O
with	O
cerebrovascular	O
insufficiency	O
and	O
could	O
prove	O
a	O
valuable	O
addition	O
to	O
long-term	O
therapy	O
if	O
further	O
studies	O
support	O
the	O
trend	O
shown	O
in	O
this	O
study	O
.	O

Acceptability	O
of	O
an	O
Electronic	O
Self-Report	O
Assessment	O
Program	O
for	O
patients	O
with	O
cancer	O
.	O

Eliciting	O
symptom	O
and	O
quality	O
of	O
life	O
information	O
from	O
patients	O
is	O
an	O
important	O
component	O
of	O
medical	O
and	O
nursing	O
care	O
processes	O
.	O

Traditionally	O
,	O
this	O
information	O
has	O
been	O
collected	O
with	O
paper	O
and	O
pencil	O
.	O

However	O
,	O
this	O
approach	O
presents	O
several	O
barriers	O
,	O
including	O
delays	O
in	O
receiving	O
information	O
,	O
difficulty	O
in	O
integrating	O
responses	O
with	O
electronic	O
records	O
,	O
and	O
the	O
time	O
required	O
to	O
manually	O
score	O
questionnaires	O
for	O
measurement	O
purposes	O
.	O

One	O
solution	O
that	O
addresses	O
many	O
of	O
these	O
barriers	O
is	O
the	O
adoption	O
of	O
computerized	O
screening	O
for	O
symptom	O
and	O
quality-of-life	O
information	O
.	O

This	O
research	O
explored	O
the	O
acceptability	Others
of	O
asking	O
symptom	O
and	O
quality-of-life	O
questions	O
using	O
the	O
Electronic	O
Self	O
Report	O
Assessment-Cancer	O
program	O
on	O
wireless	O
laptops	O
equipped	O
with	O
touch-screen	O
format	O
.	O

Acceptability	Others
data	Others
were	O
explored	O
with	O
respect	O
to	O
whether	O
any	O
differences	O
may	O
be	O
attributed	O
to	O
demographics	O
and	O
symptom	O
and	O
quality-of-life	Others
levels	Others
,	O
such	O
as	O
depression	Mental
and	Mental
cognitive	Mental
and	Mental
emotional	Mental
functioning	Mental
.	O

This	O
evaluation	O
used	O
descriptive	O
and	O
univariate	O
statistics	O
to	O
examine	O
data	O
from	O
342	O
participants	O
from	O
the	O
ongoing	O
ESRA-C	O
randomized	O
clinical	O
trial	O
.	O

Research	O
participants	O
for	O
the	O
ESRA-C	O
study	O
were	O
recruited	O
from	O
the	O
Seattle	O
Cancer	O
Care	O
Alliance	O
,	O
a	O
consortium	O
among	O
the	O
University	O
of	O
Washington	O
Medical	O
Center	O
,	O
Fred	O
Hutchinson	O
Cancer	O
Research	O
Center	O
,	O
and	O
Children	O
's	O
Hospital	O
and	O
Regional	O
Medical	O
Center	O
in	O
Seattle	O
,	O
WA	O
.	O

The	O
sample	O
consisted	O
of	O
342	O
adult	O
participants	O
who	O
completed	O
both	O
baseline	O
and	O
follow-up	O
survey	O
sessions	O
.	O

Medical	O
oncology	O
represented	O
the	O
largest	O
recruitment	O
group	O
(	O
45.3	O
%	O
)	O
,	O
followed	O
by	O
stem	O
cell	O
transplant	O
(	O
34.5	O
%	O
)	O
and	O
radiation	O
oncology	O
(	O
20.2	O
%	O
)	O
.	O

The	O
primary	O
finding	O
was	O
that	O
patients	O
were	O
generally	O
able	Others
to	Others
use	Others
ESRA-C	Others
quickly	Others
and	O
without	O
difficulty	O
in	O
a	O
real-world	O
clinical	O
setting	O
and	O
that	O
they	O
were	O
overall	O
quite	O
satisfied	Others
with	Others
the	Others
ESRA-C	Others
program	Others
.	O

Significant	O
differences	O
were	O
found	O
in	O
several	O
acceptability	Others
areas	O
with	O
respect	O
to	O
demographics	O
and	O
quality	O
of	O
life	O
measures	O
such	O
as	O
age	O
,	O
sex	O
,	O
and	O
severe	O
distress	O
.	O

This	O
analysis	O
confirms	O
that	O
the	O
ESRA-C	O
application	O
for	O
collecting	O
symptom	O
and	O
quality	O
of	O
life	O
information	O
is	O
easy	O
for	O
patients	O
to	O
use	O
and	O
acceptable	O
across	O
a	O
range	O
of	O
user	O
characteristics	O
.	O

We	O
intend	O
to	O
build	O
on	O
our	O
work	O
by	O
using	O
the	O
survey	O
platform	O
in	O
other	O
modalities	O
while	O
ensuring	O
that	O
the	O
patient	O
's	O
preferences	O
are	O
considered	O
at	O
all	O
times	O
.	O

Butorphanol	O
and	O
meperidine	O
compared	O
in	O
patients	O
with	O
acute	O
ureteral	O
colic	O
.	O

Pain	O
relief	O
was	O
evaluated	O
in	O
81	O
patients	O
with	O
acute	O
ureteral	O
colic	O
and	O
the	O
confirmed	O
presence	O
of	O
a	O
calculus	O
.	O

A	O
randomized	O
double-blind	O
comparison	O
of	O
intramuscular	O
2	O
and	O
4	O
mg.	O
butorphanol	O
and	O
80	O
mg.	O
meperidine	O
was	O
used	O
.	O

Pain	Pain
intensity	Pain
and	O
pain	Pain
relief	Pain
were	O
evaluated	O
at	O
half	O
hour	O
and	O
hourly	O
intervals	O
for	O
4	O
hours	O
.	O

A	O
2	O
mg.	O
dose	O
of	O
butorphanol	O
was	O
found	O
to	O
be	O
analgesically	O
equivalent	O
to	O
80	O
mg.	O
meperidine	O
,	O
while	O
a	O
4	O
mg.	O
dose	O
of	O
butorphanol	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
80	O
mg.	O
meperidine	O
and	O
2	O
mg.	O
butorphanol	O
.	O

Each	O
patient	O
received	O
up	O
to	O
2	O
doses	O
of	O
analgesic	O
medication	O
when	O
necessary	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	Adverseeffect
of	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
among	O
treatments	O
.	O

One	O
patient	O
had	O
visual	Physical
hallucinations	Physical
after	O
a	O
2	O
mg.	O
dose	O
of	O
butorphanol	O
,	O
possibly	O
owing	O
to	O
its	O
antagonistic	O
activity	O
to	O
significant	O
narcotic	O
experience	O
given	O
previously	O
at	O
another	O
hospital	O
.	O

There	O
was	O
no	O
other	O
evidence	O
of	O
toxicity	Adverseeffect
with	O
butorphanol	O
.	O

It	O
was	O
found	O
to	O
be	O
a	O
safe	Others
,	Others
effective	Others
and	Others
wall	Others
tolerated	Others
drug	O
for	O
the	O
treatment	O
of	O
ureteral	O
colic	O
and	O
is	O
recommended	O
in	O
place	O
of	O
narcotics	O
.	O

Use	O
of	O
a	O
clay	O
modeling	O
task	O
to	O
reduce	O
chocolate	Mental
craving	Mental
.	O

Elaborated	O
Intrusion	O
theory	O
(	O
EI	O
theory	O
;	O
Kavanagh	O
,	O
Andrade	O
,	O
&	O
May	O
,	O
2005	O
)	O
posits	O
two	O
main	O
cognitive	O
components	O
in	O
craving	Mental
:	O
associative	O
processes	O
that	O
lead	O
to	O
intrusive	O
thoughts	O
about	O
the	O
craved	O
substance	O
or	O
activity	O
,	O
and	O
elaborative	O
processes	O
supporting	O
mental	O
imagery	O
of	O
the	O
substance	O
or	O
activity	O
.	O

We	O
used	O
a	O
novel	O
visuospatial	O
task	O
to	O
test	O
the	O
hypothesis	O
that	O
visual	O
imagery	O
plays	O
a	O
key	O
role	O
in	O
craving	Mental
.	O

Experiment	O
1	O
showed	O
that	O
spending	O
10	O
min	O
constructing	O
shapes	O
from	O
modeling	O
clay	O
(	O
plasticine	O
)	O
reduced	O
participants	O
'	O
craving	Mental
for	Mental
chocolate	Mental
compared	O
with	O
spending	O
10	O
min	O
'letting	O
your	O
mind	O
wander	O
'	O
.	O

Increasing	O
the	O
load	O
on	O
verbal	O
working	O
memory	O
using	O
a	O
mental	O
arithmetic	O
task	O
(	O
counting	O
backwards	O
by	O
threes	O
)	O
did	O
not	O
reduce	O
craving	Mental
further	O
.	O

Experiment	O
2	O
compared	O
effects	O
on	O
craving	Mental
of	O
a	O
simpler	O
verbal	O
task	O
(	O
counting	O
by	O
ones	O
)	O
and	O
clay	O
modeling	O
.	O

Clay	O
modeling	O
reduced	O
overall	Mental
craving	Mental
strength	Mental
and	O
strength	Mental
of	Mental
craving	Mental
imagery	Mental
,	O
and	O
reduced	O
the	O
frequency	Mental
of	Mental
thoughts	Mental
about	Mental
chocolate	Mental
.	O

The	O
results	O
are	O
consistent	O
with	O
EI	O
theory	O
,	O
showing	O
that	O
craving	Mental
is	O
reduced	O
by	O
loading	O
the	O
visuospatial	O
sketchpad	O
of	O
working	O
memory	O
but	O
not	O
by	O
loading	O
the	O
phonological	O
loop	O
.	O

Clay	O
modeling	O
might	O
be	O
a	O
useful	O
self-help	O
tool	O
to	O
help	O
manage	O
craving	Mental
for	O
chocolate	O
,	O
snacks	O
and	O
other	O
foods	O
.	O

Combination	O
therapy	O
with	O
methotrexate	O
and	O
hydroxychloroquine	O
for	O
rheumatoid	O
arthritis	O
increases	O
exposure	O
to	O
methotrexate	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
bioavailability	O
of	O
methotrexate	O
(	O
MTX	O
)	O
in	O
the	O
presence	O
of	O
hydroxychloroquine	O
(	O
HCQ	O
)	O
,	O
and	O
vice	O
versa	O
,	O
to	O
determine	O
a	O
possible	O
pharmacokinetic	O
explanation	O
for	O
the	O
observation	O
that	O
combination	O
treatment	O
of	O
rheumatoid	O
arthritis	O
with	O
MTX	O
and	O
HCQ	O
has	O
been	O
shown	O
,	O
clinically	O
,	O
to	O
be	O
more	O
potent	O
than	O
MTX	O
used	O
alone	O
.	O

METHODS	O
In	O
a	O
randomized	O
crossover	O
study	O
,	O
10	O
healthy	O
subjects	O
received	O
,	O
on	O
each	O
of	O
5	O
dosing	O
occasions	O
,	O
MTX	O
alone	O
as	O
tablets	O
or	O
intravenous	O
solution	O
,	O
HCQ	O
alone	O
as	O
a	O
tablet	O
or	O
oral	O
solution	O
,	O
or	O
a	O
coadministered	O
dose	O
of	O
MTX	O
tablets	O
with	O
an	O
HCQ	O
tablet	O
.	O

The	O
area	O
under	O
the	O
concentration-time	Others
curve	Others
(	Others
AUC	Others
)	Others
was	O
determined	O
for	O
each	O
subject	O
,	O
on	O
each	O
dosing	O
occasion	O
,	O
for	O
each	O
compound	O
.	O

RESULTS	O
The	O
mean	Others
AUC	Others
for	Others
MTX	Others
was	O
increased	O
(	O
p	O
=	O
0.005	O
)	O
and	O
the	O
maximum	Others
MTX	Others
concentration	Others
(	Others
Cmax	Others
)	Others
decreased	O
(	O
p	O
=	O
0.025	O
)	O
when	O
MTX	O
was	O
coadministered	O
with	O
HCQ	O
,	O
compared	O
to	O
MTX	O
administered	O
alone	O
.	O

The	O
time	Others
to	Others
reach	Others
Cmax	Others
for	Others
MTX	Others
administration	Others
,	Others
tmax	Others
,	O
was	O
also	O
increased	O
during	O
the	O
coadministration	O
with	O
HCQ	O
(	O
p	O
=	O
0.072	O
)	O
.	O

The	O
AUC	O
of	O
HCQ	O
showed	O
no	O
significant	O
difference	O
(	O
p	O
=	O
0.957	O
)	O
between	O
any	O
of	O
the	O
dosing	O
occasions	O
.	O

CONCLUSION	O
These	O
results	O
may	O
explain	O
the	O
increased	O
potency	O
of	O
the	O
MTX-HCQ	O
combination	O
over	O
MTX	O
as	O
a	O
single	O
agent	O
and	O
also	O
the	O
sustained	O
effects	O
of	O
MTX	O
when	O
administered	O
with	O
HCQ	O
.	O

In	O
addition	O
,	O
the	O
reduced	O
Cmax	O
of	O
MTX	O
observed	O
during	O
the	O
coadministration	O
may	O
explain	O
diminution	O
of	O
acute	O
liver	O
adverse	O
effects	O
.	O

Extra	O
vigilance	O
for	O
MTX	O
adverse	O
effects	O
during	O
combination	O
therapy	O
with	O
HCQ	O
is	O
recommended	O
,	O
especially	O
if	O
renal	O
function	O
is	O
known	O
to	O
be	O
decreased	O
.	O

The	O
Social	O
Communication	O
Assessment	O
for	O
Toddlers	O
with	O
Autism	O
(	O
SCATA	O
)	O
:	O
an	O
instrument	O
to	O
measure	O
the	O
frequency	Others
,	O
form	O
and	O
function	Mental
of	Mental
communication	Mental
in	O
toddlers	O
with	O
autism	O
spectrum	O
disorder	O
.	O

The	O
Social	O
Communication	O
Assessment	O
for	O
Toddlers	O
with	O
Autism	O
(	O
SCATA	O
)	O
was	O
designed	O
to	O
measure	O
non-verbal	Mental
communication	Mental
,	Mental
including	Mental
early	Mental
and	Mental
atypical	Mental
communication	Mental
,	O
in	O
young	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Each	O
communicative	O
act	O
is	O
scored	O
according	O
to	O
its	O
form	O
,	O
function	O
,	O
role	O
and	O
complexity	O
.	O

The	O
SCATA	O
was	O
used	O
to	O
measure	O
communicative	O
ability	O
longitudinally	O
in	O
two	O
samples	O
of	O
toddlers	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Overall	Mental
frequency	Mental
of	Mental
non-verbal	Mental
communicative	Mental
acts	Mental
did	O
not	O
change	O
between	O
the	O
two	O
assessments	O
.	O

However	O
,	O
the	O
form	Mental
and	Mental
complexity	Mental
,	Mental
the	Mental
function	Mental
and	Mental
the	Mental
role	Mental
the	O
child	O
took	O
in	O
the	O
interaction	O
did	O
change	O
with	O
time	O
.	O

Both	O
frequency	Mental
and	Mental
function	Mental
of	Mental
communicative	Mental
acts	Mental
in	O
toddlerhood	O
were	O
positively	O
associated	O
with	O
later	Mental
language	Mental
ability	Mental
:	Mental
social	Mental
acts	Mental
,	Mental
comments	Mental
and	Mental
initiations	Mental
showed	O
greater	O
predictive	O
association	O
than	O
requests	O
and	O
responses	O
.	O

Analysis	O
of	O
face	O
gaze	O
in	O
autism	O
using	O
Bubbles	O
.	O

One	O
of	O
the	O
components	O
of	O
abnormal	O
social	O
functioning	O
in	O
autism	O
is	O
an	O
impaired	O
ability	O
to	O
direct	O
eye	O
gaze	O
onto	O
other	O
people	O
's	O
faces	O
in	O
social	O
situations	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
gaze	Mental
onto	Mental
the	Mental
eye	Mental
and	Mental
mouth	Mental
regions	Mental
of	Mental
faces	Mental
,	O
and	O
the	O
visual	O
information	O
that	O
was	O
present	O
within	O
those	O
regions	O
.	O

We	O
used	O
the	O
Bubbles	O
method	O
to	O
vary	O
the	O
facial	O
information	O
available	O
on	O
any	O
given	O
trial	O
by	O
revealing	O
only	O
small	O
parts	O
of	O
the	O
face	O
,	O
and	O
measured	O
the	O
eye	Mental
movements	Mental
made	O
as	O
participants	O
viewed	O
these	O
stimuli	O
.	O

Compared	O
to	O
ten	O
IQ-	O
and	O
age-matched	O
healthy	O
controls	O
,	O
eight	O
participants	O
with	O
autism	O
showed	O
less	O
fixation	Mental
specificity	Mental
to	O
the	O
eyes	O
and	O
mouth	O
,	O
a	O
greater	O
tendency	O
to	O
saccade	O
away	O
from	O
the	O
eyes	O
when	O
information	O
was	O
present	O
in	O
those	O
regions	O
,	O
and	O
abnormal	O
directionality	O
of	O
saccades	O
.	O

The	O
findings	O
provide	O
novel	O
detail	O
to	O
the	O
abnormal	O
way	O
in	O
which	O
people	O
with	O
autism	O
look	O
at	O
faces	O
,	O
an	O
impairment	O
that	O
likely	O
influences	O
all	O
subsequent	O
face	O
processing	O
.	O

Targeting	O
alpha-7	O
nicotinic	O
neurotransmission	O
in	O
schizophrenia	O
:	O
a	O
novel	O
agonist	O
strategy	O
.	O

Alpha7	O
nicotinic	O
acetylcholine	O
receptor	O
(	O
?7	O
nAChR	O
)	O
agonists	O
may	O
be	O
valuable	O
treatments	O
for	O
negative	O
symptoms	O
and	O
cognitive	O
impairment	O
in	O
schizophrenia	O
.	O

Unfortunately	O
,	O
chronic	O
exposure	O
to	O
an	O
agonist	O
may	O
reduce	O
the	O
receptor	O
's	O
sensitivity	O
.	O

Therefore	O
,	O
we	O
combined	O
CDP-choline	O
,	O
a	O
dietary	O
source	O
of	O
the	O
direct	O
agonist	O
choline	O
,	O
with	O
galantamine	O
,	O
a	O
positive	O
allosteric	O
modulator	O
(	O
PAM	O
)	O
of	O
nicotinic	O
acetylcholine	O
receptors	O
,	O
to	O
improve	O
the	O
efficiency	O
of	O
transducing	O
the	O
choline	O
signal	O
and	O
,	O
possibly	O
,	O
preserve	O
the	O
receptor	O
in	O
a	O
sensitive	O
state	O
.	O

We	O
conducted	O
a	O
single-site	O
,	O
double-blind	O
randomized	O
clinical	O
trial	O
comparing	O
galantamine/CDP-choline	O
to	O
placebos	O
in	O
schizophrenia	O
patients	O
with	O
negative	O
symptoms	O
who	O
were	O
receiving	O
second	O
generation	O
antipsychotics	O
.	O

Forty-three	O
subjects	O
received	O
galantamine	O
and	O
CDP-choline	O
or	O
matching	O
placebos	O
for	O
16weeks	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	O
5-item	O
Marder	O
negative-symptoms	O
factor	O
of	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
.	O

Cognition	O
and	O
functioning	O
were	O
also	O
assessed	O
.	O

Trial	O
completion	O
was	O
high	O
;	O
79	O
%	O
.	O

There	O
was	O
no	O
significant	O
treatment	O
effect	O
on	O
negative	O
symptoms	O
,	O
other	O
PANSS	O
symptom	O
factors	O
,	O
or	O
the	O
MATRICS	O
Cognitive	O
Consensus	O
Battery	O
.	O

There	O
were	O
significant	O
treatment	O
effects	O
in	O
overall	O
functioning	O
and	O
a	O
test	O
of	O
free	O
verbal	O
recall	O
.	O

Three	O
subjects	O
discontinued	O
treatment	O
in	O
the	O
active	O
treatment	O
group	O
for	O
gastro-intestinal	O
adverse	O
events	O
(	O
AE	O
)	O
.	O

The	O
most	O
common	O
AE	O
for	O
galantamine/CDP-choline	O
was	O
abdominal	O
pain	O
;	O
for	O
placebo	O
it	O
was	O
headache	O
and	O
sweating	O
.	O

Although	O
there	O
was	O
no	O
significant	O
treatment	O
effect	O
on	O
negative	O
symptoms	O
,	O
the	O
direction	O
of	O
effect	O
mirrored	O
the	O
effects	O
on	O
a	O
cognitive	O
measure	O
and	O
overall	O
functioning	O
.	O

Further	O
study	O
of	O
?7	O
nAChR	O
agonist/PAMs	O
is	O
warranted	O
in	O
larger	O
studies	O
that	O
will	O
have	O
greater	O
power	O
.	O

Effectiveness	Others
of	O
aromatherapy	O
massage	O
in	O
the	O
management	O
of	O
anxiety	Mental
and	Mental
depression	Mental
in	O
patients	O
with	O
cancer	O
:	O
a	O
multicenter	O
randomized	O
controlled	O
trial	O
.	O

PURPOSE	O
To	O
test	O
the	O
effectiveness	Others
of	O
supplementing	O
usual	O
supportive	O
care	O
with	O
aromatherapy	O
massage	O
in	O
the	O
management	O
of	O
anxiety	O
and	O
depression	O
in	O
cancer	O
patients	O
through	O
a	O
pragmatic	O
two-arm	O
randomized	O
controlled	O
trial	O
in	O
four	O
United	O
Kingdom	O
cancer	O
centers	O
and	O
a	O
hospice	O
.	O

PATIENTS	O
AND	O
METHODS	O
Two	O
hundred	O
eighty-eight	O
cancer	O
patients	O
,	O
referred	O
to	O
complementary	O
therapy	O
services	O
with	O
clinical	O
anxiety	O
and/or	O
depression	O
,	O
were	O
allocated	O
randomly	O
to	O
a	O
course	O
of	O
aromatherapy	O
massage	O
or	O
usual	O
supportive	O
care	O
alone	O
.	O

RESULTS	O
Patients	O
who	O
received	O
aromatherapy	O
massage	O
had	O
no	O
significant	O
improvement	O
in	O
clinical	Mental
anxiety	Mental
and/or	Mental
depression	Mental
compared	O
with	O
those	O
receiving	O
usual	O
care	O
at	O
10	O
weeks	O
postrandomization	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.3	O
;	O
95	O
%	O
CI	O
,	O
0.9	O
to	O
1.7	O
;	O
P	O
=	O
.1	O
)	O
,	O
but	O
did	O
at	O
6	O
weeks	O
postrandomization	O
(	O
OR	O
,	O
1.4	O
;	O
95	O
%	O
CI	O
,	O
1.1	O
to	O
1.9	O
;	O
P	O
=	O
.01	O
)	O
.	O

Patients	O
receiving	O
aromatherapy	O
massage	O
also	O
described	O
greater	O
improvement	O
in	O
self-reported	Mental
anxiety	Mental
at	O
both	O
6	O
and	O
10	O
weeks	O
postrandomization	O
(	O
OR	O
,	O
3.4	O
;	O
95	O
%	O
CI	O
,	O
0.2	O
to	O
6.7	O
;	O
P	O
=	O
.04	O
and	O
OR	O
,	O
3.4	O
;	O
95	O
%	O
CI	O
,	O
0.2	O
to	O
6.6	O
;	O
P	O
=	O
.04	O
)	O
,	O
respectively	O
.	O

CONCLUSION	O
Aromatherapy	O
massage	O
does	O
not	O
appear	O
to	O
confer	O
benefit	O
on	O
cancer	O
patients	O
'	O
anxiety	Physical
and/or	O
depression	Physical
in	O
the	O
long-term	O
,	O
but	O
is	O
associated	O
with	O
clinically	O
important	O
benefit	Others
up	O
to	O
2	O
weeks	O
after	O
the	O
intervention	O
.	O

Multicenter	O
randomized	O
controlled	O
trial	O
of	O
the	O
management	O
of	O
unresectable	O
malignant	O
mesothelioma	O
proposed	O
by	O
the	O
British	O
Thoracic	O
Society	O
and	O
the	O
British	O
Medical	O
Research	O
Council	O
.	O

Malignant	O
mesothelioma	O
is	O
almost	O
invariably	O
fatal	O
.	O

The	O
incidence	O
of	O
the	O
disease	O
is	O
rising	O
rapidly	O
in	O
many	O
countries	O
,	O
and	O
there	O
is	O
no	O
generally	O
accepted	O
standard	O
treatment	O
for	O
patients	O
with	O
unresectable	O
disease	O
.	O

According	O
to	O
current	O
British	O
Thoracic	O
Society	O
(	O
BTS	O
)	O
guidelines	O
,	O
patients	O
should	O
be	O
treated	O
with	O
active	O
symptom	O
control	O
(	O
ASC	O
)	O
,	O
involving	O
(	O
1	O
)	O
regular	O
follow-up	O
in	O
a	O
specialist	O
clinic	O
;	O
(	O
2	O
)	O
structured	O
assessments	O
of	O
physical	O
,	O
psychological	O
and	O
social	O
problems	O
with	O
appropriate	O
action	O
;	O
(	O
3	O
)	O
rapid	O
involvement	O
of	O
additional	O
specialists	O
;	O
and	O
(	O
4	O
)	O
parallel	O
nursing	O
support	O
.	O

Although	O
many	O
nonrandomized	O
studies	O
have	O
reported	O
tumor	O
responses	O
to	O
anticancer	O
chemotherapy	O
,	O
few	O
have	O
studied	O
palliation	O
and	O
it	O
is	O
not	O
known	O
whether	O
chemotherapy	O
prolongs	O
survival	O
or	O
provides	O
clinically	O
worthwhile	O
palliation	O
with	O
acceptable	O
toxicity	O
when	O
given	O
in	O
addition	O
to	O
ASC	O
.	O

We	O
therefore	O
plan	O
to	O
conduct	O
a	O
multicenter	O
randomized	O
controlled	O
trial	O
comparing	O
(	O
1	O
)	O
ASC	O
alone	O
,	O
(	O
2	O
)	O
ASC	O
plus	O
mitomycin	O
vinblastine	O
and	O
cisplatin	O
(	O
MVP	O
)	O
,	O
and	O
(	O
3	O
)	O
ASC	O
plus	O
vinorelbine	O
(	O
N	O
;	O
Navelbine	O
,	O
Pierre	O
Fabre	O
Oncology	O
,	O
Winchester	O
,	O
UK	O
)	O
.	O

We	O
chose	O
these	O
chemotherapy	O
regimens	O
because	O
they	O
have	O
been	O
shown	O
in	O
nonrandomized	O
studies	O
to	O
provide	O
good	O
symptom	O
control	O
as	O
recorded	O
by	O
patients	O
.	O

The	O
outcome	O
measures	O
are	O
overall	Mortality
survival	Mortality
,	O
palliation	Physical
of	Physical
symptoms	Physical
,	O
performance	Others
status	Others
,	O
analgesic	Pain
usage	Pain
,	Physical
toxicity	Physical
,	O
quality	Others
of	Others
life	Others
,	O
tumor	Physical
response	Physical
,	O
and	O
recurrence/progression-free	Mortality
survival	Mortality
.	O

In	O
a	O
preliminary	O
feasibility	O
study	O
,	O
we	O
are	O
assessing	O
the	O
acceptability	O
of	O
the	O
trial	O
design	O
to	O
patients	O
and	O
the	O
suitability	O
of	O
two	O
standard	O
quality-of-life	Others
instruments	O
in	O
mesothelioma	O
.	O

Data	O
will	O
help	O
us	O
to	O
decide	O
the	O
final	O
details	O
of	O
the	O
large	O
multicenter	O
trial	O
.	O

Prophylaxis	O
with	O
meropenem	O
of	O
septic	Physical
complications	Physical
in	O
acute	O
pancreatitis	O
:	O
a	O
randomized	O
,	O
controlled	O
trial	O
versus	O
imipenem	O
.	O

OBJECTIVES	O
Prophylactic	O
antibiotics	O
are	O
helpful	O
in	O
decreasing	O
the	O
incidence	O
of	O
septic	Physical
complications	Physical
in	O
acute	O
pancreatitis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
meropenem	O
,	O
a	O
new	O
carbapenem	O
antibiotic	O
,	O
with	O
that	O
of	O
imipenem	O
,	O
which	O
is	O
the	O
standard	O
prophylactic	O
treatment	O
in	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

METHODS	O
One	O
hundred	O
seventy-six	O
patients	O
with	O
necrotizing	O
pancreatitis	O
were	O
prospectively	O
randomized	O
to	O
prophylactic	O
treatment	O
with	O
0.5	O
g	O
meropenem	O
t.i.d	O
.	O

intravenously	O
or	O
0.5	O
g	O
imipenem	O
q.i.d	O
.	O

intravenously	O
.	O

The	O
occurrence	Physical
of	Physical
infection	Physical
of	Physical
pancreatic	Physical
necrosis	Physical
,	O
rate	Physical
of	Physical
extrapancreatic	Physical
infections	Physical
,	O
systemic	Adverseeffect
and	Adverseeffect
local	Adverseeffect
complications	Adverseeffect
,	O
need	Others
for	Others
surgery	Others
,	O
mortality	Mortality
rate	Mortality
,	O
and	O
length	Others
of	Others
hospitalization	Others
were	O
recorded	O
for	O
each	O
group	O
.	O

When	O
a	O
septic	Physical
complication	Physical
of	O
pancreatic	O
necrosis	O
was	O
suspected	O
,	O
fine	O
needle	O
aspiration	O
with	O
cultures	O
of	O
the	O
sample	O
was	O
performed	O
.	O

Surgery	O
was	O
performed	O
in	O
cases	O
of	O
verified	O
infected	O
necrosis	O
.	O

CONCLUSION	O
No	O
difference	O
was	O
observed	O
between	O
patients	O
treated	O
with	O
meropenem	O
and	O
those	O
treated	O
with	O
imipenem	O
in	O
terms	O
of	O
incidence	Physical
of	Physical
pancreatic	Physical
infection	Physical
(	O
11.4	O
%	O
versus	O
13.6	O
%	O
)	O
and	O
extrapancreatic	Physical
infections	Physical
(	O
21.6	O
%	O
versus	O
23.9	O
%	O
)	O
and	O
clinical	Physical
outcome	Physical
.	O

Meropenem	O
is	O
as	O
effective	O
as	O
imipenem	O
in	O
preventing	O
septic	Physical
complications	Physical
of	O
patients	O
with	O
severe	O
acute	O
pancreatitis	O
.	O

Report	O
on	O
the	O
second	O
myelomatosis	O
trial	O
after	O
five	O
years	O
of	O
follow-up	O
.	O

Medical	O
Research	O
Council	O
's	O
Working	O
Party	O
on	O
Leukaemia	O
in	O
Adults	O
.	O

Three	O
hundred	O
and	O
seventy-two	O
patients	O
were	O
randomized	O
between	O
3	O
regimens	O
of	O
chemotherapy	O
:	O
cyclophosphamide	O
,	O
intermittent	O
melphalan	O
,	O
and	O
melphalan	O
with	O
prednisone	O
,	O
and	O
were	O
followed	O
up	O
to	O
death	O
or	O
for	O
at	O
least	O
5	O
years	O
.	O

There	O
was	O
no	O
difference	O
in	O
survival	Mortality
between	O
the	O
treatments	O
,	O
either	O
overall	O
or	O
in	O
any	O
subgroup	O
of	O
patients	O
.	O

Therefore	O
,	O
the	O
choice	O
among	O
these	O
3	O
treatments	O
should	O
be	O
guided	O
by	O
the	O
patient	O
's	O
comfort	O
and	O
convenience	O
.	O

The	O
most	O
important	O
prognostic	O
feature	O
at	O
presentation	O
was	O
the	O
quality	O
of	O
renal	Physical
function	Physical
.	O

It	O
was	O
possible	O
to	O
define	O
good	O
,	O
intermediate	O
and	O
poor	O
renal-function	O
groups	O
which	O
were	O
highly	O
correlated	O
with	O
prognosis	O
(	O
X2	O
for	O
trend	O
=	O
62.6	O
)	O
.	O

The	O
haemoglobin	Physical
level	Physical
at	O
presentation	O
was	O
strongly	O
correlated	O
with	O
prognosis	O
among	O
patients	O
in	O
the	O
good	O
renal-function	O
group	O
.	O

Among	O
107	O
patients	O
who	O
presented	O
with	O
good	O
renal	O
function	O
and	O
with	O
haemoglobin	O
above	O
100	O
g/l	O
,	O
the	O
5-year	O
survival	Mortality
was	O
43	O
%	O
.	O

Other	O
prognostic	O
features	O
were	O
much	O
less	O
important	O
when	O
account	O
was	O
taken	O
of	O
renal	O
function	O
and	O
haemoglobin	O
level	O
.	O

Adequacy	O
of	O
vitamin	O
B6	O
supplementation	O
during	O
pregnancy	O
:	O
a	O
prospective	O
study	O
.	O

This	O
prospective	O
study	O
assesses	O
the	O
effect	O
of	O
2.5	O
,	O
4	O
,	O
and	O
10	O
mg	O
of	O
pyridoxine	O
supplementation	O
during	O
pregnancy	O
on	O
maternal	Physical
and	Physical
fetal	Physical
plasma	Physical
levels	Physical
of	Physical
pyridoxal	Physical
5'-phosphate	Physical
(	Physical
PLP	Physical
)	Physical
and	O
on	O
the	O
degree	Physical
of	Physical
coenzyme	Physical
saturation	Physical
(	Physical
activation	Physical
factor	Physical
)	Physical
of	Physical
aspartate	Physical
aminotransferase	Physical
and	O
alanine	Physical
aminotransferase	Physical
(	Physical
alphaEGOT	Physical
and	Physical
alphaEGPT	Physical
)	Physical
in	Physical
maternal	Physical
erythrocytes	Physical
.	O

More	O
than	O
4	O
mg	O
of	O
pyridoxine	O
supplementation	O
daily	O
was	O
required	O
for	O
most	O
pregnancies	O
to	O
maintain	O
maternal	Physical
plasma	Physical
PLP	Physical
levels	Physical
within	O
the	O
range	O
observed	O
during	O
the	O
first	O
trimester	O
and	O
in	O
the	O
nonpregnant	O
state	O
.	O

The	O
plasma	Physical
PLP	Physical
concentrations	Physical
in	Physical
maternal	Physical
and	Physical
cord	Physical
blood	Physical
were	O
highly	O
correlated	O
and	O
indicated	O
a	O
dependence	O
of	O
fetal	O
vitamin	O
B6	O
nutrition	O
on	O
maternal	O
circulating	O
PLP	O
.	O

Measurements	Physical
of	Physical
alphaEGOT	Physical
and	Physical
alphaEGPT	Physical
were	O
not	O
as	O
reproducible	O
as	O
plasma	Physical
PLP	Physical
assays	Physical
and	O
were	O
less	O
sensitive	O
and	O
quantitative	O
indicators	O
.	O

In	O
the	O
majority	O
of	O
subjects	O
,	O
the	O
changes	Physical
in	Physical
alphaEGOT	Physical
and	Physical
alphaEGPT	Physical
with	O
time	O
correlated	O
poorly	O
with	O
the	O
changes	O
in	O
plasma	Physical
PLP	Physical
.	O

However	O
,	O
when	O
the	O
data	O
were	O
analyzed	O
without	O
regard	O
for	O
their	O
dependence	O
on	O
time	O
,	O
they	O
demonstrated	O
a	O
negative	O
,	O
linear	O
correlation	O
between	O
alphaEGOT	Physical
and	O
log	O
plasma	Physical
PLP	Physical
and	O
between	O
alphaEGPT	Physical
and	O
log	Physical
plasma	Physical
PLP	Physical
for	O
the	O
group	O
on	O
2.5	O
mg	O
of	O
pyridoxine	O
and	O
for	O
all	O
the	O
subjects	O
combined	O
.	O

Finally	O
,	O
the	O
dietary	O
records	O
showed	O
that	O
most	O
of	O
the	O
subjects	O
consumed	O
less	O
than	O
2	O
mg	O
of	O
vitamin	O
B6	O
daily	O
from	O
their	O
food	O
.	O

The	O
results	O
indicate	O
that	O
the	O
current	O
Recommended	O
Dietary	O
Allowance	O
for	O
vitamin	O
B6	O
during	O
pregnancy	O
(	O
2.5	O
mg	O
)	O
is	O
too	O
low	O
and	O
that	O
supplementation	O
of	O
this	O
vitamin	O
in	O
an	O
amount	O
more	O
than	O
4	O
mg	O
daily	O
is	O
recommended	O
.	O

Handwarming	O
and	O
relaxation	O
in	O
temperature	O
feedback	O
:	O
positive	O
placebo	O
effects	O
.	O

Sixteen	O
males	O
and	O
females	O
were	O
randomly	O
assigned	O
to	O
either	O
temperature	O
feedback	O
groups	O
warm-relax	O
(	O
WR	O
)	O
or	O
cool-relax	O
(	O
CR	O
)	O
to	O
determine	O
how	O
successful	O
hand-warming	O
and	O
-cooling	O
alters	O
the	O
subjective	O
report	O
of	O
relaxation	O
.	O

After	O
eight	O
1/2-hour	O
sessions	O
the	O
WR	O
and	O
CR	O
demonstrated	O
a	O
significant	O
difference	O
in	O
temperature	Others
change	Others
,	O
but	O
there	O
were	O
no	O
significant	O
main	O
effects	O
in	O
reported	O
subjective	Mental
relaxation	Mental
.	O

The	O
reported	O
feelings	O
of	O
relaxation	Mental
were	O
negatively	O
correlated	O
to	O
the	O
directionality	O
of	O
temperature	O
change	O
and	O
were	O
primarily	O
attributed	O
to	O
nonspecific	O
expectancies	O
.	O

Impact	O
of	O
prior	O
pharmacotherapy	O
on	O
remission	Physical
of	Physical
psychotic	Physical
depression	Physical
in	O
a	O
randomized	O
controlled	O
trial	O
.	O

Having	O
failed	O
to	O
respond	O
to	O
an	O
adequate	O
antidepressant	O
treatment	O
course	O
predicts	O
poorer	O
treatment	O
outcomes	O
in	O
patients	O
with	O
major	O
depression	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
impact	O
of	O
prior	O
treatment	O
on	O
the	O
outcome	O
of	O
major	O
depression	O
with	O
psychotic	O
features	O
(	O
MDpsy	O
)	O
.	O

We	O
examined	O
the	O
effect	O
of	O
prior	O
treatment	O
history	O
on	O
the	O
outcome	Physical
of	Physical
pharmacotherapy	Physical
of	O
MDpsy	O
in	O
patients	O
who	O
participated	O
in	O
the	O
STOPD-PD	O
study	O
,	O
a	O
randomized	O
,	O
double-blind	O
,	O
clinical	O
trial	O
comparing	O
a	O
combination	O
of	O
olanzapine	O
plus	O
sertraline	O
vs.	O
olanzapine	O
plus	O
placebo	O
.	O

The	O
strength	O
of	O
treatment	O
courses	O
received	O
prior	O
to	O
randomization	O
was	O
classified	O
using	O
a	O
validated	O
method	O
.	O

A	O
hierarchy	O
of	O
outcomes	O
was	O
hypothesized	O
based	O
on	O
treatments	O
received	O
prior	O
to	O
randomization	O
and	O
randomized	O
treatment	O
.	O

A	O
high	Physical
remission	Physical
rate	Physical
was	O
observed	O
in	O
subjects	O
with	O
a	O
history	O
of	O
no	O
prior	O
treatment	O
or	O
inadequate	O
treatment	O
who	O
were	O
treated	O
with	O
a	O
combination	O
of	O
olanzapine	O
and	O
sertraline	O
.	O

A	O
low	Physical
remission	Physical
rate	Physical
was	O
observed	O
in	O
subjects	O
who	O
had	O
previously	O
failed	O
to	O
respond	O
to	O
an	O
antidepressant	O
alone	O
and	O
who	O
were	O
treated	O
with	O
olanzapine	O
monotherapy	O
.	O

A	O
low	Physical
remission	Physical
rate	Physical
was	O
also	O
observed	O
in	O
subjects	O
who	O
had	O
previously	O
failed	O
to	O
respond	O
to	O
a	O
combination	O
of	O
an	O
antipsychotic	O
and	O
an	O
antidepressant	O
.	O

Similar	O
to	O
patients	O
with	O
major	O
depression	O
,	O
these	O
results	O
emphasize	O
the	O
impact	Physical
of	Physical
prior	Physical
pharmacotherapy	Physical
on	O
treatment	O
outcomes	O
in	O
patients	O
with	O
MDpsy	O
.	O

[	O
Safety	O
of	O
adjuvant	O
dose-dense	O
chemotherapy	O
with	O
paclitaxel	O
and	O
epirubicin	O
for	O
high-risk	O
breast	O
cancer	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
safety	Others
and	Others
tolerance	Others
of	O
adjuvant	O
dose-dense	O
chemotherapy	O
with	O
paclitaxel	O
and	O
epirubicin	O
for	O
high-risk	O
breast	O
cancer	O
.	O

METHODS	O
From	O
January	O
2004	O
to	O
December	O
2006	O
,	O
101	O
patients	O
with	O
high-risk	O
breast	O
cancer	O
after	O
surgical	O
resection	O
were	O
enrolled	O
into	O
this	O
study	O
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
dose-dense	O
and	O
regular	O
groups	O
.	O

Each	O
patient	O
received	O
6	O
cycles	O
of	O
chemotherapy	O
with	O
intravenous	O
administration	O
of	O
paclitaxel	O
(	O
175	O
mg/m2	O
,	O
on	O
D3	O
)	O
and	O
epirubicin	O
(	O
60	O
mg/m2	O
,	O
on	O
Dl	O
and	O
D2	O
)	O
.	O

The	O
dose-dense	O
group	O
had	O
repeated	O
treatment	O
every	O
two	O
weeks	O
,	O
while	O
the	O
regular	O
group	O
repeated	O
it	O
every	O
three	O
weeks	O
.	O

G-CSF	O
was	O
used	O
in	O
a	O
dose	O
of	O
3	O
microg/kg	O
on	O
D5-D9	O
during	O
each	O
cycle	O
in	O
the	O
dose-dense	O
group	O
.	O

While	O
in	O
the	O
regular	O
group	O
,	O
it	O
was	O
used	O
only	O
under	O
the	O
condition	O
that	O
grade	O
II	O
neutropenia	O
occurred	O
.	O

RESULTS	O
The	O
toxicity	Adverseeffect
could	O
be	O
evaluated	O
in	O
101	O
patients	O
.	O

Major	Adverseeffect
grade	Adverseeffect
II-IV	Adverseeffect
toxicities	Adverseeffect
included	Adverseeffect
:	Adverseeffect
neutropenia	Adverseeffect
,	O
nausea	Adverseeffect
,	O
vomiting	Adverseeffect
and	Adverseeffect
alopecia	Adverseeffect
.	O

The	O
incidence	O
of	O
grade	Physical
III-IV	Physical
neutropenia	Physical
was	O
16.0	O
%	O
in	O
the	O
dose-dense	O
group	O
versus	O
54.9	O
%	O
in	O
the	O
regular	O
group	O
(	O
P	O
=	O
0.000	O
)	O
;	O
postponing	O
of	O
chemotherapy	O
was	O
2.4	O
%	O
versus	O
6.0	O
%	O
(	O
P	O
=	O
0.027	O
)	O
.	O

Ninety-eight	O
patients	O
completed	O
the	O
chemotherapy	O
as	O
planed	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
24	O
months	O
,	O
the	O
median	Physical
DFS	Physical
and	Physical
OS	Physical
were	O
not	O
reached	O
.	O

The	O
relapse-free	Mortality
rate	Mortality
and	Mortality
survival	Mortality
rate	Mortality
were	O
89.8	O
%	O
and	O
100	O
%	O
in	O
the	O
dose-dense	O
group	O
,	O
which	O
were	O
87.8	O
%	O
and	O
93.9	O
%	O
in	O
the	O
regular	O
group	O
.	O

The	O
relapse-free	O
rate	O
of	O
the	O
high-risk	O
patients	O
in	O
the	O
dose-dense	O
group	O
was	O
86.8	O
%	O
versus	O
81.3	O
%	O
in	O
the	O
regular	O
group	O
,	O
and	O
the	O
corresponding	O
survival	O
rate	O
was	O
100	O
%	O
versus	O
90.6	O
%	O
.	O

CONCLUSION	O
Adjuvant	O
dose-dense	O
chemotherapy	O
with	O
paclitaxel	O
and	O
epirubicin	O
is	O
safe	O
,	O
tolerable	O
and	O
promising	O
for	O
high-risk	O
breast	O
cancer	O
.	O

Problem-based	O
learning	O
:	O
is	O
anatomy	O
a	O
casualty	O
?	O
INTRODUCTION	O
The	O
teaching	O
of	O
medical	O
anatomy	O
is	O
changing	O
.	O

Medical	O
schools	O
worldwide	O
are	O
moving	O
away	O
from	O
dissection	O
and	O
lectures	O
to	O
a	O
more	O
integrated	O
course	O
,	O
where	O
basic	O
science	O
and	O
clinical	O
skills	O
are	O
taught	O
simultaneously	O
.	O

Medical	O
students	O
on	O
these	O
integrated	O
courses	O
have	O
reported	O
a	O
lack	O
of	O
confidence	O
in	O
their	O
basic	O
science	O
knowledge	O
,	O
especially	O
concerning	O
anatomy	O
.	O

Our	O
aim	O
was	O
to	O
perform	O
a	O
randomised	O
controlled	O
trial	O
(	O
RCT	O
)	O
to	O
compare	O
anatomical	O
knowledge	O
of	O
two	O
groups	O
of	O
second-year	O
medical	O
students	O
,	O
the	O
first	O
group	O
taught	O
on	O
a	O
traditional	O
course	O
,	O
the	O
second	O
on	O
an	O
integrated	O
course	O
.	O

MATERIALS	O
AND	O
METHODS	O
Testing	O
was	O
done	O
using	O
a	O
Questionnaire	O
in	O
a	O
True/False	O
format	O
.	O

There	O
were	O
80	O
students	O
in	O
each	O
group	O
.	O

There	O
was	O
no	O
penalty	O
for	O
an	O
incorrect	O
answer	O
.	O

The	O
test	O
was	O
performed	O
under	O
examination	O
conditions	O
.	O

Papers	O
were	O
marked	O
under	O
blind	O
conditions	O
.	O

Results	O
were	O
analysed	O
using	O
a	O
Student	O
's	O
t	O
test	O
analysis	O
.	O

RESULTS	O
Those	O
students	O
taught	O
on	O
a	O
traditional	O
course	O
exhibited	O
a	O
significantly	O
higher	O
level	Others
of	Others
basic	Others
anatomical	Others
knowledge	Others
(	O
p	O
<	O
0.001	O
)	O
than	O
those	O
taught	O
on	O
an	O
integrated	O
course	O
.	O

The	O
students	O
taught	O
on	O
an	O
integrated	O
course	O
showed	O
a	O
much	O
greater	O
range	Others
of	Others
results	Others
.	O

CONCLUSIONS	O
Students	O
taught	O
on	O
a	O
traditional	O
course	O
have	O
a	O
higher	O
level	O
of	O
anatomical	Others
knowledge	Others
than	O
those	O
taught	O
on	O
an	O
integrated	O
course	O
.	O

Our	O
results	O
differ	O
from	O
previous	O
studies	O
done	O
in	O
Europe	O
which	O
show	O
no	O
difference	O
between	O
the	O
courses	O
.	O

The	O
importance	O
of	O
the	O
dual-switch	O
valve	O
for	O
the	O
treatment	O
of	O
adult	O
normotensive	O
or	O
hypertensive	O
hydrocephalus	O
.	O

Since	O
the	O
beginning	O
of	O
1995	O
the	O
new	O
hydrostatic	O
dual-switch	O
valve	O
(	O
DSV	O
)	O
was	O
implanted	O
in	O
35	O
adult	O
patients	O
with	O
hydrocephalus	O
of	O
different	O
etiology	O
.	O

26	O
patients	O
suffered	O
from	O
normotensive	O
hydrocephalus	O
(	O
10	O
idiopathic	O
and	O
16	O
symptomatic	O
)	O
,	O
and	O
9	O
patients	O
from	O
hypertensive	O
hydrocephalus	O
of	O
various	O
origin	O
.	O

The	O
first	O
21	O
cases	O
of	O
this	O
cohort	O
were	O
compared	O
in	O
a	O
randomized	O
study	O
with	O
a	O
comparable	O
group	O
of	O
21	O
hydrocephalic	O
patients	O
who	O
received	O
a	O
conventional	O
differential-pressure	O
(	O
DP-	O
)	O
valve	O
.	O

The	O
clinical	O
status	O
and	O
CT	O
were	O
assessed	O
prior	O
to	O
shunting	O
,	O
14	O
days	O
and	O
3	O
and	O
6	O
months	O
after	O
the	O
operation	O
.	O

The	O
reduction	O
of	O
ventricular	Physical
size	Physical
was	O
evaluated	O
by	O
the	O
measurement	O
of	O
the	O
Evans	O
Index	O
.	O

The	O
CT	O
follow-up	O
in	O
the	O
DSV	O
group	O
was	O
characterized	O
by	O
an	O
only	O
minimal	O
(	O
14	O
)	O
or	O
only	O
slight	O
(	O
16	O
)	O
reduction	O
of	O
ventricular	O
size	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
.	O

A	O
comparison	O
of	O
21	O
patients	O
with	O
a	O
DSV	O
and	O
the	O
patients	O
with	O
DP	O
valves	O
,	O
evaluated	O
by	O
measuring	O
the	O
reduction	O
of	O
the	O
Evans	Physical
Index	Physical
,	O
revealed	O
a	O
distinctly	O
higher	O
percentage	O
of	O
significant	O
regressions	O
in	O
the	O
DP	O
valve	O
collective	O
,	O
without	O
doubt	O
due	O
to	O
chronic	O
overdrainage	O
.	O

The	O
overall	O
clinical	O
result	O
of	O
our	O
35	O
patients	O
with	O
a	O
DSV	O
was	O
excellent	O
and	O
good	O
in	O
31	O
patients	O
,	O
but	O
the	O
outcome	O
seems	O
to	O
be	O
more	O
dependent	O
on	O
the	O
preshunt	Physical
damage	Physical
of	Physical
the	Physical
brain	Physical
than	O
on	O
hydrocephalic	Physical
aspects	Physical
.	Physical

A	O
neglegible	O
incidence	O
of	O
subdural	Physical
effusions	Physical
in	O
the	O
DSV	O
group	O
compared	O
to	O
11	O
cases	O
in	O
the	O
DP	O
valve	O
collective	O
reflects	O
the	O
ability	O
of	O
the	O
DSV	O
to	O
prevent	O
overdrainage	Physical
.	O

The	O
capability	O
of	O
the	O
DSV	O
to	O
maintain	O
the	O
IVP	Physical
within	O
physiological	O
limits	O
after	O
shunting	O
,	O
especially	O
in	O
the	O
upright	O
position	O
,	O
is	O
documented	O
by	O
a	O
comparison	O
with	O
possible	Physical
unphysiological	Physical
IVP	Physical
variations	Physical
in	O
other	O
valve	O
constructions	O
,	O
which	O
depend	O
on	O
the	O
level	Physical
of	Physical
implantation	Physical
,	Physical
subcutaneous	Physical
pressure	Physical
or	Physical
CSF	Physical
flow	Physical
through	Physical
the	Physical
valve	Physical
.	Physical

Memory	O
aids	O
in	O
longitudinal	O
health	O
surveys	O
:	O
results	O
from	O
a	O
field	O
experiment	O
.	O

The	O
use	O
of	O
memory	O
aids	O
to	O
improve	O
respondent	O
recall	O
is	O
becoming	O
increasingly	O
popular	O
in	O
health	O
surveys	O
.	O

In	O
a	O
one-year	O
field	O
experiment	O
involving	O
over	O
1,200	O
respondents	O
,	O
people	O
assigned	O
memory	O
aids	O
reported	O
over	O
50	O
per	O
cent	O
more	O
symptom	O
episodes	O
than	O
those	O
not	O
assigned	O
memory	O
aids	O
.	O

Differences	O
in	O
reporting	O
levels	O
were	O
particularly	O
striking	O
during	O
the	O
first	O
six	O
to	O
12	O
weeks	O
of	O
the	O
survey	O
,	O
for	O
symptoms	O
related	O
to	O
acute	O
,	O
transitory	O
illness	O
,	O
and	O
among	O
minorities	O
and	O
the	O
lower	O
socioeconomic	O
groups	O
.	O

Respondents	O
assigned	O
memory	O
aids	O
were	O
also	O
more	O
likely	O
to	O
report	O
a	O
doctor	O
contact	O
--	O
especially	O
during	O
the	O
fall/winter	O
months	O
.	O

Among	O
respondent	O
who	O
used	O
their	O
memory	O
aids	O
at	O
least	O
once	O
(	O
N	O
=	O
252	O
)	O
,	O
nearly	O
35	O
per	O
cent	O
said	O
they	O
were	O
influenced	Mental
by	Mental
the	Mental
information	Mental
recorded	Mental
in	Mental
their	Mental
memory	Mental
aids	Mental
,	O
and	O
most	O
of	O
those	O
who	O
were	O
influenced	O
said	O
that	O
they	O
became	Mental
more	Mental
aware	Mental
of	Mental
their	Mental
health	Mental
.	O

Ten	O
of	O
these	O
people	O
said	O
that	O
they	O
became	O
more	Mental
worried	Mental
or	Mental
depressed	Mental
because	O
of	O
the	O
information	O
recorded	O
in	O
their	O
memory	O
aids	O
.	O

This	O
constitutes	O
about	O
a	O
four	O
per	O
cent	O
risk	O
among	O
those	O
people	O
who	O
reported	O
using	O
their	O
memory	O
aids	O
at	O
least	O
once	O
.	O

There	O
was	O
no	O
evidence	O
to	O
suggest	O
that	O
the	O
memory	O
aids	O
influenced	O
perceptions	Mental
of	Mental
health	Mental
status	Mental
.	O

Lidocaine	O
and	O
bupivacaine	O
mixtures	O
for	O
epidural	O
blockade	O
.	O

In	O
a	O
prospective	O
double-blind	O
clinical	O
study	O
,	O
single-dose	O
lumbar	O
epidural	O
blockade	O
was	O
instituted	O
in	O
60	O
healthy	O
patients	O
undergoing	O
lower	O
abdominal	O
surgery	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
five	O
groups	O
.	O

Each	O
group	O
received	O
treatment	O
with	O
a	O
different	O
local	O
anesthetic	O
solution	O
containing	O
1:200,000	O
epinephrine	O
.	O

Local	O
anesthetic	O
solutions	O
used	O
were	O
0.5	O
per	O
cent	O
bupivacaine	O
HCl	O
,	O
2	O
per	O
cent	O
lidocaine	O
HCl	O
,	O
and	O
lidocaine-bupivacaine	O
mixtures	O
in	O
the	O
ratios	O
of	O
1:3	O
,	O
1:1	O
or	O
3:1	O
by	O
volume	O
.	O

Onset	Mental
and	Mental
complete	Mental
spread	Mental
of	Mental
sensory	Physical
blockade	Physical
were	O
similar	O
in	O
all	O
five	O
groups	O
.	O

Time	O
to	O
regression	O
to	O
two	O
segments	O
of	O
partial	O
and	O
complete	O
sensory	O
blockade	O
was	O
positively	O
correlated	O
(	O
P	O
less	O
than	O
0.05	O
)	O
with	O
increasing	O
dose	O
of	O
bupivacaine	O
in	O
the	O
solutions	O
and	O
ranged	O
from	O
84	O
min	O
(	O
partial	O
)	O
and	O
70	O
min	O
(	O
complete	O
)	O
for	O
lidocaine	O
,	O
to	O
128	O
min	O
(	O
partial	O
)	O
and	O
101	O
min	O
(	O
complete	O
)	O
for	O
bupivacaine	O
.	O

Using	O
skin	O
temperature	O
as	O
a	O
criterion	O
of	O
sympathetic	O
blockade	O
,	O
all	O
three	O
mixtures	O
demonstrated	O
a	O
duration	Others
of	Others
action	Others
intermediate	O
between	O
the	O
two	O
single	O
drugs	O
,	O
lidocaine	O
(	O
124	O
+/-	O
13	O
min	O
)	O
and	O
bupivacaine	O
(	O
286	O
+/-	O
32	O
min	O
)	O
.	O

Onset	Physical
of	Physical
complete	Physical
motor	Physical
blockade	Physical
was	O
fastest	O
and	O
the	O
degree	Physical
of	Physical
motor	Physical
blockade	Physical
was	O
most	O
profound	O
with	O
the	O
mixture	O
containing	O
equal	O
proportions	O
of	O
lidocaine	O
and	O
bupivacaine	O
.	O

Pharmacokinetics	O
of	O
individual	O
drugs	O
were	O
unaltered	O
in	O
any	O
of	O
the	O
mixtures	O
.	O

Adjuvant	O
therapy	O
with	O
pegylated	O
interferon	O
alfa-2b	O
versus	O
observation	O
in	O
resected	O
stage	O
III	O
melanoma	O
:	O
a	O
phase	O
III	O
randomized	O
controlled	O
trial	O
of	O
health-related	O
quality	O
of	O
life	O
and	O
symptoms	O
by	O
the	O
European	O
Organisation	O
for	O
Research	O
and	O
Treatment	O
of	O
Cancer	O
Melanoma	O
Group	O
.	O

PURPOSE	O
Interferon	O
(	O
IFN	O
)	O
-based	O
adjuvant	O
therapy	O
in	O
melanoma	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
,	O
which	O
necessitates	O
evaluation	O
of	O
health-related	Others
quality	Others
of	Others
life	Others
(	O
HRQOL	O
)	O
.	O

Our	O
trial	O
examined	O
the	O
HRQOL	O
effects	O
of	O
adjuvant	O
pegylated	O
IFN-alpha-2b	O
(	O
PEG-IFN-alpha-2b	O
)	O
versus	O
observation	O
in	O
patients	O
with	O
stage	O
III	O
melanoma	O
.	O

METHODS	O
A	O
total	O
of	O
1,256	O
patients	O
with	O
stage	O
III	O
melanoma	O
were	O
randomly	O
assigned	O
after	O
full	O
lymphadenectomy	O
to	O
receive	O
either	O
observation	O
(	O
n	O
=	O
629	O
)	O
or	O
PEG-IFN-alpha-2b	O
(	O
n	O
=	O
627	O
)	O
:	O
induction	O
6	O
micrograms/kg/wk	O
[	O
DOSAGE	O
ERROR	O
CORRECTED	O
]	O
for	O
8	O
weeks	O
then	O
maintenance	O
3	O
micrograms/kg/wk	O
[	O
DOSAGE	O
ERROR	O
CORRECTED	O
]	O
for	O
an	O
intended	O
total	O
duration	O
of	O
5	O
years	O
.	O

The	O
European	Others
Organisation	Others
for	Others
Research	Others
and	Others
Treatment	Others
of	Others
Cancer	Others
Quality	Others
of	Others
Life	Others
Questionnaire	Others
C30	Others
was	O
used	O
to	O
assess	O
HRQOL	O
.	O

RESULTS	O
At	O
3.8	O
years	O
of	O
median	O
follow-up	O
,	O
for	O
the	O
primary	O
end	O
point	O
,	O
recurrence-free	Mortality
survival	Mortality
(	Mortality
RFS	Mortality
)	Mortality
,	O
risk	O
was	O
reduced	O
by	O
18	O
%	O
(	O
hazard	O
rate	O
=	O
0.82	O
;	O
P	O
=	O
.01	O
)	O
in	O
the	O
PEG-IFN-alpha-2b	O
arm	O
compared	O
with	O
observation	O
.	O

Significant	O
and	O
clinically	O
meaningful	O
differences	O
occurred	O
with	O
the	O
PEG-IFN-alpha-2b	O
treatment	O
arm	O
compared	O
with	O
the	O
observation	O
group	O
,	O
showing	O
decreased	O
global	O
HRQOL	Others
at	O
month	O
3	O
(	O
-11.6	O
points	O
;	O
99	O
%	O
CI	O
,	O
-8.2	O
to	O
-15.0	O
)	O
and	O
year	O
2	O
(	O
-10.5	O
points	O
;	O
99	O
%	O
CI	O
,	O
-6.6	O
to	O
-14.4	O
)	O
.	O

Many	O
of	O
the	O
other	O
scales	O
showed	O
statistically	O
significant	O
differences	O
between	O
scores	O
when	O
comparing	O
the	O
two	O
arms	O
.	O

From	O
a	O
clinical	O
point	O
of	O
view	O
,	O
important	O
differences	O
were	O
found	O
for	O
five	O
scales	O
:	O
two	O
functioning	O
scales	O
(	O
social	Others
and	Mental
role	Others
functioning	Others
)	O
and	O
three	O
symptom	O
scales	O
(	O
appetite	Physical
loss	Physical
,	O
fatigue	Physical
,	O
and	O
dyspnea	Physical
)	O
,	O
with	O
the	O
PEG-IFN-alpha-2b	O
arm	O
being	O
most	O
impaired	O
.	O

CONCLUSION	O
PEG-IFN-alpha-2b	O
leads	O
to	O
a	O
significant	O
and	O
sustained	O
improvement	O
in	O
RFS	O
.	O

There	O
is	O
an	O
expected	O
negative	O
effect	O
on	O
global	Others
HRQOL	Others
and	O
selected	O
symptoms	O
when	O
patients	O
undergo	O
PEG-IFN-alpha-2b	O
treatment	O
.	O

Generalizability	Others
and	O
durability	Others
of	O
treatment	O
effects	O
in	O
an	O
intervention	O
program	O
for	O
coronary-prone	O
(	O
Type	O
A	O
)	O
managers	O
.	O

To	O
test	O
the	O
reliability	Others
and	O
durability	Others
of	Others
positive	Others
treatment	Others
effects	Others
obtained	O
in	O
a	O
type	O
A	O
intervention	O
project	O
for	O
healthy	O
managers	O
,	O
the	O
analysis	O
was	O
extended	O
to	O
data	O
available	O
from	O
a	O
third	O
treatment	O
group	O
(	O
a	O
special	O
behavior	O
therapy	O
group	O
for	O
participants	O
eliminated	O
from	O
the	O
main	O
sample	O
because	O
of	O
manifestations	O
of	O
clinical	O
CHD	O
)	O
and	O
to	O
measures	O
obtained	O
6	O
months	O
following	O
the	O
end	O
of	O
treatment	O
.	O

Immediately	O
after	O
treatment	O
all	O
three	O
groups	O
showed	O
a	O
similar	O
pattern	O
of	O
improvement	O
,	O
although	O
the	O
two	O
behavior	O
therapy	O
groups	O
did	O
show	O
a	O
greater	O
decrease	O
in	O
serum	Physical
cholesterol	Physical
levels	Physical
.	O

Six	O
months	O
after	O
treatment	O
the	O
sample	O
as	O
a	O
whole	O
showed	O
good	Others
maintenance	Others
of	Others
treatment	Others
effects	Others
,	O
but	O
the	O
differences	O
between	O
groups	O
had	O
become	O
somewhat	O
sharper	O
,	O
with	O
the	O
special	O
behavior	O
therapy	O
group	O
faring	O
best	O
,	O
the	O
regular	O
behavior	O
therapy	O
group	O
intermediate	O
,	O
and	O
the	O
psychotherapy	O
group	O
worst	O
.	O

The	O
logical	O
consistency	O
of	O
these	O
findings	O
increases	O
our	O
confidence	O
in	O
the	O
initial	O
treatment	O
results	O
,	O
as	O
well	O
as	O
permitting	O
cautious	O
optimism	O
concerning	O
the	O
possibility	O
of	O
developing	O
effective	O
intervention	O
programs	O
for	O
coronary-type	O
(	O
type	O
A	O
)	O
behavior	O
.	O

[	O
Impact	O
of	O
heparin	O
on	O
coagulation	Physical
index	Physical
during	O
the	O
therapy	O
of	O
molecular	O
adsorbent	O
recirculating	O
system	O
in	O
patients	O
with	O
liver	O
failure	O
]	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
impact	O
of	O
coagulative	O
parameters	O
on	O
different	Others
anticoagulation	Others
systems	Others
in	O
molecular	O
adsorbent	O
recirculating	O
system	O
(	O
MARS	O
)	O
in	O
subjects	O
with	O
liver	O
failure	O
,	O
and	O
to	O
evaluate	O
the	O
safety	O
of	O
different	O
anticoagulation	Physical
methods	O
.	O

METHODS	O
A	O
prospective	O
experimental	O
observation	O
was	O
designed	O
.	O

According	O
to	O
anticoagulation	O
Methods	O
,	O
174	O
MARS	O
treatment	O
sessions	O
for	O
146	O
patients	O
with	O
liver	O
failure	O
and	O
prothrombin	O
time	O
activity	O
percentage	O
(	O
PTA	O
)	O
?	O
40	O
%	O
were	O
randomly	O
divided	O
into	O
2	O
groups	O
:	O
92	O
MARS	O
treatment	O
sessions	O
in	O
the	O
heparin-free	O
group	O
and	O
82	O
in	O
the	O
low-dose	O
heparin	O
group	O
.	O

Time	O
points	O
of	O
0	O
,	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
and	O
6	O
h	O
were	O
selected	O
to	O
observe	O
the	O
coagulation	O
changes	O
of	O
prothrombin	O
time	O
(	O
PT	O
)	O
,	O
PTA	O
,	O
thrombin	O
time	O
(	O
TT	O
)	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
and	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
dynamically	O
.	O

Adverse	O
events	O
such	O
as	O
line	O
/	O
filter	O
coagulation	O
,	O
rupture	O
and	O
bleeding	O
were	O
also	O
investigated	O
and	O
compared	O
due	O
to	O
frequency	O
and	O
severity	O
between	O
the	O
2	O
groups	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
in	O
PT	O
,	O
PTA	O
,	O
INR	O
between	O
the	O
2	O
groups	O
,	O
but	O
significant	O
differences	O
were	O
observed	O
in	O
APTT	O
and	O
TT	O
and	O
fibrinogen	O
(	O
Fbg	O
)	O
.	O

APTT	O
and	O
TT	O
levels	O
in	O
the	O
low-dose	O
heparin	O
group	O
was	O
increased	O
rapidly	O
after	O
the	O
first	O
given	O
dose	O
of	O
anticoagulant	O
heparin	O
and	O
reached	O
the	O
peak	O
within	O
30	O
min.The	O
levels	O
at	O
each	O
time	O
point	O
was	O
statistically	O
different	O
between	O
the	O
2	O
groups	O
(	O
P	O
<	O
0.05	O
)	O
.	O

A	O
significant	O
difference	O
in	O
the	O
Fbg	O
level	O
was	O
obtained	O
between	O
the	O
2	O
groups	O
.	O

In	O
the	O
low-dose	O
heparin	O
group	O
it	O
was	O
stabilized	O
and	O
increased	O
slightly	O
at	O
the	O
end	O
of	O
the	O
treatment	O
.	O

While	O
in	O
the	O
heparin-free	O
group	O
it	O
was	O
decreased	O
gradually	O
and	O
reached	O
a	O
ravine	O
at	O
the	O
end	O
of	O
the	O
treatment	O
.	O

A	O
curve	O
was	O
observed	O
after	O
2.5	O
h	O
treatment	O
between	O
the	O
2	O
groups	O
(	O
P=0.001	O
)	O
.	O

There	O
were	O
2	O
cases	O
of	O
severe	O
bleeding	O
after	O
MARS	O
was	O
finished	O
in	O
the	O
heparin	O
group	O
,	O
and	O
1	O
was	O
terminated	O
because	O
of	O
degree	O
III	O
clotting	O
in	O
the	O
heparin-free	O
group	O
.	O

CONCLUSION	O
Fibrinogen	O
should	O
be	O
adsorbed	O
while	O
the	O
blood	O
touches	O
the	O
MARS	O
circuit	O
path	O
and	O
anticoagulants	O
can	O
prevent	O
it	O
.	O

Comprehensive	O
analysis	O
of	O
blood	O
platelet	O
count	O
(	O
BPC	O
)	O
,	O
fibrin	O
degradation	O
products	O
(	O
FDP	O
)	O
,	O
D-dimer	O
and	O
clinical	O
symptoms	O
is	O
critical	O
and	O
required	O
to	O
determine	O
the	O
coagulation	O
status	O
to	O
select	O
an	O
anticoagulation	O
system	O
before	O
MARS	O
.	O

The	O
use	O
of	O
low	O
dose	O
heparin	O
in	O
MARS	O
improves	O
the	O
disorder	O
of	O
hypercoagulable	O
state	O
during	O
the	O
high	O
coaguation	O
period	O
,	O
while	O
heparin-free	O
during	O
low	O
coagulation	O
period	O
can	O
effectively	O
prevent	O
the	O
occurrence	O
of	O
bleeding	O
and	O
improve	O
the	O
mechanism	O
of	O
blood	O
coagulation	O
by	O
reducing	O
heparin-like	O
substance	O
in	O
the	O
blood	O
.	O

Effect	O
of	O
a	O
mixed	O
kinesio	O
taping-compression	O
technique	O
on	O
quality	Others
of	Others
life	Others
and	O
clinical	Others
and	O
gait	Physical
parameters	Physical
in	O
postmenopausal	O
women	O
with	O
chronic	O
venous	O
insufficiency	O
:	O
double-blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
short-term	O
effect	O
of	O
a	O
mixed	O
Kinesio	O
taping	O
(	O
KT	O
)	O
model	O
on	O
range	Physical
of	Physical
ankle	Physical
motion	Physical
(	Physical
ROAM	Physical
)	Physical
,	Physical
gait	Physical
,	Physical
pain	Pain
,	Physical
perimeter	Physical
of	Physical
lower	Physical
limbs	Physical
,	Physical
and	Physical
quality	Physical
of	Physical
life	Physical
in	O
postmenopausal	O
women	O
with	O
chronic	O
venous	O
insufficiency	O
(	O
CVI	O
)	O
.	O

DESIGN	O
Double-blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

SETTING	O
Clinical	O
setting	O
.	O

PARTICIPANTS	O
Consecutive	O
postmenopausal	O
women	O
(	O
N=130	O
;	O
mean	O
age	O
?	O
SD	O
,	O
65.44?14.7y	O
)	O
with	O
mild	O
CVI	O
.	O

No	O
participant	O
withdrew	O
because	O
of	O
adverse	O
effects	O
.	O

INTERVENTION	O
Participants	O
were	O
randomly	O
assigned	O
to	O
either	O
(	O
1	O
)	O
an	O
experimental	O
group	O
to	O
receive	O
a	O
mixed	O
KT-compression	O
treatment	O
following	O
KT	O
recommendations	O
for	O
gastrocnemius	O
muscle	O
enhancement	O
and	O
functional	O
correction	O
of	O
the	O
ankle	O
,	O
and	O
adding	O
2	O
tapes	O
to	O
simulate	O
traditional	O
compression	O
bandages	O
(	O
no	O
KT	O
guidelines	O
)	O
;	O
or	O
(	O
2	O
)	O
a	O
placebo	O
control	O
group	O
for	O
sham	O
KT	O
.	O

Both	O
interventions	O
were	O
performed	O
3	O
times	O
a	O
week	O
during	O
a	O
4-week	O
period	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
ROAM	O
,	O
gait	O
,	O
pain	O
,	O
perimeter	O
of	O
right	O
and	O
left	O
lower	O
limb	O
,	O
and	O
quality	O
of	O
life	O
were	O
assessed	O
at	O
baseline	O
and	O
48	O
hours	O
posttreatment	O
.	O

RESULTS	O
Quality	O
of	O
life	O
was	O
better	O
in	O
the	O
intervention	O
group	O
by	O
a	O
mean	O
of	O
8.76	O
points	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
4.96-12.55	O
)	O
.	O

The	O
experimental	O
group	O
also	O
showed	O
significant	O
pre-/posttreatment	O
improvements	O
in	O
both	O
lower	O
limbs	O
in	O
gait	O
dorsiflexion	O
ROAM	O
(	O
95	O
%	O
CI	O
,	O
1.02-2.49	O
)	O
,	O
cadence	O
(	O
95	O
%	O
CI	O
,	O
3.45-1.47	O
)	O
,	O
stride	O
length	O
(	O
95	O
%	O
CI	O
,	O
21.48-10.83	O
)	O
,	O
step	O
length	O
(	O
95	O
%	O
CI	O
,	O
1.68-6.61	O
)	O
,	O
stance	O
phase	O
(	O
95	O
%	O
CI	O
,	O
61-107	O
)	O
,	O
and	O
foot	O
(	O
95	O
%	O
CI	O
,	O
.56-.92	O
)	O
and	O
malleolus	O
(	O
95	O
%	O
CI	O
,	O
1.15-1.63	O
)	O
circumference	O
.	O

None	O
of	O
these	O
variables	O
were	O
significantly	O
modified	O
in	O
the	O
placebo	O
group	O
.	O

Both	O
groups	O
reported	O
a	O
significant	O
reduction	O
in	O
pain	O
.	O

CONCLUSIONS	O
Ankle	O
dorsiflexion	O
during	O
gait	O
,	O
walking	O
parameters	O
,	O
peripheral	O
edema	O
,	O
venous	O
pain	O
,	O
and	O
quality	O
of	O
life	O
remain	O
improved	O
in	O
patients	O
with	O
CVI	O
at	O
1	O
month	O
after	O
mixed	O
KT-compression	O
therapy	O
.	O

KT	O
may	O
have	O
a	O
placebo	O
effect	O
on	O
pain	O
perception	O
.	O

Laparoscopic	O
hysterectomy	O
:	O
is	O
dissecting	O
the	O
ureter	O
necessary	O
?	O
Laparoscopic	O
hysterectomy	O
has	O
been	O
first	O
reported	O
by	O
Reich	O
et	O
al	O
.	O

in	O
1989	O
,	O
which	O
confirmed	O
the	O
possibility	O
of	O
laparoscopic	O
hysterectomy	O
being	O
employed	O
as	O
a	O
replacement	O
of	O
the	O
vast	O
majority	O
of	O
traditional	O
abdominal	O
hysterectomies	O
.	O

There	O
are	O
three	O
critical	O
points	O
in	O
laparoscopic	O
hysterectomy	O
.	O

The	O
most	O
important	O
critical	O
point	O
is	O
to	O
identify	O
uterine	O
arteries	O
from	O
the	O
ureter	O
in	O
the	O
paracervical	O
area	O
.	O

Several	O
ureteral	Physical
injuries	Physical
at	O
operative	O
laparoscopy	O
have	O
been	O
reported	O
.	O

We	O
performed	O
two	O
hundred	O
and	O
thirty	O
laparoscopic	O
hysterectomies	O
during	O
the	O
period	O
from	O
March	O
1991	O
to	O
October	O
1993	O
.	O

Sixty	O
patients	O
were	O
later	O
included	O
in	O
this	O
study	O
.	O

Thirty	O
of	O
these	O
applied	O
the	O
technique	O
of	O
dissecting	O
the	O
ureter	O
at	O
the	O
initiation	O
of	O
laparoscopic	O
hysterectomy	O
.	O

Most	O
of	O
the	O
patients	O
were	O
discharged	O
on	O
the	O
second	O
postoperative	O
day	O
.	O

Although	O
dissecting	O
the	O
ureter	O
at	O
the	O
beginning	O
of	O
the	O
operation	O
did	O
not	O
produce	O
a	O
significant	O
discrepancy	Physical
in	O
operation	Others
time	Others
,	Others
blood	Physical
loss	Physical
,	Physical
hospitalization	Others
day	Others
and	Physical
ureter	Physical
injury	Physical
when	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
uterine	O
arteries	O
,	O
however	O
,	O
may	O
be	O
confidently	O
desiccated	O
once	O
the	O
path	O
of	O
the	O
ureter	O
near	O
the	O
uterosacral	O
ligament	O
is	O
identified	O
.	O

Clinical	O
trial	O
:	O
marine	O
lipid	O
suppositories	O
as	O
laxatives	O
.	O

UNLABELLED	O
Cod-liver	O
oil	O
and	O
other	O
marine	O
products	O
containing	O
polyunsaturated	O
fatty	O
acids	O
have	O
anti-inflammatory	O
,	O
anti-bacterial	O
and	O
anti-viral	O
effects	O
and	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
various	O
inflammatory	O
and	O
infectious	O
diseases	O
.	O

We	O
developed	O
suppositories	O
and	O
ointment	O
with	O
30	O
%	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
extract	O
from	O
omega-3	O
fish	O
oil	O
.	O

Our	O
purpose	O
was	O
to	O
evaluate	O
the	O
safety	Others
of	O
marine	O
lipid	O
suppositories	O
and	O
ointment	O
in	O
healthy	O
volunteers	O
and	O
to	O
explore	O
the	O
laxative	Physical
effect	Physical
of	O
the	O
suppositories	O
.	O

Thirty	O
healthy	O
volunteers	O
were	O
randomized	O
either	O
to	O
a	O
study	O
group	O
administrating	O
30	O
%	O
FFA	O
suppositories	O
and	O
applying	O
30	O
%	O
FFA	O
ointment	O
to	O
the	O
perianal	O
region	O
twice	O
per	O
day	O
for	O
two	O
weeks	O
,	O
or	O
to	O
a	O
control	O
group	O
using	O
placebo	O
suppositories	O
and	O
ointment	O
in	O
a	O
double	O
blinded	O
manner	O
.	O

RESULTS	O
No	O
serious	Adverseeffect
toxic	Adverseeffect
effects	Adverseeffect
or	Adverseeffect
irritation	Adverseeffect
were	O
observed	O
.	O

In	O
the	O
study	O
group	O
93	O
%	O
felt	O
the	O
urge	Physical
to	Physical
defecate	Physical
after	O
administration	O
of	O
the	O
suppositories	O
as	O
compared	O
to	O
37	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0.001	O
)	O
.	O

Subsequently	O
90	O
%	O
in	O
the	O
study	O
group	O
defecated	Physical
,	O
compared	O
to	O
33	O
%	O
in	O
the	O
control	O
group	O
(	O
P	O
=	O
0.001	O
)	O
.	O

CONCLUSION	O
The	O
marine	O
lipid	O
suppositories	O
and	O
ointment	O
were	O
well	O
tolerated	O
with	O
no	O
significant	O
toxic	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
observed	O
during	O
the	O
study	O
period	O
.	O

The	O
suppositories	O
have	O
a	O
distinct	O
laxative	Physical
effect	Physical
and	O
we	O
aim	O
to	O
explore	O
this	O
effect	O
in	O
further	O
clinical	O
trials	O
.	O

The	O
effects	O
of	O
ezetimibe/simvastatin	O
versus	O
simvastatin	O
monotherapy	O
on	O
platelet	Physical
and	O
inflammatory	Physical
biomarkers	Physical
in	O
patients	O
with	O
metabolic	O
syndrome	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
study	O
of	O
15	O
aspirin-naive	O
patients	O
(	O
mean	O
age	O
48.8	O
?	O
10.2	O
years	O
)	O
with	O
the	O
metabolic	O
syndrome	O
,	O
statin	O
monotherapy	O
(	O
simvastatin	O
40	O
mg	O
daily	O
)	O
was	O
compared	O
to	O
combination	O
therapy	O
(	O
simvastatin	O
40	O
mg	O
and	O
ezetimibe	O
10	O
mg	O
daily	O
)	O
on	O
biomarkers	O
of	O
inflammation	O
and	O
platelet	O
activity	O
.	O

The	O
addition	O
of	O
ezetimibe	O
to	O
simvastatin	O
over	O
a	O
4-week	O
period	O
was	O
associated	O
with	O
reduced	O
expression	O
of	O
CD141	O
(	O
thrombomodulin	O
;	O
p	O
=	O
0.02	O
)	O
,	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
(	O
p	O
<	O
0.0001	O
)	O
and	O
CD51/61	O
(	O
vitronectin	O
receptor	O
;	O
p	O
=	O
0.048	O
)	O
compared	O
to	O
statin	O
monotherapy	O
.	O

Ezetimibe	O
added	O
to	O
simvastatin	O
improves	O
several	O
indices	O
of	O
platelet	O
reactivity	O
beyond	O
statin	O
monotherapy	O
.	O

However	O
,	O
the	O
clinical	O
relevance	O
of	O
these	O
findings	O
await	O
results	O
of	O
the	O
IMPROVE-IT	O
trial	O
(	O
Improved	O
Reduction	O
of	O
Outcomes	O
:	O
Vytorin	O
Efficacy	O
International	O
Trial	O
)	O
.	O

Endoscopic	O
sphincterotomy	O
by	O
using	O
pure-cut	O
electrosurgical	O
current	O
and	O
the	O
risk	O
of	O
post-ERCP	O
pancreatitis	O
:	O
a	O
prospective	O
randomized	O
trial	O
.	O

BACKGROUND	O
It	O
has	O
been	O
suggested	O
that	O
the	O
use	O
of	O
pure-cut	O
electrosurgical	O
current	O
for	O
endoscopic	O
sphincterotomy	O
may	O
reduce	O
the	O
risk	O
of	O
post-ERCP	O
pancreatitis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
pure-cut	O
current	O
reduces	O
the	O
risk	O
of	O
pancreatitis	Physical
compared	O
with	O
blend	O
current	O
.	O

METHODS	O
Patients	O
were	O
randomly	O
assigned	O
to	O
undergo	O
sphincterotomy	O
over	O
a	O
non-conductive	O
guidewire	O
with	O
30	O
W/sec	O
pure-cut	O
current	O
or	O
30	O
W/sec	O
blend-2	O
current	O
by	O
a	O
blinded	O
endoscopist	O
.	O

Serum	O
amylase	O
and	O
lipase	O
levels	O
were	O
determined	O
1	O
day	O
before	O
and	O
within	O
24	O
hours	O
after	O
ERCP	O
.	O

Post-ERCP	Physical
pancreatitis	Physical
was	O
the	O
primary	O
outcome	O
of	O
interest	O
.	O

Secondary	O
outcomes	O
were	O
as	O
follows	O
:	O
severity	Adverseeffect
of	Adverseeffect
immediate	Adverseeffect
bleeding	Adverseeffect
,	Adverseeffect
as	O
graded	O
by	O
a	O
3-point	O
scale	O
from	O
1	O
(	O
no	O
bleeding	O
)	O
to	O
3	O
(	O
injection	O
or	O
balloon	Others
tamponade	O
therapy	O
required	O
to	O
stop	O
bleeding	O
)	O
and	O
evidence	Adverseeffect
of	Adverseeffect
delayed	Adverseeffect
bleeding	Adverseeffect
24	O
hours	O
after	O
ERCP	O
.	O

Analyses	O
were	O
performed	O
in	O
intention-to-treat	O
fashion	O
.	O

RESULTS	O
A	O
total	O
of	O
246	O
patients	O
were	O
randomized	O
(	O
116	O
pure-cut	O
current	O
,	O
130	O
blend	O
current	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
baseline	O
characteristics	O
between	O
the	O
groups	O
.	O

The	O
overall	O
frequency	O
of	O
post-ERCP	Physical
pancreatitis	Physical
was	O
6.9	O
%	O
,	O
with	O
no	O
significant	O
difference	O
in	O
frequency	O
between	O
treatment	O
arms	O
(	O
pure	O
cut	O
,	O
7.8	O
%	O
vs.	O
blend	O
,	O
6.1	O
%	O
;	O
p	O
=	O
0.62	O
)	O
.	O

The	O
difference	O
in	O
rates	O
of	O
pancreatitis	Physical
between	O
the	O
two	O
groups	O
was	O
1.7	O
%	O
:	O
95	O
%	O
CI	O
[	O
-4.8	O
%	O
,	O
8.2	O
%	O
]	O
.	O

Six	O
patients	O
(	O
2.4	O
%	O
)	O
had	O
delayed	Physical
bleeding	Physical
after	O
ERCP	O
,	O
of	O
which	O
two	O
required	O
transfusion	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
minor	Adverseeffect
bleeding	Adverseeffect
episodes	Adverseeffect
(	O
grade	O
2	O
)	O
in	O
the	O
pure-cut	O
group	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Delayed	Adverseeffect
episodes	Adverseeffect
of	Adverseeffect
bleeding	Adverseeffect
were	O
equal	O
(	O
n	O
=	O
3	O
)	O
in	O
each	O
arm	O
.	O

CONCLUSIONS	O
The	O
type	O
of	O
current	O
used	O
when	O
performing	O
endoscopic	O
sphincterotomy	O
does	O
not	O
appear	O
to	O
alter	O
the	O
risk	O
of	O
post-ERCP	O
pancreatitis	O
.	O

The	O
selection	O
of	O
electrosurgical	O
current	O
for	O
biliary	O
endoscopic	O
sphincterotomy	O
should	O
be	O
based	O
on	O
endoscopist	O
preference	O
.	O

A	O
controlled	O
trial	O
of	O
intravenous	O
immune	O
globulin	O
to	O
reduce	O
nosocomial	Physical
infections	Physical
in	O
very-low-birth-weight	O
infants	O
.	O

National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
Neonatal	O
Research	O
Network	O
.	O

BACKGROUND	O
Nosocomial	Physical
infections	Physical
are	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
premature	O
infants	O
.	O

As	O
a	O
rule	O
,	O
their	O
low	O
serum	O
gamma	O
globulin	O
levels	O
at	O
birth	O
subsequently	O
decline	O
to	O
hypogammaglobulinemic	O
values	O
;	O
hence	O
,	O
prophylactic	O
administration	O
of	O
intravenous	O
immune	O
globulin	O
may	O
reduce	O
the	O
rate	O
of	O
hospital-acquired	O
infections	O
.	O

METHODS	O
In	O
this	O
prospective	O
,	O
multicenter	O
,	O
two-phase	O
controlled	O
trial	O
,	O
2416	O
infants	O
were	O
stratified	O
according	O
to	O
birth	O
weight	O
(	O
501	O
to	O
1000	O
g	O
and	O
1001	O
to	O
1500	O
g	O
)	O
and	O
randomly	O
assigned	O
to	O
an	O
intravenous	O
immune	O
globulin	O
group	O
(	O
n	O
=	O
1204	O
)	O
or	O
a	O
control	O
group	O
(	O
n	O
=	O
1212	O
)	O
.	O

Control	O
infants	O
were	O
given	O
placebo	O
infusions	O
during	O
phase	O
1	O
of	O
the	O
study	O
(	O
n	O
=	O
623	O
)	O
but	O
were	O
not	O
given	O
any	O
infusions	O
during	O
phase	O
2	O
(	O
n	O
=	O
589	O
)	O
.	O

Infants	O
weighing	O
501	O
to	O
1000	O
g	O
at	O
birth	O
were	O
given	O
900	O
mg	O
of	O
immune	O
globulin	O
per	O
kilogram	O
of	O
body	O
weight	O
,	O
and	O
infants	O
weighing	O
1001	O
to	O
1500	O
g	O
at	O
birth	O
were	O
given	O
a	O
dose	O
of	O
700	O
mg	O
per	O
kilogram	O
.	O

The	O
immune	O
globulin	O
infusions	O
were	O
repeated	O
every	O
14	O
days	O
until	O
the	O
infants	O
weighed	O
1800	O
g	O
,	O
were	O
transferred	O
to	O
another	O
center	O
,	O
died	O
,	O
or	O
were	O
sent	O
home	O
from	O
the	O
hospital	O
.	O

RESULTS	O
Nosocomial	Physical
infections	Physical
of	Physical
the	Physical
blood	Physical
,	Physical
meninges	Physical
,	Physical
or	Physical
urinary	Physical
tract	Physical
occurred	O
in	O
439	O
of	O
the	O
2416	O
infants	O
(	O
18.2	O
percent	O
)	O
:	O
208	O
(	O
17.3	O
percent	O
)	O
in	O
the	O
immune	O
globulin	O
group	O
and	O
231	O
(	O
19.1	O
percent	O
)	O
in	O
the	O
control	O
group	O
(	O
relative	O
risk	O
,	O
0.91	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
0.77	O
to	O
1.08	O
)	O
.	O

Septicemia	Physical
occurred	O
in	O
15.5	O
percent	O
of	O
the	O
immune	O
globulin	O
recipients	O
and	O
17.2	O
percent	O
of	O
the	O
controls	O
.	O

During	O
phase	O
1	O
the	O
rate	O
of	O
nosocomial	Physical
infections	Physical
was	O
13.4	O
percent	O
in	O
the	O
immune	O
globulin	O
group	O
and	O
17.8	O
percent	O
in	O
the	O
control	O
group	O
;	O
the	O
respective	O
rates	O
during	O
phase	O
2	O
were	O
21.0	O
percent	O
and	O
20.4	O
percent	O
.	O

The	O
predominant	O
organisms	O
included	O
gram-positive	O
cocci	O
(	O
53.0	O
percent	O
)	O
,	O
gram-negative	O
bacilli	O
(	O
22.4	O
percent	O
)	O
,	O
and	O
candida	O
species	O
(	O
16.0	O
percent	O
)	O
.	O

Adverse	Adverseeffect
reactions	Adverseeffect
were	O
rarely	O
observed	O
during	O
the	O
infusions	O
.	O

Immune	O
globulin	O
therapy	O
had	O
no	O
effect	O
on	O
respiratory	Physical
distress	Physical
syndrome	Physical
,	Physical
bronchopulmonary	Physical
dysplasia	Physical
,	Physical
intracranial	Physical
hemorrhage	Physical
,	O
the	Others
duration	Others
of	Others
hospitalization	Others
,	O
or	O
mortality	Mortality
.	O

The	O
incidence	O
of	O
necrotizing	Physical
enterocolitis	Physical
was	O
12.0	O
percent	O
in	O
the	O
immune	O
globulin	O
group	O
and	O
9.5	O
percent	O
in	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
Prophylactic	O
use	O
of	O
intravenous	O
immune	O
globulin	O
failed	O
to	O
reduce	O
the	O
incidence	O
of	O
hospital-acquired	Physical
infections	Physical
in	O
very-low-birth-weight	O
infants	O
.	O

Prospective	O
,	O
blinded	O
exploratory	O
evaluation	O
of	O
the	O
PlayWisely	O
program	O
in	O
children	O
with	O
autism	O
spectrum	O
disorder	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
explore	O
a	O
low-cost	O
intervention	O
that	O
targets	O
an	O
increasingly	O
common	O
developmental	O
disorder	O
.	O

The	O
study	O
was	O
a	O
blinded	O
,	O
exploratory	O
evaluation	O
of	O
the	O
PlayWisely	O
program	O
on	O
autism	Mental
symptoms	Mental
and	Mental
essential	Mental
learning	Mental
foundation	Mental
skills	Mental
(	Mental
attention	Mental
,	Mental
recognition	Mental
,	Mental
and	Mental
memory	Mental
skills	Mental
)	Mental
in	O
children	O
with	O
a	O
diagnosis	O
of	O
autism	O
,	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
pervasive	O
developmental	O
disorder	O
-	O
not	O
otherwise	O
specified	O
(	O
PDD-NOS	O
)	O
,	O
and	O
Asperger	O
syndrome	O
(	O
AS	O
)	O
.	O

Eighteen	O
children	O
,	O
1	O
to	O
10	O
years	O
of	O
age	O
,	O
were	O
evaluated	O
using	O
the	O
Childhood	O
Autism	O
Rating	O
Scale	O
,	O
Second	O
Edition	O
(	O
CARS2	O
)	O
;	O
the	O
PlayWisely	O
Interactive	O
Test	O
of	O
Attention	O
,	O
Recognition	O
,	O
and	O
Memory	O
Skills	O
;	O
Autism	O
Treatment	O
Evaluation	O
Checklist	O
(	O
ATEC	O
)	O
,	O
and	O
the	O
Modified	O
Checklist	O
for	O
Autism	O
in	O
Toddlers	O
(	O
M-CHAT	O
)	O
.	O

There	O
were	O
significant	O
treatment	O
effects	O
for	O
the	O
PlayWisely	O
measure	O
on	O
the	O
Yellow	O
Sets	O
that	O
examine	O
recognition	Mental
;	O
Purple	O
Sets	O
that	O
examine	O
brain	Mental
region	Mental
agility	Mental
and	O
early	Mental
memory	Mental
skills	Mental
;	O
Blue	O
Sets	O
that	O
examine	O
phonemic	Mental
awareness	Mental
and	Mental
recognition	Mental
;	O
and	O
for	O
the	O
Total	O
Sets	O
,	O
with	O
a	O
similar	O
trend	O
toward	O
improvement	O
in	O
the	O
Green	O
Sets	O
that	O
examine	O
perception	O
and	O
Red	O
Sets	O
that	O
examine	O
attention	Mental
.	O

No	O
other	O
measures	O
reached	O
statistical	O
significance	O
.	O

The	O
results	O
suggest	O
that	O
PlayWisely	O
can	O
improve	O
recognition	Mental
,	O
brain	Mental
region	Mental
agility	Mental
,	O
phonemic	Mental
awareness	Mental
,	O
letter	Mental
recognition	Mental
,	O
and	O
early	Mental
memory	Mental
skills	Mental
in	O
ASD	O
.	O

It	O
was	O
observed	O
by	O
the	O
parents	O
,	O
coaches	O
,	O
and	O
study	O
investigators	O
that	O
the	O
children	O
who	O
were	O
less	O
than	O
3	O
years	O
of	O
age	O
showed	O
improvements	O
in	O
autism	Mental
symptoms	Mental
;	O
however	O
,	O
the	O
group	O
was	O
too	O
small	O
to	O
reach	O
statistical	O
significance	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
see	O
if	O
this	O
intervention	O
can	O
mitigate	O
autism	Mental
symptoms	Mental
in	O
very	O
young	O
children	O
with	O
ASD	O
.	O

Osteopontin	O
is	O
a	O
prognostic	O
factor	O
for	O
survival	Mortality
of	O
acute	O
myeloid	O
leukemia	O
patients	O
.	O

Osteopontin	Physical
(	Physical
OPN	Physical
)	Physical
is	O
a	O
glycoprotein	O
that	O
is	O
secreted	O
by	O
osteoblasts	O
and	O
hematopoietic	O
cells	O
.	O

OPN	O
suppresses	O
the	O
proliferation	O
of	O
hematopoietic	O
stem	O
cells	O
in	O
vitro	O
and	O
may	O
regulate	O
the	O
hematopoietic	O
stem	O
cell	O
pool	O
.	O

Increased	O
serum	O
OPN	O
concentrations	O
occur	O
in	O
chronic	O
myeloid	O
leukemia	O
,	O
multiple	O
myeloma	O
,	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
prognostic	O
impact	O
of	O
OPN	O
in	O
AML	O
by	O
investigating	O
the	O
expression	Physical
and	Physical
relevance	Physical
of	Physical
OPN	Physical
in	O
newly	O
diagnosed	O
AML	O
patients	O
from	O
2	O
large	O
study	O
groups	O
(	O
the	O
German	O
AML	O
Cooperative	O
Group	O
and	O
the	O
Dutch-Belgian	O
Hematology	O
Oncology	O
Cooperative	O
group	O
)	O
.	O

IHC	Physical
(	O
n	O
=	O
84	O
)	O
,	O
ELISAs	O
of	O
blood/BM	O
sera	O
(	O
n	O
=	O
41	O
)	O
,	O
and	O
microarray	O
data	O
for	O
mRNA	O
levels	O
(	O
n	O
=	O
261	O
)	O
were	O
performed	O
.	O

Expression	Physical
of	Physical
OPN	Physical
protein	Physical
was	O
increased	O
in	O
AML	O
patients	O
both	O
in	O
BM	O
blasts	O
(	O
IHC	O
)	O
and	O
in	O
BM	O
serum	O
(	O
ELISA	O
)	O
compared	O
with	O
healthy	O
controls	O
.	O

Patients	O
expressing	O
high	O
levels	Physical
of	Physical
OPN	Physical
within	Physical
the	Physical
BM	Physical
(	O
IHC	O
)	O
experienced	O
shortened	O
overall	Mortality
survival	Mortality
(	O
OS	O
;	O
P	O
=	O
.025	O
)	O
.	O

Multivariate	O
analysis	O
identified	O
karyotype	Others
,	O
blast	Others
clearance	Others
(	O
day	O
16	O
)	O
,	O
and	O
the	O
level	Physical
of	Physical
OPN	Physical
expression	Physical
as	O
independent	O
prognostic	O
factors	O
for	O
OS	Mortality
.	O

This	O
prompted	O
us	O
to	O
analyze	O
microarray	O
data	O
from	O
261	O
patients	O
from	O
a	O
third	O
cohort	O
.	O

The	O
analysis	O
confirmed	O
OPN	O
as	O
a	O
prognostic	O
marker	O
.	O

In	O
summary	O
,	O
high	O
OPN	Physical
mRNA	Physical
expression	Physical
indicated	O
decreased	O
event-free	Mortality
survival	Mortality
(	O
P	O
=	O
.0002	O
)	O
and	O
OS	O
(	O
P	O
=	O
.001	O
)	O
.	O

The	O
prognostic	O
role	O
of	O
OPN	O
was	O
most	O
prominent	O
in	O
intermediate-risk	O
AML	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
OPN	Physical
expression	Physical
is	O
an	O
independent	O
prognostic	O
factor	O
in	O
AML	O
.	O

Is	O
hands-on	O
experience	O
more	O
effective	O
than	O
didactic	O
workshops	O
in	O
postgraduate	O
cancer	O
pain	O
education	O
?	O
BACKGROUND	O
This	O
study	O
examined	O
the	O
nurse	Others
outcomes	Others
of	O
a	O
cancer	O
pain	O
education	O
program	O
for	O
nurses	O
of	O
patients	O
from	O
11	O
different	O
ethnic	O
groups	O
.	O

METHODS	O
Four	O
hundred	O
ninety	O
six	O
home	O
,	O
hospital	O
,	O
and	O
hospice	O
nurses	O
participated	O
in	O
a	O
one-day	O
workshop	O
or	O
two	O
half-day	O
workshops	O
on	O
cancer	O
pain	O
assessment	O
and	O
management	O
.	O

Of	O
these	O
,	O
116	O
were	O
randomized	O
to	O
participate	O
in	O
a	O
bedside-precepted	O
visit	O
with	O
an	O
oncology	O
nurse	O
specialist	O
with	O
pain	O
specialization	O
and	O
a	O
focus	O
group	O
to	O
discuss	O
attitudinal	O
issues	O
.	O

Eighty-six	O
nurses	O
served	O
as	O
controls	O
.	O

Pre-	O
,	O
post-	O
and	O
one-year	O
follow-up	O
tests	O
were	O
administered	O
.	O

RESULTS	O
Attitudes	Others
,	Others
knowledge	Others
,	Others
and	Others
application	Others
skills	Others
significantly	O
improved	O
for	O
workshop-only	O
and	O
enriched-model	O
nurses	O
relative	O
to	O
controls	O
.	O

CONCLUSION	O
For	O
postgraduate	O
nurses	O
,	O
daylong	O
cancer	O
pain	O
education	O
workshops	O
were	O
,	O
in	O
the	O
group	O
studied	O
,	O
as	O
effective	O
as	O
hands-on	O
experience	O
in	O
improving	O
cancer	Others
pain	Others
knowledge	Others
and	Others
changing	Others
attitudes	Others
.	O

Both	O
the	O
workshop-only	O
and	O
the	O
enriched-model	O
nurses	O
relative	O
to	O
controls	O
had	O
significantly	O
improved	O
knowledge	O
and	O
changed	O
attitudes	O
towards	O
optimal	O
pain	O
management	O
.	O

Effect	O
of	O
delayed	O
cord	O
clamping	O
on	O
iron	Physical
stores	Physical
in	O
infants	O
born	O
to	O
anemic	O
mothers	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
effects	O
of	O
cord	O
clamping	O
on	O
iron	O
stores	O
of	O
infants	O
born	O
to	O
anemic	O
mothers	O
at	O
3	O
months	O
of	O
age	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Teaching	O
hospital	O
.	O

METHODS	O
Infants	O
born	O
to	O
mothers	O
with	O
hemoglobin	O
(	O
Hb	O
)	O
<	O
100	O
g/L	O
were	O
randomized	O
at	O
delivery	O
to	O
either	O
immediate	O
cord	O
clamping	O
(	O
early	O
group	O
)	O
or	O
cord	O
clamping	O
delayed	O
till	O
descent	O
of	O
placenta	O
into	O
vagina	O
(	O
delayed	O
group	O
)	O
.	O

The	O
outcome	O
measures	O
were	O
infant	Physical
's	Physical
hemoglobin	Physical
and	Physical
serum	Physical
ferritin	Physical
3	Physical
months	Physical
after	Physical
delivery	Physical
.	O

RESULTS	O
There	O
were	O
102	O
neonates	O
randomized	O
to	O
early	O
(	O
n	O
=	O
43	O
)	O
or	O
delayed	O
cord	O
clamping	O
(	O
n	O
=	O
59	O
)	O
.	O

The	O
groups	O
were	O
comparable	O
for	O
maternal	O
age	O
,	O
parity	O
,	O
weight	O
and	O
supplemental	O
iron	O
intake	O
,	O
infant	O
s	O
birth	O
weight	O
,	O
gestation	O
and	O
sex	O
.	O

The	O
mean	Physical
infant	Physical
ferritin	Physical
and	Physical
Hb	Physical
at	Physical
3	Physical
months	Physical
were	O
significantly	O
higher	O
in	O
the	O
delayed	O
clamping	O
group	O
(	O
118.4	O
microg/L	O
and	O
99	O
g/L	O
)	O
than	O
in	O
the	O
early	O
clamping	O
group	O
(	O
73	O
microg/L	O
and	O
88	O
g/L	O
)	O
.	O

The	O
mean	O
decrease	O
in	O
Hb	Physical
(	O
g/L	O
)	O
at	O
3	O
months	O
adjusted	O
for	O
co-variates	O
was	O
significantly	O
less	O
in	O
the	O
delayed	O
clamping	O
group	O
compared	O
to	O
the	O
early	O
clamping	O
group	O
(	O
-1.09	O
,	O
95	O
%	O
CI-1.58	O
to	O
-0.62	O
,	O
p	O
>	O
0.001	O
)	O
.	O

The	O
odds	O
for	O
anemia	Physical
(	O
<	O
100	O
g/L	O
)	O
at	O
3	O
months	O
was	O
7.7	O
(	O
95	O
%	O
CI	O
1.84-34.9	O
)	O
times	O
higher	O
in	O
the	O
early	O
compared	O
to	O
the	O
delayed	O
clamping	O
group	O
.	O

CONCLUSION	O
Iron	Physical
stores	Physical
and	O
Hb	Physical
in	O
infancy	O
can	O
be	O
improved	O
in	O
neonates	O
born	O
to	O
anemic	O
mothers	O
by	O
delaying	O
cord	O
clamping	O
at	O
birth	O
.	O

The	O
effects	O
of	O
delay	O
in	O
standard	O
treatment	O
due	O
to	O
induction	O
chemotherapy	O
in	O
two	O
randomized	O
prospective	O
studies	O
.	O

It	O
is	O
often	O
suggested	O
that	O
tumors	O
will	O
respond	O
to	O
induction	O
chemotherapy	O
and	O
result	O
in	O
improved	O
survival	Mortality
for	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

Two	O
regimens	O
of	O
induction	O
chemotherapy	O
were	O
studied	O
in	O
separate	O
randomized	O
,	O
prospective	O
trials	O
over	O
the	O
last	O
6	O
years	O
.	O

Eighty-three	O
patients	O
with	O
advanced	O
disease	O
were	O
entered	O
into	O
the	O
first	O
study	O
(	O
43/chemotherapy	O
;	O
40/control	O
)	O
,	O
and	O
60	O
into	O
the	O
second	O
(	O
27/chemotherapy	O
;	O
33/control	O
)	O
.	O

Patient	O
randomization	O
was	O
stratified	O
by	O
stage	O
(	O
III/IV	O
)	O
and	O
site	O
(	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
nasopharynx	O
,	O
hypopharynx	O
,	O
larynx	O
,	O
paranasal	O
sinuses	O
)	O
.	O

The	O
first	O
study	O
utilized	O
bleomycin	O
,	O
Cytoxan	O
,	O
methotrexate	O
and	O
5-fluorouracil	O
in	O
two	O
cycles	O
(	O
one	O
cycle	O
if	O
no	O
tumor	O
response	O
)	O
,	O
followed	O
by	O
standard	O
treatment	O
which	O
consisted	O
of	O
combined	O
irradiation	O
and	O
surgery	O
or	O
,	O
in	O
some	O
instances	O
,	O
primary	O
irradiation	O
alone	O
.	O

The	O
second	O
study	O
utilized	O
cisplatin	O
and	O
5-fluorouracil	O
in	O
three	O
cycles	O
prior	O
to	O
standard	O
treatment	O
.	O

An	O
objective	Others
tumor	Others
response	Others
to	O
chemotherapy	O
was	O
observed	O
in	O
68	O
%	O
in	O
the	O
first	O
study	O
and	O
85	O
%	O
in	O
the	O
second	O
.	O

The	O
patient	Mortality
survival	Mortality
in	O
both	O
studies	O
(	O
at	O
24	O
months	O
in	O
the	O
first	O
;	O
at	O
19	O
in	O
the	O
second	O
)	O
was	O
better	O
in	O
the	O
control	O
than	O
that	O
in	O
the	O
experimental	O
groups	O
(	O
43	O
%	O
to	O
31	O
%	O
;	O
69	O
%	O
to	O
46	O
%	O
)	O
.	O

In	O
the	O
second	O
study	O
,	O
the	O
average	Others
length	Others
of	Others
delay	Others
of	Others
standard	Others
treatment	Others
was	O
longer	O
than	O
in	O
the	O
first	O
study	O
(	O
95	O
days	O
vs.	O
66	O
days	O
;	O
P	O
less	O
than	O
.02	O
)	O
.	O

Results	O
combining	O
the	O
P-values	O
of	O
both	O
studies	O
indicate	O
that	O
the	O
relative	O
risk	O
of	O
having	O
persistent	O
disease	O
was	O
2.9	O
times	O
greater	O
for	O
patients	O
who	O
received	O
chemotherapy	O
.	O

While	O
toxicity	Physical
to	Physical
chemotherapy	Physical
was	O
not	O
a	O
factor	O
in	O
survival	O
,	O
the	O
number	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
studies	O
and	O
those	O
who	O
did	O
not	O
comply	O
with	O
treatment	O
were	O
greater	O
in	O
the	O
chemotherapy	O
groups	O
.	O

Except	O
for	O
new	O
drug	O
regimens	O
of	O
exceptional	O
promise	O
,	O
it	O
is	O
recommended	O
that	O
future	O
studies	O
be	O
designed	O
so	O
that	O
chemotherapy	O
is	O
given	O
concurrent	O
with	O
,	O
or	O
following	O
the	O
completion	O
of	O
standard	O
treatment	O
.	O

Effect	O
of	O
resistance	O
exercise	O
contraction	O
mode	O
and	O
protein	O
supplementation	O
on	O
members	O
of	O
the	O
STARS	O
signalling	O
pathway	O
.	O

The	O
striated	O
muscle	O
activator	O
of	O
Rho	O
signalling	O
(	O
STARS	O
)	O
pathway	O
is	O
suggested	O
to	O
provide	O
a	O
link	O
between	O
external	O
stress	O
responses	O
and	O
transcriptional	O
regulation	O
in	O
muscle	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
STARS	O
signalling	O
to	O
different	O
mechanical	O
stresses	O
has	O
not	O
been	O
investigated	O
.	O

In	O
a	O
comparative	O
study	O
,	O
we	O
examined	O
the	O
regulation	O
of	O
the	O
STARS	O
signalling	O
pathway	O
in	O
response	O
to	O
unilateral	O
resistance	O
exercise	O
performed	O
as	O
either	O
eccentric	O
(	O
ECC	O
)	O
or	O
concentric	O
(	O
CONC	O
)	O
contractions	O
as	O
well	O
as	O
prolonged	O
training	O
;	O
with	O
and	O
without	O
whey	O
protein	O
supplementation	O
.	O

Skeletal	O
muscle	O
STARS	O
,	O
myocardian-related	O
transcription	O
factor-A	O
(	O
MRTF-A	O
)	O
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
mRNA	O
and	O
protein	O
,	O
as	O
well	O
as	O
muscle	O
cross-sectional	O
area	O
and	O
maximal	O
voluntary	O
contraction	O
,	O
were	O
measured	O
.	O

A	O
single-bout	O
of	O
exercise	O
produced	O
increases	O
in	O
STARS	Physical
and	Physical
SRF	Physical
mRNA	Physical
and	Physical
decreases	Physical
in	Physical
MRTF-A	Physical
mRNA	Physical
with	Physical
both	Physical
ECC	Physical
and	Physical
CONC	Physical
exercise	Physical
,	O
but	O
with	O
an	O
enhanced	O
response	O
occurring	O
following	O
ECC	O
exercise	O
.	O

A	O
31	O
%	O
increase	O
in	O
STARS	Physical
protein	Physical
was	O
observed	O
exclusively	O
after	O
CONC	O
exercise	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
pSRF	Physical
protein	O
levels	O
increased	O
similarly	O
by	O
48	O
%	O
with	O
both	O
CONC	O
and	O
ECC	O
exercise	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Prolonged	O
ECC	O
and	O
CONC	O
training	O
equally	O
stimulated	O
muscle	O
hypertrophy	O
and	O
produced	O
increases	O
in	O
MRTF-A	Physical
protein	Physical
of	O
125	O
%	O
and	O
99	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
changes	O
occurred	O
for	O
total	Physical
SRF	Physical
protein	Physical
.	O

There	O
was	O
no	O
effect	O
of	O
whey	Physical
protein	Physical
supplementation	Physical
.	Physical

These	O
results	O
show	O
that	O
resistance	O
exercise	O
provides	O
an	O
acute	Physical
stimulation	Physical
of	Physical
the	Physical
STARS	Physical
pathway	Physical
that	O
is	O
contraction	O
mode	O
dependent	O
.	O

The	O
responses	O
to	O
acute	O
exercise	O
were	O
more	O
pronounced	O
than	O
responses	O
to	O
accumulated	O
training	O
,	O
suggesting	O
that	O
STARS	O
signalling	O
is	O
primarily	O
involved	O
in	O
the	O
initial	O
phase	O
of	O
exercise-induced	O
muscle	O
adaptations	O
.	O

Partial-area	O
method	O
in	O
bioequivalence	O
assessment	O
:	O
naproxen	O
.	O

Regulatory	O
authorities	O
require	O
demonstration	O
of	O
bioequivalence	O
through	O
comparisons	O
of	O
different	O
pharmacokinetic	O
parameters	O
,	O
the	O
area	Physical
under	Physical
the	Physical
plasma	Physical
concentration-time	Physical
curve	Physical
(	Physical
AUC	Physical
)	Physical
,	Physical
the	Physical
maximum	Physical
plasma	Physical
concentration	Physical
(	Physical
Cmax	Physical
)	Physical
,	O
and	O
the	Physical
time	Physical
to	Physical
reach	Physical
peak	Physical
concentration	Physical
(	Others
Tmax	Others
)	Others
.	O

The	O
applicability	O
and	O
validity	O
of	O
regulatory	O
requirements	O
have	O
been	O
widely	O
criticized	O
on	O
statistical	O
and	O
clinical	O
relevance	O
grounds	O
.	O

For	O
most	O
noncomplicated	O
absorption	O
models	O
,	O
the	O
AUC	Others
correlates	O
well	O
with	O
the	O
extent	O
of	O
absorption	O
.	O

However	O
,	O
in	O
nonlinear	O
models	O
of	O
absorption	O
,	O
in	O
mechanisms	O
involving	O
recycling	O
of	O
drugs	O
,	O
and	O
for	O
drugs	O
with	O
long	O
half-life	O
,	O
the	O
use	O
of	O
total	O
AUC	Others
(	O
from	O
zero	O
to	O
infinity	O
)	O
can	O
give	O
erroneous	O
and	O
clinically	O
irrelevant	O
results	O
since	O
the	O
area	O
is	O
mostly	O
determined	O
by	O
elimination	O
phase	O
or	O
by	O
recycling	O
.	O

The	O
calculation	O
of	O
total	O
AUC	Others
also	O
involves	O
prolonged	O
sampling	O
,	O
adding	O
to	O
the	O
cost	O
and	O
risks	O
associated	O
with	O
bioequivalence	O
studies	O
.	O

The	O
use	O
of	O
Cmax	Others
or	O
Tmax	Others
as	O
a	O
measure	O
of	O
rate	O
of	O
absorption	O
,	O
to	O
correlate	O
with	O
clinical	O
relevance	O
,	O
is	O
widely	O
criticized	O
on	O
logical	O
,	O
technical	O
,	O
and	O
statistical	O
grounds	O
.	O

For	O
drugs	O
used	O
on	O
a	O
multiple-dose	O
basis	O
,	O
Cmax	Others
and	O
Tmax	Others
evaluations	O
become	O
redundant	O
since	O
the	O
average	O
plateau	Physical
concentration	Physical
is	O
not	O
affected	O
by	O
these	O
parameters	O
.	O

To	O
resolve	O
the	O
drawbacks	O
in	O
the	O
traditional	O
methodology	O
of	O
bioequivalence	O
evaluation	O
,	O
the	O
use	O
of	O
partial	O
areas	O
in	O
lieu	O
of	O
total	O
AUC	Others
,	O
Tmax	Others
,	O
and	O
Cmax	Others
is	O
suggested	O
.	O

This	O
study	O
investigates	O
the	O
logic	O
and	O
robustness	O
of	O
the	O
partial-area	O
method	O
in	O
establishing	O
bioequivalence	O
.	O

We	O
conclude	O
that	O
the	O
5h	Others
AUC	Others
is	O
a	O
more	O
relevant	O
parameter	O
to	O
establish	O
naproxen	O
bioequivalence	O
than	O
AUCinf	Others
.	O

We	O
recommend	O
against	O
using	O
symmetrical	O
confidence	O
intervals	O
and	O
report	O
excellent	O
agreement	O
among	O
several	O
methods	O
of	O
calculating	O
confidence	O
intervals	O
,	O
probability	O
values	O
,	O
and	O
nonparametric	O
tests	O
.	O

We	O
suggest	O
that	O
a	O
single-point	Others
short-term	Others
AUC	Others
is	O
a	O
better	O
indicator	O
of	O
the	O
bioequivalence	O
of	O
generic	O
products	O
than	O
the	O
total	O
AUC	Others
,	O
Cmax	Others
,	O
and	O
Tmax	Others
as	O
required	O
currently	O
by	O
the	O
regulatory	O
authorities	O
.	O

Total	O
anthelmintic	O
failure	O
to	O
control	O
nematode	O
parasites	O
of	O
small	O
ruminants	O
on	O
government	O
breeding	O
farms	O
in	O
Sabah	O
,	O
East	O
Malaysia	O
.	O

Government-owned	O
small-ruminant	O
breeding	O
farms	O
in	O
Malaysia	O
provide	O
the	O
source	O
of	O
sheep	O
and	O
goats	O
to	O
smallholder	O
farmers	O
in	O
the	O
country	O
.	O

In	O
the	O
eastern	O
Malaysian	O
state	O
of	O
Sabah	O
,	O
high-level	O
stock	O
losses	O
have	O
been	O
recorded	O
on	O
these	O
farms	O
for	O
several	O
years	O
,	O
frequently	O
accompanied	O
by	O
clinical	O
signs	O
indicating	O
pathogenic	O
levels	O
of	O
infections	O
with	O
the	O
nematode	O
parasite	O
Haemonchus	O
contortus	O
.	O

This	O
suggests	O
that	O
their	O
dependence	O
on	O
chemotherapy	O
to	O
control	O
parasite	O
infections	O
had	O
failed	O
.	O

Accordingly	O
,	O
tests	O
for	O
anthelmintic	Others
efficacy	Others
using	O
the	O
faecal	Physical
egg	Physical
count	Physical
reduction	Physical
test	Physical
(	Physical
FECRT	Physical
)	Physical
on	O
the	O
range	O
of	O
drugs	O
used	O
to	O
control	O
nematode	O
parasites	O
were	O
carried	O
out	O
on	O
the	O
five	O
government	O
small-ruminant	O
breeding	O
farms	O
in	O
Sabah	O
.	O

These	O
tests	O
showed	O
a	O
total	O
failure	Others
of	Others
the	Others
benzimidazole	Others
,	Others
imidothiazole	Others
,	Others
macrocyclic	Others
lactone	Others
and	Others
salicylanilide	Others
groups	Others
of	Others
anthelmintics	Others
to	O
control	O
H.	O
contortus	O
infections	O
of	O
sheep	O
and	O
goats	O
on	O
all	O
farms	O
.	O

Drastic	O
changes	O
in	O
animal	O
management	O
need	O
to	O
be	O
made	O
in	O
an	O
attempt	O
to	O
deal	O
with	O
this	O
situation	O
,	O
for	O
which	O
suggestions	O
are	O
made	O
.	O

Protective	O
effect	O
of	O
high-dose	O
medroxyprogesterone	O
acetate	O
(	O
HD-MPA	O
)	O
on	O
hematological	Physical
toxicity	Physical
induced	O
by	O
chemotherapy	O
for	O
advanced	O
solid	O
tumors	O
:	O
a	O
multicentric	O
controlled	O
clinical	O
trial	O
.	O

MPA-Hematology	O
Italian	O
Cooperative	O
Group	O
.	O

A	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
conducted	O
comparing	O
active	O
treatment	O
with	O
placebo	O
in	O
227	O
patients	O
with	O
breast	O
,	O
colorectal	O
,	O
lung	O
and	O
other	O
solid	O
forms	O
of	O
cancer	O
.	O

Combination	O
therapy	O
,	O
(	O
CT	O
)	O
conventionally	O
employed	O
for	O
the	O
various	O
types	O
of	O
tumor	O
involved	O
,	O
was	O
associated	O
with	O
MPA	O
(	O
117	O
patients	O
)	O
or	O
placebo	O
(	O
110	O
patients	O
)	O
.	O

MPA	O
was	O
given	O
orally	O
as	O
tablets	O
,	O
as	O
a	O
dose	O
of	O
500	O
mg	O
b.i.d	O
.	O

for	O
6	O
months	O
.	O

The	O
results	O
were	O
,	O
briefly	O
,	O
as	O
follows	O
:	O
The	O
incidence	Physical
of	Physical
leukopenia	Physical
was	O
significantly	O
lower	O
in	O
the	O
groups	O
receiving	O
MPA	O
in	O
patients	O
with	O
breast	O
and	O
colorectal	O
cancer	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Tumors	Physical
of	Physical
the	Physical
lung	Physical
and	Physical
other	Physical
solid	Physical
forms	Physical
showed	O
no	O
such	O
difference	O
.	O

The	O
incidence	Physical
of	Physical
thrombocytopenia	Physical
was	O
the	O
same	O
in	O
all	O
disease	O
groups	O
.	O

Objective	Physical
responses	Physical
(	Physical
CR	Physical
+	Physical
PR	Physical
)	Physical
were	O
observed	O
in	O
23/46	O
(	O
50	O
%	O
)	O
of	O
breast	O
cancer	O
patients	O
treated	O
with	O
CT	O
+	O
MPA	O
,	O
and	O
in	O
13/47	O
(	O
28	O
%	O
)	O
of	O
those	O
given	O
CT	O
+	O
placebo	O
.	O

The	O
difference	O
was	O
significant	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Subjective	Others
parameters	Others
also	O
showed	O
more	O
improvement	O
in	O
the	O
MPA	O
group	O
than	O
in	O
the	O
patients	O
given	O
CT	O
alone	O
.	O

No	O
significant	O
differences	O
were	O
found	O
for	O
the	O
other	O
types	O
of	O
tumor	O
,	O
but	O
the	O
numbers	O
in	O
this	O
population	O
were	O
very	O
limited	O
.	O

In	O
a	O
group	O
of	O
45	O
patients	O
,	O
antithrombin	Physical
III	Physical
a	Physical
(	Physical
%	Physical
)	Physical
,	Physical
antithrombin	Physical
III	Physical
R	Physical
:	Physical
Ag	Physical
(	Physical
%	Physical
)	Physical
,	Physical
plasminogen	Physical
(	Physical
mg/dl	Physical
)	Physical
,	Physical
alpha-2	Physical
macroglobulin	Physical
(	Physical
%	Physical
)	Physical
,	Physical
factor	Physical
VIII	Physical
C	Physical
(	Physical
%	Physical
)	Physical
,	Physical
factor	Physical
VIII	Physical
R	Physical
:	Physical
Ag	Physical
(	Physical
%	Physical
)	Physical
and	Physical
factor	Physical
IX	Physical
C	Physical
(	Physical
%	Physical
)	Physical
were	O
determined	O
.	O

The	O
most	O
interesting	O
post-treatment	O
findings	O
were	O
an	O
increase	O
in	O
anti-thrombin	Physical
III	Physical
(	Physical
activity	Physical
and	Physical
antigen	Physical
level	Physical
)	Physical
and	Physical
in	Physical
plasminogen	Physical
.	O

This	O
suggests	O
that	O
MPA	O
does	O
not	O
increase	O
the	O
risk	O
of	O
thrombosis	O
,	O
and	O
might	O
even	O
,	O
to	O
some	O
extent	O
,	O
impede	O
tumor-induced	O
thrombophilia	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
The	O
use	O
of	O
adrenocorticotrophic	O
hormone	O
(	O
4-9	O
)	O
analog	O
ORG	O
2766	O
in	O
autistic	O
children	O
:	O
effects	O
on	O
the	O
organization	O
of	O
behavior	O
.	O

In	O
a	O
double-blind	O
placebo-controlled	O
crossover	O
trial	O
,	O
14	O
autistic	O
children	O
were	O
treated	O
with	O
the	O
neuropeptide	O
ORG	O
2766	O
,	O
a	O
synthetic	O
analog	O
of	O
adrenocorticotrophic	O
hormone	O
(	O
ACTH	O
)	O
(	O
4-9	O
)	O
.	O

ORG	O
2766	O
treatment	O
(	O
20	O
mg	O
per	O
day	O
during	O
4	O
weeks	O
)	O
was	O
associated	O
with	O
an	O
increased	O
amount	O
and	O
an	O
improved	O
quality	O
of	O
the	O
social	O
interaction	O
of	O
the	O
autistic	O
children	O
with	O
a	O
familiar	O
experimenter	O
.	O

These	O
changes	O
in	O
interaction	O
were	O
clinically	O
relevant	O
.	O

Following	O
treatment	O
with	O
ORG	O
2766	O
gaze	Mental
and	Mental
smile	Mental
behaviors	Mental
of	O
child	O
and	O
experimenter	O
showed	O
stronger	Mental
temporal	Mental
contingencies	Mental
.	Mental

Further	O
,	O
after	O
ORG	O
2766	O
,	O
stereotypies	O
were	O
temporally	O
disconnected	O
from	O
verbal	Mental
initiatives	Mental
.	Mental

The	O
data	O
supported	O
the	O
notion	O
of	O
a	O
stimulating	O
effect	O
of	O
ORG	O
2766	O
on	O
social	O
interaction	O
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
endogenous	O
opioid	O
theory	O
of	O
autism	O
are	O
discussed	O
.	O

Haloperidol	O
blood	O
levels	O
and	O
effects	O
in	O
schizophrenia	Physical
and	O
schizoaffective	Physical
disorder	O
:	O
a	O
progress	O
report	O
.	O

To	O
test	O
the	O
hypothesis	O
of	O
a	O
therapeutic	O
window	O
,	O
we	O
have	O
randomly	O
assigned	O
acutely	O
exacerbating	O
schizophrenic	Physical
or	O
schizoaffective	Physical
patients	O
to	O
one	O
of	O
three	O
plasma	O
levels	O
of	O
haloperidol	O
(	O
HAL	O
)	O
:	O
2-13	O
,	O
13.1-24	O
,	O
or	O
24.1-35	O
ng/ml	O
.	O

Patients	O
who	O
did	O
not	O
improve	O
after	O
6	O
weeks	O
of	O
this	O
treatment	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
haloperidol	O
levels	O
for	O
another	O
6	O
weeks	O
.	O

The	O
improvement	O
was	O
defined	O
as	O
at	O
least	O
50	O
percent	O
reduction	O
of	O
the	O
Brief	Mental
Psychiatric	Mental
Rating	Mental
Scale	Mental
(	Mental
BPRS	Mental
)	Mental
total	Mental
score	Mental
.	O

The	O
results	O
obtained	O
in	O
111	O
patients	O
do	O
not	O
support	O
any	O
consistent	O
relationship	O
between	O
plasma	Physical
level	Physical
of	Physical
haloperidol	Physical
and	O
clinical	Others
improvement	Others
.	Others

Patients	O
in	O
the	O
high	O
haloperidol	O
plasma	O
range	O
tended	O
to	O
have	O
more	O
side	Adverseeffect
effects	Adverseeffect
.	Adverseeffect

These	O
results	O
suggest	O
that	O
the	O
haloperidol	O
doses	O
used	O
in	O
clinical	O
practice	O
may	O
be	O
higher	O
than	O
necessary	O
.	O

Acute	O
effects	O
of	O
different	O
stretching	O
durations	O
on	O
passive	Physical
torque	Physical
,	Physical
mobility	Physical
,	Physical
and	Physical
isometric	Physical
muscle	Physical
force	Physical
.	Physical

Static	O
stretching	O
is	O
widely	O
applied	O
in	O
various	O
disciplines	O
.	O

However	O
,	O
the	O
acute	O
effects	O
of	O
different	O
durations	O
of	O
stretching	O
are	O
unclear	O
.	O

Therefore	O
,	O
this	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
acute	O
effects	O
of	O
different	O
stretching	O
durations	O
on	O
muscle	O
function	O
and	O
flexibility	O
,	O
and	O
provide	O
an	O
insight	O
into	O
the	O
optimal	O
duration	O
of	O
static	O
stretching	O
.	O

This	O
randomized	O
crossover	O
trial	O
included	O
24	O
healthy	O
students	O
(	O
17	O
men	O
and	O
7	O
women	O
)	O
who	O
stretched	O
their	O
right	O
hamstrings	O
for	O
durations	O
of	O
20	O
,	O
60	O
,	O
180	O
,	O
and	O
300	O
seconds	O
in	O
a	O
random	O
order	O
.	O

The	O
following	O
outcomes	O
were	O
assessed	O
using	O
an	O
isokinetic	O
dynamometer	O
as	O
markers	O
of	O
lower-limb	Physical
function	Physical
and	Physical
flexibility	Physical
:	Physical
static	Physical
passive	Physical
torque	Physical
(	Physical
SPT	Physical
)	Physical
,	Physical
dynamic	Physical
passive	Physical
torque	Physical
(	Physical
DPT	Physical
)	Physical
,	Physical
stiffness	Physical
,	Physical
straight	Physical
leg	Physical
raise	Physical
(	Physical
SLR	Physical
)	Physical
,	Physical
and	Physical
isometric	Physical
muscle	Physical
force	Physical
.	Physical

Static	Physical
passive	Physical
torque	Physical
was	O
significantly	O
decreased	O
after	O
all	O
stretching	O
durations	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Static	Physical
passive	Physical
torque	Physical
was	O
significantly	O
lower	O
after	O
60	O
,	O
180	O
,	O
and	O
300	O
seconds	O
of	O
stretching	O
compared	O
with	O
that	O
after	O
20-second	O
stretching	O
,	O
and	O
stiffness	O
decreased	O
significantly	O
after	O
180-	O
and	O
300-second	O
stretching	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
DPT	Physical
and	Physical
stiffness	Physical
were	O
significantly	O
lower	O
after	O
300	O
seconds	O
than	O
after	O
20-second	O
stretching	O
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
SLR	O
increased	O
significantly	O
after	O
all	O
stretching	O
durations	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Straight	Physical
leg	Physical
raise	Physical
was	O
higher	O
after	O
180-	O
and	O
300-second	O
stretching	O
than	O
after	O
20-second	O
stretching	O
and	O
higher	O
after	O
300-second	O
stretching	O
than	O
after	O
60-second	O
stretching	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Isometric	Physical
muscle	Physical
force	Physical
significantly	Physical
decreased	Physical
after	O
all	O
stretching	O
durations	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Therefore	O
,	O
increased	O
duration	O
of	O
stretching	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
SPT	Physical
but	O
an	O
increase	O
in	O
SLR	O
.	O

Over	O
180	O
seconds	O
of	O
stretching	O
was	O
required	O
to	O
decrease	O
DPT	Physical
and	Physical
stiffness	Physical
,	O
but	O
isometric	O
muscle	O
force	O
decreased	O
regardless	O
of	O
the	O
stretching	O
duration	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
indicate	O
that	O
longer	O
durations	O
of	O
stretching	O
are	O
needed	O
to	O
provide	O
better	O
flexibility	O
.	O

Delineation	O
of	O
cryptogenic	O
Lennox-Gastaut	O
syndrome	O
and	O
myoclonic	O
astatic	O
epilepsy	O
using	O
multiple	O
correspondence	O
analysis	O
.	O

PURPOSE	O
To	O
distinguish	O
various	O
types	O
of	O
childhood	O
severe	O
cryptogenic/idiopathic	O
generalised	O
epilepsy	O
on	O
the	O
basis	O
of	O
reproducible	O
diagnostic	O
criteria	O
,	O
using	O
multiple	O
correspondence	O
analysis	O
(	O
MCA	O
)	O
.	O

METHODS	O
We	O
applied	O
MCA	O
to	O
a	O
series	O
of	O
72	O
children	O
with	O
no	O
evidence	O
of	O
brain	O
damage	O
,	O
starting	O
epilepsy	O
between	O
1	O
and	O
10	O
years	O
,	O
with	O
two	O
or	O
more	O
types	O
of	O
generalised	O
seizures	O
.	O

We	O
excluded	O
patients	O
with	O
infantile	O
spasms	O
or	O
typical	O
absences	O
.	O

MCA	O
was	O
performed	O
on	O
all	O
clinical	O
and	O
EEG	O
parameters	O
,	O
first	O
throughout	O
follow-up	O
,	O
then	O
restricted	O
to	O
the	O
first	O
year	O
of	O
the	O
disease	O
.	O

RESULTS	O
When	O
including	O
all	O
follow-up	O
variables	O
,	O
there	O
were	O
three	O
groups	O
:	O
(	O
1	O
)	O
Thirty-seven	O
children	O
with	O
male	O
predominance	O
,	O
familial	O
history	O
of	O
epilepsy	O
,	O
simple	O
febrile	O
convulsions	O
,	O
massive	O
myoclonus	O
,	O
tonic-clonic	O
fits	O
.	O

Outcome	O
was	O
favourable	O
,	O
with	O
no	Physical
seizures	Physical
and	Physical
mildly	Physical
affected	Physical
cognitive	Physical
functions	Physical
.	O

Interictal	O
EEG	O
showed	O
short	Others
sequences	Others
of	Others
irregular	Others
3-Hz	Others
spike-waves	Others
.	O

(	O
2	O
)	O
In	O
18	O
children	O
,	O
clinical	Physical
characteristics	Physical
were	O
similar	O
to	O
those	O
of	O
the	O
first	O
group	O
at	O
the	O
early	O
stage	O
,	O
but	O
95	O
%	O
exhibited	O
myoclonic	Physical
status	Physical
and	O
vibratory	Physical
tonic	Physical
seizures	Physical
,	O
with	O
persisting	O
seizures	O
on	O
follow-up	O
.	O

EEG	O
showed	O
long	Others
sequences	Others
of	Others
generalised	Others
irregular	Others
spike	Others
and	Others
slow	Others
waves	Others
.	O

Those	O
two	O
groups	O
meet	O
the	O
characteristics	O
of	O
childhood	O
onset	O
myoclonic-astatic	O
epilepsy	O
(	O
MAE	O
)	O
with	O
respectively	O
,	O
favourable	O
and	O
unfavourable	O
outcome	O
.	O

(	O
3	O
)	O
Eleven	O
children	O
had	O
later	O
onset	O
,	O
atypical	Physical
absences	Physical
,	O
tonic	Physical
and	Physical
partial	Physical
seizures	Physical
,	O
and	O
no	O
myoclonus	O
,	O
or	O
vibratory	O
tonic	O
seizures	O
.	O

All	O
had	O
mental	Mental
retardation	Mental
and	Mental
persisting	Mental
seizures	Mental
.	O

EEG	O
showed	O
long	Others
sequences	Others
of	Others
slow	Others
spike-wave	Others
activity	Others
and	Others
half	Others
the	Others
patients	Others
had	Others
spike	Others
and	Others
slow	Others
wave	Others
foci	Others
.	O

These	O
patients	O
met	O
the	O
major	O
characteristics	O
of	O
Lennox-Gastaut	O
syndrome	O
.	O

Initial	O
parameters	O
failed	O
to	O
distinguish	O
the	O
first	O
two	O
groups	O
,	O
but	O
Lennox-Gastaut	O
syndrome	O
(	O
the	O
third	O
group	O
)	O
was	O
distinct	O
from	O
both	O
groups	O
of	O
myoclonic	O
astatic	O
epilepsy	O
from	O
the	O
onset	O
.	O

Within	O
MAE	O
groups	O
combined	O
,	O
clinical	O
and	O
EEG	O
risk	O
factors	O
for	O
mental	O
retardation	O
could	O
be	O
identified	O
.	O

CONCLUSION	O
It	O
is	O
possible	O
to	O
validate	O
statistically	O
the	O
distinction	O
between	O
discrete	O
epileptic	O
syndromes	O
.	O

Myoclonic	O
astatic	O
epilepsy	O
is	O
therefore	O
distinct	O
from	O
Lennox-Gastaut	O
syndrome	O
,	O
and	O
the	O
distinction	O
appears	O
from	O
the	O
first	O
year	O
of	O
the	O
disorder	O
.	O

Maternal	O
dietary	O
counseling	O
in	O
the	O
first	O
year	O
of	O
life	O
is	O
associated	O
with	O
a	O
higher	O
healthy	Physical
eating	Physical
index	Physical
in	O
childhood	O
.	O

Food	O
preferences	O
are	O
established	O
in	O
early	O
childhood	O
and	O
track	O
later	O
in	O
life	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
promote	O
healthy	O
feeding	O
practices	O
as	O
early	O
as	O
possible	O
.	O

A	O
randomized	O
field	O
trial	O
was	O
conducted	O
with	O
500	O
mother-child	O
pairs	O
from	O
a	O
low-income	O
area	O
of	O
S?o	O
Leopoldo	O
,	O
State	O
of	O
Rio	O
Grande	O
do	O
Sul	O
,	O
Brazil	O
,	O
to	O
evaluate	O
the	O
impact	O
of	O
a	O
nutritional	O
intervention	O
in	O
the	O
first	O
year	O
of	O
life	O
on	O
the	O
dietary	O
quality	O
of	O
3-	O
to	O
4-y-old	O
children	O
.	O

Mother-child	O
pairs	O
were	O
randomized	O
either	O
to	O
intervention	O
and	O
control	O
groups	O
and	O
dietary	O
counseling	O
was	O
provided	O
for	O
mothers	O
in	O
the	O
intervention	O
group	O
during	O
10	O
home	O
visits	O
in	O
the	O
course	O
of	O
the	O
first	O
year	O
of	O
life	O
.	O

These	O
visits	O
were	O
carried	O
out	O
by	O
fieldworkers	O
who	O
counseled	O
the	O
mothers	O
about	O
the	O
Ten	O
Steps	O
for	O
Healthy	O
Feeding	O
from	O
Birth	O
to	O
Two	O
Years	O
of	O
Age	O
,	O
based	O
on	O
the	O
WHO	O
guidelines	O
.	O

Dietary	O
intake	O
was	O
assessed	O
at	O
3-4	O
y	O
of	O
age	O
for	O
345	O
children	O
using	O
two	O
24-h	O
food	O
recalls	O
.	O

Overall	O
diet	O
quality	O
was	O
determined	O
by	O
the	O
Healthy	O
Eating	O
Index	O
.	O

The	O
prevalence	O
of	O
poor	O
diet	O
in	O
the	O
intervention	O
group	O
was	O
lower	O
compared	O
with	O
the	O
control	O
group	O
[	O
relative	O
risk	O
(	O
RR	O
)	O
=	O
0.30	O
;	O
95	O
%	O
CI	O
=	O
0.13-0.71	O
)	O
.	O

The	O
number	O
of	O
children	O
who	O
achieved	O
the	O
75th	O
percentile	O
for	O
the	O
vegetable	O
and	O
fruit	O
component	O
score	O
was	O
higher	O
in	O
the	O
intervention	O
than	O
in	O
control	O
group	O
(	O
RR	O
=	O
1.95	O
;	O
95	O
%	O
CI	O
=	O
1.31-2.89	O
and	O
RR	O
=	O
1.49	O
;	O
95	O
%	O
CI	O
=	O
1.07-2.07	O
,	O
respectively	O
)	O
.	O

Such	O
data	O
provide	O
evidence	O
that	O
dietary	O
counseling	O
for	O
mothers	O
during	O
the	O
first	O
year	O
of	O
life	O
improves	O
the	O
overall	O
dietary	O
quality	O
of	O
children	O
in	O
a	O
low-income	O
population	O
.	O

First-line	O
cisplatin	O
with	O
docetaxel	O
or	O
vinorelbine	O
in	O
patients	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
:	O
a	O
quality	O
of	O
life	O
directed	O
phase	O
II	O
randomized	O
trial	O
of	O
Gruppo	O
Oncologico	O
Italia	O
Meridionale	O
.	O

BACKGROUND	O
Quality	Mental
of	Mental
life	Mental
(	Mental
QoL	Mental
)	Mental
has	O
gained	O
greater	O
importance	O
in	O
the	O
management	O
of	O
metastatic	O
non-small-cell	O
lung	O
cancer	O
due	O
to	O
the	O
palliative	O
nature	O
of	O
treatment	O
.	O

Docetaxel	O
(	O
DCT	O
)	O
and	O
cisplatin	O
(	O
CDDP	O
)	O
doublet	O
has	O
been	O
reported	O
to	O
be	O
associated	O
to	O
a	O
better	O
QoL	O
than	O
the	O
weekly	O
vinorelbine	O
(	O
VNR	O
)	O
and	O
CDDP	O
regimen	O
.	O

Recently	O
a	O
newer	O
more	O
tolerated	O
schedule	O
of	O
the	O
VNR/CDDP	O
regimen	O
has	O
been	O
published	O
and	O
is	O
widely	O
employed	O
in	O
medical	O
practice	O
.	O

The	O
impact	O
of	O
these	O
regimens	O
on	O
patients	O
'	O
QoL	O
as	O
well	O
as	O
symptoms	Physical
control	Physical
and	O
type	O
and	O
grading	O
chemo-related	O
side-effects	Physical
has	O
been	O
compared	O
prospectically	O
.	O

METHODS	O
Patients	O
received	O
CDDP	O
75	O
mg/m	O
(	O
2	O
)	O
plus	O
DCT	O
75	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
every	O
weeks	O
(	O
arm	O
A	O
)	O
or	O
CDDP	O
80	O
mg/m	O
(	O
2	O
)	O
on	O
day	O
1	O
plus	O
VNR	O
30	O
mg/m	O
(	O
2	O
)	O
day	O
1	O
and	O
8	O
every	O
3	O
weeks	O
(	O
arm	O
B	O
)	O
.	O

G-CSF	O
and/or	O
EPO	O
were	O
employed	O
as	O
needed	O
.	O

Health-related	Mental
QoL	Mental
was	O
assessed	O
at	O
entry	O
and	O
after	O
every	O
cycle	O
by	O
the	O
EORTC-QLQ-C30	O
and	O
LC13	Mental
questionnaires	Mental
,	O
toxicity	Physical
by	O
the	O
NCI-NCCN	O
CTC	O
vs	O
2	O
,	O
and	O
intent-to-treat	O
objective	Physical
response	Physical
by	O
the	O
Recist	O
criteria	O
.	O

RESULTS	O
The	O
QoL	Physical
questionnaires	Physical
were	O
completed	O
by	O
37	O
pts	O
(	O
88	O
%	O
)	O
in	O
the	O
DCT/CDDP	O
arm	O
and	O
39	O
pts	O
(	O
87	O
%	O
)	O
in	O
the	O
VNR/CDDP	O
one	O
.	O

Baseline	O
mean	O
scores	O
and	O
rates	O
at	O
which	O
pts	O
failed	O
to	O
complete	O
QoL	O
assessment	O
were	O
similar	O
in	O
the	O
two	O
arms	O
.	O

Global	Mental
health	Mental
status	Mental
of	O
the	O
EORTC	Physical
QLQ-C30	Physical
scale	Physical
and	O
specific	O
symptoms	O
control	O
(	O
LC13	O
module	O
)	O
improved	O
during	O
treatment	O
without	O
any	O
statistically	O
significant	O
difference	O
between	O
the	O
two	O
arms	O
.	O

Emotional	Mental
functioning	Mental
remained	O
stable	O
in	O
both	O
groups	O
during	O
treatment	O
,	O
whereas	O
physical	Mental
and	O
role	Mental
improved	O
slightly	O
.	O

In	O
the	O
DCT/CDDP	O
arm	O
14	O
pts	O
(	O
33	O
%	O
;	O
95	O
%	O
CL	O
24-40	O
%	O
)	O
had	O
PR	O
,	O
and	O
10	O
(	O
24	O
%	O
)	O
SD	O
for	O
a	O
57	O
%	O
TGCR	O
.	O

In	O
the	O
VNR/CDDP	O
arm	O
12	O
pts	O
(	O
27	O
%	O
)	O
achieved	O
PR	Physical
,	O
18	O
(	O
41	O
%	O
)	O
SD	O
a	O
68	O
%	O
TGCR	O
.	O

Differences	O
were	O
not	O
statistically	O
significant	O
.	O

Median	Physical
time-to-progression	Physical
was	O
4.2	O
months	O
in	O
the	O
DCT/CDDP	O
arm	O
and	O
4.5	O
months	O
in	O
the	O
VNR/CDDP	O
one	O
,	O
and	O
median	Mortality
overall	Mortality
survival	Mortality
was	O
12.1	O
(	O
range	O
1-26+	O
months	O
)	O
and	O
12.5	O
months	O
(	O
range	O
1-28+	O
months	O
)	O
for	O
DCT/CDDP	O
and	O
VNR/CDDP	O
arms	O
,	O
respectively	O
.	O

Febrile	Physical
neutropenia	Physical
rate	Physical
was	O
higher	O
in	O
the	O
VNR/CDDP	O
arm	O
(	O
p=0.02	O
)	O
as	O
well	O
as	O
G3-4	O
anemia	Physical
(	O
p=0.005	O
)	O
and	O
G-CSF/EPO	O
use	O
(	O
p=0.019	O
)	O
.	O

CONCLUSIONS	O
Global	Physical
and	Physical
specific	Physical
health-related	Physical
QoL	Physical
data	O
similar	O
in	O
both	O
treatment	O
groups	O
with	O
no	O
statistically	O
significant	O
difference	O
.	O

Efficacy	Others
measures	Others
,	O
overall	O
response	Physical
rate	Physical
,	O
time-to-progression	Physical
and	O
overall	Mortality
survival	Mortality
were	O
equivalent	O
in	O
both	O
arms	O
.	O

However	O
,	O
severe	Physical
anemia	Physical
and	O
febrile	Physical
neutropenia	Physical
are	O
statistically	O
more	O
frequent	O
in	O
the	O
VNR/CDDP	O
arm	O
than	O
in	O
the	O
DCT/CDDP	O
one	O
.	O

These	O
data	O
should	O
be	O
considered	O
in	O
treatment	O
decision-making	O
for	O
pts	O
with	O
advanced	O
non-small-cell	O
lung	O
cancer	O
and	O
for	O
the	O
design	O
of	O
future	O
trials	O
with	O
chemotherapy	O
plus	O
biologics	O
.	O

A	O
randomized	O
controlled	O
trial	O
of	O
nonlinear	O
frequency	O
compression	O
versus	O
conventional	O
processing	O
in	O
hearing	O
aids	O
:	O
speech	O
and	O
language	O
of	O
children	O
at	O
three	O
years	O
of	O
age	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
effect	O
of	O
nonlinear	O
frequency	O
compression	O
(	O
NLFC	O
)	O
on	O
children	O
's	O
development	O
of	O
speech	O
and	O
language	O
at	O
three	O
years	O
of	O
age	O
.	O

DESIGN	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
as	O
part	O
of	O
the	O
population-based	O
longitudinal	O
study	O
on	O
outcomes	O
of	O
children	O
with	O
hearing	O
impairment	O
(	O
LOCHI	O
)	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
fitting	O
with	O
NLFC	O
(	O
Phonak	O
Naida	O
V	O
SP	O
or	O
UP	O
)	O
or	O
with	O
conventional	O
processing	O
in	O
hearing	O
aids	O
,	O
prescribed	O
by	O
using	O
either	O
the	O
NAL	O
or	O
the	O
DSL	O
formula	O
.	O

Standardized	O
tests	O
of	O
speech	Mental
production	Mental
,	Mental
receptive	Mental
and	Mental
expressive	Mental
language	Mental
were	O
administered	O
,	O
and	O
parent	O
ratings	O
were	O
collected	O
.	O

All	O
assessments	O
were	O
double-blinded	O
.	O

STUDY	O
SAMPLE	O
Participants	O
were	O
44	O
of	O
the	O
450	O
children	O
in	O
the	O
LOCHI	O
cohort	O
.	O

RESULTS	O
Compared	O
to	O
children	O
using	O
conventional	O
processing	O
,	O
receptive	Mental
and	Mental
expressive	Mental
language	Mental
was	O
higher	O
but	O
receptive	Mental
vocabulary	Mental
and	Mental
consonant	Mental
articulation	Mental
scores	Mental
were	O
lower	O
for	O
children	O
who	O
use	O
NLFC	O
.	O

There	O
was	O
increased	O
substitution	Mental
of	Mental
affricates	Mental
by	Mental
fricatives	Mental
for	O
children	O
using	O
NLFC	O
,	O
compared	O
to	O
children	O
using	O
conventional	O
amplification	O
.	O

After	O
allowing	O
for	O
the	O
effect	O
of	O
multiple	O
demographic	O
variables	O
,	O
the	O
difference	O
in	O
global	Mental
language	Mental
scores	Mental
between	O
groups	O
was	O
not	O
significant	O
(	O
effect	O
:	O
0.8	O
[	O
95	O
%	O
confidence	O
interval	O
:	O
-	O
6.7	O
,	O
8.3	O
]	O
)	O
.	O

CONCLUSIONS	O
There	O
is	O
insufficient	O
evidence	O
to	O
indicate	O
a	O
difference	O
in	O
language	Mental
ability	Mental
between	O
children	O
using	O
NLFC	O
and	O
those	O
using	O
conventional	O
amplification	O
.	O

Caregiver-mediated	O
intervention	O
for	O
low-resourced	O
preschoolers	O
with	O
autism	O
:	O
an	O
RCT	O
.	O

OBJECTIVES	O
To	O
compare	O
2	O
short-term	O
,	O
community	O
caregiver	O
training	O
interventions	O
for	O
preschool-aged	O
children	O
with	O
Autism	O
Spectrum	O
Disorder	O
who	O
had	O
low	O
resources	O
.	O

Low	O
resource	O
was	O
defined	O
by	O
the	O
US	O
Department	O
of	O
Housing	O
and	O
Urban	O
Development	O
low-income	O
index	O
or	O
1	O
indicator	O
,	O
(	O
e.g.	O
,	O
Medicaid	O
eligibility	O
)	O
.	O

Child	O
outcomes	O
focused	O
on	O
joint	O
engagement	Mental
,	O
joint	O
attention	O
,	O
and	O
play	O
.	O

METHODS	O
Participants	O
included	O
112	O
families	O
of	O
a	O
child	O
who	O
had	O
Autism	O
Spectrum	O
Disorder	O
who	O
met	O
criteria	O
for	O
being	O
low-resourced	O
and	O
who	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
2	O
3-month	O
interventions	O
,	O
group	O
caregiver	O
education	O
or	O
individualized	O
caregiver-mediated	O
intervention	O
(	O
CMM	O
)	O
.	O

Children	O
were	O
assessed	O
for	O
social	O
communication	O
skills	O
pre-	Physical
and	Physical
post-treatment	Physical
,	O
and	O
followed	O
up	O
at	O
3	O
months	O
.	O

RESULTS	O
All	O
children	O
improved	O
in	O
joint	Mental
engagement	Mental
and	O
initiating	Mental
joint	Mental
attention	Mental
,	O
with	O
significantly	O
greater	O
improvement	O
by	O
the	O
CMM	O
group	O
.	O

Outcomes	O
on	O
play	Mental
skills	Mental
were	O
mixed	O
,	O
with	O
improvement	O
of	O
symbolic	Mental
play	Mental
for	O
the	O
CMM	O
group	O
and	O
no	O
change	O
in	O
functional	Mental
play	Mental
skills	Mental
.	O

Joint	O
engagement	O
maintained	O
over	O
time	O
for	O
the	O
CMM	O
group	O
,	O
and	O
initiating	O
joint	O
attention	O
maintained	O
for	O
both	O
groups	O
over	O
time	O
.	O

CONCLUSIONS	O
This	O
study	O
is	O
among	O
the	O
first	O
randomized	O
trials	O
comparing	O
2	O
active	O
interventions	O
with	O
a	O
large	O
sample	O
of	O
low-resourced	O
families	O
.	O

Results	O
suggest	O
improvements	O
in	O
core	O
autism	O
deficits	O
of	O
joint	O
engagement	O
,	O
joint	Mental
attention	Mental
,	O
and	O
symbolic	O
play	O
with	O
relatively	O
brief	O
,	O
caregiver-mediated	O
interventions	O
,	O
but	O
additional	O
support	O
is	O
necessary	O
to	O
maintain	O
and	O
generalize	O
these	O
gains	O
over	O
time	O
.	O

[	O
Rapidity	Pain
of	Pain
pain	Pain
relief	Pain
,	O
medication	Others
requirement	Others
and	O
patient	Others
satisfaction	Others
with	O
reflux	O
treatment	O
in	O
the	O
physician	O
's	O
office	O
]	O
.	O

Treatment	O
of	O
gastroesophageal	Physical
reflux	Physical
disease	Physical
(	Physical
GERD	Physical
)	Physical
with	O
proton	O
pump	O
inhibitors	O
was	O
investigated	O
in	O
three	O
controlled	O
prospective	O
,	O
randomized	O
open	O
studies	O
.	O

Lansoprazole	O
,	O
omeprazole	O
MUPS	O
and	O
esomeprazole	O
were	O
compared	O
under	O
doctor	O
's	O
office	O
conditions	O
.	O

The	O
outcomes	O
of	O
interest	O
were	O
the	O
rapidity	Pain
of	Pain
pain	Pain
relief	Pain
achieved	O
with	O
a	O
single	Others
dose	Others
,	O
effectiveness	Others
and	O
patient	Others
satisfaction	Others
with	O
on	O
demand	O
therapy	O
.	O

In	O
the	O
first	O
study	O
,	O
180	O
patients	O
with	O
chronic	O
and	O
prolonged	O
episodes	O
of	O
reflux	O
were	O
investigated	O
.	O

Time	O
to	O
pain	Pain
relief	Pain
following	O
a	O
single	O
dose	O
was	O
1.1	O
+/-	O
0.8	O
hours	O
with	O
30	O
mg	O
lansoprazole	O
,	O
3.0	O
+/-	O
2.5	O
hours	O
with	O
20	O
mgomeprazole	O
MUPS	O
and	O
2.1	O
+/-	O
1.2	O
hours	O
with	O
40	O
mg	O
esomeprazole	O
.	O

Studies	O
2	O
and	O
3	O
were	O
designed	O
as	O
cross-over	O
studies	O
intended	O
to	O
investigate	O
drug	Physical
consumption	Physical
.	O

In	O
study	O
2	O
,	O
the	O
amount	Others
of	Others
lansoprazole	Others
consumed	Others
was	O
approximately	O
50	O
%	O
less	O
than	O
that	O
of	O
omeprazole	O
,	O
and	O
this	O
translated	O
to	O
81	O
%	O
patient	Others
satisfaction	Others
with	O
lansoprazole	O
compared	O
with	O
only	O
9.5	O
%	O
for	O
omeprazole	O
.	O

In	O
study	O
3	O
comparing	O
lansoprazole	O
and	O
esomeprazole	O
,	O
consumption	Others
of	O
the	O
former	O
was	O
85	O
%	O
that	O
of	O
the	O
latter	O
.	O

58	O
%	O
of	O
the	O
patients	O
opted	O
to	O
continuetreatment	Others
with	O
lansoprazole	O
,	O
compared	O
with	O
only	O
25	O
%	O
in	O
the	O
case	O
of	O
esomeprazole	O
.	O

The	O
appreciably	O
greater	O
patient	Others
satisfaction	Others
with	O
lansoprazole	O
was	O
due	O
tothe	O
faster	Pain
pain	Pain
relief	Pain
achieved	O
with	O
this	O
drug	O
.	O

The	O
effect	O
of	O
halothane	O
and	O
isoflurane	O
on	O
plasma	Physical
cytokine	Physical
levels	Physical
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
halothane	O
vs.	O
isoflurane	O
on	O
cytokine	Physical
production	Physical
during	O
minor	O
elective	O
surgery	O
.	O

Forty	O
adult	O
patients	O
,	O
ASA	O
I-II	O
were	O
randomly	O
allocated	O
to	O
receive	O
halothane	O
or	O
isoflurane	O
.	O

Venous	O
samples	O
for	O
interleukin	O
(	O
IL	O
)	O
-1beta	O
,	O
IL-2	O
,	O
IL-6	O
,	O
tumour	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
and	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
were	O
taken	O
before	O
anaesthesia	O
,	O
before	O
incision	O
,	O
at	O
the	O
end	O
of	O
anaesthesia	O
and	O
24	O
h	O
postoperatively	O
.	O

In	O
both	O
groups	O
,	O
IL-6	Physical
and	Physical
TNF-alpha	Physical
levels	Physical
remained	O
low	O
throughout	O
the	O
study	O
period	O
.	O

Before	O
incision	O
,	O
in	O
both	O
groups	O
IL-1beta	Physical
and	Physical
IFN-gamma	Physical
showed	O
a	O
decrease	O
(	O
p	O
<	O
0.01	O
for	O
IL-1beta	Physical
in	O
isoflurane	O
group	O
and	O
p	O
<	O
0.05	O
for	O
the	O
others	O
)	O
compared	O
with	O
pre-induction	O
.	O

By	O
the	O
end	O
of	O
anaesthesia	O
and	O
surgery	O
,	O
IL-1beta	Physical
had	O
increased	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
and	O
IFN-gamma	Physical
had	O
decreased	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
in	O
both	O
groups	O
compared	O
with	O
pre-incisional	O
levels	O
.	O

By	O
24	O
h	O
postoperatively	O
in	O
both	O
groups	O
,	O
IL-1beta	Physical
had	O
decreased	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
IFN-gamma	Physical
had	O
increased	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
compared	O
with	O
the	O
end	O
of	O
anaesthesia	O
and	O
surgery	O
level	O
.	O

Pre-incisionally	O
,	O
IL-2	Physical
increased	O
in	O
the	O
halothane	O
group	O
(	O
p	O
<	O
0.01	O
)	O
,	O
whereas	O
it	O
decreased	O
significantly	O
in	O
the	O
isoflurane	O
group	O
(	O
p	O
<	O
0.001	O
)	O
compared	O
with	O
the	O
pre-induction	O
level	O
.	O

By	O
the	O
end	O
of	O
anaesthesia	O
and	O
surgery	O
and	O
by	O
24	O
h	O
postoperatively	O
,	O
IL-2	Physical
had	O
decreased	O
significantly	O
in	O
the	O
halothane	O
group	O
(	O
p	O
<	O
0.001	O
)	O
,	O
whereas	O
it	O
increased	O
significantly	O
in	O
the	O
isoflurane	O
group	O
(	O
p	O
<	O
0.001	O
)	O
compared	O
with	O
pre-incision	O
and	O
end	O
of	O
anaesthesia	O
and	O
surgery	O
levels	O
,	O
respectively	O
.	O

Reactivation	Physical
of	Physical
unstable	Physical
angina	Physical
after	O
the	O
discontinuation	O
of	O
heparin	O
.	O

BACKGROUND	O
Heparin	O
is	O
an	O
effective	O
,	O
widely	O
used	O
treatment	O
for	O
unstable	O
angina	O
.	O

Among	O
patients	O
enrolled	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
comparing	O
intravenous	O
heparin	O
,	O
aspirin	O
,	O
both	O
treatments	O
,	O
and	O
neither	O
during	O
the	O
acute	O
phase	O
of	O
unstable	O
angina	O
,	O
we	O
encountered	O
patients	O
in	O
whom	O
unstable	O
angina	O
was	O
reactivated	O
after	O
heparin	O
was	O
discontinued	O
.	O

METHODS	O
The	O
study	O
population	O
included	O
403	O
of	O
the	O
original	O
479	O
patients	O
in	O
the	O
trial	O
who	O
had	O
completed	O
six	O
days	O
of	O
blinded	O
therapy	O
without	O
refractory	O
angina	O
or	O
myocardial	O
infarction	O
.	O

After	O
the	O
discontinuation	O
of	O
therapy	O
,	O
clinical	Physical
events	Physical
,	Physical
including	Physical
reactivation	Physical
of	Physical
unstable	Physical
angina	Physical
and	Physical
myocardial	Physical
infarction	Physical
occurring	Physical
within	Physical
96	Physical
hours	Physical
after	Physical
hospitalization	Physical
,	O
were	O
closely	O
monitored	O
.	O

RESULTS	O
Early	Physical
reactivation	Physical
occurred	O
in	O
14	O
of	O
the	O
107	O
patients	O
who	O
received	O
heparin	O
alone	O
,	O
as	O
compared	O
with	O
only	O
5	O
patients	O
in	O
each	O
of	O
the	O
other	O
three	O
study	O
groups	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

These	O
reactivations	Physical
required	O
urgent	O
intervention	O
(	O
thrombolysis	O
,	O
angioplasty	O
,	O
or	O
coronary-bypass	O
surgery	O
)	O
in	O
11	O
patients	O
treated	O
with	O
heparin	O
alone	O
,	O
but	O
in	O
only	O
2	O
patients	O
in	O
the	O
other	O
groups	O
combined	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Four	O
of	O
the	O
six	O
patients	O
who	O
had	O
a	O
myocardial	Physical
infarction	Physical
during	O
a	O
reactivation	O
of	O
their	O
disease	O
were	O
in	O
the	O
heparin	O
group	O
.	O

Reactivations	Physical
in	O
this	O
group	O
occurred	O
in	O
a	O
cluster	O
a	O
mean	O
(	O
+/-	O
SD	O
)	O
of	O
9.5	O
+/-	O
5	O
hours	O
after	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
but	O
were	O
randomly	O
distributed	O
over	O
the	O
initial	O
96	O
hours	O
in	O
the	O
other	O
three	O
groups	O
.	O

CONCLUSIONS	O
Although	O
heparin	O
is	O
beneficial	O
in	O
treating	O
unstable	O
angina	O
,	O
the	O
disease	O
process	O
may	O
be	O
reactivated	Physical
within	O
hours	O
of	O
the	O
discontinuation	O
of	O
this	O
drug	O
.	O

Concomitant	O
therapy	O
with	O
aspirin	O
may	O
prevent	O
this	O
withdrawal	O
phenomenon	O
.	O

Lack	O
of	O
benefit	O
of	O
a	O
single	O
dose	O
of	O
synthetic	O
human	O
secretin	O
in	O
the	O
treatment	O
of	O
autism	O
and	O
pervasive	O
developmental	O
disorder	O
.	O

BACKGROUND	O
Secretin	O
is	O
a	O
peptide	O
hormone	O
that	O
stimulates	O
pancreatic	O
secretion	O
.	O

After	O
recent	O
publicity	O
about	O
a	O
child	O
with	O
autism	O
whose	O
condition	O
markedly	O
improved	O
after	O
a	O
single	O
dose	O
of	O
secretin	O
,	O
thousands	O
of	O
children	O
with	O
autistic	O
disorders	O
may	O
have	O
received	O
secretin	O
injections	O
.	O

METHODS	O
We	O
conducted	O
a	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
a	O
single	O
intravenous	O
dose	O
of	O
synthetic	O
human	O
secretin	O
in	O
60	O
children	O
(	O
age	O
,	O
3	O
to	O
14	O
years	O
)	O
with	O
autism	O
or	O
pervasive	O
developmental	O
disorder	O
.	O

The	O
children	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
an	O
intravenous	O
infusion	O
of	O
synthetic	O
human	O
secretin	O
(	O
0.4	O
microg	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
or	O
saline	O
placebo	O
.	O

We	O
used	O
standardized	O
behavioral	O
measures	O
of	O
the	O
primary	O
and	O
secondary	O
features	O
of	O
autism	O
,	O
including	O
the	O
Autism	O
Behavior	O
Checklist	O
,	O
to	O
assess	O
the	O
degree	O
of	O
impairment	O
at	O
base	O
line	O
and	O
over	O
the	O
course	O
of	O
a	O
four-week	O
period	O
after	O
treatment	O
.	O

RESULTS	O
Of	O
the	O
60	O
children	O
,	O
4	O
could	O
not	O
be	O
evaluated	O
-	O
2	O
received	O
secretin	O
outside	O
the	O
study	O
,	O
and	O
2	O
did	O
not	O
return	O
for	O
follow-up	O
.	O

Thus	O
,	O
56	O
children	O
(	O
28	O
in	O
each	O
group	O
)	O
completed	O
the	O
study	O
.	O

As	O
compared	O
with	O
placebo	O
,	O
secretin	O
treatment	O
was	O
not	O
associated	O
with	O
significant	Others
improvements	Others
in	Others
any	Others
of	Others
the	Others
outcome	Others
measures	Others
.	O

Among	O
the	O
children	O
in	O
the	O
secretin	O
group	O
,	O
the	O
mean	Mental
total	Mental
score	Mental
on	Mental
the	Mental
Autism	Mental
Behavior	Mental
Checklist	Mental
at	O
base	O
line	O
was	O
59.0	O
(	O
range	O
of	O
possible	O
values	O
,	O
0	O
to	O
158	O
,	O
with	O
a	O
larger	O
value	O
corresponding	O
to	O
greater	O
impairment	O
)	O
,	O
and	O
among	O
those	O
in	O
the	O
placebo	O
group	O
it	O
was	O
63.2	O
.	O

The	O
mean	Others
decreases	Others
in	Others
scores	Mental
over	O
the	O
four-week	O
period	O
were	O
8.9	O
in	O
the	O
secretin	O
group	O
and	O
17.8	O
in	O
the	O
placebo	O
group	O
(	O
mean	O
difference	O
,	O
-8.9	O
;	O
95	O
percent	O
confidence	O
interval	O
,	O
-19.4	O
to	O
1.6	O
;	O
P=0.11	O
)	O
.	O

None	O
of	O
the	O
children	O
had	O
treatment-limiting	Adverseeffect
adverse	Adverseeffect
effects	Adverseeffect
.	O

After	O
they	O
were	O
told	O
the	O
results	O
,	O
69	O
percent	O
of	O
the	O
parents	O
of	O
the	O
children	O
in	O
this	O
study	O
said	O
they	O
remained	O
interested	O
in	O
secretin	O
as	O
a	O
treatment	O
for	O
their	O
children	O
.	O

CONCLUSIONS	O
A	O
single	O
dose	O
of	O
synthetic	O
human	O
secretin	O
is	O
not	Others
an	Others
effective	Others
treatment	Others
for	O
autism	O
or	O
pervasive	O
developmental	O
disorder	O
.	O

Tracheal	O
soiling	O
with	O
blood	O
during	O
intranasal	O
surgery	O
--	O
comparison	O
of	O
two	O
endotracheal	O
tubes	O
.	O

Sixty	O
adult	O
patients	O
,	O
ASA	O
Classes	O
I	O
&	O
II	O
,	O
were	O
involved	O
in	O
a	O
study	O
to	O
compare	O
the	O
effectiveness	O
of	O
Mallinckrodt	O
Hi-Lo-Evac	O
tube	O
and	O
Portex	O
blue	O
line	O
tube	O
in	O
preventing	O
soiling	O
of	O
the	O
lower	O
airways	O
during	O
intranasal	O
surgery	O
.	O

The	O
Hi-Lo-Evac	O
tube	O
with	O
and	O
without	O
pack	O
was	O
significantly	O
more	O
effective	Others
than	O
the	O
Portex	O
tube	O
with	O
pharyngeal	O
pack	O
(	O
P	O
less	O
than	O
0.002	O
)	O
and	O
(	O
P	O
less	O
than	O
0.01	O
respectively	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
when	O
the	O
Hi-Lo-Evac	O
tube	O
was	O
used	O
with	O
or	O
without	O
a	O
pack	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
.	O

The	O
more	O
effective	Physical
protection	Physical
of	Physical
the	Physical
lower	Physical
airways	Physical
by	O
the	O
Hi-Lo-Evac	O
tube	O
is	O
attributed	O
to	O
the	O
facility	O
of	O
subglottic	O
aspiration	O
during	O
surgery	O
.	O

It	O
is	O
suggested	O
that	O
the	O
Hi-Lo-Evac	O
tube	O
could	O
be	O
used	O
with	O
safety	Others
during	O
intranasal	O
surgery	O
in	O
order	O
to	O
reduce	O
postoperative	Mortality
morbidity	Mortality
associated	O
with	O
the	O
use	O
of	O
pharyngeal	O
pack	O
.	O

Torasemide	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
cirrhosis	O
and	O
ascites	O
.	O

The	O
effects	O
of	O
torasemide	O
(	O
20	O
mg/day	O
)	O
and	O
furosemide	O
(	O
50	O
mg/day	O
)	O
,	O
each	O
given	O
over	O
4	O
days	O
,	O
were	O
compared	O
in	O
a	O
randomized	O
and	O
crossover	O
study	O
carried	O
out	O
in	O
seven	O
patients	O
with	O
cirrhosis	O
and	O
tense	O
ascites	O
.	O

Patients	O
also	O
received	O
a	O
low-sodium	O
(	O
40	O
mmol/day	O
)	O
diet	O
and	O
the	O
aldosterone	O
antagonist	O
,	O
potassium	O
canrenoate	O
(	O
100	O
mg	O
b.i.d.	O
)	O
.	O

Torasemide	O
induced	O
a	O
remarkably	O
higher	O
natriuretic	Physical
(	O
120	O
+/-	O
15	O
vs.	O
33	O
+/-	O
6	O
mmol/day	O
,	O
p	O
<	O
0.02	O
)	O
and	O
diuretic	Physical
(	O
1450	O
+/-	O
63	O
vs.	O
900	O
+/-	O
58	O
ml	O
,	O
p	O
<	O
0.005	O
)	O
effect	O
than	O
furosemide	O
.	O

Body	Physical
weight	Physical
loss	Physical
was	O
also	O
significantly	O
higher	O
(	O
2.5	O
+/-	O
1.6	O
vs.	O
0.2	O
+/-	O
1.3	O
kg	O
,	O
p	O
<	O
0.01	O
)	O
during	O
the	O
torasemide	O
period	O
.	O

Kaliuresis	Physical
was	O
similar	O
during	O
the	O
two	O
treatment	O
periods	O
,	O
despite	O
the	O
striking	O
differences	O
observed	O
in	O
natriuresis	O
.	O

Neither	O
torasemide	O
nor	O
furosemide	O
induced	O
any	O
significant	O
change	O
in	O
serum	Physical
electrolyte	Physical
or	Physical
creatinine	Physical
concentrations	Physical
,	Physical
or	Physical
in	Physical
ammonia	Physical
levels	Physical
.	Physical

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
torasemide	O
is	O
suitable	O
for	O
the	O
treatment	O
of	O
sodium	O
retention	O
in	O
patients	O
with	O
cirrhosis	O
and	O
ascites	O
.	O

Effect	O
of	O
rosuvastatin	O
monotherapy	O
or	O
in	O
combination	O
with	O
fenofibrate	O
or	O
?-3	O
fatty	O
acids	O
on	O
lipoprotein	O
subfraction	O
profile	O
in	O
patients	O
with	O
mixed	O
dyslipidaemia	O
and	O
metabolic	O
syndrome	O
.	O

BACKGROUND	O
Raised	O
triglycerides	O
(	O
TG	O
)	O
,	O
decreased	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
)	O
levels	O
and	O
a	O
predominance	O
of	O
small	O
dense	O
low	O
density	O
lipoproteins	O
(	O
sdLDL	O
)	O
are	O
characteristics	O
of	O
the	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effect	O
of	O
high-dose	O
rosuvastatin	O
monotherapy	O
with	O
moderate	O
dosing	O
combined	O
with	O
fenofibrate	O
or	O
?-3	O
fatty	O
acids	O
on	O
the	O
lipoprotein	O
subfraction	O
profile	O
in	O
patients	O
with	O
mixed	O
dyslipidaemia	O
and	O
MetS	O
.	O

METHODS	O
We	O
previously	O
randomised	O
patients	O
with	O
low-density	O
lipoprotein	O
cholesterol	O
(	O
LDL-C	O
)	O
>	O
160	O
and	O
TG	O
>	O
200	O
mg/dl	O
to	O
rosuvastatin	O
monotherapy	O
40	O
mg/day	O
(	O
R	O
group	O
,	O
n	O
=	O
30	O
)	O
or	O
rosuvastatin	O
10	O
mg/day	O
combined	O
with	O
fenofibrate	O
200	O
mg/day	O
(	O
RF	O
group	O
,	O
n	O
=	O
30	O
)	O
or	O
?-3	O
fatty	O
acids	O
2	O
g/day	O
(	O
R?	O
group	O
,	O
n	O
=	O
30	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
only	O
patients	O
with	O
MetS	O
were	O
included	O
(	O
24	O
,	O
23	O
and	O
24	O
in	O
the	O
R	O
,	O
RF	O
and	O
R?	O
groups	O
respectively	O
)	O
.	O

At	O
baseline	O
and	O
after	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
lipoprotein	O
subfraction	O
profile	O
was	O
determined	O
by	O
polyacrylamide	O
3	O
%	O
gel	O
electrophoresis	O
.	O

RESULTS	O
The	O
mean	O
LDL	O
size	O
was	O
significantly	O
increased	O
in	O
all	O
groups	O
.	O

This	O
change	O
was	O
more	O
prominent	O
with	O
RF	O
than	O
with	O
other	O
treatments	O
in	O
parallel	O
with	O
its	O
greater	O
hypotriglyceridemic	O
capacity	O
(	O
p	O
<	O
0.05	O
compared	O
with	O
R	O
and	O
R?	O
)	O
.	O

A	O
decrease	O
in	O
insulin	O
resistance	O
by	O
RF	O
was	O
also	O
noted	O
.	O

Only	O
RF	O
significantly	O
raised	O
HDL-C	O
levels	O
(	O
by	O
7.7	O
%	O
,	O
p	O
<	O
0.05	O
)	O
by	O
increasing	O
the	O
cholesterol	O
of	O
small	O
HDL	O
particles	O
.	O

The	O
cholesterol	O
of	O
larger	O
HDL	O
subclasses	O
was	O
significantly	O
increased	O
by	O
R	O
and	O
R?	O
.	O

CONCLUSIONS	O
All	O
regimens	O
increased	O
mean	O
LDL	O
size	O
;	O
RF	O
was	O
the	O
most	O
effective	O
.	O

A	O
differential	O
effect	O
of	O
treatments	O
was	O
noted	O
on	O
the	O
HDL	O
subfraction	O
profile	O
.	O

Depiction	Physical
of	Physical
hypervascular	Physical
hepatocellular	Physical
carcinoma	Physical
with	O
64-MDCT	Physical
:	O
comparison	O
of	O
moderate-	O
and	O
high-concentration	O
contrast	O
material	O
with	O
and	O
without	O
saline	O
flush	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
prospectively	O
the	O
depiction	Physical
of	Physical
hypervascular	Physical
hepatocellular	Physical
carcinoma	Physical
on	O
64-MDCT	O
scans	O
obtained	O
with	O
contrast	O
agents	O
of	O
varying	O
iodine	O
concentrations	O
administered	O
with	O
and	O
without	O
saline	O
flush	O
.	O

SUBJECTS	O
AND	O
METHODS	O
The	O
study	O
included	O
149	O
patients	O
,	O
among	O
whom	O
36	O
patients	O
with	O
hypervascular	O
hepatocellular	O
carcinoma	O
were	O
identified	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
protocols	O
:	O
A	O
,	O
contrast	O
material	O
of	O
300	O
mg	O
I/mL	O
;	O
B	O
,	O
370	O
mg	O
I/mL	O
;	O
C	O
,	O
370	O
mg	O
I/mL	O
plus	O
saline	O
flush	O
.	O

In	O
all	O
protocols	O
,	O
the	O
same	O
iodine	O
load	O
per	O
kilogram	O
of	O
body	O
weight	O
(	O
516	O
mg/kg	O
)	O
was	O
administered	O
for	O
the	O
same	O
injection	O
duration	O
(	O
30	O
seconds	O
)	O
.	O

Enhancement	Physical
values	Physical
in	Physical
the	Physical
aorta	Physical
,	Physical
liver	Physical
,	Physical
and	Physical
portal	Physical
vein	Physical
and	Physical
tumor-liver	Physical
contrast	Physical
were	O
measured	O
at	O
multiphase	O
CT	O
.	O

RESULTS	O
Aortic	Physical
enhancement	Physical
was	O
significantly	O
different	O
between	O
protocols	O
A	O
and	O
B	O
(	O
p	O
=	O
0.04	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
protocols	O
B	O
and	O
C	O
(	O
p	O
=	O
0.02	O
,	O
p	O
<	O
0.001	O
)	O
in	O
the	O
first	O
and	O
second	O
phases	O
.	O

Portal	Physical
venous	Physical
enhancement	Physical
was	O
significantly	O
different	O
between	O
protocols	O
B	O
and	O
C	O
(	O
p	O
=	O
0.02	O
)	O
in	O
the	O
first	O
phase	O
and	O
between	O
protocols	O
B	O
and	O
C	O
and	O
protocols	O
A	O
and	O
C	O
(	O
p	O
<	O
0.01	O
,	O
p	O
=	O
0.02	O
)	O
in	O
the	O
second	O
phase	O
.	O

Tumor-liver	Others
contrast	Others
was	O
significantly	O
different	O
between	O
protocols	O
A	O
and	O
B	O
(	O
p	O
=	O
0.03	O
,	O
p	O
=	O
0.02	O
)	O
and	O
protocols	O
B	O
and	O
C	O
(	O
p	O
=	O
0.03	O
,	O
p	O
=	O
0.04	O
)	O
in	O
the	O
first	O
and	O
second	O
phases	O
but	O
not	O
between	O
protocols	O
A	O
and	O
C.	O
There	O
was	O
no	O
significant	O
difference	O
in	O
hepatic	Physical
enhancement	Physical
among	O
the	O
three	O
protocols	O
.	O

CONCLUSION	O
Use	O
of	O
moderate	O
concentration	O
was	O
more	O
effective	O
than	O
use	O
of	O
a	O
high	O
concentration	O
of	O
contrast	O
material	O
for	O
depiction	O
of	O
hepatocellular	O
carcinoma	O
.	O

Adding	O
a	O
saline	O
flush	O
to	O
the	O
high-concentration	O
protocol	O
eliminated	O
the	O
difference	O
in	O
depiction	Physical
of	Physical
hepatocellular	Physical
carcinoma	Physical
between	O
the	O
moderate-	O
and	O
high-concentration	O
protocols	O
.	O

[	O
Effects	O
of	O
betamethasone	O
on	O
neuromuscular	Physical
blockade	Physical
induced	O
by	O
vecuronium	O
in	O
continuous	O
infusion	O
]	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
a	O
possible	O
interaction	O
between	O
a	O
corticosteroid	O
(	O
betamethasone	O
)	O
and	O
vecuronium	O
,	O
a	O
nondepolarizing	O
muscle	O
relaxant	O
.	O

The	O
authors	O
studied	O
20	O
patients	O
,	O
ASA	O
I-II	O
,	O
aged	O
20-54	O
,	O
both	O
sexes	O
,	O
scheduled	O
for	O
abdominal	O
surgery	O
.	O

Mechanomyographic	Physical
and	Physical
clinical	Physical
evaluation	Physical
by	Physical
single	Physical
twitch	Physical
and	O
TOF	Physical
stimulation	Physical
of	Physical
the	Physical
ulnar	Physical
nerve	Physical
at	Physical
the	Physical
wrist	Physical
and	O
measurement	O
of	O
the	O
concomitant	Physical
abductor	Physical
pollicis	Physical
muscle	Physical
was	O
applied	O
.	O

The	O
onset	Others
time	Others
of	O
vecuronium	O
after	O
a	O
single	O
bolus	O
dose	O
of	O
0.08	O
mg/kg	O
,	O
duration	Others
of	Others
action	Others
to	O
10	O
%	O
single	Physical
twitch	Physical
recovery	Physical
,	O
duration	O
of	O
continuous	O
infusion	O
of	O
0.4-0.5	O
micrograms/kg/min	O
of	O
vecuronium	O
started	O
at	O
10	O
%	O
single	Physical
twitch	Physical
recovery	Physical
,	O
and	O
the	O
effects	O
of	O
0.1	O
mg/kg	O
betamethasone	O
administration	O
10	O
min	O
after	O
continuous	O
infusion	O
were	O
evaluated	O
.	O

The	O
recovery	Physical
rate	Physical
of	Physical
vecuronium	Physical
after	O
stopping	O
infusion	O
at	O
10	O
%	O
recovery	O
was	O
also	O
evaluated	O
.	O

Corticosteroids	O
may	O
interact	O
with	O
non-depolarizing	O
muscle	O
relaxants	O
both	O
in	O
prejunctional	O
and	O
postjunctional	O
acetylcholine	O
receptors	O
by	O
several	O
mechanisms	O
of	O
action	O
.	O

The	O
effect	O
of	O
prethrombolytic	O
cyclosporine-A	O
injection	O
on	O
clinical	O
outcome	O
of	O
acute	O
anterior	O
ST-elevation	O
myocardial	O
infarction	O
.	O

INTRODUCTION	O
Reperfusion	O
injury	O
reduces	O
the	O
benefits	O
of	O
early	O
reperfusion	O
therapies	O
after	O
acute	O
ST-elevation	O
myocardial	O
infarction	O
(	O
STEMI	O
)	O
.	O

Cyclosporine-A	O
(	O
CsA	O
)	O
is	O
a	O
potent	O
inhibitor	O
of	O
opening	O
of	O
the	O
mitochondrial	O
permeability	O
transition	O
pore	O
,	O
which	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
myocardial	O
reperfusion	O
injury	O
.	O

The	O
impact	O
of	O
this	O
treatment	O
on	O
clinical	O
outcomes	O
of	O
acute	O
STEMI	O
remains	O
unknown	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
clinical	O
outcomes	O
of	O
using	O
this	O
drug	O
in	O
patients	O
with	O
acute	O
anterior	O
STEMI	O
receiving	O
thrombolytic	O
treatment	O
(	O
TLT	O
)	O
.	O

METHODS	O
In	O
this	O
double-blinded	O
randomized	O
clinical	O
trial	O
,	O
101	O
patients	O
with	O
acute	O
anterior	O
STEMI	O
who	O
were	O
candidate	O
for	O
TLT	O
,	O
were	O
enrolled	O
and	O
randomly	O
assigned	O
into	O
treatment	O
or	O
control	O
groups	O
.	O

Patients	O
in	O
the	O
treatment	O
group	O
received	O
an	O
intravenous	O
bolus	O
injection	O
of	O
2.5	O
mg/kg	O
of	O
CsA	O
immediately	O
before	O
TLT	O
.	O

The	O
patients	O
in	O
the	O
control	O
group	O
received	O
an	O
equivalent	O
volume	O
of	O
normal	O
saline	O
.	O

Infarct	Physical
size	Physical
,	Physical
occurrence	Physical
of	Physical
major	Physical
arrhythmias	Physical
,	Physical
heart	Physical
failure	Physical
,	Physical
left	Physical
ventricular	Physical
ejection	Physical
fraction	Physical
(	Physical
LVEF	Physical
)	Physical
,	Physical
TLT-related	Adverseeffect
complications	Adverseeffect
,	Physical
in-hospital	Mortality
and	Mortality
6-month	Mortality
mortality	Mortality
rates	Mortality
were	O
investigated	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
among	O
the	O
demographics	Physical
,	Physical
myocardial	Physical
enzyme	Physical
release	Physical
,	Physical
occurrence	Physical
of	Physical
major	Physical
arrhythmias	Physical
[	O
9	O
(	O
18	O
%	O
)	O
vs.	O
12	O
(	O
23.5	O
%	O
)	O
,	O
P	O
=	O
0.80	O
]	O
,	O
heart	Physical
failure	Physical
[	O
18	O
(	O
36	O
%	O
)	O
vs.	O
19	O
(	O
38.3	O
%	O
)	O
,	O
P	O
=	O
0.83	O
]	O
,	O
LVEF	Physical
at	Physical
first	Physical
day	Physical
[	O
34.7	O
?	O
9.9	O
%	O
vs.	O
33.5	O
?	O
8.1	O
%	O
,	O
P	O
=	O
0.50	O
]	O
or	O
at	O
discharge	O
[	O
37.7	O
?	O
10	O
%	O
vs.	O
36.1	O
?	O
8.2	O
%	O
,	O
P	O
=	O
0.43	O
]	O
,	O
and	O
in-hospital	O
[	O
4	O
(	O
8	O
%	O
)	O
vs.	O
6	O
(	O
11.8	O
%	O
)	O
,	O
P	O
=	O
0.74	O
]	O
or	O
6-month	Mortality
mortality	Mortality
rates	Mortality
[	O
9	O
(	O
18	O
%	O
)	O
vs.	O
10	O
(	O
19.6	O
%	O
)	O
,	O
P	O
=	O
0.99	O
]	O
between	O
the	O
CsA	O
vs.	O
the	O
control	O
group	O
.	O

CONCLUSION	O
In	O
this	O
study	O
,	O
the	O
prethrombolytic	O
administration	O
of	O
CsA	O
was	O
not	O
associated	O
with	O
a	O
reduction	O
in	O
the	O
infarct	O
size	O
or	O
any	O
improvement	O
in	O
clinical	O
outcomes	O
.	O

Rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
:	O
prevention	O
of	O
fasciculations	Physical
with	O
pancuronium	O
versus	O
minidose	O
succinylcholine	O
.	O

INTRODUCTION	O
Fasciculations	Physical
during	O
rapid-sequence	O
intubation	O
may	O
lead	O
to	O
increased	O
intracranial	O
pressure	O
and	O
emesis	Physical
with	O
aspiration	O
.	O

Standard	O
rapid-sequence	O
intubation	O
requires	O
a	O
nondepolarizing	O
blocking	O
agent	O
before	O
succinylcholine	O
administration	O
.	O

HYPOTHESIS	O
Prevention	O
of	O
fasciculations	Physical
during	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
can	O
be	O
accomplished	O
as	O
safely	O
and	O
effectively	O
with	O
minidose	O
succinylcholine	O
as	O
with	O
a	O
defasciculating	O
dose	O
of	O
pancuronium	O
.	O

DESIGN	O
A	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
.	O

SETTING	O
An	O
inner-city	O
county	O
trauma	O
center	O
with	O
70,000	O
patient	O
visits	O
per	O
year	O
.	O

PARTICIPANTS	O
Sequential	O
adult	O
head	O
trauma	O
patients	O
requiring	O
rapid-sequence	O
intubation	O
who	O
had	O
no	O
contraindications	O
to	O
succinylcholine	O
or	O
pancuronium	O
.	O

INTERVENTIONS	O
Each	O
head	O
trauma	O
patient	O
requiring	O
rapid-sequence	O
intubation	O
who	O
met	O
the	O
inclusion	O
criteria	O
received	O
standard	O
rapid-sequence	O
intubation	O
maneuvers	O
and	O
lidocaine	O
(	O
1	O
mg/kg	O
)	O
IV	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
either	O
minidose	O
succinylcholine	O
(	O
0.1	O
mg/kg	O
)	O
or	O
pancuronium	O
(	O
0.03	O
mg/kg	O
)	O
IV	O
one	O
minute	O
prior	O
to	O
the	O
full	O
paralytic	O
dose	O
of	O
succinylcholine	O
(	O
1.5	O
mg/kg	O
)	O
IV	O
.	O

Fasciculations	Physical
were	O
recorded	O
using	O
a	O
graded	Others
visual	Others
scale	Others
.	O

RESULTS	O
Of	O
46	O
patients	O
,	O
eight	O
of	O
19	O
(	O
42	O
%	O
)	O
in	O
the	O
pancuronium	O
group	O
and	O
six	O
of	O
27	O
(	O
22	O
%	O
)	O
in	O
the	O
succinylcholine	O
group	O
experienced	O
fasciculations	Physical
.	O

No	O
statistically	O
significant	O
difference	O
in	O
fasciculations	Physical
was	O
detected	O
between	O
the	O
two	O
groups	O
using	O
chi	O
2	O
analysis	O
.	O

Complete	Physical
relaxation	Physical
of	Physical
the	Physical
cords	Physical
was	O
present	O
in	O
all	O
but	O
two	O
patients	O
,	O
one	O
in	O
each	O
group	O
.	O

No	O
patient	O
in	O
either	O
group	O
experienced	O
emesis	Physical
or	O
significant	Physical
dysrhythmias	Physical
.	O

CONCLUSION	O
Pretreatment	O
with	O
minidose	O
succinylcholine	O
causes	O
no	O
greater	O
incidence	O
of	O
fasciculations	Physical
than	O
pancuronium	O
in	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
in	O
an	O
ED	O
setting	O
.	O

Thus	O
succinylcholine	O
may	O
be	O
used	O
as	O
the	O
sole	O
paralytic	O
agent	O
in	O
rapid-sequence	O
intubation	O
of	O
head	O
trauma	O
patients	O
.	O

A	O
comparison	O
between	O
oral	O
ciprofloxacin	O
and	O
intra-peritoneal	O
vancomycin	O
and	O
gentamicin	O
in	O
the	O
treatment	O
of	O
CAPD	Physical
peritonitis	Physical
.	O

Fifty-one	O
patients	O
were	O
included	O
in	O
a	O
prospective	O
,	O
randomized	O
comparison	O
of	O
oral	O
ciprofloxacin	O
and	O
intraperitoneal	O
vancomycin/gentamicin	O
in	O
the	O
treatment	O
of	O
CAPD	O
peritonitis	O
.	O

Staphylococcal	O
species	O
accounted	O
for	O
40	O
%	O
of	O
the	O
isolates	O
with	O
an	O
equal	O
incidence	O
of	O
Staphylococcus	Others
aureus	Others
and	O
coagulase	Others
negative	Others
staphylococci	Others
.	O

Although	O
,	O
overall	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
regimens	O
in	O
outcome	O
,	O
ciprofloxacin	O
was	O
significantly	O
less	O
effective	Others
when	O
peritonitis	O
was	O
due	O
to	O
coagulase	O
negative	O
staphylococci	O
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
study	O
of	O
the	O
efficacy	O
of	O
transdermal	O
clonidine	O
in	O
autism	O
.	O

BACKGROUND	O
Autistic	O
individuals	O
often	O
exhibit	O
hyperarousal	O
behaviors	O
(	O
e.g.	O
,	O
stereotyped	O
body	O
movements	O
,	O
self-stimulation	O
,	O
hypervigilance	O
,	O
and	O
hyperactivity	O
)	O
.	O

Clonidine	O
,	O
an	O
alpha	O
2-adrenergic	O
receptor	O
agonist	O
,	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
reducing	O
impulsivity	O
,	O
inattention	O
,	O
and	O
hyperactivity	O
associated	O
with	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
.	O

This	O
study	O
investigated	O
the	O
efficacy	Physical
and	Physical
safety	Physical
of	O
transdermal	O
clonidine	O
in	O
reducing	O
hyperarousal	O
behaviors	O
associated	O
with	O
autism	O
.	O

METHOD	O
A	O
double-blind	O
,	O
placebo-crossover	O
study	O
with	O
transdermal	O
clonidine	O
was	O
performed	O
in	O
nine	O
autistic	O
males	O
(	O
aged	O
5	O
to	O
33	O
years	O
)	O
.	O

Subjects	O
received	O
either	O
clonidine	O
(	O
approximately	O
0.005	O
mg/kg/day	O
)	O
or	O
placebo	O
by	O
a	O
weekly	O
transdermal	O
patch	O
.	O

Each	O
trial	O
lasted	O
4	O
weeks	O
with	O
a	O
2-week	O
washout	O
period	O
between	O
treatment	O
phases	O
.	O

Subjects	O
were	O
evaluated	O
every	O
2	O
weeks	O
by	O
clinician	O
raters	O
and	O
weekly	O
by	O
parents	O
.	O

RESULTS	O
The	O
clonidine	O
treatment	O
showed	O
a	O
significant	O
difference	O
from	O
placebo	O
treatment	O
on	O
three	O
subscales	O
of	O
the	O
Ritvo-Freeman	Physical
Real	Physical
Life	Physical
Rating	Physical
Scale	Physical
(	Physical
i.e.	Physical
,	O
social	Mental
relationship	Mental
to	Mental
people	Mental
,	O
affectual	Mental
responses	Mental
,	O
and	O
sensory	O
responses	O
)	O
.	O

The	O
Clinical	Physical
Global	Physical
Impressions	Physical
scale	Physical
indicated	O
that	O
clonidine	O
produced	O
a	O
significant	O
improvement	O
on	O
severity	Physical
of	Physical
illness	Physical
,	O
global	Others
improvement	Others
,	O
and	O
efficacy	Others
index	Others
for	O
therapeutic	O
effect	O
of	O
the	O
drug	O
.	O

A	O
patient	Others
global	Others
rating	Others
scale	Others
showed	O
clonidine	O
treatment	O
resulted	O
in	O
significant	O
improvement	O
in	O
comparison	O
with	O
placebo	O
.	O

Adverse	Adverseeffect
effects	Adverseeffect
included	Adverseeffect
sedation	Adverseeffect
and	Adverseeffect
fatigue	Adverseeffect
during	O
the	O
first	O
2	O
weeks	O
of	O
clonidine	O
treatment	O
.	O

CONCLUSION	O
Results	O
from	O
this	O
preliminary	O
study	O
show	O
that	O
clonidine	O
was	O
effective	O
in	O
reducing	O
several	Mental
hyperarousal	Mental
behaviors	Mental
and	O
improved	O
social	Mental
relationships	Mental
in	O
some	O
autistic	O
subjects	O
.	O

Further	O
studies	O
are	O
needed	O
in	O
a	O
larger	O
autistic	O
population	O
to	O
determine	O
the	O
dose-response	O
relationship	O
of	O
clonidine	O
.	O

Bismuth	O
subsalicylate	O
in	O
the	O
treatment	O
of	O
gastritis	O
due	O
to	O
Campylobacter	O
pylori	O
.	O

Fifty	O
patients	O
completed	O
an	O
investigator-blind	O
trial	O
comparing	O
bismuth	O
subsalicylate	O
,	O
erythromycin	O
ethylsuccinate	O
,	O
and	O
placebo	O
matched	O
to	O
the	O
bismuth	O
salt	O
in	O
the	O
treatment	O
of	O
gastritis	O
associated	O
with	O
Campylobacter	O
pylori	O
.	O

C.	O
pylori	O
was	O
cleared	O
from	O
14	O
(	O
77.8	O
%	O
)	O
of	O
18	O
patients	O
given	O
locally	O
active	O
bismuth	O
,	O
from	O
one	O
(	O
6.7	O
%	O
)	O
of	O
15	O
patients	O
given	O
erythromycin	O
,	O
and	O
from	O
none	O
of	O
17	O
patients	O
given	O
placebo	O
.	O

Gastritis	O
resolved	O
in	O
13	O
(	O
81	O
%	O
)	O
of	O
16	O
patients	O
treated	O
with	O
bismuth	O
but	O
in	O
only	O
three	O
of	O
13	O
receiving	O
erythromycin	O
and	O
in	O
none	O
of	O
16	O
patients	O
given	O
placebo	O
.	O

Results	O
of	O
endoscopic	O
examination	O
showed	O
greater	O
improvement	O
in	O
patients	O
cleared	O
of	O
C.	O
pylori	O
than	O
in	O
those	O
with	O
persistent	O
infection	O
.	O

Heartburn	Physical
improved	O
in	O
50	O
%	O
of	O
patients	O
who	O
received	O
bismuth	O
compared	O
with	O
17	O
%	O
of	O
those	O
given	O
placebo	O
.	O

The	O
success	O
of	O
bismuth	O
is	O
probably	O
due	O
to	O
its	O
local	Physical
antimicrobial	Physical
activity	Physical
.	O

Erythromycin	O
may	O
have	O
been	O
inactivated	O
by	O
the	O
low	O
pH	O
in	O
the	O
areas	O
colonized	O
with	O
C.	O
pylori	O
.	O

Relapse	Physical
is	O
less	O
frequent	O
when	O
a	O
combination	O
of	O
bismuth	O
and	O
an	O
antimicrobial	O
agent	O
is	O
used	O
;	O
such	O
a	O
combination	O
is	O
characterized	O
by	O
local	Physical
and	Physical
systemic	Physical
activity	Physical
,	O
stability	Physical
at	Physical
low	Physical
pH	Physical
,	O
and	O
good	Physical
penetration	Physical
into	Physical
gastric	Physical
mucus	Physical
.	O

[	O
Potentiation	O
of	O
the	O
effect	O
of	O
non-depolarizing	O
muscle	O
relaxants	O
by	O
acylaminopenicillins	O
.	O

Studies	O
on	O
the	O
example	O
of	O
vecuronium	O
]	O
.	O

In	O
a	O
prospective	O
controlled	O
clinical	O
study	O
interactions	O
between	O
nondepolarizing	O
muscle	O
relaxants	O
and	O
acylaminopenicillins	O
were	O
investigated	O
electromyographically	O
.	O

Six	O
patients	O
in	O
each	O
group	O
received	O
either	O
apalcillin	O
,	O
azlocillin	O
,	O
mezlocillin	O
or	O
piperacillin	O
during	O
the	O
operation	O
.	O

Muscle	Physical
relaxation	Physical
was	O
maintained	O
using	O
the	O
short	O
acting	O
nondepolarizing	O
relaxant	O
vecuronium	O
,	O
which	O
shows	O
no	O
cumulative	O
effect	O
within	O
clinical	O
dosages	O
.	O

The	O
intra-individual	O
comparison	O
with	O
the	O
control	O
period	O
(	O
100	O
%	O
)	O
showed	O
a	O
significant	O
prolongation	Others
of	Others
the	Others
duration	Others
of	Others
action	Others
after	O
a	O
fixed	O
dose	O
of	O
vecuronium	O
.	O

The	O
mean	Others
increase	Others
was	O
+26	O
%	O
following	O
apalcillin	O
,	O
+46	O
%	O
after	O
piperacillin	O
,	O
+38	O
%	O
following	O
mezlocillin	O
and	O
+55	O
%	O
following	O
azlocillin	O
.	O

The	O
shortest	Others
time	Others
of	O
the	O
control	O
periods	O
was	O
8.6	O
min	O
and	O
the	O
maximum	O
time	O
was	O
32.6	O
min	O
.	O

We	O
also	O
found	O
a	O
significant	O
depression	Mental
of	O
the	O
EMG-response	Physical
.	O

No	O
significant	O
differences	O
could	O
be	O
detected	O
between	O
the	O
four	O
antibiotics	O
.	O

The	O
method	O
described	O
here	O
has	O
proven	O
to	O
be	O
sensitive	O
enough	O
to	O
detect	O
clinically	Pain
relevant	Pain
interactions	Pain
with	O
muscle	Pain
relaxants	Pain
.	O

As	O
a	O
result	O
of	O
our	O
study	O
,	O
caution	O
seems	O
to	O
be	O
necessary	O
if	O
acylaminopenicillins	O
are	O
administered	O
in	O
the	O
early	O
postoperative	O
period	O
.	O

[	O
The	O
effects	O
of	O
antidepressant	O
treatment	O
on	O
efficacy	Others
of	O
antihypertensive	O
therapy	O
in	O
elderly	O
hypertension	O
]	O
.	O

OBJECTIVE	O
To	O
explore	O
the	O
effect	O
of	O
antidepressant	O
treatment	O
on	O
antihypertensive	O
therapy	O
of	O
senile	O
hypertension	Physical
.	O

METHODS	O
138	O
cases	O
of	O
senile	O
hypertension	O
complicating	O
with	O
depression	O
were	O
studied	O
.	O

103	O
senile	O
hypertensive	O
patients	O
without	O
depression	O
in	O
the	O
same	O
period	O
served	O
as	O
controls	O
.	O

The	O
patients	O
were	O
randomly	O
divided	O
into	O
3	O
groups	O
as	O
A	O
,	O
B	O
and	O
C	O
for	O
study	O
.	O

12.5	O
mg/d	O
hydrochlorothiazide	O
and	O
30	O
mg/d	O
release-controlling	O
tablets	O
of	O
nifedipine	O
were	O
orally	O
administrated	O
as	O
basic	O
antihypertensive	O
medication	O
each	O
group	O
.	O

Besides	O
,	O
20	O
mg/d	O
fluoxetine	O
was	O
additionally	O
given	O
to	O
groups	O
A	O
and	O
one	O
tablet	O
of	O
almitrine	O
l/d	O
and	O
20	O
mg	O
oryzanol	O
3/d	O
were	O
given	O
to	O
group	O
B	O
.	O

The	O
treatment	O
lasted	O
12	O
weeks	O
.	O

RESULTS	O
In	O
comparison	O
with	O
pre-treatment	O
,	O
the	O
blood	Physical
pressure	Physical
at	O
base	O
line	O
in	O
sitting	O
position	O
and	O
the	O
average	Physical
circadian	Physical
SBP	Physical
and	Physical
DBP	Physical
monitored	Physical
with	Physical
24-hour	Physical
ambulatory	Physical
blood	Physical
pressure	Physical
monitoring	Physical
(	Physical
ABPM	Physical
)	Physical
was	O
remarkably	O
decreased	O
in	O
group	O
A	O
with	O
statistical	O
significance	O
(	O
P	O
<	O
0.01	O
)	O
.	O

These	O
blood	Physical
pressure	Physical
parameters	Physical
in	O
group	O
B	O
were	O
also	O
decreased	O
as	O
compared	O
ith	O
the	O
pretreatment	O
level	O
brt	O
with	O
less	O
statistical	O
significance	O
(	O
P	O
>	O
0.05	O
)	O
.	O

It	O
was	O
also	O
noted	O
tha	O
with	O
the	O
addition	O
of	O
antidepressant	O
fluoxetine	O
,	O
the	O
manifestations	O
of	O
depression	Mental
ere	O
alleviated	O
as	O
shown	O
by	O
Hamilton	Mental
depression	Mental
(	Mental
HAMD	Mental
)	Mental
scale	Mental
.	O

untoward	O
reactions	O
such	O
as	O
nausea	Adverseeffect
,	Physical
perspiration	Adverseeffect
and	Physical
skin	Adverseeffect
rash	Adverseeffect
were	O
noted	O
in	O
a	O
few	O
patients	O
,	O
but	O
none	O
withdrew	O
from	O
the	O
study	O
.	O

CONCLUSIONS	O
Antidepressant	O
and	O
antianxiety	O
treatment	O
is	O
of	O
benefit	O
to	O
the	O
antihypertensive	O
therapy	O
in	O
senile	O
hypertensive	O
patients	O
with	O
complications	O
of	O
depression	O
and/or	O
anxiety	O
neurosis	O
.	O

Based	O
on	O
the	O
results	O
of	O
this	O
study	O
,	O
it	O
is	O
suggested	O
that	O
routine	O
administration	O
of	O
antidepressants	O
and	O
antianxiety	O
drugs	O
should	O
be	O
carried	O
out	O
in	O
senile	O
hypertensive	O
patients	O
complicating	O
with	O
depression	O
or	O
anxiety	O
.	O

A	O
randomized	O
,	O
controlled	O
trial	O
of	O
the	O
efficacy	Others
of	O
a	O
heparin	O
and	O
vancomycin	O
solution	O
in	O
preventing	O
central	Physical
venous	Physical
catheter	Physical
infections	Physical
in	O
children	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
adding	O
vancomycin	O
to	O
central	O
venous	O
catheter	O
(	O
CVC	O
)	O
flush	O
solution	O
would	O
significantly	O
reduce	O
the	O
incidence	O
of	O
bacteremia	O
attributable	O
to	O
luminal	O
colonization	O
with	O
vancomycin-susceptible	O
organisms	O
.	O

STUDY	O
DESIGN	O
Fifty-five	O
children	O
with	O
cancer	O
and	O
eight	O
children	O
given	O
total	O
parenteral	O
nutrition	O
by	O
the	O
surgery	O
or	O
nutrition	O
support	O
services	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
heparin	O
CVC	O
flush	O
solution	O
(	O
n	O
=	O
31	O
)	O
or	O
a	O
heparin-vancomycin	O
CVC	O
flush	O
solution	O
(	O
n	O
=	O
32	O
)	O
.	O

RESULTS	O
During	O
9158	O
catheter	O
days	O
,	O
6.5	O
%	O
of	O
the	O
patients	O
in	O
the	O
heparin	O
group	O
and	O
15.6	O
%	O
of	O
the	O
patients	O
in	O
the	O
heparin-vancomycin	O
group	O
had	O
bacteremia	O
attributable	O
to	O
luminal	O
colonization	O
with	O
vancomycin-susceptible	O
organisms	O
(	O
p	O
=	O
0.43	O
)	O
.	O

The	O
mean	Physical
rates	Physical
of	Physical
bacteremia	Physical
attributable	O
to	O
luminal	O
colonization	O
with	O
vancomycin-susceptible	O
organisms	O
were	O
0.6/1000	O
catheter	O
days	O
in	O
the	O
heparin	O
group	O
and	O
1.4/1000	O
catheter	O
days	O
in	O
the	O
heparin-vancomycin	O
group	O
(	O
p	O
=	O
0.25	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
when	O
the	O
time	Physical
to	Physical
the	Physical
first	Physical
episode	Physical
of	Physical
bacteremia	Physical
attributable	O
to	O
luminal	O
colonization	O
with	O
a	O
vancomycin-susceptible	O
organism	O
was	O
compared	O
by	O
means	O
of	O
Kaplan-Meier	O
survival	O
estimates	O
.	O

Streptococcus	Physical
viridans	Physical
infection	Physical
was	O
not	O
attributable	O
to	O
luminal	O
colonization	O
.	O

CONCLUSION	O
The	O
addition	O
of	O
vancomycin	O
to	O
heparin	O
CVC	O
flush	O
solution	O
did	O
not	O
reduce	O
bacteremia	Physical
with	O
vancomycin-susceptible	O
organisms	O
.	O

Bacteremia	Physical
with	O
Streptococcus	O
viridans	O
was	O
not	O
related	O
to	O
the	O
use	O
of	O
a	O
CVC	O
.	O

The	O
treatment	O
of	O
asthma	O
in	O
adults	O
using	O
sodium	O
cromoglycate	O
pressurized	O
aerosol	O
:	O
a	O
double-blind	O
controlled	O
trial	O
.	O

Sodium	O
cromoglycate	O
formulated	O
as	O
a	O
pressurized	O
aerosol	O
(	O
2	O
mg	O
4-times	O
daily	O
)	O
and	O
placebo	O
were	O
compared	O
in	O
31	O
adult	O
asthmatic	O
patients	O
in	O
a	O
double-blind	O
crossover	O
trial	O
lasting	O
12	O
weeks	O
.	O

Sodium	O
cromoglycate	O
was	O
superior	O
to	O
placebo	O
in	O
improving	O
breathlessness	Physical
at	Physical
rest	Physical
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
breathlessness	Physical
on	Physical
exertion	Physical
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
the	O
quality	Physical
of	Physical
sleep	Physical
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
also	O
in	O
improving	O
the	O
morning	Physical
peak	Physical
expiratory	Physical
flow	Physical
rate	Physical
value	Physical
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Both	O
the	O
patients	O
'	O
(	O
p	O
less	O
than	O
0.05	O
)	O
and	O
the	O
clinicians	O
'	O
(	O
p	O
less	O
than	O
0.01	O
)	O
treatment	O
opinions	O
,	O
and	O
their	O
treatment	Mental
preferences	Mental
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
favoured	O
sodium	O
cromoglycate	O
.	O

Moreover	O
,	O
usage	Others
of	Others
bronchodilators	Others
(	O
theophylline	O
and	O
aerosol	O
beta-stimulants	O
combined	O
)	O
declined	O
significantly	O
(	O
p	O
less	O
than	O
0.001	O
)	O
during	O
sodium	O
cromoglycate	O
treatment	O
compared	O
to	O
placebo	O
.	O

No	O
side-effects	Adverseeffect
were	O
reported	O
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
sodium	O
cromoglycate	O
delivered	O
by	O
pressurized	O
aerosol	O
was	O
significantly	O
superior	O
to	O
placebo	O
,	O
not	O
only	O
in	O
improving	O
asthmatic	Physical
symptoms	Physical
,	O
but	O
also	O
in	O
reducing	O
the	O
amount	Others
of	Others
concomitant	Others
bronchodilator	Others
therapy	Others
required	Others
.	O

Warfarin	O
versus	O
aspirin	O
for	O
prevention	O
of	O
thromboembolism	O
in	O
atrial	O
fibrillation	O
:	O
Stroke	O
Prevention	O
in	O
Atrial	O
Fibrillation	O
II	O
Study	O
.	O

Warfarin	O
is	O
an	O
established	O
treatment	O
for	O
prevention	O
of	O
ischaemic	O
stroke	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
,	O
but	O
the	O
value	O
of	O
this	O
agent	O
relative	O
to	O
aspirin	O
in	O
unclear	O
.	O

In	O
the	O
first	O
Stroke	O
Prevention	O
in	O
Atrial	O
Fibrillation	O
(	O
SPAF-I	O
)	O
study	O
,	O
direct	O
comparison	O
of	O
warfarin	O
with	O
aspirin	O
was	O
limited	O
by	O
the	O
small	O
number	O
of	O
thromboembolic	O
events	O
.	O

SPAF-II	O
aims	O
to	O
address	O
this	O
issue	O
and	O
also	O
to	O
assess	O
the	O
differential	O
effects	O
of	O
the	O
two	O
treatments	O
according	O
to	O
age	O
.	O

We	O
compared	O
warfarin	O
(	O
prothrombin	O
time	O
ratio	O
1.3-1.8	O
,	O
international	O
normalised	O
ratio	O
2.0-4.5	O
)	O
with	O
aspirin	O
325	O
mg	O
daily	O
for	O
prevention	O
of	O
ischaemic	O
stroke	O
and	O
systemic	O
embolism	O
(	O
primary	O
events	O
)	O
in	O
two	O
parallel	O
randomised	O
trials	O
involving	O
715	O
patients	O
aged	O
75	O
years	O
or	O
less	O
and	O
385	O
patients	O
older	O
than	O
75	O
;	O
we	O
sought	O
reductions	O
in	O
the	O
absolute	O
rate	O
of	O
primary	O
events	O
by	O
warfarin	O
compared	O
with	O
aspirin	O
of	O
2	O
%	O
per	O
year	O
and	O
4	O
%	O
per	O
year	O
,	O
respectively	O
.	O

In	O
the	O
younger	O
patients	O
,	O
warfarin	O
decreased	O
the	O
absolute	Physical
rate	Physical
of	Physical
primary	Physical
events	Physical
by	O
0.7	O
%	O
per	O
year	O
(	O
95	O
%	O
CI-0.4	O
to	O
1.7	O
)	O
.	O

The	O
primary	Physical
event	Physical
rate	Physical
per	Physical
year	Physical
was	O
1.3	O
%	O
with	O
warfarin	O
and	O
1.9	O
%	O
with	O
aspirin	O
(	O
relative	O
risk	O
[	O
RR	O
]	O
0.67	O
,	O
p	O
=	O
0.24	O
)	O
.	O

The	O
absolute	O
rate	O
of	O
primary	O
events	O
in	O
low-risk	O
younger	O
patients	O
(	O
without	O
hypertension	O
,	O
recent	O
heart	O
failure	O
,	O
or	O
previous	O
thromboembolism	O
)	O
on	O
aspirin	O
was	O
0.5	O
%	O
per	O
year	O
(	O
95	O
%	O
CI	O
0.1	O
to	O
1.9	O
)	O
.	O

Among	O
older	O
patients	O
,	O
warfarin	O
decreased	O
the	O
absolute	O
rate	O
of	O
primary	O
events	O
by	O
1.2	O
%	O
per	O
year	O
(	O
95	O
%	O
CI-1.7	O
to	O
4.1	O
)	O
.	O

The	O
primary	O
event	O
rate	O
per	O
year	O
was	O
3.6	O
%	O
with	O
warfarin	O
and	O
4.8	O
%	O
with	O
aspirin	O
(	O
RR	O
0.73	O
,	O
p	O
=	O
0.39	O
)	O
.	O

In	O
this	O
older	O
group	O
,	O
the	O
rate	O
of	O
all	O
stroke	O
with	O
residual	O
deficit	O
(	O
ischaemic	O
or	O
haemorrhagic	O
)	O
was	O
4.3	O
%	O
per	O
year	O
with	O
aspirin	O
and	O
4.6	O
%	O
per	O
year	O
with	O
warfarin	O
(	O
RR	O
1.1	O
)	O
.	O

Warfarin	O
may	O
be	O
more	O
effective	O
than	O
aspirin	O
for	O
prevention	O
of	O
ischaemic	O
stroke	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
,	O
but	O
the	O
absolute	O
reduction	O
in	O
stroke	O
rate	O
by	O
warfarin	O
is	O
small	O
.	O

Younger	O
patients	O
without	O
risk	O
factors	O
had	O
a	O
low	O
rate	O
of	O
stroke	O
when	O
treated	O
with	O
aspirin	O
.	O

In	O
older	O
patients	O
the	O
rate	O
of	O
stroke	O
(	O
ischaemic	O
and	O
haemorrhagic	O
)	O
was	O
substantial	O
,	O
irrespective	O
of	O
which	O
agent	O
was	O
given	O
.	O

Patient	O
age	O
and	O
the	O
inherent	O
risk	O
of	O
thromboembolism	O
should	O
be	O
considered	O
in	O
the	O
choice	O
of	O
antithrombotic	O
prophylaxis	O
for	O
patients	O
with	O
atrial	O
fibrillation	O
.	O

Uvulopalatopharyngoplasty	O
versus	O
laser	O
assisted	O
uvulopalatoplasty	O
for	O
the	O
treatment	O
of	O
snoring	O
:	O
an	O
objective	O
randomised	O
clinical	O
trial	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
objectively	O
the	O
clinical	O
effectiveness	O
of	O
surgery	O
for	O
snoring	O
and	O
to	O
compare	O
the	O
results	O
of	O
conventional	O
uvulopalatopharyngoplasty	O
(	O
UPPP	O
)	O
and	O
laser	O
assisted	O
uvulopalatoplasty	O
(	O
LAUP	O
)	O
in	O
the	O
treatment	O
of	O
snoring	O
.	O

Patients	O
who	O
had	O
been	O
referred	O
for	O
investigation	O
and	O
treatment	O
of	O
their	O
snoring	O
were	O
randomly	O
allocated	O
to	O
receive	O
either	O
UPPP	O
or	O
LAUP	O
.	O

Forty-seven	O
patients	O
with	O
confirmed	O
palatal	O
flutter	O
had	O
surgery	O
and	O
all	O
of	O
them	O
had	O
a	O
preoperative	O
and	O
postoperative	O
objective	O
assessment	O
of	O
their	O
snoring	Physical
loudness	Physical
and	O
duration	Others
in	Others
the	Others
home	Others
.	O

The	O
recording	O
device	O
(	O
Snore	O
Box	O
)	O
is	O
simple	O
for	O
the	O
patient	O
to	O
operate	O
,	O
portable	O
with	O
a	O
built	O
in	O
microphone	O
,	O
and	O
able	O
to	O
produce	O
objective	O
results	O
,	O
which	O
can	O
be	O
automatically	O
analysed	O
.	O

Of	O
the	O
38	O
patients	O
,	O
who	O
had	O
technically	O
valid	O
recordings	O
,	O
22	O
underwent	O
LAUP	O
and	O
16	O
UPPP	O
.	O

Overall	O
the	O
mean	Physical
postoperative	Physical
Snore	Physical
Index	Physical
(	Physical
SI	Physical
)	Physical
was	O
less	O
than	O
the	O
preoperative	O
SI	Physical
(	O
P	O
<	O
0.0001	O
)	O
,	O
the	O
average	O
difference	O
being	O
78.2	O
snores/h	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
LAUP	O
and	O
UPPP	O
regarding	O
the	O
fall	Physical
in	Physical
the	Physical
SI	Physical
.	O

This	O
study	O
is	O
the	O
first	O
objective	O
comparative	O
study	O
to	O
demonstrate	O
the	O
effectiveness	Others
of	Others
snoring	Others
surgery	Others
.	O

The	O
role	O
of	O
ethnic	O
matching	O
between	O
patient	O
and	O
provider	O
on	O
the	O
effectiveness	Others
of	O
brief	O
alcohol	O
interventions	O
with	O
Hispanics	O
.	O

BACKGROUND	O
Evaluating	O
the	O
effectiveness	O
of	O
treatments	O
such	O
as	O
brief	O
alcohol	O
interventions	O
among	O
Hispanics	O
is	O
essential	O
to	O
effectively	O
addressing	O
their	O
treatment	O
needs	O
.	O

Clinicians	O
of	O
the	O
same	O
ethnicity	O
as	O
the	O
client	O
may	O
be	O
more	O
likely	O
to	O
understand	O
the	O
culture-specific	O
values	O
,	O
norms	O
,	O
and	O
attitudes	O
and	O
,	O
therefore	O
,	O
the	O
intervention	O
may	O
be	O
more	O
effective	O
.	O

Thus	O
,	O
in	O
cases	O
in	O
which	O
Hispanic	O
patients	O
were	O
provided	O
intervention	O
by	O
a	O
Hispanic	O
clinician	O
improved	O
drinking	O
outcomes	O
were	O
expected	O
.	O

METHODS	O
Patients	O
were	O
recruited	O
from	O
an	O
urban	O
Level	O
I	O
Trauma	O
following	O
screening	O
for	O
an	O
alcohol-related	O
injury	O
or	O
alcohol	O
problems	O
.	O

Five	O
hundred	O
thirty-seven	O
Hispanics	O
were	O
randomly	O
assigned	O
to	O
brief	O
intervention	O
or	O
treatment	O
as	O
usual	O
.	O

Hierarchical	O
linear	O
modeling	O
was	O
used	O
to	O
determine	O
the	O
effects	Mental
of	Mental
ethnic	Mental
match	Mental
on	Mental
drinking	Mental
outcomes	Mental
including	O
volume	Mental
per	Mental
week	Mental
,	Mental
maximum	Mental
amount	Mental
,	Mental
and	Mental
frequency	Mental
of	Mental
5	Mental
or	Mental
more	Mental
drinks	Mental
per	Mental
occasion	Mental
.	O

Analyses	O
controlled	O
for	O
level	O
of	O
acculturation	O
and	O
immigration	O
status	O
.	O

RESULTS	O
For	O
Hispanics	O
who	O
received	O
brief	O
motivational	O
intervention	O
,	O
an	O
ethnic	O
match	O
between	O
patient	O
and	O
provider	O
resulted	O
in	O
a	O
significant	Mental
reduction	Mental
in	Mental
drinking	Mental
outcomes	Mental
at	O
12-month	O
follow-up	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
tendency	O
for	O
ethnic	O
match	O
to	O
be	O
most	O
beneficial	Others
to	O
foreign-born	O
Hispanics	O
and	O
less	Others
acculturated	O
Hispanics	O
.	O

CONCLUSION	O
As	O
hypothesized	O
,	O
an	O
ethnic	O
match	O
between	O
patient	O
and	O
provider	O
significantly	O
enhanced	O
the	O
effectiveness	Others
of	O
brief	O
intervention	O
among	O
Hispanics	O
.	O

Ethnic	O
concordance	O
between	O
patient	O
and	O
provider	O
may	O
have	O
impacted	O
the	O
effectiveness	Others
of	O
the	O
intervention	O
through	O
several	O
mechanisms	O
including	O
cultural	O
scripts	O
,	O
ethnic-specific	O
perceptions	O
pertaining	O
to	O
substance	O
abuse	O
,	O
and	O
ethnic-specific	O
preferred	O
channels	O
of	O
communication	O
.	O

The	O
effects	O
of	O
amantadine	O
and	O
pemoline	O
on	O
cognitive	O
functioning	O
in	O
multiple	O
sclerosis	O
.	O

BACKGROUND	O
Amantadine	O
hydrochloride	O
and	O
pemoline	O
,	O
both	O
frequently	O
used	O
to	O
treat	O
the	O
fatigue	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
may	O
also	O
improve	O
attention	O
and	O
other	O
cognitive	O
functions	O
in	O
MS.	O
To	O
our	O
knowledge	O
,	O
these	O
agents	O
have	O
never	O
been	O
compared	O
in	O
a	O
placebo-controlled	O
trial	O
of	O
patients	O
with	O
MS	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effects	O
of	O
amantadine	O
and	O
pemoline	O
on	O
cognitive	O
functioning	O
in	O
MS.	O
METHODS	O
A	O
total	O
of	O
45	O
ambulatory	O
patients	O
with	O
MS	O
and	O
severe	O
fatigue	O
were	O
treated	O
for	O
6	O
weeks	O
with	O
amantadine	O
,	O
pemoline	O
,	O
or	O
placebo	O
using	O
a	O
parallel	O
group	O
design	O
.	O

They	O
underwent	O
comprehensive	O
neuropsychological	O
testing	O
to	O
determine	O
treatment	O
effects	O
on	O
cognitive	O
functioning	O
.	O

Primary	O
outcome	O
measures	O
were	O
tests	O
of	O
attention	O
(	O
Digit	Mental
Span	Mental
,	Mental
Trail	Mental
Making	Mental
Test	Mental
,	Mental
and	Mental
Symbol	Mental
Digit	Mental
Modalities	Mental
Test	Mental
)	Mental
,	O
verbal	Mental
memory	Mental
(	Mental
Selective	Mental
Reminding	Mental
Test	Mental
)	Mental
,	Mental
nonverbal	Mental
memory	Mental
(	Mental
Benton	Mental
Visual	Mental
Retention	Mental
Test	Mental
)	Mental
,	Mental
and	O
motor	Mental
speed	Mental
(	Mental
Finger	Mental
Tapping	Mental
Test	Mental
)	Mental
.	O

RESULTS	O
Fatigue	Mental
did	O
not	O
significantly	O
correlate	O
with	O
any	O
of	O
the	O
neuropsychological	O
outcome	O
measures	O
at	O
baseline	O
or	O
after	O
treatment	O
.	O

All	O
three	O
treatment	O
groups	O
improved	O
on	O
tests	Mental
of	Mental
attention	Mental
(	O
P	O
<	O
.003	O
)	O
,	O
verbal	Mental
memory	Mental
(	O
P	O
<	O
.001	O
)	O
,	O
and	O
motor	Mental
speed	Mental
(	O
P	O
<	O
.002	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
amantadine	O
,	O
pemoline	O
,	O
and	O
placebo	O
.	O

CONCLUSIONS	O
Cognitive	O
functioning	O
in	O
MS	O
is	O
independent	O
of	O
fatigue	O
.	O

Neither	O
amantadine	O
nor	O
pemoline	O
enhances	O
cognitive	O
performance	O
in	O
MS	O
compared	O
with	O
placebo	O
.	O

Effect	O
of	O
negative	O
air	O
ionization	O
on	O
hyperactive	O
and	O
autistic	O
children	O
.	O

Twenty-one	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
and	O
seven	O
autistic	O
children	O
were	O
randomly	O
exposed	O
to	O
negatively	O
ionized	O
and	O
ambient	O
atmospheres	O
under	O
rigorously	O
controlled	O
experimental	O
conditions	O
.	O

The	O
negatively	O
ionized	O
condition	O
did	O
not	O
significantly	O
affect	O
measurements	O
of	O
activity	Mental
level	Mental
,	O
impulsivity	Mental
,	O
reality	Mental
orientation	Mental
,	O
destructive/constructiveness	Mental
,	O
attention	Mental
,	O
or	O
task	Mental
performance	Mental
.	O

Significant	O
results	O
might	O
be	O
obtained	O
if	O
subgroups	O
of	O
known	O
hyperserotoninemic	O
autistic	O
and	O
attention	O
deficit	O
disorder	O
children	O
were	O
exposed	O
to	O
negatively	O
ionized	O
conditions	O
.	O

Analgesic	O
effect	O
of	O
expressed	O
breast	O
milk	O
in	O
procedural	O
pain	O
in	O
term	O
neonates	O
:	O
a	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
.	O

AIM	O
To	O
assess	O
the	O
effectiveness	O
of	O
expressed	O
breast	O
milk	O
(	O
EBM	O
)	O
in	O
reducing	O
pain	Physical
due	O
to	O
venepuncture	O
,	O
in	O
term	O
neonates	O
,	O
as	O
measured	O
by	O
behavioural	O
and	O
physiological	O
observations	O
.	O

METHODS	O
This	O
randomized	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
involved	O
81	O
full-term	O
neonates	O
,	O
up	O
to	O
4	O
wk	O
of	O
postnatal	O
age	O
,	O
who	O
needed	O
venepuncture	O
for	O
blood	O
investigations	O
.	O

Two	O
minutes	O
before	O
the	O
venepuncture	O
,	O
in	O
the	O
intervention	O
arm	O
,	O
40	O
babies	O
received	O
5	O
ml	O
of	O
EBM	O
,	O
while	O
41	O
babies	O
in	O
control	O
group	O
received	O
5	O
ml	O
of	O
distilled	O
water	O
(	O
DW	O
)	O
as	O
placebo	O
.	O

Two	O
observers	O
who	O
were	O
blinded	O
to	O
the	O
intervention	O
recorded	O
the	O
physiological	Physical
(	Physical
heart	Physical
rate	Physical
and	Physical
oxygen	Physical
saturation	Physical
)	Physical
and	Physical
behavioural	Physical
parameters	Physical
[	Physical
duration	Physical
of	Physical
crying	Physical
and	Physical
modified	Physical
Neonatal	Physical
Facial	Physical
Coding	Physical
Scores	Physical
(	Physical
NFCS	Physical
)	Physical
]	Physical
after	O
the	O
venepuncture	O
.	O

RESULTS	O
There	O
was	O
no	O
difference	O
in	O
the	O
baseline	O
characteristics	O
of	O
the	O
neonates	O
in	O
the	O
two	O
groups	O
.	O

The	O
duration	O
of	O
crying	O
was	O
significantly	O
shorter	O
in	O
babies	O
fed	O
EBM	O
[	O
median	O
38.5	O
s	O
,	O
interquartile	O
range	O
(	O
IQR	O
)	O
9.5-57.5	O
s	O
]	O
than	O
in	O
those	O
fed	O
DW	O
(	O
median	O
90	O
s	O
,	O
IQR	O
28-210	O
s	O
)	O
.	O

The	O
mean	Physical
duration	Physical
of	Physical
crying	Physical
in	O
EBM	O
group	O
was	O
shorter	O
by	O
70.7	O
(	O
95	O
%	O
confidence	O
interval	O
36.6-104.9	O
)	O
s.	O
The	O
modified	O
NFCS	O
at	O
0	O
,	O
1	O
and	O
3	O
min	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.01	O
)	O
in	O
the	O
EBM	O
than	O
in	O
the	O
DW	O
group	O
.	O

The	O
change	Physical
in	Physical
heart	Physical
rate	Physical
and	Physical
oxygen	Physical
saturation	Physical
was	O
significantly	O
lower	O
in	O
the	O
EBM	O
group	O
and	O
returned	O
to	O
baseline	O
values	O
sooner	O
than	O
in	O
the	O
DW	O
group	O
.	O

CONCLUSION	O
Feeding	O
5	O
ml	O
of	O
EBM	O
before	O
venepuncture	O
is	O
effective	O
in	O
reducing	O
symptoms	Physical
due	O
to	O
pain	O
in	O
term	O
neonates	O
.	O

Dopamine	O
transporter	O
gene	O
moderates	O
response	O
to	O
behavioral	O
parent	O
training	O
in	O
children	O
with	O
ADHD	O
:	O
a	O
pilot	O
study	O
.	O

There	O
is	O
great	O
variability	O
in	O
the	O
degree	O
to	O
which	O
children	O
with	O
attention	O
deficit/hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
improve	O
through	O
behavioral	O
treatments	O
.	O

This	O
study	O
investigates	O
the	O
influence	O
of	O
the	O
dopamine	O
transporter	O
gene	O
(	O
SCL6A3/DAT1	O
)	O
on	O
outcome	O
of	O
behavioral	O
parent	O
training	O
(	O
BPT	O
)	O
.	O

Study	O
subjects	O
were	O
a	O
subsample	O
(	O
n	O
=	O
50	O
,	O
for	O
whom	O
DAT1	O
genotypes	O
were	O
available	O
)	O
of	O
a	O
randomized	O
controlled	O
BPT	O
effectiveness	O
study	O
(	O
N	O
=	O
94	O
)	O
comparing	O
BPT	O
plus	O
ongoing	O
routine	O
clinical	O
care	O
(	O
RCC	O
)	O
versus	O
RCC	O
alone	O
in	O
referred	O
children	O
(	O
4-12	O
years	O
old	O
)	O
with	O
ADHD	O
.	O

Treatment	O
outcome	O
was	O
based	O
on	O
parent-reported	O
ADHD	O
symptoms	O
and	O
behavioral	O
problems	O
.	O

Presence	O
of	O
2	O
versus	O
no	O
or	O
1	O
DAT1	O
10-repeat	O
allele	O
served	O
as	O
moderator	O
variable	O
.	O

Time	O
?	O
Treatment	O
?	O
Genotype	O
effect	O
was	O
analyzed	O
with	O
repeated-measures	O
analysis	O
of	O
variance	O
,	O
controlling	O
for	O
baseline	O
medication	O
status	O
.	O

Results	O
indicate	O
that	O
DAT1	O
moderated	O
treatment	O
response	O
(	O
p	O
=	O
.009	O
)	O
.	O

In	O
children	O
with	O
no	O
or	O
1	O
DAT1	O
10-repeat	O
allele	O
,	O
superior	O
treatment	O
effects	O
of	O
BPT	O
+	O
RCC	O
compared	O
with	O
RCC	O
alone	O
were	O
present	O
(	O
p	O
=	O
.005	O
)	O
,	O
which	O
was	O
not	O
the	O
case	O
in	O
children	O
with	O
2	O
DAT1	O
10-repeat	O
alleles	O
(	O
p	O
=	O
.57	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
genetic	O
differences	O
in	O
DAT1	O
in	O
children	O
with	O
ADHD	O
influence	O
their	O
susceptibility	O
to	O
a	O
behavioral	O
intervention	O
directed	O
at	O
shaping	O
their	O
environment	O
through	O
their	O
parents	O
.	O

The	O
role	O
of	O
the	O
dopamine	O
system	O
in	O
motivation	O
and	O
learning	O
and	O
in	O
the	O
aberrant	O
sensitivity	O
to	O
reinforcement	O
in	O
children	O
with	O
ADHD	O
may	O
explain	O
this	O
moderating	O
effect	O
,	O
given	O
that	O
the	O
management	O
of	O
contingencies	O
is	O
typically	O
addressed	O
in	O
BPT	O
.	O

Treatment	O
of	O
adult	O
asthma	O
:	O
controlled	O
double-blind	O
clinical	O
trial	O
of	O
oxitropium	O
bromide	O
.	O

Sixteen	O
young	O
adult	O
sufferers	O
from	O
extrinsic	O
paroxysmal	O
asthma	O
with	O
pollen	O
hypersensitivity	O
took	O
part	O
in	O
a	O
therapeutic	O
trial	O
of	O
the	O
synthetic	O
anticholinergic	O
agent	O
oxitropium	O
bromide	O
administered	O
by	O
a	O
metered	O
dose	O
inhaler	O
.	O

The	O
study	O
comprised	O
three	O
3-week	O
periods	O
.	O

The	O
first	O
,	O
run-in	O
period	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
ability	O
of	O
the	O
patients	O
to	O
maintain	O
a	O
daily	O
record	O
of	O
symptoms	O
.	O

During	O
the	O
second	O
and	O
third	O
periods	O
,	O
the	O
patient	O
received	O
3	O
X	O
2	O
inhalations	O
of	O
drug	O
or	O
placebo	O
in	O
a	O
cross-over	O
design	O
.	O

The	O
medical	O
staff	O
was	O
blind	O
to	O
the	O
nature	O
of	O
the	O
aerosol	O
(	O
drug	O
or	O
placebo	O
)	O
,	O
which	O
was	O
given	O
in	O
random	O
order	O
.	O

The	O
run-in	O
clinical	O
score	O
was	O
high	O
.	O

Asymptomatic	Physical
days	Physical
were	O
relatively	O
infrequent	O
and	O
daily	Mental
drug	Mental
consumption	Mental
was	O
high	O
.	O

Functional	O
studies	O
between	O
the	O
cross-over	O
periods	O
showed	O
flow-rate	Others
values	Others
close	O
to	O
normal	O
,	O
with	O
an	O
increase	O
in	O
residual	Physical
volume	Physical
and	Physical
functional	Physical
residual	Physical
capacity	Physical
.	Physical

During	O
treatment	O
either	O
with	O
placebo	O
or	O
oxitropium	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
clinical	Physical
scores	Physical
.	Physical

Results	O
for	O
oxitropium	O
bromide	O
treatment	O
were	O
significantly	Physical
better	Physical
than	O
the	O
run-in	Physical
values	Physical
(	O
p	O
less	O
than	O
0.005	O
)	O
and	O
the	O
placebo	O
period	O
(	O
p	O
less	O
than	O
0.02	O
)	O
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
non-trial	Others
drug	Others
consumption	Others
.	O

Functional	O
values	O
showed	O
no	O
difference	O
in	O
terms	O
of	O
flow	Physical
rate	Physical
,	O
although	O
oxitropium	O
did	O
cause	O
a	O
significant	O
improvement	O
in	O
the	O
RV/TLC	Physical
ratio	Physical
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

No	O
adverse	Physical
reactions	Physical
were	O
reported	O
.	O

A	O
comparative	Others
study	Others
of	Others
the	Others
pharmacokinetics	Others
of	O
ibuprofen	O
arginate	O
versus	O
dexibuprofen	O
in	O
healthy	O
volunteers	O
.	O

OBJECTIVE	O
Ibuprofen	O
arginate	O
is	O
a	O
salt	O
formulation	O
of	O
ibuprofen	O
designed	O
to	O
reach	O
target	O
concentrations	O
rapidly	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
12-h	O
pharmacokinetic	Others
profile	Others
of	O
S	O
(	O
+	O
)	O
-ibuprofen	O
following	O
administration	O
of	O
single	O
doses	O
of	O
ibuprofen	O
arginate	O
(	O
600	O
mg	O
)	O
and	O
dexibuprofen	O
(	O
400	O
mg	O
)	O
in	O
healthy	O
volunteers	O
.	O

METHODS	O
Twenty-four	O
volunteers	O
were	O
recruited	O
into	O
an	O
open-label	O
,	O
randomised	O
,	O
two-period	O
,	O
single-centre	O
study	O
with	O
crossover	O
design	O
.	O

RESULTS	O
Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

Ibuprofen	O
arginate	O
and	O
dexibuprofen	O
showed	O
similar	O
bioavailability	Others
for	Others
S	Others
(	Others
+	Others
)	Others
-ibuprofen	Others
.	O

Compared	O
with	O
dexibuprofen	O
,	O
ibuprofen	O
arginate	O
demonstrated	O
a	O
45	O
%	O
higher	O
maximum	Others
concentration	Others
(	Others
C	Others
(	Others
max	Others
)	Others
)	Others
,	O
and	O
a	O
time	Others
to	Others
peak	Others
concentration	Others
(	Others
T	Others
(	Others
max	Others
)	Others
)	Others
2	O
h	O
sooner	O
.	O

CONCLUSION	O
Ibuprofen	O
arginate	O
approaches	O
maximum	O
concentrations	O
of	O
S	O
(	O
+	O
)	O
-ibuprofen	O
faster	O
and	O
higher	O
than	O
dexibuprofen	O
.	O

Codeine/acetaminophen	O
and	O
hydrocodone/acetaminophen	O
combination	O
tablets	O
for	O
the	O
management	O
of	O
chronic	O
cancer	O
pain	O
in	O
adults	O
:	O
a	O
23-day	O
,	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
parallel-group	O
study	O
.	O

BACKGROUND	O
Analgesics	O
are	O
an	O
essential	O
component	O
of	O
the	O
treatment	O
of	O
cancer-associated	O
pain	O
.	O

Pharmacologic	O
treatment	O
is	O
usually	O
begun	O
with	O
nonopioid	O
analgesics	O
,	O
most	O
frequently	O
acetaminophen	O
.	O

If	O
pain	Pain
relief	Pain
is	O
not	O
achieved	O
,	O
the	O
so-called	O
weak	O
opioids	O
,	O
such	O
as	O
codeine	O
and	O
hydrocodone	O
,	O
may	O
be	O
used	O
in	O
combination	O
with	O
acetaminophen	O
.	O

Adverse	O
effects	O
(	O
AEs	O
)	O
of	O
the	O
opioids	O
include	O
constipation	O
,	O
somnolence	O
,	O
nausea	O
,	O
and	O
vomiting	O
.	O

Based	O
on	O
the	O
results	O
of	O
a	O
literature	O
search	O
,	O
data	O
comparing	O
the	O
effects	O
of	O
the	O
opioids	O
are	O
lacking	O
.	O

OBJECTIVE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
analgesic	Others
efficacy	Others
and	Others
tolerability	Others
of	O
codeine	O
phosphate	O
versus	O
hydrocodone	O
bitartrate	O
in	O
combination	O
with	O
acetaminophen	O
in	O
the	O
relief	O
of	O
cancer-related	O
pain	O
.	O

METHODS	O
This	O
23-day	O
,	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
parallel-group	O
study	O
was	O
conducted	O
at	O
3	O
Colombian	O
centers	O
:	O
University	O
Libre	O
,	O
Social	O
Security	O
Institute	O
,	O
and	O
General	O
Hospital	O
of	O
Medell?n	O
,	O
Cali	O
,	O
Colombia	O
.	O

Outpatients	O
with	O
cancer	O
were	O
eligible	O
for	O
the	O
study	O
if	O
they	O
were	O
aged	O
>	O
-18	O
years	O
and	O
had	O
chronic	O
(	O
duration	O
,	O
>	O
/=	O
3	O
months	O
)	O
moderate	O
to	O
severe	O
cancer-related	O
pain	O
(	O
score	O
on	O
10-cm	O
visual	O
analog	O
scale	O
[	O
VAS	O
]	O
,	O
>	O
3	O
cm	O
[	O
moderate	O
]	O
;	O
score	O
on	O
a	O
4-point	O
verbal	O
pain-intensity	O
scale	O
,	O
>	O
1	O
[	O
moderate	O
]	O
)	O
.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
1	O
tablet	O
of	O
codeine/acetaminophen	O
(	O
C/A	O
)	O
30/500	O
mg	O
or	O
hydrocodone/acetaminophen	O
(	O
H/A	O
)	O
5/500	O
mg	O
PO	O
q4h	O
(	O
total	O
daily	O
doses	O
,	O
150/2500	O
and	O
25/2500	O
mg	O
,	O
respectively	O
)	O
for	O
23	O
days	O
.	O

In	O
both	O
groups	O
,	O
if	O
pain	O
intensity	O
was	O
rated	O
as	O
>	O
3	O
on	O
the	O
VAS	O
at	O
week	O
1	O
or	O
2	O
,	O
the	O
dosage	O
was	O
doubled	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
who	O
achieved	O
pain	O
relief	O
(	O
defined	O
as	O
a	O
score	O
of	O
>	O
1	O
on	O
a	O
5-point	O
verbal	O
rating	O
scale	O
[	O
VRS	O
]	O
(	O
0	O
=	O
none	O
;	O
1	O
=	O
a	O
little	O
;	O
2	O
=	O
some	O
;	O
3	O
=	O
a	O
lot	O
;	O
and	O
4	O
=	O
complete	O
)	O
on	O
study	O
days	O
1	O
and	O
2	O
and	O
weeks	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

The	O
secondary	O
end	O
point	O
was	O
the	O
proportion	O
of	O
patients	O
in	O
whom	O
pain	O
was	O
decreased	O
(	O
VAS	O
score	O
,	O
<	O
-	O
3	O
cm	O
)	O
.	O

AEs	O
were	O
self-reported	O
on	O
a	O
4-point	O
VRS	O
(	O
0	O
=	O
absent	O
;	O
1	O
=	O
mild	O
;	O
2	O
=	O
moderate	O
;	O
and	O
3	O
=	O
severe	O
)	O
.	O

RESULTS	O
Of	O
the	O
121	O
patients	O
who	O
participated	O
,	O
59	O
received	O
C/A	O
and	O
62	O
received	O
H/A	O
.	O

Of	O
the	O
total	O
number	O
of	O
cases	O
,	O
59	O
%	O
were	O
aged	O
60	O
to	O
89	O
years	O
,	O
and	O
55	O
%	O
were	O
men	O
.	O

At	O
baseline	O
,	O
88	O
%	O
of	O
the	O
patients	O
described	O
their	O
pain	O
intensity	O
as	O
moderate	O
;	O
12	O
%	O
,	O
severe	O
.	O

Of	O
the	O
patients	O
who	O
received	O
C/A	O
,	O
58	O
%	O
responded	O
to	O
the	O
initial	O
dosage	O
of	O
150/2500	O
mg/d	O
,	O
and	O
8	O
%	O
of	O
the	O
patients	O
responded	O
to	O
the	O
double	O
dosage	O
;	O
34	O
%	O
did	O
not	O
experience	O
pain	O
relief	O
.	O

In	O
patients	O
with	O
H/A	O
,	O
pain	O
was	O
reported	O
as	O
absent	O
or	O
mild	O
in	O
56	O
%	O
of	O
patients	O
at	O
the	O
starting	O
dosage	O
of	O
25/2500	O
mg/d	O
;	O
an	O
additional	O
15	O
%	O
of	O
the	O
patients	O
responded	O
to	O
the	O
double	O
dosage	O
;	O
the	O
remaining	O
29	O
%	O
of	O
patients	O
did	O
not	O
experience	O
any	O
pain	O
relief	O
.	O

None	O
of	O
the	O
between-group	O
differences	O
in	O
response	O
rates	O
were	O
significant	O
.	O

The	O
most	O
common	O
AEs	O
in	O
the	O
C/A	O
and	O
H/A	O
groups	O
were	O
constipation	O
(	O
36	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
dizziness	O
(	O
24	O
%	O
and	O
19	O
%	O
)	O
,	O
vomiting	O
(	O
24	O
%	O
and	O
16	O
%	O
)	O
,	O
and	O
dry	O
mouth	O
(	O
15	O
%	O
and	O
18	O
%	O
)	O
,	O
with	O
no	O
significant	O
differences	O
between	O
groups	O
.	O

CONCLUSION	O
In	O
this	O
study	O
,	O
efficacy	O
and	O
tolerability	O
were	O
comparable	O
between	O
C/A	O
and	O
H/A	O
over	O
23	O
days	O
of	O
treatment	O
in	O
these	O
patients	O
with	O
moderate	O
or	O
severe	O
,	O
chronic	O
,	O
cancer-related	O
pain	O
.	O

Helicobacter	Physical
pylori	Physical
eradication	Physical
in	O
children	O
and	O
adolescents	O
by	O
a	O
once	O
daily	O
6-day	O
treatment	O
with	O
or	O
without	O
a	O
proton	O
pump	O
inhibitor	O
in	O
a	O
double-blind	O
randomized	O
trial	O
.	O

AIM	O
To	O
evaluate	O
two	O
simplified	O
Helicobacter	Physical
pylori	Physical
eradication	Physical
treatment	O
alternatives	O
for	O
children	O
and	O
adolescents	O
.	O

METHODS	O
Study	O
subjects	O
were	O
identified	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
and	O
immunoblot	O
in	O
a	O
family	O
screening	O
project	O
.	O

Helicobacter	O
pylori	O
infected	O
10-21	O
year	O
olds	O
were	O
offered	O
treatment	O
,	O
individuals	O
with	O
abdominal	O
pain	O
underwent	O
upper	O
endoscopy	O
and	O
those	O
with	O
peptic	O
ulcers	O
were	O
excluded	O
.	O

Participants	O
were	O
randomized	O
to	O
either	O
azithromycin	O
500	O
mg	O
daily	O
and	O
tinidazole	O
500	O
mg	O
two	O
tablets	O
daily	O
in	O
combination	O
with	O
lansoprasole	O
30	O
mg	O
daily	O
for	O
6	O
days	O
(	O
ATL-group	O
)	O
or	O
with	O
placebo	O
(	O
ATP-group	O
)	O
.	O

Urea	O
Breath	O
Test	O
was	O
performed	O
at	O
inclusion	O
and	O
after	O
a	O
minimum	O
of	O
6	O
weeks	O
after	O
end	O
of	O
therapy	O
.	O

RESULTS	O
In	O
total	O
,	O
131	O
individuals	O
were	O
randomized	O
,	O
of	O
whom	O
31	O
(	O
24	O
%	O
)	O
had	O
undergone	O
upper	O
endoscopy	O
.	O

Full	Mental
compliance	Mental
was	O
achieved	O
in	O
93	O
%	O
(	O
122	O
of	O
131	O
)	O
.	O

The	O
intention-to-treat	Others
eradication	Others
rate	Others
was	O
67	O
%	O
(	O
44	O
of	O
66	O
)	O
and	O
58	O
%	O
(	O
38	O
of	O
65	O
)	O
for	O
the	O
ATL-	O
and	O
the	O
ATP-group	O
,	O
respectively	O
.	O

CONCLUSION	O
The	O
double-blind	O
randomized	O
clinical	O
trial	O
did	O
not	O
identify	O
a	O
simplified	O
,	O
successful	O
once	O
daily	O
H.	O
pylori	O
treatment	O
for	O
children	O
and	O
adolescents	O
.	O

Thus	O
,	O
twice	O
daily	O
proton	O
pump	O
inhibitor	O
(	O
PPI	O
)	O
-based	O
triple	O
therapies	O
for	O
7	O
days	O
remain	O
as	O
the	O
choice	O
of	O
treatment	O
in	O
children	O
.	O

Further	O
,	O
powerful	O
and	O
controlled	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
best	O
treatment	O
strategies	O
for	O
H.	O
pylori	O
eradication	O
in	O
this	O
age	O
group	O
.	O

Effects	O
of	O
enalapril	O
and	O
eprosartan	O
on	O
the	O
renal	O
vascular	O
nitric	O
oxide	O
system	O
in	O
human	O
essential	O
hypertension	O
.	O

BACKGROUND	O
Experimental	O
data	O
in	O
humans	O
on	O
the	O
contribution	O
of	O
angiotensin-converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
blockers	O
to	O
the	O
nitric	O
oxide	O
system	O
of	O
the	O
renal	O
vasculature	O
are	O
inconsistent	O
.	O

Enalapril	O
and	O
eprosartan	O
,	O
alone	O
and	O
in	O
combination	O
,	O
were	O
used	O
to	O
determine	O
their	O
short-term	O
effects	Others
on	O
the	O
renal	O
nitric	O
oxide	O
system	O
and	O
renal	O
hemodynamics	O
of	O
human	O
subjects	O
with	O
essential	O
hypertension	O
.	O

METHODS	O
Twenty	O
male	O
,	O
white	O
patients	O
(	O
27	O
+/-	O
1	O
years	O
)	O
with	O
mild	O
essential	O
hypertension	O
(	O
143	O
+/-	O
11/95	O
+/-	O
6	O
mm	O
Hg	O
)	O
were	O
included	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
fourfold	O
cross-over	O
study	O
with	O
placebo	O
,	O
enalapril	O
(	O
20	O
mg/day	O
)	O
,	O
eprosartan	O
(	O
600	O
mg/day	O
)	O
,	O
or	O
combination	O
of	O
both	O
drugs	O
(	O
10	O
and	O
300	O
mg/day	O
,	O
respectively	O
)	O
each	O
over	O
a	O
one	O
week	O
period	O
followed	O
by	O
a	O
two-week	O
washout	O
phase	O
.	O

After	O
each	O
study	O
phase	O
the	O
glomerular	Physical
filtration	Physical
rate	Physical
(	Physical
GFR	Physical
)	Physical
and	Physical
renal	Physical
plasma	Physical
flow	Physical
(	Physical
RPF	Physical
)	Physical
were	O
determined	O
.	O

Basal	O
nitric	O
oxide	O
synthesis	O
of	O
the	O
renal	Physical
vasculature	Physical
was	O
assessed	O
by	O
the	O
decrease	O
in	O
RPF	Physical
after	O
inhibition	O
of	O
nitric	O
oxide	O
synthase	O
with	O
NG-monomethyl-L-arginine	O
(	O
L-NMMA	O
;	O
4.25	O
mg/kg	O
)	O
.	O

RESULTS	O
After	O
one	O
week	O
of	O
therapy	O
,	O
the	O
combination	O
therapy	O
decreased	O
casual	Physical
blood	Physical
pressure	Physical
by	O
5	O
+/-	O
2/3	O
+/-	O
1	O
mm	O
Hg	O
versus	O
placebo	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Neither	O
enalapril	O
alone	O
(	O
-2	O
+/-	O
2/1	O
+/-	O
2	O
mm	O
Hg	O
,	O
NS	O
vs.	O
placebo	O
)	O
nor	O
eprosartan	O
alone	O
(	O
-1	O
+/-	O
1/0	O
+/-	O
2	O
mm	O
Hg	O
,	O
NS	O
vs.	O
placebo	O
)	O
had	O
a	O
clear-cut	O
significant	O
effect	O
on	O
casual	Physical
blood	Physical
pressure	Physical
.	O

In	O
the	O
combination	O
phase	O
,	O
RPF	Physical
increased	O
by	O
123	O
+/-	O
36	O
mL/min	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Neither	O
enalapril	O
alone	O
(	O
+59	O
+/-	O
46	O
mL/min	O
,	O
P	O
=	O
0.21	O
)	O
nor	O
eprosartan	O
alone	O
(	O
+113	O
+/-	O
51	O
mL/min	O
,	O
P	O
=	O
0.06	O
)	O
had	O
a	O
clear-cut	O
significant	O
effect	O
on	O
RPF	Physical
.	O

Changes	O
of	O
RPF	O
induced	O
by	O
treatment	O
correlated	O
with	O
the	O
L-NMMA	O
induced	O
decrease	O
in	O
RPF	Physical
in	O
the	O
combination	O
(	O
r	O
=	O
0.70	O
,	O
P	O
<	O
0.01	O
)	O
and	O
eprosartan	O
phase	O
(	O
r	O
=	O
0.86	O
,	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	O
in	O
the	O
enalapril	O
phase	O
(	O
r	O
=	O
-0.44	O
,	O
P	O
=	O
0.10	O
)	O
.	O

Renal	Physical
vascular	Physical
resistance	Physical
was	O
reduced	O
by	O
each	O
active	O
treatment	O
with	O
the	O
most	O
prominent	O
reduction	O
in	O
the	O
combination	O
phase	O
.	O

GFR	Physical
was	O
unaffected	O
by	O
any	O
treatment	O
.	O

CONCLUSIONS	O
In	O
contrast	O
to	O
the	O
effects	O
of	O
either	O
substance	O
alone	O
,	O
a	O
combination	O
of	O
half	O
the	O
dose	O
of	O
eprosartan	O
with	O
half	O
the	O
dose	O
of	O
enalapril	O
had	O
a	O
prominent	O
effect	O
on	O
renal	Physical
perfusion	Physical
.	O

The	O
effects	O
of	O
eprosartan	O
on	O
RPF	O
are	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
an	O
increased	O
bioavailability	Others
of	Others
nitric	Others
oxide	Others
in	O
the	O
renal	O
vasculature	O
.	O

[	O
Myocardial	O
ischemia	O
with	O
stable	O
angina	O
pectoris	O
:	O
clinico-ergometric	O
evaluation	O
after	O
the	O
use	O
of	O
diltiazem	O
]	O
.	O

PURPOSE	O
To	O
evaluate	O
the	O
efficacy	O
of	O
diltiazem	O
versus	O
placebo	O
in	O
patients	O
with	O
stable	O
angina	O
.	O

METHODS	O
Eight-seven	O
angina	O
pectoris	O
patients	O
,	O
mean	O
age	O
of	O
57	O
+/-	O
9	O
,	O
82	O
white	O
and	O
79	O
male	O
were	O
evaluated	O
in	O
a	O
randomized	O
,	O
double-blind	O
trial	O
of	O
two	O
groups	O
of	O
patients	O
diltiazem	O
and	O
placebo	O
,	O
3	O
to	O
4	O
tablets	O
a	O
day	O
(	O
diltiazem	O
180	O
to	O
240	O
mg	O
daily	O
)	O
.	O

The	O
patients	O
were	O
evaluated	O
after	O
laboratory	O
tests	O
and	O
clinical-ergometric	O
examinations	O
.	O

A	O
coronary	O
arteriography	O
was	O
performed	O
on	O
study	O
entry	O
.	O

RESULTS	O
The	O
average	Physical
of	Physical
anginal	Physical
attacks	Physical
,	Others
number	Others
of	Others
weekly	Others
sublingual	Others
nitrate	Others
,	Others
heart	Physical
rate	Physical
,	Others
systolic	Physical
and	Physical
diastolic	Physical
pressure	Physical
at	Physical
rest	Physical
and	Physical
at	Physical
the	Physical
end	Physical
of	Physical
diltiazem	Physical
period	Physical
were	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
regarding	O
same	O
periods	O
on	O
placebo	O
.	O

The	O
percentage	O
of	O
depression	Physical
for	Physical
ST-segment	Physical
was	O
lower	O
for	O
diltiazem	O
when	O
compared	O
with	O
placebo	O
(	O
p	O
<	O
0.05	O
)	O
and	O
the	O
percentage	O
of	O
patients	O
that	O
reach	O
higher	O
stages	O
in	O
the	O
ergometric	O
test	O
was	O
significantly	O
better	O
for	O
diltiazem	O
.	O

Heart	Physical
rate	Physical
and	Others
systolic	Physical
plus	Physical
diastolic	Physical
pressures	Physical
after	O
exercise	O
did	O
not	O
differ	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
Diltiazem	O
reduced	O
the	O
clinical	O
and	O
electrocardiographical	O
aspects	O
and	O
raises	O
the	O
effort	O
tolerance	O
during	O
the	O
ergometric	O
test	O
in	O
patients	O
with	O
stable	O
angina	O
.	O

The	O
effect	O
of	O
leukocyte	O
reduction	O
filters	O
on	O
inflammatory	O
mediator	O
release	O
during	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

BACKGROUND	O
Extracorporeal	O
circulation	O
used	O
during	O
coronary	O
artery	O
bypass	O
grafting	O
triggers	O
systemic	O
inflammatory	O
response	O
with	O
neutrophil	O
activation	O
which	O
adversely	O
affects	O
ischaemic/reperfused	O
myocardium	O
.	O

One	O
method	O
of	O
myocardial	O
protection	O
during	O
cardiac	O
surgery	O
is	O
the	O
use	O
of	O
blood	O
cardioplegia	O
.	O

Its	O
protective	O
effect	O
is	O
related	O
to	O
cardiac	O
cooling	O
and	O
metabolism	O
reduction	O
,	O
oxygen	O
supply	O
from	O
erythrocytes	O
,	O
and	O
reactive	O
oxygen	O
species	O
scavenging	O
.	O

However	O
,	O
blood	O
cardioplegia	O
is	O
also	O
associated	O
with	O
myocardial	O
damage	O
induced	O
by	O
undesirable	O
morphotic	O
blood	O
elements	O
.	O

AIM	O
To	O
evaluate	O
the	O
effect	O
of	O
the	O
use	O
of	O
leukocyte	O
reduction	O
filters	O
on	O
the	O
activity	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMN	O
)	O
in	O
patients	O
undergoing	O
surgical	O
myocardial	O
revascularisation	O
.	O

PMN	O
activity	O
was	O
evaluated	O
based	O
on	O
measurements	O
of	O
plasma	O
activity	O
of	O
granulocyte	O
enzymes	O
,	O
lysozyme	O
and	O
beta-glucuronidase	O
.	O

METHODS	O
We	O
studied	O
40	O
patients	O
who	O
underwent	O
myocardial	O
revascularisation	O
using	O
extracorporeal	O
circulation	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
two	O
equal	O
groups	O
:	O
in	O
Group	O
I	O
,	O
blood	O
cardioplegia	O
was	O
administered	O
using	O
leukocyte	O
reduction	O
filters	O
,	O
and	O
in	O
Group	O
II	O
,	O
leukocyte	O
reduction	O
filters	O
were	O
not	O
used	O
for	O
blood	O
cardioplegia	O
.	O

Measurements	O
were	O
performed	O
in	O
plasma	O
of	O
arterial	O
and	O
coronary	O
sinus	O
blood	O
samples	O
collected	O
before	O
aortic	O
clamping	O
,	O
immediately	O
after	O
unclamping	O
,	O
and	O
after	O
25	O
min	O
of	O
reperfusion	O
.	O

In	O
addition	O
,	O
blood	O
cardioplegic	O
solution	O
samples	O
were	O
collected	O
in	O
Group	O
I	O
from	O
the	O
lines	O
proximal	O
and	O
distal	O
to	O
the	O
filter	O
during	O
first	O
and	O
last	O
administration	O
.	O

Plasma	Physical
levels	Physical
of	Physical
lysozyme	Physical
and	Physical
beta-glucuronidase	Physical
were	O
determined	O
using	O
previously	O
described	O
methods	O
.	O

RESULTS	O
We	O
found	O
a	O
significant	O
decrease	O
in	O
PMN	Physical
count	Physical
in	O
filtered	O
blood	Physical
cardioplegic	Physical
solution	Physical
during	O
its	O
first	O
administration	O
(	O
0.27	O
?	O
0.07	O
G/L	O
)	O
compared	O
to	O
samples	O
collected	O
before	O
filter	O
passage	O
(	O
1.73	O
?	O
0.049	O
G/L	O
)	O
.	O

Also	O
during	O
last	O
administration	O
,	O
PMN	O
count	O
in	O
filtered	O
blood	O
cardioplegic	O
solution	O
was	O
decreased	O
compared	O
to	O
samples	O
collected	O
before	O
filter	O
passage	O
(	O
0.66	O
?	O
0.35	O
G/L	O
vs.	O
3.64	O
?	O
1.14	O
G/L	O
,	O
respectively	O
)	O
.	O

Significantly	O
lower	O
(	O
p	O
<	O
0.02	O
)	O
plasma	O
beta-glucuronidase	O
levels	O
were	O
found	O
in	O
arterial	O
blood	O
samples	O
in	O
Group	O
I	O
compared	O
to	O
Group	O
II	O
(	O
5.59	O
?	O
1.63	O
?g/mL	O
immediately	O
after	O
aortic	O
unclamping	O
and	O
6.59	O
?	O
1.98	O
?g/mL	O
after	O
25	O
min	O
of	O
reperfusion	O
in	O
Group	O
I	O
vs.	O
10.19	O
?	O
2.66	O
and	O
12.83	O
?	O
1.88	O
?g/mL	O
,	O
respectively	O
,	O
in	O
Group	O
II	O
)	O
.	O

Beta-glucuronidase	O
levels	O
in	O
coronary	O
sinus	O
blood	O
samples	O
collected	O
after	O
aortic	O
unclamping	O
and	O
at	O
the	O
end	O
of	O
reperfusion	O
were	O
significantly	O
higher	O
in	O
Group	O
II	O
compared	O
to	O
Group	O
I	O
(	O
p	O
<	O
0.04	O
)	O
.	O

In	O
Group	O
I	O
,	O
plasma	O
lysozyme	O
levels	O
in	O
arterial	O
and	O
venous	O
blood	O
samples	O
did	O
not	O
show	O
significant	O
changes	O
during	O
the	O
surgery	O
.	O

In	O
contrast	O
,	O
plasma	O
lysozyme	O
level	O
in	O
coronary	O
sinus	O
blood	O
samples	O
at	O
the	O
end	O
of	O
reperfusion	O
in	O
Group	O
II	O
was	O
significantly	O
higher	O
compared	O
to	O
that	O
in	O
pre-clamping	O
samples	O
(	O
p	O
<	O
0.014	O
)	O
.	O

CONCLUSIONS	O
With	O
the	O
use	O
of	O
leukocyte	O
reduction	O
filters	O
,	O
we	O
found	O
significantly	O
lower	O
beta-glucuronidase	O
levels	O
in	O
arterial	O
and	O
coronary	O
sinus	O
blood	O
samples	O
.	O

These	O
findings	O
seem	O
to	O
confirm	O
reduced	O
PMN	O
activation	O
and/or	O
reduced	O
myocardial	O
infiltration	O
by	O
activated	O
PMN	O
.	O

Plasma	O
levels	O
of	O
lysozyme	O
,	O
a	O
characteristic	O
product	O
of	O
PMN	O
degranulation	O
,	O
did	O
not	O
show	O
significant	O
differences	O
between	O
the	O
study	O
groups	O
.	O

Pulse	O
versus	O
continuous	O
terbinafine	O
for	O
onychomycosis	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
trial	O
.	O

BACKGROUND	O
Effective	O
treatments	O
for	O
onychomycosis	O
are	O
expensive	O
.	O

Previous	O
studies	O
suggest	O
that	O
less	O
costly	O
,	O
pulsed	O
doses	O
of	O
antifungal	O
medications	O
may	O
be	O
as	O
effective	O
as	O
standard	O
,	O
continuous	O
doses	O
.	O

Terbinafine	O
is	O
the	O
current	O
treatment	O
of	O
choice	O
for	O
toenail	O
onychomycosis	O
.	O

OBJECTIVE	O
Our	O
purpose	O
was	O
to	O
determine	O
whether	O
pulse-dose	O
terbinafine	O
is	O
as	O
effective	O
as	O
standard	O
continuous-dose	O
terbinafine	O
for	O
treatment	O
of	O
toenail	O
onychomycosis	O
.	O

METHODS	O
We	O
conducted	O
a	O
double-blind	O
,	O
randomized	O
,	O
noninferiority	O
,	O
clinical	O
intervention	O
trial	O
in	O
the	O
Minneapolis	O
Veterans	O
Affairs	O
Medical	O
Center	O
.	O

The	O
main	O
inclusion	O
criteria	O
for	O
participants	O
were	O
a	O
positive	O
dermatophyte	O
culture	O
and	O
at	O
least	O
25	O
%	O
distal	O
subungual	O
clinical	O
involvement	O
.	O

Six	O
hundred	O
eighteen	O
volunteers	O
were	O
screened	O
;	O
306	O
were	O
randomized	O
.	O

Terbinafine	O
,	O
250	O
mg	O
daily	O
for	O
3	O
months	O
(	O
continuous	O
)	O
or	O
terbinafine	O
,	O
500	O
mg	O
daily	O
for	O
1	O
week	O
per	O
month	O
for	O
3	O
months	O
(	O
pulse	O
)	O
was	O
administered	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
mycological	Physical
cure	Physical
of	Others
the	Others
target	Others
toenail	Others
at	Others
18	Others
months	Others
.	O

Secondary	O
outcome	O
measures	O
included	O
clinical	Others
cure	Others
and	Others
complete	Others
(	Others
clinical	Others
plus	Others
mycological	Others
)	Others
cure	Others
of	Others
the	Others
target	Others
toenail	Others
and	O
complete	Others
cure	Others
of	Others
all	Others
10	Others
toenails	Others
.	O

RESULTS	O
Results	O
of	O
an	O
intent-to-treat	O
analysis	O
did	O
not	O
meet	O
the	O
prespecified	O
criterion	O
for	O
noninferiority	O
but	O
did	O
demonstrate	O
the	O
superiority	O
of	O
continuous-dose	O
terbinafine	O
for	O
:	O
mycological	Physical
cure	Physical
of	O
the	O
target	O
toenail	O
(	O
70.9	O
%	O
[	O
105/148	O
]	O
vs	O
58.7	O
%	O
[	O
84/143	O
]	O
;	O
P	O
=.03	O
,	O
relative	O
risk	O
[	O
RR	O
]	O
of	O
1.21	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
1.02-1.43	O
]	O
)	O
;	O
clinical	Physical
cure	Physical
of	O
the	O
target	O
toenail	O
(	O
44.6	O
%	O
[	O
66/148	O
]	O
vs	O
29.3	O
%	O
[	O
42/143	O
]	O
;	O
P	O
=.007	O
,	O
RR	O
=1.52	O
[	O
95	O
%	O
CI	O
,	O
1.11-2.07	O
)	O
;	O
complete	Others
cure	Others
of	O
the	O
target	O
toenail	O
(	O
40.5	O
%	O
[	O
60/148	O
]	O
vs	O
28.0	O
%	O
[	O
40/143	O
]	O
;	O
P	O
=.02	O
,	O
RR=1.45	O
[	O
95	O
%	O
CI	O
,	O
1.04-2.01	O
)	O
;	O
and	O
complete	Others
cure	Others
of	O
all	O
10	O
toenails	O
(	O
25.2	O
%	O
[	O
36/143	O
]	O
vs	O
14.7	O
%	O
[	O
21/143	O
]	O
;	O
P	O
=.03	O
,	O
RR	O
=1.71	O
[	O
95	O
%	O
CI	O
,	O
1.05-2.79	O
)	O
.	O

Tolerability	Mental
of	O
the	O
regimens	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
(	O
chi2	O
=1.63	O
;	O
P	O
=.65	O
)	O
.	O

LIMITATIONS	O
The	O
study	O
population	O
primarily	O
consisted	O
of	O
older	O
men	O
with	O
severe	O
onychomycosis	O
.	O

CONCLUSIONS	O
This	O
study	O
demonstrated	O
the	O
superiority	O
of	O
continuous-	O
over	O
pulse-dose	O
terbinafine	O
.	O

We	O
also	O
found	O
this	O
expensive	O
therapy	O
to	O
be	O
much	O
less	O
effective	O
than	O
previously	O
believed	O
,	O
particularly	O
for	O
achieving	O
complete	O
cure	O
of	O
all	O
10	O
toenails	O
.	O

Differential	O
effects	O
on	O
bone	Physical
density	Physical
of	O
progestogen-only	O
methods	O
for	O
contraception	O
in	O
premenopausal	O
women	O
.	O

The	O
question	O
of	O
differential	O
effects	O
on	O
bone	O
density	O
by	O
two	O
different	O
types	O
of	O
progestogen-only	O
methods	O
for	O
contraception	O
in	O
premenopausal	O
women	O
was	O
addressed	O
.	O

Data	O
from	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
among	O
22	O
premenopausal	O
women	O
,	O
age	O
32.6	O
(	O
range	O
20-45	O
years	O
)	O
,	O
who	O
were	O
randomly	O
assigned	O
to	O
either	O
of	O
two	O
treatments	O
with	O
continuous	O
progestogens	O
for	O
contraception	O
were	O
analyzed	O
;	O
depot-medroxyprogesterone	O
acetate	O
(	O
DMPA	O
)	O
or	O
continuous	O
levonorgestrel	O
treatment	O
with	O
subdermal	O
implants	O
(	O
Norplant	O
)	O
,	O
respectively	O
.	O

Forearm	Physical
bone	Physical
density	Physical
(	Physical
BMDprox	Physical
)	Physical
increased	O
with	O
2.94	O
%	O
(	O
p	O
=	O
0.006	O
)	O
in	O
women	O
who	O
were	O
prescribed	O
levonorgestrel	O
,	O
which	O
was	O
in	O
contrast	O
to	O
stable	O
values	O
in	O
those	O
prescribed	O
depot-medroxy-progesterone	O
acetate	O
;	O
group	O
difference	O
at	O
6	O
months	O
for	O
BMDprox	Physical
3.4	O
%	O
(	O
95	O
%	O
CI	O
1.3	O
,	O
5.5	O
;	O
p	O
=	O
0.025	O
)	O
and	O
BMDdist	Physical
4.1	O
%	O
(	O
95	O
%	O
CI	O
-	O
1.3	O
,	O
9.6	O
;	O
p	O
=	O
0.077	O
)	O
.	O

The	O
changes	O
in	O
bone	Physical
density	Physical
were	O
consistent	O
with	O
the	O
changes	O
in	O
biochemical	Physical
indices	Physical
for	Physical
bone	Physical
metabolism	Physical
;	O
DMPA	O
users	O
showed	O
signs	O
of	O
increased	O
bone	Physical
turnover	Physical
and	O
users	O
of	O
levonorgestrel	O
showed	O
increased	Physical
bone	Physical
formation	Physical
with	O
increased	O
levels	O
of	O
both	O
alkaline	O
phosphatase	O
(	O
p	O
=	O
0.004	O
)	O
and	O
osteocalcin	O
(	O
p	O
=	O
0.007	O
)	O
.	O

The	O
findings	O
suggest	O
an	O
increase	O
in	O
bone	Physical
density	Physical
during	O
treatment	O
with	O
levonorgestrel	O
and	O
stable	O
values	O
during	O
short-term	O
administration	O
of	O
DMPA	O
,	O
in	O
standard	O
clinical	O
doses	O
for	O
contraception	O
.	O

A	O
comparison	O
of	O
acupuncture	O
with	O
advice	O
and	O
exercises	O
on	O
the	O
symptomatic	Physical
treatment	Physical
of	O
osteoarthritis	O
of	O
the	O
hip	O
--	O
a	O
randomised	O
controlled	O
trial	O
.	O

Acupuncture	O
is	O
becoming	O
a	O
common	O
technique	O
within	O
the	O
physiotherapy	O
profession	O
as	O
a	O
treatment	O
modality	O
for	O
pain	Pain
relief	Pain
;	O
however	O
,	O
few	O
randomised	O
controlled	O
trials	O
have	O
been	O
undertaken	O
to	O
assess	O
the	O
effectiveness	O
of	O
acupuncture	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
osteoarthritis	O
(	O
OA	O
)	O
of	O
the	O
hip	O
.	O

Therefore	O
,	O
a	O
randomised	O
trial	O
to	O
compare	O
the	O
effectiveness	O
of	O
acupuncture	O
with	O
advice	O
and	O
exercises	O
on	O
the	O
symptomatic	O
treatment	O
of	O
OA	O
of	O
the	O
hip	O
was	O
carried	O
out	O
.	O

Thirty-two	O
patients	O
awaiting	O
a	O
total	O
hip	O
arthroplasty	O
were	O
randomly	O
allocated	O
to	O
either	O
the	O
experimental	O
group	O
,	O
(	O
A	O
)	O
,	O
to	O
have	O
six	O
sessions	O
of	O
acupuncture	O
each	O
lasting	O
up	O
to	O
25	O
minutes	O
,	O
or	O
the	O
control	O
group	O
,	O
(	O
B	O
)	O
,	O
to	O
be	O
given	O
advice	O
and	O
exercises	O
for	O
their	O
hip	O
over	O
a	O
six	O
week	O
period	O
.	O

Group	O
A	O
consisted	O
of	O
three	O
men	O
and	O
13	O
women	O
,	O
and	O
group	O
B	O
consisted	O
of	O
four	O
men	O
and	O
eight	O
women	O
.	O

The	O
average	O
age	O
in	O
group	O
A	O
was	O
66	O
years	O
and	O
in	O
group	O
B	O
it	O
was	O
68	O
years	O
.	O

Patients	O
were	O
assessed	O
for	O
pain	O
and	O
functional	O
ability	O
,	O
using	O
a	O
modified	O
version	O
of	O
the	O
WOMAC	Others
questionnaire	Others
,	O
pre-treatment	O
,	O
immediately	O
post-treatment	O
and	O
at	O
eight	O
weeks	O
post-treatment	O
.	O

The	O
pre-treatment	O
WOMAC	Others
scores	Others
in	O
the	O
two	O
groups	O
were	O
similar	O
(	O
p=0.85	O
)	O
.	O

There	O
was	O
a	O
significant	O
improvement	O
in	O
group	O
A	O
(	O
decrease	O
in	O
WOMAC	Others
score	Others
)	O
immediately	O
post-treatment	O
(	O
p=0.002	O
)	O
and	O
this	O
was	O
maintained	O
at	O
the	O
eight-week	O
follow-up	O
(	O
p=0.03	O
)	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
group	O
B	O
.	O

When	O
the	O
changes	O
in	O
WOMAC	Others
scores	Others
were	O
compared	O
between	O
groups	O
,	O
a	O
significantly	O
greater	O
improvement	O
was	O
found	O
between	O
pre-treatment	O
and	O
immediately	O
post-treatment	O
in	O
group	O
A	O
,	O
compared	O
with	O
group	O
B	O
(	O
p=0.02	O
)	O
.	O

The	O
changes	O
between	O
pre-treatment	O
and	O
the	O
eight-week	O
follow-up	O
also	O
showed	O
a	O
significant	O
improvement	O
in	O
group	O
A	O
compared	O
with	O
group	O
B	O
(	O
p=0.03	O
)	O
.	O

In	O
conclusion	O
,	O
this	O
trial	O
supports	O
the	O
hypothesis	O
that	O
acupuncture	O
is	O
more	O
effective	Others
than	O
advice	O
and	O
exercises	O
in	O
the	O
symptomatic	O
treatment	O
of	O
OA	O
of	O
the	O
hip	O
.	O

Enhancing	O
implementation	O
of	O
tobacco	O
use	O
prevention	O
and	O
cessation	O
counselling	O
guideline	O
among	O
dental	O
providers	O
:	O
a	O
cluster	O
randomised	O
controlled	O
trial	O
.	O

BACKGROUND	O
Tobacco	O
use	O
adversely	O
affects	O
oral	O
health	O
.	O

Tobacco	O
use	O
prevention	O
and	O
cessation	O
(	O
TUPAC	O
)	O
counselling	O
guidelines	O
recommend	O
that	O
healthcare	O
providers	O
ask	O
about	O
each	O
patient	O
's	O
tobacco	O
use	O
,	O
assess	O
the	O
patient	O
's	O
readiness	O
and	O
willingness	O
to	O
stop	O
,	O
document	O
tobacco	O
use	O
habits	O
,	O
advise	O
the	O
patient	O
to	O
stop	O
,	O
assist	O
and	O
help	O
in	O
quitting	O
,	O
and	O
arrange	O
monitoring	O
of	O
progress	O
at	O
follow-up	O
appointments	O
.	O

Adherence	O
to	O
such	O
guidelines	O
,	O
especially	O
among	O
dental	O
providers	O
,	O
is	O
poor	O
.	O

To	O
improve	O
guideline	O
implementation	O
,	O
it	O
is	O
essential	O
to	O
understand	O
factors	O
influencing	O
it	O
and	O
find	O
effective	O
ways	O
to	O
influence	O
those	O
factors	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
protocol	O
is	O
to	O
introduce	O
a	O
theory-based	O
approach	O
to	O
diagnose	O
implementation	O
difficulties	O
of	O
TUPAC	O
counselling	O
guidelines	O
among	O
dental	O
providers	O
.	O

METHODS	O
Theories	Mental
of	Mental
behaviour	Mental
change	Mental
have	O
been	O
used	O
to	O
identify	O
key	O
theoretical	O
domains	O
relevant	O
to	O
the	O
behaviours	O
of	O
healthcare	O
providers	O
involved	O
in	O
implementing	O
clinical	O
guidelines	O
.	O

These	O
theoretical	O
domains	O
will	O
inform	O
the	O
development	O
of	O
a	O
questionnaire	Others
aimed	O
at	O
assessing	O
the	O
implementation	O
of	O
the	O
TUPAC	O
counselling	O
guidelines	O
among	O
Finnish	O
municipal	O
dental	O
providers	O
.	O

Specific	O
items	O
will	O
be	O
drawn	O
from	O
the	O
guidelines	O
and	O
the	O
literature	O
on	O
TUPAC	O
studies	O
.	O

After	O
identifying	O
potential	O
implementation	O
difficulties	O
,	O
we	O
will	O
design	O
two	O
interventions	O
using	O
theories	O
of	O
behaviour	O
change	O
to	O
link	O
them	O
with	O
relevant	O
behaviour	O
change	O
techniques	O
aiming	O
to	O
improve	O
guideline	O
adherence	O
.	O

For	O
assessing	O
the	O
implementation	O
of	O
TUPAC	O
guidelines	O
,	O
the	O
electronic	Others
dental	Others
record	Others
audit	Others
and	O
self-reported	Others
questionnaires	Others
will	O
be	O
used	O
.	O

DISCUSSION	O
To	O
improve	O
guideline	O
adherence	O
,	O
the	O
theoretical-domains	O
approach	O
could	O
provide	O
a	O
comprehensive	O
basis	O
for	O
assessing	O
implementation	O
difficulties	O
,	O
as	O
well	O
as	O
designing	O
and	O
evaluating	O
interventions	O
.	O

After	O
having	O
identified	O
implementation	O
difficulties	O
,	O
we	O
will	O
design	O
and	O
test	O
two	O
interventions	O
to	O
enhance	O
TUPAC	O
guideline	O
adherence	O
.	O

Using	O
the	O
cluster	O
randomised	O
controlled	O
design	O
,	O
we	O
aim	O
to	O
provide	O
further	O
evidence	O
on	O
intervention	O
effects	O
,	O
as	O
well	O
as	O
on	O
the	O
validity	O
and	O
feasibility	O
of	O
the	O
theoretical-domain	O
approach	O
.	O

The	O
empirical	O
data	O
collected	O
within	O
this	O
trial	O
will	O
be	O
useful	O
in	O
testing	O
whether	O
this	O
theoretical-domain	O
approach	O
can	O
improve	O
our	O
understanding	O
of	O
the	O
implementation	O
of	O
TUPAC	O
guidelines	O
among	O
dental	O
providers	O
.	O

TRIAL	O
REGISTRATION	O
Current	O
Controlled	O
Trials	O
ISRCTN15427433	O
.	O

Enhanced	O
inotropic	O
state	O
of	O
the	O
failing	O
left	O
ventricle	O
by	O
cardiac	O
contractility	O
modulation	O
electrical	O
signals	O
is	O
not	O
associated	O
with	O
increased	O
myocardial	Physical
oxygen	Physical
consumption	Physical
.	Physical

BACKGROUND	O
Previous	O
studies	O
in	O
patients	O
and	O
in	O
dogs	O
with	O
experimentally	O
induced	O
heart	O
failure	O
(	O
HF	O
)	O
showed	O
that	O
electrical	O
signals	O
applied	O
to	O
the	O
failing	O
myocardium	O
during	O
the	O
absolute	O
refractory	O
period	O
improved	O
left	Physical
ventricular	Physical
(	Physical
LV	Physical
)	Physical
function	Physical
.	Physical

We	O
examined	O
the	O
effects	O
these	O
same	O
cardiac	O
contractility	O
modulating	O
(	O
CCM	O
)	O
electrical	O
signals	O
on	O
myocardial	Physical
oxygen	Physical
consumption	Physical
(	Physical
MVO	Physical
(	Physical
2	Physical
)	Physical
)	Physical
in	O
both	O
patients	O
and	O
dogs	O
with	O
chronic	O
HF	O
.	O

METHODS	O
AND	O
RESULTS	O
Six	O
dogs	O
with	O
microembolizations-induced	O
HF	O
and	O
9	O
HF	O
patients	O
underwent	O
CCM	O
leads	O
and	O
generator	O
(	O
OPTIMIZER	O
II	O
)	O
implantation	O
.	O

After	O
baseline	O
measurements	O
,	O
CCM	O
signals	O
were	O
delivered	O
continuously	O
for	O
2	O
hours	O
in	O
dogs	O
and	O
for	O
30	O
minutes	O
in	O
patients	O
.	O

MVO	Physical
(	Physical
2	Physical
)	Physical
was	O
measured	O
before	O
and	O
after	O
CCM	O
therapy	O
.	O

In	O
dogs	O
,	O
CCM	O
therapy	O
increased	O
LV	Physical
ejection	Physical
fraction	Physical
at	O
2	O
hours	O
(	O
26	O
+/-	O
1	O
versus	O
31	O
+/-	O
2	O
%	O
,	O
P	O
=	O
.001	O
)	O
without	O
increasing	O
MVO	Physical
(	Physical
2	Physical
)	Physical
(	O
257	O
+/-	O
41	O
versus	O
180	O
+/-	O
34	O
micromol/min	O
)	O
.	O

In	O
patients	O
,	O
CCM	O
therapy	O
increased	O
LV	Physical
peak	Physical
+dP/dt	Physical
by	O
10.1	O
+/-	O
1.5	O
%	O
.	O

As	O
with	O
dogs	O
,	O
the	O
increase	O
in	O
LV	Physical
function	Physical
after	O
30	O
minutes	O
of	O
CCM	O
therapy	O
was	O
not	O
associated	O
with	O
increased	O
MVO	Physical
(	Physical
2	Physical
)	Physical
(	O
13.6	O
+/-	O
9.7	O
versus	O
12.5	O
+/-	O
7.2	O
mL	O
O	O
(	O
2	O
)	O
/min	O
)	O
.	O

CONCLUSIONS	O
The	O
study	O
results	O
suggest	O
that	O
unlike	O
cAMP-dependent	O
positive	O
inotropic	O
drugs	O
,	O
the	O
increase	O
in	O
LV	Physical
function	Physical
during	O
CCM	O
therapy	O
is	O
elicited	O
without	O
increasing	O
MVO	O
(	O
2	O
)	O
.	O

Delayed	O
perceptual	O
awareness	O
in	O
rapid	O
perceptual	O
decisions	O
.	O

The	O
flourishing	O
of	O
studies	O
on	O
the	O
neural	O
correlates	O
of	O
decision-making	O
calls	O
for	O
an	O
appraisal	O
of	O
the	O
relation	O
between	O
perceptual	O
decisions	O
and	O
conscious	O
perception	O
.	O

By	O
exploiting	O
the	O
long	O
integration	O
time	O
of	O
noisy	O
motion	O
stimuli	O
,	O
and	O
by	O
forcing	O
human	O
observers	O
to	O
make	O
difficult	O
speeded	O
decisions	O
--	O
sometimes	O
a	O
blind	O
guess	O
--	O
about	O
stimulus	O
direction	O
,	O
we	O
traced	O
the	O
temporal	O
buildup	O
of	O
motion	O
discrimination	O
capability	O
and	O
perceptual	O
awareness	O
,	O
as	O
assessed	O
trial	O
by	O
trial	O
through	O
direct	O
rating	O
.	O

We	O
found	O
that	O
both	O
increased	O
gradually	O
with	O
motion	Mental
coherence	Mental
and	Mental
viewing	Mental
time	Mental
,	O
but	O
discrimination	Mental
was	Mental
systematically	Mental
leading	Mental
awareness	Mental
,	Mental
reaching	Mental
a	Mental
plateau	Mental
much	Mental
earlier	Mental
.	Mental

Sensitivity	O
and	O
criterion	O
changes	O
contributed	O
jointly	O
to	O
the	O
slow	Mental
buildup	Mental
of	Mental
perceptual	Mental
awareness	Mental
.	Mental

It	O
made	O
no	O
difference	O
whether	O
motion	Mental
discrimination	Mental
was	O
accomplished	O
by	O
saccades	Mental
or	Mental
verbal	Mental
responses	Mental
.	Mental

These	O
findings	O
suggest	O
that	O
perceptual	Mental
awareness	Mental
emerges	O
on	O
the	O
top	O
of	O
a	O
developing	O
or	O
even	O
mature	O
perceptual	O
decision	O
.	O

We	O
argue	O
that	O
the	O
middle	O
temporal	O
(	O
MT	O
)	O
cortical	O
region	O
does	O
not	O
confer	O
us	O
the	O
full	Mental
phenomenic	Mental
depth	Mental
of	Mental
motion	Mental
perception	Mental
,	O
although	O
it	O
may	O
represent	O
a	O
precursor	Mental
stage	Mental
in	Mental
building	Mental
our	Mental
subjective	Mental
sense	Mental
of	Mental
visual	Mental
motion	Mental
.	Mental

The	O
comparative	O
safety	Others
and	O
diagnostic	Others
accuracy	Others
of	O
adenosine	O
myocardial	O
perfusion	O
imaging	O
in	O
women	O
versus	O
men	O
.	O

STUDY	O
OBJECTIVE	O
To	O
determine	O
if	O
the	O
diagnostic	O
accuracy	O
and	O
safety	O
of	O
intravenous	O
adenosine	O
myocardial	O
perfusion	O
imaging	O
is	O
significantly	O
different	O
in	O
men	O
compared	O
with	O
women	O
.	O

DESIGN	O
Prospective	O
,	O
comparative	O
,	O
open-label	O
clinical	O
trial	O
.	O

SETTING	O
Nuclear	O
medicine	O
laboratory	O
in	O
a	O
university-affiliated	O
hospital	O
.	O

PATIENTS	O
Consecutive	O
patients	O
who	O
were	O
referred	O
for	O
evaluation	O
of	O
known	O
or	O
suspected	O
coronary	O
artery	O
disease	O
.	O

Patients	O
were	O
judged	O
not	O
to	O
be	O
able	O
to	O
exercise	O
adequately	O
.	O

INTERVENTIONS	O
Coronary	O
angiography	O
was	O
conducted	O
within	O
6	O
weeks	O
of	O
an	O
adenosine	O
thallium-201	O
myocardial	O
perfusion	O
imaging	O
study	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Diagnostic	Others
accuracy	Others
is	O
shown	O
in	O
the	O
table	O
.	O

[	O
table	O
:	O
see	O
text	O
]	O
Overall	O
,	O
side	Adverseeffect
effects	Adverseeffect
from	O
adenosine	O
were	O
not	O
different	O
between	O
men	O
and	O
women	O
.	O

The	O
frequencies	Physical
of	Physical
ST	Physical
depression	Physical
and	O
chest	Physical
pain	Physical
were	O
significantly	O
greater	O
in	O
women	O
than	O
men	O
,	O
although	O
their	O
etiologies	O
are	O
unknown	O
.	O

The	O
frequency	O
of	O
severe	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
such	O
as	O
heart	Adverseeffect
block	Adverseeffect
and	Adverseeffect
hypotension	Adverseeffect
was	O
not	O
different	O
between	O
men	O
and	O
women	O
.	O

CONCLUSIONS	O
The	O
diagnostic	O
accuracy	O
and	O
safety	O
of	O
adenosine	O
thallium-201	O
myocardial	O
perfusion	O
imaging	O
are	O
generally	O
similar	O
in	O
women	O
and	O
men	O
.	O

Stimulus	Physical
over-selectivity	Physical
in	O
temporal	O
brain	O
injury	O
:	O
mindfulness	O
as	O
a	O
potential	O
intervention	O
.	O

OBJECTIVE	O
The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
impact	O
of	O
brief	O
mindfulness	O
training	O
on	O
the	O
performance	O
of	O
a	O
sample	O
of	O
patients	O
with	O
TBI	O
in	O
an	O
over-selectivity	Mental
task	O
.	O

PARTICIPANTS	O
Twenty-four	O
patients	O
who	O
had	O
suffered	O
TBI	O
and	O
reported	O
problems	O
with	O
focused	O
or	O
sustained	O
attention	O
.	O

METHOD	O
The	O
study	O
was	O
a	O
between-subjects	O
design	O
(	O
mindfulness	O
intervention	O
vs	O
control	O
)	O
with	O
difference	O
between	O
number	O
of	O
most	O
and	O
least	O
chosen	O
stimulus	O
selections	O
on	O
an	O
over-selectivity	O
task	O
as	O
the	O
dependent	O
measure	O
.	O

RESULTS	O
The	O
results	O
of	O
this	O
study	O
indicated	O
that	O
stimulus	Physical
over-selectivity	Physical
was	O
present	O
in	O
a	O
group	O
of	O
patients	O
with	O
TBI	O
.	O

However	O
,	O
the	O
level	Mental
of	Mental
emergent	Mental
over-selectivity	Mental
was	O
significantly	O
reduced	O
by	O
a	O
mindfulness	O
induction	O
when	O
compared	O
to	O
a	O
no-	O
intervention	O
control	O
group	O
.	O

CONCLUSIONS	O
The	O
findings	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
efficacy	Others
of	O
mindfulness	O
training	O
in	O
reducing	O
TBI-related	Mental
cognitive	Mental
deficits	Mental
.	O

A	O
controlled	O
crossover	O
trial	O
of	O
fenfluramine	O
in	O
autism	O
.	O

We	O
report	O
a	O
12	O
month	O
double-blind	O
randomized	O
crossover	O
trial	O
of	O
fenfluramine	O
in	O
20	O
children	O
with	O
the	O
syndrome	O
of	O
autism	O
.	O

On	O
active	O
drug	O
most	O
of	O
the	O
children	O
lost	Physical
weight	Physical
and	O
blood	Physical
serotonin	Physical
levels	Physical
fell	O
by	O
an	O
average	O
of	O
60	O
%	O
.	O

There	O
was	O
a	O
fall	O
in	O
urinary	Physical
dopamine	Physical
(	Physical
DA	Physical
)	Physical
and	O
noradrenaline	Physical
(	Physical
NA	Physical
)	Physical
levels	Physical
and	O
increased	Physical
excretion	Physical
of	Physical
homovanillic	Physical
acid	Physical
(	Physical
HVA	Physical
)	Physical
.	O

Some	O
of	O
the	O
children	O
showed	O
improvement	O
in	O
tests	Mental
of	Mental
cognitive	Mental
and	Mental
language	Mental
function	Mental
,	O
although	O
the	O
results	O
did	O
not	O
achieve	O
overall	O
statistical	O
significance	O
.	O

Event-related	Physical
brain	Physical
potentials	Physical
(	Physical
ERPs	Physical
)	Physical
were	O
obtained	O
in	O
seven	O
subjects	O
on	O
an	O
auditory	O
choice	O
reaction	O
time	O
task	O
.	O

Side	Adverseeffect
effects	Adverseeffect
of	O
the	O
drug	O
included	O
irritability	Adverseeffect
and	Adverseeffect
lethargy	Adverseeffect
.	O

Fenfluramine	O
may	O
have	O
a	O
limited	O
place	O
in	O
the	O
management	O
of	O
some	O
patients	O
with	O
autistic	O
disorder	O
.	O

Randomized	O
controlled	O
trial	O
:	O
Multimodal	O
Anxiety	O
and	O
Social	O
Skill	O
Intervention	O
for	O
adolescents	O
with	O
autism	O
spectrum	O
disorder	O
.	O

Anxiety	O
is	O
common	O
among	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
and	O
may	O
amplify	O
the	O
core	O
social	O
disability	O
,	O
thus	O
necessitating	O
combined	O
treatment	O
approaches	O
.	O

This	O
pilot	O
,	O
randomized	O
controlled	O
trial	O
evaluated	O
the	O
feasibility	Others
and	O
preliminary	Others
outcomes	Others
of	O
the	O
Multimodal	O
Anxiety	O
and	O
Social	O
Skills	O
Intervention	O
(	O
MASSI	O
)	O
program	O
in	O
a	O
sample	O
of	O
30	O
adolescents	O
with	O
ASD	O
and	O
anxiety	O
symptoms	O
of	O
moderate	O
or	O
greater	O
severity	O
.	O

The	O
treatment	O
was	O
acceptable	O
to	O
families	O
,	O
subject	Others
adherence	Others
was	O
high	O
,	O
and	O
therapist	Others
fidelity	Others
was	O
high	O
.	O

A	O
16	O
%	O
improvement	O
in	O
ASD	Mental
social	Mental
impairment	Mental
(	O
within-group	O
effect	O
size	O
=	O
1.18	O
)	O
was	O
observed	O
on	O
a	O
parent-reported	O
scale	O
.	O

Although	O
anxiety	Mental
symptoms	Mental
declined	O
by	O
26	O
%	O
,	O
the	O
change	O
was	O
not	O
statistically	O
significant	O
.	O

These	O
findings	O
suggest	O
MASSI	O
is	O
a	O
feasible	Others
treatment	O
program	O
and	O
further	O
evaluation	O
is	O
warranted	O
.	O

Biventricular	O
pacing	O
improves	O
cardiac	Physical
function	Physical
and	O
prevents	O
further	O
left	Physical
atrial	Physical
remodeling	Physical
in	O
patients	O
with	O
symptomatic	O
atrial	O
fibrillation	O
after	O
atrioventricular	O
node	O
ablation	O
.	O

BACKGROUND	O
Randomized	O
trials	O
have	O
demonstrated	O
benefits	O
of	O
biventricular	O
(	O
BiV	O
)	O
pacing	O
in	O
patients	O
with	O
advanced	O
heart	O
failure	O
,	O
intraventricular	O
conduction	O
delay	O
,	O
and	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
post-atrioventricular	O
(	O
AV	O
)	O
node	O
ablation	O
.	O

The	O
AV	O
Node	O
Ablation	O
with	O
CLS	O
and	O
CRT	O
Pacing	O
Therapies	O
for	O
Treatment	O
of	O
AF	O
trial	O
(	O
AVAIL	O
CLS/CRT	O
)	O
was	O
designed	O
to	O
demonstrate	O
superiority	O
of	O
BiV	O
pacing	O
in	O
patients	O
with	O
AF	O
after	O
AV	O
node	O
ablation	O
,	O
to	O
evaluate	O
its	O
effects	O
on	O
cardiac	O
structure	O
and	O
function	O
,	O
and	O
to	O
investigate	O
additional	O
benefits	O
of	O
Closed	O
Loop	O
Stimulation	O
(	O
CLS	O
)	O
(	O
BIOTRONIK	O
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

METHODS	O
Patients	O
with	O
refractory	O
AF	O
underwent	O
AV	O
node	O
ablation	O
and	O
were	O
randomized	O
(	O
2:2:1	O
)	O
to	O
BiV	O
pacing	O
with	O
CLS	O
,	O
BiV	O
pacing	O
with	O
accelerometer	O
,	O
or	O
right	O
ventricular	O
(	O
RV	O
)	O
pacing	O
.	O

Echocardiography	O
was	O
performed	O
at	O
baseline	O
and	O
6	O
months	O
,	O
with	O
paired	O
data	O
available	O
for	O
108	O
patients	O
.	O

RESULTS	O
The	O
RV	O
pacing	O
contributed	O
to	O
significant	O
increase	O
in	O
left	Physical
atrial	Physical
volume	Physical
,	Physical
left	Physical
ventricular	Physical
(	Physical
LV	Physical
)	Physical
end-systolic	Physical
volume	Physical
,	Physical
and	Physical
LV	Physical
mass	Physical
compared	O
to	O
BiV	O
pacing	O
.	O

Ejection	Physical
fraction	Physical
decreased	O
insignificantly	O
with	O
RV	O
pacing	O
compared	O
to	O
significant	O
increase	O
with	O
BiV	O
pacing	O
.	O

Interventricular	Physical
dyssynchrony	Physical
significantly	O
decreased	O
with	O
BiV	O
compared	O
with	O
RV	O
pacing	O
.	O

Closed	O
Loop	O
Stimulation	O
did	O
not	O
result	O
in	O
additional	O
echocardiographic	Physical
changes	Physical
;	O
heart	Physical
rate	Physical
distribution	Physical
was	O
significantly	O
wider	O
with	O
CLS	O
.	O

All	O
groups	O
showed	O
significant	O
improvement	O
in	O
6-minute	Physical
walk	Physical
distance	Physical
,	O
quality-of-life	Others
score	Others
,	O
and	O
New	Others
York	Others
Heart	Others
Association	Others
class	Others
.	O

CONCLUSION	O
In	O
conclusion	O
,	O
RV	O
pacing	O
results	O
in	O
significant	O
increase	O
in	O
left	Physical
atrial	Physical
volume	Physical
,	O
LV	O
mass	O
,	O
and	O
worsening	Physical
of	Physical
LV	Physical
contractility	Physical
compared	O
to	O
patients	O
receiving	O
BiV	O
pacing	O
post-AV	O
node	O
ablation	O
for	O
refractory	O
AF	O
.	O

Closed	O
Loop	O
Stimulation	O
was	O
not	O
associated	O
with	O
additional	O
structural	Physical
changes	Physical
but	O
resulted	O
in	O
significantly	O
wider	Physical
heart	Physical
rate	Physical
distribution	Physical
.	O

A	O
randomized	O
trial	O
of	O
an	O
interim	O
methadone	O
maintenance	O
clinic	O
.	O

BACKGROUND	O
Interim	O
methadone	O
maintenance	O
has	O
been	O
proposed	O
as	O
a	O
method	O
of	O
providing	O
clinically	Others
effective	Others
services	O
to	O
heroin	O
addicts	O
waiting	O
for	O
treatment	O
in	O
standard	O
comprehensive	O
methadone	O
maintenance	O
programs	O
.	O

METHODS	O
A	O
clinic	O
that	O
provided	O
initial	O
medical	O
evaluation	O
,	O
methadone	O
medication	O
,	O
and	O
AIDS	O
education	O
,	O
but	O
did	O
not	O
include	O
formal	O
drug	O
abuse	O
counseling	O
or	O
other	O
social	O
support	O
services	O
was	O
established	O
in	O
New	O
York	O
City	O
.	O

A	O
sample	O
of	O
301	O
volunteer	O
subjects	O
recruited	O
from	O
the	O
waiting	O
list	O
for	O
treatment	O
in	O
the	O
Beth	O
Israel	O
methadone	O
program	O
were	O
randomly	O
assigned	O
to	O
immediate	O
entry	O
into	O
the	O
interim	O
clinic	O
or	O
a	O
control	O
group	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
in	O
initial	O
levels	Physical
of	Physical
illicit	Physical
drug	Physical
use	Physical
across	O
the	O
experimental	O
and	O
control	O
groups	O
.	O

One-month	O
urinalysis	O
follow-up	O
data	O
showed	O
a	O
significant	O
reduction	Mental
in	Mental
heroin	Mental
use	Mental
in	O
the	O
experimental	O
group	O
(	O
from	O
63	O
%	O
positive	O
at	O
intake	O
to	O
29	O
%	O
positive	O
)	O
with	O
no	O
change	O
in	O
the	O
control	O
group	O
(	O
62	O
%	O
to	O
60	O
%	O
positive	O
)	O
.	O

No	O
significant	O
change	O
was	O
observed	O
in	O
cocaine	Physical
urinalyses	Physical
(	O
approximately	O
70	O
%	O
positive	O
for	O
both	O
groups	O
at	O
intake	O
and	O
follow-up	O
)	O
.	O

A	O
higher	O
percentage	O
of	O
the	O
experimental	O
group	O
were	O
in	O
treatment	O
at	O
16-month	O
follow-up	O
(	O
72	O
%	O
vs	O
56	O
%	O
)	O
.	O

CONCLUSIONS	O
Limited	O
services	O
interim	O
methadone	O
maintenance	O
can	O
reduce	O
heroin	Mental
use	Mental
among	O
persons	O
awaiting	O
entry	O
into	O
comprehensive	O
treatment	O
and	O
increase	O
the	O
percentage	O
entering	O
treatment	O
.	O

A	O
prospective	O
,	O
double-blind	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
comparing	O
standard	O
wound	O
care	O
with	O
adjunctive	O
hyperbaric	O
oxygen	O
therapy	O
(	O
HBOT	O
)	O
to	O
standard	O
wound	O
care	O
only	O
for	O
the	O
treatment	O
of	O
chronic	Physical
,	Physical
non-healing	Physical
ulcers	Physical
of	O
the	O
lower	O
limb	O
in	O
patients	O
with	O
diabetes	O
mellitus	O
:	O
a	O
study	O
protocol	O
.	O

BACKGROUND	O
It	O
has	O
been	O
suggested	O
that	O
the	O
use	O
of	O
adjunctive	O
hyperbaric	O
oxygen	O
therapy	O
improves	O
the	O
healing	O
of	O
diabetic	Physical
foot	Physical
ulcers	Physical
,	O
and	O
decreases	O
the	O
risk	O
of	O
lower	Physical
extremity	Physical
amputations	Physical
.	O

A	O
limited	O
number	O
of	O
studies	O
have	O
used	O
a	O
double	O
blind	O
approach	O
to	O
evaluate	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
in	O
the	O
treatment	O
of	O
diabetic	O
ulcers	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
plus	O
standard	O
wound	O
care	O
compared	O
with	O
standard	O
wound	O
care	O
alone	O
in	O
preventing	O
the	O
need	O
for	O
major	Others
amputation	Others
in	O
patients	O
with	O
diabetes	O
mellitus	O
and	O
chronic	O
ulcers	O
of	O
the	O
lower	O
limb	O
.	O

METHODS/DESIGN	O
One	O
hundred	O
and	O
eighteen	O
(	O
59	O
patients	O
per	O
arm	O
)	O
patients	O
with	O
non-healing	O
diabetic	O
ulcers	O
of	O
the	O
lower	O
limb	O
,	O
referred	O
to	O
the	O
Judy	O
Dan	O
Research	O
and	O
Treatment	O
Centre	O
are	O
being	O
recruited	O
if	O
they	O
are	O
at	O
least	O
18	O
years	O
of	O
age	O
,	O
have	O
either	O
Type	O
1	O
or	O
2	O
diabetes	O
with	O
a	O
Wagner	O
grading	O
of	O
foot	O
lesions	O
2	O
,	O
3	O
or	O
4	O
on	O
lower	O
limb	O
not	O
healing	O
for	O
at	O
least	O
4	O
weeks	O
.	O

Patients	O
receive	O
hyperbaric	O
oxygen	O
therapy	O
every	O
day	O
for	O
6	O
weeks	O
during	O
the	O
treatment	O
phase	O
and	O
are	O
provided	O
ongoing	O
wound	O
care	O
and	O
weekly	O
assessments	O
.	O

Patients	O
are	O
required	O
to	O
return	O
to	O
the	O
study	O
centre	O
every	O
week	O
for	O
an	O
additional	O
6	O
weeks	O
of	O
follow-up	O
for	O
wound	O
evaluation	O
and	O
management	O
.	O

The	O
primary	O
outcome	O
is	O
freedom	Physical
from	Physical
having	Physical
,	Physical
or	Physical
meeting	Physical
the	Physical
criteria	Physical
for	Physical
,	Physical
a	Physical
major	Physical
amputation	Physical
(	Physical
below	Physical
knee	Physical
amputation	Physical
,	Physical
or	Physical
metatarsal	Physical
level	Physical
)	Physical
up	O
to	O
12	O
weeks	O
after	O
randomization	O
.	O

The	O
decision	O
to	O
amputate	O
is	O
made	O
by	O
a	O
vascular	O
surgeon	O
.	O

Other	O
outcomes	O
include	O
wound	Physical
healing	Physical
,	O
effectiveness	Others
,	O
safety	Others
,	O
healthcare	Others
resource	Others
utilization	Others
,	O
quality	Mental
of	Mental
life	Mental
,	Physical
and	O
cost-effectiveness	Physical
.	O

The	O
study	O
will	O
run	O
for	O
a	O
total	O
of	O
about	O
3	O
years	O
.	O

DISCUSSION	O
The	O
results	O
of	O
this	O
study	O
will	O
provide	O
detailed	O
information	O
on	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
for	O
the	O
treatment	O
of	O
non-healing	O
ulcers	O
of	O
the	O
lower	O
limb	O
.	O

This	O
will	O
be	O
the	O
first	O
double-blind	O
randomized	O
controlled	O
trial	O
for	O
this	O
health	O
technology	O
which	O
evaluates	O
the	O
efficacy	O
of	O
hyperbaric	O
oxygen	O
therapy	O
in	O
prevention	O
of	O
amputations	Adverseeffect
in	O
diabetic	O
patients	O
.	O

TRIAL	O
REGISTRATION	O
ClinicalTrials.gov	O
Identifier	O
:	O
NCT00621608	O
.	O

Long-term	O
decrease	O
in	O
bladder	Physical
cancer	Physical
recurrence	Physical
with	O
hexaminolevulinate	O
enabled	O
fluorescence	O
cystoscopy	O
.	O

PURPOSE	O
We	O
assessed	O
the	O
impact	O
of	O
hexaminolevulinate	O
fluorescence	O
cystoscopic	O
detection	O
of	O
papillary	O
,	O
nonmuscle	O
invasive	O
bladder	O
cancer	O
on	O
the	O
long-term	Physical
recurrence	Physical
rate	Physical
.	O

MATERIALS	O
AND	O
METHODS	O
Long-term	O
followup	O
was	O
assessed	O
in	O
551	O
participants	O
enrolled	O
in	O
a	O
prospective	O
,	O
randomized	O
study	O
of	O
fluorescence	O
cystoscopy	O
for	O
Ta	O
or	O
T1	O
urothelial	O
bladder	O
cancer	O
.	O

In	O
the	O
original	O
study	O
280	O
patients	O
in	O
the	O
white	O
light	O
cystoscopy	O
group	O
and	O
271	O
in	O
the	O
fluorescence	O
cystoscopy	O
group	O
were	O
followed	O
with	O
cystoscopy	O
for	O
3	O
,	O
6	O
and	O
9	O
months	O
after	O
initial	O
resection	O
or	O
until	O
recurrence	O
.	O

A	O
study	O
extension	O
protocol	O
was	O
done	O
for	O
long-term	O
followup	O
of	O
these	O
patients	O
.	O

RESULTS	O
Followup	O
information	O
was	O
obtained	O
for	O
261	O
of	O
the	O
280	O
patients	O
(	O
93	O
%	O
)	O
in	O
the	O
white	O
light	O
group	O
and	O
255	O
of	O
the	O
271	O
(	O
94	O
%	O
)	O
in	O
the	O
fluorescence	O
group	O
.	O

Median	O
followup	O
in	O
the	O
white	O
light	O
and	O
fluorescence	O
groups	O
was	O
53.0	O
and	O
55.1	O
months	O
,	O
and	O
83	O
(	O
31.8	O
%	O
)	O
and	O
97	O
patients	O
(	O
38	O
%	O
)	O
remained	O
tumor	O
free	O
,	O
respectively	O
.	O

Median	Physical
time	Physical
to	Physical
recurrence	Physical
was	O
9.4	O
months	O
in	O
the	O
white	O
light	O
group	O
and	O
16.4	O
months	O
in	O
the	O
fluorescence	O
group	O
(	O
p	O
=	O
0.04	O
)	O
.	O

The	O
intravesical	Others
therapy	Others
rate	Others
was	O
similar	O
in	O
the	O
2	O
groups	O
(	O
46	O
%	O
and	O
45	O
%	O
,	O
respectively	O
)	O
.	O

Cystectomy	O
was	O
done	O
in	O
22	O
of	O
280	O
cases	O
(	O
7.9	O
%	O
)	O
in	O
the	O
white	O
light	O
group	O
and	O
in	O
13	O
of	O
the	O
271	O
(	O
4.8	O
%	O
)	O
in	O
the	O
fluorescence	O
group	O
(	O
p	O
=	O
0.16	O
)	O
.	O

CONCLUSIONS	O
Hexaminolevulinate	O
fluorescence	O
cystoscopy	O
significantly	O
improves	O
long-term	Physical
bladder	Physical
cancer	Physical
time	Physical
to	Physical
recurrence	Physical
with	O
a	O
trend	O
toward	O
improved	O
bladder	O
preservation	O
.	O

A	O
comparative	O
study	O
of	O
ofloxacin	O
and	O
amoxycillin/clavulanate	O
in	O
hospitalized	O
patients	O
with	O
lower	Physical
respiratory	Physical
tract	Physical
infections	Physical
.	Physical

We	O
conducted	O
an	O
open	O
randomized	O
trial	O
to	O
compare	O
the	O
efficacy	O
of	O
parenteral	O
and	O
oral	O
ofloxacin	O
with	O
that	O
of	O
amoxycillin/clavulanate	O
.	O

A	O
total	O
of	O
121	O
patients	O
was	O
studied	O
;	O
92	O
were	O
clinically	O
evaluable	O
.	O

Of	O
these	O
,	O
59	O
patients	O
were	O
treated	O
with	O
ofloxacin	O
and	O
33	O
with	O
the	O
comparator	O
drug	O
.	O

Patients	O
were	O
given	O
the	O
drugs	O
intravenously	O
for	O
a	O
minimum	O
of	O
three	O
days	O
followed	O
by	O
oral	O
preparations	O
for	O
the	O
next	O
seven	O
to	O
ten	O
days	O
.	O

Ofloxacin	O
was	O
usually	O
administered	O
as	O
a	O
200	O
mg	O
dose	O
bd	O
.	O

In	O
the	O
ofloxacin	O
treated	O
group	O
all	O
patients	O
showed	O
clinical	Physical
improvement	Physical
.	Physical

In	O
the	O
comparator	O
group	O
94	O
%	O
improved	O
clinically	O
(	O
either	O
a	O
complete	O
or	O
partial	O
response	O
)	O
,	O
while	O
6	O
%	O
were	O
clinical	O
failures	O
.	O

Of	O
the	O
bacteriologically	O
evaluable	O
patients	O
19	O
of	O
20	O
showed	O
a	O
satisfactory	Physical
bacteriological	Physical
response	Physical
in	O
the	O
ofloxacin	O
treated	O
group	O
,	O
while	O
in	O
the	O
comparator	O
group	O
the	O
bacteriological	O
response	O
was	O
judged	O
satisfactory	O
in	O
14	O
of	O
17	O
patients	O
.	O

A	O
small	O
proportion	O
of	O
patients	O
(	O
7	O
%	O
)	O
treated	O
with	O
ofloxacin	O
suffered	O
mild	O
adverse	O
effects	O
(	O
nausea	O
,	O
vomiting	O
,	O
headache	O
,	O
hypotension	O
and	O
rash	O
)	O
.	O

On	O
the	O
whole	O
,	O
ofloxacin	O
was	O
well	O
tolerated	Others
by	O
our	O
patients	O
.	O

The	O
two	O
deaths	O
that	O
occurred	O
were	O
in	O
the	O
comparator	O
group	O
.	O

We	O
conclude	O
that	O
ofloxacin	O
in	O
both	O
oral	O
and	O
parenteral	O
forms	O
is	O
an	O
effective	O
and	O
safe	O
drug	O
in	O
the	O
treatment	O
of	O
lower	O
respiratory	O
tract	O
infections	O
.	O

Mandibular	O
overdentures	O
supported	O
by	O
two	O
Br?nemark	O
,	O
IMZ	O
or	O
ITI	O
implants	O
:	O
a	O
5-year	O
prospective	O
study	O
.	O

OBJECTIVES	O
The	O
aim	O
of	O
this	O
prospective	O
comparative	O
study	O
was	O
to	O
evaluate	O
the	O
survival	O
rate	O
and	O
the	O
condition	O
of	O
the	O
peri-implant	O
tissues	O
of	O
the	O
IMZ	O
implant	O
system	O
(	O
two-stage	O
cylindertype	O
)	O
,	O
the	O
Br?nemark	O
implant	O
system	O
(	O
two-stage	O
screwtype	O
)	O
and	O
the	O
ITI	O
implant	O
system	O
(	O
one-stage	O
screwtype	O
)	O
supporting	O
a	O
mandibular	O
overdenture	O
during	O
a	O
5-year	O
follow-up	O
period	O
.	O

MATERIAL	O
AND	O
METHODS	O
Three	O
groups	O
of	O
30	O
edentulous	O
patients	O
were	O
treated	O
with	O
two	O
endosseous	O
implants	O
in	O
the	O
interforaminal	O
region	O
of	O
the	O
mandible	O
.	O

Clinical	O
and	O
radiographic	O
parameters	O
were	O
evaluated	O
immediately	O
after	O
completion	O
of	O
the	O
prosthetic	O
treatment	O
and	O
after	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
5	O
years	O
of	O
functional	O
loading	O
.	O

RESULTS	O
The	O
five-year	O
survival	O
rate	O
is	O
98.3	O
%	O
for	O
the	O
IMZ	O
group	O
,	O
98.3	O
%	O
for	O
the	O
Br?	O
group	O
and	O
100	O
%	O
for	O
the	O
ITI	O
group	O
.	O

Mean	O
scores	O
on	O
indices	O
for	O
plaque	O
,	O
calculus	O
,	O
gingiva	O
and	O
bleeding	O
were	O
very	O
low	O
at	O
all	O
evaluation	O
periods	O
.	O

Mean	O
marginal	O
bone	O
loss	O
over	O
a	O
period	O
of	O
5	O
years	O
,	O
was	O
1.4	O
mm	O
for	O
the	O
IMZ	O
group	O
,	O
0.7	O
mm	O
for	O
the	O
Br?	O
group	O
and	O
0.9	O
mm	O
for	O
the	O
ITI	O
group	O
.	O

CONCLUSION	O
It	O
is	O
concluded	O
that	O
two	O
implants	O
placed	O
in	O
the	O
interforaminal	O
region	O
,	O
connected	O
with	O
a	O
bar	O
,	O
supply	O
a	O
proper	O
base	O
for	O
the	O
support	O
of	O
a	O
mandibular	O
overdenture	O
in	O
the	O
edentulous	O
patient	O
.	O

After	O
5	O
years	O
no	O
clinically	O
relevant	O
and	O
statistically	O
significant	O
radiographic	O
changes	O
had	O
developed	O
between	O
the	O
three	O
implant	O
systems	O
.	O

Beneficial	Others
effects	Others
of	O
a	O
diabetes	O
specific	O
formula	O
on	O
insulin	Physical
sensitivity	Physical
and	O
free	Physical
fatty	Physical
acid	Physical
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

BACKGROUND	O
This	O
prospective	O
,	O
randomized	O
,	O
controlled	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
diabetes	O
specific	O
formula	O
(	O
Diason	O
low	O
energy	O
:	O
313.8	O
kJ/100	O
ml	O
)	O
,	O
compared	O
with	O
a	O
standard	O
formula	O
,	O
on	O
insulin	Physical
sensitivity	Physical
,	O
serum	Physical
C	Physical
peptide	Physical
,	O
serum	Physical
lipids	Physical
and	O
free	Physical
fatty	Physical
acid	Physical
(	Physical
FFA	Physical
)	Physical
in	O
type	O
2	O
diabetics	O
.	O

METHODS	O
In	O
total	O
of	O
71	O
type	O
2	O
diabetics	O
completed	O
the	O
study	O
.	O

Enteral	O
formulas	O
were	O
given	O
orally	O
as	O
the	O
sole	O
source	O
of	O
nutrition	O
to	O
the	O
subjects	O
for	O
6	O
days	O
.	O

Venous	O
blood	O
samples	O
(	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
hours	O
)	O
were	O
collected	O
at	O
day-7	O
after	O
a	O
75	O
g	O
oral	O
glucose	O
tolerance	O
test	O
(	O
OGTT	O
)	O
,	O
day	O
1	O
after	O
a	O
standard	O
test	O
meal	O
(	O
1673.6	O
kJ	O
)	O
and	O
after	O
6	O
days	O
of	O
either	O
the	O
test	O
diabetes	O
specific	O
formula	O
or	O
a	O
standard	O
formula	O
.	O

Plasma	Physical
glucose	Physical
,	O
serum	Physical
insulin	Physical
,	O
C	Physical
peptide	Physical
and	O
lipids	Physical
were	O
measured	O
.	O

RESULTS	O
After	O
the	O
intervention	O
period	O
,	O
the	O
diabetes	O
specific	O
formula	O
resulted	O
in	O
a	O
significantly	O
lower	O
postprandial	Physical
rise	Physical
in	Physical
blood	Physical
glucose	Physical
concentrations	Physical
at	O
0.5	O
hour	O
(	O
P	O
<	O
0.05	O
)	O
and	O
1	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
;	O
significantly	O
lower	O
peak	Physical
height	Physical
of	Physical
plasma	Physical
glucose	Physical
(	O
P	O
=	O
0.05	O
)	O
;	O
significantly	O
lower	O
plasma	Physical
insulin	Physical
concentrations	Physical
at	O
0.5	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
,	O
1	O
hour	O
(	O
P	O
<	O
0.01	O
)	O
and	O
2	O
hours	O
(	O
P	O
<	O
0.01	O
)	O
;	O
and	O
a	O
significantly	O
lower	O
plasma	Physical
insulin	Physical
peak	Physical
compared	O
to	O
controls	O
;	O
both	O
OGTT	O
and	O
a	O
standard	O
test	O
meal	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
glucose	Physical
and	Physical
insulin	Physical
area	O
under	O
the	O
curve	O
after	O
the	O
diabetes	O
specific	O
formula	O
compared	O
to	O
the	O
standard	O
formula	O
were	O
significantly	O
lower	O
.	O

The	O
C	Physical
peptide	Physical
level	Physical
was	O
lower	O
after	O
6	O
days	O
of	O
both	O
nutrition	O
formulas	O
compare	O
to	O
75	O
g	O
OGTT	O
,	O
but	O
not	O
different	O
from	O
the	O
standard	O
mixed	O
meal	O
.	O

Both	O
formulas	O
were	O
well	O
tolerated	O
.	O

CONCLUSIONS	O
In	O
summary	O
the	O
diabetes	O
specific	O
formula	O
with	O
a	O
relatively	O
high	O
monounsaturated	O
fatty	O
acid	O
and	O
high	O
multi	O
fiber	O
proportion	O
significantly	O
improved	O
glycemic	Physical
control	Physical
.	O

On	O
top	O
of	O
this	O
,	O
the	O
insulin	Physical
sensitivity	Physical
(	Physical
HOMA-IS	Physical
)	Physical
was	O
significantly	O
improved	O
and	O
may	O
therefore	O
directly	O
improve	O
the	O
impact	O
on	O
long	O
term	O
complications	O
.	O

The	O
disease	O
specific	O
formula	O
should	O
therefore	O
be	O
the	O
preferred	O
option	O
to	O
be	O
used	O
by	O
diabetic	O
and	O
hyperglycemic	O
patients	O
in	O
need	O
of	O
nutritional	O
support	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
crossover	O
study	O
of	O
Cappra?	O
for	O
the	O
treatment	O
of	O
mild	O
or	O
mild	O
to	O
moderate	O
erectile	O
dysfunction	O
in	O
Thai	O
male	O
.	O

Erectile	O
dysfunction	O
(	O
ED	O
)	O
is	O
one	O
of	O
the	O
major	O
health	O
concerns	O
affects	O
the	O
quality	O
of	O
life	O
among	O
Thai	O
male	O
.	O

The	O
treatment	O
of	O
ED	O
by	O
the	O
first-line	O
drugs	O
is	O
limited	O
to	O
a	O
certain	O
group	O
of	O
patients	O
due	O
to	O
their	O
side	O
effects	O
and	O
costs	O
.	O

Alternative	O
medicine	O
can	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
ED	O
.	O

This	O
is	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
aimed	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
Cappra	O
(	O
?	O
)	O
,	O
a	O
traditional	O
herbal	O
medicine	O
which	O
was	O
used	O
in	O
Thailand	O
for	O
decades	O
,	O
for	O
the	O
treatment	O
of	O
mild	O
and	O
mild	O
to	O
moderate	O
ED	O
in	O
Thai	O
patients	O
.	O

A	O
total	O
of	O
63	O
patients	O
with	O
mild	O
or	O
mild	O
to	O
moderate	O
ED	O
were	O
randomized	O
to	O
receive	O
Cappra	O
(	O
?	O
)	O
or	O
placebo	O
for	O
two	O
weeks	O
in	O
the	O
first	O
period	O
,	O
followed	O
by	O
one	O
week	O
washout	O
period	O
.	O

The	O
patients	O
were	O
switched	O
to	O
the	O
alternative	O
treatment	O
in	O
the	O
second	O
period	O
.	O

The	O
efficacy	Others
was	O
assessed	O
by	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
(	O
IIEF	O
)	O
questionnaire	O
and	O
adverse	O
events	O
.	O

Sixty	O
one	O
patients	O
completed	O
the	O
study	O
.	O

There	O
was	O
an	O
improvement	O
of	O
IIEF	Physical
score	Physical
for	O
all	O
domains	O
in	O
Cappra	O
(	O
?	O
)	O
group	O
compared	O
with	O
placebo	O
group	O
.	O

The	O
mean	Physical
change	Physical
of	Physical
IIEF	Physical
score	Physical
from	O
baseline	O
for	O
erectile	O
function	O
domain	O
of	O
Cappra	O
(	O
?	O
)	O
was	O
significantly	O
higher	O
than	O
placebo	O
(	O
4.87	O
vs	O
3.44	O
,	O
p	O
=	O
0.032	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
dizziness	O
(	O
13.3	O
%	O
Cappra	O
(	O
?	O
)	O
,	O
9.6	O
%	O
placebo	O
)	O
,	O
face	O
numbness	O
(	O
1.6	O
%	O
Cappra	O
(	O
?	O
)	O
,	O
0	O
%	O
placebo	O
)	O
,	O
and	O
tachycardia	O
(	O
1.6	O
%	O
Cappra	O
(	O
?	O
)	O
,	O
0	O
%	O
placebo	O
)	O
.	O

The	O
results	O
from	O
this	O
study	O
demonstrated	O
that	O
Cappra	O
(	O
?	O
)	O
is	O
effective	O
and	O
well-tolerated	O
and	O
can	O
be	O
used	O
as	O
alternative	O
therapy	O
for	O
mild	O
and	O
mild	O
to	O
moderate	O
ED	O
.	O

The	O
effect	O
of	O
nebivolol	O
treatment	O
on	O
oxidative	Physical
stress	Physical
and	Physical
antioxidant	Physical
status	Physical
in	O
patients	O
with	O
cardiac	O
syndrome-X	O
.	O

BACKGROUND	O
Free	O
radical-mediated	O
oxidative	O
stress	O
has	O
been	O
implicated	O
in	O
the	O
etiopathogenesis	O
of	O
several	O
disorders	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
the	O
effect	O
of	O
treatment	O
with	O
nebivolol	O
on	O
the	O
metabolic	Physical
state	Physical
of	Physical
oxidative	Physical
stress	Physical
,	O
and	O
antioxidant	O
status	O
markers	O
in	O
patients	O
with	O
cardiac	O
syndrome-X	O
(	O
CSX	O
)	O
,	O
additionally	O
,	O
to	O
compare	O
with	O
the	O
effect	O
of	O
metoprolol	O
treatment	O
.	O

METHODS	O
Thirty	O
patients	O
,	O
17	O
female	O
and	O
13	O
male	O
,	O
with	O
CSX	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Nebivolol	O
(	O
5	O
mg/day	O
)	O
or	O
metoprolol	O
(	O
50	O
mg/day	O
)	O
was	O
administrated	O
for	O
12	O
weeks	O
.	O

Twelve	O
hour	O
fasting	O
blood	O
samples	O
,	O
taken	O
at	O
the	O
initiation	O
and	O
on	O
the	O
third	O
month	O
of	O
therapy	O
,	O
were	O
analyzed	O
for	O
the	O
levels	Physical
of	Physical
malondialdehyde	Physical
(	Physical
MDA	Physical
)	O
,	O
nitrite+nitrate	Physical
(	Physical
NOx	Physical
)	Physical
,	O
and	O
the	Physical
activity	Physical
of	Physical
myeloperoxidase	Physical
(	Physical
MPO	Physical
)	Physical
,	O
superoxide	Physical
dismutase	Physical
(	Physical
SOD	Physical
)	Physical
.	O

No	O
patient	O
presented	O
additional	O
risk	O
factors	O
for	O
increased	O
reactive	O
oxygen	O
species	O
levels	O
.	O

RESULTS	O
Compared	O
with	O
sixteen	O
control	O
participants	O
,	O
patients	O
with	O
CSX	O
had	O
significantly	O
higher	O
activity	Physical
of	Physical
MPO	Physical
and	O
levels	Physical
of	Physical
MDA	Physical
,	O
but	O
significantly	O
lower	Physical
SOD	Physical
activity	Physical
and	O
levels	Physical
of	Physical
NOx	Physical
before	O
treatment	O
.	O

After	O
treatment	O
,	O
MPO	Physical
activity	Physical
and	O
MDA	Physical
levels	Physical
were	O
significantly	O
reduced	O
;	O
SOD	Physical
activity	Physical
and	O
NOx	Physical
levels	Physical
were	O
significantly	O
increased	O
with	O
nebivolol	O
but	O
remained	O
unchanged	O
with	O
metoprolol	O
.	O

CONCLUSION	O
We	O
have	O
shown	O
that	O
patients	O
with	O
CSX	O
who	O
taken	O
nebivolol	O
have	O
lower	O
serum	O
MPO	Physical
activity	Physical
,	O
levels	Physical
of	Physical
MDA	Physical
and	O
higher	O
serum	Physical
SOD	Physical
activity	Physical
,	O
NOx	Physical
levels	Physical
when	O
compared	O
with	O
metoprolol	O
treatment	O
.	O

Exercise	O
stress	O
test	O
parameters	O
were	O
also	O
ameliorated	O
in	O
patients	O
who	O
had	O
taken	O
nebivolol	O
in	O
contrast	O
to	O
metoprolol	O
.	O

Nebivolol	O
treatment	O
may	O
be	O
a	O
novel	O
treatment	O
strategy	O
in	O
cases	O
with	O
CSX	O
in	O
the	O
future	O
.	O

Two	O
different	O
methods	O
for	O
donor	O
hepatic	O
transection	O
:	O
cavitron	O
ultrasonic	O
surgical	O
aspirator	O
with	O
bipolar	O
cautery	O
versus	O
cavitron	O
ultrasonic	O
surgical	O
aspirator	O
with	O
radiofrequency	O
coagulator-A	O
randomized	O
controlled	O
trial	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
Cavitron	O
ultrasonic	O
surgical	O
aspirator	O
(	O
CUSA	O
)	O
with	O
bipolar	O
cautery	O
(	O
BP	O
)	O
to	O
CUSA	O
with	O
a	O
radiofrequency	O
coagulator	O
[	O
TissueLink	O
(	O
TL	O
)	O
]	O
in	O
terms	O
of	O
efficacy	O
and	O
safety	O
for	O
hepatic	O
transection	O
in	O
living	O
donor	O
liver	O
transplantation	O
.	O

Twenty-four	O
living	O
liver	O
donors	O
(	O
n	O
=	O
12	O
for	O
each	O
group	O
)	O
were	O
randomized	O
to	O
undergo	O
hepatic	O
transection	O
using	O
CUSA	O
with	O
BP	O
or	O
CUSA	O
with	O
TL	O
.	O

Blood	Physical
loss	Physical
during	Physical
parenchymal	Physical
transection	Physical
and	Physical
speed	Physical
of	Physical
transection	Physical
were	O
the	O
primary	O
endpoints	O
,	O
whereas	O
the	O
degree	Physical
of	Physical
postoperative	Physical
liver	Physical
injury	Physical
and	Physical
morbidity	Physical
were	O
secondary	O
endpoints	O
.	O

Median	Physical
blood	Physical
loss	Physical
during	Physical
liver	Physical
transection	Physical
was	O
significantly	O
lower	O
in	O
the	O
TL	O
group	O
than	O
in	O
the	O
BP	O
group	O
(	O
195.2	O
+/-	O
84.5	O
versus	O
343.3	O
+/-	O
198.4	O
mL	O
;	O
P	O
=	O
0.023	O
)	O
,	O
and	O
liver	Others
transection	Others
was	O
significantly	O
faster	O
in	O
the	O
TL	O
group	O
than	O
in	O
the	O
BP	O
group	O
(	O
0.7	O
+/-	O
0.2	O
versus	O
0.5	O
+/-	O
0.2	O
cm	O
(	O
2	O
)	O
/minute	O
;	O
P	O
=	O
0.048	O
)	O
.	O

Significantly	O
fewer	Physical
ties	Physical
were	O
required	O
during	O
liver	O
transection	O
in	O
the	O
TL	O
group	O
than	O
in	O
the	O
BP	O
group	O
(	O
15.8	O
+/-	O
4.8	O
versus	O
22.8	O
+/-	O
7.9	O
ties	O
;	O
P	O
=	O
0.023	O
)	O
.	O

The	O
morbidity	Others
rates	Others
were	O
similar	O
for	O
the	O
2	O
groups	O
.	O

In	O
conclusion	O
,	O
CUSA	O
with	O
TL	O
is	O
superior	O
to	O
CUSA	O
with	O
BP	O
for	O
donor	O
hepatectomy	O
in	O
terms	O
of	O
blood	Physical
loss	Physical
and	O
speed	Others
of	Others
transection	Others
with	O
no	O
increase	O
in	O
morbidity	Physical
.	O

Enjoyment	O
mediates	O
effects	O
of	O
a	O
school-based	O
physical-activity	O
intervention	O
.	O

PURPOSE	O
The	O
study	O
evaluated	O
whether	O
targeted	O
changes	O
in	O
factors	O
influencing	O
enjoyment	O
of	O
physical	O
education	O
(	O
PE	O
)	O
,	O
physical	O
activity	O
enjoyment	O
,	O
and	O
self-efficacy	O
beliefs	O
about	O
participating	O
in	O
physical	O
activity	O
mediated	O
the	O
effect	O
of	O
the	O
Lifestyle	O
Education	O
for	O
Activity	O
Program	O
(	O
LEAP	O
)	O
intervention	O
on	O
participation	O
in	O
physical	O
activity	O
.	O

METHODS	O
High	O
schools	O
(	O
N=24	O
)	O
paired	O
on	O
enrollment	O
size	O
,	O
racial	O
composition	O
,	O
urban	O
or	O
rural	O
location	O
,	O
and	O
class	O
structure	O
were	O
randomized	O
into	O
control	O
(	O
N=12	O
)	O
or	O
experimental	O
(	O
N=12	O
)	O
groups	O
.	O

Of	O
the	O
4044	O
girls	O
enrolled	O
and	O
eligible	O
,	O
2087	O
(	O
51.6	O
%	O
)	O
participated	O
in	O
the	O
measurement	O
component	O
of	O
the	O
study	O
.	O

There	O
were	O
1038	O
girls	O
in	O
the	O
control	O
group	O
and	O
1049	O
girls	O
in	O
the	O
experimental	O
group	O
.	O

INTERVENTION	O
LEAP	O
was	O
a	O
comprehensive	O
school-based	O
intervention	O
emphasizing	O
changes	O
in	O
instruction	O
and	O
school	O
environment	O
designed	O
to	O
increase	O
physical	O
activity	O
among	O
black	O
and	O
white	O
adolescent	O
girls	O
.	O

It	O
was	O
organized	O
according	O
to	O
the	O
Coordinated	O
School	O
Health	O
Program	O
and	O
included	O
a	O
PE	O
component	O
with	O
core	O
objectives	O
of	O
promoting	O
enjoyment	O
of	O
PE	O
,	O
physical	O
activity	O
enjoyment	O
,	O
and	O
self-efficacy	O
.	O

RESULTS	O
Latent	O
variable	O
structural	O
equation	O
modeling	O
indicated	O
that	O
:	O
1	O
)	O
the	O
intervention	O
had	O
direct	O
,	O
positive	O
effects	O
on	O
physical	O
activity	O
and	O
factors	O
influencing	O
enjoyment	O
of	O
PE	O
,	O
which	O
subsequently	O
explained	O
the	O
effects	O
of	O
increased	O
physical	O
activity	O
enjoyment	O
and	O
self-efficacy	Others
on	O
increased	O
physical	O
activity	O
;	O
and	O
2	O
)	O
an	O
additional	O
,	O
indirect	O
effect	O
of	O
physical	O
activity	O
enjoyment	O
on	O
physical	O
activity	O
operated	O
by	O
an	O
influence	O
on	O
self-efficacy	Mental
.	O

CONCLUSIONS	O
Increases	O
in	O
enjoyment	O
partially	O
mediated	O
the	O
positive	O
effect	O
of	O
the	O
LEAP	O
intervention	O
.	O

To	O
our	O
knowledge	O
,	O
we	O
have	O
provided	O
the	O
first	O
experimental	O
evidence	O
from	O
a	O
randomized	O
controlled	O
trial	O
linking	O
increased	O
enjoyment	O
with	O
increased	O
physical	O
activity	O
among	O
black	O
and	O
white	O
adolescent	O
girls	O
.	O

Salmeterol	O
versus	O
slow-release	O
theophylline	O
combined	O
with	O
ketotifen	O
in	O
nocturnal	O
asthma	O
:	O
a	O
multicentre	O
trial	O
.	O

French	O
Multicentre	O
Study	O
Group	O
.	O

We	O
wished	O
to	O
assess	O
the	O
efficacy	Others
of	O
inhaled	O
salmeterol	O
(	O
SML	O
;	O
50	O
micrograms	O
b.i.d	O
.	O

)	O
compared	O
to	O
a	O
combination	O
of	O
slow-release	O
theophylline	O
and	O
ketotifen	O
p.o	O
.	O

(	O
TK	O
;	O
T	O
300	O
mg+K	O
1	O
mg	O
b.i.d	O
.	O

)	O
for	O
the	O
treatment	O
of	O
nocturnal	O
asthma	O
.	O

Ninety	O
six	O
patients	O
with	O
nocturnal	O
asthma	O
,	O
(	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
60-90	O
%	O
of	O
predicted	O
value	O
,	O
reversibility	O
>	O
or	O
=	O
15	O
%	O
,	O
at	O
least	O
two	O
nocturnal	O
awakenings	O
per	O
week	O
)	O
were	O
eligible	O
for	O
a	O
multicentre	O
,	O
double-blind	O
,	O
double-dummy	O
cross-over	O
study	O
(	O
14-day	O
run-in	O
,	O
two	O
successive	O
28-day	O
treatment	O
periods	O
)	O
.	O

Efficacy	Others
was	O
assessed	O
as	O
success/failure	Others
,	Others
success	Others
being	O
defined	O
as	O
the	O
complete	O
disappearance	O
of	O
nocturnal	O
symptoms/awakening	O
during	O
the	O
last	O
week	O
of	O
each	O
treatment	O
period	O
.	O

There	O
was	O
a	O
statistically	Others
significant	Others
difference	Others
between	O
SML	O
and	O
TK	O
for	O
this	O
criterion	O
:	O
46	O
%	O
and	O
39	O
%	O
success	O
with	O
SML	O
during	O
periods	O
I	O
(	O
first	O
28-day	O
period	O
)	O
and	O
II	O
(	O
following	O
the	O
cross-over	O
)	O
,	O
compared	O
to	O
only	O
15	O
%	O
and	O
26	O
%	O
with	O
TK	O
,	O
respectively	O
(	O
p	O
<	O
0.01	O
)	O
.	O

SML	O
was	O
also	O
significantly	O
better	O
for	O
the	O
other	O
criteria	O
(	O
lung	Physical
function	Physical
,	Physical
rescue	Physical
salbutamol	Physical
intake	Physical
during	Physical
day	Physical
and	Physical
night	Physical
)	O
.	O

Side-effects	Adverseeffect
were	O
five	O
times	O
less	O
frequent	O
in	O
SML-treated	O
patients	O
(	O
p	O
<	O
0.004	O
)	O
.	O

Efficacy	Others
and	Others
tolerance	Others
of	O
SML	O
were	O
obviously	O
far	O
better	O
than	O
those	O
of	O
TK	O
in	O
patients	O
with	O
nocturnal	O
asthma	O
.	O

Variations	O
in	O
EEG	Physical
discharges	Physical
predict	O
ADHD	O
severity	O
within	O
individual	O
Smith-Lemli-Opitz	O
patients	O
.	O

OBJECTIVE	O
We	O
sought	O
to	O
examine	O
the	O
prevalence	O
of	O
EEG	O
abnormalities	O
in	O
Smith-Lemli-Opitz	O
syndrome	O
(	O
SLOS	O
)	O
as	O
well	O
as	O
the	O
relationship	O
between	O
interictal	O
epileptiform	O
discharges	O
(	O
IEDs	O
)	O
and	O
within-subject	O
variations	O
in	O
attentional	O
symptom	O
severity	O
.	O

METHODS	O
In	O
the	O
context	O
of	O
a	O
clinical	O
trial	O
for	O
SLOS	O
,	O
we	O
performed	O
cross-sectional	O
and	O
repeated-measure	O
observational	O
studies	O
of	O
the	O
relationship	O
between	O
EEG	O
findings	O
and	O
cognitive/behavioral	O
factors	O
on	O
23	O
children	O
(	O
aged	O
4-17	O
years	O
)	O
.	O

EEGs	O
were	O
reviewed	O
for	O
clinical	O
abnormalities	O
,	O
including	O
IEDs	O
,	O
by	O
readers	O
blinded	O
to	O
participants	O
'	O
behavioral	O
symptoms	O
.	O

Between-group	O
differences	O
in	O
baseline	O
characteristics	O
of	O
participants	O
with	O
and	O
without	O
IEDs	O
were	O
analyzed	O
.	O

Within-subject	O
analyses	O
examined	O
the	O
association	O
between	O
the	O
presence	O
of	O
IEDs	O
and	O
changes	O
in	O
attention-deficit/hyperactivity	Physical
disorder	Physical
(	Physical
ADHD	Physical
)	Physical
symptoms	Physical
.	Physical

RESULTS	O
Of	O
85	O
EEGs	O
,	O
43	O
(	O
51	O
%	O
)	O
were	O
abnormal	Physical
,	O
predominantly	O
because	O
of	O
IEDs	O
.	O

Only	O
one	O
subject	O
had	O
documented	O
clinical	Adverseeffect
seizures	Adverseeffect
.	Adverseeffect

IEDs	O
clustered	O
in	O
13	O
subjects	O
(	O
57	O
%	O
)	O
,	O
whereas	O
9	O
subjects	O
(	O
39	O
%	O
)	O
had	O
EEGs	O
consistently	O
free	O
of	O
IEDs	O
.	O

While	O
there	O
were	O
no	O
significant	O
group	O
differences	O
in	O
sex	Mental
,	Mental
age	Mental
,	Mental
intellectual	Mental
disability	Mental
,	Mental
language	Mental
level	Mental
,	Mental
or	Mental
baseline	Mental
ADHD	Mental
symptoms	Mental
,	Mental
autistic	Mental
symptoms	Mental
tended	O
to	O
be	O
more	O
prevalent	O
in	O
the	O
IED	O
group	O
(	O
according	O
to	O
Autism	Mental
Diagnostic	Mental
Observation	Mental
Schedule-2	Mental
criteria	Mental
)	Mental
.	O

Within	O
individuals	O
,	O
the	O
presence	O
of	O
IEDs	O
on	O
a	O
particular	O
EEG	O
predicted	O
,	O
on	O
average	O
,	O
a	O
27	O
%	O
increase	O
in	O
ADHD	Mental
symptom	Mental
severity	Mental
.	Mental

CONCLUSIONS	O
Epileptiform	O
discharges	O
are	O
common	O
in	O
SLOS	O
,	O
despite	O
a	O
relatively	O
low	O
prevalence	O
of	O
epilepsy	O
.	O

Fluctuations	O
in	O
the	O
presence	O
of	O
epileptiform	O
discharges	O
within	O
individual	O
children	O
with	O
a	O
developmental	O
disability	O
syndrome	O
may	O
be	O
associated	O
with	O
fluctuations	O
in	O
ADHD	O
symptomatology	O
,	O
even	O
in	O
the	O
absence	O
of	O
clinical	O
seizures	O
.	O

[	O
Study	O
on	O
classification	O
and	O
treatment	O
of	O
vulvovaginal	O
candidiasis	O
]	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
clinical	O
manifestations	O
of	O
vulvovaginal	O
candidiasis	O
(	O
VVC	O
)	O
and	O
to	O
study	O
the	O
mycologic	Physical
eradication	Physical
rate	Physical
of	O
different	O
miconazole	O
treatment	O
courses	O
for	O
VVC	O
.	O

METHODS	O
Three	O
hundred	O
cases	O
of	O
VVC	O
were	O
recruited	O
.	O

The	O
Candidas	O
were	O
cultured	O
.	O

A	O
prospective	O
and	O
randomized	O
study	O
was	O
performed	O
to	O
compare	O
the	O
treatment	O
effect	O
of	O
3	O
day	O
miconazole	O
(	O
400	O
mg/d	O
)	O
,	O
6	O
day	O
miconazole	O
(	O
400	O
mg/d	O
)	O
,	O
and	O
7	O
day	O
miconazole	O
(	O
200	O
mg/d	O
)	O
for	O
uncomplicated	O
and	O
complicated	O
VVC	O
.	O

RESULTS	O
Among	O
300	O
cases	O
of	O
VVC	O
,	O
uncomplicated	O
,	O
complicated	O
and	O
recurrent	O
VVC	O
were	O
56.0	O
%	O
,	O
44.0	O
%	O
and	O
9.7	O
%	O
(	O
29/300	O
)	O
respectively	O
.	O

C.	O
albicans	O
was	O
isolated	O
most	O
frequently	O
90.3	O
%	O
(	O
271/300	O
)	O
,	O
followed	O
by	O
C.	O
glabrata	O
(	O
7.3	O
%	O
)	O
,	O
C.	O
tropicalis	O
(	O
1.3	O
%	O
)	O
,	O
C.	O
krusei	O
(	O
0.7	O
%	O
)	O
,	O
and	O
C.	O
parapsilosis	O
(	O
0.3	O
%	O
)	O
.	O

Mycologic	Physical
eradication	Physical
rate	Physical
of	O
3	O
day	O
,	O
6	O
day	O
and	O
7	O
day	O
miconazole	O
courses	O
for	O
uncomplicated	O
VVC	O
at	O
day	O
14	O
was	O
96.0	O
%	O
,	O
93.5	O
%	O
and	O
98.0	O
%	O
,	O
respectively	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Eradication	Physical
rate	Physical
of	O
3	O
day	O
,	O
6	O
day	O
and	O
7	O
day	O
miconazole	O
courses	O
for	O
complicated	O
VVC	O
at	O
day	O
14	O
was	O
86.7	O
%	O
,	O
92.5	O
%	O
,	O
and	O
86.4	O
%	O
,	O
respectively	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Eradication	Physical
rate	Physical
of	O
3	O
day	O
,	O
6	O
day	O
and	O
7	O
day	O
miconazole	O
courses	O
for	O
uncomplicated	O
VVC	O
at	O
day	O
35	O
was	O
93.8	O
%	O
,	O
95.3	O
%	O
,	O
and	O
89.8	O
%	O
,	O
respectively	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Eradication	Physical
rate	Physical
of	O
3	O
day	O
,	O
6	O
day	O
and	O
7	O
day	O
miconazole	O
courses	O
for	O
complicated	O
VVC	O
at	O
day	O
35	O
was	O
89.7	O
%	O
,	O
97.3	O
%	O
and	O
86.8	O
%	O
,	O
respectively	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
Treatment	O
of	O
VVC	O
should	O
be	O
individualized	O
,	O
and	O
women	O
with	O
complicated	O
VVC	O
achieve	O
superior	O
mycologic	Physical
eradication	Physical
by	O
a	O
6	O
day	O
miconazole	O
course	O
.	O

[	O
Antazoline/tetryzoline	O
eyedrops	O
in	O
comparison	O
with	O
levocabastine	O
eyedrops	O
in	O
acute	O
allergic	O
conjunctivitis	O
]	O
.	O

BACKGROUND	O
Allergic	O
conjunctivitis	O
is	O
one	O
of	O
the	O
most	O
frequent	O
allergic	O
diseases	O
of	O
the	O
anterior	O
eye	O
segment	O
.	O

METHODS	O
This	O
multicentre	O
,	O
clinical	O
trial	O
was	O
an	O
investigation	O
to	O
compare	O
the	O
antiallergic	O
efficacy	O
,	O
local	O
tolerance	O
and	O
safety	O
of	O
Antazolin/Tetryzolin	O
eye	O
drops	O
and	O
Levocabastine	O
eye	O
drops	O
.	O

69	O
patients	O
were	O
treated	O
over	O
a	O
2	O
weeks	O
course	O
of	O
therapy	O
.	O

The	O
subjective	Physical
and	Physical
objective	Physical
ocular	Physical
symptoms	Physical
were	O
documented	O
over	O
the	O
treatment	O
period	O
.	O

RESULTS	O
Both	O
eye	O
drops	O
reduced	O
subjective	Physical
and	Physical
objective	Physical
ocular	Physical
symptoms	Physical
effective	O
.	O

The	O
difference	O
between	O
the	O
treatments	O
(	O
p	O
=	O
0.0395	O
)	O
was	O
the	O
faster	O
onset	Others
of	Others
action	Others
of	O
Antazolin/Tetryzolin	O
30	O
minutes	O
after	O
administration	O
of	O
the	O
first	O
drop	O
of	O
trial	O
medication	O
.	O

CONCLUSION	O
A	O
fast	O
and	O
effective	O
onset	O
of	O
action	O
is	O
of	O
high	O
clinical	O
relevance	O
.	O

Therefore	O
the	O
benefits	O
of	O
using	O
Antazolin/Tetryzolin	O
eye	O
drops	O
was	O
clearly	O
outweigh	O
.	O

Rationale	O
and	O
design	O
of	O
RE-LY	O
:	O
randomized	O
evaluation	O
of	O
long-term	O
anticoagulant	O
therapy	O
,	O
warfarin	O
,	O
compared	O
with	O
dabigatran	O
.	O

Vitamin	O
K	O
antagonists	O
(	O
VKAs	O
)	O
are	O
effective	O
for	O
stroke	O
prevention	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
but	O
are	O
difficult	O
to	O
use	O
.	O

Dabigatran	O
etexilate	O
is	O
a	O
prodrug	O
that	O
is	O
rapidly	O
converted	O
to	O
the	O
active	O
direct	O
thrombin	O
inhibitor	O
dabigatran	O
.	O

It	O
is	O
administered	O
in	O
a	O
fixed	O
dose	O
without	O
laboratory	O
monitoring	O
and	O
is	O
being	O
compared	O
with	O
warfarin	O
(	O
international	O
normalized	O
ratio	O
2-3	O
)	O
in	O
the	O
RE-LY	O
trial	O
.	O

Two	O
doses	O
of	O
dabigatran	O
(	O
110	O
and	O
150	O
mg	O
BID	O
)	O
are	O
being	O
evaluated	O
.	O

RE-LY	O
is	O
a	O
phase	O
3	O
,	O
prospective	O
,	O
randomized	O
,	O
open-label	O
multinational	O
(	O
44	O
countries	O
)	O
trial	O
of	O
patients	O
with	O
nonvalvular	O
AF	O
and	O
at	O
least	O
1	O
risk	O
factor	O
for	O
stroke	O
.	O

Recruitment	O
concluded	O
with	O
a	O
total	O
of	O
18,113	O
patients	O
.	O

Patients	O
who	O
were	O
VKA-naive	O
and	O
experienced	O
are	O
included	O
in	O
balanced	O
proportions	O
.	O

The	O
primary	O
outcome	O
is	O
stroke	Physical
(	Physical
including	Physical
hemorrhagic	Physical
)	Physical
or	O
systemic	Physical
embolism	Physical
.	O

Safety	O
outcomes	O
are	O
bleeding	Adverseeffect
,	Adverseeffect
liver	Physical
function	Physical
abnormalities	Physical
,	O
and	O
other	Physical
adverse	Physical
events	Physical
.	O

Adjudication	O
of	O
end	O
points	O
is	O
blinded	O
to	O
drug	O
assignment	O
.	O

The	O
trial	O
is	O
expected	O
to	O
accrue	O
a	O
minimum	O
of	O
450	O
events	O
with	O
a	O
minimum	O
1-year	O
of	O
follow-up	O
.	O

RE-LY	O
is	O
the	O
largest	O
AF	O
stroke	O
prevention	O
trial	O
yet	O
undertaken	O
.	O

It	O
is	O
unique	O
because	O
it	O
includes	O
equal	O
numbers	O
of	O
VKA-experienced	O
and	O
naive	O
patients	O
and	O
evaluates	O
2	O
different	O
dosages	O
of	O
dabigatran	O
,	O
which	O
may	O
allow	O
tailoring	O
of	O
dosing	O
to	O
individual	O
patient	O
needs	O
.	O

The	O
worldwide	O
site	O
distribution	O
and	O
broad	O
range	O
of	O
stroke	O
risk	O
further	O
increase	O
the	O
general	O
applicability	O
of	O
the	O
trial	O
.	O

Results	O
are	O
expected	O
in	O
2009	O
.	O

[	O
Clinilal	O
study	O
of	O
medical	O
ozone	O
therapy	O
in	O
chronic	O
hepatitis	O
B	O
of	O
20	O
patients	O
]	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
effect	O
of	O
medical	O
ozone	O
in	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
B	O
.	O

METHODS	O
42	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
were	O
divided	O
randomly	O
into	O
two	O
groups	O
.	O

22	O
patients	O
treated	O
with	O
basic	O
therapy	O
were	O
as	O
a	O
control	O
group	O
.	O

20	O
patients	O
treated	O
with	O
basic	O
therapy	O
plus	O
ozone	O
therapy	O
were	O
taken	O
as	O
a	O
treatment	O
group	O
.	O

Index	Physical
of	Physical
biochemistry	Physical
and	O
virology	Physical
were	O
studied	O
at	O
initial	O
and	O
post-treatment	O
8	O
weeks	O
.	O

RESULTS	O
After	O
the	O
treatment	O
,	O
liver	O
function	O
of	O
the	O
treatment	O
group	O
and	O
the	O
control	O
group	O
had	O
more	O
significant	O
improvement	O
.	O

The	O
treatment	O
group	O
complete	Others
effective	Others
and	O
partial	Others
effective	Others
were	O
10	O
%	O
and	O
35	O
%	O
difference	O
.	O

The	O
control	O
group	O
complete	O
effective	O
and	O
partial	O
effective	O
were	O
4.6	O
%	O
and	O
13.6	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
Treatment	O
of	O
medical	O
ozone	O
on	O
patients	O
with	O
chronic	O
hepatitis	O
B	O
is	O
effective	Others
.	O

Effect	O
of	O
pravastatin	O
on	O
cardiovascular	Physical
events	Physical
in	O
women	O
after	O
myocardial	O
infarction	O
:	O
the	O
cholesterol	O
and	O
recurrent	O
events	O
(	O
CARE	O
)	O
trial	O
.	O

OBJECTIVES	O
We	O
sought	O
to	O
determine	O
the	O
effect	O
of	O
pravastatin	O
on	O
recurrent	Physical
cardiovascular	Physical
events	Physical
in	O
women	O
with	O
average	O
cholesterol	O
levels	O
after	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

BACKGROUND	O
Little	O
information	O
is	O
available	O
on	O
the	O
effectiveness	O
of	O
lipid	O
lowering	O
in	O
secondary	O
prevention	O
of	O
coronary	O
heart	O
disease	O
(	O
CHD	O
)	O
in	O
women	O
;	O
in	O
particular	O
,	O
those	O
with	O
CHD	O
and	O
average	O
cholesterol	O
levels	O
.	O

METHODS	O
In	O
the	O
Cholesterol	O
and	O
Recurrent	O
Events	O
(	O
CARE	O
)	O
trial	O
,	O
576	O
postmenopausal	O
women	O
,	O
between	O
3	O
and	O
20	O
months	O
after	O
MI	O
,	O
with	O
a	O
total	O
cholesterol	O
level	O
<	O
240	O
mg/dl	O
and	O
a	O
low	O
density	O
lipoprotein	O
cholesterol	O
level	O
115	O
to	O
174	O
mg/dl	O
,	O
were	O
randomized	O
to	O
receive	O
pravastatin	O
40	O
mg/day	O
or	O
matching	O
placebo	O
for	O
a	O
median	O
follow-up	O
period	O
of	O
5	O
years	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
combined	Physical
coronary	Physical
events	Physical
(	Physical
coronary	Physical
death	Physical
,	Physical
nonfatal	Physical
MI	Physical
,	Physical
percutaneous	Physical
transluminal	Physical
coronary	Physical
angioplasty	Physical
[	Physical
PTCA	Physical
]	Physical
or	Physical
coronary	Physical
artery	Physical
bypass	Physical
graft	Physical
surgery	Physical
[	Physical
CABG	Physical
]	Physical
)	Physical
,	Physical
the	Physical
primary	Physical
trial	Physical
end	Physical
point	Physical
(	Physical
coronary	Physical
death	Physical
or	Physical
nonfatal	Physical
MI	Physical
)	Physical
and	Physical
stroke	Physical
.	Others

RESULTS	O
Women	O
treated	O
with	O
pravastatin	O
had	O
a	O
risk	Physical
reduction	Physical
of	O
43	O
%	O
for	O
the	O
primary	O
end	O
point	O
(	O
p	O
=	O
0.035	O
)	O
,	O
46	O
%	O
for	O
combined	O
coronary	O
events	O
(	O
p	O
=	O
0.001	O
)	O
,	O
48	O
%	O
for	O
PTCA	O
(	O
p	O
=	O
0.025	O
)	O
,	O
40	O
%	O
for	O
CABG	O
(	O
p	O
=	O
0.14	O
)	O
and	O
56	O
%	O
for	O
stroke	O
(	O
p	O
=	O
0.07	O
)	O
.	O

The	O
3,583	O
men	O
in	O
the	O
CARE	O
trial	O
also	O
showed	O
a	O
reduction	O
in	O
risk	Physical
,	O
but	O
the	O
magnitude	O
tended	O
to	O
be	O
less	O
.	O

Pravastatin	O
improved	O
plasma	Physical
lipids	Physical
similarly	O
in	O
men	O
and	O
women	O
.	O

There	O
were	O
no	O
differences	O
in	O
risk	Physical
of	Physical
coronary	Physical
events	Physical
in	O
the	O
placebo	O
group	O
between	O
men	O
and	O
women	O
.	O

Minor	O
differences	O
between	O
men	O
and	O
women	O
were	O
present	O
in	O
baseline	O
characteristics	O
and	O
treatment	O
for	O
MI	O
,	O
in	O
general	O
,	O
conferring	O
a	O
higher	O
risk	O
status	O
and	O
a	O
lower	O
incidence	O
of	O
CABG	O
in	O
the	O
women	O
.	O

CONCLUSIONS	O
Pravastatin	O
led	O
to	O
significant	O
early	O
reduction	O
of	O
a	O
wide	O
range	O
of	O
cardiovascular	O
events	O
in	O
post-MI	O
women	O
with	O
average	O
cholesterol	O
levels	O
.	O

Cardiovascular	Others
safety	Others
and	Others
gastrointestinal	Others
tolerability	Others
of	O
etoricoxib	O
vs	O
diclofenac	O
in	O
a	O
randomized	O
controlled	O
clinical	O
trial	O
(	O
The	O
MEDAL	O
study	O
)	O
.	O

OBJECTIVE	O
To	O
compare	O
cardiovascular	Others
(	Others
CV	Others
)	Others
and	Others
other	Others
safety	Others
and	Others
efficacy	Others
parameters	Others
of	O
etoricoxib	O
60	O
and	O
90	O
mg	O
,	O
and	O
diclofenac	O
150	O
mg.	O
METHODS	O
This	O
double-blind	O
study	O
randomized	O
OA	O
patients	O
to	O
etoricoxib	O
90	O
mg	O
,	O
then	O
to	O
60	O
mg	O
once	O
daily	O
vs	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
;	O
RA	O
patients	O
were	O
randomized	O
to	O
etoricoxib	O
90	O
mg	O
once	O
daily	O
or	O
diclofenac	O
75	O
mg	O
twice	O
daily	O
.	O

The	O
primary	O
endpoint	O
was	O
non-inferiority	O
of	O
etoricoxib	O
vs	O
diclofenac	O
for	O
thrombotic	O
CV	O
events	O
(	O
95	O
%	O
CI	O
upper	O
bound	O
of	O
hazard	O
ratio	O
<	O
1.30	O
)	O
.	O

Other	Others
safety	Others
and	Others
efficacy	Others
parameters	Others
were	O
evaluated	O
in	O
cohorts	O
of	O
patients	O
based	O
on	O
etoricoxib	O
dose	O
and	O
disease	O
.	O

RESULTS	O
A	O
total	O
of	O
23	O
504	O
patients	O
were	O
randomized	O
with	O
mean	O
treatment	O
duration	O
from	O
19.4	O
to	O
20.8	O
months	O
.	O

The	O
thrombotic	Others
CV	Others
risk	Others
hazard	Others
ratio	Others
(	Physical
HR	Physical
)	Physical
(	O
etoricoxib	O
to	O
diclofenac	O
)	O
was	O
0.96	O
(	O
95	O
%	O
CI	O
0.81	O
,	O
1.15	O
)	O
,	O
consistent	O
with	O
non-inferiority	O
of	O
etoricoxib	O
to	O
diclofenac	O
.	O

The	O
cumulative	Adverseeffect
gastrointestinal	Adverseeffect
(	Adverseeffect
GI	Adverseeffect
)	Adverseeffect
/liver	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
(	Adverseeffect
AEs	Adverseeffect
)	Adverseeffect
discontinuation	Adverseeffect
rate	Adverseeffect
was	O
significantly	O
lower	O
for	O
etoricoxib	O
than	O
diclofenac	O
in	O
each	O
patient	O
cohort	O
;	O
HR	O
(	O
95	O
%	O
CI	O
)	O
of	O
0.46	O
(	O
0.39	O
,	O
0.54	O
)	O
,	O
0.52	O
(	O
0.42	O
,	O
0.63	O
)	O
and	O
0.49	O
(	O
0.39	O
,	O
0.62	O
)	O
for	O
the	O
60	O
mg	O
OA	O
,	O
90	O
mg	O
OA	O
and	O
RA	O
cohorts	O
.	O

The	O
maximum	O
average	O
change	O
in	O
systolic	Physical
blood	Physical
pressure	Physical
(	O
BP	O
)	O
with	O
etoricoxib	O
was	O
3.4-3.6	O
mmHg	O
(	O
diastolic	O
BP	O
:	O
1.0-1.5	O
mmHg	O
)	O
,	O
while	O
diclofenac	O
produced	O
a	O
maximum	O
average	O
change	O
of	O
0.9-1.9	O
mmHg	O
(	O
diastolic	O
BP	O
:	O
0.0-0.5	O
mmHg	O
)	O
.	O

Both	O
agents	O
resulted	O
in	O
similar	O
efficacy	Others
regardless	O
of	O
etoricoxib	O
dose	O
.	O

CONCLUSION	O
Long-term	O
etoricoxib	O
use	O
is	O
associated	O
with	O
a	O
risk	Physical
of	Physical
thrombotic	Physical
CV	Physical
events	Physical
comparable	O
with	O
that	O
of	O
diclofenac	O
.	O

Compared	O
with	O
diclofenac	O
,	O
etoricoxib	O
demonstrated	O
a	O
greater	O
risk	O
of	O
renovascular	Physical
AEs	Physical
,	O
but	O
a	O
more	O
favourable	O
GI/liver	Others
tolerability	Others
profile	Others
.	Others

The	O
effects	O
of	O
moderate	O
to	O
vigorous	Others
aerobic	O
exercise	O
on	O
the	O
sleep	O
need	O
of	O
sedentary	O
young	O
adults	O
.	O

Exercise	O
has	O
been	O
recommended	O
for	O
enhancing	O
sleep	O
;	O
a	O
claim	O
linked	O
to	O
the	O
belief	O
that	O
sleep	O
need	O
-	O
defined	O
by	O
sleep	O
duration	O
and	O
depth	O
-	O
is	O
increased	O
post-exercise	O
to	O
allow	O
tissue	O
recovery	O
.	O

Objective	O
studies	O
investigating	O
exercise-sleep	O
responses	O
have	O
produced	O
mixed	O
outcomes	O
,	O
and	O
the	O
disparity	O
in	O
results	O
between	O
studies	O
may	O
be	O
due	O
to	O
differences	O
in	O
individual	O
characteristics	O
and/or	O
exercise	O
protocol	O
,	O
emphasising	O
the	O
importance	O
of	O
carefully	O
controlled	O
trials	O
.	O

We	O
investigated	O
the	O
role	O
of	O
exercise	O
on	O
the	O
sleep	O
need	O
of	O
sedentary	O
adults	O
,	O
after	O
controlling	O
for	O
exercise	O
mode	O
,	O
timing	O
and	O
duration	O
.	O

Twelve	O
healthy	O
volunteers	O
(	O
25.2	O
?	O
4.0	O
years	O
,	O
9	O
females	O
,	O
[	O
Vdot	O
]	O
O	O
(	O
2	O
)	O
max	O
35.4	O
?	O
8.8	O
ml?	O
kg	O
(	O
-1	O
)	O
?	O
min	O
(	O
-1	O
)	O
)	O
were	O
randomised	O
to	O
no-exercise	O
or	O
to	O
a	O
bout	O
of	O
treadmill	O
exercise	O
at	O
45	O
%	O
,	O
55	O
%	O
,	O
65	O
%	O
or	O
75	O
%	O
[	O
Vdot	O
]	O
O	O
(	O
2	O
)	O
max	O
in	O
a	O
crossover	O
design	O
.	O

Sleep	O
on	O
no-exercise	O
and	O
exercise	O
nights	O
were	O
assessed	O
by	O
polysomnography	O
.	O

Participants	O
spent	O
a	O
greater	O
proportion	O
of	O
sleep	O
in	O
light	Physical
sleep	Physical
(	O
stage	O
1	O
+	O
stage	O
2	O
)	O
after	O
exercise	O
at	O
both	O
65	O
%	O
and	O
75	O
%	O
[	O
Vdot	O
]	O
O	O
(	O
2	O
)	O
max	O
(	O
P	O
<	O
0.05	O
)	O
than	O
the	O
no-exercise	O
condition	O
.	O

There	O
was	O
a	O
trend	O
of	O
a	O
reduced	O
proportion	O
of	O
rapid	Physical
eye	Physical
movement	Physical
sleep	Physical
with	Physical
increased	Physical
exercise	Physical
intensity	Physical
(	O
P	O
=	O
0.067	O
)	O
.	O

No	O
other	O
changes	O
were	O
observed	O
in	O
any	O
other	O
sleep	O
variables	O
.	O

Two	O
findings	O
emerged	O
:	O
vigorous	O
exercise	O
did	O
not	O
increase	O
sleep	O
need	O
;	O
however	O
,	O
this	O
level	O
of	O
exercise	O
increased	O
light	O
sleep	O
.	O

The	O
peroxisome	O
proliferator-activated	O
receptor-gamma	O
agonist	O
pioglitazone	O
increases	O
number	Physical
and	Physical
function	Physical
of	Physical
endothelial	Physical
progenitor	Physical
cells	Physical
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
and	O
normal	O
glucose	O
tolerance	O
.	O

OBJECTIVE	O
Peroxisome	O
proliferator-activated	O
receptor-gamma	O
(	O
PPAR	O
gamma	O
)	O
agonists	O
(	O
thiazolidinediones	O
[	O
TZDs	O
]	O
)	O
are	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O

Bone	O
marrow-derived	O
endothelial	O
progenitor	O
cells	O
(	O
EPCs	O
)	O
improve	O
vascular	Physical
function	Physical
and	O
predict	O
cardiovascular	Physical
risk	Physical
.	Physical

The	O
effect	O
of	O
pioglitazone	O
therapy	O
on	O
EPCs	O
was	O
examined	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
AND	O
RESULTS	O
We	O
performed	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
on	O
patients	O
with	O
documented	O
stable	O
coronary	O
artery	O
disease	O
and	O
normal	O
glucose	O
tolerance	O
.	O

Of	O
54	O
patients	O
with	O
normal	O
fasting	O
glucose	O
levels	O
,	O
18	O
showed	O
impaired	O
glucose	O
tolerance	O
and	O
36	O
patients	O
with	O
normal	O
glucose	O
tolerance	O
were	O
randomized	O
to	O
30-day	O
treatment	O
with	O
pioglitazone	O
(	O
45	O
mg	O
)	O
or	O
placebo	O
in	O
addition	O
to	O
optimal	O
medical	O
therapy	O
.	O

All	O
patients	O
in	O
the	O
TZD	O
group	O
showed	O
an	O
increase	O
of	O
adiponectin	Physical
levels	Physical
as	O
an	O
indicator	O
of	O
compliance	O
(	O
11.4	O
+/-	O
1.1	O
to	O
36.8	O
+/-	O
2.1	O
microg/ml	O
;	O
P	O
<	O
0.001	O
)	O
.	O

TZD	O
,	O
but	O
not	O
placebo	O
,	O
decreased	O
mean	Physical
high-sensitivity	Physical
C-reactive	Physical
protein	Physical
to	O
43	O
+/-	O
19	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pioglitazone	O
increased	O
CD34	Physical
(	Physical
+	Physical
)	Physical
/kinase	Physical
insert	Physical
domain	Physical
receptor	Physical
(	Physical
+	Physical
)	Physical
EPCs	Physical
to	O
142	O
+/-	O
9	O
%	O
and	O
cultured	Physical
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled	Physical
acetylated	Physical
LDL	Physical
(	Physical
+	Physical
)	Physical
/lectin	Physical
(	Physical
+	Physical
)	Physical
EPCs	Physical
to	O
180	O
+/-	O
3	O
%	O
(	O
P	O
<	O
0.05	O
)	O
.	O

EPC	Physical
numbers	Physical
were	O
not	O
changed	O
in	O
the	O
placebo	O
group	O
.	O

TZD	O
increased	O
the	O
SDF-1-induced	Physical
migratory	Physical
capacity	Physical
to	O
146	O
+/-	O
9	O
%	O
per	O
EPC	O
number	O
(	O
P	O
<	O
0.05	O
)	O
and	O
upregulated	O
the	O
clonogenic	Physical
potential	Physical
of	Physical
EPCs	Physical
,	O
increasing	O
the	Physical
colony-forming	Physical
units	Physical
to	O
172	O
+/-	O
12	O
%	O
(	O
P	O
<	O
0.001	O
)	O
.	O

In	O
cultured	O
human	O
EPCs	O
,	O
TZD	O
increased	O
EPC	Physical
numbers	Physical
and	Physical
migration	Physical
and	Physical
reduced	Physical
NADPH-oxidase	Physical
activity	Physical
.	Physical

The	O
TZD	O
effect	O
was	O
reversed	O
by	O
the	O
PPAR	O
gamma	O
antagonist	O
GW9662	O
and	O
mimicked	O
by	O
treatment	O
with	O
adiponectin	O
.	O

CONCLUSIONS	O
The	O
PPAR	O
gamma	O
agonist	O
pioglitazone	O
increases	O
the	O
number	Physical
and	Physical
function	Physical
of	Physical
EPCs	Physical
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

The	O
effect	O
represents	O
a	O
potential	O
regenerative	O
mechanism	O
in	O
atherosclerosis	O
and	O
is	O
observed	O
in	O
normoglycemic	O
individuals	O
with	O
stable	O
coronary	O
artery	O
disease	O
.	O

Interactions	O
of	O
morphine	O
and	O
methotrimeprazine	O
in	O
mouse	O
and	O
man	O
with	O
respect	O
to	O
analgesia	Physical
,	Physical
respiration	Physical
and	Physical
sedation	Physical
.	O

Interactions	O
between	O
morphine	O
and	O
methotrimeprazine	O
have	O
been	O
studied	O
in	O
mice	O
and	O
man	O
with	O
respect	O
to	O
analgesia	Physical
or	Physical
antinociceptive	Physical
activity	Physical
,	O
respiratory	Physical
effects	Physical
and	O
sedation	Physical
.	O

The	O
volunteer	O
study	O
was	O
a	O
double-blind	O
cross-over	O
trial	O
with	O
10	O
volunteers	O
.	O

In	O
mice	O
,	O
methotrimeprazine	O
only	O
possessed	O
antinociceptive	Physical
activity	Physical
in	O
doses	O
which	O
caused	O
marked	Physical
sedation	Physical
.	O

However	O
,	O
small	O
non-sedative	O
doses	O
of	O
methotrimeprazine	O
potentiated	O
the	O
analgesic	Pain
action	Pain
of	Pain
morphine	Pain
.	O

The	O
volunteer	O
study	O
did	O
not	O
confirm	O
this	O
finding	O
in	O
man	O
.	O

Methotrimeprazine	O
7.5	O
mg	O
i.m	O
.	O

caused	O
significant	Physical
sedation	Physical
,	O
but	O
did	O
not	O
alter	O
the	O
effects	O
of	O
morphine	O
5	O
mg	O
on	O
pain	Pain
threshold	Pain
or	O
ventilatory	Physical
response	Physical
to	O
carbon	O
dioxide	O
.	O

Most	O
effective	O
regimen	O
of	O
tranexamic	O
acid	O
in	O
knee	O
arthroplasty	O
:	O
a	O
prospective	O
randomized	O
controlled	O
study	O
in	O
240	O
patients	O
.	O

BACKGROUND	O
The	O
antifibrinolytic	O
tranexamic	O
acid	O
reduces	O
surgical	O
blood	O
loss	O
,	O
but	O
studies	O
have	O
not	O
identified	O
an	O
optimal	O
regimen	O
.	O

QUESTIONS/PURPOSES	O
We	O
studied	O
different	O
dosages	O
,	O
timings	O
,	O
and	O
modes	O
of	O
administration	O
to	O
identify	O
the	O
most	O
effective	O
regimen	O
of	O
tranexamic	O
acid	O
in	O
achieving	O
maximum	O
reduction	O
of	O
blood	O
loss	O
in	O
TKA	O
.	O

METHODS	O
We	O
prospectively	O
studied	O
five	O
regimens	O
(	O
four	O
intravenous	O
,	O
one	O
local	O
;	O
40	O
patients	O
each	O
)	O
with	O
a	O
control	O
group	O
(	O
no	O
tranexamic	O
acid	O
)	O
.	O

The	O
four	O
intravenous	O
(	O
10-mg/kg	O
dose	O
)	O
regimens	O
included	O
(	O
1	O
)	O
intraoperative	O
dose	O
(	O
IO	O
)	O
given	O
before	O
tourniquet	O
deflation	O
,	O
(	O
2	O
)	O
additional	O
preoperative	O
dose	O
(	O
POIO	O
)	O
,	O
(	O
3	O
)	O
additional	O
postoperative	O
dose	O
(	O
IOPO	O
)	O
,	O
and	O
(	O
4	O
)	O
all	O
three	O
doses	O
(	O
POIOPO	O
)	O
.	O

The	O
fifth	O
regimen	O
was	O
a	O
single	O
local	O
application	O
(	O
LA	O
)	O
.	O

Two	O
independent	O
parameters	O
of	O
drain	Physical
loss	Physical
and	O
total	Physical
blood	Physical
loss	Physical
,	O
calculated	O
by	O
the	O
hemoglobin	O
balance	O
method	O
,	O
were	O
evaluated	O
statistically	O
.	O

RESULTS	O
Both	O
parameters	O
were	O
reduced	O
in	O
all	O
five	O
regimens	O
as	O
against	O
the	O
control	O
.	O

A	O
significant	O
reduction	O
in	O
drain	Physical
loss	Physical
was	O
seen	O
in	O
the	O
POIO	O
,	O
IOPO	O
,	O
and	O
POIOPO	O
groups	O
whereas	O
total	O
blood	Physical
loss	Physical
was	O
significantly	O
reduced	O
in	O
the	O
POIO	O
,	O
POIOPO	O
,	O
and	O
LA	O
groups	O
.	O

The	O
POIOPO	O
group	O
had	O
the	O
least	O
drain	Physical
loss	Physical
(	O
303	O
mL	O
)	O
and	O
least	O
total	O
blood	Physical
loss	Physical
(	O
688	O
mL	O
)	O
.	O

The	O
IO	O
group	O
had	O
the	O
greatest	O
drain	Physical
loss	Physical
and	O
the	O
IOPO	O
group	O
the	O
greatest	O
total	Physical
blood	Physical
loss	Physical
.	O

CONCLUSIONS	O
Single-dose	O
tranexamic	O
acid	O
did	O
not	O
give	O
effective	O
results	O
.	O

The	O
two-dose	O
regimen	O
of	O
POIO	O
was	O
the	O
least	O
amount	O
necessary	O
for	O
effective	O
results	O
.	O

When	O
compared	O
against	O
the	O
control	O
,	O
this	O
regimen	O
produced	O
reduction	O
of	O
drain	Physical
loss	Physical
and	O
total	Physical
blood	Physical
loss	Physical
,	O
whereas	O
the	O
IOPO	O
regimen	O
did	O
not	O
.	O

The	O
three-dose	O
regimen	O
of	O
POIOPO	O
produced	O
maximum	O
effective	O
reduction	O
of	O
drain	Physical
loss	Physical
and	O
total	Physical
blood	Physical
loss	Physical
.	O

[	O
Prevention	O
of	O
vascular	Adverseeffect
complications	Adverseeffect
following	O
cerebral	O
ischemia	O
of	O
arterial	O
origin	O
;	O
the	O
ESPRIT	O
trial	O
:	O
mild	O
anticoagulant	O
therapy	O
,	O
combination	O
treatment	O
with	O
acetylsalicylic	O
acid	O
plus	O
dipyridamole	O
or	O
treatment	O
with	O
acetylsalicylic	O
acid	O
alone	O
?	O
]	O
.	O

The	O
European	O
and	O
Australian	O
Stroke	O
Prevention	O
in	O
Reversible	O
Ischaemia	O
Trial	O
(	O
ESPRIT	O
)	O
is	O
a	O
randomised	O
clinical	O
trial	O
in	O
which	O
patients	O
with	O
cerebral	O
ischaemia	O
of	O
arterial	O
origin	O
will	O
be	O
randomised	O
between	O
oral	O
anticoagulation	O
(	O
international	O
normalized	O
ratio	O
(	O
INR	O
)	O
:	O
2.0-3.0	O
)	O
,	O
the	O
combination	O
of	O
acetylsalicylic	O
acid	O
(	O
in	O
any	O
dose	O
between	O
30	O
and	O
325	O
mg	O
per	O
day	O
)	O
plus	O
dipyridamole	O
(	O
400	O
mg	O
daily	O
)	O
and	O
acetylsalicylic	O
acid	O
only	O
(	O
in	O
any	O
dose	O
between	O
30	O
and	O
325	O
mg	O
per	O
day	O
)	O
.	O

It	O
is	O
planned	O
to	O
enroll	O
4500	O
patients	O
with	O
a	O
mean	O
follow-up	O
of	O
three	O
years	O
.	O

Primary	O
outcome	O
is	O
the	O
composite	Mortality
event	Mortality
of	Mortality
vascular	Mortality
death	Mortality
,	Mortality
stroke	Physical
,	Mortality
myocardial	Physical
infarction	Physical
,	Mortality
or	Mortality
major	Adverseeffect
bleeding	Adverseeffect
complication	Adverseeffect
;	Mortality
outcome	O
assessment	O
will	O
be	O
blinded	O
.	O

ESPRIT	O
is	O
an	O
international	O
,	O
multicentre	O
study	O
in	O
which	O
60-80	O
hospitals	O
in	O
the	O
Netherlands	O
and	O
other	O
countries	O
in	O
Europe	O
and	O
Australia	O
will	O
participate	O
.	O

The	O
effect	O
of	O
phenytoin	O
on	O
the	O
absorption	O
of	O
synthetic	O
folic	O
acid	O
polyglutamate	O
.	O

The	O
absorption	O
of	O
synthetic	O
pteroyltriglutamate	O
has	O
been	O
measured	O
in	O
nine	O
normal	O
students	O
with	O
and	O
without	O
the	O
anticonvulsant	O
drug	O
phenytoin	O
.	O

It	O
has	O
been	O
shown	O
that	O
phenytoin	O
has	O
no	O
effect	O
on	O
the	O
absorption	O
of	O
this	O
folate	Physical
polyglutamate	Physical
.	O

The	O
reasons	O
are	O
discussed	O
for	O
the	O
disparity	O
between	O
this	O
result	O
and	O
those	O
reported	O
in	O
the	O
literature	O
when	O
folate	O
polyglutamates	O
derived	O
from	O
yeast	O
were	O
used	O
.	O

Concurrent	O
administration	O
of	O
donepezil	O
HCl	O
and	O
digoxin	O
:	O
assessment	O
of	O
pharmacokinetic	O
changes	O
.	O

AIM	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
pharmacokinetics	O
of	O
donepezil	O
HCl	O
and	O
digoxin	O
separately	O
,	O
and	O
in	O
combination	O
,	O
following	O
administration	O
of	O
single	O
oral	O
doses	O
.	O

Changes	O
in	O
cardiac	O
conduction	O
parameters	O
following	O
drug	O
administration	O
were	O
also	O
assessed	O
.	O

METHODS	O
This	O
was	O
an	O
open-label	O
,	O
randomized	O
,	O
three-period	O
crossover	O
study	O
in	O
healthy	O
male	O
volunteers	O
(	O
n=12	O
)	O
.	O

During	O
each	O
treatment	O
period	O
,	O
subjects	O
received	O
a	O
single	O
dose	O
of	O
either	O
donepezil	O
HCl	O
(	O
5	O
mg	O
)	O
,	O
digoxin	O
(	O
0.25	O
mg	O
)	O
,	O
or	O
a	O
combination	O
of	O
both	O
drugs	O
.	O

Each	O
treatment	O
period	O
was	O
followed	O
by	O
a	O
2-week	O
,	O
drug-free	O
washout	O
period	O
.	O

RESULTS	O
All	O
12	O
volunteers	O
completed	O
the	O
study	O
without	O
incident	O
.	O

No	O
statistically	O
significant	O
differences	O
in	O
donepezil	Physical
pharmacokinetics	Physical
(	O
Cmax	O
,	O
tmax	O
,	O
AUC	O
(	O
0-120	O
)	O
,	O
AUC	O
(	O
0-infinity	O
)	O
or	O
t1/2	O
)	O
were	O
observed	O
when	O
donepezil	O
administered	O
alone	O
was	O
compared	O
with	O
donepezil	O
administered	O
in	O
combination	O
with	O
digoxin	O
.	O

Similarly	O
,	O
no	O
statistically	O
significant	O
differences	O
in	O
digoxin	O
pharmacokinetics	O
were	O
observed	O
when	O
digoxin	O
was	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
donepezil	O
.	O

No	O
clinically	O
relevant	O
changes	O
in	O
cardiac	Physical
conduction	Physical
(	O
lead	O
II	O
ECG	O
)	O
were	O
observed	O
in	O
any	O
subject	O
during	O
any	O
treatment	O
period	O
.	O

CONCLUSIONS	O
Co-administration	O
of	O
single	O
doses	O
of	O
donepezil	O
HCl	O
(	O
5	O
mg	O
)	O
and	O
digoxin	O
(	O
0.25	O
mg	O
)	O
produced	O
no	O
changes	O
in	O
the	O
pharmacokinetic	O
profile	O
of	O
either	O
drug	O
.	O

In	O
addition	O
,	O
co-administration	O
produced	O
no	O
changes	O
in	O
cardiac	O
conduction	O
parameters	O
during	O
the	O
24	O
h	O
of	O
telemetry	O
monitoring	O
following	O
drug	O
administration	O
.	O

Effects	O
of	O
insufficient	O
sleep	O
on	O
blood	Physical
pressure	Physical
in	O
hypertensive	O
patients	O
:	O
a	O
24-h	O
study	O
.	O

The	O
influence	O
of	O
acute	O
sleep	O
deprivation	O
during	O
the	O
first	O
part	O
of	O
the	O
night	O
on	O
24-h	O
blood	Physical
pressure	Physical
monitoring	O
(	O
ABPM	O
)	O
was	O
studied	O
in	O
36	O
never-treated	O
mild	O
to	O
moderate	O
hypertensive	O
patients	O
.	O

According	O
to	O
a	O
crossover	O
design	O
,	O
they	O
were	O
randomized	O
to	O
have	O
either	O
sleep	O
deprivation	O
or	O
a	O
full	O
night	O
's	O
sleep	O
1	O
week	O
apart	O
,	O
during	O
which	O
they	O
were	O
monitored	O
with	O
ABPM	O
.	O

Urine	O
samples	O
for	O
analysis	O
of	O
nocturnal	O
urinary	O
excretion	Physical
of	Physical
norepinephrine	Physical
were	O
collected	O
.	O

During	O
the	O
sleep-deprivation	O
day	O
,	O
both	O
mean	O
24-h	O
blood	Physical
pressure	Physical
and	O
mean	O
24-h	O
heart	O
rate	O
were	O
higher	O
in	O
comparison	O
with	O
those	O
recorded	O
during	O
the	O
routine	O
workday	O
,	O
the	O
difference	O
being	O
more	O
pronounced	O
during	O
the	O
nighttime	O
(	O
P	O
<	O
.01	O
)	O
.	O

Urinary	Physical
excretion	Physical
of	Physical
norepinephrine	Physical
showed	O
a	O
significant	O
increase	O
at	O
night	O
during	O
sleep	O
deprivation	O
(	O
P	O
<	O
.05	O
)	O
.	O

Blood	Physical
pressure	Physical
and	O
heart	Physical
rate	Physical
significantly	O
increased	O
in	O
the	O
morning	O
after	O
a	O
sleep-insufficient	O
night	O
(	O
P	O
<	O
.05	O
)	O
.	O

These	O
data	O
suggest	O
that	O
lack	O
of	O
sleep	O
in	O
hypertensive	O
patients	O
may	O
increase	O
sympathetic	Physical
nervous	Physical
activity	Physical
during	O
the	O
night	O
and	O
the	O
following	O
morning	O
,	O
leading	O
to	O
increased	O
blood	Physical
pressure	Physical
and	O
heart	Physical
rate	Physical
.	O

This	O
situation	O
might	O
represent	O
an	O
increased	O
risk	Physical
for	Physical
both	Physical
target	Physical
organ	Physical
damage	Physical
and	Physical
acute	Physical
cardiovascular	Physical
diseases	Physical
.	O

Faux	O
pas	O
detection	O
and	O
intentional	O
action	O
in	O
Asperger	O
Syndrome	O
.	O

A	O
replication	O
on	O
a	O
French	O
sample	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
mind	O
reading	O
abilities	O
in	O
a	O
group	O
of	O
adults	O
with	O
Asperger	O
Syndrome	O
(	O
AS	O
)	O
by	O
using	O
the	O
faux	O
pas	O
task	O
,	O
an	O
advanced	O
test	O
of	O
theory	O
of	O
mind	O
(	O
Baron-Cohen	O
et	O
al	O
.	O

(	O
1999	O
)	O
.	O

Journal	O
of	O
Autism	O
and	O
Developmental	O
Disorders	O
,	O
29	O
,	O
407-418	O
)	O
.	O

The	O
faux	O
pas	O
is	O
a	O
particular	O
case	O
of	O
a	O
non-intentional	O
action	O
reflecting	O
an	O
involuntary	O
socially	O
inappropriate	O
behavior	O
.	O

Here	O
,	O
individuals	O
with	O
AS	O
over-detected	O
faux	Mental
pas	Mental
stories	Mental
,	O
failed	O
to	O
provide	Mental
correct	Mental
justifications	Mental
of	Mental
the	Mental
speaker	Mental
's	Mental
behavior	Mental
and	O
were	O
unaware	O
of	O
the	O
mistaken	Mental
belief	Mental
and	Mental
of	Mental
the	Mental
resulting	Mental
emotional	Mental
impact	Mental
,	O
whereas	O
they	O
appeared	O
to	O
be	O
responsive	O
to	O
social	O
rule	O
violations	O
.	O

We	O
hypothesized	O
that	O
because	O
of	O
an	O
impaired	O
theory-of-mind	O
,	O
individuals	O
with	O
AS	O
may	O
develop	O
compensatory	O
cognitive	O
strategies	O
based	O
on	O
overlearned	O
abstract	O
knowledge	O
about	O
normative	O
rules	O
.	O

The	O
development	O
of	O
a	O
web-	O
and	O
a	O
print-based	O
decision	O
aid	O
for	O
prostate	Mental
cancer	Mental
screening	Mental
.	Others

BACKGROUND	O
Whether	O
early	O
detection	O
and	O
treatment	O
of	O
prostate	O
cancer	O
(	O
PCa	O
)	O
will	O
reduce	O
disease-related	Mortality
mortality	Mortality
remains	O
uncertain	O
.	O

As	O
a	O
result	O
,	O
tools	O
are	O
needed	O
to	O
facilitate	O
informed	O
decision	Mental
making	Mental
.	Others

While	O
there	O
have	O
been	O
several	O
decision	O
aids	O
(	O
DAs	O
)	O
developed	O
and	O
tested	O
,	O
very	O
few	O
have	O
included	O
an	O
exercise	O
to	O
help	O
men	O
clarify	O
their	O
values	Mental
and	Mental
preferences	Mental
about	O
PCa	O
screening	O
.	O

Further	O
,	O
only	O
one	O
DA	O
has	O
utilized	O
an	O
interactive	O
web-based	O
format	O
,	O
which	O
allows	O
for	O
an	O
expansion	O
and	O
customization	O
of	O
the	O
material	O
.	O

We	O
describe	O
the	O
development	O
of	O
two	O
DAs	O
,	O
a	O
booklet	O
and	O
an	O
interactive	O
website	O
,	O
each	O
with	O
a	O
values	O
clarification	O
component	O
and	O
designed	O
for	O
use	O
in	O
diverse	O
settings	O
.	O

METHODS	O
We	O
conducted	O
two	O
feasibility	O
studies	O
to	O
assess	O
men	O
's	O
(	O
45-70	O
years	O
)	O
Internet	O
access	O
and	O
their	O
willingness	O
to	O
use	O
a	O
web-	O
vs.	O
a	O
print-based	O
tool	O
.	O

The	O
booklet	O
was	O
adapted	O
from	O
two	O
previous	O
versions	O
evaluated	O
in	O
randomized	O
controlled	O
trials	O
(	O
RCTs	O
)	O
and	O
the	O
website	O
was	O
created	O
to	O
closely	O
match	O
the	O
content	O
of	O
the	O
revised	O
booklet	O
.	O

Usability	Others
testing	O
was	O
conducted	O
to	O
obtain	O
feedback	O
regarding	O
draft	O
versions	O
of	O
the	O
materials	O
.	O

The	O
tools	O
were	O
also	O
reviewed	O
by	O
a	O
plain	O
language	O
expert	O
and	O
the	O
interdisciplinary	O
research	O
team	O
.	O

Feedback	O
on	O
the	O
content	O
and	O
presentation	O
led	O
to	O
iterative	O
modifications	O
of	O
the	O
tools	O
.	O

RESULTS	O
The	O
feasibility	O
studies	O
confirmed	O
that	O
the	O
Internet	Others
was	O
a	O
viable	O
medium	O
,	O
as	O
the	O
majority	O
of	O
men	O
used	Mental
a	Mental
computer	Mental
,	O
had	O
access	Mental
to	Mental
the	Mental
Internet	Mental
,	O
and	O
Internet	Mental
use	Mental
increased	O
over	O
time	O
.	O

Feedback	O
from	O
the	O
usability	O
testing	O
on	O
the	O
length	Others
,	Others
presentation	Others
,	Others
and	Others
content	Others
of	Others
the	Others
materials	Others
was	O
incorporated	O
into	O
the	O
final	O
versions	O
of	O
the	O
booklet	O
and	O
website	O
.	O

Both	O
the	O
feasibility	Others
studies	O
and	O
the	O
usability	Others
testing	O
highlighted	O
the	O
need	O
to	O
address	O
men	O
's	O
informed	O
decision	O
making	O
regarding	O
screening	O
.	O

CONCLUSIONS	O
Informed	O
decision	O
making	O
for	O
PCa	O
screening	O
is	O
crucial	O
at	O
present	O
and	O
may	O
be	O
important	O
for	O
some	O
time	O
,	O
particularly	O
if	O
a	O
definitive	O
recommendation	O
either	O
for	O
or	O
against	O
screening	O
does	O
not	O
emerge	O
from	O
ongoing	O
prostate	O
cancer	O
screening	O
trials	O
.	O

We	O
have	O
detailed	O
our	O
efforts	O
at	O
developing	O
print-	O
and	O
web-based	O
DAs	O
to	O
assist	O
men	O
in	O
determining	O
how	O
to	O
best	O
meet	O
their	O
PCa	O
screening	O
preferences	O
.	O

Following	O
completion	O
of	O
our	O
ongoing	O
RCT	O
designed	O
to	O
test	O
these	O
materials	O
,	O
our	O
goal	O
will	O
be	O
to	O
develop	O
a	O
dissemination	O
project	O
for	O
the	O
more	O
effective	O
tool	O
.	O

TRIAL	O
REGISTRATION	O
NCT00623090	O
.	O

A	O
randomised	O
open	O
multicentre	O
comparative	O
trial	O
of	O
lamotrigine	O
and	O
carbamazepine	O
as	O
monotherapy	O
in	O
patients	O
with	O
newly	O
diagnosed	O
or	O
recurrent	O
epilepsy	O
.	O

The	O
efficacy	Others
and	Others
safety	Others
of	O
lamotrigine	O
and	O
carbamazepine	O
as	O
monotherapy	O
in	O
patients	O
with	O
untreated	O
,	O
newly	O
diagnosed	O
or	O
recurrent	O
partial	O
and/or	O
generalised	O
tonic-clonic	O
seizures	O
,	O
were	O
compared	O
in	O
a	O
randomised	O
,	O
open	O
,	O
multicentre	O
study	O
.	O

Patients	O
received	O
24	O
weeks	O
'	O
treatment	O
with	O
oral	O
lamotrigine	O
100	O
mg	O
(	O
LTG	O
100	O
,	O
n	O
=	O
115	O
)	O
or	O
200	O
mg	O
(	O
LTG	O
200	O
,	O
n	O
=	O
111	O
)	O
or	O
carbamazepine	O
600	O
mg	O
(	O
CBZ	O
600	O
,	O
n	O
=	O
117	O
)	O
.	O

Efficacy	Others
measurements	Others
were	O
comparable	O
between	O
the	O
three	O
treatment	O
groups	O
,	O
although	O
the	O
higher	O
lamotrigine	O
dose	O
was	O
possibly	O
most	O
effective	O
,	O
with	O
60.4	O
%	O
completing	O
seizure	O
free	O
compared	O
with	O
51.3	O
%	O
(	O
LTG	O
100	O
)	O
and	O
54.7	O
%	O
(	O
CBZ	O
600	O
)	O
.	O

Both	O
dosage	O
regimens	O
of	O
lamotrigine	O
were	O
well	O
tolerated	Others
.	Others

More	O
patients	O
on	O
CBZ	O
600	O
reported	O
adverse	Adverseeffect
experiences	Adverseeffect
,	O
66	O
%	O
versus	O
53	O
%	O
(	O
LTG	O
100	O
)	O
and	O
58	O
%	O
(	O
LTG	O
200	O
)	O
,	O
and	O
of	O
these	O
a	O
greater	O
proportion	O
were	O
attributed	O
to	O
CBZ	O
600	O
treatment	O
,	O
53	O
%	O
versus	O
23	O
%	O
(	O
LTG	O
100	O
)	O
and	O
28	O
%	O
(	O
LTG	O
200	O
)	O
.	O

Similarly	O
,	O
a	O
greater	O
proportion	O
of	O
the	O
CBZ	O
600	O
group	O
required	O
a	O
change	O
in	O
dose	O
,	O
47	O
%	O
versus	O
20	O
%	O
(	O
LTG	O
100	O
)	O
and	O
17	O
%	O
(	O
LTG	O
200	O
)	O
or	O
withdrew	O
completely	O
due	O
to	O
adverse	Adverseeffect
experiences	Adverseeffect
,	O
10.3	O
%	O
versus	O
4.3	O
%	O
(	O
LTG	O
100	O
)	O
and	O
4.5	O
%	O
(	O
LTG	O
200	O
)	O
.	O

The	O
most	O
common	O
adverse	Adverseeffect
experience	Adverseeffect
leading	O
to	O
withdrawal	O
was	O
rash	Adverseeffect
,	O
with	O
approximately	O
double	O
the	O
proportion	O
of	O
reports	O
occurring	O
in	O
patients	O
on	O
CBZ	O
600	O
(	O
5.1	O
%	O
)	O
compared	O
with	O
lamotrigine	O
(	O
1.7	O
%	O
on	O
LTG	O
100	O
and	O
2.7	O
%	O
on	O
LTG	O
200	O
)	O
.	O

Overall	O
lamotrigine	O
appeared	O
equally	O
effective	O
but	O
better	O
tolerated	O
compared	O
with	O
carbamazepine	O
.	O

Custom-fit	O
minimally	O
invasive	O
total	O
knee	O
arthroplasty	O
:	O
effect	O
on	O
blood	Physical
loss	Physical
and	O
early	Physical
clinical	Physical
outcomes	Physical
.	Physical

PURPOSE	O
Recently	O
,	O
new	O
custom-fit	O
pin	O
guides	O
in	O
total	O
knee	O
arthroplasty	O
(	O
TKA	O
)	O
have	O
been	O
introduced	O
.	O

Use	O
of	O
these	O
guides	O
may	O
reduce	O
operating	O
time	O
.	O

Use	O
of	O
the	O
guides	O
combined	O
with	O
the	O
absence	O
of	O
intramedullary	O
alignment	O
jigs	O
may	O
lead	O
to	O
reduced	O
blood	Physical
loss	Physical
and	O
improved	O
early	Physical
outcomes	Physical
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
blood	O
loss	O
and	O
early	Physical
clinical	Physical
outcomes	Physical
in	O
patients	O
undergoing	O
minimally	O
invasive	O
TKA	O
using	O
custom-fit	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
-based	O
pin	O
guides	O
.	O

METHODS	O
A	O
prospective	O
study	O
in	O
80	O
patients	O
was	O
carried	O
out	O
.	O

Patients	O
were	O
divided	O
randomly	O
into	O
2	O
equal	O
groups	O
.	O

In	O
one	O
group	O
,	O
intramedullary	O
alignment	O
jigs	O
were	O
used	O
.	O

In	O
the	O
second	O
group	O
,	O
custom-fit	O
MRI-based	O
pin	O
guides	O
were	O
used	O
.	O

All	O
patients	O
received	O
the	O
same	O
cemented	O
posterior-stabilized	O
implant	O
through	O
a	O
mini-midvastus	O
approach	O
.	O

The	O
volume	O
in	O
the	O
drain	O
bottles	O
was	O
recorded	O
after	O
48	O
h.	O
Hb	Physical
loss	Physical
was	O
estimated	O
by	O
subtracting	O
the	O
postoperative	O
from	O
the	O
preoperative	O
Hb	O
level	O
.	O

Transfusion	Physical
requirements	Physical
and	O
surgical	Others
time	Others
were	O
recorded	O
.	O

Outcome	O
measures	O
were	O
Knee	Physical
Society	Physical
Scores	Physical
(	Physical
KSS	Physical
)	Physical
,	Physical
knee	Physical
flexion	Physical
,	Physical
knee	Physical
swelling	Physical
and	Physical
pain	Physical
.	O

RESULTS	O
There	O
was	O
lower	O
mean	Physical
drainage	Physical
of	Physical
blood	Physical
in	O
the	O
custom-fit	O
group	O
(	O
391	O
ml	O
vs.	O
603	O
ml	O
;	O
p	O
<	O
0.0001	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
estimated	O
loss	Physical
of	Physical
Hb	Physical
(	O
3.6	O
g/dl	O
vs.	O
4.1	O
g/dl	O
;	O
n.s	O
.	O

)	O
and	O
in	O
transfusion	O
requirements	O
(	O
7.5	O
%	O
vs.	O
10	O
%	O
;	O
n.s.	O
)	O
.	O

Surgical	O
time	O
was	O
reduced	O
in	O
the	O
custom-fit	O
group	O
(	O
12	O
min	O
less	O
;	O
p	O
=	O
0.001	O
)	O
.	O

KSS	O
measured	O
at	O
week	O
2	O
,	O
6	O
and	O
12	O
showed	O
no	O
significant	O
difference	O
between	O
groups	O
.	O

Knee	Physical
flexion	Physical
measured	O
on	O
days	O
7	O
,	O
10	O
and	O
at	O
week	O
6	O
,	O
12	O
and	O
knee	Physical
swelling	Physical
and	Physical
pain	Physical
measured	O
on	O
days	O
1	O
,	O
3	O
,	O
10	O
and	O
at	O
week	O
6	O
,	O
12	O
showed	O
no	O
significant	O
difference	O
between	O
groups	O
.	O

CONCLUSIONS	O
Using	O
custom-fit	O
pin	O
guides	O
reduces	O
blood	O
drainage	O
,	O
but	O
not	O
the	O
estimated	O
Hb	O
loss	O
in	O
minimally	O
invasive	O
TKA	O
and	O
does	O
not	O
affect	O
transfusion	O
rate	O
.	O

Surgical	O
time	O
is	O
reduced	O
.	O

There	O
is	O
no	O
effect	O
on	O
the	O
early	Physical
clinical	Physical
outcomes	Physical
.	O

LEVEL	O
OF	O
EVIDENCE	O
Therapeutic	O
study	O
,	O
Level	O
I	O
.	O

Inhaled	O
fluticasone	O
reduces	O
sputum	Physical
inflammatory	Physical
indices	Physical
in	O
severe	O
bronchiectasis	O
.	O

Although	O
corticosteroid	O
therapy	O
might	O
be	O
clinically	O
beneficial	O
for	O
bronchiectasis	O
,	O
very	O
little	O
is	O
known	O
of	O
its	O
effects	O
on	O
the	O
inflammatory	Physical
and	Physical
infective	Physical
markers	Physical
in	O
bronchiectasis	O
.	O

We	O
have	O
therefore	O
performed	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
to	O
evaluate	O
the	O
effects	O
of	O
a	O
4-wk	O
administration	O
of	O
inhaled	O
fluticasone	O
in	O
bronchiectasis	O
.	O

Twenty-four	O
patients	O
(	O
12	O
female	O
;	O
mean	O
age	O
51	O
yr	O
)	O
were	O
randomized	O
into	O
receiving	O
either	O
inhaled	O
fluticasone	O
(	O
500	O
microgram	O
twice	O
daily	O
)	O
via	O
the	O
Accuhaler	O
device	O
(	O
n	O
=	O
12	O
)	O
or	O
placebo	O
.	O

At	O
each	O
visit	O
,	O
spirometry	O
,	O
24-h	O
sputum	O
volume	O
,	O
sputum	O
leukocyte	O
density	O
,	O
bacterial	O
densities	O
,	O
and	O
concentrations	Physical
of	Physical
interleukin	Physical
(	Physical
IL	Physical
)	Physical
-1beta	Physical
,	O
IL-8	Physical
,	Physical
tumor	Physical
necrosis	Physical
factor-alpha	Physical
(	Physical
TNF-alpha	Physical
)	Physical
,	O
and	O
leukotriene	Physical
B4	Physical
(	Physical
LTB4	Physical
)	Physical
were	O
determined	O
.	O

There	O
was	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decrease	O
in	O
sputum	Physical
leukocyte	Physical
density	Physical
and	O
IL-1beta	Physical
,	O
IL-8	Physical
,	O
and	O
LTB4	Physical
after	O
fluticasone	O
treatment	O
.	O

The	O
fluticasone	O
group	O
had	O
one	O
and	O
the	O
placebo	O
group	O
three	O
episodes	O
of	O
exacerbation	Adverseeffect
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
spirometry	Physical
(	O
p	O
>	O
0.05	O
)	O
or	O
any	O
reported	O
adverse	Adverseeffect
reactions	Adverseeffect
in	O
either	O
group	O
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
high-dose	O
fluticasone	O
is	O
effective	O
in	O
reducing	O
the	O
sputum	Physical
inflammatory	Physical
indices	Physical
in	O
bronchiectasis	O
.	O

Large-scale	O
and	O
long-term	O
studies	O
are	O
indicated	O
to	O
evaluate	O
the	O
effects	O
of	O
inhaled	O
steroid	O
therapy	O
on	O
the	O
inflammatory	O
components	O
in	O
bronchiectasis	O
.	O

Double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
risperidone	O
plus	O
topiramate	O
in	O
children	O
with	O
autistic	O
disorder	O
.	O

BACKGROUND	O
Autism	O
is	O
a	O
complex	O
neurodevelopmental	O
disorder	O
that	O
forms	O
part	O
of	O
a	O
spectrum	O
of	O
related	O
disorders	O
referred	O
to	O
as	O
Autism	O
Spectrum	O
Disorders	O
.	O

The	O
present	O
study	O
assessed	O
the	O
effects	O
of	O
topiramate	O
plus	O
risperidone	O
in	O
the	O
treatment	O
of	O
autistic	O
disorder	O
.	O

METHOD	O
Forty	O
children	O
between	O
the	O
ages	O
of	O
4	O
and	O
12	O
years	O
with	O
a	O
DSM	O
IV	O
clinical	O
diagnosis	O
of	O
autism	O
who	O
were	O
outpatients	O
from	O
a	O
specialty	O
clinic	O
for	O
children	O
were	O
recruited	O
.	O

The	O
children	O
presented	O
with	O
a	O
chief	O
complaint	O
of	O
severely	O
disruptive	O
symptoms	O
related	O
to	O
autistic	O
disorder	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
topiramate+risperidone	O
(	O
Group	O
A	O
)	O
or	O
placebo+risperidone	O
(	O
Group	O
B	O
)	O
for	O
an	O
8-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

The	O
dose	O
of	O
risperidone	O
was	O
titrated	O
up	O
to	O
2	O
mg/day	O
for	O
children	O
between	O
10	O
and	O
40	O
kg	O
and	O
3	O
mg/day	O
for	O
children	O
weighting	O
above	O
40	O
kg	O
.	O

The	O
dose	O
of	O
topiramate	O
was	O
titrated	O
up	O
to	O
200	O
mg/day	O
depending	O
on	O
weight	O
(	O
100	O
mg/day	O
for	O
<	O
30	O
kg	O
and	O
200	O
mg/day	O
for	O
>	O
30	O
kg	O
)	O
.	O

Patients	O
were	O
assessed	O
at	O
baseline	O
and	O
after	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
weeks	O
after	O
starting	O
medication	O
.	O

Measure	O
of	O
outcome	O
was	O
the	O
Aberrant	Others
Behavior	Others
Checklist-Community	Others
(	Others
ABC-C	Others
)	Others
Rating	Others
Scale	Others
.	O

RESULTS	O
Difference	O
between	O
the	O
two	O
protocols	O
was	O
significant	O
as	O
the	O
group	O
that	O
received	O
topiramate	O
had	O
a	O
greater	O
reduction	Others
in	Others
ABC-C	Others
subscale	Others
scores	Others
for	Others
irritability	Others
,	O
stereotypic	Physical
behavior	Physical
and	O
hyperactivity/noncompliance	Mental
.	O

CONCLUSION	O
The	O
results	O
suggest	O
that	O
the	O
combination	O
of	O
topiramate	O
with	O
risperidone	O
may	O
be	O
superior	O
to	O
risperidone	O
monotherapy	O
for	O
children	O
with	O
autistic	O
disorder	O
.	O

However	O
the	O
results	O
need	O
to	O
be	O
further	O
confirmed	O
by	O
a	O
larger	O
randomized	O
controlled	O
trial	O
.	O

Reversal	O
of	O
skeletal	O
effects	Others
of	O
endocrine	O
treatments	O
in	O
the	O
Intergroup	O
Exemestane	O
Study	O
.	O

The	O
adjuvant	O
use	O
of	O
aromatase	O
inhibitors	O
in	O
breast	O
cancer	O
is	O
associated	O
with	O
adverse	O
effects	O
on	O
bone	O
health	O
.	O

We	O
previously	O
reported	O
a	O
decline	O
in	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
following	O
the	O
switch	O
from	O
tamoxifen	O
to	O
exemestane	O
in	O
the	O
Intergroup	O
Exemestane	O
Study	O
(	O
IES	O
)	O
.	O

Here	O
we	O
report	O
effects	O
of	O
endocrine	O
treatment	O
withdrawal	O
on	O
BMD	O
,	O
bone	O
turnover	O
markers	O
(	O
BTM	O
)	O
and	O
fracture	O
rates	O
.	O

4,724	O
patients	O
took	O
part	O
in	O
IES	O
,	O
and	O
206	O
patients	O
were	O
included	O
in	O
a	O
bone	O
sub-study	O
.	O

BMD	O
and	O
BTM	O
were	O
assessed	O
pre-randomization	O
,	O
during	O
and	O
after	O
the	O
end	O
of	O
treatment	O
(	O
EOT	O
)	O
.	O

To	O
evaluate	O
treatment	O
withdrawal	O
effects	O
,	O
12-	O
and	O
24-month	O
post	O
EOT	O
BMD	O
results	O
are	O
available	O
for	O
122	O
and	O
126	O
patients	O
,	O
respectively	O
.	O

Similar	O
patient	O
numbers	O
had	O
BTM	O
measured	O
post	O
EOT	O
.	O

Following	O
treatment	O
withdrawal	O
,	O
the	O
differences	O
in	O
BMD	O
observed	O
between	O
the	O
two	O
endocrine	O
strategies	O
were	O
partially	O
reversed	O
.	O

At	O
24	O
months	O
from	O
EOT	O
,	O
spine	Physical
BMD	Physical
increased	O
by	O
1.53	O
%	O
(	O
95	O
%	O
CI	O
0.63-2.43	O
;	O
p	O
=	O
0.001	O
)	O
after	O
stopping	O
exemestane	O
and	O
fell	O
by	O
1.93	O
%	O
(	O
95	O
%	O
CI	O
-2.91	O
to	O
0.95	O
;	O
p	O
=	O
0.0002	O
)	O
following	O
tamoxifen	O
withdrawal	O
.	O

A	O
similar	O
pattern	O
of	O
changes	O
was	O
observed	O
at	O
the	O
hip	O
.	O

At	O
2	O
years	O
post	O
EOT	O
,	O
BMD	Physical
changes	Physical
from	O
baseline	O
were	O
similar	O
with	O
both	O
treatment	O
strategies	O
.	O

Corresponding	O
inverse	Physical
changes	Physical
in	Physical
BTM	Physical
were	O
seen	O
,	O
with	O
an	O
increase	O
following	O
tamoxifen	O
withdrawal	O
and	O
a	O
reduction	O
after	O
exemestane	O
.	O

A	O
higher	O
number	Physical
of	Physical
fractures	Physical
occurred	Physical
during	O
exemestane	O
treatment	O
,	O
but	O
fracture	Physical
rates	Physical
were	O
similar	O
after	O
treatment	O
withdrawal	O
.	O

With	O
the	O
switch	O
strategy	O
used	O
in	O
IES	O
,	O
the	O
on	O
treatment	O
adverse	Adverseeffect
bone	Adverseeffect
effects	Adverseeffect
of	O
exemestane	O
are	O
reversed	O
.	O

Ongoing	O
monitoring	O
of	O
BMD	O
is	O
therefore	O
not	O
routinely	O
required	O
.	O

Service	O
variation	O
in	O
baseline	O
variables	O
and	O
prediction	O
of	O
risk	O
in	O
a	O
randomised	O
controlled	O
trial	O
of	O
psychological	O
treatment	O
in	O
repeated	O
parasuicide	O
:	O
the	O
POPMACT	O
Study	O
.	O

The	O
treatment	O
protocol	O
and	O
baseline	O
characteristics	O
of	O
480	O
subjects	O
with	O
a	O
history	O
of	O
repeated	O
parasuicide	O
recruited	O
in	O
five	O
centres	O
to	O
a	O
randomised	O
therapeutic	O
trial	O
of	O
manual	O
assisted	O
cognitive-behaviour	O
therapy	O
(	O
MACT	O
)	O
and	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
are	O
described	O
.	O

Most	O
patients	O
had	O
significant	O
anxiety	Mental
and	O
depressive	Mental
disturbance	Mental
with	O
42	O
%	O
having	O
a	O
personality	O
disorder	O
.	O

Variation	O
in	O
service	O
policies	O
influenced	O
recruitment	O
,	O
with	O
earlier	O
assessment	O
centres	O
seeing	O
people	O
with	O
more	O
frequent	O
episodes	Mental
of	Mental
self-harm	Mental
and	O
greater	O
parasuicide	Mental
risk	Mental
than	O
later	O
ones	O
.	O

Parasuicide	Mental
risk	Mental
was	O
also	O
significantly	O
greater	O
in	O
those	O
with	O
their	O
first	O
parasuicide	O
episode	O
at	O
an	O
earlier	O
age	O
and	O
in	O
those	O
with	O
a	O
more	O
recent	O
latest	O
episode	O
.	O

Intensive	O
insulin	O
therapy	O
improves	O
endothelial	Physical
function	Physical
and	O
microvascular	O
reactivity	O
in	O
young	O
people	O
with	O
type	O
1	O
diabetes	O
.	O

AIMS/HYPOTHESIS	O
Macrovascular	O
disease	O
is	O
an	O
important	O
cause	O
of	O
the	O
increased	O
morbidity	O
and	O
mortality	O
rates	O
associated	O
with	O
type	O
1	O
diabetes	O
,	O
and	O
this	O
vascular	O
impairment	O
begins	O
in	O
childhood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
introducing	O
intensive	O
diabetes	O
management	O
[	O
intensive	O
insulin	O
therapy	O
(	O
IIT	O
)	O
and	O
'Sweet	O
Talk	O
'	O
text-messaging	O
support	O
]	O
produces	O
measurable	O
improvements	O
in	O
endothelial	Physical
function	Physical
.	O

METHODS	O
One	O
hundred	O
and	O
twenty-six	O
patients	O
fulfilled	O
the	O
eligibility	O
criteria	O
(	O
type	O
1	O
diabetes	O
for	O
>	O
1	O
year	O
;	O
on	O
conventional	O
insulin	O
therapy	O
(	O
CIT	O
)	O
;	O
aged	O
between	O
8	O
and	O
18	O
years	O
)	O
,	O
of	O
whom	O
92	O
enrolled	O
.	O

Patients	O
were	O
randomised	O
to	O
group	O
1	O
,	O
CIT	O
only	O
(	O
n=28	O
)	O
;	O
group	O
2	O
,	O
CIT	O
and	O
Sweet	O
Talk	O
(	O
n=33	O
)	O
;	O
or	O
group	O
3	O
,	O
IIT	O
and	O
Sweet	O
Talk	O
(	O
n=31	O
)	O
.	O

Vascular	Physical
assessments	Physical
(	Physical
including	Physical
measures	Physical
of	Physical
endothelial	Physical
damage	Physical
,	Physical
activation	Physical
,	Physical
dysfunction	Physical
and	Physical
oxidative	Physical
stress	Physical
)	Physical
and	O
HbA1c	Physical
were	O
performed	O
at	O
baseline	O
and	O
repeated	O
after	O
12	O
months	O
of	O
the	O
study	O
.	O

RESULTS	O
Glycaemic	Physical
control	Physical
deteriorated	O
in	O
patients	O
on	O
CIT	O
,	O
but	O
improved	O
significantly	O
in	O
patients	O
allocated	O
to	O
IIT	O
(	O
p=0.007	O
)	O
.	O

IIT	O
was	O
associated	O
with	O
significantly	O
greater	O
improvements	O
in	O
E-selectin	Physical
(	O
p	O
<	O
0.0001	O
)	O
than	O
CIT	O
(	O
group	O
1	O
,	O
p=0.026	O
and	O
group	O
2	O
,	O
p=0.053	O
)	O
.	O

Vascular	Physical
responses	Physical
to	O
acetylcholine	O
improved	O
in	O
patients	O
on	O
IIT	O
(	O
p=0.017	O
)	O
,	O
but	O
not	O
in	O
patients	O
receiving	O
CIT	O
.	O

These	O
changes	O
were	O
all	O
independent	O
of	O
HbA1c	O
level	O
.	O

CONCLUSIONS/INTERPRETATION	O
IIT	O
appears	O
to	O
be	O
associated	O
with	O
improvements	O
in	O
vascular	Physical
markers	Physical
,	O
independently	O
of	O
changes	O
in	O
HbA1c	O
,	O
suggesting	O
that	O
IIT	O
may	O
confer	O
vascular	O
protection	O
in	O
addition	O
to	O
improving	O
glycaemic	Physical
control	Physical
.	O

Oral	O
ganciclovir	O
dosing	O
in	O
transplant	O
recipients	O
and	O
dialysis	O
patients	O
based	O
on	O
renal	O
function	O
.	O

BACKGROUND	O
An	O
oral	O
formulation	O
of	O
ganciclovir	O
(	O
GCV	O
)	O
was	O
recently	O
approved	O
for	O
the	O
prevention	O
of	O
cytomegalovirus	O
disease	O
in	O
solid	O
organ	O
transplant	O
recipients	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
bioavailability	O
of	O
GCV	O
and	O
to	O
test	O
a	O
dosing	O
algorithm	O
in	O
transplant	O
and	O
dialysis	O
patients	O
with	O
different	O
levels	O
of	O
renal	O
function	O
.	O

METHODS	O
Pharmacokinetic	O
studies	O
were	O
carried	O
out	O
in	O
23	O
patients	O
who	O
were	O
either	O
a	O
recipient	O
of	O
an	O
organ	O
transplant	O
or	O
on	O
hemodialysis	O
.	O

Drug	O
dosing	O
was	O
established	O
by	O
the	O
following	O
algorithm	O
based	O
on	O
calculated	O
creatinine	O
clearance	O
(	O
CrCl	O
)	O
:	O
CrCl	O
=	O
[	O
(	O
140-age	O
)	O
x	O
body	O
weight	O
]	O
/	O
(	O
72	O
x	O
Cr	O
)	O
x	O
0.85	O
for	O
women	O
that	O
is	O
,	O
CrCl	O
>	O
50	O
ml/min	O
,	O
1000	O
mg	O
every	O
8	O
hr	O
;	O
CrCl	O
of	O
25-50	O
ml/min	O
,	O
1000	O
mg	O
every	O
24	O
hr	O
;	O
CrCl	O
of	O
10-24	O
ml/	O
min	O
,	O
500	O
mg	O
every	O
day	O
;	O
CrCl	O
<	O
10	O
ml/min	O
(	O
or	O
on	O
dialysis	O
)	O
,	O
500	O
mg	O
every	O
other	O
day	O
after	O
dialysis	O
.	O

GCV	O
was	O
taken	O
within	O
30	O
min	O
after	O
a	O
meal	O
.	O

The	O
patients	O
received	O
oral	O
GCV	O
for	O
between	O
12	O
days	O
and	O
14	O
weeks	O
.	O

Serum	Physical
specimens	Physical
(	Physical
or	Physical
plasma	Physical
from	Physical
patients	Physical
on	Physical
hemodialysis	Physical
)	O
obtained	O
at	O
steady	O
state	O
were	O
analyzed	O
for	O
GCV	O
concentrations	O
by	O
high-performance	O
liquid	O
chromatography	O
.	O

In	O
nine	O
of	O
the	O
transplant	O
recipients	O
,	O
absolute	Physical
bioavailability	Physical
was	O
determined	O
by	O
comparing	O
GCV	Physical
levels	Physical
after	O
single	O
oral	O
and	O
intravenous	O
doses	O
of	O
GCV	O
.	O

RESULTS	O
The	O
following	O
GCV	Physical
concentrations	Physical
(	O
mean	O
+/-SD	O
)	O
were	O
determined	O
:	O
with	O
CrCl	O
of	O
>	O
or	O
=70	O
ml/min	O
,	O
the	O
minimum	O
steady-state	O
concentration	O
(	O
Cmin	O
)	O
and	O
maximum	O
concentration	O
(	O
Cmax	O
)	O
were	O
0.78+/-0.46	O
microg/ml	O
and	O
1.42+/-0.37	O
microg/ml	O
,	O
respectively	O
,	O
with	O
a	O
24-hr	O
area	O
under	O
the	O
concentration	O
time	O
curve	O
(	O
AUC0-24	O
)	O
of	O
24.7+/-7.8	O
microg	O
x	O
hr/ml	O
;	O
with	O
CrCl	O
of	O
50-69	O
ml/min	O
,	O
the	O
Cmin	O
and	O
Cmax	O
were	O
1.93+/-0.48	O
and	O
2.57+/-0.39	O
microg/ml	O
,	O
respectively	O
,	O
with	O
an	O
AUC0-24	O
of	O
52.1+/-10.1	O
microg	O
x	O
hr/ml	O
;	O
with	O
CrCl	O
of	O
25-50	O
ml/min	O
,	O
the	O
Cmin	O
and	O
Cmax	O
were	O
0.41+/-0.27	O
and	O
1.17+/-0.32	O
microg/ml	O
,	O
respectively	O
,	O
with	O
an	O
AUC0-24	O
of	O
14.6+/-7.4	O
microg	O
x	O
hr/ml	O
.	O

For	O
one	O
patient	O
with	O
a	O
CrCl	O
of	O
23.8	O
ml/min	O
,	O
the	O
Cmin	O
and	O
Cmax	O
were	O
0.32	O
and	O
0.7	O
microg/ml	O
,	O
respectively	O
,	O
with	O
an	O
AUC0-24	O
of	O
10.7	O
microg	O
x	O
hr/ml	O
.	O

With	O
CrCl	O
of	O
<	O
10	O
ml/min	O
,	O
the	O
mean	O
Cmin	O
and	O
Cmax	O
were	O
0.75+/-0.42	O
and	O
1.59+/-0.55	O
microg/ml	O
,	O
respectively	O
,	O
with	O
a	O
mean	O
AUC0-24	O
of	O
64.6+/-18.8	O
microg	O
x	O
hr/ml	O
.	O

Absolute	Physical
bioavailability	Physical
,	O
for	O
the	O
nine	O
patients	O
so	O
analyzed	O
,	O
was	O
7.2+/-2.4	O
%	O
.	O

For	O
those	O
patients	O
with	O
end-stage	O
renal	O
failure	O
,	O
GCV	Physical
concentrations	Physical
fell	O
during	O
dialysis	O
from	O
a	O
mean	O
of	O
1.47+/-0.48	O
microg/ml	O
before	O
dialysis	O
to	O
0.69+/-0.38	O
microg/ml	O
after	O
dialysis	O
.	O

CONCLUSIONS	O
The	O
bioavailability	O
of	O
oral	O
GCV	O
in	O
transplant	O
patients	O
was	O
similar	O
to	O
that	O
observed	O
in	O
human	O
immunodeficiency	O
virus-infected	O
patients	O
.	O

However	O
,	O
levels	O
between	O
0.5	O
and	O
1	O
microg/ml	O
(	O
within	O
the	O
IC50	O
of	O
most	O
cytomegalovirus	O
isolates	O
)	O
could	O
be	O
achieved	O
with	O
tolerable	O
oral	O
doses	O
.	O

The	O
proposed	O
dosing	O
algorithm	O
resulted	O
in	O
adequate	O
levels	O
for	O
patients	O
with	O
CrCl	O
greater	O
than	O
50	O
ml/min	O
and	O
for	O
patients	O
on	O
dialysis	O
.	O

For	O
patients	O
with	O
CrCl	O
between	O
10	O
and	O
50	O
ml/min	O
,	O
the	O
levels	O
achieved	O
were	O
low	O
and	O
these	O
patients	O
would	O
likely	O
benefit	O
from	O
increased	O
doses	O
.	O

BNP-guided	O
vs	O
symptom-guided	O
heart	O
failure	O
therapy	O
:	O
the	O
Trial	O
of	O
Intensified	O
vs	O
Standard	O
Medical	O
Therapy	O
in	O
Elderly	O
Patients	O
With	O
Congestive	O
Heart	O
Failure	O
(	O
TIME-CHF	O
)	O
randomized	O
trial	O
.	O

CONTEXT	O
It	O
is	O
uncertain	O
whether	O
intensified	O
heart	O
failure	O
therapy	O
guided	O
by	O
N-terminal	O
brain	O
natriuretic	O
peptide	O
(	O
BNP	O
)	O
is	O
superior	O
to	O
symptom-guided	O
therapy	O
.	O

OBJECTIVE	O
To	O
compare	O
18-month	O
outcomes	O
of	O
N-terminal	O
BNP-guided	O
vs	O
symptom-guided	O
heart	O
failure	O
therapy	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PATIENTS	O
Randomized	O
controlled	O
multicenter	O
Trial	O
of	O
Intensified	O
vs	O
Standard	O
Medical	O
Therapy	O
in	O
Elderly	O
Patients	O
With	O
Congestive	O
Heart	O
Failure	O
(	O
TIME-CHF	O
)	O
of	O
499	O
patients	O
aged	O
60	O
years	O
or	O
older	O
with	O
systolic	O
heart	O
failure	O
(	O
ejection	O
fraction	O
<	O
or	O
=	O
45	O
%	O
)	O
,	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
class	O
of	O
II	O
or	O
greater	O
,	O
prior	O
hospitalization	O
for	O
heart	O
failure	O
within	O
1	O
year	O
,	O
and	O
N-terminal	O
BNP	O
level	O
of	O
2	O
or	O
more	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O

The	O
study	O
had	O
an	O
18-month	O
follow-up	O
and	O
it	O
was	O
conducted	O
at	O
15	O
outpatient	O
centers	O
in	O
Switzerland	O
and	O
Germany	O
between	O
January	O
2003	O
and	O
June	O
2008	O
.	O

INTERVENTION	O
Uptitration	O
of	O
guideline-based	O
treatments	O
to	O
reduce	O
symptoms	O
to	O
NYHA	O
class	O
of	O
II	O
or	O
less	O
(	O
symptom-guided	O
therapy	O
)	O
and	O
BNP	O
level	O
of	O
2	O
times	O
or	O
less	O
the	O
upper	O
limit	O
of	O
normal	O
and	O
symptoms	O
to	O
NYHA	O
class	O
of	O
II	O
or	O
less	O
(	O
BNP-guided	O
therapy	O
)	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
outcomes	O
were	O
18-month	Mortality
survival	Mortality
free	Mortality
of	Mortality
all-cause	Mortality
hospitalizations	Mortality
and	Mortality
quality	Mortality
of	Mortality
life	Mortality
as	Mortality
assessed	Mortality
by	Mortality
structured	Mortality
validated	Mortality
questionnaires	Mortality
.	Mortality

RESULTS	O
Heart	O
failure	O
therapy	O
guided	O
by	O
N-terminal	O
BNP	O
and	O
symptom-guided	O
therapy	O
resulted	O
in	O
similar	O
rates	O
of	O
survival	Mortality
free	Mortality
of	Mortality
all-cause	Mortality
hospitalizations	Mortality
(	O
41	O
%	O
vs	O
40	O
%	O
,	O
respectively	O
;	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0.91	O
[	O
95	O
%	O
CI	O
,	O
0.72-1.14	O
]	O
;	O
P	O
=	O
.39	O
)	O
.	O

Patients	Others
'	Others
quality-of-life	Others
metrics	Others
improved	O
over	O
18	O
months	O
of	O
follow-up	O
but	O
these	O
improvements	O
were	O
similar	O
in	O
both	O
the	O
N-terminal	O
BNP-guided	O
and	O
symptom-guided	O
strategies	O
.	O

Compared	O
with	O
the	O
symptom-guided	O
group	O
,	O
survival	Mortality
free	Mortality
of	Mortality
hospitalization	Mortality
for	Mortality
heart	Mortality
failure	Mortality
,	O
a	O
secondary	O
end	O
point	O
,	O
was	O
higher	O
among	O
those	O
in	O
the	O
N-terminal	O
BNP-guided	O
group	O
(	O
72	O
%	O
vs	O
62	O
%	O
,	O
respectively	O
;	O
HR	O
,	O
0.68	O
[	O
95	O
%	O
CI	O
,	O
0.50-0.92	O
]	O
;	O
P	O
=	O
.01	O
)	O
.	O

Heart	O
failure	O
therapy	O
guided	O
by	O
N-terminal	O
BNP	O
improved	O
outcomes	O
in	O
patients	O
aged	O
60	O
to	O
75	O
years	O
but	O
not	O
in	O
those	O
aged	O
75	O
years	O
or	O
older	O
(	O
P	O
<	O
.02	O
for	O
interaction	O
)	O
CONCLUSION	O
Heart	O
failure	O
therapy	O
guided	O
by	O
N-terminal	O
BNP	O
did	O
not	O
improve	O
overall	O
clinical	O
outcomes	O
or	O
quality	Others
of	Others
life	Others
compared	O
with	O
symptom-guided	O
treatment	O
.	O

TRIAL	O
REGISTRATION	O
isrctn.org	O
Identifier	O
:	O
ISRCTN43596477	O
.	O

Randomised	O
multicentre	O
trial	O
of	O
circular	O
stapling	O
devices	O
.	O

PURPOSE	O
In	O
a	O
register	O
study	O
,	O
the	O
risk	O
of	O
anastomotic	Physical
leakage	Physical
correlated	O
to	O
the	O
choice	O
of	O
circular	O
stapling	O
device	O
with	O
a	O
4	O
%	O
difference	O
between	O
the	O
two	O
brands	O
used	O
.	O

Based	O
on	O
those	O
data	O
,	O
a	O
randomised	O
multicentre	O
study	O
was	O
started	O
to	O
explore	O
the	O
risk	O
of	O
an	O
anastomotic	Physical
leakage	Physical
based	O
upon	O
the	O
surgical	O
device	O
.	O

METHODS	O
Patients	O
above	O
18	O
years	O
with	O
a	O
rectal	O
cancer	O
,	O
able	O
to	O
give	O
informed	O
consent	O
,	O
and	O
scheduled	O
for	O
an	O
anterior	O
resection	O
were	O
eligible	O
for	O
the	O
study	O
.	O

Perioperative	O
randomisation	O
was	O
to	O
Ethicon?	O
PROXIMATE?	O
ILS?	O
or	O
Autosuture?	O
Premium	O
Plus	O
CEEA?	O
.	O

Anastomotic	O
leakage	O
was	O
defined	O
as	O
a	O
clinically	O
manifest	O
leak	O
.	O

RESULTS	O
Five	O
hundred	O
twenty-nine	O
patients	O
were	O
randomised	O
(	O
58	O
%	O
male	O
)	O
.	O

A	O
leak	O
occurred	O
in	O
8.3	O
%	O
.	O

The	O
anastomoses	O
created	O
by	O
PROXIMATE?	O
ILS?	O
leaked	O
in	O
25/265	O
(	O
9.4	O
%	O
)	O
anastomoses	O
,	O
and	O
the	O
Premium	O
Plus	O
CEEA?	O
leaked	O
in	O
19/260	O
(	O
7.3	O
%	O
)	O
,	O
p	O
=	O
.419	O
.	O

CONCLUSION	O
No	O
difference	O
in	O
the	O
leak	O
rate	O
could	O
be	O
revealed	O
.	O

Several	O
centres	O
replaced	O
one	O
of	O
the	O
staplers	O
by	O
a	O
new	O
product	O
,	O
and	O
the	O
study	O
was	O
ended	O
before	O
the	O
stipulated	O
number	O
of	O
patients	O
was	O
reached	O
.	O

In	O
the	O
future	O
,	O
surgical	O
devices	O
may	O
have	O
to	O
prove	O
superiority	O
in	O
randomised	O
trials	O
or	O
be	O
monitored	O
in	O
quality	O
registers	O
before	O
they	O
can	O
be	O
introduced	O
into	O
day	O
to	O
day	O
surgical	O
practice	O
.	O

The	O
study	O
was	O
registered	O
at	O
ClinicalTrials.gov	O
:	O
NCT00399009	O
.	O

Long-term	Mortality
quality	Mortality
of	Mortality
life	Mortality
measures	O
after	O
functional	O
endoscopic	O
sinus	O
surgery	O
.	O

BACKGROUND	O
Chronic	O
rhinosinusitis	O
(	O
CRS	O
)	O
is	O
a	O
common	O
disease	O
that	O
has	O
a	O
significant	O
impact	O
on	O
quality	Mortality
of	Mortality
life	Mortality
(	O
QOL	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
longer-term	O
effects	O
of	O
combined	O
medical	O
and	O
surgical	O
therapy	O
for	O
CRS	O
on	O
overall	O
health	O
status	O
and	O
QOL	O
.	O

METHODS	O
We	O
used	O
a	O
prospective	O
study	O
that	O
utilized	O
the	O
Short-Form	O
36	O
Survey	O
at	O
baseline	O
presentation	O
and	O
at	O
a	O
mean	O
time	O
of	O
3	O
years	O
post-functional	O
endoscopic	O
sinus	O
surgery	O
to	O
assess	O
the	O
general	O
health	O
status	O
of	O
patients	O
who	O
presented	O
for	O
their	O
initial	O
visitfrom	O
1996	O
to	O
1998	O
.	O

Of	O
the	O
200	O
randomly	O
selected	O
patients	O
,	O
150	O
respondents	O
completed	O
follow-up	O
surveys	O
(	O
a	O
75	O
%	O
response	O
rate	O
)	O
.	O

RESULTS	O
Eighty-nine	O
(	O
59.3	O
%	O
)	O
women	O
and	O
61	O
(	O
40.7	O
%	O
)	O
men	O
were	O
included	O
in	O
the	O
study	O
.	O

Baseline	Others
QOL	Others
scores	Others
indicated	O
significant	O
differences	O
between	O
patients	O
with	O
CRS	O
and	O
published	O
norms	O
in	O
6/8	O
subscale	O
parameters	O
(	O
role	Physical
physical	Physical
,	Physical
bodily	Pain
pain	Pain
,	O
general	Physical
health	Physical
,	O
social	Mental
function	Mental
,	O
vitality	Physical
,	O
and	O
mental	O
health	O
)	O
.	O

Significant	O
improvement	O
in	O
all	O
six	O
categories	O
was	O
maintained	O
at	O
the	O
end	O
of	O
the	O
study	O
period	O
(	O
p	O
<	O
0.05	O
)	O
with	O
QOL	Others
scores	Others
within	O
limits	O
of	O
published	O
norms	O
for	O
the	O
general	O
population	O
.	O

CONCLUSION	O
Our	O
data	O
indicate	O
that	O
functional	O
endoscopic	O
sinus	O
surgery	O
,	O
combined	O
with	O
appropriate	O
postoperative	O
care	O
,	O
is	O
effective	O
at	O
maintaining	O
a	O
significant	O
improvement	O
in	O
the	O
overall	O
general	O
health	O
status	O
of	O
patients	O
for	O
at	O
least	O
3	O
years	O
after	O
surgical	O
intervention	O
and	O
that	O
the	O
overall	O
scores	O
return	O
to	O
a	O
range	O
of	O
normative	O
values	O
for	O
the	O
general	O
population	O
.	O

Stapled	Others
hemorrhoidopexy	Others
versus	O
milligan-morgan	Others
hemorrhoidectomy	Others
:	O
a	O
prospective	O
,	O
randomized	O
,	O
multicenter	O
trial	O
with	O
2-year	O
postoperative	O
follow	O
up	O
.	O

PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
outcome	O
of	O
stapled	Others
hemorrhoidopexy	Others
(	O
SH	O
group	O
)	O
performed	O
using	O
a	O
circular	O
stapler	O
with	O
that	O
of	O
the	O
Milligan-Morgan	O
technique	O
(	O
MM	O
group	O
)	O
.	O

The	O
goals	O
of	O
the	O
study	O
were	O
to	O
evaluate	O
the	O
efficacy	Others
and	Others
reproducibility	Others
of	O
stapled	O
hemorrhoidopexy	O
and	O
define	O
its	O
place	O
among	O
conventional	O
techniques	O
.	O

METHODS	O
A	O
series	O
of	O
134	O
patients	O
were	O
included	O
at	O
7	O
hospital	O
centers	O
.	O

They	O
were	O
randomized	O
according	O
to	O
a	O
single-masked	O
design	O
and	O
stratified	O
by	O
center	O
(	O
with	O
balancing	O
every	O
4	O
patients	O
)	O
.	O

Patients	O
were	O
clinically	O
evaluated	O
preoperatively	O
and	O
at	O
6	O
weeks	O
,	O
1	O
year	O
,	O
and	O
a	O
minimum	O
of	O
2	O
years	O
after	O
treatment	O
.	O

Patients	O
completed	O
a	O
questionnaire	O
before	O
and	O
1	O
year	O
after	O
surgery	O
to	O
evaluate	O
symptoms	O
,	O
function	O
,	O
and	O
overall	O
satisfaction	O
.	O

RESULTS	O
The	O
mean	O
follow-up	O
period	O
was	O
2.21	O
years	O
+/-	O
0.26	O
(	O
1.89-3.07	O
)	O
.	O

Nine	O
patients	O
(	O
7	O
%	O
)	O
could	O
not	O
be	O
monitored	O
at	O
1	O
or	O
2	O
years	O
,	O
but	O
4	O
of	O
these	O
9	O
nevertheless	O
filled	O
in	O
the	O
1-year	O
questionnaire	O
.	O

The	O
patients	O
in	O
the	O
SH	O
group	O
experienced	O
less	O
postoperative	Pain
pain/discomfort	Pain
as	O
scored	O
by	O
pain	Pain
during	Pain
bowel	Pain
movement	Pain
(	O
P	O
<	O
0.001	O
)	O
,	O
total	Others
analgesic	Others
requirement	Others
over	Others
the	Others
first	Others
3	Others
days	Others
(	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
[	O
WHO	O
]	O
class	O
II	O
analgesics	O
[	O
P	O
=	O
0.002	O
]	O
;	O
class	O
III	O
[	O
P	O
=	O
0.066	O
]	O
)	O
,	O
and	O
per-patient	O
consumption	O
frequency	O
of	O
class	O
III	O
analgesics	O
(	O
P	O
=	O
0.089	O
)	O
.	O

A	O
clear	O
difference	O
in	O
morphine	Others
requirement	Others
became	O
evident	O
after	O
24	O
hours	O
(	O
P	O
=	O
0.010	O
)	O
.	O

Hospital	Physical
stay	Physical
was	O
significantly	O
shorter	O
in	O
the	O
SH	O
group	O
(	O
SH	O
2.2	O
+/-	O
1.2	O
[	O
0	O
;	O
5.0	O
]	O
versus	O
MM	O
3.1	O
+/-	O
1.7	O
[	O
1	O
;	O
8.0	O
]	O
P	O
<	O
0.001	O
)	O
.	O

At	O
1	O
year	O
,	O
no	O
differences	O
in	O
the	O
resolution	Others
of	Others
symptoms	Others
were	O
observed	O
between	O
the	O
2	O
groups	O
,	O
and	O
over	O
2	O
years	O
,	O
the	O
overall	Adverseeffect
incidence	Adverseeffect
of	Adverseeffect
complications	Adverseeffect
was	O
the	O
same	O
,	O
specifically	O
fecaloma	Adverseeffect
(	O
P	O
=	O
0.003	O
)	O
in	O
the	O
MM	O
group	O
and	O
external	Adverseeffect
hemorrhoidal	Adverseeffect
thrombosis	Adverseeffect
(	O
P	O
=	O
0.006	O
)	O
in	O
the	O
SH	O
group	O
.	O

Impaired	Adverseeffect
sphincter	Adverseeffect
function	Adverseeffect
was	O
observed	O
at	O
1	O
year	O
with	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
for	O
urgency	O
(	O
12	O
%	O
)	O
,	O
continence	O
problems	O
(	O
10	O
%	O
)	O
,	O
or	O
tenesmus	O
(	O
3	O
%	O
)	O
.	O

No	O
patient	O
needed	O
a	O
second	O
procedure	O
for	O
recurrence	O
within	O
2	O
years	O
,	O
although	O
partial	Adverseeffect
residual	Adverseeffect
prolapse	Adverseeffect
was	O
detected	O
in	O
4	O
SH	O
patients	O
(	O
7.5	O
%	O
)	O
versus	O
1	O
MM	O
patient	O
(	O
1.8	O
%	O
)	O
(	O
P	O
=	O
0.194	O
)	O
.	O

CONCLUSION	O
Stapled	O
hemorrhoidopexy	O
causes	O
significantly	O
less	O
postoperative	Pain
pain	Pain
.	O

The	O
technique	O
is	O
reproducible	O
and	O
can	O
achieve	O
comparable	O
outcomes	O
as	O
those	O
of	O
the	O
MM	O
technique	O
as	O
long	O
as	O
the	O
well-described	O
steps	O
of	O
the	O
technique	O
are	O
followed	O
.	O

Like	O
with	O
conventional	O
surgery	O
,	O
anorectal	Physical
dysfunction	Physical
can	O
occur	O
after	O
stapled	O
hemorrhoidopexy	O
in	O
some	O
patients	O
.	O

Its	O
effectiveness	Others
in	O
relieving	O
symptoms	O
is	O
equivalent	O
to	O
conventional	O
surgery	O
,	O
and	O
the	O
number	Adverseeffect
of	Adverseeffect
hemorrhoidal	Adverseeffect
prolapse	Adverseeffect
recurrences	Adverseeffect
at	Adverseeffect
2	Adverseeffect
years	Adverseeffect
is	O
not	O
significantly	O
different	O
.	O

Hemorroidopexy	O
is	O
applicable	O
for	O
treating	O
reducible	O
hemorrhoidal	O
prolapse	O
.	O

Clinical	O
impact	O
of	O
leak	O
compensation	O
during	O
non-invasive	O
ventilation	O
.	O

BACKGROUND	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
leak	O
compensation	O
capabilities	O
during	O
pressure-	O
and	O
volume-limited	O
non-invasive	O
positive-pressure	O
ventilation	O
(	O
NPPV	O
)	O
in	O
COPD	O
patients	O
.	O

METHODS	O
Fourteen	O
patients	O
with	O
stable	O
hypercapnic	O
COPD	O
who	O
were	O
receiving	O
long-term	O
NPPV	O
were	O
included	O
in	O
the	O
study	O
.	O

For	O
both	O
modes	O
of	O
NPPV	O
,	O
a	O
full	O
face	O
mask	O
and	O
an	O
artificial	O
leak	O
in	O
the	O
ventilatory	O
circuit	O
were	O
used	O
at	O
three	O
different	O
settings	O
,	O
and	O
applied	O
during	O
daytime	O
NPPV	O
,	O
either	O
without	O
leakage	O
(	O
setting	O
I	O
)	O
,	O
with	O
leakage	O
during	O
inspiration	O
only	O
(	O
setting	O
II	O
)	O
,	O
and	O
with	O
leakage	O
during	O
inspiration	O
and	O
expiration	O
(	O
setting	O
III	O
)	O
.	O

Ventilation	Physical
pattern	Physical
was	O
pneumotachy-graphically	O
recorded	O
.	O

RESULTS	O
NPPV	O
was	O
feasible	O
with	O
negligible	O
leak	Physical
volumes	Physical
,	O
indicating	O
optimal	O
mask	O
fitting	O
during	O
the	O
daytime	O
(	O
setting	O
I	O
)	O
.	O

In	O
the	O
presence	O
of	O
leakage	Physical
(	O
settings	O
II	O
and	O
III	O
)	O
,	O
the	O
attempt	O
to	O
compensate	O
for	O
leak	O
was	O
only	O
evident	O
during	O
pressure-limited	O
NPPV	O
,	O
since	O
inspiratory	Others
volumes	Others
delivered	Others
by	Others
the	Others
ventilator	Others
increased	O
from	O
726+/-129	O
(	O
setting	O
I	O
)	O
to	O
1104+/-164	O
(	O
setting	O
II	O
)	O
,	O
and	O
to	O
1257+/-166	O
(	O
setting	O
III	O
)	O
ml	O
during	O
pressure-limited	O
NPPV	O
,	O
respectively	O
(	O
all	O
p	O
<	O
0.001	O
)	O
;	O
however	O
,	O
they	O
remained	O
stable	O
during	O
volume-limited	O
NPPV	O
.	O

Leak	O
compensation	O
resulted	O
in	O
a	O
decrease	O
in	O
leakage-induced	Physical
dyspnea	Physical
.	Physical

However	O
,	O
83	O
%	O
/87	O
%	O
(	O
setting	O
II/III	O
)	O
of	O
the	O
additionally-delivered	O
inspiratory	O
volume	O
during	O
pressure-limited	O
NPPV	O
was	O
also	O
lost	O
via	O
leakage	O
.	O

Expiratory	Others
volume	Others
was	O
higher	O
in	O
setting	O
II	O
compared	O
to	O
setting	O
III	O
(	O
both	O
p	O
<	O
0.001	O
)	O
,	O
indicating	O
the	O
presence	O
of	O
significant	O
expiratory	O
leakage	O
.	O

CONCLUSIONS	O
The	O
attempt	O
at	O
leak	O
compensation	O
largely	O
feeds	O
the	O
leakage	O
itself	O
and	O
only	O
results	O
in	O
a	O
marginal	O
increase	O
of	O
tidal	O
volume	O
.	O

However	O
,	O
pressure-limited	O
--	O
but	O
not	O
volume-limited	O
--	O
NPPV	O
results	O
in	O
a	O
clinically-important	O
leak	O
compensation	O
in	O
vivo	O
.	O

TRIAL	O
REGISTRATION	O
www.uniklinik-freiburg.de/zks/live/uklregister/Oeffentlich.html	O
Identifier	O
:	O
UKF001272	O
.	O

Pharmacodynamic	O
effects	O
on	O
biochemical	Physical
markers	Physical
of	Physical
bone	Physical
turnover	Physical
and	O
pharmacokinetics	Physical
of	O
the	O
cathepsin	O
K	O
inhibitor	O
,	O
ONO-5334	O
,	O
in	O
an	O
ascending	O
multiple-dose	O
,	O
phase	O
1	O
study	O
.	O

Selective	O
inhibitors	O
of	O
cathepsin	O
K	O
,	O
which	O
has	O
a	O
major	O
role	O
in	O
the	O
degradation	O
of	O
bone	O
collagen	O
,	O
are	O
potential	O
new	O
treatments	O
for	O
osteoporosis	O
.	O

The	O
pharmacokinetics	Physical
and	Physical
the	Physical
pharmacodynamic	Physical
effects	Physical
on	Physical
biochemical	Physical
markers	Physical
of	Physical
bone	Physical
turnover	Physical
of	O
the	O
new	O
cathepsin	O
K	O
inhibitor	O
,	O
ONO-5334	O
,	O
were	O
investigated	O
in	O
a	O
multiple	O
ascending	O
dose	O
,	O
phase	O
1	O
study	O
.	O

A	O
total	O
of	O
120	O
healthy	O
postmenopausal	O
women	O
were	O
enrolled	O
,	O
and	O
doses	O
of	O
10	O
to	O
600	O
mg	O
once	O
daily	O
and	O
50	O
and	O
300	O
mg	O
twice	O
daily	O
were	O
evaluated	O
in	O
15-	O
and	O
28-day	O
multiple-dosing	O
cohorts	O
.	O

Plasma	O
ONO-5334	O
concentration	O
reached	O
steady	O
state	O
within	O
2	O
days	O
.	O

Twenty-four	O
hours	O
after	O
the	O
last	O
dose	O
in	O
the	O
15-day	O
multiple-dose	O
cohort	O
,	O
100	O
,	O
300	O
,	O
and	O
600	O
mg	O
once	O
daily	O
reduced	O
urinary	Physical
C-terminal	Physical
telopeptide	Physical
of	Physical
type	Physical
I	Physical
collagen	Physical
by	O
a	O
mean	O
(	O
?	O
standard	O
deviation	O
)	O
44.9	O
%	O
?	O
13.6	O
%	O
,	O
84.5	O
%	O
?	O
4.4	O
%	O
,	O
and	O
92.5	O
%	O
?	O
1.3	O
%	O
,	O
respectively	O
.	O

The	O
28-day	O
cohort	O
showed	O
similar	O
effects	O
.	O

There	O
were	O
far	O
smaller	O
effects	O
on	O
bone-specific	O
alkaline	O
phosphatase	O
(	O
B-ALP	O
)	O
,	O
tartrate-resistant	O
acid	O
phosphatase	O
5b	O
(	O
TRAP5b	O
)	O
,	O
or	O
osteocalcin	O
(	O
OC	O
)	O
(	O
measured	O
after	O
28	O
days	O
)	O
.	O

ONO-5334	O
was	O
well	O
tolerated	O
up	O
to	O
600	O
mg/d	O
and	O
for	O
up	O
to	O
28	O
days	O
of	O
multiple	O
dosing	O
.	O

Multiple	O
dosing	O
with	O
ONO-5334	O
100	O
mg	O
resulted	O
in	O
considerable	O
suppression	O
of	O
bone	O
resorption	O
markers	O
with	O
no	O
appreciable	O
effects	O
on	O
bone	O
formation	O
markers	O
(	O
B-ALP	O
,	O
OC	O
)	O
or	O
osteoclast	O
number	O
(	O
TRAP5b	O
)	O
.	O

[	O
A	O
randomized	O
trial	O
of	O
PVB	O
,	O
VAB-6	O
,	O
BVP	O
regimen	O
versus	O
PEB	O
chemotherapy	O
in	O
patients	O
with	O
disseminated	O
testicular	O
tumors	O
]	O
.	O

During	O
2	O
years	O
and	O
7	O
months	O
from	O
June	O
,	O
1985	O
to	O
December	O
,	O
1987	O
,	O
a	O
randomized	O
multi-center	O
trial	O
of	O
PVB	O
,	O
VAB-6	O
,	O
BVP	O
regimen	O
(	O
group	O
A	O
)	O
without	O
etoposide	O
versus	O
PEB	O
chemotherapy	O
(	O
bleomycin	O
,	O
etoposide	O
and	O
cisplatinum	O
)	O
(	O
group	O
B	O
)	O
was	O
given	O
to	O
patients	O
with	O
disseminated	O
testicular	O
tumors	O
.	O

Of	O
34	O
patients	O
registered	O
,	O
10	O
patients	O
were	O
with	O
minimal	O
disease	O
in	O
stages	O
IIA	O
,	O
IIIO	O
and	O
IIIA	O
and	O
24	O
with	O
extensive	O
disease	O
in	O
IIB	O
,	O
IIIB2	O
and	O
IIIC	O
.	O

Seminomas	O
were	O
found	O
in	O
10	O
patients	O
,	O
while	O
non-seminomatous	O
tumors	O
in	O
24	O
.	O

Among	O
groups	O
A	O
and	O
B	O
,	O
there	O
was	O
no	O
statistical	O
difference	O
in	O
clinicopathological	O
profiles	O
.	O

A	O
group	O
patients	O
were	O
given	O
either	O
PVB	O
,	O
VAB-6	O
or	O
BVP	O
according	O
to	O
the	O
physician	O
's	O
discretion	O
.	O

In	O
groups	O
A	O
and	O
B	O
,	O
35	O
%	O
and	O
43	O
%	O
of	O
the	O
patients	O
achieved	O
complete	Physical
response	Physical
,	O
and	O
45	O
%	O
and	O
50	O
%	O
achieved	O
partial	Physical
response	Physical
,	O
respectively	O
.	O

The	O
difference	O
in	O
CR	Physical
rates	Physical
among	O
both	O
groups	O
was	O
not	O
statistically	O
significant	O
even	O
when	O
calculated	O
according	O
to	O
the	O
stage	O
or	O
histologic	O
grouping	O
.	O

Salvage	O
treatments	O
mainly	O
with	O
surgical	O
resection	O
of	O
residual	O
tumors	O
after	O
the	O
chemotherapy	O
,	O
however	O
,	O
were	O
more	O
successful	O
in	O
group	O
B	O
(	O
88	O
%	O
)	O
than	O
group	O
A	O
(	O
61	O
%	O
)	O
.	O

It	O
appears	O
likely	O
that	O
the	O
higher	O
response	O
of	O
induction	O
chemotherapy	O
in	O
patients	O
with	O
extensive	O
disease	O
made	O
the	O
salvage	O
surgery	O
more	O
successful	O
in	O
group	O
B	O
than	O
in	O
group	O
A	O
.	O

The	O
3	Mortality
year	Mortality
survival	Mortality
rate	Mortality
was	O
100	O
%	O
in	O
group	O
B	O
,	O
whereas	O
it	O
was	O
76	O
%	O
in	O
group	O
A	O
.	O

Although	O
the	O
incidence	Adverseeffect
of	Adverseeffect
myelosuppression	Adverseeffect
and	Adverseeffect
alopecia	Adverseeffect
was	O
significantly	O
higher	O
in	O
group	O
B	O
,	O
neuropathy	Adverseeffect
was	O
significantly	O
more	O
frequent	O
in	O
group	O
A	O
.	O

From	O
the	O
above	O
results	O
,	O
PEB	O
seems	O
to	O
be	O
a	O
better	O
induction	O
chemotherapy	O
than	O
the	O
conventional	O
one	O
for	O
advanced	O
testicular	O
tumors	O
.	O

Intra-articular	O
hyaluronic	O
acid	O
compared	O
to	O
exercise	O
therapy	O
in	O
osteoarthritis	O
of	O
the	O
ankle	O
.	O

A	O
prospective	O
randomized	O
trial	O
with	O
long-term	O
follow-up	O
.	O

OBJECTIVE	O
The	O
goal	O
of	O
this	O
study	O
has	O
been	O
to	O
determine	O
whether	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
or	O
exercise	O
therapy	O
can	O
improve	O
functional	O
parameters	O
in	O
patients	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
of	O
the	O
ankle	O
.	O

METHODS	O
In	O
a	O
prospective	O
clinical	O
trial	O
,	O
43	O
ankles	O
(	O
30	O
patients	O
)	O
with	O
radiographic	O
Kellgren	O
Lawrence	O
grade	O
III	O
OA	O
were	O
randomized	O
to	O
receive	O
three	O
intra-articular	O
HA	O
injections	O
,	O
with	O
one-week	O
interval	O
of	O
or	O
exercise	O
therapy	O
for	O
six	O
weeks	O
.	O

Patients	O
were	O
evaluated	O
by	O
the	O
American	Physical
Orthopaedic	Physical
Foot	Physical
and	Physical
Ankle	Physical
Society	Physical
(	Physical
AOFAS	Physical
)	Physical
Ankle-Hindfoot	Physical
Scale	Physical
and	O
followed-up	O
after	O
12	O
months	O
.	O

RESULTS	O
Total	Physical
AOFAS	Physical
Ankle-Hindfoot	Physical
score	Physical
of	Physical
OA	Physical
patients	Physical
has	O
improved	O
in	O
both	O
groups	O
,	O
varying	O
from	O
61.6+/-16.8	O
to	O
90.1+/-9.7	O
with	O
HA	O
treatment	O
and	O
from	O
72.1+/-16.6	O
to	O
87.5+/-17.5	O
using	O
exercise	O
therapy	O
at	O
the	O
end	O
of	O
the	O
trial	O
(	O
p	O
<	O
0.01	O
)	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
.	O

CONCLUSION	O
This	O
prospective	O
randomized	O
trial	O
confirmed	O
that	O
,	O
both	O
HA	O
injections	O
and	O
exercise	O
therapy	O
provide	O
functional	O
improvement	O
.	O

However	O
,	O
larger	O
trials	O
with	O
longer	O
follow-up	O
are	O
necessary	O
for	O
more	O
definite	O
conclusions	O
.	O

Valsartan	O
alone	O
or	O
with	O
a	O
diuretic	O
or	O
ACE	O
inhibitor	O
as	O
treatment	O
for	O
African	O
American	O
hypertensives	O
:	O
relation	O
to	O
salt	O
intake	O
.	O

Previous	O
clinical	O
trials	O
have	O
demonstrated	O
the	O
important	O
influence	O
of	O
ethnicity	O
and	O
dietary	O
salt	O
on	O
the	O
antihypertensive	O
efficacy	O
of	O
drugs	O
that	O
block	O
the	O
renin	O
angiotensin	O
system	O
.	O

Angiotensin	O
II	O
receptor	O
blockers	O
are	O
a	O
new	O
therapeutic	O
entity	O
that	O
have	O
not	O
been	O
widely	O
studied	O
in	O
African	O
American	O
hypertensives	O
,	O
either	O
alone	O
,	O
or	O
in	O
combination	O
with	O
other	O
therapies	O
such	O
as	O
diuretics	O
or	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
.	O

We	O
performed	O
a	O
pilot	O
,	O
prospective	O
,	O
open	O
label	O
,	O
randomized	O
design	O
clinical	O
trial	O
to	O
evaluate	O
the	O
effects	O
of	O
the	O
angiotensin	O
II	O
receptor	O
blocker	O
valsartan	O
(	O
160	O
mg	O
once	O
a	O
day	O
)	O
on	O
systolic	Physical
and	Physical
diastolic	Physical
blood	Physical
pressure	Physical
in	O
hypertensive	O
African	O
Americans	O
(	O
n	O
=	O
88	O
)	O
on	O
a	O
low	O
salt	O
(	O
100	O
mEq	O
Na+/day	O
)	O
for	O
2	O
weeks	O
and	O
the	O
same	O
diet	O
supplemented	O
by	O
100	O
mEq	O
Na+	O
for	O
4	O
weeks	O
.	O

After	O
this	O
evaluation	O
,	O
while	O
continuing	O
the	O
Na+	O
supplementation	O
,	O
patients	O
were	O
randomized	O
to	O
valsartan	O
320	O
mg/day	O
(	O
n	O
=	O
28	O
)	O
,	O
or	O
the	O
addition	O
of	O
hydrochlorothiazide	O
(	O
HCTZ	O
)	O
12.5	O
mg/day	O
(	O
n	O
=	O
30	O
)	O
,	O
or	O
benazepril	O
20	O
mg/day	O
to	O
the	O
valsartan	O
160	O
mg/day	O
for	O
an	O
additional	O
6	O
weeks	O
.	O

Valsartan	O
(	O
160	O
mg/day	O
)	O
lowered	O
blood	Physical
pressure	Physical
significantly	O
in	O
African	O
American	O
patients	O
on	O
both	O
low	O
salt	O
(	O
-6.4/-4.8	O
mm	O
Hg	O
:	O
P	O
<	O
.001	O
)	O
and	O
a	O
high	O
salt	O
diet	O
(	O
-4.9/-3.8	O
mm	O
Hg	O
:	O
P	O
=	O
.01	O
)	O
.	O

The	O
high	O
salt	O
diet	O
attenuated	O
the	O
antihypertensive	Physical
effect	Physical
slightly	O
(	O
1.6/1.3	O
mm	O
Hg	O
,	O
P	O
=	O
not	O
significant	O
)	O
.	O

When	O
comparing	O
the	O
efficacy	O
of	O
the	O
three	O
randomized	O
therapeutic	O
regimens	O
while	O
on	O
the	O
Na+	O
supplement	O
,	O
the	O
valsartan	O
160	O
mg/HCTZ	O
12.5	O
mg	O
was	O
the	O
most	O
effective	O
therapy	O
with	O
an	O
incremental	O
reduction	O
in	O
blood	Physical
pressure	Physical
of	O
-10.5/-6.9	O
mm	O
Hg	O
(	O
P	O
<	O
.01	O
)	O
,	O
compared	O
to	O
valsartan	O
160	O
mg/day	O
alone	O
.	O

Doubling	O
the	O
dose	O
of	O
valsartan	O
to	O
320	O
mg	O
incrementally	O
lowered	O
blood	Physical
pressure	Physical
by	O
-3.8/-3.3	O
mm	O
Hg	O
(	O
P	O
=	O
not	O
significant	O
)	O
.	O

The	O
least	O
effective	O
approach	O
was	O
adding	O
benazepril	O
20	O
mg/day	O
to	O
valsartan	O
160	O
mg/day	O
with	O
no	O
incremental	O
reduction	O
in	O
systolic	Physical
blood	Physical
pressure	Physical
and	Physical
diastolic	Physical
blood	Physical
pressure	Physical
reduction	O
of	O
only	O
1.7	O
mm	O
Hg	O
(	O
P	O
=	O
not	O
significant	O
)	O
.	O

We	O
conclude	O
that	O
in	O
our	O
open	O
label	O
pilot	O
study	O
,	O
the	O
antihypertensive	O
activity	O
of	O
valsartan	O
is	O
not	O
significantly	O
attenuated	O
by	O
supplemented	O
salt	O
diet	O
in	O
hypertensive	O
African	O
Americans	O
.	O

Moreover	O
,	O
adding	O
a	O
low	O
dose	O
of	O
HCTZ	O
appears	O
to	O
be	O
the	O
most	O
effective	O
strategy	O
in	O
enhancing	O
the	O
antihypertensive	O
activity	O
of	O
this	O
angiotensin	O
II	O
receptor	O
blocker	O
in	O
contrast	O
to	O
either	O
doubling	O
the	O
dose	O
or	O
adding	O
an	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
.	O

Carotid	O
sinus	O
syndrome	O
:	O
a	O
modifiable	O
risk	O
factor	O
for	O
nonaccidental	Physical
falls	Physical
in	O
older	O
adults	O
(	O
SAFE	O
PACE	O
)	O
.	O

OBJECTIVES	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
cardiac	O
pacing	O
reduces	O
falls	Physical
in	O
older	O
adults	O
with	O
cardioinhibitory	O
carotid	O
sinus	O
hypersensitivity	O
(	O
CSH	O
)	O
.	O

BACKGROUND	O
Cardioinhibitory	O
carotid	O
sinus	O
syndrome	O
causes	O
syncope	O
,	O
and	O
symptoms	O
respond	O
to	O
cardiac	O
pacing	O
.	O

There	O
is	O
circumstantial	O
evidence	O
for	O
an	O
association	O
between	O
falls	Physical
and	O
the	O
syndrome	O
.	O

METHODS	O
A	O
randomized	O
controlled	O
trial	O
was	O
done	O
of	O
consecutive	O
older	O
patients	O
(	O
>	O
50	O
years	O
)	O
attending	O
an	O
accident	O
and	O
emergency	O
facility	O
because	O
of	O
a	O
non-accidental	Physical
fall	Physical
.	O

Patients	O
were	O
randomized	O
to	O
dual-chamber	O
pacemaker	O
implant	O
(	O
paced	O
patients	O
)	O
or	O
standard	O
treatment	O
(	O
controls	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
number	Physical
of	Physical
falls	Physical
during	Physical
one	Physical
year	Physical
of	Physical
follow-up	Physical
.	O

RESULTS	O
One	O
hundred	O
seventy-five	O
eligible	O
patients	O
(	O
mean	O
age	O
73	O
+/-	O
10	O
years	O
;	O
60	O
%	O
women	O
)	O
were	O
randomized	O
to	O
the	O
trial	O
:	O
pacemaker	O
87	O
;	O
controls	O
88	O
.	O

Falls	Physical
(	Physical
without	Physical
loss	Physical
of	Physical
consciousness	Physical
)	Physical
were	O
reduced	O
by	O
two-thirds	O
:	O
controls	O
reported	O
669	O
falls	O
(	O
mean	O
9.3	O
;	O
range	O
0	O
to	O
89	O
)	O
,	O
and	O
paced	O
patients	O
216	O
falls	O
(	O
mean	O
4.1	O
;	O
range	O
0	O
to	O
29	O
)	O
.	O

Thus	O
,	O
paced	O
patients	O
were	O
significantly	O
less	O
likely	O
to	O
fall	Physical
(	O
odds	O
ratio	O
0.42	O
;	O
95	O
%	O
confidence	O
interval	O
:	O
0.23	O
,	O
0.75	O
)	O
than	O
were	O
controls	O
.	O

Syncopal	Physical
events	Physical
were	O
also	O
reduced	O
during	O
the	O
follow-up	O
period	O
,	O
but	O
there	O
were	O
much	O
fewer	O
syncopal	Physical
events	Physical
than	O
falls-28	Physical
episodes	O
in	O
paced	O
patients	O
and	O
47	O
in	O
controls	O
.	O

Injurious	Physical
events	Physical
were	O
reduced	O
by	O
70	O
%	O
(	O
202	O
in	O
controls	O
compared	O
to	O
61	O
in	O
paced	O
patients	O
)	O
.	O

CONCLUSIONS	O
There	O
is	O
a	O
strong	O
association	O
between	O
non-accidental	Physical
falls	O
and	O
cardioinhibitory	O
CSH	O
.	O

These	O
patients	O
would	O
not	O
usually	O
be	O
referred	O
for	O
cardiovascular	O
assessment	O
.	O

Carotid	O
sinus	O
hypersensitivity	O
should	O
be	O
considered	O
in	O
all	O
older	O
adults	O
who	O
have	O
non-accidental	O
falls	O
.	O

Should	O
snacks	O
be	O
recommended	O
in	O
obesity	O
treatment	O
?	O
A	O
1-year	O
randomized	O
clinical	O
trial	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
effect	O
to	O
recommend	O
no	O
snacks	O
vs	O
three	O
snacks	O
per	O
day	O
on	O
1-year	O
weight	O
loss	O
.	O

The	O
hypothesis	O
was	O
that	O
it	O
is	O
easier	O
to	O
control	O
energy	O
intake	O
and	O
lose	O
weight	O
if	O
snacks	O
in	O
between	O
meals	O
are	O
omitted	O
.	O

SUBJECTS/METHOD	O
In	O
total	O
140	O
patients	O
(	O
36	O
men	O
,	O
104	O
women	O
)	O
,	O
aged	O
18-60	O
years	O
and	O
body	O
mass	O
index	O
>	O
30	O
kg/m	O
(	O
2	O
)	O
were	O
randomized	O
and	O
93	O
patients	O
(	O
27	O
men	O
,	O
66	O
women	O
)	O
completed	O
the	O
study	O
.	O

A	O
1-year	O
randomized	O
intervention	O
trial	O
was	O
conducted	O
with	O
two	O
treatment	O
arms	O
with	O
different	O
eating	O
frequencies	O
;	O
3	O
meals/day	O
(	O
3M	O
)	O
or	O
3	O
meals	O
and	O
3	O
snacks/day	O
(	O
3+3M	O
)	O
.	O

The	O
patients	O
received	O
regular	O
and	O
individualized	O
counseling	O
by	O
dieticians	O
.	O

Information	Mental
on	Mental
eating	Mental
patterns	Mental
,	O
dietary	Mental
intake	Mental
,	O
weight	Physical
and	O
metabolic	Physical
variables	Physical
was	O
collected	O
at	O
baseline	O
and	O
after	O
1	O
year	O
.	O

RESULTS	O
Over	O
1	O
year	O
the	O
3M	O
group	O
reported	O
a	O
decrease	O
in	O
the	O
number	Mental
of	Mental
snacks	Mental
whereas	O
the	O
3+3M	O
group	O
reported	O
an	O
increase	O
(	O
-1.1	O
vs	O
+0.4	O
snacks/day	O
,	O
respectively	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Both	O
groups	O
decreased	O
energy	Mental
intake	Mental
and	O
E	O
%	O
(	O
energy	O
percent	O
)	O
fat	O
and	O
increased	O
E	Physical
%	Physical
protein	Physical
and	Physical
fiber	Physical
intake	Physical
but	O
there	O
was	O
no	O
differences	O
between	O
the	O
groups	O
.	O

Both	O
groups	O
lost	Others
weight	Others
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
weight	Others
loss	Others
after	O
1	O
year	O
of	O
treatment	O
(	O
3M	O
vs	O
3+3M=-4.1+/-6.1	O
vs	O
-5.9+/-9.4	O
kg	O
;	O
P=0.31	O
)	O
.	O

Changes	O
in	O
metabolic	Physical
variables	Physical
did	O
not	O
differ	O
between	O
the	O
groups	O
,	O
except	O
for	O
high-density	Physical
lipoprotein	Physical
that	O
increased	O
in	O
the	O
3M	O
group	O
but	O
not	O
in	O
3+3M	O
group	O
(	O
P	O
<	O
0.033	O
for	O
group	O
difference	O
)	O
.	O

CONCLUSION	O
Recommending	O
snacks	O
or	O
not	O
between	O
meals	O
does	O
not	O
influence	O
1-year	Others
weight	Others
loss	Others
.	O

Medium	O
chain	O
triglyceride	O
oil	O
consumption	O
as	O
part	O
of	O
a	O
weight	O
loss	O
diet	O
does	O
not	O
lead	O
to	O
an	O
adverse	O
metabolic	O
profile	O
when	O
compared	O
to	O
olive	O
oil	O
.	O

OBJECTIVE	O
Medium	O
chain	O
triglyceride	O
(	O
MCT	O
)	O
consumption	O
may	O
have	O
a	O
beneficial	O
impact	O
on	O
weight	O
management	O
,	O
however	O
,	O
some	O
studies	O
point	O
to	O
a	O
negative	O
impact	O
of	O
MCT	O
oil	O
consumption	O
on	O
cardiovascular	O
disease	O
risk	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
MCT	O
oil	O
consumption	O
,	O
as	O
part	O
of	O
a	O
weight	O
loss	O
diet	O
,	O
on	O
metabolic	O
risk	O
profile	O
compared	O
to	O
olive	O
oil	O
.	O

DESIGN	O
Thirty-one	O
men	O
and	O
women	O
,	O
age	O
19-50	O
y	O
and	O
body	O
mass	O
index	O
27-33	O
kg/m	O
(	O
2	O
)	O
,	O
completed	O
this	O
randomized	O
,	O
controlled	O
,	O
16-week	O
weight	O
loss	O
program	O
.	O

Oils	O
were	O
consumed	O
at	O
a	O
level	O
of	O
approximately	O
12	O
%	O
of	O
the	O
subjects	O
'	O
prescribed	O
energy	O
intakes	O
in	O
the	O
form	O
of	O
muffins	O
and	O
liquid	O
oil	O
.	O

RESULTS	O
After	O
controlling	O
for	O
body	O
weight	O
,	O
there	O
was	O
a	O
significant	O
effect	O
of	O
time	O
on	O
fasting	Physical
serum	Physical
glucose	Physical
(	O
P	O
=	O
0.0177	O
)	O
and	O
total	Physical
cholesterol	Physical
(	O
P	O
=	O
0.0386	O
)	O
concentrations	O
,	O
and	O
on	O
diastolic	Physical
blood	Physical
pressure	Physical
(	O
P	O
=	O
0.0413	O
)	O
,	O
with	O
reductions	O
in	O
these	O
variables	O
occurring	O
over	O
time	O
;	O
there	O
was	O
no	O
time-by-diet	O
interaction	O
for	O
any	O
of	O
the	O
parameters	O
studied	O
.	O

Two	O
of	O
the	O
3	O
subjects	O
in	O
the	O
MCT	O
oil	O
group	O
with	O
evidence	O
of	O
the	O
metabolic	O
syndrome	O
at	O
baseline	O
did	O
not	O
have	O
metabolic	O
syndrome	O
at	O
endpoint	O
.	O

In	O
the	O
olive	O
oil	O
group	O
,	O
6	O
subjects	O
had	O
the	O
metabolic	O
syndrome	O
at	O
baseline	O
;	O
2	O
subjects	O
no	O
longer	O
had	O
metabolic	O
syndrome	O
at	O
endpoint	O
,	O
1	O
person	O
developed	O
metabolic	O
syndrome	O
,	O
and	O
4	O
subjects	O
did	O
not	O
have	O
any	O
change	O
in	O
their	O
metabolic	O
syndrome	O
status	O
.	O

CONCLUSIONS	O
Our	O
results	O
suggest	O
that	O
MCT	O
oil	O
can	O
be	O
incorporated	O
into	O
a	O
weight	O
loss	O
program	O
without	O
fear	O
of	O
adversely	O
affecting	O
metabolic	O
risk	O
factors	O
.	O

Distinction	O
should	O
be	O
made	O
regarding	O
chain	O
length	O
when	O
it	O
comes	O
to	O
discussing	O
the	O
effects	O
of	O
saturated	O
fats	O
on	O
metabolic	O
risk	O
factors	O
.	O

LDL	O
cholesterol-raising	O
effect	O
of	O
low-dose	O
docosahexaenoic	O
acid	O
in	O
middle-aged	O
men	O
and	O
women	O
.	O

BACKGROUND	O
Long-chain	O
n-3	O
polyunsaturated	O
fatty	O
acids	O
have	O
variable	O
effects	O
on	O
LDL	O
cholesterol	O
,	O
and	O
the	O
effects	O
of	O
docosahexaenoic	O
acid	O
(	O
DHA	O
)	O
are	O
uncertain	O
.	O

OBJECTIVE	O
The	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
effect	Physical
on	Physical
blood	Physical
lipids	Physical
of	O
a	O
daily	O
intake	O
of	O
0.7	O
g	O
DHA	O
as	O
triacylglycerol	O
in	O
middle-aged	O
men	O
and	O
women	O
.	O

DESIGN	O
Men	O
and	O
women	O
aged	O
40-65	O
y	O
(	O
n	O
=	O
38	O
)	O
underwent	O
a	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
crossover	O
trial	O
of	O
treatment	O
with	O
0.7	O
g	O
DHA/d	O
for	O
3	O
mo	O
.	O

RESULTS	O
DHA	O
supplementation	O
increased	Others
the	O
DHA	Physical
concentration	Physical
in	Physical
plasma	Physical
by	O
76	O
%	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
the	O
proportion	Physical
in	Physical
erythrocyte	Physical
lipids	Physical
by	O
58	O
%	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

Values	O
for	O
serum	Physical
total	Physical
cholesterol	Physical
,	Physical
LDL	Physical
cholesterol	Physical
,	Physical
and	Physical
plasma	Physical
apolipoprotein	Physical
B	Physical
concentrations	Physical
were	O
4.2	O
%	O
(	O
0.22	O
mmol/L	O
;	O
P	O
=	O
0.04	O
)	O
,	O
7.1	O
%	O
(	O
0.23	O
mmol/L	O
;	O
P	O
=	O
0.004	O
)	O
,	O
and	O
3.4	O
%	O
(	O
P	O
=	O
0.03	O
)	O
higher	O
,	O
respectively	O
,	O
with	O
DHA	O
treatment	O
than	O
with	O
placebo	O
.	O

In	O
addition	O
,	O
the	O
LDL	Physical
cholesterol	Physical
:	Physical
apolipoprotein	Physical
B	Physical
ratio	Physical
was	O
3.1	O
%	O
higher	O
with	O
DHA	O
treatment	O
than	O
with	O
placebo	O
(	O
P	O
=	O
0.04	O
)	O
,	O
which	O
suggested	O
an	O
increase	Physical
in	Physical
LDL	Physical
size	Physical
.	O

Plasma	Physical
lathosterol	Physical
and	Physical
plant	Physical
sterol	Physical
concentrations	Physical
were	O
unaffected	O
by	O
treatment	O
.	O

CONCLUSION	O
A	O
daily	O
intake	O
of	O
approximately	O
0.7	O
g	O
DHA	O
increases	Physical
LDL	Physical
cholesterol	Physical
by	O
7	O
%	O
in	O
middle-aged	O
men	O
and	O
women	O
.	O

It	O
is	O
suggested	O
that	O
DHA	O
down-regulates	O
the	O
expression	O
of	O
the	O
LDL	O
receptor	O
.	O

Do	O
physicians	O
'	O
implicit	O
views	O
of	O
African	O
Americans	O
affect	O
clinical	O
decision	O
making	O
?	O
BACKGROUND	O
Total	O
knee	O
replacement	O
(	O
TKR	O
)	O
is	O
a	O
cost-effective	O
treatment	O
option	O
for	O
severe	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

While	O
prevalence	O
of	O
OA	O
is	O
higher	O
among	O
blacks	O
than	O
whites	O
,	O
TKR	O
rates	O
are	O
lower	O
among	O
blacks	O
.	O

Physicians	O
'	O
implicit	O
preferences	O
might	O
explain	O
racial	O
differences	O
in	O
TKR	O
recommendation	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
the	O
magnitude	O
of	O
implicit	O
racial	O
bias	O
predicts	O
physician	O
recommendation	O
of	O
TKR	O
for	O
black	O
and	O
white	O
patients	O
with	O
OA	O
and	O
to	O
assess	O
the	O
effectiveness	O
of	O
a	O
web-based	O
instrument	O
as	O
an	O
intervention	O
to	O
decrease	O
the	O
effect	O
of	O
implicit	O
racial	O
bias	O
on	O
physician	O
recommendation	O
of	O
TKR	O
.	O

METHODS	O
In	O
this	O
web-based	O
study	O
,	O
543	O
family	O
and	O
internal	O
medicine	O
physicians	O
were	O
given	O
a	O
scenario	O
describing	O
either	O
a	O
black	O
or	O
white	O
patient	O
with	O
severe	O
OA	O
refractory	O
to	O
medical	O
treatment	O
.	O

Questionnaires	O
evaluating	O
the	O
likelihood	O
of	O
recommending	O
TKR	O
,	O
perceived	O
medical	O
cooperativeness	O
,	O
and	O
measures	O
of	O
implicit	O
racial	O
bias	O
were	O
administered	O
.	O

The	O
main	O
outcome	O
measures	O
included	O
TKR	O
recommendation	O
,	O
implicit	O
racial	O
preference	O
,	O
and	O
medical	O
cooperativeness	O
stereotypes	O
measured	O
with	O
implicit	O
association	O
tests	O
.	O

RESULTS	O
Subjects	O
displayed	O
a	O
strong	O
implicit	O
preference	O
for	O
whites	O
over	O
blacks	O
(	O
P	O
<	O
.0001	O
)	O
and	O
associated	O
medically	Mental
cooperative	Mental
with	O
whites	O
over	O
blacks	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Physicians	O
reported	O
significantly	O
greater	O
liking	Mental
for	O
whites	O
over	O
blacks	O
(	O
P	O
<	O
.0001	O
)	O
and	O
reported	O
believing	O
whites	O
were	O
more	O
medically	Mental
cooperative	Mental
than	O
blacks	O
(	O
P	O
<	O
.0001	O
)	O
.	O

Participants	O
reported	O
providing	O
similar	O
care	Others
for	O
white	O
and	O
black	O
patients	O
(	O
P	O
=	O
.10	O
)	O
but	O
agreed	O
that	O
subconscious	O
biases	O
could	O
influence	O
their	O
treatment	O
decisions	O
(	O
P	O
<	O
.0001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
rate	Physical
of	Physical
recommendation	Physical
for	Physical
TKR	Physical
when	O
the	O
patient	O
was	O
black	O
(	O
47	O
%	O
)	O
versus	O
white	O
(	O
38	O
%	O
)	O
(	O
P	O
=	O
.439	O
)	O
,	O
and	O
neither	O
implicit	O
nor	O
explicit	O
racial	O
biases	O
predicted	O
differential	O
treatment	O
recommendations	O
by	O
race	O
(	O
all	O
P	O
>	O
.06	O
)	O
.	O

Although	O
participants	O
were	O
more	O
likely	O
to	O
recommend	Physical
TKR	Physical
when	O
completing	O
the	O
implicit	O
association	O
test	O
before	O
the	O
decision	O
,	O
patient	O
race	O
was	O
not	O
significant	O
in	O
the	O
association	O
(	O
P	O
=	O
.960	O
)	O
.	O

CONCLUSIONS	O
Physicians	O
possessed	O
explicit	O
and	O
implicit	O
racial	O
biases	O
,	O
but	O
those	O
biases	O
did	O
not	O
predict	O
treatment	O
recommendations	O
.	O

Clinicians	O
'	O
biases	O
about	O
the	O
medical	O
cooperativeness	O
of	O
blacks	O
versus	O
whites	O
,	O
however	O
,	O
may	O
have	O
influenced	O
treatment	O
decisions	O
.	O

Chlorthalidone	O
does	O
not	O
increase	O
the	O
hypotensive	Physical
effect	Physical
of	O
nifedipine	O
in	O
essential	O
hypertensives	O
:	O
a	O
crossover	O
multicentre	O
study	O
.	O

To	O
determine	O
whether	O
the	O
combination	O
of	O
nifedipine	O
+	O
chlorthalidone	O
exerts	O
an	O
additive	Physical
antihypertensive	Physical
effect	Physical
when	O
compared	O
with	O
single-drug	O
treatment	O
,	O
we	O
studied	O
66	O
uncomplicated	O
essential	O
hypertensives	O
,	O
with	O
diastolic	O
blood	O
pressure	O
of	O
greater	O
than	O
100	O
and	O
less	O
than	O
115	O
mmHg	O
.	O

At	O
the	O
end	O
of	O
a	O
1-month	O
washout	O
placebo	O
period	O
,	O
using	O
a	O
double-blind	O
crossover	O
design	O
,	O
the	O
patients	O
were	O
randomly	O
allocated	O
to	O
nifedipine	O
(	O
20	O
mg	O
twice	O
a	O
day	O
)	O
,	O
chlorthalidone	O
(	O
25	O
mg	O
once	O
a	O
day	O
)	O
,	O
the	O
two	O
drugs	O
combined	O
at	O
the	O
same	O
doses	O
and	O
the	O
corresponding	O
placebo	O
.	O

Compared	O
with	O
the	O
randomly	O
allocated	O
placebo	O
,	O
the	O
three	O
active	O
treatments	O
significantly	O
reduced	O
blood	Physical
pressure	Physical
without	O
changing	O
the	O
heart	Physical
rate	Physical
or	Physical
body	Physical
weight	Physical
.	Physical

Both	O
the	O
absolute	O
and	O
percentage	O
decreases	O
in	O
mean	Physical
blood	Physical
pressure	Physical
induced	O
by	O
nifedipine	O
and	O
the	O
combination	O
compared	O
with	O
placebo	O
were	O
similar	O
and	O
significantly	O
greater	O
than	O
those	O
induced	O
by	O
chlorthalidone	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
combination	O
of	O
nifedipine	O
+	O
chlorthalidone	O
does	O
not	O
exert	O
any	O
additive	Physical
antihypertensive	Physical
effect	Physical
compared	O
with	O
nifedipine	O
alone	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
combination	O
of	O
a	O
dihydropyridine	O
calcium	O
antagonist	O
+	O
a	O
thiazide	O
diuretic	O
is	O
probably	O
devoid	O
of	O
any	O
particular	O
clinical	Physical
significance	Physical
in	O
the	O
treatment	O
of	O
uncomplicated	O
essential	O
hypertensives	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
phase	O
II	O
study	O
of	O
two	O
doses	O
of	O
pemetrexed	O
as	O
first-line	O
chemotherapy	O
for	O
advanced	O
breast	O
cancer	O
.	O

PURPOSE	O
Pemetrexed	O
has	O
shown	O
varied	O
response	O
rates	O
in	O
advanced	O
breast	O
cancer	O
.	O

This	O
randomized	O
,	O
double-blind	O
,	O
phase	O
II	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
efficacy	Others
and	O
safety	Others
of	O
two	O
doses	O
of	O
pemetrexed	O
in	O
a	O
homogeneous	O
population	O
.	O

A	O
secondary	O
objective	O
was	O
to	O
identify	O
molecular	O
biomarkers	O
correlating	O
with	O
response	Physical
and	O
toxicity	Adverseeffect
.	O

EXPERIMENTAL	O
DESIGN	O
Patients	O
with	O
newly	O
diagnosed	O
metastatic	O
breast	O
cancer	O
or	O
locally	O
recurrent	O
breast	O
cancer	O
received	O
600	O
mg/m	O
(	O
2	O
)	O
(	O
P600	O
arm	O
)	O
or	O
900	O
mg/m	O
(	O
2	O
)	O
(	O
P900	O
arm	O
)	O
of	O
pemetrexed	O
on	O
day	O
1	O
of	O
a	O
21-day	O
cycle	O
.	O

All	O
patients	O
received	O
folic	O
acid	O
and	O
vitamin	O
B	O
(	O
12	O
)	O
supplementation	O
.	O

RESULTS	O
The	O
P600	O
(	O
47	O
patients	O
)	O
and	O
P900	O
(	O
45	O
patients	O
)	O
arms	O
had	O
response	Others
rates	Others
of	O
17.0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
7.7-30.8	O
%	O
)	O
and	O
15.6	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
6.5-29.5	O
%	O
)	O
with	O
approximately	O
50	O
%	O
stable	O
disease	O
per	O
arm	O
,	O
median	Mortality
progression-free	Mortality
survival	Mortality
of	O
4.2	O
and	O
4.1	O
months	O
,	O
and	O
median	Others
times	Physical
to	Physical
tumor	Physical
progression	Physical
of	O
4.2	O
and	O
4.6	O
months	O
,	O
respectively	O
.	O

Both	O
arms	O
exhibited	O
minimal	Adverseeffect
toxicity	Adverseeffect
(	O
grade	O
3/4	O
neutropenia	Adverseeffect
<	O
20	O
%	O
,	O
leukopenia	Adverseeffect
<	O
9	O
%	O
,	O
and	O
other	Adverseeffect
toxicities	Adverseeffect
<	O
5	O
%	O
)	O
.	O

Tumor	O
samples	O
from	O
49	O
patients	O
were	O
assessed	O
for	O
the	O
expression	O
levels	O
of	O
12	O
pemetrexed-related	O
genes	O
.	O

Folylpolyglutamate	O
synthetase	O
and	O
thymidine	O
phosphorylase	O
correlated	O
with	O
efficacy	Others
.	O

Best	Others
response	Others
rates	Others
and	O
median	Others
time	Physical
to	Physical
tumor	Physical
progression	Physical
for	O
high	O
versus	O
low	O
thymidine	O
phosphorylase	O
expression	O
were	O
27.6	O
%	O
versus	O
6.3	O
%	O
(	O
P	O
=	O
0.023	O
)	O
and	O
5.4	O
versus	O
1.9	O
months	O
(	O
P	O
=	O
0.076	O
)	O
,	O
and	O
for	O
folylpolyglutamate	O
synthetase	O
were	O
37.5	O
%	O
versus	O
10.0	O
%	O
(	O
P	O
=	O
0.115	O
)	O
and	O
8.6	O
versus	O
3.0	O
months	O
(	O
P	O
=	O
0.019	O
)	O
,	O
respectively	O
.	O

gamma-Glutamyl	O
hydrolase	O
expression	O
correlated	O
with	O
grade	Adverseeffect
3/4	Adverseeffect
toxicities	Adverseeffect
:	O
78.6	O
%	O
for	O
high	O
versus	O
27.3	O
%	O
for	O
low	O
gamma-glutamyl	O
hydrolase	O
(	O
P	O
=	O
0.024	O
)	O
.	O

CONCLUSION	O
The	O
two	O
pemetrexed	O
doses	O
yielded	O
similar	O
efficacy	Others
and	O
safety	Others
profiles	O
.	O

Exploratory	O
biomarker	O
analysis	O
identified	O
efficacy	Others
and	O
toxicity	Adverseeffect
correlations	O
and	O
warrants	O
further	O
evaluation	O
.	O

Estrogen	O
therapy	O
for	O
severe	O
persistent	O
depressions	O
in	O
women	O
.	O

Positive	O
results	O
are	O
reported	O
from	O
a	O
double-blind	O
study	O
of	O
estrogen	O
therapy	O
administered	O
to	O
severely	O
depressed	O
,	O
inpatient	O
women	O
who	O
had	O
failed	O
to	O
respond	O
to	O
various	O
conventional	O
treatments	O
of	O
depression	O
.	O

Large	O
doses	O
of	O
oral	O
conjugated	O
estrogen	O
were	O
administered	O
for	O
a	O
three-month	O
period	O
to	O
23	O
premenopausal	O
and	O
postmenopausal	O
inpatient	O
women	O
.	O

Placebos	O
were	O
administered	O
for	O
a	O
comparable	O
period	O
to	O
17	O
similar	O
patients	O
.	O

The	O
posttreatment	Mental
Hamilton	Mental
ratings	Mental
of	Mental
depression	Mental
were	O
significantly	O
reduced	Others
in	O
the	O
estrogen-treated	O
group	O
,	O
but	O
not	O
in	O
the	O
placebo	O
group	O
.	O

Possible	O
physiological	O
mechanisms	O
are	O
discussed	O
.	O

The	O
risk-benefit	Others
ratio	Others
for	O
estrogen	O
therapy	O
of	O
depression	Mental
in	O
these	O
patients	O
was	O
judged	O
to	O
be	O
favorable	Others
.	O

However	O
,	O
periodic	O
endometrial	O
biopsies	O
are	O
required	O
to	O
monitor	O
the	O
endometrial	O
response	O
of	O
women	O
receiving	O
high	O
doses	O
of	O
estrogens	O
.	O

Age	O
and	O
autonomic	O
effects	O
on	O
interrelationships	O
between	O
lung	O
volume	O
and	O
heart	O
rate	O
.	O

To	O
determine	O
effects	O
of	O
aging	O
and	O
autonomic	O
input	O
on	O
interrelationships	O
between	O
respiratory	O
and	O
heart	O
rate	O
variability	O
,	O
we	O
collected	O
5	O
min	O
of	O
lung	O
volume	O
of	O
R-R	O
interval	O
data	O
from	O
7	O
young	O
[	O
27	O
+/-	O
3	O
(	O
SD	O
)	O
yr	O
]	O
and	O
10	O
older	O
(	O
69	O
+/-	O
6	O
yr	O
)	O
healthy	O
supine	O
humans	O
before	O
and	O
after	O
double	O
pharmacological	O
autonomic	O
blockade	O
with	O
propranolol	O
(	O
0.2	O
mg/kg	O
iv	O
)	O
and	O
atropine	O
(	O
0.04	O
mg/kg	O
iv	O
)	O
.	O

Estimates	O
of	O
respiratory	O
and	O
heart	O
rate	O
power	O
spectra	O
and	O
linear	O
transfer	O
functions	O
between	O
the	O
two	O
groups	O
were	O
generated	O
by	O
Fourier	O
analysis	O
.	O

Age	O
,	O
double	O
blockade	O
effects	O
,	O
the	O
age-drug	O
interactions	O
were	O
determined	O
by	O
analysis	O
of	O
variance	O
for	O
repeated	O
measures	O
.	O

Basal	O
R-R	O
intervals	O
were	O
unaffected	O
by	O
age	O
.	O

Double	O
blockade	O
decreased	O
R-R	Physical
intervals	Physical
and	O
variability	Physical
in	O
both	O
age	O
groups	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
but	O
R-R	O
intervals	O
decreased	O
less	O
in	O
older	O
than	O
in	O
young	O
subjects	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

In	O
contrast	O
,	O
basal	Physical
respiratory	Physical
intervals	Physical
and	O
standard	O
deviation	O
were	O
greater	O
in	O
older	O
subjects	O
(	O
P	O
=	O
0.05	O
)	O
and	O
were	O
unaffected	O
by	O
double	O
blockade	O
in	O
young	O
and	O
older	O
subjects	O
.	O

Lung	Physical
volume-to-heart	Physical
rate	Physical
spectral	Physical
coherence	Physical
was	O
highest	O
at	O
frequencies	O
associated	O
with	O
respiration	O
and	O
greater	O
in	O
young	O
than	O
in	O
older	O
subjects	O
(	O
P	O
<	O
0.07	O
)	O
.	O

Double	O
blockade	O
decreased	O
lung	Physical
volume-to-heart	Physical
rate	Physical
variability	Physical
transfer	Physical
function	Physical
magnitude	Physical
(	O
P	O
<	O
0.007	O
)	O
and	O
increased	O
phase	Physical
angle	Physical
(	O
P	O
<	O
0.02	O
)	O
without	O
age	O
effects	O
or	O
age-drug	O
interactions	O
.	O

In	O
conclusion	O
,	O
heart	Physical
rate	Physical
,	Physical
respiration	Physical
,	Physical
and	Physical
respiration-heart	Physical
rate	Physical
interrelations	Physical
are	O
altered	O
by	O
aging	O
,	O
and	O
double	O
autonomic	O
pharmacological	O
blockade	O
does	O
not	O
eliminate	O
all	O
age-related	O
differences	O
.	O

The	O
effect	O
of	O
person-centred	O
dementia	O
care	O
to	O
prevent	O
agitation	O
and	O
other	O
neuropsychiatric	O
symptoms	O
and	O
enhance	O
quality	O
of	O
life	O
in	O
nursing	O
home	O
patients	O
:	O
a	O
10-month	O
randomized	O
controlled	O
trial	O
.	O

AIMS	O
We	O
examined	O
whether	O
Dementia	O
Care	O
Mapping	O
(	O
DCM	O
)	O
or	O
the	O
VIPS	O
practice	O
model	O
(	O
VPM	O
)	O
is	O
more	O
effective	O
than	O
education	O
of	O
the	O
nursing	O
home	O
staff	O
about	O
dementia	O
(	O
control	O
group	O
)	O
in	O
reducing	O
agitation	O
and	O
other	O
neuropsychiatric	O
symptoms	O
as	O
well	O
as	O
in	O
enhancing	O
the	O
quality	O
of	O
life	O
among	O
nursing	O
home	O
patients	O
.	O

METHODS	O
A	O
10-month	O
three-armed	O
cluster-randomized	O
controlled	O
trial	O
compared	O
DCM	O
and	O
VPM	O
with	O
control	O
.	O

Of	O
624	O
nursing	O
home	O
patients	O
with	O
dementia	O
,	O
446	O
completed	O
follow-up	O
assessments	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
on	O
the	O
Brief	Mental
Agitation	Mental
Rating	Mental
Scale	Mental
(	Mental
BARS	Mental
)	Mental
.	Mental

Secondary	O
outcomes	O
were	O
changes	O
on	O
the	O
10-item	Mental
version	Mental
of	Mental
the	Mental
Neuropsychiatric	Mental
Inventory	Mental
Questionnaire	Mental
(	Mental
NPI-Q	Mental
)	Mental
,	Mental
the	Mental
Cornell	Mental
Scale	Mental
for	Mental
Depression	Mental
in	Mental
Dementia	Mental
(	Mental
CSDD	Mental
)	Mental
and	Mental
the	Mental
Quality	Mental
of	Mental
Life	Mental
in	Mental
Late-Stage	Mental
Dementia	Mental
(	Mental
QUALID	Mental
)	Mental
scale	Mental
.	Mental

RESULTS	O
Changes	O
in	O
the	O
BARS	Mental
score	Mental
did	O
not	O
differ	O
significantly	O
between	O
the	O
DCM	O
and	O
the	O
control	O
group	O
or	O
between	O
the	O
VPM	O
and	O
the	O
control	O
group	O
after	O
10	O
months	O
.	O

Positive	O
differences	O
were	O
found	O
for	O
changes	O
in	O
the	O
secondary	O
outcomes	O
:	O
the	O
NPI-Q	Mental
sum	Mental
score	Mental
as	O
well	O
as	O
the	O
subscales	O
NPI-Q	Mental
agitation	Mental
and	Mental
NPI-Q	Mental
psychosis	Mental
were	O
in	O
favour	O
of	O
both	O
interventions	O
versus	O
control	O
,	O
the	O
QUALID	Mental
score	Mental
was	O
in	O
favour	O
of	O
DCM	O
versus	O
control	O
and	O
the	O
CSDD	Mental
score	Mental
was	O
in	O
favour	O
of	O
VPM	O
versus	O
control	O
.	O

CONCLUSIONS	O
This	O
study	O
failed	O
to	O
find	O
a	O
significant	O
effect	O
of	O
both	O
interventions	O
on	O
the	O
primary	O
outcome	O
.	O

Positive	O
effects	O
on	O
the	O
secondary	O
outcomes	O
indicate	O
that	O
the	O
methods	O
merit	O
further	O
investigation	O
.	O

A	O
randomized	O
trial	O
of	O
genetic	O
and	O
environmental	O
risk	O
assessment	O
(	O
GERA	O
)	O
for	O
colorectal	O
cancer	O
risk	O
in	O
primary	O
care	O
:	O
trial	O
design	O
and	O
baseline	O
findings	O
.	O

PURPOSE	O
This	O
paper	O
describes	O
an	O
ongoing	O
randomized	O
controlled	O
trial	O
designed	O
to	O
assess	O
the	O
impact	Others
of	O
genetic	O
and	O
environmental	O
risk	O
assessment	O
(	O
GERA	O
)	O
on	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
screening	O
.	O

METHODS	O
The	O
trial	O
includes	O
asymptomatic	O
patients	O
who	O
are	O
50-79years	O
and	O
are	O
not	O
up-to-date	O
with	O
CRC	O
screening	O
guidelines	O
.	O

Patients	O
who	O
responded	O
to	O
a	O
baseline	O
telephone	Others
survey	Others
are	O
randomized	O
to	O
a	O
GERA	O
or	O
Control	O
group	O
.	O

GERA	O
group	O
participants	O
meet	O
with	O
a	O
nurse	O
,	O
decide	O
whether	O
to	O
have	O
a	O
GERA	O
blood	O
test	O
(	O
a	O
combination	O
of	O
genetic	O
polymorphism	O
and	O
folate	O
)	O
,	O
and	O
,	O
if	O
tested	O
,	O
receive	O
GERA	O
feedback	O
.	O

Follow-up	O
telephone	Others
surveys	Others
are	O
conducted	O
at	O
1	O
and	O
6months	O
.	O

A	O
chart	Others
audit	Others
is	O
performed	O
at	O
6months	O
.	O

RESULTS	O
Of	O
2,223	O
eligible	O
patients	O
,	O
562	O
(	O
25	O
%	O
)	O
have	O
enrolled	O
.	O

Patients	O
who	O
enrolled	O
in	O
the	O
study	O
were	O
significantly	O
younger	O
than	O
those	O
who	O
did	O
not	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Participants	O
tended	O
to	O
be	O
50-59years	O
(	O
64	O
%	O
)	O
,	O
female	O
(	O
58	O
%	O
)	O
,	O
white	O
(	O
52	O
%	O
)	O
,	O
married	O
(	O
51	O
%	O
)	O
,	O
and	O
have	O
more	O
than	O
a	O
high	O
school	O
education	O
(	O
67	O
%	O
)	O
.	O

At	O
baseline	O
,	O
most	O
participants	O
had	O
some	O
knowledge	Others
of	Others
CRC	Others
screening	Others
and	O
GERA	O
,	O
viewed	O
CRC	O
screening	O
favorably	O
,	O
and	O
reported	O
that	O
they	O
had	O
decided	O
to	O
do	O
screening	O
.	O

Almost	O
half	O
had	O
worries	Others
and	Others
concerns	Others
about	O
CRC	O
.	O

CONCLUSIONS	O
One	O
in	O
four	O
eligible	O
primary	O
care	O
patients	O
enrolled	O
in	O
the	O
study	O
.	O

Age	O
was	O
negatively	O
associated	O
with	O
enrollment	O
.	O

Prospective	O
analyses	O
using	O
data	O
for	O
all	O
participants	O
will	O
provide	O
more	O
definitive	O
information	O
on	O
GERA	O
uptake	O
and	O
the	O
impact	O
of	O
GERA	O
feedback	O
.	O

Effect	O
of	O
L-ornithine-L-aspartate	O
on	O
patients	O
with	O
and	O
without	O
TIPS	O
undergoing	O
glutamine	O
challenge	O
:	O
a	O
double	O
blind	O
,	O
placebo	O
controlled	O
trial	O
.	O

BACKGROUND	O
AND	O
AIM	O
An	O
oral	O
glutamine	O
load	O
in	O
cirrhotic	O
patients	O
awaiting	O
liver	O
transplantation	O
was	O
shown	O
to	O
cause	O
a	O
rise	O
in	O
blood	Physical
ammonia	Physical
and	O
psychometric	Physical
abnormalities	Physical
which	O
were	O
reversed	O
by	O
hepatic	O
transplantation	O
.	O

L-Ornithine-L-aspartate	O
(	O
LOLA	O
)	O
has	O
been	O
shown	O
to	O
reduce	O
ammonia	Physical
and	O
improve	O
psychometric	Mental
function	Mental
in	O
patients	O
with	O
hepatic	O
encephalopathy	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
LOLA	O
in	O
healthy	O
patients	O
with	O
cirrhosis	O
and	O
no	O
evidence	O
of	O
clinical	O
encephalopathy	O
after	O
challenging	O
the	O
central	O
nervous	O
system	O
by	O
administration	O
of	O
oral	O
glutamine	O
.	O

PATIENTS	O
AND	O
METHODS	O
Eight	O
cirrhotics	O
(	O
Child	O
's	O
B	O
or	O
C	O
)	O
without	O
transjugular	O
intrahepatic	O
portosystemic	O
shunts	O
(	O
TIPS	O
)	O
and	O
seven	O
with	O
TIPS	O
underwent	O
two	O
oral	O
glutamine	O
(	O
20	O
g	O
)	O
challenges	O
,	O
receiving	O
LOLA	O
(	O
5	O
g	O
intravenously	O
)	O
on	O
one	O
occasion	O
and	O
placebo	O
on	O
the	O
other	O
in	O
random	O
order	O
.	O

Psychometric	O
tests	O
,	O
including	O
choice	O
reaction	O
time	O
(	O
CRT	O
)	O
and	O
number	O
connection	O
test	O
,	O
were	O
performed	O
before	O
and	O
after	O
glutamine	O
,	O
together	O
with	O
electroencephalography	O
and	O
blood	O
ammonia	O
.	O

RESULTS	O
Mean	Physical
basal	Physical
ammonia	Physical
was	O
27	O
(	O
SEM	O
5	O
)	O
micromol/l	O
in	O
non-TIPS	O
and	O
76	O
(	O
10	O
)	O
micromol/l	O
in	O
TIPS	O
patients	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Basal	Physical
CRT	Physical
2	Physical
was	O
0.643	O
(	O
0.033	O
)	O
s	O
in	O
non-TIPS	O
and	O
0.825	O
(	O
0.076	O
)	O
s	O
in	O
TIPS	O
patients	O
(	O
p	O
<	O
0.02	O
)	O
.	O

In	O
non-TIPS	O
patients	O
,	O
ammonia	Physical
increased	O
to	O
36	O
(	O
10	O
)	O
micromol/l	O
when	O
LOLA	O
was	O
administered	O
and	O
to	O
62	O
(	O
13	O
)	O
micromol/l	O
with	O
placebo	O
(	O
p	O
<	O
0.02	O
)	O
.	O

There	O
was	O
no	O
alteration	O
in	O
psychometric	Mental
function	Mental
in	O
non-TIPS	O
patients	O
after	O
glutamine	O
when	O
LOLA	O
was	O
given	O
but	O
when	O
placebo	O
was	O
given	O
,	O
glutamine	O
caused	O
prolongation	O
of	O
CRT	Physical
(	O
p=0.02	O
)	O
.	O

Glutamine	O
did	O
not	O
affect	O
psychometric	Mental
function	Mental
in	O
TIPS	O
patients	O
with	O
or	O
without	O
LOLA	O
.	O

CONCLUSION	O
This	O
study	O
showed	O
that	O
LOLA	O
ameliorated	O
the	O
deleterious	O
psychometric	Mental
effects	Mental
of	O
glutamine	O
in	O
Child	O
's	O
grade	O
B	O
and	O
C	O
patients	O
with	O
cirrhosis	O
without	O
TIPS	O
and	O
supports	O
its	O
use	O
in	O
clinical	O
practice	O
in	O
hepatic	O
encephalopathy	O
.	O

Human	O
achaete-scute	O
homologue	O
(	O
hASH1	O
)	O
mRNA	O
level	O
as	O
a	O
diagnostic	O
marker	O
to	O
distinguish	O
esthesioneuroblastoma	O
from	O
poorly	O
differentiated	O
tumors	O
arising	O
in	O
the	O
sinonasal	O
tract	O
.	O

Distinction	O
of	O
high-grade	O
esthesioneuroblastomas	O
from	O
other	O
poorly	O
differentiated	O
tumors	O
arising	O
in	O
the	O
nasal	O
cavity	O
is	O
an	O
important	O
diagnostic	O
challenge	O
because	O
it	O
determines	O
patient	O
management	O
and	O
prognosis	O
.	O

The	O
human	O
achaete-scute	O
homologue	O
(	O
hASH1	O
)	O
gene	O
is	O
critical	O
in	O
olfactory	O
neuronal	O
differentiation	O
and	O
is	O
expressed	O
in	O
immature	O
olfactory	O
cells	O
;	O
therefore	O
,	O
it	O
could	O
have	O
potential	O
use	O
as	O
a	O
diagnostic	O
marker	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
value	O
of	O
hASH1	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
in	O
differentiating	O
esthesioneuroblastoma	O
from	O
other	O
poorly	O
differentiated	O
tumors	O
.	O

A	O
real-time	O
polymerase	O
chain	O
reaction	O
assay	O
was	O
developed	O
,	O
permitting	O
the	O
comparative	O
determination	O
of	O
hASH1	Physical
mRNA	Physical
levels	Physical
in	O
triplicate	O
in	O
a	O
double-blind	O
pilot	O
study	O
including	O
24	O
frozen	O
cases	O
of	O
esthesioneuroblastoma	O
and	O
poorly	O
differentiated	O
tumors	O
.	O

All	O
4	O
positive	O
cases	O
were	O
esthesioneuroblastomas	Physical
,	O
and	O
all	O
19	O
poorly	O
differentiated	O
tumors	O
were	O
negative	O
.	O

In	O
addition	O
,	O
there	O
was	O
an	O
inverse	O
association	O
between	O
the	O
grade	Physical
of	Physical
esthesioneuroblastomas	Physical
and	O
hASH1	O
mRNA	O
levels	O
.	O

The	O
hASH1	O
mRNA	O
level	O
might	O
represent	O
a	O
useful	O
tool	O
for	O
distinguishing	O
esthesioneuroblastoma	O
from	O
poorly	O
differentiated	O
tumors	O
of	O
the	O
sinonasal	O
region	O
.	O

[	Physical
Acute	Physical
cardiovascular	Physical
and	Physical
metabolic	Physical
changes	Physical
in	O
interval	O
and	O
endurance	O
training	O
in	O
selected	O
patients	O
following	O
aortocoronary	O
bypass	O
operation	O
]	O
.	O

UNLABELLED	O
This	O
study	O
compared	O
the	O
acute	Physical
changes	Physical
of	Physical
cardiovascular	Physical
and	Physical
metabolic	Physical
reactions	Physical
during	O
interval	O
and	O
continuous	O
training	O
after	O
coronary	O
bypass	O
surgery	O
.	O

Two	O
groups	O
of	O
9	O
male	O
patients	O
(	O
age	O
:	O
59	O
+/-	O
4	O
and	O
56	O
+/-	O
6	O
years	O
,	O
resp	O
.	O

)	O
each	O
trained	O
on	O
bicycle	O
ergometer	O
start	O
on	O
post-operative	O
days	O
24	O
and	O
26	O
,	O
resp	O
.	O

In	O
both	O
training	O
groups	O
training	Physical
heart	Physical
rate	Physical
was	O
set	O
at	O
86	O
%	O
of	O
individual	O
maximum	O
heart	O
rate	O
.	O

In	O
the	O
last	O
week	O
of	O
training	O
the	O
exercise	O
intensity	O
in	O
the	O
group	O
of	O
patients	O
who	O
were	O
trained	O
by	O
the	O
continuous	O
method	O
was	O
at	O
83	O
watts	O
,	O
and	O
at	O
20:121	O
watts	O
in	O
the	O
group	O
of	O
patients	O
who	O
were	O
trained	O
by	O
interval	O
method	O
(	O
rest	O
:	O
work	O
each	O
1:1	O
min	O
)	O
.	O

At	O
this	O
exercise	O
training	O
that	O
lasted	O
for	O
20	O
min	O
the	O
acute	Physical
response	Physical
of	Physical
heart	Physical
rate	Physical
,	O
blood	Physical
pressure	Physical
,	O
rate-pressure	Physical
product	Physical
,	O
glucose	Physical
,	O
lactate	Physical
and	O
catecholamines	Physical
was	O
measured	O
.	O

RESULTS	O
In	O
both	O
methods	O
there	O
were	O
no	O
significant	O
differences	O
in	O
systolic	Others
and	Others
diastolic	Others
pressure	Others
,	O
rate-pressure	Others
product	Others
,	O
in	O
glucose	Others
or	O
catecholamine	Others
levels	O
.	O

However	O
,	O
there	O
was	O
a	O
significantly	O
higher	O
rate	Physical
of	Physical
lactate	Physical
in	O
the	O
second	O
10	O
min	O
of	O
the	O
interval	O
training	O
.	O

And	O
,	O
in	O
spite	O
of	O
higher	O
peripheral	O
exercise	O
intensity	O
by	O
interval	O
training	O
,	O
there	O
was	O
no	O
higher	O
cardiac	Physical
work	Physical
than	O
by	O
the	O
continuous	O
training	O
.	O

These	O
findings	O
suggest	O
that	O
interval	O
training	O
strains	O
the	O
oxidative	O
capacity	O
of	O
the	O
trained	O
muscles	O
in	O
a	O
more	O
intensive	O
and	O
direct	O
way	O
than	O
does	O
continuous	O
training	O
.	O

Effects	O
of	O
low	O
and	O
high	O
doses	O
of	O
atorvastatin	O
on	O
arterial	O
compliance	O
.	O

At	O
the	O
beginning	O
of	O
atherosclerosis	O
before	O
evidence	O
of	O
morphological	Physical
lesions	Physical
or	Physical
plaques	Physical
,	O
vascular	Physical
distensibility	Physical
or	O
arterial	Physical
compliance	Physical
decreased	O
gradually	O
.	O

This	O
endothelial	O
dysfunction	O
is	O
regarded	O
as	O
an	O
early	O
feature	O
of	O
atherosclerosis	O
.	O

In	O
a	O
randomized	O
,	O
double-blind	O
study	O
design	O
,	O
group	O
1	O
(	O
12	O
patients	O
;	O
7	O
males	O
,	O
5	O
females	O
)	O
with	O
serum	Physical
LDL-C	Physical
levels	Physical
higher	O
than	O
170	O
mg/dL	O
and	O
without	O
any	O
other	O
risk	O
factor	O
for	O
atherosclerosis	O
received	O
three	O
months	O
of	O
20	O
mg/day	O
atorvastatin	O
treatment	O
while	O
group	O
11	O
(	O
8	O
males	O
,	O
4	O
females	O
)	O
with	O
the	O
same	O
characteristics	O
received	O
80	O
mg/day	O
.	O

Baseline	O
and	O
posttreatment	O
serum	Physical
lipid	Physical
fractions	Physical
and	O
arterial	Physical
compliance	Physical
were	O
measured	O
.	O

Arterial	Physical
compliance	Physical
was	O
measured	O
noninvasively	O
in	O
the	O
left	O
common	O
carotid	O
artery	O
with	O
color	O
Doppler	O
ultrasound	O
.	O

Atorvastatin	O
reduced	Physical
total	Physical
cholesterol	Physical
(	Physical
TC	Physical
)	Physical
,	O
LDL-C	Physical
,	O
and	O
triglyceride	Physical
levels	Physical
by	O
32	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
40.8	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
19	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
and	O
increased	Physical
HDL-C	Physical
by	O
6.9	O
%	O
,	O
(	O
P	O
=	O
0.002	O
)	O
in	O
the	O
first	O
group	O
.	O

In	O
the	O
second	O
group	O
these	O
reductions	O
were	O
38.5	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
46.2	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
and	O
26.78	O
%	O
(	O
P	O
<	O
0.001	O
)	O
,	O
respectively	O
,	O
and	O
the	O
increase	Physical
in	Physical
HDL	Physical
was	O
7.8	O
%	O
(	O
P	O
=	O
0.03	O
)	O
.	O

It	O
was	O
observed	O
that	O
the	O
decrease	Physical
in	Physical
serum	Physical
TC	Physical
,	O
LDL-C	Physical
and	O
triglyceride	Physical
levels	Physical
were	O
significantly	O
higher	O
in	O
the	O
second	O
group	O
than	O
the	O
first	O
group	O
.	O

With	O
atorvastatin	O
,	O
the	O
distensibility	Physical
coefficient	Physical
(	Physical
DC	Physical
)	Physical
and	O
compliance	Physical
coefficient	Physical
(	Physical
CC	Physical
)	Physical
increased	Physical
from	O
18.7	O
+/-	O
3.4	O
to	O
21.3	O
+/-	O
2.9	O
10	O
(	O
-3	O
)	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
and	O
from	O
0.69	O
+/-	O
0.05	O
to	O
0.77	O
+/-	O
0.03	O
mm2	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
in	O
the	O
first	O
group	O
while	O
they	O
changed	O
from	O
18.3	O
+/-	O
3.6	O
to	O
21.9	O
+/-	O
3.0	O
10	O
(	O
-3	O
)	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
and	O
from	O
0.70	O
+/-	O
0.04	O
to	O
0.81	O
+/-	O
0.01	O
mm2	O
x	O
kPa	O
(	O
-1	O
)	O
(	O
P	O
<	O
0.001	O
)	O
respectively	O
,	O
in	O
the	O
second	O
group	O
.	O

DC	Physical
and	O
CC	Mental
increased	Physical
in	O
both	O
groups	O
,	O
but	O
the	O
differences	O
between	O
the	O
groups	O
were	O
not	O
significant	O
.	O

High	O
doses	O
of	O
atorvastatin	O
reduce	Physical
blood	Physical
lipid	Physical
levels	Physical
more	O
than	O
conventional	O
doses	O
,	O
however	O
,	O
the	O
change	O
in	O
compliance	O
is	O
not	O
dose-dependent	O
.	O

As	O
endothelial	O
dysfunction	O
is	O
regarded	O
as	O
an	O
early	O
feature	O
of	O
atherosclerosis	O
,	O
there	O
would	O
be	O
no	O
need	O
to	O
administer	O
aggressive	O
doses	O
in	O
a	O
patient	O
without	O
any	O
risk	O
factors	O
other	O
than	O
hyperlipidemia	O
.	O

Efficacy	Others
and	Others
safety	Others
of	O
sildenafil	O
in	O
Asian	O
males	O
with	O
erectile	O
dysfunction	O
and	O
cardiovascular	O
risk	O
.	O

OBJECTIVE	O
Assess	O
the	O
effectiveness	O
of	O
sildenafil	O
in	O
Asian	O
males	O
with	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
and	O
one	O
or	O
more	O
of	O
the	O
co-morbidities	O
,	O
mild-to-moderate	O
hypertension	O
,	O
dyslipidemia	O
,	O
and	O
diabetes	O
.	O

MATERIAL	O
AND	O
METHOD	O
A	O
six-week	O
,	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
,	O
multicenter	O
study	O
was	O
carried	O
out	O
in	O
Thailand	O
,	O
Malaysia	O
and	O
Singapore	O
.	O

One	O
hundred	O
and	O
fifty	O
five	O
male	O
subjects	O
were	O
randomized	O
(	O
2:1	O
)	O
to	O
sildenafil	O
(	O
n	O
=	O
104	O
)	O
or	O
placebo	O
(	O
n	O
=	O
51	O
)	O
.	O

Sildenafil	O
was	O
started	O
at	O
50	O
mg	O
and	O
increased	O
(	O
100	O
mg	O
)	O
or	O
decreased	O
(	O
25	O
mg	O
)	O
at	O
week	O
2	O
if	O
necessary	O
.	O

RESULTS	O
On	O
the	O
primary	O
efficacy	O
endpoint	O
,	O
sildenafil-treated	O
subjects	O
had	O
significantly	O
better	O
scores	O
on	O
the	O
International	Physical
Index	Physical
of	Physical
Erectile	Physical
Function	Physical
(	Physical
IIEF	Physical
)	Physical
questions	Physical
3	Physical
and	Physical
4	Physical
than	O
placebo	O
(	O
p	O
<	O
0.001	O
,	O
both	O
questions	O
)	O
.	O

When	O
accumulated	O
into	O
IIEF	O
domains	O
,	O
all	O
five	O
domains	O
were	O
significant	O
in	O
favor	O
of	O
sildenafil	O
.	O

In	O
addition	O
,	O
sildenafil-treated	O
subjects	O
were	O
more	O
satisfied	O
with	O
treatment	O
and	O
had	O
a	O
higher	O
intercourse	Physical
success	Physical
rate	Physical
.	O

The	O
majority	O
of	O
adverse	O
events	O
were	O
mild	O
in	O
severity	O
;	O
the	O
most	O
commonly	O
reported	O
treatment-related	O
events	O
were	O
dizziness	Adverseeffect
(	O
7.7	O
%	O
)	O
and	O
tinnitus	Adverseeffect
(	O
2.9	O
%	O
)	O
.	O

CONCLUSION	O
Sildenafil	O
(	O
25	O
,	O
50	O
,	O
and	O
100	O
mg	O
)	O
was	O
found	O
to	O
be	O
an	O
effective	O
,	O
safe	O
,	O
and	O
well-tolerated	O
treatment	O
for	O
ED	O
in	O
the	O
present	O
study	O
population	O
of	O
Thai	O
,	O
Malaysian	O
,	O
and	O
Singaporean	O
males	O
who	O
also	O
had	O
increased	O
cardiovascular	O
risk	O
Value	O
of	O
an	O
anal	O
dilator	O
after	O
anal	O
stretch	O
for	O
haemorrhoids	Physical
.	Physical

A	O
prospective	O
randomized	O
trial	O
compared	O
anal	O
stretch	O
with	O
or	O
without	O
continued	O
dilatation	O
for	O
three	O
months	O
in	O
89	O
consecutive	O
patients	O
with	O
haemorrhoids	O
.	O

Complications	Adverseeffect
of	Adverseeffect
therapy	Adverseeffect
occurred	O
in	O
only	O
4	O
patients	O
,	O
3	O
of	O
whom	O
had	O
transient	O
incontinence	Physical
of	O
flatus	O
.	O

When	O
patients	O
were	O
reviewed	O
four	O
months	O
after	O
treatment	O
,	O
only	O
4	O
of	O
44	O
patients	O
(	O
9	O
%	O
)	O
who	O
used	O
a	O
dilator	O
had	O
not	O
been	O
improved	O
and	O
required	O
additional	O
therapy	O
,	O
compared	O
with	O
15	O
of	O
42	O
patients	O
(	O
36	O
%	O
)	O
who	O
had	O
anal	O
stretch	O
alone	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

It	O
is	O
concluded	O
that	O
the	O
use	O
of	O
an	O
anal	O
dilator	O
improves	O
the	O
results	O
of	O
anal	Physical
stretch	Physical
.	Physical

The	O
efficacy	Others
of	O
intramammary	O
tilmicosin	O
at	O
drying-off	O
,	O
and	O
other	O
risk	O
factors	O
for	O
the	O
prevention	O
of	O
new	O
intramammary	O
infections	O
during	O
the	O
dry	O
period	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
of	O
an	O
intramammary	O
infusion	O
,	O
containing	O
tilmicosin	O
phosphate	O
,	O
to	O
an	O
infusion	O
of	O
a	O
negative	O
control	O
intramammary	O
placebo	O
for	O
preventing	O
new	O
intramammary	Physical
infections	Physical
(	O
IMI	O
)	O
during	O
the	O
dry	O
period	O
.	O

Cows	O
were	O
enrolled	O
from	O
24	O
dairy	O
herds	O
from	O
three	O
geographical	O
regions	O
of	O
Canada	O
.	O

Data	O
from	O
248	O
cows	O
and	O
938	O
bacteriologically	O
negative	O
quarters	O
at	O
drying-off	O
are	O
summarized	O
.	O

Overall	O
,	O
the	O
rate	Physical
of	Physical
new	Physical
IMI	Physical
during	O
the	O
dry	O
period	O
was	O
16.7	O
%	O
of	O
quarters	O
.	O

The	O
new	Physical
infection	Physical
rates	Physical
for	O
quarters	O
that	O
received	O
intramammary	O
tilmicosin	O
compared	O
with	O
the	O
intramammary	O
placebo	O
were	O
14.4	O
and	O
19.4	O
%	O
,	O
respectively	O
.	O

The	O
majority	O
of	O
new	Physical
IMI	Physical
was	O
caused	O
by	O
coagulase-negative	O
staphylococci	O
(	O
49	O
%	O
)	O
and	O
environmental	O
streptococcal	O
organisms	O
(	O
26.8	O
%	O
)	O
.	O

The	O
probability	O
for	O
quarters	O
to	O
develop	O
new	Physical
IMI	Physical
in	O
the	O
dry	O
period	O
was	O
significantly	O
increased	O
when	O
cows	O
had	O
higher	O
milk	O
production	O
before	O
drying-off	O
(	O
P	O
=	O
0.04	O
)	O
,	O
when	O
cows	O
had	O
longer	O
dry	O
periods	O
(	O
P	O
=	O
0.02	O
)	O
,	O
and	O
when	O
dry	O
cows	O
were	O
housed	O
in	O
tie-stall	O
barns	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Higher	O
parity	O
cows	O
and	O
those	O
that	O
had	O
a	O
linear	Physical
score	Physical
somatic	Physical
cell	Physical
count	Physical
(	Physical
SCC	Physical
)	Physical
above	O
4	O
on	O
the	O
last	O
DHI	O
test	O
were	O
also	O
at	O
increased	O
risk	Physical
for	Physical
new	Physical
IMI	Physical
(	O
P	O
<	O
0.10	O
)	O
.	O

Administration	O
of	O
intramammary	O
tilmicosin	O
appears	O
to	O
be	O
an	O
efficacious	O
therapy	O
for	O
prevention	Physical
of	Physical
new	Physical
IMI	Physical
;	Physical
however	O
,	O
there	O
is	O
currently	O
no	O
approved	O
intramammary	O
formulation	O
of	O
this	O
product	O
available	O
.	O

Use	O
of	O
blanket	O
dry	O
cow	O
antibiotic	O
therapy	O
compared	O
to	O
selective	O
dry	O
cow	O
therapy	O
,	O
as	O
well	O
as	O
the	O
importance	O
of	O
identifying	O
risk	O
factors	O
and	O
managing	O
the	O
environment	O
of	O
dry	O
cows	O
are	O
discussed	O
.	O

Effectiveness	O
of	O
active	O
physical	O
training	O
as	O
treatment	O
for	O
long-standing	O
adductor-related	O
groin	O
pain	O
in	O
athletes	O
:	O
randomised	O
trial	O
.	O

BACKGROUND	O
Groin	O
pain	O
is	O
common	O
among	O
athletes	O
.	O

A	O
major	O
cause	O
of	O
long-standing	O
problems	O
is	O
adductor-related	O
groin	O
pain	O
.	O

The	O
purpose	O
of	O
this	O
randomised	O
clinical	O
trial	O
was	O
to	O
compare	O
an	O
active	O
training	O
programme	O
(	O
AT	O
)	O
with	O
a	O
physiotherapy	O
treatment	O
without	O
active	O
training	O
(	O
PT	O
)	O
in	O
the	O
treatment	O
of	O
adductor-related	O
groin	O
pain	O
in	O
athletes	O
.	O

METHODS	O
68	O
athletes	O
with	O
long-standing	O
(	O
median	O
40	O
weeks	O
)	O
adductor-related	O
groin	O
pain	O
--	O
after	O
examination	O
according	O
to	O
a	O
standardised	O
protocol	O
--	O
were	O
randomly	O
assigned	O
to	O
AT	O
or	O
PT	O
.	O

The	O
treatment	O
period	O
was	O
8-12	O
weeks	O
.	O

4	O
months	O
after	O
the	O
end	O
of	O
treatment	O
a	O
standardised	O
examination	O
was	O
done	O
.	O

The	O
examining	O
physician	O
was	O
unaware	O
of	O
the	O
treatment	O
allocation	O
.	O

The	O
ultimate	O
outcome	O
measure	O
was	O
full	Pain
return	Pain
to	Pain
sports	Pain
at	Pain
the	Pain
same	Pain
level	Pain
without	Pain
groin	Pain
pain	Pain
.	O

Analyses	O
were	O
by	O
intention	O
to	O
treat	O
.	O

FINDINGS	O
23	O
patients	O
in	O
the	O
AT	O
group	O
and	O
four	O
in	O
the	O
PT	O
group	O
returned	O
to	O
sports	O
without	O
groin	Pain
pain	Pain
(	O
odds	O
ratio	O
,	O
multiple-logistic-regression	O
analysis	O
,	O
12.7	O
[	O
95	O
%	O
CI	O
3.4-47.2	O
]	O
)	O
.	O

The	O
subjective	O
global	O
assessments	O
of	O
the	O
effect	O
of	O
the	O
treatments	O
showed	O
a	O
significant	O
(	O
p=0.006	O
)	O
linear	O
trend	O
towards	O
a	O
better	O
effect	O
in	O
the	O
AT	O
group	O
.	O

A	O
per-protocol	O
analysis	O
did	O
not	O
show	O
appreciably	O
different	O
results	O
.	O

INTERPRETATION	O
AT	O
with	O
a	O
programme	O
aimed	O
at	O
improving	O
strength	O
and	O
coordination	O
of	O
the	O
muscles	O
acting	O
on	O
the	O
pelvis	O
,	O
in	O
particular	O
the	O
adductor	O
muscles	O
,	O
is	O
very	O
effective	O
in	O
the	O
treatment	O
of	O
athletes	O
with	O
long-standing	O
adductor-related	O
groin	O
pain	O
.	O

The	O
potential	O
preventive	O
value	O
of	O
a	O
short	O
programme	O
based	O
upon	O
the	O
principles	O
of	O
AT	O
should	O
be	O
assessed	O
in	O
future	O
,	O
randomised	O
,	O
clinical	O
trials	O
.	O

Prospective	O
randomized	O
multicenter	O
trial	O
of	O
sevelamer	O
hydrochloride	O
and	O
calcium	O
carbonate	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	Physical
in	O
hemodialysis	O
patients	O
in	O
Japan	O
.	O

A	O
prospective	O
,	O
randomized	O
open-label	O
trial	O
of	O
sevelamer	O
hydrochloride	O
with	O
or	O
without	O
calcium	O
carbonate	O
(	O
CC	O
)	O
involved	O
86	O
hemodialysis	O
patients	O
in	O
Japan	O
.	O

The	O
dosage	O
of	O
CC	O
was	O
fixed	O
at	O
3.0	O
g/day	O
for	O
the	O
12-week	O
study	O
.	O

After	O
the	O
first	O
4	O
weeks	O
all	O
subjects	O
were	O
changed	O
from	O
CC	O
to	O
sevelamer	O
3.0	O
g/day	O
for	O
another	O
4	O
weeks	O
,	O
then	O
allocated	O
randomly	O
to	O
three	O
groups	O
for	O
the	O
final	O
4	O
weeks	O
:	O
group	O
A	O
,	O
sevelamer	O
6.0	O
g/day	O
;	O
group	O
B	O
,	O
sevelamer	O
3.0	O
g/day	O
and	O
CC	O
3.0	O
g/day	O
;	O
group	O
C	O
,	O
CC	O
3.0	O
g/day	O
.	O

The	O
target	Physical
serum	Physical
phosphorous	Physical
concentration	Physical
(	O
P	O
)	O
=5.5	O
mg/dL	O
and	O
the	O
corrected	Physical
calcium	Physical
concentration	Physical
(	Physical
Ca	Physical
)	Physical
was	O
9.0-10.0	O
mg/dL	O
.	O

Of	O
the	O
86	O
patients	O
,	O
62	O
finished	O
the	O
study	O
without	O
a	O
change	O
of	O
dosage	O
and	O
their	O
data	O
were	O
analyzed	O
(	O
group	O
A	O
,	O
N=16	O
;	O
group	O
B	O
,	O
N=26	O
;	O
group	O
C	O
,	O
N=20	O
)	O
.	O

At	O
week	O
8	O
compared	O
with	O
week	O
4	O
,	O
the	O
concentration	Physical
of	Physical
P	Physical
increased	O
from	O
5.7+/-1.4	O
to	O
6.4+/-1.7	O
mg/dL	O
in	O
group	O
A	O
,	O
and	O
decreased	O
significantly	O
in	O
groups	O
B	O
and	O
C	O
,	O
and	O
in	O
group	O
B	O
compared	O
with	O
groups	O
A	O
and	O
C	O
;	O
groups	O
A	O
and	O
C	O
had	O
similar	O
concentrations	O
at	O
week	O
8	O
.	O

The	O
Ca	Physical
concentration	Physical
decreased	O
significantly	O
from	O
9.7+/-1.0	O
to	O
9.1+/-0.7	O
mg/dL	O
after	O
the	O
change	O
to	O
sevelamer	O
.	O

At	O
week	O
8	O
Ca	Physical
was	O
not	O
significantly	O
changed	O
in	O
group	O
A	O
,	O
whereas	O
a	O
significant	O
increase	O
occurred	O
in	O
groups	O
B	O
and	O
C.	O
Side-effects	Adverseeffect
with	O
sevelamer	O
administration	O
occurred	O
in	O
34	O
of	O
the	O
86	O
patients	O
and	O
24	O
dropped	O
out	O
of	O
the	O
study	O
,	O
with	O
a	O
high	O
frequency	O
in	O
group	O
A	O
(	O
13/29	O
;	O
44.8	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
an	O
additive	Adverseeffect
effect	Adverseeffect
of	O
sevelamer	O
for	O
the	O
treatment	O
of	O
hyperphosphatemia	O
with	O
CC	O
.	O

The	O
combination	O
therapy	O
was	O
better	O
tolerated	Others
and	O
showed	O
higher	O
patient	Mental
compliance	Mental
than	O
CC	O
or	O
sevelamer	O
monotherapy	O
.	O

Effect	O
of	O
granulocyte/colony-stimulating	O
factor	O
on	O
the	O
onset	O
of	O
the	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
granulocyte/colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
on	O
the	O
onset	O
of	O
the	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
,	O
we	O
investigated	O
whether	O
the	O
incidence	O
of	O
ARDS	O
due	O
to	O
pulmonary	O
infection	O
differed	O
between	O
the	O
G-CSF	O
group	O
which	O
received	O
chemotherapy	O
with	O
G-CSF	O
and	O
historical	O
controls	O
without	O
G-CSF	O
.	O

We	O
evaluated	O
132	O
patients	O
with	O
hematological	O
malignancy	O
in	O
complete	O
remission	O
without	O
any	O
main	O
organ	O
dysfunction	O
who	O
had	O
been	O
treated	O
between	O
April	O
1983	O
and	O
December	O
1997	O
.	O

We	O
compared	O
the	O
incidence	O
of	O
ARDS	O
due	O
to	O
pulmonary	O
infection	O
between	O
those	O
who	O
received	O
G-CSF	O
and	O
those	O
who	O
did	O
not	O
.	O

There	O
was	O
no	O
remarkable	O
difference	O
in	O
the	O
number	O
of	O
patients	O
,	O
gender	O
,	O
age	O
,	O
or	O
distribution	O
of	O
primary	O
diseases	O
between	O
the	O
two	O
groups	O
.	O

The	O
intensity	Others
of	Others
chemotherapy	Others
was	O
not	O
considered	O
to	O
significantly	O
differ	O
between	O
the	O
two	O
groups	O
,	O
though	O
the	O
chemotherapy	O
regimens	O
administered	O
differed	O
slightly	O
.	O

In	O
the	O
G-CSF	O
group	O
,	O
the	O
duration	Physical
of	Physical
neutropenia	Physical
was	O
significantly	O
shorter	O
and	O
the	O
frequency	O
of	O
documented	O
infection	O
was	O
significantly	O
decreased	O
.	O

We	O
could	O
not	O
find	O
any	O
relationship	O
between	O
ARDS	O
due	O
to	O
pulmonary	Physical
infection	Physical
and	O
any	O
anticancer	O
agent	O
or	O
antibiotics	O
.	O

There	O
was	O
no	O
relationship	O
between	O
the	O
kind	O
of	O
G-CSF	O
and	O
the	O
incidence	O
of	O
ARDS	O
due	O
to	O
pulmonary	Physical
infection	Physical
(	O
per	O
chemotherapy	O
session	O
;	O
p	O
>	O
0.10	O
,	O
per	O
case	O
;	O
p	O
>	O
0.30	O
,	O
chi2	O
test	O
)	O
.	O

The	O
incidence	Physical
of	Physical
ARDS	Physical
due	Physical
to	Physical
pulmonary	Physical
infection	Physical
per	Physical
chemotherapy	Physical
session	Physical
was	O
4.21	O
%	O
,	O
and	O
showed	O
a	O
higher	O
tendency	O
in	O
the	O
G-CSF	O
group	O
(	O
p	O
<	O
0.100	O
,	O
chi2	O
test	O
)	O
.	O

The	O
incidence	O
of	O
ARDS	O
due	O
to	O
pulmonary	O
infection	O
per	O
case	O
was	O
25.4	O
%	O
and	O
was	O
significantly	O
higher	O
in	O
the	O
G-CSF	O
group	O
(	O
p	O
<	O
0.025	O
,	O
chi2	O
test	O
)	O
.	O

The	O
incidence	Physical
of	Physical
ARDS	Physical
due	Physical
to	Physical
pulmonary	Physical
infection	Physical
was	Physical
higher	Physical
in	Physical
the	Physical
G-CSF	Physical
group	Physical
than	O
in	O
the	O
controls	O
,	O
suggesting	O
that	O
G-CSF	O
promotes	O
the	O
development	O
of	O
ARDS	O
due	O
to	O
pulmonary	O
infection	O
.	O

Safety	O
of	O
injectable	O
opioid	O
maintenance	O
treatment	O
for	O
heroin	O
dependence	O
.	O

BACKGROUND	O
There	O
is	O
a	O
growing	O
debate	O
about	O
injectable	O
opioid	O
treatment	O
programs	O
in	O
many	O
Western	O
countries	O
.	O

This	O
is	O
the	O
first	O
placebo-controlled	O
study	O
of	O
the	O
safety	O
of	O
injectable	O
opioids	O
in	O
a	O
controlled	O
treatment	O
setting	O
.	O

METHODS	O
Twenty-five	O
opioid-dependent	O
patients	O
on	O
intravenous	O
(	O
IV	O
)	O
heroin	O
or	O
IV	O
methadone	O
maintenance	O
treatment	O
were	O
randomly	O
assigned	O
to	O
either	O
their	O
individual	O
prescribed	O
IV	O
maintenance	O
dose	O
or	O
placebo	O
.	O

Acute	Others
drug	Others
effects	Others
were	O
recorded	O
,	O
focusing	O
on	O
electrocardiography	Others
,	O
respiratory	Physical
movements	Physical
,	O
arterial	Physical
blood	Physical
oxygen	Physical
saturation	Physical
,	O
and	O
electroencephalography	Physical
(	Physical
EEG	Physical
)	Physical
.	O

RESULTS	O
After	O
heroin	O
injection	O
,	O
marked	O
respiratory	Physical
depression	Physical
progressing	O
to	O
a	O
Cheyne-Stokes	Physical
pattern	Physical
occurred	O
.	O

Peripheral	Physical
arterial	Physical
blood	Physical
oxygenation	Physical
decreased	O
to	O
78.9	O
+/-	O
8.7	O
%	O
(	O
mean	O
+/-	O
SD	O
)	O
ranging	O
from	O
52	O
%	O
-90	O
%	O
.	O

During	O
hypoxia	Physical
,	O
7	O
of	O
the	O
16	O
subjects	O
experienced	O
intermittent	O
and	O
somewhat	O
severe	O
bradycardia	Physical
.	O

Five	O
subjects	O
exhibited	O
paroxysmal	Physical
EEG	Physical
patterns	Physical
.	O

After	O
methadone	O
injection	O
,	O
respiratory	Physical
depression	Physical
was	O
less	O
pronounced	O
than	O
after	O
heroin	O
injection	O
.	O

No	O
relevant	O
bradycardia	Physical
was	O
noted	O
.	O

CONCLUSIONS	O
Opioid	O
doses	O
commonly	O
prescribed	O
in	O
IV	O
opioid	O
treatment	O
induce	O
marked	O
respiratory	Physical
and	Physical
circulatory	Physical
depression	Physical
,	O
as	O
well	O
as	O
occasionally	O
irregular	Physical
paroxysmal	Physical
EEG	Physical
activity	Physical
.	O

Further	O
studies	O
are	O
needed	O
to	O
optimize	O
the	O
clinical	O
practice	O
of	O
IV	O
opioid	O
treatment	O
to	O
prevent	O
serious	O
complications	O
.	O

Moreover	O
,	O
the	O
extent	O
of	O
the	O
observed	O
effects	O
raises	O
questions	O
about	O
the	O
appropriateness	O
of	O
IV	O
opioid	O
treatment	O
in	O
the	O
present	O
form	O
.	O

The	O
effect	O
of	O
neighborhood-based	O
community	O
organizing	O
:	O
results	O
from	O
the	O
Seattle	O
Minority	O
Youth	O
Health	O
Project	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
effect	O
of	O
a	O
community	O
mobilization	O
and	O
youth	O
development	O
strategy	O
to	O
prevent	O
drug	Mental
abuse	Mental
,	O
violence	Mental
,	O
and	O
risky	Mental
sexual	Mental
activity	Mental
.	O

DATA	O
SOURCES/STUDY	O
SETTING	O
Primary	O
surveys	O
of	O
youth	O
,	O
parents	O
,	O
and	O
key	O
neighborhood	O
leaders	O
were	O
carried	O
out	O
at	O
baseline	O
(	O
1994	O
)	O
and	O
at	O
the	O
end	O
of	O
the	O
intervention	O
period	O
(	O
1997	O
)	O
.	O

The	O
study	O
took	O
place	O
in	O
four	O
intervention	O
and	O
six	O
control	O
neighborhoods	O
in	O
Seattle	O
.	O

STUDY	O
DESIGN	O
The	O
study	O
was	O
designed	O
as	O
a	O
randomized	O
controlled	O
trial	O
with	O
neighborhood	O
as	O
the	O
unit	O
of	O
randomization	O
.	O

The	O
intervention	O
consisted	O
of	O
a	O
paid	O
community	O
organizer	O
in	O
each	O
neighborhood	O
who	O
recruited	O
a	O
group	O
of	O
residents	O
to	O
serve	O
as	O
a	O
community	O
action	O
board	O
.	O

Key	O
variables	O
included	O
perceptions	Mental
of	Mental
neighborhood	Mental
mobilization	Mental
by	O
youth	O
,	O
parents	O
,	O
and	O
key	O
neighborhood	O
leaders	O
.	O

DATA	O
COLLECTION/EXTRACTION	O
METHODS	O
Youth	O
surveys	O
were	O
self-administered	O
during	O
school	O
hours	O
.	O

Parent	O
and	O
neighborhood	O
leader	O
surveys	O
were	O
conducted	O
over	O
the	O
phone	O
by	O
trained	O
interviewers	O
.	O

PRINCIPAL	O
FINDINGS	O
Survey	O
results	O
showed	O
that	O
mobilization	Mental
increased	O
to	O
the	O
same	O
degree	O
in	O
both	O
intervention	O
and	O
control	O
neighborhoods	O
with	O
no	O
evidence	O
of	O
an	O
overall	O
intervention	O
effect	O
.	O

There	O
did	O
appear	O
to	O
be	O
a	O
relative	O
increase	O
in	O
mobilization	Mental
in	O
the	O
neighborhood	O
with	O
the	O
highest	O
level	Mental
of	Mental
intervention	Mental
activity	Mental
.	O

CONCLUSION	O
This	O
randomized	O
study	O
failed	O
to	O
demonstrate	O
a	O
measurable	O
effect	O
for	O
a	O
community	O
mobilization	Others
intervention	Others
.	O

It	O
is	O
uncertain	O
whether	O
the	O
negative	O
finding	O
was	O
because	O
of	O
a	O
lack	O
of	O
strength	O
of	O
the	O
interventions	O
or	O
problems	O
detecting	O
intervention	O
effects	O
using	O
individual-level	O
closed-end	O
surveys	O
.	O

Isoflurane	O
and	O
propofol	O
for	O
long-term	O
sedation	O
in	O
the	O
intensive	O
care	O
unit	O
.	O

A	O
crossover	O
study	O
.	O

Propofol	O
and	O
isoflurane	O
have	O
been	O
reported	O
recently	O
to	O
offer	O
better	O
sedation	Others
than	O
alternative	O
agents	O
in	O
patients	O
who	O
require	O
long-term	O
ventilation	O
in	O
the	O
Intensive	O
Care	O
Unit	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
direct	O
comparison	O
between	O
propofol	O
and	O
isoflurane	O
.	O

Twenty-four	O
patients	O
predicted	O
to	O
require	O
artificial	O
ventilation	O
for	O
at	O
least	O
48	O
h	O
were	O
entered	O
into	O
a	O
randomised	O
crossover	O
study	O
to	O
monitor	O
sedation	Others
quality	Others
and	Physical
time	Others
to	Others
recovery	Others
from	Others
sedation	Others
.	Physical

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
agents	O
in	O
either	O
end-point	O
,	O
with	O
over	O
95	O
%	O
optimal	Others
sedation	Others
achieved	O
by	O
the	O
use	O
of	O
each	O
drug	O
.	O

Few	O
adverse	Adverseeffect
events	Adverseeffect
were	O
noted	O
.	O

Technological	O
advances	O
in	O
the	O
administration	O
of	O
volatile	O
agents	O
as	O
long-term	O
sedatives	O
in	O
the	O
Intensive	O
Care	O
Unit	O
may	O
facilitate	O
their	O
more	O
widespread	O
use	O
.	O

Controlled-release	O
melatonin	O
,	O
singly	O
and	O
combined	O
with	O
cognitive	O
behavioural	O
therapy	O
,	O
for	O
persistent	O
insomnia	Physical
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
:	O
a	O
randomized	O
placebo-controlled	O
trial	O
.	O

Although	O
melatonin	O
and	O
cognitive-behavioural	O
therapy	O
have	O
shown	O
efficacy	O
in	O
treating	O
sleep	O
disorders	O
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
,	O
little	O
is	O
known	O
about	O
their	O
relative	O
or	O
combined	O
efficacy	O
.	O

One	O
hundred	O
and	O
sixty	O
children	O
with	O
autism	O
spectrum	O
disorders	O
,	O
aged	O
4-10	O
years	O
,	O
suffering	O
from	O
sleep	O
onset	O
insomnia	O
and	O
impaired	O
sleep	O
maintenance	O
,	O
were	O
assigned	O
randomly	O
to	O
either	O
(	O
1	O
)	O
combination	O
of	O
controlled-release	O
melatonin	O
and	O
cognitive-behavioural	O
therapy	O
;	O
(	O
2	O
)	O
controlled-release	O
melatonin	O
;	O
(	O
3	O
)	O
four	O
sessions	O
of	O
cognitive-behavioural	O
therapy	O
;	O
or	O
(	O
4	O
)	O
placebo	O
drug	O
treatment	O
condition	O
for	O
12	O
weeks	O
in	O
a	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
ratio	O
.	O

Children	O
were	O
studied	O
at	O
baseline	O
and	O
after	O
12	O
weeks	O
of	O
treatment	O
.	O

Treatment	O
response	O
was	O
assessed	O
with	O
1-week	O
actigraphic	O
monitoring	O
,	O
sleep	O
diary	O
and	O
sleep	O
questionnaire	O
.	O

Main	O
outcome	O
measures	O
,	O
derived	O
actigraphically	O
,	O
were	O
sleep	Physical
latency	Physical
,	Physical
total	Physical
sleep	Physical
time	Physical
,	Physical
wake	Physical
after	Physical
sleep	Physical
onset	Physical
and	Physical
number	Physical
of	Physical
awakenings	Physical
.	Physical

The	O
active	O
treatment	O
groups	O
all	O
resulted	O
in	O
improvements	O
across	O
all	O
outcome	O
measures	O
,	O
with	O
moderate-to-large	O
effect	O
sizes	O
from	O
baseline	O
to	O
a	O
12-week	O
assessment	O
.	O

Melatonin	O
treatment	O
was	O
mainly	O
effective	O
in	O
reducing	O
insomnia	Physical
symptoms	Physical
,	O
while	O
cognitive-behavioural	O
therapy	O
had	O
a	O
light	O
positive	O
impact	O
mainly	O
on	O
sleep	Physical
latency	Physical
,	O
suggesting	O
that	O
some	O
behavioural	O
aspects	O
might	O
play	O
a	O
role	O
in	O
determining	O
initial	Physical
insomnia	Physical
.	Physical

The	O
combination	O
treatment	O
group	O
showed	O
a	O
trend	O
to	O
outperform	O
other	O
active	O
treatment	O
groups	O
,	O
with	O
fewer	O
dropouts	O
and	O
a	O
greater	O
proportion	O
of	O
treatment	O
responders	O
achieving	O
clinically	O
significant	O
changes	O
(	O
63.38	O
%	O
normative	O
sleep	O
efficiency	O
criterion	O
of	O
>	O
85	O
%	O
and	O
84.62	O
%	O
,	O
sleep	O
onset	O
latency	O
<	O
30	O
min	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
adding	O
behavioural	O
intervention	O
to	O
melatonin	O
treatment	O
seems	O
to	O
result	O
in	O
a	O
better	O
treatment	O
response	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O

Videotaped	O
training	O
in	O
alcohol	O
counseling	O
for	O
obstetric	O
care	O
practitioners	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

OBJECTIVE	O
To	O
determine	O
the	O
feasibility	O
of	O
videotaped	O
training	O
for	O
obstetric	O
care	O
practitioners	O
in	O
motivational	O
interviewing	O
skills	O
that	O
could	O
be	O
used	O
in	O
brief	O
patient	O
consultations	O
on	O
problem	O
drinking	O
.	O

METHODS	O
Thirty	O
health	O
care	O
practitioners	O
participated	O
in	O
a	O
clinical	O
trial	O
using	O
a	O
20-minute	O
videotape	O
to	O
instruct	O
them	O
in	O
motivational	O
interviewing	O
.	O

Participants	O
engaged	O
in	O
a	O
pretest	O
roleplay	O
with	O
an	O
actress	O
playing	O
a	O
drinking	O
pregnant	O
woman	O
.	O

Those	O
randomly	O
assigned	O
to	O
the	O
experimental	O
condition	O
watched	O
the	O
motivational	O
interviewing	O
videotape	O
.	O

Control	O
condition	O
participants	O
watched	O
a	O
20-minute	O
docudrama	O
of	O
a	O
pregnant	O
problem	O
drinker	O
.	O

Both	O
groups	O
then	O
engaged	O
in	O
a	O
post-test	O
roleplay	O
similar	O
to	O
the	O
pretest	O
.	O

Behavioral	Mental
ratings	Mental
of	Mental
the	Mental
roleplays	Mental
and	O
participant	Mental
evaluations	Mental
of	Mental
the	Mental
motivational	Mental
interviewing	Mental
video	Mental
constituted	O
the	O
outcome	O
measures	O
.	O

RESULTS	O
Participant	O
evaluations	O
indicated	O
that	O
the	O
training	O
video	O
was	O
clear	O
in	O
explaining	O
and	O
demonstrating	O
the	O
principles	O
and	O
skills	O
of	O
motivational	O
interviewing	O
.	O

Change	O
in	O
behavioral	O
ratings	O
from	O
pretest	O
to	O
post-test	O
showed	O
significant	O
differences	O
in	O
motivational	O
interviewing	O
skills	O
between	O
the	O
experimental	O
and	O
control	O
groups	O
.	O

Obstetric	O
care	O
practitioners	O
who	O
viewed	O
the	O
training	O
video	O
were	O
rated	O
as	O
showing	O
greater	O
empathy	Mental
,	O
minimizing	O
patient	Mental
defensiveness	Mental
,	O
and	O
supporting	Mental
women	Mental
's	Mental
beliefs	Mental
in	Mental
their	Mental
ability	Mental
to	Mental
change	Mental
.	O

CONCLUSION	O
Obstetric	O
care	O
practitioners	O
can	O
improve	O
their	O
alcohol	O
intervention	O
skills	O
through	O
the	O
use	O
of	O
a	O
20-minute	O
videotaped	O
instruction	O
in	O
motivational	O
interviewing	O
.	O

Clinicians	O
who	O
improve	O
their	O
skills	O
in	O
motivational	O
interviewing	O
can	O
intervene	O
more	O
effectively	O
with	O
their	O
drinking	O
pregnant	O
patients	O
.	O

Using	O
motivational	O
interviewing	O
with	O
this	O
population	O
holds	O
promise	O
for	O
helping	O
prevent	O
alcohol-related	O
health	O
problems	O
.	O

Adult	O
height	O
in	O
short	O
children	O
born	O
SGA	O
treated	O
with	O
growth	O
hormone	O
and	O
gonadotropin	O
releasing	O
hormone	O
analog	O
:	O
results	O
of	O
a	O
randomized	O
,	O
dose-response	O
GH	O
trial	O
.	O

CONTEXT	O
GH	O
treatment	O
is	O
effective	O
in	O
improving	O
height	O
in	O
short	O
children	O
born	O
small	O
for	O
gestational	O
age	O
(	O
SGA	O
)	O
.	O

GH	O
is	O
thought	O
to	O
have	O
limited	O
effect	O
when	O
started	O
during	O
adolescence	O
.	O

OBJECTIVE	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
GH	O
treatment	O
efficacy	Others
in	O
short	O
SGA	O
children	O
when	O
treatment	O
was	O
started	O
during	O
adolescence	O
;	O
to	O
assess	O
whether	O
GH	O
2	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
during	O
puberty	O
improves	O
adult	O
height	O
(	O
AH	O
)	O
compared	O
with	O
1	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
;	O
and	O
to	O
assess	O
whether	O
an	O
additional	O
2-yr	O
postponement	O
of	O
puberty	O
by	O
GnRH	O
analog	O
(	O
GnRHa	O
)	O
improves	O
AH	O
in	O
children	O
who	O
are	O
short	O
at	O
the	O
start	O
of	O
puberty	O
(	O
<	O
140	O
cm	O
)	O
,	O
with	O
a	O
poor	O
AH	O
expectation	O
.	O

PATIENTS	O
AND	O
DESIGN	O
In	O
this	O
longitudinal	O
,	O
randomized	O
,	O
dose-response	O
GH	O
trial	O
,	O
we	O
included	O
121	O
short	O
SGA	O
children	O
(	O
60	O
boys	O
)	O
at	O
least	O
8	O
yr	O
of	O
age	O
.	O

We	O
performed	O
intention-to-treat	O
analyses	O
on	O
all	O
children	O
and	O
uncensored	O
case	O
analyses	O
on	O
84	O
children	O
who	O
reached	O
AH	O
.	O

Besides	O
,	O
we	O
evaluated	O
growth	O
during	O
2	O
yr	O
of	O
combined	O
GH/GnRHa	O
and	O
subsequent	O
GH	O
treatment	O
until	O
AH	O
in	O
a	O
subgroup	O
of	O
40	O
pubertal	O
children	O
with	O
a	O
height	O
of	O
less	O
than	O
140	O
cm	O
at	O
the	O
start	O
.	O

RESULTS	O
Short	O
SGA	O
children	O
started	O
treatment	O
at	O
a	O
median	O
age	O
of	O
11.2	O
yr	O
,	O
when	O
46	O
%	O
had	O
already	O
started	O
puberty	O
.	O

Median	O
height	O
increased	O
from	O
-2.9	O
at	O
start	O
to	O
-1.7	O
sd	O
score	O
(	O
SDS	O
)	O
at	O
AH	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Treatment	O
with	O
GH	O
2	O
vs.	O
1	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
during	O
puberty	O
resulted	O
in	O
significantly	O
better	O
AH	O
(	O
P	O
=	O
0.001	O
)	O
,	O
also	O
after	O
correction	O
for	O
gender	O
,	O
age	O
at	O
start	O
,	O
height	O
SDS	O
at	O
start	O
,	O
treatment	O
years	O
before	O
puberty	O
,	O
and	O
target	O
height	O
SDS	O
.	O

AH	O
was	O
similar	O
in	O
children	O
who	O
started	O
puberty	O
at	O
less	O
than	O
140	O
cm	O
and	O
received	O
GH/GnRHa	O
,	O
compared	O
with	O
children	O
who	O
started	O
puberty	O
greater	O
than	O
140	O
cm	O
and	O
received	O
GH	O
only	O
(	O
P	O
=	O
0.795	O
)	O
.	O

CONCLUSION	O
When	O
started	O
in	O
adolescence	O
,	O
GH	O
treatment	O
significantly	O
improves	O
AH	O
in	O
short	O
SGA	O
children	O
,	O
particularly	O
with	O
GH	O
2	O
mg/m	O
(	O
2	O
)	O
?	O
d	O
during	O
puberty	O
.	O

When	O
SGA	O
children	O
are	O
short	O
at	O
the	O
start	O
of	O
puberty	O
,	O
they	O
can	O
benefit	O
from	O
combined	O
GH/GnRHa	O
treatment	O
.	O

Control	O
of	O
perioperative	O
hypertension	Physical
during	O
coronary	O
artery	O
surgery	O
.	O

A	O
randomised	O
double-blind	O
study	O
comparing	O
isosorbide	O
dinitrate	O
and	O
nitroglycerin	O
.	O

A	O
reduction	O
in	O
the	O
causes	O
of	O
myocardial	Physical
ischaemia	Physical
remains	O
of	O
prime	O
importance	O
during	O
coronary	O
artery	O
surgery	O
.	O

Hypertension	Physical
with	O
the	O
ensuing	O
increase	O
in	O
myocardial	Physical
oxygen	Physical
demand	Physical
is	O
a	O
major	O
factor	O
in	O
the	O
aetiology	O
of	O
perioperative	O
myocardial	Physical
ischaemia	Physical
.	O

Nitroglycerin	O
(	O
NTG	O
)	O
has	O
long	O
been	O
used	O
beneficially	O
to	O
reduce	O
myocardial	Physical
oxygen	Physical
demand	Physical
by	O
its	O
effects	O
on	O
the	O
systemic	O
and	O
peripheral	O
vascular	O
resistances	O
.	O

An	O
alternative	O
nitrate	O
,	O
isosorbide	O
dinitrate	O
(	O
ISDN	O
)	O
is	O
now	O
available	O
as	O
an	O
intravenous	O
preparation	O
,	O
and	O
may	O
offer	O
technical	O
advantages	O
,	O
both	O
due	O
to	O
its	O
stability	O
in	O
solution	O
and	O
also	O
its	O
longer	O
in	O
vivo	O
half-life	O
.	O

We	O
designed	O
and	O
carried	O
out	O
a	O
multi-centre	O
study	O
to	O
compare	O
and	O
evaluate	O
the	O
efficacy	Others
of	Others
ISDN	Others
and	Others
NTG	Others
in	O
the	O
management	O
of	O
perioperative	O
hypertension	O
in	O
85	O
patients	O
undergoing	O
elective	O
coronary	O
artery	O
surgery	O
.	O

A	O
total	O
of	O
288	O
events	O
in	O
which	O
the	O
systolic	Physical
blood	Physical
pressure	Physical
(	Physical
SBP	Physical
)	Physical
exceeded	O
a	O
predetermined	O
trigger	O
value	O
were	O
observed	O
.	O

ISDN	O
was	O
successful	Others
in	O
treating	O
hypertension	Physical
in	O
63	O
%	O
of	O
the	O
events	O
,	O
whereas	O
NTG	O
had	O
an	O
83	O
%	O
success	O
.	O

The	O
SBP	Physical
was	O
significantly	O
lowered	O
after	O
treatment	O
with	O
either	O
ISDN	O
,	O
155	O
mmHg	O
to	O
138	O
mmHg	O
,	O
or	O
NTG	O
,	O
160	O
mmHg	O
to	O
130	O
mmHg	O
.	O

The	O
mean	Others
successful	Others
dose	Others
rate	Others
for	O
ISDN	O
was	O
6.5	O
micrograms	O
kg-1	O
min-1	O
,	O
whereas	O
for	O
NTG	O
this	O
was	O
3.8	O
micrograms	O
kg-1	O
min-1	O
.	O

In	O
the	O
ISDN	O
group	O
less	O
events	Physical
took	O
place	O
possibly	O
due	O
to	O
the	O
longer	O
duration	O
of	O
this	O
drug	O
.	O

In	O
many	O
previous	O
studies	O
NTG	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
controlling	O
hypertension	Physical
;	O
ISDN	O
offers	O
and	O
alternative	O
approach	O
in	O
reducing	Physical
hypertension	Physical
.	O

Topical	O
retapamulin	O
ointment	O
(	O
1	O
%	O
,	O
wt/wt	O
)	O
twice	O
daily	O
for	O
5	O
days	O
versus	O
oral	O
cephalexin	O
twice	O
daily	O
for	O
10	O
days	O
in	O
the	O
treatment	O
of	O
secondarily	O
infected	O
dermatitis	O
:	O
results	O
of	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
New	O
antibacterial	O
agents	O
with	O
activity	O
against	O
pathogenic	O
strains	O
resistant	O
to	O
established	O
antibiotics	O
are	O
needed	O
to	O
treat	O
patients	O
with	O
secondarily	O
infected	O
dermatitis	O
(	O
SID	O
)	O
.	O

OBJECTIVE	O
We	O
sought	O
to	O
determine	O
the	O
clinical	O
safety	O
and	O
efficacy	O
of	O
topical	O
retapamulin	O
ointment	O
1	O
%	O
versus	O
oral	O
cephalexin	O
for	O
the	O
treatment	O
of	O
SID	O
.	O

METHODS	O
Patients	O
with	O
SID	O
were	O
randomly	O
assigned	O
to	O
retapamulin	O
ointment	O
1	O
%	O
(	O
twice	O
daily	O
[	O
bid	O
]	O
)	O
for	O
5	O
days	O
,	O
or	O
oral	O
cephalexin	O
(	O
500	O
mg	O
bid	O
)	O
for	O
10	O
days	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
clinical	Physical
response	Physical
at	O
follow-up	O
.	O

Secondary	O
outcomes	O
included	O
microbiologic	Physical
response	Physical
at	O
follow-up	O
,	O
safety	Others
,	O
and	O
compliance	Mental
.	Mental

RESULTS	O
Retapamulin	O
was	O
as	O
effective	O
as	O
cephalexin	O
(	O
clinical	O
success	O
rates	O
at	O
follow-up	O
:	O
85.9	O
%	O
and	O
89.7	O
%	O
,	O
respectively	O
)	O
.	O

Microbiologic	Physical
success	Physical
rates	Physical
at	O
follow-up	O
were	O
87.2	O
%	O
for	O
retapamulin	O
and	O
91.8	O
%	O
for	O
cephalexin	O
.	O

Retapamulin	O
was	O
well	O
tolerated	Others
and	O
the	O
topical	O
formulation	O
was	O
preferred	O
over	O
the	O
oral	O
drug	O
.	O

LIMITATIONS	O
An	O
imbalance	O
existed	O
in	O
the	O
number	O
of	O
patients	O
with	O
the	O
clinical	O
outcome	O
unable	O
to	O
determine	O
(	O
15	O
retapamulin	O
,	O
2	O
cephalexin	O
)	O
,	O
mainly	O
because	O
of	O
their	O
failure	O
to	O
attend	O
the	O
study	O
visit	O
.	O

If	O
those	O
who	O
failed	O
to	O
attend	O
visits	O
(	O
who	O
did	O
not	O
withdraw	O
as	O
a	O
result	O
of	O
drug-related	O
events	O
)	O
are	O
removed	O
from	O
the	O
analysis	O
,	O
the	O
clinical	O
success	O
rates	O
are	O
89.9	O
%	O
for	O
retapamulin	O
and	O
89.7	O
%	O
for	O
cephalexin	O
.	O

CONCLUSIONS	O
Retapamulin	O
ointment	O
1	O
%	O
(	O
bid	O
)	O
for	O
5	O
days	O
was	O
as	O
effective	O
as	O
oral	O
cephalexin	O
(	O
bid	O
)	O
for	O
10	O
days	O
in	O
treatment	O
of	O
patients	O
with	O
SID	O
,	O
and	O
was	O
well	O
tolerated	O
.	O

Aerobic	O
exercise	O
improves	O
self-reported	Mental
sleep	Mental
and	O
quality	Others
of	Others
life	Others
in	O
older	O
adults	O
with	O
insomnia	O
.	O

OBJECTIVE	O
To	O
assess	O
the	O
efficacy	Others
of	O
moderate	O
aerobic	O
physical	O
activity	O
with	O
sleep	O
hygiene	O
education	O
to	O
improve	Mental
sleep	Mental
,	Mental
mood	Mental
and	O
quality	Physical
of	Physical
life	Physical
in	O
older	O
adults	O
with	O
chronic	O
insomnia	O
.	O

METHODS	O
Seventeen	O
sedentary	O
adults	O
aged	O
>	O
or=55	O
years	O
with	O
insomnia	O
(	O
mean	O
age	O
61.6	O
[	O
SD?4.3	O
]	O
years	O
;	O
16	O
female	O
)	O
participated	O
in	O
a	O
randomized	O
controlled	O
trial	O
comparing	O
16	O
weeks	O
of	O
aerobic	O
physical	O
activity	O
plus	O
sleep	O
hygiene	O
to	O
non-physical	O
activity	O
plus	O
sleep	O
hygiene	O
.	O

Eligibility	O
included	O
primary	O
insomnia	O
for	O
at	O
least	O
3	O
months	O
,	O
habitual	O
sleep	O
duration	O
<	O
6.5h	O
and	O
a	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
(	O
PSQI	O
)	O
score	O
>	O
5	O
.	O

Outcomes	O
included	O
sleep	O
quality	O
,	O
mood	O
and	O
quality	O
of	O
life	O
questionnaires	O
(	O
PSQI	O
,	O
Epworth	O
Sleepiness	O
Scale	O
[	O
ESS	O
]	O
,	O
Short-form	O
36	O
[	O
SF-36	O
]	O
,	O
Center	O
for	O
Epidemiological	O
Studies	O
Depression	O
Scale	O
[	O
CES-D	O
]	O
)	O
.	O

RESULTS	O
The	O
physical	O
activity	O
group	O
improved	O
in	O
sleep	O
quality	O
on	O
the	O
global	O
PSQI	O
(	O
p	O
<	O
.0001	O
)	O
,	O
sleep	O
latency	O
(	O
p=.049	O
)	O
,	O
sleep	O
duration	O
(	O
p=.04	O
)	O
,	O
daytime	O
dysfunction	O
(	O
p=.027	O
)	O
,	O
and	O
sleep	O
efficiency	O
(	O
p=.036	O
)	O
PSQI	O
sub-scores	O
compared	O
to	O
the	O
control	O
group	O
.	O

The	O
physical	O
activity	O
group	O
also	O
had	O
reductions	O
in	O
depressive	O
symptoms	O
(	O
p=.044	O
)	O
,	O
daytime	O
sleepiness	O
(	O
p=.02	O
)	O
and	O
improvements	O
in	O
vitality	O
(	O
p=.017	O
)	O
compared	O
to	O
baseline	O
scores	O
.	O

CONCLUSION	O
Aerobic	O
physical	O
activity	O
with	O
sleep	O
hygiene	O
education	O
is	O
an	O
effective	O
treatment	O
approach	O
to	O
improve	O
sleep	O
quality	O
,	O
mood	O
and	O
quality	O
of	O
life	O
in	O
older	O
adults	O
with	O
chronic	O
insomnia	O
.	O

Airway	Others
management	Others
training	O
using	O
the	O
laryngeal	O
mask	O
airway	O
:	O
a	O
comparison	O
of	O
two	O
different	O
training	O
programmes	O
.	O

Nurses	O
without	O
prior	O
experience	O
in	O
the	O
use	O
of	O
the	O
laryngeal	O
mask	O
airway	O
(	O
LMA	O
)	O
were	O
randomly	O
allocated	O
to	O
one	O
of	O
two	O
groups	O
to	O
be	O
trained	O
in	O
the	O
emergency	O
technique	O
of	O
insertion	O
of	O
an	O
LMA	O
.	O

Group	O
A	O
(	O
32	O
nurses	O
)	O
were	O
trained	O
only	O
on	O
a	O
manikin	O
and	O
group	O
B	O
(	O
20	O
nurses	O
)	O
were	O
trained	O
on	O
a	O
manikin	O
and	O
with	O
live	O
anaesthetised	O
patient	O
practice	O
in	O
theatre	O
(	O
five	O
successful	O
insertions	O
)	O
.	O

Without	O
further	O
practice	O
,	O
both	O
groups	O
were	O
asked	O
to	O
insert	O
an	O
LMA	O
in	O
a	O
live	O
patient	O
in	O
theatre	O
3	O
months	O
after	O
initial	O
training	O
.	O

Three	O
attempts	O
per	O
nurse	O
were	O
allowed	O
.	O

In	O
group	O
A	O
,	O
75	O
%	O
passed	O
the	O
LMA	Others
successfully	Others
at	O
the	O
first	O
attempt	O
,	O
22	O
%	O
at	O
the	O
second	O
attempt	O
and	O
3	O
%	O
(	O
one	O
nurse	O
)	O
at	O
the	O
third	O
attempt	O
.	O

In	O
group	O
B	O
,	O
80	O
%	O
were	O
successful	Mental
at	O
first	O
attempt	O
and	O
20	O
%	O
at	O
the	O
second	O
attempt	O
.	O

Skill	Mental
performance	Mental
and	Mental
retention	Mental
were	O
shown	O
to	O
be	O
high	O
following	O
either	O
training	O
method	O
,	O
with	O
no	O
significant	O
difference	O
between	O
the	O
performance	Mental
of	O
either	O
group	O
(	O
chi	O
2	O
)	O
.	O

We	O
have	O
shown	O
that	O
manikin-only	O
training	O
in	O
the	O
emergency	O
technique	O
for	O
LMA	O
insertion	O
is	O
as	O
effective	Others
as	O
live	O
patient	O
training	O
.	O

It	O
is	O
proposed	O
that	O
manikin	O
training	O
alone	O
may	O
be	O
adopted	O
as	O
a	O
future	O
training	O
modality	O
if	O
,	O
as	O
is	O
expected	O
,	O
the	O
use	O
of	O
the	O
LMA	O
in	O
resuscitation	O
becomes	O
more	O
commonplace	O
.	O

The	O
effects	O
of	O
face	O
expertise	O
training	O
on	O
the	Mental
behavioral	Mental
performance	Mental
and	O
brain	Mental
activity	Mental
of	O
adults	O
with	O
high	O
functioning	O
autism	O
spectrum	O
disorders	O
.	O

The	O
effect	O
of	O
expertise	O
training	O
with	O
faces	O
was	O
studied	O
in	O
adults	O
with	O
ASD	O
who	O
showed	O
initial	O
impairment	O
in	O
face	O
recognition	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
a	O
computerized	O
training	O
program	O
involving	O
either	O
faces	O
or	O
houses	O
.	O

Pre-	O
and	O
post-testing	O
included	O
standardized	O
and	O
experimental	O
measures	O
of	O
behavior	Mental
and	Mental
event-related	Mental
brain	Mental
potentials	Mental
(	Mental
ERPs	Mental
)	O
,	O
as	O
well	O
as	O
interviews	Mental
after	O
training	O
.	O

After	O
training	O
,	O
all	O
participants	O
met	O
behavioral	Mental
criteria	Mental
for	O
expertise	O
with	O
the	O
specific	O
stimuli	O
on	O
which	O
they	O
received	O
training	O
.	O

Scores	Mental
on	Mental
standardized	Mental
measures	Mental
improved	O
after	O
training	O
for	O
both	O
groups	O
,	O
but	O
only	O
the	O
face	O
training	O
group	O
showed	O
an	O
increased	O
face	Mental
inversion	Mental
effect	Mental
behaviorally	Mental
and	Mental
electrophysiological	Mental
changes	Mental
to	Mental
faces	Mental
in	O
the	O
P100	O
component	O
.	O

These	O
findings	O
suggest	O
that	O
individuals	O
with	O
ASD	O
can	O
gain	O
expertise	O
in	O
face	Mental
processing	Mental
through	O
training	O
.	O

Effect	O
of	O
prophylactic	O
amiodarone	O
in	O
patients	O
with	O
rheumatic	O
valve	O
disease	O
undergoing	O
valve	O
replacement	O
surgery	O
.	O

The	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
effect	O
of	O
prophylactic	O
single-dose	O
intravenous	O
amiodarone	O
in	O
patients	O
undergoing	O
valve	O
replacement	O
surgery	O
.	O

Maintenance	O
of	O
sinus	O
rhythm	O
is	O
better	O
than	O
maintenance	O
of	O
fixed	O
ventricular	O
rate	O
in	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
especially	O
in	O
the	O
presence	O
of	O
irritable	O
left	O
or	O
right	O
atrium	O
because	O
of	O
enlargement	O
.	O

Fifty-six	O
patients	O
with	O
valvular	O
heart	O
disease	O
with	O
or	O
without	O
AF	O
were	O
randomly	O
divided	O
into	O
two	O
groups	O
.	O

Group	O
I	O
or	O
the	O
amiodarone	O
group	O
(	O
n=28	O
)	O
received	O
amiodarone	O
(	O
3	O
mg/kg	O
in	O
100	O
ml	O
normal	O
saline	O
)	O
and	O
group	O
II	O
or	O
the	O
control	O
group	O
received	O
same	O
volume	O
of	O
normal	O
saline	O
.	O

The	O
standardized	O
protocol	O
for	O
cardiopulmonary	O
bypass	O
was	O
maintained	O
for	O
all	O
the	O
patients	O
.	O

AF	Physical
occurred	O
in	O
7.14	O
%	O
patients	O
in	O
group	O
I	O
,	O
and	O
in	O
group	O
II	O
,	O
28.57	O
%	O
(	O
P=0.035	O
)	O
;	O
ventricular	Physical
tachycardia/fibrillation	Physical
was	O
observed	O
in	O
21.43	O
%	O
patients	O
in	O
group	O
I	O
and	O
46.43	O
%	O
patients	O
in	O
group	O
II	O
(	O
P=0.089	O
)	O
after	O
release	O
of	O
aortic	O
clamp	O
.	O

Most	O
of	O
the	O
patients	O
in	O
group	O
I	O
(	O
92.86	O
%	O
)	O
maintained	O
sinus	Physical
rhythm	Physical
without	Physical
cardioversion	Physical
or	Physical
defibrillation	Physical
after	O
release	O
of	O
aortic	O
cross	O
clamp	O
(	O
P=0.002	O
)	O
.	O

Defibrillation	Physical
or	Physical
cardio	Physical
version	Physical
was	O
needed	O
in	O
7.14	O
%	O
patients	O
in	O
group	O
I	O
and	O
28.57	O
%	O
patients	O
in	O
group	O
II	O
(	O
P=0.078	O
)	O
.	O

A	O
single	O
prophylactic	O
intraoperative	O
dose	O
of	O
intravenous	O
amiodarone	O
decreased	O
post	Physical
bypass	Physical
arrhythmia	Physical
in	O
this	O
study	O
in	O
comparison	O
to	O
the	O
control	O
group	O
.	O

Single	O
dose	O
of	O
intraoperative	O
amiodarone	O
may	O
be	O
used	O
to	O
decrease	O
postoperative	O
arrhythmia	O
in	O
open	O
heart	O
surgery	O
.	O

Reduction	Physical
of	Physical
oral	Physical
mucositis	Physical
by	O
filgrastim	O
(	O
r-metHuG-CSF	O
)	O
in	O
patients	O
receiving	O
chemotherapy	O
.	O

Mucositis	Physical
,	O
the	O
inflammation	O
and	O
necrosis	O
of	O
mucosal	O
membranes	O
,	O
is	O
a	O
serious	O
and	O
debilitating	O
consequence	O
of	O
many	O
cancer	O
therapies	O
.	O

We	O
were	O
interested	O
in	O
the	O
potential	O
role	O
of	O
filgrastim	O
(	O
recombinant	O
methionyl	O
human	O
granulocyte	O
colony-stimulating	O
factor	O
,	O
r-metHuG-CSF	O
)	O
in	O
the	O
reduction	Physical
of	Physical
mucositis	Physical
.	Physical

Patients	O
with	O
newly	O
diagnosed	O
small-cell	O
lung	O
cancer	O
(	O
SCLC	O
)	O
were	O
treated	O
with	O
CAE	O
chemotherapy	O
(	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
etoposide	O
)	O
and	O
placebo	O
or	O
filgrastim	O
.	O

If	O
patients	O
had	O
an	O
episode	O
of	O
febrile	O
neutropenia	O
,	O
they	O
received	O
unblinded	O
filgrastim	O
in	O
subsequent	O
CAE	O
cycles	O
.	O

Oral	Physical
mucositis	Physical
was	O
considered	O
to	O
have	O
occurred	O
if	O
a	O
patient	O
reported	O
any	O
clinical	O
sign	O
or	O
symptom	Physical
of	Physical
oral	Physical
mucositis	Physical
with	Physical
or	Physical
without	Physical
oral	Physical
candidiasis	Physical
.	Physical

Oral	Physical
mucositis	Physical
was	O
analyzed	O
using	O
the	O
unadjusted	O
chi-square	O
test	O
,	O
and	O
time	Physical
to	Physical
first	Physical
episode	Physical
of	Physical
mucositis	Physical
was	O
analyzed	O
using	O
the	O
stratified	O
log-rank	O
test	O
as	O
well	O
as	O
the	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
.	O

During	O
cycle	O
1	O
,	O
placebo-treated	O
patients	O
had	O
more	O
episodes	O
of	O
mucositis	Physical
(	O
47	O
%	O
)	O
compared	O
with	O
those	O
patients	O
randomized	O
to	O
filgrastim	O
(	O
28	O
%	O
)	O
.	O

Across	O
all	O
cycles	O
of	O
treatment	O
,	O
70	O
%	O
of	O
placebo-treated	O
patients	O
experienced	O
mucositis	Physical
,	O
compared	O
with	O
53	O
%	O
of	O
patients	O
randomized	O
to	O
filgrastim	O
.	O

A	O
significant	O
reduction	O
in	O
the	O
incidence	O
of	O
chemotherapy-related	O
oral	Physical
mucositis	Physical
occurred	O
across	O
multiple	O
cycles	O
of	O
treatment	O
in	O
patients	O
treated	O
with	O
filgrastim	O
.	O

Use	O
of	O
recombinant	O
human	O
granulocyte	O
colony-stimulating	O
factor	O
to	O
increase	O
chemotherapy	O
dose-intensity	O
:	O
a	O
randomized	O
trial	O
in	O
very	O
high-risk	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
.	O

PURPOSE	O
To	O
determine	O
whether	O
the	O
use	O
of	O
a	O
recombinant	O
human	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
[	O
G-CSF	O
]	O
lenogastrim	O
)	O
can	O
increase	O
the	O
chemotherapy	O
dose-intensity	O
(	O
CDI	O
)	O
delivered	O
during	O
consolidation	O
chemotherapy	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
Sixty-seven	O
children	O
with	O
very	O
high-risk	O
ALL	O
were	O
randomized	O
(	O
slow	O
early	O
response	O
to	O
therapy	O
,	O
55	O
patients	O
;	O
translocation	O
t	O
(	O
9	O
;	O
22	O
)	O
or	O
t	O
(	O
4	O
;	O
11	O
)	O
,	O
12	O
patients	O
)	O
.	O

Consolidation	O
consisted	O
of	O
six	O
courses	O
of	O
chemotherapy	O
;	O
the	O
first	O
,	O
third	O
,	O
and	O
fifth	O
courses	O
were	O
a	O
combination	O
of	O
high-dose	O
cytarabine	O
,	O
etoposide	O
,	O
and	O
dexamethasone	O
(	O
R3	O
)	O
,	O
whereas	O
the	O
second	O
,	O
fourth	O
,	O
and	O
sixth	O
courses	O
included	O
vincristine	O
,	O
prednisone	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
methotrexate	O
(	O
COPADM	O
)	O
.	O

G-CSF	O
was	O
given	O
after	O
each	O
course	O
,	O
and	O
the	O
next	O
scheduled	O
course	O
was	O
started	O
as	O
soon	O
as	O
neutrophil	O
count	O
was	O
>	O
1	O
x	O
10	O
(	O
9	O
)	O
/L	O
and	O
platelet	O
count	O
was	O
>	O
100	O
x	O
10	O
(	O
9	O
)	O
/L	O
.	O

CDI	Physical
was	O
calculated	O
using	O
the	O
interval	O
from	O
day	O
1	O
of	O
the	O
first	O
course	O
to	O
hematologic	O
recovery	O
after	O
the	O
fifth	O
course	O
(	O
100	O
%	O
CDI	O
=	O
105-day	O
interval	O
)	O
.	O

RESULTS	O
CDI	Physical
was	O
significantly	O
increased	Physical
in	O
the	O
G-CSF	O
group	O
compared	O
with	O
the	O
non-G-CSF	O
group	O
(	O
mean	O
+/-	O
95	O
%	O
confidence	O
interval	O
,	O
105	O
+/-	O
5	O
%	O
v	O
91	O
+/-	O
4	O
%	O
;	O
P	O
<	O
.001	O
)	O
.	O

This	O
higher	Physical
intensity	Physical
was	O
a	O
result	O
of	O
shorter	O
post-R3	Physical
intervals	Physical
in	O
the	O
G-CSF	O
group	O
,	O
whereas	O
the	O
post-COPADM	O
intervals	O
were	O
not	O
statistically	O
reduced	O
.	O

After	O
the	O
R3	O
courses	O
,	O
the	O
number	Others
of	Others
days	Others
with	Others
fever	Others
and	Others
intravenous	Others
antibiotics	Others
and	Others
duration	Others
of	Others
hospitalization	Others
were	Others
significantly	Others
decreased	Others
by	O
G-CSF	O
,	O
whereas	O
reductions	O
observed	O
after	O
COPADM	O
were	O
not	O
statistically	O
significant	O
.	O

Duration	Physical
of	Physical
granulocytopenia	Physical
was	Physical
reduced	Physical
in	O
the	O
G-CSF	O
group	O
,	O
but	O
thrombocytopenia	Physical
was	O
prolonged	O
,	O
and	O
the	O
number	Physical
of	Physical
platelet	Physical
transfusions	Physical
was	O
increased	O
.	O

Finally	O
,	O
the	O
3-year	O
probability	O
of	O
event-free	Mortality
survival	Mortality
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
G-CSF	O
can	O
increase	O
CDI	O
in	O
high-risk	O
childhood	O
ALL	O
.	O

Its	O
effects	O
depend	O
on	O
the	O
chemotherapy	O
regimen	O
given	O
before	O
G-CSF	O
administration	O
.	O

In	O
our	O
study	O
,	O
a	O
higher	O
CDI	O
did	O
not	O
improve	O
disease	O
control	O
.	O

An	O
open	O
,	O
parallel	O
group	O
comparison	O
of	O
quinapril	O
and	O
captopril	O
,	O
when	O
added	O
to	O
diuretic	O
therapy	O
,	O
in	O
the	O
treatment	O
of	O
elderly	O
patients	O
with	O
heart	O
failure	O
.	O

This	O
study	O
aimed	O
to	O
compare	O
the	O
efficacy	Others
,	Others
tolerability	Others
and	Others
first-dose	Others
blood-pressure	Others
response	Others
of	O
once-daily	O
quinapril	O
and	O
twice-daily	O
captopril	O
when	O
added	O
to	O
diuretic	O
therapy	O
in	O
elderly	O
patients	O
with	O
heart	O
failure	O
.	O

The	O
study	O
was	O
performed	O
at	O
a	O
single	O
centre	O
as	O
an	O
open	O
randomised	O
parallel-group	O
study	O
,	O
patients	O
being	O
selected	O
for	O
inclusion	O
from	O
the	O
outpatient	O
population	O
.	O

Following	O
a	O
starting	O
dose	O
of	O
either	O
2.5	O
mg	O
once-daily	O
quinapril	O
,	O
or	O
6.25	O
mg	O
twice-daily	O
captopril	O
,	O
patients	O
were	O
reviewed	O
at	O
two-weekly	O
intervals	O
,	O
and	O
following	O
clinical	O
assessment	O
a	O
decision	O
was	O
made	O
either	O
to	O
titrate	O
up	O
to	O
the	O
next	O
medication	O
stage	O
or	O
to	O
enter	O
the	O
patient	O
into	O
the	O
16-week	O
maintenance	O
phase	O
.	O

Efficacy	Others
was	O
assessed	Others
using	O
a	O
six-minute	Others
walking	Others
test	Others
,	Others
the	Others
New	Others
York	Others
Heart	Others
Association	Others
(	Others
NYHA	Others
)	Others
class	Others
,	Others
a	Others
functional	Others
lifescale	Others
(	Others
FLS	Others
)	Others
questionnaire	Others
and	Others
the	Others
cardiothoracic	Others
ratio	Others
(	Others
CTR	Others
)	Others
-at	Others
study	Others
entry	Others
and	Others
at	Others
the	Others
end	Others
of	Others
the	Others
maintenance	Others
phase	Others
.	Others

Blood	Physical
pressure	Physical
was	O
measured	O
for	O
5	O
h	O
post-first-dose	O
of	O
medication	O
.	O

Sixty-one	O
patients	O
were	O
randomised	O
to	O
treatment	O
:	O
30	O
to	O
quinapril	O
and	O
31	O
to	O
captopril	O
.	O

Following	O
withdrawals	O
,	O
data	O
from	O
36	O
patients	O
(	O
20	O
on	O
quinapril	O
,	O
16	O
on	O
captopril	O
)	O
were	O
available	O
for	O
analysis	O
.	O

The	O
distance	Physical
walked	Physical
during	Physical
the	Physical
six-minute	Physical
walking	Physical
test	Physical
improved	Physical
in	O
both	O
groups	O
;	O
the	O
difference	O
between	O
the	O
treatment	O
groups	O
was	O
not	O
statistically	Others
significant	Others
.	Others

There	O
were	O
no	O
significant	O
changes	O
in	O
the	O
FLS	Physical
or	Physical
CTR	Physical
.	O

An	O
analysis	O
of	O
change	O
in	O
the	O
NYHA	O
status	O
from	O
study	O
entry	O
to	O
study	O
end	O
showed	O
a	O
statistically	Others
significant	Others
difference	Others
between	O
the	O
two	O
groups	O
(	O
p	O
=	O
0.02	O
)	O
in	O
favour	O
of	O
quinapril	O
.	O

Five	O
patients	O
in	O
each	O
group	O
experienced	O
hypotension	Physical
during	O
the	O
5	O
h	O
following	O
the	O
first	O
dose	O
of	O
medication	O
.	O

This	O
study	O
has	O
shown	O
heart	O
failure	O
to	O
be	O
as	O
well	O
controlled	O
by	O
once-daily	O
quinapril	O
as	O
by	O
twice-daily	O
captopril	O
,	O
with	O
comparable	O
effects	O
on	O
first-dose	Physical
blood-pressure	Physical
response	Physical
.	Others

Effect	O
of	O
developmental	O
speech	O
and	O
language	O
training	O
through	O
music	O
on	O
speech	Mental
production	Mental
in	O
children	O
with	O
autism	O
spectrum	O
disorders	O
.	O

The	O
study	O
compared	O
the	O
effect	O
of	O
music	O
training	O
,	O
speech	O
training	O
and	O
no-training	O
on	O
the	O
verbal	O
production	O
of	O
children	O
with	O
Autism	O
Spectrum	O
Disorders	O
(	O
ASD	O
)	O
.	O

Participants	O
were	O
50	O
children	O
with	O
ASD	O
,	O
age	O
range	O
3	O
to	O
5	O
years	O
,	O
who	O
had	O
previously	O
been	O
evaluated	O
on	O
standard	O
tests	O
of	O
language	O
and	O
level	O
of	O
functioning	O
.	O

They	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
3-day	O
conditions	O
.	O

Participants	O
in	O
music	O
training	O
(	O
n	O
=	O
18	O
)	O
watched	O
a	O
music	O
video	O
containing	O
6	O
songs	O
and	O
pictures	O
of	O
the	O
36	O
target	O
words	O
;	O
those	O
in	O
speech	O
training	O
(	O
n	O
=	O
18	O
)	O
watched	O
a	O
speech	O
video	O
containing	O
6	O
stories	O
and	O
pictures	O
,	O
and	O
those	O
in	O
the	O
control	O
condition	O
(	O
n	O
=	O
14	O
)	O
received	O
no	O
treatment	O
.	O

Participants	O
'	O
verbal	O
production	O
including	O
semantics	O
,	O
phonology	O
,	O
pragmatics	O
,	O
and	O
prosody	O
was	O
measured	O
by	O
an	O
experimenter	O
designed	O
verbal	O
production	O
evaluation	O
scale	O
.	O

Results	O
showed	O
that	O
participants	O
in	O
both	O
music	O
and	O
speech	O
training	O
significantly	O
increased	O
their	O
pre	Mental
to	Mental
posttest	Mental
verbal	Mental
production	Mental
.	Mental

Results	O
also	O
indicated	O
that	O
both	O
high	O
and	O
low	O
functioning	O
participants	O
improved	O
their	O
speech	Mental
production	Mental
after	O
receiving	O
either	O
music	O
or	O
speech	O
training	O
;	O
however	O
,	O
low	O
functioning	O
participants	O
showed	O
a	O
greater	O
improvement	Others
after	O
the	O
music	O
training	O
than	O
the	O
speech	O
training	O
.	O

Children	O
with	O
ASD	O
perceive	O
important	O
linguistic	O
information	O
embedded	O
in	O
music	O
stimuli	O
organized	O
by	O
principles	O
of	O
pattern	O
perception	O
,	O
and	O
produce	O
the	O
functional	O
speech	O
.	O

Adjuvant	O
goserelin	O
and	O
ovarian	O
preservation	O
in	O
chemotherapy	O
treated	O
patients	O
with	O
early	O
breast	O
cancer	O
:	O
results	O
from	O
a	O
randomized	O
trial	O
.	O

The	O
purpose	O
of	O
this	O
randomized	O
study	O
was	O
to	O
examine	O
if	O
goserelin	O
concomitant	O
to	O
CMF-chemotherapy	O
as	O
adjuvant	O
treatment	O
for	O
premenopausal	O
breast	O
cancer	O
,	O
protects	Mental
the	Mental
ovaries	Mental
from	O
premature	O
failure	O
.	O

A	O
total	O
of	O
285	O
premenopausal	O
breast	O
cancer	O
patients	O
,	O
in	O
a	O
randomized	O
adjuvant	O
trial	O
(	O
Zoladex	O
in	O
premenopausal	O
patients	O
(	O
ZIPP	O
)	O
)	O
,	O
were	O
assigned	O
to	O
a	O
study	O
on	O
ovarian	O
function	O
.	O

Node	O
positive	O
patients	O
were	O
assigned	O
to	O
CMF-	O
(	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
5-fluorouracil	O
)	O
chemotherapy	O
in	O
addition	O
to	O
endocrine	O
therapy	O
.	O

All	O
patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
2	O
years	O
of	O
goserelin	O
,	O
goserelin	O
plus	O
tamoxifen	O
,	O
tamoxifen	O
alone	O
or	O
no	O
endocrine	O
treatment	O
.	O

We	O
studied	O
,	O
if	O
menses	Pain
were	O
affected	O
in	O
the	O
treatment	O
groups	O
,	O
up	O
to	O
36	O
months	O
after	O
randomization	O
.	O

One	O
year	O
after	O
completed	O
CMF-	O
and	O
endocrine	O
therapy	O
,	O
36	O
%	O
of	O
the	O
women	O
in	O
the	O
goserelin	O
group	O
reported	O
menses	Physical
,	O
compared	O
to	O
7	O
%	O
in	O
the	O
goserelin	O
plus	O
tamoxifen	O
group	O
,	O
13	O
%	O
in	O
the	O
tamoxifen	O
group	O
and	O
10	O
%	O
of	O
the	O
controls	O
.	O

Among	O
women	O
treated	O
with	O
goserelin	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	Physical
in	O
the	O
proportion	Physical
of	Physical
menstruating	Physical
women	Physical
,	O
1	O
year	O
after	O
completed	O
treatment	O
compared	O
to	O
at	O
24	O
months	O
of	O
treatment	O
(	O
P	O
=	O
0.006	O
)	O
,	O
in	O
contrast	O
to	O
all	O
other	O
treatment	O
groups	O
,	O
who	O
were	O
unchanged	O
or	O
more	O
often	O
amenorrheic	Others
.	Others

In	O
our	O
study	O
,	O
there	O
is	O
some	O
evidence	O
of	O
protective	Others
effect	Others
of	Others
goserelin	Others
on	Others
ovarian	Others
function	Others
in	O
CMF	O
treated	O
women	O
.	O

This	O
effect	O
was	O
not	O
observed	O
in	O
the	O
combined	O
tamoxifen	O
and	O
goserelin	O
treatment	O
.	O

Effects	O
of	O
sensory-level	O
high-volt	O
pulsed	O
electrical	O
current	O
ondelayed-onset	Physical
muscle	Physical
soreness	Physical
.	Physical

Ten	O
healthy	O
males	O
and	O
ten	O
healthy	O
females	O
aged	O
21.5	O
+/-	O
3.2	O
years	O
(	O
mean	O
+/-	O
s	O
)	O
participated	O
in	O
the	O
study	O
,	O
which	O
was	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
sensory	O
level-high	O
volt	O
pulsed	O
electrical	O
current	O
(	O
HVPC	O
)	O
on	O
delayed-onset	Physical
muscle	Physical
soreness	Physical
(	Physical
DOMS	Physical
)	Physical
.	O

Arm	O
discomfort	O
,	O
elbow	O
extension	O
range	O
of	O
motion	O
and	O
isometric	O
elbow	O
flexion	O
strength	O
were	O
obtained	O
as	O
baseline	O
measurements	O
.	O

Delayed-onset	Physical
muscle	Physical
soreness	Physical
was	O
induced	O
in	O
the	O
participants	O
'	O
dominant	O
or	O
non-dominant	O
arm	O
using	O
two	O
sets	O
of	O
20	O
maximal	O
eccentric	O
elbow	O
flexion	O
contractions	O
.	O

After	O
the	O
induction	O
of	O
DOMS	Physical
,	O
the	O
participants	O
were	O
randomly	O
divided	O
into	O
an	O
experimental	O
condition	O
(	O
HVPC	O
)	O
or	O
a	O
placebo	O
condition	O
.	O

The	O
experimental	O
condition	O
consisted	O
of	O
20	O
min	O
of	O
HVPC	O
immediately	O
after	O
the	O
induction	O
of	O
DOMS	Physical
,	O
and	O
20	O
min	O
every	O
24	O
h	O
for	O
three	O
consecutive	O
days	O
thereafter	O
.	O

The	O
participants	O
in	O
the	O
placebo	O
condition	O
received	O
an	O
intervention	O
similar	O
in	O
design	O
;	O
however	O
,	O
no	O
electrical	O
current	O
was	O
administered	O
.	O

Baseline	Physical
measurements	Physical
were	O
reevaluated	O
at	O
24	O
,	O
48	O
,	O
72	O
and	O
96	O
h	O
after	O
the	O
induction	O
of	O
DOMS	Physical
.	O

Three	O
weeks	O
later	O
,	O
the	O
participants	O
returned	O
and	O
the	O
protocol	O
was	O
repeated	O
on	O
the	O
contralateral	O
limb	O
,	O
using	O
the	O
opposite	O
intervention	O
(	O
HVPC	O
or	O
placebo	O
)	O
.	O

Repeated-measures	O
analysis	O
of	O
variance	O
revealed	O
a	O
significant	O
increase	O
in	O
overall	Physical
arm	Physical
discomfort	Physical
,	O
decrease	O
in	O
elbow	Physical
extension	Physical
and	O
decrease	O
in	O
isometric	Physical
strength	Physical
for	O
both	Physical
conditions	Physical
over	O
time	O
.	O

No	Physical
significant	Physical
main	Physical
effect	Physical
of	Physical
treatment	Physical
,	O
or	O
time-by-treatment	Others
interaction	Others
,	O
was	O
found	O
for	O
the	O
HVPC	O
condition	O
when	O
compared	O
with	O
the	O
placebo	O
condition	O
for	O
any	O
variable	O
.	O

Sensory-level	O
HVPC	O
,	O
as	O
utilized	O
in	O
our	O
application	O
,	O
was	O
ineffective	O
in	O
reducing	O
the	O
measured	O
variables	O
associated	O
with	O
DOMS	Physical
.	O

Pre-exposure	O
studies	O
with	O
purified	O
chick	O
embryo	O
cell	O
culture	O
rabies	O
vaccine	O
and	O
human	O
diploid	O
cell	O
vaccine	O
:	O
serological	O
and	O
clinical	O
responses	O
in	O
man	O
.	O

Clinical	O
reactions	O
and	O
neutralizing	O
antibody	O
responses	O
to	O
six	O
pre-exposure	O
regimens	O
of	O
purified	O
chick	O
embryo	O
cell	O
culture	O
rabies	O
vaccine	O
(	O
PCECV	O
)	O
and	O
human	O
diploid	O
cell	O
strain	O
rabies	O
vaccine	O
(	O
HDCSV	O
)	O
were	O
studied	O
in	O
177	O
volunteers	O
.	O

Antibody	O
kinetics	O
,	O
height	O
of	O
the	O
response	Physical
and	O
persistence	Physical
of	Physical
antibody	Physical
over	Physical
two	Physical
years	Physical
were	O
virtually	O
identical	O
after	O
PCECV	O
and	O
HDCSV	O
.	O

An	O
antibody	Mental
response	Mental
was	O
detected	O
in	O
all	O
subjects	O
on	O
day	O
14	O
when	O
the	O
highest	O
titres	O
were	O
found	O
after	O
two	O
intramuscular	O
(	O
i.m	O
.	O

)	O
1.0	O
ml	O
doses	O
of	O
a	O
schedule	O
of	O
immunization	O
on	O
days	O
0	O
,	O
7	O
and	O
21	O
.	O

In	O
comparison	O
,	O
a	O
schedule	O
of	O
immunization	O
on	O
days	O
0	O
,	O
28	O
and	O
56	O
ultimately	O
evoked	O
the	O
highest	O
titres	Physical
21	Physical
days	Physical
after	Physical
the	Physical
final	Physical
injection	Physical
,	O
but	O
antibody	O
persisted	O
equally	O
well	O
over	O
two	O
years	O
with	O
either	O
schedule	O
.	O

Neutralizing	Physical
antibody	Physical
titres	Physical
were	O
lower	O
after	O
intradermal	O
(	O
i.d	O
.	O

)	O
vaccination	O
with	O
0.1	O
ml	O
compared	O
to	O
1.0	O
ml	O
i.m	O
.	O

on	O
days	O
0	O
,	O
7	O
and	O
21	O
,	O
but	O
when	O
given	O
on	O
days	O
0	O
,	O
28	O
and	O
56	O
the	O
responses	O
were	O
comparable	O
.	O

Three	O
subjects	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
atopy	O
developed	O
urticarial	Physical
lesions	Physical
after	O
PCECV	O
.	O

Both	O
vaccines	O
were	O
otherwise	O
well	O
tolerated	O
.	O

CDP571	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
to	O
tumour	O
necrosis	O
factor-alpha	O
,	O
for	O
steroid-dependent	O
Crohn	O
's	O
disease	O
:	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

BACKGROUND	O
More	O
than	O
50	O
%	O
of	O
patients	O
with	O
Crohn	O
's	O
disease	O
become	O
either	O
steroid	O
resistant	O
or	O
dependent	O
.	O

Accordingly	O
,	O
development	O
of	O
new	O
treatments	O
for	O
steroid-dependent	O
Crohn	O
's	O
disease	O
is	O
a	O
research	O
priority	O
.	O

AIM	O
To	O
evaluate	O
CDP571	O
,	O
a	O
humanized	O
antibody	O
to	O
tumour	O
necrosis	O
factor-alpha	O
,	O
for	O
the	O
treatment	O
of	O
steroid-dependent	O
Crohn	O
's	O
disease	O
.	O

METHODS	O
Patients	O
with	O
steroid-dependent	O
Crohn	O
's	O
disease	O
(	O
n	O
=	O
271	O
)	O
were	O
enrolled	O
in	O
a	O
36-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
.	O

Steroid	O
dependence	O
was	O
defined	O
as	O
use	O
of	O
prednisolone	O
or	O
prednisone	O
(	O
15-40	O
mg/day	O
)	O
or	O
budesonide	O
(	O
9	O
mg/day	O
)	O
for	O
>	O
or	O
=8	O
weeks	O
,	O
a	O
previous	O
failed	O
attempt	O
to	O
decrease	O
or	O
discontinue	O
steroids	O
within	O
8	O
weeks	O
of	O
screening	O
,	O
and	O
a	O
Crohn	O
's	O
Disease	O
Activity	O
Index	O
score	O
of	O
<	O
or	O
=150	O
points	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
intravenous	O
CDP571	O
10	O
mg/kg	O
or	O
placebo	O
8-weekly	O
through	O
to	O
week	O
32	O
.	O

Steroids	O
were	O
then	O
tapered	O
using	O
a	O
defined	O
schedule	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
percentage	Physical
of	Physical
patients	Physical
with	Physical
steroid	Physical
sparing	Physical
,	O
defined	O
as	O
discontinuation	O
of	O
steroid	O
therapy	O
without	O
a	O
disease	O
flare	O
(	O
Crohn	O
's	O
Disease	O
Activity	O
Index	O
score	O
>	O
or	O
=220	O
points	O
)	O
at	O
week	O
36	O
.	O

RESULTS	O
Steroid	Physical
sparing	Physical
occurred	O
in	O
53	O
of	O
181	O
(	O
29.3	O
%	O
)	O
CDP571	O
patients	O
and	O
33	O
of	O
90	O
(	O
36.7	O
%	O
)	O
placebo	O
patients	O
(	O
P	O
=	O
0.24	O
)	O
.	O

Adverse	Adverseeffect
events	Adverseeffect
occurred	O
at	O
similar	O
frequencies	O
in	O
both	O
treatment	O
groups	O
.	O

CONCLUSIONS	O
CDP571	O
was	O
ineffective	O
for	O
sparing	Adverseeffect
steroids	Adverseeffect
in	O
patients	O
with	O
steroid-dependent	O
Crohn	O
's	O
disease	O
.	O

CDP571	O
was	O
well	O
tolerated	O
.	O

[	O
Neoton	O
and	O
thrombolytic	O
therapy	O
of	O
myocardial	O
infarction	O
]	O
.	O

AIM	O
To	O
evaluate	O
neoton	O
therapy	O
effects	O
in	O
acute	O
myocardial	O
infarction	O
(	O
MI	O
)	O
on	O
systolic	Physical
function	Physical
of	Physical
the	Physical
left	Physical
ventricle	Physical
,	O
arrhythmia	Physical
and	O
clinical	Physical
symptoms	Physical
in	O
patients	O
on	O
thrombolytic	O
therapy	O
(	O
TLT	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
106	O
males	O
with	O
Q-MI	O
entered	O
the	O
study	O
.	O

47	O
received	O
treatment	O
without	O
TLT	O
and	O
neoton	O
,	O
30	O
patients	O
received	O
TLT	O
with	O
streptokinase	O
preparations	O
,	O
29	O
patients	O
were	O
given	O
streptokinase	O
preparations	O
and	O
neoton	O
.	O

Left	Physical
ventricular	Physical
systolic	Physical
function	Physical
was	O
measured	O
by	O
echocardiography	O
on	O
day	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
21	O
and	O
28	O
;	O
arrhythmia	Physical
was	O
analysed	O
at	O
Holter	O
monitoring	O
in	O
day	O
1	O
and	O
2	O
of	O
MI	O
.	O

RESULTS	O
TLT	O
failed	O
to	O
arrest	O
progression	Physical
of	Physical
left	Physical
ventricular	Physical
dilation	Physical
by	O
the	O
end	O
of	O
the	O
hospital	O
stay	O
.	O

Patients	O
given	O
neoton	O
in	O
acute	O
period	O
of	O
MI	O
had	O
no	O
increase	O
in	O
the	O
end	Physical
systolic	Physical
and	Physical
diastolic	Physical
volumes	Physical
of	Physical
the	Physical
left	Physical
ventricle	Physical
in	O
the	O
course	O
of	O
the	O
first	O
months	O
after	O
MI	O
onset	O
.	O

Antiarrhythmic	Physical
action	Physical
of	O
neoton	O
manifested	O
on	O
MI	O
day	O
2	O
.	O

CONCLUSION	O
Neoton	O
given	O
to	O
MI	O
patients	O
receiving	O
TLT	O
prevents	O
progression	O
of	O
left	Physical
ventricular	Physical
systolic	Physical
dysfunction	Physical
and	O
establishment	O
of	O
predictors	O
of	O
unfavourable	O
outcome	O
.	O

Effectiveness	O
of	O
nonpharmacologic	O
treatments	O
for	O
acute	O
seasonal	O
allergic	O
conjunctivitis	O
.	O

OBJECTIVE	O
To	O
investigate	O
whether	O
artificial	O
tears	O
and	O
cold	O
compress	O
alone	O
or	O
in	O
combination	O
provide	O
a	O
treatment	O
benefit	O
and	O
whether	O
they	O
were	O
as	O
effective	O
as	O
or	O
could	O
enhance	O
topical	O
antiallergic	O
medication	O
.	O

DESIGN	O
Randomized	O
,	O
masked	O
clinical	O
trial	O
.	O

PARTICIPANTS	O
Eighteen	O
subjects	O
(	O
mean	O
age	O
,	O
29.5?11.0	O
years	O
)	O
allergic	O
to	O
grass	O
pollen	O
.	O

INTERVENTION	O
Controlled	O
exposure	O
to	O
grass	O
pollen	O
using	O
an	O
environmental	O
chamber	O
to	O
stimulate	O
an	O
ocular	O
allergic	O
reaction	O
followed	O
by	O
application	O
of	O
artificial	O
tears	O
(	O
ATs	O
)	O
,	O
5	O
minutes	O
of	O
cold	O
compress	O
(	O
CC	O
)	O
,	O
ATs	O
combined	O
with	O
CC	O
,	O
or	O
no	O
treatment	O
applied	O
at	O
each	O
separate	O
visit	O
in	O
random	O
order	O
.	O

A	O
subset	O
of	O
11	O
subjects	O
also	O
had	O
epinastine	O
hydrochloride	O
(	O
EH	O
)	O
applied	O
alone	O
and	O
combined	O
with	O
CC	O
in	O
random	O
order	O
or	O
instillation	O
of	O
a	O
volume-matched	O
saline	O
control	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Bulbar	Physical
conjunctival	Physical
hyperemia	Physical
,	O
ocular	Physical
surface	Physical
temperature	Physical
,	O
and	O
ocular	Physical
symptoms	Physical
repeated	O
before	O
and	O
every	O
10	O
minutes	O
after	O
treatment	O
for	O
1	O
hour	O
.	O

RESULTS	O
Bulbar	Physical
conjunctival	Physical
hyperemia	Physical
and	O
ocular	Physical
symptoms	Physical
decreased	O
and	O
temperature	O
recovered	O
to	O
baseline	O
faster	O
with	O
nonpharmaceutical	O
treatments	O
compared	O
with	O
no	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Artificial	O
tears	O
combined	O
with	O
CC	O
reduced	O
hyperemia	Physical
more	O
than	O
other	O
treatments	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
treatment	O
effect	O
of	O
EH	O
was	O
enhanced	O
by	O
combining	O
it	O
with	O
a	O
CC	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Cold	O
compress	O
combined	O
with	O
ATs	O
or	O
EH	O
lowered	O
the	O
antigen-raised	O
ocular	Physical
surface	Physical
temperature	Physical
to	O
less	O
than	O
the	O
pre-exposure	O
baseline	O
.	O

Artificial	O
tear	O
instillation	O
alone	O
or	O
CC	O
combined	O
with	O
ATs	O
or	O
EH	O
significantly	O
reduced	O
the	O
temperature	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Cold	O
compress	O
combined	O
with	O
ATs	O
or	O
EH	O
had	O
a	O
similar	O
cooling	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
.	O

At	O
all	O
measurement	O
intervals	O
,	O
symptoms	O
were	O
reduced	O
for	O
both	O
EH	O
and	O
EH	O
combined	O
with	O
CC	O
than	O
CC	O
or	O
ATs	O
alone	O
or	O
in	O
combination	O
(	O
P	O
<	O
0.014	O
)	O
.	O

CONCLUSIONS	O
After	O
controlled	O
exposure	O
to	O
grass	O
pollen	O
,	O
CC	O
and	O
AT	O
treatment	O
showed	O
a	O
therapeutic	O
effect	O
on	O
the	O
signs	O
and	O
symptoms	O
of	O
allergic	O
conjunctivitis	O
.	O

A	O
CC	O
enhanced	O
the	O
use	O
of	O
EH	O
alone	O
and	O
was	O
the	O
only	O
treatment	O
to	O
reduce	O
symptoms	O
to	O
baseline	O
within	O
1	O
hour	O
of	O
antigenic	O
challenge	O
.	O

Signs	O
of	O
allergic	O
conjunctivitis	O
generally	O
were	O
reduced	O
most	O
by	O
a	O
combination	O
of	O
a	O
CC	O
in	O
combination	O
with	O
ATs	O
or	O
EH	O
.	O

An	O
interactive	O
computer	O
program	O
can	O
effectively	O
educate	O
potential	O
users	O
of	O
cystic	O
fibrosis	O
carrier	O
tests	O
.	O

The	O
demand	O
for	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
carrier	O
testing	O
is	O
steadily	O
growing	O
,	O
not	O
only	O
from	O
individuals	O
with	O
raised	O
a	O
priori	O
carrier	O
risk	O
,	O
but	O
also	O
from	O
the	O
general	O
population	O
.	O

This	O
trend	O
will	O
likely	O
exceed	O
the	O
availability	O
of	O
genetic	O
counselors	O
,	O
making	O
it	O
impossible	O
to	O
provide	O
standard	O
face-to-face	O
genetic	O
counseling	O
to	O
all	O
those	O
asking	O
for	O
the	O
test	O
.	O

In	O
order	O
to	O
reduce	O
the	O
time	O
needed	O
to	O
educate	O
individuals	O
on	O
the	O
basics	O
of	O
the	O
disease	O
,	O
its	O
genetic	O
transmission	O
,	O
and	O
carrier	O
testing	O
peculiarities	O
,	O
we	O
developed	O
an	O
educational	O
method	O
based	O
on	O
an	O
interactive	O
computer	O
program	O
(	O
IC	O
)	O
.	O

To	O
assess	O
the	O
effectiveness	O
of	O
this	O
program	O
and	O
to	O
compare	O
it	O
to	O
a	O
classical	O
genetic	O
counseling	O
session	O
,	O
we	O
conducted	O
a	O
comparative	O
trial	O
.	O

In	O
a	O
population	O
setting	O
of	O
people	O
undergoing	O
assisted	O
reproduction	O
,	O
44	O
individuals	O
were	O
randomly	O
assigned	O
to	O
either	O
receiving	O
standard	O
one-on-one	O
genetic	O
counseling	O
or	O
education	O
by	O
the	O
IC	O
program	O
.	O

We	O
measured	O
pre-	O
and	O
post-intervention	O
knowledge	O
about	O
CF	O
genetic	O
transmission	O
and	O
carrier	O
testing	O
.	O

Starting	O
from	O
an	O
equivalent	O
baseline	O
of	O
correct	O
answers	O
to	O
a	O
specially	O
designed	O
multiple-choice	O
questionnaire	O
(	O
47	O
%	O
in	O
the	O
counselor	O
group	O
and	O
45	O
%	O
in	O
the	O
computer	O
group	O
)	O
both	O
groups	O
showed	O
a	O
highly	O
significant	O
and	O
similar	O
increase	O
(	O
reaching	O
84	O
%	O
in	O
the	O
counselor	O
group	O
and	O
85	O
%	O
in	O
the	O
computer	O
group	O
)	O
.	O

The	O
computer	O
program	O
under	O
evaluation	O
can	O
successfully	O
educate	O
individuals	O
considering	O
genetic	O
testing	O
for	O
CF	O
.	O

[	O
Intravesical	O
electrostimulation	O
and	O
magnetophoresis	O
in	O
overactive	O
bladder	O
in	O
females	O
:	O
efficacy	O
of	O
Amus-01-Intramag	O
device	O
with	O
Intrastim	O
attachment	O
]	O
.	O

High-frequency	O
intravesical	O
electroneurostimulation	O
was	O
made	O
simultaneously	O
with	O
magnetophoresis	O
of	O
the	O
mixture	O
based	O
on	O
oxibutinin	O
.	O

Compared	O
to	O
effects	O
of	O
oral	O
intake	O
of	O
oxibutinin	O
,	O
such	O
method	O
was	O
two	O
times	O
more	O
effective	O
in	O
relation	O
to	O
overactive	Physical
bladder	Physical
symptoms	Physical
relief	Physical
in	O
shorter	O
duration	O
of	O
the	O
treatment	O
and	O
reduced	O
side	Adverseeffect
effects	Adverseeffect
.	O

Laser	O
Doppler	O
flowmetry	O
discovered	O
that	O
the	O
above	O
combined	O
treatment	O
corrects	O
microcirculation	O
in	O
bladder	O
mucosa	O
.	O

Early	O
effects	O
of	O
continuous	O
low-dosage	O
all-norgestrel	O
administered	O
alone	O
or	O
with	O
estrogen	O
.	O

Twenty-six	O
postmenopausal	O
women	O
participated	O
in	O
a	O
double-blind	O
trial	O
involving	O
treatment	O
according	O
to	O
a	O
Latin	O
square	O
design	O
with	O
either	O
(	O
i	O
)	O
dl-norgestrel	O
alone	O
(	O
0.075	O
mg/day	O
)	O
continuously	O
for	O
two	O
cycles	O
,	O
(	O
ii	O
)	O
estradiol-17	O
beta	O
alone	O
(	O
1	O
mg	O
on	O
25	O
of	O
28	O
days	O
)	O
for	O
two	O
cycles	O
,	O
or	O
(	O
iii	O
)	O
the	O
combined	O
hormones	O
for	O
six	O
cycles	O
.	O

A	O
placebo	O
control	O
cycle	O
followed	O
each	O
hormonal	O
treatment	O
.	O

Plasma	Physical
triglycerides	Physical
decreased	Physical
by	O
an	O
average	O
22	O
%	O
during	O
treatment	O
with	O
either	O
dl-norgestrel	O
alone	O
(	O
123	O
+/-	O
11	O
vs.	O
160	O
+/-	O
10	O
mg/dl	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.005	O
)	O
or	O
combination	O
therapy	O
(	O
126	O
+/-	O
11	O
vs.	O
162	O
+/-	O
11	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.005	O
)	O
as	O
compared	O
with	O
control	O
.	O

Plasma	Physical
total	Physical
cholesterol	Physical
fell	O
by	O
5	O
%	O
during	O
two	O
cycles	O
of	O
treatment	O
with	O
either	O
dl-norgestrel	O
alone	O
(	O
229	O
+/-	O
11	O
vs.	O
242	O
+/-	O
10	O
mg/dl	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.02	O
)	O
or	O
combination	O
therapy	O
(	O
233	O
+/-	O
11	O
vs.	O
246	O
+/-	O
10	O
,	O
n	O
=	O
25	O
,	O
P	O
<	O
0.05	O
)	O
versus	O
placebo	O
.	O

During	O
the	O
fifth	O
and	O
sixth	O
cycles	O
of	O
combination	O
therapy	O
94	O
%	O
of	O
cycles	O
were	O
free	Physical
of	Physical
flushing	Physical
(	O
vs.	O
31	O
%	O
for	O
control	O
,	O
P	O
<	O
0.01	O
)	O
,	O
64	O
%	O
of	O
cycles	O
were	O
free	Physical
of	Physical
spotting	Physical
not	Physical
requiring	Physical
protection	Physical
(	O
control	O
75	O
%	O
)	O
,	O
96	O
%	O
of	O
cycles	O
were	O
free	Physical
of	Physical
vaginal	Physical
bleeding	Physical
(	O
control	O
100	O
%	O
)	O
,	O
endometrial	O
biopsy	O
showed	O
inactive	Physical
endometrium	Physical
in	O
nine	O
of	O
the	O
10	O
subjects	O
re-biopsied	O
,	O
fasting	Physical
blood	Physical
pyruvate	Physical
decreased	Physical
by	O
20	O
%	O
(	O
P	O
<	O
0.05	O
)	O
and	O
diastolic	Physical
blood	Physical
pressure	Physical
fell	Physical
by	O
4	O
%	O
compared	O
with	O
control	O
(	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
glucose	Physical
tolerance	Physical
was	Physical
unchanged	Physical
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
vasomotor	Physical
flushing	Physical
beginning	O
with	O
the	O
third	O
to	O
fourth	O
cycles	O
of	O
combination	O
therapy	O
.	O

Effect	O
of	O
gravity	O
on	O
robot-assisted	O
motor	O
training	O
after	O
chronic	Physical
stroke	Physical
:	O
a	O
randomized	O
trial	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
efficacy	O
of	O
2	O
distinct	O
6-week	O
robot-assisted	O
reaching	O
programs	O
compared	O
with	O
an	O
intensive	O
conventional	O
arm	O
exercise	O
program	O
(	O
ICAE	O
)	O
for	O
chronic	Physical
,	Physical
stroke-related	Physical
upper-extremity	Physical
(	Physical
UE	Physical
)	Physical
impairment	O
.	O

To	O
examine	O
whether	O
the	O
addition	O
of	O
robot-assisted	O
training	O
out	O
of	O
the	O
horizontal	O
plane	O
leads	O
to	O
improved	O
outcomes	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
,	O
single-blinded	O
,	O
with	O
12-week	O
follow-up	O
.	O

SETTING	O
Research	O
setting	O
in	O
a	O
large	O
medical	O
center	O
.	O

PARTICIPANTS	O
Adults	O
(	O
N=62	O
)	O
with	O
chronic	O
,	O
stroke-related	O
arm	O
weakness	O
stratified	O
by	O
impairment	O
severity	O
using	O
baseline	O
UE	O
motor	O
assessments	O
.	O

INTERVENTIONS	O
Sixty	O
minutes	O
,	O
3	O
times	O
a	O
week	O
for	O
6	O
weeks	O
of	O
robot-assisted	O
planar	O
reaching	O
(	O
gravity	O
compensated	O
)	O
,	O
combined	O
planar	O
with	O
vertical	O
robot-assisted	O
reaching	O
,	O
or	O
intensive	O
conventional	O
arm	O
exercise	O
program	O
.	O

MAIN	O
OUTCOME	O
MEASURE	O
UE	Physical
Fugl-Meyer	Physical
Assessment	Physical
(	Physical
FMA	Physical
)	Physical
mean	Physical
change	Physical
from	O
baseline	O
to	O
final	O
training	O
.	O

RESULTS	O
All	O
groups	O
showed	O
modest	Others
gains	Others
in	Others
the	Others
FMA	Physical
from	O
baseline	O
to	O
final	O
with	O
no	O
significant	O
between	O
group	O
differences	O
.	O

Most	O
change	O
occurred	O
in	O
the	O
planar	O
robot	O
group	O
(	O
mean	O
change	O
?	O
SD	O
,	O
2.94	O
?	O
0.77	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.40-4.47	O
)	O
.	O

Participants	O
with	O
greater	O
motor	O
impairment	O
(	O
n=41	O
)	O
demonstrated	O
a	O
larger	O
difference	O
in	O
response	O
(	O
mean	O
change	O
?	O
SD	O
,	O
2.29	O
?	O
0.72	O
;	O
95	O
%	O
CI	O
,	O
0.85-3.72	O
)	O
for	O
planar	O
robot-assisted	O
exercise	O
compared	O
with	O
the	O
intensive	O
conventional	O
arm	O
exercise	O
program	O
(	O
mean	O
change	O
?	O
SD	O
,	O
0.43	O
?	O
0.72	O
;	O
95	O
%	O
CI	O
,	O
-1.00	O
to	O
1.86	O
)	O
.	O

CONCLUSIONS	O
Chronic	O
UE	O
deficits	O
because	O
of	O
stroke	O
are	O
responsive	O
to	O
intensive	O
motor	O
task	O
training	O
.	O

However	O
,	O
training	O
outside	O
the	O
horizontal	O
plane	O
in	O
a	O
gravity	O
present	O
environment	O
using	O
a	O
combination	O
of	O
vertical	O
with	O
planar	O
robots	O
was	O
not	O
superior	O
to	O
training	O
with	O
the	O
planar	O
robot	O
alone	O
.	O

The	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
.	O

The	O
aim	O
of	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
is	O
to	O
assess	O
the	O
efficacy	Others
of	O
an	O
intensive	O
diet-exercise	O
programme	O
in	O
preventing	O
or	O
delaying	O
type	Physical
2	Physical
diabetes	Physical
in	O
individuals	O
with	O
impaired	O
glucose	O
tolerance	O
(	O
IGT	O
)	O
and	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
programme	O
on	O
the	O
risk	O
factors	O
of	O
atherosclerotic	O
vascular	O
diseases	O
and	O
the	O
incidence	O
of	O
cardiovascular	O
events	O
.	O

In	O
this	O
ongoing	O
study	O
,	O
a	O
total	O
of	O
523	O
overweight	O
subjects	O
with	O
IGT	O
based	O
on	O
two	O
oral	O
glucose	O
tolerance	O
tests	O
were	O
randomized	O
to	O
either	O
an	O
intervention	O
group	O
or	O
a	O
control	O
group	O
.	O

The	O
main	O
measure	O
in	O
the	O
intervention	O
group	O
is	O
individual	Others
dietary	Others
advice	Others
aimed	O
at	O
reducing	O
weight	O
and	O
intake	O
of	O
saturated	O
fat	O
and	O
increasing	O
intake	O
of	O
dietary	O
fibre	O
.	O

The	O
intervention	O
subjects	O
are	O
individually	O
guided	O
to	O
increase	Physical
their	Physical
level	Physical
of	Physical
physical	Physical
activity	Physical
.	O

The	O
control	O
group	O
receives	O
general	O
information	O
about	O
the	O
benefits	O
of	O
weight	O
reduction	O
,	O
physical	O
activity	O
and	O
healthy	O
diet	O
in	O
the	O
prevention	O
of	O
diabetes	O
.	O

A	O
pilot	O
study	O
began	O
in	O
1993	O
,	O
and	O
recruitment	O
ended	O
in	O
1998	O
.	O

By	O
the	O
end	O
of	O
April	O
1999	O
there	O
were	O
65	O
new	O
cases	O
of	O
diabetes	O
,	O
34	O
drop-outs	O
and	O
one	O
death	Mortality
.	Mortality

The	O
weight	Physical
reduction	Physical
was	O
greater	O
(	O
-4.6	O
kg	O
)	O
at	O
1	O
year	O
in	O
the	O
intervention	O
group	O
(	O
n	O
=	O
152	O
)	O
than	O
in	O
the	O
control	O
group	O
(	O
n	O
=	O
143	O
,	O
-0.9	O
kg	O
,	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
this	O
difference	O
was	O
sustained	O
in	O
the	O
second	O
year	O
of	O
follow-up	O
.	O

At	O
1	O
year	O
43.4	O
%	O
and	O
at	O
2	O
years	O
41.8	O
%	O
of	O
the	O
intervention	O
subjects	O
had	O
achieved	O
a	O
weight	Physical
reduction	Physical
of	O
at	O
least	O
5	O
kg	O
,	O
while	O
the	O
corresponding	O
figures	O
for	O
the	O
control	O
subjects	O
were	O
14.0	O
and	O
12.0	O
%	O
(	O
P	O
<	O
0.001	O
between	O
the	O
groups	O
)	O
.	O

At	O
1	O
year	O
the	O
intervention	O
group	O
showed	O
significantly	O
greater	O
reductions	O
in	O
2	Physical
h	Physical
glucose	Physical
,	O
fasting	Physical
and	Physical
2	Physical
h	Physical
insulin	Physical
,	O
systolic	Physical
and	Physical
diastolic	Physical
blood	Physical
pressure	Physical
,	O
and	O
serum	Physical
triglycerides	Physical
.	O

Most	O
of	O
the	O
beneficial	O
changes	O
in	O
cardiovascular	Physical
risk	Physical
factors	Physical
were	O
sustained	O
for	O
2	O
years	O
.	O

These	O
interim	O
results	O
of	O
the	O
ongoing	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
demonstrate	O
the	O
efficacy	Others
and	Others
feasibility	Others
of	O
the	O
lifestyle	O
intervention	O
programme	O
.	O

Effects	O
of	O
two	O
different	O
short-term	O
training	O
programs	O
on	O
the	O
physical	O
and	O
technical	O
abilities	O
of	O
adolescent	O
basketball	O
players	O
.	O

This	O
study	O
evaluated	O
and	O
compared	O
the	O
effectiveness	O
of	O
two	O
different	O
off-season	O
,	O
short-term	O
basketball	O
training	O
programs	O
on	O
physical	O
and	O
technical	O
abilities	O
of	O
young	O
basketball	O
players	O
.	O

Twenty-seven	O
adolescent	O
basketball	O
players	O
(	O
14.7+/-0.5	O
years	O
;	O
Tanner	O
stage	O
:	O
3.5+/-0.5	O
)	O
were	O
randomly	O
divided	O
into	O
a	O
specialized	O
basketball	O
training	O
group	O
(	O
SP	O
,	O
n=10	O
)	O
,	O
a	O
mixed	O
basketball	O
plus	O
conditioning	O
training	O
group	O
(	O
MX	O
,	O
n=10	O
)	O
and	O
a	O
control	O
group	O
(	O
n=7	O
)	O
.	O

Training	O
included	O
five	O
sessions	O
per	O
week	O
(	O
100-120	O
min	O
each	O
)	O
and	O
was	O
performed	O
for	O
4	O
weeks	O
.	O

Maximal	Physical
oxygen	Physical
uptake	Physical
was	O
similarly	O
improved	O
after	O
SP	O
(	O
4.9+/-1.8	O
%	O
)	O
and	O
MX	O
(	O
4.9+/-1.4	O
%	O
)	O
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
ventilatory	Physical
threshold	Physical
.	Physical

Peak	Physical
and	Physical
mean	Physical
power	Physical
output	Physical
measured	O
during	O
the	O
Wingate	O
test	O
were	O
also	O
improved	O
by	O
a	O
similar	O
magnitude	O
after	O
SP	O
(	O
21+/-5	O
%	O
)	O
and	O
MX	O
(	O
15+/-6	O
%	O
)	O
.	O

Trunk	Physical
muscle	Physical
endurance	Physical
was	O
equally	O
increased	O
(	O
SP	O
:	O
23+/-4	O
%	O
,	O
MX	O
:	O
25+/-5	O
%	O
)	O
,	O
but	O
arms	Physical
endurance	Physical
was	O
improved	O
significantly	O
more	O
after	O
MX	O
(	O
50+/-11	O
%	O
)	O
compared	O
to	O
SP	O
(	O
11+/-14	O
%	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Performance	Mental
in	O
four	O
basketball	Others
technical	Others
skills	Others
was	O
similarly	O
increased	O
(	O
by	O
17-27	O
%	O
)	O
in	O
both	O
groups	O
,	O
with	O
a	O
tendency	O
for	O
greater	O
improvement	O
of	O
the	O
SP	O
groups	O
in	O
the	O
technical	O
skills	O
of	O
shooting	Mental
and	Mental
passing	Mental
.	O

These	O
results	O
indicate	O
that	O
a	O
SP	O
basketball	O
training	O
program	O
,	O
performed	O
exclusively	O
on-court	O
was	O
as	O
effective	O
as	O
a	O
MX	O
training	O
program	O
in	O
terms	O
of	O
aerobic	O
and	O
anaerobic	O
fitness	O
improvement	O
.	O

Furthermore	O
,	O
the	O
decrease	O
of	O
the	O
total	O
on-court	O
training	O
time	O
in	O
the	O
MX	O
group	O
resulted	O
in	O
a	O
tendency	O
for	O
a	O
smaller	O
improvement	O
of	O
basketball	O
technical	O
skills	O
.	O

In	O
conclusion	O
,	O
both	O
SP	O
and	O
MX	O
training	O
are	O
equally	O
effective	O
in	O
order	O
to	O
limit	O
and/or	O
reverse	O
the	O
detraining	O
effects	O
that	O
occur	O
during	O
the	O
off-season	O
in	O
basketball	O
.	O

The	O
influence	O
of	O
adult	O
intervention	O
on	O
infants	Mental
'	Mental
level	Mental
of	Mental
attention	Mental
.	O

The	O
effects	O
of	O
adult	O
intervention	O
on	O
infants	O
'	O
level	Mental
of	Mental
attention	Mental
to	O
objects	O
were	O
studied	O
with	O
10-month-old	O
infants	O
.	O

After	O
a	O
baseline	O
measure	O
of	O
spontaneous	O
attention	O
was	O
obtained	O
,	O
infants	O
were	O
randomly	O
assigned	O
to	O
1	O
of	O
4	O
conditions	O
(	O
low	O
,	O
medium	O
,	O
high	O
intervention	O
,	O
or	O
no-intervention	O
control	O
)	O
.	O

Level	O
of	O
intervention	O
was	O
controlled	O
by	O
systematically	O
varying	O
the	O
manner	O
and	O
frequency	O
with	O
which	O
objects	O
were	O
presented	O
,	O
the	O
extent	O
to	O
which	O
the	O
experimenter	O
talked	O
to	O
the	O
infant	O
,	O
and	O
physical	O
proximity	O
.	O

Infant	O
attention	O
was	O
defined	O
as	O
duration	Mental
of	Mental
time	Mental
spent	Mental
examining	Mental
objects	Mental
.	O

The	O
overall	Mental
duration	Mental
of	Mental
infant	Mental
attention	Mental
increased	O
during	O
medium	O
intervention	O
when	O
compared	O
to	O
the	O
control	O
group	O
.	O

Baseline	O
attention	O
was	O
then	O
used	O
to	O
separate	O
low	O
and	O
high	O
attenders	O
.	O

Low	O
attending	O
infants	O
attended	Mental
more	O
in	O
medium	O
and	O
high	O
intervention	O
than	O
in	O
the	O
low	O
condition	O
,	O
while	O
high	O
attending	O
infants	O
were	O
unaffected	O
by	O
intervention	O
.	O

The	O
results	O
show	O
that	O
level	O
of	O
intervention	O
interacts	O
with	O
the	O
child	Mental
's	Mental
spontaneous	Mental
tendency	Mental
to	Mental
focus	Mental
attention	Mental
on	O
objects	O
.	O

Changes	O
of	O
activated	O
circulating	O
endothelial	O
cells	O
and	O
survivin	O
in	O
patients	O
with	O
non-small	O
cell	O
lung	O
cancer	O
after	O
antiangiogenesis	O
therapy	O
.	O

BACKGROUND	O
Although	O
antiangiogenesis	O
therapy	O
plays	O
an	O
important	O
role	O
in	O
anti-neoplastic	O
treatment	O
with	O
its	O
recognized	O
efficacy	O
and	O
slight	O
adverse	O
effect	O
,	O
there	O
is	O
no	O
prospective	O
clinical	O
trial	O
to	O
define	O
ideal	O
markers	O
for	O
predicting	O
efficacy	O
of	O
antiangiogenic	O
therapy	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
investigate	O
the	O
changes	O
of	O
activated	O
circulating	O
endothelial	O
cells	O
(	O
aCECs	O
)	O
and	O
survivin	O
after	O
anti-angiogenesis	O
therapy	O
and	O
their	O
significance	O
in	O
predicting	O
the	O
efficacy	O
of	O
the	O
therapy	O
.	O

METHODS	O
Patients	O
of	O
non-small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
treated	O
with	O
chemotherapy	O
with	O
or	O
without	O
Endostar	O
were	O
observed	O
.	O

The	O
amount	O
of	O
activated	O
CECs	O
was	O
detected	O
by	O
flow	O
cytometry	O
,	O
and	O
the	O
expression	O
of	O
survivin	O
mRNA	O
was	O
determined	O
by	O
real-time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
amount	O
of	O
activated	Physical
CECs	Physical
decreased	O
significantly	O
in	O
clinical	O
benefit	O
cases	O
(	O
P	O
=	O
0.021	O
in	O
chemotherapy	O
alone	O
,	O
P	O
=	O
0.001	O
in	O
chemotherapy	O
plus	O
Endostar	O
)	O
,	O
increased	O
in	O
disease	Physical
progressive	Physical
cases	Physical
(	O
P	O
=	O
0.015	O
in	O
chemotherapy	O
alone	O
,	O
but	O
P	O
=	O
0.293	O
in	O
chemotherapy	O
with	O
Endotatar	O
)	O
.	O

After	O
therapy	O
,	O
the	O
expression	Physical
of	Physical
survivin	Physical
mRNA	Physical
decreased	O
in	O
clinical	O
benefit	O
cases	O
(	O
P	O
=	O
0.001	O
)	O
and	O
increased	O
in	O
disease	Physical
progressive	Physical
cases	Physical
(	O
P	O
=	O
0.018	O
)	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
activated	Physical
CECs	Physical
and	O
survivin	O
in	O
the	O
chemotherapy	O
group	O
pre-	O
and	O
post-therapy	O
(	O
P	O
=	O
0.001	O
and	O
0.021	O
,	O
respectively	O
)	O
,	O
but	O
only	O
in	O
the	O
chemotherapy	O
with	O
Endostar	O
group	O
pre-therapy	O
(	O
P	O
=	O
0.030	O
)	O
rather	O
than	O
post-therapy	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
the	O
decreased	O
activated	Physical
CECs	Physical
after	O
therapy	O
and	O
time	Physical
to	Physical
progression	Physical
(	Physical
TTP	Physical
)	Physical
(	O
r	O
=	O
0.322	O
,	O
P	O
=	O
0.012	O
)	O
;	O
a	O
negative	O
correlation	O
was	O
found	O
between	O
the	O
amount	Physical
of	Physical
survivin	Physical
mRNA	Physical
in	Physical
serum	Physical
post-therapy	Physical
and	Physical
TTP	Physical
(	O
r	O
=	O
-0.291	O
,	O
P	O
=	O
0.048	O
)	O
.	O

CONCLUSIONS	O
Activated	O
CECs	O
and	O
survivin	O
may	O
be	O
ideal	O
markers	O
forecasting	O
efficacy	O
and	O
prognosis	O
of	O
NSCLC	O
.	O

The	O
former	O
can	O
reflect	O
more	O
sensitively	O
antiangiogenic	O
efficacy	O
and	O
the	O
latter	O
is	O
more	O
sensitive	O
to	O
shrinkage	O
or	O
swelling	O
of	O
tumors	O
.	O

Their	O
combination	O
can	O
evaluate	O
more	O
accurately	O
the	O
efficacy	O
of	O
antiangiogenic	O
therapy	O
of	O
NSCLC	O
.	O

Intraperitoneal	O
cisplatin	O
versus	O
no	O
further	O
treatment	O
:	O
8-year	O
results	O
of	O
EORTC	O
55875	O
,	O
a	O
randomized	O
phase	O
III	O
study	O
in	O
ovarian	O
cancer	O
patients	O
with	O
a	O
pathologically	O
complete	O
remission	O
after	O
platinum-based	O
intravenous	O
chemotherapy	O
.	O

First-line	O
intravenous	O
chemotherapy	O
(	O
CT	O
)	O
following	O
debulking	O
surgery	O
is	O
associated	O
with	O
prolonged	Mortality
survival	Mortality
,	O
in	O
particular	O
in	O
patients	O
who	O
achieve	O
a	O
pathological	O
complete	O
remission	O
(	O
pCR	O
)	O
at	O
second-look	O
surgery	O
but	O
in	O
whom	O
a	O
high	O
rate	O
of	O
relapses	O
still	O
occurs	O
.	O

Between	O
1988	O
and	O
1997	O
,	O
153	O
patients	O
in	O
pCR	O
following	O
platinum-based	O
intravenous	O
CT	O
were	O
randomized	O
between	O
four	O
courses	O
of	O
intraperitoneal	O
cisplatin	O
(	O
P	O
)	O
(	O
90	O
mg/m2	O
every	O
3	O
weeks	O
)	O
or	O
observation	O
.	O

Overall	Mortality
survival	Mortality
(	Mortality
OS	Mortality
)	Mortality
was	O
the	O
primary	O
endpoint	O
,	O
while	O
progression-free	O
survival	O
(	O
PFS	O
)	O
was	O
a	O
secondary	O
endpoint	O
.	O

This	O
intent-to-treat	O
analysis	O
includes	O
16	O
patients	O
who	O
were	O
not	O
eligible	O
and	O
17	O
patients	O
who	O
had	O
protocol	O
violations	O
.	O

The	O
two	O
groups	O
were	O
well	O
balanced	O
in	O
terms	O
of	O
age	O
(	O
median	O
=	O
55	O
years	O
)	O
,	O
performance	O
status	O
(	O
78	O
%	O
P.S	O
.	O

O	O
)	O
,	O
FIGO	O
stage	O
(	O
96	O
%	O
stage	O
III	O
)	O
,	O
histology	O
(	O
serous	O
in	O
66	O
%	O
)	O
,	O
grade	O
(	O
2	O
or	O
3	O
in	O
80	O
%	O
)	O
,	O
and	O
residuum	O
before	O
intravenous	O
CT	O
(	O
>	O
1	O
cm	O
in	O
40	O
%	O
)	O
.	O

Intraperitoneal	O
CT	O
was	O
delivered	O
mainly	O
through	O
intraperitoneal	O
catheters	O
(	O
Port-a-Cath	O
61	O
%	O
and	O
Tenckhoff	O
25	O
%	O
)	O
.	O

Side	O
effects	O
of	O
intraperitoneal	O
cisplatin	O
included	O
vomiting	Adverseeffect
[	O
>	O
or	O
=grade	O
2	O
(	O
82	O
%	O
)	O
]	O
,	O
rise	Adverseeffect
in	Adverseeffect
serum	Adverseeffect
creatinine	Adverseeffect
[	O
>	O
or	O
=grade	O
2	O
(	O
14	O
%	O
)	O
]	O
,	O
abdominal	Adverseeffect
pain	Adverseeffect
[	O
grade	O
1-2	O
(	O
38	O
%	O
)	O
]	O
,	O
and	O
neurotoxicity	Adverseeffect
[	O
grade	O
2-3	O
(	O
15	O
%	O
)	O
]	O
.	O

After	O
a	O
median	O
follow-up	O
of	O
8	O
years	O
,	O
80	O
patients	O
(	O
52	O
%	O
)	O
have	O
progressed	O
with	O
no	O
difference	O
in	O
the	O
pattern	Adverseeffect
of	Adverseeffect
relapse	Adverseeffect
between	O
the	O
two	O
groups	O
and	O
75	O
patients	O
(	O
49	O
%	O
)	O
have	O
died	Mortality
;	O
the	O
respective	O
hazard	O
ratios	O
for	O
PFS	O
and	O
OS	O
with	O
95	O
%	O
CI	O
are	O
0.89	O
(	O
0.59-1.33	O
)	O
and	O
0.82	O
(	O
0.52-1.29	O
)	O
.	O

These	O
results	O
are	O
suggestive	O
of	O
a	O
treatment	O
benefit	O
but	O
do	O
not	O
support	O
a	O
change	O
in	O
clinical	O
practice	O
.	O

Other	O
randomized	O
clinical	O
trials	O
of	O
intraperitoneal	O
CT	O
are	O
reviewed	O
and	O
briefly	O
discussed	O
.	O

RCT	O
of	O
a	O
manualized	O
social	O
treatment	O
for	O
high-functioning	O
autism	O
spectrum	O
disorders	O
.	O

This	O
RCT	O
examined	O
the	O
efficacy	O
of	O
a	O
manualized	O
social	O
intervention	O
for	O
children	O
with	O
HFASDs	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
treatment	O
or	O
wait-list	O
conditions	O
.	O

Treatment	O
included	O
instruction	O
and	O
therapeutic	O
activities	O
targeting	O
social	O
skills	O
,	O
face-emotion	O
recognition	O
,	O
interest	O
expansion	O
,	O
and	O
interpretation	O
of	O
non-literal	O
language	O
.	O

A	O
response-cost	O
program	O
was	O
applied	O
to	O
reduce	O
problem	O
behaviors	O
and	O
foster	O
skills	O
acquisition	O
.	O

Significant	O
treatment	O
effects	O
were	O
found	O
for	O
five	O
of	O
seven	O
primary	O
outcome	O
measures	O
(	O
parent	Mental
ratings	Mental
and	O
direct	O
child	O
measures	O
)	O
.	O

Secondary	O
measures	O
based	O
on	O
staff	Others
ratings	Others
(	O
treatment	O
group	O
only	O
)	O
corroborated	O
gains	O
reported	O
by	O
parents	O
.	O

High	O
levels	O
of	O
parent	Others
,	Others
child	Others
and	Others
staff	Others
satisfaction	Others
were	O
reported	O
,	O
along	O
with	O
high	O
levels	O
of	O
treatment	Mental
fidelity	Mental
.	Mental

Standardized	O
effect	O
size	O
estimates	O
were	O
primarily	O
in	O
the	O
medium	O
and	O
large	O
ranges	O
and	O
favored	O
the	O
treatment	O
group	O
.	O

Prospective	O
,	O
randomized	O
comparison	O
of	O
transperitoneal	O
versus	O
retroperitoneal	O
laparoscopic	O
adrenalectomy	O
.	O

PURPOSE	O
We	O
report	O
a	O
prospective	O
,	O
randomized	O
comparison	O
of	O
transperitoneal	O
laparoscopic	O
adrenalectomy	O
(	O
TLA	O
)	O
vs	O
retroperitoneal	O
laparoscopic	O
adrenalectomy	O
(	O
RLA	O
)	O
for	O
adrenal	O
lesions	O
with	O
long-term	O
followup	O
.	O

MATERIALS	O
AND	O
METHODS	O
Between	O
December	O
1997	O
and	O
November	O
1999	O
,	O
57	O
consecutive	O
eligible	O
patients	O
with	O
surgical	O
adrenal	O
disease	O
were	O
prospectively	O
randomized	O
to	O
undergo	O
TLA	O
(	O
25	O
)	O
or	O
RLA	O
(	O
32	O
)	O
.	O

Study	O
exclusion	O
criteria	O
were	O
patient	O
age	O
greater	O
than	O
80	O
years	O
,	O
body	O
mass	O
index	O
greater	O
than	O
40	O
,	O
bilateral	O
adrenalectomy	O
and	O
significant	O
prior	O
abdominal	O
surgery	O
in	O
the	O
quadrant	O
of	O
interest	O
.	O

Mean	O
followup	O
was	O
5.96	O
years	O
in	O
the	O
2	O
groups	O
.	O

RESULTS	O
The	O
groups	O
were	O
matched	O
in	O
regard	O
to	O
patient	O
age	O
(	O
p	O
=	O
0.84	O
)	O
,	O
body	O
mass	O
index	O
(	O
p	O
=	O
0.43	O
)	O
,	O
American	O
Society	O
of	O
Anesthesiologists	O
class	O
(	O
p	O
=	O
0.81	O
)	O
and	O
laterality	O
(	O
p	O
=	O
0.12	O
)	O
.	O

Median	O
adrenal	Physical
mass	Physical
size	Physical
was	O
2.7	O
cm	O
(	O
range	O
1	O
to	O
9	O
)	O
in	O
the	O
TLA	O
group	O
and	O
2.6	O
cm	O
(	O
range	O
0.5	O
to	O
6	O
)	O
in	O
the	O
RLA	O
group	O
(	O
p	O
=	O
0.83	O
)	O
.	O

TLA	O
was	O
comparable	O
to	O
RLA	O
in	O
terms	O
of	O
operative	Others
time	Others
(	O
130	O
vs	O
126.5	O
minutes	O
,	O
p	O
=	O
0.64	O
)	O
,	O
estimated	Physical
blood	Physical
loss	Physical
(	O
p	O
=	O
0.92	O
)	O
,	O
specimen	Physical
weight	Physical
(	O
p	O
=	O
0.81	O
)	O
,	O
analgesic	Pain
requirements	Pain
(	O
p	O
=	O
0.25	O
)	O
,	O
hospital	Others
stay	Others
(	O
p	O
=	O
0.56	O
)	O
and	O
the	O
complication	Adverseeffect
rate	Adverseeffect
(	O
p	O
=	O
0.58	O
)	O
.	O

One	O
case	O
per	O
group	O
was	O
electively	O
converted	O
to	O
open	O
surgery	O
.	O

Pathology	O
data	O
on	O
the	O
intact	O
extracted	O
specimens	O
were	O
similar	O
between	O
the	O
groups	O
.	O

Averaged	O
convalescence	Others
was	O
4.7	O
weeks	O
in	O
the	O
TLA	O
group	O
and	O
2.3	O
weeks	O
in	O
the	O
RLA	O
group	O
(	O
p	O
=	O
0.02	O
)	O
.	O

During	O
a	O
mean	O
followup	O
of	O
6	O
years	O
2	O
patients	O
in	O
the	O
TLA	O
group	O
had	O
a	O
late	Adverseeffect
complication	Adverseeffect
(	Adverseeffect
port	Adverseeffect
site	Adverseeffect
hernia	Adverseeffect
)	Adverseeffect
.	O

Mortality	Mortality
occurred	O
in	O
5	O
patients	O
,	O
including	O
1	O
with	O
TLA	O
and	O
4	O
with	O
RLA	O
,	O
during	O
the	O
6-year	O
followup	O
.	O

CONCLUSIONS	O
For	O
most	O
benign	O
adrenal	O
lesions	O
requiring	O
surgery	O
laparoscopic	O
adrenalectomy	O
can	O
be	O
performed	O
safely	Others
and	O
effectively	Others
by	O
the	O
transperitoneal	O
or	O
the	O
retroperitoneal	O
approach	O
.	O

Increased	O
repetitive	O
behaviours	O
and	O
prolactin	O
responsivity	O
to	O
oral	O
m-chlorophenylpiperazine	O
in	O
adults	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Autism	O
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
dysfunction	O
in	O
three	O
primary	O
behavioural	O
domains	O
:	O
repetitive	O
behaviours	O
,	O
social	O
deficits	O
,	O
and	O
language	O
abnormalities	O
.	O

There	O
is	O
evidence	O
that	O
abnormalities	O
exist	O
in	O
the	O
serotonin	O
(	O
5-HT	O
)	O
system	O
in	O
autism	O
spectrum	O
patients	O
.	O

Furthermore	O
,	O
5-HT	O
is	O
known	O
to	O
play	O
a	O
role	O
in	O
repetitive	O
and	O
social	O
behaviours	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
m-chlorophenylpiperazine	O
(	O
m-CPP	O
)	O
on	O
repetitive	O
behaviours	O
and	O
prolactin	O
response	O
in	O
11	O
adults	O
with	O
autism	O
or	O
Aspergers	O
disorder	O
and	O
8	O
age-	O
and	O
gender-matched	O
healthy	O
controls	O
via	O
randomized	O
double-blind	O
,	O
m-CPP	O
and	O
placebo	O
challenges	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
an	O
instrument	Mental
rating	Mental
six	Mental
repetitive	Mental
behaviours	Mental
:	Mental
need	Mental
to	Mental
know	Mental
,	Mental
repeating	Mental
,	Mental
ordering	Mental
,	Mental
need	Mental
to	Mental
tell/ask	Mental
,	Mental
self-injury	Mental
,	Mental
and	Mental
touching	Mental
.	O

Patients	O
with	O
autism	O
spectrum	O
disorders	O
showed	O
a	O
significant	O
increase	O
in	O
repetitive	Mental
behaviours	Mental
at	O
end-point	O
following	O
oral	Physical
m-CPP	Physical
in	O
comparison	O
to	O
placebo	O
.	O

Additionally	O
subjects	O
with	O
autism	O
spectrum	O
disorders	O
showed	O
a	O
significantly	O
increased	O
prolactin	Physical
response	Physical
to	Physical
m-CPP	Physical
compared	O
to	O
normal	O
controls	O
,	O
with	O
neither	O
group	O
responding	O
to	O
placebo	O
.	O

This	O
study	O
provides	O
further	O
evidence	O
for	O
altered	O
5-HT	O
sensitivity	O
in	O
individuals	O
with	O
autism	O
spectrum	O
disorders	O
,	O
as	O
well	O
as	O
a	O
possible	O
relationship	O
between	O
repetitive	O
behaviours	O
in	O
autism	O
spectrum	O
disorders	O
and	O
abnormalities	O
in	O
the	O
5-HT	O
system	O
.	O

Abstinence	O
or	O
controlled	O
drinking	O
in	O
clinical	O
practice	O
:	O
indications	O
at	O
initial	O
assessment	O
.	O

Previous	O
research	O
has	O
suggested	O
two	O
leading	O
hypotheses	O
concerning	O
which	O
excessive	O
drinkers	O
can	O
re-establish	O
control	O
:	O
one	O
based	O
upon	O
level	O
of	O
dependence	O
,	O
the	O
other	O
upon	O
the	O
client	O
's	O
personal	O
persuasion	O
.	O

Using	O
initial	O
assessment	O
data	O
from	O
46	O
clients	O
of	O
a	O
clinical	O
psychology	O
alcohol	O
problems	O
service	O
(	O
30	O
men	O
,	O
16	O
women	O
)	O
,	O
an	O
attempt	O
was	O
made	O
to	O
operationalize	O
the	O
concepts	O
of	O
dependence	O
and	O
personal	O
persuasion	O
using	O
a	O
variety	O
of	O
indicators	O
of	O
each	O
.	O

Although	O
SADQ	Mental
scores	Mental
and	O
Rand	Mental
definite	Mental
alcoholism	Mental
were	O
in	O
general	O
agreement	O
,	O
there	O
were	O
a	O
number	O
of	O
borderline	O
instances	O
and	O
cases	O
of	O
disagreement	O
,	O
and	O
neither	O
was	O
in	O
good	O
agreement	O
with	O
estimates	O
of	O
problem	O
duration	O
,	O
nor	O
with	O
reports	O
of	O
recent	O
or	O
earlier	O
attainment	O
of	O
abstinence	O
or	O
control	O
.	O

Indicators	O
of	O
personal	Mental
persuasion	Mental
were	O
more	O
consistent	O
.	O

Those	O
with	O
dependence	O
indicators	Mental
for	Mental
abstinence	Mental
tended	O
to	O
prefer	O
abstinence	O
as	O
a	O
goal	O
,	O
but	O
there	O
were	O
many	O
departures	O
from	O
this	O
pattern	O
particularly	O
for	O
women	O
.	O

It	O
is	O
concluded	O
that	O
in	O
clinical	O
practice	O
it	O
will	O
be	O
very	O
difficult	O
to	O
make	O
a	O
clear	O
cut	O
recommendation	O
about	O
treatment	O
goal	O
at	O
initial	O
assessment	O
except	O
in	O
a	O
few	O
cases	O
.	O

Weight	Physical
and	O
leptin	Physical
changes	Physical
among	O
risperidone-treated	O
youths	O
with	O
autism	O
:	O
6-month	O
prospective	O
data	O
.	O

OBJECTIVE	O
The	O
authors	O
examined	O
the	O
developmental	O
impact	O
and	O
temporal	O
characteristics	O
of	O
risperidone-associated	O
weight	Physical
change	Physical
.	O

METHOD	O
Weight	Physical
change	Physical
was	O
measured	O
for	O
63	O
children	O
and	O
adolescents	O
with	O
autism	O
treated	O
with	O
risperidone	O
for	O
6	O
months	O
.	O

Change	Physical
in	Physical
serum	Physical
leptin	Physical
levels	Physical
after	O
2	O
months	O
was	O
examined	O
as	O
a	O
predictor	O
of	O
final	Physical
weight	Physical
gain	Physical
in	O
mixed	O
regression	O
models	O
that	O
controlled	O
for	O
site	O
,	O
gender	O
,	O
age	O
,	O
and	O
risperidone	O
dose	O
.	O

RESULTS	O
Age-	O
and	O
gender-standardized	O
weight	Physical
increased	Physical
after	O
6	O
months	O
of	O
treatment	O
(	O
gross	O
:	O
mean=5.6	O
kg	O
[	O
SD=3.9	O
]	O
;	O
standardized	O
:	O
mean=0.6	O
z	O
[	O
SD=0.5	O
]	O
)	O
and	O
was	O
positively	O
correlated	O
with	O
weight	Physical
gained	Physical
after	O
1	O
month	O
.	O

Change	Physical
in	Physical
leptin	Physical
levels	Physical
after	O
2	O
months	O
of	O
treatment	O
(	O
mean=-0.3	O
ng/ml	O
,	O
SD=6.2	O
)	O
(	O
N=48	O
)	O
did	O
not	O
predict	O
final	Physical
weight	Physical
gain	Physical
.	O

CONCLUSIONS	O
Chronic	O
risperidone	O
exposure	O
in	O
children	O
with	O
autism	O
causes	O
weight	Physical
gain	Physical
in	O
excess	O
of	O
developmentally	O
expected	O
norms	O
that	O
follows	O
a	O
curvilinear	O
trajectory	O
and	O
decelerates	O
over	O
time	O
.	O

Serum	Physical
leptin	Physical
change	Physical
does	O
not	O
reliably	O
predict	O
risperidone-associated	O
weight	Physical
gain	Physical
.	O

[	O
Therapeutic	O
value	O
of	O
a	O
combination	O
of	O
trimetazidine	O
with	O
a	O
calcium	O
inhibitor	O
in	O
the	O
treatment	O
of	O
chronic	O
coronary	O
insufficiency	O
]	O
.	O

This	O
double-blind	O
,	O
placebo-controlled	O
study	O
sought	O
to	O
examine	O
the	O
short-term	O
benefit	O
of	O
adding	O
60	O
mg	O
of	O
trimetazidine	O
to	O
the	O
daily	O
therapeutic	O
regimen	O
of	O
29	O
male	O
patients	O
with	O
coronary	O
insufficiency	O
who	O
had	O
persistent	O
ST	O
depression	O
on	O
exercise	O
tolerance	O
test	O
(	O
greater	O
than	O
or	O
equal	O
to	O
1	O
mm	O
)	O
,	O
despite	O
treatment	O
with	O
nifedipine	O
40	O
mg	O
per	O
day	O
.	O

As	O
compared	O
with	O
the	O
placebo	O
group	O
,	O
after	O
only	O
14	O
days	O
,	O
the	O
patients	O
treated	O
with	O
trimetazidine	O
showed	O
statistically	O
significant	O
increases	O
in	O
the	O
maximum	O
workload	O
level	O
attained	O
before	O
ST	O
depression	O
occurred	O
(	O
31	O
%	O
versus	O
-	O
6	O
%	O
;	O
P	O
=	O
0.009	O
)	O
,	O
the	O
total	O
work	O
performed	O
(	O
31	O
%	O
versus	O
2	O
%	O
;	O
P	O
=	O
0.024	O
)	O
and	O
a	O
significant	O
decrease	O
in	O
the	O
systolic	O
tension	O
time	O
(	O
double	O
product	O
)	O
/workload	O
ratio	O
(	O
-5	O
%	O
versus	O
+11	O
%	O
;	O
P	O
=	O
0.005	O
)	O
.	O

Throughout	O
the	O
study	O
the	O
clinical	O
acceptability	O
was	O
excellent	O
,	O
with	O
no	O
side	O
effects	O
attributable	O
to	O
trimetazidine	O
being	O
recorded	O
.	O

This	O
study	O
shows	O
that	O
the	O
addition	O
of	O
trimetazidine	O
to	O
a	O
calcium	O
antagonist	O
brings	O
a	O
valuable	O
improvement	O
in	O
therapeutic	O
results	O
.	O

Duration	O
of	O
untreated	O
negative	O
and	O
positive	O
symptoms	O
of	O
psychosis	O
and	O
cognitive	O
impairment	O
in	O
first	O
episode	O
psychosis	O
.	O

BACKGROUND	O
Duration	O
of	O
untreated	O
psychosis	O
(	O
DUP	O
)	O
has	O
been	O
significantly	O
associated	O
with	O
poor	Others
clinical	Others
and	Others
social	Others
outcomes	Others
in	O
First	O
Episode	O
Psychosis	O
(	O
FEP	O
)	O
patients	O
,	O
but	O
an	O
association	O
with	O
cognitive	O
outcomes	O
has	O
not	O
been	O
clearly	O
established	O
.	O

METHOD	O
Seventy-seven	O
consecutively	O
admitted	O
,	O
drug-na?ve	O
patients	O
with	O
FEP	O
were	O
assessed	O
at	O
baseline	O
and	O
at	O
1month	O
and	O
6months	O
.	O

Underlying	O
dimensions	O
of	O
DUP	O
(	O
general	O
prodrome	O
and	O
positive	O
,	O
negative	O
and	O
disorganisation	O
symptoms	O
)	O
were	O
assessed	O
using	O
the	O
Symptom	O
Onset	O
in	O
Schizophrenia	O
(	O
SOS	O
)	O
inventory	O
(	O
Perkins	O
et	O
al.	O
,	O
2000	O
)	O
.	O

To	O
assess	O
the	O
effect	O
of	O
DUP	O
on	O
the	O
neuropsychological	O
status	O
of	O
the	O
patients	O
,	O
a	O
linear	O
mixed-effect	O
model	O
was	O
fitted	O
to	O
each	O
neuropsychological	O
dimension	O
.	O

These	O
models	O
included	O
a	O
dichotomised	O
version	O
of	O
DUP	O
(	O
short	O
versus	O
long	O
duration	O
)	O
as	O
a	O
fixed	O
effect	O
,	O
several	O
adjusting	O
variables	O
to	O
account	O
for	O
patient	O
differences	O
,	O
and	O
a	O
random	O
effect	O
to	O
incorporate	O
the	O
longitudinal	O
structure	O
of	O
the	O
data	O
.	O

RESULTS	O
Patients	O
with	O
a	O
short	O
duration	O
of	O
untreated	O
negative	O
symptoms	O
(	O
DUNS	O
)	O
or	O
a	O
short	O
duration	O
of	O
untreated	O
positive	O
symptoms	O
(	O
DUPS	O
)	O
outperformed	O
patients	O
with	O
a	O
long	O
duration	O
of	O
untreated	O
symptoms	O
on	O
memory	Mental
tasks	Mental
and	Mental
a	Mental
pre-attentional	Mental
visual	Mental
task	Mental
but	O
not	O
on	O
measures	Mental
of	Mental
verbal	Mental
fluency	Mental
,	Mental
attention	Mental
,	Mental
reaction	Mental
time	Mental
,	Mental
visual	Mental
processing	Mental
and	Mental
executive	Mental
functions	Mental
.	O

CONCLUSIONS	O
This	O
study	O
provides	O
additional	O
support	O
for	O
an	O
early	O
intervention	O
to	O
shorten	O
DUP	O
to	O
facilitate	O
a	O
better	O
outcome	O
in	O
memory	O
and	O
attentional	O
domains	O
of	O
FEP	O
patients	O
.	O

Lack	O
of	O
a	O
pharmacokinetic	Physical
interaction	Physical
between	O
steady-state	O
roflumilast	O
and	O
single-dose	O
midazolam	O
in	O
healthy	O
subjects	O
.	O

AIMS	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
roflumilast	O
,	O
an	O
investigational	O
PDE4	O
inhibitor	O
for	O
the	O
treatment	O
of	O
COPD	O
and	O
asthma	O
,	O
on	O
the	O
pharmacokinetics	Physical
of	Physical
the	Physical
CYP3A	Physical
probe	Physical
drug	O
midazolam	O
and	O
its	O
major	O
metabolites	O
.	O

METHODS	O
In	O
an	O
open	O
,	O
randomized	O
(	O
for	O
midazolam	O
treatment	O
sequence	O
)	O
study	O
,	O
18	O
healthy	O
male	O
subjects	O
received	O
single	O
doses	O
of	O
midazolam	O
(	O
2	O
mg	O
oral	O
and	O
1	O
mg	O
i.v.	O
,	O
1	O
day	O
apart	O
)	O
alone	O
,	O
repeated	O
doses	O
of	O
roflumilast	O
(	O
500	O
microg	O
once	O
daily	O
for	O
14	O
days	O
)	O
alone	O
,	O
and	O
repeated	O
doses	O
of	O
roflumilast	O
together	O
with	O
single	O
doses	O
of	O
midazolam	O
(	O
2	O
mg	O
oral	O
and	O
1	O
mg	O
i.v.	O
,	O
1	O
day	O
apart	O
)	O
.	O

RESULTS	O
A	O
comparison	O
of	O
clearance	Physical
and	Physical
peak	Physical
and	Physical
systemic	Physical
exposure	Physical
to	O
midazolam	O
following	O
administration	O
of	O
roflumilast	O
indicated	O
no	O
effect	O
of	O
roflumilast	O
dosed	O
to	O
steady	O
state	O
on	O
the	O
pharmacokinetics	Physical
of	Physical
midazolam	Physical
.	Physical

Point	O
estimates	O
(	O
90	O
%	O
CI	O
)	O
were	O
0.97	O
(	O
0.84	O
,	O
1.13	O
)	O
for	O
the	O
AUC	O
of	O
i.v	O
.	O

midazolam	O
and	O
0.98	O
(	O
0.82	O
,	O
1.17	O
)	O
for	O
that	O
of	O
oral	O
midazolam	O
with	O
and	O
without	O
roflumilast	O
.	O

CONCLUSIONS	O
Therapeutic	O
steady	O
state	O
concentrations	O
of	O
roflumilast	O
and	O
its	O
N-oxide	O
do	O
not	O
alter	O
the	O
disposition	Physical
of	Physical
the	Physical
CYP3A	Physical
substrate	Physical
midazolam	Physical
in	O
healthy	O
subjects	O
.	O

This	O
finding	O
suggests	O
that	O
roflumilast	O
is	O
unlikely	O
to	O
alter	O
the	O
clearance	O
of	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP3A4	O
.	O

A	O
comparison	O
of	O
human	O
papillomavirus	O
testing	O
of	O
clinician-collected	O
and	O
self-collected	O
samples	O
during	O
follow-up	O
after	O
screen-and-treat	O
.	O

Screen-and-treat	O
cervical	O
cancer	O
prevention	O
programs	O
based	O
on	O
high-risk	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
testing	O
and	O
cryotherapy	O
have	O
been	O
shown	O
to	O
be	O
effective	O
in	O
resource-limited	O
settings	O
.	O

However	O
,	O
because	O
cryotherapy	O
is	O
not	O
100	O
%	O
effective	O
,	O
follow-up	O
is	O
needed	O
after	O
treatment	O
to	O
detect	O
post-treatment	O
failures	O
.	O

We	O
compared	O
the	O
test	O
performances	O
of	O
high-risk	O
HPV	O
testing	O
(	O
Hybrid	O
Capture	O
2	O
)	O
using	O
self-collected	O
and	O
clinician-collected	O
samples	O
as	O
well	O
as	O
cervical	O
cytology	O
for	O
identifying	O
cervical	O
intraepithelial	O
neoplasia	O
grades	O
2	O
or	O
3	O
or	O
invasive	O
cervical	O
cancer	O
(	O
CIN2+	O
)	O
among	O
women	O
who	O
did	O
(	O
n=812	O
)	O
and	O
did	O
not	O
(	O
n=1858	O
)	O
undergo	O
cryotherapy	O
in	O
a	O
South	O
African	O
screen-and-treat	O
trial	O
.	O

At	O
6	O
months	O
after	O
enrolment	O
(	O
and	O
after	O
cryotherapy	O
,	O
if	O
performed	O
)	O
,	O
women	O
were	O
tested	O
using	O
all	O
three	O
screening	O
methods	O
and	O
then	O
underwent	O
colposcopy/biopsy	O
.	O

A	O
predefined	O
subset	O
of	O
women	O
(	O
n=1,455	O
)	O
had	O
extended	O
follow-up	O
with	O
colposcopy/biopsy	O
at	O
12	O
months	O
.	O

A	O
total	O
of	O
33	O
and	O
91	O
cases	O
of	O
CIN2+	O
were	O
detected	O
among	O
treated	O
and	O
untreated	O
women	O
,	O
respectively	O
.	O

The	O
sensitivity	Physical
of	Physical
HPV	Physical
testing	Physical
using	O
clinician-collected	O
samples	O
and	O
cervical	O
cytology	O
did	O
not	O
differ	O
by	O
treatment	O
status	O
.	O

HPV	O
testing	O
of	O
clinician-collected	O
samples	O
detected	O
the	O
most	O
cases	O
of	O
CIN2+	Physical
among	O
both	O
treated	O
(	O
85	O
%	O
)	O
and	O
untreated	O
(	O
91	O
%	O
)	O
women	O
(	O
p=0.31	O
)	O
.	O

Cytology	Others
(	O
at	O
a	O
cutoff	O
of	O
atypical	O
squamous	O
cells	O
of	O
undetermined	O
significance	O
or	O
greater	O
)	O
detected	O
76	O
%	O
of	O
cases	O
among	O
both	O
treated	O
and	O
untreated	O
women	O
.	O

However	O
,	O
the	O
sensitivity	Physical
of	Physical
HPV	Physical
testing	Physical
using	O
self-collected	O
samples	O
was	O
significantly	O
lower	O
among	O
treated	O
versus	O
untreated	O
women	O
(	O
55	O
%	O
vs.	O
78	O
%	O
,	O
p=0.01	O
)	O
.	O

HPV	O
testing	O
using	O
self-collected	O
vaginal	O
specimens	O
may	O
be	O
useful	O
in	O
primary	O
screening	O
but	O
performs	O
poorly	O
for	O
detecting	O
post-treatment	Adverseeffect
failures	Adverseeffect
.	O

Comparison	O
between	O
the	O
central	O
effects	O
of	O
camazepam	O
and	O
temazepam	O
.	O

Computerized	O
analysis	O
of	O
sleep	O
recordings	O
.	O

The	O
effects	O
of	O
acute	O
administration	O
per	O
os	O
of	O
30	O
mg	O
camazepam	O
and	O
the	O
same	O
dose	O
of	O
temazepam	O
,	O
were	O
compared	O
with	O
placebo	O
in	O
8	O
young	O
male	O
volunteers	O
,	O
fully	O
adapted	O
to	O
the	O
laboratory	O
environment	O
by	O
6	O
nights	O
of	O
adaptation	O
.	O

The	O
study	O
was	O
double-blind	O
,	O
in	O
a	O
random	O
order	O
,	O
10	O
days	O
separating	O
each	O
session	O
.	O

Spectral	O
analysis	O
was	O
performed	O
on	O
the	O
all-night	O
records	O
(	O
1-min	O
epochs	O
)	O
,	O
and	O
the	O
relative	O
power	O
of	O
six	O
frequency	O
bands	O
calculated	O
.	O

Concerning	O
sleep	Physical
parameters	Physical
,	O
temazepam	O
induces	O
a	O
statistically	O
significant	O
reduction	O
of	O
:	O
phase	O
shifts	O
;	O
number	O
of	O
awakenings	O
;	O
percent	O
duration	O
of	O
sleep	O
stages	O
I	O
and	O
IV	O
.	O

A	O
significant	O
increase	O
of	O
the	O
percent	Physical
duration	Physical
of	Physical
stage	Physical
II	Physical
and	O
sleep	Others
efficiency	Others
was	O
also	O
found	O
.	O

Camazepam	Others
shows	Others
modification	Others
,	O
with	O
the	O
same	O
trend	O
,	O
but	O
not	O
reaching	O
statistical	O
significance	O
.	O

Concerning	O
spectral	O
analysis	O
,	O
temazepam	Others
induces	O
a	O
light	O
increase	O
of	O
the	O
relative	O
power	O
of	O
the	O
slowest	O
frequencies	O
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
fast	O
bands	O
,	O
while	O
major	O
effects	O
are	O
found	O
on	O
the	O
characteristic	O
periodicity	O
of	O
delta	O
activities	O
,	O
which	O
appear	O
disrupted	O
by	O
the	O
drug	O
.	O

These	O
effects	O
are	O
not	O
evident	O
with	O
camazepam	O
,	O
which	O
does	O
not	O
seem	O
to	O
distort	O
the	O
normal	O
sleep	O
pattern	O
.	O

Is	O
altered	O
central	O
pain	O
processing	O
related	O
to	O
disease	O
stage	O
in	O
chronic	O
pancreatitis	O
patients	O
with	O
pain	O
?	O
An	O
exploratory	O
study	O
.	O

BACKGROUND	O
The	O
most	O
dominant	O
feature	O
in	O
chronic	O
pancreatitis	O
is	O
intense	O
abdominal	O
pain	O
.	O

Changes	O
in	O
spinal	O
and/or	O
supraspinal	O
central	O
nervous	O
system	O
pain	O
processing	O
due	O
to	O
visceral	O
nociceptive	O
input	O
play	O
an	O
important	O
role	O
in	O
this	O
pain	O
.	O

How	O
altered	O
pain	O
processing	O
is	O
related	O
to	O
disease	O
stage	O
still	O
needs	O
study	O
.	O

METHODOLOGY/PRINCIPAL	O
FINDINGS	O
Sixty	O
chronic	O
pancreatitis	O
patients	O
were	O
compared	O
to	O
15	O
healthy	O
controls	O
.	O

Two	O
subgroups	O
of	O
pancreatitis	O
patients	O
were	O
defined	O
based	O
on	O
the	O
M-ANNHEIM	O
severity	O
index	O
of	O
chronic	O
pancreatitis	O
;	O
i.e	O
.	O

moderate	O
and	O
severe	O
.	O

Pain	Pain
detection	Pain
and	Pain
tolerance	Pain
thresholds	Pain
for	Pain
pressure	Pain
and	Pain
electric	Pain
stimuli	Pain
were	O
measured	O
in	O
six	O
selected	O
dermatomes	O
(	O
C5	O
,	O
T4	O
,	O
T10	O
,	O
L1	O
,	O
L4	O
and	O
T10BACK	O
)	O
.	O

In	O
addition	O
,	O
the	O
conditioned	O
pain	O
modulation	O
response	O
to	O
cold	O
pressor	O
task	O
was	O
determined	O
.	O

These	O
measures	O
were	O
compared	O
between	O
the	O
healthy	O
controls	O
and	O
chronic	O
pancreatitis	O
patients	O
.	O

Severe	O
pancreatitis	O
patients	O
showed	O
lower	O
pain	Pain
thresholds	Pain
than	O
moderate	O
pancreatitis	O
patients	O
or	O
healthy	O
volunteers	O
.	O

Healthy	O
controls	O
showed	O
a	O
significantly	O
larger	O
conditioned	O
pain	Pain
modulation	Pain
response	O
compared	O
to	O
all	O
chronic	O
pancreatitis	O
patients	O
taken	O
together	O
.	O

CONCLUSIONS/SIGNIFICANCE	O
The	O
present	O
study	O
confirms	O
that	O
chronic	O
pancreatitis	O
patients	O
show	O
signs	O
of	O
altered	O
central	O
processing	O
of	O
nociception	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
study	O
further	O
suggests	O
that	O
these	O
changes	O
,	O
i.e	O
.	O

central	O
sensitization	O
,	O
may	O
be	O
influenced	O
by	O
disease	O
stage	O
.	O

These	O
findings	O
underline	O
the	O
need	O
to	O
take	O
altered	O
central	O
pain	O
processing	O
into	O
account	O
when	O
managing	O
the	O
pain	O
of	O
chronic	O
pancreatitis	O
.	O

A	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
porcine	O
versus	O
synthetic	O
secretin	O
for	O
reducing	O
symptoms	Physical
of	Physical
autism	Physical
.	O

OBJECTIVE	O
To	O
compare	O
the	O
effects	O
of	O
a	O
single	O
dose	O
of	O
biologic	O
and	O
synthetic	O
porcine	O
secretin	O
to	O
placebo	O
on	O
a	O
variety	O
of	O
autism	O
symptoms	O
.	O

METHOD	O
Eighty-five	O
children	O
with	O
autism	O
without	O
other	O
medical	O
conditions	O
and	O
not	O
taking	O
other	O
psychotropic	O
medications	O
participated	O
(	O
ages	O
between	O
3	O
and	O
12	O
years	O
,	O
mean	O
IQ	O
=	O
55	O
)	O
.	O

Children	O
were	O
grouped	O
into	O
trios	O
matched	O
by	O
age	O
and	O
communication	O
level	O
and	O
then	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
treatment	O
groups	O
:	O
biologic	O
secretin	O
(	O
2	O
CU/kg	O
)	O
,	O
synthetic	O
secretin	O
(	O
0.4	O
microg/kg	O
)	O
,	O
and	O
placebo	O
.	O

Measures	O
collected	O
1	O
week	O
before	O
and	O
4	O
weeks	O
after	O
infusion	O
included	O
autism	Mental
symptoms	Mental
,	Mental
language	Mental
skills	Mental
,	Mental
and	Mental
problem	Mental
behaviors	Mental
,	O
gathered	Others
from	Others
parents	Others
,	Others
teachers	Others
,	Others
and	Others
investigators	Others
,	O
who	O
were	O
all	O
blind	O
to	O
treatment	O
.	O

Two-factor	O
,	O
repeated-measures	O
analyses	O
of	O
variance	O
(	O
3	O
treatment	O
levels	O
by	O
2	O
repeated	O
measures	O
,	O
pre-	O
and	O
postinfusion	O
)	O
were	O
used	O
to	O
examine	O
efficacy	O
.	O

RESULTS	O
Direct	O
observation	O
measures	O
did	O
not	O
show	O
change	O
over	O
time	O
related	O
to	O
secretin	O
.	O

Parent	O
reports	O
showed	O
an	O
overall	O
reduction	O
of	O
symptom	Physical
severity	Physical
for	O
all	O
treatment	O
groups	O
,	O
including	O
the	O
placebo	O
group	O
.	O

One	O
teacher-report	O
measure	O
showed	O
decreases	O
in	O
autism	O
symptoms	O
in	O
the	O
placebo	O
and	O
synthetic	O
secretin	O
groups	O
.	O

CONCLUSIONS	O
No	O
evidence	O
that	O
either	O
biologic	O
or	O
synthetic	O
secretin	O
provided	O
amelioration	O
of	O
symptoms	O
beyond	O
placebo	O
was	O
observed	O
.	O

This	O
held	O
true	O
when	O
children	O
with	O
and	O
without	O
gastrointestinal	O
problems	O
were	O
examined	O
separately	O
.	O

Randomized	O
clinical	O
trial	O
of	O
behavioral	O
intervention	O
and	O
nutrition	O
education	O
to	O
improve	O
caloric	O
intake	O
and	O
weight	O
in	O
children	O
with	O
cystic	O
fibrosis	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
efficacy	O
of	O
a	O
behavioral	O
plus	O
nutrition	O
education	O
intervention	O
,	O
Be	O
In	O
CHARGE	O
!	O
,	O
compared	O
with	O
that	O
of	O
a	O
nutrition	O
education	O
intervention	O
alone	O
on	O
caloric	Physical
intake	Physical
and	O
weight	Physical
gain	Physical
in	O
children	O
with	O
cystic	O
fibrosis	O
and	O
pancreatic	O
insufficiency	O
.	O

DESIGN	O
Randomized	O
controlled	O
trial	O
.	O

SETTING	O
Cystic	O
fibrosis	O
centers	O
in	O
the	O
eastern	O
,	O
midwestern	O
,	O
and	O
southern	O
United	O
States	O
.	O

PARTICIPANTS	O
Seventy-nine	O
children	O
aged	O
4	O
to	O
12	O
years	O
below	O
the	O
40th	O
percentile	O
for	O
weight	O
for	O
age	O
were	O
recruited	O
.	O

Sixty-seven	O
completed	O
the	O
intervention	O
and	O
59	O
completed	O
a	O
24-month	O
follow-up	O
assessment	O
.	O

INTERVENTION	O
Comparison	O
of	O
a	O
behavioral	O
plus	O
nutrition	O
education	O
intervention	O
with	O
a	O
nutrition	O
education	O
intervention	O
alone	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
outcomes	O
were	O
changes	O
from	O
pretreatment	O
to	O
posttreatment	O
in	O
caloric	Physical
intake	Physical
and	O
weight	Physical
gain	Physical
.	O

Secondary	O
outcomes	O
were	O
changes	O
from	O
pretreatment	O
to	O
posttreatment	O
in	O
percentage	Physical
of	Physical
the	Physical
estimated	Physical
energy	Physical
requirement	Physical
and	Physical
body	Physical
mass	Physical
index	Physical
z	Physical
score	Physical
.	O

These	O
outcomes	O
were	O
also	O
examined	O
24	O
months	O
posttreatment	O
.	O

RESULTS	O
After	O
treatment	O
,	O
the	O
behavioral	O
plus	O
nutrition	O
education	O
intervention	O
as	O
compared	O
with	O
the	O
nutrition	O
education	O
intervention	O
alone	O
had	O
a	O
statistically	O
greater	O
average	O
increase	O
on	O
the	O
primary	O
and	O
secondary	O
outcomes	O
of	O
caloric	Physical
intake	Physical
(	O
mean	O
,	O
872	O
vs	O
489	O
cal/d	O
,	O
respectively	O
)	O
,	O
percentage	Physical
of	Physical
the	Physical
estimated	Physical
energy	Physical
requirement	Physical
(	O
mean	O
,	O
148	O
%	O
vs	O
127	O
%	O
,	O
respectively	O
)	O
,	O
weight	Physical
gain	Physical
(	O
mean	O
,	O
1.47	O
vs	O
0.92	O
kg	O
,	O
respectively	O
)	O
,	O
and	O
body	Physical
mass	Physical
index	Physical
z	Physical
score	Physical
(	O
0.38	O
vs	O
0.18	O
,	O
respectively	O
)	O
.	O

At	O
the	O
24-month	O
follow-up	O
,	O
children	O
in	O
both	O
conditions	O
maintained	O
an	O
estimated	O
energy	Physical
requirement	Physical
of	O
around	O
120	O
%	O
and	O
did	O
not	O
significantly	O
differ	O
on	O
any	O
outcomes	O
.	O

CONCLUSIONS	O
A	O
behavioral	O
plus	O
nutrition	O
education	O
intervention	O
was	O
more	O
effective	O
than	O
a	O
nutrition	O
education	O
intervention	O
alone	O
at	O
increasing	O
dietary	O
intake	O
and	O
weight	O
over	O
a	O
9-week	O
period	O
.	O

However	O
,	O
across	O
the	O
24-month	O
follow-up	O
,	O
both	O
treatments	O
achieved	O
similar	O
outcomes	O
.	O

Trial	O
Registration	O
clinicaltrials.gov	O
Identifier	O
:	O
NCT00006169	O
.	O

Lung	O
function	O
measurement	O
in	O
general	O
practice	O
:	O
a	O
comparison	O
of	O
the	O
Escort	O
spirometer	O
with	O
the	O
Micromed	O
turbine	O
spirometer	O
and	O
the	O
mini-Wright	O
peak	O
flow	O
meter	O
.	O

It	O
is	O
important	O
that	O
new	O
types	O
of	O
spirometer	O
for	O
widespread	O
clinical	O
use	O
are	O
pragmatically	O
evaluated	O
in	O
primary	O
care	O
.	O

This	O
study	O
compared	O
measurements	O
taken	O
by	O
a	O
new	O
portable	O
Fleisch	O
pneumotachograph	O
spirometer	O
(	O
known	O
as	O
the	O
Escort	O
)	O
with	O
those	O
of	O
the	O
commonly	O
used	O
mini-Wright	O
peak	O
flow	O
meter	O
and	O
the	O
Micromed	O
Pocket	O
turbine	O
spirometer	O
.	O

A	O
pragmatic	O
study	O
was	O
conducted	O
in	O
two	O
phases	O
during	O
routine	O
surgeries	O
at	O
Aldermoor	O
Health	O
Centre	O
,	O
Southampton	O
.	O

Phase	O
I	O
compared	O
the	O
new	O
spirometer	O
with	O
the	O
mini-Wright	O
peak	O
flow	O
meter	O
and	O
Phase	O
2	O
compared	O
the	O
new	O
spirometer	O
and	O
the	O
turbine	O
spirometer	O
.	O

One	O
hundred	O
patients	O
aged	O
5-88	O
years	O
(	O
56	O
patients	O
with	O
a	O
history	O
of	O
chronic	O
respiratory	O
complaints	O
and	O
44	O
patients	O
without	O
)	O
entered	O
Phase	O
1	O
,	O
and	O
100	O
patients	O
aged	O
6-82	O
years	O
(	O
62	O
patients	O
with	O
a	O
history	O
of	O
chronic	O
respiratory	O
complaints	O
and	O
38	O
patients	O
without	O
)	O
entered	O
Phase	O
2	O
.	O

Each	O
patient	O
contributed	O
only	O
once	O
to	O
each	O
phase	O
,	O
but	O
some	O
entered	O
both	O
phases	O
on	O
separate	O
occasions	O
.	O

Ninety-five	O
percent	O
limits	O
of	O
agreement	O
(	O
mean	O
+/-	O
SD	O
)	O
were	O
wide	O
for	O
all	O
comparisons	O
.	O

Graphical	O
plots	O
revealed	O
trends	O
towards	O
higher	O
Escort	Physical
values	Physical
as	O
mean	O
values	O
rose	O
compared	O
with	O
both	O
mini-Wright	O
and	O
turbine	O
readings	O
for	O
peak	Physical
expiratory	Physical
flow	Physical
rate	Physical
and	Physical
forced	Physical
expiratory	Physical
volume	Physical
in	Physical
one	Physical
second	Physical
.	Physical

Possible	O
over-reading	O
of	O
peak	Physical
expiratory	Physical
flow	Physical
rate	Physical
with	O
the	O
mini-Wright	O
meter	O
at	O
low	O
mean	O
values	O
was	O
also	O
seen	O
.	O

Readings	O
taken	O
with	O
these	O
different	O
types	O
of	O
meter	O
can	O
not	O
be	O
interchanged	O
with	O
confidence	O
in	O
clinical	O
practice	O
.	O

The	O
clinical	O
significance	O
of	O
the	O
theoretically	O
more	O
accurate	O
measures	Physical
of	Physical
lung	Physical
function	Physical
produced	O
with	O
the	O
new	O
meter	O
,	O
and	O
indeed	O
of	O
spirometry	O
itself	O
,	O
needs	O
further	O
investigation	O
.	O

The	O
reversibility	O
of	O
increased	O
airways	O
resistance	O
in	O
chronic	O
heart	O
failure	O
measured	O
by	O
impulse	O
oscillometry	O
.	O

BACKGROUND	O
Patients	O
with	O
chronic	O
heart	O
failure	O
complain	O
of	O
breathlessness	O
and	O
fatigue	O
on	O
exercise	O
.	O

Airways	O
resistance	O
is	O
increased	O
and	O
lung	O
compliance	O
is	O
reduced	O
in	O
chronic	O
heart	O
failure	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
pulmonary	O
abnormalities	O
are	O
reversible	O
and	O
whether	O
any	O
improvements	O
lead	O
to	O
changes	O
to	O
exercise	O
capacity	O
or	O
symptoms	O
.	O

METHODS	O
Twelve	O
patients	O
with	O
stable	O
chronic	O
heart	O
failure	O
and	O
10	O
matched	O
controls	O
underwent	O
repeated	O
assessment	O
of	O
airways	O
resistance	O
using	O
impulse	O
oscillometry	O
and	O
peak	O
exercise	O
testing	O
with	O
metabolic	O
gas	O
exchange	O
after	O
receiving	O
nebulized	O
saline	O
as	O
placebo	O
or	O
combined	O
salbutamol	O
and	O
ipratropium	O
bromide	O
in	O
a	O
double-blind	O
crossover	O
randomized	O
fashion	O
.	O

RESULTS	O
Patients	O
had	O
lower	O
peak	Physical
oxygen	Physical
consumption	Physical
and	O
a	O
steeper	O
slope	O
relating	O
ventilation	O
to	O
carbon	O
dioxide	O
production	O
than	O
controls	O
.	O

Bronchodilators	O
reduced	O
peripheral	O
airways	O
resistance	O
in	O
patients	O
(	O
0.53	O
versus	O
0.38	O
,	O
P	O
<	O
.02	O
)	O
and	O
controls	O
(	O
0.21	O
versus	O
0.19	O
,	O
P	O
<	O
.005	O
)	O
and	O
increased	O
measures	O
of	O
compliance	O
in	O
both	O
groups	O
.	O

There	O
was	O
no	O
effect	O
on	O
the	O
peak	Physical
oxygen	Physical
consumption	Physical
,	Physical
exercise	Physical
time	Physical
,	Physical
ventilation	Physical
to	Physical
carbon	Physical
dioxide	Physical
slope	Physical
,	Physical
or	Physical
anaerobic	Physical
threshold	Physical
.	Physical

There	O
was	O
an	O
increase	O
in	O
peak	Physical
tidal	Physical
volume	Physical
(	Physical
VT	Physical
)	Physical
in	O
both	O
groups	O
but	O
this	O
did	O
not	O
lead	O
to	O
an	O
increase	O
in	O
peak	Physical
ventilation	Physical
.	Physical

The	O
slope	O
relating	O
symptoms	O
to	O
ventilation	Physical
(	O
ie	O
,	O
Borg/VE	O
)	O
was	O
significantly	O
reduced	O
in	O
the	O
patients	O
after	O
bronchodilators	O
(	O
17	O
%	O
+/-8	O
%	O
,	O
P	O
<	O
.05	O
)	O
.	O

The	O
relationship	O
between	O
the	O
improvement	O
in	O
VT	O
and	O
reduction	O
in	O
gradient	O
of	O
the	O
Borg/VE	Physical
slope	Physical
was	O
significant	O
(	O
r=.40	O
,	O
P	O
<	O
.05	O
)	O
.	O

CONCLUSIONS	O
Nebulized	O
bronchodilators	O
improve	O
airways	Physical
resistance	Physical
,	Physical
lung	Physical
reactance	Physical
,	O
and	O
peak	Physical
tidal	Physical
volume	Physical
during	O
exercise	O
in	O
chronic	O
heart	O
failure	O
but	O
do	O
not	O
increase	O
peak	O
exercise	O
capacity	O
.	O

They	O
do	O
,	O
however	O
,	O
reduce	O
the	O
symptom	Physical
of	Physical
breathlessness	Physical
.	Physical

Randomised	O
clinical	O
trial	O
of	O
physiotherapy	O
after	O
open	O
abdominal	O
surgery	O
in	O
high	O
risk	O
patients	O
.	O

Postoperative	O
physiotherapy	O
has	O
been	O
shown	O
to	O
reduce	Others
the	Others
incidence	Others
of	O
postoperative	O
pulmonary	O
complications	O
after	O
open	O
abdominal	O
surgery	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
if	O
the	O
addition	O
of	O
deep	O
breathing	O
exercises	O
and	O
secretion	O
clearing	O
techniques	O
to	O
a	O
standardised	O
physiotherapist-directed	O
program	O
of	O
early	O
mobilisation	O
improved	O
clinical	O
outcomes	O
in	O
patients	O
undergoing	O
open	O
abdominal	O
surgery	O
.	O

Fifty-six	O
patients	O
undergoing	O
open	O
abdominal	O
surgery	O
,	O
at	O
high	O
risk	O
of	O
developing	O
postoperative	O
pulmonary	O
complications	O
,	O
were	O
randomised	O
before	O
operation	O
to	O
an	O
early	O
mobilisation-only	O
group	O
or	O
an	O
early	O
mobilisation-plus-deep	O
breathing	O
and	O
coughing	O
group	O
.	O

Mobility	Physical
duration	Physical
,	O
frequency	Physical
and	Physical
intensity	Physical
of	Physical
breathing	Physical
interventions	Physical
were	O
quantified	O
for	O
both	O
groups	O
.	O

All	O
outcomes	O
were	O
assessed	O
by	O
a	O
blinded	O
outcomes	O
researcher	O
using	O
a	O
standardised	O
outcomes	O
measurement	O
tool	O
developed	O
specifically	O
for	O
this	O
population	O
.	O

Outcomes	O
included	O
incidence	Physical
of	Physical
clinically	Physical
significant	Physical
postoperative	Physical
pulmonary	Physical
complications	Physical
,	O
fever	Physical
,	O
length	Others
of	Others
stay	Others
,	O
and	O
restoration	Physical
of	Physical
mobility	Physical
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
in	O
mean	Others
age	Others
,	Mental
anaesthetic	Others
time	Others
,	O
perioperative	Physical
morbidity	Physical
,	Physical
or	Physical
postoperative	Physical
mobility	Physical
.	O

Outcome	O
data	O
were	O
available	O
for	O
89	O
%	O
of	O
enrolled	O
subjects	O
.	O

Overall	O
incidence	O
of	O
postoperative	Physical
pulmonary	Physical
complications	Physical
was	O
16	O
%	O
.	O

The	O
incidence	O
of	O
postoperative	Physical
pulmonary	Physical
complications	Physical
in	O
the	O
non-deep	O
breathing	O
and	O
coughing	O
group	O
was	O
14	O
%	O
,	O
and	O
the	O
incidence	O
of	O
postoperative	Physical
pulmonary	Physical
complications	Physical
in	O
the	O
deep	O
breathing	O
and	O
coughing	O
group	O
was	O
17	O
%	O
,	O
(	O
absolute	O
risk	O
reduction	O
-3	O
%	O
,	O
95	O
%	O
C1	O
-22	O
to	O
19	O
%	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
incidence	O
of	O
fever	Physical
,	O
physiotherapist	Others
time	Others
,	O
or	O
the	O
number	Physical
of	Physical
treatments	Physical
.	O

This	O
study	O
suggests	O
that	O
,	O
in	O
this	O
clinical	O
setting	O
,	O
the	O
addition	O
of	O
deep	O
breathing	O
and	O
coughing	O
exercises	O
to	O
a	O
physiotherapist-directed	O
program	O
of	O
early	O
mobilisation	O
does	O
not	O
significantly	O
reduce	O
the	O
incidence	O
of	O
clinically	O
significant	O
postoperative	O
pulmonary	O
complications	O
in	O
high	O
risk	O
open	O
abdominal	O
surgery	O
subjects	O
.	O

Evaluation	O
of	O
a	O
novel	O
technique	O
for	O
wound	O
closure	O
using	O
a	O
barbed	O
suture	O
.	O

BACKGROUND	O
Suture	O
knots	O
present	O
several	O
disadvantages	O
in	O
wound	O
closure	O
,	O
because	O
they	O
are	O
tedious	O
to	O
tie	O
and	O
place	O
ischemic	O
demands	O
on	O
tissue	O
.	O

Bulky	O
knots	O
may	O
be	O
a	O
nidus	O
for	O
infection	O
,	O
and	O
they	O
may	O
extrude	O
through	O
skin	O
weeks	O
after	O
surgery	O
.	O

Needle	O
manipulations	O
during	O
knot-tying	O
predispose	O
the	O
surgeon	O
to	O
glove	O
perforation	O
.	O

A	O
barbed	O
suture	O
was	O
developed	O
that	O
is	O
self-anchoring	O
,	O
requiring	O
no	O
knots	O
or	O
slack	O
management	O
for	O
wound	O
closure	O
.	O

The	O
elimination	O
of	O
knot	O
tying	O
may	O
have	O
advantages	O
over	O
conventional	O
wound	O
closure	O
methods	O
.	O

METHODS	O
This	O
prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
was	O
designed	O
to	O
show	O
that	O
the	O
use	O
of	O
barbed	O
suture	O
in	O
dermal	O
closure	O
of	O
the	O
Pfannenstiel	O
incision	O
during	O
nonemergent	O
cesarean	O
delivery	O
surgery	O
produces	O
scar	O
cosmesis	O
at	O
5	O
weeks	O
that	O
is	O
no	O
worse	O
than	O
that	O
observed	O
with	O
conventional	O
closure	O
using	O
3-0	O
polydioxanone	O
suture	O
.	O

Cosmesis	Physical
was	O
assessed	O
by	O
review	O
of	O
postoperative	O
photographs	O
by	O
a	O
blinded	O
,	O
independent	O
plastic	O
surgeon	O
using	O
the	O
modified	O
Hollander	O
cosmesis	O
score	O
.	O

Secondary	O
endpoints	O
included	O
infection	Adverseeffect
,	O
dehiscence	Adverseeffect
,	O
pain	Pain
,	O
closure	Physical
time	Physical
,	Physical
and	O
other	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
.	O

RESULTS	O
The	O
study	O
enrolled	O
195	O
patients	O
,	O
of	O
whom	O
188	O
were	O
eligible	O
for	O
analysis	O
.	O

Cosmesis	Physical
scores	Physical
did	O
not	O
significantly	O
differ	O
between	O
the	O
barbed	O
suture	O
group	O
and	O
the	O
control	O
group	O
.	O

Rates	Adverseeffect
of	Adverseeffect
infection	Adverseeffect
,	Physical
dehiscence	Physical
,	O
and	O
other	O
adverse	Adverseeffect
events	Adverseeffect
did	O
not	O
significantly	O
differ	O
between	O
the	O
two	O
groups	O
.	O

Closure	Pain
time	Pain
and	Pain
pain	Pain
scores	Pain
were	O
comparable	O
between	O
the	O
groups	O
.	O

CONCLUSIONS	O
The	O
barbed	O
suture	O
represents	O
an	O
innovative	O
option	O
for	O
wound	O
closure	O
.	O

With	O
a	O
cosmesis	Others
and	Others
safety	Others
profile	Others
that	O
is	O
similar	O
to	O
that	O
of	O
conventional	O
suture	O
technique	O
,	O
it	O
avoids	O
the	O
drawbacks	O
inherent	O
to	O
suture	O
knots	O
.	O

Intervention	O
pilot	O
for	O
parents	O
of	O
children	O
with	O
autistic	O
spectrum	O
disorder	O
.	O

Parents	O
of	O
children	O
who	O
receive	O
the	O
diagnosis	O
of	O
autistic	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
experience	O
a	O
situational	O
crisis	O
related	O
to	O
receiving	O
the	O
diagnosis	O
,	O
which	O
causes	O
feelings	O
of	O
distress	O
and	O
urgency	O
to	O
access	O
services	O
for	O
the	O
affected	O
child	O
.	O

This	O
paper	O
describes	O
a	O
randomized	O
trial	O
(	O
n	O
=	O
31	O
)	O
that	O
was	O
conducted	O
at	O
a	O
regional	O
diagnostic	O
center	O
of	O
a	O
large	O
metropolitan	O
children	O
's	O
hospital	O
to	O
(	O
a	O
)	O
refine	O
a	O
nursing	O
intervention	O
designed	O
for	O
parents	O
of	O
children	O
with	O
ASD	O
and	O
(	O
b	O
)	O
to	O
identify	O
methodological	O
revisions	O
for	O
a	O
larger	O
study	O
.	O

A	O
secondary	O
purpose	O
was	O
to	O
test	O
the	O
effects	O
of	O
a	O
post-diagnosis	O
nursing	O
intervention	O
on	O
parents	Mental
'	Mental
reports	Mental
of	Mental
stress	Mental
,	O
impact	Mental
of	Mental
event	Mental
(	Mental
diagnosis	Mental
)	Mental
,	O
and	O
use	Others
of	Others
services	Others
after	O
a	O
child	O
is	O
newly	O
diagnosed	O
with	O
ASD	O
.	O

The	O
intervention	O
consisted	O
of	O
usual	O
care	O
plus	O
3	O
hours	O
contact	O
with	O
a	O
pediatric	O
nurse	O
practitioner	O
(	O
PNP	O
)	O
for	O
counseling	O
,	O
instruction	O
,	O
and	O
assistance	O
with	O
implementation	O
of	O
the	O
recommended	O
treatment	O
plan	O
.	O

The	O
control	O
group	O
received	O
only	O
the	O
usual	O
care	O
post-diagnosis	O
,	O
which	O
consisted	O
of	O
a	O
1-hour	O
consultation	O
session	O
to	O
receive	O
the	O
results	O
of	O
diagnostic	O
tests	O
and	O
a	O
written	O
copy	O
of	O
the	O
recommended	O
treatment	O
plan	O
provided	O
by	O
a	O
developmental	O
pediatrician	O
and/or	O
PNP	O
.	O

Between	O
group	O
differences	O
in	O
measures	O
of	O
impact	Mental
of	Mental
event	Mental
and	O
perceived	Mental
stress	Mental
were	O
not	O
statistically	O
significant	O
.	O

This	O
was	O
attributed	O
to	O
a	O
small	O
sample	O
size	O
.	O

A	O
larger	O
study	O
is	O
feasible	O
and	O
recommended	O
with	O
an	O
expanded	O
nursing	O
intervention	O
and	O
a	O
significantly	O
larger	O
sample	O
recruited	O
from	O
an	O
additional	O
recruitment	O
site	O
.	O

Nurses	O
working	O
with	O
this	O
special	O
population	O
must	O
recognize	O
that	O
parents	O
have	O
information	O
and	O
counseling	O
needs	O
that	O
begin	O
after	O
they	O
receive	O
the	O
diagnosis	O
of	O
ASD	O
for	O
their	O
child	O
and	O
can	O
address	O
these	O
needs	O
with	O
a	O
standardized	O
nursing	O
intervention	O
.	O

Economic	Others
evaluation	Others
of	O
aquatic	O
exercise	O
for	O
persons	O
with	O
osteoarthritis	O
.	O

OBJECTIVES	O
To	O
estimate	O
cost	Others
and	O
outcomes	O
of	O
the	O
Arthritis	O
Foundation	O
aquatic	O
exercise	O
classes	O
from	O
the	O
societal	O
perspective	O
.	O

DESIGN	O
Randomized	O
trial	O
of	O
20-week	O
aquatic	O
classes	O
.	O

Cost	Others
per	Others
quality-adjusted	Others
life	Others
year	Others
(	Others
QALY	Others
)	Others
gained	O
was	O
estimated	O
using	O
trial	O
data	O
.	O

Sample	O
size	O
was	O
based	O
on	O
80	O
%	O
power	O
to	O
reject	O
the	O
null	O
hypothesis	O
that	O
the	O
cost/QALY	Others
gained	O
would	O
not	O
exceed	O
$	O
50,000	O
.	O

SUBJECTS	O
AND	O
METHODS	O
Recruited	O
249	O
adults	O
from	O
Washington	O
State	O
aged	O
55	O
to	O
75	O
with	O
a	O
doctor-confirmed	O
diagnosis	O
of	O
osteoarthritis	O
to	O
participate	O
in	O
aquatic	O
classes	O
.	O

The	O
Quality	Others
of	Others
Well-Being	Others
Scale	Others
(	Others
QWB	Others
)	Others
and	O
Current	Others
Health	Others
Desirability	Others
Rating	Others
(	Others
CHDR	Others
)	Others
were	O
used	O
for	O
economic	O
evaluation	O
,	O
supplemented	O
by	O
the	O
arthritis-specific	Physical
Health	Physical
Assessment	Physical
Questionnaire	Physical
(	Physical
HAQ	Physical
)	Physical
,	O
Center	Physical
for	Physical
Epidemiologic	Physical
Studies-Depression	Physical
Scale	Physical
(	Physical
CES-D	Physical
)	O
,	O
and	O
Perceived	Others
Quality	Others
of	Others
Life	Others
Scale	Others
(	Others
PQOL	Others
)	Others
collected	O
at	O
baseline	O
and	O
postclass	O
.	O

Outcome	O
results	O
applied	O
to	O
life	O
expectancy	O
tables	O
were	O
used	O
to	O
estimate	O
QALYs	Others
.	O

Use	Others
of	Others
health	Others
care	Others
facilities	Others
was	O
assessed	O
from	O
diaries/questionnaires	O
and	O
Medicare	Others
reimbursement	Others
rates	Others
used	O
to	O
estimate	O
costs	O
.	O

Nonparametric	O
bootstrap	O
sampling	O
of	O
costs/QALY	Others
ratios	Others
established	O
the	O
95	O
%	O
CI	O
around	O
the	O
estimates	O
.	O

RESULTS	O
Aquatic	O
exercisers	O
reported	O
equal	O
(	Physical
QWB	Physical
)	Physical
or	O
better	O
(	Physical
CHDR	Physical
,	Physical
HAQ	Physical
,	Physical
PQOL	Physical
)	Physical
health-related	Physical
quality	Physical
of	Physical
life	Physical
compared	O
with	O
controls	O
.	O

Outcomes	O
improved	O
with	O
regular	O
class	O
attendance	O
.	O

Costs/QALY	Others
gained	O
discounted	O
at	O
3	O
%	O
were	O
$	O
205,186	O
using	O
the	O
QWB	Physical
and	O
$	O
32,643	O
using	O
the	O
CHRD	Physical
.	O

CONCLUSION	O
Aquatic	O
exercise	O
exceeded	O
$	O
50,000	O
per	O
QALY	Others
gained	O
using	O
the	O
community-weighted	O
outcome	O
but	O
fell	O
below	O
this	O
arbitrary	O
budget	O
constraint	O
when	O
using	O
the	O
participant-weighted	O
measure	O
.	O

Confidence	O
intervals	O
around	O
these	O
ratios	O
suggested	O
wide	O
variability	O
of	O
cost	Others
effectiveness	Others
of	O
aquatic	O
exercise	O
.	O

A	O
high	O
intake	O
of	O
trans	O
fatty	O
acids	O
has	O
little	O
effect	O
on	O
markers	Physical
of	Physical
inflammation	Physical
and	Physical
oxidative	Physical
stress	Physical
in	O
humans	O
.	O

Consumption	O
of	O
industrial	O
trans	O
fatty	O
acids	O
(	O
iTFA	O
)	O
increases	O
LDL	O
cholesterol	O
,	O
decreases	O
HDL	O
cholesterol	O
,	O
and	O
is	O
strongly	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

However	O
,	O
changes	O
in	O
circulating	O
cholesterol	O
can	O
not	O
explain	O
the	O
entire	O
effect	O
.	O

Therefore	O
,	O
we	O
studied	O
whether	O
iTFA	O
and	O
conjugated	O
linoleic	O
acid	O
(	O
CLA	O
)	O
affect	O
markers	Physical
of	Physical
inflammation	Physical
and	Physical
oxidative	Physical
stress	Physical
.	O

Sixty-one	O
healthy	O
adults	O
consumed	O
each	O
of	O
3	O
diets	O
for	O
3	O
wk	O
,	O
in	O
random	O
order	O
.	O

Diets	O
were	O
identical	O
except	O
for	O
7	O
%	O
of	O
energy	O
provided	O
by	O
oleic	O
acid	O
(	O
control	O
diet	O
)	O
,	O
iTFA	O
,	O
or	O
CLA	O
.	O

At	O
the	O
end	O
of	O
the	O
3	O
wk	O
,	O
we	O
measured	O
plasma	O
inflammatory	O
markers	O
IL-6	O
,	O
C-reactive	O
protein	O
,	O
tumor	O
necrosis	O
factor	O
receptors	O
I	O
and	O
II	O
(	O
TNF-RI	O
and	O
-RII	O
)	O
,	O
monocyte	O
chemotactic	O
protein-1	O
and	O
E-selectin	O
,	O
and	O
urinary	O
8-iso-PGF	O
(	O
2?	O
)	O
,	O
a	O
marker	O
of	O
lipid	O
peroxidation	O
.	O

Consumption	O
of	O
iTFA	O
caused	O
4	O
%	O
lower	O
TNF-RI	O
concentrations	O
and	O
6	O
%	O
higher	O
E-selectin	O
concentrations	O
compared	O
with	O
oleic	O
acid	O
(	O
control	O
)	O
and	O
had	O
no	O
significant	O
effect	O
on	O
other	O
inflammatory	O
markers	O
.	O

CLA	O
did	O
not	O
significantly	O
affect	O
inflammatory	O
markers	O
.	O

The	O
urine	O
concentration	O
of	O
8-iso-PGF	O
(	O
2?	O
)	O
[	O
geometric	O
mean	O
(	O
95	O
%	O
CI	O
)	O
]	O
was	O
greater	O
after	O
the	O
iTFA	O
[	O
0.54	O
(	O
0.48	O
,	O
0.60	O
)	O
nmol/mmol	O
creatinine	O
]	O
and	O
the	O
CLA	O
[	O
1.2	O
(	O
1.1	O
,	O
1.3	O
)	O
nmol/mmol	O
creatinine	O
]	O
diet	O
periods	O
than	O
after	O
the	O
control	O
period	O
[	O
0.45	O
(	O
0.41	O
,	O
0.50	O
)	O
nmol/mmol	O
creatinine	O
;	O
P	O
<	O
0.05	O
]	O
.	O

In	O
conclusion	O
,	O
high	O
intakes	O
of	O
iTFA	O
and	O
CLA	O
did	O
not	O
substantially	O
affect	O
plasma	O
concentrations	O
of	O
inflammatory	O
markers	O
,	O
but	O
they	O
increased	O
the	O
urine	O
8-iso-PGF	O
(	O
2?	O
)	O
concentration	O
.	O

However	O
,	O
it	O
is	O
unlikely	O
this	O
plays	O
a	O
major	O
role	O
in	O
the	O
mechanism	O
by	O
which	O
iTFA	O
increase	O
the	O
risk	O
of	O
CVD	O
.	O

However	O
,	O
more	O
research	O
is	O
needed	O
to	O
fully	O
understand	O
the	O
implications	O
of	O
these	O
findings	O
.	O

Skeletal	O
muscle	O
total	O
creatine	O
content	O
and	O
creatine	O
transporter	O
gene	O
expression	O
in	O
vegetarians	O
prior	O
to	O
and	O
following	O
creatine	O
supplementation	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
vegetarianism	O
on	O
skeletal	Physical
muscle	Physical
total	Physical
creatine	Physical
(	Physical
TCr	Physical
)	Physical
content	Physical
and	O
creatine	Physical
transporter	Physical
(	Physical
CreaT	Physical
)	Physical
gene	Physical
expression	Physical
,	O
prior	O
to	O
and	O
during	O
5	O
d	O
of	O
Cr	O
supplementation	O
(	O
CrS	O
)	O
.	O

In	O
a	O
double-blind	O
,	O
crossover	O
design	O
,	O
7	O
vegetarians	O
(	O
VEG	O
)	O
and	O
nonvegetarians	O
(	O
NVEG	O
)	O
were	O
assigned	O
Cr	O
or	O
placebo	O
supplements	O
for	O
5	O
d	O
and	O
after	O
5	O
wk	O
,	O
received	O
the	O
alternative	O
treatment	O
.	O

Muscle	O
sampling	O
occurred	O
before	O
,	O
and	O
after	O
1	O
and	O
5	O
d	O
of	O
treatment	O
ingestion	O
.	O

Basal	Physical
muscle	Physical
TCr	Physical
content	O
was	O
lower	O
(	O
P	O
<	O
0.05	O
)	O
in	O
VEG	O
compared	O
with	O
NVEG	O
.	O

Muscle	O
TCr	O
increased	O
(	O
P	O
<	O
0.05	O
)	O
throughout	O
the	O
Cr	O
trial	O
in	O
both	O
groups	O
but	O
was	O
greater	O
(	O
P	O
<	O
0.05	O
)	O
in	O
VEG	O
compared	O
with	O
NVEG	O
,	O
at	O
days	O
1	O
and	O
5	O
.	O

CreaT	Physical
gene	Physical
expression	Physical
was	O
not	O
different	O
between	O
VEG	O
and	O
NVEG	O
.	O

The	O
results	O
indicate	O
that	O
VEG	O
have	O
a	O
lower	O
muscle	Physical
TCr	Physical
content	Physical
and	O
an	O
increased	O
capacity	Physical
to	O
load	O
Cr	O
into	O
muscle	O
following	O
CrS	O
.	O

Muscle	Physical
CreaT	Physical
gene	Physical
expression	Physical
does	O
not	O
appear	O
to	O
be	O
affected	O
by	O
vegetarianism	O
.	O

Fine	O
needle	O
aspiration	O
coupled	O
with	O
real-time	O
PCR	O
:	O
a	O
painless	O
methodology	O
to	O
study	O
adaptive	O
functional	O
changes	O
in	O
skeletal	O
muscle	O
.	O

BACKGROUND	O
AND	O
AIM	O
In	O
this	O
study	O
we	O
developed	O
a	O
new	O
methodology	O
for	O
obtaining	O
human	O
skeletal	O
muscle	O
samples	O
to	O
evaluate	O
gene	O
expression	O
.	O

This	O
approach	O
is	O
based	O
on	O
a	O
fine	O
needle	O
aspiration	O
technique	O
,	O
which	O
allows	O
us	O
to	O
extract	O
a	O
small	O
tissue	O
sample	O
in	O
a	O
significantly	O
less	O
invasive	O
manner	O
than	O
with	O
classic	O
biopsy	O
.	O

METHODS	O
AND	O
RESULTS	O
Multiplex	O
tandem	O
RT-PCR	O
was	O
used	O
to	O
determine	O
the	O
mRNA	O
levels	O
of	O
genes	O
involved	O
in	O
ATP	O
production	O
and	O
mitochondrial	O
biogenesis	O
in	O
muscle	O
tissue	O
.	O

Samples	O
of	O
vastus	O
lateralis	O
muscle	O
were	O
obtained	O
from	O
21	O
healthy	O
subjects	O
with	O
different	O
fitness	O
levels	O
.	O

The	O
principal	O
findings	O
in	O
our	O
study	O
show	O
a	O
strong	O
correlation	O
between	O
PGC-1alpha	Physical
and	Physical
COX5B	Physical
(	O
p	O
<	O
0.001	O
)	O
and	O
between	O
PGC-1alpha	Physical
and	Physical
MT-CO2	Physical
(	O
p=0.017	O
)	O
expression	O
.	O

Furthermore	O
,	O
a	O
significant	O
positive	O
correlation	O
between	O
mtDNA	O
content	O
and	O
the	O
percentage	O
of	O
MHCI	O
present	O
in	O
the	O
aspired	O
samples	O
were	O
found	O
(	O
p=0.028	O
)	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
current	O
knowledge	O
on	O
skeletal	O
muscle	O
physiology	O
and	O
show	O
the	O
reliability	O
of	O
the	O
proposed	O
method	O
.	O

CONCLUSION	O
This	O
painless	O
methodology	O
can	O
be	O
used	O
to	O
investigate	O
,	O
in	O
vivo	O
,	O
human	O
muscle	O
RNA	O
and	O
DNA	O
adaptations	O
in	O
response	O
to	O
either	O
physiological	O
and/or	O
pharmacological	O
stimuli	O
.	O

This	O
method	O
has	O
major	O
clinical	O
relevance	O
,	O
such	O
as	O
its	O
application	O
in	O
clarifying	O
the	O
mechanisms	O
underling	O
metabolic	O
and	O
systemic	O
disorders	O
.	O

Comparison	O
of	O
chemotherapy	O
with	O
chemohormonal	O
therapy	O
as	O
first-line	O
therapy	O
for	O
metastatic	O
,	O
hormone-sensitive	O
breast	O
cancer	O
:	O
An	O
Eastern	O
Cooperative	O
Oncology	O
Group	O
study	O
.	O

PURPOSE	O
Although	O
hormonal	O
therapy	O
represents	O
standard	O
therapy	O
for	O
metastatic	O
hormone-sensitive	O
disease	O
,	O
many	O
patients	O
receive	O
initial	O
chemotherapy	O
because	O
of	O
the	O
location	O
,	O
bulk	O
,	O
or	O
aggressiveness	O
of	O
their	O
disease	O
.	O

It	O
is	O
uncertain	O
whether	O
simultaneous	O
hormonal	O
therapy	O
provides	O
additional	O
benefit	O
compared	O
with	O
chemotherapy	O
alone	O
.	O

Eastern	O
Cooperative	O
Oncology	O
Group	O
trial	O
E3186	O
was	O
initiated	O
to	O
explore	O
this	O
question	O
.	O

PATIENTS	O
AND	O
METHODS	O
Between	O
January	O
1988	O
and	O
December	O
1992	O
,	O
231	O
patients	O
with	O
estrogen	O
receptor	O
(	O
ER	O
)	O
-positive	O
or	O
ER-unknown	O
metastatic	O
breast	O
cancer	O
were	O
randomized	O
to	O
receive	O
either	O
chemotherapy	O
(	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
and	O
fluorouracil	O
?CAF	O
)	O
or	O
chemohormonal	O
therapy	O
(	O
CAF	O
plus	O
tamoxifen	O
and	O
Halotestin	O
?fluoxymesterone	O
;	O
Pharmacia-Upjohn	O
,	O
Kalamazoo	O
,	O
MI	O
?CAFTH	O
)	O
as	O
front-line	O
therapy	O
for	O
metastatic	O
breast	O
cancer	O
.	O

Patients	O
who	O
experienced	O
a	O
complete	O
response	O
to	O
induction	O
therapy	O
either	O
received	O
or	O
did	O
not	O
receive	O
maintenance	O
cyclophosphamide	O
,	O
methotrexate	O
,	O
fluorouracil	O
,	O
prednisone	O
,	O
and	O
TH	O
as	O
a	O
secondary	O
randomization	O
.	O

RESULTS	O
The	O
response	O
rates	O
(	O
complete	O
response	O
and	O
partial	O
response	O
)	O
of	O
patients	O
who	O
received	O
CAF	O
and	O
CAFTH	O
were	O
similar	O
(	O
69.2	O
%	O
v	O
68.9	O
%	O
,	O
respectively	O
;	O
P	O
=.99	O
)	O
.	O

Time	O
to	O
treatment	O
failure	O
(	O
TTF	O
)	O
was	O
slightly	O
longer	O
for	O
patients	O
who	O
received	O
chemohormonal	O
therapy	O
compared	O
with	O
chemotherapy	O
alone	O
patients	O
(	O
13.4	O
months	O
v	O
10.3	O
months	O
,	O
respectively	O
;	O
P	O
=.087	O
)	O
,	O
and	O
TTF	O
was	O
significantly	O
longer	O
in	O
ER-positive	O
compared	O
with	O
ER-negative	O
patients	O
(	O
17.4	O
months	O
v	O
10.3	O
months	O
,	O
respectively	O
;	O
P	O
=.048	O
)	O
.	O

However	O
,	O
ER	O
status	O
had	O
no	O
effect	O
on	O
overall	O
survival	O
(	O
30.0	O
months	O
for	O
CAF	O
v	O
29.3	O
months	O
for	O
CAFTH	O
)	O
.	O

CONCLUSION	O
In	O
patients	O
with	O
potentially	O
hormone-sensitive	O
metastatic	O
breast	O
cancer	O
,	O
chemohormonal	O
therapy	O
prolongs	O
TTF	O
for	O
ER-positive	O
patients	O
without	O
improving	O
overall	O
survival	O
.	O

Treatment	O
of	O
anal	O
fissures	O
using	O
a	O
combination	O
of	O
minoxidil	O
and	O
lignocaine	O
:	O
a	O
randomized	O
,	O
double-blind	O
trial	O
.	O

AIM	O
Anal	O
fissures	O
are	O
associated	O
with	O
hypertonia	O
of	O
the	O
internal	O
anal	O
sphincter	O
and	O
pain	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
local	O
application	O
of	O
a	O
combination	O
of	O
minoxidil	O
and	O
lignocaine	O
in	O
healing	O
anal	O
fissures	O
.	O

METHODS	O
In	O
this	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
study	O
,	O
90	O
patients	O
with	O
anal	O
fissure	O
were	O
recruited	O
.	O

Patients	O
received	O
local	O
applications	O
of	O
ointments	O
containing	O
5	O
%	O
lignocaine	O
(	O
n=28	O
)	O
,	O
0.5	O
%	O
minoxidil	O
(	O
n=36	O
)	O
,	O
or	O
both	O
(	O
n=26	O
)	O
.	O

Healing	Physical
of	Physical
anal	Physical
fissure	Physical
at	O
6	O
weeks	O
was	O
used	O
as	O
the	O
primary	O
end-point	O
.	O

RESULTS	O
Rates	Physical
of	Physical
complete	Physical
healing	Physical
of	Physical
fissure	Physical
were	O
similar	O
in	O
the	O
three	O
groups	O
(	O
lignocaine	O
alone	O
8/27	O
,	O
minoxidil	O
alone	O
10/34	O
,	O
combination	O
7/22	O
;	O
p=ns	O
)	O
.	O

Mean	Physical
(	Physical
SD	Physical
)	Physical
time	Physical
taken	Physical
for	Physical
complete	Physical
healing	Physical
with	Physical
combination	Physical
treatment	Physical
[	O
1.9	O
(	O
0.6	O
)	O
weeks	O
]	O
was	O
significantly	O
shorter	O
than	O
that	O
with	O
minoxidil	O
alone	O
(	O
3.1	O
[	O
1.7	O
]	O
weeks	O
;	O
p=0.001	O
)	O
or	O
with	O
lignocaine	O
alone	O
(	O
3.3	O
[	O
0.8	O
]	O
weeks	O
;	O
p=0.002	O
)	O
.	O

Rates	Physical
of	Physical
pain	Pain
relief	Pain
were	O
similar	O
in	O
the	O
three	O
groups	O
.	O

Stoppage	Physical
of	Physical
bleeding	Physical
occurred	O
more	O
often	O
with	O
combination	O
treatment	O
than	O
with	O
lignocaine	O
alone	O
.	O

No	O
patient	O
had	O
systemic	Adverseeffect
or	Adverseeffect
local	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
.	O

CONCLUSION	O
Combination	O
treatment	O
with	O
minoxidil	O
and	O
lignocaine	O
helps	O
in	O
faster	O
healing	O
of	O
anal	O
fissures	O
and	O
provides	O
better	O
symptomatic	O
relief	O
than	O
either	O
drug	O
alone	O
.	O

Modafinil	O
effects	O
during	O
acute	O
continuous	O
positive	O
airway	O
pressure	O
withdrawal	O
:	O
a	O
randomized	O
crossover	O
double-blind	O
placebo-controlled	O
trial	O
.	O

RATIONALE	O
Continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
use	O
is	O
associated	O
with	O
reduced	O
motor	O
vehicle	O
accidents	O
in	O
patients	O
with	O
obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
.	O

However	O
,	O
interruption	O
of	O
CPAP	O
therapy	O
is	O
common	O
and	O
is	O
associated	O
with	O
a	O
decline	O
in	O
daytime	O
function	O
.	O

OBJECTIVES	O
We	O
hypothesized	O
that	O
the	O
wakefulness	O
promoter	O
,	O
modafinil	O
,	O
would	O
ameliorate	O
this	O
decline	O
.	O

METHODS	O
Patients	O
were	O
admitted	O
to	O
the	O
laboratory	O
for	O
three	O
consecutive	O
nights	O
.	O

CPAP	O
was	O
used	O
for	O
the	O
first	O
night	O
,	O
followed	O
by	O
a	O
baseline	O
day	O
,	O
and	O
was	O
then	O
withdrawn	O
for	O
the	O
two	O
subsequent	O
nights	O
(	O
nasal	O
airflow	O
monitored	O
)	O
.	O

On	O
each	O
of	O
the	O
mornings	O
after	O
the	O
two	O
CPAP	O
withdrawal	O
nights	O
,	O
patients	O
received	O
200	O
mg	O
modafinil	O
or	O
placebo	O
(	O
n	O
=	O
21	O
)	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
crossover	O
design	O
.	O

Treatment	O
periods	O
were	O
separated	O
by	O
a	O
5-week	O
washout	O
.	O

Driving	Mental
simulator	Mental
performance	Mental
,	Mental
neurocognitive	Mental
performance	Mental
,	O
and	O
subjective	Mental
alertness	Mental
were	O
measured	O
by	O
the	O
AusEd	O
driving	O
simulator	O
,	O
psychomotor	O
vigilance	O
task	O
,	O
and	O
Karolinska	O
Sleepiness	O
Scale	O
,	O
respectively	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
During	O
CPAP	O
withdrawal	O
,	O
severe	Physical
sleep-disordered	Physical
breathing	Physical
was	O
evident	O
and	O
administration	O
of	O
modafinil	O
improved	O
simulated	Mental
driving	Mental
performance	Mental
(	Mental
steering	Mental
variability	Mental
,	O
P	O
<	O
0.0001	O
;	O
mean	Mental
reaction	Mental
time	Mental
,	O
P	O
<	O
or=	O
0.0002	O
;	O
lapses	Mental
,	O
P	O
<	O
or=	O
0.01	O
on	O
a	O
concurrent	O
task	O
)	O
,	O
psychomotor	Mental
vigilance	Mental
task	Mental
(	O
mean	O
1/reaction	O
time	O
and	O
lapses	O
,	O
both	O
P	O
<	O
or=	O
0.0002	O
)	O
,	O
and	O
subjective	Mental
sleepiness	Mental
(	O
P	O
<	O
or=	O
0.01	O
)	O
.	O

CONCLUSIONS	O
Modafinil	O
prevented	O
the	O
decline	O
in	O
simulated	O
driving	Mental
performance	Mental
,	O
neurocognitive	Mental
performance	Mental
,	O
and	O
subjective	Mental
sleepiness	Mental
in	O
patients	O
with	O
OSA	O
with	O
acutely	O
interrupted	O
CPAP	O
therapy	O
.	O

Clinical	O
trial	O
registered	O
with	O
the	O
Australian	O
New	O
Zealand	O
Clinical	O
Trials	O
Registry	O
at	O
www.anzctr.org.au	O
(	O
ACTRN12606000027516	O
)	O
.	O

Randomised	O
controlled	O
study	O
of	O
clinical	O
outcome	O
following	O
trophic	O
feeding	O
.	O

AIMS	O
To	O
determine	O
the	O
effect	O
of	O
trophic	O
feeding	O
on	O
clinical	O
outcome	O
in	O
ill	O
preterm	O
infants	O
.	O

METHODS	O
A	O
randomised	O
,	O
controlled	O
,	O
prospective	O
study	O
of	O
100	O
preterm	O
infants	O
,	O
weighing	O
less	O
than	O
1750	O
g	O
at	O
birth	O
and	O
requiring	O
ventilatory	O
support	O
and	O
parenteral	O
nutrition	O
,	O
was	O
performed	O
.	O

Group	O
TF	O
(	O
48	O
infants	O
)	O
received	O
trophic	O
feeding	O
from	O
day	O
3	O
(	O
0.5-1	O
ml/h	O
)	O
along	O
with	O
parenteral	O
nutrition	O
until	O
ventilatory	O
support	O
finished	O
.	O

Group	O
C	O
(	O
52	O
infants	O
)	O
received	O
parenteral	O
nutrition	O
alone	O
.	O

Nutritive	O
milk	O
feeding	O
was	O
then	O
introduced	O
to	O
both	O
groups	O
.	O

Clinical	O
outcomes	O
measured	O
included	O
total	O
energy	Physical
intake	Physical
and	Physical
growth	Physical
over	Physical
the	Physical
first	Physical
six	Physical
postnatal	Physical
weeks	Physical
,	O
sepsis	Physical
incidence	Physical
,	O
liver	Physical
function	Physical
,	O
milk	Physical
tolerance	Physical
,	O
duration	Others
of	Others
respiratory	Others
support	Others
,	O
duration	Others
of	Others
hospital	Others
stay	Others
and	O
complication	Adverseeffect
incidence	Adverseeffect
.	O

RESULTS	O
Groups	O
were	O
well	O
matched	O
for	O
birthweight	O
,	O
gestation	O
and	O
CRIB	O
scores	O
.	O

Infants	O
in	O
group	O
TF	O
had	O
significantly	O
greater	O
energy	Physical
intake	Physical
,	O
mean	O
difference	O
41.4	O
(	O
95	O
%	O
confidence	O
interval	O
9	O
,	O
73.7	O
)	O
kcal/kg	O
p=0.02	O
;	O
weight	Physical
gain	Physical
,	O
130	O
(	O
CI	O
1	O
,	O
250	O
)	O
g	O
p	O
=	O
0.02	O
;	O
head	Physical
circumference	Physical
gain	Physical
,	O
mean	O
difference	O
0.7	O
(	O
CI	O
0.1	O
,	O
1.3	O
)	O
cm	O
,	O
p	O
=	O
0.04	O
;	O
fewer	O
episodes	Physical
of	Physical
culture	Physical
confirmed	Physical
sepsis	Physical
,	O
mean	O
difference	O
-0.7	O
(	O
-1.3	O
,	O
-0.2	O
)	O
episodes	O
,	O
p	O
=	O
0.04	O
;	O
less	O
parenteral	Others
nutrition	Others
,	O
mean	O
difference	O
-11.5	O
(	O
CI	O
-20	O
,	O
-3	O
)	O
days	O
,	O
p	O
=	O
0	O
.	O

03	O
;	O
tolerated	Physical
full	Physical
milk	Physical
feeds	Physical
(	O
165	O
ml/kg/day	O
)	O
earlier	O
,	O
mean	O
difference	O
-11.2	O
(	O
CI	O
-19	O
,	O
-3	O
)	O
days	O
,	O
p	O
=	O
0.03	O
;	O
reduced	O
requirement	Others
for	Others
supplemental	Others
oxygen	Others
,	O
mean	O
difference	O
-22.4	O
(	O
CI-41.5	O
,	O
-3.3	O
)	O
days	O
,	O
p	O
=	O
0.02	O
;	O
and	O
were	O
discharged	Others
home	Others
earlier	O
,	O
mean	O
difference	O
-22.1	O
(	O
CI	O
-42.1	O
,	O
-2.2	O
)	O
days	O
,	O
p	O
=	O
0.04	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
relative	O
risk	Adverseeffect
of	Adverseeffect
any	Adverseeffect
complication	Adverseeffect
.	O

CONCLUSIONS	O
Trophic	O
feeding	O
improves	O
clinical	O
outcome	O
in	O
ill	O
preterm	O
infants	O
requiring	O
parenteral	O
nutrition	O
.	O

Reflexive	O
orienting	O
in	O
response	O
to	O
eye	O
gaze	O
and	O
an	O
arrow	O
in	O
children	O
with	O
and	O
without	O
autism	O
.	O

BACKGROUND	O
This	O
study	O
investigated	O
whether	O
another	O
person	O
's	O
social	O
attention	Mental
,	O
specifically	O
the	O
direction	O
of	O
their	O
eye	O
gaze	O
,	O
and	O
a	O
non-social	O
directional	O
cue	O
,	O
an	O
arrow	O
,	O
triggered	O
reflexive	Mental
orienting	Mental
in	O
children	O
with	O
and	O
without	O
autism	O
in	O
an	O
experimental	O
situation	O
.	O

METHODS	O
Children	O
with	O
autism	O
and	O
typically	O
developed	O
children	O
participated	O
in	O
one	O
of	O
two	O
experiments	O
.	O

Both	O
experiments	O
involved	O
the	O
localization	O
of	O
a	O
target	O
that	O
appeared	O
to	O
the	O
left	O
or	O
right	O
of	O
the	O
fixation	O
point	O
.	O

Before	O
the	O
target	O
appeared	O
,	O
the	O
participant	O
's	O
attention	O
was	O
cued	O
to	O
the	O
left	O
or	O
right	O
by	O
either	O
an	O
arrow	O
or	O
the	O
direction	O
of	O
eye	O
gaze	O
on	O
a	O
computerized	O
face	O
.	O

RESULTS	O
Children	O
with	O
autism	O
were	O
slower	Mental
to	Mental
respond	Mental
,	O
which	O
suggests	O
a	O
slight	O
difference	O
in	O
the	O
general	O
cognitive	Mental
ability	Mental
of	O
the	O
groups	O
.	O

In	O
Experiment	O
1	O
,	O
although	O
the	O
participants	O
were	O
instructed	O
to	O
disregard	O
the	O
cue	O
and	O
the	O
target	O
was	O
correctly	O
cued	O
in	O
only	O
50	O
%	O
of	O
the	O
trials	O
,	O
both	O
groups	O
of	O
children	O
responded	Physical
significantly	O
faster	O
to	O
cued	O
targets	O
than	O
to	O
uncued	O
targets	O
,	O
regardless	O
of	O
the	O
cue	O
.	O

In	O
Experiment	O
2	O
,	O
children	O
were	O
instructed	O
to	O
attend	O
to	O
the	O
direction	O
opposite	O
that	O
of	O
the	O
cues	O
and	O
the	O
target	O
was	O
correctly	O
cued	O
in	O
only	O
20	O
%	O
of	O
the	O
trials	O
.	O

Typically	O
developed	O
children	O
located	Mental
targets	Mental
cued	Mental
by	Mental
eye	Mental
gaze	Mental
more	O
quickly	O
,	O
while	O
the	O
arrow	O
cue	O
did	O
not	O
trigger	O
such	O
reflexive	Mental
orienting	Mental
in	O
these	O
children	O
.	O

However	O
,	O
both	O
social	O
and	O
non-social	O
cues	O
shifted	O
attention	Mental
to	O
the	O
cued	O
location	O
in	O
children	O
with	O
autism	O
.	O

CONCLUSION	O
These	O
results	O
indicate	O
that	O
eye	O
gaze	O
attracted	O
attention	Physical
more	O
effectively	O
than	O
the	O
arrow	O
in	O
typically	O
developed	O
children	O
,	O
while	O
children	O
with	O
autism	O
shifted	O
their	O
attention	O
equally	O
in	O
response	O
to	O
eye	O
gaze	O
and	O
arrow	O
direction	O
,	O
failing	O
to	O
show	O
preferential	O
sensitivity	Mental
to	O
the	O
social	O
cue	O
.	O

Difficulty	O
in	O
shifting	O
controlled	O
attention	Physical
to	O
the	O
instructed	O
side	O
was	O
also	O
found	O
in	O
children	O
with	O
autism	O
.	O

Sodium-potassium	O
pump	O
activity	O
in	O
white	O
blood	O
cells	O
from	O
children	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
hypertension	O
--	O
The	O
Odense	O
Schoolchild	O
Study	O
.	O

We	O
have	O
measured	O
the	O
capacity	O
of	O
the	O
sodium-potassium	O
pump	O
,	O
as	O
assessed	O
by	O
86rubidium	O
uptake	O
and	O
the	O
number	O
of	O
[	O
3H	O
]	O
-ouabain	O
binding	O
sites	O
on	O
white	O
blood	O
cells	O
,	O
in	O
children	O
aged	O
9-11	O
years	O
,	O
partly	O
cross-sectionally	O
and	O
partly	O
longitudinally	O
after	O
a	O
physical	O
training	O
programme	O
.	O

Children	O
from	O
a	O
hypertensive	O
subgroup	O
comprising	O
the	O
upper	O
5	O
%	O
of	O
the	O
blood	O
pressure	O
distribution	O
and	O
children	O
from	O
a	O
randomly	O
selected	O
normotensive	O
subgroup	O
were	O
eligible	O
for	O
the	O
study	O
.	O

In	O
the	O
cross-sectional	O
study	O
40	O
children	O
from	O
the	O
hypertensive	O
subgroup	O
and	O
40	O
children	O
from	O
the	O
normotensive	O
subgroup	O
were	O
evaluated	O
.	O

A	O
significant	O
increase	O
in	O
86rubidium	Physical
uptake	Physical
was	O
present	O
in	O
boys	O
as	O
compared	O
to	O
girls	O
.	O

After	O
adjustment	O
for	O
differences	O
in	O
sexual	O
maturation	O
the	O
observed	O
significant	O
difference	O
disappeared	O
.	O

Important	O
correlates	O
of	O
pump	O
activity	O
were	O
height	O
,	O
plasma	O
glucose	O
,	O
and	O
physical	O
fitness	O
.	O

In	O
the	O
training	O
study	O
10	O
boys	O
from	O
the	O
hypertensive	O
subgroup	O
and	O
10	O
boys	O
from	O
the	O
normotensive	O
subgroup	O
were	O
also	O
evaluated	O
after	O
eight	O
months	O
of	O
physical	O
training	O
.	O

A	O
significant	O
fall	O
in	O
86rubidium	Physical
uptake	Physical
was	O
observed	O
.	O

No	O
control	O
group	O
was	O
examined	O
and	O
probably	O
the	O
changes	O
reflect	O
some	O
effects	O
of	O
sexual	Physical
maturation	Physical
on	Physical
cation	Physical
handling	Physical
of	Physical
cells	Physical
.	O

These	O
results	O
indicate	O
a	O
significant	O
effect	O
of	O
sexual	Physical
maturation	Physical
in	Physical
capacity	Physical
of	Physical
sodium-potassium	Physical
pump	Physical
in	O
children	O
.	O

Dietary	O
status	O
and	O
impact	O
of	O
risperidone	O
on	O
nutritional	Physical
balance	Physical
in	O
children	O
with	O
autism	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
Risperidone	O
may	O
be	O
effective	O
in	O
improving	O
tantrums	Physical
,	O
aggression	Physical
,	O
or	O
self-injurious	Physical
behaviour	Physical
in	O
children	O
with	O
autism	O
,	O
but	O
often	O
leads	O
to	O
weight	Physical
gain	Physical
.	O

METHOD	O
Using	O
a	O
quantitative	O
Food	Mental
Frequency	Mental
Questionnaire	Mental
(	Mental
FFQ	Mental
)	Mental
,	O
we	O
prospectively	O
examined	O
the	O
nutritional	O
intake	O
of	O
20	O
children	O
with	O
autism	O
participating	O
in	O
a	O
randomised	O
placebo-controlled	O
trial	O
of	O
risperidone	O
for	O
disruptive	O
behaviours	O
.	O

RESULTS	O
At	O
baseline	O
,	O
the	O
mean	Physical
intakes	Physical
for	Physical
macronutrients	Physical
,	Physical
vitamins	Physical
and	Physical
minerals	Physical
exceeded	O
Dietary	O
Reference	O
Intakes	O
(	O
DRIs	O
)	O
.	O

However	O
there	O
was	O
substantial	O
inter-participant	O
variability	O
,	O
with	O
individual	Physical
deficiencies	Physical
(	O
<	O
80	O
%	O
of	O
DRI	O
)	O
in	O
the	O
intake	Physical
of	Physical
calcium	Physical
(	O
9	O
of	O
20	O
participants	O
)	O
,	O
pantothenic	Physical
acid	Physical
(	O
6	O
of	O
20	O
)	O
,	O
vitamin	Physical
D	Physical
(	O
5	O
of	O
20	O
)	O
and	O
vitamin	O
K	O
(	O
8	O
of	O
20	O
)	O
.	O

For	O
the	O
participants	O
for	O
whom	O
FFQs	O
were	O
available	O
,	O
there	O
was	O
an	O
increase	Physical
in	Physical
weight	Physical
and	O
an	O
increase	Physical
in	Physical
vitamin	Physical
K	Physical
intake	Physical
after	O
2	O
months	O
of	O
risperidone	O
treatment	O
(	O
n	O
=	O
9	O
)	O
compared	O
to	O
placebo	O
(	O
n	O
=	O
8	O
)	O
.	O

An	O
additional	O
4	O
months	O
of	O
risperidone	O
treatment	O
(	O
n	O
=	O
8	O
)	O
did	O
not	O
result	O
in	O
significant	O
changes	O
in	O
reported	O
nutritional	Physical
balance	Physical
.	O

CONCLUSION	O
These	O
pilot	O
data	O
suggest	O
that	O
treatment	O
with	O
risperidone	O
did	O
not	O
significantly	O
affect	O
the	O
nutritional	O
balance	O
of	O
this	O
small	O
group	O
of	O
children	O
.	O

Comparison	O
of	O
coronary	O
bypass	O
surgery	O
with	O
angioplasty	O
in	O
patients	O
with	O
multivessel	O
disease	O
.	O

The	O
Bypass	O
Angioplasty	O
Revascularization	O
Investigation	O
(	O
BARI	O
)	O
Investigators	O
.	O

BACKGROUND	O
Coronary-artery	O
bypass	O
grafting	O
(	O
CABG	O
)	O
and	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
are	O
alternative	O
methods	O
of	O
revascularization	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
in	O
selected	O
patients	O
with	O
multivessel	O
disease	O
suitable	O
for	O
treatment	O
with	O
either	O
procedure	O
,	O
an	O
initial	O
strategy	O
of	O
PTCA	O
does	O
not	O
result	O
in	O
a	O
poorer	O
five-year	O
clinical	O
outcome	O
than	O
CABG	O
.	O

METHODS	O
Patients	O
with	O
multivessel	O
disease	O
were	O
randomly	O
assigned	O
to	O
an	O
initial	O
treatment	O
strategy	O
of	O
CABG	O
(	O
n	O
=	O
914	O
)	O
or	O
PTCA	O
(	O
n	O
=	O
915	O
)	O
and	O
were	O
followed	O
for	O
an	O
average	O
of	O
5.4	O
years	O
.	O

Analysis	O
of	O
outcome	O
events	O
was	O
performed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
.	O

RESULTS	O
The	O
respective	O
in-hospital	O
event	O
rates	O
for	O
CABG	O
and	O
PTCA	O
were	O
1.3	O
percent	O
and	O
1.1	O
percent	O
for	O
mortality	Mortality
,	O
4.6	O
percent	O
and	O
2.1	O
percent	O
for	O
Q-wave	Physical
myocardial	Physical
infarction	Physical
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
0.8	O
percent	O
and	O
0.2	O
percent	O
for	O
stroke	Physical
.	O

The	O
five-year	Mortality
survival	Mortality
rate	Mortality
was	O
89.3	O
percent	O
for	O
those	O
assigned	O
to	O
CABG	O
and	O
86.3	O
percent	O
for	O
those	O
assigned	O
to	O
PTCA	O
(	O
P	O
=	O
0.19	O
;	O
95	O
percent	O
confidence	O
interval	O
of	O
the	O
difference	O
in	O
survival	O
,	O
-0.2	O
percent	O
to	O
6.0	O
percent	O
)	O
.	O

The	O
respective	Mortality
five-year	Mortality
survival	Mortality
rates	Mortality
free	Mortality
from	Mortality
Q-wave	Mortality
myocardial	Mortality
infarction	Mortality
were	O
80.4	O
percent	O
and	O
78.7	O
percent	O
.	O

By	O
five	O
years	O
after	O
study	O
entry	O
,	O
8	O
percent	O
of	O
the	O
patients	O
assigned	O
to	O
CABG	O
had	O
undergone	O
additional	O
revascularization	Others
procedures	Others
,	O
as	O
compared	O
with	O
54	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
;	O
69	O
percent	O
of	O
those	O
assigned	O
to	O
PTCA	O
did	O
not	O
subsequently	O
undergo	O
CABG	O
.	O

Among	O
diabetic	O
patients	O
who	O
were	O
being	O
treated	O
with	O
insulin	O
or	O
oral	O
hypoglycemic	O
agents	O
at	O
base	O
line	O
,	O
a	O
subgroup	O
not	O
specified	O
by	O
the	O
protocol	O
,	O
five-year	Mortality
survival	Mortality
was	O
80.6	O
percent	O
for	O
the	O
CABG	O
group	O
as	O
compared	O
with	O
65.5	O
percent	O
for	O
the	O
PTCA	O
group	O
(	O
P	O
=	O
0.003	O
)	O
.	O

CONCLUSIONS	O
As	O
compared	O
with	O
CABG	O
,	O
an	O
initial	O
strategy	O
of	O
PTCA	O
did	O
not	O
significantly	O
compromise	O
five-year	Mortality
survival	Mortality
in	O
patients	O
with	O
multivessel	O
disease	O
,	O
although	O
subsequent	Others
revascularization	Others
was	O
required	O
more	O
often	O
with	O
this	O
strategy	O
.	O

For	O
treated	O
diabetics	O
,	O
five-year	Mortality
survival	Mortality
was	O
significantly	O
better	O
after	O
CABG	O
than	O
after	O
PTCA	O
.	O

Anxiolytics	O
in	O
patients	O
suffering	O
a	O
suspected	O
acute	O
coronary	O
syndrome	O
:	O
multi-centre	O
randomised	O
controlled	O
trial	O
in	O
Emergency	O
Medical	O
Service	O
.	O

BACKGROUND	O
The	O
prehospital	O
treatment	O
of	O
pain	O
and	O
discomfort	O
among	O
patients	O
who	O
suffer	O
from	O
acute	O
coronary	O
syndrome	O
(	O
ACS	O
)	O
needs	O
a	O
treatment	O
strategy	O
which	O
combines	O
relief	O
of	O
pain	O
with	O
relief	O
of	O
anxiety	O
.	O

AIM	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
on	O
pain	O
and	O
anxiety	O
of	O
the	O
combination	O
of	O
an	O
anxiolytic	O
and	O
an	O
analgesic	O
as	O
compared	O
with	O
an	O
analgesic	O
alone	O
in	O
the	O
prehospital	O
setting	O
of	O
suspected	O
ACS	O
.	O

METHODS	O
A	O
multi-centre	O
randomised	O
controlled	O
trial	O
compared	O
the	O
combination	O
of	O
Midazolam	O
(	O
Mi	O
)	O
+Morphine	O
(	O
Mo	O
)	O
and	O
Mo	O
alone	O
.	O

All	O
measures	O
took	O
part	O
:	O
Prior	O
to	O
randomisation	O
,	O
15	O
min	O
thereafter	O
and	O
on	O
admission	O
to	O
a	O
hospital	O
.	O

Inclusion	O
criteria	O
were	O
:	O
1	O
)	O
pain	O
raising	O
suspicion	O
of	O
ACS	O
and	O
2	O
)	O
pain	O
score	O
?4	O
.	O

PRIMARY	O
ENDPOINT	O
Pain	O
score	O
after	O
15	O
min	O
.	O

RESULTS	O
In	O
all	O
,	O
890	O
patients	O
were	O
randomised	O
to	O
Mi+Mo	O
and	O
873	O
to	O
Mo	O
alone	O
.	O

Pain	O
was	O
reduced	O
from	O
a	O
median	O
of	O
6	O
to	O
4	O
and	O
finally	O
to	O
3	O
in	O
both	O
groups	O
.	O

The	O
mean	O
dose	O
of	O
Mo	O
was	O
5.3	O
mg	O
in	O
Mi+Mo	O
and	O
6.0	O
mg	O
in	O
Mo	O
alone	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Anxiety	O
was	O
reported	O
in	O
66	O
%	O
in	O
Mi+Mo	O
and	O
in	O
64	O
%	O
in	O
Mo	O
alone	O
at	O
randomisation	O
(	O
NS	O
)	O
;	O
15	O
min	O
thereafter	O
in	O
31	O
%	O
and	O
39	O
%	O
(	O
p=0.002	O
)	O
and	O
finally	O
in	O
12	O
%	O
and	O
26	O
%	O
respectively	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

On	O
admission	O
to	O
a	O
hospital	O
nausea	Adverseeffect
or	Adverseeffect
vomiting	Adverseeffect
was	O
reported	O
in	O
9	O
%	O
in	O
Mi+Mo	O
and	O
in	O
13	O
%	O
in	O
Mo	O
alone	O
(	O
p=0.003	O
)	O
.	O

Drowsiness	O
differed	O
;	O
15	O
%	O
and	O
14	O
%	O
were	O
drowsy	O
in	O
Mi+Mo	O
versus	O
2	O
%	O
and	O
3	O
%	O
in	O
Mo	O
alone	O
respectively	O
(	O
p	O
<	O
0.001	O
)	O
.	O

CONCLUSION	O
Despite	O
the	O
fact	O
that	O
the	O
combination	O
of	O
anxiolytics	O
and	O
analgesics	O
as	O
compared	O
with	O
analgesics	O
alone	O
reduced	O
anxiety	O
and	O
the	O
requirement	O
of	O
Morphine	O
in	O
the	O
prehospital	O
setting	O
of	O
acute	O
coronary	O
syndrome	O
,	O
this	O
strategy	O
did	O
not	O
reduce	O
patients	O
'	O
estimation	O
of	O
pain	O
(	O
primary	O
endpoint	O
)	O
.	O

More	O
effective	O
pain	O
relief	O
among	O
these	O
patients	O
is	O
warranted	O
.	O

Vitamin	O
D	O
supplementation	O
increases	O
calcium	Physical
absorption	Physical
without	O
a	O
threshold	O
effect	O
.	O

BACKGROUND	O
The	O
maximal	O
calcium	O
absorption	O
in	O
response	O
to	O
vitamin	O
D	O
has	O
been	O
proposed	O
as	O
a	O
biomarker	O
for	O
vitamin	O
D	O
sufficiency	O
.	O

OBJECTIVE	O
The	O
objective	O
was	O
to	O
determine	O
whether	O
there	O
is	O
a	O
threshold	O
beyond	O
which	O
increasing	O
doses	O
of	O
vitamin	O
D	O
,	O
or	O
concentrations	O
of	O
serum	O
25-hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
,	O
no	O
longer	O
increase	O
calcium	Physical
absorption	Physical
.	O

DESIGN	O
This	O
was	O
a	O
placebo-controlled	O
,	O
dose-response	O
,	O
randomized	O
,	O
double-blind	O
study	O
of	O
the	O
effect	O
of	O
vitamin	O
D	O
on	O
calcium	O
absorption	O
in	O
healthy	O
postmenopausal	O
women	O
.	O

Seventy-six	O
healthy	O
postmenopausal	O
women	O
were	O
randomly	O
assigned	O
to	O
placebo	O
or	O
800	O
IU	O
(	O
20	O
?g	O
)	O
,	O
2000	O
IU	O
(	O
50	O
?g	O
)	O
,	O
or	O
4000	O
IU	O
(	O
100	O
?g	O
)	O
vitamin	O
D?	O
for	O
8	O
wk	O
.	O

The	O
technique	O
of	O
dual	O
isotopes	O
of	O
stable	O
calcium	O
was	O
used	O
with	O
a	O
calcium	O
carrier	O
to	O
measure	O
calcium	O
absorption	O
at	O
baseline	O
and	O
after	O
8	O
wk	O
.	O

RESULTS	O
Seventy-one	O
women	O
with	O
a	O
mean	O
?	O
SD	O
age	O
of	O
58.8	O
?	O
4.9	O
y	O
completed	O
the	O
study	O
.	O

The	O
mean	O
calcium	O
intake	O
was	O
1142	O
?	O
509	O
mg/d	O
and	O
serum	O
25	O
(	O
OH	O
)	O
D	O
was	O
63	O
?	O
14	O
nmol/L	O
at	O
baseline	O
.	O

A	O
statistically	O
significant	O
linear	O
trend	O
of	O
an	O
increase	O
in	O
calcium	O
absorption	O
adjusted	O
for	O
age	O
and	O
body	O
mass	O
index	O
with	O
increasing	O
vitamin	O
D?	O
dose	O
or	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
observed	O
.	O

A	O
6.7	O
%	O
absolute	O
increase	O
in	O
calcium	O
absorption	O
was	O
found	O
in	O
the	O
highest	O
vitamin	O
D?	O
group	O
(	O
100	O
?g	O
)	O
.	O

No	O
evidence	O
of	O
nonlinearity	O
was	O
observed	O
in	O
the	O
dose-response	O
curve	O
.	O

CONCLUSIONS	O
No	O
evidence	O
of	O
a	O
threshold	O
of	O
calcium	O
absorption	O
was	O
found	O
with	O
a	O
serum	O
25	O
(	O
OH	O
)	O
D	O
range	O
from	O
40	O
to	O
130	O
nmol/L	O
.	O

Calcium	O
absorption	O
in	O
this	O
range	O
is	O
not	O
a	O
useful	O
biomarker	O
to	O
determine	O
nutritional	O
recommendations	O
for	O
vitamin	O
D	O
.	O

Therapeutic	O
effects	O
of	O
combined	O
treatment	O
using	O
tetracycline-immobilized	O
collagen	O
film	O
and	O
root	O
planing	O
in	O
periodontal	O
furcation	O
pockets	O
.	O

46	O
upper	O
and	O
lower	O
molars	O
with	O
furcation	O
grade	O
II	O
involvement	O
were	O
selected	O
from	O
16	O
patients	O
with	O
periodontal	O
disease	O
.	O

The	O
teeth	O
were	O
randomly	O
allocated	O
to	O
the	O
following	O
groups	O
according	O
to	O
treatment	O
;	O
(	O
1	O
)	O
4	O
consecutive	O
administrations	O
of	O
tetracycline-immobilized	O
cross-linked	O
collagen	O
film	O
(	O
TC	O
film	O
)	O
at	O
intervals	O
of	O
1	O
week	O
(	O
TC	O
group	O
)	O
;	O
(	O
2	O
)	O
1	O
root	O
planing	O
treatment	O
(	O
RP	O
group	O
)	O
;	O
(	O
3	O
)	O
combination	O
treatment	O
(	O
TC	O
+	O
RP	O
group	O
)	O
;	O
(	O
4	O
)	O
no	O
treatment	O
(	O
control	O
group	O
)	O
.	O

The	O
therapeutic	O
effects	O
of	O
each	O
treatment	O
were	O
compared	O
both	O
clinically	O
and	O
microbiologically	O
.	O

Records	O
of	O
plaque	Physical
index	Physical
,	Physical
gingival	Physical
index	Physical
,	Physical
bleeding	Physical
on	Physical
probing	Physical
,	Physical
probing	Physical
depth	Physical
,	Physical
probing	Physical
attachment	Physical
level	Physical
and	Physical
microscopic	Physical
counts	Physical
were	O
obtained	O
at	O
0	O
,	O
4	O
,	O
6	O
and	O
8	O
weeks	O
.	O

The	O
results	O
showed	O
marked	O
decreases	O
in	O
probing	Physical
depth	Physical
and	Physical
density	Physical
of	Physical
micro-organisms	Physical
in	O
both	O
the	O
RP	O
and	O
TC	O
+	O
RP	O
groups	O
.	O

In	O
particular	O
,	O
the	O
TC	O
+	O
RP	O
group	O
was	O
characterized	O
by	O
a	O
decreased	O
rate	Physical
of	Physical
bleeding	Physical
on	Physical
pocket	Physical
probing	Physical
and	O
an	O
increased	O
probing	Physical
attachment	Physical
gain	Physical
.	Physical

The	O
above	O
findings	O
demonstrated	O
that	O
root	O
planning	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
furcation	O
involvement	O
and	O
that	O
the	O
effects	O
are	O
enhanced	O
by	O
the	O
local	O
administration	O
of	O
TC	O
films	O
.	O

Iobitridol	O
300	O
compared	O
to	O
iopromide	O
300	O
--	O
a	O
double-blind	O
randomized	O
phase-III	O
study	O
of	O
clinical	O
tolerance	O
in	O
total	O
body	O
CT.	O
UNLABELLED	O
PURPOSE	O
,	O
MATERIAL	O
AND	O
METHODS	O
:	O
The	O
clinical	O
safety	O
of	O
iobitriodol	O
300	O
mg	O
I/ml	O
and	O
iopromide	O
300	O
mg	O
I/ml	O
were	O
compared	O
in	O
a	O
randomized	O
double	O
blind	O
phase-III	O
study	O
conducted	O
on	O
60	O
patients	O
undergoing	O
abdominal	O
CT	O
for	O
a	O
variety	O
of	O
indications	O
.	O

Each	O
examination	O
was	O
rated	O
as	O
diagnostic	O
or	O
nondiagnostic	O
and	O
the	O
image	O
quality	O
was	O
noted	O
.	O

Nature	O
,	O
onset	Others
,	O
intensity	O
as	O
well	O
as	O
outcome	O
of	O
each	O
adverse	Adverseeffect
reaction	Adverseeffect
were	O
recorded	O
.	O

RESULTS	O
There	O
was	O
no	O
significant	O
difference	O
in	O
imaging	Others
quality	Others
and	O
side	Adverseeffect
effects	Adverseeffect
between	O
the	O
contrast	O
media	O
.	O

In	O
this	O
study	O
,	O
both	O
iobitridol	O
and	O
iopromide	O
provided	O
excellent	Others
image	Others
quality	Others
and	O
a	O
low	Adverseeffect
rate	Adverseeffect
of	Adverseeffect
side	Adverseeffect
effects	Adverseeffect
.	O

CONCLUSION	O
Iobitridol	O
is	O
a	O
safe	Others
and	O
effective	Others
nonionic	Others
contrast	Others
agent	Others
for	O
contrast-enhanced	O
body	O
CT	O
.	O

Magnocellular	O
visual	O
evoked	O
potential	O
delay	O
with	O
high	O
autism	O
spectrum	O
quotient	O
yields	O
a	O
neural	O
mechanism	O
for	O
altered	Physical
perception	Physical
.	Physical

Everyone	O
has	O
autistic	O
characteristics	O
to	O
a	O
greater	O
or	O
lesser	O
degree	O
,	O
encapsulated	O
in	O
the	O
Autism	Physical
Spectrum	Physical
Quotient	Physical
,	O
a	O
scale	O
that	O
measures	O
the	O
degree	O
to	O
which	O
an	O
adult	O
of	O
normal	O
intelligence	O
displays	O
traits	O
associated	O
with	O
autism	O
spectrum	O
disorders	O
.	O

Recent	O
psychophysical	O
analyses	O
of	O
autism	O
spectrum	O
disorders	O
point	O
to	O
superior	O
local	O
processing	O
,	O
and	O
impaired	O
or	O
ignored	O
global	O
and	O
contextual	O
processing	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
low-	O
and	O
high-scoring	O
individuals	O
on	O
the	O
Autism	O
Spectrum	O
Quotient	O
differ	O
on	O
a	O
measure	O
of	O
local	Physical
and	Physical
global	Physical
processing	Physical
,	O
motion	O
processing	O
and	O
visual	O
pathway	O
integrity	O
.	O

Fifteen	O
low-scoring	O
individuals	O
and	O
14	O
high-scoring	O
individuals	O
derived	O
from	O
a	O
normal	O
population	O
participated	O
in	O
the	O
study	O
.	O

The	O
results	O
indicate	O
that	O
the	O
initial	O
cortical	Physical
response	Physical
to	O
the	O
magnocellular	O
afferents	O
is	O
weaker	O
at	O
low	O
contrast	O
in	O
the	O
high	O
autistic	O
tendency	O
group	O
and	O
that	O
a	O
second-order	O
response	O
,	O
reflecting	O
magnocellular	O
activity	O
,	O
demonstrated	O
a	Others
delay	Others
for	O
high	O
versus	O
low	O
scorers	O
when	O
the	O
parvocellular	O
pathway	O
was	O
also	O
active	O
in	O
response	O
to	O
a	O
high	O
contrast	O
stimulus	O
.	O

High-scoring	O
individuals	O
also	O
demonstrated	O
difficulty	O
in	O
identifying	Others
the	Others
global	Others
components	Others
of	O
locally	O
salient	O
hierarchical	O
Navon	O
figures	O
.	O

Furthermore	O
,	O
cross-validated	O
discriminant	O
analysis	O
,	O
using	O
four	O
physiologically	O
and	O
three	O
psychophysically	O
derived	O
parameters	O
,	O
correctly	O
classified	O
83	O
%	O
of	O
individuals	O
who	O
scored	O
either	O
high	O
or	O
low	O
on	O
the	O
Autism	O
Spectrum	O
Quotient	O
.	O

These	O
findings	O
in	O
the	O
group	O
scoring	O
high	O
on	O
the	O
Autism	O
Spectrum	O
Quotient	O
indicate	O
that	O
a	O
delay	O
in	O
primary	O
visual/prestriate	O
cortical	O
processing	O
of	O
magnocellular	O
input	O
diminishes	O
the	O
advantage	O
of	O
its	O
early	O
arrival	O
to	O
primary	O
visual	O
cortex	O
.	O

This	O
appears	O
to	O
be	O
associated	O
with	O
impaired	Others
global	Others
visual	Others
perception	Others
,	O
predicting	O
with	O
high	O
accuracy	O
behavioural	Physical
tendencies	Physical
associated	O
with	O
autism	O
spectrum	O
disorders	O
.	O

It	O
has	O
been	O
proposed	O
that	O
perceptual	O
impairment	O
in	O
autism	O
may	O
be	O
attributed	O
to	O
a	O
dysfunction	O
of	O
horizontal	O
connections	O
within	O
early	O
visual	O
areas	O
,	O
presumably	O
parvocellular	O
in	O
nature	O
.	O

However	O
,	O
the	O
timing	O
of	O
such	O
form	O
processing	O
aberrations	O
is	O
much	O
later	O
than	O
the	O
timing	O
of	O
abnormal	O
magnocellular	O
visual	O
processing	O
measured	O
directly	O
here	O
.	O

Thus	O
it	O
is	O
proposed	O
that	O
a	O
magnocellular	O
processing	O
delay	O
decreases	O
the	O
ability	O
of	O
autistic	O
individuals	O
to	O
benefit	O
perceptually	O
from	O
feedback	O
normally	O
associated	O
with	O
the	O
magnocellular	O
advantage	O
.	O

Low	O
body	O
mass	O
index	O
and	O
dyslipidemia	O
in	O
dialysis	O
patients	O
linked	O
to	O
elevated	O
plasma	O
fibroblast	O
growth	O
factor	O
23	O
.	O

BACKGROUND	O
Fibroblast	O
growth	O
factor	O
23	O
(	O
FGF23	O
)	O
has	O
been	O
associated	O
with	O
death	O
in	O
dialysis	O
patients	O
.	O

Since	O
FGF23	O
shares	O
structural	O
features	O
with	O
FGF19	O
subfamily	O
members	O
that	O
exert	O
hormonal	O
control	O
of	O
fat	O
mass	O
,	O
we	O
hypothesized	O
that	O
high	O
circulating	O
FGF23	O
concentrations	O
would	O
be	O
associated	O
with	O
the	O
development	O
of	O
a	O
uremic	O
lipid	O
profile	O
and	O
lower	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
.	O

METHODS	O
This	O
study	O
was	O
conducted	O
among	O
654	O
patients	O
receiving	O
chronic	O
hemodialysis	O
.	O

C-terminal	Physical
FGF23	Physical
concentrations	Physical
were	O
measured	O
in	O
stored	O
plasma	O
samples	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
examine	O
the	O
cross-sectional	O
associations	O
of	O
plasma	Physical
FGF23	Physical
concentrations	Physical
with	Physical
BMI	Physical
,	Physical
total	Physical
cholesterol	Physical
(	Physical
TC	Physical
)	Physical
,	Physical
low-density	Physical
lipoprotein-cholesterol	Physical
(	Physical
LDL-C	Physical
)	Physical
,	Physical
high-density	Physical
lipoprotein-cholesterol	Physical
(	Physical
HDL-C	Physical
)	Physical
and	Physical
triglycerides	Physical
.	Physical

Cox	O
proportional	O
hazard	O
models	O
were	O
used	O
to	O
examine	O
the	O
association	O
between	O
FGF23	O
concentrations	O
and	O
all-cause	O
mortality	O
.	O

RESULTS	O
Participants	O
had	O
a	O
mean	O
age	O
of	O
60	O
?	O
11	O
years	O
and	O
a	O
median	O
(	O
IQR	O
)	O
FGF23	O
concentration	O
of	O
4,212	O
(	O
1,411-13,816	O
)	O
RU/ml	O
.	O

An	O
increase	O
per	O
SD	O
in	O
log10	O
FGF23	O
was	O
associated	O
with	O
lower	O
BMI	O
(	O
?	O
=	O
-1.11	O
;	O
p	O
=	O
0.008	O
)	O
,	O
TC	O
(	O
?	O
=	O
-6.46	O
;	O
p	O
=	O
0.02	O
)	O
,	O
LDL-C	O
(	O
?	O
=	O
-4.73	O
;	O
p	O
=	O
0.04	O
)	O
and	O
HDL-C	O
(	O
?	O
=	O
-2.14	O
;	O
p	O
=	O
0.03	O
)	O
;	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
race	O
,	O
cardiovascular	O
risk	O
factors	O
,	O
serum	O
albumin	O
,	O
markers	O
of	O
mineral	O
metabolism	O
,	O
and	O
use	O
of	O
lipid-lowering	O
drugs	O
.	O

The	O
association	O
of	O
FGF23	O
with	O
death	O
was	O
attenuated	O
after	O
adjustment	O
for	O
HDL-C	O
(	O
HR	O
of	O
highest	O
quartile	O
1.53	O
,	O
95	O
%	O
CI	O
1.06-2.20	O
compared	O
to	O
lowest	O
quartile	O
)	O
.	O

CONCLUSION	O
These	O
results	O
indicate	O
that	O
higher	O
plasma	O
FGF23	O
levels	O
are	O
associated	O
with	O
lower	O
BMI	O
and	O
dyslipidemia	O
in	O
dialysis	O
patients	O
.	O

The	O
association	O
between	O
FGF23	O
and	O
death	O
may	O
be	O
mediated	O
through	O
unexplored	O
metabolic	O
risk	O
factors	O
unrelated	O
to	O
mineral	O
metabolism	O
.	O

The	O
effect	O
of	O
magnesium	O
added	O
to	O
levobupivacaine	O
for	O
femoral	O
nerve	O
block	O
on	O
postoperative	O
analgesia	O
in	O
patients	O
undergoing	O
ACL	O
reconstruction	O
.	O

PURPOSE	O
The	O
aim	O
of	O
this	O
prospective	O
randomised	O
double-blind	O
study	O
is	O
to	O
investigate	O
the	O
effect	O
of	O
magnesium	O
added	O
to	O
local	O
anaesthetics	O
on	O
postoperative	O
VAS	O
scores	O
,	O
total	O
opioid	O
consumption	O
,	O
time	O
to	O
first	O
mobilisation	O
,	O
patient	O
satisfaction	O
and	O
rescue	O
analgesic	O
requirements	O
in	O
arthroscopic	O
ACL	O
reconstruction	O
surgery	O
.	O

METHODS	O
A	O
total	O
of	O
107	O
American	O
Society	O
of	O
Anaesthesiologists	O
physical	O
status	O
grade	O
I	O
and	O
II	O
patients	O
between	O
18	O
and	O
65	O
years	O
of	O
age	O
who	O
were	O
scheduled	O
to	O
undergo	O
elective	O
anterior	O
crucial	O
ligament	O
(	O
ACL	O
)	O
reconstruction	O
with	O
hamstring	O
autografts	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
to	O
Groups	O
L	O
(	O
n	O
=	O
51	O
)	O
and	O
LM	O
(	O
n	O
=	O
56	O
)	O
using	O
the	O
closed-envelope	O
method	O
.	O

Group	O
LM	O
was	O
administered	O
19	O
ml	O
of	O
0.25	O
%	O
levobupivacaine	O
and	O
1	O
ml	O
of	O
15	O
%	O
magnesium	O
sulphate	O
,	O
while	O
Group	O
L	O
was	O
administered	O
20	O
ml	O
of	O
0.25	O
%	O
levobupivacaine	O
for	O
femoral	O
blockade	O
.	O

General	O
anaesthesia	O
was	O
administered	O
using	O
laryngeal	O
airway	O
masks	O
following	O
neural	O
blockade	O
in	O
both	O
groups	O
.	O

The	O
patients	O
were	O
evaluated	O
for	O
heart	Physical
rate	Physical
and	Physical
mean	Physical
arterial	Physical
pressure	Physical
,	O
oxygen	Physical
saturation	Physical
,	O
visual	Physical
analogue	Physical
score	Physical
(	Physical
VAS	Physical
)	Physical
,	Physical
verbal	Physical
rating	Physical
scale	Physical
(	Physical
VRS	Physical
)	Physical
,	O
rescue	Others
analgesic	Others
requirements	Others
,	O
total	Others
opioid	Others
consumption	Others
,	O
side	O
effects	O
and	O
time	O
to	O
first	O
mobilisation	O
at	O
the	O
1st	O
,	O
2nd	O
,	O
4th	O
,	O
6th	O
,	O
12th	O
and	O
24th	O
hours	O
postoperatively	O
.	O

RESULTS	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
terms	O
of	O
demographic	Physical
data	Physical
,	Physical
mean	Physical
arterial	Physical
pressure	Physical
,	Physical
heart	Physical
rate	Physical
or	Physical
oxygen	Physical
saturation	Physical
between	O
groups	O
.	O

The	O
area	Physical
under	Physical
the	Physical
curve	Physical
VAS	Physical
and	Physical
VRS	Physical
scores	Physical
were	O
lower	O
at	O
4	O
,	O
6	O
,	O
12	O
and	O
24	O
h	O
in	O
Group	O
LM	O
(	O
p	O
=	O
0.001	O
,	O
p	O
=	O
0.016	O
,	O
respectively	O
)	O
.	O

The	O
rescue	Physical
analgesic	Physical
requirement	Physical
and	Physical
the	Physical
total	Physical
opioid	Physical
consumption	Physical
were	O
significantly	O
lower	O
in	O
Group	O
LM	O
(	O
p	O
=	O
0.015	O
,	O
p	O
=	O
0.019	O
,	O
respectively	O
)	O
.	O

The	O
time	Others
to	Others
first	Others
mobilisation	Others
and	O
the	O
Likert	O
score	O
(	O
completely	O
comfortable	O
;	O
quite	O
comfortable	O
;	O
slight	O
discomfort	O
;	O
painful	O
;	O
very	O
painful	O
)	O
were	O
higher	O
,	O
and	O
the	O
block	Others
onset	Others
time	Others
was	O
lower	O
in	O
Group	O
LM	O
(	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.012	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
terms	O
of	O
side	O
effects	O
.	O

CONCLUSIONS	O
The	O
addition	O
of	O
magnesium	O
to	O
levobupivacaine	O
prolongs	O
the	O
sensory	O
and	O
motor	O
block	O
duration	O
without	O
increasing	O
side	O
effects	O
,	O
enhances	O
the	O
quality	O
of	O
postoperative	O
analgesia	O
and	O
increases	O
patient	O
satisfaction	O
;	O
however	O
,	O
the	O
addition	O
of	O
magnesium	O
delays	O
the	O
time	O
to	O
first	O
mobilisation	O
and	O
decreases	O
rescue	O
analgesic	O
requirements	O
.	O

A	O
web-based	O
approach	O
to	O
address	O
cardiovascular	Physical
risks	Physical
in	O
managers	O
:	O
results	O
of	O
a	O
randomized	O
trial	O
.	O

OBJECTIVES	O
To	O
examine	O
whether	O
a	O
Web-based	O
health	O
and	O
leadership	O
development	O
program	O
--	O
designed	O
specifically	O
for	O
managers	O
--	O
was	O
associated	O
with	O
changes	O
in	O
self-reported	Physical
and	Physical
biometric	Physical
indicators	Physical
of	Physical
cardiovascular	Physical
disease	Physical
within	O
the	O
context	O
of	O
a	O
randomized	O
control	O
trial	O
.	O

METHODS	O
A	O
total	O
of	O
145	O
managers	O
from	O
8	O
organizations	O
participated	O
in	O
a	O
6-month	O
Internet-based	O
program	O
or	O
a	O
control	O
condition	O
.	O

They	O
completed	O
pre-	O
and	O
posttest	O
assessments	O
that	O
included	O
both	O
self-reported	Physical
attitudes	Physical
(	Physical
on	Physical
diet	Physical
,	Physical
exercise	Physical
,	Physical
and	Physical
mental	Physical
health	Physical
)	Physical
and	O
biometric	Physical
measures	Physical
(	Physical
eg	Physical
,	Physical
body	Physical
weight	Physical
,	Physical
waist	Physical
circumference	Physical
)	Physical
.	Physical

RESULTS	O
The	O
intervention	O
was	O
associated	O
with	O
improvements	O
in	O
dietary	Mental
attitudes	Mental
,	Mental
dietary	Mental
self-efficacy	Mental
,	Mental
and	Mental
exercise	Mental
,	Mental
and	Mental
reductions	Mental
in	Mental
distress	Mental
symptoms	Mental
.	O

Women	O
in	O
the	O
program	O
reduced	O
their	O
waist	Physical
circumference	Physical
significantly	O
more	O
than	O
controls	O
.	O

CONCLUSIONS	O
The	O
program	O
showed	O
promise	O
for	O
reducing	O
cardiovascular	Physical
disease	Physical
risk	Physical
factors	Physical
.	Physical

Similar	O
results	O
across	O
diverse	O
organizations	O
suggest	O
the	O
program	O
may	O
be	O
useful	O
across	O
industry	O
types	O
.	O

A	O
randomised	O
group	O
comparison	O
controlled	O
trial	O
of	O
'preschoolers	O
with	O
autism	O
'	O
:	O
a	O
parent	O
education	O
and	O
skills	O
training	O
intervention	O
for	O
young	O
children	O
with	O
autistic	O
disorder	O
.	O

AIM	O
To	O
determine	O
the	O
effect	O
of	O
parent	O
education	O
on	O
adaptive	Mental
behaviour	Mental
,	O
autism	Physical
symptoms	Physical
and	O
cognitive/language	Mental
skills	Mental
of	O
young	O
children	O
with	O
autistic	O
disorder	O
.	O

METHOD	O
A	O
randomised	O
group	O
comparison	O
design	O
involving	O
a	O
parent	O
education	O
and	O
counselling	O
intervention	O
and	O
a	O
parent	O
education	O
and	O
behaviour	O
management	O
intervention	O
to	O
control	O
for	O
parent	O
skills	O
training	O
and	O
a	O
control	O
sample	O
.	O

Two	O
rural	O
and	O
two	O
metropolitan	O
regions	O
were	O
randomly	O
allocated	O
to	O
intervention	O
groups	O
(	O
n	O
=	O
70	O
)	O
or	O
control	O
(	O
n	O
=	O
35	O
)	O
.	O

Parents	O
from	O
autism	O
assessment	O
services	O
in	O
the	O
intervention	O
regions	O
were	O
randomly	O
allocated	O
to	O
parent	O
education	O
and	O
behaviour	O
management	O
(	O
n	O
=	O
35	O
)	O
or	O
parent	O
education	O
and	O
counselling	O
(	O
n	O
=	O
35	O
)	O
.	O

RESULTS	O
Parent	O
education	O
and	O
behaviour	O
management	O
resulted	O
in	O
significant	O
improvement	O
in	O
adaptive	Mental
behaviour	Mental
and	O
autism	Physical
symptoms	Physical
at	O
6	O
months	O
follow-up	O
for	O
children	O
with	O
greater	O
delays	O
in	O
adaptive	Mental
behaviour	Mental
.	O

Parent	O
education	O
and	O
behaviour	O
management	O
was	O
superior	O
to	O
parent	O
education	O
and	O
counselling	O
.	O

We	O
conclude	O
that	O
a	O
20-week	O
parent	O
education	O
programme	O
including	O
skills	O
training	O
for	O
parents	O
of	O
young	O
children	O
with	O
autistic	O
disorder	O
provides	O
significant	O
improvements	O
in	O
child	Mental
adaptive	Mental
behaviour	Mental
and	O
symptoms	Mental
of	Mental
autism	Mental
for	O
low-functioning	O
children	O
.	O

Mandibular	O
advancement	O
splint	O
improves	O
indices	O
of	O
obstructive	O
sleep	O
apnoea	O
and	O
snoring	O
but	O
side	O
effects	O
are	O
common	O
.	O

AIM	O
To	O
assess	O
the	O
efficacy	O
of	O
a	O
mandibular	O
advancement	O
splint	O
(	O
MAS	O
)	O
in	O
the	O
treatment	O
of	O
obstructive	Physical
sleep	Physical
apnoea	Physical
syndrome	Physical
(	Physical
OSAS	Physical
)	Physical
.	Physical

METHODS	O
Nineteen	O
patients	O
using	O
a	O
MAS	O
for	O
symptomatic	O
OSAS	O
underwent	O
polysomnography	O
,	O
with	O
MAS	O
use	O
randomised	O
to	O
one	O
half	O
of	O
the	O
night	O
.	O

Indices	Physical
of	Physical
snoring	Physical
and	O
OSAS	Physical
were	O
compared	O
.	O

Side	Adverseeffect
effects	Adverseeffect
,	O
compliance	Others
and	O
treatment	Physical
response	Physical
were	O
evaluated	O
by	O
questionnaire	O
.	O

RESULTS	O
Use	O
of	O
the	O
MAS	O
improved	O
total	Physical
respiratory	Physical
disturbance	Physical
index	Physical
(	Physical
RDI	Physical
)	Physical
from	O
22.2	O
+/-	O
19.8	O
(	O
SD	O
)	O
events	Physical
per	Physical
hour	Physical
to	O
16.5	O
+/-	O
21.4/hr	O
(	O
p	O
=	O
0.03	O
)	O
,	O
supine	Physical
RDI	Physical
(	O
30.8	O
+/-	O
23.8/hr	O
to	O
18.8	O
+/-	O
22.1/hr	O
,	O
p	O
=	O
0.01	O
)	O
,	O
arousal	Physical
index	Physical
(	O
25.2	O
+/-	O
18.9/hr	O
to	O
19.3	O
+/-	O
14.2/hr	O
,	O
p	O
=	O
0.01	O
)	O
and	O
snoring	Physical
intensity	Physical
(	O
52.7	O
+/-	O
4.1	O
to	O
50.7	O
+/-	O
2.7	O
dB	O
,	O
p	O
=	O
0.02	O
)	O
but	O
not	O
total	Physical
snore	Physical
frequency	Physical
(	O
p	O
>	O
0.05	O
)	O
.	O

Using	O
polysomnographic	O
criteria	O
,	O
MAS	O
treatment	O
was	O
completely	Others
successful	Others
in	O
four	O
(	O
21	O
%	O
)	O
patients	O
,	O
partially	Others
successful	Others
in	O
ten	O
(	O
52.6	O
%	O
)	O
and	O
a	O
failure	Others
in	O
five	O
(	O
26.3	O
%	O
)	O
.	O

Treatment	O
over	O
a	O
median	O
of	O
6.5	O
weeks	O
(	O
range	O
2-48	O
)	O
was	O
perceived	O
as	O
beneficial	O
by	O
ten	O
of	O
eleven	O
partners	O
.	O

Fifteen	O
patients	O
(	O
79	O
%	O
)	O
reported	O
side	Adverseeffect
effects	Adverseeffect
,	O
9	O
(	O
46	O
%	O
)	O
did	O
not	O
use	O
the	O
device	O
every	O
night	O
and	O
four	O
(	O
21	O
%	O
)	O
used	O
the	O
device	O
less	O
than	O
three	O
nights	O
per	O
week	O
.	O

CONCLUSION	O
The	O
use	O
of	O
the	O
MAS	O
resulted	O
in	O
significant	O
reductions	O
in	O
indices	O
of	O
OSAS	Physical
and	O
snoring	Physical
.	O

However	O
,	O
a	O
significant	O
number	O
of	O
patients	O
had	O
difficulty	O
tolerating	O
and	O
regularly	O
using	O
the	O
device	O
.	O

Phosphate	O
binder	O
impact	O
on	O
bone	Physical
remodeling	Physical
and	O
coronary	Physical
calcification	Physical
--	O
results	O
from	O
the	O
BRiC	O
study	O
.	O

BACKGROUND	O
AND	O
AIMS	O
Calcium-containing	O
phosphate	O
binders	O
have	O
been	O
shown	O
to	O
increase	O
the	O
progression	O
of	O
vascular	Physical
calcification	Physical
in	O
hemodialysis	O
patients	O
.	O

This	O
is	O
a	O
prospective	O
study	O
that	O
compares	O
the	O
effects	O
of	O
calcium	O
acetate	O
and	O
sevelamer	O
on	O
coronary	Physical
calcification	Physical
(	O
CAC	O
)	O
and	O
bone	Physical
histology	Physical
.	O

METHODS	O
101	O
hemodialysis	O
patients	O
were	O
randomized	O
for	O
each	O
phosphate	O
binder	O
and	O
submitted	O
to	O
multislice	O
coronary	O
tomographies	O
and	O
bone	O
biopsies	O
at	O
entry	O
and	O
12	O
months	O
.	O

RESULTS	O
The	O
71	O
patients	O
who	O
concluded	O
the	O
study	O
had	O
similar	O
baseline	O
characteristics	O
.	O

On	O
follow-up	O
,	O
the	O
sevelamer	O
group	O
had	O
higher	O
levels	O
of	O
intact	Physical
parathyroid	Physical
hormone	Physical
(	O
498	O
+/-	O
352	O
vs.	O
326	O
+/-	O
236	O
pg/ml	O
,	O
p	O
=	O
0.017	O
)	O
,	O
bone	Physical
alkaline	Physical
phosphatase	Physical
(	O
38	O
+/-	O
24	O
vs.	O
28	O
+/-	O
15	O
U/l	O
,	O
p	O
=	O
0.03	O
)	O
and	O
deoxypyridinoline	Physical
(	O
135	O
+/-	O
107	O
vs.	O
89	O
+/-	O
71	O
nmol/l	O
,	O
p	O
=	O
0.03	O
)	O
and	O
lower	Physical
LDL	Physical
cholesterol	Physical
(	O
74	O
+/-	O
21	O
vs.	O
91	O
+/-	O
28	O
mg/dl	O
,	O
p	O
=	O
0.015	O
)	O
.	O

Phosphorus	Physical
(	O
5.8	O
+/-	O
1.0	O
vs.	O
6	O
+/-	O
1.0	O
mg/dl	O
,	O
p	O
=	O
0.47	O
)	O
and	O
calcium	Physical
(	O
1.27	O
+/-	O
0.07	O
vs.	O
1.23	O
+/-	O
0.08	O
mmol/l	O
,	O
p	O
=	O
0.68	O
)	O
levels	O
did	O
not	O
differ	O
between	O
groups	O
.	O

CAC	Physical
progression	Physical
(	O
35	O
vs.	O
24	O
%	O
,	O
p	O
=	O
0.94	O
)	O
and	O
bone	Physical
histological	Physical
diagnosis	Physical
at	O
baseline	O
and	O
12	O
months	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Patients	O
of	O
the	O
sevelamer	O
group	O
with	O
a	O
high	O
turnover	O
at	O
baseline	O
had	O
an	O
increase	O
in	O
bone	Physical
resorption	Physical
(	O
eroded	O
surface	O
,	O
ES/BS	O
=	O
9.0	O
+/-	O
5.9	O
vs.	O
13.1	O
+/-	O
9.5	O
%	O
,	O
p	O
=	O
0.05	O
)	O
,	O
whereas	O
patients	O
of	O
both	O
groups	O
with	O
low	O
turnover	O
at	O
baseline	O
had	O
an	O
improvement	O
in	O
bone	Physical
formation	Physical
rate	Physical
(	O
BFR/BS	O
=	O
0.015	O
+/-	O
0.016	O
vs.	O
0.062	O
+/-	O
0.078	O
,	O
p	O
=	O
0.003	O
for	O
calcium	O
and	O
0.017	O
+/-	O
0.016	O
vs.	O
0.071	O
+/-	O
0.084	O
microm	O
(	O
3	O
)	O
/microm	O
(	O
2	O
)	O
/day	O
,	O
p	O
=	O
0.010	O
for	O
sevelamer	O
)	O
.	O

CONCLUSIONS	O
There	O
was	O
no	O
difference	O
in	O
CAC	Physical
progression	Physical
or	O
changes	O
in	O
bone	Physical
remodeling	Physical
between	O
the	O
calcium	O
and	O
the	O
sevelamer	O
groups	O
.	O

Phase	O
II	O
multi-institutional	O
prospective	O
randomised	O
trial	O
comparing	O
S-1+paclitaxel	O
with	O
S-1+cisplatin	O
in	O
patients	O
with	O
unresectable	O
and/or	O
recurrent	O
advanced	O
gastric	O
cancer	O
.	O

BACKGROUND	O
A	O
combination	O
of	O
S-1	O
and	O
cisplatin	O
has	O
been	O
shown	O
to	O
be	O
effective	O
with	O
acceptable	O
safety	O
for	O
the	O
first-line	O
treatment	O
of	O
far-advanced	O
gastric	O
cancer	O
in	O
Japan	O
.	O

This	O
is	O
the	O
first	O
randomised	O
phase	O
II	O
trial	O
to	O
compare	O
S-1+paclitaxel	O
with	O
S-1+cisplatin	O
in	O
this	O
setting	O
.	O

METHODS	O
Patients	O
with	O
unresectable	O
and/or	O
recurrent	O
advanced	O
gastric	O
cancer	O
were	O
randomly	O
assigned	O
to	O
receive	O
one	O
of	O
the	O
two	O
regimens	O
:	O
S-1	O
(	O
40	O
mg	O
m	O
(	O
-2	O
)	O
twice	O
daily	O
)	O
on	O
days	O
1-14	O
plus	O
paclitaxel	O
(	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
days	O
1	O
,	O
8	O
,	O
and	O
15	O
of	O
a	O
4-week	O
cycle	O
(	O
S-1+paclitaxel	O
)	O
or	O
S-1	O
(	O
40	O
mg	O
m	O
(	O
-2	O
)	O
twice	O
daily	O
)	O
on	O
days	O
1-21	O
plus	O
cisplatin	O
(	O
60	O
mg	O
m	O
(	O
-2	O
)	O
)	O
on	O
day	O
8	O
of	O
a	O
5-week	O
cycle	O
(	O
S-1+cisplatin	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
response	Others
rate	Others
(	Others
RR	Others
)	Others
.	O

Secondary	O
end	O
points	O
included	O
progression-free	Others
survival	Others
(	Others
PFS	Others
)	Others
,	O
overall	Others
survival	Others
(	Others
OS	Others
)	Others
,	O
and	O
safety	Others
.	O

RESULTS	O
A	O
total	O
of	O
83	O
patients	O
were	O
eligible	O
for	O
safety	O
and	O
efficacy	O
analyses	O
.	O

In	O
the	O
S-1+paclitaxel	O
and	O
S-1+cisplatin	O
groups	O
,	O
RRs	Others
(	O
52.3	O
%	O
vs	O
48.7	O
%	O
;	O
P=0.74	O
)	O
and	O
median	O
PFS	O
(	O
9	O
vs	O
6	O
months	O
;	O
P=0.50	O
)	O
were	O
similar	O
.	O

The	O
median	Others
OS	Others
was	O
similar	O
in	O
the	O
S-1+paclitaxel	O
and	O
S-1+cisplatin	O
groups	O
(	O
16	O
vs	O
17	O
months	O
;	O
P=0.84	O
)	O
.	O

The	O
incidence	Physical
of	Physical
grade	Physical
3	Physical
or	Physical
higher	Physical
haematological	Physical
toxicity	Physical
was	O
19.0	O
%	O
with	O
S-1+paclitaxel	O
and	O
19.5	O
%	O
with	O
S-1+cisplatin	O
.	O

The	O
incidence	Adverseeffect
of	Adverseeffect
grade	Adverseeffect
3	Adverseeffect
or	Adverseeffect
higher	Adverseeffect
non-haematological	Adverseeffect
toxicity	Adverseeffect
was	O
14.2	O
%	O
with	O
S-1+paclitaxel	O
and	O
17.1	O
%	O
with	O
S-1+cisplatin	O
.	O

CONCLUSION	O
S-1+paclitaxel	O
was	O
suggested	O
to	O
be	O
a	O
feasible	O
and	O
effective	O
non-platinum-based	O
regimen	O
for	O
chemotherapy	O
in	O
patients	O
with	O
advanced	O
gastric	O
cancer	O
.	O

Our	O
results	O
should	O
be	O
confirmed	O
in	O
multicenter	O
,	O
phase	O
III-controlled	O
clinical	O
trials	O
.	O

Carpal	O
tunnel	O
release	O
by	O
limited	O
palmar	O
incision	O
vs	O
traditional	O
open	O
technique	O
:	O
randomized	O
controlled	O
trial	O
.	O

AIM	O
To	O
compare	O
a	O
limited	O
palmar	O
incision	O
for	O
carpal	O
tunnel	O
release	O
(	O
CTR	O
)	O
with	O
a	O
traditional	O
open	O
technique	O
,	O
which	O
is	O
still	O
considered	O
the	O
gold	O
standard	O
.	O

METHODS	O
Seventy-two	O
patients	O
with	O
a	O
carpal	O
tunnel	O
syndrome	O
were	O
individually	O
randomized	O
into	O
the	O
trial	O
(	O
limited	O
incision	O
CTR	O
)	O
(	O
n=36	O
)	O
and	O
control	O
group	O
(	O
traditional	O
technique	O
CTR	O
)	O
(	O
n=36	O
)	O
.	O

In	O
the	O
trial	O
group	O
,	O
skin	O
incision	O
parallel	O
to	O
the	O
thenar	O
crease	O
was	O
made	O
up	O
to	O
2.5	O
cm	O
in	O
length	O
,	O
under	O
an	O
operating	O
microscope	O
and	O
endoscopic	O
transillumination	O
.	O

Skin	O
incision	O
in	O
the	O
control	O
group	O
began	O
at	O
the	O
distal	O
border	O
of	O
the	O
carpal	O
ligament	O
,	O
followed	O
the	O
longitudinal	O
crease	O
of	O
the	O
palm	O
,	O
and	O
crossed	O
the	O
base	O
of	O
the	O
palm	O
in	O
a	O
zigzag	O
fashion	O
.	O

Three	O
months	O
after	O
surgery	O
,	O
the	O
patients	O
were	O
asked	O
about	O
symptomatic	Physical
relief	Physical
and	Physical
intervals	Physical
between	Physical
the	Physical
operation	Physical
and	Physical
return	Physical
to	Physical
their	Physical
daily	Physical
activities	Physical
and	Physical
work	Physical
,	Physical
and	Physical
examined	Physical
for	Physical
scar	Physical
tenderness	Physical
and	Physical
esthetic	Physical
outcome	Physical
.	Physical

Distal	Physical
motor	Physical
latency	Physical
,	Physical
conduction	Physical
velocity	Physical
,	Physical
scar	Physical
length	Physical
,	Physical
scar	Physical
width	Physical
,	Physical
and	Physical
operation	Physical
time	Physical
were	O
measured	O
.	O

RESULTS	O
There	O
were	O
no	O
differences	O
between	O
the	O
two	O
groups	O
in	O
symptomatic	Physical
relief	Physical
and	Physical
electrophysiological	Physical
parameters	Physical
.	Physical

Intervals	Physical
between	Physical
the	Physical
operation	Physical
and	Physical
return	Physical
to	Physical
daily	Physical
activities	Physical
(	O
median	O
5	O
days	O
,	O
range	O
2-15	O
)	O
were	O
shorter	O
in	O
the	O
trial	O
group	O
than	O
in	O
the	O
control	O
group	O
(	O
median	O
10	O
days	O
,	O
range	O
2-21	O
;	O
p	O
<	O
0.001	O
)	O
,	O
as	O
well	O
as	O
the	O
intervals	Physical
between	Physical
the	Physical
operation	Physical
and	Physical
return	Physical
to	Physical
work	Physical
(	O
median	O
15	O
days	O
,	O
range	O
5-45	O
vs	O
median	O
30	O
days	O
,	O
range	O
10-60	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Scar/pillar	Physical
tenderness	Physical
,	Physical
scar	Physical
length	Physical
and	Physical
width	Physical
,	Physical
esthetic	Physical
outcome	Physical
,	Physical
and	Physical
operation	Physical
time	Physical
were	O
significantly	O
better	O
in	O
the	O
trial	O
group	O
.	O

CONCLUSION	O
Limited	O
palmar	O
incision	O
CTR	O
is	O
as	O
effective	O
and	O
safe	O
as	O
traditional	O
CTR	O
technique	O
,	O
but	O
with	O
better	O
postoperative	O
recovery	O
and	O
cosmetic	O
results	O
.	O

Should	O
insertion	O
of	O
intramedullary	O
nails	O
for	O
tibial	O
fractures	O
be	O
with	O
or	O
without	O
reaming	O
?	O
A	O
prospective	O
,	O
randomized	O
study	O
with	O
3.8	O
years	O
'	O
follow-up	O
.	O

OBJECTIVE	O
To	O
determine	O
if	O
any	O
differences	O
exist	O
in	O
healing	Physical
and	O
complications	O
between	O
reamed	O
and	O
unreamed	O
nailing	O
in	O
patients	O
with	O
tibial	O
shaft	O
fractures	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
.	O

SETTING	O
Level	O
1	O
trauma	O
center	O
.	O

PATIENTS	O
Forty-five	O
patients	O
with	O
displaced	O
closed	O
and	O
open	O
Gustilo	O
type	O
I-IIIA	O
fractures	O
of	O
the	O
central	O
two	O
thirds	O
of	O
the	O
tibia	O
.	O

INTERVENTION	O
Stabilization	O
of	O
tibial	O
fractures	O
either	O
with	O
a	O
slotted	O
,	O
stainless	O
steel	O
reamed	O
nail	O
or	O
a	O
solid	O
,	O
titanium	O
unreamed	O
nail	O
.	O

MAIN	O
OUTCOME	O
MEASUREMENTS	O
Nonunions	Physical
,	O
time	Others
to	Others
fracture	Others
healing	Others
,	Others
and	Others
rate	Others
of	Others
malunions	Others
.	O

RESULTS	O
The	O
average	Others
time	Others
to	Others
fracture	Others
healing	Others
was	O
16.7	O
weeks	O
in	O
the	O
reamed	O
group	O
and	O
25.7	O
weeks	O
in	O
the	O
unreamed	O
group	O
.	O

The	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
=	O
0.004	O
)	O
.	O

There	O
were	O
three	O
nonunions	Physical
,	O
all	O
in	O
the	O
unreamed	O
nail	O
group	O
.	O

Two	O
of	O
these	O
fractures	O
healed	Physical
after	Physical
dynamization	Physical
by	Physical
removing	Physical
static	Physical
interlocking	Physical
screws	Physical
.	O

The	O
third	O
nonunion	O
did	O
not	O
heal	Physical
despite	O
exchange	O
reamed	O
nailing	O
2	O
years	O
after	O
the	O
primary	O
surgery	O
and	O
dynamization	O
with	O
a	O
fibular	O
osteotomy	O
after	O
an	O
additional	O
1	O
year	O
.	O

There	O
were	O
two	O
malunions	Physical
in	O
the	O
reamed	O
group	O
and	O
four	O
malunions	Physical
in	O
the	O
unreamed	O
group	O
.	O

There	O
were	O
no	O
differences	O
for	O
all	O
other	O
outcome	O
measurements	O
.	O

CONCLUSION	O
Unreamed	O
nailing	O
in	O
patients	O
with	O
tibial	O
shaft	O
fractures	O
may	O
be	O
associated	O
with	O
higher	O
rates	Others
of	Others
secondary	Others
operations	Others
and	Others
malunions	Others
compared	O
with	O
reamed	O
nailing	O
.	O

The	O
time	Others
to	Others
fracture	Others
healing	Others
was	O
significantly	O
longer	O
with	O
unreamed	O
nails	O
.	O

Intensive	O
case	O
management	O
before	O
and	O
after	O
prison	O
release	O
is	O
no	O
more	O
effective	O
than	O
comprehensive	O
pre-release	O
discharge	O
planning	O
in	O
linking	O
HIV-infected	O
prisoners	O
to	O
care	O
:	O
a	O
randomized	O
trial	O
.	O

Imprisonment	O
provides	O
opportunities	O
for	O
the	O
diagnosis	O
and	O
successful	O
treatment	O
of	O
HIV	O
,	O
however	O
,	O
the	O
benefits	O
of	O
antiretroviral	O
therapy	O
are	O
frequently	O
lost	O
following	O
release	O
due	O
to	O
suboptimal	O
access	O
and	O
utilization	O
of	O
health	O
care	O
and	O
services	O
.	O

In	O
response	O
,	O
some	O
have	O
advocated	O
for	O
development	O
of	O
intensive	O
case-management	O
interventions	O
spanning	O
incarceration	O
and	O
release	O
to	O
support	O
treatment	O
adherence	O
and	O
community	O
re-entry	O
for	O
HIV-infected	O
releasees	O
.	O

We	O
conducted	O
a	O
randomized	O
controlled	O
trial	O
of	O
a	O
motivational	O
Strengths	O
Model	O
bridging	O
case	O
management	O
intervention	O
(	O
BCM	O
)	O
beginning	O
approximately	O
3	O
months	O
prior	O
to	O
and	O
continuing	O
6	O
months	O
after	O
release	O
versus	O
a	O
standard	O
of	O
care	O
prison-administered	O
discharge	O
planning	O
program	O
(	O
SOC	O
)	O
for	O
HIV-infected	O
state	O
prison	O
inmates	O
.	O

The	O
primary	O
outcome	O
variable	O
was	O
self-reported	O
access	O
to	O
post-release	O
medical	O
care	O
.	O

Of	O
the	O
104	O
inmates	O
enrolled	O
,	O
89	O
had	O
at	O
least	O
1	O
post-release	O
study	O
visit	O
.	O

Of	O
these	O
,	O
65.1	O
%	O
of	O
BCM	O
and	O
54.4	O
%	O
of	O
SOC	O
assigned	O
participants	O
attended	O
a	O
routine	O
medical	O
appointment	O
within	O
4	O
weeks	O
of	O
release	O
(	O
P	O
>	O
0.3	O
)	O
.	O

By	O
week	O
12	O
post-release	O
,	O
88.4	O
%	O
of	O
the	O
BCM	O
arm	O
and	O
78.3	O
%	O
of	O
the	O
SOC	O
arm	O
had	O
at	O
attended	O
at	O
least	O
one	O
medical	O
appointment	O
(	O
P	O
=	O
0.2	O
)	O
,	O
increasing	O
in	O
both	O
arms	O
at	O
week	O
24-90.7	O
%	O
with	O
BCM	O
and	O
89.1	O
%	O
with	O
SOC	O
(	O
P	O
>	O
0.5	O
)	O
.	O

No	O
participant	O
without	O
a	O
routine	O
medical	O
visit	O
by	O
week	O
24	O
attended	O
an	O
appointment	O
from	O
weeks	O
24	O
to	O
48	O
.	O

The	O
mean	O
number	O
of	O
clinic	O
visits	O
during	O
the	O
48	O
weeks	O
post	O
release	O
was	O
5.23	O
(	O
SD	O
=	O
3.14	O
)	O
for	O
BCM	O
and	O
4.07	O
(	O
SD	O
=	O
3.20	O
)	O
for	O
SOC	O
(	O
P	O
>	O
0.5	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
arms	O
in	O
social	O
service	O
utilization	O
and	O
re-incarceration	O
rates	O
were	O
also	O
similar	O
.	O

We	O
found	O
that	O
a	O
case	O
management	O
intervention	O
bridging	O
incarceration	O
and	O
release	O
was	O
no	O
more	O
effective	O
than	O
a	O
less	O
intensive	O
pre-release	O
discharge	O
planning	O
program	O
in	O
supporting	O
health	O
and	O
social	O
service	O
utilization	O
for	O
HIV-infected	O
individuals	O
released	O
from	O
prison	O
.	O

The	O
effect	O
of	O
values	O
affirmation	O
on	O
race-discordant	O
patient-provider	O
communication	O
.	O

BACKGROUND	O
Communication	O
between	O
African	O
American	O
patients	O
and	O
white	O
health	O
care	O
providers	O
has	O
been	O
shown	O
to	O
be	O
of	O
poorer	O
quality	O
when	O
compared	O
with	O
race-concordant	O
patient-provider	O
communication	O
.	O

Fear	O
on	O
the	O
part	O
of	O
patients	O
that	O
providers	O
stereotype	O
them	O
negatively	O
might	O
be	O
one	O
cause	O
of	O
this	O
poorer	O
communication	O
.	O

This	O
stereotype	O
threat	O
may	O
be	O
lessened	O
by	O
a	O
values-affirmation	O
intervention	O
.	O

METHODS	O
In	O
a	O
blinded	O
experiment	O
,	O
we	O
randomized	O
99	O
African	O
American	O
patients	O
with	O
hypertension	O
to	O
perform	O
a	O
values-affirmation	O
exercise	O
or	O
a	O
control	O
exercise	O
before	O
a	O
visit	O
with	O
their	O
primary	O
care	O
provider	O
.	O

We	O
compared	O
patient-provider	O
communication	O
for	O
the	O
2	O
groups	O
using	O
audio	O
recordings	O
of	O
the	O
visit	O
analyzed	O
with	O
the	O
Roter	O
Interaction	O
Analysis	O
System	O
.	O

We	O
also	O
evaluated	O
visit	O
satisfaction	O
,	O
trust	O
,	O
stress	O
,	O
and	O
mood	O
after	O
the	O
visit	O
by	O
means	O
of	O
a	O
questionnaire	O
.	O

RESULTS	O
Patients	O
in	O
the	O
intervention	O
group	O
requested	O
and	O
provided	O
more	O
information	Others
about	O
their	O
medical	Others
condition	Others
(	O
mean	O
[	O
SE	O
]	O
number	O
of	O
utterances	O
,	O
66.3	O
[	O
6.8	O
]	O
in	O
the	O
values-affirmation	O
group	O
vs	O
48.1	O
[	O
5.9	O
]	O
in	O
the	O
control	O
group	O
[	O
P	O
=	O
.03	O
]	O
)	O
.	O

Patient-provider	O
communication	O
in	O
the	O
intervention	O
group	O
was	O
characterized	O
as	O
being	O
more	O
interested	Mental
,	Mental
friendly	Mental
,	Mental
responsive	Mental
,	Mental
interactive	Mental
,	Mental
and	Mental
respectful	Mental
(	O
P	O
=	O
.02	O
)	O
and	O
less	O
depressed	Mental
and	Mental
distressed	Mental
(	O
P	O
=	O
.03	O
)	O
.	O

Patient	O
questionnaires	O
did	O
not	O
detect	O
differences	O
in	O
visit	Others
satisfaction	Others
,	O
trust	Mental
,	Mental
stress	Mental
,	Mental
or	Mental
mood	Mental
.	O

Mean	Others
visit	Others
duration	Others
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
(	O
19.2	O
minutes	O
in	O
the	O
control	O
group	O
vs	O
20.5	O
minutes	O
in	O
the	O
intervention	O
group	O
[	O
P	O
=	O
.29	O
]	O
)	O
.	O

CONCLUSIONS	O
A	O
values-affirmation	O
exercise	O
improves	O
aspects	O
of	O
patient-provider	O
communication	O
in	O
race-discordant	O
primary	O
care	O
visits	O
.	O

The	O
clinical	O
impact	O
of	O
the	O
intervention	O
must	O
be	O
defined	O
before	O
widespread	O
implementation	O
can	O
be	O
recommended	O
.	O

Hodgkin	O
's	O
disease	O
in	O
childhood	O
and	O
adolescence	O
:	O
results	O
of	O
chemotherapy-radiotherapy	O
in	O
clinical	O
stages	O
IA-IIB	O
.	O

From	O
April	O
1972	O
to	O
May	O
1980	O
,	O
72	O
children	O
and	O
adolescents	O
(	O
aged	O
5	O
to	O
19	O
years	O
old	O
,	O
median	O
16	O
)	O
with	O
Hodgkin	O
's	O
disease	O
,	O
clinical	O
stages	O
IA-IIB	O
(	O
IA	O
,	O
18	O
;	O
II2A	O
,	O
two	O
areas	O
involved	O
on	O
the	O
same	O
side	O
of	O
the	O
diaphragm	O
,	O
23	O
;	O
II3+A	O
,	O
three	O
areas	O
or	O
more	O
,	O
16	O
;	O
IIB	O
,	O
15	O
)	O
were	O
prospectively	O
treated	O
in	O
two	O
successive	O
clinical	O
trials	O
(	O
H	O
72	O
and	O
H	O
77	O
)	O
.	O

Clinical	O
stages	O
IA	O
and	O
II2A	O
received	O
three	O
courses	O
of	O
mechlorethamine	O
,	O
Oncovin	O
,	O
procarbazine	O
,	O
and	O
prednisone	O
(	O
MOPP	O
)	O
and	O
supradiaphragmatic	O
radiotherapy	O
(	O
40	O
Gy	O
)	O
,	O
and	O
no	O
laparotomy	O
was	O
performed	O
.	O

Clinical	O
stages	O
II3+A	O
and	O
IIB	O
received	O
either	O
six	O
cycles	O
of	O
MOPP	O
(	O
H	O
72	O
)	O
,	O
three	O
cycles	O
of	O
MOPP	O
,	O
or	O
three	O
cycles	O
of	O
CCNU	O
,	O
vinblastine	O
,	O
procarbazine	O
,	O
and	O
prednisone	O
(	O
CVPP	O
)	O
(	O
H	O
77	O
)	O
and	O
subsequently	O
had	O
a	O
laparotomy	O
followed	O
by	O
supradiaphragmatic	O
radiotherapy	O
and	O
a	O
lumboaortic	O
field	O
if	O
results	O
of	O
laparotomy	O
were	O
positive	O
.	O

Patients	O
without	O
evidence	O
of	O
mediastinal	O
involvement	O
did	O
not	O
have	O
mediastinal	O
radiotherapy	O
.	O

At	O
the	O
completion	O
of	O
therapy	O
,	O
the	O
disease	O
in	O
70	O
of	O
72	O
patients	O
was	O
in	O
complete	O
remission	O
(	O
one	O
failure	Adverseeffect
,	O
one	O
death	Mortality
during	O
treatment	O
)	O
.	O

Eight	O
patients	O
relapsed	Adverseeffect
(	O
in	O
situ	O
,	O
1	O
;	O
marginal	O
,	O
1	O
;	O
nonirradiated	O
subdiaphragmatic	O
area	O
,	O
6	O
)	O
after	O
three	O
to	O
57	O
months	O
of	O
complete	O
remission	O
(	O
median	O
20	O
months	O
)	O
;	O
one	O
patient	O
died	O
after	O
relapse	O
.	O

There	O
were	O
three	O
deaths	O
after	O
complete	O
remission	O
of	O
the	O
disease	O
(	O
infection	O
,	O
two	O
;	O
acute	O
nonlymphocytic	Physical
leukemia	Physical
[	O
ANLL	O
]	O
,	O
one	O
)	O
.	O

As	O
of	O
June	O
1984	O
the	O
median	O
follow-up	O
was	O
82	O
months	O
(	O
range	O
,	O
49	O
to	O
145	O
months	O
)	O
,	O
the	Mortality
actuarial	Mortality
probabilities	Mortality
for	Mortality
survival	Mortality
and	Mortality
freedom	Mortality
from	Mortality
relapse	Mortality
for	O
all	O
patients	O
being	O
91.6	O
%	O
and	O
87.6	O
%	O
,	O
respectively	O
.	O

There	O
was	O
no	O
statistical	O
difference	O
according	O
to	O
clinical	O
stage	O
,	O
age	O
(	O
greater	O
than	O
15	O
or	O
less	O
than	O
15	O
years	O
)	O
,	O
sex	O
,	O
or	O
number	Others
of	Others
cycles	Others
of	Others
chemotherapy	Others
(	O
six	O
or	O
three	O
)	O
.	O

Bone	Adverseeffect
growth	Adverseeffect
defects	Adverseeffect
related	Adverseeffect
to	Adverseeffect
radiotherapy	Adverseeffect
were	O
reduced	O
particularly	O
in	O
the	O
29	O
patients	O
who	O
did	O
not	O
receive	O
mediastinal	O
radiotherapy	O
.	O

None	O
of	O
these	O
patients	O
had	O
a	O
mediastinal	Physical
relapse	Physical
.	Physical

Azoospermia	Physical
was	O
the	O
rule	O
for	O
the	O
male	O
patients	O
studied	O
,	O
but	O
young	O
girls	O
and	O
young	O
women	O
retained	O
reproductive	O
integrity	O
.	O

Evaluation	O
of	O
the	O
topical	O
hemostatic	O
efficacy	Others
and	Others
safety	Others
of	O
TISSEEL	O
VH	O
S/D	O
fibrin	O
sealant	O
compared	O
with	O
currently	O
licensed	O
TISSEEL	O
VH	O
in	O
patients	O
undergoing	O
cardiac	O
surgery	O
:	O
a	O
phase	O
3	O
,	O
randomized	O
,	O
double-blind	O
clinical	O
study	O
.	O

AIM	O
TISSEEL	O
VH	O
is	O
the	O
only	O
commercially	O
available	O
fibrin	O
sealant	O
indicated	O
as	O
an	O
adjunct	O
to	O
conventional	O
methods	O
of	O
hemostasis	O
during	O
cardiac	O
surgery	O
.	O

A	O
next	O
generation	O
fibrin	O
sealant	O
(	O
TISSEEL	O
VH	O
S/D	O
)	O
has	O
been	O
developed	O
in	O
frozen	O
,	O
ready-to-use	O
form	O
with	O
an	O
added	O
virus	O
inactivation	O
step	O
(	O
solvent/detergent	O
[	O
S/D	O
]	O
treatment	O
)	O
to	O
provide	O
added	O
safety	O
and	O
convenience	O
to	O
the	O
currently	O
licensed	O
product	O
.	O

This	O
study	O
was	O
performed	O
to	O
compare	O
efficacy	Others
and	Others
safety	Others
of	O
the	O
two	O
products	O
.	O

METHODS	O
Phase	O
3	O
,	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
multicenter	O
study	O
to	O
compare	O
TISSEEL	O
VH	O
S/D	O
to	O
TISSEEL	O
VH	O
during	O
cardiac	O
surgery	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	O
proportion	Physical
of	Physical
patients	Physical
who	Physical
achieved	Physical
hemostasis	Physical
at	O
the	O
primary	O
treatment	O
site	O
within	O
5	O
min	O
,	O
and	O
maintained	O
hemostasis	O
until	O
surgical	O
closure	O
.	O

RESULTS	O
The	O
proportion	Physical
of	Physical
patients	Physical
who	Physical
achieved	Physical
hemostasis	Physical
at	O
the	O
primary	O
treatment	O
site	O
within	O
5	O
min	O
,	O
and	O
maintained	Physical
hemostasis	Physical
until	O
surgical	O
closure	O
was	O
88.2	O
%	O
for	O
TISSEEL	O
VH	O
S/D	O
and	O
89.6	O
%	O
for	O
TISSEEL	O
VH	O
in	O
the	O
intent-to-treat	O
population	O
.	O

The	O
difference	O
in	O
proportions	O
,	O
TISSEEL	O
VH	O
S/D	O
minus	O
TISSEEL	O
VH	O
,	O
was	O
1.4	O
%	O
with	O
a	O
standard	O
error	O
of	O
3.70	O
%	O
.	O

The	O
lower	O
97.5	O
%	O
confidence	O
bound	O
of	O
this	O
difference	O
was	O
8.6	O
%	O
,	O
which	O
is	O
above	O
the	O
predefined	O
noninferiority	O
margin	O
of	O
15	O
%	O
.	O

Therefore	O
,	O
TISSEEL	O
VH	O
S/D	O
is	O
at	O
least	O
as	O
efficacious	O
as	O
TISSEEL	O
VH	O
.	O

The	O
safety	O
profile	O
of	O
TISSEEL	O
VH	O
S/D	O
was	O
very	O
similar	O
to	O
that	O
of	O
currently	O
licensed	O
TISSEEL	O
VH	O
as	O
assessed	O
by	O
the	O
safety	O
endpoints	O
.	O

CONCLUSION	O
TISSEEL	O
VH	O
S/D	O
is	O
safe	Others
and	O
effective	Others
for	O
use	O
as	O
an	O
adjunct	O
to	O
hemostasis	O
in	O
patients	O
undergoing	O
cardiac	O
surgery	O
.	O

Falls	Physical
and	Physical
mobility	Physical
in	O
Parkinson	O
's	O
disease	O
:	O
protocol	O
for	O
a	O
randomised	O
controlled	O
clinical	O
trial	O
.	O

BACKGROUND	O
Although	O
physical	O
therapy	O
and	O
falls	O
prevention	O
education	O
are	O
argued	O
to	O
reduce	O
falls	Physical
and	O
disability	Physical
in	O
people	O
with	O
idiopathic	O
Parkinson	O
's	O
disease	O
,	O
this	O
has	O
not	O
yet	O
been	O
confirmed	O
with	O
a	O
large	O
scale	O
randomised	O
controlled	O
clinical	O
trial	O
.	O

The	O
study	O
will	O
investigate	O
the	O
effects	O
on	O
falls	Physical
,	O
mobility	Physical
and	O
quality	Others
of	Others
life	Others
of	O
(	O
i	O
)	O
movement	O
strategy	O
training	O
combined	O
with	O
falls	O
prevention	O
education	O
,	O
(	O
ii	O
)	O
progressive	O
resistance	O
strength	O
training	O
combined	O
with	O
falls	O
prevention	O
education	O
,	O
(	O
iii	O
)	O
a	O
generic	O
life-skills	O
social	O
program	O
(	O
control	O
group	O
)	O
.	O

METHODS/DESIGN	O
People	O
with	O
idiopathic	O
Parkinson	O
's	O
disease	O
who	O
live	O
at	O
home	O
will	O
be	O
recruited	O
and	O
randomly	O
allocated	O
to	O
one	O
of	O
three	O
groups	O
.	O

Each	O
person	O
shall	O
receive	O
therapy	O
in	O
an	O
out-patient	O
setting	O
in	O
groups	O
of	O
3-4	O
.	O

Each	O
group	O
shall	O
be	O
scheduled	O
to	O
meet	O
once	O
per	O
week	O
for	O
2	O
hours	O
for	O
8	O
consecutive	O
weeks	O
.	O

All	O
participants	O
will	O
also	O
have	O
a	O
structured	O
2	O
hour	O
home	O
practice	O
program	O
for	O
each	O
week	O
during	O
the	O
8	O
week	O
intervention	O
phase	O
.	O

Assessments	O
will	O
occur	O
before	O
therapy	O
,	O
after	O
the	O
8	O
week	O
therapy	O
program	O
,	O
and	O
at	O
3	O
and	O
12	O
months	O
after	O
the	O
intervention	O
.	O

A	O
falls	O
calendar	O
will	O
be	O
kept	O
by	O
each	O
participant	O
for	O
12	O
months	O
after	O
outpatient	O
therapy.Consistent	O
with	O
the	O
recommendations	O
of	O
the	O
Prevention	O
of	O
Falls	O
Network	O
Europe	O
group	O
,	O
three	O
falls	Physical
variables	O
will	O
be	O
used	O
as	O
the	O
primary	O
outcome	O
measures	O
:	O
the	Physical
number	Physical
of	Physical
fallers	Physical
,	Others
the	Physical
number	Physical
of	Physical
multiple	Physical
fallers	Physical
and	O
the	O
falls	Physical
rate	Physical
.	O

In	O
addition	O
to	O
quantifying	O
falls	Physical
,	O
we	O
shall	O
measure	O
mobility	Physical
,	O
activity	Physical
limitations	Physical
and	O
quality	Mental
of	Mental
life	Mental
as	O
secondary	O
outcomes	O
.	O

DISCUSSION	O
This	O
study	O
has	O
the	O
potential	O
to	O
determine	O
whether	O
outpatient	O
movement	O
strategy	O
training	O
combined	O
with	O
falls	O
prevention	O
education	O
or	O
progressive	O
resistance	O
strength	O
training	O
combined	O
with	O
falls	O
prevention	O
education	O
are	O
effective	O
for	O
reducing	Physical
falls	Physical
and	O
improving	Physical
mobility	Physical
and	O
life	Physical
quality	Physical
in	O
people	O
with	O
Parkinson	O
's	O
disease	O
who	O
live	O
at	O
home	O
.	O

TRIAL	O
REGISTRATION	O
Australia	O
and	O
New	O
Zealand	O
Clinical	O
Trials	O
Register	O
(	O
ANZCTR	O
)	O
:	O
ACTRN12606000344594	O
.	O

[	O
No	Others
effect	Others
of	O
spironolactone	O
on	O
bulimia	O
nervosa	O
symptoms	O
]	O
.	O

Some	O
case	O
reports	O
mention	O
that	O
Spironolactone	O
,	O
a	O
mineral	O
corticoid	O
antagonist	O
and	O
aldosterone	O
antagonist	O
,	O
reduces	O
binging	Mental
in	O
patients	O
with	O
bulimia	O
nervosa	O
.	O

Therefore	O
,	O
we	O
decided	O
to	O
study	O
these	O
findings	O
by	O
using	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo	O
controlled	O
study	O
design	O
.	O

In	O
one	O
study	O
arm	O
,	O
patients	O
with	O
bulimia	O
nervosa	O
were	O
treated	O
with	O
150	O
mg	O
Spironolactone	O
per	O
day	O
;	O
in	O
the	O
other	O
arm	O
,	O
patients	O
received	O
a	O
placebo	O
for	O
a	O
total	O
of	O
8	O
weeks	O
.	O

The	O
target	O
variables	O
were	O
the	O
number	Mental
of	Mental
binges	Mental
and	O
the	O
bulimia	Mental
scale	Mental
of	Mental
the	Mental
Eating	Mental
Disorder	Mental
Inventory	Mental
.	O

The	O
study	O
included	O
93	O
patients	O
.	O

The	O
results	O
show	O
that	O
the	O
number	Mental
of	Mental
binges	Mental
and	Mental
the	Mental
scores	Mental
on	Mental
the	Mental
bulimia	Mental
scale	Mental
decreased	O
somewhat	O
,	O
but	O
this	O
occurred	O
in	O
both	O
groups	O
.	O

We	O
were	O
not	O
able	O
to	O
show	O
any	O
significant	Others
statistical	Others
differences	Others
between	O
the	O
Spironolactone	O
group	O
and	O
the	O
placebo	O
group	O
.	O

Additional	O
evaluations	O
,	O
executed	O
with	O
data	O
from	O
the	O
Symptom-Check-List	Mental
(	Mental
SCL-90R	Mental
)	Mental
and	O
with	O
other	O
scales	O
from	O
the	O
EDI-2	O
also	O
showed	O
no	O
effect	O
of	O
Spironolactone	O
.	O

Therefore	O
,	O
a	O
treatment	O
with	O
Spironolactone	O
seems	O
to	O
have	O
no	Others
effect	Others
on	O
bulimia	O
nervosa	O
symptoms	O
.	O

Non-Hodgkin	O
's	O
malignant	O
lymphomas	O
:	O
treatment	O
of	O
localized	O
relapses	O
with	O
chemo	O
+	O
radio	O
+	O
BCG-therapy	O
.	O

16	O
patients	O
with	O
relapsing	O
non-Hodgkin	O
's	O
malignant	O
lymphomas	O
considered	O
as	O
clinical	O
stage	O
I	O
or	O
II	O
were	O
treated	O
by	O
an	O
association	O
of	O
chemo	O
+	O
radiotherapy	O
and	O
thereafter	O
by	O
maintenance	O
BCG	O
therapy	O
.	O

5	O
of	O
them	O
were	O
included	O
in	O
a	O
randomized	O
trial	O
and	O
have	O
a	O
significantly	O
different	O
disease-free	Mortality
survival	Mortality
from	O
patients	O
receiving	O
the	O
same	O
treatment	O
but	O
without	O
BCG	O
.	O

11	O
were	O
systematically	O
treated	O
by	O
BCG	O
and	O
they	O
also	O
have	O
a	O
fairly	O
good	O
disease-free	Mortality
survival	Mortality
.	O

Such	O
a	O
treatment	O
appears	O
to	O
be	O
of	O
value	O
in	O
treating	O
these	O
patients	O
and	O
even	O
probably	O
of	O
curing	O
some	O
of	O
them	O
.	O

A	O
good	O
response	O
to	O
oil	O
with	O
medium-	O
and	O
long-chain	O
fatty	O
acids	O
in	O
body	Physical
fat	Physical
and	O
blood	Physical
lipid	Physical
profiles	Physical
of	O
male	O
hypertriglyceridemic	O
subjects	O
.	O

A	O
double	O
blind	O
clinical	O
trial	O
was	O
carried	O
out	O
to	O
clarify	O
the	O
effects	O
of	O
oil	O
with	O
medium-	O
and	O
long-chain	O
triglyceride	O
(	O
MLCT	O
)	O
on	O
body	Physical
fat	Physical
and	O
blood	Physical
lipid	Physical
profiles	Physical
in	O
hypertriglyceridemic	O
subjects	O
.	O

One-hundred-and-twelve	O
subjects	O
were	O
enrolled	O
and	O
divided	O
into	O
two	O
groups	O
;	O
those	O
that	O
consumed	O
MLCT	O
oil	O
and	O
those	O
that	O
consumed	O
long-chain	O
triglyceride	O
(	O
LCT	O
)	O
oil	O
for	O
8	O
weeks	O
.	O

All	O
subjects	O
were	O
requested	O
to	O
consume	O
25-30	O
g	O
of	O
the	O
oils	O
daily	O
and	O
maintain	O
a	O
fixed	O
level	O
of	O
energy	O
intake	O
and	O
exercise	O
.	O

Anthropometric	Physical
and	Physical
blood	Physical
biochemical	Physical
parameters	Physical
were	O
measured	O
when	O
the	O
study	O
was	O
initiated	O
and	O
completed	O
.	O

The	O
LCT	O
group	O
consisted	O
of	O
50	O
subjects	O
(	O
34	O
men	O
and	O
16	O
women	O
)	O
,	O
while	O
the	O
MLCT	O
group	O
consisted	O
of	O
51	O
subjects	O
(	O
33	O
men	O
and	O
18	O
women	O
)	O
who	O
completed	O
the	O
study	O
.	O

Larger	O
decreases	O
in	O
body	Physical
weight	Physical
,	Physical
body	Physical
mass	Physical
index	Physical
,	Physical
waist	Physical
circumference	Physical
,	Physical
body	Physical
fat	Physical
,	Physical
total	Physical
fat	Physical
area	Physical
and	Physical
subcutaneous	Physical
fat	Physical
area	Physical
in	Physical
the	Physical
abdomen	Physical
and	Physical
serum	Physical
triglycerides	Physical
,	Physical
low-density	Physical
lipoprotein	Physical
cholesterol	Physical
,	Physical
apolipoprotein	Physical
B	Physical
,	Physical
C2	Physical
,	Physical
C3	Physical
and	Physical
E	Physical
were	O
observed	O
in	O
male	O
subjects	O
in	O
the	O
MLCT	O
group	O
than	O
those	O
in	O
the	O
LCT	O
group	O
.	O

However	O
,	O
no	O
significant	O
differences	O
in	O
these	Others
parameters	Others
between	O
the	O
female	O
subjects	O
in	O
the	O
two	O
groups	O
were	O
observed	O
.	O

Data	O
from	O
this	O
study	O
indicate	O
that	O
consumption	O
of	O
medium-and	O
long-chain	O
triglycerides	O
can	O
reduce	O
body	Physical
weight	Physical
and	O
body	Physical
fat	Physical
and	O
improve	O
blood	Physical
lipid	Physical
profiles	Others
in	O
male	O
hypertriglyceridemic	O
subjects	O
.	O

Seven-star	O
needle	O
stimulation	O
improves	O
language	Mental
and	Mental
social	Mental
interaction	Mental
of	O
children	O
with	O
autistic	O
spectrum	O
disorders	O
.	O

This	O
is	O
a	O
randomized	O
controlled	O
trial	O
that	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
the	O
Seven-star	O
Needle	O
Stimulation	O
treatment	O
on	O
children	O
with	O
Autistic	O
Spectrum	O
Disorders	O
(	O
ASD	O
)	O
.	O

Thirty-two	O
children	O
with	O
ASD	O
were	O
assigned	O
randomly	O
into	O
the	O
treatment	O
and	O
control	O
groups	O
.	O

Children	O
in	O
the	O
treatment	O
group	O
underwent	O
30	O
sessions	O
of	O
stimulation	O
over	O
6	O
weeks	O
,	O
while	O
children	O
in	O
the	O
control	O
group	O
were	O
on	O
a	O
waiting	O
list	O
and	O
did	O
not	O
receive	O
treatment	O
during	O
this	O
period	O
of	O
time	O
.	O

Intervention	O
consisted	O
of	O
a	O
treatment	O
regime	O
comprising	O
of	O
30	O
sessions	O
of	O
Seven-star	O
Needle	O
Stimulation	O
,	O
delivered	O
over	O
6	O
weeks	O
.	O

Each	O
session	O
lasted	O
5	O
to	O
10	O
min	O
,	O
children	O
in	O
the	O
treatment	O
group	O
were	O
stimulated	O
at	O
the	O
front	O
and	O
back	O
sides	O
of	O
their	O
body	O
and	O
the	O
head	O
by	O
using	O
Seven-star	O
Needles	O
.	O

The	O
change	O
in	O
the	O
children	Mental
's	Mental
behavior	Mental
was	O
evaluated	O
using	O
parents	O
'	O
report	O
and	O
neurophysiological	O
changes	O
were	O
measured	O
by	O
quantitative	O
EEG	O
(	O
qEEG	O
)	O
.	O

Results	O
showed	O
that	O
the	O
treatment	O
group	O
demonstrated	O
significant	O
improvement	O
in	O
language	Mental
and	Mental
social	Mental
interaction	Mental
,	O
but	O
not	O
in	O
stereotyped	Mental
behavior	Mental
or	Mental
motor	Mental
function	Mental
,	O
compared	O
to	O
the	O
control	O
group	O
.	O

qEEG	Physical
spectral	Physical
amplitudes	Physical
in	O
the	O
treatment	O
,	O
but	O
not	O
in	O
the	O
control	O
group	O
,	O
were	O
also	O
reduced	O
significantly	O
.	O

The	O
results	O
suggested	O
that	O
Seven-star	O
Needle	O
Stimulation	O
might	O
be	O
an	O
effective	O
intervention	O
to	O
improve	O
language	Mental
and	Mental
social	Mental
functioning	Mental
of	O
children	O
with	O
ASD	O
.	O

Asthma	O
and	O
the	O
home	O
environment	O
of	O
low-income	O
urban	O
children	O
:	O
preliminary	O
findings	O
from	O
the	O
Seattle-King	O
County	O
healthy	O
homes	O
project	O
.	O

OBJECTIVES	O
Childhood	O
asthma	O
is	O
a	O
growing	O
public	O
health	O
concern	O
in	O
low-income	O
urban	O
communities	O
.	O

Indoor	O
exposure	O
to	O
asthma	O
triggers	O
has	O
emerged	O
as	O
an	O
important	O
cause	O
of	O
asthma	O
exacerbations	O
.	O

We	O
describe	O
indoor	O
environmental	O
conditions	O
related	O
to	O
asthma	O
triggers	O
among	O
a	O
low-income	O
urban	O
population	O
in	O
Seattle/King	O
County	O
,	O
Washington	O
,	O
as	O
well	O
as	O
caregiver	O
knowledge	O
and	O
resources	O
related	O
to	O
control	O
of	O
these	O
triggers	O
.	O

METHODS	O
Data	O
are	O
obtained	O
from	O
in-person	O
,	O
structured	O
,	O
closed-end	O
interviews	O
with	O
the	O
caretakers	O
of	O
children	O
aged	O
4-12	O
years	O
with	O
persistent	O
asthma	O
living	O
in	O
households	O
with	O
incomes	O
less	O
than	O
200	O
%	O
of	O
poverty	O
.	O

Additional	O
information	O
is	O
collected	O
during	O
a	O
home	O
inspection	O
.	O

The	O
children	O
and	O
their	O
caregivers	O
are	O
participants	O
in	O
the	O
ongoing	O
Seattle-King	O
County	O
Healthy	O
Homes	O
Project	O
,	O
a	O
randomized	O
controlled	O
trial	O
of	O
an	O
intervention	O
to	O
empower	O
low-income	O
families	O
to	O
reduce	O
exposure	O
to	O
indoor	O
asthma	O
triggers	O
.	O

We	O
report	O
findings	O
on	O
the	O
conditions	O
of	O
the	O
homes	O
prior	O
to	O
this	O
intervention	O
among	O
the	O
first	O
112	O
enrolled	O
households	O
.	O

RESULTS	O
A	O
smoker	O
was	O
present	O
in	O
37.5	O
%	O
of	O
homes	O
.	O

Mold	Others
was	Others
visible	Others
in	O
26.8	O
%	O
of	O
homes	O
,	O
water	Others
damage	Others
was	O
present	O
in	O
18.6	O
%	O
of	O
homes	O
,	O
and	O
damp	Others
conditions	Others
occurred	O
in	O
64.8	O
%	O
of	O
households	O
,	O
while	O
39.6	O
%	O
of	O
caregivers	O
were	O
aware	O
that	O
excessive	O
moisture	O
can	O
increase	O
exposures	O
to	O
allergens	O
.	O

Dust-trapping	Others
reservoirs	Others
were	O
common	O
;	O
76.8	O
%	O
of	O
children	O
's	O
bedrooms	O
had	O
carpeting	O
.	O

Cockroach	Others
infestation	Others
in	Others
the	Others
past	Others
3	Others
months	Others
was	O
reported	O
by	O
23.4	O
%	O
of	O
caregivers	O
,	O
while	O
57.1	O
%	O
were	O
unaware	O
of	O
the	O
association	Others
of	Others
roaches	Others
and	Others
asthma	Others
.	O

Only	O
19.8	O
%	O
of	O
the	O
children	O
had	O
allergy-control	Others
mattress	Others
covers	Others
.	Others

CONCLUSIONS	O
Many	O
low-income	O
urban	O
children	O
with	O
asthma	O
in	O
King	O
County	O
live	O
in	O
indoor	O
environments	O
that	O
place	O
them	O
at	O
substantial	O
risk	O
of	O
ongoing	O
exposure	O
to	O
asthma	O
triggers	O
.	O

Substandard	O
housing	O
and	O
lack	O
of	O
resources	O
often	O
underlie	O
these	O
exposures	O
.	O

Initiatives	O
involving	O
health	O
educators	O
,	O
outreach	O
workers	O
,	O
medical	O
providers	O
,	O
health	O
care	O
insurers	O
,	O
housing	O
agencies	O
,	O
and	O
elected	O
officials	O
are	O
needed	O
to	O
reduce	O
these	O
exposures	O
.	O

Safety	O
and	O
efficacy	O
of	O
donepezil	O
in	O
children	O
and	O
adolescents	O
with	O
autism	O
:	O
neuropsychological	O
measures	O
.	O

OBJECTIVE	O
There	O
has	O
been	O
recent	O
interest	O
in	O
the	O
use	O
of	O
cognitive	O
enhancing	O
drugs	O
,	O
such	O
as	O
cholinesterase	O
inhibitors	O
,	O
as	O
a	O
possible	O
treatment	O
for	O
executive	Mental
functioning	Mental
(	O
EF	O
)	O
deficits	O
in	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
tolerability	Others
,	Others
safety	Others
,	Others
and	Others
efficacy	Others
of	O
donepezil	O
on	O
EF	O
in	O
a	O
sample	O
of	O
children	O
and	O
adolescents	O
with	O
ASD	O
.	O

METHOD	O
Thirty-four	O
children	O
and	O
adolescents	O
with	O
ASD	O
(	O
age	O
range	O
8-17	O
years	O
;	O
IQ	O
>	O
75	O
)	O
were	O
enrolled	O
in	O
a	O
10-week	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
of	O
donepezil	O
(	O
doses	O
of	O
5	O
and	O
10	O
mg	O
)	O
,	O
followed	O
by	O
a	O
10-week	O
open	O
label	O
trial	O
for	O
placebo	O
nonresponders	O
.	O

RESULTS	O
The	O
effect	O
of	O
donepezil	O
treatment	O
on	O
EF	O
was	O
examined	O
.	O

Despite	O
improvement	O
on	O
a	O
number	O
of	O
EF	O
measures	O
,	O
no	O
statistically	O
significant	O
between-group	O
differences	O
were	O
found	O
(	O
with	O
gains	O
observed	O
for	O
both	O
the	O
placebo	O
and	O
donepezil	O
groups	O
)	O
.	O

CONCLUSIONS	O
The	O
results	O
suggest	O
that	O
short-term	O
treatment	O
with	O
donepezil	O
may	O
have	O
limited	O
impact	O
on	O
cognitive	O
functioning	O
in	O
ASD	O
.	O

Future	O
controlled	O
trials	O
may	O
need	O
to	O
consider	O
a	O
longer	O
treatment	O
period	O
to	O
detect	O
significant	O
gains	O
on	O
EF	O
measures	O
.	O

The	O
effects	O
of	O
single	O
oral	O
doses	O
of	O
17	O
beta-oestradiol	O
and	O
progesterone	O
on	O
finger	Physical
skin	Physical
circulation	Physical
in	O
healthy	O
women	O
and	O
in	O
women	O
with	O
primary	O
Raynaud	O
's	O
phenomenon	O
.	O

The	O
effects	O
of	O
sex	O
,	O
the	O
menstrual	O
cycle	O
,	O
oral	O
contraceptives	O
,	O
pregnancy	O
,	O
and	O
the	O
menopause	O
on	O
skin	O
perfusion	O
in	O
healthy	O
women	O
and	O
in	O
patients	O
with	O
Raynaud	O
's	O
phenomenon	O
suggest	O
a	O
role	O
of	O
female	O
sex	O
hormones	O
.	O

However	O
,	O
no	O
clear	O
relation	O
between	O
skin	Physical
blood	Physical
flow	Physical
and	O
circulating	O
concentrations	O
of	O
oestrogens	O
or	O
progestogens	O
has	O
yet	O
been	O
found	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
orally	O
administered	O
17	O
beta-oestradiol	O
and	O
progesterone	O
on	O
finger	Physical
skin	Physical
blood	Physical
flow	Physical
before	O
and	O
during	O
heat	O
and	O
cold	O
challenge	O
in	O
17	O
healthy	O
normotensive	O
women	O
and	O
in	O
12	O
women	O
with	O
Raynaud	O
's	O
phenomenon	O
.	O

In	O
each	O
subject	O
standardized	O
finger	O
heating	O
(	O
45	O
degrees	O
C	O
water	O
bath	O
,	O
10	O
min	O
)	O
and	O
cooling	O
tests	O
(	O
15	O
degrees	O
C	O
water	O
bath	O
,	O
5	O
min	O
and	O
20	O
min	O
recovery	O
)	O
were	O
performed	O
twice	O
on	O
the	O
second	O
(	O
or	O
third	O
)	O
day	O
of	O
two	O
consecutive	O
menstrual	O
cycles	O
.	O

17	O
beta-Oestradiol	O
(	O
9	O
mg	O
)	O
or	O
progesterone	O
(	O
300	O
mg	O
)	O
were	O
given	O
before	O
the	O
second	O
test	O
,	O
after	O
a	O
first	O
test	O
with	O
placebo	O
.	O

Both	O
hormonal	O
doses	O
resulted	O
in	O
(	O
high	O
)	O
physiological	Physical
concentrations	Physical
.	O

Fingertip	Physical
skin	Physical
temperature	Physical
and	O
laser	Physical
Doppler	Physical
flux	Physical
were	O
measured	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
test	Physical
results	Physical
after	O
placebo	O
and	O
after	O
progesterone	O
.	O

Although	O
values	O
of	O
fingertip	O
skin	O
temperature	O
and	O
laser	O
Doppler	O
flux	O
after	O
17	O
beta-oestradiol	O
tended	O
to	O
be	O
higher	O
only	O
the	O
precooling	O
values	O
in	O
the	O
healthy	O
subjects	O
reached	O
significance	O
:	O
fingertip	O
skin	O
temperature	O
respectively	O
with	O
placebo	O
and	O
with	O
oestradiol	O
(	O
mean	O
(	O
SD	O
)	O
)	O
:	O
32.7	O
(	O
1.0	O
)	O
and	O
33.1	O
(	O
0.8	O
)	O
degrees	O
C	O
;	O
laser	O
Doppler	O
flux	O
with	O
placebo	O
and	O
with	O
oestradiol	O
:	O
33.6	O
(	O
11.7	O
)	O
and	O
42.2	O
(	O
9.5	O
)	O
perfusion	O
units	O
;	O
both	O
P	O
<	O
0.05	O
)	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Interventions	O
in	O
the	O
initial	O
prodromal	O
states	O
of	O
psychosis	O
in	O
Germany	O
:	O
concept	O
and	O
recruitment	O
.	O

BACKGROUND	O
The	O
Early	O
Detection	O
and	O
Intervention	O
Programme	O
of	O
the	O
German	O
Research	O
Network	O
on	O
Schizophrenia	O
(	O
GRNS	O
)	O
investigates	O
the	O
initial	O
prodromal	O
phase	O
of	O
psychosis	O
in	O
a	O
multidimensional	O
approach	O
.	O

Two	O
intervention	O
strategies	O
are	O
being	O
studied	O
by	O
two	O
large-scale	O
multicentre	O
projects	O
.	O

AIMS	O
To	O
present	O
the	O
concept	O
of	O
the	O
intervention	O
studies	O
,	O
and	O
to	O
provide	O
an	O
interim	O
report	O
of	O
the	O
recruitment	O
procedure	O
.	O

METHOD	O
Comprehensive	O
cognitive-behavioural	O
therapy	O
has	O
been	O
developed	O
for	O
patients	O
in	O
the	O
early	O
initial	O
prodromal	O
state	O
.	O

For	O
patients	O
in	O
the	O
late	O
initial	O
prodromal	O
state	O
the	O
atypical	O
neuroleptic	O
amisulpride	O
is	O
explored	O
.	O

Both	O
interventions	O
are	O
evaluated	O
in	O
randomised	O
controlled	O
trials	O
using	O
clinical	O
management	O
as	O
the	O
control	O
condition	O
.	O

RESULTS	O
Between	O
January	O
2001	O
and	O
March	O
2003	O
,	O
1212	O
individuals	O
seeking	O
help	O
for	O
mental	O
health	O
problems	O
were	O
screened	O
for	O
putative	O
prodromal	O
symptoms	O
at	O
four	O
university	O
centres	O
.	O

More	O
than	O
388	O
individuals	O
fulfilled	O
criteria	O
for	O
both	O
interventions	O
and	O
188	O
(	O
48.5	O
%	O
)	O
gave	O
informed	Mental
consent	Mental
to	O
participate	O
in	O
the	O
trials	O
.	O

CONCLUSIONS	O
The	O
screening	O
procedure	O
appears	O
to	O
be	O
feasible	Others
and	O
trial	Mental
participation	Mental
seems	O
to	O
be	O
acceptable	O
to	O
a	O
relevant	O
proportion	O
of	O
people	O
at	O
increased	O
risk	O
of	O
developing	O
psychosis	O
.	O

PRL-8-53	O
:	O
enhanced	O
learning	Mental
and	O
subsequent	O
retention	Mental
in	O
humans	O
as	O
a	O
result	O
of	O
low	O
oral	O
doses	O
of	O
new	O
psychotropic	O
agent	O
.	O

The	O
effect	O
of	O
3-	O
(	O
2-benzylmethylaminoethyl	O
)	O
benzoic	O
acid	O
methyl	O
ester	O
hydrochloride	O
(	O
PRL-8-53	O
)	O
on	O
learning	Mental
and	O
on	O
retention	Mental
of	Mental
verbal	Mental
information	Mental
in	O
human	O
subjects	O
was	O
investigated	O
.	O

Using	O
the	O
serial	O
anticipation	O
method	O
under	O
double-blind	O
conditions	O
it	O
was	O
found	O
that	O
PRL-8-53	O
causes	O
slight	O
improvement	O
of	O
acquisition	Mental
.	Mental

Retinetion	Mental
of	Mental
verbal	Mental
information	Mental
was	O
found	O
improved	O
to	O
a	O
statistically	O
significant	O
degree	O
(	O
most	O
P	O
values	O
better	O
than	O
0.01	O
,	O
some	O
better	O
than	O
0.001	O
)	O
.	O

No	O
significant	O
changes	O
were	O
found	O
for	O
either	O
visual	Mental
reaction	Mental
time	Mental
or	Mental
motor	Mental
control	Mental
after	O
drug	O
when	O
compared	O
with	O
placebo	O
values	O
.	O

Double	O
blind	O
,	O
placebo	O
controlled	O
study	O
of	O
metronidazole	O
as	O
a	O
disease	O
modifying	O
agent	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

Anecdotal	O
reports	O
suggest	O
that	O
metronidazole	O
may	O
have	O
disease	O
modifying	O
activity	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

To	O
assess	O
possible	O
beneficial	Others
effects	Others
a	O
double	O
blind	O
,	O
comparative	O
trial	O
of	O
metronidazole	O
and	O
placebo	O
was	O
performed	O
.	O

Fifty	O
patients	O
with	O
active	O
rheumatoid	O
arthritis	O
were	O
randomly	O
allocated	O
to	O
receive	O
active	O
drug	O
(	O
n	O
=	O
24	O
)	O
or	O
placebo	O
(	O
n	O
=	O
26	O
)	O
and	O
reviewed	O
at	O
weeks	O
0	O
,	O
1	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
and	O
24	O
.	O

Detailed	Others
assessment	Others
of	O
drug	Physical
safety	Physical
,	Physical
biochemical	Physical
and	Physical
haematological	Physical
parameters	Physical
,	O
and	O
efficacy	Others
was	O
made	O
at	O
these	O
dates	O
.	O

Dose	O
regimen	O
was	O
400	O
mg	O
twice	O
daily	O
from	O
weeks	O
0	O
to	O
eight	O
,	O
increasing	O
to	O
400	O
mg	O
three	O
times	O
a	O
day	O
from	O
weeks	O
nine	O
to	O
24	O
provided	O
that	O
no	O
adverse	O
effects	O
were	O
recorded	O
.	O

Most	O
patients	O
were	O
unable	O
to	O
tolerate	Others
metronidazole	Others
because	O
of	O
side	Adverseeffect
effects	Adverseeffect
or	O
lack	Others
of	Others
efficacy	Others
,	O
with	O
only	O
five	O
(	O
21	O
%	O
)	O
continuing	O
to	O
take	O
the	O
drug	O
at	O
24	O
weeks	O
.	O

For	O
those	O
patients	O
attaining	O
12	O
weeks	O
of	O
treatment	O
an	O
overall	Physical
improvement	Physical
in	Physical
articular	Physical
index	Physical
and	O
morning	Adverseeffect
stiffness	Adverseeffect
was	O
found	O
.	O

No	O
improvement	Others
in	O
laboratory	Physical
indices	Physical
of	Physical
disease	Physical
activity	Physical
was	O
seen	O
,	O
however	O
.	O

In	O
this	O
study	O
metronidazole	O
did	O
not	O
have	O
disease	Physical
modifying	Physical
properties	Physical
and	O
was	O
unacceptably	Adverseeffect
toxic	Adverseeffect
.	Adverseeffect

Nordic	O
walking	O
and	O
chronic	O
low	O
back	O
pain	O
:	O
design	O
of	O
a	O
randomized	O
clinical	O
trial	O
.	O

BACKGROUND	O
Low	O
Back	O
Pain	O
is	O
a	O
major	O
public	O
health	O
problem	O
all	O
over	O
the	O
western	O
world	O
.	O

Active	O
approaches	O
including	O
exercise	O
in	O
the	O
treatment	O
of	O
low	O
back	O
pain	O
results	O
in	O
better	O
outcomes	O
for	O
patients	O
,	O
but	O
it	O
is	O
not	O
known	O
exactly	O
which	O
types	O
of	O
back	O
exercises	O
are	O
most	O
beneficial	O
or	O
whether	O
general	O
physical	O
activity	O
provide	O
similar	O
benefits	O
.	O

Nordic	O
Walking	O
is	O
a	O
popular	O
and	O
fast	O
growing	O
type	O
of	O
exercise	O
in	O
Northern	O
Europe	O
.	O

Initial	O
studies	O
have	O
demonstrated	O
that	O
persons	O
performing	O
Nordic	O
Walking	O
are	O
able	O
to	O
exercise	O
longer	O
and	O
harder	O
compared	O
to	O
normal	O
walking	O
thereby	O
increasing	O
their	O
cardiovascular	O
metabolism	O
.	O

Until	O
now	O
no	O
studies	O
have	O
been	O
performed	O
to	O
investigate	O
whether	O
Nordic	O
Walking	O
has	O
beneficial	O
effects	Others
in	O
relation	O
to	O
low	O
back	O
pain	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
supervised	O
Nordic	O
Walking	O
can	O
reduce	Pain
pain	Pain
and	O
improve	Others
function	Others
in	O
a	O
population	O
of	O
chronic	O
low	O
back	O
pain	O
patients	O
when	O
compared	O
to	O
unsupervised	O
Nordic	O
Walking	O
and	O
advice	O
to	O
stay	O
active	O
.	O

In	O
addition	O
we	O
investigate	O
whether	O
there	O
is	O
an	O
increase	O
in	O
the	O
cardiovascular	O
metabolism	O
in	O
persons	O
performing	O
supervised	O
Nordic	O
Walking	O
compared	O
to	O
persons	O
who	O
are	O
advised	O
to	O
stay	O
active	O
.	O

Finally	O
,	O
we	O
investigate	O
whether	O
there	O
is	O
a	O
difference	O
in	O
compliance	Others
between	O
persons	O
receiving	O
supervised	O
Nordic	O
Walking	O
and	O
persons	O
doing	O
unsupervised	O
Nordic	O
Walking	O
.	O

METHODS	O
One	O
hundred	O
and	O
fifty	O
patients	O
with	O
low	O
back	O
pain	O
for	O
at	O
least	O
eight	O
weeks	O
and	O
referred	O
to	O
a	O
specialized	O
secondary	O
sector	O
outpatient	O
back	O
pain	O
clinic	O
are	O
included	O
in	O
the	O
study	O
.	O

After	O
completion	O
of	O
the	O
standard	O
back	O
centre	O
treatment	O
patients	O
are	O
randomized	O
into	O
one	O
of	O
three	O
groups	O
:	O
A	O
)	O
Nordic	O
Walking	O
twice	O
a	O
week	O
for	O
eight	O
weeks	O
under	O
supervision	O
of	O
a	O
specially	O
trained	O
instructor	O
;	O
B	O
)	O
Unsupervised	O
Nordic	O
Walking	O
for	O
eight	O
weeks	O
after	O
one	O
training	O
session	O
with	O
an	O
instructor	O
;	O
C	O
)	O
A	O
one	O
hour	O
motivational	O
talk	O
including	O
advice	O
to	O
stay	O
active	O
.	O

Outcome	O
measures	O
are	O
pain	Pain
,	O
function	Pain
,	O
overall	Others
health	Others
,	O
cardiovascular	Physical
ability	Physical
and	O
activity	Pain
level	Pain
.	O

RESULTS	O
No	O
results	O
available	O
at	O
this	O
point	O
.	O

DISCUSSION	O
This	O
study	O
will	O
investigate	O
the	O
effect	O
of	O
Nordic	O
Walking	O
on	O
pain	O
and	O
function	O
in	O
a	O
population	O
of	O
people	O
with	O
chronic	O
LBP	O
.	O

[	Adverseeffect
Complication	Adverseeffect
rate	Adverseeffect
after	O
gastrectomy	O
and	O
pouch	O
reconstruction	O
with	O
Longmire	O
interposition	O
]	O
.	O

BACKGROUND/AIMS	O
To	O
determine	O
whether	O
a	O
Longmire-Interposition	O
with	O
or	O
without	O
a	O
pouch	O
used	O
for	O
reconstruction	O
after	O
gastrectomy	O
influences	O
the	O
postoperative	O
complication	O
rate	O
.	O

METHODOLOGY	O
49	O
patients	O
who	O
underwent	O
gastrectomy	O
with	O
Longmire-Interposition	O
with	O
(	O
n	O
=	O
33	O
)	O
or	O
without	O
(	O
n	O
=	O
16	O
)	O
an	O
additional	O
pouch	O
and	O
46	O
patients	O
with	O
a	O
Roux-en-Y-reconstruction	O
were	O
analysed	O
retrospectively	O
.	O

Complication	Physical
rate	Physical
and	O
mortality	Mortality
were	O
studied	O
.	O

RESULTS	O
There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
reconstruction	O
groups	O
for	O
postoperative	Adverseeffect
complications	Adverseeffect
(	O
Roux-en-Y	O
vs.	O
Longmire-Interposition	O
with	O
and	O
without	O
pouch	O
:	O
30.4	O
%	O
vs.	O
28.6	O
%	O
for	O
the	O
morbidity	Mortality
;	Others
4.3	O
%	O
vs.	O
4.1	O
%	O
for	O
the	O
mortality	Mortality
)	O
.	O

CONCLUSION	O
These	O
findings	O
suggest	O
that	O
a	O
Longmire-Interposition	O
with	O
or	O
without	O
a	O
pouch	O
for	O
reconstruction	O
after	O
total	O
gastrectomy	O
is	O
not	O
connected	O
with	O
a	O
higher	O
morbidity	Mortality
or	O
mortality	Mortality
in	O
comparison	O
to	O
a	O
Roux-en-Y-reconstruction	O
.	O

A	O
novel	O
methodology	O
for	O
generating	O
3D	O
finite	O
element	O
models	O
of	O
the	O
hip	O
from	O
2D	O
radiographs	O
.	O

Finite	O
element	O
(	O
FE	O
)	O
modelling	O
has	O
been	O
proposed	O
as	O
a	O
tool	O
for	O
estimating	O
fracture	Physical
risk	Physical
and	O
patient-specific	O
FE	O
models	O
are	O
commonly	O
based	O
on	O
computed	O
tomography	O
(	O
CT	O
)	O
.	O

Here	O
,	O
we	O
present	O
a	O
novel	O
method	O
to	O
automatically	O
create	O
personalised	O
3D	O
models	O
from	O
standard	O
2D	O
hip	O
radiographs	O
.	O

A	O
set	O
of	O
geometrical	O
parameters	O
of	O
the	O
femur	O
were	O
determined	O
from	O
seven	O
a-p	O
hip	O
radiographs	O
and	O
compared	O
to	O
the	O
3D	O
femoral	O
shape	O
obtained	O
from	O
CT	O
as	O
training	O
material	O
;	O
the	O
error	O
in	O
reconstructing	O
the	O
3D	O
model	O
from	O
the	O
2D	O
radiographs	O
was	O
assessed	O
.	O

Using	O
the	O
geometry	O
parameters	O
as	O
the	O
input	O
,	O
the	O
3D	O
shape	O
of	O
another	O
21	O
femora	O
was	O
built	O
and	O
meshed	O
,	O
separating	O
a	O
cortical	O
and	O
trabecular	O
compartment	O
.	O

The	O
material	O
properties	O
were	O
derived	O
from	O
the	O
homogeneity	Physical
index	Physical
assessed	O
by	O
texture	O
analysis	O
of	O
the	O
radiographs	O
,	O
with	O
focus	O
on	O
the	O
principal	O
tensile	O
and	O
compressive	O
trabecular	O
systems	O
.	O

The	O
ability	O
of	O
these	O
FE	O
models	O
to	O
predict	O
failure	Physical
load	Physical
as	O
determined	O
by	O
experimental	O
biomechanical	O
testing	O
was	O
evaluated	O
and	O
compared	O
to	O
the	O
predictive	O
ability	O
of	O
DXA	O
.	O

The	O
average	Others
reconstruction	Others
error	Others
of	O
the	O
3D	O
models	O
was	O
1.77	O
mm	O
(	O
?1.17	O
mm	O
)	O
,	O
with	O
the	O
error	O
being	O
smallest	O
in	O
the	O
femoral	O
head	O
and	O
neck	O
,	O
and	O
greatest	O
in	O
the	O
trochanter	O
.	O

The	O
correlation	O
of	O
the	O
FE	O
predicted	O
failure	O
load	O
with	O
the	O
experimental	O
failure	O
load	O
was	O
r	O
(	O
2	O
)	O
=64	O
%	O
for	O
the	O
reconstruction	O
FE	O
model	O
,	O
which	O
was	O
significantly	O
better	O
(	O
p	O
<	O
0.05	O
)	O
than	O
that	O
for	O
DXA	O
(	O
r	O
(	O
2	O
)	O
=24	O
%	O
)	O
.	O

This	O
novel	O
method	O
for	O
automatically	O
constructing	O
a	O
patient-specific	O
3D	O
finite	O
element	O
model	O
from	O
standard	O
2D	O
radiographs	O
shows	O
encouraging	O
results	O
in	O
estimating	O
patient-specific	O
failure	O
loads	O
.	O

Promoting	O
imitation	O
in	O
young	O
children	O
with	O
autism	O
:	O
a	O
comparison	O
of	O
reciprocal	O
imitation	O
training	O
and	O
video	O
modeling	O
.	O

The	O
inability	O
to	O
imitate	O
is	O
a	O
salient	O
diagnostic	O
marker	O
for	O
autism	O
.	O

It	O
has	O
been	O
suggested	O
that	O
for	O
children	O
with	O
autism	O
,	O
imitation	O
may	O
be	O
a	O
prerequisite	O
skill	O
that	O
can	O
assist	O
in	O
the	O
development	O
of	O
various	O
skills	O
.	O

Using	O
a	O
multiple	O
baseline	O
design	O
across	O
subjects	O
,	O
the	O
purpose	O
of	O
this	O
research	O
was	O
to	O
determine	O
if	O
two	O
interventions	O
,	O
reciprocal	O
imitation	O
training	O
and	O
video	O
modeling	O
were	O
effective	O
in	O
promoting	Mental
imitation	Mental
acquisition	Mental
in	O
young	O
children	O
with	O
autism	O
.	O

Six	O
boys	O
were	O
matched	O
across	O
various	O
features	O
(	O
i.e.	O
,	O
age	O
,	O
language	O
,	O
autism	O
severity	O
)	O
and	O
randomly	O
placed	O
in	O
a	O
treatment	O
condition	O
.	O

Results	O
indicated	O
that	O
all	O
six	O
participants	O
increased	O
their	O
imitation	Mental
skills	Mental
to	O
varying	O
degrees	O
in	O
both	O
conditions	O
,	O
and	O
imitation	O
maintained	O
and	O
generalized	O
at	O
higher	O
than	O
baseline	O
levels	O
post	O
treatment	O
.	O

Early	O
reperfusion	O
and	O
late	O
clinical	O
outcomes	O
in	O
patients	O
presenting	O
with	O
acute	O
myocardial	O
infarction	O
randomly	O
assigned	O
to	O
primary	O
percutaneous	O
coronary	O
intervention	O
or	O
streptokinase	O
.	O

BACKGROUND	O
Primary	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
has	O
become	O
an	O
alternative	O
to	O
thrombolytic	O
therapy	O
as	O
a	O
reperfusion	O
strategy	O
for	O
ST-elevation	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O

METHODS	O
The	O
main	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
PCI	O
and	O
thrombolytic	O
therapy	O
achieve	O
comparable	O
reperfusion	O
rates	O
,	O
as	O
evidenced	O
by	O
ST-segment	O
resolution	O
.	O

Secondary	O
end	O
points	O
included	O
infarct	Physical
vessel	Physical
patency	Physical
rates	Physical
before	O
hospital	O
discharge	O
and	O
short-	O
and	O
long-term	O
outcomes	O
.	O

Patients	O
with	O
ischemic	O
chest	O
pain	O
with	O
duration	O
<	O
or	O
=12	O
hours	O
and	O
no	O
contraindication	O
for	O
thrombolytic	O
therapy	O
were	O
included	O
.	O

RESULTS	O
Between	O
October	O
1993	O
and	O
August	O
1995	O
,	O
58	O
patients	O
were	O
randomly	O
assigned	O
to	O
streptokinase	O
(	O
SK	O
)	O
and	O
54	O
patients	O
to	O
primary	O
PCI	O
.	O

Baseline	O
clinical	O
characteristics	O
and	O
infarct	O
location	O
were	O
well	O
balanced	O
in	O
both	O
groups	O
.	O

Median	O
age	O
(	O
interquartile	O
range	O
)	O
was	O
68	O
(	O
58	O
,	O
75	O
)	O
years	O
,	O
29	O
%	O
were	O
women	O
,	O
and	O
78	O
%	O
of	O
the	O
patients	O
met	O
at	O
least	O
one	O
criterion	O
for	O
not	O
low	O
risk	O
AMI	O
(	O
anterior	O
location	O
,	O
age	O
>	O
70	O
years	O
old	O
,	O
previous	O
MI	O
,	O
systolic	O
blood	Physical
pressure	Physical
<	O
100	O
mm	O
Hg	O
,	O
and/or	O
heart	O
rate	O
>	O
100	O
bpm	O
)	O
.	O

The	O
median	Physical
time	Physical
from	Physical
symptom	Physical
onset	Physical
to	O
random	O
assignment	O
was	O
217	O
(	O
139	O
,	O
335	O
)	O
minutes	O
in	O
the	O
PCI	O
group	O
and	O
210	O
(	O
145	O
,	O
334	O
)	O
minutes	O
in	O
the	O
SK	O
group	O
.	O

Median	O
random	O
assignment	O
to	O
balloon	Physical
time	Physical
was	O
82	O
(	O
55	O
,	O
100	O
)	O
minutes	O
,	O
and	O
median	O
random	O
assignment	O
to	O
needle	Others
time	Others
was	O
15	O
(	O
10	O
,	O
26	O
)	O
minutes	O
(	O
P	O
<	O
.0001	O
)	O
.	O

TIMI	Physical
grade	Physical
3	Physical
flow	Physical
after	O
primary	O
PCI	O
was	O
obtained	O
in	O
85	O
%	O
of	O
patients	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
ST-segment	Physical
resolution	Physical
>	O
or	O
=50	O
%	O
at	O
120	O
minutes	O
was	O
80	O
%	O
in	O
the	O
PCI	O
group	O
and	O
50	O
%	O
in	O
the	O
SK	O
group	O
(	O
P	O
=.001	O
)	O
.	O

The	O
predischarge	O
angiogram	O
showed	O
the	O
presence	Physical
of	Physical
TIMI	Physical
3	Physical
flow	Physical
in	O
96	O
%	O
of	O
patients	O
who	O
received	O
PCI	O
and	O
65	O
%	O
of	O
patients	O
who	O
received	O
SK	O
(	O
P	O
<	O
.001	O
)	O
.	O

A	O
composite	O
of	O
in-hospital	Mortality
death	Mortality
,	O
reinfarction	Physical
,	O
severe	Physical
heart	Physical
failure	Physical
,	O
stroke	Physical
,	O
and	O
major	Physical
bleeding	Physical
occurred	O
in	O
15	O
%	O
of	O
patients	O
who	O
received	O
PCI	O
and	O
21	O
%	O
of	O
patients	O
who	O
received	O
SK	O
(	O
P	O
=.4	O
)	O
.	O

At	O
3	O
years	O
,	O
freedom	O
from	O
the	O
composite	Mortality
end	Mortality
point	Mortality
of	Mortality
AMI	Mortality
,	O
postdischarge	Physical
revascularization	Physical
,	O
and	O
death	Mortality
was	O
61	O
%	O
in	O
the	O
PCI	O
group	O
and	O
40	O
%	O
in	O
the	O
SK	O
group	O
(	O
P	O
=.025	O
)	O
.	O

CONCLUSIONS	O
Our	O
study	O
shows	O
that	O
primary	O
PCI	O
,	O
as	O
compared	O
with	O
SK	O
,	O
is	O
associated	O
with	O
more	O
effective	O
ST-segment	Physical
resolution	Physical
,	O
higher	O
patency	Physical
rates	Physical
in	O
the	O
infarct	O
vessel	O
at	O
7	O
days	O
,	O
and	O
more	O
favorable	O
clinical	O
outcomes	O
at	O
3	O
years	O
of	O
follow-up	O
.	O

Analysis	O
of	O
prevention	O
program	O
effectiveness	O
with	O
clustered	O
data	O
using	O
generalized	O
estimating	O
equations	O
.	O

Experimental	O
studies	O
of	O
prevention	O
programs	O
often	O
randomize	O
clusters	O
of	O
individuals	O
rather	O
than	O
individuals	O
to	O
treatment	O
conditions	O
.	O

When	O
the	O
correlation	O
among	O
individuals	O
within	O
clusters	O
is	O
not	O
accounted	O
for	O
in	O
statistical	O
analysis	O
,	O
the	O
standard	O
errors	O
are	O
biased	O
,	O
potentially	O
resulting	O
in	O
misleading	O
conclusions	O
about	O
the	O
significance	O
of	O
treatment	O
effects	O
.	O

This	O
study	O
demonstrates	O
the	O
generalized	O
estimating	O
equations	O
(	O
GEE	O
)	O
method	O
,	O
focusing	O
specifically	O
on	O
the	O
GEE-independent	O
method	O
,	O
to	O
control	O
for	O
within-cluster	O
correlation	O
in	O
regression	O
models	O
with	O
either	O
continuous	Others
or	O
binary	Others
outcomes	Others
.	Others

The	O
GEE-independent	O
method	O
yields	O
consistent	Others
and	O
robust	Others
variance	Others
estimates	Others
.	Others

Data	O
from	O
project	O
DARE	O
,	O
a	O
youth	O
substance	O
abuse	O
prevention	O
program	O
,	O
are	O
used	O
for	O
illustration	O
.	O

Clinical	O
massage	O
and	O
modified	O
Proprioceptive	O
Neuromuscular	O
Facilitation	O
stretching	O
in	O
males	O
with	O
latent	O
myofascial	O
trigger	O
points	O
.	O

OBJECTIVES	O
To	O
determine	O
the	O
immediate	O
effects	O
of	O
modified	O
Proprioceptive	O
Neuromuscular	O
Facilitation	O
(	O
PNF	O
)	O
stretching	O
(	O
group	O
I	O
)	O
versus	O
Myofascial	O
Trigger	O
Point	O
(	O
MTrP	O
)	O
therapy	O
plus	O
modified	O
PNF	O
stretching	O
(	O
group	O
II	O
)	O
in	O
comparison	O
to	O
a	O
control	O
group	O
receiving	O
no	O
treatment	O
.	O

DESIGN	O
Randomized	O
,	O
assessor-blind	O
,	O
(	O
3	O
x	O
4	O
)	O
mixed-model	O
repeated	O
measures	O
.	O

SETTING	O
University	O
laboratory	O
.	O

PARTICIPANTS	O
Thirty	O
physically	O
active	O
males	O
with	O
tight	O
hamstrings	O
and	O
at	O
least	O
one	O
latent	O
MTrP	O
on	O
muscles	O
innervated	O
by	O
the	O
lumbosacral	O
,	O
sciatic	O
,	O
tibial	O
and	O
common	O
peroneal	O
nerves	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Knee	Physical
range	Physical
of	Physical
motion	Physical
(	Physical
ROM	Physical
)	Physical
,	O
stretch	Physical
perception	Physical
,	O
pressure	Pain
pain	Pain
threshold	Pain
(	Pain
PPT	Pain
)	Pain
and	Pain
subjective	Pain
pain	Pain
intensity	Pain
.	O

Outcomes	O
were	O
evaluated	O
at	O
baseline	O
,	O
immediately	O
after	O
treatment	O
,	O
at	O
10	O
and	O
30	O
min	O
.	O

RESULTS	O
Significant	O
changes	O
over	O
time	O
occurred	O
for	O
group	O
II	O
in	O
all	O
outcomes	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O

Group	O
II	O
also	O
showed	O
lower	Pain
pain	Pain
intensity	Pain
scores	Pain
than	O
group	O
I	O
immediately	O
post-treatment	O
(	O
p	O
=	O
0.045	O
)	O
and	O
a	O
strong	O
clinical	Others
effect	Others
over	O
group	O
I	O
in	O
ROM	Physical
at	O
all	O
follow-ups	O
(	O
effect	O
sizes	O
=	O
0.9-1.0	O
,	O
p	O
<	O
or	O
=	O
0.05	O
)	O
.	O

Other	O
differences	O
were	O
found	O
between	O
both	O
stretching	O
groups	O
as	O
compared	O
to	O
the	O
control	O
group	O
(	O
p	O
<	O
or	O
=	O
0.05	O
)	O
.	O

CONCLUSION	O
The	O
results	O
indicate	O
immediate	O
pre-	O
to	O
post-treatment	O
benefits	O
from	O
MTrP	O
therapy	O
combined	O
with	O
modified	O
PNF	O
stretching	O
in	O
young	O
and	O
physically	O
active	O
males	O
with	O
latent	O
MTrPs	O
.	O

The	O
nightly	O
use	O
of	O
sodium	O
oxybate	O
is	O
associated	O
with	O
a	O
reduction	O
in	O
nocturnal	Physical
sleep	Physical
disruption	Physical
:	Physical
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
in	O
patients	O
with	O
narcolepsy	O
.	O

OBJECTIVE	O
To	O
further	O
explore	O
the	O
effects	O
of	O
sodium	O
oxybate	O
(	O
SXB	O
)	O
administration	O
on	O
nocturnal	Physical
sleep	Physical
in	O
narcolepsy	O
patients	O
during	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
study	O
conducted	O
with	O
228	O
adult	O
patients	O
with	O
narcolepsy/cataplexy	O
in	O
the	O
United	O
States	O
,	O
Canada	O
,	O
and	O
Europe	O
.	O

METHOD	O
Patients	O
were	O
withdrawn	O
from	O
antidepressants	O
and	O
sedative/hypnotics	O
,	O
and	O
then	O
randomized	O
to	O
receive	O
4.5	O
,	O
6	O
,	O
or	O
9	O
g	O
SXB	O
or	O
placebo	O
nightly	O
for	O
8	O
weeks	O
.	O

Patients	O
receiving	O
6	O
and	O
9	O
g/night	O
doses	O
were	O
titrated	O
to	O
their	O
final	O
dose	O
in	O
weekly	O
1.5	O
g	O
increments	O
,	O
while	O
patients	O
receiving	O
placebo	O
were	O
randomized	O
to	O
undergo	O
a	O
similar	O
mock	O
dose	O
titration	O
.	O

The	O
use	O
of	O
stimulant	O
therapy	O
continued	O
unchanged	O
.	O

Changes	Others
in	Others
sleep	Others
architecture	Others
were	Physical
measured	Physical
using	Physical
centrally	Others
scored	Others
nocturnal	Others
polysomnograms	Others
.	Physical

Daily	O
diaries	O
were	O
used	O
to	O
record	O
changes	Adverseeffect
in	Adverseeffect
narcolepsy	Adverseeffect
symptoms	Adverseeffect
and	Adverseeffect
adverse	Adverseeffect
events	Adverseeffect
.	Adverseeffect

RESULTS	O
Following	O
8	O
weeks	O
of	O
SXB	O
treatment	O
,	O
study	O
patients	O
demonstrated	O
significant	O
dose-related	O
increases	O
in	O
the	O
duration	Others
of	Others
stage	Others
3	Others
and	Others
4	Others
sleep	Others
,	O
reaching	O
a	O
median	O
increase	O
of	O
52.5	O
minutes	O
in	O
patients	O
receiving	O
9	O
g	O
nightly	O
.	O

Compared	O
to	O
placebo-treated	O
patients	O
,	O
delta	Others
power	Others
was	O
significantly	O
increased	O
in	O
all	O
dose	O
groups	O
.	O

Stage	Others
1	Others
sleep	Others
and	Others
the	Others
frequency	Others
of	Others
nocturnal	Others
awakenings	Others
were	O
each	O
significantly	O
decreased	O
at	O
the	O
6	O
and	O
9	O
g/night	O
doses	O
.	O

The	O
changes	Physical
in	Physical
nocturnal	Physical
sleep	Physical
coincided	O
with	O
significant	O
decreases	O
in	O
the	O
severity	Physical
and	Physical
frequency	Physical
of	Physical
narcolepsy	Physical
symptoms	Physical
.	Physical

CONCLUSIONS	O
The	O
nightly	O
administration	O
of	O
SXB	O
to	O
narcolepsy	O
patients	O
significantly	O
impacts	O
measures	O
of	O
slow	Physical
wave	Physical
sleep	Physical
,	Physical
wake	Physical
after	Physical
sleep	Physical
onset	Physical
,	Physical
awakenings	Physical
,	Physical
total	Others
sleep	Others
time	Others
,	Physical
and	Physical
stage	Physical
1	Physical
sleep	Physical
in	O
a	O
dose-related	O
manner	O
.	O

The	O
frequency	Others
and	Others
severity	Others
of	Others
narcolepsy	Others
symptoms	Others
decreased	O
with	O
treatment	O
.	O

The	O
sequencing	O
of	O
chemotherapy	O
and	O
radiation	O
therapy	O
after	O
conservative	O
surgery	O
for	O
early-stage	O
breast	O
cancer	O
.	O

BACKGROUND	O
Patients	O
with	O
early-stage	O
breast	O
cancer	O
who	O
are	O
at	O
substantial	O
risk	O
for	O
systemic	O
metastases	O
are	O
increasingly	O
treated	O
with	O
breast-conserving	O
therapy	O
and	O
adjuvant	O
chemotherapy	O
.	O

However	O
,	O
the	O
optimal	O
sequencing	O
of	O
chemotherapy	O
and	O
radiation	O
therapy	O
is	O
not	O
clear	O
.	O

METHODS	O
Two	O
hundred	O
forty-four	O
patients	O
with	O
stage	O
I	O
or	O
II	O
breast	O
cancer	O
who	O
were	O
at	O
substantial	O
risk	O
for	O
distant	O
metastases	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	O
12-week	O
course	O
of	O
chemotherapy	O
either	O
before	O
or	O
after	O
radiation	O
therapy	O
.	O

All	O
had	O
had	O
breast-conserving	O
surgery	O
.	O

The	O
median	O
length	O
of	O
follow-up	O
in	O
surviving	O
patients	O
was	O
58	O
months	O
(	O
range	O
,	O
10	O
to	O
124	O
)	O
.	O

RESULTS	O
The	O
five-year	Physical
actuarial	Physical
rates	Physical
of	Physical
cancer	Physical
recurrence	Physical
at	O
any	O
site	O
and	O
of	O
distant	O
metastases	O
in	O
the	O
radiotherapy-first	O
group	O
and	O
the	O
chemotherapy-first	O
group	O
were	O
38	O
percent	O
and	O
31	O
percent	O
(	O
P	O
=	O
0.17	O
)	O
and	O
36	O
percent	O
and	O
25	O
percent	O
(	O
P	O
=	O
0.05	O
)	O
,	O
respectively	O
.	O

Overall	Mortality
survival	Mortality
was	O
73	O
percent	O
and	O
81	O
percent	O
(	O
P	O
=	O
0.11	O
)	O
,	O
respectively	O
.	O

The	O
five-year	Physical
crude	Physical
rates	Physical
of	Physical
first	Physical
recurrence	Physical
according	O
to	O
site	O
in	O
the	O
radiotherapy-first	O
and	O
chemotherapy-first	O
groups	O
,	O
respectively	O
,	O
were	O
5	O
percent	O
and	O
14	O
percent	O
for	O
local	O
recurrence	O
and	O
32	O
percent	O
and	O
20	O
percent	O
for	O
distant	O
or	O
regional	O
recurrence	O
or	O
both	O
.	O

This	O
difference	O
in	O
the	O
pattern	Physical
of	Physical
recurrence	Physical
was	O
of	O
borderline	O
statistical	O
significance	O
(	O
P	O
=	O
0.07	O
)	O
.	O

CONCLUSIONS	O
This	O
study	O
suggests	O
that	O
for	O
patients	O
ar	O
substantial	O
risk	O
for	O
systemic	O
metastases	O
,	O
it	O
is	O
preferable	O
to	O
give	O
a	O
12-week	O
course	O
of	O
chemotherapy	O
followed	O
by	O
radiation	O
therapy	O
,	O
rather	O
than	O
radiation	O
therapy	O
followed	O
by	O
chemotherapy	O
.	O

An	O
occupation	O
based	O
physical	O
activity	O
intervention	O
program	O
:	O
improving	Mental
fitness	Mental
and	O
decreasing	Physical
obesity	Physical
.	O

The	O
purpose	O
of	O
this	O
quasi-experimental	O
study	O
was	O
to	O
determine	O
the	O
effectiveness	O
of	O
an	O
occupation	O
based	O
health	O
and	O
fitness	O
program	O
.	O

Subjects	O
were	O
1,504	O
police	O
trainees	O
(	O
85	O
%	O
male	O
,	O
15	O
%	O
female	O
)	O
with	O
an	O
ethnic	O
distribution	O
of	O
82	O
%	O
white	O
,	O
16	O
%	O
African	O
American	O
,	O
and	O
2	O
%	O
other	O
.	O

Data	O
were	O
collected	O
at	O
25	O
sites	O
across	O
the	O
state	O
of	O
North	O
Carolina	O
.	O

The	O
sites	O
were	O
randomly	O
assigned	O
to	O
either	O
the	O
experimental	O
group	O
(	O
implemented	O
the	O
intervention	O
)	O
or	O
the	O
control	O
group	O
(	O
continued	O
usual	O
training	O
)	O
.	O

As	O
compared	O
with	O
controls	O
,	O
subjects	O
at	O
the	O
experimental	O
sites	O
improved	O
significantly	O
in	O
cardiovascular	Physical
fitness	Physical
(	Physical
aerobic	Physical
power	Physical
)	Physical
,	O
general	Physical
muscular	Physical
strength	Physical
(	O
number	Physical
of	Physical
sit	Physical
ups	Physical
per	Physical
minute	Physical
)	O
,	O
and	O
flexibility	Physical
,	O
and	O
lowered	Others
their	Others
body	Others
fat	Others
.	O

The	O
intervention	O
required	O
minimal	O
equipment	O
and	O
was	O
taught	O
primarily	O
by	O
peers	O
who	O
received	O
a	O
1	O
week	O
training	O
program	O
.	O

This	O
occupational	O
approach	O
to	O
improving	O
health	O
could	O
be	O
particularly	O
useful	O
in	O
occupations	O
with	O
many	O
workers	O
who	O
seldom	O
engage	O
in	O
leisure	O
time	O
physical	O
activity	O
.	O

A	O
randomised	O
comparison	O
of	O
UK	O
genetic	O
risk	O
counselling	O
services	O
for	O
familial	O
cancer	O
:	O
psychosocial	Mental
outcomes	Mental
.	Mental

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
compare	O
psychosocial	Mental
outcomes	Mental
for	O
50	O
new	O
clinic	O
attendees	O
,	O
referred	O
for	O
cancer	O
genetic	O
counselling	O
to	O
five	O
UK	O
centres	O
.	O

The	O
centres	O
represented	O
England	O
,	O
Scotland	O
and	O
Wales	O
,	O
and	O
were	O
randomly	O
selected	O
from	O
groups	O
ranked	O
by	O
different	O
levels	O
of	O
clinical	O
activity	O
in	O
cancer	O
genetics	O
practice	O
.	O

Questionnaires	O
assessed	O
demographic	Others
data	Others
,	O
risk	Mental
perception	Mental
,	Mental
mental	Mental
health	Mental
and	O
use	Others
of	Others
health	Others
services	Others
pre-consultation	Others
and	O
at	O
1	O
and	O
12	O
months	O
follow-up	O
.	O

Satisfaction	Others
was	O
measured	O
for	O
attendees	O
and	O
referring	O
doctors	O
at	O
follow-up	O
.	O

A	O
total	O
of	O
256	O
unaffected	O
adults	O
fulfilled	O
the	O
study	O
criteria	O
.	O

The	O
five	O
centres	O
varied	O
widely	O
with	O
respect	O
to	O
service	O
organisation	O
and	O
activity	O
,	O
but	O
all	O
had	O
a	O
greater	O
proportion	O
of	O
unaffected	O
attendees	O
with	O
a	O
breast	O
cancer	O
risk	O
(	O
61-91	O
%	O
)	O
than	O
either	O
a	O
bowel	O
cancer	O
risk	O
(	O
0-33	O
%	O
)	O
or	O
ovarian	O
cancer	O
risk	O
(	O
3-25	O
%	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
psychosocial	Mental
data	Mental
between	O
centres	O
pre-counselling	O
.	O

No	O
significant	O
change	O
over	O
time	O
occurred	O
for	O
any	O
of	O
the	O
centres	O
for	O
risk	Others
perception	Others
or	O
general	Mental
psychological	Mental
distress	Mental
.	O

There	O
were	O
significant	O
differences	O
between	O
centres	O
in	O
reduction	O
of	O
cancer	Physical
worry	O
from	O
baseline	O
to	O
12	O
months	O
and	O
with	O
the	O
number	O
of	O
women	O
who	O
were	O
recommended	O
to	O
have	O
mammographic	O
surveillance	O
who	O
had	O
not	O
received	O
this	O
.	O

Overall	O
,	O
one-third	O
of	O
women	O
for	O
whom	O
mammography	O
had	O
been	O
recommended	O
had	O
not	O
been	O
screened	O
within	O
1	O
year	O
of	O
follow-up	O
.	O

Subsequent	O
attendance	O
at	O
the	O
GP	O
,	O
but	O
not	O
at	O
a	O
hospital	O
,	O
was	O
associated	O
with	O
risk	O
level	O
,	O
but	O
differences	O
between	O
centres	O
could	O
not	O
be	O
analysed	O
.	O

Satisfaction	Others
differed	O
significantly	O
between	O
centres	O
for	O
4	O
:	O
14	O
aspects	O
of	O
service	O
provision	O
and	O
with	O
3	O
:	O
17	O
items	O
concerning	O
communication	O
;	O
satisfaction	O
was	O
high	O
overall	O
.	O

Over	O
90	O
%	O
of	O
referring	O
doctors	O
were	O
moderately/very	O
satisfied	O
with	O
the	O
service	O
,	O
but	O
23	O
%	O
were	O
dissatisfied	O
with	O
waiting	O
times	O
and	O
19	O
%	O
with	O
access	O
to	O
preventive	O
treatment	O
.	O

Results	O
differed	O
significantly	O
between	O
centres	O
for	O
doctor	O
's	O
satisfaction	O
with	O
the	O
provision	O
of	O
referral	O
criteria	O
and	O
prescribing	O
information	O
.	O

In	O
conclusion	O
,	O
there	O
were	O
relatively	O
few	O
significant	O
differences	O
in	O
psychosocial	Mental
outcomes	Mental
between	O
centres	O
,	O
considering	O
the	O
wide	O
variation	O
in	O
service	O
organisation	O
and	O
activity	O
.	O

These	O
significant	O
differences	O
were	O
not	O
consistent	O
across	O
the	O
centres	O
,	O
therefore	O
,	O
differences	O
could	O
not	O
be	O
linked	O
to	O
specific	O
aspects	O
of	O
service	O
provision	O
.	O

Comparison	O
of	O
the	O
effects	O
of	O
terazosin	O
and	O
enalapril	O
on	O
laboratory	O
stress	O
testing	O
blood	O
pressure	O
in	O
patients	O
with	O
essential	O
hypertension	O
.	O

It	O
is	O
the	O
current	O
opinion	O
that	O
an	O
ideal	O
antihypertensive	O
drug	O
should	O
reduce	O
blood	O
pressure	O
(	O
BP	O
)	O
not	O
only	O
at	O
rest	O
but	O
also	O
during	O
stressful	O
situations	O
.	O

The	O
current	O
study	O
was	O
aimed	O
to	O
compare	O
the	O
effects	O
of	O
the	O
selective	O
alpha	O
1-adrenergic	O
blocker	O
terazosin	O
(	O
5	O
mg	O
once	O
daily	O
)	O
and	O
of	O
the	O
angiotensin-converting	O
enzyme	O
inhibitor	O
enalapril	O
(	O
20	O
mg	O
once	O
daily	O
)	O
on	O
cardiovascular	O
response	O
to	O
a	O
set	O
of	O
standardized	O
laboratory	O
stressors	O
,	O
such	O
as	O
mental	O
arithmetic	O
,	O
handgrip	O
test	O
and	O
cycle	O
ergometry	O
,	O
in	O
a	O
group	O
of	O
16	O
essential	O
hypertensive	O
patients	O
.	O

The	O
study	O
was	O
a	O
randomized	O
,	O
double-blind	O
,	O
cross-over	O
trial	O
preceded	O
by	O
a	O
placebo	O
run-in	O
period	O
.	O

Terazosin	O
and	O
enalapril	O
had	O
a	O
comparable	O
effect	O
on	O
resting	Physical
BP	Physical
,	Physical
reducing	Physical
systolic	Physical
(	Physical
SBP	Physical
)	Physical
and	Physical
diastolic	Physical
(	Physical
DBP	Physical
)	Physical
blood	Physical
pressure	Physical
from	O
159.5	O
+/-	O
13.9/101.6	O
+/-	O
8.8	O
mm	O
Hg	O
during	O
placebo	O
by	O
7.8	O
%	O
/6.7	O
%	O
and	O
by	O
11.3	O
%	O
/10.2	O
%	O
,	O
respectively	O
.	O

The	O
response	Others
rate	Others
to	O
the	O
two	O
treatments	O
was	O
approximately	O
the	O
same	O
,	O
being	O
69	O
%	O
and	O
75	O
%	O
after	O
terazosin	O
and	O
enalapril	O
,	O
respectively	O
.	O

During	O
mental	O
arithmetic	O
,	O
from	O
an	O
average	O
of	O
181.6	O
+/-	O
17.8/118.6	O
+/-	O
11.5	O
mm	O
Hg	O
during	O
placebo	O
,	O
BP	Physical
was	O
reduced	O
by	O
11.5	O
%	O
/7.9	O
%	O
after	O
terazosin	O
and	O
by	O
13.6	O
%	O
/8.5	O
%	O
after	O
enalapril	O
;	O
during	O
handgrip	O
test	O
,	O
BP	Physical
decreased	O
from	O
207.2	O
+/-	O
22.2/142.2	O
+/-	O
13.6	O
mm	O
Hg	O
by	O
7.3	O
%	O
/8.4	O
%	O
after	O
terazosin	O
and	O
by	O
7.7	O
%	O
/7.1	O
%	O
after	O
enalapril	O
;	O
finally	O
,	O
during	O
cycle	O
ergometry	O
,	O
terazosin	O
and	O
enalapril	O
lowered	O
BP	Physical
by	O
5.4	O
%	O
/6.7	O
%	O
and	O
7	O
%	O
/3.1	O
%	O
,	O
respectively	O
,	O
from	O
a	O
placebo	O
value	O
of	O
215.5	O
+/-	O
17.3/127.6	O
+/-	O
11.2	O
.	O

No	O
significant	O
difference	O
in	O
antihypertensive	O
efficacy	O
was	O
observed	O
between	O
the	O
two	O
drugs	O
,	O
either	O
at	O
rest	O
and	O
during	O
stress	O
testing	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Liposome-entrapped	O
D.	O
pteronyssinus	O
vaccination	O
in	O
mild	O
asthma	O
patients	O
:	O
effect	O
of	O
1-year	O
double-blind	O
,	O
placebo-controlled	O
trial	O
on	O
inflammation	O
,	O
bronchial	O
hyperresponsiveness	O
and	O
immediate	O
and	O
late	O
bronchial	O
responses	O
to	O
the	O
allergen	O
.	O

BACKGROUND	O
Allergen	O
vaccination	O
is	O
effective	O
in	O
mite-allergic	O
asthma	O
.	O

Liposomes	O
are	O
immunological	O
adjuvants	O
that	O
can	O
act	O
as	O
allergen	O
carriers	O
.	O

OBJECTIVE	O
To	O
evaluate	O
the	O
immunological	O
and	O
functional	O
effects	O
of	O
a	O
liposome-entrapped	O
D.	O
pteronyssinus	O
vaccine	O
on	O
mite	O
monosensitive	O
,	O
mild	O
asthma	O
patients	O
.	O

METHODS	O
A	O
double-blind	O
,	O
placebo-controlled	O
trial	O
was	O
conducted	O
on	O
26	O
asthma	O
patients	O
who	O
randomly	O
received	O
vaccination	O
or	O
placebo	O
for	O
1	O
year	O
.	O

The	O
levels	O
of	O
exposure	O
to	O
Der	O
p	O
1	O
allergen	O
were	O
constant	O
during	O
the	O
study	O
.	O

Allergen	O
bronchial	O
challenge	O
was	O
made	O
at	O
the	O
beginning	O
(	O
T0	O
)	O
and	O
after	O
1	O
year	O
of	O
treatment	O
(	O
T12	O
)	O
.	O

The	O
day	O
before	O
and	O
24	O
h	O
after	O
the	O
allergen	O
provocation	O
,	O
patients	O
were	O
challenged	O
with	O
methacholine	O
(	O
Mth	O
)	O
(	O
until	O
FEV1	O
fell	O
by	O
40	O
%	O
)	O
and	O
blood	O
and	O
sputum	O
samples	O
were	O
obtained	O
.	O

Dose-response	O
curves	O
to	O
Mth	O
were	O
evaluated	O
in	O
terms	O
of	O
Mth-PD20	O
(	O
dose	O
of	O
Mth	O
that	O
induced	O
20	O
%	O
drop	O
in	O
FEV1	O
)	O
,	O
slope	O
(	O
Mth-DRS	O
)	O
and	O
level	O
of	O
plateau	O
.	O

Blood	Physical
and	Physical
sputum	Physical
eosinophils	Physical
and	Physical
serum	Physical
levels	Physical
of	Physical
eosinophil	Physical
cationic	Physical
protein	Physical
(	Physical
ECP	Physical
)	Physical
and	Physical
intercellular	Physical
adhesion	Physical
molecule-1	Physical
(	Physical
ICAM-1	Physical
)	Physical
were	O
measured	O
.	O

RESULTS	O
Groups	O
were	O
comparable	O
at	O
the	O
start	O
of	O
the	O
trial	O
.	O

At	O
TI2	O
,	O
previous	O
to	O
the	O
allergen	O
challenge	O
,	O
the	O
active	O
group	O
showed	O
higher	O
values	O
of	O
both	O
FEV1	Physical
and	Physical
Mth-PD20	Physical
and	O
lower	O
values	O
of	O
Mth-DRS	Physical
.	O

The	O
number	Physical
of	Physical
patients	Physical
presenting	Physical
a	Physical
level	Physical
of	Physical
plateau	Physical
increased	O
in	O
the	O
active	O
group	O
(	O
from	O
two	O
to	O
four	O
)	O
and	O
decreased	O
in	O
the	O
placebo	O
group	O
(	O
from	O
two	O
to	O
one	O
)	O
.	O

At	O
T12	O
,	O
before	O
the	O
allergen	O
challenge	O
,	O
serum	Physical
ECP	Physical
levels	Physical
increased	O
in	O
the	O
placebo	O
group	O
and	O
blood	O
eosinophils	O
showed	O
a	O
trend	O
towards	O
lower	O
numbers	O
in	O
the	O
active	O
one	O
.	O

The	O
immediate	O
response	O
and	O
the	O
changes	O
in	O
Mth-DRS	Physical
values	Physical
,	Physical
sputum	Physical
eosinophils	Physical
and	Physical
serum	Physical
ECP	Physical
levels	Physical
following	O
the	O
allergen	O
challenge	O
were	O
attenuated	O
in	O
the	O
active	O
group	O
.	O

CONCLUSION	O
Liposome-entrapped	O
D.	O
Pteronyssinus	O
vaccination	O
:	O
(	O
i	O
)	O
protects	O
mild	O
asthma	O
patients	O
from	O
the	O
worsening	O
of	O
asthma	O
due	O
to	O
sustained	O
mite	O
exposure	O
;	O
and	O
(	O
ii	O
)	O
reduces	O
the	O
functional	O
and	O
inflammatory	O
changes	O
induced	O
by	O
allergen	O
bronchial	O
provocation	O
.	O

Removal	O
of	O
hypertrophied	O
anal	O
papillae	O
and	O
fibrous	O
anal	O
polyps	O
increases	O
patient	Others
satisfaction	Others
after	O
anal	O
fissure	O
surgery	O
.	O

BACKGROUND	O
Hypertrophied	O
anal	O
papillae	O
and	O
fibrous	O
anal	O
polyps	O
are	O
frequently	O
found	O
in	O
association	O
with	O
chronic	O
fissure	O
in	O
ano	O
.	O

Usually	O
,	O
no	O
specific	O
attention	O
is	O
given	O
to	O
them	O
and	O
they	O
are	O
considered	O
normal	O
findings	O
.	O

The	O
present	O
prospective	O
study	O
was	O
aimed	O
at	O
determining	O
whether	O
removal	O
of	O
hypertrophied	O
anal	O
papillae	O
and	O
fibrous	O
anal	O
polyps	O
while	O
dealing	O
with	O
chronic	O
fissure	O
in	O
ano	O
confers	O
long-term	Others
benefit	Others
to	O
patients	O
.	O

METHODS	O
Between	O
July	O
1999	O
and	O
December	O
2000	O
,	O
140	O
patients	O
undergoing	O
anal	O
sphincterotomy	O
were	O
randomized	O
into	O
two	O
groups	O
to	O
have	O
their	O
fibrous	O
polyps	O
and	O
hypertrophied	O
anal	O
papillae	O
either	O
removed	O
by	O
radiofrequency	O
surgery	O
or	O
left	O
intact	O
.	O

After	O
two	O
years	O
,	O
they	O
underwent	O
a	O
detailed	O
interview	Others
by	Others
an	Others
independent	Others
,	Others
masked	Others
investigator	Others
.	Others

RESULTS	O
Overall	O
84	O
%	O
of	O
patients	O
who	O
had	O
polyp	O
and	O
papilla	O
removal	O
rated	O
the	O
outcome	O
of	O
their	O
surgery	O
as	O
excellent	O
or	O
good	O
in	O
comparison	O
to	O
58	O
%	O
of	O
controls	O
.	O

The	O
mean	O
satisfaction	O
grading	O
was	O
9.2	O
on	O
a	O
visual	Others
analogue	Others
scale	Others
in	O
the	O
treatment	O
group	O
compared	O
to	O
8.1	O
in	O
controls	O
(	O
p=0.004	O
)	O
.	O

CONCLUSION	O
Removal	O
of	O
hypertrophied	O
anal	O
papillae	O
and	O
fibrous	O
anal	O
polyps	O
should	O
be	O
an	O
essential	O
part	O
of	O
treatment	O
of	O
chronic	O
fissure	O
in	O
ano	O
.	O

Persistence	O
of	O
these	O
structures	O
leaves	O
behind	O
a	O
sense	O
of	O
incomplete	O
treatment	O
,	O
reducing	O
the	O
overall	Others
satisfaction	Others
on	O
the	O
part	O
of	O
the	O
patient	O
.	O

Radiofrequency	O
procedure	O
is	O
useful	O
in	O
eradication	O
of	O
these	O
concomitant	O
pathologies	O
.	O

Ciprofloxacin/dexamethasone	O
drops	O
decrease	O
the	O
incidence	O
of	O
physician	O
and	O
patient	O
outcomes	O
of	O
otorrhea	Physical
after	O
tube	O
placement	O
.	O

OBJECTIVE	O
To	O
evaluate	O
ciprofloxacin	O
0.3	O
%	O
/dexamethasone	O
0.1	O
%	O
(	O
CIPRODEX	O
,	O
Alcon	O
,	O
Ft.	O
Worth	O
,	O
TX	O
)	O
for	O
the	O
prevention	O
of	O
early	O
post-operative	O
otorrhea	O
following	O
TT	O
placement	O
.	O

METHODS	O
This	O
was	O
a	O
single-center	O
,	O
randomized	O
,	O
evaluator-blinded	O
,	O
parallel-group	O
study	O
.	O

Two	O
hundred	O
children	O
undergoing	O
bilateral	O
TT	O
placement	O
were	O
categorized	O
as	O
having	O
unilateral	O
(	O
wet/dry	O
)	O
,	O
bilateral	O
(	O
wet/wet	O
)	O
,	O
or	O
no	O
(	O
dry/dry	O
)	O
effusion	O
at	O
the	O
time	O
of	O
surgery	O
.	O

All	O
patients	O
received	O
Ciprodex	O
or	O
no	O
treatment	O
for	O
5	O
days	O
post-operatively	O
and	O
returned	O
at	O
2	O
weeks	O
.	O

RESULTS	O
Physician-observed	Physical
otorrhea	Physical
was	O
reported	O
in	O
5	O
(	O
4.95	O
%	O
)	O
patients	O
receiving	O
Ciprodex	O
and	O
39	O
(	O
39.39	O
%	O
)	O
patients	O
receiving	O
no	O
treatment	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Treatment	O
decreased	O
otorrhea	Physical
in	O
all	O
groups	O
,	O
while	O
the	O
greatest	O
benefit	O
was	O
observed	O
in	O
patients	O
with	O
bilateral	O
effusion	O
(	O
93	O
%	O
reduction	O
)	O
.	O

Ciprodex	O
treatment	O
also	O
decreased	O
the	O
rate	Physical
of	Physical
clinically	Physical
diagnosed	Physical
otitis	Physical
media	Physical
(	Physical
OM	Physical
)	Physical
and	O
effusion	Physical
following	O
TT	O
placement	O
(	O
p	O
<	O
or	O
=0.0006	O
)	O
.	O

CONCLUSION	O
Ciprodex	O
reduced	O
early	Physical
post-operative	Physical
otorrhea	Physical
,	O
clinically	Physical
diagnosed	Physical
OM	Physical
and	O
effusion	Physical
following	O
TT	O
insertion	O
.	O

The	O
greatest	O
reduction	O
in	O
otorrhea	Physical
was	O
observed	O
in	O
patients	O
with	O
bilateral	O
effusion	O
at	O
the	O
time	O
of	O
surgery	O
.	O

Twice-a-day	O
versus	O
four-times-a-day	O
ofloxacin	O
treatment	O
of	O
external	O
ocular	O
infection	O
.	O

PURPOSE	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
efficacies	Others
of	O
0.3	O
%	O
ofloxacin	O
eyedrops	O
,	O
when	O
given	O
twice-a-day	O
(	O
BID	O
)	O
versus	O
four-times-a-day	O
(	O
QID	O
)	O
,	O
for	O
the	O
treatment	O
of	O
external	O
ocular	O
disease	O
.	O

METHOD	O
Fifty	O
patients	O
with	O
blepharitis	O
,	O
conjuctivitis	O
,	O
or	O
blepharoconjunctivitis	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
0.3	O
%	O
ofloxacin	O
eyedrops	O
,	O
BID	O
or	O
QID	O
,	O
for	O
10	O
days	O
.	O

Signs	O
,	O
symptoms	O
,	O
and	O
cultures	O
were	O
evaluated	O
at	O
the	O
beginning	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

RESULTS	O
The	O
clinical	O
outcome	O
was	O
virtually	O
identical	O
in	O
the	O
two	O
groups	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
clinical	Others
scores	Others
in	O
the	O
BID	O
and	O
QID	O
groups	O
by	O
days	O
3	O
to	O
5	O
(	O
2.6-3.0	O
points	O
)	O
and	O
a	O
further	O
decrease	O
by	O
day	O
11	O
(	O
4.3-5.0	O
points	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
two	O
groups	O
at	O
any	O
time	O
interval	O
.	O

Microbiologic	O
studies	O
showed	O
a	O
reduction	O
in	O
colony-forming	Physical
units	Physical
in	O
87	O
%	O
of	O
the	O
BID	O
group	O
and	O
in	O
80	O
%	O
of	O
the	O
QID	O
group	O
.	O

CONCLUSION	O
The	O
treatment	O
of	O
external	Physical
ocular	Physical
disease	Physical
with	O
0.3	O
%	O
ofloxacin	Others
eyedrops	Others
was	Others
equally	Others
effective	Others
when	Others
given	Others
BID	Others
or	Others
QID	Others
.	O

Transitions	O
during	O
effective	O
treatment	O
for	O
cocaine-abusing	O
homeless	O
persons	O
:	O
establishing	O
abstinence	O
,	O
lapse	O
,	O
and	O
relapse	O
,	O
and	O
reestablishing	O
abstinence	O
.	O

Data	O
are	O
reported	O
on	O
drug	O
use	O
among	O
cocaine-dependent	O
homeless	O
persons	O
who	O
participated	O
in	O
a	O
clinical	O
trial	O
that	O
compared	O
day	O
treatment	O
only	O
(	O
DT	O
,	O
n	O
=	O
69	O
)	O
with	O
day	O
treatment	O
plus	O
abstinent-contingent	O
housing	O
and	O
work	O
(	O
DT+	O
,	O
n	O
=	O
72	O
)	O
.	O

Drug	Physical
use	Physical
was	Physical
measured	Physical
with	Physical
multiple	Physical
weekly	Physical
urine	Physical
toxicologies	Physical
.	Physical

Compared	O
with	O
DT	O
participants	O
,	O
more	O
DT+	O
participants	O
established	O
abstinence	Mental
,	Mental
maintained	Mental
abstinence	Mental
for	Mental
longer	Mental
durations	Mental
,	O
were	O
marginally	O
significantly	O
more	O
likely	O
to	O
lapse	Mental
,	O
and	O
significantly	O
less	O
likely	O
to	O
relapse	Mental
.	O

Of	O
all	O
participants	O
who	O
established	O
abstinence	O
and	O
then	O
relapsed	O
,	O
DT+	O
participants	O
relapsed	O
later	O
and	O
were	O
more	O
likely	O
to	O
reestablish	Mental
abstinence	Mental
.	Others

These	O
analyses	O
yield	O
information	O
on	O
the	O
processes	O
involved	O
in	O
the	O
manner	O
in	O
which	O
drug	O
use	O
changes	O
as	O
a	O
result	O
of	O
abstinent-contingent	O
housing	O
and	O
work	O
.	O

Effect	O
of	O
carbon	O
monoxide	O
on	O
exercise	O
performance	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
breathing	O
100	O
ppm	O
of	O
carbon	O
monoxide	O
versus	O
compressed	O
,	O
purified	O
air	O
for	O
1	O
hour	O
on	O
exercise	Physical
performance	Physical
in	O
10	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
in	O
a	O
double-blind	O
,	O
randomized	O
,	O
crossover	O
study	O
.	O

The	O
mean	Physical
arterial	Physical
carboxyhemoglobin	Physical
was	O
1.48	O
per	O
cent	O
in	O
the	O
carbon	O
monoxide	O
control	O
period	O
and	O
increased	O
from	O
1.43	O
to	O
4.08	O
per	O
cent	O
after	O
breathing	O
carbon	O
monoxide	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
mean	Physical
arterial	Physical
carboxyhemoglobin	Physical
level	Physical
was	O
1.52	O
percent	O
in	O
the	O
air	O
control	O
period	O
and	O
decreased	O
from	O
1.47	O
to	O
1.34	O
per	O
cent	O
after	O
purified	O
air	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
mean	Physical
exercise	Physical
time	Physical
until	Physical
marked	Physical
dyspnea	Physical
decreased	O
from	O
218.5	O
seconds	O
in	O
the	O
carbon	O
monoxide	O
control	O
period	O
to	O
146.6	O
seconds	O
after	O
breathing	O
carbon	O
monoxide	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

The	O
mean	Physical
exercise	Physical
time	Physical
was	O
219.9	O
seconds	O
in	O
the	O
air	O
control	O
period	O
and	O
221.3	O
seconds	O
after	O
purified	O
air	O
(	O
P	O
not	O
significant	O
)	O
.	O

Breathing	O
100	O
ppm	O
of	O
carbon	O
monoxide	O
for	O
1	O
hour	O
caused	O
a	O
significant	O
reduction	O
in	O
exercise	O
performance	O
in	O
patients	O
with	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

A	O
clinical	O
evaluation	O
of	O
a	O
blood	O
conservation	O
device	O
in	O
medical	O
intensive	O
care	O
unit	O
patients	O
.	O

OBJECTIVES	O
This	O
study	O
was	O
designed	O
to	O
a	O
)	O
document	O
the	O
efficacy	O
of	O
a	O
device	O
intended	O
to	O
conserve	O
blood	O
in	O
critically	O
ill	O
patients	O
;	O
b	O
)	O
determine	O
the	O
effect	O
of	O
this	O
blood	O
conservation	O
on	O
hemoglobin	Physical
concentration	Physical
and	O
the	O
need	Physical
for	Physical
blood	Physical
transfusions	Physical
;	O
c	O
)	O
determine	O
if	O
the	O
blood	O
conservation	O
device	O
resulted	O
in	O
interference	O
with	O
arterial	O
pressure	O
waveforms	O
;	O
d	O
)	O
determine	O
if	O
use	O
of	O
the	O
blood	O
conservation	O
device	O
resulted	O
in	O
a	O
difference	O
in	O
the	O
number	O
of	O
accidental	O
needle	O
punctures	O
suffered	O
by	O
healthcare	O
workers	O
.	O

DESIGN	O
Prospective	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

A	O
clinical	O
trial	O
using	O
prospective	O
,	O
random	O
allocation	O
of	O
consecutive	O
eligible	O
patients	O
.	O

SETTING	O
The	O
medical	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
of	O
a	O
university	O
hospital	O
located	O
in	O
a	O
large	O
metropolitan	O
area	O
.	O

PATIENTS	O
A	O
total	O
of	O
100	O
patients	O
who	O
were	O
admitted	O
to	O
the	O
medical	O
ICU	O
,	O
required	O
arterial	O
line	O
monitoring	O
for	O
clinical	O
purposes	O
,	O
and	O
were	O
managed	O
by	O
the	O
ICU	O
medical	O
service	O
.	O

Exclusion	O
criteria	O
included	O
active	O
bleeding	O
or	O
chronic	O
renal	O
failure	O
at	O
the	O
time	O
of	O
ICU	O
admission	O
.	O

INTERVENTIONS	O
Patients	O
in	O
the	O
experimental	O
group	O
had	O
a	O
blood	O
conservation	O
device	O
incorporated	O
into	O
the	O
arterial	O
pressure	O
monitoring	O
system	O
,	O
while	O
patients	O
in	O
the	O
control	O
group	O
received	O
a	O
conventional	O
arterial	O
pressure	O
monitoring	O
system	O
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
Data	O
gathered	O
included	O
:	O
age	O
;	O
gender	O
;	O
ICU	O
discharge	O
status	O
;	O
the	O
duration	Others
of	Others
ICU	Others
stay	Others
;	Others
time	Others
in	Others
the	Others
study	Others
;	Others
volume	Others
of	Others
all	Others
blood	Others
drawn	Others
,	Others
discarded	Others
,	Others
or	Others
lost	Others
due	Others
to	Others
leakage	Others
;	Others
hemoglobin	Physical
concentrations	Physical
;	O
blood	Physical
transfusions	Physical
;	O
and	O
accidental	Mental
needle	Mental
injuries	Mental
.	O

Arterial	Physical
pressure	Physical
waveforms	Physical
were	O
recorded	O
and	O
inspected	O
for	O
dampening	O
or	O
other	O
deformation	O
.	O

Mean	Physical
hemoglobin	Physical
concentrations	Physical
were	O
compared	O
on	O
ICU	O
admission	O
and	O
at	O
12-hr	O
intervals	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
two	O
groups	O
were	O
not	O
significantly	O
different	O
.	O

The	O
volume	Others
of	Others
blood	Others
drawn	Others
and	Others
discarded	Others
from	Others
arterial	Others
catheters	Others
was	O
significantly	O
lower	O
in	O
the	O
blood	O
conservation	O
group	O
(	O
blood	O
conservation	O
device	O
:	O
5.7	O
+/-	O
7.5	O
mL	O
;	O
control	O
:	O
96.4	O
+/-	O
88.5	O
mL	O
;	O
p	O
<	O
.0001	O
)	O
,	O
as	O
was	O
the	O
total	Others
volume	Others
of	Others
blood	Others
discarded	Others
(	O
blood	O
conservation	O
device	O
:	O
19.4	O
+/-	O
47.4	O
mL	O
;	O
control	O
:	O
103.5	O
+/-	O
99.9	O
mL	O
;	O
p	O
<	O
.0001	O
)	O
.	O

Mean	Physical
hemoglobin	Physical
concentration	Physical
on	O
admission	O
was	O
similar	O
in	O
the	O
two	O
groups	O
(	O
blood	O
conservation	O
device	O
group	O
:	O
11.8	O
+/-	O
2.5	O
g/dL	O
;	O
control	O
group	O
:	O
12.6	O
+/-	O
2.3	O
g/dL	O
)	O
.	O

In	O
both	O
groups	O
,	O
the	O
mean	Physical
hemoglobin	Physical
concentration	Physical
declined	O
most	O
rapidly	O
in	O
the	O
first	O
24	O
hrs	O
of	O
ICU	O
care	O
and	O
,	O
thereafter	O
,	O
declined	O
more	O
slowly	O
.	O

Although	O
the	O
mean	Physical
hemoglobin	Physical
concentration	Physical
was	O
higher	O
in	O
the	O
blood	O
conservation	O
group	O
after	O
6	O
days	O
,	O
statistical	O
significance	O
was	O
not	O
reached	O
until	O
9.5	O
days	O
of	O
ICU	O
care	O
.	O

The	O
mean	Physical
change	Physical
in	Physical
hemoglobin	Physical
concentration	Physical
(	O
overall	O
:	O
1.2	O
+/-	O
2.2	O
g/dL	O
)	O
during	O
the	O
study	O
represents	O
a	O
statistically	O
significant	O
(	O
p	O
<	O
.0001	O
)	O
decrease	O
of	O
9.7	O
%	O
.	O

Hemoglobin	Physical
concentration	Physical
during	O
the	O
study	O
decreased	O
by	O
1.4	O
+/-	O
2.2	O
g/dL	O
in	O
the	O
control	O
group	O
and	O
1.0	O
+/-	O
2.3	O
g/dL	O
in	O
the	O
blood	O
conservation	O
group	O
(	O
p	O
=	O
nonsignificant	O
)	O
.	O

Univariate	Physical
and	Physical
multiple	Physical
regression	Physical
analysis	Physical
demonstrated	O
discarded	O
blood	Physical
volume	Physical
to	O
be	O
a	O
significant	O
and	O
independent	O
predictor	O
of	O
the	O
decline	O
in	O
hemoglobin	O
concentration	O
.	O

Transfusion	Physical
requirements	Physical
were	O
similar	O
in	O
both	O
groups	O
.	O

The	O
blood	O
conservation	O
system	O
did	O
not	O
alter	O
or	O
interfere	O
with	O
pressure	Physical
waveforms	Physical
.	O

There	O
were	O
no	O
accidental	Mental
needle	Mental
injuries	Mental
noted	O
.	O

CONCLUSIONS	O
The	O
conservation	O
of	O
blood	O
in	O
critically	O
ill	O
patients	O
must	O
be	O
a	O
high-priority	O
concern	O
of	O
all	O
healthcare	O
workers	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
blood	O
conservation	O
system	O
eliminates	O
a	O
significant	O
factor	O
in	O
the	O
decline	O
in	O
hemoglobin	Physical
concentration	Physical
.	O

With	O
devices	O
as	O
described	O
here	O
,	O
there	O
is	O
no	O
reason	O
to	O
continue	O
the	O
practice	O
of	O
wasting	O
the	O
blood	O
of	O
critically	O
ill	O
patients	O
in	O
order	O
to	O
prevent	O
preanalytic	O
error	O
.	O

[	O
The	O
comparison	O
of	O
the	O
effect	O
of	O
enalapril	O
and	O
indapamide	O
on	O
the	O
peripheral	Physical
blood	Physical
pressure	Physical
and	Physical
central	Physical
blood	Physical
pressure	Physical
through	O
pulse	O
wave	O
analysis	O
]	O
.	O

OBJECTIVES	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	Others
of	O
the	O
angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
enalapril	O
and	O
diuretic	O
indapamide	O
on	O
the	O
peripheral	Physical
blood	Physical
pressure	Physical
and	Physical
the	Physical
central	Physical
blood	Physical
pressure	Physical
in	O
Chinese	O
patients	O
with	O
essential	O
hypertension	O
.	O

METHODS	O
This	O
study	O
was	O
a	O
double	O
blind	O
,	O
randomized	O
study	O
.	O

Informed	O
consent	O
were	O
given	O
by	O
all	O
patients	O
.	O

After	O
2	O
weeks	O
of	O
placebo	O
run-in	O
period	O
,	O
105	O
patients	O
with	O
mild	O
or	O
moderate	O
essential	O
hypertension	O
were	O
randomized	O
to	O
receive	O
either	O
enalapril	O
(	O
10	O
mg	O
per	O
day	O
)	O
or	O
indapamide	O
(	O
2.5	O
mg	O
per	O
day	O
)	O
for	O
8	O
weeks	O
.	O

Radial	O
pulse	O
wave	O
recordings	O
were	O
performed	O
in	O
all	O
the	O
patients	O
before	O
the	O
active	O
treatments	O
were	O
given	O
and	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

Only	O
those	O
patients	O
who	O
have	O
finished	O
8	O
weeks	O
of	O
active	O
treatment	O
in	O
both	O
groups	O
were	O
included	O
into	O
the	O
final	O
analysis	O
.	O

RESULTS	O
One	O
hundred	O
one	O
patients	O
(	O
51	O
in	O
enalapril	O
group	O
and	O
50	O
in	O
indapamide	O
group	O
)	O
completed	O
the	O
study	O
.	O

No	O
significant	O
difference	O
(	O
all	O
P	O
values	O
>	O
0.05	O
)	O
was	O
found	O
in	O
baseline	O
data	O
between	O
the	O
two	O
groups	O
.	O

After	O
8	O
weeks	O
of	O
treatment	O
,	O
all	O
the	O
parameters	Physical
of	Physical
pulse	Physical
wave	Physical
(	O
except	O
heart	O
rates	O
in	O
both	O
groups	O
and	O
augmentation	O
index	O
in	O
indapamide	O
group	O
)	O
decreased	O
significantly	O
.	O

Comparison	O
of	O
the	O
2	O
groups	O
showed	O
that	O
there	O
were	O
no	O
significant	O
differences	O
(	O
all	O
P	O
values	O
>	O
0.05	O
)	O
in	O
all	O
the	O
parameters	O
of	O
pulse	O
wave	O
except	O
that	O
the	O
central	Physical
systolic	Physical
blood	Physical
pressure	Physical
,	Physical
augmentation	Physical
and	Physical
augmentation	Physical
index	Physical
were	O
significantly	O
lower	O
in	O
enalapril	O
group	O
than	O
in	O
indapamide	O
group	O
.	O

In	O
enalapril	O
group	O
,	O
the	O
reduced	O
values	O
of	O
systolic	Physical
blood	Physical
pressure	Physical
and	Physical
pulse	Physical
pressure	Physical
in	Physical
central	Physical
aorta	Physical
were	O
significantly	O
larger	O
than	O
those	O
in	O
brachial	O
artery	O
.	O

However	O
,	O
the	O
difference	Physical
was	O
not	O
observed	O
in	O
indapamide	O
group	O
.	O

CONCLUSIONS	O
Enalapril	O
and	O
indapamide	O
are	O
both	O
similarly	O
effective	O
in	O
reducing	O
peripheral	Physical
arterial	Physical
blood	Physical
pressure	Physical
.	O

Moreover	O
,	O
enalapril	O
is	O
more	O
effective	O
in	O
reducing	O
central	Physical
systolic	Physical
pressure	Physical
and	Physical
augmentation	Physical
index	Physical
than	O
indapamide	O
.	O

The	O
difference	O
is	O
probably	O
due	O
to	O
the	O
reduction	O
of	O
wave	Physical
reflection	Physical
caused	O
by	O
enalapril	O
.	O

Anti-angiogenic	O
effect	O
of	O
tamoxifen	O
combined	O
with	O
epirubicin	O
in	O
breast	O
cancer	O
patients	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
A	O
(	O
VEGF-A	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
VEGFR2	O
)	O
are	O
the	O
key	O
factors	O
mediating	O
neo-vascularization	O
.	O

They	O
are	O
often	O
coexpressed	O
in	O
breast	O
cancer	O
.	O

Sex	O
steroids	O
may	O
stimulate	O
angiogenesis	O
via	O
the	O
estrogen	O
receptor	O
(	O
ER	O
)	O
pathway	O
.	O

We	O
investigated	O
to	O
compare	O
the	O
effects	O
of	O
the	O
addition	O
of	O
tamoxifen	O
to	O
epirubicin	O
versus	O
epirubicin	O
alone	O
on	O
VEGF	O
and	O
VEGFR2	O
expression	O
in	O
breast	O
cancer	O
patients	O
.	O

The	O
expression	O
of	O
VEGF	Physical
and	Physical
VEGFR2	Physical
was	O
assessed	O
on	O
tissue	O
microarray	O
by	O
immunohistochemistry	O
at	O
baseline	O
conditions	O
and	O
after	O
treatments	O
in	O
the	O
case	O
of	O
191	O
patients	O
with	O
T2-4	O
N0-1	O
breast	O
cancer	O
enrolled	O
in	O
a	O
randomized	O
trial	O
comparing	O
four	O
cycles	O
of	O
single	O
agent	O
epirubicin	O
versus	O
epirubicin	O
plus	O
tamoxifen	O
as	O
primary	O
systemic	O
treatment	O
.	O

Epirubicin	O
alone	O
failed	O
to	O
induce	O
changes	Physical
in	Physical
VEGF	Physical
expression	Physical
(	O
P	O
=	O
0.54	O
)	O
,	O
while	O
the	O
addition	O
of	O
tamoxifen	O
to	O
epirubicin	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
VEGF	Physical
expression	Physical
(	O
P	O
<	O
0.001	O
)	O
.	O

As	O
a	O
consequence	O
,	O
baseline	Physical
VEGF	Physical
had	O
a	O
negative	O
prognostic	O
role	O
in	O
patients	O
who	O
received	O
epirubicin	O
alone	O
but	O
not	O
in	O
patients	O
receiving	O
epirubicin	O
plus	O
tamoxifen	O
(	O
interaction	O
test	O
P	O
<	O
0.05	O
)	O
.	O

VEGFR2	Physical
expression	Physical
increased	O
at	O
residual	O
tumor	O
histology	O
in	O
both	O
treatment	O
arms	O
,	O
with	O
a	O
lesser	O
extent	O
in	O
patients	O
receiving	O
tamoxifen	O
plus	O
epirubicin	O
.	O

Decrease	O
in	O
VEGFR2	Physical
expression	Physical
was	O
significantly	O
associated	O
with	O
response	Physical
rate	Physical
(	O
P	O
=	O
0.02	O
)	O
.	O

The	O
addition	O
of	O
tamoxifen	O
to	O
epirubicin	O
resulted	O
in	O
a	O
suppression	Others
of	Others
a	Others
key	Others
angiogenic	Others
pathway	Others
.	O

These	O
data	O
suggest	O
a	O
potential	O
synergism	O
of	O
these	O
two	O
drugs	O
.	O

Randomized	O
controlled	O
trial	O
for	O
early	O
intervention	O
for	O
autism	O
:	O
a	O
pilot	O
study	O
of	O
the	O
Autism	O
1-2-3	O
Project	O
.	O

We	O
piloted	O
a	O
2-week	O
Autism-1-2-3	O
early	O
intervention	O
for	O
children	O
with	O
autism	O
and	O
their	O
parents	O
immediately	O
after	O
diagnosis	O
that	O
targeted	O
at	O
(	O
1	O
)	O
eye	O
contact	O
,	O
(	O
2	O
)	O
gesture	O
and	O
(	O
3	O
)	O
vocalization/words	O
.	O

Seventeen	O
children	O
were	O
randomized	O
into	O
the	O
Intervention	O
(	O
n	O
=	O
9	O
)	O
and	O
Control	O
(	O
n	O
=	O
8	O
)	O
groups	O
.	O

Outcome	O
measures	O
included	O
the	O
Autism	Mental
Diagnostic	Mental
Observation	Mental
Schedule	Mental
,	Mental
Ritvo-Freeman	Mental
Real	Mental
Life	Mental
Rating	Mental
Scale	Mental
,	O
Symbolic	Mental
Play	Mental
Test	Mental
,	O
and	O
Parenting	Mental
Stress	Mental
Index	Mental
.	O

Children	O
with	O
autism	O
improved	O
in	O
language/communication	Mental
,	Mental
reciprocal	Mental
social	Mental
interaction	Mental
,	Mental
and	Mental
symbolic	Mental
play	Mental
.	Mental

Parents	O
perceived	O
significant	O
improvement	O
in	O
their	O
children	Mental
's	Mental
language	Mental
,	Mental
social	Mental
interaction	Mental
,	O
and	O
their	Mental
own	Mental
stress	Mental
level	Mental
.	O

This	O
intervention	O
can	O
serve	O
as	O
short-term	O
training	O
on	O
communication	O
and	O
social	O
interaction	O
for	O
children	O
with	O
autism	O
,	O
and	O
reduce	O
the	O
stress	O
of	O
their	O
parents	O
during	O
the	O
long	O
waiting	O
time	O
for	O
public	O
health	O
services	O
.	O

Including	O
a	O
'no	O
active	O
intervention	O
'	O
arm	O
in	O
surgical	O
trials	O
is	O
possible	O
:	O
evidence	O
from	O
the	O
CLasP	O
randomised	O
trial	O
.	O

OBJECTIVES	O
To	O
examine	O
the	O
impact	O
of	O
including	O
a	O
'no	O
active	O
intervention	O
'	O
arm	O
(	O
called	O
'conservative	O
management	O
'	O
)	O
in	O
a	O
randomised	O
controlled	O
trial	O
comparing	O
treatments	O
(	O
including	O
surgery	O
)	O
for	O
men	O
with	O
lower	O
urinary	O
tract	O
symptoms	O
related	O
to	O
benign	O
prostatic	O
enlargement	O
.	O

METHODS	O
Outcomes	O
7.5	O
months	O
after	O
randomisation	O
were	O
acceptability	Others
of	Others
randomisation	Others
,	Others
overall	Others
acceptability	Others
of	Others
and	Others
satisfaction	Others
with	Others
conservative	Others
management	Others
,	O
impact	O
on	O
quality	Others
of	Others
life	Others
,	Others
perceived	Others
need	Others
for	Others
further	Others
treatment	Others
and	O
treatment	Others
failure	Others
(	Others
defined	Others
a	Others
priori	Others
)	Others
.	Others

RESULTS	O
In	O
total	O
,	O
177	O
(	O
out	O
of	O
755	O
)	O
patients	O
refused	O
randomisation	O
,	O
including	O
31	O
%	O
who	O
did	O
not	O
want	O
surgery	O
and	O
22	O
%	O
who	O
wanted	O
surgery	O
.	O

Most	O
men	O
randomised	O
to	O
conservative	O
management	O
were	O
willing	O
to	O
undertake	O
it	O
as	O
part	O
of	O
a	O
trial	O
but	O
at	O
the	O
end	O
of	O
the	O
trial	O
they	O
were	O
divided	O
between	O
those	O
who	O
wanted	O
to	O
continue	O
with	O
it	O
and	O
those	O
who	O
expected	O
surgery	O
.	O

At	O
follow-up	O
,	O
39	O
%	O
of	O
conservative	O
management	O
patients	O
requested	O
surgery	O
,	O
and	O
interference	Others
of	Others
symptoms	Others
with	Others
life	Others
and	O
an	O
unsuccessful	Mental
outcome	Mental
were	O
more	O
commonly	O
reported	O
in	O
this	O
arm	O
.	O

There	O
were	O
no	O
appreciable	O
differences	O
between	O
treatment	O
groups	O
in	O
terms	O
of	O
treatment	Others
failures	Others
.	O

CONCLUSIONS	O
Including	O
a	O
'no	O
active	O
intervention	O
'	O
arm	O
did	O
not	O
appear	O
to	O
have	O
a	O
detrimental	O
effect	O
on	O
patient	O
recruitment	O
or	O
the	O
completion	O
of	O
this	O
trial	O
in	O
the	O
short-term	O
;	O
overall	O
,	O
conservative	O
management	O
was	O
successfully	O
completed	O
by	O
the	O
majority	O
of	O
patients	O
during	O
the	O
trial	O
period	O
,	O
suggesting	O
that	O
researchers	O
need	O
not	O
avoid	O
including	O
a	O
no-intervention	O
arm	O
in	O
surgical	O
trials	O
as	O
long	O
as	O
they	O
take	O
care	O
with	O
its	O
presentation	O
.	O

Evaluation	O
of	O
the	O
effect	O
of	O
topical	O
agents	O
on	O
radiation-induced	Physical
skin	Physical
disease	Physical
by	O
reflectance	O
spectrophotometry	O
.	O

OBJECTIVES	O
Radiotherapy	O
may	O
cause	O
severe	O
skin	O
changes	O
that	O
significantly	O
interfere	O
with	O
the	O
patient	O
's	O
quality	O
of	O
life	O
and	O
reduce	O
radiotherapy	O
effectiveness	O
.	O

Many	O
skin	O
care	O
instructions	O
and	O
various	O
topical	O
agents	O
are	O
recommended	O
to	O
help	O
patients	O
in	O
the	O
management	O
of	O
radiation	O
skin	O
reactions	O
,	O
but	O
evidence	O
to	O
support	O
the	O
value	O
of	O
the	O
topical	O
treatments	O
of	O
the	O
irradiated	O
skin	O
is	O
lacking	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
topical	O
agents	O
used	O
as	O
supportive	O
care	O
to	O
minimise	O
radiation-induced	Physical
skin	Physical
disease	Physical
using	O
an	O
instrumental	O
method	O
.	O

METHODS	O
Subjects	O
who	O
were	O
undergoing	O
a	O
planned	O
course	O
of	O
radiation	O
therapy	O
after	O
breast-conserving	O
surgery	O
were	O
randomised	O
to	O
treatment	O
(	O
using	O
one	O
of	O
two	O
topical	O
agents	O
)	O
or	O
non-treatment	O
(	O
control	O
)	O
groups	O
and	O
monitored	O
over	O
8	O
weeks	O
.	O

The	O
intensity	Physical
of	Physical
skin	Physical
erythema	Physical
was	O
evaluated	O
once	O
per	O
week	O
by	O
non-invasive	O
instrumental	O
reflectance	O
spectrophotometry	O
in	O
comparison	O
with	O
a	O
visual	O
scoring	O
system	O
.	O

KEY	O
FINDINGS	O
Examination	O
of	O
the	O
erythema	Physical
time	Physical
course	Physical
by	O
a	O
sensitive	O
spectrophotometric	O
reflectance	O
method	O
showed	O
a	O
significant	O
increase	O
of	O
skin	Adverseeffect
reactions	Adverseeffect
in	O
the	O
non-treated	O
group	O
after	O
the	O
second	O
week	O
of	O
treatment	O
and	O
maximal	O
alterations	O
between	O
the	O
fourth	O
and	O
sixth	O
week	O
.	O

CONCLUSIONS	O
From	O
the	O
results	O
obtained	O
,	O
we	O
observed	O
that	O
application	O
of	O
topical	O
agents	O
used	O
in	O
radio-induced	O
skin	O
disease	O
were	O
able	O
to	O
significantly	O
reduce	O
the	O
erythema	Physical
extent	O
compared	O
to	O
the	O
non-treated	O
group	O
.	O

Comparable	O
patencies	O
of	O
the	O
radial	O
artery	O
and	O
right	O
internal	O
thoracic	O
artery	O
or	O
saphenous	O
vein	O
beyond	O
5	O
years	O
:	O
results	O
from	O
the	O
Radial	O
Artery	O
Patency	O
and	O
Clinical	O
Outcomes	O
trial	O
.	O

OBJECTIVE	O
To	O
investigate	O
the	O
optimum	O
conduit	O
for	O
coronary	O
targets	O
other	O
than	O
the	O
left	O
anterior	O
descending	O
artery	O
,	O
we	O
evaluated	O
long-term	O
patencies	O
and	O
clinical	O
outcomes	O
of	O
the	O
radial	O
artery	O
,	O
right	O
internal	O
thoracic	O
artery	O
,	O
and	O
saphenous	O
vein	O
through	O
the	O
Radial	O
Artery	O
Patency	O
and	O
Clinical	O
Outcomes	O
trial	O
.	O

METHODS	O
As	O
part	O
of	O
a	O
10-year	O
prospective	O
,	O
randomized	O
,	O
single-center	O
trial	O
,	O
patients	O
undergoing	O
primary	O
coronary	O
surgery	O
were	O
allocated	O
to	O
the	O
radial	O
artery	O
(	O
n	O
=	O
198	O
)	O
or	O
free	O
right	O
internal	O
thoracic	O
artery	O
(	O
n	O
=	O
196	O
)	O
if	O
aged	O
less	O
than	O
70	O
years	O
(	O
group	O
1	O
)	O
,	O
or	O
radial	O
artery	O
(	O
n	O
=	O
113	O
)	O
or	O
saphenous	O
vein	O
(	O
n	O
=	O
112	O
)	O
if	O
aged	O
at	O
least	O
70	O
years	O
(	O
group	O
2	O
)	O
.	O

All	O
patients	O
received	O
a	O
left	O
internal	O
thoracic	O
artery	O
to	O
the	O
left	O
anterior	O
descending	O
,	O
and	O
the	O
randomized	O
conduit	O
was	O
used	O
to	O
graft	O
the	O
second	O
largest	O
target	O
.	O

Protocol-directed	O
angiography	O
has	O
been	O
performed	O
at	O
randomly	O
assigned	O
intervals	O
,	O
weighted	O
toward	O
the	O
end	O
of	O
the	O
study	O
period	O
.	O

Grafts	O
are	O
defined	O
as	O
failed	O
if	O
there	O
was	O
occlusion	O
,	O
string	O
sign	O
,	O
or	O
greater	O
than	O
80	O
%	O
stenosis	O
,	O
independently	O
reported	O
by	O
3	O
assessors	O
.	O

Analysis	O
is	O
by	O
intention	O
to	O
treat	O
.	O

RESULTS	O
At	O
mean	O
follow	O
up	O
of	O
5.5	O
years	O
,	O
protocol	O
angiography	O
has	O
been	O
performed	O
in	O
groups	O
1	O
and	O
2	O
in	O
237	O
and	O
113	O
patients	O
,	O
respectively	O
.	O

There	O
are	O
no	O
significant	O
differences	O
within	O
each	O
group	O
in	O
preoperative	O
comorbidity	O
,	O
age	O
,	O
or	O
urgency	O
.	O

Patencies	Physical
were	O
similar	O
for	O
either	O
of	O
the	O
2	O
conduits	O
in	O
each	O
group	O
(	O
log	O
rank	O
analysis	O
,	O
P	O
=	O
.06	O
and	O
P	O
=	O
.54	O
,	O
respectively	O
)	O
.	O

The	O
differences	O
in	O
estimated	O
5-year	Physical
patencies	Physical
were	O
6.6	O
%	O
(	O
radial	O
minus	O
right	O
internal	O
thoracic	O
artery	O
)	O
in	O
group	O
1	O
and	O
2.9	O
%	O
(	O
radial	O
minus	O
saphenous	O
vein	O
graft	O
)	O
in	O
group	O
2	O
.	O

CONCLUSION	O
At	O
mean	O
5-year	O
angiography	O
in	O
largely	O
asymptomatic	O
patients	O
,	O
the	O
selection	O
of	O
arterial	O
or	O
venous	O
conduit	O
for	O
the	O
second	O
graft	O
has	O
not	O
significantly	O
affected	O
patency	O
.	O

This	O
finding	O
offers	O
surgeons	O
,	O
for	O
now	O
,	O
enhanced	O
flexibility	O
in	O
planning	O
revascularization	O
.	O

Long-term	Physical
consequences	Physical
of	O
different	O
immunosuppressive	O
regimens	O
for	O
renal	O
allografts	O
.	O

The	O
long-term	Physical
effects	Physical
of	O
four	O
different	O
immunosuppressive	O
regimens	O
on	O
renal	O
allografts	O
have	O
been	O
investigated	O
up	O
to	O
four	O
years	O
.	O

A	O
total	O
of	O
128	O
recipients	O
of	O
first	O
cadaveric	O
renal	O
allograft	O
were	O
randomized	O
,	O
after	O
an	O
initial	O
induction	O
period	O
,	O
to	O
receive	O
either	O
triple	O
drug	O
therapy	O
--	O
i.e.	O
,	O
(	O
low-dose	O
)	O
cyclosporine	O
,	O
azathioprine	O
,	O
and	O
methylprednisolone	O
,	O
or	O
any	O
possible	O
combination	O
of	O
two	O
drugs	O
--	O
i.e.	O
,	O
Aza	O
plus	O
CsA	O
,	O
Aza	O
plus	O
MP	O
,	O
and	O
CsA	O
plus	O
MP	O
.	O

The	O
actual	O
four-year	O
graft	Mortality
survival	Mortality
rates	Mortality
for	O
the	O
triple	O
therapy	O
,	O
Aza	O
plus	O
CsA	O
,	O
Aza	O
plus	O
MP	O
,	O
and	O
CsA	O
plus	O
MP	O
groups	O
were	O
72	O
%	O
,	O
69	O
%	O
,	O
75	O
%	O
,	O
and	O
59	O
%	O
,	O
and	O
patient	O
survival	O
rates	O
were	O
78	O
%	O
,	O
81	O
%	O
,	O
81	O
%	O
,	O
and	O
84	O
%	O
,	O
respectively	O
,	O
with	O
no	O
significant	O
differences	O
.	O

The	O
cumulative	O
number	O
of	O
chronic	Others
rejections	Others
up	O
to	O
4	O
years	O
was	O
0.09	O
,	O
0.29	O
,	O
0.25	O
,	O
and	O
0.34	O
per	O
patient	O
per	O
group	O
(	O
P	O
=	O
ns	O
)	O
,	O
respectively	O
.	O

At	O
2	O
,	O
3	O
,	O
and	O
4	O
years	O
posttransplantation	O
,	O
the	O
graft	Others
function	Others
was	O
significantly	O
worse	O
in	O
the	O
Aza	O
plus	O
MP	O
group	O
compared	O
with	O
the	O
triple	O
therapy	O
group	O
(	O
P	O
<	O
.05	O
)	O
.	O

Of	O
the	O
98	O
patients	O
who	O
did	O
not	O
have	O
type	O
I	O
or	O
II	O
diabetes	O
at	O
the	O
time	O
of	O
transplantation	O
,	O
17	O
developed	O
posttransplantation	Physical
diabetes	Physical
mellitus	Physical
or	O
an	O
abnormal	Physical
glucose	Physical
tolerance	Physical
test	Physical
within	O
2	O
years	O
posttransplantation	O
.	O

All	O
these	O
patients	O
had	O
received	O
steroids	O
and	O
none	O
of	O
the	O
patients	O
without	O
steroids	O
had	O
these	O
abnormalities	O
.	O

At	O
two	O
years	O
the	O
mean	O
cholesterol	Physical
level	Physical
was	O
highest	O
in	O
the	O
Aza	O
plus	O
MP	O
group	O
,	O
6.8	O
mmol/L	O
and	O
lowest	O
in	O
the	O
group	O
receiving	O
triple	O
therapy	O
,	O
5.8	O
mmol/L	O
(	O
P	O
=	O
ns	O
)	O
.	O

The	O
use	O
of	O
(	O
low-dose	O
)	O
CsA	O
was	O
not	O
associated	O
with	O
lipid	Physical
abnormalities	Physical
or	O
with	O
disturbances	Physical
in	Physical
glucose	Physical
metabolism	Physical
.	O

A	O
protocol	O
graft	O
biopsy	O
was	O
performed	O
at	O
two	O
years	O
on	O
all	O
functioning	O
kidneys	O
,	O
and	O
the	O
histological	Others
changes	Others
were	O
scored	O
blindly	O
.	O

No	O
CsA-specific	Others
changes	Others
,	O
except	O
isometric	Physical
vacuolation	Physical
in	Physical
tubuli	Physical
,	O
were	O
found	O
.	O

Histological	O
alterations	O
characteristic	O
of	O
chronic	O
rejection	O
were	O
expressed	O
as	O
chronic	Others
allograft	Others
damage	Others
index	Others
.	Others

Chronic	Others
allograft	Others
damage	Others
index	Others
was	O
lowest	O
in	O
the	O
triple	O
therapy	O
group	O
,	O
1.5	O
,	O
compared	O
with	O
the	O
other	O
groups	O
,	O
3.2-4.3	O
(	O
P	O
=	O
.01	O
)	O
,	O
indicating	O
the	O
least	O
histopathological	Others
change	Others
in	O
the	O
triple	O
therapy	O
group	O
.	O

In	O
conclusion	O
,	O
this	O
long-term	O
study	O
did	O
not	O
show	O
any	O
serious	O
cyclosporine-related	Adverseeffect
side-effects	Adverseeffect
when	O
used	O
in	O
low	O
dose	O
in	O
combination	O
with	O
two	O
other	O
drugs	O
.	O

Some	O
side-effects	O
,	O
such	O
as	O
posttransplant	Physical
diabetes	Physical
mellitus	Physical
and	O
probably	O
some	Adverseeffect
lipid	Adverseeffect
abnormalities	Adverseeffect
,	O
could	O
rather	O
be	O
traced	O
to	O
a	O
higher	O
dose	O
of	O
steroids	O
.	O

Moreover	O
,	O
the	O
triple	O
drug	O
therapy	O
was	O
more	O
efficacious	O
than	O
any	O
double	O
drug	O
regimen	O
in	O
the	O
prevention	O
of	O
chronic	Physical
histological	Physical
changes	Physical
in	Physical
renal	Physical
allografts	Physical
.	O

Amphotericin	O
versus	O
pentamidine	O
in	O
antimony-unresponsive	O
kala-azar	O
.	O

We	O
compared	O
the	O
efficacy	O
of	O
amphotericin	O
B	O
and	O
pentamidine	O
isethionate	O
in	O
a	O
prospective	O
randomised	O
trial	O
in	O
120	O
uncomplicated	O
and	O
parasitologically	O
confirmed	O
cases	O
of	O
antimony-unresponsive	O
kala-azar	O
.	O

Doses	O
were	O
twenty	O
intramuscular	O
injections	O
of	O
pentamidine	O
4	O
mg/kg	O
on	O
alternate	O
days	O
or	O
fourteen	O
definitive	O
doses	O
of	O
amphotericin	O
0.5	O
mg/kg	O
infused	O
in	O
5	O
%	O
dextrose	O
on	O
alternate	O
days	O
.	O

48	O
(	O
80	O
%	O
)	O
patients	O
given	O
pentamidine	O
showed	O
initial	Others
cure	Others
and	O
46	O
(	O
77	O
%	O
)	O
showed	O
definitive	Others
cure	Others
compared	O
with	O
60	O
(	O
100	O
%	O
)	O
and	O
59	O
(	O
98	O
%	O
)	O
cases	O
,	O
respectively	O
,	O
on	O
amphotericin	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Amphotericin	O
also	O
brought	O
about	O
quicker	O
abatement	Physical
of	Physical
fever	Physical
and	O
more	O
complete	Adverseeffect
spleen	Adverseeffect
regression	Adverseeffect
.	Physical

The	O
effects	Adverseeffect
of	O
prophylactic	O
management	O
and	O
therapeutics	O
on	O
hypertensive	Physical
disease	Physical
in	O
pregnancy	O
:	O
preliminary	O
studies	O
.	O

A	O
controlled	O
prospective	O
evaluation	O
of	O
pregnancy	O
complicated	O
by	O
chronic	O
hypertension	O
is	O
proposed	O
and	O
preliminary	O
data	O
on	O
population	Others
selection	Others
and	Physical
pregnancy	Physical
outcome	Physical
are	O
presented	O
.	O

Sixty-three	O
women	O
with	O
evidence	O
of	O
underlying	O
hypertensive	O
disease	O
were	O
followed	O
prospectively	O
throughout	O
pregnancy	O
.	O

Twenty-three	O
patients	O
were	O
followed	O
in	O
a	O
protocol	O
of	O
intensified	O
prenatal	O
care	O
and	O
randomized	O
assignment	O
of	O
antihypertensive	O
agents	O
:	O
placebo	O
,	O
hydralazine	O
,	O
or	O
methyldopa	O
.	O

Forty	O
patients	O
were	O
followed	O
in	O
the	O
high-risk	O
pregnancy	O
clinics	O
at	O
Duke	O
University	O
.	O

The	O
incidence	Physical
of	Physical
preeclampsia	Physical
in	O
the	O
randomized	O
prophylactic	O
antihypertensive	O
group	O
was	O
statistically	O
lower	O
than	O
that	O
in	O
the	O
nonrandomized	O
group	O
(	O
8.7	O
versus	O
32.5	O
%	O
;	O
P	O
less	O
than	O
.01	O
)	O
.	O

There	O
were	O
no	O
other	O
statistically	O
significant	O
differences	Others
between	O
the	O
groups	O
.	O

The	O
63	O
hypertensive	O
women	O
had	O
a	O
high	O
incidence	O
of	O
diabetes	Physical
mellitus	Physical
diagnosed	O
during	O
pregnancy	O
(	O
49.2	O
%	O
)	O
as	O
compared	O
to	O
the	O
authors	O
'	O
general	O
obstetric	O
population	O
(	O
8.1	O
%	O
)	O
.	O

Effects	O
of	O
saxagliptin	O
added	O
to	O
sub-maximal	O
doses	O
of	O
metformin	O
compared	O
with	O
uptitration	O
of	O
metformin	O
in	O
type	O
2	O
diabetes	O
:	O
the	O
PROMPT	O
study	O
.	O

OBJECTIVE	O
The	O
PROMPT	O
study	O
compared	O
efficacy	O
and	O
tolerability	O
of	O
two	O
treatment	O
intensification	O
strategies	O
:	O
adding	O
saxagliptin	O
or	O
uptitrating	O
metformin	O
monotherapy	O
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
and	O
inadequate	O
glycaemic	O
control	O
on	O
a	O
sub-maximal	O
metformin	O
dose	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
this	O
double-blind	O
,	O
24-week	O
study	O
,	O
metformin-tolerant	O
patients	O
with	O
T2D	O
on	O
metformin	O
monotherapy	O
were	O
randomised	O
to	O
receive	O
fixed-dose	O
metformin	O
1500	O
mg/day	O
,	O
plus	O
either	O
add-on	O
saxagliptin	O
5	O
mg/day	O
(	O
SAXA-MET	O
)	O
or	O
a	O
two-step	O
metformin	O
uptitration	O
(	O
MET-UP	O
)	O
to	O
a	O
maximum	O
dose	O
(	O
2500	O
mg/day	O
)	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
NCT01006590	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Primary	O
:	O
absolute	O
change	O
from	O
baseline	O
in	O
glycated	O
haemoglobin	O
A	O
(	O
1c	O
)	O
(	O
HbA	O
(	O
1c	O
)	O
)	O
(	O
Week	O
24	O
)	O
.	O

Secondary	O
:	O
proportion	O
of	O
patients	O
achieving	O
a	O
therapeutic	O
glycaemic	O
response	O
(	O
Week	O
24	O
)	O
;	O
change	O
from	O
baseline	O
in	O
fasting	O
plasma	O
glucose	O
(	O
Week	O
24	O
)	O
;	O
safety	O
and	O
tolerability	O
.	O

Exploratory	O
analyses	O
comprised	O
three	O
patient-related	O
questionnaires	O
,	O
including	O
the	O
validated	O
5-dimension	O
Digestive	O
Health	O
Status	O
Index	O
(	O
DHSI	O
)	O
.	O

RESULTS	O
A	O
total	O
of	O
286	O
patients	O
were	O
randomised	O
:	O
(	O
SAXA-MET	O
:	O
147	O
;	O
MET-UP	O
:	O
139	O
)	O
.	O

Baseline	O
mean	O
(	O
SD	O
)	O
HbA	O
(	O
1c	O
)	O
:	O
7.71	O
(	O
0.85	O
;	O
SAXA-MET	O
)	O
;	O
7.80	O
(	O
0.82	O
;	O
MET-UP	O
)	O
.	O

Adjusted	O
mean	O
reductions	O
from	O
baseline	O
in	O
HbA	O
(	O
1c	O
)	O
(	O
Week	O
24	O
)	O
:	O
-0.47	O
%	O
(	O
SAXA-MET	O
)	O
;	O
-0.38	O
%	O
(	O
MET-UP	O
)	O
;	O
mean	O
(	O
95	O
%	O
CI	O
)	O
difference	O
in	O
treatment	O
effect	O
,	O
-0.10	O
%	O
(	O
-0.26	O
,	O
0.07	O
)	O
;	O
p	O
=	O
0.260	O
.	O

The	O
proportion	O
of	O
patients	O
(	O
95	O
%	O
CI	O
)	O
achieving	O
a	O
therapeutic	O
glycaemic	O
response	O
(	O
HbA	O
(	O
1c	O
)	O
<	O
7	O
%	O
)	O
:	O
43.8	O
%	O
(	O
34.8	O
,	O
49.6	O
)	O
(	O
SAXA-MET	O
)	O
vs.	O
35.0	O
%	O
(	O
29.0	O
,	O
43.8	O
)	O
(	O
MET-UP	O
)	O
.	O

Of	O
the	O
five	O
DHSI	O
domains	O
,	O
mean	O
(	O
95	O
%	O
CI	O
)	O
differences	O
were	O
observed	O
for	O
diarrhoea-predominant	O
score	O
(	O
+0.8	O
[	O
-2.5	O
,	O
4.0	O
]	O
vs.	O
+7.9	O
[	O
4.6	O
,	O
11.2	O
]	O
)	O
and	O
dysmotility	O
score	O
(	O
-0.5	O
[	O
-2.0	O
,	O
1.0	O
]	O
vs.	O
+1.9	O
[	O
0.3	O
,	O
3.4	O
]	O
)	O
,	O
(	O
SAXA-MET	O
and	O
MET-UP	O
,	O
respectively	O
)	O
.	O

The	O
most	O
common	O
adverse	O
event	O
was	O
diarrhoea	O
:	O
6.1	O
%	O
(	O
SAXA-MET	O
)	O
vs.	O
12.2	O
%	O
(	O
MET-UP	O
)	O
.	O

CONCLUSIONS	O
In	O
metformin-tolerant	O
patients	O
with	O
T2D	O
(	O
inadequately	O
controlled	O
on	O
sub-maximal	O
metformin	O
monotherapy	O
)	O
,	O
saxagliptin	O
was	O
well	O
tolerated	O
.	O

Although	O
HbA	O
(	O
1c	O
)	O
reduction	O
was	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
,	O
the	O
lower	O
occurrence	O
of	O
gastrointestinal	O
symptoms	O
in	O
the	O
SAXA-MET	O
group	O
suggests	O
that	O
saxagliptin	O
add-on	O
treatment	O
may	O
be	O
a	O
suitable	O
alternative	O
treatment	O
strategy	O
to	O
metformin	O
uptitration	O
.	O

Public	O
and	O
private	O
heart	O
rate	O
feedback	O
in	O
social	O
phobia	O
:	O
a	O
manipulation	O
of	O
anxiety	Mental
visibility	Mental
.	Mental

According	O
to	O
cognitive	O
behavioural	O
models	O
of	O
social	O
phobia	O
,	O
bodily	O
symptoms	O
are	O
the	O
main	O
source	O
of	O
information	O
concerning	O
social	Mental
evaluation	Mental
for	O
social	O
phobics	O
.	O

Experience	O
and	O
perception	O
of	O
bodily	O
symptoms	O
therefore	O
play	O
an	O
important	O
role	O
in	O
social	O
anxiety	O
.	O

In	O
this	O
study	O
we	O
evaluated	O
the	O
effects	O
of	O
anxiety	Mental
visibility	Mental
on	O
patients	O
and	O
controls	O
using	O
feedback	O
of	O
veridical	O
heart	O
sounds	O
.	O

A	O
total	O
of	O
32	O
social	O
phobics	O
and	O
32	O
controls	O
were	O
asked	O
twice	O
to	O
sit	O
in	O
a	O
chair	O
and	O
appear	O
relaxed	O
while	O
being	O
evaluated	O
.	O

Half	O
of	O
the	O
participants	O
heard	O
their	O
heart	O
sounds	O
first	O
via	O
headphones	O
and	O
then	O
via	O
loudspeakers	O
which	O
were	O
also	O
audible	O
to	O
observers	O
.	O

The	O
presentation	O
order	O
of	O
the	O
heart	Physical
sound	Physical
was	O
reversed	O
for	O
the	O
other	O
half	O
of	O
the	O
subjects	O
.	O

Social	O
phobics	O
reported	O
substantially	O
more	O
anxiety	Mental
than	O
controls	O
.	O

Both	O
groups	O
showed	O
habituation	Physical
in	Physical
heart	Physical
rate	Physical
from	O
the	O
first	O
to	O
the	O
second	O
presentation	O
,	O
and	O
both	O
groups	O
reported	O
perception	O
of	O
a	O
higher	Physical
heart	Physical
rate	Physical
,	O
but	O
only	O
social	O
phobics	O
reported	O
significantly	O
more	O
anxiety	Mental
and	O
were	O
more	O
worried	Mental
about	Mental
their	Mental
heart	Physical
rates	Physical
in	O
the	O
public	O
than	O
in	O
the	O
private	O
condition	O
.	O

These	O
effects	O
were	O
in	O
excess	O
of	O
actual	Physical
heart	Physical
rate	Physical
differences	Physical
.	O

In	O
conclusion	O
,	O
social	O
phobics	O
worried	O
about	O
the	O
broadcast	O
of	O
a	O
bodily	Physical
anxiety	Physical
symptom	Physical
,	O
whereas	O
controls	O
did	O
not	O
.	O

Information	O
about	O
arousal	O
made	O
public	O
has	O
a	O
strong	O
potential	O
to	O
increase	O
anxiety	Mental
levels	Mental
in	O
social	O
phobics	O
.	O

Relief	O
of	O
osteoporotic	Pain
backache	Pain
with	O
fluoride	O
,	O
calcium	O
,	O
and	O
calciferol	O
.	O

In	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
comprising	O
22	O
postmenopausal	O
women	O
with	O
backache	O
and	O
a	O
halisteretic	O
spine	O
with	O
crush	O
fracture	O
(	O
s	O
)	O
,	O
12	O
women	O
completed	O
a	O
12-week	O
therapy	O
with	O
sodium	O
fluoride	O
,	O
calcium	O
and	O
calciferol	O
and	O
10	O
with	O
placebo	O
.	O

A	O
statistically	O
significant	O
improvement	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
evaluated	O
by	O
a	O
four-stage	Pain
scale	Pain
on	Pain
pains	Pain
,	Pain
infirmity	Pain
,	Pain
and	Pain
consumption	Others
of	Others
analgesics	Others
,	O
was	O
observed	O
in	O
the	O
actively	O
treated	O
patients	O
.	O

An	O
evaluation	O
of	O
family	O
therapy	O
in	O
anorexia	O
nervosa	O
and	O
bulimia	O
nervosa	O
.	O

A	O
controlled	O
trial	O
comparing	O
family	O
therapy	O
with	O
individual	O
supportive	O
therapy	O
in	O
anorexia	O
nervosa	O
and	O
bulimia	O
nervosa	O
was	O
undertaken	O
.	O

Eighty	O
patients	O
(	O
57	O
with	O
anorexia	O
nervosa	O
;	O
23	O
with	O
bulimia	O
nervosa	O
)	O
were	O
first	O
admitted	O
to	O
a	O
specialized	O
unit	O
to	O
restore	O
their	O
weight	O
to	O
normal	O
.	O

Before	O
discharge	O
,	O
they	O
were	O
randomly	O
allocated	O
to	O
family	O
therapy	O
or	O
the	O
control	O
treatment	O
(	O
individual	O
supportive	O
therapy	O
)	O
.	O

After	O
one	O
year	O
of	O
psychological	O
treatment	O
,	O
they	O
were	O
reassessed	O
,	O
using	O
body	Physical
weight	Physical
,	Physical
menstrual	Physical
function	Physical
,	Physical
and	Physical
ratings	Physical
on	Physical
the	Physical
Morgan	Physical
and	Physical
Russell	Physical
scales	Physical
.	Physical

Family	Physical
therapy	Physical
was	Physical
found	Physical
to	Physical
be	Physical
more	Physical
effective	Physical
than	Physical
individual	Physical
therapy	Physical
in	O
patients	O
whose	O
illness	O
was	O
not	O
chronic	O
and	O
had	O
begun	O
before	O
the	O
age	O
of	O
19	O
years	O
.	O

A	O
more	O
tentative	O
finding	O
was	O
the	O
greater	O
value	O
of	O
individual	O
supportive	O
therapy	O
in	O
older	O
patients	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
controlled	O
trial	O
of	O
family	O
therapy	O
in	O
anorexia	O
nervosa	O
and	O
clarifies	O
the	O
specific	O
indications	O
for	O
this	O
treatment	O
.	O

Aortic	O
valve	O
replacement	O
.	O

A	O
randomized	O
study	O
comparing	O
the	O
Bj?rk-Shiley	O
and	O
Lillehei-Kaster	O
disc	O
valves	O
.	O

Late	O
haemodynamics	O
related	O
to	O
clinical	O
results	O
.	O

In	O
this	O
study	O
,	O
78	O
randomized	O
patients	O
with	O
either	O
Bj?rk-Shiley	O
(	O
B-S	O
)	O
or	O
Lillehei-Kaster	O
(	O
L-K	O
)	O
aortic	O
disc	O
valve	O
prostheses	O
were	O
re-admitted	O
for	O
clinical	O
and	O
haemodynamic	O
evaluation	O
.	O

The	O
patients	O
were	O
selected	O
that	O
those	O
with	O
narrow	O
aortic	O
roots	O
were	O
over-represented	O
.	O

Cine-aortography	O
was	O
carried	O
out	O
in	O
75	O
patients	O
and	O
left	O
ventricular	O
catheterisation	O
via	O
the	O
transseptal	O
approach	O
was	O
performed	O
in	O
42	O
.	O

The	O
clinical	O
improvement	O
was	O
striking	O
,	O
although	O
the	O
number	O
of	O
patients	O
still	O
incapacitated	O
was	O
relatively	O
large	O
in	O
patients	O
with	O
the	O
small	O
L-K	O
valves	O
(	O
Nos	O
.	O

14	O
&	O
16	O
)	O
.	O

Peak-to-peak	O
and	O
mean	O
systolic	O
pressure	O
differences	O
across	O
the	O
valves	O
were	O
significantly	O
lower	O
in	O
the	O
B-S	O
than	O
in	O
the	O
L-K	O
valves	O
,	O
particularly	O
when	O
the	O
small	O
valve	O
sizes	O
were	O
compared	O
.	O

Left	O
ventricular	O
end-diastolic	O
pressure	O
(	O
LVEDP	O
)	O
,	O
which	O
was	O
elevated	O
in	O
most	O
patients	O
before	O
operation	O
,	O
decreased	O
significantly	O
to	O
normal	O
levels	O
in	O
the	O
B-S	O
group	O
.	O

In	O
the	O
L-K	O
group	O
,	O
LVEDP	O
did	O
not	O
decrease	O
significantly	O
and	O
was	O
on	O
the	O
average	O
still	O
above	O
the	O
normal	O
level	O
after	O
operation	O
,	O
probably	O
due	O
to	O
the	O
relatively	O
large	O
pressure	O
gradients	O
.	O

The	O
study	O
indicates	O
that	O
the	O
L-K	O
valves	O
Nos	O
.	O

14	O
&	O
16	O
in	O
particular	O
represents	O
a	O
resistance	O
to	O
flow	O
that	O
is	O
too	O
large	O
to	O
be	O
acceptable	O
in	O
clinical	O
practice	O
.	O

Further	O
evaluation	O
of	O
docosahexaenoic	O
acid	O
in	O
patients	O
with	O
retinitis	O
pigmentosa	O
receiving	O
vitamin	O
A	O
treatment	O
:	O
subgroup	O
analyses	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
docosahexaenoic	O
acid	O
will	O
slow	O
the	O
course	O
of	O
retinal	O
degeneration	O
in	O
subgroups	O
of	O
patients	O
with	O
retinitis	O
pigmentosa	O
who	O
are	O
receiving	O
vitamin	O
A	O
.	O

DESIGN	O
A	O
cohort	O
of	O
208	O
patients	O
with	O
retinitis	O
pigmentosa	O
,	O
aged	O
18	O
to	O
55	O
years	O
,	O
were	O
randomly	O
assigned	O
to	O
1200	O
mg	O
of	O
docosahexaenoic	O
acid	O
plus	O
15	O
000	O
IU/d	O
of	O
vitamin	O
A	O
given	O
as	O
retinyl	O
palmitate	O
(	O
DHA	O
+	O
A	O
group	O
)	O
or	O
control	O
fatty	O
acid	O
plus	O
15	O
000	O
IU/d	O
of	O
vitamin	O
A	O
(	O
control	O
+	O
A	O
group	O
)	O
and	O
followed	O
up	O
over	O
4	O
years	O
.	O

Seventy	O
percent	O
of	O
the	O
patients	O
in	O
each	O
group	O
were	O
taking	O
vitamin	O
A	O
,	O
15	O
000	O
IU/d	O
,	O
prior	O
to	O
entry	O
.	O

We	O
compared	O
rates	O
of	O
decline	O
in	O
ocular	O
function	O
in	O
the	O
DHA	O
+	O
A	O
vs	O
control	O
+	O
A	O
groups	O
among	O
the	O
subgroups	O
defined	O
by	O
use	O
or	O
nonuse	O
of	O
vitamin	O
A	O
prior	O
to	O
entry	O
.	O

We	O
also	O
determined	O
whether	O
decline	O
in	O
ocular	O
function	O
was	O
related	O
to	O
red	O
blood	O
cell	O
phosphatidylethanolamine	O
docosahexaenoic	O
acid	O
level	O
,	O
dietary	O
omega-3	O
fatty	O
acid	O
intake	O
,	O
or	O
duration	O
of	O
vitamin	O
A	O
use	O
.	O

Main	O
outcome	O
measures	O
were	O
Humphrey	Physical
Field	Physical
Analyzer	Physical
visual	Physical
field	Physical
sensitivity	Physical
,	O
30-Hz	Others
electroretinogram	Others
amplitude	Others
,	O
and	O
visual	Physical
acuity	Physical
.	O

RESULTS	O
Among	O
patients	O
not	O
taking	O
vitamin	O
A	O
prior	O
to	O
entry	O
,	O
those	O
in	O
the	O
DHA	O
+	O
A	O
group	O
had	O
a	O
slower	O
decline	O
in	O
field	Physical
sensitivity	Physical
and	Physical
electroretinogram	Others
amplitude	Others
than	O
those	O
in	O
the	O
control	O
+	O
A	O
group	O
over	O
the	O
first	O
2	O
years	O
(	O
P	O
=.01	O
and	O
P	O
=.03	O
,	O
respectively	O
)	O
;	O
these	O
differences	O
were	O
not	O
observed	O
in	O
years	O
3	O
and	O
4	O
of	O
follow-up	O
or	O
among	O
patients	O
taking	O
vitamin	O
A	O
prior	O
to	O
entry	O
.	O

In	O
the	O
entire	O
cohort	O
,	O
red	O
blood	O
cell	O
phosphatidylethanolamine	O
docosahexaenoic	O
acid	O
level	O
was	O
inversely	O
related	O
to	O
rate	O
of	O
decline	O
in	O
total	Physical
field	Physical
sensitivity	Physical
over	O
4	O
years	O
(	O
test	O
for	O
trend	O
,	O
P	O
=.05	O
)	O
.	O

This	O
was	O
particularly	O
evident	O
over	O
the	O
first	O
2	O
years	O
among	O
those	O
not	O
on	O
vitamin	O
A	O
prior	O
to	O
entry	O
(	O
test	O
for	O
trend	O
,	O
P	O
=.003	O
)	O
.	O

In	O
the	O
entire	O
control	O
+	O
A	O
group	O
,	O
dietary	O
omega-3	O
fatty	O
acid	O
intake	O
was	O
inversely	O
related	O
to	O
loss	O
of	O
total	Physical
field	Physical
sensitivity	Physical
over	O
4	O
years	O
(	O
intake	O
,	O
<	O
0.20	O
vs	O
>	O
or	O
=0.20	O
g/d	O
;	O
P	O
=.02	O
)	O
.	O

The	O
duration	Physical
of	Physical
vitamin	Physical
A	Physical
supplementation	Physical
prior	O
to	O
entry	O
was	O
inversely	O
related	O
to	O
rate	O
of	O
decline	O
in	O
electroretinogram	O
amplitude	O
(	O
P	O
=.008	O
)	O
.	O

CONCLUSIONS	O
For	O
patients	O
with	O
retinitis	O
pigmentosa	O
beginning	O
vitamin	O
A	O
therapy	O
,	O
addition	O
of	O
docosahexaenoic	O
acid	O
,	O
1200	O
mg/d	O
,	O
slowed	O
the	O
course	O
of	O
disease	O
for	O
2	O
years	O
.	O

Among	O
patients	O
on	O
vitamin	O
A	O
for	O
at	O
least	O
2	O
years	O
,	O
a	O
diet	O
rich	O
in	O
omega-3	O
fatty	O
acids	O
(	O
>	O
or	O
=0.20	O
g/d	O
)	O
slowed	O
the	O
decline	O
in	O
visual	O
field	O
sensitivity	O
.	O

Gabapentin	O
but	O
not	O
vigabatrin	O
is	O
effective	O
in	O
the	O
treatment	O
of	O
acquired	O
nystagmus	O
in	O
multiple	O
sclerosis	O
:	O
How	O
valid	O
is	O
the	O
GABAergic	O
hypothesis	O
?	O
Acquired	O
nystagmus	O
occurs	O
frequently	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
and	O
is	O
often	O
the	O
cause	O
of	O
illusory	O
motion	O
of	O
the	O
environment	O
(	O
oscillopsia	O
)	O
,	O
and	O
blurring	O
of	O
vision	O
.	O

Based	O
primarily	O
on	O
the	O
beneficial	O
effect	O
of	O
gabapentin	O
on	O
acquired	O
pendular	O
nystagmus	O
(	O
APN	O
)	O
,	O
a	O
GABAergic	O
mechanism	O
in	O
controlling	O
nystagmus	O
has	O
been	O
hypothesised	O
.	O

If	O
increasing	O
GABA	O
concentrations	O
in	O
the	O
CNS	O
are	O
critical	O
for	O
the	O
treatment	O
of	O
nystagmus	O
,	O
then	O
a	O
selective	O
GABAergic	O
drug	O
should	O
be	O
highly	O
successful	O
.	O

However	O
,	O
as	O
gabapentin	O
is	O
not	O
a	O
selective	O
GABAergic	O
agent	O
,	O
vigabatrin	O
,	O
a	O
pure	O
GABAergic	O
medication	O
,	O
and	O
gabapentin	O
,	O
were	O
compared	O
in	O
a	O
single	O
blind	O
cross	O
over	O
trial	O
in	O
eight	O
patients	O
with	O
definite	O
multiple	O
sclerosis	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
begin	O
with	O
gabapentin	O
(	O
1200	O
mg	O
daily	O
)	O
or	O
vigabatrin	O
(	O
2000	O
mg	O
daily	O
)	O
.	O

Neuro-ophthalmological	O
and	O
electro-oculographic	O
(	O
EOG	O
)	O
evaluations	O
were	O
performed	O
four	O
and	O
three	O
times	O
,	O
respectively	O
.	O

Treatment	O
efficacy	Others
was	O
based	O
on	O
improving	O
visual	Physical
acuity	Physical
and	O
EOG	Physical
indices	Physical
(	Physical
amplitude	Physical
or	Physical
frequency	Physical
of	Physical
nystagmus	Physical
,	Physical
or	Physical
both	Physical
)	Physical
by	O
at	O
least	O
50	O
%	O
of	O
pretreatment	O
values	O
.	O

Three	O
out	O
of	O
eight	O
patients	O
dropped	O
out	O
due	O
to	O
adverse	Adverseeffect
effects	Adverseeffect
.	O

In	O
the	O
remaining	O
five	O
patients	O
gabapentin	O
improved	O
symptomatic	Physical
pendular	Physical
or	Physical
gaze	Physical
evoked	Physical
jerk	Physical
nystagmus	Physical
in	O
four	O
.	O

Three	O
patients	O
decided	O
to	O
continue	O
gabapentin	O
therapy	O
.	O

Importantly	O
,	O
vigabatrin	O
proved	O
useful	O
in	O
only	O
one	O
out	O
of	O
five	O
patients	O
,	O
suggesting	O
that	O
gabapentin	O
effectiveness	O
may	O
be	O
related	O
to	O
additional	O
non-GABAergic	O
mechanisms	O
of	O
action	O
.	O

Interaction	O
with	O
cerebral	O
glutamate	O
transmission	O
by	O
inhibition	O
of	O
NMDA	O
receptor	O
might	O
be	O
an	O
alternative	O
hypothesis	O
for	O
the	O
therapeutic	O
action	O
of	O
gabapentin	O
.	O

